PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Gonzalez, E; Fernandez, MR; Larroy, C; Sola, L; Pericas, MA; Pares, X; Biosca, JA				Gonzalez, E; Fernandez, MR; Larroy, C; Sola, L; Pericas, MA; Pares, X; Biosca, JA			Characterization of a (2R,3R)-2,3-butanediol dehydrogenase as the Saccharomyces cerevisiae YAL060W gene product - Disruption and induction of the gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST ALCOHOL-DEHYDROGENASE; BACILLUS-STEAROTHERMOPHILUS; MOLECULAR CHARACTERIZATION; NUCLEOTIDE-SEQUENCE; ACETOIN REDUCTASE; BREWERS-YEAST; DNA-SEQUENCE; 2,3-BUTANEDIOL; PURIFICATION; FORMALDEHYDE	The completion of the Saccharomyces cerevisiae genome project-in 1996 showed that almost 60% of the potential open reading frames of the genome had no experimentally determined function. Using a conserved sequence motif present in the zinc-containing medium-chain alcohol dehydrogenases, we found several potential alcohol dehydrogenase genes with no defined function. One of these, YAL060W, was overexpressed using a multicopy inducible vector, and its protein product was purified to homogeneity. The enzyme was found to be a homodimer that, in the presence of NAD(+), but not of NADP, could catalyze the stereospecific oxidation of (2R,3R)-2,3-butanediol (K(m) = 14 mM, k(cat) = 78,000 min(-1)) and meso-butanediol (K(m) = 65 mM, k(cat) = 46,000 min(-1)) to (3R)-acetoin and (SS)-acetoin, respectively. It was unable, however, to further oxidize these acetoins to diacetyl, In the presence of NADH, it could catalyze the stereospecific reduction of racemic acetoin ((3R/3S)acetoin K(m) = 4.5 mM, k(cat) = 98,000 min(-1)) to (2R,3R)-2,3-butanediol and meso-butanediol, respectively. The substrate stereospecificity was determined by analysis of products by gas-liquid chromatography, The YALOGOW gene product can therefore be classified as an NAD-dependent (2R,3R)-2,3-butanediol dehydrogenase (BDH). S. cerevisiae could grow on 2,3-butanediol as the sole carbon and energy source. hTnder these conditions, a 3.5-fold: increase in (2R,3R)-2,3-butanediol dehydrogenase activity was observed in the total cell extracts. The isoelectric focusing pattern of the induced enzyme coincided with that of the pure BDH (pI 6.9). The disruption of the YALOGOW gene was not lethal for the yeast under laboratory conditions. The disrupted strain could also grow on 2,3-butanediol, although attaining a lesser cell density than the wild-type strain. Taking into consideration the substrate specificity of the YALOGOW gene product, we propose the name of BDH for this gene. The corresponding enzyme is the first eukaryotic (2R,3R)2,3-butanediol dehydrogenase characterized of the medium-chain dehydrogenase/reductase family.	Univ Autonoma Barcelona, Fac Sci, Dept Biochem & Mol Biol, E-08193 Bellaterra, Barcelona, Spain; Univ Barcelona, Dept Quim Organ, Unitat Recerca Sintesi Asimetr, E-08028 Barcelona, Spain	Autonomous University of Barcelona; University of Barcelona	Pares, X (corresponding author), Univ Autonoma Barcelona, Fac Sci, Dept Biochem & Mol Biol, E-08193 Bellaterra, Barcelona, Spain.	xavier.pares@uab.es	Pericàs, Miquel A./B-1085-2009; Larroy, Carol/AAB-3170-2021; Fernandez, Maria Rosario R/F-4015-2016; Biosca, Josep/G-3137-2013; Pares, Xavier/K-8228-2017	Pericàs, Miquel A./0000-0003-0195-8846; Larroy, Carol/0000-0002-4717-5612; Fernandez, Maria Rosario R/0000-0002-1750-7786; Biosca, Josep/0000-0003-2794-3124; Pares, Xavier/0000-0002-5071-9465; Gonzalez-Roca, Eva/0000-0002-1126-0321				ARONSON BD, 1989, J BIOL CHEM, V264, P5226; ATRIAN S, 1990, GENE, V93, P205, DOI 10.1016/0378-1119(90)90226-H; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3018; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BLOMQVIST K, 1991, APPL ENVIRON MICROB, V57, P2796, DOI 10.1128/AEM.57.10.2796-2803.1991; BLOMQVIST K, 1993, J BACTERIOL, V175, P1392, DOI 10.1128/JB.175.5.1392-1404.1993; Botstein D, 1997, SCIENCE, V277, P1259, DOI 10.1126/science.277.5330.1259; CHAOCHEN G, 1984, BIOCHEMISTRY-US, V23, P3576; CIRIACY M, 1975, MOL GEN GENET, V138, P157, DOI 10.1007/BF02428119; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DREWKE C, 1988, BIOCHIM BIOPHYS ACTA, V950, P54, DOI 10.1016/0167-4781(88)90072-3; EKLUND H, 1982, J BIOL CHEM, V257, P4349; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; FERNANDEZ MR, 1995, FEBS LETT, V370, P23; Fernandez MR, 1999, J BIOL CHEM, V274, P37869, DOI 10.1074/jbc.274.53.37869; FERNANDEZ MR, 1998, THESIS U AUTONOMA BA; GANZHORN AJ, 1987, J BIOL CHEM, V262, P3754; Giovannini PP, 1996, TETRAHEDRON, V52, P1669, DOI 10.1016/0040-4020(95)00995-7; Giovannini PP, 1996, BIOORGAN MED CHEM, V4, P1197; HEIDLAS J, 1990, EUR J BIOCHEM, V188, P165, DOI 10.1111/j.1432-1033.1990.tb15384.x; HEIDLAS J, 1990, ARCH MICROBIOL, V154, P267, DOI 10.1007/BF00248966; HOOG JO, 1993, ENZYMOLOGY MOL BIOL, V4, P439; HUANG M, 1994, FEMS MICROBIOL LETT, V124, P141, DOI 10.1111/j.1574-6968.1994.tb07276.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JORNVALI H, 1977, EUR J BIOCHEM, V16, P25; JORNVALL H, 1993, ENZYMOLOGY MOL BIOL, V4, P533; JORNVALL H, 1994, MOL BASIS ALCOHOL US, P221; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liebs P., 1969, Nahrung, V13, P455, DOI 10.1002/food.19690130602; NEISH AC, 1950, CAN J RES B, V28, P660, DOI 10.1139/cjr50b-079; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PERSSON B, 1993, FEBS LETT, V324, P9, DOI 10.1016/0014-5793(93)81522-2; PERSSON B, 1994, EUR J BIOCHEM, V226, P15, DOI 10.1111/j.1432-1033.1994.tb20021.x; PLAPP BV, 1991, ADV EXP MED BIOL, V284, P241; REID MF, 1994, CRIT REV MICROBIOL, V20, P13, DOI 10.3109/10408419409113545; Richard P, 1999, FEBS LETT, V457, P135, DOI 10.1016/S0014-5793(99)01016-9; ROBERTSON EF, 1987, ANAL BIOCHEM, V167, P290, DOI 10.1016/0003-2697(87)90166-7; ROMANO P, 1993, FEMS MICROBIOL LETT, V108, P23; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUSSELL DW, 1983, J BIOL CHEM, V258, P2674; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 2002, MOL CLONING LAB MANU; SARTHY AV, 1994, GENE, V140, P121, DOI 10.1016/0378-1119(94)90741-2; Smania AM, 1997, GENE, V197, P231, DOI 10.1016/S0378-1119(97)00267-9; STIVERS JT, 1993, BIOCHEMISTRY-US, V32, P13472, DOI 10.1021/bi00212a012; SUN HW, 1992, J MOL EVOL, V34, P522, DOI 10.1007/BF00160465; SUOMALAINEN H, 1968, NATURE, V220, P792, DOI 10.1038/220792a0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TITTEL D, 1979, MONAT BRAUEREI, V32, P260; Ui S, 1997, J FERMENT BIOENG, V84, P185, DOI 10.1016/S0922-338X(97)82052-1; Ui S, 1998, J FERMENT BIOENG, V86, P290, DOI 10.1016/S0922-338X(98)80132-3; VERDUYN C, 1988, YEAST, V4, P127, DOI 10.1002/yea.320040206; VERDUYN C, 1988, YEAST, V4, P135, DOI 10.1002/yea.320040207; WEHNER EP, 1993, MOL GEN GENET, V237, P351, DOI 10.1007/BF00279438; Wilkin JM, 1999, EUR J BIOCHEM, V262, P299, DOI 10.1046/j.1432-1327.1999.00369.x; WILLIAMSON VM, 1987, MOL GEN GENET, V209, P374, DOI 10.1007/BF00329668; WILLS C, 1979, EUR J BIOCHEM, V99, P323, DOI 10.1111/j.1432-1033.1979.tb13260.x; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; YOUNG ET, 1985, MOL CELL BIOL, V5, P3024, DOI 10.1128/MCB.5.11.3024	60	107	139	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35876	35885		10.1074/jbc.M003035200	http://dx.doi.org/10.1074/jbc.M003035200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10938079	hybrid			2022-12-27	WOS:000165382000035
J	Miyagishi, M; Fujii, R; Hatta, M; Yoshida, E; Araya, N; Nagafuchi, A; Ishihara, S; Nakajima, T; Fukamizu, A				Miyagishi, M; Fujii, R; Hatta, M; Yoshida, E; Araya, N; Nagafuchi, A; Ishihara, S; Nakajima, T; Fukamizu, A			Regulation of Lef-mediated transcription and p53-dependent pathway by associating beta-catenin with CBP/p300	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING-PROTEIN; NF-KAPPA-B; DEPENDENT KINASES; COLON-CARCINOMA; CELL-ADHESION; CBP; P300; COACTIVATOR; MODULATION; ACTIVATION	CBP and its homologue p300 play significant roles in cell differentiation, cell cycle, and anti-oncogenesis, We demonstrated that beta -catenin, recently known as a potent oncogene; and CBP/p300 are associated through its CH3 region, which is a primary target of adenoviral oncoprotein E1A and various nuclear proteins, such as p53, cyclin E, and AP-1, and both are colocalized in the nuclear :bodies. CBP/p300 potentiated Lef-mediated transactivation of beta -catenin, and E1A, a potent inhibitor of CBP/p300, repressed its transactivation. Furthermore, overexpression of stable beta -catenin mutant competitively suppressed the p53-dependent pathway. These may be a key mechanism of beta -catenin involved in oncogenic events underlying disruption of tumor suppressor function through CBP/p300.	Univ Tsukuba, Inst Appl Biochem, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Kyoto Univ, Fac Med, Dept Cell Biol, Kyoto 6068501, Japan	University of Tsukuba; Kyoto University	Fukamizu, A (corresponding author), Univ Tsukuba, Inst Appl Biochem, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan.		fukamizu, akiyoshi/J-5350-2012; Miyagishi, Makoto/L-8174-2016	fukamizu, akiyoshi/0000-0002-8786-6020; Miyagishi, Makoto/0000-0001-7654-3616				Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muraoka M, 1996, ONCOGENE, V12, P1565; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Scolnick DM, 1997, CANCER RES, V57, P3693; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Yoshida E, 1997, BIOCHEM BIOPH RES CO, V241, P664, DOI 10.1006/bbrc.1997.7871; Yoshida Y, 1998, HUM GENE THER, V9, P2503, DOI 10.1089/hum.1998.9.17-2503	36	99	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35170	35175		10.1074/jbc.C000258200	http://dx.doi.org/10.1074/jbc.C000258200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10906119	hybrid			2022-12-27	WOS:000165422800047
J	Schuler-Metz, A; Knochel, S; Kaufmann, E; Knochel, W				Schuler-Metz, A; Knochel, S; Kaufmann, E; Knochel, W			The homeodomain transcription factor Xvent-2 mediates autocatalytic regulation of BMP-4 expression in Xenopus embryos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-4; HOMEOBOX GENE; HEMATOPOIETIC MESODERM; VENTRALIZING FACTOR; INDUCTION; DROSOPHILA; PROMOTER; LAEVIS; DEFINES; SUPPRESSION	Like other genes of the transforming growth factor-p family, the BMP-4 gene is regulated by an autocatalytic loop. In Xenopus embryos this loop can be ectopically induced by injection of BMP-2 RNA. However, cycloheximide treatment subsequent to BMP-2 overexpression revealed that BMP signaling is not direct but requires additional factor(s), As putative mediator we have identified Xvent-2 which is activated by BMP-2/4 signaling and, in turn, activates BMP-4 transcription. Using promoter/reporter assays we have delineated Xvent-2 responsive elements within the BMP-4 gene. We further demonstrate that Xvent-2 which has recently been characterized as a transcriptional repressor can also act, context dependent, as an activator binding two copies of a 5'-CTAATT-3' motif in the second intron of the BMP-4 gene. Replacement of Xvent-2 target sites within the goosecoid (gsc) promoter by the BMP-4 enhancer converts Xvent-2 caused repression of gse to strong activation. This switch is obviously due to adjacent nucleotides probably binding a transcriptional co-activator interacting with Xvent-2, A model is presented describing the mechanism of BMP-4 gene activation in Xenopus embryos at the early gastrula stage.	Univ Ulm, Biochem Abt, D-89081 Ulm, Germany	Ulm University	Knochel, W (corresponding author), Univ Ulm, Biochem Abt, Albert Einstein Allee 11, D-89081 Ulm, Germany.							Ault KT, 1996, P NATL ACAD SCI USA, V93, P6415, DOI 10.1073/pnas.93.13.6415; CLEMENT JH, 1995, MECH DEVELOP, V52, P357, DOI 10.1016/0925-4773(95)00413-U; DALE L, 1992, DEVELOPMENT, V115, P573; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FENG JQ, 1995, J BIOL CHEM, V270, P28364, DOI 10.1074/jbc.270.47.28364; Friedle H, 1998, EMBO J, V17, P2298, DOI 10.1093/emboj/17.8.2298; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HARPER JW, 1993, CELL, V75, P805; Hild M, 1999, DEVELOPMENT, V126, P2149; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hoppler S, 1998, MECH DEVELOP, V71, P119, DOI 10.1016/S0925-4773(98)00004-5; HUANG JD, 1993, GENE DEV, V7, P694, DOI 10.1101/gad.7.4.694; HURSH DA, 1993, DEVELOPMENT, V117, P1211; JACKSON PD, 1994, DEV DYNAM, V199, P28, DOI 10.1002/aja.1001990104; JONES CM, 1992, DEVELOPMENT, V115, P639; KELLEY C, 1994, DEV BIOL, V165, P193, DOI 10.1006/dbio.1994.1246; Kim J, 1998, BIOCHEM BIOPH RES CO, V250, P516, DOI 10.1006/bbrc.1998.9280; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kishimoto Y, 1997, DEVELOPMENT, V124, P4457; KOSTER M, 1991, MECH DEVELOP, V33, P191, DOI 10.1016/0925-4773(91)90027-4; KURIHARA T, 1993, BIOCHEM BIOPH RES CO, V192, P1049, DOI 10.1006/bbrc.1993.1523; LADHER R, 1996, DEVELOPMENT, V122, P1769; Lemaire P, 1996, BIOESSAYS, V18, P701, DOI 10.1002/bies.950180904; Maeno M, 1996, BLOOD, V88, P1965, DOI 10.1182/blood.V88.6.1965.bloodjournal8861965; MARDON G, 1990, MOL CELL BIOL, V10, P681, DOI 10.1128/MCB.10.2.681; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Melby AE, 1999, DEV BIOL, V211, P293, DOI 10.1006/dbio.1999.9296; Metz A, 1998, MECH DEVELOP, V74, P29, DOI 10.1016/S0925-4773(98)00059-8; Nieuwkoop P. D., 1975, NORMAL TABLE XENOPUS; NISHIMATSU S, 1992, BIOCHEM BIOPH RES CO, V186, P1487, DOI 10.1016/S0006-291X(05)81574-8; Onichtchouk D, 1998, DEVELOPMENT, V125, P1447; Onichtchouk D, 1996, DEVELOPMENT, V122, P3045; Papalopulu N, 1996, DEV BIOL, V174, P104, DOI 10.1006/dbio.1996.0055; Rastegar S, 1999, MECH DEVELOP, V81, P139, DOI 10.1016/S0925-4773(98)00239-1; RiesgoEscovar JR, 1997, SCIENCE, V278, P669, DOI 10.1126/science.278.5338.669; Schmidt JE, 1996, DEVELOPMENT, V122, P1711; SCHWYTER DH, 1995, MOL CELL BIOL, V15, P3960; Shapira E, 2000, MECH DEVELOP, V90, P77, DOI 10.1016/S0925-4773(99)00283-X; SHODA A, 1993, GROWTH FACTORS, V8, P165, DOI 10.3109/08977199309011019; Shore EM, 1998, CALCIFIED TISSUE INT, V63, P221, DOI 10.1007/s002239900518; Suzuki A, 1997, DEVELOPMENT, V124, P3037; Sykes TG, 1998, DEVELOPMENT, V125, P4595; THURINGER F, 1993, P NATL ACAD SCI USA, V90, P3899, DOI 10.1073/pnas.90.9.3899; Trindade M, 1999, DEV BIOL, V216, P442, DOI 10.1006/dbio.1999.9507; Ueno N, 1992, GROWTH FACTORS, V7, DOI 10.3109/08977199209046927; vandenWijngaard A, 1996, BIOCHEM BIOPH RES CO, V219, P789, DOI 10.1006/bbrc.1996.0312; YAMAJI N, 1994, BIOCHEM BIOPH RES CO, V205, P1944, DOI 10.1006/bbrc.1994.2898	49	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34365	34374		10.1074/jbc.M003915200	http://dx.doi.org/10.1074/jbc.M003915200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10938274	hybrid			2022-12-27	WOS:000165095300051
J	Lee, SH; Schloss, DJ; Swain, JL				Lee, SH; Schloss, DJ; Swain, JL			Maintenance of vascular integrity in the embryo requires signaling through the fibroblast growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; NUCLEAR-LOCALIZATION; TARGETED EXPRESSION; TRANSGENIC MICE; IN-VITRO; FGF; ANGIOGENESIS; TRANSDUCTION; VASCULOGENESIS; FAMILY	Basic fibroblast growth factor (FGF)-2 is important for vessel formation and/or maintenance of vascular integrity in the embryo. FGF signaling may be mediated through transmembrane tyrosine kinase receptors or directly through intracellular pathways that do not involve receptor activation. To determine the role of receptor-mediated signaling in endothelial cells, an adenovirus encoding truncated FGF receptor (FGFR)-1, under the control of the cytomegalovirus promoter, was expressed in endothelial cells. FGF signaling was impaired, as indicated by inhibition of MAPK phosphorylation, Functional consequences included inhibition of endothelial cell migration and induction of apoptosis. To address the role of endothelial FGFR signaling in vascular development, recombinant adenovirus encoding a dominant-negative FGFR was injected into the sinus venosus of embryonic day 9.0 cultured mouse embryos. Previous studies demonstrated that transgenes delivered via adenovirus, under the control of the cytomegalovirus promoter, are expressed selectively in the developing vasculature, Embryos expressing a control adenovirus developed normally, whereas those expressing the FGFR-1 mutant exhibited abnormal embryonic and extra-embryonic vascular development. These data demonstrate that FGF, by signaling through the FGFR, plays a pivotal role in the development and maintenance of a mature vascular network in the embryo.	Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA	Stanford University	Swain, JL (corresponding author), Stanford Univ, Dept Med, Sch Med, S-102,300 Pasteur Dr, Stanford, CA 94305 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL026831, T32HL007708, R01HL026831] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26831, T32 HL07708] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMAYA E, 1993, DEVELOPMENT, V118, P477; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; Arese M, 1999, MOL BIOL CELL, V10, P1429, DOI 10.1091/mbc.10.5.1429; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; Baldwin HS, 1997, GENE THER, V4, P1142, DOI 10.1038/sj.gt.3300525; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BIKALVI A, 1995, J CELL BIOL, V129, P233; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; FLAMME I, 1993, ANAT REC, V237, P49, DOI 10.1002/ar.1092370106; FLAMME I, 1992, DEVELOPMENT, V116, P435; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GRAHAM FL, 1995, MOL BIOTECHNOL, V3, P207, DOI 10.1007/BF02789331; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; HERBERT JM, 1994, CELL, V78, P1017; Hogan B, 1994, MANIPULATING MOUSE E; HUANG L, 1995, MOL CELL BIOL, V16, P1349; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P2165, DOI 10.1073/pnas.90.6.2165; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; Klingenberg O, 2000, J BIOL CHEM, V275, P11972, DOI 10.1074/jbc.275.16.11972; Leconte I, 1998, DEV DYNAM, V213, P421, DOI 10.1002/(SICI)1097-0177(199812)213:4<421::AID-AJA7>3.0.CO;2-B; Levine JE, 1995, NEUROIMMUNOMODULAT, V2, P290, DOI 10.1159/000097208; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MINA T, 1995, P NATL ACAD SCI USA, V92, P467; Miyamoto T, 1998, J CELL PHYSIOL, V177, P58, DOI 10.1002/(SICI)1097-4652(199810)177:1<58::AID-JCP6>3.0.CO;2-D; Nishimura T, 1999, BBA-GENE STRUCT EXPR, V1444, P148, DOI 10.1016/S0167-4781(98)00255-3; Ohbayashi N, 1998, J BIOL CHEM, V273, P18161, DOI 10.1074/jbc.273.29.18161; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Pepper MS, 1997, ARTERIOSCL THROM VAS, V17, P605, DOI 10.1161/01.ATV.17.4.605; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Scata KA, 1999, EXP CELL RES, V250, P10, DOI 10.1006/excr.1999.4506; SCHLAEGER TM, 1995, DEVELOPMENT, V121, P1089; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; Stachowiak MK, 1997, MOL NEUROBIOL, V15, P257, DOI 10.1007/BF02740663; STRUM K, 1993, METHOD ENZYMOL, V225, P164; UENO H, 1992, J BIOL CHEM, V267, P1470; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; YAMAGUCHI TP, 1994, GENE DEV, V8, P3022; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yayon A, 1997, ONCOGENE, V14, P2999, DOI 10.1038/sj.onc.1201159; Zhou M, 1998, NAT MED, V4, P201, DOI 10.1038/nm0298-201	58	71	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33679	33687		10.1074/jbc.M004994200	http://dx.doi.org/10.1074/jbc.M004994200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10930413	hybrid			2022-12-27	WOS:000090104600070
J	Pena, MMO; Puig, S; Thiele, DJ				Pena, MMO; Puig, S; Thiele, DJ			Characterization of the Saccharomyces cerevisiae high affinity copper transporter Ctr3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR MAC1; ENDOPLASMIC-RETICULUM; MEMBRANE GLYCOPROTEIN; SECRETORY PATHWAY; QUALITY-CONTROL; IRON TRANSPORT; YEAST; PROTEIN; GENE; EXPRESSION	Copper is an essential nutrient required for the activity of a number of enzymes with diverse biological roles, In the bakers' yeast Saccharomyces cerevisiae, copper is transported into cells by two high affinity copper transport proteins, Ctr1 and Ctr3. Although Ctr1 and Ctr3 are functionally redundant, they bear little homology at the amino acid sequence level, In this report, me characterize Ctr3 with respect to its localization, assembly, and post-transcriptional regulation. Ctr3 is an integral membrane protein that assembles as a trimer to form a competent copper uptake permease at the plasma membrane, Whereas the CTR1 and CTR3 genes are similarly regulated at the transcriptional level in response to copper, post-transcriptional regulation of these proteins is distinct, Unlike Ctr1, the Ctr3 transporter is neither regulated at the level of protein degradation nor endocytosis as a function of elevated copper levels. Our studies suggest that Ctr3 constitutes a fundamental module found in all eukaryotic high affinity copper transporters to date, which is sufficient for copper uptake but lacks elements for post-transcriptional regulation by copper.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Thiele, DJ (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.		Puig, Sergi/E-4788-2010	Puig, Sergi/0000-0002-1856-490X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018089, R01GM041840] Funding Source: NIH RePORTER; NIGMS NIH HHS [5F32GM18089, GM41840] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELLA PM, 1979, BIOCHEM BIOPH RES CO, V87, P734, DOI 10.1016/0006-291X(79)92020-5; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Belden WJ, 1996, J BIOL CHEM, V271, P26939, DOI 10.1074/jbc.271.43.26939; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FANKHAUSER C, 1991, EUR J BIOCHEM, V195, P439, DOI 10.1111/j.1432-1033.1991.tb15723.x; Georgatsou E, 1999, YEAST, V15, P573, DOI 10.1002/(SICI)1097-0061(199905)15:7<573::AID-YEA404>3.3.CO;2-Z; Georgatsou E, 1997, J BIOL CHEM, V272, P13786, DOI 10.1074/jbc.272.21.13786; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; INOUYE S, 1994, FEBS LETT, V341, P277, DOI 10.1016/0014-5793(94)80472-9; Jensen LT, 1998, J BIOL CHEM, V273, P23805, DOI 10.1074/jbc.273.37.23805; Jensen LT, 1998, EMBO J, V17, P5400, DOI 10.1093/emboj/17.18.5400; Joshi A, 1999, J BIOL CHEM, V274, P218, DOI 10.1074/jbc.274.1.218; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KNAPPIK A, 1994, BIOTECHNIQUES, V17, P754; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Koch KA, 1997, CHEM BIOL, V4, P549, DOI 10.1016/S1074-5521(97)90241-6; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Labbe S, 1999, J BIOL CHEM, V274, P36252, DOI 10.1074/jbc.274.51.36252; Labbe S, 1999, TRENDS MICROBIOL, V7, P500, DOI 10.1016/S0966-842X(99)01638-8; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Linder M, 1991, BIOCH COPPER; Liu XD, 1997, EMBO J, V16, P6466, DOI 10.1093/emboj/16.21.6466; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; Pena MMO, 1998, MOL CELL BIOL, V18, P2514, DOI 10.1128/MCB.18.5.2514; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; Rolfs A, 1999, J PHYSIOL-LONDON, V518, P1, DOI 10.1111/j.1469-7793.1999.0001r.x; SERRANO R, 1991, MOL CELLULAR BIOL YE, V1, P523; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; Wang QQ, 1999, EMBO J, V18, P5972, DOI 10.1093/emboj/18.21.5972; Winge DR, 1998, PROG NUCLEIC ACID RE, V58, P165; YamaguchiIwai Y, 1997, J BIOL CHEM, V272, P17711, DOI 10.1074/jbc.272.28.17711	44	147	150	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33244	33251		10.1074/jbc.M005392200	http://dx.doi.org/10.1074/jbc.M005392200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10924521	hybrid			2022-12-27	WOS:000090104600012
J	Wong, J; Ishiai, M; Kurosaki, T; Chan, AC				Wong, J; Ishiai, M; Kurosaki, T; Chan, AC			Functional complementation of BLNK by SLP-76 and LAT linker proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-RECEPTOR; TYROSINE-PHOSPHORYLATED SLP-76; ANTIGEN RECEPTOR; ADAPTER PROTEIN; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE C-GAMMA-1; EXCHANGE FACTOR; RAS PATHWAY; B-CELLS; ACTIVATION	Recent studies have demonstrated a requirement for the SLP-76 (SH2 domain-containing leukocyte protein of 76 kDa) and LAT (linker for activation of cells) adaptor/linker proteins in T cell antigen receptor activation and T cell development as well as the BLNK. (B cell linker) linker protein in B cell antigen receptor (BCR) signal transduction and B cell development. Whereas the SLP-76 and LAT adaptor proteins are expressed in T, natural killer, and myeloid cells and platelets, BLNK is preferentially expressed in B cells and monocytes, Although BLNK is structurally homologous to SLP-76, BLNK interacts with a variety of downstream signaling proteins that interact directly with both SLP-76 and LAT, Here, we demonstrate that neither SLP-76 nor LAT alone is sufficient to restore the signaling deficits observed in BLNK-deficient B cells. Conversely, the coexpression of SLP-76 and LAT together restored BCR-inducible calcium responses as well as activation of all three families of mitogen-activated protein kinases, Together, these data suggest functional complementation of SLP-76 and LAT in T cell antigen receptor function with BLNK in BCR function.	Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Nephrol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Rheumatol, Dept Internal Med & Pathol, St Louis, MO 63110 USA; Kansai Med Univ, Inst Liver Res, Dept Mol Genet, Moriguchi, Osaka 5708506, Japan	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Kansai Medical University	Chan, AC (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, 660 S Euclid Ave,POB 8022, St Louis, MO 63110 USA.	achan@im.wustl.edu	Kurosaki, Tomohiro/D-1306-2009	Kurosaki, Tomohiro/0000-0002-6352-304X	NIAID NIH HHS [R01AI42787, K08AI0168702] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001687, R01AI042787] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Asada H, 1999, J EXP MED, V189, P1383, DOI 10.1084/jem.189.9.1383; BUDAY L, 1994, J BIOL CHEM, V269, P9019; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; Cheng AM, 1997, P NATL ACAD SCI USA, V94, P9797, DOI 10.1073/pnas.94.18.9797; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; Fu C, 1997, J BIOL CHEM, V272, P27362, DOI 10.1074/jbc.272.43.27362; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Genot E, 2000, CURR OPIN IMMUNOL, V12, P289, DOI 10.1016/S0952-7915(00)00089-3; Goitsuka R, 1998, J IMMUNOL, V161, P5804; Hashimoto S, 1999, BLOOD, V94, P2357, DOI 10.1182/blood.V94.7.2357.419k40_2357_2364; HEMPEL WM, 1992, J IMMUNOL, V148, P3021; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Kelly ME, 2000, CURR OPIN IMMUNOL, V12, P267, DOI 10.1016/S0952-7915(00)00086-8; Kurosaki T, 2000, CURR OPIN IMMUNOL, V12, P276, DOI 10.1016/S0952-7915(00)00087-X; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; Law CL, 1999, J EXP MED, V189, P1243, DOI 10.1084/jem.189.8.1243; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Musci MA, 1997, J IMMUNOL, V159, P1639; Myung PS, 2000, CURR OPIN IMMUNOL, V12, P256, DOI 10.1016/S0952-7915(00)00085-6; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; Onodera H, 1996, J BIOL CHEM, V271, P22225, DOI 10.1074/jbc.271.36.22225; Pivniouk VI, 1999, J CLIN INVEST, V103, P1737; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; Schaeffer EM, 2000, CURR OPIN IMMUNOL, V12, P282, DOI 10.1016/S0952-7915(00)00088-1; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Trub T, 1997, J BIOL CHEM, V272, P894, DOI 10.1074/jbc.272.2.894; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; Villalba M, 2000, IMMUNITY, V12, P151, DOI 10.1016/S1074-7613(00)80168-5; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Wunderlich L, 1999, EUR J IMMUNOL, V29, P1068, DOI 10.1002/(SICI)1521-4141(199904)29:04<1068::AID-IMMU1068>3.0.CO;2-P; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yang WC, 2000, IMMUNITY, V12, P373, DOI 10.1016/S1074-7613(00)80189-2; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	47	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33116	33122		10.1074/jbc.M004467200	http://dx.doi.org/10.1074/jbc.M004467200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10934198	hybrid			2022-12-27	WOS:000090003800100
J	Wu, H; Rao, GN; Dai, BS; Singh, P				Wu, H; Rao, GN; Dai, BS; Singh, P			Autocrine gastrins in colon cancer cells up-regulate cytochrome c oxidase Vb and down-regulate efflux of cytochrome c and activation of caspase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; DIFFERENT TISSUES; TRANSGENIC MICE; PROTEIN-KINASE; GROWTH-FACTOR; CARCINOMA; APOPTOSIS; INDUCTION; SUBUNIT; RELEASE	Suppression of the gastrin gene in human colon cancer cells by stably expressing antisense (AS) gastrin RNA results in significant growth suppression of AS cells. To understand mechanisms mediating the growth effects of autocrine gastrins, differential expression of transcripts by AS and control (C) clones of a representative cell line (HCT-116) was analyzed to identify target genes of autocrine gastrins, Six differentially expressed transcripts were confirmed and sequenced. Of these, the RNA and protein levels of cytochrome c oxidase (COX) Vb were significantly higher in C versus AS cells. The expression of COX Vb by colon cancer cells was proportional to the expression of gastrin. Higher levels of COX Vb coprecipitated with cytochrome c in the mitochondria of C versus AS cells. Treatment of mitochondria with digitonin resulted in a a-fold higher release of cytochrome c from AS versus C mitochondria. As a corollary, the cytosolic levels of cytochrome c were significantly higher in AS versus C cells, which correlated with similar to2- and similar to3-fold higher activation of caspase-9 and -3, respectively, in AS versus C cells in response to camptothecin. Thus, autocrine gastrins may support growth/ survival of cells by up-regulating COX Vb, which may decrease the sensitivity of the cancer cells to apoptotic stimuli by increasing retention of cytochrome c in mitochondria.	Univ Texas, Med Branch, Dept Anat & Neurosci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Singh, P (corresponding author), Univ Texas, Med Branch, Dept Anat & Neurosci, 301 Univ Blvd,Rte 1043, Galveston, TX 77555 USA.	posingh@utmb.edu			NCI NIH HHS [CA60087, CA72992] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072992] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN LA, 1995, J BIOL CHEM, V270, P110, DOI 10.1074/jbc.270.1.110; Bachman NJ, 1996, ARCH BIOCHEM BIOPHYS, V333, P152, DOI 10.1006/abbi.1996.0376; BALDWIN GS, 1992, CANCER RES, V52, P2261; Basu A, 1997, J BIOL CHEM, V272, P5899, DOI 10.1074/jbc.272.9.5899; Bini L, 1997, ELECTROPHORESIS, V18, P2832, DOI 10.1002/elps.1150181519; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CAPALDI RA, 1990, ARCH BIOCHEM BIOPHYS, V280, P252, DOI 10.1016/0003-9861(90)90327-U; Capaldi RA, 1995, METHOD ENZYMOL, V260, P117, DOI 10.1016/0076-6879(95)60134-1; Dai BS, 1997, ENDOCRINOLOGY, V138, P332, DOI 10.1210/en.138.1.332; FINLEY GG, 1993, CANCER RES, V53, P2919; GOSHORN SC, 1991, J BIOL CHEM, V266, P2134; GUO YS, 1990, IN VITRO CELL DEV B, V26, P871; Heerdt BG, 1998, CANCER RES, V58, P2869; HIGUCHI E, 1999, HOKKAIDO MED SCI, V74, P23123; Hollande F, 1997, GASTROENTEROLOGY, V113, P1576, DOI 10.1053/gast.1997.v113.pm9352860; HOOSEIN NM, 1988, CANCER RES, V48, P7179; Jarvis WD, 1996, J BIOL CHEM, V271, P8275, DOI 10.1074/jbc.271.14.8275; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JEMMERSON R, 1991, EUR J IMMUNOL, V21, P143, DOI 10.1002/eji.1830210122; JOHNSON LR, 1981, PHYSL GASTROINTESTIN, P169; Johnson N, 1997, LEUKEMIA RES, V21, P961, DOI 10.1016/S0145-2126(97)00077-5; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kato MV, 1999, LEUKEMIA LYMPHOMA, V33, P181, DOI 10.3109/10428199909093740; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOCHMAN ML, 1992, BIOCHEM BIOPH RES CO, V189, P1165, DOI 10.1016/0006-291X(92)92326-S; Koh TJ, 1999, J CLIN INVEST, V103, P1119, DOI 10.1172/JCI4910; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; NEMETH J, 1993, GUT, V34, P90, DOI 10.1136/gut.34.1.90; Nobumoto M, 1998, J BIOCHEM, V123, P128; Papadopoulou LC, 1996, BIOCHEM PHARMACOL, V52, P713, DOI 10.1016/0006-2952(96)00349-8; Patel S, 1997, MOL MED, V3, P674, DOI 10.1007/BF03401706; POLLACK C, 1998, NAT GENET, V20, P291; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; Ragno S, 1998, INFECT IMMUN, V66, P3952, DOI 10.1128/IAI.66.8.3952-3958.1998; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Rothenberg ML, 1997, ANN ONCOL, V8, P837, DOI 10.1023/A:1008270717294; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; SEVA C, 1994, SCIENCE, V265, P410, DOI 10.1126/science.8023165; SHARP MGF, 1992, J PATHOL, V168, P163, DOI 10.1002/path.1711680203; Shirafuji N, 1997, BLOOD, V90, P4567, DOI 10.1182/blood.V90.11.4567.4567_4567_4577; SINGH P, 1994, AM J PHYSIOL, V267, pG235, DOI 10.1152/ajpgi.1994.267.2.G235; SINGH P, 1986, CANCER RES, V46, P1612; SINGH P, 1994, AM J PHYSIOL, V266, pG459, DOI 10.1152/ajpgi.1994.266.3.G459; SINGH P, 1987, CANCER RES, V47, P5000; Singh P, 2000, CURR OPIN GASTROEN, V16, P68, DOI 10.1097/00001574-200001000-00013; Singh P, 2000, GASTROENTEROLOGY, V119, P162, DOI 10.1053/gast.2000.8527; Singh P, 1996, CANCER RES, V56, P4111; SINGH P, 1995, J BIOL CHEM, V270, P8429, DOI 10.1074/jbc.270.15.8429; Singh P, 2000, AM J PHYSIOL-GASTR L, V278, pG390, DOI 10.1152/ajpgi.2000.278.3.G390; SINGH P, 1994, AM J PHYSIOL-GASTR L, V267, pG608, DOI 10.1152/ajpgi.1994.267.4.G608; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SMITH JP, 1988, GASTROENTEROLOGY, V95, P1541; Taanman JW, 1996, BBA-MOL BASIS DIS, V1315, P199, DOI 10.1016/0925-4439(95)00127-1; Vijayasarathy C, 1998, BBA-BIOMEMBRANES, V1371, P71, DOI 10.1016/S0005-2736(97)00278-2; WALSH JH, 1994, GUT PEPTIDES BIOCH P, P75; Wang FL, 1996, CANCER RES, V56, P3634; Wang TC, 1999, AM J PHYSIOL-GASTR L, V277, pG6, DOI 10.1152/ajpgi.1999.277.1.G6; Wang TC, 1996, J CLIN INVEST, V98, P1918, DOI 10.1172/JCI118993; Watanabe T, 1998, MOL CELL BIOL, V18, P442, DOI 10.1128/MCB.18.1.442; WATSON SA, 1988, BRIT J SURG, V75, P342, DOI 10.1002/bjs.1800750416; XU ZD, 1994, LIFE SCI, V54, P671, DOI 10.1016/0024-3205(94)00550-8; Yang WL, 1998, BIOCHEMISTRY-US, V37, P14175, DOI 10.1021/bi981402a; 1998, APOPTOSIS APPL REAGE	66	53	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32491	32498		10.1074/jbc.M002458200	http://dx.doi.org/10.1074/jbc.M002458200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10915781	hybrid			2022-12-27	WOS:000090003800017
J	Chen, X; Liu, Z; Wang, JQ; Fang, JW; Fan, HN; Wang, PG				Chen, X; Liu, Z; Wang, JQ; Fang, JW; Fan, HN; Wang, PG			Changing the donor cofactor bovine alpha 1,3-galactosyltransferase by fusion with UDP-galactose 4-epimerase - More efficient biocatalysis for synthesis of alpha-Gal epitopes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOENZYMATIC SYNTHESIS; ENZYME; OLIGOSACCHARIDES; SEQUENCES; BINDING; TRANSPLANTATION; IDENTIFICATION; REGENERATION; ANTIBODIES; XENOGRAFTS	Two fusion enzymes consisting of uridine diphosphogalactose 4-epimerase (UDP-galactose 4-epimerase, EC 5.1.3.2) and alpha 1,3-galactosyltransferase (EC 2.4.1.151) with an N-terminal His(6) tag and an intervening three-glycine linker were constructed by in-frame fusion of the Escherichia coli galE gene either to the 3' terminus (fl) or to the 5' terminus (f2) of a truncated bovine alpha 1,3-galactosyltransferase gene, respectively. Both fusion proteins were expressed in cell lysate as active, soluble forms as well as in inclusion bodies as improperly folded proteins. Both f1 and f2 were determined to be homodimers, based on a single band observed at about 67 kDa in SDS-polyacrylamide gel electrophoresis and on a single peak with a molecular mass around 140 kDa determined by gel filtration chromatography for each of the enzymes. Without altering the acceptor specificity of the transferase, the fusion with the epimerase changed the donor requirement of alpha 1,3-galactosyltransferase from UDP-galactose to UDP-glucose and decreased the cost for the synthesis of biomedically important Ga1 alpha 1, 3Gal-terminated oligosaccharides by more than 40-fold. For enzymatic synthesis of Ga1 alpha 1,3Gal beta 1,4Glc from UDP-glucose and lactose, the genetically fused enzymes fl and f2 exhibited kinetic advantages with overall reaction rates that were 300 and 50%, respectively, higher than that of the system containing equal amounts of epimerase and galactosyltransferase. These results indicated that the active sites of the epimerase and the transferase in fusion enzymes were in proximity. The kinetic parameters suggested a random mechanism for the substrate binding of the alpha 1,3-galactosyltransferase. This work demonstrated a general approach that fusion of a glycosyltransferase with an epimerase can change the required but expensive sugar nucleotide to a less expensive one.	Wayne State Univ, Dept Chem, Detroit, MI 48202 USA	Wayne State University	Wang, PG (corresponding author), Wayne State Univ, Dept Chem, Detroit, MI 48202 USA.		Chen, Xi/H-1811-2018	Chen, Xi/0000-0002-3160-614X	NIAID NIH HHS [AI44040] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044040] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUGE C, 1986, CARBOHYD RES, V151, P147, DOI 10.1016/S0008-6215(00)90336-7; BAYNA EM, 1988, CELL, V53, P145, DOI 10.1016/0092-8674(88)90496-5; BEYER TA, 1981, ADV ENZYMOL, V52, P24; BLANKEN WM, 1985, J BIOL CHEM, V260, P2927; BULOW L, 1991, TRENDS BIOTECHNOL, V9, P226, DOI 10.1016/0167-7799(91)90075-S; BURKE JR, 1993, BIOCHEMISTRY-US, V32, P13220, DOI 10.1021/bi00211a034; Chen X, 1999, CURR OPIN CHEM BIOL, V3, P650, DOI 10.1016/S1367-5931(99)00022-8; Chen X, 2000, BIOTECHNOL PROGR, V16, P595, DOI 10.1021/bp000052s; Chen X, 1999, BIOTECHNOL LETT, V21, P1131, DOI 10.1023/A:1005678225031; Fang JW, 1998, J AM CHEM SOC, V120, P6635, DOI 10.1021/ja9808898; Fang JW, 1999, J ORG CHEM, V64, P4089, DOI 10.1021/jo990159y; GALILI U, 1993, BLOOD, V82, P2485, DOI 10.1182/blood.V82.8.2485.bloodjournal8282485; GALILI U, 1991, P NATL ACAD SCI USA, V88, P7401, DOI 10.1073/pnas.88.16.7401; GOOD AH, 1992, TRANSPL P, V24, P559; Janczuk A, 1999, CURR MED CHEM, V6, P155; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; Kapitonov D, 1999, GLYCOBIOLOGY, V9, P961, DOI 10.1093/glycob/9.10.961; KOIKE K, 1987, CARBOHYD RES, V163, P189, DOI 10.1016/0008-6215(87)80181-7; LJUNGCRANTZ P, 1989, BIOCHEMISTRY-US, V28, P8786, DOI 10.1021/bi00448a016; Lougheed B, 1999, J BIOL CHEM, V274, P37717, DOI 10.1074/jbc.274.53.37717; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MATSUZAKI Y, 1993, TETRAHEDRON LETT, V34, P1061, DOI 10.1016/S0040-4039(00)77492-2; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; Parker W, 1996, IMMUNOL TODAY, V17, P373, DOI 10.1016/0167-5699(96)10028-1; REDDY GV, 1994, CARBOHYD RES, V263, P67, DOI 10.1016/0008-6215(94)00153-7; SANDRIN MS, 1993, P NATL ACAD SCI USA, V90, P11391, DOI 10.1073/pnas.90.23.11391; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; Simon PM, 1998, TRANSPLANTATION, V65, P346, DOI 10.1097/00007890-199802150-00009; TAMADA Y, 1994, BIOCONJUGATE CHEM, V5, P660, DOI 10.1021/bc00030a023; THIEM J, 1992, SYNTHESIS STUTTGART, V1, P141; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P5137, DOI 10.1021/bi9601114; Wang JQ, 1999, J AM CHEM SOC, V121, P8174, DOI 10.1021/ja990219h; WILSON DB, 1964, J BIOL CHEM, V239, P2469; WONG CH, 1992, J ORG CHEM, V57, P4343, DOI 10.1021/jo00042a008; WONG CH, 1982, J ORG CHEM, V47, P5416, DOI 10.1021/jo00148a045; Zhang W, 1999, CURR ORG CHEM, V3, P241; Zhang YN, 1999, GLYCOBIOLOGY, V9, P815, DOI 10.1093/glycob/9.8.815	38	30	32	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31594	31600		10.1074/jbc.M004005200	http://dx.doi.org/10.1074/jbc.M004005200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10913140	hybrid			2022-12-27	WOS:000089858900008
J	Gonzalez-Barroso, MD; Pecqueur, C; Gelly, C; Sanchis, D; Alves-Guerra, MC; Bouillaud, F; Ricquier, D; Cassard-Doulcier, AM				Gonzalez-Barroso, MD; Pecqueur, C; Gelly, C; Sanchis, D; Alves-Guerra, MC; Bouillaud, F; Ricquier, D; Cassard-Doulcier, AM			Transcriptional activation of the human ucp1 gene in a rodent cell line - Synergism of retinoids, isoproterenol, and thiazolidinedione is mediated by a multipartite response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCOUPLING PROTEIN GENE; BROWN ADIPOSE-TISSUE; CIS-ACTING ELEMENTS; MESSENGER-RNA; PPAR-GAMMA; ADIPOCYTE DIFFERENTIATION; 5'-FLANKING REGION; HORMONE RECEPTOR; X-RECEPTOR; EXPRESSION	Uncoupling protein 1 (UCP1) is uniquely expressed in brown adipocytes and generates heat production by uncoupling respiration from ATP synthesis. The activatory effects of norepinephrine and retinoic acid (RA) on rodent ucp1 gene transcription have been well characterized. These effects are mediated by a 211-base pair (bp) enhancer which is also sufficient to restrict expression to brown adipose tissue. The molecular mechanisms controlling the transcription of the human ucp1 gene are unknown. In order to study the transcriptional regulation of the human gene, we set up chloramphenicol acetyltransferase constructs containing the entire or deleted 5' regions upstream of the transcriptional start site of the gene. These constructs were transiently transfected in a mouse cell line. A 350-bp hormone response region showing a significant homology with the rat ucp1 enhancer and located between the BclI polymorphic site and an AatII site (bp -3820/-3470) was detected. This region was sufficient to mediate the stimulation by RA and by combined treatments (RA + isoproterenol (ISO), RA + thiazolidinedione (TZD), or RA + ISO + TZD). The highest stimulation, a 26-fold increase in basal activity, was obtained by RA + ISO + TZD treatment. In contrast to the rodent gene, under our conditions, the effect of ISO and/or TZD is dependent on RA stimulation. Analysis of 105 bp inside the 350-bp element by site-directed mutagenesis and gel retardation experiments demonstrated that a multipartite response element mediates the drug stimulation. This region binds RARs and RXRs nuclear factors, CREB/ATF factors, and also PPAR gamma despite the absence of a consensus peroxisome-proliferator response element. The activation of the human ucp1 gene transcription by certain hormones or drugs, and the identification of the cis-elements involved, will help to identify new compounds activating fat oxidation and energy expenditure in humans.	CNRS, CEREMOD, Ctr Rech Endocrinol Mol & Dev, F-92190 Meudon, France	Centre National de la Recherche Scientifique (CNRS)	Cassard-Doulcier, AM (corresponding author), CNRS, CEREMOD, Ctr Rech Endocrinol Mol & Dev, 9 Rue Jules Hetzel, F-92190 Meudon, France.		CASSARD, Anne-Marie/B-6095-2019; Alves-Guerra, Marie-Clotilde/P-4356-2017; Pecqueur, Claire/L-3073-2015; Bouillaud, Frédéric R/L-3238-2017; Sanchis, Daniel/B-5644-2009; Sanchis, Daniel/C-8077-2009	CASSARD, Anne-Marie/0000-0002-1813-5128; Alves-Guerra, Marie-Clotilde/0000-0002-7918-1216; Pecqueur, Claire/0000-0002-7612-1672; Bouillaud, Frédéric R/0000-0002-7518-9237; Sanchis, Daniel/0000-0003-0047-8533; GONZALEZ BARROSO, MARIA DEL MAR/0000-0002-0278-8298				ALVAREZ R, 1995, J BIOL CHEM, V270, P5666, DOI 10.1074/jbc.270.10.5666; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; CASSARD AM, 1990, J CELL BIOCHEM, V43, P255, DOI 10.1002/jcb.240430306; Cassard-Doulcier AM, 1998, BIOCHEM J, V333, P243, DOI 10.1042/bj3330243; CassardDoulcier AM, 1996, INT J OBESITY, V20, P278; CASSARDDOULCIER AM, 1993, MOL ENDOCRINOL, V7, P497, DOI 10.1210/me.7.4.497; CASSARDDOULCIER AM, 1994, J BIOL CHEM, V269, P24335; CASTEILLA L, 1989, BIOCHEM J, V257, P665, DOI 10.1042/bj2570665; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Digby JE, 1998, DIABETES, V47, P138, DOI 10.2337/diabetes.47.1.138; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Finn D, 1998, CELL TISSUE RES, V294, P461, DOI 10.1007/s004410051197; FoellmiAdams LA, 1996, BIOCHEM PHARMACOL, V52, P693, DOI 10.1016/0006-2952(96)00345-0; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; GARRUTI G, 1992, INT J OBESITY, V16, P383; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; HIMMSHAGEN J, 1985, ANNU REV NUTR, V5, P69, DOI 10.1146/annurev.nu.05.070185.000441; HIMMSHAGEN J, 1999, HDB OBESITY, P415; HUTTUNEN P, 1981, EUR J APPL PHYSIOL O, V46, P339, DOI 10.1007/BF00422121; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; Jansa P, 1996, NUCLEIC ACIDS RES, V24, P694, DOI 10.1093/nar/24.4.694; KLAUS S, 1994, J CELL SCI, V107, P313; Kliewer SA, 1998, CURR OPIN GENET DEV, V8, P576, DOI 10.1016/S0959-437X(98)80014-2; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KOZAK UC, 1994, MOL CELL BIOL, V14, P59, DOI 10.1128/MCB.14.1.59; KRIEF S, 1993, J CLIN INVEST, V91, P344, DOI 10.1172/JCI116191; Kumar MV, 1999, J LIPID RES, V40, P824; Larose M, 1996, J BIOL CHEM, V271, P31533, DOI 10.1074/jbc.271.49.31533; LEAN MEJ, 1986, CLIN SCI, V71, P291, DOI 10.1042/cs0710291; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; Nagy L, 1996, J BIOL CHEM, V271, P4355; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; OPPERT JM, 1994, INT J OBESITY, V18, P526; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rabelo R, 1996, ENDOCRINOLOGY, V137, P3488, DOI 10.1210/en.137.8.3488; Rabelo R, 1997, ENDOCRINOLOGY, V138, P5325, DOI 10.1210/en.138.12.5325; RAISHER BD, 1992, J BIOL CHEM, V267, P20264; REHNMARK S, 1992, AM J PHYSIOL, V262, pE58, DOI 10.1152/ajpendo.1992.262.1.E58; RICQUIER D, 1982, J CLIN ENDOCR METAB, V54, P803; RICQUIER D, 1984, FEBS LETT, V178, P240, DOI 10.1016/0014-5793(84)80608-0; RICQUIER D, 1986, J BIOL CHEM, V261, P13905; Sears IB, 1996, MOL CELL BIOL, V16, P3410; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Serra F, 1999, INT J OBESITY, V23, P650, DOI 10.1038/sj.ijo.0800897; Silva JE, 1997, EUR J ENDOCRINOL, V136, P251, DOI 10.1530/eje.0.1360251; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Zhu YJ, 2000, J BIOL CHEM, V275, P13510, DOI 10.1074/jbc.275.18.13510	53	49	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31722	31732		10.1074/jbc.M001678200	http://dx.doi.org/10.1074/jbc.M001678200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10921912	hybrid			2022-12-27	WOS:000089858900027
J	Corvera, S; DiBonaventura, C; Shpetner, HS				Corvera, S; DiBonaventura, C; Shpetner, HS			Cell confluence-dependent remodeling of endothelial membranes mediated by cholesterol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANNEXIN-II TETRAMER; TYROSINE PHOSPHORYLATION; E-CADHERIN; GROWTH-FACTOR; ADHERENS JUNCTIONS; CRYSTAL-STRUCTURE; BETA-CATENIN; ADHESION; INHIBITION; BINDING	The plasma membranes of endothelial cells reaching confluence undergo profound structural and functional modifications, including the formation of adherens junctions, crucial for the regulation of vascular permeability and angiogenesis. Adherens junction formation is accompanied by the tyrosine dephosphorylation of adherens junctions proteins, which has been correlated with the strength and stability of adherens junctions. Here we show that cholesterol is a critical determinant of plasma membrane remodeling in cultures of growing cow pulmonary aortic endothelial cells. Membrane cholesterol increased dramatically at an early stage in the formation of confluent cow pulmonary aortic endothelial cell monolayers, prior to formation of intercellular junctions. This increase was accompanied by the redistribution of caveolin from a high density to a low density membrane compartment, previously shown to require cholesterol, and increased binding of the annexin II-pll complex to membranes, consistent with other studies indicating cholesterol-dependent binding of annexin II to membranes. Furthermore, partial depletion of cholesterol from confluent cells with methyl-P-cyclodextrin both induced tyrosine phosphorylation of multiple membrane proteins, including adherens junctions proteins, and disrupted adherens junctions. Both effects were dramatically reduced by prior complexing of methyl-P-cyclodextrin with cholesterol. Our results reveal a novel physiological role for cholesterol regulating the formation of adherens junctions and other plasma membrane remodeling events as endothelial cells reach confluence.	Univ Massachusetts, Med Ctr, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Dept Cell Biol, Sch Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Shpetner, HS (corresponding author), Univ Massachusetts, Med Ctr, Sch Med, Program Mol Med, 373 Plantat St,Suite 107, Worcester, MA 01605 USA.							AOKI J, 1991, J CELL BIOL, V115, P1751, DOI 10.1083/jcb.115.6.1751; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BREVIARIO F, 1995, ARTERIOSCL THROM VAS, V15, P1229, DOI 10.1161/01.ATV.15.8.1229; Burger A, 1996, J MOL BIOL, V257, P839, DOI 10.1006/jmbi.1996.0205; Cansell M, 1997, LIPIDS, V32, P39, DOI 10.1007/s11745-997-0006-3; Caveda L, 1996, J CLIN INVEST, V98, P886, DOI 10.1172/JCI118870; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; DANIELSEN EM, 1995, BIOCHEMISTRY-US, V34, P1596, DOI 10.1021/bi00005a016; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; Duh E, 1999, DIABETES, V48, P1899, DOI 10.2337/diabetes.48.10.1899; ELIAS PM, 1978, J CELL BIOL, V78, P577, DOI 10.1083/jcb.78.2.577; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; GIROLDI LA, 1993, CANCER METAST REV, V12, P29, DOI 10.1007/BF00689788; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; Harder T, 1997, MOL BIOL CELL, V8, P533, DOI 10.1091/mbc.8.3.533; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; JOHNSTONE SA, 1992, J BIOL CHEM, V267, P25976; KANAI Y, 1995, BIOCHEM BIOPH RES CO, V208, P1067, DOI 10.1006/bbrc.1995.1443; Kandikonda S, 1996, CELL ADHES COMMUN, V4, P13, DOI 10.3109/15419069609010760; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; Konig J, 1998, J BIOL CHEM, V273, P19679, DOI 10.1074/jbc.273.31.19679; Korlach J, 1999, P NATL ACAD SCI USA, V96, P8461, DOI 10.1073/pnas.96.15.8461; LANGE Y, 1989, J BIOL CHEM, V264, P3786; Levenberg S, 1999, ONCOGENE, V18, P869, DOI 10.1038/sj.onc.1202396; LUECKE H, 1995, NATURE, V378, P512, DOI 10.1038/378512a0; LUSCINSKAS FW, 1991, J IMMUNOL, V146, P1617; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; Moss SE, 1997, TRENDS CELL BIOL, V7, P87, DOI 10.1016/S0962-8924(96)10049-0; Oh P, 1999, J BIOL CHEM, V274, P23144, DOI 10.1074/jbc.274.33.23144; Park H, 1998, J BIOL CHEM, V273, P32304, DOI 10.1074/jbc.273.48.32304; PASSANTI A, 1989, J CELL SCI, V92, P287; PEARSE BMF, 1982, P NATL ACAD SCI-BIOL, V79, P451, DOI 10.1073/pnas.79.2.451; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; POMERANTZ KB, 1995, ADV EXP MED BIOL, V369, P49; POWELL MA, 1987, BIOCHEM J, V247, P321, DOI 10.1042/bj2470321; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SCHNITZER JE, 1993, TRENDS CARDIOVAS MED, V3, P124, DOI 10.1016/1050-1738(93)90012-U; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; Smith LEH, 1999, NAT MED, V5, P1390, DOI 10.1038/70963; SPRINGER TA, 1990, NATURE, V346, P426; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; STADDON JM, 1995, J CELL BIOL, V130, P369, DOI 10.1083/jcb.130.2.369; Stan RV, 1997, MOL BIOL CELL, V8, P595, DOI 10.1091/mbc.8.4.595; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; Takahashi K, 1996, EXP CELL RES, V226, P214, DOI 10.1006/excr.1996.0221; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; Ukropec JA, 2000, J BIOL CHEM, V275, P5983, DOI 10.1074/jbc.275.8.5983; VANE JR, 1990, NEW ENGL J MED, V323, P27; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WIDENMANN B, 1985, J CELL BIOL, V101, P12; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; ZAKS WJ, 1991, BIOCHEMISTRY-US, V30, P9607, DOI 10.1021/bi00104a007; ZETTER BR, 1993, SEMIN CANCER BIOL, V4, P219	64	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31414	31421		10.1074/jbc.M001708200	http://dx.doi.org/10.1074/jbc.M001708200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10903311	hybrid			2022-12-27	WOS:000089762700094
J	Mao, CG; Xu, RJ; Bielawska, A; Szulc, ZM; Obeid, LM				Mao, CG; Xu, RJ; Bielawska, A; Szulc, ZM; Obeid, LM			Cloning and characterization of a Saccharomyces cerevisiae alkaline ceramidase with specificity for dihydroceramide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-RESPONSE; SPHINGOLIPIDS; IDENTIFICATION; PROLIFERATION; METABOLISM; GROWTH	In a previous study, we reported that the Saccharomyces cerevisiae gene YPC1 encodes an alkaline ceramidase with a dual activity, catalyzing both hydrolysis and synthesis of yeast ceramide (Mao, C., Xu, R., Bielawska, A., and Obeid, L., M., (2000) J. Biol. Chem. 275, 6876-6884). In this study, we have identified a YPC1 homologue in S. cerevisiae that also encodes an alkaline ceramidase, We show that these two ceramidases have different substrate specificity, such that YPC1p preferentially hydrolyzes phytoceramide, whereas the new ceramidase YDC1p hydrolyzes dihydroceramide preferentially and phytoceramide only slightly. Neither enzyme hydrolyzes unsaturated mammalian-type ceramide. In contrast to YPC1p, YDC1p had only minor in vitro reverse activity of catalyzing dihydroceramide formation from a free fatty acid and dihydrosphingosine and no activity with phytosphingosine, Overexpression of YDC1p had no reverse activity in non-stressed yeast cells, but like YPC1p suppressed the inhibition of growth by fumonisin B1 albeit more modestly. Deletion of YDC1 and YPC1 or both did not apparently affect growth, suggesting neither gene is essential, However, the Delta ydc1 deletion mutant but not the Delta ypc1 deletion mutant was sensitive to heat stress, indicating a role for dihydroceramide but not phytoceramide in heat stress responses, and suggesting that the two enzymes have distinct physiological functions.	Ralph H Johnson Vet Affairs Hosp, Div Gen Internal Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem, Charleston, SC 29425 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Medical University of South Carolina; Medical University of South Carolina	Obeid, LM (corresponding author), Ralph H Johnson Vet Affairs Hosp, Div Gen Internal Med, 114 Doughty St,Rm 604 STB,POB 250779, Charleston, SC 29425 USA.	obeidl@musc.edu	xu, rui/GRX-5734-2022	obeid, lina/0000-0002-0734-0847	NIA NIH HHS [AG12467, AG16583] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG016583, R29AG012467, R55AG012467] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bielawska A, 2000, METHOD ENZYMOL, V311, P499; Bielawska A, 2000, METHOD ENZYMOL, V311, P518; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Dickson RC, 1999, BBA-MOL CELL BIOL L, V1438, P305, DOI 10.1016/S1388-1981(99)00068-2; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; El Bawab S, 1999, J BIOL CHEM, V274, P27948, DOI 10.1074/jbc.274.39.27948; Grilley MM, 1998, J BIOL CHEM, V273, P11062, DOI 10.1074/jbc.273.18.11062; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Hannun YA, 1997, ADV EXP MED BIOL, V400, P305; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 1997, ADV EXP MED BIOL, V407, P145; Hannun YA, 1997, BIOCHEM SOC T, V25, P1171, DOI 10.1042/bst0251171; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; Luberto C, 1999, LIPIDS, V34, pS5, DOI 10.1007/BF02562221; Lucci A, 1999, INT J ONCOL, V15, P541; Mao CG, 1999, BIOCHEM J, V342, P667, DOI 10.1042/0264-6021:3420667; Mao CG, 1997, J BIOL CHEM, V272, P28690, DOI 10.1074/jbc.272.45.28690; Mao CG, 2000, J BIOL CHEM, V275, P6876, DOI 10.1074/jbc.275.10.6876; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; Ohnishi Y, 1999, CLIN DIAGN LAB IMMUN, V6, P101, DOI 10.1128/CDLI.6.1.101-104.1999; Okino N, 1999, J BIOL CHEM, V274, P36616, DOI 10.1074/jbc.274.51.36616; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; Tani M, 2000, J BIOL CHEM, V275, P11229, DOI 10.1074/jbc.275.15.11229; Tani M, 2000, J BIOL CHEM, V275, P3462, DOI 10.1074/jbc.275.5.3462; Wells GB, 1998, J BIOL CHEM, V273, P7235, DOI 10.1074/jbc.273.13.7235	28	114	131	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31369	31378		10.1074/jbc.M003683200	http://dx.doi.org/10.1074/jbc.M003683200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10900202	hybrid			2022-12-27	WOS:000089762700088
J	Scott, S; Abul-Hamd, AT; Cooper, TG				Scott, S; Abul-Hamd, AT; Cooper, TG			Roles of the Dal82p domains in allophanate/oxalurate-dependent gene expression in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UPSTREAM INDUCTION SEQUENCE; TRANSCRIPTION; PATHWAY; PROTEIN; YEAST; OPERATION; ELEMENTS; URE2P; SAGA; SPT	Allophanate/oxalurate-induced gene expression in Saccharomyces cerevisiae requires at least five transcription factors, four of which act positively (Gln3p, Gat1p, Dal81p, and Dal82p) and one negatively (Dal80p). Gln3p binds to and Gat1p is proposed to bind to single GATA sequences; Dal80p binds to pairs of specifically oriented and spaced GATA sequences, and Dal82p binds to a pathway-specific element, UISALL. Dal82p consists of at least three domains as follows: (i) UIS, DNA-binding, (ii) transcriptional activation, and (iii) coil(DAL82). Here we show that the coiled-coil(DAL82) domain possesses two demonstrable functions. (i) It prevents Dal82p-mediated transcription when inducer is absent. (ii) It is a major, although not exclusive, domain through which the inducer signal is received. Supporting the latter conclusion, a 38-amino acid fragment, containing little more than the coiled-coil(DAL82) domain, supports oxalurate-inducible, Dal81p-dependent, reporter gene transcription. Dal81p is required for inducer responsiveness of LexAp-Dal82p and LexAp coiled-coil(DAL82)-mediated transcription but isn't needed for inducer-dependent activation mediated by a Dal82p containing deletions in both the coiled-coil(DAL82), UISALL-binding domains. There may be an interaction between Dal81p and the coiled-coil(DAL82) domain since (i) Dal81p is required for transcription mediated by LexA-coiled-coil(DAL82)p and (ii) a Dal81p-Dal82p complex is detected by two-hybrid assay.	Univ Tennessee, Ctr Hlth Sci, Dept Microbiol & Immunol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Cooper, TG (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Microbiol & Immunol, Memphis, TN 38163 USA.			Cooper, Terrance G./0000-0002-7651-9963	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035642] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35642, R01 GM035642] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; BRICMONT PA, 1991, MOL CELL BIOL, V11, P1161, DOI 10.1128/MCB.11.2.1161; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Cooper TG, 1996, MYCOTA, V3, P139; Cox KH, 2000, J BIOL CHEM, V275, P17611, DOI 10.1074/jbc.M001648200; Cunningham TS, 2000, J BIOL CHEM, V275, P14408, DOI 10.1074/jbc.275.19.14408; DAUGHERTY JR, 1993, J BACTERIOL, V175, P64, DOI 10.1128/JB.175.1.64-73.1993; DORRINGTON RA, 1993, NUCLEIC ACIDS RES, V21, P3777, DOI 10.1093/nar/21.16.3777; Edskes HK, 2000, P NATL ACAD SCI USA, V97, P6625, DOI 10.1073/pnas.120168697; Edskes HK, 1999, GENETICS, V153, P585; Edskes HK, 1999, P NATL ACAD SCI USA, V96, P1498, DOI 10.1073/pnas.96.4.1498; GOLEMIS EA, 1996, CURRENT PROTOCOLS MO; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Miller J.H., 1972, EXPT MOL GENETICS; MINEHART PL, 1991, MOL CELL BIOL, V11, P6216, DOI 10.1128/MCB.11.12.6216; OLIVE MG, 1991, J BACTERIOL, V173, P255, DOI 10.1128/jb.173.1.255-261.1991; Park HD, 1999, J BACTERIOL, V181, P7052, DOI 10.1128/JB.181.22.7052-7064.1999; Rai R, 1999, J BIOL CHEM, V274, P28026, DOI 10.1074/jbc.274.39.28026; Roberts SM, 1997, GENETICS, V147, P451; Scott S, 2000, J BIOL CHEM, V275, P7198, DOI 10.1074/jbc.275.10.7198; SVETLOV V, 1997, THESIS U TENNESSEE M; ter Schure EG, 2000, FEMS MICROBIOL REV, V24, P67, DOI 10.1016/S0168-6445(99)00030-3; Thevelein JM, 1999, MOL MICROBIOL, V33, P904, DOI 10.1046/j.1365-2958.1999.01538.x; VANVUUREN HJJ, 1991, J BACTERIOL, V173, P7186, DOI 10.1128/jb.173.22.7186-7195.1991; Winston F, 1998, COLD SPRING HARB SYM, V63, P553, DOI 10.1101/sqb.1998.63.553; YOO HS, 1989, MOL CELL BIOL, V9, P3231, DOI 10.1128/MCB.9.8.3231	28	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30886	30893		10.1074/jbc.M005624200	http://dx.doi.org/10.1074/jbc.M005624200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906145	Green Accepted, hybrid			2022-12-27	WOS:000089762700024
J	Verastegui, C; Bille, K; Ortonne, JP; Ballotti, R				Verastegui, C; Bille, K; Ortonne, JP; Ballotti, R			Regulation of the microphthalmia-associated transcription factor gene by the Waardenburg syndrome type 4 gene, SOX10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HOMOLOG; MUTATIONS; MITF; PROTEIN; LEF-1	The absence of melanocytes from the cochlea and epidermis is responsible of deafness and hypopigmentation, two symptoms shared by the four Waardenburg syndrome (WS) subtypes, Microphthalmia-associated transcription factor (MITF) controls melanocyte survival and differentiation. Mutations, which impair MITF function or expression, result in an abnormal melanocyte development leading to the WS2, WS1 and WS3 are caused by mutation in the gene encoding the transcription factor Pax3, which regulates MITF expression. Recently, mutations in SOX10, a gene encoding a SRY-related transcription factor, have been reported in patients with WS4, However, the molecular basis of the defective melanocyte development in these patients remained to be elucidated. In the present report, we demonstrate that Sox10 is a strong activator of the MITF promoter, and we identify a Sox10 binding site between -264 and -266 of the MITF promoter. Finally, we show that three SOX10 mutations found in WS4 abolish the transcriptional activity of the resulting Sox10 proteins toward the MITF promoter. Taken together, our observations bring new and meaningful information concerning the molecular process that leads to a defective melanocyte development in WS4 patients with SOX10 mutations.	Fac Med, INSERM, U385, F-06107 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Ballotti, R (corresponding author), Fac Med, INSERM, U385, Ave Valombrose, F-06107 Nice, France.	ballotti@unice.fr	BALLOTTI, Robert/F-8825-2013	BALLOTTI, Robert/0000-0002-7322-4908				Bertolotto C, 1998, MOL CELL BIOL, V18, P694, DOI 10.1128/MCB.18.2.694; Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827; Dorsky RI, 1998, NATURE, V396, P370, DOI 10.1038/24620; Dorsky RI, 2000, GENE DEV, V14, P158; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; HUGHES AE, 1994, NAT GENET, V7, P509, DOI 10.1038/ng0894-509; Kuhlbrodt K, 1998, J BIOL CHEM, V273, P23033, DOI 10.1074/jbc.273.36.23033; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; Pingault V, 1998, NAT GENET, V18, P171, DOI 10.1038/ng0298-171; Southard-Smith EM, 1998, NAT GENET, V18, P60, DOI 10.1038/ng0198-60; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; Tachibana M, 1996, NAT GENET, V14, P50, DOI 10.1038/ng0996-50; Takeda K, 2000, J BIOL CHEM, V275, P14013, DOI 10.1074/jbc.C000113200; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TASSABEHJI M, 1995, HUM MOL GENET, V4, P2131, DOI 10.1093/hmg/4.11.2131; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; UDONO T, 2000, BIOCHIM BIOPHYS ACTA, V149, P2005; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283	20	135	137	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30757	30760		10.1074/jbc.C000445200	http://dx.doi.org/10.1074/jbc.C000445200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10938265	hybrid			2022-12-27	WOS:000089762700004
J	Verrecchia, F; Pessah, M; Atfi, A; Mauviel, A				Verrecchia, F; Pessah, M; Atfi, A; Mauviel, A			Tumor necrosis factor-alpha inhibits transforming growth factor-beta/Smad signaling in human dermal fibroblasts via AP-1 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE COL7A1 PROMOTER; FACTOR-KAPPA-B; TGF-BETA; TRANSCRIPTIONAL ACTIVATION; BINDING SEQUENCE; COACTIVATOR P300; DNA-BINDING; JUN FAMILY; C-JUN; SMAD3	Understanding the molecular mechanisms underlying the antagonistic activities of tumor necrosis factor-alpha (TNF-alpha) against transforming growth factor-beta (TGF-beta) is of utmost importance given the physiopathological implications of these cytokines. In this report, we demonstrate that TNF-alpha prevents TGF-beta-induced Smad-specific gene transactivation without inducing detectable levels of inhibitory Smad7 in human dermal fibroblasts. On the other hand, c-Jun and JunB, both induced by TNF-alpha, block Smad3-mediated transcription. Expression of antisense c-Jun mRNA prevents TNF-alpha inhibition of TGF-beta/Smad signaling whereas that of dominant-negative I kappa-B kinase-alpha or antisense Smad7 does not. We provide evidence for off-DNA interactions between Smad3 and both c-Jun and JunB accompanied with reduced Smad3-DNA interactions. Finally, we show that overexpression of the transcriptional co-activator p300 prevents TNF-alpha/AP-1 inhibition of TGF-beta/Smad signaling. These data suggest that TNF-alpha interferes with Smad signaling through the induction of AP-1 components, the latter forming off-DNA complexes with Smad3 and preventing its binding to specific cis element(s). In addition, Jun members compete with Smad3 for the common transcription co-activator p300. These two mechanisms are likely to act in concert to decrease Smad-specific transcription.	Hop St Louis, INSERM, U532, F-75010 Paris, France; Hop St Antoine, INSERM, U482, F-75012 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Mauviel, A (corresponding author), Hop St Louis, Skin Res Inst, INSERM, U532, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.		MAUVIEL, Alain/F-6251-2013; Verrecchia, Franck/G-5535-2018	Verrecchia, Franck/0000-0003-4920-2554; Mauviel, Alain/0000-0002-0438-2793				Alevizopoulos A, 1996, J BIOL CHEM, V271, P29672, DOI 10.1074/jbc.271.47.29672; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BAUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141; Bitzer M, 2000, GENE DEV, V14, P187; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; DeLuca C, 1999, CYTOKINE GROWTH F R, V10, P235, DOI 10.1016/S1359-6101(99)00015-5; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Goldring MB, 1999, CONNECT TISSUE RES, V40, P1, DOI 10.3109/03008209909005273; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; Kon A, 1999, ONCOGENE, V18, P1837, DOI 10.1038/sj.onc.1202495; Kouba DJ, 1999, J IMMUNOL, V162, P4226; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Letterio JJ, 1997, CLIN IMMUNOL IMMUNOP, V84, P244, DOI 10.1006/clin.1997.4409; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Maggirwar SB, 2000, J NEUROCHEM, V74, P527, DOI 10.1046/j.1471-4159.2000.740527.x; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; MAUVIEL A, 1993, WOUNDS, V5, P137; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; Nagarajan RP, 2000, BIOCHEM J, V348, P591, DOI 10.1042/0264-6021:3480591; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	45	149	152	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30226	30231		10.1074/jbc.M005310200	http://dx.doi.org/10.1074/jbc.M005310200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10903323	hybrid			2022-12-27	WOS:000089577900044
J	Wang, XY; Moore, SC; Laszckzak, M; Ausio, J				Wang, XY; Moore, SC; Laszckzak, M; Ausio, J			Acetylation increases the alpha-helical content of the histone tails of the nucleosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; CORE PARTICLE; CIRCULAR-DICHROISM; MODEL PEPTIDES; CHROMATIN; DNA; BINDING; H4; TRIFLUOROETHANOL; TRANSCRIPTION	The nature of the structural changes induced by histone acetylation at the different levels of chromatin organization has been very elusive. At the histone level, it has been proposed on several occasions that acetylation may induce an alpha -helical conformation of their acetylated N-terminal domains (tails). In an attempt to provide experimental support for this hypothesis, we have purified and characterized the tail of histone H4 in its native and mono-, di-, tri-, and tetra- acetylated form. The circular dichroism analysis of these peptides shows conclusively that acetylation does increase their alpha -helical content. Furthermore, the same spectroscopic analysis shows that this is also true for both the acetylated nucleosome core particle and the whole histone octamer in solution. In contrast to the native tails in which the alpha -helical organization appears to be dependent upon interaction of these histone regions with DNA, the acetylated tails show an increase in alpha -helical content that does not depend on such an interaction.	Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada	University of Victoria	Ausio, J (corresponding author), Univ Victoria, Dept Biochem & Microbiol, POB 3055,Petch Bldg 220, Victoria, BC V8W 3P6, Canada.	jausio@uvic.ca						ALDER AJ, 1974, J BIOL CHEM, V249, P2911; ALLAN J, 1982, J CELL BIOL, V93, P285, DOI 10.1083/jcb.93.2.285; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; AUSIO J, 1984, J MOL BIOL, V176, P77, DOI 10.1016/0022-2836(84)90383-8; Ausio J, 1998, METHODS, V15, P333, DOI 10.1006/meth.1998.0637; Baneres JL, 1997, J MOL BIOL, V273, P503, DOI 10.1006/jmbi.1997.1297; BOHM L, 1984, BIOSCIENCE REP, V4, P365, DOI 10.1007/BF01122502; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; BRADBURY EM, 1975, BIOCHEMISTRY-US, V14, P1876, DOI 10.1021/bi00680a012; CANDIDO EPM, 1971, J BIOL CHEM, V246, P3182; CARLOS S, 1993, J BIOL CHEM, V268, P185; CARY PD, 1982, EUR J BIOCHEM, V127, P137, DOI 10.1111/j.1432-1033.1982.tb06847.x; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Cirillo LA, 1999, MOL CELL, V4, P961, DOI 10.1016/S1097-2765(00)80225-7; Creighton T.E., 1996, PROTEINS; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; DIMITROV S, 1986, FEBS LETT, V197, P217, DOI 10.1016/0014-5793(86)80329-5; EICKBUSH TH, 1978, BIOCHEMISTRY-US, V17, P4955, DOI 10.1021/bi00616a016; FASMAN GD, 1976, BIOPHYS J, V16, P1201, DOI 10.1016/S0006-3495(76)85768-2; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; Georgel PT, 1997, EMBO J, V16, P4717, DOI 10.1093/emboj/16.15.4717; Georgieva EI, 1999, ANAL BIOCHEM, V269, P399, DOI 10.1006/abio.1999.4050; GILBRAT JF, 1987, J MOL BIOL, V198, P425; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; HONG L, 1993, J BIOL CHEM, V268, P305; Howe LW, 1998, MOL CELL BIOL, V18, P1156, DOI 10.1128/MCB.18.3.1156; Johnson CA, 1999, SEMIN CELL DEV BIOL, V10, P179, DOI 10.1006/scdb.1999.0299; JOHNSON LM, 1992, EMBO J, V11, P2201, DOI 10.1002/j.1460-2075.1992.tb05279.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LEHRMAN SR, 1990, BIOCHEMISTRY-US, V29, P5590, DOI 10.1021/bi00475a025; LI W, 1993, BIOCHEM J, V296, P737, DOI 10.1042/bj2960737; Logie C, 1999, BIOCHEMISTRY-US, V38, P2514, DOI 10.1021/bi982109d; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MCGHEE JD, 1983, NUCLEIC ACIDS RES, V11, P4065, DOI 10.1093/nar/11.12.4065; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; Mutskov V, 1998, MOL CELL BIOL, V18, P6293, DOI 10.1128/MCB.18.11.6293; NELSON JW, 1989, BIOCHEMISTRY-US, V28, P5256, DOI 10.1021/bi00438a050; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; Panetta G, 1998, J MOL BIOL, V282, P683, DOI 10.1006/jmbi.1998.2087; Peng HF, 1997, BIOCHEMISTRY-US, V36, P12371, DOI 10.1021/bi971046g; PERRY M, 1981, J BIOL CHEM, V256, P3313; PREVELIGE PE, 1987, BIOCHEMISTRY-US, V26, P2944, DOI 10.1021/bi00384a041; Puig OM, 1998, BBA-GENE STRUCT EXPR, V1397, P79, DOI 10.1016/S0167-4781(98)00008-6; SEGAWA S, 1991, BIOPOLYMERS, V31, P497, DOI 10.1002/bip.360310505; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; Smith ER, 2000, MOL CELL BIOL, V20, P312, DOI 10.1128/MCB.20.1.312-318.2000; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; Spencer VA, 1999, GENE, V240, P1, DOI 10.1016/S0378-1119(99)00405-9; STEIN A, 1979, J MOL BIOL, V130, P103, DOI 10.1016/0022-2836(79)90421-2; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; SUNG MT, 1970, P NATL ACAD SCI USA, V67, P1616, DOI 10.1073/pnas.67.3.1616; VERDAGUER N, 1993, EUR J BIOCHEM, V214, P879, DOI 10.1111/j.1432-1033.1993.tb17991.x; WALKER IO, 1984, BIOCHEMISTRY-US, V23, P5622, DOI 10.1021/bi00318a037; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; XU XB, 1995, BIOPOLYMERS, V35, P93, DOI 10.1002/bip.360350110; YAGER TD, 1984, J BIOL CHEM, V259, P4212; YANG JT, 1986, METHOD ENZYMOL, V130, P208; ZHONG LX, 1992, P NATL ACAD SCI USA, V89, P4462, DOI 10.1073/pnas.89.10.4462	64	141	141	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35013	35020		10.1074/jbc.M004998200	http://dx.doi.org/10.1074/jbc.M004998200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10938086	hybrid			2022-12-27	WOS:000165422800027
J	Oikonomakos, NG; Schnier, JB; Zographos, SE; Skamnaki, VT; Tsitsanou, KE; Johnson, LN				Oikonomakos, NG; Schnier, JB; Zographos, SE; Skamnaki, VT; Tsitsanou, KE; Johnson, LN			Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; GLUCOSE ANALOG INHIBITORS; STRUCTURAL BASIS; POTENT INHIBITION; IN-VIVO; CAFFEINE; DESIGN; SPIROHYDANTOIN; GLUCOPYRANOSE; L86-8275	Flavopiridol (L86-8275) ((-)-cis-5,7-dihydroxy-2-(2-chlorophenyl)-8-[4-(3-hydroxy-1-methyl) -piperidinyl]-4H-benzopyran-4-one), a potential antitumor drug, currently in phase II trials, has been shown to be an inhibitor of muscle glycogen phosphorylase (GP) and to cause glycogen accumulation in A549 non-small cell lung carcinoma cells (Kaiser, A, Nishi, a, Gorin, F.A., Walsh, D.A., Bradbury, E. M., and Schnier, J. B., unpublished data). Kinetic experiments reported here show that flavopiridol inhibits GPb with an IC50 = 15.5 muM The inhibition is synergistic with glucose resulting in a reduction of IC50 for flavopiridol to 2.3 muM and mimics the inhibition of caffeine. In order to elucidate the structural basis of inhibition, we determined the structures of GPb complexed with flavopiridol, GPb complexed with caffeine, and GPa complexed with both glucose and flavopiridol at 1.76-, 2.30-, and 2.23-Angstrom resolution, and refined to crystallographic R values of 0.216 (R-free, = 0.247), 0.189 (R-free = 0.219), and 0.195 (R-free = 0.252), respectively. The structures provide a rational for flavopiridol potency and synergism with glucose inhibitory action. Flavopiridol binds at the allosteric inhibitor site, situated at the entrance to the catalytic site, the site where caffeine binds. Flavopiridol intercalates between the two aromatic rings of Phe(285) and Tyr(613). Both flavopiridol and glucose promote the less active T-state through localization of the closed position of the 280s loop which blocks access to the catalytic site, thereby explaining their synergistic inhibition. The mode of interactions of flavopiridol with GP is different from that of des-chloro-flavopiridol with CDK2, illustrating how different functional parts of the inhibitor can be used to provide specific and potent binding to two different enzymes.	Natl Hellen Res Fdn, Inst Biol Res & Biotechnol, Athens 11635, Greece; Univ Calif Davis, Dept Biol Chem, Davis, CA 95616 USA; Univ Oxford, Mol Biophys Lab, Oxford OX1 3QU, England	National Hellenic Research Foundation; University of California System; University of California Davis; University of Oxford	Oikonomakos, NG (corresponding author), Natl Hellen Res Fdn, Inst Biol Res & Biotechnol, 48 Vas Constantinou Ave, Athens 11635, Greece.	ngo@eie.gr	Zographos, Spyros/H-9058-2013	Zographos, Spyros/0000-0001-8455-2352; E. Tsitsanou, Katerina/0000-0001-9657-1390				Acharya K.R., 1991, GLYCOGEN PHOSPHORYLA, V2nd; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARFORD D, 1991, J MOL BIOL, V218, P233, DOI 10.1016/0022-2836(91)90887-C; BICHARD CJF, 1995, TETRAHEDRON LETT, V36, P2145, DOI 10.1016/0040-4039(95)00197-K; BRUNGER AT, 1996, XPLOR VERSION 3 8 DE; CZECH J, 1995, INT J ONCOL, V6, P31; deAzevedo WF, 1996, P NATL ACAD SCI USA, V93, P2735, DOI 10.1073/pnas.93.7.2735; Drees M, 1997, CLIN CANCER RES, V3, P273; ErcanFang N, 1997, J PHARMACOL EXP THER, V280, P1312; FISCHER EH, 1962, METHOD ENZYMOL, V5, P369, DOI 10.1016/S0076-6879(62)05243-X; Gregoriou M, 1998, PROTEIN SCI, V7, P915; HELMREICH E, 1964, P NATL ACAD SCI USA, V51, P131, DOI 10.1073/pnas.51.1.131; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; HUBBARD SJ, 1993, NACCESS DEP BIOL MOL; Johnson L. N., 1989, ALLOSTERIC ENZYMES, P81; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KASTENSCHMIDT LL, 1968, BIOCHEMISTRY-US, V7, P3590, DOI 10.1021/bi00850a037; KASVINSKY PJ, 1981, CAN J BIOCHEM CELL B, V59, P387, DOI 10.1139/o81-054; KASVINSKY PJ, 1978, J BIOL CHEM, V253, P9102; Kim S H, 1996, Prog Cell Cycle Res, V2, P137; Lommerse JPM, 1996, J AM CHEM SOC, V118, P3108, DOI 10.1021/ja953281x; LOSIEWICZ MD, 1994, BIOCHEM BIOPH RES CO, V201, P589, DOI 10.1006/bbrc.1994.1742; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MADSEN NB, 1983, BIOCHEMISTRY-US, V22, P4460, DOI 10.1021/bi00288a017; MARTIN JL, 1990, BIOCHEMISTRY-US, V29, P10745, DOI 10.1021/bi00500a005; MARTIN JL, 1991, BIOCHEMISTRY-US, V30, P10101, DOI 10.1021/bi00106a006; Martin WH, 1998, P NATL ACAD SCI USA, V95, P1776, DOI 10.1073/pnas.95.4.1776; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; Noble MEM, 1999, PHARMACOL THERAPEUT, V82, P269, DOI 10.1016/S0163-7258(98)00051-5; Oikonomakos NG, 1999, PROTEIN SCI, V8, P1930, DOI 10.1110/ps.8.10.1930; OIKONOMAKOS NG, 1995, PROTEIN SCI, V4, P2469, DOI 10.1002/pro.5560041203; Oikonomakos NG, 2000, STRUCTURE, V8, P575, DOI 10.1016/S0969-2126(00)00144-1; OIKONOMAKOS NG, 1985, BIOCHIM BIOPHYS ACTA, V832, P248, DOI 10.1016/0167-4838(85)90257-2; OIKONOMAKOS NG, 1992, POST TRANSLATIONAL M, P81; OTWINOWSKI Z, 1993, P CCP4 STUD WEEK DAT; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Sausville EA, 1999, PHARMACOL THERAPEUT, V82, P285, DOI 10.1016/S0163-7258(98)00062-X; Sedlacek HH, 1996, INT J ONCOL, V9, P1143, DOI 10.3892/ijo.9.6.1143; Segel I. H, 1975, ENZYME KINETICS, P465; Senderowicz AM, 1999, INVEST NEW DRUG, V17, P313, DOI 10.1023/A:1006353008903; Senderowicz AM, 1998, J CLIN ONCOL, V16, P2986, DOI 10.1200/JCO.1998.16.9.2986; SPRANG S, 1982, BIOCHEMISTRY-US, V21, P2036, DOI 10.1021/bi00538a010; SPRANG SR, 1991, SCIENCE, V254, P1367, DOI 10.1126/science.1962195; STURA EA, 1983, J MOL BIOL, V170, P529, DOI 10.1016/S0022-2836(83)80160-0; WATSON KA, 1994, BIOCHEMISTRY-US, V33, P5745, DOI 10.1021/bi00185a011; WATSON KA, 1995, ACTA CRYSTALLOGR D, V51, P458, DOI 10.1107/S090744499401348X; Zographos SE, 1997, STRUCTURE, V5, P1413, DOI 10.1016/S0969-2126(97)00292-X	48	117	121	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34566	34573		10.1074/jbc.M004485200	http://dx.doi.org/10.1074/jbc.M004485200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10924512	hybrid			2022-12-27	WOS:000165095300077
J	Yao, M; Ose, T; Sugimoto, H; Horiuchi, A; Nakagawa, A; Wakatsuki, S; Yokoi, D; Murakami, T; Honma, M; Tanaka, I				Yao, M; Ose, T; Sugimoto, H; Horiuchi, A; Nakagawa, A; Wakatsuki, S; Yokoi, D; Murakami, T; Honma, M; Tanaka, I			Crystal structure of 1-aminocyclopropane-1-carboxylate deaminase from Hartsenula saturnus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; ACID DEAMINASE; PROTEIN CRYSTALLOGRAPHY; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; PSEUDOMONAS SP; ENZYME; CRYSTALLIZATION; REPLACEMENT; RESOLUTION	The pyridoxal 5'-phosphate (PLP)-dependent enzyme 1-aminocyclopropane-1-carboxylate deaminase (ACCD) catalyzes a reaction that involves a ring opening of cyclopropanoid amino acid, yielding alpha -ketobutyrate and ammonia. Unlike other PUP-dependent enzymes, this enzyme has no alpha -hydrogen atom in the substrate. Thus, a unique mechanism for the bond cleavage is expected. The crystal structure of ACCD from Hansenula saturnus has been determined at 2.0 Angstrom resolution by the multiple wavelength anomalous diffraction method using mercury atoms as anomalous scatterers. The model was built on the electron density map, which was obtained by the density averaging of multiple crystal forms. The final model was refined to an R-factor of 22.5% and an R-free-factor of 26.8%. The ACCD folds into two domains, each of which has an open twisted alpha/beta structure similar to the beta -subunit of tryptophan synthase, However, in ACCD, unlike in other members of the beta family of PLP-dependent enzymes, PLP is buried deep in the molecule, The structure provides the first view of the catalytic center of the cyclopropane ring opening.	Hokkaido Univ, Grad Sch Sci, Sapporo, Hokkaido 0600810, Japan; Hokkaido Univ, Grad Sch Agr, Sapporo, Hokkaido 0608589, Japan; European Synchrotron Radiat Facil, F-38043 Grenoble, France	Hokkaido University; Hokkaido University; European Synchrotron Radiation Facility (ESRF)	Tanaka, I (corresponding author), Hokkaido Univ, Grad Sch Sci, Sapporo, Hokkaido 0600810, Japan.		Sugimoto, Hiroshi/AAR-5442-2021; Nakagawa, Atsushi/D-4329-2009; yao, min/F-5287-2011; Sugimoto, Hiroshi/K-4041-2017; Ose, Toyoyuki/AAW-7821-2020; Nakagawa, Atsushi/M-5731-2019	Nakagawa, Atsushi/0000-0002-1700-7861; yao, min/0000-0003-1687-5904; Sugimoto, Hiroshi/0000-0002-3140-8362; Ose, Toyoyuki/0000-0002-2001-9388; Nakagawa, Atsushi/0000-0002-1700-7861; Wakatsuki, Soichi/0000-0001-5896-7968				Abola EE, 1997, METHOD ENZYMOL, V277, P556, DOI 10.1016/S0076-6879(97)77031-9; Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ADAMS DO, 1979, P NATL ACAD SCI USA, V76, P170, DOI 10.1073/pnas.76.1.170; ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burkhard P, 1998, J MOL BIOL, V283, P121, DOI 10.1006/jmbi.1998.2037; BURROUGHS LF, 1957, NATURE, V179, P360, DOI 10.1038/179360a0; Clausen T, 2000, EMBO J, V19, P831, DOI 10.1093/emboj/19.5.831; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DUNATHAN HC, 1966, P NATL ACAD SCI USA, V55, P712, DOI 10.1073/pnas.55.4.712; FORD GC, 1980, P NATL ACAD SCI-BIOL, V77, P2559, DOI 10.1073/pnas.77.5.2559; Gallagher DT, 1998, STRUCTURE, V6, P465, DOI 10.1016/S0969-2126(98)00048-3; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; HONMA M, 1985, AGR BIOL CHEM TOKYO, V49, P567, DOI 10.1080/00021369.1985.10866774; HONMA M, 1979, AGR BIOL CHEM TOKYO, V43, P1677, DOI 10.1080/00021369.1979.10863687; HONMA M, 1978, AGR BIOL CHEM TOKYO, V42, P1825, DOI 10.1080/00021369.1978.10863261; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kern AD, 1999, STRUCTURE, V7, P567, DOI 10.1016/S0969-2126(99)80073-2; KLEE HJ, 1991, PLANT CELL, V3, P1187, DOI 10.1105/tpc.3.11.1187; Kleywegt GJ, 1997, STRUCTURE, V5, P1557, DOI 10.1016/S0969-2126(97)00305-5; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KNIGHT S, 1989, THESIS SWEDISH U AGR; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li KQ, 1996, J AM CHEM SOC, V118, P8763, DOI 10.1021/ja960822p; Minami R, 1998, J BIOCHEM, V123, P1112; Murakami T, 1997, BIOSCI BIOTECH BIOCH, V61, P506, DOI 10.1271/bbb.61.506; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Reed AJ, 1996, J AGR FOOD CHEM, V44, P388, DOI 10.1021/jf9504071; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; SHEEHY RE, 1991, J BACTERIOL, V173, P5260, DOI 10.1128/jb.173.17.5260-5265.1991; SHELDRICK GM, 1993, ACTA CRYSTALLOGR D, V49, P18, DOI 10.1107/S0907444992007364; WALSH C, 1981, BIOCHEMISTRY-US, V20, P7509, DOI 10.1021/bi00529a028; YAO M, 1995, PROTEIN PEPTIDE LETT, V2, P305; YAO M, 1994, J STRUCT BIOL, V113, P251, DOI 10.1006/jsbi.1994.1060	40	52	53	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34557	34565		10.1074/jbc.M004681200	http://dx.doi.org/10.1074/jbc.M004681200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10938279	hybrid, Green Published			2022-12-27	WOS:000165095300076
J	Aufurth, S; Schagger, H; Muller, V				Aufurth, S; Schagger, H; Muller, V			Identification of subunits a, b, and c(1) from Acetobacterium woodii Na+-F1F0-ATPase - Subunits c(1), c(2), and c(3) constitute a mixed c-oligomer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-TRANSLOCATING F1F0-ATPASE; F1F0 ATP SYNTHASE; ESCHERICHIA-COLI; PROPIONIGENIUM-MODESTUM; ENERGY TRANSDUCTION; PURIFICATION; SEQUENCE; RECONSTITUTION; SPECIFICITY; DEPENDENCE	The Na+-F1F0-ATPase operon of Acetobacterium woodii was recently shown to contain, among eleven atp genes, those genes that encode subunit a and b, a gene encoding a 16-kDa proteolipid (subunit c(1)), and two genes encoding 8-kDa proteolipids (subunits c(2) and c(3)). Because subunits a, b, and c(1) were not found in previous enzyme preparations, we re-determined the subunit composition of the enzyme. The genes were overproduced, and specific antibodies were raised. Western blots revealed that subunits a, b, and c(1) are produced and localized in the cytoplasmic membrane. Membrane protein complexes were solubilized by dodecylmaltoside and separated by blue native-polyacrylamide gel electrophoresis, and the ATPase subunits were resolved by SDS-polyacrylamide gel electrophoresis. N-terminal sequence analyses revealed the presence of subunits a, c(2), c(3), b, delta, alpha, gamma, beta, and epsilon. Biochemical and immunological analyses revealed that subunits c(1), c(2), and c(3) are all part of the c-oligomer, the first of a F1F0-ATPase that contains 8- and 16-kDa proteolipids.	Univ Munich, Lehrstuhl Mikrobiol, D-80638 Munich, Germany; Univ Frankfurt Klinikum, Zentrum Biol Chem, D-60590 Frankfurt, Germany	University of Munich; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Muller, V (corresponding author), Univ Munich, Lehrstuhl Mikrobiol, Maria Ward Str 1a, D-80638 Munich, Germany.		Mueller, Volker/ABE-4305-2021	Mueller, Volker/0000-0001-7955-5508				AssadiPorter FM, 1995, BIOCHEMISTRY-US, V34, P16186, DOI 10.1021/bi00049a034; Beechey R B, 1979, Methods Enzymol, V55, P426; Das A, 1997, J BACTERIOL, V179, P3746, DOI 10.1128/jb.179.11.3746-3755.1997; Das A, 1997, J BACTERIOL, V179, P1714, DOI 10.1128/jb.179.5.1714-1720.1997; Dimroth P, 1999, P NATL ACAD SCI USA, V96, P4924, DOI 10.1073/pnas.96.9.4924; DMITRIEV OY, 1995, EUR J BIOCHEM, V233, P478, DOI 10.1111/j.1432-1033.1995.478_2.x; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; FILLINGAME RH, 1976, J BIOL CHEM, V251, P6630; FORSTER A, 1994, BIOCHIM BIOPHYS ACTA, V1229, P393; GERIKE U, 1993, FEBS LETT, V316, P89, DOI 10.1016/0014-5793(93)81742-I; GIRVIN ME, 1993, BIOCHEMISTRY-US, V32, P12167, DOI 10.1021/bi00096a029; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HEISE R, 1991, FEBS LETT, V295, P119, DOI 10.1016/0014-5793(91)81400-3; HEISE R, 1993, FEMS MICROBIOL LETT, V112, P261, DOI 10.1111/j.1574-6968.1993.tb06460.x; HEISE R, 1989, J BACTERIOL, V171, P5473, DOI 10.1128/jb.171.10.5473-5478.1989; Kaim G, 1997, BIOCHEMISTRY-US, V36, P9185, DOI 10.1021/bi970831q; Muller V, 1995, ARCH MICROBIOL, V164, P363, DOI 10.1007/s002030050276; Muller V, 1999, J BIOENERG BIOMEMBR, V31, P15, DOI 10.1023/A:1005451311009; Muller V., 1994, ACETOGENESIS, P127; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; Rahlfs S, 1997, FEBS LETT, V404, P269, DOI 10.1016/S0014-5793(97)00088-4; Rahlfs S, 1999, FEBS LETT, V453, P35, DOI 10.1016/S0014-5793(99)00576-1; Rahlfs S, 1999, J BIOL CHEM, V274, P33999, DOI 10.1074/jbc.274.48.33999; REIDLINGER J, 1994, FEBS LETT, V356, P17, DOI 10.1016/0014-5793(94)01222-9; REIDLINGER J, 1994, EUR J BIOCHEM, V223, P275, DOI 10.1111/j.1432-1033.1994.tb18992.x; Ruppert C, 1999, J BIOL CHEM, V274, P25281, DOI 10.1074/jbc.274.36.25281; Sch?gger, 1994, PRACTICAL GUIDE MEMB, P81; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P369; Schemidt RA, 1998, J BACTERIOL, V180, P3205, DOI 10.1128/JB.180.12.3205-3208.1998; SPRUTH M, 1995, BBA-BIOENERGETICS, V1229, P96, DOI 10.1016/0005-2728(94)00192-8; WALKER JE, 1983, METHOD ENZYMOL, V97, P195; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; ZHANG Y, 1995, J BIOL CHEM, V270, P87, DOI 10.1074/jbc.270.1.87	34	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33297	33301		10.1074/jbc.M005134200	http://dx.doi.org/10.1074/jbc.M005134200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10913149	hybrid			2022-12-27	WOS:000090104600019
J	Grzesiak, A; Krokoszynska, I; Krowarsch, D; Buczek, O; Dadlez, M; Otlewski, J				Grzesiak, A; Krokoszynska, I; Krowarsch, D; Buczek, O; Dadlez, M; Otlewski, J			Inhibition of six serine proteinases of the human coagulation system by mutants of bovine pancreatic trypsin inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KUNITZ DOMAIN INHIBITORS; X-RAY STRUCTURE; TICK ANTICOAGULANT PEPTIDE; FACTOR PATHWAY INHIBITOR; FACTOR-FACTOR VIIA; TISSUE FACTOR; CRYSTAL-STRUCTURE; PHAGE DISPLAY; ACTIVE-SITE; ITERATIVE OPTIMIZATION	series of 12 bovine pancreatic trypsin inhibitor variants mutated in the P-4 and P-3 positions of the canonical binding loop containing additional R15R and M52L mutations mere used to probe the role of single amino acid substitutions on binding to bovine trypsin and to the following human proteinases involved in blood clotting: plasmin, plasma kallikrein, factors X-a and XIIa, thrombin, and protein C. The mutants were expressed in Escherichia coli as fusion proteins with the LE1413 hydrophobic polypeptide and purified from inclusion bodies; these steps were followed by CNBr cleavage and oxidative refolding, The mutants inhibited the blood-clotting proteinases with association constants in the range of 10(3)-10(10) M-1. Inhibition of plasma kallikrein, factors X-a and XIIa, thrombin, and protein C could be improved by up to 2 orders of magnitude by the K15R substitution The highest increase in the association constant for P-3 mutant was measured for factor XIIa; P13S substitution increased the K-a value 58-fold, Several other substitutions at P-3 resulted in about 10-fold increase for factor X-a, thrombin, and protein C. The cumulative P-3 and P-1 effects on K-alpha values for the strongest mutant compared with the wild type bovine pancreatic trypsin inhibitor were in the range of 2,2- (plasmin) to 4,000-fold (factors XIIa and X-a). The substitutions at the P-4 site always caused negative effects (a decrease in the range from over 1.000- to 1.3-fold) on binding to all studied enzymes, including trypsin, Thermal stability studies showed a very large decrease of the denaturation temperature (about 22 degreesC) for all P-4 mutants, suggesting that substitution of the mild type Gly-12 residue leads to a change in the binding loop conformation manifesting itself in non-optimal binding to the proteinase active site.	Univ Wroclaw, Inst Biochem & Mol Biol, Lab Prot Engn, PL-50137 Wroclaw, Poland; Polish Acad Sci, Inst Biochem & Biophys, PL-02106 Warsaw, Poland	University of Wroclaw; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences	Otlewski, J (corresponding author), Univ Wroclaw, Inst Biochem & Mol Biol, Lab Prot Engn, Tamka 2, PL-50137 Wroclaw, Poland.	otlewski@bf.uni.wroc.pl	Otlewski, Jacek/B-6340-2008	Dadlez, Michal/0000-0001-8811-5176				Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Bode W, 1997, THROMB HAEMOSTASIS, V78, P501; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BODE W, 1992, PROTEIN SCI, V1, P426; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; Brandstetter H, 1996, J BIOL CHEM, V271, P29988, DOI 10.1074/jbc.271.47.29988; BRINKMANN T, 1991, EUR J BIOCHEM, V202, P95, DOI 10.1111/j.1432-1033.1991.tb16348.x; BROZE GJ, 1995, ANNU REV MED, V46, P103, DOI 10.1146/annurev.med.46.1.103; Burgering MJM, 1997, J MOL BIOL, V269, P395, DOI 10.1006/jmbi.1997.1029; CHASE T, 1970, METHOD ENZYMOL, V19, P20; CHO K, 1984, BIOCHEMISTRY-US, V23, P644, DOI 10.1021/bi00299a009; DENNIS MS, 1995, J BIOL CHEM, V270, P25411, DOI 10.1074/jbc.270.43.25411; DENNIS MS, 1994, J BIOL CHEM, V269, P22129; DENNIS MS, 1994, J BIOL CHEM, V269, P22137; DROHAN WN, 1994, ADVANCES IN BIOPROCESS ENGINEERING, P501; EMPIE MW, 1982, BIOCHEMISTRY-US, V21, P2274, DOI 10.1021/bi00539a002; FRITZ H, 1983, ARZNEIMITTELFORSCH, V33-1, P479; Grzesiak A, 2000, J MOL BIOL, V301, P205, DOI 10.1006/jmbi.2000.3935; HARDY JF, 1992, CAN J ANAESTH, V39, P353, DOI 10.1007/BF03009046; Helland R, 1999, ACTA CRYSTALLOGR D, V55, P139, DOI 10.1107/S090744499801052X; HOFMANN KJ, 1992, BIOCHEM J, V287, P943, DOI 10.1042/bj2870943; HUBER R, 1974, J MOL BIOL, V89, P73, DOI 10.1016/0022-2836(74)90163-6; Katoh T, 1997, BIOSCI BIOTECH BIOCH, V61, P389, DOI 10.1271/bbb.61.389; KISIEL W, 1981, METHOD ENZYMOL, V80, P320; Kraunsoe JAE, 1996, BIOCHEMISTRY-US, V35, P9090, DOI 10.1021/bi953013b; Krokoszynska I, 1998, J MOL BIOL, V275, P503, DOI 10.1006/jmbi.1997.1460; Krowarsch D, 1999, J MOL BIOL, V289, P175, DOI 10.1006/jmbi.1999.2757; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lamba D, 1996, J MOL BIOL, V258, P117, DOI 10.1006/jmbi.1996.0238; Lapatto R, 1997, EMBO J, V16, P5151, DOI 10.1093/emboj/16.17.5151; LOTTENBERG R, 1986, BIOCHIM BIOPHYS ACTA, V874, P326, DOI 10.1016/0167-4838(86)90032-4; MAKHATADZE GI, 1993, PROTEIN SCI, V2, P2028, DOI 10.1002/pro.5560021204; Markland W, 1996, BIOCHEMISTRY-US, V35, P8058, DOI 10.1021/bi952629y; Markland W, 1996, BIOCHEMISTRY-US, V35, P8045, DOI 10.1021/bi9526286; Mather T, 1996, EMBO J, V15, P6822, DOI 10.1002/j.1460-2075.1996.tb01073.x; MOSES E, 1983, J MOL BIOL, V170, P765, DOI 10.1016/S0022-2836(83)80130-2; NEEPER MP, 1990, J BIOL CHEM, V265, P17746; OTLEWSKI J, 1994, BIOCHEMISTRY-US, V33, P200, DOI 10.1021/bi00167a026; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; Parry MAA, 1998, NAT STRUCT BIOL, V5, P917, DOI 10.1038/2359; PRADO ES, 1986, BIOL CHEM H-S, V367, P199, DOI 10.1515/bchm3.1986.367.1.199; Pritchard L, 1999, J MOL BIOL, V285, P1589, DOI 10.1006/jmbi.1998.2437; ROBERTS BL, 1992, P NATL ACAD SCI USA, V89, P2429, DOI 10.1073/pnas.89.6.2429; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SILVERBERG M, 1980, J BIOL CHEM, V255, P7281; STALEY JP, 1994, PROTEIN SCI, V3, P1822, DOI 10.1002/pro.5560031021; STASSEN JM, 1995, THROMB HAEMOSTASIS, V74, P646; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TSCHESCHE H, 1987, BIOCHIM BIOPHYS ACTA, V913, P97, DOI 10.1016/0167-4838(87)90238-X; Wei AZ, 1998, J MOL BIOL, V283, P147, DOI 10.1006/jmbi.1998.2069; WENZEL HR, 1982, FEBS LETT, V140, P53, DOI 10.1016/0014-5793(82)80519-X; WLODAWER A, 1984, J MOL BIOL, V180, P301, DOI 10.1016/S0022-2836(84)80006-6	53	34	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33346	33352		10.1074/jbc.M006085200	http://dx.doi.org/10.1074/jbc.M006085200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10930417	hybrid			2022-12-27	WOS:000090104600026
J	Hashimoto, K; Zanger, K; Hollenberg, AN; Cohen, LE; Radovick, S; Wondisford, FE				Hashimoto, K; Zanger, K; Hollenberg, AN; Cohen, LE; Radovick, S; Wondisford, FE			cAMP response element-binding protein-binding protein mediates thyrotropin-releasing hormone signaling on thyrotropin subunit genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PIT-1/GHF-1; KINASE-C; CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE; GLYCOPROTEIN HORMONES; PITUITARY-CELLS; ALPHA-GENE; EXPRESSION; PIT-1; CBP; ACTIVATION	Transcription of pituitary alpha -glycoprotein hormone subunit (alpha -GSU) and thyrotropin beta subunit (TSH-beta) genes is stimulated by thyrotropin-releasing hormone (TRH). Since cAMP response element-binding protein (CREB)-binding protein (CBP) integrates a number of cell signaling pathways, we investigated whether CBP is important for TRH stimulation of the TSH subunit genes. Cotransfection of E1A in GH(3) cells completely blocked TRH stimulation of the TSH subunit genes, suggesting that CBP is a key factor for TRH signaling in the pituitary. CBP and Pit-1 acted synergistically in TRH stimulation of the TSH-beta promoter, and amino acids 1-450 of CBP were sufficient for the TRH effect. In contrast, on the human alpha -GSU promoter, CREB and P-Lim mediated TRH signaling. Intriguingly, CREB was phosphorylated upon TRH stimulation, leading to CBP recruitment to the alpha -GSU promoter. CBP also interacted with P-Lim in a TRH-dependent manner, suggesting that P-Lim is an important factor for non-cAMP response element-mediated TRH stimulation of this promoter. Distinct domains of CBP were required for TRH signaling by CREB and P-Lim on the alpha -GSU promoter, amino acids 450-700 and 1-450, respectively. Thus, the amino terminus of CBP plays a critical role in TRH signaling in the anterior pituitary via both Pit-1-dependent and -independent pathways, yielding differential regulation of pituitary gene products.	Beth Israel Deaconess Med Ctr, Div Endocrinol, Thyroid Unit, Boston, MA 02215 USA; Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Boston Children's Hospital; Harvard Medical School	Wondisford, FE (corresponding author), Univ Chicago, Dept Med, Endocrinol Sect, 5841 S Maryland Ave, Chicago, IL 60637 USA.	fwondisf@medicine.bsd.uchicago.edu						ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; CARR FE, 1993, ENDOCRINOLOGY, V133, P1700, DOI 10.1210/en.133.4.1700; CARR FE, 1991, BIOCHEMISTRY-US, V30, P3721, DOI 10.1021/bi00229a019; CARR FE, 1989, MOL ENDOCRINOL, V3, P717, DOI 10.1210/mend-3-4-717; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Cohen LE, 1999, J CLIN INVEST, V104, P1123, DOI 10.1172/JCI7308; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; GERSHENGORN MC, 1989, ANN NY ACAD SCI, V553, P191; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORDON DF, 1988, DNA-J MOLEC CELL BIO, V7, P679, DOI 10.1089/dna.1988.7.679; Haugen BR, 1996, J BIOL CHEM, V271, P385, DOI 10.1074/jbc.271.1.385; HECKERT LL, 1995, J BIOL CHEM, V270, P26497, DOI 10.1074/jbc.270.44.26497; HORN F, 1992, MOL CELL BIOL, V12, P2143, DOI 10.1128/MCB.12.5.2143; JAMESON JL, 1988, J BIOL CHEM, V263, P9879; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KENNEDY GC, 1990, J BIOL CHEM, V265, P6279; KIM DS, 1994, MOL ENDOCRINOL, V8, P528, DOI 10.1210/me.8.4.528; KONZAK KE, 1992, MOL ENDOCRINOL, V6, P241, DOI 10.1210/me.6.2.241; KOURIDES IA, 1984, RECENT PROG HORM RES, V40, P79; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LICHT P, 1990, PROG CLIN BIOL RES, V342, P427; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MORRIS AE, 1992, NUCLEIC ACIDS RES, V20, P1355, DOI 10.1093/nar/20.6.1355; Muthusamy N, 1998, J BIOL CHEM, V273, P22841, DOI 10.1074/jbc.273.35.22841; OKIMURA Y, 1994, MOL ENDOCRINOL, V8, P1559, DOI 10.1210/me.8.11.1559; PENNATHUR S, 1993, MOL ENDOCRINOL, V7, P797, DOI 10.1210/me.7.6.797; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; ROBERSON MS, 1994, MOL CELL BIOL, V14, P2985, DOI 10.1128/MCB.14.5.2985; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHUPNIK MA, 1992, MOL ENDOCRINOL, V6, P43, DOI 10.1210/me.6.1.43; SHUPNIK MA, 1986, J BIOL CHEM, V261, P2675; STEGER DJ, 1991, MOL ENDOCRINOL, V5, P243, DOI 10.1210/mend-5-2-243; Steinfelder HJ, 1997, EXP CLIN ENDOCR DIAB, V105, P196, DOI 10.1055/s-0029-1211751; STEINFELDER HJ, 1992, J CLIN INVEST, V89, P409, DOI 10.1172/JCI115600; STEINFELDER HJ, 1991, P NATL ACAD SCI USA, V88, P3130, DOI 10.1073/pnas.88.8.3130; STEINFELDER HJ, 1992, P NATL ACAD SCI USA, V89, P5942, DOI 10.1073/pnas.89.13.5942; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; THEILL LE, 1992, EMBO J, V11, P2261, DOI 10.1002/j.1460-2075.1992.tb05285.x; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; WONDISFORD FE, 1989, J BIOL CHEM, V264, P14601; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zanger K, 1999, MOL ENDOCRINOL, V13, P268, DOI 10.1210/me.13.2.268	49	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33365	33372		10.1074/jbc.M006819200	http://dx.doi.org/10.1074/jbc.M006819200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10931853	hybrid			2022-12-27	WOS:000090104600028
J	McIntosh, JM; Corpuz, GO; Layer, RT; Garrett, JE; Wagstaff, JD; Bulaj, G; Vyazovkina, A; Yoshikami, D; Cruz, LJ; Olivera, BM				McIntosh, JM; Corpuz, GO; Layer, RT; Garrett, JE; Wagstaff, JD; Bulaj, G; Vyazovkina, A; Yoshikami, D; Cruz, LJ; Olivera, BM			Isolation and characterization of a novel Conus peptide with apparent antinociceptive activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL NERVOUS-SYSTEM; MUSCARINIC CHOLINERGIC RECEPTORS; RAT-BRAIN MEMBRANES; SEROTONIN UPTAKE; SODIUM-CHANNELS; 5-HT3 RECEPTORS; SCIATIC-NERVE; BINDING-SITES; MARINE SNAIL; MOUSE-BRAIN	Cone snails are tropical marine mollusks that envenomate prey with a complex mixture of neuropharmacologically active compounds. We report the discovery and biochemical characterization of a structurally unique peptide isolated from the venom of Conus marmoreus, The new peptide, mr10a, potently increased withdrawal latency in a hot plate assay (a test of analgesia) at intrathecal doses that do not produce motor impairment as measured by rotarod test. The sequence of mr10a is NGVCCGYKLCHOC, where O is 4-trans-hydroxyproline. This sequence is highly divergent from all other known conotoxins, Analysis of a cDNA clone encoding the toxin, however, indicates that it is a member of the recently described T-superfamily, Total chemical synthesis of the three possible disulfide arrangements of mr10a was achieved, acid elution studies indicate that the native form has a disulfide connectivity of Cys1-Cys4 and Cys2-Cys3, This disulfide linkage is unprecedented among conotoxins and defines a new family of Conus peptides.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Psychiat, Salt Lake City, UT 84112 USA; Cognetix Inc, Salt Lake City, UT 84108 USA; Univ Philippines, Inst Marine Sci, Quezon City 1101, Philippines	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of the Philippines System; University of the Philippines Diliman	McIntosh, JM (corresponding author), Univ Utah, Dept Biol, 257 South 1400 East, Salt Lake City, UT 84112 USA.	mcintosh@biology.utah.edu			NIGMS NIH HHS [GM48677] Funding Source: Medline; NIMH NIH HHS [MH53631] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH053631, R01MH053631] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adams DJ, 1999, DRUG DEVELOP RES, V46, P219; AKIYAMA K, 1985, P NATL ACAD SCI USA, V82, P2543, DOI 10.1073/pnas.82.8.2543; BROWN NL, 1986, EUR J PHARMACOL, V123, P161, DOI 10.1016/0014-2999(86)90700-4; Buchanan S, 1996, NEUROSCI LETT, V219, P131, DOI 10.1016/S0304-3940(96)13189-X; CATTERALL WA, 1980, ANNU REV PHARMACOL, V20, P15, DOI 10.1146/annurev.pa.20.040180.000311; CHANG RSL, 1979, J NEUROCHEM, V32, P1653, DOI 10.1111/j.1471-4159.1979.tb02276.x; CLARK C, 1981, TOXICON, V19, P691, DOI 10.1016/0041-0101(81)90106-9; Craig AG, 1998, BIOCHEMISTRY-US, V37, P16019, DOI 10.1021/bi981690a; Craig AG, 1999, J BIOL CHEM, V274, P13752, DOI 10.1074/jbc.274.20.13752; CRUZ LJ, 1986, J BIOL CHEM, V261, P6230; DAMATO RJ, 1987, J PHARMACOL EXP THER, V242, P364; DODD J, 1983, J PHYSIOL-LONDON, V334, P255, DOI 10.1113/jphysiol.1983.sp014493; Ecker A., 1889, ANATOMY FROG; ENNA SJ, 1977, BRAIN RES, V124, P185, DOI 10.1016/0006-8993(77)90878-2; Erlanger J., 1937, AM J PSYCHIAT, V93, P1472, DOI [10.1176/AJP.93.6.1472-A, DOI 10.1176/AJP.93.6.1472-A]; FALCH E, 1986, J NEUROCHEM, V47, P898; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GILLAN MGC, 1982, BRIT J PHARMACOL, V77, P461, DOI 10.1111/j.1476-5381.1982.tb09319.x; GOEDERT M, 1984, BRAIN RES, V304, P71, DOI 10.1016/0006-8993(84)90862-X; GOLDSTEIN A, 1989, MOL PHARMACOL, V36, P265; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; GULLY D, 1993, P NATL ACAD SCI USA, V90, P65, DOI 10.1073/pnas.90.1.65; HAAKSMA EEJ, 1990, PHARMACOL THERAPEUT, V47, P73, DOI 10.1016/0163-7258(90)90046-5; HEADING C, 1999, CURR OPIN CPNS INVES, V1, P153; HILLYARD DR, 1992, NEURON, V9, P69, DOI 10.1016/0896-6273(92)90221-X; HOYER D, 1988, MOL PHARMACOL, V33, P303; HYLDEN JLK, 1980, EUR J PHARMACOL, V67, P313, DOI 10.1016/0014-2999(80)90515-4; JAVITCH JA, 1984, MOL PHARMACOL, V26, P35; Jones RM, 2000, CURR PHARM DESIGN, V6, P1249, DOI 10.2174/1381612003399653; KALARIA RN, 1989, J NEUROCHEM, V53, P1772, DOI 10.1111/j.1471-4159.1989.tb09242.x; KINOUCHI K, 1991, EUR J PHARM-MOLEC PH, V207, P135, DOI 10.1016/0922-4106(91)90088-Y; Kobayashi JI, 1996, NEUROSCI LETT, V221, P9, DOI 10.1016/S0304-3940(96)13269-9; LAHTI RA, 1985, EUR J PHARMACOL, V109, P281, DOI 10.1016/0014-2999(85)90431-5; LANGER SZ, 1981, EUR J PHARMACOL, V72, P423, DOI 10.1016/0014-2999(81)90592-6; LEHMANN J, 1988, J PHARMACOL EXP THER, V246, P65; Lu Y, 1998, J PHARMACOL EXP THER, V287, P648; LUMMIS SCR, 1990, EUR J PHARM-MOLEC PH, V189, P223, DOI 10.1016/0922-4106(90)90026-T; Luo SQ, 1998, J NEUROSCI, V18, P8571; LUTHIN GR, 1984, MOL PHARMACOL, V26, P164; LUTHIN GR, 1984, J PHARMACOL EXP THER, V228, P648; MADRAS BK, 1989, MOL PHARMACOL, V36, P518; MARTINEZMIR MI, 1990, BRAIN RES, V526, P322, DOI 10.1016/0006-8993(90)91240-H; McIntosh J M, 1999, Methods Enzymol, V294, P605; McIntosh JM, 2000, EUR J PHARMACOL, V393, P205, DOI 10.1016/S0014-2999(99)00887-0; MCINTOSH JM, 1995, J BIOL CHEM, V270, P16796, DOI 10.1074/jbc.270.28.16796; MCINTOSH JM, 1984, J BIOL CHEM, V259, P4343; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; MINNEMAN KP, 1979, MOL PHARMACOL, V16, P34; MURPHY DE, 1987, J PHARMACOL EXP THER, V240, P778; Olivera BM, 2001, TOXICON, V39, P7, DOI 10.1016/S0041-0101(00)00157-4; OROURKE MF, 1994, J PHARMACOL EXP THER, V268, P1362; PABREZA LA, 1991, MOL PHARMACOL, V39, P9; RAISMAN R, 1982, EUR J PHARMACOL, V78, P345, DOI 10.1016/0014-2999(82)90036-X; READER TA, 1987, J NEURAL TRANSM, V68, P79, DOI 10.1007/BF01244641; Rigby AC, 1999, P NATL ACAD SCI USA, V96, P5758, DOI 10.1073/pnas.96.10.5758; Rockel D, 1995, MANUAL LIVING CONIDA; ROTHMAN RB, 1992, PEPTIDES, V13, P977, DOI 10.1016/0196-9781(92)90059-C; RUIZGOMEZ A, 1989, J NEUROCHEM, V52, P1775, DOI 10.1111/j.1471-4159.1989.tb07256.x; SOFUOGLU M, 1992, EUR J PHARMACOL, V216, P273, DOI 10.1016/0014-2999(92)90370-J; Terlau H, 1996, NATURE, V381, P148, DOI 10.1038/381148a0; TIMMERMANS PBMWM, 1981, MOL PHARMACOL, V20, P295; TYERS MB, 1991, THERAPIE, V46, P431; Walker CS, 1999, J BIOL CHEM, V274, P30664, DOI 10.1074/jbc.274.43.30664; YAMAMURA HI, 1974, P NATL ACAD SCI USA, V71, P1725, DOI 10.1073/pnas.71.5.1725; YOUNG AB, 1974, MOL PHARMACOL, V10, P790	65	88	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32391	32397		10.1074/jbc.M003619200	http://dx.doi.org/10.1074/jbc.M003619200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10900201	hybrid			2022-12-27	WOS:000090003800004
J	Sudoh, M; Yamazaki, T; Masubuchi, K; Taniguchi, M; Shimma, N; Arisawa, M; Yamada-Okabe, H				Sudoh, M; Yamazaki, T; Masubuchi, K; Taniguchi, M; Shimma, N; Arisawa, M; Yamada-Okabe, H			Identification of a novel inhibitor specific to the fungal chitin synthase - Inhibition of chitin synthase 1 arrests the cell growth, but inhibition of chitin synthase 1 and 2 is lethal in the pathogenic fungus Candida albicans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE; EXPRESSION; YEAST	As in Saccharomyces cerevisiae, the pathogenic fungus Candida albicans harbors three chitin synthases called CaChs1p, CaChs2p, and CaChs3p, which are structurally and functionally analogous to the S. cerevisiae ScChs2p, ScChs1p, and ScChs3p, respectively. In S. cerevisiae, ScCHS1, ScCHS2, and ScCHS3 are all nonessential genes; only the simultaneous disruption of ScCHS2 and ScCHS3 is lethal. The fact that a null mutation of the CaCHS1 is impossible, however, implies that CaCHS1 is required for the viability of C. albicans. To gain more insight into the physiological importance of CaCHS1, we identified and characterized a novel inhibitor that was highly specific to CaChs1p. RO-09-3143 inhibited CaChs1p with a K-i value of 0.55 nM in a manner that was non-competitive to the substrate UDP-N-acetylglucosamine. RO-09-3143 also hampered the growth of the C. albicans cells with an MIC50 value of 0.27 muM. In the presence of RO-09-3143, the C. albicans cells failed to form septa and displayed an aberrant morphology, confirming the involvement of the C. albicans Chs1p in septum formation. Although the effect of RO-09-3143 on the wild-type C. albicans was fungistatic, it caused cell death in the cachs2 Delta null mutants but not in the cachs3 Delta null mutants. Thus, it appears that in C. albicans, inhibition of CaChs1p causes cell growth arrest, but simultaneous inhibition of CaChs1p and CaChs2p is lethal.	Nippon Roche Res Ctr, Dept Mycol & Oncol, Kamakura, Kanagawa 2478530, Japan; Nippon Roche Res Ctr, Dept Chem, Kamakura, Kanagawa 2478530, Japan	Roche Holding; Roche Holding	Yamada-Okabe, H (corresponding author), Nippon Roche Res Ctr, Dept Oncol, 200 Kajiwara, Kamakura, Kanagawa 2478530, Japan.	hisafumi.okabe@roche.com						AUYOUNG J, 1990, MOL MICROBIOL, V4, P197, DOI 10.1111/j.1365-2958.1990.tb00587.x; BULAWA C, 1995, P NATL ACAD SCI USA, V92, P6216; BULAWA CE, 1986, CELL, V46, P213, DOI 10.1016/0092-8674(86)90738-5; CABIB E, 1989, J CELL BIOL, V108, P1665, DOI 10.1083/jcb.108.5.1665; CABIB E, 1991, ANTIMICROB AGENTS CH, V35, P170, DOI 10.1128/AAC.35.1.170; CHENWU JL, 1992, MOL MICROBIOL, V6, P497, DOI 10.1111/j.1365-2958.1992.tb01494.x; DURAN A, 1978, J BIOL CHEM, V253, P4419; FONZI WA, 1993, GENETICS, V134, P717; GAUGHRAN JP, 1994, J BACTERIOL, V176, P5857, DOI 10.1128/JB.176.18.5857-5860.1994; GOW NAR, 1994, P NATL ACAD SCI USA, V91, P6216, DOI 10.1073/pnas.91.13.6216; Masubuchi K, 2000, BIOORG MED CHEM LETT, V10, P1459, DOI 10.1016/S0960-894X(00)00257-2; Mio T, 1996, J BACTERIOL, V178, P2416, DOI 10.1128/jb.178.8.2416-2419.1996; MOTOYAMA T, 1994, BIOSCI BIOTECH BIOCH, V58, P1685, DOI 10.1271/bbb.58.1685; Munro CA, 1998, MICROBIOL-SGM, V144, P391, DOI 10.1099/00221287-144-2-391; NAGAHASHI S, 1995, J BIOL CHEM, V270, P13961, DOI 10.1074/jbc.270.23.13961; Newbery G, 1928, J CHEM SOC, P3046, DOI 10.1039/jr9280003046; Sambrook J, 1989, MOL CLONING LAB MANU, V2; SBURLATI A, 1986, J BIOL CHEM, V261, P5147; SHAW JA, 1991, J CELL BIOL, V114, P111, DOI 10.1083/jcb.114.1.111; SILVERMAN SJ, 1988, P NATL ACAD SCI USA, V85, P4735, DOI 10.1073/pnas.85.13.4735; STGEORGIEV V, 1998, INFECT DIS IMMUNOCOM, P739; SUDOH M, 1995, MICROBIOL-UK, V141, P2673, DOI 10.1099/13500872-141-10-2673; SUDOH M, 1993, MOL GEN GENET, V241, P351, DOI 10.1007/BF00284688; VALDIVIESO MH, 1991, J CELL BIOL, V114, P101, DOI 10.1083/jcb.114.1.101	24	46	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32901	32905		10.1074/jbc.M003634200	http://dx.doi.org/10.1074/jbc.M003634200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10930406	hybrid			2022-12-27	WOS:000090003800072
J	Zhang, Y; Chen, Q				Zhang, Y; Chen, Q			Changes of matrilin forms during endochondral ossification - Molecular basis of oligomeric assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; HELICAL COILED-COIL; C-TERMINAL DOMAIN; EXTRACELLULAR-MATRIX; FILAMENTOUS NETWORK; X COLLAGEN; CARTILAGE; PROTEIN; EXPRESSION; FAMILY	To understand the molecular properties of matrilin-3, a newly discovered member of the novel extracellular matrix protein family, we cloned a MAT-3 cDNA from developing chicken sterna. Real time quantitative reverse-transcription polymerase chain reaction indicates that MAT-3 mRNA is mainly expressed in the proliferation zone of a growth plate. It is also expressed in the maturation zone, overlapping with that of the mature chondrocyte-abundant matrilin-1 mRNA This suggests that matrilin-3 may self-assemble in the proliferation zone, in addition to its co-assembly with matrilin-1 during endochondral ossification. Transfection of a MAT-3 cDNA into COS-7 cells shows that MAT-3 predominantly forms a homotetramer but also a trimer and a dimer. Co-transfection of both MAT-3 and MAT-I cDNAs results in three major matrilins as follows: (MAT-1)(3), (MAT-3)(4), and (MAT-1)(2)(MAT-3)(2), Thus matrilin-3 may assemble into both homotypic and heterotypic oligomers, Our analysis shows that the assembly of MAT-3 does not depend on the number of epidermal growth factor repeats within the molecule, but the presence of Cys(412) and Cys(414) within the coiled-coil domain, which form covalent disulfide linkage responsible for both homooligomerization of MAT-3 and hetero-oligomerization of MAT-3 and MAT-1. Our data suggest that the varying synthetic levels of matrilins in different zones of a growth plate may result in a change of matrilin oligomeric forms during endochondral ossification.	Penn State Univ, Coll Med, Dept Orthopaed & Rehabil, Musculoskeletal Res Lab, Hershey, PA 17033 USA; Penn State Univ, Coll Med, Dept Cell & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Chen, Q (corresponding author), Penn State Univ, Coll Med, Dept Orthopaed & Rehabil, Musculoskeletal Res Lab, Hershey, PA 17033 USA.		Chen, Qian/C-4354-2011	Chen, Qian/0000-0003-4406-5618	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM104937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG014399, R01AG014399] Funding Source: NIH RePORTER; NIA NIH HHS [AG14399, AG00811] Funding Source: Medline; NIGMS NIH HHS [P20 GM104937] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beck K, 1996, J MOL BIOL, V256, P909, DOI 10.1006/jmbi.1996.0137; CHEN Q, 1995, DEV BIOL, V172, P293, DOI 10.1006/dbio.1995.0024; CHEN Q, 1995, MOL BIOL CELL, V6, P1743, DOI 10.1091/mbc.6.12.1743; Chen Q, 1999, MOL BIOL CELL, V10, P2149, DOI 10.1091/mbc.10.7.2149; Deak F, 1999, MATRIX BIOL, V18, P55, DOI 10.1016/S0945-053X(98)00006-7; Deak F, 1997, J BIOL CHEM, V272, P9268; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HAUDENSCHILD DR, 1995, J BIOL CHEM, V270, P23150, DOI 10.1074/jbc.270.39.23150; KISS I, 1989, J BIOL CHEM, V264, P8126; NINOMIYA Y, 1986, J BIOL CHEM, V261, P5041; Pan OH, 1998, J BIOL CHEM, V273, P14205, DOI 10.1074/jbc.273.23.14205; PAULSSON M, 1979, BIOCHEM J, V183, P539, DOI 10.1042/bj1830539; Piecha D, 1999, J BIOL CHEM, V274, P13353, DOI 10.1074/jbc.274.19.13353; Sambrook J., 2002, MOL CLONING LAB MANU; Suryanarayana K, 1998, AIDS RES HUM RETROV, V14, P183, DOI 10.1089/aid.1998.14.183; Wagener R, 1997, FEBS LETT, V413, P129, DOI 10.1016/S0014-5793(97)00895-8; WINTERBOTTOM N, 1992, DEV DYNAM, V193, P266, DOI 10.1002/aja.1001930307; Wu JJ, 1998, J BIOL CHEM, V273, P17433, DOI 10.1074/jbc.273.28.17433; Wu QQ, 2000, EXP CELL RES, V256, P383, DOI 10.1006/excr.2000.4847; Zhang Y, 1999, J BIOL CHEM, V274, P22409, DOI 10.1074/jbc.274.32.22409	20	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32628	32634		10.1074/jbc.M002594200	http://dx.doi.org/10.1074/jbc.M002594200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10930403	hybrid			2022-12-27	WOS:000090003800036
J	Uttaro, AD; Altabe, SG; Rider, MH; Michels, PAM; Opperdoes, FR				Uttaro, AD; Altabe, SG; Rider, MH; Michels, PAM; Opperdoes, FR			A family of highly conserved glycosomal 2-hydroxyacid dehydrogenases from Phytomonas sp.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALATE-DEHYDROGENASE; TRYPANOSOMA-BRUCEI; MOLECULAR-CLONING; LACTATE-DEHYDROGENASE; EUPHORBIA-CHARACIAS; ESCHERICHIA-COLI; PROTEIN; MITOCHONDRIAL; EXPRESSION; METABOLISM	Phytomonas sp. contains two malate dehydrogenase isoforms, a mitochondrial isoenzyme with a high specificity for oxaloacetate and a glycosomal isozyme that acts on a broad range of substrates (Uttaro, A. D., and Opperdoes, F.R, (1997) Mol. Biochem. Parasitol. 89, 51-59). Here, we show that the low specificity of the latter isoenzyme is the result of a number of recent gene duplications that gave rise to a family of glycosomal 2-hydroxyacid dehydrogenase genes. Two of these genes were cloned, sequenced, and overexpressed in Escherichia coli. Although both gene products have 322 amino acids, share 90.4% identical residues, and have a similar hydrophobicity profile and net charge, their kinetic properties were strikingly different. One isoform behaved as a real malate dehydrogenase with a high specificity for oxaloacetate, whereas the other showed no activity with oxaloacetate but was able to reduce other oxoacids, such as phenyl pyruvate, 2-oxoisocaproate, 2-oxovalerate, 2-oxobutyrate, 2-oxo-4-methiolbutyrate, and pyruvate.	Christian de Duve Inst Cellular Pathol, ICP, Trop Dis Res Unit, B-1200 Brussels, Belgium; Catholic Univ Louvain, B-1200 Brussels, Belgium; Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Dept Microbiol, RA-2000 Rosario, Santa Fe, Argentina; Christian de Duve Inst Cellular Pathol, Hormone & Metab Res Unit, B-1200 Brussels, Belgium	Universite Catholique Louvain; National University of Rosario	Opperdoes, FR (corresponding author), Christian de Duve Inst Cellular Pathol, ICP, Trop Dis Res Unit, B-1200 Brussels, Belgium.	opperdoes@trop.ucl.ac.be	Opperdoes, Fred/N-9922-2019; Michels, Paul A/A-5637-2009; Opperdoes, Frederik R/C-8897-2018	Opperdoes, Fred/0000-0003-1984-3764; Michels, Paul A/0000-0003-3726-6104; Opperdoes, Frederik R/0000-0003-1984-3764				ALLERT S, 1991, EUR J BIOCHEM, V200, P19, DOI 10.1111/j.1432-1033.1991.tb21043.x; Anderson SA, 1998, EXP PARASITOL, V89, P63, DOI 10.1006/expr.1998.4260; Anderson SA, 1998, MOL BIOCHEM PARASIT, V96, P185, DOI 10.1016/S0166-6851(98)00116-9; BANASZAK LJ, 1975, ENZYMES, V11, P369; BIRKTOFT JJ, 1982, P NATL ACAD SCI-BIOL, V79, P6166, DOI 10.1073/pnas.79.20.6166; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAUMONT F, 1994, MOL BIOCHEM PARASIT, V67, P321, DOI 10.1016/0166-6851(94)00141-3; Chua N. H, 1980, METHOD ENZYMOL, V69, P434; DOLLET M, 1982, CR ACAD SCI III-VIE, V295, P547; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; Hannaert V, 1998, J MOL EVOL, V47, P728, DOI 10.1007/PL00006432; Hunter GR, 2000, MOL BIOCHEM PARASIT, V105, P203, DOI 10.1016/S0166-6851(99)00176-0; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAKE JA, 1988, P NATL ACAD SCI USA, V85, P4779, DOI 10.1073/pnas.85.13.4779; Musrati RA, 1998, GEN PHYSIOL BIOPHYS, V17, P193; NICHOLLS DJ, 1992, BIOCHEM BIOPH RES CO, V189, P1057, DOI 10.1016/0006-291X(92)92311-K; PARK SJ, 1995, J BACTERIOL, V177, P6652, DOI 10.1128/jb.177.22.6652-6656.1995; RIDER MH, 1995, EUR J BIOCHEM, V230, P258; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANCHEZMORENO M, 1992, MOL BIOCHEM PARASIT, V54, P185, DOI 10.1016/0166-6851(92)90111-V; SMITH K, 1984, J BACTERIOL, V157, P684, DOI 10.1128/JB.157.2.684-687.1984; Stevens JR, 1999, PARASITOL TODAY, V15, P432, DOI 10.1016/S0169-4758(99)01532-X; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; SUNDARAM TK, 1980, BIOCHEMISTRY-US, V19, P2017, DOI 10.1021/bi00551a002; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uttaro AD, 1997, MOL BIOCHEM PARASIT, V89, P51, DOI 10.1016/S0166-6851(97)00100-X; Uttaro AD, 1997, MOL BIOCHEM PARASIT, V90, P337, DOI 10.1016/S0166-6851(97)00142-4; WILKS HM, 1988, SCIENCE, V242, P1541, DOI 10.1126/science.3201242	30	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31833	31837		10.1074/jbc.M006080200	http://dx.doi.org/10.1074/jbc.M006080200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10900211	hybrid			2022-12-27	WOS:000089858900042
J	Hu, SM; Yang, XL				Hu, SM; Yang, XL			dFADD, a novel death domain-containing adapter protein for the Drosophila caspase DREDD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; C-ELEGANS; APOPTOSIS; ACTIVATION; OLIGOMERIZATION; CED-4; PROCASPASE-9; INTERACTS; GENETICS; PATHWAY	Apoptotic cell death occurs through activation of procaspases, the precursors of a group of aspartate-specific cysteine proteases known as caspases. Procaspase activation is mediated by death adapter proteins such as the mammalian proteins FADD and Apaf-1 and the Caenorhabditis elegans protein CED-4. These adapters bind to procaspases and facilitate oligomerization and subsequent auto-proteolytic processing of the zymogens, Here we report cloning and characterization of dFADD, a FADD homologue in Drosophila. dFADD contains a death domain that is highly homologous to the FADD death domain, and it also shares a novel domain with;a Drosophila caspase DREDD, which we call death-inducing domain, dFADD binds to DREDD through the death-inducing domain and enhances the cell death activity and proteolytic processing of DREDD. dFADD and DREDD are stabilized by their interaction. The structural and functional similarities between dFADD and FADD suggest the existence of a FADD-like apoptosis pathway in Drosophila.	Univ Penn, Sch Med, Dept Mol & Cellular Engn, Philadelphia, PA 19104 USA	University of Pennsylvania	Yang, XL (corresponding author), Univ Penn, Sch Med, Dept Mol & Cellular Engn, 421 Curie Blvd,610 BRBII-III, Philadelphia, PA 19104 USA.		Hu, Shimin/H-3427-2019	Hu, Shimin/0000-0001-7110-3814				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chen P, 1998, DEV BIOL, V201, P202, DOI 10.1006/dbio.1998.9000; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kanuka H, 1999, MOL CELL, V4, P757, DOI 10.1016/S1097-2765(00)80386-X; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Zhou L, 1999, MOL CELL, V4, P745, DOI 10.1016/S1097-2765(00)80385-8; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	31	102	116	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30761	30764		10.1074/jbc.C000341200	http://dx.doi.org/10.1074/jbc.C000341200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10934188	hybrid			2022-12-27	WOS:000089762700005
J	Ishigaki, Y; Oikawa, S; Suzuki, T; Usui, S; Magoori, K; Kim, DH; Suzuki, H; Sasaki, J; Sasano, H; Okazaki, M; Toyota, T; Saito, T; Yamamoto, TT				Ishigaki, Y; Oikawa, S; Suzuki, T; Usui, S; Magoori, K; Kim, DH; Suzuki, H; Sasaki, J; Sasano, H; Okazaki, M; Toyota, T; Saito, T; Yamamoto, TT			Virus-mediated transduction of apolipoprotein E (ApoE)-Sendai develops lipoprotein glomerulopathy in ApoE-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID DELETION; MUTATION; RECEPTOR; GENE; HYPERCHOLESTEROLEMIA; ATHEROSCLEROSIS; PROTEIN	Lipoprotein glomerulopathy (LPG) is a unique renal disease characterized by thrombus-like substances in markedly dilated glomerular capillaries, dysbetalipoproteinemia, and elevated plasma concentrations of apoE, Recent studies identified several apoE mutations in patients with LPG, including apoE2(R145P) Sendai (apoE-Sendai). Virus-mediated transduction of apoE-Sendai in apoE-deficient hypercholesterolemic mice resulted in insufficient correction of hypercholesterolemia and a marked and temporal induction of plasma triglyceride levels. In vitro binding studies showed that apoE-Sendai has a reduced affinity for the low density lipoprotein receptor, suggesting that dysbetalipoproteinemia in LPG is caused by the apoE mutation. Furthermore, histological examination revealed marked intraglomerular depositions of apoE-containing lipoproteins in mice injected with apoE-Sendai virus. These LPG-like depositions were detected 6 days after virus injection and were sustained for at least 60 days. Our results demonstrated that apoE-Sendai is an etiological cause of LPG.	Tohoku Univ, Ctr Gene Res, Sendai, Miyagi 9818555, Japan; Tohoku Univ, Sch Med, Dept Pathol, Sendai, Miyagi 9808574, Japan; Tohoku Univ, Sch Med, Dept Internal Med 3, Sendai, Miyagi 9808574, Japan; Tokyo Med & Dent Univ, Coll Liberal Arts & Sci, Chem Lab, Chiba 2820827, Japan; Fukuoka Univ, Sch Med, Dept Internal Med, Fukuoka 8140180, Japan	Tohoku University; Tohoku University; Tohoku University; Tokyo Medical & Dental University (TMDU); Fukuoka University	Yamamoto, TT (corresponding author), Tohoku Univ, Ctr Gene Res, 1-1 Tsutsumidori Amamiya, Sendai, Miyagi 9818555, Japan.		USUI, Shinichi/B-1800-2011	USUI, Shinichi/0000-0002-9671-9866				Ando M, 1999, KIDNEY INT, V56, P1317, DOI 10.1046/j.1523-1755.1999.00677.x; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Boren J, 1998, J CLIN INVEST, V101, P2658, DOI 10.1172/JCI2265; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; KASHYAP VS, 1995, J CLIN INVEST, V96, P1612, DOI 10.1172/JCI118200; Konishi K, 1999, NEPHRON, V83, P214, DOI 10.1159/000045513; MAHLEY RW, 1991, JAMA-J AM MED ASSOC, V265, P78, DOI 10.1001/jama.265.1.78; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Matsunaga A, 1999, KIDNEY INT, V56, P421, DOI 10.1046/j.1523-1755.1999.00572.x; Ogawa T, 2000, PEDIATR NEPHROL, V14, P149, DOI 10.1007/s004670050032; Oikawa S, 1997, J AM SOC NEPHROL, V8, P820; OIKAWA S, 1991, AM J KIDNEY DIS, V18, P553, DOI 10.1016/S0272-6386(12)80649-4; Okazaki M, 1998, J CHROMATOGR B, V709, P179, DOI 10.1016/S0378-4347(98)00064-4; OKAZAKI M, 2000, HDB LIPOPROTEIN TEST, P647; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; SAITO T, 1989, AM J KIDNEY DIS, V13, P148, DOI 10.1016/S0272-6386(89)80134-9; Saito T, 1999, NEPHRON, V83, P193, DOI 10.1159/000045511; SHIBUI T, 1991, J BIOTECHNOL, V17, P109, DOI 10.1016/0168-1656(91)90002-D; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; Tsukamoto K, 1997, J CLIN INVEST, V100, P107, DOI 10.1172/JCI119501; Usui S, 2000, CLIN CHEM, V46, P63; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	23	52	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31269	31273		10.1074/jbc.M005906200	http://dx.doi.org/10.1074/jbc.M005906200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10903326	hybrid			2022-12-27	WOS:000089762700074
J	Kishi, H; Ascoli, M				Kishi, H; Ascoli, M			Multiple distant amino acid residues present in the serpentine region of the follitropin receptor modulate the rate of agonist-induced internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; C-TERMINAL TAIL; LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; MUSCARINIC ACETYLCHOLINE-RECEPTOR; FOLLICLE-STIMULATING-HORMONE; LUTROPIN/CHORIOGONADOTROPIN RECEPTOR; INDUCED PHOSPHORYLATION; MEDIATED ENDOCYTOSIS; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING	The amino acid sequences of the human (h) and rat (r) follitropin receptors (FSHR) are similar to 89% identical, but the half-time of internalization of agonist mediated by the rFSHR is similar to 3 times faster than that of the hFSHR. Chimeras of the hFSHR and the rFSHR showed that this difference in rate is dictated mostly by the serpentine domain. Further analysis identified six residues, two non-contiguous residues in the transmembrane helix 4 (Leu/Thr in the rFSHR and Met/Ile in the hFSHR), three non-contiguous residues in the third intracellular loop (Thr/Thr/Lys in the rFSHR and Ile/Asn/Arg in the hFSHR), and one in transmembrane helix 7 (Tyr in the rFSHR and His in the hFSHR) that are fully responsible for the difference in the rates of internalization of the hFSHR and the rFSHR.	Univ Iowa, Dept Pharmacol, Iowa City, IA 52242 USA	University of Iowa	Ascoli, M (corresponding author), Univ Iowa, Dept Pharmacol, 2-319B,51 Newton Rd, Iowa City, IA 52242 USA.		Kishi, Hiroko/AAR-9148-2021	Kishi, Hiroko/0000-0003-2896-7355	NICHD NIH HHS [HD-28962] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028962] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASCOLI M, 1984, J CELL BIOL, V99, P1242, DOI 10.1083/jcb.99.4.1242; ASCOLI M, 1978, P NATL ACAD SCI USA, V75, P99, DOI 10.1073/pnas.75.1.99; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Baratti-Elbaz C, 1999, MOL ENDOCRINOL, V13, P1751, DOI 10.1210/me.13.10.1751; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Bunemann M, 1999, ANNU REV PHYSIOL, V61, P169, DOI 10.1146/annurev.physiol.61.1.169; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; CODINA J, 1994, J BIOL CHEM, V269, P29339; Fanelli F, 2000, J MOL BIOL, V296, P1333, DOI 10.1006/jmbi.2000.3516; Faussner A, 1998, J BIOL CHEM, V273, P2617, DOI 10.1074/jbc.273.5.2617; Ferguson SSG, 1998, SEMIN CELL DEV BIOL, V9, P119, DOI 10.1006/scdb.1997.0216; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; GHINEA N, 1992, J CELL BIOL, V118, P1347, DOI 10.1083/jcb.118.6.1347; GOODMAN J, 1996, NATURE, V383, P447; Hauser F, 1997, J BIOL CHEM, V272, P1002, DOI 10.1074/jbc.272.2.1002; HIPKIN RW, 1995, J BIOL CHEM, V270, P26683, DOI 10.1074/jbc.270.44.26683; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1830, DOI 10.1210/me.12.12.1830; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lazari MDM, 1999, MOL ENDOCRINOL, V13, P866, DOI 10.1210/me.13.6.866; Lazari RDM, 1998, J BIOL CHEM, V273, P18316, DOI 10.1074/jbc.273.29.18316; Lee KB, 2000, J BIOL CHEM, V275, P9284, DOI 10.1074/jbc.275.13.9284; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; Martens JWM, 1998, MOL ENDOCRINOL, V12, P775, DOI 10.1210/me.12.6.775; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MINEGISH T, 1990, BIOCHEM BIOPH RES CO, V172, P1049, DOI 10.1016/0006-291X(90)91552-4; MINEGISH T, 1991, BIOCHEM BIOPH RES CO, V175, P1125, DOI 10.1016/0006-291X(91)91682-3; Mukherjee S, 1999, J BIOL CHEM, V274, P12984, DOI 10.1074/jbc.274.19.12984; Nakamura K, 1998, MOL ENDOCRINOL, V12, P580, DOI 10.1210/me.12.4.580; Nakamura K, 1999, J BIOL CHEM, V274, P25426, DOI 10.1074/jbc.274.36.25426; Nakamura K, 2000, J BIOL CHEM, V275, P241, DOI 10.1074/jbc.275.1.241; Nakamura K, 1999, MOL PHARMACOL, V56, P728; Nakamura K, 1999, MOL ENDOCRINOL, V13, P1295, DOI 10.1210/me.13.8.1295; Nakamura K, 1998, J BIOL CHEM, V273, P24346, DOI 10.1074/jbc.273.38.24346; NOTHACKER HP, 1993, BIOCHEM BIOPH RES CO, V197, P1062, DOI 10.1006/bbrc.1993.2586; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; Rapoport B, 1998, ENDOCR REV, V19, P673, DOI 10.1210/er.19.6.673; Riezman H, 1997, CELL, V91, P731, DOI 10.1016/S0092-8674(00)80461-4; Schlador ML, 2000, J BIOL CHEM, V275, P23295, DOI 10.1074/jbc.M002380200; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; TENSEN CP, 1994, P NATL ACAD SCI USA, V91, P4816, DOI 10.1073/pnas.91.11.4816; WILEY HS, 1982, J BIOL CHEM, V257, P4222; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836	55	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31030	31037		10.1074/jbc.M005528200	http://dx.doi.org/10.1074/jbc.M005528200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10915803	hybrid			2022-12-27	WOS:000089762700043
J	Outten, FW; Outten, CE; Hale, J; O'Halloran, TV				Outten, FW; Outten, CE; Hale, J; O'Halloran, TV			Transcriptional activation of an Escherichia coli copper efflux regulon by the chromosomal MerR homologue, CueR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-GENETICS; RESISTANCE; REPRESSOR; TRANSPORT; PROTEIN	Because copper ions are both essential cofactors and cytotoxic agents, the net accumulation of this element in a cell must be carefully balanced. Depending upon the cellular copper status, copper ions must either be imported or ejected. CopA, the principal copper efflux ATPase in Escherichia coli, is induced by elevated copper in the medium, but the copper-sensing regulatory factor is unknown. Inspection of the copA promoter reveals signature elements of promoters controlled by metalloregulatory proteins in the MerR family. These same elements are also present upstream of yacK, which encodes a putative multi-copper oxidase. Homologues of YacK are found in copper resistance determinants that facilitate copper efflux. Here we show by targeted gene deletion and promoter fusion assays that both copA and yacK are regulated in a copper-responsive manner by the MerR homologue, ybbI. We have designated ybbI as cueR for the Cu efflux regulator. This represents the first example of a copper-responsive regulon on the E. coli chromosome and further extends the roles of MerR family members in prokaryotic stress response.	Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University; Northwestern University	O'Halloran, TV (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.	t-ohalloran@northwestern.edu	O'Halloran, Thomas/ABE-6125-2021; Outten, Caryn E./I-9433-2019	O'Halloran, Thomas/0000-0001-8732-5059; Outten, Caryn E./0000-0003-0335-6531; Outten, Franklin/0000-0002-9095-0194	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038784, T32GM008061, R01GM054111, T32GM008382] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM08061, R01 GM38784, T32 GM08382, R01 GM054111] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI AZ, 1995, NATURE, V374, P371; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Brocklehurst KR, 1999, MOL MICROBIOL, V31, P893, DOI 10.1046/j.1365-2958.1999.01229.x; BROWN NL, 1995, MOL MICROBIOL, V17, P1153, DOI 10.1111/j.1365-2958.1995.mmi_17061153.x; Bryson J. W., 1993, BIOINORGANIC CHEM CO, P101; COOKSEY DA, 1994, FEMS MICROBIOL REV, V14, P381, DOI 10.1016/0168-6445(94)90056-6; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; De Wulf P, 1999, J BACTERIOL, V181, P6772, DOI 10.1128/JB.181.21.6772-6778.1999; FONG ST, 1995, MOL MICROBIOL, V15, P1127, DOI 10.1111/j.1365-2958.1995.tb02286.x; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LUND PA, 1989, J MOL BIOL, V205, P343, DOI 10.1016/0022-2836(89)90345-8; MELLANO MA, 1988, J BACTERIOL, V170, P2879, DOI 10.1128/jb.170.6.2879-2883.1988; MESSERSCHMIDT A, 1989, J MOL BIOL, V206, P513, DOI 10.1016/0022-2836(89)90498-1; Munson GP, 2000, J BACTERIOL, V182, P5864, DOI 10.1128/JB.182.20.5864-5871.2000; NUNOSHIBA T, 1992, J BACTERIOL, V174, P6054, DOI 10.1128/JB.174.19.6054-6060.1992; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; Outten CE, 1999, J BIOL CHEM, V274, P37517, DOI 10.1074/jbc.274.53.37517; Outten FW, 2000, BACTERIAL STRESS RESPONSES, P145; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Rensing C, 2000, P NATL ACAD SCI USA, V97, P652, DOI 10.1073/pnas.97.2.652; SAIER MH, 1994, MOL MICROBIOL, V11, P841, DOI 10.1111/j.1365-2958.1994.tb00362.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; Stanley NR, 2000, J BIOL CHEM, V275, P11591, DOI 10.1074/jbc.275.16.11591; Strausak D, 1997, J BIOL CHEM, V272, P8932	26	237	247	2	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31024	31029		10.1074/jbc.M006508200	http://dx.doi.org/10.1074/jbc.M006508200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10915804	Green Published, hybrid			2022-12-27	WOS:000089762700042
J	Weihofen, A; Lemberg, MK; Ploegh, HL; Bogyo, M; Martoglio, B				Weihofen, A; Lemberg, MK; Ploegh, HL; Bogyo, M; Martoglio, B			Release of signal peptide fragments into the cytosol requires cleavage in the transmembrane region by a protease activity that is specifically blocked by a novel cysteine protease inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-DERIVED PEPTIDES; HLA-E BINDS; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; ROUGH MICROSOMES; CATHEPSIN-K; TRANSLOCATION; MEMBRANE; SITE; TRANSCRIPTION	Signal peptides of secretory and membrane proteins are generated by proteolytic processing of precursor proteins after insertion into the endoplasmic reticulum membrane. Liberated signal peptides can be further processed, and the resulting N-terminal fragments are released toward the cytosol, where they may interact with target proteins like calmodulin. We show here that the processing of signal peptides requires a protease activity distinct from signal peptidase, This activity is inhibited specifically with a newly developed cysteine protease inhibitor, 1,3-di-(N-carboxybenzoyl-L-leucyl-L-leucyl)amino acetone ((Z-LL)(2) ketone). Inhibitor studies revealed that the final, (Z-LL)(2) ketone sensitive cleavage event occurs within the hydrophobic transmembrane region of the signal peptide, thus promoting the release of an N-terminal fragment into the cytosol.	ETH Zentrum, Inst Biochem, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Martoglio, B (corresponding author), ETH Zentrum, Inst Biochem, Universitatstr 16, CH-8092 Zurich, Switzerland.	bruno.martoglio@bc.biol.ethz.ch	Lemberg, Marius K/B-8881-2016; Weihofen, Andreas/A-1566-2011	Lemberg, Marius K/0000-0002-0996-1268; Weihofen, Andreas/0000-0001-6265-9087; Bogyo, Matthew/0000-0003-3753-4412				An FY, 1999, J BACTERIOL, V181, P5915, DOI 10.1128/JB.181.19.5915-5921.1999; Bai AL, 1997, J IMMUNOL, V159, P2139; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; Borrego F, 1998, J EXP MED, V187, P813, DOI 10.1084/jem.187.5.813; Braud V, 1997, EUR J IMMUNOL, V27, P1164, DOI 10.1002/eji.1830270517; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; GILMORE R, 1991, METHOD CELL BIOL, V34, P223; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; HAUSER S, 1995, EMBO J, V14, P5485, DOI 10.1002/j.1460-2075.1995.tb00235.x; HIGH S, 1993, J BIOL CHEM, V268, P26745; Klappa P, 1996, EUR J BIOCHEM, V239, P509, DOI 10.1111/j.1432-1033.1996.0509u.x; LYKO F, 1995, J BIOL CHEM, V270, P19873, DOI 10.1074/jbc.270.34.19873; Marquis RW, 1999, BIOORGAN MED CHEM, V7, P581, DOI 10.1016/S0968-0896(99)00011-5; Marquis RW, 1998, J MED CHEM, V41, P3563, DOI 10.1021/jm980295f; Martoglio B, 1999, PROTOPLASMA, V207, P141, DOI 10.1007/BF01282993; Martoglio B, 1997, EMBO J, V16, P6636, DOI 10.1093/emboj/16.22.6636; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; Martoglio B, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P265; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; NILSSON I, 1993, J BIOL CHEM, V268, P5798; NOVAK P, 1988, J BACTERIOL, V170, P5067, DOI 10.1128/jb.170.11.5067-5075.1988; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Rudner DZ, 1999, P NATL ACAD SCI USA, V96, P14765, DOI 10.1073/pnas.96.26.14765; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; Stroud RM, 1999, CURR OPIN STRUC BIOL, V9, P754, DOI 10.1016/S0959-440X(99)00040-8; van Klompenburg W, 1998, J MEMBRANE BIOL, V162, P1, DOI 10.1007/s002329900336; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332	33	100	113	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30951	30956		10.1074/jbc.M005980200	http://dx.doi.org/10.1074/jbc.M005980200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10921927	hybrid			2022-12-27	WOS:000089762700032
J	Chen, SY; Sarlis, NJ; Simons, SS				Chen, SY; Sarlis, NJ; Simons, SS			Evidence for a common step in three different processes for modulating the kinetic properties of glucocorticoid receptor-induced gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING-PROTEIN; TYROSINE AMINOTRANSFERASE GENE; THYROID-HORMONE RECEPTOR; ESTROGEN-REGULATED RNAS; NUCLEAR RECEPTORS; HISTONE ACETYLTRANSFERASE; PROMOTER-CONTEXT; AGONIST ACTIVITY; DEPENDENT TRANSCRIPTION; COACTIVATOR COMPLEXES	The dose-response curve of steroid hormones and the associated EC50 value are critical parameters both in the development of new pharmacologically active compounds and in the endocrine therapy of various disease states. We have recently described three different variables that can reposition the dose-response curve of agonist-bound glucocorticoid receptors (GRs): a 21-base pair sequence of the rat tyrosine aminotransferase gene called a glucocorticoid modulatory element (GME), GR concentration, and coactivator concentration, At the same time, each of these three components was found to influence the partial agonist activity of antiglucocorticoids. In an effort to determine whether these three processes proceed via independent pathways or a common intermediate, we have examined several mechanistic details. The effects of increasing concentrations of both GR and the coactivator TIF2 are found to be saturable. Furthermore, saturating levels of either GR or TIF2 inhibit the ability of each protein, and the GME, to affect further changes in the dose-response curve or partial agonist activity of antisteroids. This competitive inhibition suggests that all three modulators proceed through a common step involving a titratable factor. Support for this hypothesis comes from the observation that a fragment of the coactivator TIF2 retaining intrinsic transactivation activity is a dominant negative inhibitor of each component (GME, GR, and coactivator). This inhibition was not due to nonspecific effects on the general transcription machinery as the VP16 transactivation domain was inactive. The viral protein E1A also prevented the action of each of the three components in a manner that was independent of E1A's ability to block the histone acetyltransferase activity of CBP. Collectively, these results suggest that three different inputs (GME, GR, and coactivator) for perturbing the dose-response curve, and partial agonist activity, of GR-steroid complexes act by converging at a single step that involves a limiting factor prior to transcription initiation.	NIDDKD, Steroid Hormones Sect, Mol & Cellular Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Simons, SS (corresponding author), NIDDKD, Steroid Hormones Sect, Mol & Cellular Biol Lab, NIH, Bldg 8,Rm B2A-07, Bethesda, MD 20892 USA.		Sarlis, Nicholas/AAN-9444-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK057800, ZIADK057800] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AMARA JF, 1987, ENDOCRINOLOGY, V120, P264, DOI 10.1210/endo-120-1-264; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BAXTER JD, 1971, P NATL ACAD SCI USA, V68, P932, DOI 10.1073/pnas.68.5.932; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; CHAKRABORTI PK, 1991, J BIOL CHEM, V266, P22075; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Collier CD, 1996, MOL ENDOCRINOL, V10, P463, DOI 10.1210/me.10.5.463; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; EVANS MI, 1987, P NATL ACAD SCI USA, V84, P8493, DOI 10.1073/pnas.84.23.8493; Flint J, 1997, ANNU REV GENET, V31, P177, DOI 10.1146/annurev.genet.31.1.177; Folkers GE, 1998, J BIOL CHEM, V273, P32200, DOI 10.1074/jbc.273.48.32200; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Freedman LP, 1999, TRENDS ENDOCRIN MET, V10, P403, DOI 10.1016/S1043-2760(99)00208-8; Gee AC, 1999, MOL ENDOCRINOL, V13, P1912, DOI 10.1210/me.13.11.1912; Glass CK, 2000, GENE DEV, V14, P121; Guido EC, 1996, MOL ENDOCRINOL, V10, P1178, DOI 10.1210/me.10.10.1178; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1999, J BIOL CHEM, V274, P3496, DOI 10.1074/jbc.274.6.3496; Jackson DA, 1998, J STEROID BIOCHEM, V66, P79, DOI 10.1016/S0960-0760(98)00048-X; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kaul S, 2000, MOL ENDOCRINOL, V14, P1010, DOI 10.1210/me.14.7.1010; KAUL S, 1999, ENDOCR SOC P, V3, P284; Kino T, 1999, J STEROID BIOCHEM, V70, P15, DOI 10.1016/S0960-0760(99)00100-4; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Li Q, 1999, EMBO J, V18, P5634, DOI 10.1093/emboj/18.20.5634; Liu Z, 1999, P NATL ACAD SCI USA, V96, P9485, DOI 10.1073/pnas.96.17.9485; MAHLER HR, 1966, BIOL CHEM, P250; MAY FEB, 1988, J BIOL CHEM, V263, P12901; MERCIER L, 1983, ENDOCRINOLOGY, V112, P601, DOI 10.1210/endo-112-2-601; MERCIER L, 1986, J STEROID BIOCHEM, V25, P11, DOI 10.1016/0022-4731(86)90275-X; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Misiti S, 1998, ENDOCRINOLOGY, V139, P2493, DOI 10.1210/en.139.5.2493; MUNCK A, 1984, J BIOL CHEM, V259, P820; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ONATE SA, 1995, SCIENCE, V270, P1354; OSHIMA H, 1995, J BIOL CHEM, V270, P21893, DOI 10.1074/jbc.270.37.21893; OSHIMA H, 1993, J BIOL CHEM, V268, P26858; OSHIMA H, 1992, MOL ENDOCRINOL, V6, P416, DOI 10.1210/me.6.3.416; OSHIMA H, 1992, ENDOCRINOLOGY, V130, P2106, DOI 10.1210/en.130.4.2106; Perissi V, 1999, P NATL ACAD SCI USA, V96, P3652, DOI 10.1073/pnas.96.7.3652; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; ROUSSEAU GG, 1977, J STEROID BIOCHEM, V8, P911, DOI 10.1016/0022-4731(77)90187-X; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Sarlis NJ, 1999, J STEROID BIOCHEM, V68, P89, DOI 10.1016/S0960-0760(99)00021-7; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; SIMONS SS, 1980, J ORG CHEM, V45, P3084, DOI 10.1021/jo01303a030; SIMONS SS, 1992, MOL ENDOCRINOL, V6, P995, DOI 10.1210/me.6.7.995; SISTARE FD, 1987, MOL ENDOCRINOL, V1, P648, DOI 10.1210/mend-1-9-648; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Szapary D, 1996, J BIOL CHEM, V271, P30576, DOI 10.1074/jbc.271.48.30576; Szapary D, 1999, MOL ENDOCRINOL, V13, P2108, DOI 10.1210/me.13.12.2108; SZAPARY D, 1992, ENDOCRINOLOGY, V130, P3492, DOI 10.1210/en.130.6.3492; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Thenot S, 1999, MOL ENDOCRINOL, V13, P2137, DOI 10.1210/me.13.12.2137; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TURCOTTE B, 1990, MOL CELL BIOL, V10, P5002, DOI 10.1128/MCB.10.9.5002; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WASNER G, 1988, MOL ENDOCRINOL, V2, P1009, DOI 10.1210/mend-2-11-1009; WESTLEY BR, 1989, J STEROID BIOCHEM, V32, P365, DOI 10.1016/0022-4731(89)90208-2; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; Xu Y, 2000, MOL CELL BIOL, V20, P2138, DOI 10.1128/MCB.20.6.2138-2146.2000; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zeng HW, 2000, MOL CELL ENDOCRINOL, V162, P221, DOI 10.1016/S0303-7207(99)00208-7; Zeng HW, 1998, J BIOL CHEM, V273, P17756, DOI 10.1074/jbc.273.28.17756	82	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30106	30117		10.1074/jbc.M005418200	http://dx.doi.org/10.1074/jbc.M005418200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10899170	hybrid			2022-12-27	WOS:000089577900028
J	Ohki, R; Nemoto, J; Murasawa, H; Oda, E; Inazawa, J; Tanaka, N; Taniguchi, T				Ohki, R; Nemoto, J; Murasawa, H; Oda, E; Inazawa, J; Tanaka, N; Taniguchi, T			Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G(2) phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR IRF-1; IFN-BETA-GENE; DNA-DAMAGE; DIFFERENTIAL DISPLAY; P53-INDUCIBLE GENE; P53; APOPTOSIS; PROTEIN; EXPRESSION; CHECKPOINT	A novel gene, Reprimo, in which induction in cells exposed to X-irradiation is dependent on p53 expression, has been isolated. Ectopic p53 expression results in the induction of its mRNA. Reprimo is a highly glycosylated protein and, when ectopically expressed, it is localized in the cytoplasm and induces G(2) arrest of the cell cycle. In the arrested cells, both Cdc2 activity and nuclear translocation of cyclin El are inhibited, suggesting the involvement of Reprimo in the Cdc2.cyclin B1 regulation pathway. Thus, Reprimo may be a new member involved in the regulation of p53-dependent G(2) arrest of the cell cycle.	Univ Tokyo, Grad Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Fac Med, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Div Genet,Bunkyo Ku, Tokyo 1138519, Japan	University of Tokyo; University of Tokyo; Tokyo Medical & Dental University (TMDU)	Taniguchi, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Immunol, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.		MURASAWA, Hideki/AAP-9514-2021	MURASAWA, Hideki/0000-0003-4897-1239; Tanaka, Nobuyuki/0000-0002-6373-2220				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Carrier F, 1999, MOL CELL BIOL, V19, P1673; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Fan JQ, 1997, J BIOL CHEM, V272, P27058, DOI 10.1074/jbc.272.43.27058; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Inazawa J, 1996, GENOMICS, V31, P240, DOI 10.1006/geno.1996.0039; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; ITO T, 1994, FEBS LETT, V351, P231, DOI 10.1016/0014-5793(94)00867-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Nozawa H, 1999, GENE DEV, V13, P1240, DOI 10.1101/gad.13.10.1240; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Otsuka T, 1996, GENE CHROMOSOME CANC, V16, P113, DOI 10.1002/(SICI)1098-2264(199606)16:2<113::AID-GCC5>3.0.CO;2-2; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Sato M, 1998, FEBS LETT, V425, P112, DOI 10.1016/S0014-5793(98)00210-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; TAKITA J, 1995, ONCOGENE, V11, P1829; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; Wang XT, 1999, J BIOL CHEM, V274, P29599, DOI 10.1074/jbc.274.42.29599; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; Yamano S, 1999, J VIROL, V73, P10095, DOI 10.1128/JVI.73.12.10095-10103.1999; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; ZHAN QM, 1994, ONCOGENE, V9, P3743; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	39	145	150	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22627	22630		10.1074/jbc.C000235200	http://dx.doi.org/10.1074/jbc.C000235200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10930422	hybrid			2022-12-27	WOS:000088419400006
J	Hasegawa, J; Uchiyama, S; Tanimoto, Y; Mizutani, M; Kobayashi, Y; Sambongi, Y; Igarashi, Y				Hasegawa, J; Uchiyama, S; Tanimoto, Y; Mizutani, M; Kobayashi, Y; Sambongi, Y; Igarashi, Y			Selected mutations in a mesophilic cytochrome c confer the stability of a thermophilic counterpart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL SCANNING CALORIMETRY; HYDROGEN-OXIDIZING BACTERIUM; TRIPLE-RESONANCE NMR; LARGER PROTEINS; THERMOSTABILITY; SPECTRA; SPECTROSCOPY; RESOLUTION; H2O; H-1	Mesophilic cytochrome c(551) of Pseudomonas aeruginosa (PA c(551)) became as stable as its thermophilic counterpart, Hydrogenobacter thermophilus cytochrome c(552) (HT c(552)), through only five amino acid substitutions. The five residues, distributed in three spatially separated regions, were selected and mutated with reference to the corresponding residues in HT c(552) through careful structure comparison. Thermodynamic analysis indicated that the stability of the quintuple mutant of PA c(551) could be partly attained through an enthalpic factor. The solution structure of the mutant showed that, as in HT c(552), there were tighter side chain packings in the mutated regions. Furthermore, the mutant had an increased total accessible surface area, resulting in great negative hydration free energy. Our results provide a novel example of protein stabilization in that limited amino acid substitutions can confer the overall stability of a natural highly thermophilic protein upon a mesophilic molecule.	Daiichi Pharmaceut Co Ltd, Edogawa Ku, Tokyo 1348630, Japan; Osaka Univ, Fac Pharmaceut Sci, Suita, Osaka 5650871, Japan; Univ Tokyo, Dept Biotechnol, Bunkyo Ku, Tokyo 1130032, Japan; Osaka Univ, Inst Sci & Ind Res, Ibaraki, Osaka 5670047, Japan	Daiichi Sankyo Company Limited; Osaka University; University of Tokyo; Osaka University	Hasegawa, J (corresponding author), Daiichi Pharmaceut Co Ltd, Edogawa Ku, Tokyo 1348630, Japan.		UCHIYAMA, Susumu/F-9590-2017	UCHIYAMA, Susumu/0000-0002-5181-179X				ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; Bogin O, 1998, PROTEIN SCI, V7, P1156, DOI 10.1002/pro.5560070509; Brunger A.T., 1993, X PLOR VERSION 3 1 S; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Eidsness MK, 1997, BIOCHEMISTRY-US, V36, P10406, DOI 10.1021/bi970110r; FREIRE E, 1994, METHOD ENZYMOL, V240, P502; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Gromiha MM, 1999, BIOPHYS CHEM, V82, P51, DOI 10.1016/S0301-4622(99)00103-9; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; Hasegawa J, 1999, J BIOL CHEM, V274, P37533, DOI 10.1074/jbc.274.53.37533; Hasegawa J, 1998, BIOCHEMISTRY-US, V37, P9641, DOI 10.1021/bi9803067; Hollien J, 1999, P NATL ACAD SCI USA, V96, P13674, DOI 10.1073/pnas.96.24.13674; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; KAY LE, 1993, J AM CHEM SOC, V115, P2055, DOI 10.1021/ja00058a072; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; KELLER RM, 1978, BIOCHIM BIOPHYS ACTA, V533, P195, DOI 10.1016/0005-2795(78)90564-0; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; MAKHATADZE GI, 1992, J MOL BIOL, V226, P491, DOI 10.1016/0022-2836(92)90963-K; Malakauskas SM, 1998, NAT STRUCT BIOL, V5, P470, DOI 10.1038/nsb0698-470; MARKY LA, 1987, BIOPOLYMERS, V26, P1601, DOI 10.1002/bip.360260911; MATSUURA Y, 1982, J MOL BIOL, V156, P389, DOI 10.1016/0022-2836(82)90335-7; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; OOBATAKE M, 1993, PROG BIOPHYS MOL BIO, V59, P237, DOI 10.1016/0079-6107(93)90002-2; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; Perl D, 2000, NAT STRUCT BIOL, V7, P380; Plotnikov VV, 1997, ANAL BIOCHEM, V250, P237, DOI 10.1006/abio.1997.2236; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; Sambongi Y, 1996, MOL MICROBIOL, V19, P1193, DOI 10.1111/j.1365-2958.1996.tb02465.x; SANBONGI Y, 1989, J BACTERIOL, V171, P65, DOI 10.1128/jb.171.1.65-69.1989; SANBONGI Y, 1989, BIOCHEMISTRY-US, V28, P9574, DOI 10.1021/bi00451a004; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SERRANO L, 1993, J MOL BIOL, V233, P305, DOI 10.1006/jmbi.1993.1508; STURTEVANT JM, 1987, ANNU REV PHYS CHEM, V38, P463, DOI 10.1146/annurev.pc.38.100187.002335; Vetriani C, 1998, P NATL ACAD SCI USA, V95, P12300, DOI 10.1073/pnas.95.21.12300; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; VUISTER GW, 1992, J MAGN RESON, V98, P428, DOI 10.1016/0022-2364(92)90144-V; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	43	59	61	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37824	37828		10.1074/jbc.M005861200	http://dx.doi.org/10.1074/jbc.M005861200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10918067	hybrid, Green Published			2022-12-27	WOS:000165618700070
J	Wittemann, S; Mark, MD; Rettig, J; Herlitze, S				Wittemann, S; Mark, MD; Rettig, J; Herlitze, S			Synaptic localization and presynaptic function of calcium channel beta(4)-subunits in cultured hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; CA2+ CHANNELS; NEUROTRANSMITTER RELEASE; ALPHA(1C) SUBUNIT; NERVOUS-SYSTEM; EXPRESSION; MODULATION; SYNAPTOBREVIN; TRAFFICKING; RECEPTOR	Neurotransmitter release is triggered by the influx of Ca2+ into the presynaptic terminal through voltage gated Ca2+-channels. The shape of the presynaptic Ca2+ signal largely determines the amount of released quanta and thus the size of the synaptic response, Ca2+-channel function is modulated in particular by the auxiliary beta -subunits that interact intracellularly with the pore-forming alpha (1)-subunit, Using retrovirus-mediated gene transfer in cultured hippocampal neurons, we demonstrate that functional GFP-beta (4) constructs colocalize with the synaptic vesicle marker synaptobrevin II and endogenous P/Q-type channels, indicating that beta (4)-subunits are localized to synaptic sites. Costaining with the dendritic marker MAPS revealed that the beta (4)-subunit is transported to dendrites as well as axons, The nonconserved amino- and carboxyl-termini of the beta (2)-subunit were found to target the protein to the synapse. Physiological measurements in autaptic hippocampal neurons infected with green fluorescent protein (GFP)-beta (4) revealed an increase in both excitatory post-synaptic current amplitude and paired pulse facilitation ratio, whereas the GFP-beta (4) mutant, GFP-beta (4)(Delta 50-407), which demonstrated a cytosolic localization pattern, did not alter these synaptic properties. In summary, our data suggest a presynaptic function of the Ca2+-channel beta (4)-subunit in synaptic transmission.	Univ Tubingen, Dept Physiol 2, D-72074 Tubingen, Germany; Max Planck Inst Biophys Chem, Dept Membrane Biophys, D-37077 Gottingen, Germany	Eberhard Karls University of Tubingen; Max Planck Society	Herlitze, S (corresponding author), Univ Tubingen, Dept Physiol 2, Heimmelreich 7, D-72074 Tubingen, Germany.		Rettig, Jens/K-5103-2013; Mark, Melanie/ABF-9102-2020	Rettig, Jens/0000-0001-6160-3954; Mark, Melanie/0000-0002-2788-6003				Ahmari SE, 2000, NAT NEUROSCI, V3, P445, DOI 10.1038/74814; Ashery U, 1999, EUR J CELL BIOL, V78, P525, DOI 10.1016/S0171-9335(99)80017-X; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; Betz A, 1998, NEURON, V21, P123, DOI 10.1016/S0896-6273(00)80520-6; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; Bogdanov Y, 2000, EUR J NEUROSCI, V12, P894, DOI 10.1046/j.1460-9568.2000.00981.x; Bradke F, 1998, BBA-MOL CELL RES, V1404, P245, DOI 10.1016/S0167-4889(98)00060-3; Brody DL, 2000, J NEUROSCI, V20, P889, DOI 10.1523/JNEUROSCI.20-03-00889.2000; Caddick SJ, 1999, J NEUROPHYSIOL, V81, P2066, DOI 10.1152/jn.1999.81.5.2066; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; Catterall WA, 1998, CELL CALCIUM, V24, P307, DOI 10.1016/S0143-4160(98)90055-0; Day NC, 1998, MOL BRAIN RES, V60, P259, DOI 10.1016/S0169-328X(98)00186-7; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; Fisher SA, 1997, TRENDS NEUROSCI, V20, P170, DOI 10.1016/S0166-2236(96)01001-6; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; Gerster U, 1999, J PHYSIOL-LONDON, V517, P353, DOI 10.1111/j.1469-7793.1999.0353t.x; Gregg RG, 1996, P NATL ACAD SCI USA, V93, P13961, DOI 10.1073/pnas.93.24.13961; Hanlon MR, 1999, FEBS LETT, V445, P366, DOI 10.1016/S0014-5793(99)00156-8; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Jareb M, 1998, NEURON, V20, P855, DOI 10.1016/S0896-6273(00)80468-7; Keller P, 1997, J CELL SCI, V110, P3001; Lao GF, 2000, NEURON, V25, P191, DOI 10.1016/S0896-6273(00)80882-X; Li JY, 1996, J NEUROSCI, V16, P137; Lie AA, 1999, NEUROSCIENCE, V93, P449, DOI 10.1016/S0306-4522(99)00162-1; Lin FH, 1999, MOL BRAIN RES, V71, P1, DOI 10.1016/S0169-328X(99)00141-2; Ludwig A, 1997, J NEUROSCI, V17, P1339; MARK MD, 1995, J CELL BIOL, V130, P701, DOI 10.1083/jcb.130.3.701; McEnery MW, 1998, J BIOL CHEM, V273, P21435, DOI 10.1074/jbc.273.34.21435; Qian J, 2000, J NEUROSCI, V20, P163, DOI 10.1523/JNEUROSCI.20-01-00163.2000; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; Stowell JN, 1999, NEURON, V22, P525, DOI 10.1016/S0896-6273(00)80707-2; Volsen SG, 1997, NEUROSCIENCE, V80, P161, DOI 10.1016/S0306-4522(97)00115-2; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; Walker D, 1998, J BIOL CHEM, V273, P2361, DOI 10.1074/jbc.273.4.2361; West AE, 1997, J CELL BIOL, V139, P917, DOI 10.1083/jcb.139.4.917; Westenbroek RE, 1998, J NEUROSCI, V18, P6319; Yamaguchi H, 1998, J BIOL CHEM, V273, P19348, DOI 10.1074/jbc.273.30.19348; Zucker RS, 1999, CURR OPIN NEUROBIOL, V9, P305, DOI 10.1016/S0959-4388(99)80045-2	41	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37807	37814		10.1074/jbc.M004653200	http://dx.doi.org/10.1074/jbc.M004653200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10931840	hybrid			2022-12-27	WOS:000165618700068
J	Donate, F; Yanez, AJ; Iriarte, A; Martinez-Carrion, M				Donate, F; Yanez, AJ; Iriarte, A; Martinez-Carrion, M			Interaction of the precursor to mitochondrial aspartate aminotransferase and its presequence peptide with model membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-VESICLES; SIGNAL SEQUENCE; CONFORMATIONAL-CHANGES; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; BINDING-PROPERTIES; PENETRATION DEPTH; ESCHERICHIA-COLI; PARALLAX METHOD; ALPHA-HELICES	The possible contribution of the mature portion of a mitochondrial precursor protein to its interaction with membrane lipids is unclear. To address this issue, we examined the interaction of the precursor to mitochondrial aspartate aminotransferase (pmAAT) and of a synthetic peptide corresponding to the 29-residue presequence peptide (mAAT-pp) with anionic phospholipid vesicles. The affinity of mAAT-pp and pmAAT for anionic vesicles is nearly identical. Results obtained by analyzing the effect of mAAT-pp or full-length pmAAT on either the permeability or microviscosity of the phospholipid vesicles are consistent with only a shallow insertion of the presequence peptide in the bilayer. Analysis of the quenching of Trp-17 fluorescence by brominated phospholipids reveals that this presequence residue inserts to a depth of approximately 9 Angstrom hom the center of the bilayer, Furthermore, in membrane-bound pmAAT or mAAT-pp, both Arg-8 and Arg-28 are accessible to the solvent. These results suggest that the presequence segment lies close to the surface of the membrane and that the mature portion of the precursor protein has little effect on the affinity or mode of binding of the presequence to model membranes. Tn the presence of vesicles, mAAT-pp adopts considerable a-helical structure. Hydrolysis by trypsin after Arg-g results in the dissociation of the remaining 21-residue C-terminal peptide fragment from the membrane bilayer, suggesting that the N-terminal portion of the presequence is essential for membrane binding. Based on these results, we propose that the presequence peptide may contain dual recognition elements for both the lipid and import receptor components of the mitochondrial membrane.	Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Kansas City, MO 64110 USA; Univ Austral Chile, Fac Ciencias, Inst Bioquim, Valdivia, Chile	University of Missouri System; University of Missouri Kansas City; Universidad Austral de Chile	Martinez-Carrion, M (corresponding author), Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, 5007 Rockhill Rd, Kansas City, MO 64110 USA.	martinezcm@umkc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038341] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-38341] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; ALTIERI F, 1989, J BIOL CHEM, V264, P4782; ARDAIL D, 1990, J BIOL CHEM, V265, P18797; Artigues A, 1997, J BIOL CHEM, V272, P16852, DOI 10.1074/jbc.272.27.16852; Barlett G.R., 1959, J BIOL CHEM, V234, P466; Berezov A, 1996, ARCH BIOCHEM BIOPHYS, V336, P173, DOI 10.1006/abbi.1996.0546; BEREZOV A, 1994, J BIOL CHEM, V269, P22222; BRUCH MD, 1992, BIOCHIM BIOPHYS ACTA, V1159, P81, DOI 10.1016/0167-4838(92)90078-R; CHATTOPADHYAY A, 1991, BIOCHEMISTRY-US, V30, P7159, DOI 10.1021/bi00243a017; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; Chupin V, 1996, BIOCHEMISTRY-US, V35, P3141, DOI 10.1021/bi952482a; CHUPIN V, 1995, FEBS LETT, V373, P239, DOI 10.1016/0014-5793(95)01054-I; DEMEL RA, 1989, J BIOL CHEM, V264, P3988; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; Donate F, 1998, PROTEIN SCI, V7, P1811, DOI 10.1002/pro.5560070817; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; ENDO T, 1989, FEBS LETT, V249, P173, DOI 10.1016/0014-5793(89)80618-0; GILBERT GE, 1990, J BIOL CHEM, V265, P815; HAMMEN PK, 1994, BIOCHEMISTRY-US, V33, P8610, DOI 10.1021/bi00194a028; Hammen PK, 1996, BIOCHEMISTRY-US, V35, P3772, DOI 10.1021/bi951848g; HARTMANN CM, 1993, EUR J BIOCHEM, V218, P905, DOI 10.1111/j.1432-1033.1993.tb18446.x; HORKOVICSKOVATS S, 1990, BIOCHEMISTRY-US, V29, P8652, DOI 10.1021/bi00489a022; HOYT DW, 1991, J BIOL CHEM, V266, P14406; HOYT DW, 1991, BIOCHEMISTRY-US, V30, P10155, DOI 10.1021/bi00106a012; HOYT DW, 1991, J BIOL CHEM, V266, P21693; IRIARTE A, 1990, ENZYMES DEPENDENT PR; KARSLAKE C, 1990, BIOCHEMISTRY-US, V29, P9872, DOI 10.1021/bi00494a017; Keller RCA, 1996, BIOCHEMISTRY-US, V35, P3063, DOI 10.1021/bi951870+; KILLIAN JA, 1990, BIOCHEMISTRY-US, V29, P8131, DOI 10.1021/bi00487a021; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; Lacroix E, 1998, J MOL BIOL, V284, P173, DOI 10.1006/jmbi.1998.2145; Ladokhin AS, 1999, BIOPHYS J, V76, P946, DOI 10.1016/S0006-3495(99)77258-9; Lain B, 1998, J BIOL CHEM, V273, P4406, DOI 10.1074/jbc.273.8.4406; Lakowicz J.R., 1983, PRINC FLUORESC SPECT, P341, DOI [10.1007/978-1-4615-7658-7_11, DOI 10.1007/978-1-4615-7658-7_11]; LEWIS BA, 1983, J MOL BIOL, V166, P211, DOI 10.1016/S0022-2836(83)80007-2; MAO D, 1984, BIOCHEMISTRY-US, V23, P2667, DOI 10.1021/bi00307a020; MARTINEZCARRION M, 1990, ANN NY ACAD SCI, V585, P346, DOI 10.1111/j.1749-6632.1990.tb28067.x; MATTINGLY JR, 1987, BIOCHEM BIOPH RES CO, V149, P859, DOI 10.1016/0006-291X(87)90487-6; MATTINGLY JR, 1993, J BIOL CHEM, V268, P3925; MCINTOSH TJ, 1987, BIOCHEMISTRY-US, V26, P1783, DOI 10.1021/bi00380a042; MCKNIGHT CJ, 1991, P NATL ACAD SCI USA, V88, P5799, DOI 10.1073/pnas.88.13.5799; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; NISHI T, 1989, J BIOL CHEM, V264, P6044; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; Schleiff E, 1999, FEBS LETT, V461, P9, DOI 10.1016/S0014-5793(99)01415-5; Schleiff E, 1998, BIOCHEMISTRY-US, V37, P13052, DOI 10.1021/bi980746y; Schulke N, 1997, P NATL ACAD SCI USA, V94, P7314, DOI 10.1073/pnas.94.14.7314; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; TAMM LK, 1991, BIOCHIM BIOPHYS ACTA, V1071, P123, DOI 10.1016/0304-4157(91)90021-N; THORNTON K, 1993, J BIOL CHEM, V268, P19906; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; Waltner M, 1996, J BIOL CHEM, V271, P21226, DOI 10.1074/jbc.271.35.21226; WEINSTEIN S, 1979, P NATL ACAD SCI USA, V76, P4230, DOI 10.1073/pnas.76.9.4230; YU YG, 1994, BIOCHEMISTRY-US, V33, P14221, DOI 10.1021/bi00251a034	57	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34147	34156		10.1074/jbc.M004494200	http://dx.doi.org/10.1074/jbc.M004494200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10938277	hybrid			2022-12-27	WOS:000165095300023
J	Montano, MM; Wittmann, BM; Bianco, NR				Montano, MM; Wittmann, BM; Bianco, NR			Identification and characterization of a novel factor that regulates quinone reductase gene transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ESTROGEN-RECEPTOR; PLANAR AROMATIC-COMPOUNDS; HORMONE-BINDING DOMAIN; YA-SUBUNIT GENE; RESPONSIVE ELEMENT; INDUCIBLE EXPRESSION; MOLECULAR-CLONING; INDUCTION; ANTIESTROGENS; ELECTROPHILE	The regulation of the quinone reductase (QR) gene as well as other genes involved in detoxification is known to be mediated by an electrophile/antioxidant response element (EpRE/ARE). We have previously observed that QR is up-regulated by the antiestrogen trans-hydroxytamoxifen in breast cancer cells. QR gene regulation by the antiestrogen-occupied estrogen receptor (ER) is mediated by the EpRE-containing region of the human QR gene, and the ER is one of the complex of proteins that binds to the EpRE. In an effort to further understand the mechanism for ER regulation of QR gene we identified other protein factors that regulate QR gene transcriptional activity in breast cancer cells. One of these protein factors, hPMC2 (human homolog of Xenopus gene which prevents mitotic catastrophe), directly binds to the EpRE and interacts with the ER in yeast genetic screening and in vitro assays. Interestingly hPMC2 interacts more strongly to ER beta when compared with ER alpha. In transient transfection assays using reporter constructs containing the EpRE, hPMC2 alone can slightly activate reporter in ER-negative MDA-MB-231 breast cancer cells. The activation of QR gene activity by hPMC2 is enhanced in the presence of ER beta.	Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44122 USA	Case Western Reserve University	Montano, MM (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, HG Wood Bldg W307,2109 Adelbert Rd, Cleveland, OH 44122 USA.	mxm126@po.cwru.edu			NCI NIH HHS [CA80959] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chusacultanachai S, 1999, J BIOL CHEM, V274, P23591, DOI 10.1074/jbc.274.33.23591; Crute BE, 1996, J BIOL CHEM, V271, P26251, DOI 10.1074/jbc.271.42.26251; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; Gongora C, 1997, J BIOL CHEM, V272, P19457, DOI 10.1074/jbc.272.31.19457; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; JIN WD, 1994, MOL ENDOCRINOL, V8, P1377, DOI 10.1210/me.8.10.1377; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KRAUS WL, 1994, MOL ENDOCRINOL, V8, P952, DOI 10.1210/me.8.8.952; Kwiatkowska J, 1997, GENOMICS, V44, P350, DOI 10.1006/geno.1997.4874; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; Montano MM, 1997, P NATL ACAD SCI USA, V94, P2581, DOI 10.1073/pnas.94.6.2581; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Montano MM, 1998, J BIOL CHEM, V273, P25443, DOI 10.1074/jbc.273.39.25443; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; Pentecost BT, 1998, J STEROID BIOCHEM, V64, P25, DOI 10.1016/S0960-0760(97)00140-4; PRESTERA T, 1995, P NATL ACAD SCI USA, V92, P8965, DOI 10.1073/pnas.92.19.8965; PRESTERA T, 1993, ADV ENZYME REGUL, V33, P281; Qiu XB, 1996, J BIOL CHEM, V271, P31915, DOI 10.1074/jbc.271.50.31915; REESE JC, 1992, MOL CELL BIOL, V12, P4531, DOI 10.1128/MCB.12.10.4531; REESE JC, 1991, J BIOL CHEM, V266, P10880; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SU JY, 1995, MOL GEN GENET, V246, P387, DOI 10.1007/BF00288613; TALALAY P, 1989, ADV ENZYME REGUL, V28, P237; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; WRENN CK, 1993, J BIOL CHEM, V268, P24089; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XIE T, 1995, J BIOL CHEM, V270, P6894, DOI 10.1074/jbc.270.12.6894; Yu R, 1999, J BIOL CHEM, V274, P27545, DOI 10.1074/jbc.274.39.27545	34	25	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34306	34313		10.1074/jbc.M003880200	http://dx.doi.org/10.1074/jbc.M003880200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10908561	hybrid			2022-12-27	WOS:000165095300043
J	Ferguson, KL; Callaghan, SM; O'Hare, MJ; Park, DS; Slack, RS				Ferguson, KL; Callaghan, SM; O'Hare, MJ; Park, DS; Slack, RS			The Rb-CDK4/6 signaling pathway is critical in neural precursor cell cycle regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE-ACTIVITY; RETINOBLASTOMA PROTEIN; CDK INHIBITORS; RESTRICTION POINT; NUCLEAR-PROTEIN; DISTINCT ROLES; GANGLION-CELLS; DIFFERENTIATION; PHASE; MOUSE	The tumor suppressor, retinoblastoma (Rb), is involved in both terminal mitosis and neuronal differentiation. We hypothesized that activation of the Rb pathway would induce cell cycle arrest in primary neural precursor cells, independent of the proposed function of cyclin-dependent kinases 4/6 (CDK4/6) to sequester the CIP/KIP CDK inhibitors (CKIs) p21 and p27 from CDK2, We expressed dominant negative adenovirus mutants of CDKs 2, 4, and 6 (dnCDK2, dnCDK4, and dnCDK6) in neural progenitor cells derived from E12.5 wild type and Rb-deficient mouse embryos. In contrast to previous studies, our results demonstrate that in addition to dnCDK2, the dnCDK4/6 mutants can induce growth arrest. Moreover, the dnCDK4/6-mediated inhibition is Rb-dependent. The dnCDK2 partially inhibited cell growth in Rb-deficient cells, suggesting that CDK2 may have additional targets, A previously proposed function of CDK4/6 is CKI sequestration, thereby preventing the resulting inhibition of CDK2, believed to be the key regulator of cell cycle. However, our immunoprecipitations revealed that the dominant negative CDK mutants could arrest cell growth despite their interaction with p21 and p27, Taken together, our results demonstrate that both CDK2 and CDK4/6 are crucial for cell cycle regulation. Furthermore, our data underscore the importance of the Rb regulatory pathway in neuronal development and cell cycle regulation, independent of CRI sequestration.	Univ Ottawa, Neurosci Res Inst, Ottawa, ON K1H 8M5, Canada	University of Ottawa	Slack, RS (corresponding author), Univ Ottawa, Neurosci Res Inst, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.			Slack, Ruth/0000-0002-1552-2835; Park, David/0000-0002-4490-3784				Callaghan DA, 1999, DEV BIOL, V207, P257, DOI 10.1006/dbio.1998.9162; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Cregan SP, 2000, GENE THER, V7, P1200, DOI 10.1038/sj.gt.3301208; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ElShamy WM, 1998, NEURON, V21, P1003, DOI 10.1016/S0896-6273(00)80619-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GHOSH A, 1995, NEURON, V15, P89, DOI 10.1016/0896-6273(95)90067-5; Gill RM, 1998, EXP CELL RES, V244, P157, DOI 10.1006/excr.1998.4197; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; INO H, 1994, BRAIN RES, V661, P196, DOI 10.1016/0006-8993(94)91197-5; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KATO J, 1993, GENE DEV, V7, P331; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; MCLOON SC, 1989, J NEUROSCI, V9, P1424; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Park DS, 1997, J NEUROSCI, V17, P8975; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; SEWING A, 1993, J CELL SCI, V104, P545; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Slack RS, 1996, DEV GENET, V18, P81, DOI 10.1002/(SICI)1520-6408(1996)18:1<81::AID-DVG9>3.0.CO;2-Y; Slack RS, 1998, J CELL BIOL, V140, P1497, DOI 10.1083/jcb.140.6.1497; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VESCOVI AL, 1993, NEURON, V11, P951, DOI 10.1016/0896-6273(93)90124-A; WAID DK, 1995, NEURON, V14, P117, DOI 10.1016/0896-6273(95)90245-7	40	61	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33593	33600		10.1074/jbc.M004879200	http://dx.doi.org/10.1074/jbc.M004879200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10915795	hybrid			2022-12-27	WOS:000090104600059
J	Huse, JT; Pijak, DS; Leslie, GJ; Lee, VMY; Doms, RW				Huse, JT; Pijak, DS; Leslie, GJ; Lee, VMY; Doms, RW			Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme - The Alzheimer's disease beta-secretase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT4 GLUCOSE-TRANSPORTER; ENDOCYTIC PATHWAY; NT2N CELLS; RECEPTOR; CLEAVAGE; CATENIN; COMPARTMENT; COMPLEX; INTERNALIZATION; LYSOSOMES	The amyloidogenic A beta peptide is liberated from the amyloid precursor protein (APP) by two proteolytic activities, beta -secretase and gamma -secretase. Recently, a type I membrane protein termed RACE (beta -site APP cleaving enzyme) with characteristics of an aspartyl protease has been identified as the beta -secretase. We undertook a series of biochemical and morphological investigations designed to characterize the basic properties of this protein. Initial studies indicated that RACE undergoes N-linked glycosylation at three of four potential sites. Metabolic pulse-chase experiments revealed that after core glycosylation, RACE is rapidly and efficiently transported to the Gels apparatus and distal secretory pathway. RACE was also found to be quite stable, being turned over with a t(1/2) of similar to 16 h. Retention of RACE in the endoplasmic reticulum by introduction of a C-terminal dilysine motif prevented complex carbohydrate processing and demonstrated that propeptide cleavage occurs after exit from this organelle. RACE exhibited intramolecular disulfide bonding but did not form oligomeric structures by standard SDS-polyacrylamide gel electrophoresis analysis and sedimented as a monomer in sucrose velocity gradients. Immunofluorescence studies showed a largely vesicular staining pattern for RACE that colocalized web with endosomal, but not lysosomal, markers. Measurable levels of RACE were also detected on the plasma membrane by both immunostaining and cell surface biotinylation, and cycling of the protein between the cell membrane and the endosomes was documented. A cytoplasmic dileucine motif was found to be necessary for normal targeting of RACE to the endosomal system and accumulation of the protein in this intracellular site.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Doms, RW (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 806 Abramson Bldg,34th & Civic Ctr Blvd, Philadelphia, PA 19104 USA.	doms@mail.med.upenn.edu			NIA NIH HHS [P01 AG11542] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG011542] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bennett BD, 2000, J BIOL CHEM, V275, P20647, DOI 10.1074/jbc.M002688200; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; Kang DE, 1999, J NEUROSCI, V19, P4229; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; KOO EH, 1994, J BIOL CHEM, V269, P17386; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; MARSH BJ, 1995, J CELL BIOL, V130, P1081, DOI 10.1083/jcb.130.5.1081; MCGRAW TE, 1991, J CELL BIOL, V112, P853, DOI 10.1083/jcb.112.5.853; Mellquist JL, 1998, BIOCHEMISTRY-US, V37, P6833, DOI 10.1021/bi972217k; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; Nishimura M, 1999, NAT MED, V5, P164, DOI 10.1038/5526; PELCHENMATTHEWS A, 1991, J EXP MED, V173, P575, DOI 10.1084/jem.173.3.575; Pitcher C, 1999, MOL BIOL CELL, V10, P677, DOI 10.1091/mbc.10.3.677; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; Reich Z, 1997, NATURE, V387, P617, DOI 10.1038/42500; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; SETTE A, 1994, ANNU REV IMMUNOL, V12, P413, DOI 10.1146/annurev.immunol.12.1.413; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sisodia SS, 1999, J CLIN INVEST, V104, P1169, DOI 10.1172/JCI8508; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208	42	368	386	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33729	33737		10.1074/jbc.M004175200	http://dx.doi.org/10.1074/jbc.M004175200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10924510	hybrid			2022-12-27	WOS:000090104600076
J	Imokawa, G; Kobayasi, T; Miyagishi, M				Imokawa, G; Kobayasi, T; Miyagishi, M			Intracellular signaling mechanisms leading to synergistic effects of endothelin-1 and stem cell factor on proliferation of cultured human melanocytes - Cross-talk vla trans-activation of the tyrosine kinase c-kit receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE; WAARDENBURG-SYNDROME; HUMAN PIEBALDISM; BIOLOGICAL CHARACTERIZATION; HIRSCHSPRUNG DISEASE; DEPENDENT MECHANISM; LOCUS PROTEIN; RAF-1 KINASE; MAST-CELLS	We previously reported that activation of mitogen-activated protein kinase (MAPK) is involved in the mitogenic stimulation of normal human melanocytes (NHMC) by endothelin-l (ET-1). In the present study, we determined signaling mechanisms upstream of MAPK activation that are involved in ET-1 stimulation and their synergism with stem cell factor (SCF). Pretreatment of cultured NHMC with ETB receptor antagonists, pertussis toxin, a specific phospholipase C inhibitor (U73122), or a protein kinase C inhibitor (calphostine) blocked a transient tyrosine phosphorylation of MAPK induced by ET-1, whereas the addition of a calcium chelator (BAPTA) failed to inhibit that tyrosine phosphorylation of MAPK. Treatment with ET-1 and SCF together synergistically increased DNA synthesis, which was accompanied by synergism for MAPK phosphorylation. The time course of inositol 1,4,5-trisphosphate formation revealed that there is no difference in the level of inositol 1,4,5-trisphosphate stimulated by ET-1 + SCF or by ET-1 alone. Evaluations of the serine phosphorylation of MEK and Raf-l activity showed a synergistic effect in SCF + ET-l-treated NHMC. Stimulation with SCF + ET-1 induced a more rapid and stronger tyrosyl phosphorylation of proteins corresponding to p52 and p66 Shc than did stimulation with SCF only, and this was accompanied by a stronger association of tyrosine-phosphorylated Shc with Grb2. Interestingly, a more rapid and marked tyrosine phosphorylation of c-kit was also detected in NHMC-treated with SCF + ET-1 than NHMC treated with SCF only. These data indicate that the synergistic cross-talk between SCF and ET-1 signaling is initiated through the pathway of tyrosine phosphorylation of c-kit, which results in the enhanced formation of the Shc-Grb(2) complex which leads in turn to the synergistic activation of the Ras/Raf-1/MEK/MAP kinase loop.	Kao Biol Sci Labs, Haga, Tochigi 3213497, Japan		Imokawa, G (corresponding author), Kao Biol Sci Labs, 2606 Akabane, Haga, Tochigi 3213497, Japan.		Miyagishi, Makoto/L-8174-2016	Miyagishi, Makoto/0000-0001-7654-3616; Kobayashi, Takeshi/0000-0002-4372-5285				ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; Amiel J, 1996, HUM MOL GENET, V5, P355, DOI 10.1093/hmg/5.3.355; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; Cacace AM, 1996, ONCOGENE, V13, P2517; CAZAUBON S, 1993, BIOCHEM J, V293, P381, DOI 10.1042/bj2930381; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; Dabrowski A, 1996, J BIOL CHEM, V271, P27125, DOI 10.1074/jbc.271.43.27125; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Edery P, 1996, NAT GENET, V12, P442, DOI 10.1038/ng0496-442; EZOE K, 1995, AM J HUM GENET, V56, P58; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; HORI Y, 1996, MELANOGENESIS MALIGN, P35; Imokawa G, 1998, BIOCHEM J, V330, P1235, DOI 10.1042/bj3301235; Imokawa G, 1996, BIOCHEM J, V314, P305, DOI 10.1042/bj3140305; Imokawa G, 1997, PIGM CELL RES, V10, P218, DOI 10.1111/j.1600-0749.1997.tb00488.x; IMOKAWA G, 1992, J BIOL CHEM, V267, P24675; Ito A, 1999, BLOOD, V93, P1189, DOI 10.1182/blood.V93.4.1189.404k32_1189_1196; Iwasaki H, 1999, ENDOCRINOLOGY, V140, P4659, DOI 10.1210/en.140.10.4659; KOBAYASHI T, 1994, EMBO J, V13, P5818, DOI 10.1002/j.1460-2075.1994.tb06925.x; KOBAYASHI T, 1994, J BIOL CHEM, V269, P29198; Kobayashi T, 1998, J BIOL CHEM, V273, P31801, DOI 10.1074/jbc.273.48.31801; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Lennartsson J, 1999, ONCOGENE, V18, P5546, DOI 10.1038/sj.onc.1202929; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; LONGLEY BJ, 1993, NEW ENGL J MED, V328, P1302, DOI 10.1056/NEJM199305063281803; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MCNIECE IK, 1991, EXP HEMATOL, V19, P226; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; Read AP, 1997, J MED GENET, V34, P656, DOI 10.1136/jmg.34.8.656; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; Sakai C, 1997, EMBO J, V16, P3544, DOI 10.1093/emboj/16.12.3544; SPRITZ RA, 1992, AM J HUM GENET, V50, P261; Sui XW, 1998, BLOOD, V92, P1142, DOI 10.1182/blood.V92.4.1142.416k42_1142_1149; Tachibana M, 1996, NAT GENET, V14, P50, DOI 10.1038/ng0996-50; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; Tsujimura T, 1996, BLOOD, V88, P1225, DOI 10.1182/blood.V88.4.1225.bloodjournal8841225; Ueffing M, 1997, ONCOGENE, V15, P2921, DOI 10.1038/sj.onc.1201477; VAN BT, 1995, NATURE, V376, P781; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; vanDijk MCM, 1997, BIOCHEM J, V325, P303, DOI 10.1042/bj3250303; YADA Y, 1991, J BIOL CHEM, V266, P18352; Yamazaki T, 1996, J BIOL CHEM, V271, P3221, DOI 10.1074/jbc.271.6.3221; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4	48	95	97	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33321	33328		10.1074/jbc.M004346200	http://dx.doi.org/10.1074/jbc.M004346200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10921922	hybrid			2022-12-27	WOS:000090104600023
J	Tipnis, SR; Hooper, NM; Hyde, R; Karran, E; Christie, G; Turner, AJ				Tipnis, SR; Hooper, NM; Hyde, R; Karran, E; Christie, G; Turner, AJ			A human homolog of angiotensin-converting enzyme - Cloning and functional expression as a captopril-insensitive carboxypeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL CARBOXYPEPTIDASE; MOLECULAR-CLONING; BLOOD-PRESSURE; PROTEINS; MEMBRANE; GENE; FERTILITY; FLUID; ACID; MICE	A novel human zinc metalloprotease that has considerable homology to human angiotensin-converting enzyme (ACE) (40% identity and 61% similarity) has been identified, This metalloprotease (angiotensin-converting enzyme homolog (ACEH)) contains a single HEXXH zinc-binding domain and conserves other critical residues typical of the ACE family. The predicted protein sequence consists of 805 amino acids, including a potential 17-amino acid N-terminal signal peptide sequence and a putative C-terminal membrane anchor. Expression in Chinese hamster ovary cells of a soluble, truncated form of ACEH, lacking the transmembrane and cytosolic domains, produces a glycoprotein of 120 kDa, which is able to cleave angiotensin I and angiotensin II but not bradykinin or Hip-His-Leu. In the hydrolysis of the angiotensins, ACEH functions exclusively as a carboxypeptidase, ACEH activity is inhibited by EDTA but not by classical ACE inhibitors such as captopril, lisinopril, or enalaprilat, Identification of the genomic sequence of ACEH has shown that the ACEH gene contains 18 exons, of which several have considerable size similarity with the first 17 exons of human ACE. The gene maps to chromosomal location Xp22, Northern blotting analysis has shown that the ACEH mRNA transcript is similar to3.4 kilobase pairs and is most highly expressed in testis, kidney, and heart. This is the first report of a mammalian homolog of ACE and has implications for our understanding of cardiovascular and renal function.	Univ Leeds, Sch Biochem & Mol Biol, Proteolysis Res Grp, Leeds LS2 9JT, W Yorkshire, England; SmithKline Beecham Pharmaceut, Neurosci Res, Harlow CM19 5AW, Essex, England	University of Leeds; GlaxoSmithKline	Tipnis, SR (corresponding author), Univ Leeds, Sch Biochem & Mol Biol, Proteolysis Res Grp, Leeds LS2 9JT, W Yorkshire, England.			Hooper, Nigel/0000-0002-5811-3484				BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CORNEL MJ, 1995, J BIOL CHEM, V270, P13613, DOI 10.1074/jbc.270.23.13613; CORVOL P, 1998, HDB PROTEOLYTIC ENZY, P1066; DAS M, 1977, J BIOL CHEM, V252, P1316; EHLERS MRW, 1989, P NATL ACAD SCI USA, V86, P7741, DOI 10.1073/pnas.86.20.7741; ELDORRY HA, 1983, BIOCHEM BIOPH RES CO, V115, P1096, DOI 10.1016/S0006-291X(83)80048-5; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; Esther CR, 1996, LAB INVEST, V74, P953; FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095-130; HOOPER NM, 1987, BIOCHEM J, V247, P85, DOI 10.1042/bj2470085; Houard X, 1998, EUR J BIOCHEM, V257, P599, DOI 10.1046/j.1432-1327.1998.2570599.x; HUBERT C, 1991, J BIOL CHEM, V266, P15377; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMANGO N, 1993, BIOCHEM SOC T, V21, P245; LATTION AL, 1989, FEBS LETT, V252, P99, DOI 10.1016/0014-5793(89)80897-X; OPPONG SY, 1993, BIOCHEM J, V292, P597, DOI 10.1042/bj2920597; RIEGER KJ, 1993, BIOCHEM J, V296, P373, DOI 10.1042/bj2960373; SKEGGS LT, 1956, J EXP MED, V103, P295, DOI 10.1084/jem.103.3.295; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; Sugimura K, 1998, BIOCHEM BIOPH RES CO, V247, P466, DOI 10.1006/bbrc.1998.8813; Taylor CAM, 1996, GENE, V181, P191, DOI 10.1016/S0378-1119(96)00503-3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Turner AJ, 1997, FASEB J, V11, P355, DOI 10.1096/fasebj.11.5.9141502; Vendrell J, 2000, BBA-PROTEIN STRUCT M, V1477, P284, DOI 10.1016/S0167-4838(99)00280-0; WILLIAMS TA, 1994, J BIOL CHEM, V269, P29430; Woodman ZL, 2000, BIOCHEM J, V347, P711, DOI 10.1042/0264-6021:3470711; YANG HYT, 1970, BIOCHIM BIOPHYS ACTA, V214, P374, DOI 10.1016/0005-2795(70)90017-6; YASUI T, 1984, J LAB CLIN MED, V104, P741	31	1504	1665	5	62	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33238	33243		10.1074/jbc.M002615200	http://dx.doi.org/10.1074/jbc.M002615200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10924499	hybrid			2022-12-27	WOS:000090104600011
J	Wang, SL; Shi, Y; Gorshkova, I; Schwarz, FP				Wang, SL; Shi, Y; Gorshkova, I; Schwarz, FP			RNA polymerase-cNMP-ligated cAMP receptor protein (CRP) mutant interactions in the enhancement of transcription by CRP mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-DNA COMPLEX; ESCHERICHIA-COLI; ACTIVATOR PROTEIN; LAC PROMOTER; BINDING; MUTATIONS; IDENTIFICATION; PURIFICATION; POSITION-127; OPERON	The enhancement of the transcription of three synthetic promoters by cNMP-ligated cAMP receptor protein (CRP)/mutant complexes was determined from the transcription yields of a short AAUU transcript in an abortive initiation in vitro transcription assay, The cNMP-ligated CRP and mutants were cAMP, cGMP, and cIMP ligated with CRP, T127L CRP, S128A CRP, and T127L/S128A CRP, The transcriptional activation of a 152-base pair lacUV5 promoter (synlac promoter) with a CRP consensus binding site sequence (syncon promoter) was enhanced by an average factor of 12.3 +/- 0.5 with the cAMP-ligated complexes of CRP/mutants and cGMP-ligated T127L, although their promoter binding site affinities varied by a factor of 5. However, in the presence of bound RNA polymerase, the binding affinities only ranged from 0.8 +/- 0.2 x 10(7) M-1 for cAMP-ligated CRP* to 1.8 +/- 0.3 x 10(7) M-1 for cAMP-ligated CRP, indicating that the CRP/mutant interacts with the bound RNA polymerase, which would account for the near constancy of the enhancement factors. The corresponding enhancement factors for the synlac promoter and a promoter with a different CRP binding site sequence (syngal promoter) were also nearly the same, 7.2 +/- 0.7 and 6 +/- 1, respectively, The binding reaction of the syncon promoter to the RNA polymerase is exothermic, with a binding constant (K-b) = 2.1 +/- 0.2 x 10(7) m(-1).	NIST, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA	National Institute of Standards & Technology (NIST) - USA	Schwarz, FP (corresponding author), NIST, Ctr Adv Res Biotechnol, 9600 Gudelsky Dr, Rockville, MD 20850 USA.							ANDERSON W, 1971, J BIOL CHEM, V246, P5926; Baichoo N, 1999, J MOL BIOL, V290, P37, DOI 10.1006/jmbi.1999.2858; BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; BRUNNER M, 1987, EMBO J, V6, P3139, DOI 10.1002/j.1460-2075.1987.tb02624.x; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; HEYDUK T, 1993, NATURE, V364, P548, DOI 10.1038/364548a0; LEE FJ, 1994, NUCLEIC ACIDS RES, V22, P2894; Leu SF, 1999, BIOCHEMISTRY-US, V38, P6222, DOI 10.1021/bi982938z; LOWE PA, 1979, BIOCHEMISTRY-US, V18, P1344, DOI 10.1021/bi00574a034; MALAN TP, 1984, CELL, V39, P173, DOI 10.1016/0092-8674(84)90203-4; MALAN TP, 1984, J MOL BIOL, V180, P881, DOI 10.1016/0022-2836(84)90262-6; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; Moore JL, 1996, J BIOL CHEM, V271, P21273, DOI 10.1074/jbc.271.35.21273; MOORE JL, 1993, THESIS G WASHINGTON; PINKNEY M, 1988, BIOCHEM J, V250, P897, DOI 10.1042/bj2500897; RYU S, 1994, P NATL ACAD SCI USA, V91, P8582, DOI 10.1073/pnas.91.18.8582; SAMBROOK J, 1989, MOL CLONING LAB MANU, pE5; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; Shi Y, 1999, J BIOL CHEM, V274, P6946, DOI 10.1074/jbc.274.11.6946; STRANEY DC, 1989, J MOL BIOL, V206, P41, DOI 10.1016/0022-2836(89)90522-6; TAGAMI H, 1995, NUCLEIC ACIDS RES, V23, P599, DOI 10.1093/nar/23.4.599; YANG CP, 1990, MICROCAL DATA ORIGIN, P66; ZHANG XP, 1992, J BIOL CHEM, V267, P8136; ZHOU YH, 1993, P NATL ACAD SCI USA, V90, P6081, DOI 10.1073/pnas.90.13.6081	27	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33457	33463		10.1074/jbc.M004877200	http://dx.doi.org/10.1074/jbc.M004877200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10934201	hybrid			2022-12-27	WOS:000090104600040
J	Frankel, A; Clarke, S				Frankel, A; Clarke, S			PRMT3 is a distinct member of the protein arginine N-methyltransferase family - Conferral of substrate specificity by a zinc-finger domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN BASIC-PROTEIN; BINDING PROTEINS; RNA RECOGNITION; K-PROTEIN; METHYLATION; IDENTIFICATION; YEAST; PURIFICATION; INTERACTS; HRMT1L1	S-Adenosyl-L-methionine-dependent protein arginine N-methyltransferases (PRMTs) catalyze the methylation of arginine residues within a variety of proteins. At least four distinct mammalian family members have now been described, including PRMT1, PRMT3, CARM1/PRMT4, and JBP1/PRMT5. To more fully define the physiological role of PRMT3, we characterized its unique putative zinc-finger domain and how it can affect its enzymatic activity. Here we show that PRMT3 does contain a single zinc-finger domain in its amino terminus. Although the zinc-liganded form of this domain is not required for methylation of an artificial substrate such as the glutathione S-transferase-fibrillarin amino-terminal fusion protein (GST-GAR), it is required for the enzyme to recognize RNA-associated substrates in RAT1 cell extracts. The recombinant form of PRMT3 is inhibited by high concentrations of ZnCl2 as well as N-ethylmaleimide, reagents that can modify cysteine sulfhydryl groups. We found that we could distinguish PRMT family members by their sensitivity to these reagents; JBP1/PRMT5 and HsI7 methyltransferases were inhibited in a similar manner as PRMT3, whereas Rmt1, PRMT1, and CARM1/PRMT4 were not affected. We were also able to define differences in these enzymes by their sensitivity to inhibition by Tris and free arginine. Finally, we found that the treatment of RAT1 cell extracts with N-ethylmaleimide leads to a loss of the major PRMT1-associated activity that was immune to inhibition under the same conditions as a GST fusion protein. These results suggest that native forms of PRMTs can have different properties than their GST-catalytic chain fusion protein counterparts, which may lack associated noncatalytic subunits.	Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biochem & Chem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Clarke, S (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, 611 Charles E Young Dr E, Los Angeles, CA 90095 USA.				NIGMS NIH HHS [GM26020, T32 GM07185] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026020, R37GM026020, T32GM007185] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; Aleta JM, 1998, TRENDS BIOCHEM SCI, V23, P89, DOI 10.1016/S0968-0004(98)01185-2; Bailey JL, 1967, TECHNIQUES PROTEIN C, P340; BALDWIN GS, 1971, SCIENCE, V171, P579, DOI 10.1126/science.171.3971.579; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; Brahms H, 2000, J BIOL CHEM, V275, P17122, DOI 10.1074/jbc.M000300200; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Denisenko ON, 1996, J BIOL CHEM, V271, P27701, DOI 10.1074/jbc.271.44.27701; DRAPER DE, 1995, ANNU REV BIOCHEM, V64, P593, DOI 10.1146/annurev.bi.64.070195.003113; Frankel A, 1999, BIOCHEM BIOPH RES CO, V259, P391, DOI 10.1006/bbrc.1999.0779; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; GHOSH SK, 1988, J BIOL CHEM, V263, P19024; HAN LM, 1995, MOL CELL BIOL, V15, P1318; Henry MF, 1996, MOL CELL BIOL, V16, P3668; Katsanis N, 1997, MAMM GENOME, V8, P526, DOI 10.1007/s003359900491; Kim S, 1997, BIOCHEMISTRY-US, V36, P5185, DOI 10.1021/bi9625509; KUMAR A, 1986, J BIOL CHEM, V261, P1266; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JH, 2000, BIOCHEM BIOPH RES CO, V274, P105, DOI 10.1006/bbrc.2000.3049; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; LISCHWE MA, 1982, J BIOL CHEM, V257, P4600; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; LIU Q, 1995, MOL CELL BIOL, V15, P2800; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531; RAJPUROHIT R, 1994, J BIOL CHEM, V269, P1075; Scott HS, 1998, GENOMICS, V48, P330, DOI 10.1006/geno.1997.5190; Siebel CW, 1996, P NATL ACAD SCI USA, V93, P13641, DOI 10.1073/pnas.93.24.13641; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; STEPHENSON RC, 1992, J BIOL CHEM, V267, P13314; STONER GL, 1984, J NEUROCHEM, V43, P433, DOI 10.1111/j.1471-4159.1984.tb00919.x; Tang J, 2000, J BIOL CHEM, V275, P19866, DOI 10.1074/jbc.M000023200; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; Yoo BC, 1999, AMINO ACIDS, V17, P391, DOI 10.1007/BF01361664	41	91	94	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32974	32982		10.1074/jbc.M006445200	http://dx.doi.org/10.1074/jbc.M006445200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10931850	hybrid			2022-12-27	WOS:000090003800082
J	Garcia-Martinez, C; Morenilla-Palao, C; Planells-Cases, R; Merino, JM; Ferrer-Montiel, A				Garcia-Martinez, C; Morenilla-Palao, C; Planells-Cases, R; Merino, JM; Ferrer-Montiel, A			Identification of an aspartic residue in the P-loop of the vanilloid receptor that modulates pore properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED ION-CHANNEL; CAPSAICIN-RECEPTOR; CA2+ CHANNEL; BINDING SITE; AFFINITY; NOCICEPTORS; CYSTEINES; CALCIUM; HEAT	Vanilloid receptor subunit 1 (VR1) is a nonselective cation channel that integrates multiple pain-producing stimuli. VR1 channels are blocked with high efficacy by the well established noncompetitive antagonist ruthenium red and exhibit high permeability to divalent cations. The molecular determinants that define these functional properties remain elusive. We have addressed this question and evaluated by site-specific neutralization the contribution on pore properties of acidic residues located in the putative VR1 pore region; Mutant receptors expressed in Xenopus oocytes exhibited capsaicin-operated ionic currents akin to those of wild type channels. Incorporation of glutamine residues at Glu(648) and Glu(651) rendered minor effects on VR1 pore attributes, while Glu(636) slightly modulated pore blockade. In contrast, replacement of Asp(646) by asparagine decreased 10-fold ruthenium red blockade efficacy and reduced 1-fold the relative permeability of the divalent cation Mg2+ with respect to Na+ without changing the selectivity of monovalent cations, At variance with wild type channels and E636Q, E648Q, and E651Q mutant receptors, ruthenium red blockade of D646N mutants was weakly sensitive to extracellular pH acidification. Collectively, our results suggest that Asp(646) is a molecular determinant of VR1 pore properties and imply that this residue may form a ring of negative charges that structures a high affinity binding site for cationic molecules at the extracellular entryway.	Univ Miguel Hernandez, Ctr Biol Mol & Celular, Alicante 03202, Spain; Univ Extremadura, Dept Bioquim & Biol Mol, Badajoz 06071, Spain	Universidad Miguel Hernandez de Elche; Universidad de Extremadura	Ferrer-Montiel, A (corresponding author), Univ Miguel Hernandez, Ctr Biol Mol & Celular, Avda Ferrocarril S-N,Elche, Alicante 03202, Spain.	aferrer@umh.es	Ferrer-Montiel, Antonio/C-3072-2015	Ferrer-Montiel, Antonio/0000-0002-2973-6607; Merino, Jaime M./0000-0002-5316-9200; Morenilla-Palao, Cruz/0000-0002-8159-1206				BASH H, 1992, CHEM ACID DERIV 1 SB, V2, P1; Beck C, 1999, NEURON, V22, P559, DOI 10.1016/S0896-6273(00)80710-2; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, CURR OPIN NEUROBIOL, V9, P525, DOI 10.1016/S0959-4388(99)00009-4; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; DRAY A, 1990, NEUROSCI LETT, V110, P52, DOI 10.1016/0304-3940(90)90786-9; ELLINOR PT, 1995, NEURON, V15, P1121, DOI 10.1016/0896-6273(95)90100-0; Ferrer-Montiel Antonio V., 1994, Methods (Orlando), V6, P60, DOI 10.1006/meth.1994.1008; Ferrer-Montiel AV, 2000, EUR J NEUROSCI, V12, P124; Ferrer-Montiel AV, 1999, METH MOL B, V128, P167; FERRERMONTIEL AV, 1995, P NATL ACAD SCI USA, V92, P8021, DOI 10.1073/pnas.92.17.8021; FerrerMontiel AV, 1996, BIOPHYS J, V71, P749, DOI 10.1016/S0006-3495(96)79274-3; Fersht A., 1985, ENZYME STRUCTURE MEC; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Jung J, 1999, J NEUROSCI, V19, P529; Klockner U, 1996, J BIOL CHEM, V271, P22293; LEWIS CA, 1979, J PHYSL, V286, P501; MILEDI R, 1985, J PHYSL, V357, P173; Nagy I, 1999, J NEUROSCI, V19, P10647, DOI 10.1523/JNEUROSCI.19-24-10647.1999; PASCUAL JM, 1995, NEURON, V14, P1055, DOI 10.1016/0896-6273(95)90344-5; Premkumar LS, 1996, NEURON, V16, P869, DOI 10.1016/S0896-6273(00)80107-5; Schumacher MA, 2000, J BIOL CHEM, V275, P2756, DOI 10.1074/jbc.275.4.2756; Seifert R, 1999, EMBO J, V18, P119, DOI 10.1093/emboj/18.1.119; Sterner O, 1999, TRENDS PHARMACOL SCI, V20, P459, DOI 10.1016/S0165-6147(99)01393-0; Suzuki M, 1999, J BIOL CHEM, V274, P6330, DOI 10.1074/jbc.274.10.6330; Szallasi A, 1999, PHARMACOL REV, V51, P159; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Williams M, 1999, J MED CHEM, V42, P1481, DOI 10.1021/jm9805034; Williamson AV, 1999, BIOPHYS J, V77, P2575, DOI 10.1016/S0006-3495(99)77092-X; Wood J, 1993, CAPSAICIN STUDY PAIN; ZALAWESKI RI, 1992, CHEM ACID DERIVAT SB, V2, P305; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	35	145	150	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32552	32558		10.1074/jbc.M002391200	http://dx.doi.org/10.1074/jbc.M002391200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10931826	hybrid			2022-12-27	WOS:000090003800025
J	Kaldis, P; Cheng, AY; Solomon, MJ				Kaldis, P; Cheng, AY; Solomon, MJ			The effects of changing the site of activating phosphorylation in CDK2 from threonine to serine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; RING FINGER PROTEIN; CELL-CYCLE; BUDDING YEAST; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; STRUCTURAL BASIS; CDC28 MUTATION; IN-VITRO; CAK	Cyclin-dependent kinases (CDKs) that control cell, cycle progression are regulated in many ways, including activating phosphorylation of a conserved threonine residue. This essential phosphorylation is carried out by the CDK-activating kinase (CAK). Here we examine the effects of replacing this threonine residue in human CDK2 by serine. We found that cyclin A bound equally well to wild-type CDK2 (CDK2(Thr-160)) or to the mutant CDK2 (CDK2(Ser-160)). I, the absence of activating phosphorylation, CDK2(Ser-160)-cyclin A complexes were more active than wild-type CDK2(Thr-160)-cyclin A complexes. In contrast, following activating phosphorylation, CDK2(Ser-160)-cyclin A complexes were less active than phosphorylated CDK2(Thr-160)-cyclin A complexes, reflecting a much smaller effect of activating phosphorylation on CDK2(Ser-160). The kinetic parameters for phosphorylating histone H1 were similar for mutant and wild-type CDK2, ruling out a general defect in catalytic activity. Interestingly, the CDK2(Ser-160) mutant was selectively defective in phosphorylating a peptide derived from the C-terminal domain of RNA polymerase II. CDK2(Ser-160) was efficiently phosphorylated by CAKs, both human p40(MO15)(CDK7)-cyclin H and budding yeast Caklp. In fact, the k(cat) values for phosphorylation of CDK2(Ser-160) were significantly higher than for phosphorylation of CDK2(Thr-160), indicating that CDK2(Ser-160) is actually phosphorylated more efficiently than wild-type CDK2. In contrast, dephosphorylation proceeded more slowly with CDK2(Ser-160) than with wild-type CDK2, either in HeLa cell extract or by purified PP2C beta. Combined with the more efficient phosphorylation of CDK2(Ser-160) by CAK, we suggest that one reason for the conservation of threonine as the site of activating phosphorylation may be to favor unphosphorylated CDKs following the degradation of cyclins.	Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University	Kaldis, P (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Regulat Cell Growth Lab, Bldg 560,W 7th St, Frederick, MD 21702 USA.	kaldis@ncifcrf.gov	Kaldis, Philipp/G-2714-2010	Kaldis, Philipp/0000-0002-7247-7591	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047830] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47830] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 1999, MOL CELL BIOL, V19, P1068; Adams PD, 1996, MOL CELL BIOL, V16, P6623; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Cheng AY, 1999, GENE DEV, V13, P2946, DOI 10.1101/gad.13.22.2946; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; DEANA AD, 1990, BIOCHIM BIOPHYS ACTA, V1051, P199, DOI 10.1016/0167-4889(90)90194-I; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DESAI D, 1995, MOL CELL BIOL, V15, P345, DOI 10.1128/MCB.15.1.345; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; Egan EA, 1998, MOL CELL BIOL, V18, P3659, DOI 10.1128/MCB.18.7.3659; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; Enke DA, 1999, J BIOL CHEM, V274, P1949, DOI 10.1074/jbc.274.4.1949; Espinoza FH, 1996, SCIENCE, V273, P1714, DOI 10.1126/science.273.5282.1714; Espinoza FH, 1998, MOL CELL BIOL, V18, P6365, DOI 10.1128/MCB.18.11.6365; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HIGASHI H, 1995, BIOCHEM BIOPH RES CO, V216, P520, DOI 10.1006/bbrc.1995.2653; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Iavarone A, 1997, NATURE, V387, P417; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Kaldis P, 1999, CELL MOL LIFE SCI, V55, P284, DOI 10.1007/s000180050290; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; Kaldis P, 1998, MOL BIOL CELL, V9, P2545, DOI 10.1091/mbc.9.9.2545; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; Kimmelman J, 1999, MOL CELL BIOL, V19, P4774; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kisselev AF, 2000, J BIOL CHEM, V275, P14831, DOI 10.1074/jbc.275.20.14831; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; LABBE JC, 1994, EMBO J, V13, P5155, DOI 10.1002/j.1460-2075.1994.tb06845.x; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; POON RYC, 1994, J CELL SCI, V107, P2789; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; Ross KE, 2000, MOL BIOL CELL, V11, P1597, DOI 10.1091/mbc.11.5.1597; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Solomon M J, 1998, Results Probl Cell Differ, V22, P79; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x	59	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32578	32584		10.1074/jbc.M003212200	http://dx.doi.org/10.1074/jbc.M003212200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10931829	hybrid			2022-12-27	WOS:000090003800029
J	Petronzelli, F; Riccio, A; Markham, GD; Seeholzer, SH; Stoerker, J; Genuardi, M; Yeung, AT; Matsumoto, Y; Bellacosa, A				Petronzelli, F; Riccio, A; Markham, GD; Seeholzer, SH; Stoerker, J; Genuardi, M; Yeung, AT; Matsumoto, Y; Bellacosa, A			Biphasic kinetics of the human DNA repair protein MED1 (MBD4), a mismatch-specific DNA N-glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-NUCLEOTIDE POLYMORPHISMS; BASE EXCISION-REPAIR; G-A MISPAIRS; ENDONUCLEASE-III; MAMMALIAN-CELLS; GUANINE BASES; HELA-CELLS; METHYLATION; BINDING; GENE	The human protein MED1 (also known as MBD4) was previously isolated in a two-hybrid screening using the mismatch repair protein MLH1 as a bait, and shown to have homology to bacterial base excision repair DNA N-glycosylases/lyases. To define the mechanisms of action of MED1, we implemented a sensitive glycosylase assay amenable to kinetic analysis. We show that MED1 functions as a mismatch-specific DNA N-glycosylase active on thymine, uracil, and 5-fluorouracil when these bases are opposite to guanine, MED1 lacks uracil glycosylase activity on single-strand DNA and abasic site lyase activity. The glycosylase activity of MED1 prefers substrates containing a G:T mismatch within methylated or unmethylated CpG sites; since G:T mismatches can originate via deamination of 5-methylcytosine to thymine, MED1 may act as a caretaker of genomic fidelity at CpG sites. A kinetic analysis revealed that MED1 displays a fast first cleavage reaction followed by slower subsequent reactions, resulting in biphasic time course; this is due to the tight binding of MED1 to the abasic site reaction product rather than a consequence of enzyme inactivation. Comparison of kinetic profiles revealed that the MED1 5-methylcytosine binding domain and methylation of the mismatched CpG site are not required for efficient catalysis.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Univ Cattolica Sacro Cuore, Sch Med, Dept Med Genet, I-00168 Rome, Italy; Bruker Daltonics Inc, Billerica, MA 01821 USA	Fox Chase Cancer Center; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Bruker Corporation	Bellacosa, A (corresponding author), Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	a_bellacosa@fccc.edu	Genuardi, Maurizio/K-3049-2018	Genuardi, Maurizio/0000-0002-7410-8351; Matsumoto, Yoshihiro/0000-0001-6580-7188	NATIONAL CANCER INSTITUTE [R01CA078412, R01CA071426, R29CA078412, P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927, CA71426, CA78412] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON KS, 1988, BIOCHEMISTRY-US, V27, P7395, DOI 10.1021/bi00419a034; ASAHARA H, 1989, BIOCHEMISTRY-US, V28, P4444, DOI 10.1021/bi00436a048; AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; Bader S, 1999, ONCOGENE, V18, P8044, DOI 10.1038/sj.onc.1203229; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; Bird AP, 1996, CANCER SURV, V28, P87; BOLT HM, 1988, CRIT REV TOXICOL, V18, P299, DOI 10.3109/10408448809037469; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; GRIFFIN S, 1994, BIOCHEMISTRY-US, V33, P4787, DOI 10.1021/bi00182a006; GRIFFIN S, 1993, BIOCHEMISTRY-US, V32, P13032, DOI 10.1021/bi00211a012; Hacia JG, 1999, NAT GENET, V22, P164, DOI 10.1038/9674; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; HCIKSON ID, 1997, BASE EXCISION REPAIR, P1; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Horst JP, 1996, EMBO J, V15, P5459, DOI 10.1002/j.1460-2075.1996.tb00929.x; KATCHER HL, 1983, BIOCHEMISTRY-US, V22, P4071, DOI 10.1021/bi00286a013; Kleihues P, 1997, AM J PATHOL, V150, P1; Krokan HE, 1997, BIOCHEM J, V325, P1; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Loeb KR, 2000, CARCINOGENESIS, V21, P379, DOI 10.1093/carcin/21.3.379; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; Mol CD, 1999, ANNU REV BIOPH BIOM, V28, P101, DOI 10.1146/annurev.biophys.28.1.101; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; NEDDERMANN P, 1994, P NATL ACAD SCI USA, V91, P1642, DOI 10.1073/pnas.91.5.1642; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; Oleykowski CA, 1998, NUCLEIC ACIDS RES, V26, P4597, DOI 10.1093/nar/26.20.4597; Petronzelli F, 2000, J CELL PHYSIOL, V185, P473, DOI 10.1002/1097-4652(200012)185:3<473::AID-JCP19>3.0.CO;2-#; PIERSEN CE, 1995, J BIOL CHEM, V270, P23475, DOI 10.1074/jbc.270.40.23475; Porello SL, 1998, BIOCHEMISTRY-US, V37, P14756, DOI 10.1021/bi981594+; Riccio A, 1999, NAT GENET, V23, P266, DOI 10.1038/15443; Saparbaev M, 1999, IARC SCI PUBL, P249; Sard L, 1997, GENOMICS, V44, P222, DOI 10.1006/geno.1997.4843; Scharer OD, 1997, P NATL ACAD SCI USA, V94, P4878, DOI 10.1073/pnas.94.10.4878; Schmutte C, 1998, BIOL CHEM, V379, P377; Schmutte C, 1997, CANCER RES, V57, P3010; SibghatUllah, 1996, BIOCHEMISTRY-US, V35, P12926, DOI 10.1021/bi961022u; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; WALLACE SS, 1994, INT J RADIAT BIOL, V66, P579, DOI 10.1080/09553009414551661; Waters TR, 1998, J BIOL CHEM, V273, P20007, DOI 10.1074/jbc.273.32.20007; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67; Wyatt MD, 1999, BIOESSAYS, V21, P668, DOI 10.1002/(SICI)1521-1878(199908)21:8<668::AID-BIES6>3.3.CO;2-4; YEUNG AT, 1988, NUCLEIC ACIDS RES, V16, P4539, DOI 10.1093/nar/16.10.4539; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	48	147	156	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32422	32429		10.1074/jbc.M004535200	http://dx.doi.org/10.1074/jbc.M004535200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10930409	hybrid			2022-12-27	WOS:000090003800008
J	Ridgeway, AG; Petropoulos, H; Wilton, S; Skerjanc, IS				Ridgeway, AG; Petropoulos, H; Wilton, S; Skerjanc, IS			Wnt signaling regulates the function of MyoD and myogenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; MOUSE PARAXIAL MESODERM; BHLH GENE-EXPRESSION; DORSAL NEURAL-TUBE; TRANSCRIPTION FACTOR; MUSCLE DIFFERENTIATION; SKELETAL MYOGENESIS; BINDING-PROTEIN; SONIC HEDGEHOG; DNA-BINDING	The myogenic regulatory factors (MRFs), MyoD and myogenin, can induce myogenesis in a variety of cell lines but not efficiently in monolayer cultures of P19 embryonal carcinoma stem cells. Aggregation of cells expressing MRFs, termed P19[MRF] cells, results in an approximately 30-fold enhancement of myogenesis, Here we examine molecular events occurring during P19 cell aggregation to identify potential mechanisms regulating MRF activity. Although myogenin protein was continually present in the nuclei of >90% of P19[myogenin] cells, only a fraction of these cells differentiated. Consequently, it appears that post-translational regulation controls myogenin activity in a cell lineage-specific manner. A correlation was obtained between the expression of factors involved in somite patterning, including Wnt3a, Wnt5b, BMP-2/4, and Pax3, and the induction of myogenesis, Co-culturing P19[Wnt3a] cells with P19[MRF] cells in monolayer resulted in a 5- to 8-fold increase in myogenesis, Neither BMP-4 nor Pax3 was efficient in enhancing MRF activity in unaggregated P19 cultures. Furthermore, BMP-4 abrogated the enhanced myogenesis induced by Wnt signaling. Consequently, signaling events resulting from Wnt3a expression but not BMP-4 signaling or Pax3 expression, regulate MRF function. Therefore, the P19 cell culture system can be used to study the link between somite patterning events and myogenesis.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Skerjanc, IS (corresponding author), Univ Western Ontario, Dept Biochem, Med Sci Bldg, London, ON N6A 5C1, Canada.	skerjanc@julian.uwo.ca	Skerjanc, Ilona/AAN-3318-2020					ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; Amthor H, 1999, DEVELOPMENT, V126, P1041; Angello JC, 1997, DEV BIOL, V192, P93, DOI 10.1006/dbio.1997.8722; Arias AM, 1999, CURR OPIN GENET DEV, V9, P447, DOI 10.1016/S0959-437X(99)80068-9; Armour C, 1999, EXP CELL RES, V251, P79, DOI 10.1006/excr.1999.4567; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; Borycki AG, 1999, DEVELOPMENT, V126, P4053; Borycki AG, 1998, DEVELOPMENT, V125, P777; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BUFFINGER N, 1995, DEV BIOL, V169, P96, DOI 10.1006/dbio.1995.1130; BUFFINGER N, 1994, DEVELOPMENT, V120, P1443; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cossu G, 1996, DEVELOPMENT, V122, P429; Cossu G, 1996, TRENDS GENET, V12, P218, DOI 10.1016/0168-9525(96)10025-1; Cossu G, 1999, EMBO J, V18, P6867, DOI 10.1093/emboj/18.24.6867; Currie PD, 1998, MECH DEVELOP, V73, P3, DOI 10.1016/S0925-4773(98)00036-7; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; GARFINKEL LI, 1982, J BIOL CHEM, V257, P1078; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Gofflot F, 1997, DEV DYNAM, V210, P431, DOI 10.1002/(SICI)1097-0177(199712)210:4<431::AID-AJA7>3.0.CO;2-H; Gossler A, 1998, CURR TOP DEV BIOL, V38, P225; GOULDING M, 1994, DEVELOPMENT, V120, P957; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HENTHORN P, 1990, NUCLEIC ACIDS RES, V18, P677, DOI 10.1093/nar/18.3.677; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; Ikeya M, 1998, DEVELOPMENT, V125, P4969; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Marcelle C, 1997, DEVELOPMENT, V124, P3955; Maroto M, 1997, CELL, V89, P139, DOI 10.1016/S0092-8674(00)80190-7; MCBURNEY MW, 1994, SOMAT CELL MOLEC GEN, V20, P529, DOI 10.1007/BF02255843; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; MUNSTERBERG AE, 1995, DEVELOPMENT, V121, P651; MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911; MURRAY SS, 1993, J CELL BIOCHEM, V53, P51, DOI 10.1002/jcb.240530107; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAIDU PS, 1995, MOL CELL BIOL, V15, P2707; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; PARI G, 1991, MOL CELL BIOL, V11, P4796, DOI 10.1128/MCB.11.9.4796; Petropoulos H, 2000, J BIOL CHEM, V275, P25095, DOI 10.1074/jbc.M004251200; Pourquie O, 1996, CELL, V84, P461, DOI 10.1016/S0092-8674(00)81291-X; PRUITT SC, 1992, DEVELOPMENT, V116, P573; Puri PL, 2000, GENE DEV, V14, P574; Reshef R, 1998, GENE DEV, V12, P290, DOI 10.1101/gad.12.3.290; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; Ridgeway AG, 1999, FEBS LETT, V456, P399, DOI 10.1016/S0014-5793(99)00993-X; Ridgeway AG, 2000, J BIOL CHEM, V275, P41, DOI 10.1074/jbc.275.1.41; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; RUDNICKI MA, 1990, DEV BIOL, V138, P348, DOI 10.1016/0012-1606(90)90202-T; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SHANI M, 1992, SYM SOC EXP BIOL, V46, P19; SKERJANC IS, 1994, MOL CELL BIOL, V14, P8451, DOI 10.1128/MCB.14.12.8451; Skerjanc IS, 1996, J BIOL CHEM, V271, P3555, DOI 10.1074/jbc.271.7.3555; Skerjanc IS, 1998, J BIOL CHEM, V273, P34904, DOI 10.1074/jbc.273.52.34904; Skerjanc IS, 1999, TRENDS CARDIOVAS MED, V9, P139, DOI 10.1016/S1050-1738(99)00017-1; STERN HM, 1995, DEVELOPMENT, V121, P3675; Tajbakhsh S, 1997, CURR OPIN GENET DEV, V7, P634, DOI 10.1016/S0959-437X(97)80011-1; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; Tajbakhsh S, 1998, DEVELOPMENT, V125, P4155; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; Tremblay P, 1998, DEV BIOL, V203, P49, DOI 10.1006/dbio.1998.9041; VIDRICAIRE G, 1994, DEVELOPMENT, V120, P115; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; Wilton S, 1999, IN VITRO CELL DEV-AN, V35, P175; Wright WE, 1996, DEV GENET, V19, P131, DOI 10.1002/(SICI)1520-6408(1996)19:2<131::AID-DVG4>3.0.CO;2-A; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193	86	117	128	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32398	32405		10.1074/jbc.M004349200	http://dx.doi.org/10.1074/jbc.M004349200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10915791	hybrid			2022-12-27	WOS:000090003800005
J	Henklein, P; Bruns, K; Sherman, MP; Tessmer, U; Licha, K; Kopp, J; de Noronha, CMC; Greene, WC; Wray, V; Schubert, U				Henklein, P; Bruns, K; Sherman, MP; Tessmer, U; Licha, K; Kopp, J; de Noronha, CMC; Greene, WC; Wray, V; Schubert, U			Functional and structural characterization of synthetic HIV-1 Vpr that transduces cells, localizes to the nucleus, and induces G(2) cell cycle arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; VIRAL PROTEIN-R; PREINTEGRATION COMPLEX; BIOLOGICAL FUNCTIONS; TERMINAL DOMAIN; GAG PRECURSOR; P6 DOMAIN; IN-VIVO; TYPE-1; INFECTION	Human immunodeficiency virus (HIV) Vpr contributes to nuclear import of the viral pre-integration complex and induces G(2), cell cycle arrest. We describe the production of synthetic Vpr that permitted the first studies on the structure and folding of the full-length protein. Vpr is unstructured at neutral pH whereas under acidic conditions or upon addition of trifluorethanol it adopts a-helical structures. Vpr forms dimers in aqueous trifluorethanol, whereas oligomers exist in pure water. H-1 NMR spectroscopy allows the signal assignment of N- and C-terminal amino acid residues; however, the central section of the molecule is obscured by self-association. These findings suggest that the in vivo folding of Vpr may require structure-stabilizing interacting factors such as previously described interacting cellular and viral proteins or nucleic acids. In biological studies we found that Vpr is efficiently taken up from the extracellular medium by cells in a process that occurs independent of other HIV-1 proteins and appears to be independent of cellular receptors. Following cellular uptake, Vpr is efficiently imported into the nucleus of transduced cells. Extracellular addition of Vpr induces G(2), cell cycle arrest in dividing cells. Together, these findings raise the possibility that circulating forms of Vpr observed in HIV-infected patients may exert biological effects on a broad range of host target cells.	NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA; NIDDKD, Kidney Dis Sect, Viral Dis Lab, NIH, Bethesda, MD 20892 USA; Humboldt Univ, Inst Biochem, D-10115 Berlin, Germany; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Gesell Biotechnol Forsch GmbH, Dept Mol Struct Res, D-38124 Braunschweig, Germany; Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94143 USA; Free Univ Berlin, Inst Diagnost Res GmbH, D-1000 Berlin, Germany	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Humboldt University of Berlin; Heinrich Pette Institute; University of Hamburg; Gesellschaft fur Biotechnologische Forschung mbH; University of California System; University of California San Francisco; The J David Gladstone Institutes; Free University of Berlin	Schubert, U (corresponding author), NIAID, Viral Dis Lab, NIH, Rm 205,Bldg 4,4 Ctr Dr,MSC 0440, Bethesda, MD 20892 USA.		Kopp, Jeffrey B/O-2681-2015	Kopp, Jeffrey B/0000-0001-9052-186X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045324, Z01AI000658, ZIAAI000658] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK043308, Z01DK043308] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI45324] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Ayyavoo V, 1997, NAT MED, V3, P1117, DOI 10.1038/nm1097-1117; Bachand F, 1999, J BIOL CHEM, V274, P9083, DOI 10.1074/jbc.274.13.9083; Bukrinsky M, 1999, REV MED VIROL, V9, P39, DOI 10.1002/(SICI)1099-1654(199901/03)9:1<39::AID-RMV235>3.0.CO;2-3; CARPINO LA, 1993, J AM CHEM SOC, V115, P4397, DOI 10.1021/ja00063a082; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; Cornille F, 1999, J PEPT RES, V54, P427, DOI 10.1034/j.1399-3011.1999.00129.x; de Rocquigny H, 1997, J BIOL CHEM, V272, P30753, DOI 10.1074/jbc.272.49.30753; Emerman M, 1996, CURR BIOL, V6, P1096, DOI 10.1016/S0960-9822(02)00676-0; Felzien LK, 1998, P NATL ACAD SCI USA, V95, P5281, DOI 10.1073/pnas.95.9.5281; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; GIBBS JS, 1995, J VIROL, V69, P2378, DOI 10.1128/JVI.69.4.2378-2383.1995; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; GRASMASSE H, 1990, INT J PEPT PROT RES, V36, P219; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; Hrimech M, 1999, J VIROL, V73, P4101, DOI 10.1128/JVI.73.5.4101-4109.1999; Jenkins Y, 1998, J CELL BIOL, V143, P875, DOI 10.1083/jcb.143.4.875; Kino T, 1999, J EXP MED, V189, P51, DOI 10.1084/jem.189.1.51; KONDO E, 1995, J VIROL, V69, P2759, DOI 10.1128/JVI.69.5.2759-2764.1995; LANG SM, 1993, J VIROL, V67, P902, DOI 10.1128/JVI.67.2.902-912.1993; LEVY DN, 1993, CELL, V72, P541, DOI 10.1016/0092-8674(93)90073-Y; LEVY DN, 1995, J VIROL, V69, P1243, DOI 10.1128/JVI.69.2.1243-1252.1995; LEVY DN, 1994, P NATL ACAD SCI USA, V91, P10873, DOI 10.1073/pnas.91.23.10873; Lundgren S, 1997, J HISTOCHEM CYTOCHEM, V45, P383, DOI 10.1177/002215549704500306; Luo ZW, 1998, BIOCHEM BIOPH RES CO, V244, P732, DOI 10.1006/bbrc.1998.8330; Macreadie IG, 1996, MOL MICROBIOL, V19, P1185, DOI 10.1111/j.1365-2958.1996.tb02464.x; MACREADIE IG, 1995, P NATL ACAD SCI USA, V91, P27770; Moestrup SK, 1996, P NATL ACAD SCI USA, V93, P8612, DOI 10.1073/pnas.93.16.8612; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Nie ZL, 1998, J VIROL, V72, P4104, DOI 10.1128/JVI.72.5.4104-4115.1998; Piller SC, 1996, P NATL ACAD SCI USA, V93, P111, DOI 10.1073/pnas.93.1.111; Piller SC, 1998, P NATL ACAD SCI USA, V95, P4595, DOI 10.1073/pnas.95.8.4595; Poon B, 1998, SCIENCE, V281, P266, DOI 10.1126/science.281.5374.266; Popov S, 1998, J BIOL CHEM, V273, P13347, DOI 10.1074/jbc.273.21.13347; Popov S, 1998, EMBO J, V17, P909, DOI 10.1093/emboj/17.4.909; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; Roques BP, 1997, BIOCHIMIE, V79, P673, DOI 10.1016/S0300-9084(97)83501-8; Schuler W, 1999, J MOL BIOL, V285, P2105, DOI 10.1006/jmbi.1998.2381; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Selig L, 1999, J VIROL, V73, P592, DOI 10.1128/JVI.73.1.592-600.1999; Stark LA, 1998, J VIROL, V72, P3037, DOI 10.1128/JVI.72.4.3037-3044.1998; Stewart SA, 1997, J VIROL, V71, P5579, DOI 10.1128/JVI.71.7.5579-5592.1997; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; Wang LL, 1996, GENE, V178, P7, DOI 10.1016/0378-1119(96)00312-5; WANG LL, 1995, J BIOL CHEM, V270, P25564, DOI 10.1074/jbc.270.43.25564; Wecker K, 1999, EUR J BIOCHEM, V266, P359, DOI 10.1046/j.1432-1327.1999.00858.x; WRAY V, 1995, INT J PEPT PROT RES, V45, P35; Yao SG, 1998, PROTEIN PEPTIDE LETT, V5, P127; Zhang SG, 1998, GENE, V212, P157, DOI 10.1016/S0378-1119(98)00178-4; ZHAO LJ, 1994, J BIOL CHEM, V269, P32131	51	96	100	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32016	32026		10.1074/jbc.M004044200	http://dx.doi.org/10.1074/jbc.M004044200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10903315	hybrid			2022-12-27	WOS:000089858900065
J	Vuong, H; Patterson, T; Shapiro, P; Kalvakolanu, DV; Wu, R; Ma, WY; Dong, ZG; Kleeberger, SR; Reddy, SPM				Vuong, H; Patterson, T; Shapiro, P; Kalvakolanu, DV; Wu, R; Ma, WY; Dong, ZG; Kleeberger, SR; Reddy, SPM			Phorbol ester-induced expression of airway squamous cell differentiation marker, SPRR1B, is regulated by protein kinase C delta/Ras/MEKK1/MKK1-dependent/AP-1 signal transduction pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE-RICH PROTEINS; BRONCHIAL EPITHELIAL-CELLS; C-DELTA; GENE-EXPRESSION; SPR1 GENE; KERATINOCYTE DIFFERENTIATION; MALIGNANT KERATINOCYTES; MEK KINASE; ACTIVATION; RAS	The transcriptional induction of SPRR1B by phorbol 12-myristate 13-acetate (PMA) is mainly mediated by the first -152-base pair 5'-flanking region containing two functional AP-1 sites. In this study, we have analyzed the signaling pathways that mediate the induction in tracheobronchial epithelial cells. PKC inhibitor ablated PMA-stimulated expression of endogenous SPRR1B and reporter gene expression driven by SPRR1B promoter. PKC activator promoted the transcription. The dominant negative protein kinase C delta (dn-PKC delta) and rottlerin (PKC delta inhibitor) completely suppressed PMA-stimulated promoter activity, dn-Ras or dn-MEKK1 inhibited PMA-stimulated promoter activity, while their corresponding constitutively active mutants augmented it. dn-c-Raf-1 did not have any effect on reporter gene expression. Since MEKK1 activates multiple parallel pathways, we examined involvement of JNK/SAPK, p38, and MKK1 in promoter regulation. Go-expression of the dominant negative forms of MKK4, MKK7, JNK/SAPK, MKK3, MKK6, or p38 alpha did not suppress PMA-stimulated reporter gene expression. However, MKK1 inhibitors UO126 and PD98095 suppressed gene expression. Consistent with this, expression of dn-MKK1 strongly suppressed PMA-stimulated promoter activity, while the constitutively active MKK1 augmented it. However, MKK1-mediated induction of SPRR1B probably does not depend on extracellular signal-regulated kinases 1 and 2, suggesting the requirement of another kinase(s). dnc-Jun mutants abolished PMA-stimulated expression supporting an important role for AP-l proteins in SPRR1B expression. Together, these results suggest that a PKC delta/Ras/MEKK1/MKK1-dependent/AP-1 pathway regulates the PMA-inducible expression of the SPRR1B in tracheobronchial epithelial cells.	Johns Hopkins Univ, Dept Environm Hlth Sci, Div Physiol, Sch Publ Hlth, Baltimore, MD 21205 USA; Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Greenbaum Canc Ctr, Baltimore, MD 21201 USA; Univ Calif Davis, Dept Internal Med, Sch Med, Davis, CA 95616 USA; Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of California System; University of California Davis; University of Minnesota System	Reddy, SPM (corresponding author), Johns Hopkins Univ, Dept Environm Hlth Sci, Div Physiol, Sch Publ Hlth, Rm W7006,615 N Wolfe St, Baltimore, MD 21205 USA.	sreddy@jhsph.edu	Kleeberger, Steven R/F-1807-2019	Kleeberger, Steven R/0000-0003-2948-8452	NCI NIH HHS [CA-71401] Funding Source: Medline; NHLBI NIH HHS [HL-58122] Funding Source: Medline; NIEHS NIH HHS [ES-06230] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071401] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058122, R29HL058122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006230, Z01ES100513, Z01ES100512] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AN G, 1993, J CELL PHYSIOL, V157, P562, DOI 10.1002/jcp.1041570316; AN G, 1993, J BIOL CHEM, V268, P10977; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Anisowicz A, 1999, MOL MED, V5, P526, DOI 10.1007/BF03401980; BASBAUM C, 1990, AM J PHYSIOL, V259, pL38, DOI 10.1152/ajplung.1990.259.2.L38; BECCI PJ, 1978, J NATL CANCER I, V61, P577; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DeMuth JP, 1998, AM J RESP CELL MOL, V19, P25, DOI 10.1165/ajrcmb.19.1.3078; Deng J, 2000, AM J RESP CELL MOL, V22, P597, DOI 10.1165/ajrcmb.22.5.3520; Deng J, 2000, J BIOL CHEM, V275, P5739, DOI 10.1074/jbc.275.8.5739; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; Eckert RL, 1996, MOL BIOL REP, V23, P59, DOI 10.1007/BF00357073; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Efimova T, 2000, J BIOL CHEM, V275, P1601, DOI 10.1074/jbc.275.3.1601; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; GANDARILLAS A, 1995, MAMM GENOME, V6, P680, DOI 10.1007/BF00352383; GANG A, 1992, AM J RESP CELL MOL, V7, P104, DOI 10.1165/ajrcmb/7.1.104; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GIBBS S, 1993, GENOMICS, V16, P630, DOI 10.1006/geno.1993.1240; Griffiths G, 1996, BIOCHEM BIOPH RES CO, V222, P802, DOI 10.1006/bbrc.1996.0830; HARRIS CC, 1972, JNCI-J NATL CANCER I, V48, P743; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; HOHL D, 1995, J INVEST DERMATOL, V104, P902, DOI 10.1111/1523-1747.ep12606176; Jetten A M, 1992, J Natl Cancer Inst Monogr, P93; Jetten Anton M., 1997, Journal of Dermatology (Tokyo), V24, P711; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kato Y, 2000, J BIOL CHEM, V275, P18534, DOI 10.1074/jbc.M001573200; Koizumi H, 1996, BRIT J DERMATOL, V134, P686, DOI 10.1111/j.1365-2133.1996.tb06971.x; KUMAR CC, 1995, CANCER RES, V55, P5106; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; Lau D, 2000, AM J RESP CELL MOL, V22, P92, DOI 10.1165/ajrcmb.22.1.3637; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIEDTKE CM, 1995, AM J PHYSIOL-LUNG C, V268, pL414, DOI 10.1152/ajplung.1995.268.3.L414; Lohman FP, 1997, EXP CELL RES, V231, P141, DOI 10.1006/excr.1996.3458; Lohman FP, 1997, ONCOGENE, V14, P1623, DOI 10.1038/sj.onc.1200974; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; Mischke D, 1996, J INVEST DERMATOL, V106, P989, DOI 10.1111/1523-1747.ep12338501; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; PFEIFER AMA, 1989, ENVIRON HEALTH PERSP, V80, P209, DOI 10.2307/3430746; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Reddy SPM, 1998, GENE, V224, P59, DOI 10.1016/S0378-1119(98)00507-1; REDDY SPM, 1995, J BIOL CHEM, V270, P26451, DOI 10.1074/jbc.270.44.26451; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Sark MWJ, 1999, EXP CELL RES, V250, P475, DOI 10.1006/excr.1999.4532; Sark MWJ, 1998, J BIOL CHEM, V273, P24683, DOI 10.1074/jbc.273.38.24683; SEGER R, 1995, J BIOL CHEM, V270, P28325; Steinert PM, 1998, J STRUCT BIOL, V122, P76, DOI 10.1006/jsbi.1998.3957; Steinert PM, 1999, MOL BIOL CELL, V10, P4247, DOI 10.1091/mbc.10.12.4247; Tesfaigzi J, 1996, EXP CELL RES, V228, P277, DOI 10.1006/excr.1996.0327; Tesfaigzi J, 1996, J CELL PHYSIOL, V166, P480, DOI 10.1002/(SICI)1097-4652(199603)166:3<480::AID-JCP2>3.0.CO;2-L; Tesfaigzi J, 1996, AM J RESP CELL MOL, V14, P478, DOI 10.1165/ajrcmb.14.5.8624253; Tesfaigzi Johannes, 1999, Cell Biochemistry and Biophysics, V30, P243, DOI 10.1007/BF02738069; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Tolwinski NS, 1999, J BIOL CHEM, V274, P6168, DOI 10.1074/jbc.274.10.6168; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Welter JF, 1995, ONCOGENE, V11, P2681; WILLEY JC, 1984, CANCER RES, V44, P5124; WILLEY JC, 1984, CARCINOGENESIS, V5, P209, DOI 10.1093/carcin/5.2.209; Wu R, 1997, EUR RESPIR J, V10, P2398, DOI 10.1183/09031936.97.10102398; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; YAAR M, 1995, EXP CELL RES, V217, P217, DOI 10.1006/excr.1995.1081; Yamamoto T, 1999, J BIOCHEM-TOKYO, V126, P799, DOI 10.1093/oxfordjournals.jbchem.a022519; YAN MH, 1994, NATURE, V372, P798; YAN MH, 1994, J BIOL CHEM, V269, P19067; YUSPA SH, 1982, CANCER RES, V42, P2344; YUSPA SH, 1994, J INVEST DERMATOL, V103, pS90, DOI 10.1111/1523-1747.ep12399255	75	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32250	32259		10.1074/jbc.M005227200	http://dx.doi.org/10.1074/jbc.M005227200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10918063	hybrid			2022-12-27	WOS:000089858900096
J	Waltner-Law, M; Daniels, MC; Sutherland, C; Granner, DK				Waltner-Law, M; Daniels, MC; Sutherland, C; Granner, DK			NF-kappa B inhibits glucocorticoid and cAMP-mediated expression of the phosphoenolpyruvate carboxykinase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING PROTEIN; CULTURED RAT HEPATOCYTES; TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR; RESPONSE ELEMENT; CAENORHABDITIS-ELEGANS; ACCESSORY FACTOR; PEPCK GENE; GTP GENE; PHOSPHATIDYLINOSITOL 3-KINASE	Transcription of the phosphoenolpyruvate carboxykinase (PEPCK) gene is regulated by a variety of agents. Glucocorticoids, retinoic acid, and glucagon (via its second messenger, cAMP) stimulate PEPCK gene transcription, whereas insulin, phorbol esters, cytokines, and oxidative stress have an opposing effect. Stimulation of PEPCK gene expression has been extensively studied, and a number of important DNA elements and binding proteins that regulate the transcription of this gene have been identified. However, the mechanisms utilized to turn off expression of this gene are not well-defined. Many of the negative regulators of PEPCK gene transcription also stimulate the nuclear localization and activation of the transcription factor NF-kappa B, so we hypothesized that this factor could be involved in the repression of PEPCK gene expression. We find that the p65 subunit of NF-kappa B represses the increase of PEPCK gene transcription mediated by glucocorticoids and cAMP in a concentration-dependent manner. The mutation of an NF-kappa B binding element identified in the PEPCK gene promoter fails to abrogate this repression. Further analysis suggests that p65 represses PEPCK gene transcription through a protein protein interaction with the coactivator, CREB binding protein.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Granner, DK (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 707 Light Hall, Nashville, TN 37232 USA.	daryl.granner@mcmail.vanderbilt.edu		Sutherland, Calum/0000-0003-4398-7434	NIDDK NIH HHS [DK35107, DK20593, DK07563] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, R01DK035107, P30DK020593, R37DK035107] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agati JM, 1998, J BIOL CHEM, V273, P18751, DOI 10.1074/jbc.273.30.18751; ANGRAND PO, 1994, CELL GROWTH DIFFER, V5, P957; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Bertrand F, 1998, J BIOL CHEM, V273, P2931, DOI 10.1074/jbc.273.5.2931; BERTRAND F, 1995, J BIOL CHEM, V270, P24435, DOI 10.1074/jbc.270.41.24435; CHANG KSS, 1993, CANCER LETT, V74, P75, DOI 10.1016/0304-3835(93)90047-D; CHEN D, 1994, J EXP MED, V179, P931, DOI 10.1084/jem.179.3.931; CHRIST B, 1994, HEPATOLOGY, V20, P1577, DOI 10.1002/hep.1840200629; Christ B, 1996, BIOCHEM J, V320, P161, DOI 10.1042/bj3200161; CHU DTW, 1987, MOL ENDOCRINOL, V1, P53, DOI 10.1210/mend-1-1-53; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; Dubnicoff T, 1997, GENE DEV, V11, P2952, DOI 10.1101/gad.11.22.2952; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HALL RK, 1992, MOL CELL BIOL, V12, P5527, DOI 10.1128/MCB.12.12.5527; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HILL MR, 1992, INFECT IMMUN, V60, P4040, DOI 10.1128/IAI.60.10.4040-4050.1992; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; KIROV N, 1993, EMBO J, V12, P3193, DOI 10.1002/j.1460-2075.1993.tb05988.x; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; Liao JF, 1998, J BIOL CHEM, V273, P27320, DOI 10.1074/jbc.273.42.27320; LIU JS, 1991, J BIOL CHEM, V266, P19095; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; OBRIEN RM, 1994, BIOCHEM J, V303, P737, DOI 10.1042/bj3030737; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1991, P NATL ACAD SCI USA, V88, P6580, DOI 10.1073/pnas.88.15.6580; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Park EA, 1999, J BIOL CHEM, V274, P211, DOI 10.1074/jbc.274.1.211; Parker D, 1996, MOL CELL BIOL, V16, P694; Parry GCN, 1997, J IMMUNOL, V159, P5450; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PETERSEN DD, 1988, MOL CELL BIOL, V8, P96, DOI 10.1128/MCB.8.1.96; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; ROESLER WJ, 1995, J BIOL CHEM, V270, P8225, DOI 10.1074/jbc.270.14.8225; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Scott DK, 1998, J BIOL CHEM, V273, P24145, DOI 10.1074/jbc.273.37.24145; Scott DK, 1996, J BIOL CHEM, V271, P31909, DOI 10.1074/jbc.271.50.31909; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Sugiyama T, 1998, MOL ENDOCRINOL, V12, P1487, DOI 10.1210/me.12.10.1487; Sutherland C, 1997, DIABETES, V46, P17, DOI 10.2337/diabetes.46.1.17; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; Wissink S, 1997, J BIOL CHEM, V272, P22278, DOI 10.1074/jbc.272.35.22278; Yamada K, 1999, J BIOL CHEM, V274, P5880, DOI 10.1074/jbc.274.9.5880; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174	71	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31847	31856		10.1074/jbc.M003656200	http://dx.doi.org/10.1074/jbc.M003656200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10913132	hybrid			2022-12-27	WOS:000089858900044
J	Garinot-Schneider, C; Lellouch, AC; Geremia, RA				Garinot-Schneider, C; Lellouch, AC; Geremia, RA			Identification of essential amino acid residues in the Sinorhizobium meliloti glucosyltransferase ExoM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; RHIZOBIUM-MELILOTI; SUCCINOGLYCAN BIOSYNTHESIS; EXOPOLYSACCHARIDE BIOSYNTHESIS; STRUCTURAL CHARACTERIZATION; GLYCOSYL TRANSFERASES; GENE-CLUSTER; ACTIVE-SITE; GLYCOSYLTRANSFERASES; ENZYME	ExoM is a beta(1-4)-glucosyltransferase involved in the assembly of the repeat unit of the exopolysaccharide succinoglycan from Sinorhizobium meliloti, By comparing the sequence of ExoM to those of other members of the Pfam Glyco Domain 2 family, most notably SpsA (Bacillus subtilis) for whom the three-dimensional structure has been resolved, three potentially important aspartic acid residues of ExoM were identified, Single substitutions of each of the Asp amino acids at positions 44, 96, and 187 with Ala resulted in the loss of mutant recombinant protein activity in vitro as well as the loss of succinoglycan production in an in vivo rescue assay. Mutants harboring Glu instead of Asp 44 or Asp-96 possessed no in vitro activity but could restore succinoglycan production in vivo. However, replacement of Asp-187 with Glu completely inactivated ExoM as judged by both the in vitro and in vivo assays. These results indicate that Asp-44, Asp-96, and Asp-187 are essential for the activity of ExoM. Furthermore, these data are consistent with the functions proposed for each of the analogous aspartic acids of SpsA based on the SpsA-UDP structure, namely, that Asp-44 and Asp-96 are involved in UDP substrate binding and that Asp-187 is the catalytic base in the glycosyltransferase reaction.	Univ Grenoble 1, Ctr Rech Macromol Vegetales, CNRS, F-38041 Grenoble 9, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Geremia, RA (corresponding author), CNRS, CERMAV, BP 53, Grenoble 9, France.		Lellouch, Annemarie/E-9905-2014; Geremia, Roberto A/A-7972-2010					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Becker A, 1995, MOL GEN GENET, V249, P487, DOI 10.1007/BF00290574; BECKER A, 1993, MOL GEN GENET, V241, P367, DOI 10.1007/BF00284690; BECKER A, 1993, MOL PLANT MICROBE IN, V6, P735, DOI 10.1094/MPMI-6-735; Breton C, 1998, J BIOCHEM, V123, P1000; Breton C, 1999, CURR OPIN STRUC BIOL, V9, P563, DOI 10.1016/S0959-440X(99)00006-8; Busch C, 1998, J BIOL CHEM, V273, P19566, DOI 10.1074/jbc.273.31.19566; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; Cheng HP, 1998, J BACTERIOL, V180, P5183, DOI 10.1128/JB.180.19.5183-5191.1998; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Edwards KJ, 1999, MICROBIOL-SGM, V145, P1499, DOI 10.1099/13500872-145-6-1499; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; GLUCKSMANN MA, 1993, J BACTERIOL, V175, P7033, DOI 10.1128/jb.175.21.7033-7044.1993; GLUCKSMANN MA, 1993, J BACTERIOL, V175, P7045, DOI 10.1128/jb.175.21.7045-7055.1993; Griffiths G, 1998, J BIOL CHEM, V273, P11752, DOI 10.1074/jbc.273.19.11752; Hagen FK, 1999, J BIOL CHEM, V274, P6797, DOI 10.1074/jbc.274.10.6797; HYNES MF, 1986, MOL GEN GENET, V202, P356, DOI 10.1007/BF00333262; Kapitonov D, 1999, GLYCOBIOLOGY, V9, P961, DOI 10.1093/glycob/9.10.961; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; Lellouch AC, 1999, J BACTERIOL, V181, P1141, DOI 10.1128/JB.181.4.1141-1148.1999; LEMESLEVARLOOT L, 1990, BIOCHIMIE, V72, P555, DOI 10.1016/0300-9084(90)90120-6; McCally Michael, 1994, Med Glob Surviv, V1, P4; REINHOLD BB, 1994, J BACTERIOL, V176, P1997, DOI 10.1128/jb.176.7.1997-2002.1994; REUBER TL, 1993, CELL, V74, P269, DOI 10.1016/0092-8674(93)90418-P; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; VRIELINK A, 1994, EMBO J, V13, P3413, DOI 10.1002/j.1460-2075.1994.tb06646.x; Wang LX, 1999, J BACTERIOL, V181, P6788, DOI 10.1128/JB.181.21.6788-6796.1999; WHITFIELD C, 1993, ADV MICROB PHYSIOL, V35, P135, DOI 10.1016/S0065-2911(08)60099-5; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; York GM, 1998, P NATL ACAD SCI USA, V95, P4912, DOI 10.1073/pnas.95.9.4912; Zhang YN, 1999, GLYCOBIOLOGY, V9, P815, DOI 10.1093/glycob/9.8.815	36	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31407	31413		10.1074/jbc.M004524200	http://dx.doi.org/10.1074/jbc.M004524200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10908566	hybrid			2022-12-27	WOS:000089762700093
J	Yu, WH; Yu, SSC; Meng, Q; Brew, K; Woessner, JF				Yu, WH; Yu, SSC; Meng, Q; Brew, K; Woessner, JF			TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TISSUE INHIBITOR; CHICKEN-EMBRYO FIBROBLASTS; TRANSFORMATION-SENSITIVE PROTEIN; SORSBYS-FUNDUS-DYSTROPHY; ONCOGENIC TRANSFORMATION; ACTIVE DOMAIN; CELL-DEATH; METALLOPROTEINASES; FAMILY; INVASION	Of the four known tissue inhibitors of metalloproteinases (TIMPs), TIMP-3 is distinguished by its tighter binding to the extracellular matrix. The present results show that glycosaminoglycans such as heparin, heparan sulfate, chondroitin sulfates A, B, and C, and sulfated compounds such as suramin and pentosan efficiently extract TIMP-3 from the postpartum rat uterus. Enzymatic treatment by heparinase III or chondroitinase ABC also releases TIMP-3, but neither one alone gives complete release. Confocal microscopy shows colocalization of heparan sulfate and TIMP-3 in the endometrium subjacent to the lumen of the uterus. Immunostaining of TIMP-3 is lost upon digestion of tissue sections with heparinase III and chondroitinase ABC. The N-terminal domain of human TIMP-3 was expressed and found to bind to heparin with affinity similar to that of full-length mouse TIMP-3. The A and B P-strands of the N-terminal domain of TIMP-3 contain two potential heparin-binding sequences rich in lysine and arginine; these strands should form a double track on the outer surface of TIMP-3. Synthetic peptides corresponding to segments of these two strands compete for heparin in the DNase II binding assay. TIMP-3 binding may be important for the cellular regulation of activity of the matrix metalloproteinases.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami	Woessner, JF (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, R-127,POB 106960, Miami, FL 33101 USA.		Brew, Keith/W-1643-2019; Yu, Wei Hsuan/AAF-7129-2021; Brew, Keith/A-6746-2009	Brew, Keith/0000-0003-1306-1032; YU, WEI-HSUAN/0000-0002-1782-3738	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR016940, R01AR040994, R01AR016940] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-40994, AR-16940] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahonen M, 1998, CANCER RES, V58, P2310; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; AnandApte B, 1996, BIOCHEM CELL BIOL, V74, P853, DOI 10.1139/o96-090; Andreu T, 1998, J BIOL CHEM, V273, P13848, DOI 10.1074/jbc.273.22.13848; APTE SS, 1994, DEV DYNAM, V200, P177, DOI 10.1002/aja.1002000302; APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; BLENIS J, 1983, P NATL ACAD SCI-BIOL, V80, P770, DOI 10.1073/pnas.80.3.770; BLENIS J, 1984, J BIOL CHEM, V259, P1563; Borland G, 1999, J BIOL CHEM, V274, P2810, DOI 10.1074/jbc.274.5.2810; Breedveld FC, 1997, ARTHRITIS RHEUM, V40, P794, DOI 10.1002/art.1780400503; Burger D, 1998, ARTHRITIS RHEUM, V41, P1748, DOI 10.1002/1529-0131(199810)41:10<1748::AID-ART7>3.3.CO;2-V; Butler GS, 1999, J BIOL CHEM, V274, P10846, DOI 10.1074/jbc.274.16.10846; Douglas DA, 1997, J PROTEIN CHEM, V16, P237, DOI 10.1023/A:1026348808069; Elliot SJ, 1999, J AM SOC NEPHROL, V10, P62; Fariss RN, 1998, BRIT J OPHTHALMOL, V82, P1329, DOI 10.1136/bjo.82.11.1329; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Guo X, 1996, ANAL BIOCHEM, V235, P153, DOI 10.1006/abio.1996.0107; Hargreaves PG, 1998, BRIT J HAEMATOL, V101, P694, DOI 10.1046/j.1365-2141.1998.00754.x; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Murate T, 1999, PLATELETS, V10, P5, DOI 10.1080/09537109976293; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; Tuuttila A, 1998, J MOL BIOL, V284, P1133, DOI 10.1006/jmbi.1998.2223; WEEKS JG, 1976, BIOCHIM BIOPHYS ACTA, V445, P205, DOI 10.1016/0005-2744(76)90173-X; WILLIAMSON RA, 1994, BIOCHEMISTRY-US, V33, P11745, DOI 10.1021/bi00205a010; Williamson RA, 1996, EUR J BIOCHEM, V241, P476, DOI 10.1111/j.1432-1033.1996.00476.x; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; YANG TT, 1992, P NATL ACAD SCI USA, V89, P10676, DOI 10.1073/pnas.89.22.10676; Yu WH, 2000, J BIOL CHEM, V275, P4183, DOI 10.1074/jbc.275.6.4183	37	261	267	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31226	31232		10.1074/jbc.M000907200	http://dx.doi.org/10.1074/jbc.M000907200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10900194	hybrid			2022-12-27	WOS:000089762700068
J	Ferguson, GD; Chen, XN; Korenberg, JR; Herschman, HR				Ferguson, GD; Chen, XN; Korenberg, JR; Herschman, HR			The human synaptotagmin IV gene defines an evolutionary break point between syntenic mouse and human chromosome regions but retains ligand inducibility and tissue specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; SYNAPTIC FUNCTION; MESSENGER-RNA; SCHIZOPHRENIA; BRAIN; BINDING; DOMAIN; RAT; DEPOLARIZATION; VESICLES	Rat synaptotagmin IV (SYT IV) is a depolarization-inducible synaptic vesicle protein. SYT IV homozygous mutant mice are viable and have deficits in fine motor coordination and some forms of memory. In this study, we report the identification of a human SPT IV orthologue. The predicted amino acid sequence of the human SYT IV clone is nearly 90% identical to the rat and mouse SYT TV proteins. In addition, human SYT IV has a characteristic serine for aspartate substitution within the first C2 domain that is conserved among Drosophila, Caenorhabditis elegans, mouse, and rat SYT IV sequences. The human SYT IV gene maps to chromosome band 18912.3, a region that defines a break point in the synteny with mouse chromosome 18 and has been implicated by associated markers in two human psychiatric disorders. In the human neuroblastoma cell line SK-N-SH, SYT IV is an immediate-early gene inducible by elevated intracellular calcium and by forskolin, an activator of adenylyl cyclase. Expression of human SPT IV mRNA is restricted to brain and is not detectable in non-neuronal tissues. Within brain, human SYT IV mRNA is most highly expressed in hippocampus, with lower levels present in amygdala and thalamus. These results suggest a role for SYT TV in human brain function and in human neurological disease.	Univ Calif Los Angeles, Cedars Sinai Med Ctr, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Cedars Sinai Med Ctr, Dept Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Cedars Sinai Med Ctr, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Cedars Sinai Med Ctr, Ctr Med Genet Birth Defects, Los Angeles, CA 90095 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; Cedars Sinai Medical Center; University of California System; University of California Los Angeles	Herschman, HR (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Inst Mol Biol, 341 Boyer Hall,611 Charles E Young Dr E, Los Angeles, CA 90095 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD033113] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD017449] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028660] Funding Source: NIH RePORTER; NICHD NIH HHS [HD33113, HD17449] Funding Source: Medline; NINDS NIH HHS [NS28660] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Babity JM, 1997, P NATL ACAD SCI USA, V94, P2638, DOI 10.1073/pnas.94.6.2638; Berrettini WH, 2000, BIOL PSYCHIAT, V47, P245, DOI 10.1016/S0006-3223(99)00226-7; Berton F, 1997, J NEUROSCI, V17, P1206; Berton F, 2000, EUR J NEUROSCI, V12, P1294, DOI 10.1046/j.1460-9568.2000.00013.x; Calzolari E, 1996, AM J MED GENET, V67, P154, DOI 10.1002/(SICI)1096-8628(19960409)67:2<154::AID-AJMG5>3.3.CO;2-H; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; Crispino M, 1998, MOL BRAIN RES, V59, P178, DOI 10.1016/S0169-328X(98)00143-0; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Denovan-Wright EM, 1998, MOL BRAIN RES, V55, P350, DOI 10.1016/S0169-328X(98)00042-4; Feldman JD, 2000, J NEUROCHEM, V74, P1838, DOI 10.1046/j.1471-4159.2000.0741838.x; Feldman JD, 1998, J BIOL CHEM, V273, P16535, DOI 10.1074/jbc.273.26.16535; Ferguson GD, 2000, P NATL ACAD SCI USA, V97, P5598, DOI 10.1073/pnas.100104597; Ferguson GD, 1999, J NEUROCHEM, V72, P1821, DOI 10.1046/j.1471-4159.1999.0721821.x; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GOLD JM, 1992, J ABNORM PSYCHOL, V101, P487, DOI 10.1037/0021-843X.101.3.487; GOLD JM, 1992, CLIN NEUROPSYCHOL, V6, P367; Hampson RM, 1999, PSYCHIATR GENET, V9, P161, DOI 10.1097/00041444-199909000-00010; HILBUSH BS, 1994, P NATL ACAD SCI USA, V91, P8195, DOI 10.1073/pnas.91.17.8195; Ibata K, 2000, J NEUROCHEM, V74, P518, DOI 10.1046/j.1471-4159.2000.740518.x; Jeljeli M, 1999, BEHAV BRAIN RES, V102, P61, DOI 10.1016/S0166-4328(98)00162-4; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; Keshavan MS, 1999, J PSYCHIATR RES, V33, P513, DOI 10.1016/S0022-3956(99)00033-3; KORENBERG JR, 1995, CYTOGENET CELL GENET, V69, P196, DOI 10.1159/000133962; KORENBERG JR, 1988, CELL, V53, P391, DOI 10.1016/0092-8674(88)90159-6; Kugaya A, 2000, ANN NUCL MED, V14, P1, DOI 10.1007/BF02990472; Laruelle M, 1999, J PSYCHOPHARMACOL, V13, P358, DOI 10.1177/026988119901300405; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; Littleton JT, 1999, NATURE, V400, P757, DOI 10.1038/23462; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Preisig M, 2000, AM J PSYCHIAT, V157, P948, DOI 10.1176/appi.ajp.157.6.948; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Thomas DM, 1999, MOL BIOL CELL, V10, P2285, DOI 10.1091/mbc.10.7.2285; Ujike H, 1999, Nihon Shinkei Seishin Yakurigaku Zasshi, V19, P47; ULLRICH B, 1994, NEURON, V13, P1281, DOI 10.1016/0896-6273(94)90415-4; Van Broeckhoven C, 1999, AM J MED GENET, V88, P263, DOI 10.1002/(SICI)1096-8628(19990618)88:3<263::AID-AJMG10>3.3.CO;2-X; VICIAN L, 1995, P NATL ACAD SCI USA, V92, P2164, DOI 10.1073/pnas.92.6.2164; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314; WAGNER JA, 1985, J NEUROCHEM, V45, P1244, DOI 10.1111/j.1471-4159.1985.tb05549.x; Yamamoto J, 1997, PSYCHOPHARMACOLOGY, V131, P379, DOI 10.1007/s002130050306; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	46	10	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36920	36926		10.1074/jbc.M005801200	http://dx.doi.org/10.1074/jbc.M005801200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10938284	hybrid			2022-12-27	WOS:000165577700067
J	Zhang, J; Billingsley, ML; Kincaid, RL; Siraganian, RP				Zhang, J; Billingsley, ML; Kincaid, RL; Siraganian, RP			Phosphorylation of Syk activation loop tyrosines is essential for Syk function - An in vivo study using a specific anti-Syk activation loop phosphotyrosine antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; AFFINITY IGE RECEPTOR; BASOPHILIC LEUKEMIA-CELLS; SIGNAL-TRANSDUCTION; KINASE P72(SYK); SH2 DOMAINS; MAST-CELLS; NEGATIVE REGULATION; IMMUNOGLOBULIN-E; FAMILY KINASES	Syk is an important protein-tyrosine kinase in immunoreceptor signaling. Fc epsilon RI aggregation in mast cells induces tyrosine phosphorylation and increased enzymatic activity of Syk. The two adjacent tyrosines in the Syk activation loop are thought to be important for the propagation of Fc epsilon RI signaling. To evaluate the phosphorylation of these tyrosines in vivo and further understand the relationship of Syk tyrosine phosphorylation with its function, an antibody was developed specific for phosphorylated tyrosines in the activation loop of Syk. Fc epsilon RI aggregation on mast cells induced the phosphorylation of both tyrosine residues of the activation loop. The kinase activity of Syk played the major role in phosphorylating its activation loop tyrosines both in vivo and in vitro. In Fc epsilon RI-stimulated mast cells, the total Syk tyrosine phosphorylation paralleled the phosphorylation of its activation loop tyrosines and downstream propagation of signals for histamine release. In contrast,:the cell surface binding of anti-ganglioside monoclonal antibody AA4 induced only strong general tyrosine: phosphorylation of Syk and minimal histamine release and weak phosphorylation of activation loop tyrosines. These results demonstrate that phosphorylation:of the activation loop tyrosines is important for mediating receptor signaling and is a better marker of Syk function than is total Syk tyrosine phosphorylation.	NIDCR, RAST Sect, OIIB, NIH, Bethesda, MD 20892 USA; Penn State Univ, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Zhang, J (corresponding author), NIDCR, RAST Sect, OIIB, NIH, Bldg 10,Rm 1N106, Bethesda, MD 20892 USA.				NIDCR NIH HHS [N01-DE-62614] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [N01DE062614, Z01DE000696] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; Busse WW, 1993, ALLERGY PRINCIPLES P, P105; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; Chen T, 1996, J BIOL CHEM, V271, P25308, DOI 10.1074/jbc.271.41.25308; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; Chu DH, 1996, EMBO J, V15, P6251, DOI 10.1002/j.1460-2075.1996.tb01015.x; Costello PS, 1996, ONCOGENE, V13, P2595; Couture C, 1997, EUR J BIOCHEM, V246, P447, DOI 10.1111/j.1432-1033.1997.00447.x; Crowley MT, 1997, J EXP MED, V186, P1027, DOI 10.1084/jem.186.7.1027; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; ElHillal O, 1997, P NATL ACAD SCI USA, V94, P1919, DOI 10.1073/pnas.94.5.1919; Fitzer-Attas CJ, 1998, J IMMUNOL, V160, P145; Furlong MT, 1997, BBA-MOL CELL RES, V1355, P177, DOI 10.1016/S0167-4889(96)00131-0; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; Isakov N, 1996, J BIOL CHEM, V271, P15753, DOI 10.1074/jbc.271.26.15753; Keshvara LM, 1998, J IMMUNOL, V161, P5276; Kiefer F, 1998, MOL CELL BIOL, V18, P4209, DOI 10.1128/MCB.18.7.4209; KIHARA H, 1994, J BIOL CHEM, V269, P22427; Kimura T, 1996, MOL CELL BIOL, V16, P1471; Kong GH, 1996, MOL CELL BIOL, V16, P5026; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; MINOGUCHI K, 1994, J BIOL CHEM, V269, P16902; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RIVERA VM, 1995, MOL CELL BIOL, V15, P1582; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; Sada K, 2000, J IMMUNOL, V164, P338, DOI 10.4049/jimmunol.164.1.338; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; SWAIM WD, 1994, J BIOL CHEM, V269, P19466; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TAYLOR JA, 1995, MOL CELL BIOL, V15, P4149; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Turner M, 1997, J EXP MED, V186, P2013, DOI 10.1084/jem.186.12.2013; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Zeitlmann L, 1998, J BIOL CHEM, V273, P15445, DOI 10.1074/jbc.273.25.15445; Zhang J, 1999, J IMMUNOL, V163, P2508; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71; Zhang J, 1998, J IMMUNOL, V161, P4366; Zoller KE, 1997, J IMMUNOL, V158, P1650	49	129	131	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35442	35447		10.1074/jbc.M004549200	http://dx.doi.org/10.1074/jbc.M004549200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10931839	hybrid			2022-12-27	WOS:000165422800081
J	Jo, EJ; McLaurin, J; Yip, CM; St George-Hyslop, P; Fraser, PE				Jo, EJ; McLaurin, J; Yip, CM; St George-Hyslop, P; Fraser, PE			alpha-synuclein membrane interactions and lipid specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SYSTEM ATROPHY; FAMILIAL PARKINSONS-DISEASE; A-BETA COMPONENT; ATOMIC-FORCE MICROSCOPY; CENTRAL-NERVOUS-SYSTEM; LEWY-BODY-DISEASE; NACP/ALPHA-SYNUCLEIN; NEURODEGENERATIVE DISORDERS; ALZHEIMERS-DISEASE; TAPPING-MODE	With the discovery of missense mutations (A53T and A30P) in alpha -synuclein (alpha -Syn) in several families with early onset familial Parkinson's disease, alpha -Syn aggregation and fibril formation have been thought to play a role in the pathogenesis of alpha -synucleinopathies, such as Parkinson's disease, dementia. with Lewy bodies, and multiple system atrophy. As previous reports have suggested that alpha -Syn plays a role in lipid transport and synaptic membrane biogenesis, we investigated whether alpha -Syn binds to a specific lipid ligand using thin layer chromatography overlay and examined the changes in its secondary structure using circular dichroism spectroscopy. alpha -Syn was found to bind to acidic phospholipid vesicles and this:binding was significantly augmented by the. presence of phosphatidylethanolamine, a neutral phospholipid. We further examined the interaction of alpha -Syn with lipids by in situ atomic force microscopy. The association of soluble wild-type alpha -Syn with planar lipid bilayers resulted in extensive bilayer disruption and the formation of amorphous aggregates and small fibrils. The A53T mutant alpha -Syn disrupted the Lipid bilayers in a similar fashion but at a slower rate. These results suggest that alpha -Syn membrane interactions are physiologically important and the lipid composition of the cellular membranes may affect these interactions in vivo.	Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Lab Med & Pathobiol, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Chem Engn, Inst Biomat & Biomed Engn, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Biochem, Inst Biomat & Biomed Engn, Toronto, ON M5S 3H2, Canada; Univ Toronto, Univ Hlth Network, Dept Med Neurol, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 3H2, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Jo, EJ (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, 6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.			Jo, Euijung/0000-0003-1131-2723; Yip, Christopher/0000-0003-4507-556X				Arai T, 1999, NEUROSCI LETT, V259, P83, DOI 10.1016/S0304-3940(98)00890-8; Arima K, 1998, ACTA NEUROPATHOL, V96, P439, DOI 10.1007/s004010050917; Arima K, 1998, BRAIN RES, V808, P93, DOI 10.1016/S0006-8993(98)00734-3; Baba M, 1998, AM J PATHOL, V152, P879; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BAZZI MD, 1992, BIOCHEMISTRY-US, V31, P1125, DOI 10.1021/bi00119a022; Borden KLB, 1998, ANN NEUROL, V44, pS65, DOI 10.1002/ana.410440711; Brandsch R, 1997, LANGMUIR, V13, P6349, DOI 10.1021/la970822i; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Clayton DF, 1999, J NEUROSCI RES, V58, P120, DOI 10.1002/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.3.CO;2-5; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Cleveland JP, 1998, APPL PHYS LETT, V72, P2613, DOI 10.1063/1.121434; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; El-Agnaf OMA, 1998, FEBS LETT, V440, P71, DOI 10.1016/S0014-5793(98)01418-5; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; EPAND RM, 1995, BIOPOLYMERS, V37, P319, DOI 10.1002/bip.360370504; Epand RM, 1993, AMPHIPATHIC HELIX; GANSER AL, 1988, DEV NEUROSCI-BASEL, V10, P99, DOI 10.1159/000111961; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Goedert M, 1998, MOL PSYCHIATR, V3, P462, DOI 10.1038/sj.mp.4000458; Goedert M, 1997, NATURE, V388, P232, DOI 10.1038/40767; Goedert M, 1998, BIOCHEM SOC T, V26, P463, DOI 10.1042/bst0260463; HAUSER H, 1981, BIOCHIM BIOPHYS ACTA, V650, P21, DOI 10.1016/0304-4157(81)90007-1; Hsu LJ, 1998, J NEUROCHEM, V71, P338; Irizarry MC, 1996, J NEUROPATH EXP NEUR, V55, P889, DOI 10.1097/00005072-199608000-00004; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; IWAI A, 1995, BIOCHEMISTRY-US, V34, P10139, DOI 10.1021/bi00032a006; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; MAROTEAUX L, 1991, MOL BRAIN RES, V11, P335, DOI 10.1016/0169-328X(91)90043-W; Mezey E, 1998, MOL PSYCHIATR, V3, P493, DOI 10.1038/sj.mp.4000446; Mezey E, 1998, NAT MED, V4, P755, DOI 10.1038/nm0798-755; MICHAELSON DM, 1983, BIOCHEM J, V211, P155, DOI 10.1042/bj2110155; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; NAKAJO S, 1990, J NEUROCHEM, V55, P2031, DOI 10.1111/j.1471-4159.1990.tb05792.x; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Noy A, 1998, LANGMUIR, V14, P1508, DOI 10.1021/la970948f; Polymeropoulos MH, 1998, ANN NEUROL, V44, pS63, DOI 10.1002/ana.410440710; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Takeda A, 1998, AM J PATHOL, V152, P367; Trojanowski JQ, 1998, ARCH NEUROL-CHICAGO, V55, P151, DOI 10.1001/archneur.55.2.151; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; TYTLER EM, 1993, J BIOL CHEM, V268, P22112; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Wakabayashi K, 1998, ACTA NEUROPATHOL, V96, P445, DOI 10.1007/s004010050918; Wakabayashi K, 1997, NEUROSCI LETT, V239, P45, DOI 10.1016/S0304-3940(97)00891-4; Wakabayashi K, 2000, ACTA NEUROPATHOL, V99, P14, DOI 10.1007/PL00007400; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Winkler RG, 1996, PHYS REV B, V54, P8908, DOI 10.1103/PhysRevB.54.8908; Withers GS, 1997, DEV BRAIN RES, V99, P87, DOI 10.1016/S0165-3806(96)00210-6; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509; YIU SCK, 1992, ANAL BIOCHEM, V202, P188, DOI 10.1016/0003-2697(92)90226-W	61	468	481	0	62	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34328	34334		10.1074/jbc.M004345200	http://dx.doi.org/10.1074/jbc.M004345200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10915790	hybrid			2022-12-27	WOS:000165095300046
J	Kleifeld, O; Van den Steen, PE; Frenkel, A; Cheng, F; Jiang, HL; Opdenakker, G; Sagi, I				Kleifeld, O; Van den Steen, PE; Frenkel, A; Cheng, F; Jiang, HL; Opdenakker, G; Sagi, I			Structural characterization of the catalytic active site in the latent and active natural gelatinase B from human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST COLLAGENASE; C-TERMINAL DOMAIN; MATRIX METALLOPROTEINASES; EXTRACELLULAR-MATRIX; MULTIPLE-SCLEROSIS; CYSTEINE SWITCH; ZINC CONTENT; BINDING; STROMELYSIN-1; MECHANISM	Matrix metalloproteinases are endopeptidases that have a leading role in the catabolism of the macromolecular components of the extracellular matrix in a variety of normal and pathological processes. Human gelatinase B is a zinc-dependent proteinase and a member of the matrix metalloproteinase family that is involved in inflammation, tissue remodeling, and cancer. We have conducted x-ray absorption spectroscopy, atomic emission, and quantum mechanics studies of natural and activated human gelatinase B. Our results show that the natural enzyme contains one catalytic zinc ion that is central to catalysis. In addition, upon enzyme activation, the catalytic zinc site exhibits a conformation change that results in the expansion of the bond distances around the zinc ion and the replacement of one sulfur with oxygen. Interestingly, quantum mechanics calculations show that oxygen ligation at the catalytic zinc ion exhibits a greater affinity to the binding of an oxygen from an amino acid residue rather than from an external water molecule. These results suggest that the catalytic zinc ion plays a key role in both substrate binding and catalysis.	Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; Katholieke Univ Leuven, Rega Inst Med Res, Lab Mol Immunol, B-3000 Louvain, Belgium; Univ Illinois, Mat Res Lab, Urbana, IL 61801 USA; Chinese Acad Sci, State Key Lab Drug Res, Shanghai Inst Meteria Med, Shanghai 200031, Peoples R China	Weizmann Institute of Science; KU Leuven; University of Illinois System; University of Illinois Urbana-Champaign; Chinese Academy of Sciences	Sagi, I (corresponding author), Weizmann Inst Sci, Dept Biol Struct, POB 26, IL-76100 Rehovot, Israel.	irit.sagi@weizmann.ac.il	Cheng, Feng/A-9760-2009; Opdenakker, Ghislain/V-8562-2019; Van den Steen, Philippe E/K-5132-2012; Opdenakker, Ghislain/Q-3130-2017; Frenkel, Anatoly/D-3311-2011; Kleifeld, Oded/G-7304-2012	Cheng, Feng/0000-0003-3619-8090; Opdenakker, Ghislain/0000-0003-1714-2294; Van den Steen, Philippe E/0000-0002-7334-9145; Opdenakker, Ghislain/0000-0003-1714-2294; Frenkel, Anatoly/0000-0002-5451-1207; 				BAUSCHLICHER CW, 1995, CHEM PHYS LETT, V246, P40, DOI 10.1016/0009-2614(95)01089-R; BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913; BECKER JW, 1995, PROTEIN SCI, V4, P1966, DOI 10.1002/pro.5560041002; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Bode W, 1999, CELL MOL LIFE SCI, V55, P639, DOI 10.1007/s000180050320; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; Borkakoti N, 1998, PROG BIOPHYS MOL BIO, V70, P73, DOI 10.1016/S0079-6107(98)00003-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; Dubois B, 1999, ACTA NEUROL BELG, V99, P53; GIJBELS K, 1992, J NEUROIMMUNOL, V41, P29, DOI 10.1016/0165-5728(92)90192-N; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; GRAMS F, 1995, BIOCHEMISTRY-US, V34, P14012, DOI 10.1021/bi00043a007; HENNING B, 1995, CURR OPIN CELL BIOL, V7, P728; HOLTHAUSEN MC, 1995, CHEM PHYS LETT, V240, P245, DOI 10.1016/0009-2614(95)00535-C; Kiyama R, 1999, J MED CHEM, V42, P1723, DOI 10.1021/jm980514x; Kleifeld O, 2000, BIOCHEMISTRY-US, V39, P7702, DOI 10.1021/bi0002030; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; LIOTTA LA, 1983, LAB INVEST, V49, P636; LOVEJOY B, 1994, BIOCHEMISTRY-US, V33, P8207, DOI 10.1021/bi00193a006; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; MASURE S, 1990, BIOCHIM BIOPHYS ACTA, V1054, P317, DOI 10.1016/0167-4889(90)90103-K; MASURE S, 1991, EUR J BIOCHEM, V198, P391, DOI 10.1111/j.1432-1033.1991.tb16027.x; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Norga K, 1996, CLIN RHEUMATOL, V15, P31, DOI 10.1007/BF02231681; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; OPDENAKKER G, 1991, LYMPHOKINE CYTOK RES, V10, P317; OPDENAKKER G, 1994, IMMUNOL TODAY, V15, P103, DOI 10.1016/0167-5699(94)90151-1; Parr R. G., 1989, DENSITY FUNCTIONAL T; RAO JS, 1993, CANCER RES, V53, P2208; REHR JJ, 1991, J AM CHEM SOC, V113, P5135, DOI 10.1021/ja00014a001; RICCA A, 1995, THEOR CHIM ACTA, V92, P123; Rudd PM, 1999, BIOCHEMISTRY-US, V38, P13937, DOI 10.1021/bi991162e; Ryde U, 1999, BIOPHYS J, V77, P2777, DOI 10.1016/S0006-3495(99)77110-9; SALOWE SP, 1992, BIOCHEMISTRY-US, V31, P4535, DOI 10.1021/bi00134a001; SCOTT RA, 1985, METHOD ENZYMOL, V117, P414; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; SOLER D, 1994, BIOCHEM BIOPH RES CO, V201, P917, DOI 10.1006/bbrc.1994.1789; SPRINGMAN EB, 1995, BIOCHEMISTRY-US, V34, P15713, DOI 10.1021/bi00048a016; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STERN EA, 1995, PHYSICA B, V208, P117, DOI 10.1016/0921-4526(94)00826-H; STOCKER W, 1995, CURR OPIN STRUC BIOL, V5, P383, DOI 10.1016/0959-440X(95)80101-4; Strong RK, 1998, ACTA CRYSTALLOGR D, V54, P93, DOI 10.1107/S0907444997010615; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220; Van den Steen P, 1998, BBA-GEN SUBJECTS, V1425, P587, DOI 10.1016/S0304-4165(98)00113-5; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WILLENBROCK F, 1995, FEBS LETT, V358, P189, DOI 10.1016/0014-5793(94)01421-V; Wuyts A, 1999, EUR J BIOCHEM, V260, P421, DOI 10.1046/j.1432-1327.1999.00166.x; ZABINSKY SI, 1995, PHYS REV B, V52, P2995, DOI 10.1103/PhysRevB.52.2995	55	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34335	34343		10.1074/jbc.M005714200	http://dx.doi.org/10.1074/jbc.M005714200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10938090	hybrid			2022-12-27	WOS:000165095300047
J	Berthet, V; Rigot, V; Champion, S; Secchi, J; Fouchier, F; Marvaldi, J; Luis, J				Berthet, V; Rigot, V; Champion, S; Secchi, J; Fouchier, F; Marvaldi, J; Luis, J			Role of endoproteolytic processing in the adhesive and signaling functions of alpha(v)beta(5) integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PRECURSOR PROTEINS; CELL-ADHESION; SUBSTRATE-SPECIFICITY; SECRETORY PATHWAY; FURIN; CONVERTASE; CLEAVAGE; ACTIVATION; TRANSDUCTION	Some integrin alpha subunits undergo a post-translational cleavage in their extracellular domain. However, the role of this cleavage in integrin function is unclear. Enzymes involved in this maturation belong to the subtilisin-like endoprotease family (convertases). To understand the role of the alpha subunit cleavage in integrin function, we have designed stable transfectants (PDX39P cells) expressing alpha (1)-PDX, a convertase inhibitor. Immunoprecipitation of cell surface proteins from PDX39P showed that alpha (3), alpha (6) and alpha (v) integrins lack endoproteolytic cleavage. We have compared adhesion between PDX39P cells and mock-transfected cells on different extracellular matrix proteins. No difference in adhesion could be observed on laminin-l and type I collagen, while attachment of PDX39P cells to vitronectin (ligand of the alpha (v)beta (5) integrin) was dramatically reduced. The reduced adhesion of PDX39P cells was not due to changes in integrin affinity as determined by solid-phase receptor assay in a cell-free environment. Intracellular signaling pathways activated by alpha (v) integrin ligation were also affected in PDX39P cells. It thus seems that the absence of endoproteolytic cleavage of alpha (v) integrins has important consequences on signal transduction pathways leading to alterations in integrin function such as cell adhesion.	Fac Pharm Marseille, CNRS, UPRESA 6032, Biochim Cellulaire Lab, F-13385 Marseille 5, France	Centre National de la Recherche Scientifique (CNRS)	Luis, J (corresponding author), Fac Pharm Marseille, CNRS, UPRESA 6032, Biochim Cellulaire Lab, 27 Bd J Moulin, F-13385 Marseille 5, France.	jose.luis@pharmacie.univ-mrs.fr	LUIS, José/M-3071-2013					ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; Andre F, 1999, GASTROENTEROLOGY, V116, P64, DOI 10.1016/S0016-5085(99)70230-1; Aplin AE, 1998, PHARMACOL REV, V50, P197; Benjannet S, 1997, J BIOL CHEM, V272, P26210, DOI 10.1074/jbc.272.42.26210; Brown E, 1996, IMMUNOL LETT, V54, P189, DOI 10.1016/S0165-2478(96)02671-5; CHUN JS, 1993, MOL BIOL CELL, V4, P271; Cui YZ, 1998, EMBO J, V17, P4735, DOI 10.1093/emboj/17.16.4735; Decroly E, 1996, J BIOL CHEM, V271, P30442, DOI 10.1074/jbc.271.48.30442; Delwel GO, 1996, J BIOL CHEM, V271, P7293, DOI 10.1074/jbc.271.13.7293; DENAULT JB, 1995, J CARDIOVASC PHARM, V26, pS47; Denault JB, 1996, FEBS LETT, V379, P113, DOI 10.1016/0014-5793(95)01487-X; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HEMLER ME, 1991, RECEPTORS EXTRACELLU, P255; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; JEAN F, 1995, J BIOL CHEM, V270, P19225, DOI 10.1074/jbc.270.33.19225; Kadi A, 1998, BIOCHEM BIOPH RES CO, V246, P690, DOI 10.1006/bbrc.1998.8536; KOLODZIEJ MA, 1991, J BIOL CHEM, V266, P23499; Lehmann M, 1996, BIOCHEM J, V317, P803, DOI 10.1042/bj3170803; LEHMANN M, 1994, CANCER RES, V54, P2102; Lissitzky JC, 2000, BIOCHEM J, V346, P133, DOI 10.1042/0264-6021:3460133; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; MATTHEWS DJ, 1994, PROTEIN SCI, V3, P1197, DOI 10.1002/pro.5560030805; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MOEHRING JM, 1993, J BIOL CHEM, V268, P2590; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; Rigot V, 1998, J CELL SCI, V111, P3119; Rigot V, 1999, EUR J BIOCHEM, V261, P659, DOI 10.1046/j.1432-1327.1999.00300.x; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; SHAW SK, 1994, J BIOL CHEM, V269, P6016; Steiner DF, 1996, DIABETES METAB, V22, P94; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; TEIXIDO J, 1992, J BIOL CHEM, V267, P1786; TIMPL R, 1979, J BIOL CHEM, V254, P9933; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	37	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33308	33313		10.1074/jbc.M004834200	http://dx.doi.org/10.1074/jbc.M004834200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10913146	hybrid			2022-12-27	WOS:000090104600021
J	LaDu, MJ; Shah, JA; Reardon, CA; Getz, GS; Bu, G; Hu, JR; Guo, L; Van Eldik, LJ				LaDu, MJ; Shah, JA; Reardon, CA; Getz, GS; Bu, G; Hu, JR; Guo, L; Van Eldik, LJ			Apolipoprotein E receptors mediate the effects of beta-amyloid on astrocyte cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE SYNTHASE; E MESSENGER-RNA; LIPOPROTEIN-RECEPTOR; ALZHEIMERS-DISEASE; PROTEIN LRP; CEREBROSPINAL-FLUID; PRECURSOR PROTEIN; 39-KDA PROTEIN; APOE RECEPTOR	We have previously shown that beta -amyloid (A beta) induces astrocyte activation in vitro and that this reaction is attenuated by the addition of exogenous apolipoprotein E (apoE)-containing particles. However, the effects of A beta on endogenous apoE and apoJ levels and the potential role of apoE receptors in astrocyte activation have not been addressed. Three activating stimuli (lipopolysaccharide, dibutyryl cAMP, and aged A beta 1-42) were used to induce activation of rat astrocyte cultures, as assessed by changes in morphology and an increase in interleubin-1 beta. However, only A beta also induced similar to 50% reduction in the amount of released apoE and apoJ and an 8-fold increase in the levels of cell-associated apoE and apoJ, Experiments using two concentrations of receptor-associated protein, an inhibitor of apoE receptors with a differential affinity for the low density lipoprotein receptor (LDLR) and the LDLR-related protein (LRP), suggest that LRP mediates A beta -induced astrocyte activation, whereas LDLR mediates the A beta -induced changes in apoE levels. Receptor-associated protein had no effect on apoJ levels or on activation by either dibutyryl cAMP or lipopolysaccharide. These data suggest that apoE receptors translate the presence of extracellular A beta into cellular responses, both initiating and modulating the inflammatory response induced by A beta.	Northwestern Univ, Sch Med, NW Drug Discovery Program, Chicago, IL 60611 USA; Evanston NW Healthcare Res Inst, Dept Med, Evanston, IL 60201 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Northwestern Univ, Dept Cell & Mol Biol, Chicago, IL 60611 USA	Northwestern University; University of Chicago; Washington University (WUSTL); Washington University (WUSTL); Northwestern University	Van Eldik, LJ (corresponding author), Northwestern Univ, Sch Med, NW Drug Discovery Program, 303 E Chicago Ave,Ward 4-202, Chicago, IL 60611 USA.	vaneldik@northwestern.edu	Shah, Javeed/J-4906-2017; Shah, Javeed/J-2716-2019	Shah, Javeed/0000-0002-2997-7988; Shah, Javeed/0000-0002-2997-7988; LaDu, Mary Jo/0000-0003-2141-1450	NATIONAL INSTITUTE ON AGING [R37AG013939, P01AG015501, R01AG013939] Funding Source: NIH RePORTER; NIA NIH HHS [AG16776, AG15501, AG13939] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aleshkov S, 1997, BIOCHEMISTRY-US, V36, P10571, DOI 10.1021/bi9626362; Beffert U, 1998, J NEUROCHEM, V70, P1458; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; Bu GJ, 1998, CURR OPIN LIPIDOL, V9, P149, DOI 10.1097/00041433-199804000-00012; BU GJ, 1994, J BIOL CHEM, V269, P18521; CHOIMIURA NH, 1992, ACTA NEUROPATHOL, V83, P260, DOI 10.1007/BF00296787; Christie RH, 1996, J NEUROPATH EXP NEUR, V55, P491, DOI 10.1097/00005072-199604000-00012; Clatworthy AE, 1999, NEUROSCIENCE, V90, P903, DOI 10.1016/S0306-4522(98)00489-8; ElKhoury J, 1996, NATURE, V382, P716; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Goretzki L, 1998, BIOCHEM J, V336, P381, DOI 10.1042/bj3360381; Griffin WST, 1998, BRAIN PATHOL, V8, P65; Hammad SM, 1997, J BIOL CHEM, V272, P18644, DOI 10.1074/jbc.272.30.18644; Hu JG, 1998, BRAIN RES, V785, P195, DOI 10.1016/S0006-8993(97)01318-8; Hu JG, 1996, J BIOL CHEM, V271, P2543, DOI 10.1074/jbc.271.5.2543; Hu JR, 1998, J NEUROCHEM, V71, P1626; IADONATO SP, 1993, BIOCHEM J, V296, P867, DOI 10.1042/bj2960867; Jordan J, 1998, J NEUROSCI, V18, P195; Kang DE, 1997, NEUROLOGY, V49, P56, DOI 10.1212/WNL.49.1.56; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; Kounnas M Z, 1994, In Vivo, V8, P343; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LaDu MJ, 2000, ANN NY ACAD SCI, V903, P167, DOI 10.1111/j.1749-6632.2000.tb06365.x; LADU MJ, 1994, J BIOL CHEM, V269, P23403; LADU MJ, 1995, J BIOL CHEM, V270, P9039, DOI 10.1074/jbc.270.16.9039; LaDu MJ, 1998, J NEUROCHEM, V70, P2070; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MATSUBARA E, 1995, J BIOL CHEM, V270, P7563, DOI 10.1074/jbc.270.13.7563; MAY PC, 1992, TRENDS NEUROSCI, V15, P391, DOI 10.1016/0166-2236(92)90190-J; MCLEAN JW, 1983, J BIOL CHEM, V258, P8993; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Nakai M, 1996, NEUROSCI LETT, V211, P41, DOI 10.1016/0304-3940(96)12716-6; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; Narita M, 1997, J NEUROCHEM, V69, P1904; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; ODA T, 1995, EXP NEUROL, V136, P22, DOI 10.1006/exnr.1995.1080; Petrova TV, 1999, P NATL ACAD SCI USA, V96, P4668, DOI 10.1073/pnas.96.8.4668; PITAS RE, 1987, J BIOL CHEM, V262, P14352; Puttfarcken PS, 1997, J NEUROCHEM, V68, P760; REBECK GW, 1995, ANN NEUROL, V37, P211, DOI 10.1002/ana.410370212; REBECK GW, 1993, NEURON, V11, P575; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; Smith MA, 1997, J NEUROSCI, V17, P2653; Stone DJ, 1997, EXP NEUROL, V143, P313, DOI 10.1006/exnr.1996.6360; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Sun YL, 1998, J NEUROSCI, V18, P3261; Tolar M, 1997, J NEUROSCI, V17, P5678; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Wallace MN, 1997, EXP NEUROL, V144, P266, DOI 10.1006/exnr.1996.6373; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WHITSON JS, 1994, BIOCHEM BIOPH RES CO, V199, P163, DOI 10.1006/bbrc.1994.1209; Yan SD, 1997, P NATL ACAD SCI USA, V94, P5296, DOI 10.1073/pnas.94.10.5296; Zlokovic BV, 1996, P NATL ACAD SCI USA, V93, P4229, DOI 10.1073/pnas.93.9.4229	61	76	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33974	33980		10.1074/jbc.M000602200	http://dx.doi.org/10.1074/jbc.M000602200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10940295	hybrid			2022-12-27	WOS:000090104600110
J	Sivasothy, P; Dafforn, TR; Gettins, PGW; Lomas, DA				Sivasothy, P; Dafforn, TR; Gettins, PGW; Lomas, DA			Pathogenic alpha(1)-antitrypsin polymers are formed by reactive loop-beta-sheet A linkage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE ENERGY-TRANSFER; SERPIN-PROTEINASE COMPLEX; POLYMERIZATION; MECHANISM; ANTITHROMBIN; ALPHA-1-ANTITRYPSIN; CONFORMATION; ANGSTROM; DISEASE; LIVER	alpha (1)-Antitrypsin is the most abundant circulating protease inhibitor and the archetype of the serine protease inhibitor or serpin superfamily, Members of this family may be inactivated by point mutations that favor transition to a polymeric conformation. This polymeric conformation underlies diseases as diverse as alpha (1)-antitrypsin deficiency-related cirrhosis, thrombosis, angioedema, and dementia, The precise structural linkage within a polymer has been the subject of much debate with evidence for reactive loop insertion into beta -sheet A or C or as strand 7A. We have used site directed cysteine mutants and fluorescence resonance energy transfer (FRET) to measure a number of distances between monomeric units in polymeric alpha (1)-antitrypsin, We have then used a combinatorial approach to compare distances determined from FRET with distances obtained from 2.9 x 10(6) different possible orientations of the alpha (1)-antitrypsin polymer. The closest matches between experimental FRET measurements and theoretical structures show conclusively that polymers of alpha (1)-antitrypsin form by insertion of the reactive loop into beta -sheet A.	Univ Cambridge, Wellcome Trust Ctr Mol Mech Dis, Cambridge Inst Med Res, Dept Haematol, Cambridge CB2 2XY, England; Univ Cambridge, Wellcome Trust Ctr Mol Mech Dis, Cambridge Inst Med Res, Dept Med,Resp Med Unit, Cambridge CB2 2XY, England; Univ Illinois, Dept Biochem & Mol Biol, Chicago, IL 60612 USA	University of Cambridge; University of Cambridge; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Dafforn, TR (corresponding author), Univ Cambridge, Wellcome Trust Ctr Mol Mech Dis, Cambridge Inst Med Res, Dept Haematol, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	td214@cus.cam.ac.uk	Dafforn, Tim/A-9072-2015	Dafforn, Tim/0000-0003-2257-6679				AULAK KS, 1993, J BIOL CHEM, V268, P18088; BRUCE D, 1994, J CLIN INVEST, V94, P2265, DOI 10.1172/JCI117589; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Chang WSW, 1997, PROTEIN SCI, V6, P89; Dafforn TR, 1999, J BIOL CHEM, V274, P9548, DOI 10.1074/jbc.274.14.9548; DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; Davis RL, 1999, NATURE, V401, P376, DOI 10.1038/43897; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; Elliott PR, 2000, PROTEIN SCI, V9, P1274, DOI 10.1110/ps.9.7.1274; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; ERIKSSON S, 1965, ACTA MED SCAND, VS177, P5; ERIKSSON S, 1986, NEW ENGL J MED, V314, P736, DOI 10.1056/NEJM198603203141202; Fairclough R H, 1978, Methods Enzymol, V48, P347; Fraczkiewicz R, 1998, J COMPUT CHEM, V19, P319, DOI 10.1002/(SICI)1096-987X(199802)19:3<319::AID-JCC6>3.0.CO;2-W; Gooptu B, 2000, P NATL ACAD SCI USA, V97, P67, DOI 10.1073/pnas.97.1.67; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Lakowitcz J.R, 1999, PRINCIPLES FLUORESCE, P237, DOI DOI 10.1007/978-1-4757-3061-6_8; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1995, J BIOL CHEM, V270, P16864, DOI 10.1074/jbc.270.28.16864; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; MIKI M, 1984, BIOCHIM BIOPHYS ACTA, V790, P201, DOI 10.1016/0167-4838(84)90023-2; MIKUS P, 1993, EUR J BIOCHEM, V218, P1071, DOI 10.1111/j.1432-1033.1993.tb18467.x; PATSTON PA, 1995, FEBS LETT, V368, P401, DOI 10.1016/0014-5793(95)00694-5; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; Sharp AM, 1999, STRUCTURE, V7, P111, DOI 10.1016/S0969-2126(99)80018-5; SHERWIN SS, METHODS ENZYMOL, V49, P222; Skinner R, 1998, J MOL BIOL, V283, P9, DOI 10.1006/jmbi.1998.2083; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; Stratikos E, 1998, J BIOL CHEM, V273, P15582, DOI 10.1074/jbc.273.25.15582; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; TAYLOR DL, 1981, J CELL BIOL, V89, P362, DOI 10.1083/jcb.89.2.362; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303	34	118	127	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33663	33668		10.1074/jbc.M004054200	http://dx.doi.org/10.1074/jbc.M004054200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10924508	hybrid			2022-12-27	WOS:000090104600068
J	Koc, EC; Burkhart, W; Blackburn, K; Moseley, A; Koc, H; Spremulli, LL				Koc, EC; Burkhart, W; Blackburn, K; Moseley, A; Koc, H; Spremulli, LL			A proteomics approach to the identification of mammalian mitochondrial small subunit ribosomal proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA; LIVER; GENE	Mammalian mitochondrial small subunit ribosomal proteins were separated by two-dimensional polyacrylamide gel electrophoresis. The proteins in six individual spots were subjected to in-gel tryptic digestion. Peptides were separated by capillary liquid chromatography, and the sequences of selected peptides were obtained by electrospray tandem mass spectrometry. The peptide sequences obtained were used to screen human expressed sequence tag data bases, and complete consensus cDNAs were assembled. Mammalian mitochondrial small subunit ribosomal proteins from six different classes of ribosomal proteins were identified. Only two of these proteins have significant sequence similarities to ribosomal proteins from prokaryotes. These proteins correspond to Escherichia coli S10 and S14, Homologs of two human mitochondrial proteins not found in prokaryotes were observed in the genomes of Drosophila melanogaster and Caenorhabditis elegans. A homolog of one of these proteins was observed in D. melanogaster but not in C. elegans, while a homolog of the other was present in C. elegans but not in D, melanogaster, A homolog of one of the ribosomal proteins not found in prokaryotes was tentatively identified in the yeast genome. This latter protein is the first reported example of a ribosomal protein that is shared by mitochondrial ribosomes from lower and higher eukaryotes that does not have a homolog in prokaryotes.	Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Publ Hlth Environm Sci & Engn, Chapel Hill, NC 27599 USA; Glaxo Wellcome Res & Dev Ltd, Dept Struct Chem, Res Triangle Pk, NC 27709 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; GlaxoSmithKline	Spremulli, LL (corresponding author), Univ N Carolina, Dept Chem, CB 3290, Chapel Hill, NC 27599 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032734] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32734] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDURASHIDOVA GG, 1991, NUCLEIC ACIDS RES, V19, P1909, DOI 10.1093/nar/19.8.1909; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; CAHILL A, 1995, ANAL BIOCHEM, V232, P47, DOI 10.1006/abio.1995.9962; CHAN YL, 1993, NUCLEIC ACIDS RES, V21, P649, DOI 10.1093/nar/21.3.649; CLAROS MG, 1996, EUR J BIOCHEM, V241, P770, DOI DOI 10.1111/J.1432-1033.1996.00779.X; DEVRIES H, 1973, BIOCHEM BIOPH RES CO, V54, P308, DOI 10.1016/0006-291X(73)90924-8; Goldschmidt-Reisin S, 1998, J BIOL CHEM, V273, P34828, DOI 10.1074/jbc.273.52.34828; Graack HR, 1998, BIOCHEM J, V329, P433, DOI 10.1042/bj3290433; Graack HR, 1999, BIOCHEMISTRY-US, V38, P16569, DOI 10.1021/bi991543s; HAMILTON MG, 1974, BIOCHEMISTRY-US, V13, P5400, DOI 10.1021/bi00723a024; Jiang XY, 1996, J MASS SPECTROM, V31, P1309, DOI 10.1002/(SICI)1096-9888(199611)31:11<1309::AID-JMS423>3.0.CO;2-R; Koc EC, 1999, BIOCHEM BIOPH RES CO, V266, P141, DOI 10.1006/bbrc.1999.1785; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mariottini P, 1999, J BIOL CHEM, V274, P31853, DOI 10.1074/jbc.274.45.31853; MATTHEWS DE, 1982, J BIOL CHEM, V257, P8788; Mueller F, 1997, J MOL BIOL, V271, P545, DOI 10.1006/jmbi.1997.1211; NOLLER HF, 1990, RIBOSOME, P73; O'Brien TW, 1999, J BIOL CHEM, V274, P36043, DOI 10.1074/jbc.274.51.36043; O'Brien TW, 2000, J BIOL CHEM, V275, P18153, DOI 10.1074/jbc.M909762199; OBRIEN T, 1976, HDB GENETICS, P535; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEL HJ, 1994, MOL BIOL REP, V19, P183, DOI 10.1007/BF00986960; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SAMAHA RR, 1994, P NATL ACAD SCI USA, V91, P7884, DOI 10.1073/pnas.91.17.7884; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Tsiboli P, 1998, EUR J BIOCHEM, V256, P136, DOI 10.1046/j.1432-1327.1998.2560136.x; WITTMANN HG, 1986, STRUCTURE FUNCTION G, P1; Wittmann-Liebold B., 1985, STRUCTURE FUNCTION G, P326; Yamaguchi K, 2000, J BIOL CHEM, V275, P28455, DOI 10.1074/jbc.M004350200; Yamaguchi K, 2000, J BIOL CHEM, V275, P28466, DOI 10.1074/jbc.M005012200	31	58	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32585	32591		10.1074/jbc.M003596200	http://dx.doi.org/10.1074/jbc.M003596200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10938081	Green Published, hybrid			2022-12-27	WOS:000090003800030
J	Tanioka, T; Nakatani, Y; Semmyo, N; Murakami, M; Kudo, I				Tanioka, T; Nakatani, Y; Semmyo, N; Murakami, M; Kudo, I			Molecular identification of cytosolic prostaglandin E-2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E-2 biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY PHOSPHOLIPASE A(2)S; ARACHIDONIC-ACID RELEASE; GLUCOCORTICOID RECEPTOR; H SYNTHASE-1; HUMAN-BRAIN; PROTEIN; IIA; PURIFICATION; EXPRESSION; GENERATION	Here we report the molecular identification of cytosolic glutathione (GSH)-dependent prostaglandin (PG) E-2 synthase (cPGES), a terminal enzyme of the cyclooxygenase (COX)-1-mediated PGE(2) biosynthetic pathway. GSH-dependent PGES activity in the cytosol of rat brains, but not of other tissues, increased 3-fold after lipopolysaccharide (LPS) challenge. Peptide microsequencing of purified enzyme revealed that it was identical to p23, which is reportedly the weakly bound component of the steroid hormone receptor/hsp90 complex. Recombinant p23 expressed in Escherichia coli and 293 cells exhibited all the features of PGES activity detected in rat brain cytosol. A tyrosine residue near the N terminus (Tyr(9)), which is known to be critical for the activity of cytosolic GSH S-transferases, was essential for PGES activity. The expression of cPGES/p23 was constitutive and was unaltered by proinflammatory stimuli in various cells and tissues, except that it was increased significantly in rat brain after LPS treatment, cPGES/p23 was functionally linked with COX-1 in marked preference to COX-2 to produce PGE(2) from exogenous and endogenous arachidonic acid, the latter being supplied by cytosolic phospholipase A(2) in the immediate response. Thus, functional coupling between COX-1 and cPGES/p23 may contribute to production of the PGE(2) that plays a role in maintenance of tissue homeostasis.	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 142, Japan	Showa University	Kudo, I (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 142, Japan.							Beuckmann CT, 1999, BIOCHEMISTRY-US, V38, P8006, DOI 10.1021/bi990261p; Bohen SP, 1998, MOL CELL BIOL, V18, P3330, DOI 10.1128/MCB.18.6.3330; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; Fournier T, 1997, J BIOL CHEM, V272, P31065, DOI 10.1074/jbc.272.49.31065; Freeman BC, 2000, GENE DEV, V14, P422; Harada Y, 1996, PROSTAG OTH LIPID M, V51, P19, DOI 10.1016/0090-6980(95)00168-9; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; HUTCHISON KA, 1995, J BIOL CHEM, V270, P18841, DOI 10.1074/jbc.270.32.18841; Jakobsson PJ, 1999, PROTEIN SCI, V8, P689, DOI 10.1110/ps.8.3.689; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; Kanaoka Y, 1997, CELL, V90, P1085, DOI 10.1016/S0092-8674(00)80374-8; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Liou JY, 2000, J BIOL CHEM, V275, P15314, DOI 10.1074/jbc.275.20.15314; Morishima Y, 2000, J BIOL CHEM, V275, P6894, DOI 10.1074/jbc.275.10.6894; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; Murakami M, 1999, J BIOL CHEM, V274, P31435, DOI 10.1074/jbc.274.44.31435; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; NAGATA A, 1991, P NATL ACAD SCI USA, V88, P4020, DOI 10.1073/pnas.88.9.4020; Nakatani Y, 2000, J BIOL CHEM, V275, P1161, DOI 10.1074/jbc.275.2.1161; Naraba H, 1998, J IMMUNOL, V160, P2974; OGOROCHI T, 1987, J NEUROCHEM, V48, P900, DOI 10.1111/j.1471-4159.1987.tb05602.x; PINZAR E, 2000, IN PRESS J BIOL CHEM, V275; Salinas AE, 1999, CURR MED CHEM, V6, P279; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Suzuki T, 1999, J BIOL CHEM, V274, P241, DOI 10.1074/jbc.274.1.241; Tanaka T, 1997, J BIOL CHEM, V272, P15789, DOI 10.1074/jbc.272.25.15789; TANAKA Y, 1987, J BIOL CHEM, V262, P1374; Watanabe K, 1999, BBA-MOL CELL BIOL L, V1439, P406, DOI 10.1016/S1388-1981(99)00084-0; WATANABE K, 1985, J BIOL CHEM, V260, P7035; Weaver AJ, 2000, J BIOL CHEM, V275, P23045, DOI 10.1074/jbc.M003410200	40	592	610	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32775	32782		10.1074/jbc.M003504200	http://dx.doi.org/10.1074/jbc.M003504200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10922363	hybrid			2022-12-27	WOS:000090003800056
J	Hellmich, MR; Rui, XL; Hellmich, HL; Fleming, RYD; Evers, BM; Townsend, CM				Hellmich, MR; Rui, XL; Hellmich, HL; Fleming, RYD; Evers, BM; Townsend, CM			Human colorectal cancers express a constitutively active cholecystokinin-B/gastrin receptor that stimulates cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; HUMAN-COLON-CANCER; GASTRIN RECEPTORS; CARCINOMA; CLONING; ACTIVATION; MUTATION; SUBTYPES; TUMORS; KINASE	Although ectopic expression of the cholecystokinin B/gastrin receptor (CCK-BR) is widely reported in human colorectal cancers, its role in mediating the proliferative effects of gastrin1-17 (G-17) on these cancers is unknown. Here we report the isolation of a novel splice variant of CCK-BR that exhibits constitutive (ligand-independent) activation of pathways regulating intracellular free Ca2+ ([Ca2+](i)) and cell growth. The splice variant (designated CCK-BRi4sv for intron 4-containing splice variant) is expressed in colorectal cancers but not in normal colonic mucosa adjacent to the cancer. Balb3T3 cells expressing CCK-BRi4sv exhibited spontaneous, ligand-independent, oscillatory increases in [Ca2+](i), whereas cells expressing wild-type CCK-BR did not. Primary cultures of cells isolated from resected colorectal cancers also exhibited a similar pattern of spontaneous [Ca2+], oscillations. For both Balb3T3 and primary tumor cells, application of G-17 (10 and 200 nM, respectively) caused an increase in [Ca2+](i), Selective CCK-BR antagonists blocked the G-17-stimulated Ca2+ responses but not the spontaneous [Ca2+](i) oscillations. Cells expressing CCK-BRi4sv exhibited an increased growth rate (similar to 2.5-fold), in the absence of 6-17, compared with cells expressing wild-type CCK-BR, The selective pattern of expression, constitutive activity, and trophic action associated with CCK-BRi4sv suggest that this variant may regulate colorectal cancer cell proliferation though a gastrin-independent mechanism.	Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Internal Med, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Hellmich, MR (corresponding author), Univ Texas, Med Branch, Dept Surg, 301 Univ Blvd, Galveston, TX 77555 USA.	mhellmic@utmb.edu			NIDDK NIH HHS [R01DK48345] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048345] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; BALDWIN GS, 1990, BIOCHEM BIOPH RES CO, V170, P691, DOI 10.1016/0006-291X(90)92146-Q; Baldwin GS, 1998, GUT, V42, P581, DOI 10.1136/gut.42.4.581; Beahrs O. H., 1992, AM JOINT COMMITTEE C; Bertagnolli MM, 1997, P SOC EXP BIOL MED, V216, P266; Biagini P, 1997, LIFE SCI, V61, P1009, DOI 10.1016/S0024-3205(97)00605-X; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; BORDI C, 1995, AM J SURG PATHOL, V19, pS8; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Davis LG, 1994, BASIC METHODS MOL BI; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; Hollande F, 1997, GASTROENTEROLOGY, V113, P1576, DOI 10.1053/gast.1997.v113.pm9352860; IMDAHL A, 1995, J CANCER RES CLIN, V121, P661, DOI 10.1007/BF01218524; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; MCGREGOR DB, 1989, ARCH SURG-CHICAGO, V124, P470; MUNSHI R, 1991, J BIOL CHEM, V266, P22285; REHFELD JF, 1993, TUMOR BIOL, V14, P174, DOI 10.1159/000217833; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; Smith JP, 1996, AM J PHYSIOL-REG I, V271, pR797, DOI 10.1152/ajpregu.1996.271.3.R797; SMITH JP, 1988, GASTROENTEROLOGY, V95, P1541; SONG I, 1993, P NATL ACAD SCI USA, V90, P9085, DOI 10.1073/pnas.90.19.9085; Stepan VM, 1999, MOL MED, V5, P147, DOI 10.1007/BF03402058; STEPHENS EV, 1993, ONCOGENE, V8, P19; TODISCO A, 1995, J BIOL CHEM, V270, P28337; UPP JR, 1989, CANCER RES, V49, P488; Walsh John H., 1994, P1; Wang HL, 1997, J NEUROCHEM, V68, P1728; WANK SA, 1994, ANN NY ACAD SCI, V713, P49, DOI 10.1111/j.1749-6632.1994.tb44052.x; WATSON SA, 1995, INT J CANCER, V61, P233, DOI 10.1002/ijc.2910610216; WINSETT OE, 1986, SURGERY, V99, P302	38	117	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32122	32128		10.1074/jbc.M005754200	http://dx.doi.org/10.1074/jbc.M005754200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10913157	hybrid			2022-12-27	WOS:000089858900078
J	Ohkawa, H; Pakrasi, HB; Ogawa, T				Ohkawa, H; Pakrasi, HB; Ogawa, T			Two types of functionally distinct NAD(P)H dehydrogenases in Synechocystis sp strain PCC6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INORGANIC CARBON TRANSPORT; PHOTOSYSTEM-I; ANABAENA-VARIABILIS; CYANOBACTERIUM; GENE; IDENTIFICATION; MECHANISM; PCC-7942	The ndhD gene encodes a membrane protein component of NAD(P)H dehydrogenase. The genome of Synechocystis sp. PCC6803 contains 6 ndhD genes. Three mutants were constructed by disrupting highly homologous ndhD genes in pairs. Only the Delta ndhD1/Delta ndhD2 (Delta ndhD1/D2) mutant was unable to grow under photoheterotrophic conditions and exhibited low respiration rate, although the mutant grew normally under photoautotrophic conditions in air. The Delta ndhD3/Delta ndhD4 (Delta ndhD3/D4) mutant grew very slowly in air and did not take up CO2. The results demonstrated the presence of two types of functionally distinct NAD(P)H dehydrogenases in Synechocystis PCC6803 cells. The Delta ndhD5/Delta ndhD6 (Delta ndhD5/D6) mutant grew like the wild-type strain. Under far-red light (>710 nm), the level of P700(+) was high in Delta ndhD1/D2 and M55 (ndhB-less mutant) at low intensities. The capacity of Q(A) (tightly bound plastoquinone) reduction by plastoquinone pool, as measured by the fluorescence increase in darkness upon addition of KCN, was much less in Delta ndhD1/D2 and M55 than in Delta ndhD3/D4 and Delta ndhD5/D6. We conclude that electrons from NADPH are transferred to the plastoquinone pool mainly by the NdhD1 . NdhD2 type of NAD(P)H dehydrogenases.	Nagoya Univ, Biosci Ctr, Nagoya, Aichi 4648601, Japan; Washington Univ, Dept Biol, St Louis, MO 63130 USA	Nagoya University; Washington University (WUSTL)	Ogawa, T (corresponding author), Nagoya Univ, Biosci Ctr, Nagoya, Aichi 4648601, Japan.	h44975a@nucc.cc.nagoya-u.ac.jp						Cooley JW, 2000, J BACTERIOL, V182, P714, DOI 10.1128/JB.182.3.714-722.2000; Kaftan D, 1999, PLANT PHYSIOL, V120, P433, DOI 10.1104/pp.120.2.433; Kaneko T, 1996, DNA Res, V3, P185, DOI 10.1093/dnares/3.3.185; Kaplan A, 1999, ANNU REV PLANT PHYS, V50, P539, DOI 10.1146/annurev.arplant.50.1.539; Klughammer B, 1999, MOL MICROBIOL, V32, P1305, DOI 10.1046/j.1365-2958.1999.01457.x; MARCO E, 1993, PLANT PHYSIOL, V101, P1047, DOI 10.1104/pp.101.3.1047; MI H, 1994, PLANT CELL PHYSIOL, V35, P163; OGAWA T, 1983, BIOCHIM BIOPHYS ACTA, V724, P490, DOI 10.1016/0005-2728(83)90110-X; OGAWA T, 1992, PLANT PHYSIOL, V99, P1604, DOI 10.1104/pp.99.4.1604; OGAWA T, 1991, PLANT PHYSIOL, V96, P280, DOI 10.1104/pp.96.1.280; OGAWA T, 1985, BIOCHIM BIOPHYS ACTA, V808, P77, DOI 10.1016/0005-2728(85)90029-5; OGAWA T, 1991, P NATL ACAD SCI USA, V88, P4275, DOI 10.1073/pnas.88.10.4275; Ogawa T, 1998, STRESS RESPONSES OF PHOTOSYNTHETIC ORGANISMS, P181; OGAWA T, 1965, PHOTOCHEM PHOTOBIOL, V4, P193; OGAWA T, 1985, INORGANIC CARBON UPT, P287; Ohkawa H, 1998, CAN J BOT, V76, P1035, DOI 10.1139/b98-076; Ohkawa H, 2000, J BACTERIOL, V182, P2591, DOI 10.1128/JB.182.9.2591-2596.2000; Omata T, 1999, P NATL ACAD SCI USA, V96, P13571, DOI 10.1073/pnas.96.23.13571; Price GD, 1998, CAN J BOT, V76, P973, DOI 10.1139/b98-081; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schmetterer G, 1994, MOL BIOL CYANOBACTER, P409, DOI DOI 10.1007/0-306-48205-3_13; SCHREIBER U, 1988, Z NATURFORSCH C, V43, P686; STANIER RY, 1971, BACTERIOL REV, V35, P171, DOI 10.1128/MMBR.35.2.171-205.1971; VOLOKITA M, 1984, PLANT PHYSIOL, V76, P599, DOI 10.1104/pp.76.3.599	24	167	173	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31630	31634		10.1074/jbc.M003706200	http://dx.doi.org/10.1074/jbc.M003706200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10906128	hybrid			2022-12-27	WOS:000089858900013
J	Wintrode, PL; Miyazaki, K; Arnold, FH				Wintrode, PL; Miyazaki, K; Arnold, FH			Cold adaptation of a mesophilic subtilisin-like protease by laboratory evolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGLIN-C; PSYCHROPHILIC ENZYMES; STRUCTURAL-ANALYSIS; BACILLUS-SUBTILIS; THERMITASE; CARLSBERG; PROTEINS; SEQUENCE; TEMPERATURE; MUTAGENESIS	Enzymes isolated from organisms native to cold environments generally exhibit higher catalytic efficiency at low temperatures and greater thermosensitivity than their mesophilic counterparts. In an effort to understand the evolutionary process and the molecular basis of cold adaptation, we have used directed evolution to convert a mesophilic subtilisin-like protease from Bacillus sphaericus, SSII, into its psychrophilic counterpart. A single round of random mutagenesis followed by recombination of improved variants yielded a mutant, P3C9, with a catalytic rate constant (k(cat)) at 10 degrees C 6.6 times and a catalytic efficiency (k(cat)/K-M) 9.6 times that of wild type. Its half-life at 70 degrees C is 3.3 times less than wild type. Although there is a trend toward decreasing stability during the progression from mesophile to psychrophile, there is not a strict correlation between decreasing stability and increasing low temperature activity. A first generation mutant with a >2-fold increase in k(cat) is actually more stable than wild type. This suggests that the ultimate decrease in stability may be due to random drift rather than a physical incompatibility between low temperature activity and high temperature stability. SSII shares 77.4% identity with the naturally psychrophilic protease subtilisin S41, Although SSII and S41 differ at 85 positions, four amino acid substitutions were sufficient to generate an SSII whose low temperature activity is greater than that of S41. That none of the four are found in S41 indicates that there are multiple routes to cold adaptation.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	California Institute of Technology	Arnold, FH (corresponding author), CALTECH, Div Chem & Chem Engn, 210-41, Pasadena, CA 91125 USA.	frances@cheme.caltech.edu	Miyazaki, Kentaro/F-7022-2010	Miyazaki, Kentaro/0000-0002-4349-566X; Arnold, Frances H./0000-0002-4027-364X				BENNER SA, 1989, CHEM REV, V89, P789, DOI 10.1021/cr00094a004; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BETZEL C, 1990, PROTEIN ENG, V3, P161, DOI 10.1093/protein/3.3.161; BODE W, 1987, EUR J BIOCHEM, V166, P673, DOI 10.1111/j.1432-1033.1987.tb13566.x; DAVAIL S, 1994, J BIOL CHEM, V269, P17448; DELMAR EG, 1979, ANAL BIOCHEM, V99, P316, DOI 10.1016/S0003-2697(79)80013-5; Feller G, 1997, CELL MOL LIFE SCI, V53, P830, DOI 10.1007/s000180050103; FELLER G, 1994, EUR J BIOCHEM, V222, P441, DOI 10.1111/j.1432-1033.1994.tb18883.x; Fields PA, 1998, P NATL ACAD SCI USA, V95, P11476, DOI 10.1073/pnas.95.19.11476; Gerday C, 1997, BBA-PROTEIN STRUCT M, V1342, P119, DOI 10.1016/S0167-4838(97)00093-9; Giver L, 1998, P NATL ACAD SCI USA, V95, P12809, DOI 10.1073/pnas.95.22.12809; GROS P, 1989, J MOL BIOL, V210, P347, DOI 10.1016/0022-2836(89)90336-7; HOCHACHKA PW, 1984, BIOCHEMICAL ADAPTATI; JACOBS M, 1985, NUCLEIC ACIDS RES, V13, P8913, DOI 10.1093/nar/13.24.8913; JANEICKE R, 1990, PHILOS T R SOC LOND, V326, P535; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRISTJANSSON MM, 1997, FOOD PROTEINS LIPIDS; Lebbink JHG, 2000, BIOCHEMISTRY-US, V39, P3656, DOI 10.1021/bi991483q; LOW PS, 1973, P NATL ACAD SCI USA, V70, P430, DOI 10.1073/pnas.70.2.430; MCPHALEN CA, 1988, BIOCHEMISTRY-US, V27, P6582, DOI 10.1021/bi00417a058; MELOUN B, 1985, FEBS LETT, V183, P195, DOI 10.1016/0014-5793(85)80775-4; Merz A, 2000, BIOCHEMISTRY-US, V39, P880, DOI 10.1021/bi992333i; Miyazaki K, 1999, J MOL EVOL, V49, P716, DOI 10.1007/PL00006593; Miyazaki K, 2000, J MOL BIOL, V297, P1015, DOI 10.1006/jmbi.2000.3612; Narinx E, 1997, PROTEIN ENG, V10, P1271, DOI 10.1093/protein/10.11.1271; NARINX E, 1992, BIOCHIM BIOPHYS ACTA, V1131, P111, DOI 10.1016/0167-4781(92)90108-C; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PANTOLIANO MW, 1988, BIOCHEMISTRY-US, V27, P8311, DOI 10.1021/bi00422a004; Siezen RJ, 1997, PROTEIN SCI, V6, P501; SOMERO GN, 1995, ANNU REV PHYSIOL, V57, P43, DOI 10.1146/annurev.ph.57.030195.000355; STAHL ML, 1984, J BACTERIOL, V158, P411, DOI 10.1128/JB.158.2.411-418.1984; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; Taguchi S, 1999, J BIOCHEM, V126, P689, DOI 10.1093/oxfordjournals.jbchem.a022504; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VOLKOV A, 2000, IN PRESS METHODS ENZ; Wati MR, 1997, BBA-GENE STRUCT EXPR, V1352, P56, DOI 10.1016/S0167-4781(97)00023-7; WELLS JA, 1983, NUCLEIC ACIDS RES, V11, P7911, DOI 10.1093/nar/11.22.7911; Wintrode PL, 2001, ADV PROTEIN CHEM, V55, P161, DOI 10.1016/S0065-3233(01)55004-4; Zhao HM, 1998, NAT BIOTECHNOL, V16, P258, DOI 10.1038/nbt0398-258	39	109	114	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31635	31640		10.1074/jbc.M004503200	http://dx.doi.org/10.1074/jbc.M004503200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10906329	Green Accepted, hybrid			2022-12-27	WOS:000089858900014
J	Ding, JY; Takano, T; Gao, SY; Han, WH; Noda, C; Yanagi, S; Yamamura, H				Ding, JY; Takano, T; Gao, SY; Han, WH; Noda, C; Yanagi, S; Yamamura, H			Syk is required for the activation of Akt survival pathway in B cells exposed to oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; NF-KAPPA-B; P56/P53(LYN) TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; HYDROGEN-PEROXIDE; HEAT-SHOCK; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; LYMPHOMA-CELLS	Syk has been demonstrated to play a crucial role in oxidative stress signaling in B cells. Here we report that Syk is required for the activation of the phosphatidylinositol (PI) 3-kinase-Akt survival pathway in B cells exposed to oxidative stress. Phosphorylation and activation of the serine-threonine kinase Akt were markedly increased in B cells treated with H2O2. In Syk-deficient DT40 cells treated with low doses of H2O2 (10-100 mu M), Akt activation was considerably reduced. Pretreatment with wortmannin, a PI 3-kinase-specific inhibitor, completely blocked the Syk-dependent Akt activation. Following stimulation by low doses of H2O2, a significant increase in PI 3-kinase activity was found in wild-type but not in Syk-deficient cells. These findings suggest that PI 3-kinase mediates Syk-dependent Akt activation pathway, Furthermore, viability of Syk-deficient cells, after exposure to H2O2, was dramatically decreased and caspase-9 activity was greatly increased compared with that of the wild-type cells. These results suggest that Syk is essential for the Akt survival pathway in B cells and enhances cellular resistance to oxidative stress-induced apoptosis.	Kobe Univ, Sch Med, Dept Biochem, Kobe, Hyogo 6500017, Japan; Hyogo Coll, Kakogawa 6750101, Japan	Kobe University; Hyogo College of Medicine	Yamamura, H (corresponding author), 7-5-1 Kusunokicho,Chuo Ku, Kobe, Hyogo 6500017, Japan.							AagaardTillery KM, 1996, J IMMUNOL, V156, P4543; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Beitz LO, 1999, J BIOL CHEM, V274, P32662, DOI 10.1074/jbc.274.46.32662; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gardner AM, 1997, FREE RADICAL BIO MED, V22, P73, DOI 10.1016/S0891-5849(96)00235-3; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kelley TW, 1999, J BIOL CHEM, V274, P26393, DOI 10.1074/jbc.274.37.26393; KHARBANDA S, 1994, ONCOGENE, V9, P3005; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; Konishi H, 1999, J BIOCHEM-TOKYO, V126, P1136, DOI 10.1093/oxfordjournals.jbchem.a022559; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Lee Y, 1999, J BIOL CHEM, V274, P19792, DOI 10.1074/jbc.274.28.19792; Lee YJ, 1997, BLOOD, V89, P4480, DOI 10.1182/blood.V89.12.4480; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Qin SF, 1997, J BIOL CHEM, V272, P2098; Qin SF, 1998, BIOCHEMISTRY-US, V37, P5481, DOI 10.1021/bi9729460; Qin SF, 1996, EUR J BIOCHEM, V236, P443, DOI 10.1111/j.1432-1033.1996.00443.x; SCHIEVEN GL, 1993, J BIOL CHEM, V268, P16688; SCHIEVEN GL, 1994, J BIOL CHEM, V269, P20718; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; YANAGI S, 1994, EUR J BIOCHEM, V224, P329, DOI 10.1111/j.1432-1033.1994.00329.x; YANAGI S, 1995, CELL SIGNAL, V7, P185, DOI 10.1016/0898-6568(94)00088-S	32	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30873	30877		10.1074/jbc.M004813200	http://dx.doi.org/10.1074/jbc.M004813200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906139	hybrid			2022-12-27	WOS:000089762700022
J	Masuda, CA; Ramirez, J; Pena, A; Montero-Lomeli, M				Masuda, CA; Ramirez, J; Pena, A; Montero-Lomeli, M			Regulation of monovalent ion homeostasis and pH by the Ser-Thr protein phosphatase SIT4 in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST PLASMA-MEMBRANE; SALT TOLERANCE; TRANSDUCTION PATHWAYS; NHA1 ANTIPORTER; TOR PROTEINS; GENE; SODIUM; TRANSPORT; GLYCEROL; EFFLUX	A gene, SIT4, was identified as corresponding to a serine/threonine protein phosphatase and when overexpressed confers lithium tolerance in galactose medium to the budding yeast Saccharomyces cerevisiae, This gene has been previously identified as a regulator of the cell cycle and involved in nitrogen sensing. It is shown that the transcription levels of SIT4 are induced by low concentrations of Li+ in a time-dependent manner. Na+ and K+ at high concentrations, but not sorbitol, also induce transcription. As a response to Na+ or Li+ stress, yeast cells lower the intracellular K+ content. This effect is enhanced in cells overexpressing SIT4, which also increase Rb-86 efflux after the addition of Na+ or Lit to the extracellular medium. Another feature of SIT4-overexpressing cells is that they maintain a more alkaline pH of 6.64 compared with 6.17 in the wild type cells, It has been proposed that the main pathway of salt tolerance in yeast is mediated by a P-type ATPase, encoded by PMR2A/ENA1. However, our results show that in a sit4 strain, expression of ENA1 is still induced by mono valent cations, and overexpression of SIT4 does not alter the amount of ENA1 transcript. These results show that SIT4 acts in a parallel pathway not involving induction of transcription of ENA1 and suggest a novel function for SIT4 in response to salt stress.	Univ Fed Rio de Janeiro, CCS, ICB, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil; Univ Nacl Autonoma Mexico, IFC, Dept Mol Genet, Mexico City 04510, DF, Mexico	Universidade Federal do Rio de Janeiro; Universidad Nacional Autonoma de Mexico	Montero-Lomeli, M (corresponding author), Univ Fed Rio de Janeiro, CCS, ICB, Dept Bioquim Med, CP 68041, BR-21941590 Rio De Janeiro, Brazil.		Masuda, Claudio A/F-7214-2014; Montero-Lomeli, Monica/D-9885-2013	Masuda, Claudio A/0000-0002-0310-7108; 				ARNDT KT, 1989, CELL, V56, P527, DOI 10.1016/0092-8674(89)90576-X; Banuelos MA, 1998, MICROBIOL-UK, V144, P2749, DOI 10.1099/00221287-144-10-2749; Bastians H, 1996, J CELL SCI, V109, P2865; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; BLOMBERG A, 1989, J BACTERIOL, V171, P1087, DOI 10.1128/jb.171.2.1087-1092.1989; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; Chen XJ, 2000, J BIOL CHEM, V275, P14865, DOI 10.1074/jbc.275.20.14865; de Nadal E, 1998, P NATL ACAD SCI USA, V95, P7357, DOI 10.1073/pnas.95.13.7357; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; FERRANDO A, 1995, MOL CELL BIOL, V15, P5470; GARCIADEBLAS B, 1993, MOL GEN GENET, V236, P363, DOI 10.1007/BF00277134; Gomez MJ, 1996, FEMS MICROBIOL LETT, V135, P157, DOI 10.1016/0378-1097(95)00441-6; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Jope RS, 1999, MOL PSYCHIATR, V4, P117, DOI 10.1038/sj.mp.4000494; LIU HP, 1992, GENETICS, V132, P665; MANJI HK, 1995, ARCH GEN PSYCHIAT, V52, P531; Marquez JA, 1996, FEBS LETT, V382, P89, DOI 10.1016/0014-5793(96)00157-3; Masson JY, 1998, GENETICS, V149, P893; Masuda CA, 2000, BIOCHEM CELL BIOL, V78, P51, DOI 10.1139/bcb-78-1-51; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; Mulet JM, 1999, MOL CELL BIOL, V19, P3328; NORKRANS B, 1969, J BACTERIOL, V100, P836, DOI 10.1128/JB.100.2.836-845.1969; PENA A, 1984, ARCH BIOCHEM BIOPHYS, V231, P217, DOI 10.1016/0003-9861(84)90381-3; PENA A, 1995, J BACTERIOL, V177, P1017, DOI 10.1128/jb.177.4.1017-1022.1995; PENA A, 1991, BIOCHIM BIOPHYS ACTA, V1068, P237, DOI 10.1016/0005-2736(91)90214-S; POSAS F, 1995, J BIOL CHEM, V270, P13036, DOI 10.1074/jbc.270.22.13036; Prior C, 1996, FEBS LETT, V387, P89, DOI 10.1016/0014-5793(96)00470-X; Proft M, 1999, MOL CELL BIOL, V19, P537; Ramirez J, 1998, J BACTERIOL, V180, P5860; Ramirez J, 1996, BBA-BIOMEMBRANES, V1285, P175, DOI 10.1016/S0005-2736(96)00153-8; REED RH, 1987, APPL ENVIRON MICROB, V53, P2119, DOI 10.1128/AEM.53.9.2119-2123.1987; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHOU M, 1997, ARCH GEN PSYCHIAT, V4, P9; SKALA J, 1991, YEAST, V7, P651, DOI 10.1002/yea.320070614; Sunder S, 1996, MOL CELL BIOCHEM, V158, P121; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; Sychrova H, 1999, FEMS MICROBIOL LETT, V171, P167, DOI 10.1111/j.1574-6968.1999.tb13428.x; Varela JCS, 1996, MICROBIOL-SGM, V142, P721, DOI 10.1099/00221287-142-4-721; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WIELAND J, 1995, EMBO J, V14, P3870, DOI 10.1002/j.1460-2075.1995.tb00059.x	43	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30957	30961		10.1074/jbc.M004869200	http://dx.doi.org/10.1074/jbc.M004869200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10921924	hybrid			2022-12-27	WOS:000089762700033
J	Bowers, RC; Hevko, J; Henson, PM; Murphy, RC				Bowers, RC; Hevko, J; Henson, PM; Murphy, RC			A novel glutathione containing eicosanoid (FOG(7)) chemotactic for human granulocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; PHORBOL-MYRISTATE ACETATE; 5-OXO-6,8,11,14-EICOSATETRAENOIC ACID; HUMAN EOSINOPHILS; HUMAN NEUTROPHILS; SUBSTANCE; CELLS	A biologically active glutathione adduct of the eicosanoid 5-oxo-eicosatetraenoic acid has been observed as a product formed within the murine peritoneal macrophage. This five-ore glutathione adduct (FOG(7)) was structurally characterized using electrospray tandem mass spectrometry as a 1,4 Michael addition product 5-oxo-7-glutathionyl-8,11,14-eicosatrienoic acid. FOG(7) was found to be highly potent in stimulating eosinophil as well as neutrophil chemotaxis, also capable of initiating actin polymerization, without elevating intracellular free calcium ion concentration within either the eosinophil or polymorphonuclear leukocyte. These biological responses suggest that either FOG(7) activates a subset of receptors mediating the broader biological activity of the parent eicosanoid 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) or that a receptor not activated by 5-oxo-ETE participates in the chemotactic activity of FOG(7). The only other known biologically active glutathione adduct has been leukotriene C-4 (LTC4), another eicosanoid that exerts potent effects through the Cys-LT receptor. The biochemical parallel between the formation of LTC4 and FOG(7) suggests an interesting mechanism by which biologically active eicosanoids derived from electrophilic intermediates may have unique distribution and prolonged efficacy in vivo.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA	National Jewish Health	Murphy, RC (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, 1400 Jackson St, Denver, CO 80206 USA.	murphyr@njc.org			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024444] Funding Source: NIH RePORTER; NINDS NIH HHS [NS24444] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Blackburn ML, 1997, CHEM RES TOXICOL, V10, P1364, DOI 10.1021/tx970087a; BORGEAT P, 1976, J BIOL CHEM, V251, P7816; BUTTERFIELD JH, 1994, SAMTERS IMMUNOLOGIC, P501; Czech W, 1997, J INVEST DERMATOL, V108, P108, DOI 10.1111/1523-1747.ep12285653; FADOK VA, 1992, J IMMUNOL, V149, P4029; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; GELFAND EW, 1986, J BIOL CHEM, V261, P1520; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOWARD TH, 1985, J CELL BIOL, V101, P1078, DOI 10.1083/jcb.101.3.1078; Martin LB, 1996, INT ARCH ALLERGY IMM, V109, P207, DOI 10.1159/000237239; MURPHY RC, 1979, P NATL ACAD SCI USA, V76, P4275, DOI 10.1073/pnas.76.9.4275; O'Flaherty JT, 2000, J IMMUNOL, V164, P3345, DOI 10.4049/jimmunol.164.6.3345; OFLAHERTY JT, 1993, BIOCHEM BIOPH RES CO, V192, P129, DOI 10.1006/bbrc.1993.1391; OFLAHERTY JT, 1994, BBA-GEN SUBJECTS, V1201, P505, DOI 10.1016/0304-4165(94)90083-3; POWELL WS, 1994, BIOCHEMISTRY-US, V33, P3927, DOI 10.1021/bi00179a019; POWELL WS, 1994, J BIOL CHEM, V269, P25373; Powell WS, 1999, AM J RESP CELL MOL, V20, P163, DOI 10.1165/ajrcmb.20.1.3141; POWELL WS, 1993, J BIOL CHEM, V268, P9280; POWELL WS, 1992, J BIOL CHEM, V267, P19233; RAFTERY MJ, 1990, BIOMED ENVIRON MASS, V19, P465, DOI 10.1002/bms.1200190804; Samuelsson B, 2000, AM J RESP CRIT CARE, V161, pS2, DOI 10.1164/ajrccm.161.supplement_1.ltta-1; TALALAY P, 1989, ADV ENZYME REGUL, V28, P237, DOI 10.1016/0065-2571(89)90074-5; Wheelan P, 1999, J PHARMACOL EXP THER, V288, P326; Zhang Y, 1996, J LEUKOCYTE BIOL, V59, P847, DOI 10.1002/jlb.59.6.847; ZIGMOND SH, 1988, METHOD ENZYMOL, V162, P65	26	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					29931	29934		10.1074/jbc.C000502200	http://dx.doi.org/10.1074/jbc.C000502200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10924496	hybrid			2022-12-27	WOS:000089577900003
J	Togashi, H; Nagata, K; Takagishi, M; Saitoh, N; Inagaki, M				Togashi, H; Nagata, K; Takagishi, M; Saitoh, N; Inagaki, M			Functions of a Rho-specific guanine nucleotide exchange factor in neurite retraction - Possible role of a proline-rich motif of KIAA0380 in localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; STRESS FIBER FORMATION; SERUM RESPONSE ELEMENT; KINASE ROK-ALPHA; LYSOPHOSPHATIDIC ACID; MYOSIN PHOSPHATASE; FOCAL ADHESIONS; GDP/GTP-EXCHANGE; PHOSPHOLIPASE-D; ACTIVATION	The Rho/Rho kinase signaling pathway plays an essential role in neurite retraction and cell rounding in response to G(12/13)-coupled receptor activation in neuronal cells. The Rho guanine nucleotide exchange factor involved in these processes has not been identified. To monitor the activation state of Rho kinase, we developed a vimentin head/Rho kinase chimera, which is intramolecularly phosphorylated in a Rho-dependent manner at Ser(71) of the fused vimentin head. Using this system, we identified a clone termed KIAA0380, which contains the G alpha(12/13)-binding domain as well as a tandem of the Dbl homology/pleckstrin homology (DH/PH) domain, as an activator of Rho/Rho kinase signaling. Molecular dissection analyses revealed that a proline-rich motif C-terminally adjacent to DH/PH domain is essential for plasma membrane localization of KIAA0380 and cortical actin reorganization followed by cell rounding. In contrast, the DH/PH domain of KIAA0380 is localized in the cytoplasm, where it activates Rho/Rho kinase and induces stress fiber formation, consistent with results using p115 Rho guanine nucleotide exchange factor, which has a similar structure to KIAA0380 but lacks a proline-rich motif, These results suggest that upon stimulation, KIAA0380 translocates to the plasma membrane via the proline-rich motif and there activates Rho/Rho kinase signaling, In neuroblastoma Neuro2a cells, KIAA0380 was observed in the tips of neurites, a location where cortical actin reorganization is induced upon stimulation with lysophosphatidic acid. Ectopic expression of the N-terminal fragment inhibited lysophosphatidic acid-induced neurite retraction of Neuro2a cells. These results suggest that KIAA0380 plays an important role in neurite retraction through Rho-dependent signaling.	Aichi Canc Ctr, Res Inst, Div Biochem, Aichi 4648681, Japan; Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Aichi 4648602, Japan; Nagoya City Univ, Fac Pharmaceut Sci, Dept Chem Hyg & Nutr, Mizuho Ku, Aichi 4678603, Japan	Aichi Cancer Center; Nagoya University; Nagoya City University	Nagata, K (corresponding author), Aichi Canc Ctr, Res Inst, Div Biochem, 1-1 Chikusa Ku, Aichi 4648681, Japan.	knagata@aichi-cc.pref.aichi.jp; minagaki@aichi-cc.pref.aichi.jp	Inagaki, Masaki/B-9920-2016					Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Goto H, 1998, J BIOL CHEM, V273, P11728, DOI 10.1074/jbc.273.19.11728; GOTO H, 2000, IN PRESS MICROSC RES; HART CM, 1994, J MOL BIOL, V237, P255, DOI 10.1006/jmbi.1994.1229; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Inada H, 1999, J BIOL CHEM, V274, P34932, DOI 10.1074/jbc.274.49.34932; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; JALINK K, 1992, J CELL BIOL, V118, P411, DOI 10.1083/jcb.118.2.411; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; Katoh H, 1996, J BIOL CHEM, V271, P29780, DOI 10.1074/jbc.271.47.29780; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; Kosako H, 1999, ONCOGENE, V18, P2783, DOI 10.1038/sj.onc.1202633; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kranenburg O, 1997, J CELL SCI, V110, P2417; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Leung T, 1996, MOL CELL BIOL, V16, P5313; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; NAGATA KI, 1994, BRIT J HAEMATOL, V88, P706, DOI 10.1111/j.1365-2141.1994.tb05108.x; NISHIZAWA K, 1991, J BIOL CHEM, V266, P3074; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1991, NEW BIOL, V3, P372; Rumenapp U, 1999, FEBS LETT, V459, P313, DOI 10.1016/S0014-5793(99)01270-3; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Tigyi G, 1996, J NEUROCHEM, V66, P549; UEDA T, 1990, J BIOL CHEM, V265, P9373; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249	59	45	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29570	29578		10.1074/jbc.M003726200	http://dx.doi.org/10.1074/jbc.M003726200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10900204	hybrid			2022-12-27	WOS:000089439800053
J	Sun, XX; Wang, CC				Sun, XX; Wang, CC			The N-terminal sequence (residues 1-65) is essential for dimerization, activities, and peptide binding of Escherichia coli DSbC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; CHAPERONE-LIKE ACTIVITY; REDOX PROPERTIES; BOND FORMATION; DEHYDROGENASE; THIOREDOXIN; SUBSTRATE; ISOMERIZATION; DOMAINS; FAMILY	Limited proteolysis of DsbC with trypsin resulted in a compact and stable C-terminal fragment (residues 66-216), fDsbC, which retains the active site sequence, -Cys(98)-Gly-Tyr-Cys(101)-, and shows only minor differences in conformation compared with that of the intact molecule. The pK(a) of active site thiol and the K-SS with glutathione are very close to that of DsbC, respectively; however, fDsbC is inactive as an isomerase in catalyzing the formation of correct disulfide bonds in scrambled RNase A and denatured and reduced bovine pancreatic trypsin inhibitor and shows only 13% thiol-protein oxidoreductase activity (TPOR) of DsbC. In contrast to the dimeric DsbC, fDsbC exists as a monomer and has no chaperone activity in assisting the reactivation of denatured D-glyceraldehyde-3-phosphate dehydrogenase. The heterodimer of DsbC with the inactive DsbC carboxymethylated at both active site thiols shows about 50% TPOR activity of DsbC but no isomerase activity, indicating that the DsbC subunit in the heterodimer displays full TPOR activity but little, if any, isomerase activity. It is concluded that the N-terminal sequence (residues 1-65) is essential for dimer formation and chaperone activity of DsbC. The active sites in both subunits of the dimeric DsbC appear to be essential for its isomerase activity.	Acad Sinica, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS	Wang, CC (corresponding author), Acad Sinica, Inst Biophys, Natl Lab Biomacromol, 15 Datun Rd, Beijing 100101, Peoples R China.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAI H, 1994, J BIOL CHEM, V269, P24550; Chen J, 1999, J BIOL CHEM, V274, P19601, DOI 10.1074/jbc.274.28.19601; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; Freedman RB, 1998, BIOL CHEM, V379, P321, DOI 10.1515/bchm.1998.379.3.321; Frishman D, 1996, BIOCHEM BIOPH RES CO, V219, P686, DOI 10.1006/bbrc.1996.0295; GIROUX E, 1994, J BIOL CHEM, V269, P31404; Grant GA, 1999, J BIOL CHEM, V274, P5357, DOI 10.1074/jbc.274.9.5357; HAWKINS HC, 1991, BIOCHEM J, V275, P349, DOI 10.1042/bj2750349; Heuck AP, 1997, ANAL BIOCHEM, V248, P94, DOI 10.1006/abio.1997.2123; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; Hubbard SJ, 1998, BBA-PROTEIN STRUCT M, V1382, P191, DOI 10.1016/S0167-4838(97)00175-1; Huber-Wunderlich M, 1998, FOLD DES, V3, P161, DOI 10.1016/S1359-0278(98)00024-8; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; LAMBERT N, 1983, BIOCHEM J, V213, P225, DOI 10.1042/bj2130225; LIANG SJ, 1990, BIOCHIM BIOPHYS ACTA, V1038, P240, DOI 10.1016/0167-4838(90)90211-W; McCarthy AA, 2000, NAT STRUCT BIOL, V7, P196; Missiakas D, 1997, J BACTERIOL, V179, P2465, DOI 10.1128/jb.179.8.2465-2471.1997; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; Raina S, 1997, ANNU REV MICROBIOL, V51, P179, DOI 10.1146/annurev.micro.51.1.179; Ranson NA, 1998, BIOCHEM J, V333, P233, DOI 10.1042/bj3330233; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; SCHEEK RM, 1982, METHOD ENZYMOL, V89, P305; Sone M, 1997, J BIOL CHEM, V272, P10349; SONG JL, 1995, EUR J BIOCHEM, V231, P312, DOI 10.1111/j.1432-1033.1995.tb20702.x; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; Yao Y, 1997, EMBO J, V16, P651, DOI 10.1093/emboj/16.3.651; ZAPUN A, 1994, BIOCHEMISTRY-US, V33, P5202, DOI 10.1021/bi00183a025; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019; Zheng WD, 1997, ARCH BIOCHEM BIOPHYS, V337, P326, DOI 10.1006/abbi.1996.9783	30	64	69	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22743	22749		10.1074/jbc.M002406200	http://dx.doi.org/10.1074/jbc.M002406200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10930424	hybrid			2022-12-27	WOS:000088419400022
J	Cohen, A; Nelson, H; Nelson, N				Cohen, A; Nelson, H; Nelson, N			The family of SMF metal ion transporters in yeast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; SACCHAROMYCES-CEREVISIAE; COPPER TRANSPORT; PLASMA-MEMBRANE; FUNCTIONAL EXPRESSION; PROCESSING PROTEASE; MOLECULAR-BIOLOGY; IRON TRANSPORT; TASTE BEHAVIOR; BSD2 GENE	Metal ions are vital for all organisms, and metal ion transporters play a crucial role in maintaining their homeostasis. The yeast (Saccharomyces cerevisiae) Smf transporters and their homologs in other organisms have a central role in the accumulation of metal ions and their distribution in different tissues and cellular organelles. In this work we generated null mutations in each individual SMF gene in yeast as well as in all combinations of the genes. Each null mutation exhibited sensitivity to metal ion chelators at different concentrations. The combination of null mutants Delta SMF1 + Delta SMF2 and the triple null mutant Delta 3SMF failed to grow on medium buffered at pH 8 and 7.5, respectively. Addition of 5 muM copper or 25 muM manganese alleviated the growth arrest at the high pH or in the presence of the chelating agent, The transport of manganese was analyzed in the triple null mutant and in this mutant expressing each Smf protein. Although overexpression of Smf1p and Smf2p resulted in uptake that was higher than wild type cells, the expression of Smf3p gave no significant uptake above that of the triple mutant Delta 3SMF. Western analysis with antibody against Smf3p indicated that this transporter does not reach the plasma membrane and may function at the Gels or post-Gels complexes. The iron uptake resulting from expression of Smf1p and Smf2p was analyzed in a mutant in which its iron transporters FET3 and FET4 were inactivated. Overexpression of Smf1p gave rise to a significant iron uptake that was sensitive to the sodium concentrations in the medium. We conclude that the Smf proteins play a major role in copper and manganese homeostasis and, under certain circumstances, Smf1p may function in iron transport into the cells.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel	Tel Aviv University	Nelson, N (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel.							Andrews NC, 1998, BLOOD, V92, P1845, DOI 10.1182/blood.V92.6.1845.418k35_1845_1851; Askwith C, 1998, TRENDS BIOCHEM SCI, V23, P135, DOI 10.1016/S0968-0004(98)01192-X; Askwith CC, 1996, MOL MICROBIOL, V20, P27, DOI 10.1111/j.1365-2958.1996.tb02485.x; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; Chen XZ, 1999, J BIOL CHEM, V274, P35089, DOI 10.1074/jbc.274.49.35089; Cohen A, 1999, J BIOL CHEM, V274, P26885, DOI 10.1074/jbc.274.38.26885; Csere P, 1998, FEBS LETT, V441, P266, DOI 10.1016/S0014-5793(98)01560-9; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; EIBLE R, 1992, BIOTECHNIQUES, V13, P18; Eide D, 1996, P NATL ACAD SCI USA, V93, P5624, DOI 10.1073/pnas.93.11.5624; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Knauer R, 1999, BBA-GEN SUBJECTS, V1426, P259, DOI 10.1016/S0304-4165(98)00128-7; Knauer R, 1999, J BIOL CHEM, V274, P17249, DOI 10.1074/jbc.274.24.17249; KOLAND JG, 1986, J BIOL CHEM, V261, P5936; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; Liu XF, 1997, J BIOL CHEM, V272, P11763, DOI 10.1074/jbc.272.18.11763; Liu XF, 1999, J BIOL CHEM, V274, P4863, DOI 10.1074/jbc.274.8.4863; Lupashin VV, 1997, MOL BIOL CELL, V8, P2659, DOI 10.1091/mbc.8.12.2659; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; NELSON H, 1994, J BIOL CHEM, V269, P24150; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1983, METHOD ENZYMOL, V97, P510; Nelson N, 1999, EMBO J, V18, P4361, DOI 10.1093/emboj/18.16.4361; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; Orgad S, 1998, J EXP BIOL, V201, P115; Pinner E, 1997, J BIOL CHEM, V272, P28933, DOI 10.1074/jbc.272.46.28933; POLLOCK RA, 1988, EMBO J, V7, P3493, DOI 10.1002/j.1460-2075.1988.tb03225.x; Radisky D, 1999, J BIOL CHEM, V274, P4481, DOI 10.1074/jbc.274.8.4481; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; RODRIGUES V, 1995, EMBO J, V14, P3007, DOI 10.1002/j.1460-2075.1995.tb07303.x; Supek F, 1997, J EXP BIOL, V200, P321; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; Tabuchi M, 1999, BIOCHEM J, V344, P211, DOI 10.1042/0264-6021:3440211; WEST AH, 1992, J BIOL CHEM, V267, P24625; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x; Yuan DS, 1997, J BIOL CHEM, V272, P25787, DOI 10.1074/jbc.272.41.25787; Zhou B, 1997, P NATL ACAD SCI USA, V94, P7481, DOI 10.1073/pnas.94.14.7481	44	106	111	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33388	33394		10.1074/jbc.M004611200	http://dx.doi.org/10.1074/jbc.M004611200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10930410	hybrid			2022-12-27	WOS:000090104600031
J	Jorgensen, MM; Jensen, ON; Holst, HU; Hansen, JJ; Corydon, TJ; Bross, P; Bolund, L; Gregersen, N				Jorgensen, MM; Jensen, ON; Holst, HU; Hansen, JJ; Corydon, TJ; Bross, P; Bolund, L; Gregersen, N			Grp78 is involved in retention of mutant low density lipoprotein receptor protein in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE BIP; FAMILIAL HYPERCHOLESTEROLEMIA; LDL RECEPTOR; SELECTIVE PROTEINS; QUALITY-CONTROL; SECRETION; CELLS; STRESS; OVEREXPRESSION; DISEASE	The low density lipoprotein (LDL) receptor is responsible for removing the majority of the LDL cholesterol from the plasma. Mutations in the LDL receptor gene cause the disease familial hypercholesterolemia (FH), Approximately 50% of the mutations in the LDL receptor gene in patients with FH lead to receptor proteins that are retained in the endoplasmic reticulum (ER). Misfolding of mutant LDL receptors is a probable cause of this ER retention, resulting in no functional LDL receptors at the cell surface. However, the specific factors and mechanisms responsible for retention of mutant LDL receptors are unknown, In the present study we show that the molecular chaperone Grp78/BiP co-immunoprecipitates with both the wild type and two different mutant (W556S and C646Y) LDL receptors in lysates obtained from human liver cells overexpressing wild type or mutant LDL receptors, A pulse-chase study shows that the interaction between the wild type LDL receptor and Grp78 is no longer detectable after 2 1/2 h, whereas it persists for more than 4 h with the mutant receptors, Furthermore, about five times more Grp78 is co-immunoprecipitated with the mutant receptors than with the wild type receptor suggesting that Grp78 is involved in retention of mutant LDL receptors in the ER. Overexpression of Grp78 causes no major alterations on the steady state level of active LDL receptors at the cell surface. However, overexpression of Grp78 decreases the processing rate of newly synthesized wild type LDL receptors, This indicates that the Grp78 interaction is a rate-limiting step in the maturation of the wild type LDL receptor and that Grp78 may be an important factor in the quality control of newly synthesized LDL receptors.	Univ Aarhus, Skejby Sygehus, Res Unit Mol Med, DK-8200 Aarhus N, Denmark; Odense Univ, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark; Aarhus Univ, Inst Human Genet, DK-8000 Aarhus C, Denmark	Aarhus University; University of Southern Denmark; Aarhus University	Jorgensen, MM (corresponding author), Univ Aarhus, Skejby Sygehus, Res Unit Mol Med, Brendstrupgaardsvej, DK-8200 Aarhus N, Denmark.		Jensen, Ole N/J-1763-2012; Bross, Peter/B-7219-2013	Jensen, Ole N/0000-0003-1862-8528; Bross, Peter/0000-0001-9526-8525; Corydon, Thomas Juhl/0000-0003-3588-6350; Jorgensen, Malene Munk/0000-0002-0090-3563				Ailor E, 1998, BIOTECHNOL BIOENG, V58, P196, DOI 10.1002/(SICI)1097-0290(19980420)58:2/3<196::AID-BIT12>3.0.CO;2-B; BARAK LS, 1981, J CELL BIOL, V90, P595, DOI 10.1083/jcb.90.3.595; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; Beissinger M, 1998, BIOL CHEM, V379, P245; Belfi CA, 1999, BIOCHEM BIOPH RES CO, V257, P361, DOI 10.1006/bbrc.1999.0472; BERGER NA, 1982, CANCER RES, V42, P4382; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; Brooks DA, 1997, FEBS LETT, V409, P115, DOI 10.1016/S0014-5793(97)00423-7; Bross P, 1999, HUM MUTAT, V14, P186, DOI 10.1002/(SICI)1098-1004(1999)14:3<186::AID-HUMU2>3.0.CO;2-J; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; CARRELL RW, 1996, CHEST, V110, P243; CHATTERJEE S, 1994, CANCER RES, V54, P4405; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; DORNER AJ, 1990, P NATL ACAD SCI USA, V87, P7429, DOI 10.1073/pnas.87.19.7429; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HOBBS HH, 1990, ANNU REV GENET, V24, P133, DOI 10.1146/annurev.ge.24.120190.001025; Jensen HK, 1997, ATHEROSCLEROSIS, V131, P67, DOI 10.1016/S0021-9150(96)06059-5; Jensen O.N., 1997, PROTEIN STRUCTURE PR; Jensen ON, 1996, RAPID COMMUN MASS SP, V10, P1371, DOI 10.1002/(SICI)1097-0231(199608)10:11<1371::AID-RCM682>3.0.CO;2-5; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; Leborgne-Castel N, 1999, PLANT CELL, V11, P459, DOI 10.1105/tpc.11.3.459; LEITERSDORF E, 1990, J CLIN INVEST, V85, P1014, DOI 10.1172/JCI114531; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; Linnik KM, 1998, J BIOL CHEM, V273, P21368, DOI 10.1074/jbc.273.33.21368; MANN M, 1993, BIOL MASS SPECTROM, V22, P338, DOI 10.1002/bms.1200220605; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; Muresan Z, 1998, MOL ENDOCRINOL, V12, P458, DOI 10.1210/me.12.3.458; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Soto C, 1999, J MOL MED-JMM, V77, P412, DOI 10.1007/s001090050371; Street JC, 1996, J BIOL CHEM, V271, P4113; SUDHOF TC, 1985, SCIENCE, V228, P893, DOI 10.1126/science.3873704; Tate CG, 1999, J BIOL CHEM, V274, P17551, DOI 10.1074/jbc.274.25.17551; Yang YN, 1998, J BIOL CHEM, V273, P25552, DOI 10.1074/jbc.273.40.25552	39	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33861	33868		10.1074/jbc.M004663200	http://dx.doi.org/10.1074/jbc.M004663200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10906332	hybrid			2022-12-27	WOS:000090104600094
J	Kala, SV; Neely, MW; Kala, G; Prater, CI; Atwood, DW; Rice, JS; Lieberman, MW				Kala, SV; Neely, MW; Kala, G; Prater, CI; Atwood, DW; Rice, JS; Lieberman, MW			The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE RISK-FACTORS; ARTESIAN WELL WATER; HEPATOBILIARY TRANSPORT; MALIGNANT NEOPLASMS; BLACKFOOT DISEASE; URINARY-EXCRETION; DRINKING-WATER; PROTEIN GENE; RESISTANCE; RATS	Worldwide, millions of people are exposed to arsenic in drinking water that exceeds the World Health Organization standard of 10 mug/liter by as much as 50-300-fold, yet little is known about the molecular basis for arsenic excretion. Here me show that transport of arsenic into bile depends on the MRP2/cMOAT transporter and that glutathione is obligatory for such transport, Using reversed phase liquid chromatography/mass spectrometry, we demonstrate that two arsenic-glutathione complexes not previously identified in vivo, arsenic tri-glutathione and methylarsenic diglutathione, account for most of the arsenic in the bile. The structure of the compounds was also confirmed by nuclear magnetic resonance spectroscopy, Our findings may help explain the increased susceptibility of malnourished human populations to arsenic.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cellular & Mol Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Lieberman, MW (corresponding author), Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA.	mikel@bcm.tmc.edu			NIEHS NIH HHS [ES 10389] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010389] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aposhian HV, 1997, ANNU REV PHARMACOL, V37, P397, DOI 10.1146/annurev.pharmtox.37.1.397; Bagla P, 1996, SCIENCE, V274, P174, DOI 10.1126/science.274.5285.174; BRAY TM, 1993, CAN J PHYSIOL PHARM, V71, P746, DOI 10.1139/y93-111; Broeks A, 1996, EMBO J, V15, P6132, DOI 10.1002/j.1460-2075.1996.tb01001.x; BUCHET JP, 1987, TOXICOL APPL PHARM, V91, P65, DOI 10.1016/0041-008X(87)90194-3; CHEN CJ, 1988, ARTERIOSCLEROSIS, V8, P452, DOI 10.1161/01.ATV.8.5.452; CHEN CJ, 1985, CANCER RES, V45, P5895; CULLEN WR, 1984, J INORG BIOCHEM, V21, P179, DOI 10.1016/0162-0134(84)83002-0; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; Dey S, 1996, P NATL ACAD SCI USA, V93, P2192, DOI 10.1073/pnas.93.5.2192; ELFERINK RPJ, 1989, J CLIN INVEST, V84, P476, DOI 10.1172/JCI114189; Gregus Z, 2000, TOXICOL SCI, V56, P18, DOI 10.1093/toxsci/56.1.18; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; GYURASICS A, 1991, BIOCHEM PHARMACOL, V41, P937, DOI 10.1016/0006-2952(91)90199-F; Habib GM, 2000, HEPATOLOGY, V32, P556, DOI 10.1053/jhep.2000.9715; HSUEH YM, 1995, BRIT J CANCER, V71, P109, DOI 10.1038/bjc.1995.22; KITAMURA T, 1990, P NATL ACAD SCI USA, V87, P3557, DOI 10.1073/pnas.87.9.3557; KLAASSEN CD, 1996, CASARETT DOULLS TOXI, P691; Kool M, 1997, CANCER RES, V57, P3537; Mazumder DNG, 1998, INT J EPIDEMIOL, V27, P871, DOI 10.1093/ije/27.5.871; MOREL G, 1995, TOXICOL LETT, V78, P111, DOI 10.1016/0378-4274(94)03240-8; National Research Council, 1999, ARS DRINK WAT; Paulusma CC, 1999, BIOCHEM J, V338, P393, DOI 10.1042/0264-6021:3380393; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; SCOTT N, 1993, CHEM RES TOXICOL, V6, P102, DOI 10.1021/tx00031a016; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Tsai SM, 1999, ARCH ENVIRON HEALTH, V54, P186, DOI 10.1080/00039899909602258; VAHTER M, 1987, TOXICOL LETT, V37, P41, DOI 10.1016/0378-4274(87)90165-2; Wang ZL, 1996, TOXICOL APPL PHARM, V137, P112, DOI 10.1006/taap.1996.0062; WHO, 1999, ARS EXPS, P1; Yoshida K, 1998, J TOXICOL ENV HEAL A, V54, P179; Zakharyan RA, 1999, CHEM RES TOXICOL, V12, P1278, DOI 10.1021/tx9901231; ZHANG P, 1996, CHIN J HEMATOL, V17, P58	33	257	272	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33404	33408		10.1074/jbc.M007030200	http://dx.doi.org/10.1074/jbc.M007030200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10938093	hybrid			2022-12-27	WOS:000090104600033
J	Sharma, SC; Richards, JS				Sharma, SC; Richards, JS			Regulation of AP1 (Jun/Fos) factor expression and activation in ovarian granulosa cells - Relation of JunD and Fra2 to terminal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; GROWTH-FACTOR-BETA; C-FOS; CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE; INDUCIBLE ENHANCER; SIGNALING PATHWAY; HORMONAL-CONTROL; NULL MUTATION; TRANSCRIPTION; GENE	AP1 transcription factors control rapid responses of mammalian cells to stimuli that impact proliferation, differentiation, and transformation. To determine which AP1 factors are present in and regulated by hormones in ovarian cells during specific stages of proliferation and differentiation, we used both in vitro and in vivo models, Western blotting, immunohistochemistry, DNA binding assays, and transfections of AP1 promoter-reporter constructs. The expression patterns of Jun and Fos family members in response to hormones (follicle-stimulating hormone (FSH), luteinizing hormone (LH), and cAMP) were distinct. JunB, c-Jun, c-Fos, and Fra2 mere rapidly but transiently induced by FSH in immature granulosa cells. JunD and Fra2 were induced by LEI and maintained as granulosa cells terminally differentiated into luteal cells. Forskolin and phorbol myristate acetate acted synergistically to enhance transcription of an AP1(-73COL)-luciferase construct. JunD appears to be one mediator of this effect, since JunD was a major component of the AP1-DNA binding complex in granulosa cells, and menin, a selective inhibitor of JunD, blocked transcription of -73COL-luciferase, Thus, FSH and LH via cAMP induce specific AP1 factors, the AP1 expression patterns are distinct, and that of JunD and Fra2 correlates with the transition of proliferating granulosa cells to terminally differentiated, non-dividing luteal cells.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Richards, JS (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	joanner@bcm.tmc.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD016229] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD007495, R37HD016229, R56HD016229] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-16229, HD-07495] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alliston TN, 2000, ENDOCRINOLOGY, V141, P385, DOI 10.1210/en.141.1.385; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Ardekani AM, 1998, ENDOCRINOLOGY, V139, P3271, DOI 10.1210/en.139.7.3271; Botelho FM, 1998, J BIOL CHEM, V273, P5211, DOI 10.1074/jbc.273.9.5211; Carlone DL, 1997, MOL ENDOCRINOL, V11, P292, DOI 10.1210/me.11.3.292; Cook SJ, 1999, MOL CELL BIOL, V19, P330; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; EPSEY LL, 2000, ENDOCRINOLOGY, V141, P2385; FITZPATRICK SL, 1994, MOL ENDOCRINOL, V8, P1309, DOI 10.1210/me.8.10.1309; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; Gonzalez-Robayna IJ, 2000, MOL ENDOCRINOL, V14, P1283, DOI 10.1210/me.14.8.1283; Gonzalez-Robayna IJ, 1999, MOL ENDOCRINOL, V13, P1318, DOI 10.1210/me.13.8.1318; Habener JF, 1995, VITAM HORM, V51, P1, DOI 10.1016/S0083-6729(08)61037-7; Hagglund AC, 1999, ENDOCRINOLOGY, V140, P4351, DOI 10.1210/en.140.9.4351; HASHIMOTO M, 1993, ENDOCRINOLOGY, V133, P1934, DOI 10.1210/en.133.5.1934; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; Hu PPC, 1999, MOL ENDOCRINOL, V13, P2039, DOI 10.1210/me.13.12.2039; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; MORGAN JI, 1995, TRENDS NEUROSCI, V18, P66; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; Mukherjee A, 1996, ENDOCRINOLOGY, V137, P3234, DOI 10.1210/en.137.8.3234; Neyns B, 1999, INT J CANCER, V82, P687; Nishitani J, 1999, J BIOL CHEM, V274, P5454, DOI 10.1074/jbc.274.9.5454; PEI L, 1991, MOL ENDOCRINOL, V5, P521, DOI 10.1210/mend-5-4-521; Rao GN, 1999, J BIOL CHEM, V274, P6003, DOI 10.1074/jbc.274.9.6003; RICHARDS JS, 1994, ENDOCR REV, V15, P725, DOI 10.1210/er.15.6.725; RICHARDS JS, 2000, IN PRESS STEROIDS; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; Robker RL, 1998, BIOL REPROD, V59, P476, DOI 10.1095/biolreprod59.3.476; Robker RL, 1998, MOL ENDOCRINOL, V12, P924, DOI 10.1210/me.12.7.924; Rosenberger SF, 1999, J BIOL CHEM, V274, P1124, DOI 10.1074/jbc.274.2.1124; SEGALOFF DL, 1990, MOL ENDOCRINOL, V4, P1856, DOI 10.1210/mend-4-12-1856; Sharma SC, 1999, ENDOCRINOLOGY, V140, P4320, DOI 10.1210/en.140.9.4320; Sjin RMTT, 1999, J BIOL CHEM, V274, P28697, DOI 10.1074/jbc.274.40.28697; Smith CL, 1998, BIOL REPROD, V58, P627, DOI 10.1095/biolreprod58.3.627; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; White BR, 1999, MOL ENDOCRINOL, V13, P566, DOI 10.1210/me.13.4.566; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	47	107	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33718	33728		10.1074/jbc.M003555200	http://dx.doi.org/10.1074/jbc.M003555200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10934195	hybrid			2022-12-27	WOS:000090104600075
J	Calvert, MJ; Ward, DG; Trayer, HR; Trayer, IP				Calvert, MJ; Ward, DG; Trayer, HR; Trayer, IP			The importance of the carboxyl-terminal domain of cardiac troponin C in Ca2+-sensitive muscle regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOFIBRILLAR ADENOSINE-TRIPHOSPHATASE; CALCIUM-SATURATED STATES; MAGNESIUM BINDING-SITES; NEUTRON-SCATTERING; N-DOMAIN; CALMODULIN; COMPLEX; RESOLUTION; MYOSIN; PHOSPHORYLATION	The interactions between troponin I and troponin C are central to the Ca2+-regulated control of striated muscle. Using isothermal titration microcalorimetry we have studied the binding of human cardiac troponin C (cTnC) and its isolated domains to human cardiac troponin I (cTnI). We provide the first binding data for these proteins while they are free in solution and unmodified by reporter groups. Our data reveal that the C-terminal domain of cTnC is responsible for most of the free energy change upon cTnC cTnI binding. Importantly, the interaction between cTnI and the C-terminal domain of cTnC is 8-fold stronger in the presence of Ca2+ than in the presence of Mg2+, suggesting that the C-terminal domain of cTnC may play a modulatory role in cardiac muscle regulation. Changes in the affinity of cTnI for cTnC and its isolated C-terminal domain in response to ionic strength support this finding, with both following similar trends. At physiological ionic strength the affinity of cTnC for cTnI changed very little in response to Ca2+, although the thermodynamic data show a clear distinction between binding in the presence of Ca2+ and in the presence of Mg2+.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Trayer, IP (corresponding author), Univ Birmingham, Sch Biosci, POB 363, Birmingham B15 2TT, W Midlands, England.		Calvert, Melanie/F-7055-2011	Calvert, Melanie/0000-0002-1856-837X; Ward, Douglas/0000-0002-2328-1445				ALHILLAWI E, 1995, EUR J BIOCHEM, V228, P962; ALHILLAWI E, 1994, EUR J BIOCHEM, V225, P1195, DOI 10.1111/j.1432-1033.1994.1195b.x; BINGHAM RP, 1998, THESIS U BIRMINGHAM; CHERVENKA CH, 1970, ANAL BIOCHEM, V34, P24, DOI 10.1016/0003-2697(70)90082-5; Christensen J.J., 1976, HDB PROTON IONIZATIO; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; Dong WJ, 1997, BIOCHEMISTRY-US, V36, P6754, DOI 10.1021/bi9622276; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; Francois JM, 1997, J MUSCLE RES CELL M, V18, P323, DOI 10.1023/A:1018622109391; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; Gasmi-Seabrook GMC, 1999, BIOCHEMISTRY-US, V38, P8313, DOI 10.1021/bi9902642; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HOLROYDE MJ, 1980, J BIOL CHEM, V255, P1688; Houdusse A, 1997, STRUCTURE, V5, P1695, DOI 10.1016/S0969-2126(97)00315-8; IIO T, 1981, J BIOCHEM-TOKYO, V90, P163, DOI 10.1093/oxfordjournals.jbchem.a133446; KOMETANI K, 1983, BIOCHEM BIOPH RES CO, V114, P162, DOI 10.1016/0006-291X(83)91608-X; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; LI MX, 1994, BIOCHEMISTRY-US, V33, P917, DOI 10.1021/bi00170a010; LIAO RL, 1994, BIOCHEMISTRY-US, V33, P12729, DOI 10.1021/bi00208a026; Malnic B, 1998, J BIOL CHEM, V273, P10594, DOI 10.1074/jbc.273.17.10594; OLAH GA, 1994, BIOCHEMISTRY-US, V33, P8233, DOI 10.1021/bi00193a009; OLAH GA, 1994, BIOCHEMISTRY-US, V33, P12800, DOI 10.1021/bi00209a011; PEARLSTONE JR, 1995, BIOCHEMISTRY-US, V34, P6932, DOI 10.1021/bi00021a004; Perry SV, 1999, MOL CELL BIOCHEM, V190, P9, DOI 10.1023/A:1006939307715; POTTER JD, 1975, J BIOL CHEM, V250, P4628; Reiffert SU, 1998, BIOCHEMISTRY-US, V37, P13516, DOI 10.1021/bi980280j; ROBERTSON SP, 1981, BIOPHYS J, V34, P559, DOI 10.1016/S0006-3495(81)84868-0; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; Slupsky CM, 1995, BIOCHEMISTRY-US, V34, P15953, DOI 10.1021/bi00049a010; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Spyracopoulos L, 1998, BIOCHEMISTRY-US, V37, P18032, DOI 10.1021/bi9816960; Stone DB, 1998, J MOL BIOL, V281, P689, DOI 10.1006/jmbi.1998.1965; SWENSON CA, 1992, BIOCHEMISTRY-US, V31, P3420, DOI 10.1021/bi00128a017; Tripet B, 1997, J MOL BIOL, V271, P728, DOI 10.1006/jmbi.1997.1200; Tsvetkov PO, 1999, J BIOL CHEM, V274, P18161, DOI 10.1074/jbc.274.26.18161; VANEERD JP, 1976, BIOCHEMISTRY-US, V15, P1171, DOI 10.1021/bi00650a033; Vassylyev DG, 1998, P NATL ACAD SCI USA, V95, P4847, DOI 10.1073/pnas.95.9.4847; WEEDS AG, 1975, FEBS LETT, V49, P320, DOI 10.1016/0014-5793(75)80776-9; Wintrode PL, 1997, J MOL BIOL, V266, P1050, DOI 10.1006/jmbi.1996.0785; Yamada K, 1999, MOL CELL BIOCHEM, V190, P39, DOI 10.1023/A:1006943426370	40	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32508	32515		10.1074/jbc.M005764200	http://dx.doi.org/10.1074/jbc.M005764200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10921926	hybrid			2022-12-27	WOS:000090003800019
J	Chekanova, JA; Shaw, RJ; Wills, MA; Belostotsky, DA				Chekanova, JA; Shaw, RJ; Wills, MA; Belostotsky, DA			Poly(A) tail-dependent exonuclease AtRrp41p from Arabidopsis thaliana rescues 5.8 S rRNA processing and mRNA decay defects of the yeast ski6 mutant and is found in an exosome-sized complex in plant and yeast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; RNA; PROTEIN; DEADENYLATION; EXPRESSION; MUTATIONS; PH	Eukaryotic 3'-->5' exonucleolytic activities are essential for a wide variety of reactions of RNA maturation and metabolism, including processing of rRNA, small nuclear RNA, and small nucleolar RNA, and mRNA decay. Two related but distinct forms of a complex containing 10 3'-->5' exonucleases, the exosome, are found in yeast nucleus and cytoplasm, respectively, and related complexes exist in human cells. Here we report on the characterization of the AtRrp41p, an Arabidopsis thaliana homolog of the Saccharomyces cerevisiae exosome subunit Rrp41p (Ski6p). Purified recombinant AtRrp41p displays a processive phosphorolytic exonuclease activity and requires a single-stranded poly(A) tail on a substrate RNA as a "loading pad." The expression of the Arabidopsis RRP41 cDNA in yeast rescues the 5.8 S rRNA processing and 3'-->5' mRNA degradation defects of the yeast ski6-100 mutant. However, neither of these defects can explain the conditional lethal phenotype of the ski6-100 strain. Importantly, AtRrp41p shares additional function(s) with the yeast Rrp41p which are essential for cell viability because it also rescues the rrp41 (ski6) null mutant. AtRrp41p is found predominantly in a high molecular mass complex in Arabidopsis and in yeast cells, and it interacts in vitro with the yeast Rrp44p and Rrp4p exosome subunits, suggesting that it can participate in evolutionarily conserved interactions that could be essential for the integrity of the exosome complex.	SUNY Albany, Dept Biol Sci, Albany, NY 12222 USA; SUNY Albany, Ctr Genet Mol, Albany, NY 12222 USA	State University of New York (SUNY) System; State University of New York (SUNY) Albany; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Belostotsky, DA (corresponding author), SUNY Albany, Dept Biol Sci, 1400 Washington Ave, Albany, NY 12222 USA.	dab@csc.albany.edu		Chekanova, Julia/0000-0002-2214-8896				Allmang C, 1999, GENE DEV, V13, P2148, DOI 10.1101/gad.13.16.2148; Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Baker RE, 1998, GENETICS, V149, P73; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; Blum E, 1999, J BIOL CHEM, V274, P4009, DOI 10.1074/jbc.274.7.4009; BRINKMANN U, 1989, GENE, V85, P109, DOI 10.1016/0378-1119(89)90470-8; Brown CE, 1998, MOL CELL BIOL, V18, P6548, DOI 10.1128/MCB.18.11.6548; Burkard KTD, 2000, MOL CELL BIOL, V20, P604, DOI 10.1128/MCB.20.2.604-616.2000; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Guthrie C, 1991, METHODS ENZYMOL, V194; Harlow E., 1988, ANTIBODIES LAB MANUA; Hatfield L, 1996, MOL CELL BIOL, V16, P5830; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; Maru Y, 1996, J BIOL CHEM, V271, P15353, DOI 10.1074/jbc.271.26.15353; Mian IS, 1997, NUCLEIC ACIDS RES, V25, P3187, DOI 10.1093/nar/25.16.3187; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; Noguchi E, 1996, EMBO J, V15, P5595, DOI 10.1002/j.1460-2075.1996.tb00944.x; RIESMEIER JW, 1992, EMBO J, V11, P4705, DOI 10.1002/j.1460-2075.1992.tb05575.x; Shiomi T, 1998, J BIOCHEM-TOKYO, V123, P883; Van Hoof A, 2000, MOL CELL BIOL, V20, P441, DOI 10.1128/MCB.20.2.441-452.2000; van Hoof A, 1999, CELL, V99, P347, DOI 10.1016/S0092-8674(00)81520-2; Wang ZR, 1999, MOL CELL BIOL, V19, P4552; WEI N, 1994, CELL, V78, P117, DOI 10.1016/0092-8674(94)90578-9; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; Zhou ZH, 1997, J BACTERIOL, V179, P4391, DOI 10.1128/jb.179.13.4391-4395.1997	31	119	126	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33158	33166		10.1074/jbc.M005493200	http://dx.doi.org/10.1074/jbc.M005493200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10930416	hybrid			2022-12-27	WOS:000090003800105
J	D'Amico, M; Hulit, J; Amanatullah, DF; Zafonte, BT; Albanese, C; Bouzahzah, B; Fu, MF; Augenlicht, LH; Donehower, LA; Takemaru, KI; Moon, RT; Davis, R; Lisanti, MP; Shtutman, M; Zhurinsky, J; Ben-Ze'ev, A; Troussard, AA; Dedhar, S; Pestell, RG				D'Amico, M; Hulit, J; Amanatullah, DF; Zafonte, BT; Albanese, C; Bouzahzah, B; Fu, MF; Augenlicht, LH; Donehower, LA; Takemaru, KI; Moon, RT; Davis, R; Lisanti, MP; Shtutman, M; Zhurinsky, J; Ben-Ze'ev, A; Troussard, AA; Dedhar, S; Pestell, RG			The integrin-linked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3 beta and cAMP-responsive element-binding protein-dependent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING TRANSCRIPTION FACTOR-2; SIGNAL-TRANSDUCTION PATHWAY; FOCAL ADHESION KINASE; BETA-CATENIN; TRANSGENIC MICE; PHOSPHATIDYLINOSITOL 3-KINASE; RETINOBLASTOMA PROTEIN; CELL-ADHESION; C-JUN; PHOSPHORYLATION	The cyclin D1 gene encodes the regulatory subunit of a holoenzyme that phosphorylates and inactivates the PRE tumor suppressor protein. Cyclin D1 is overexpressed in 20-30% of human breast tumors and is induced both by oncogenes including those for Ras, Neu, and Src, and by the beta -catenin/lymphoid enhancer factor (LEF)/T cell factor (TCF) pathway. The ankyrin repeat containing serine-threonine protein kinase, integrinlinked kinase (ILK), binds to the cytoplasmic domain of beta (1) and beta (3) integrin subunits and promotes anchorage-independent growth. We show here that ILK overexpression elevates cyclin D1 protein levels and directly induces the cyclin D1 gene in mammary epithelial cells. ILK activation of the cyclin D1 promoter was abolished by point mutation of a cAMP-responsive element-binding protein (CREB)/ATF-2 binding site at nucleotide -54 in the cyclin D1 promoter, and by overexpression of either glycogen synthase kinase-3 beta (GSK-3 beta) or dominant negative mutants of CREB or ATF-2. Inhibition of the PI 3-kinase and AKT/protein kinase B, but not of the p38, ERK, or JNK signaling pathways, reduced ILK induction of cyclin D1 expression. ILK induced CREB transactivation and CREB binding to the cyclin D1 promoter CRE, Wnt-1 overexpression in mammary epithelial cells induced cyclin D1 mRNA and targeted overexpression of Wnt-1 in the mammary gland of transgenic mice increased both ILK activity and cyclin D1 levels. We conclude that the cyclin D1 gene is regulated by the Wnt-1 and ILK signaling pathways and that ILK induction of cyclin D1 involves the CREB signaling pathway in mammary epithelial cells.	Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Dev & Mol Biol Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Pharmacol, Bronx, NY 10461 USA; Baylor Coll Med, Div Mol Virol, Houston, TX 77030 USA; Univ Washington, Sch Med, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Howard Hughes Med Inst, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Program Mol Biol, Worcester, MA 01605 USA; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; British Columbia Canc Agcy, Vancouver, BC V6H 3Z6, Canada; Vancouver Hosp, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Weizmann Institute of Science; British Columbia Cancer Agency; University of British Columbia	Pestell, RG (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Dev & Mol Biol Med, Chanin 302,1300 Morris Pk Ave, Bronx, NY 10461 USA.		Shtutman, Michael/AAB-8391-2020; Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013; Moon, Randall T/B-1743-2014; Roszak, Joanna/F-4003-2010	Shtutman, Michael/0000-0002-2458-3226; Lisanti, Michael/0000-0003-2034-1382; Moon, Randall T/0000-0002-9352-1408; Amanatullah, Derek/0000-0002-6203-5853; ben-ze'ev, avri/0000-0001-6113-3921; Dedhar, Shoukat/0000-0003-4355-1657	NATIONAL CANCER INSTITUTE [R01CA077552, R01CA075503, R01CA070897] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA77552, R01CA75503, R29CA70897] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433; BOYLE W, 1990, CELL, V64, P573; Brown JD, 1998, CURR OPIN CELL BIOL, V10, P182, DOI 10.1016/S0955-0674(98)80140-3; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; IVASHKIV LB, 1992, NEW BIOL, V4, P360; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MAURER RA, 1989, J BIOL CHEM, V264, P6870; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sambrook T, 1989, MOL CLONING LAB MANU; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Staveley BE, 1998, CURR BIOL, V8, P599, DOI 10.1016/S0960-9822(98)70231-3; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Vinals F, 1999, J BIOL CHEM, V274, P26776, DOI 10.1074/jbc.274.38.26776; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Watanabe G, 1996, J BIOL CHEM, V271, P22570, DOI 10.1074/jbc.271.37.22570; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; WOODGETT JR, 1994, SEMIN CANCER BIOL, V5, P269; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Xu LF, 2000, GENE DEV, V14, P585; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	77	213	217	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32649	32657		10.1074/jbc.M000643200	http://dx.doi.org/10.1074/jbc.M000643200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10915780	hybrid			2022-12-27	WOS:000090003800039
J	Oki, M; Nishimoto, T				Oki, M; Nishimoto, T			Yrb1p interaction with the Gsp1p C terminus blocks Mog1p stimulation of GTP release from Gsp1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEAR TRANSPORT; BINDING-PROTEIN; ACTIVATING PROTEIN; RAN-GTPASE; RCC1; RANGAP1; COMPLEX; RAN/TC4; IMPORT	Mog1p, a multicopy suppressor of gsp1, the temperature-sensitive mutant of the Saccharomyces cerevisiae Ran homologue, binds to GTP-Gsp1p but not to GDP-Gsp1p. The function of Mog1p in the Ran cycle is as yet unknown. This study found that Mog1p releases a nucleotide from GTP-Gsp1p but not from GDP-Gsp1p. Yrb1p, the S. cerevisiae homologue of RanBP1, which is a strong inhibitor of RCC1-stimulated nucleotide release, also inhibited the Mog1p-stimulated nucleotide release from GTP-Gsp1p. At a concentration corresponding to the molar concentration of GTP-Gsp1p, Yrb1p completely inhibited the Mog1p-stimulated nucleotide release. Consistently, the Yrb1p.GTP-Gsp1p complex was more stable than the Mog1p.GTP-Gsp1p complex. Yrb1p did not inhibit the Mog1p-stimulated nucleotide release from GTP-Gsp1 DeltaC. The Gsp1 DeltaC protein lacks the final eight amino acids of the C terminus, and for this reason, the interaction between GTP-Gsp1 DeltaC and Yrb1p was strongly reduced. On the other hand, Mog1p binds to GTP-Gsp1 DeltaC more efficiently than to GTP-Gsp1p.	Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128582, Japan	Kyushu University	Nishimoto, T (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128582, Japan.							BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2152, DOI 10.1128/MCB.13.4.2152; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; END P, 1993, J BIOL CHEM, V268, P10066; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; HAYASHI N, 1995, MOL GEN GENET, V247, P661, DOI 10.1007/BF00290397; Kahana JA, 1999, J CELL BIOL, V146, P1205, DOI 10.1083/jcb.146.6.1205; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Kuhlmann J, 1997, BIOCHEMISTRY-US, V36, P12027, DOI 10.1021/bi970524k; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; Nakamura M, 1998, J CELL BIOL, V143, P1041, DOI 10.1083/jcb.143.4.1041; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Nishimoto T, 1999, BIOCHEM BIOPH RES CO, V262, P571, DOI 10.1006/bbrc.1999.1252; NISHIWAKI K, 1987, MOL GEN GENET, V208, P159, DOI 10.1007/BF00330437; Noguchi E, 1996, EMBO J, V15, P5595, DOI 10.1002/j.1460-2075.1996.tb00944.x; Noguchi E, 1999, J BIOCHEM-TOKYO, V125, P574, DOI 10.1093/oxfordjournals.jbchem.a022323; Noguchi E, 1997, MOL CELL BIOL, V17, P2235, DOI 10.1128/MCB.17.4.2235; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; Oki M, 1998, P NATL ACAD SCI USA, V95, P15388, DOI 10.1073/pnas.95.26.15388; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; RICHARDS SA, 1995, J BIOL CHEM, V270, P14405, DOI 10.1074/jbc.270.24.14405; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; SCHLENSTEDT G, 1995, EMBO J, V14, P5367, DOI 10.1002/j.1460-2075.1995.tb00221.x; Steggerda SM, 2000, J BIOL CHEM, V275, P23175, DOI 10.1074/jbc.C000252200; Traglia HM, 1996, P NATL ACAD SCI USA, V93, P7667, DOI 10.1073/pnas.93.15.7667; Vetter IR, 1999, NATURE, V398, P39, DOI 10.1038/17969	31	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32894	32900		10.1074/jbc.M910251199	http://dx.doi.org/10.1074/jbc.M910251199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10921930	Green Submitted, hybrid			2022-12-27	WOS:000090003800071
J	Lu, RQ; Au, WC; Yeow, WS; Hageman, N; Pitha, PM				Lu, RQ; Au, WC; Yeow, WS; Hageman, N; Pitha, PM			Regulation of the promoter activity of interferon regulatory factor-7 gene - Activation by interferon and silencing by hypermethylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR COMPLEX; CPG ISLAND METHYLATION; IFN-INDUCIBLE GENES; POSITIVE FEEDBACK; DNA METHYLATION; VIRUS-INFECTION; CELL-GROWTH; DE-NOVO; EXPRESSION; IRF-1	The molecular mechanism by which virus induces expression of the early inflammatory genes has not yet been completely elucidated. Previous studies indicated that the virus-mediated transcription of type I interferon (IFN) genes required activation of two members of IFN regulatory factor (IRF) family, IRF-3 and IRF-7, where the expression of IRF-7 was found to be indispensable for the induction of IFNA genes. To determine the factors that regulate expression of IRF-7 gene, as well as its inducibility by type I IFNs, we have isolated and characterized the promoter and first intron of the human IRF-7 gene. This region shows a presence of two potential interferon-sensitive response elements (ISRE/IRF-E). However, only the ISRE present in the first intron was functional and conferred interferon inducibility in a transient transfection assay. Using a pull-down assay with an oligodeoxynucleotide corresponding to this ISRE immobilized to magnetic beads, we have demonstrated that this ISRE binds ISGF3 complex and IRF-1 from the extract of IFN-treated cells but not from the untreated cells. We have further shown that the previously observed lack of expression of IRF-7 in 2fTGH fibrosarcoma cell line, correlated with hypermethylation of the CpG; island in the human IRF-7 promoter. The repression of the promoter activity was relieved by treatment with DNA methyltransferase inhibitor 5-azadeoxycytidine. In vitro methylation of IRF-7 promoter silenced IRF-7 directed expression of luciferase gene in HeLa cells that express endogenous IRF-7 gene. Whether silencing of IRF-7 by methylation is instrumental for the process of tumorigenesis remains to be determined.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Pitha, PM (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Oncol, Bunting & Blaustein Canc Res Bldg,Rm 351,1650 Orl, Baltimore, MD 21231 USA.			Yeow, Wen-Shuz/0000-0002-0436-9636	NIAID NIH HHS [R01 AI19737-17] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019737] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bird A, 1999, SCIENCE, V286, P2287, DOI 10.1126/science.286.5448.2287; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BOULTWOOD J, 1993, BLOOD, V82, P2611; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Deyrup AT, 1998, J BIOL CHEM, V273, P9450, DOI 10.1074/jbc.273.16.9450; Esteller M, 2000, CANCER RES, V60, P2368; Genin P, 2000, J IMMUNOL, V164, P5352, DOI 10.4049/jimmunol.164.10.5352; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; Harada H, 1996, GENES CELLS, V1, P995, DOI 10.1046/j.1365-2443.1996.870287.x; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Juang YT, 1998, P NATL ACAD SCI USA, V95, P9837, DOI 10.1073/pnas.95.17.9837; KANE MF, 1977, CANCER RES, V1, P808; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; KAWAKAMI T, 1995, FEBS LETT, V358, P225, DOI 10.1016/0014-5793(94)01426-2; Kim TK, 2000, CANCER RES, V60, P1153; Kimura T, 1996, GENES CELLS, V1, P115, DOI 10.1046/j.1365-2443.1996.08008.x; Kumar KP, 2000, MOL CELL BIOL, V20, P4159, DOI 10.1128/MCB.20.11.4159-4168.2000; Lin RT, 1999, MOL CELL BIOL, V19, P959; Lowther WJ, 1999, DNA CELL BIOL, V18, P685, DOI 10.1089/104454999314962; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pitha PM, 1998, BIOCHIMIE, V80, P651, DOI 10.1016/S0300-9084(99)80018-2; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Schafer SL, 1998, J BIOL CHEM, V273, P2714, DOI 10.1074/jbc.273.5.2714; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Ye JP, 1996, MOL CELL BIOL, V16, P6178; Yeow WS, 2000, J BIOL CHEM, V275, P6313, DOI 10.1074/jbc.275.9.6313; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Zhang LW, 1997, MOL CELL BIOL, V17, P5748, DOI 10.1128/MCB.17.10.5748; Zhang LW, 2000, J VIROL, V74, P1061, DOI 10.1128/JVI.74.3.1061-1068.2000	44	136	142	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31805	31812		10.1074/jbc.M005288200	http://dx.doi.org/10.1074/jbc.M005288200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10924517	hybrid			2022-12-27	WOS:000089858900038
J	Woo, CH; Eom, YW; Yoo, MH; You, HJ; Han, HJ; Song, WK; Yoo, YJ; Chun, JS; Kim, JH				Woo, CH; Eom, YW; Yoo, MH; You, HJ; Han, HJ; Song, WK; Yoo, YJ; Chun, JS; Kim, JH			Tumor necrosis factor-alpha generates reactive oxygen species via a cytosolic phospholipase A(2)-linked cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; PLATELET-ACTIVATING-FACTOR; LEUKOTRIENE B-4; PHOSPHATIDYLINOSITOL 3-KINASE; RAC GTPASE; ARACHIDONIC-ACID; RECEPTOR; FIBROBLASTS; WORTMANNIN; CYTOKINE	Reactive oxygen species (ROS) are important regulatory molecules implicated in the signaling cascade triggered by tumor necrosis factor (TNF)-alpha, although the events through which TNF-alpha induces ROS generation are not yet well characterized. We therefore investigated selected candidates likely to mediate TNF-alpha-induced ROS generation. Consistent with the role of Rac in that process, stable expression of Rac(Asn-17), a dominant negative Rad mutant, completely blocked TNF-alpha-induced ROS generation. To understand better the mediators downstream of Rac, we investigated the involvement of cytosolic phospholipase A(2) (cPLA(2)) activation and metabolism of the resultant arachidonic acid (AA) by B-lipoxygenase (5-LO). TNF-alpha-induced ROS generation was blocked by inhibition of cPLA(2) or 5-LO, but not cyclooxygenase, suggesting that TNF-alpha-induced ROS generation is dependent on synthesis of AA and its subsequent metabolism to leukotrienes. Consistent with that hypothesis, TNF-alpha Rac-dependently stimulated endogenous production of leukotriene B-4 (LTB4), while exogenous application of LTB4 increased levels of ROS. In contrast, application of leukotrienes C-4, D-4, and E-4 or prostaglandin E-2 had little effect. Our findings suggest that LTB4 production by 5-LO is situated downstream of the Rac-cPLA(2) cascade, and we conclude that Rac, cPLA(2), and LTB4 play pivotal roles in the ROS-generating cascade triggered by TNF-alpha.	Kwangju Inst Sci & Technol, K JIST, Dept Life Sci, Kwangju 500712, South Korea; Chonnam Natl Univ, Coll Vet Med, Dept Vet Physiol, Kwangju 500757, South Korea	Gwangju Institute of Science & Technology (GIST); Chonnam National University	Kim, JH (corresponding author), Kwangju Inst Sci & Technol, K JIST, Dept Life Sci, Kwangju 500712, South Korea.		Han, Ho Jae/M-1476-2016; Eom, Young/AAW-4659-2021; Kim, Jae-Hong/B-2530-2009	Han, Ho Jae/0000-0002-0657-1766; Kim, Jae-Hong/0000-0002-8019-0208; Eom, Young Woo/0000-0002-5985-6490				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; Ferby IM, 1996, J BIOL CHEM, V271, P11684, DOI 10.1074/jbc.271.20.11684; Goossens V, 1999, BIOFACTORS, V10, P145, DOI 10.1002/biof.5520100210; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Kim BC, 1999, J BIOL CHEM, V274, P24372, DOI 10.1074/jbc.274.34.24372; Kim BC, 1997, BIOCHEM J, V326, P333, DOI 10.1042/bj3260333; Kim BC, 1998, MOL CELLS, V8, P90; Kim BC, 1998, BIOCHEM J, V330, P1009, DOI 10.1042/bj3301009; Kim JH, 1997, FEBS LETT, V406, P93, DOI 10.1016/S0014-5793(97)00249-4; Li YQ, 1996, J CLIN INVEST, V97, P1605, DOI 10.1172/JCI118585; Lindsay MA, 1998, J IMMUNOL, V160, P4526; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; ODONNELL VB, 1995, BIOCHEM J, V310, P133, DOI 10.1042/bj3100133; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; Reiss TF, 1997, THORAX, V52, P45, DOI 10.1136/thx.52.1.45; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Shindo K, 1997, THORAX, V52, P1024, DOI 10.1136/thx.52.12.1024; Sidoti-de Fraisse C, 1998, ONCOGENE, V17, P1639, DOI 10.1038/sj.onc.1202094; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Surette ME, 1999, MOL PHARMACOL, V56, P1055, DOI 10.1124/mol.56.5.1055; Toda A, 1999, BIOCHEM BIOPH RES CO, V262, P806, DOI 10.1006/bbrc.1999.1284; Turner CR, 1996, J CLIN INVEST, V97, P381, DOI 10.1172/JCI118426; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Woo CH, 2000, BIOCHEM BIOPH RES CO, V268, P231, DOI 10.1006/bbrc.2000.2102; Woo CH, 2000, BIOCHEM J, V348, P525, DOI 10.1042/0264-6021:3480525; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	31	200	211	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32357	32362		10.1074/jbc.M005638200	http://dx.doi.org/10.1074/jbc.M005638200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10934206	hybrid			2022-12-27	WOS:000089858900109
J	Wright, SK; Kish, MM; Viola, RE				Wright, SK; Kish, MM; Viola, RE			From malate dehydrogenase to phenyllactate dehydrogenase - Incorporation of unnatural amino acids to generate an improved enzyme-catalyzed activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTATE-DEHYDROGENASE; ESCHERICHIA-COLI; ASPARTATE-AMINOTRANSFERASE; SUBSTRATE-SPECIFICITY; QUANTITATION; SUBSTITUTION; RESOLUTION; FRAMEWORK; EVOLUTION; RESIDUES	Malate dehydrogenase (MDH) from Escherichia coli is highly specific for its keto acid substrate. The placement of the active site-binding groups in MDH effectively discriminates against both the shorter and the longer keto dicarboxylic acids that could potentially serve as alternative substrates. A notable exception to this specificity is the alternative substrate phenylpyruvate. This aromatic keto acid can be reduced by MDH, albeit at a somewhat slower rate and with greatly diminished affinity, despite the presence of several substrate-binding arginyl residues and the absence of a hydrophobic pocket in the active site, The specificity of MDH for phenylpyruvate has now been enhanced, and that for the physiological substrate oxaloacetate has been diminished, through the replacement of one of the binding arginyl residues with several unnatural alkyl and aryl amino acid analogs. This approach, called site-specific modulation, incorporates systematic structural variations at a site of interest. Molecular modeling studies have suggested a structural basis for the affinity of native MDH for phenylpyruvate and a rationale for the improved catalytic activity that is observed with these new, modified phenyllactate dehydrogenases.	Univ Akron, Dept Chem, Akron, OH 44325 USA	University System of Ohio; University of Akron	Viola, RE (corresponding author), Univ Toledo, Dept Chem, 2801 W Bancroft St, Toledo, OH 43606 USA.		Viola, Ronald/C-5904-2011					BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKE AR, 1989, TRENDS BIOCHEM SCI, V14, P145, DOI 10.1016/0968-0004(89)90147-3; CLELAND WW, 1967, ADV ENZYMOL RAMB, V29, P1; DHALLA AM, 1994, PROTEIN SCI, V3, P476; ElHawrani AS, 1996, J MOL BIOL, V264, P97, DOI 10.1006/jmbi.1996.0626; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GOWARD CR, 1994, PROTEIN SCI, V3, P1883, DOI 10.1002/pro.5560031027; GRAU UM, 1981, J MOL BIOL, V151, P289, DOI 10.1016/0022-2836(81)90516-7; HALL MD, 1991, J MOL BIOL, V220, P551, DOI 10.1016/0022-2836(91)90099-R; HALL MD, 1992, J MOL BIOL, V226, P867, DOI 10.1016/0022-2836(92)90637-Y; JONES DH, 1993, PCR PROTOCOLS CURREN, P269; NICHOLLS DJ, 1994, J PROTEIN CHEM, V13, P129, DOI 10.1007/BF01892000; NICHOLLS DJ, 1992, BIOCHEM BIOPH RES CO, V189, P1057, DOI 10.1016/0006-291X(92)92311-K; PLANAS A, 1991, BIOCHEMISTRY-US, V30, P8268, DOI 10.1021/bi00247a023; Schindler JF, 1996, J PROTEIN CHEM, V15, P737, DOI 10.1007/BF01887147; SMITH HB, 1988, J BIOL CHEM, V263, P4921; TARRAGONAFIOL A, 1993, PROTEIN ENG, V6, P901, DOI 10.1093/protein/6.8.901; WILKS HM, 1992, BIOCHEMISTRY-US, V31, P7802, DOI 10.1021/bi00149a009; Wright SK, 1998, ANAL BIOCHEM, V265, P8, DOI 10.1006/abio.1998.2858; WRIGHT SK, 1995, ARCH BIOCHEM BIOPHYS, V321, P289, DOI 10.1006/abbi.1995.1397; YOSHIMURA T, 1990, J BIOCHEM-TOKYO, V108, P699, DOI 10.1093/oxfordjournals.jbchem.a123266	21	9	9	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31689	31694		10.1074/jbc.M003652200	http://dx.doi.org/10.1074/jbc.M003652200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10915786	hybrid			2022-12-27	WOS:000089858900022
J	Arispe, N; De Maio, A				Arispe, N; De Maio, A			ATP and ADP modulate a cation channel formed by Hsc70 in acidic phospholipid membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; SUBSTRATE-BINDING; CALCIUM CHANNELS; HSP70; POTASSIUM; DOMAIN; CELLS; BIP	Heat shock proteins are molecular chaperones that participate in different cellular processes, particularly the folding and translocation of polypeptides across membranes. In this regard, members of the Hsp70 family of heat shock proteins have been observed in close proximity to cellular membranes, In this study, the direct interaction between Hsc70, which is constitutively expressed in cells, and lipid membranes was investigated. Recombinant Hsc70 was incorporated into artificial lipid bilayers, and a transmembrane ion flow was detected, suggesting the incorporation of an ion pathway. This ion flow was very stable and occurred in well defined, multilevel discrete electrical current events, indicating the formation of a multiconductance ion channel, The Hsc70 channel activity is ATP-dependent and is reversibly blocked by ADP. This channel has cationic selectivity, Thus, Hsc70 can directly interact with lipid membranes to create functionally stable ATP-dependent cationic pathways.	Uniformed Serv Univ Hlth Sci, Dept Anat & Cell Biol, Bethesda, MD 20814 USA; Johns Hopkins Univ, Sch Med, Div Pediat Surg, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Uniformed Services University of the Health Sciences - USA; Johns Hopkins University; Johns Hopkins University	Arispe, N (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat & Cell Biol, Bethesda, MD 20814 USA.	narispe@usuhs.mil			NIGMS NIH HHS [GM-50878] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDER GM, 1990, BIOSCIENCE REP, V10, P509, DOI 10.1007/BF01116611; Arispe N, 1996, BIOPHYS J, V71, P1764, DOI 10.1016/S0006-3495(96)79377-3; Arispe N, 2000, BIOPHYS J, V78, p36A; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P567, DOI 10.1073/pnas.90.2.567; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; De Maio A, 1999, SHOCK, V11, P1, DOI 10.1097/00024382-199901000-00001; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; Gao BC, 1996, J BIOL CHEM, V271, P16792, DOI 10.1074/jbc.271.28.16792; Hightower LE, 1994, BIOL HEAT SHOCK PROT, P179; Kurucz I, 1999, CELL STRESS CHAPERON, V4, P139; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Mirzabekov TA, 1996, J BIOL CHEM, V271, P1988, DOI 10.1074/jbc.271.4.1988; MORIMOTO RI, 1991, CANCER CELL-MON REV, V3, P295; Morshauser RC, 1999, J MOL BIOL, V289, P1387, DOI 10.1006/jmbi.1999.2776; MULTHOFF G, 1995, INT J CANCER, V61, P272, DOI 10.1002/ijc.2910610222; Negulyaev YA, 1996, BBA-BIOMEMBRANES, V1282, P156, DOI 10.1016/0005-2736(96)00055-7; OBRIEN MC, 1995, J BIOL CHEM, V270, P2247, DOI 10.1074/jbc.270.5.2247; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; POLLARD JR, 1994, BIOPHYS J, V67, P647, DOI 10.1016/S0006-3495(94)80525-9; ROJAS E, 1992, BONE MINER, V17, P214, DOI 10.1016/0169-6009(92)90739-Z; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; WELCH WJ, 1985, J CELL BIOL, V101, P1198, DOI 10.1083/jcb.101.4.1198; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	25	93	96	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30839	30843		10.1074/jbc.M005226200	http://dx.doi.org/10.1074/jbc.M005226200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10899168	hybrid			2022-12-27	WOS:000089762700017
J	Drori, S; Jansen, G; Mauritz, R; Peters, GJ; Assaraf, YG				Drori, S; Jansen, G; Mauritz, R; Peters, GJ; Assaraf, YG			Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; THYMIDYLATE SYNTHASE INHIBITORS; METHOTREXATE TRANSPORT; MAMMALIAN-CELLS; L1210 CELLS; FOLIC-ACID; MEMBRANE-TRANSPORT; TUMOR-CELLS; LOW PH; RESISTANCE	We have studied the molecular basis for the resistance of human CEM leukemia cells to GW1843, a thymidylate synthase inhibitor. GW1843-resistant cells displayed a similar to 100-fold resistance to GW1843 and methotrexate but were collaterally sensitive to the lipophilic antifolates trimetrexate and AG337, which enter cells by diffusion. These cells exhibited a 12-fold decreased methotrexate influx but surprisingly had a a-fold decreased folic acid growth requirement. This was associated with a I-fold increased influx of folic acid, a 3.5-fold increased steady-state level of folic acid, and a 2.3-fold expansion of the cellular folate pool. Characterization of the transport kinetic properties revealed that GW1843 resistant cells had the following alterations: (a) 11-fold decreased transport K-m for folic acid; (b) 6-fold increased transport K-m for GW1843; and (c) a slightly increased transport V-max for folic acid. Sequence analysis showed that GW1843-resistant cells contained the mutations Val-29 --> Leu, Glu-45 --> Lys, and Ser-46 --> Ile in the first transmembrane domain of the reduced folate carrier, Transfection of the mutant-reduced folate carrier cDNA into methotrexate transport null cells conferred resistance to GW1843, This is the first demonstration of multiple mutations in a confined region of the human reduced folate carrier in an antifolate-resistant mutant. We conclude that certain amino acid residues in the first transmembrane domain play a key role in (anti)folate binding and in the conferring of drug resistance.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel; Free Univ Amsterdam Hosp, Dept Oncol, NL-1081 HV Amsterdam, Netherlands	Technion Israel Institute of Technology; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Assaraf, YG (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.	assaraf@tx.technion.ac.il	; Peters, Godefridus J/C-7562-2013	Jansen, Gerrit/0000-0001-8190-8368; Peters, Godefridus J/0000-0002-5447-2877				ANTONY AC, 1992, BLOOD, V79, P2807; ASSARAF YG, 1987, P NATL ACAD SCI USA, V84, P7154, DOI 10.1073/pnas.84.20.7154; Assaraf YG, 1998, J BIOL CHEM, V273, P8106, DOI 10.1074/jbc.273.14.8106; Assaraf YG, 1997, J BIOL CHEM, V272, P17460, DOI 10.1074/jbc.272.28.17460; BEARDSLEY GP, 1989, J BIOL CHEM, V264, P328; Boritzki TJ, 1996, INVEST NEW DRUG, V14, P295, DOI 10.1007/BF00194533; BRIGLE KE, 1994, BIOCHEM PHARMACOL, V47, P337, DOI 10.1016/0006-2952(94)90025-6; BRIGLE KE, 1995, J BIOL CHEM, V270, P22974, DOI 10.1074/jbc.270.39.22974; Cocconi G, 1998, J CLIN ONCOL, V16, P2943, DOI 10.1200/JCO.1998.16.9.2943; DIXON KH, 1994, J BIOL CHEM, V269, P17; DRORI S, 2000, EUR J BIOCHEM, V267, P1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Ferguson PL, 1999, J BIOL CHEM, V274, P16269, DOI 10.1074/jbc.274.23.16269; FLINTOFF WF, 1983, ARCH BIOCHEM BIOPHYS, V223, P433, DOI 10.1016/0003-9861(83)90607-0; FREISHEIM JH, 1992, ADV ENZYME REGUL, V32, P17; GOLDMAN ID, 1985, PHARMACOL THERAPEUT, V28, P77, DOI 10.1016/0163-7258(85)90083-X; GOLDMAN ID, 1971, ANN NY ACAD SCI, V186, P400; Gong MK, 1997, BLOOD, V89, P2494, DOI 10.1182/blood.V89.7.2494; Hanlon MH, 1996, CANCER RES, V56, P3301; HENDERSON GB, 1981, BIOCHEM BIOPH RES CO, V99, P163, DOI 10.1016/0006-291X(81)91727-7; HENDERSON GB, 1990, CANCER RES, V50, P1709; Jackman AL, 1995, ANN ONCOL, V6, P871, DOI 10.1093/oxfordjournals.annonc.a059353; JANSEN G, 1989, CANCER RES, V49, P1959; Jansen G, 1999, CANC DRUG DISC DEV, P293; Jansen G, 1998, J BIOL CHEM, V273, P30189, DOI 10.1074/jbc.273.46.30189; Jansen G, 1999, MOL PHARMACOL, V55, P761; Kumar CK, 1997, J BIOL CHEM, V272, P6226, DOI 10.1074/jbc.272.10.6226; LIN JT, 1991, CANCER INVEST, V9, P159, DOI 10.3109/07357909109044227; MATHERLY LH, 1992, J BIOL CHEM, V267, P23253; MAURITZ R, 1999, P AM ASSOC CANC RES, P1936; MINI E, 1985, CANCER RES, V45, P325; MOSCOW JA, 1995, CANCER RES, V55, P3790; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; PRASAD PD, 1995, BIOCHEM BIOPH RES CO, V206, P681, DOI 10.1006/bbrc.1995.1096; RHEE MS, 1994, MOL PHARMACOL, V45, P783; ROSOWSKY A, 1980, BIOCHEM PHARMACOL, V29, P648, DOI 10.1016/0006-2952(80)90391-3; Rustum YM, 1997, J CLIN ONCOL, V15, P389, DOI 10.1200/JCO.1997.15.1.389; SCHUETZ JD, 1988, J BIOL CHEM, V263, P9840; SCHUETZ JD, 1989, J BIOL CHEM, V264, P16261; Shih C, 1997, CANCER RES, V57, P1116; Sierra EE, 1997, BIOCHEM PHARMACOL, V53, P223, DOI 10.1016/S0006-2952(96)00730-7; SIROTNAK FM, 1981, CANCER RES, V41, P4447; SIROTNAK FM, 1985, CANCER RES, V45, P3992; SIROTNAK FM, 1987, NCI MONOGRAPHS, V5, P27; Stokstad ELR, 1990, FOLIC ACID METABOLIS, P1; Tse A, 1998, J BIOL CHEM, V273, P25953, DOI 10.1074/jbc.273.40.25953; Tse A, 1998, J BIOL CHEM, V273, P25944, DOI 10.1074/jbc.273.40.25944; WANG X, 1992, BIOCHEM PHARMACOL, V44, P1898; WESTERHOF GR, 1995, MOL PHARMACOL, V48, P459; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810; WILLIAMS FMR, 1995, J BIOL CHEM, V270, P2987, DOI 10.1074/jbc.270.7.2987; WONG SC, 1995, J BIOL CHEM, V270, P17468, DOI 10.1074/jbc.270.29.17468; Zhao R, 1998, J BIOL CHEM, V273, P19065, DOI 10.1074/jbc.273.30.19065; Zhao RB, 1998, J BIOL CHEM, V273, P7873, DOI 10.1074/jbc.273.14.7873; Zhao RB, 1999, MOL PHARMACOL, V56, P68, DOI 10.1124/mol.56.1.68	55	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30855	30863		10.1074/jbc.M003988200	http://dx.doi.org/10.1074/jbc.M003988200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10899164	hybrid			2022-12-27	WOS:000089762700020
J	Dranoff, JA; O'Neill, AF; Franco, AM; Cai, SY; Connolly, GC; Ballatori, N; Boyer, JL; Nathanson, MH				Dranoff, JA; O'Neill, AF; Franco, AM; Cai, SY; Connolly, GC; Ballatori, N; Boyer, JL; Nathanson, MH			A primitive ATP receptor from the little skate Raja erinacea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; NUCLEOTIDE RECEPTOR; ADENYLYL-CYCLASE; P2Y(2) RECEPTOR; EXPRESSION; RAT; CELLS; PURINOCEPTORS; MECHANISM; RELEASE	P2Y ATP receptors are widely expressed in mammalian tissues and regulate a broad range of activities. Multiple subtypes of P2Y receptors have been identified and are distinguished both on a molecular basis and by pharmacologic substrate preference. Functional evidence suggests that hepatocytes from the little skate Raja erinacea express a primitive P2Y ATP receptor lacking pharmacologic selectivity, so we cloned and characterized this receptor. Skate hepatocyte cDNA was amplified with degenerate oligonucleotide probes designed to identify known P2Y subtypes. A single polymerase chain reaction product was found and used to screen a skate liver cDNA library. A 2314-base pair cDNA clone was generated that contained a 1074-base pair open reading frame encoding a 357-amino acid gene product with 61-64% similarity to P2Y(1) receptors and 21-37% similarity to other P2Y receptor subtypes. Pharmacology of the putative P2Y receptor was examined using the Xenopus oocyte expression system and revealed activation by a range of nucleotides. The receptor was expressed widely in skate tissue and was expressed to a similar extent in other primitive organisms. Phylogenetic analysis suggested that this receptor is closely related to a common ancestor of the P2Y subtypes found in mammals, avians, and amphibians. Thus, the skate liver P2Y receptor functions as a primitive P2Y ATP receptor with broad pharmacologic selectivity and is related to the evolutionary forerunner of P2Y(1) receptors of higher organisms. This novel receptor should provide an effective comparative model for P2Y receptor pharmacology and may improve our understanding of nucleotide specificity among the family of P2Y ATP receptors.	Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Liver Study Unit, New Haven, CT 06520 USA; Mt Desert Isl Biol Lab, Salsbury Cove, ME 04672 USA; Univ Rochester, Sch Med, Dept Environm Med, Rochester, NY 14642 USA	Yale University; Yale University; Mount Desert Island Biological Laboratory; University of Rochester	Dranoff, JA (corresponding author), Yale Univ, Sch Med, Sect Digest Dis, LMP 1080,333 Cedar St, New Haven, CT 06510 USA.	jonathan.dranoff@yale.edu			NIDDK NIH HHS [DK25636, DK34989, DK45710] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK025636, R29DK045710, R01DK045710, R01DK025636, P30DK034989] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bogdanov YD, 1997, J BIOL CHEM, V272, P12583, DOI 10.1074/jbc.272.19.12583; Bogdanov YD, 1998, BRIT J PHARMACOL, V124, P428, DOI 10.1038/sj.bjp.0701880; BOYER JL, 1993, J PHARMACOL EXP THER, V267, P1140; Boyer JL, 1997, MOL PHARMACOL, V52, P928, DOI 10.1124/mol.52.6.928; BOYER JL, 1989, SCHIFFS DIS LIVER, P119; Burnstock G, 1997, NEUROPHARMACOLOGY, V36, P1127, DOI 10.1016/S0028-3908(97)00125-1; Chen ZP, 1996, ENDOCRINOLOGY, V137, P1833, DOI 10.1210/en.137.5.1833; Christoffersen BC, 1998, PFLUG ARCH EUR J PHY, V436, P33, DOI 10.1007/s004240050601; Communi D, 1997, J BIOL CHEM, V272, P31969, DOI 10.1074/jbc.272.51.31969; Cressman VL, 1999, J BIOL CHEM, V274, P26461, DOI 10.1074/jbc.274.37.26461; Fabre JE, 1999, NAT MED, V5, P1199, DOI 10.1038/13522; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Hwang TH, 1996, AM J PHYSIOL-CELL PH, V270, pC1611, DOI 10.1152/ajpcell.1996.270.6.C1611; King BF, 1996, NEUROSCIENCE, V74, P1187, DOI 10.1016/0306-4522(96)00209-6; Lazarowski ER, 1997, P NATL ACAD SCI USA, V94, P2599, DOI 10.1073/pnas.94.6.2599; Leon C, 1999, J CLIN INVEST, V104, P1731, DOI 10.1172/JCI8399; Luo X, 1999, AM J PHYSIOL-CELL PH, V277, pC205, DOI 10.1152/ajpcell.1999.277.2.C205; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; Nathanson MH, 1999, J EXP BIOL, V202, P3049; NATHANSON MH, 1992, J BIOL CHEM, V267, P23282; Nathanson MH, 1996, AM J PHYSIOL-REG I, V270, pR561, DOI 10.1152/ajpregu.1996.270.3.R561; Nicholas RA, 1996, J AUTON PHARMACOL, V16, P319, DOI 10.1111/j.1474-8673.1996.tb00044.x; OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0; PARADISO AM, 1995, NATURE, V377, P643, DOI 10.1038/377643a0; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; Ralevic V, 1998, PHARMACOL REV, V50, P413; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SMITH DJ, 1987, J EXP ZOOL, V241, P291, DOI 10.1002/jez.1402410303; TOKUYAMA Y, 1995, BIOCHEM BIOPH RES CO, V211, P211, DOI 10.1006/bbrc.1995.1798; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Webb TE, 1996, MOL PHARMACOL, V50, P258; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; Webb TE, 1998, J NEUROCHEM, V71, P1348; Zheng HL, 2000, BIOTECHNIQUES, V28, P832, DOI 10.2144/00285bm01	34	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30701	30706		10.1074/jbc.M003366200	http://dx.doi.org/10.1074/jbc.M003366200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10900200	hybrid			2022-12-27	WOS:000089577900107
J	Miyazaki, M; Kim, YC; Gray-Keller, MP; Attie, AD; Ntambi, JM				Miyazaki, M; Kim, YC; Gray-Keller, MP; Attie, AD; Ntambi, JM			The biosynthesis of hepatic cholesterol esters and triglycerides is impaired in mice with a disruption of the gene for stearoyl-CoA desaturase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; 3T3-L1 PREADIPOCYTES; A DESATURASE; DIFFERENTIATION; EXPRESSION; LIVER; ACYLTRANSFERASE; METABOLISM; COENZYME; MOUSE	Stearoyl-CoA desaturase (SCD) is a microsomal enzyme required for the biosynthesis of oleate and palmitoleate, which are the major monounsaturated fatty acids of membrane phospholipids, triglycerides, and cholesterol esters. Two well characterized isoforms of SCD, SCD1 and SCD2, exist in the mouse. Most mouse tissues express SCD1 and 2 with the exception of the liver, which expresses mainly the SCD1 isoform. We found that asebia mice homozygous for a natural mutation of the gene for SCD1 (SCD-/-) are deficient in hepatic cholesterol esters and triglycerides despite the presence of normal activities of acyl-CoA:cholesterol acyltransferase and glycerol phosphate acyltransferase, the enzymes responsible for cholesterol ester and triglyceride synthesis, respectively, in the liver of these mice. Feeding diets supplemented with triolein or tripalmitolein to the SCD-/- mice resulted in an increase in the levels of 16:1 and 18:1 in the liver but failed to restore the 18:1 and 16:1 levels of the cholesterol ester and triglycerides to the levels found in normal mice, The SCD-/- mouse had very low levels of triglycerides in the VLDL and LDL lipoprotein fractions compared with the normal animal. Transient transfection of an SCD1 expression vector into Chinese hamster ovary cells resulted in increased SCD activity and esterification of cholesterol to cholesterol esters. Taken together, our observations demonstrate that the oleoyl-CoA and palmitoleyl-CoA produced by SCD1 are necessary to synthesize enough cholesterol esters and triglycerides in the liver and suggest that regulation of SCD1 activity plays an important role in mechanisms of cellular cholesterol homeostasis.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ntambi, JM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.							BERNLOHR DA, 1985, J BIOL CHEM, V260, P5563; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; DAUMERIE CM, 1992, P NATL ACAD SCI USA, V89, P10797, DOI 10.1073/pnas.89.22.10797; ENOCH HG, 1978, BIOCHEMISTRY-US, V17, P4927, DOI 10.1021/bi00616a011; ERICKSON SK, 1980, J LIPID RES, V21, P930; GATES AH, 1965, SCIENCE, V148, P1471, DOI 10.1126/science.148.3676.1471; Heinemann FS, 1998, MOL BIOL CELL, V9, P3445, DOI 10.1091/mbc.9.12.3445; Janciauskiene S, 1999, HEPATOLOGY, V29, P434, DOI 10.1002/hep.510290217; JOSEFOWICZ WJ, 1978, GENET RES, V31, P145, DOI 10.1017/S0016672300017900; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; Kim YC, 1999, BIOCHEM BIOPH RES CO, V266, P1, DOI 10.1006/bbrc.1999.1704; Landau JM, 1997, BBA-LIPID LIPID MET, V1345, P349, DOI 10.1016/S0005-2760(97)00010-6; Lee KN, 1998, BIOCHEM BIOPH RES CO, V248, P817, DOI 10.1006/bbrc.1998.8994; Miyazaki M, 1998, LIPIDS, V33, P655, DOI 10.1007/s11745-998-0253-3; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; Ntambi JM, 1999, J LIPID RES, V40, P1549; NTAMBI JM, 1995, PROG LIPID RES, V34, P139, DOI 10.1016/0163-7827(94)00010-J; OSHINO N, 1966, BIOCHIM BIOPHYS ACTA, V128, P13, DOI 10.1016/0926-6593(66)90137-8; Sessler AM, 1996, J BIOL CHEM, V271, P29854, DOI 10.1074/jbc.271.47.29854; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; SUCKLING KE, 1985, J LIPID RES, V26, P647; SWEET H, 1978, MOUSE NEWS LETT, V59, P287; THOMAS PD, 1990, J BIOL CHEM, V265, P2684; WATERS KM, 1994, J BIOL CHEM, V269, P27773; Zheng Y, 1999, NAT GENET, V23, P268, DOI 10.1038/15446	25	355	378	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30132	30138		10.1074/jbc.M005488200	http://dx.doi.org/10.1074/jbc.M005488200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10899171	hybrid			2022-12-27	WOS:000089577900031
J	Nickoloff, BJ; Chaturvedi, V; Bacon, P; Qin, JZ; Denning, MF; Diaz, MO				Nickoloff, BJ; Chaturvedi, V; Bacon, P; Qin, JZ; Denning, MF; Diaz, MO			Id-1 delays senescence but does not immortalize keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEIN; TELOMERASE ACTIVITY; REPLICATIVE SENESCENCE; RETINOBLASTOMA PROTEIN; CELL-GROWTH; INACTIVATION; GENE; HEAD; DIFFERENTIATION; P16(INK4A)	Defining the molecular basis responsible for regulating the proliferative potential of keratinocytes has important implications for normal homeostasis and neoplasia of the skin. Under current culture conditions, neonatal foreskin-derived human keratinocytes possess a relatively short replicative lifespan, Recently it was reported that forced overexpression of the helix-loop-helix protein Id-1 was capable of immortalizing keratinocytes, secondary to activation of telomerase activity and suppression of p16/Rb-mediated growth arrest pathways. To investigate the relationship between Id-1, telomerase activity, telomere length, pie, Rb cell cycle regulators, and senescence, whole populations of keratinocytes were infected with a retrovirus to induce overexpression of Id-1. In these unselected cultures, enhanced Id-1 levels clearly extended the lifespan of keratinocytes, but Id-1 did not prevent the onset of replicative senescence. Under these experimental conditions, Id-1 expression did not trigger induction of telomerase activity, and there was progressive shortening of the telomeres that was accompanied by elevated pie levels and prevalence of active Rb, The ability of Id-1 to postpone, but not prevent, senescence may be related to partial inhibition of pie expression, as the Id-1-overexpressing cultures displayed a decreased capacity for 12-O-tetradecanoylphorbol-13-acetate-mediated p16 induction, Thus, while no immortalization was observed, Id-1 could delay the onset of replicative senescence in unselected human keratinocyte populations.	Loyola Univ, Med Ctr, Dept Pathol, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Dept Med, Maywood, IL 60153 USA	Loyola University Chicago; Loyola University Chicago	Nickoloff, BJ (corresponding author), Cardinal Bernardin Canc Ctr, Skin Canc Res Program, Bldg 112,Rm 301,2160 S 1st Ave, Maywood, IL 60153 USA.	bnickol@lumc.edu						Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; Bickenbach JR, 1998, J INVEST DERMATOL, V111, P1045, DOI 10.1046/j.1523-1747.1998.00420.x; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Campisi C, 1998, LYMPHOLOGY, V31, P1; Campisi J, 1997, J AM GERIATR SOC, V45, P482, DOI 10.1111/j.1532-5415.1997.tb05175.x; Chaturvedi V, 1999, J BIOL CHEM, V274, P23358, DOI 10.1074/jbc.274.33.23358; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DEED RW, 1993, ONCOGENE, V8, P599; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; ElNaggar AK, 1997, AM J PATHOL, V151, P1767; Hara E, 1996, DEV GENET, V18, P161; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Loughran O, 1996, ONCOGENE, V13, P561; Munro J, 1999, CANCER RES, V59, P2516; Nickoloff BJ, 1999, J CLIN INVEST, V104, P1161, DOI 10.1172/JCI8633; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; Pena JC, 1997, CELL GROWTH DIFFER, V8, P619; Qin JZ, 1999, J BIOL CHEM, V274, P37957, DOI 10.1074/jbc.274.53.37957; Reed AL, 1996, CANCER RES, V56, P3630; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687	28	109	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27501	27504						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10908559				2022-12-27	WOS:000089197100001
J	Deloulme, JC; Assard, N; Mbele, GO; Mangin, C; Kuwano, R; Baudier, J				Deloulme, JC; Assard, N; Mbele, GO; Mangin, C; Kuwano, R; Baudier, J			S100A6 and S100A11 are specific targets of the calcium- and zinc-binding S100B protein in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN CAPPING PROTEIN; C-TERMINAL DOMAIN; 2-HYBRID SYSTEM; S-100 PROTEIN; BOVINE BRAIN; RAT APO-S100B(BETA-BETA); ALZHEIMERS-DISEASE; IONS BINDING; IN-VITRO; CALMODULIN	In solution, S100B protein is a noncovalent homodimer composed of two subunits associated in an antiparallel manner. Upon calcium binding, the conformation of S100B changes dramatically, leading to the exposure of hydrophobic residues at the surface of S100B. The residues in the C-terminal domain of S100B encompassing Phe(87) and Phe(88) have been implicated in interaction with target proteins. In this study, we used two-hybrid technology to identify specific S100B target proteins. Using S100B as bait, we identify S100A6 and S100A11 as specific targets for S100B. S100A1, the closest homologue of S100B, is capable of interaction with S100B but does not interact with S100A6 or S100A11. S100B, S100A6, and S100A11 isoforms are co-regulated and,co-localized in astrocytoma U373 cells. Furthermore, co-immunoprecipitation experiments demonstrated that Ca2+/Zn2+ stabilizes S100B-S100A6 and S100B-S100A11 heterocomplexes. Deletion of the C-terminal domain or mutation of Phe(87) and Phe(88) residues has-no effect on S100B homodimerization and heterodimerization with S100A1 but drastically decreases interaction between S100B and S100A6 or S100A11. Our data, suggest that the interaction between S100B and S100A6 or S100A11 should not be viewed as a typical S100 heterodimerization but rather as a model of interaction between S100B and target proteins.	CEN G, BRCE, DBMS,CEA, INSERM Unite 244,Dept Biol Mol & Struct, F-38054 Grenoble 9, France; Niigata Univ, Res Lab Mol Genet, Niigata 951, Japan	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Niigata University	Deloulme, JC (corresponding author), CEN G, BRCE, DBMS,CEA, INSERM Unite 244,Dept Biol Mol & Struct, 17 Rue Martyrs, F-38054 Grenoble 9, France.		Deloulme, Jean Christophe/P-6858-2017; Baudier, Jacques/O-2183-2016	Deloulme, Jean Christophe/0000-0002-2234-5865; jacques, baudier/0000-0001-8427-4444				ALLORE R, 1988, SCIENCE, V239, P1311, DOI 10.1126/science.2964086; Barber KR, 1999, J BIOL CHEM, V274, P1502, DOI 10.1074/jbc.274.3.1502; BAUDIER J, 1986, J BIOL CHEM, V261, P8204; BAUDIER J, 1987, J BIOL CHEM, V262, P17577; BAUDIER J, 1986, J BIOL CHEM, V261, P8192; BAUDIER J, 1995, BIOCHEMISTRY-US, V34, P7834, DOI 10.1021/bi00024a007; BERTOGLIO JH, 1987, LYMPHOKINE RES, V6, P83; BIANCHI R, 1993, J BIOL CHEM, V268, P12669; Boni R, 1997, J CUTAN PATHOL, V24, P76, DOI 10.1111/j.1600-0560.1997.tb01100.x; Brill S, 1996, MOL CELL BIOL, V16, P4869; Camby I, 1999, BRAIN PATHOL, V9, P1; Chao S, 1996, MOL BRAIN RES, V40, P195, DOI 10.1016/0169-328X(96)00049-6; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COCHRAN AJ, 1993, MELANOMA RES, V3, P325, DOI 10.1097/00008390-199310000-00004; DELLANGELICA EC, 1994, J BIOL CHEM, V269, P28929; DELOULME J, 2000, IN PRESS METHODS BIO; Delphin C, 1999, J BIOL CHEM, V274, P10539, DOI 10.1074/jbc.274.15.10539; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Drohat AC, 1996, BIOCHEMISTRY-US, V35, P11577, DOI 10.1021/bi9612226; Drohat AC, 1998, BIOCHEMISTRY-US, V37, P2729, DOI 10.1021/bi972635p; Drohat AC, 1999, PROTEIN SCI, V8, P800; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FILIPEK A, 1990, FEBS LETT, V264, P263, DOI 10.1016/0014-5793(90)80263-I; FUJII T, 1994, J BIOCHEM-TOKYO, V116, P121, DOI 10.1093/oxfordjournals.jbchem.a124484; Garbuglia M, 1996, FASEB J, V10, P317, DOI 10.1096/fasebj.10.2.8641565; Griffin WST, 1998, NEUROBIOL AGING, V19, P401, DOI 10.1016/S0197-4580(98)00074-8; ISOBE T, 1981, EUR J BIOCHEM, V116, P79, DOI 10.1111/j.1432-1033.1981.tb05303.x; IVANENKOV VV, 1995, J BIOL CHEM, V270, P14651, DOI 10.1074/jbc.270.24.14651; Kilby PM, 1996, STRUCTURE, V4, P1041, DOI 10.1016/S0969-2126(96)00111-6; Kilby PM, 1997, PROTEIN SCI, V6, P2494; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSHAK DR, 1992, NEUROBIOL AGING, V13, P1, DOI 10.1016/0197-4580(92)90002-F; Matsumura H, 1998, STRUCTURE, V6, P233, DOI 10.1016/S0969-2126(98)00024-0; Miller J. H, 1972, EXPT MOL GENETICS; MILLER JH, 1992, SHORT COURSE BACTERI, P71; Millward TA, 1998, EMBO J, V17, P5913, DOI 10.1093/emboj/17.20.5913; Potts BCM, 1996, PROTEIN SCI, V5, P2162, DOI 10.1002/pro.5560051103; Prichard L, 1999, J BIOL CHEM, V274, P7689, DOI 10.1074/jbc.274.12.7689; Propper C, 1999, J BIOL CHEM, V274, P183, DOI 10.1074/jbc.274.1.183; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; Rustandi RR, 1999, PROTEIN SCI, V8, P1743, DOI 10.1110/ps.8.9.1743; Sakaguchi M, 2000, J CELL BIOL, V149, P1193, DOI 10.1083/jcb.149.6.1193; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Scotto C, 1998, MOL CELL BIOL, V18, P4272, DOI 10.1128/MCB.18.7.4272; Scotto C, 1999, MOL CELL BIOL, V19, P7168; Seemann J, 1997, FEBS LETT, V413, P185, DOI 10.1016/S0014-5793(97)00911-3; SKRIPNIKOVA EV, 1989, FEBS LETT, V257, P380, DOI 10.1016/0014-5793(89)81577-7; Smith SP, 1997, J BIOMOL NMR, V10, P77, DOI 10.1023/A:1018397213369; Smith SP, 1996, BIOCHEMISTRY-US, V35, P8805, DOI 10.1021/bi952698c; Smith SP, 1998, STRUCTURE, V6, P211, DOI 10.1016/S0969-2126(98)00022-7; STANLEY LC, 1994, J NEUROPATH EXP NEUR, V53, P231, DOI 10.1097/00005072-199405000-00003; VOJTEK A, 1997, YEAST 2 HYBRID SYSTE; Wang GZ, 2000, J BIOL CHEM, V275, P11141, DOI 10.1074/jbc.275.15.11141; Yamashita N, 1997, BRAIN RES, V778, P388, DOI 10.1016/S0006-8993(97)01025-1; Yamashita N, 1999, J COMP NEUROL, V404, P235; Yang Q, 1999, EXP CELL RES, V246, P501, DOI 10.1006/excr.1998.4314	58	74	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35302	35310		10.1074/jbc.M003943200	http://dx.doi.org/10.1074/jbc.M003943200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10913138	hybrid			2022-12-27	WOS:000165422800064
J	Fong, NM; Jensen, TC; Shah, AS; Parekh, NN; Saltiel, AR; Brady, MJ				Fong, NM; Jensen, TC; Shah, AS; Parekh, NN; Saltiel, AR; Brady, MJ			Identification of binding sites on protein targeting to glycogen for enzymes of glycogen metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; PHOSPHATASE 1; CATALYTIC SUBUNIT; KINASE INHIBITION; ACTIVATION; INSULIN; PHOSPHORYLATION; SYNTHASE; TRANSLOCATION; DOMAINS	The activation of protein phosphastase-1 (PP1) by insulin-plays a critical role in the regulation of glycogen metabolism. PTG is a PP1 glycogen-targeting protein, which also binds the PP1 substrates glycogen synthase, glycogen phosphorylase, and phosphorylase kinase (Printen, J.:A,, Brady, M. J., and Saltiel, A. R. (1997) Science 275, 1475-1478). Through a combination of deletion analysis and site-directed mutagenesis, the regions on PTG responsible for binding PP1 and its substrates have been delineated. Mutagenesis of Val-62 and Phe-64 in the highly conserved (K/R)VXF PP1-binding motif to alanine was sufficient to ablate PP1 binding to PTG. Phosphorylase kinase, glycogen synthase, and phosphorylase binding all mapped to the same C-terminal region of PTG. Mutagenesis of Asp-225 and Glu-228 to alanine completely blocked the interaction between PTG and these three enzymes, without affecting PP1 binding. Disruption of either PP1 or substrate binding to PTG blocked the stimulation of PP1 activity in vitro against phosphorylase, indicating that both binding sites may be important in PTG action. Transient overexpression of wild type PTG in Chinese hamster ovary cells overexpressing the insulin receptor caused a 50-fold increase in glycogen levels. Expression of PTG mutants that do not bind PP1 had no effect on glycogen accumulation, indicating that PP1 targeting is essential for PTG function. Likewise, expression of the PTG mutants that do not bind PP1 substrates did not increase glycogen levels, indicating that PP1 targeting glycogen is not sufficient for the metabolic effects of PTG, These results cumulatively demonstrate that PTG serves as a molecular scaffold, allowing PP1 to recognize its substrates at the glycogen particle.	Pfizer Global Res & Dev, Dept Cell Biol, Ann Arbor, MI 48105 USA; Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA	Pfizer; University of Michigan System; University of Michigan	Brady, MJ (corresponding author), Pfizer Global Res & Dev, Dept Cell Biol, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.		Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				Armstrong CG, 1997, FEBS LETT, V418, P210, DOI 10.1016/S0014-5793(97)01385-9; Armstrong CG, 1998, BIOCHEM J, V336, P699, DOI 10.1042/bj3360699; Berman HK, 1998, J BIOL CHEM, V273, P26421, DOI 10.1074/jbc.273.41.26421; Berndt Norbert, 1999, Frontiers in Bioscience, V4, pD22, DOI 10.2741/Berndt; Bork P, 1998, J MOL MED-JMM, V76, P77, DOI 10.1007/s001090050194; Brady MJ, 1999, J BIOL CHEM, V274, P27497, DOI 10.1074/jbc.274.39.27497; Brady MJ, 1999, TRENDS ENDOCRIN MET, V10, P408, DOI 10.1016/S1043-2760(99)00201-5; Brady MJ, 1997, J BIOL CHEM, V272, P29698, DOI 10.1074/jbc.272.47.29698; Brady MJ, 1998, J BIOL CHEM, V273, P14063, DOI 10.1074/jbc.273.23.14063; Brady MJ, 1997, J BIOL CHEM, V272, P20198, DOI 10.1074/jbc.272.32.20198; BRADY MJ, IN PRESS RECENT PROG; Cohen P, 1978, Curr Top Cell Regul, V14, P117; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Gasa R, 2000, J BIOL CHEM, V275, P26396, DOI 10.1074/jbc.M002427200; GomezLechon MJ, 1996, ANAL BIOCHEM, V236, P296, DOI 10.1006/abio.1996.0170; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HIRAGA A, 1986, EUR J BIOCHEM, V161, P763, DOI 10.1111/j.1432-1033.1986.tb10505.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P711, DOI 10.1111/j.1432-1033.1989.tb15264.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P701, DOI 10.1111/j.1432-1033.1989.tb15263.x; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Liu J, 2000, J BIOL CHEM, V275, P26074, DOI 10.1074/jbc.M003843200; Liu J, 2000, BIOCHEM J, V346, P77, DOI 10.1042/0264-6021:3460077; O'Doherty RM, 2000, J CLIN INVEST, V105, P479, DOI 10.1172/JCI8673; Peters C, 1999, SCIENCE, V285, P1084, DOI 10.1126/science.285.5430.1084; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; Schillace RV, 1999, CURR BIOL, V9, P321, DOI 10.1016/S0960-9822(99)80141-9; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; TANG PM, 1991, J BIOL CHEM, V266, P15782; Trinkle-Mulcahy L, 1999, J CELL SCI, V112, P157; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; Wu J, 1998, FEBS LETT, V439, P185, DOI 10.1016/S0014-5793(98)01371-4; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	38	77	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35034	35039		10.1074/jbc.M005541200	http://dx.doi.org/10.1074/jbc.M005541200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10938087	hybrid			2022-12-27	WOS:000165422800030
J	Gual, A; Camacho, AG; Alonso, JC				Gual, A; Camacho, AG; Alonso, JC			Functional analysis of the terminase large subunit, G2P, of Bacillus subtilis bacteriophage SPP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA PACKAGING ENZYME; KINETIC CHARACTERIZATION; NUCLEOPROTEIN COMPLEX; ENDONUCLEASE ACTIVITY; NUCLEOTIDE-SEQUENCE; LAMBDA TERMINASE; SITE PAC; PROTEIN; INITIATION; MECHANISM	The terminase of bacteriophage SPP1, constituted by a large (G2P) and a small (GIP) subunit, is essential for the initiation of DNA packaging. A hexa-histidine G2P (H6-G2P), which is functional in vivo, possesses endonuclease, ATPase, and double-stranded DNA binding activities. H6-G2P introduces a cut with preference at the 5'-RCGG down arrow CW-3' sequence. Distamycin A, which is a minor groove binder that mimics the architectural structure generated by G1P at pac, enhances the specific cut at both bona fide 5'-CTATTGCGG down arrow C-3' sequences within pacC of SPP1 and SF6 phages, H6-G2P hydrolyzes rATP or dATP to the corresponding rADP or dADP and Pi, H6-G2P interacts with two discrete G1P domains (I and II). Full-length GIP and G1P Delta N62 (lacking domain I) stimulate 3,5- and 1,9-fold, respectively, the ATPase activity of H6-G2P. The results presented suggest that a DNA structure, artificially promoted by distamycin A or facilitated by the assembly of GIP at pact and/or pacR, stimulates H6-G2P cleavage at both target sites within pacC. In the presence of two GIP decamers per H6-G2P monomer, the H6-G2P endonuclease is repressed, and the ATPase activity stimulated. Based on these results, we propose a model that can account for the role of terminase in headful packaging.	CSIC, Ctr Nacl Biotecnol, Dept Biotecnol Microbiana, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Alonso, JC (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Biotecnol Microbiana, Campus Univ Autonoma Madrid, E-28049 Madrid, Spain.		Alonso, Juan Carlos/D-2595-2009	Alonso, Juan Carlos/0000-0002-5178-7179				Alonso JC, 1997, GENE, V204, P201, DOI 10.1016/S0378-1119(97)00547-7; ALONSO JC, 1995, J BIOL CHEM, V270, P2938, DOI 10.1074/jbc.270.7.2938; ALONSO JC, 1986, EMBO J, V5, P3723, DOI 10.1002/j.1460-2075.1986.tb04706.x; Ayora S, 1996, J MOL BIOL, V256, P301, DOI 10.1006/jmbi.1996.0087; BLACK LW, 1995, BIOESSAYS, V17, P1025, DOI 10.1002/bies.950171206; BLACK LW, 1989, ANNU REV MICROBIOL, V43, P267, DOI 10.1146/annurev.micro.43.1.267; BRAVO A, 1990, NUCLEIC ACIDS RES, V18, P2881, DOI 10.1093/nar/18.10.2881; Casjens S, 1985, VIRUS STRUCTURE ASSE, P75; CATALANO CE, 1995, MOL MICROBIOL, V16, P1075, DOI 10.1111/j.1365-2958.1995.tb02333.x; CHAI S, 1992, J MOL BIOL, V224, P87, DOI 10.1016/0022-2836(92)90578-8; CHAI SH, 1994, VIROLOGY, V202, P930, DOI 10.1006/viro.1994.1415; Chai SH, 1997, GENE, V184, P251, DOI 10.1016/S0378-1119(96)00609-9; CHAI SH, 1995, J MOL BIOL, V252, P386, DOI 10.1006/jmbi.1995.0505; Chai SH, 1996, NUCLEIC ACIDS RES, V24, P282, DOI 10.1093/nar/24.2.282; COREN JS, 1995, J MOL BIOL, V249, P176, DOI 10.1006/jmbi.1995.0287; DEICHELBOHRER I, 1982, J VIROL, V42, P83, DOI 10.1128/JVI.42.1.83-90.1982; FEISS M, 1986, TRENDS GENET, V2, P100, DOI 10.1016/0168-9525(86)90193-9; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gual A, 1998, VIROLOGY, V242, P279, DOI 10.1006/viro.1997.9017; Hwang Y, 1996, J MOL BIOL, V261, P524, DOI 10.1006/jmbi.1996.0480; Leffers G, 1996, J MOL BIOL, V258, P839, DOI 10.1006/jmbi.1996.0291; Lin H, 1997, J BIOL CHEM, V272, P3495, DOI 10.1074/jbc.272.6.3495; MURIALDO H, 1991, ANNU REV BIOCHEM, V60, P125; RUBINCHIK S, 1994, J BIOL CHEM, V269, P13575; Sambrook J., 2002, MOL CLONING LAB MANU; SCOTT JF, 1977, P NATL ACAD SCI USA, V74, P193, DOI 10.1073/pnas.74.1.193; Sheridan SD, 1998, J BIOL CHEM, V273, P21298, DOI 10.1074/jbc.273.33.21298; SKORUPSKI K, 1994, J MOL BIOL, V243, P268, DOI 10.1006/jmbi.1994.1653; STERNBERG N, 1990, P NATL ACAD SCI USA, V87, P8070, DOI 10.1073/pnas.87.20.8070; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; Tavares P, 1996, J MOL BIOL, V264, P954, DOI 10.1006/jmbi.1996.0689; TAVARES P, 1992, J MOL BIOL, V225, P81, DOI 10.1016/0022-2836(92)91027-M; TOMKA MA, 1993, BIOCHEMISTRY-US, V32, P11992, DOI 10.1021/bi00096a008; TOMKA MA, 1993, J BIOL CHEM, V268, P3056; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	35	63	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35311	35319		10.1074/jbc.M004309200	http://dx.doi.org/10.1074/jbc.M004309200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10930407	hybrid, Green Submitted			2022-12-27	WOS:000165422800065
J	Keller, C; Krude, T				Keller, C; Krude, T			Requirement of cyclin/Cdk2 and protein phosphatase 1 activity for chromatin assembly factor 1-dependent chromatin assembly during DNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; CELL NUCLEAR ANTIGEN; REPLICATION INVITRO; CRYSTAL-STRUCTURE; MAMMALIAN-CELLS; BINDING DOMAINS; PURINE ANALOGS; FACTOR-I; CYCLE; PCNA	The influence of reversible protein phosphorylation on nucleosome assembly during DNA replication was analyzed in extracts from human cells. Inhibitor studies and add-back: experiments indicated requirements of cyclin A/Cdk2, cyclin E/Cdk2, and protein phosphatase type 1 (PP1) activities for nucleosome assembly during DNA synthesis by chromatin assembly factor 1 (CAF-1). The p60 subunit of CAF-1 is a molecular target for reversible phosphorylation by cyclin/Cdk complexes and PP1 during nucleosome assembly and DNA synthesis in vitro. Purified p60 can be directly phosphorylated by purified:cyclin A/Cdk2, cyclin E/Cdk2, and cyclin B1/Cdk1, but not by cyclin D/CdkB4 complexes in vitro. Cyclin B1/Cdk1:triggers hyperphosphorylation of p60 in the presence of additional cytosolic factors. CAF-1 containing hyperphosphorylated p60 prepared from mitotic cells is inactive in nucleosome assembly and becomes activated by dephosphorylation in vitro. These data provide:functional evidence for a requirement of the cell cycle machinery for nucleosome assembly by CAF-1 during DNA replication.	Univ Cambridge, CRC, Wellcome Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Zool, Cambridge CB3 7EJ, England	University of Cambridge; Wellcome Trust Sanger Institute; University of Cambridge	Krude, T (corresponding author), Univ Cambridge, CRC, Wellcome Inst, Tennis Court Rd, Cambridge CB2 1QR, England.	tk1@mole.bio.cam.ac.uk		Krude, Torsten/0000-0002-1842-1933				Adams CR, 1999, CURR OPIN GENET DEV, V9, P185, DOI 10.1016/S0959-437X(99)80028-8; Andreassen PR, 1998, J CELL BIOL, V141, P1207, DOI 10.1083/jcb.141.5.1207; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; Fanning Ellen, 1994, Trends in Cell Biology, V4, P250, DOI 10.1016/0962-8924(94)90123-6; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Gaillard PHL, 1996, CELL, V86, P887, DOI 10.1016/S0092-8674(00)80164-6; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GOUBIN F, 1995, ONCOGENE, V10, P2281; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Jackman MR, 1997, CANCER SURV, V29, P47; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Kamakaka RT, 1996, MOL CELL BIOL, V16, P810; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; KRUDE T, 1994, J BIOL CHEM, V269, P21021; KRUDE T, 1993, J BIOL CHEM, V268, P14432; Krude T, 1999, EUR J BIOCHEM, V263, P1, DOI 10.1046/j.1432-1327.1999.00508.x; Krude T, 2000, J BIOL CHEM, V275, P13699, DOI 10.1074/jbc.275.18.13699; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Krude T, 1999, CURR BIOL, V9, pR394, DOI 10.1016/S0960-9822(99)80251-6; LASSLE M, 1992, BIOCHIM BIOPHYS ACTA, V1132, P1, DOI 10.1016/0167-4781(92)90045-2; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; Marheineke K, 1998, J BIOL CHEM, V273, P15279, DOI 10.1074/jbc.273.24.15279; Martini E, 1998, J CELL BIOL, V143, P563, DOI 10.1083/jcb.143.3.563; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Moggs JG, 2000, MOL CELL BIOL, V20, P1206, DOI 10.1128/MCB.20.4.1206-1218.2000; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OSLEY MA, 1991, ANNU REV BIOCHEM, V60, P827, DOI 10.1146/annurev.biochem.60.1.827; Paulson JR, 1996, J CELL SCI, V109, P1437; PECK LJ, 1983, P NATL ACAD SCI-BIOL, V80, P6206, DOI 10.1073/pnas.80.20.6206; Philpott A, 2000, SEMIN CELL DEV BIOL, V11, P7, DOI 10.1006/scdb.1999.0346; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Reed SI, 1997, CANCER SURV, V29, P7; Roberts JM, 1999, CELL, V98, P129, DOI 10.1016/S0092-8674(00)81007-7; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Sheppeck JE, 1997, BIOORGAN MED CHEM, V5, P1739, DOI 10.1016/S0968-0896(97)00146-6; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; Shibahara K, 2000, P NATL ACAD SCI USA, V97, P7766, DOI 10.1073/pnas.97.14.7766; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Verreault A, 1998, CURR BIOL, V8, P96, DOI 10.1016/S0960-9822(98)70040-5; Verreault A, 2000, GENE DEV, V14, P1430; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; Weisshart Klaus, 1999, P295	61	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35512	35521		10.1074/jbc.M003073200	http://dx.doi.org/10.1074/jbc.M003073200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10938080	hybrid			2022-12-27	WOS:000165422800090
J	Zhang, Y; Redina, O; Altshuller, YM; Yamazaki, M; Ramos, J; Chneiweiss, H; Kanaho, Y; Frohman, MA				Zhang, Y; Redina, O; Altshuller, YM; Yamazaki, M; Ramos, J; Chneiweiss, H; Kanaho, Y; Frohman, MA			Regulation of expression of phospholipase D1 and D2 by PEA-15, a novel protein that interacts with them	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH-EFFECTOR DOMAIN; ADP-RIBOSYLATION FACTOR; KINASE-C; D DEFINES; APOPTOSIS; FAMILY; ASTROCYTES; ACTIVATION; ALPHA; PHOSPHOPROTEIN	Phospholipase D (PLD), a signal-transducing membrane-associated enzyme, is implicated in diverse processes including apoptosis, ERK activation, and glucose transport, Prior studies have identified specific PLD activators and repressors that directly regulate its enzymatic activity. Using two-hybrid screens, we have identified PEA-15 as a PLD interactor that unexpectedly functions to:alter its level of expression. PEA-15 is a widely expressed death effector domain-containing phosphoprotein involved in signal transduction, apoptosis,:ERK activation, and glucose transport. The PLD1-interacting site on PEA-15 consists of part of the death effector domain domain plus additional C-terminal flanking:sequences, whereas the PEA-15-interacting site on:PLD1 overlaps the previously identified RhoA-interacting site. PEA-15 did not affect basal or stimulated;in vitro PLD1 enzymatic activation. However, coexpression of PEA-15 increased levels of PLD1 activity. This increased activation correlated with higher PLD1 protein expression levels, as marked by faster accumulation and longer persistence of PLD1 when PEA-15 was present; PEA-15 similarly increased protein expressions level of PLDS and co-immunoprecipitated with it. These results: suggest that PEA-IB may stabilize PLD or act as a PLD chaperone. The common involvement of PEA-15 and PLD in,:apoptosis, ERK activation, and glucose transport additionally suggests functional significance.	SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA; Tokyo Metropolitan Inst Med Sci, Dept Pharmacol, Bunkyo Ku, Tokyo 1138613, Japan; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Coll France, INSERM U114, F-75231 Paris 05, France; Coll France, Chaire Neuropharmacol, F-75231 Paris 05, France	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Tokyo Metropolitan Institute of Medical Science; Scripps Research Institute; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; UDICE-French Research Universities; PSL Research University Paris; College de France	Frohman, MA (corresponding author), SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA.		herve, chneiweiss/Q-6818-2019; Ramos, Joe/G-4074-2010; Redina, Olga E/T-1650-2017	herve, chneiweiss/0000-0001-7675-5061; Ramos, Joe/0000-0002-9708-2115; Redina, Olga/0000-0003-0942-8460	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054813] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54813] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAUJO H, 1993, J BIOL CHEM, V268, P5911; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Condorelli G, 1998, EMBO J, V17, P3858, DOI 10.1093/emboj/17.14.3858; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; DANZIGER N, 1995, J NEUROCHEM, V64, P1016; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Emoto M, 2000, J BIOL CHEM, V275, P7144, DOI 10.1074/jbc.275.10.7144; Estelles A, 1999, DEV BIOL, V216, P16, DOI 10.1006/dbio.1999.9510; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Jones D, 1999, BBA-MOL CELL BIOL L, V1439, P229, DOI 10.1016/S1388-1981(99)00097-9; Kitsberg D, 1999, J NEUROSCI, V19, P8244; Leusen JHW, 1996, J LAB CLIN MED, V128, P461, DOI 10.1016/S0022-2143(96)90043-8; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; Morris AJ, 1997, ANAL BIOCHEM, V252, P1, DOI 10.1006/abio.1997.2299; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakashima S, 1999, CHEM PHYS LIPIDS, V98, P153, DOI 10.1016/S0009-3084(99)00027-4; Otsuki T, 1999, BIOCHEM BIOPH RES CO, V265, P630, DOI 10.1006/bbrc.1999.1731; Ramos JW, 2000, MOL BIOL CELL, V11, P2863, DOI 10.1091/mbc.11.9.2863; Ramos JW, 1998, J BIOL CHEM, V273, P33897, DOI 10.1074/jbc.273.51.33897; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Servitja JM, 1998, BRIT J PHARMACOL, V124, P1728, DOI 10.1038/sj.bjp.0701997; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Slaaby R, 1998, J BIOL CHEM, V273, P33722, DOI 10.1074/jbc.273.50.33722; Sugars JM, 1999, J BIOL CHEM, V274, P30023, DOI 10.1074/jbc.274.42.30023; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; Sung TC, 1999, J BIOL CHEM, V274, P3659, DOI 10.1074/jbc.274.6.3659; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wattiau P, 1996, MOL MICROBIOL, V20, P255, DOI 10.1111/j.1365-2958.1996.tb02614.x; Yamazaki M, 1999, J BIOL CHEM, V274, P6035, DOI 10.1074/jbc.274.10.6035; Zhang Y, 1999, EMBO J, V18, P6339, DOI 10.1093/emboj/18.22.6339	34	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35224	35232		10.1074/jbc.M003329200	http://dx.doi.org/10.1074/jbc.M003329200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10926929	hybrid			2022-12-27	WOS:000165422800054
J	Bennett, ER; Su, HL; Kanner, BI				Bennett, ER; Su, HL; Kanner, BI			Mutation of arginine 44 of GAT-1, a (Na++Cl-)-coupled gamma-aminobutyric acid transporter from rat brain, impairs net flux but not exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA TRANSPORTER; SEROTONIN TRANSPORTER; TRANSMEMBRANE TOPOLOGY; XENOPUS OOCYTES; SODIUM; EXPRESSION; IDENTIFICATION; SITE; PERMEATION; RESIDUES	The gamma -aminobutyric acid (GABA) transporter GAT-1 is a prototype of a large family of neurotransmitter transporters that includes those of dopamine and serotonin, GAT-1 maintains low synaptic concentrations of neurotransmitter by coupling GABA uptake to the fluxes of sodium and chloride. Here we identify a stretch of four amino acid residues predicted to lie in the juxtamembrane region prior to transmembrane domain 1 in the cytoplasmic amino-terminal tail of GAT-1, which is critical for its function. Two residues, arginine 44 and tryptophan 47, are fully conserved within the transporter family, and their deletion abolishes GABA transport in the HeLa cell expression system used. Tryptophan 47 can be replaced only by aromatic residues without Toss of activity. Arginine 44 is essential for activity, Only when it is replaced by lysine, low activity levels (around 15% of those of the wild type) are observed. Using a reconstitution assay, we show that mutants in which this residue is replaced by lysine or histidine exhibit sodium- and chloride-dependent GABA exchange similar to the wild type. This indicates that these mutants are selectively impaired in the reorientation of the unloaded transporter, a step in the translocation cycle by which net flux and exchange differ. The high degree of conservation in the consensus sequence RXXW suggests that this region may influence the reorientation step in related transporters as well.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Kanner, BI (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel.	kannerb@cc.huji.ac.il	Bennett, Estelle R/A-5067-2017		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS016708, R01NS016708] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 16708] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barker EL, 1999, J NEUROSCI, V19, P4705; Beckman ML, 1998, J NEUROSCI, V18, P6103; BENDAHAN A, 1993, FEBS LETT, V318, P41, DOI 10.1016/0014-5793(93)81323-R; Bennett ER, 1997, J BIOL CHEM, V272, P1203, DOI 10.1074/jbc.272.2.1203; Bismuth Y, 1997, J BIOL CHEM, V272, P16096, DOI 10.1074/jbc.272.26.16096; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; Clark JA, 1997, J BIOL CHEM, V272, P14695, DOI 10.1074/jbc.272.23.14695; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Golovanevsky V, 1999, J BIOL CHEM, V274, P23020, DOI 10.1074/jbc.274.33.23020; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; Hilgemann DW, 1999, J GEN PHYSIOL, V114, P459, DOI 10.1085/jgp.114.3.459; KANNER BI, 1994, FEBS LETT, V356, P191, DOI 10.1016/0014-5793(94)01255-5; KANNER BI, 1981, BIOCHEMISTRY-US, V20, P3354, DOI 10.1021/bi00515a007; KANNER BI, 1983, BIOCHIM BIOPHYS ACTA, V731, P54, DOI 10.1016/0005-2736(83)90397-8; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; Kavanaugh MP, 1997, J BIOL CHEM, V272, P1703, DOI 10.1074/jbc.272.3.1703; KESHET GI, 1995, FEBS LETT, V371, P39, DOI 10.1016/0014-5793(95)00859-8; KEYES SR, 1982, J BIOL CHEM, V257, P1172; KEYNAN S, 1988, BIOCHEMISTRY-US, V27, P12, DOI 10.1021/bi00401a003; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KLEINBERGERDORON N, 1994, J BIOL CHEM, V269, P3063; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lovry O.H., 1951, J BIOL CHEM, V193, P265; MABJEESH NJ, 1993, BIOCHEMISTRY-US, V32, P8540, DOI 10.1021/bi00084a021; MABJEESH NJ, 1992, J BIOL CHEM, V267, P2563; Mager S, 1996, J NEUROSCI, V16, P5405; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; Nelson N, 1998, J NEUROCHEM, V71, P1785; Olivares L, 1997, J BIOL CHEM, V272, P1211, DOI 10.1074/jbc.272.2.1211; RADIAN R, 1986, J BIOL CHEM, V261, P5437; Sun JZ, 1998, BIOCHEMISTRY-US, V37, P8020, DOI 10.1021/bi973192s; TAMURA S, 1995, J BIOL CHEM, V270, P28712, DOI 10.1074/jbc.270.48.28712; Yu N, 1998, FEBS LETT, V426, P174, DOI 10.1016/S0014-5793(98)00333-0	36	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34106	34113		10.1074/jbc.M004229200	http://dx.doi.org/10.1074/jbc.M004229200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10926932	hybrid			2022-12-27	WOS:000165095300018
J	Jia, HP; Wowk, SA; Schutte, BC; Lee, SK; Vivado, A; Tack, BF; Bevins, CL; McCray, PB				Jia, HP; Wowk, SA; Schutte, BC; Lee, SK; Vivado, A; Tack, BF; Bevins, CL; McCray, PB			A novel murine beta-defensin expressed in tongue, esophagus, and trachea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL PEPTIDE GENE; HUMAN BETA-DEFENSIN-1; EPITHELIAL-CELLS; AIRWAY EPITHELIA; MOUSE BETA-DEFENSIN-1; MOLECULAR-CLONING; CRYPTDIN LOCUS; PANETH CELLS; LIPOPOLYSACCHARIDE; LOCALIZATION	beta -Defensins are broad spectrum antimicrobial peptides expressed at epithelial surfaces. Two human p-defensins, HBD-1 and HBD-2, have been identified, In the lung, HBD-2 is an inducible product of airway epithelia and may play a role in innate mucosal defenses. We recently characterized rat homologs (RBD-1, RBD-2) of the human genes and used these sequences to identify novel mouse genes. Mouse beta -defensin-4 (MBD-4) was amplified from lung cDNA using polymerase chain reaction primers designed from conserved sequences of RBD-2 and HBD-2. A full-length cDNA was cloned which encodes a putative peptide with the sequence MRIHYLLFTFLLVLLSPLAAFTQIINNPITCMTNGAIC-WGPCPTAFRQIGNCGHFKVRCCKIR . The peptide shares similar to 40% identity with HBD-2. MBD-4 mRNA was expressed in the esophagus, tongue, and trachea but not in any of 20 other tissues surveyed. Cloning of the genomic sequence of MBD-4 revealed two nearly (>99%) identical sequences encoding MBD-4 and the presence of numerous additional highly similar genomic sequences. Radiation hybrid mapping localized this gene to a region of chromosome 8 near several other defensins, MBD-2, MBD-3, and alpha -defensins (cryptdins)-3 and -17, consistent with a gene cluster, Our genomic cloning and mapping data suggest that there is a large beta -defensin gene family in mice. Identification of murine beta -defensins provides an opportunity to understand further the role of these peptides in host defense through animal model studies and the generation of beta -defensin-deficient animals by gene targeting.	Univ Iowa, Coll Med, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Genet PhD Program, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Microbiol, Iowa City, IA 52242 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	University of Iowa; University of Iowa; University of Iowa; Cleveland Clinic Foundation	McCray, PB (corresponding author), Univ Iowa Hosp & Clin, Dept Pediat, 200 Hawkins Dr, Iowa City, IA 52242 USA.		jia, jhp@mm8899/AAH-6611-2020; Bevins, Charles L/P-4438-2015	Bevins, Charles L/0000-0003-2725-2622; McCray, Paul/0000-0002-4067-577X	NHLBI NIH HHS [HL-61234-01] Funding Source: Medline; NIAID NIH HHS [AI-32234, AI-32738] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL061234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI032234, R01AI032738, R01AI032234] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bals R, 1999, INFECT IMMUN, V67, P3542, DOI 10.1128/IAI.67.7.3542-3547.1999; Bals R, 1998, INFECT IMMUN, V66, P1225, DOI 10.1128/IAI.66.3.1225-1232.1998; Bals R, 1998, J CLIN INVEST, V102, P874, DOI 10.1172/JCI2410; BENSCH KW, 1995, FEBS LETT, V368, P331, DOI 10.1016/0014-5793(95)00687-5; Bevins C L, 1997, Methods Mol Biol, V78, P151; Bevins CL, 1996, GENOMICS, V31, P95, DOI 10.1006/geno.1996.0014; Chertov O, 1996, J BIOL CHEM, V271, P2935, DOI 10.1074/jbc.271.6.2935; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Diamond G, 1996, P NATL ACAD SCI USA, V93, P5156, DOI 10.1073/pnas.93.10.5156; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; DIAMOND G, 1993, P NATL ACAD SCI USA, V90, P4596, DOI 10.1073/pnas.90.10.4596; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOLDMAN MJ, 1997, CELL, V88, P1; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Harder J, 1997, GENOMICS, V46, P472, DOI 10.1006/geno.1997.5074; Hughes AL, 1997, J MOL EVOL, V44, P675, DOI 10.1007/PL00006191; Huttner KM, 1998, J NUTR, V128, p297S, DOI 10.1093/jn/128.2.297S; Huttner KM, 1997, FEBS LETT, V413, P45, DOI 10.1016/S0014-5793(97)00875-2; Huttner KM, 1999, PEDIATR RES, V45, P785, DOI 10.1203/00006450-199906000-00001; Jia HP, 1999, INFECT IMMUN, V67, P4827, DOI 10.1128/IAI.67.9.4827-4833.1999; JONES DE, 1992, J BIOL CHEM, V267, P23216; LEHRER RI, 1998, MUCOSAL IMMUNOLOGY, P89; LIN MY, 1992, GENOMICS, V14, P363, DOI 10.1016/S0888-7543(05)80227-7; Linzmeier R, 1999, GENE, V233, P205, DOI 10.1016/S0378-1119(99)00136-5; Liu L, 1998, GENE, V222, P237, DOI 10.1016/S0378-1119(98)00480-6; Liu LD, 1997, GENOMICS, V43, P316, DOI 10.1006/geno.1997.4801; Mathews M, 1999, INFECT IMMUN, V67, P2740, DOI 10.1128/IAI.67.6.2740-2745.1999; McCarthy LC, 1997, GENOME RES, V7, P1153, DOI 10.1101/gr.7.12.1153; McCray PB, 1999, AM J PHYSIOL-LUNG C, V277, pL183, DOI 10.1152/ajplung.1999.277.1.L183; McCray PB, 1997, AM J RESP CELL MOL, V16, P343, DOI 10.1165/ajrcmb.16.3.9070620; Morrison GM, 1998, MAMM GENOME, V9, P453, DOI 10.1007/s003359900795; Morrison GM, 1999, FEBS LETT, V442, P112, DOI 10.1016/S0014-5793(98)01630-5; OUELLETTE AJ, 1989, GENOMICS, V5, P233, DOI 10.1016/0888-7543(89)90051-7; OUELLETTE AJ, 1989, J CELL BIOL, V108, P1687, DOI 10.1083/jcb.108.5.1687; Russell JP, 1996, INFECT IMMUN, V64, P1565, DOI 10.1128/IAI.64.5.1565-1568.1996; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; Shi JS, 1999, INFECT IMMUN, V67, P3121, DOI 10.1128/IAI.67.6.3121-3127.1999; Singh PK, 1998, P NATL ACAD SCI USA, V95, P14961, DOI 10.1073/pnas.95.25.14961; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Tarver AP, 1998, INFECT IMMUN, V66, P1045, DOI 10.1128/IAI.66.3.1045-1056.1998; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yount NY, 1999, J BIOL CHEM, V274, P26249, DOI 10.1074/jbc.274.37.26249; Zabner J, 1998, MOL CELL, V2, P397, DOI 10.1016/S1097-2765(00)80284-1; Zhang GL, 1999, J BIOL CHEM, V274, P24031, DOI 10.1074/jbc.274.34.24031; Zhao CQ, 1996, FEBS LETT, V396, P319, DOI 10.1016/0014-5793(96)01123-4	49	66	72	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33314	33320		10.1074/jbc.M006603200	http://dx.doi.org/10.1074/jbc.M006603200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10922379	hybrid			2022-12-27	WOS:000090104600022
J	Pagano, A; Ruegg, D; Litschig, S; Stoehr, N; Stierlin, C; Heinrich, M; Floersheim, P; Prezeau, L; Carroll, F; Pin, JP; Cambria, A; Vranesic, I; Flor, PJ; Gasparini, F; Kuhn, R				Pagano, A; Ruegg, D; Litschig, S; Stoehr, N; Stierlin, C; Heinrich, M; Floersheim, P; Prezeau, L; Carroll, F; Pin, JP; Cambria, A; Vranesic, I; Flor, PJ; Gasparini, F; Kuhn, R			The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan [b]chromen-1 alpha-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR DOMAIN; AGONIST SELECTIVITY; GLUTAMATE-RECEPTOR-1; EXPRESSION; SUBTYPES; VARIANTS; PROTEINS; PROFILE; CPCCOET; TYPE-5	We have investigated the mechanism of inhibition and site of action of the novel human metabotropic glutamate receptor 5 (hmGluR5) antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP), which is structurally unrelated to classical metabotropic glutamate receptor (mGluR) ligands, Schild analysis indicated that MPEP acts in a non-competitive manner. MPEP also inhibited to a large extent constitutive receptor activity in cells transiently overexpressing rat mGluR5, suggesting that MPEP acts as an inverse agonist, To investigate the molecular determinants that govern selective ligand binding, a mutagenesis study was performed using chimeras and single amino acid substitutions of hmGluR1 and hmGluR5, The mutants were tested for binding of the novel mGluR5 radioligand [H-3]2-methyl-6-(3-methoxyphenyl)ethynyl pyridine (M-MPEP), a close analog of MPEP, Replacement of Ala-810 in transmembrane (TM) VII or Pro-655 and Ser-658 in TMIII with the homologous residues of hmGluR1 abolished radioligand binding, In contrast, the reciprocal hmGluR1 mutant bearing these three residues of hmGluR5 showed high affinity for [H-3]M-MPEP. Radioligand binding to these mutants was also inhibited by 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester (CPC-COEt), a structurally unrelated non-competitive mGluR1 antagonist previously shown to interact with residues Thr-815 and Ala-818 in TMVII of hmGluR1, These results indicate that MPEP and CPCCOEt bind to overlapping binding pockets in the TBI region of group I mGluRs but interact with different non conserved residues.	Novartis Pharma AG, Nervous Syst Res, CH-4057 Basel, Switzerland; Univ Catania, Dipartimento Sci Chim, I-95125 Catania, Italy; CNRS, Ctr INSERM, UPR 9023 CNRS, F-34094 Montpellier, France	Novartis; University of Catania; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Kuhn, R (corresponding author), Novartis Pharma AG, Nervous Syst Res, Klybeckstr 141, CH-4057 Basel, Switzerland.		Pin, Jean-Philippe/Y-6668-2019	Pin, Jean-Philippe/0000-0002-1423-345X; Carroll, Fiona/0000-0001-8951-1947				ALMOSLIH MI, 1973, J GEN VIROL, V73, P189; Annoura H, 1996, BIOORG MED CHEM LETT, V6, P763, DOI 10.1016/0960-894X(96)00104-7; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Brabet I, 1998, NEUROPHARMACOLOGY, V37, P1043, DOI 10.1016/S0028-3908(98)00091-4; Bruno V, 2000, NEUROPHARMACOLOGY, V39, P2223, DOI 10.1016/S0028-3908(00)00079-4; Casabona G, 1997, EUR J NEUROSCI, V9, P12, DOI 10.1111/j.1460-9568.1997.tb01348.x; Chapman AG, 2000, NEUROPHARMACOLOGY, V39, P1567, DOI 10.1016/S0028-3908(99)00242-7; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; DAGGETT LP, 1995, NEUROPHARMACOLOGY, V34, P871, DOI 10.1016/0028-3908(95)00085-K; Gasparini F, 1999, NEUROPHARMACOLOGY, V38, P1493, DOI 10.1016/S0028-3908(99)00082-9; Hermans E, 1998, NEUROPHARMACOLOGY, V37, P1645, DOI 10.1016/S0028-3908(98)00132-4; JOLY C, 1995, J NEUROSCI, V15, P3970; KNOEPFEL T, 1995, J MED CHEM, V38, P1417; Litschig S, 1999, MOL PHARMACOL, V55, P453; Mary S, 1998, J BIOL CHEM, V273, P425, DOI 10.1074/jbc.273.1.425; Moro S, 1998, J MED CHEM, V41, P1456, DOI 10.1021/jm970684u; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; Parmentier ML, 1998, MOL PHARMACOL, V53, P778, DOI 10.1124/mol.53.4.778; Prezeau L, 1996, MOL PHARMACOL, V49, P422; Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028-3908(99)00092-1; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341; Tones MA, 1995, NEUROREPORT, V7, P117, DOI 10.1097/00001756-199512290-00028; Varney MA, 1999, J PHARMACOL EXP THER, V290, P170; WALKER K, 2000, IN PRESS NEUROPHARMA; Wroblewska B, 1997, J NEUROCHEM, V69, P174	27	237	241	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33750	33758		10.1074/jbc.M006230200	http://dx.doi.org/10.1074/jbc.M006230200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10934211	hybrid			2022-12-27	WOS:000090104600079
J	Potter, MD; Nicchitta, CV				Potter, MD; Nicchitta, CV			Regulation of ribosome detachment from the mammalian endoplasmic reticulum membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; SECRETORY PROTEIN TRANSLOCATION; MICROSOMAL-MEMBRANES; PRESECRETORY PROTEINS; SEQUENCE RECOGNITION; NASCENT PROTEINS; BOUND POLYSOMES; CHAIN COMPLEXES; MESSENGER-RNA; BINDING	In current models, protein translocation in the endoplasmic reticulum (ER) occurs in the context of two cycles, the signal recognition particle (SRP) cycle and the ribosome cycle. Both SRP and ribosomes bind to the ER membrane as a consequence of the targeting process of translocation. Whereas SRP release from the ER membrane is regulated by the GTPase activities of SRP and the SRP receptor, ribosome release from the ER membrane is thought to occur in response to the termination of protein synthesis. We report that ER-bound ribosomes remain membrane-bound following the termination of protein synthesis and in the bound state can initiate the translation of secretory and cytoplasmic proteins. Two principal observations are reported. 1) Membrane-bound ribosomes engaged in the synthesis of proteins lacking a signal sequence are released from the ER membrane as ribosome-nascent polypeptide complexes. 2) Membrane-hound ribosomes translating secretory proteins can access the translocon in an SRP receptor-independent manner. We propose that ribosome release from the ER membrane occurs in the context of protein translation, with release occurring by default in the absence of productive nascent polypeptide-membrane interactions.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Nicchitta, CV (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Box 3709, Durham, NC 27710 USA.	C.Nicchitta@cellbio.duke.edu			NIDDK NIH HHS [DK57897] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADELMAN MR, 1973, J CELL BIOL, V56, P206, DOI 10.1083/jcb.56.1.206; ADESNIK M, 1981, EUR J BIOCHEM, V114, P271, DOI 10.1111/j.1432-1033.1981.tb05146.x; ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; Belin D, 1996, EMBO J, V15, P468, DOI 10.1002/j.1460-2075.1996.tb00379.x; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BORGESE D, 1973, J MOL BIOL, V74, P415, DOI 10.1016/0022-2836(73)90037-5; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Green R, 1999, NAT STRUCT BIOL, V6, P999, DOI 10.1038/14881; HORTSCH M, 1986, J CELL BIOL, V103, P241, DOI 10.1083/jcb.103.1.241; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; Johnson CH, 1999, YEAST, V15, P799, DOI 10.1002/(SICI)1097-0061(19990630)15:9&lt;799::AID-YEA419&gt;3.0.CO;2-N; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KLAPPA P, 1995, EUR J BIOCHEM, V232, P755, DOI 10.1111/j.1432-1033.1995.tb20870.x; LAURING B, 1995, P NATL ACAD SCI USA, V92, P9435, DOI 10.1073/pnas.92.21.9435; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; MECHLER B, 1975, J CELL BIOL, V67, P25, DOI 10.1083/jcb.67.1.25; MECHLER B, 1981, J CELL BIOL, V88, P42, DOI 10.1083/jcb.88.1.42; MECHLER B, 1975, J CELL BIOL, V67, P16, DOI 10.1083/jcb.67.1.16; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MEYER DI, 1980, J CELL BIOL, V87, P503, DOI 10.1083/jcb.87.2.503; MEYER DI, 1980, J CELL BIOL, V87, P498, DOI 10.1083/jcb.87.2.498; Moller I, 1998, P NATL ACAD SCI USA, V95, P13425, DOI 10.1073/pnas.95.23.13425; Murphy EC, 1997, J CELL BIOL, V136, P1213, DOI 10.1083/jcb.136.6.1213; Neuhof A, 1998, MOL BIOL CELL, V9, P103, DOI 10.1091/mbc.9.1.103; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; NICCHITTA CV, 1989, J CELL BIOL, V108, P789, DOI 10.1083/jcb.108.3.789; Polacek N, 2000, MOL CELL, V6, P159, DOI 10.1016/S1097-2765(00)00017-4; Potter MD, 2000, J BIOL CHEM, V275, P2037, DOI 10.1074/jbc.275.3.2037; Raden D, 1998, MOL BIOL CELL, V9, P117, DOI 10.1091/mbc.9.1.117; Rapiejko PJ, 1997, CELL, V89, P703, DOI 10.1016/S0092-8674(00)80253-6; RICHTER JD, 1981, CELL, V27, P183, DOI 10.1016/0092-8674(81)90372-X; Seiser RM, 2000, J BIOL CHEM, V275, P33820, DOI 10.1074/jbc.M004462200; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SIEGEL V, 1988, EMBO J, V7, P1769, DOI 10.1002/j.1460-2075.1988.tb03007.x; Stroud RM, 1999, CURR OPIN STRUC BIOL, V9, P754, DOI 10.1016/S0959-440X(99)00040-8; WALTER P, 1979, P NATL ACAD SCI USA, V76, P1795, DOI 10.1073/pnas.76.4.1795; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1981, J CELL BIOL, V91, P551, DOI 10.1083/jcb.91.2.551; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; Wilson KS, 1998, CELL, V92, P337, DOI 10.1016/S0092-8674(00)80927-7; Woolford Jr JL, 1991, MOL CELLULAR BIOL YE, P587; Zheng T, 1999, J BIOL CHEM, V274, P36623, DOI 10.1074/jbc.274.51.36623	48	53	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33828	33835		10.1074/jbc.M005294200	http://dx.doi.org/10.1074/jbc.M005294200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10924518	hybrid			2022-12-27	WOS:000090104600090
J	Reynaud, C; Fabre, S; Jalinot, P				Reynaud, C; Fabre, S; Jalinot, P			The PDZ protein TIP-1 interacts with the Rho effector rhotekin and is involved in Rho signaling to the serum response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; FILAMENT-BINDING PROTEIN; ESCHERICHIA-COLI; PLASMA-MEMBRANE; TAX ONCOPROTEIN; HUMAN HOMOLOG; DOMAIN; FAMILY; RECOGNITION; COMPLEXES	The human T-cell lymphotrophic virus, type 1 Tax protein can interact via its C terminus with various proteins including a PDZ domain. In this work, one of them, TIP-1, is characterized as a cytoplasmic 14-kDa protein mainly corresponding to one PDZ domain. A two-hybrid screen performed with TIP-1 as bait showed that it interacts with the human homologue of rhotekin that was previously identified in mice as a Rho effector. Both human and mouse rhotekins exhibit at their C termini the sequence QSPV-COOH that matches the X(S/T)XV-COOH consensus known for proteins recognizing PDZ domains. Mutation of the serine and valine residues to alanine impairs interaction of rhotekin with TIP-I. Transient expression experiments with a reporter construct including the c-Fos serum response element (SRE) showed that coexpression of TIP-I with the constitutively active RhoA.V14 mutant and human rhotekin caused a strong activation of the SRE. A negative mutant of Rho, RhoA.N19, was unable to cooperate with TIP-1 and rhotekin, The positive effect of TIP-I was also lost when the C terminus of rhotekin was mutated. These data show that the complex of active Rho with its effector rhotekin bound to TIP-1 produces in the cytoplasm a signal that triggers strong activation of the SRE.	Ecole Normale Super Lyon, CNRS, UMR 5665, Lab Biol Mol & Cellulaire, F-69364 Lyon 07, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet	Jalinot, P (corresponding author), Ecole Normale Super Lyon, CNRS, UMR 5665, Lab Biol Mol & Cellulaire, 46 Allee Italie, F-69364 Lyon 07, France.	pjalinot@ens-lyon.fr	FABRE, Stéphane/AAQ-8400-2020; Fabre, Stéphane/ABC-1483-2020	FABRE, Stéphane/0000-0001-7350-9500; Reynaud, Caroline/0000-0003-0760-0263				Chan AML, 1996, ONCOGENE, V12, P1259; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fanning AS, 1998, CURR TOP MICROBIOL, V228, P209; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harlow E., 1988, ANTIBODIES LAB MANUA, P447; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Hildebrand JD, 1999, CELL, V99, P485, DOI 10.1016/S0092-8674(00)81537-8; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Leung T, 1996, MOL CELL BIOL, V16, P5313; Maesaki R, 1999, MOL CELL, V4, P793, DOI 10.1016/S1097-2765(00)80389-5; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; Ponting CP, 1997, PROTEIN SCI, V6, P464; Poulat F, 1997, J BIOL CHEM, V272, P7167, DOI 10.1074/jbc.272.11.7167; Ranganathan R, 1997, CURR BIOL, V7, pR770, DOI 10.1016/S0960-9822(06)00401-5; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; Rumenapp U, 1999, FEBS LETT, V459, P313, DOI 10.1016/S0014-5793(99)01270-3; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; Scott K, 1998, NATURE, V395, P805, DOI 10.1038/27448; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Suzuki T, 1999, ONCOGENE, V18, P5967, DOI 10.1038/sj.onc.1203008; Thomas MK, 1999, MOL CELL BIOL, V19, P8492; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; VAN AL, 1997, GENE DEV, V11, P2295; WALLIS OC, 1990, J MOL ENDOCRINOL, V4, P61, DOI 10.1677/jme.0.0040061; Zhang WD, 1999, J NEUROSCI, V19, P96, DOI 10.1523/JNEUROSCI.19-01-00096.1999	38	62	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33962	33968		10.1074/jbc.M000465200	http://dx.doi.org/10.1074/jbc.M000465200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10940294	Green Published, hybrid			2022-12-27	WOS:000090104600108
J	Sun, CH; Cai, ML; Meadows, RP; Xu, N; Gunasekera, AH; Herrmann, J; Wu, JC; Fesik, SW				Sun, CH; Cai, ML; Meadows, RP; Xu, N; Gunasekera, AH; Herrmann, J; Wu, JC; Fesik, SW			NMR structure and mutagenesis of the third Bir domain of the inhibitor of apoptosis protein XIAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; ORIENTED MACROMOLECULES; BACULOVIRUS INHIBITOR; DISTANCE RESTRAINTS; CELL-DEATH; GENE; IAP; CASPASES; DYNAMICS; HOMOLOGY	The inhibitor of apoptosis proteins (IAPs) regulate the caspase family of cysteine proteases, which play an important role in the execution of programmed cell death. Human X-linked inhibitor of apoptosis protein (XIAP) is a potent inhibitor of caspases-3, -7, and -9, Here we show that the Bir3 domain is the minimal region of XIAP that is needed for potent caspase-9 inhibition. The three-dimensional structure of the Bir3 domain of XIAP, determined by NMR spectroscopy, resembles a classical zinc finger and consists of five cu-helices, a three-stranded beta -sheet, and a zinc atom chelated to three cysteines and one histidine, The structure of the Bir3 domain is similar to that of the Bir2 domain of XIAP but differs from the previously determined structure of the Bir3 domain of MIHB. Based on site-directed mutagenesis, tee have identified the regions of the Bir3 domain of XIAP that are important for inhibiting caspase-9. Despite the structural similarities of the Bir2 and Bir3 domain of XIAP, a different set of residues were found to be critical for inhibiting the individual caspases, These results suggest that XIAP inhibits caspase-3 and caspase-9 in a different manner.	Abbott Labs, Div Pharmaceut Discovery, Abbott Pk, IL 60064 USA; Idun Pharmaceut Inc, Dept Biochem, La Jolla, CA 92037 USA	Abbott Laboratories	Fesik, SW (corresponding author), Abbott Labs, Div Pharmaceut Discovery, 100 Abbott Pk Rd,D-47G,AP10-LL, Abbott Pk, IL 60064 USA.							Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Clore GM, 1998, J MAGN RESON, V133, P216, DOI 10.1006/jmre.1998.1419; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Hawkins CJ, 1996, P NATL ACAD SCI USA, V93, P13786, DOI 10.1073/pnas.93.24.13786; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hinds MG, 1999, NAT STRUCT BIOL, V6, P648; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Stein EG, 1997, J MAGN RESON, V124, P154, DOI 10.1006/jmre.1996.1027; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tjandra N, 1997, NAT STRUCT BIOL, V4, P732, DOI 10.1038/nsb0997-732; Uren AG, 1998, TRENDS BIOCHEM SCI, V23, P159, DOI 10.1016/S0968-0004(98)01198-0; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974	27	215	247	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33777	33781		10.1074/jbc.M006226200	http://dx.doi.org/10.1074/jbc.M006226200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10934209	hybrid			2022-12-27	WOS:000090104600083
J	Dormer, UH; Westwater, J; McLaren, NF; Kent, NA; Mellor, J; Jamieson, DJ				Dormer, UH; Westwater, J; McLaren, NF; Kent, NA; Mellor, J; Jamieson, DJ			Cadmium-inducible expression of the yeast GSH1 gene requires a functional sulfur-amino acid regulatory network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YAP-1 TRANSCRIPTIONAL REGULATION; OXIDATIVE STRESS RESPONSES; SACCHAROMYCES-CEREVISIAE; HYDROGEN-PEROXIDE; GLUTATHIONE-DEFICIENT; TARGET GENE; DNA-BINDING; ACTIVATION; METABOLISM; CENTROMERE	Glutathione (gamma -L-glutamyl-L-cysteinylglycine) is an important antioxidant molecule, helping to buffer the cell against free radicals and toxic electrophiles. Expression of the yeast GSH1 gene, encoding the first enzyme involved in glutathione biosynthesis, gamma -glutamylcysteine synthetase, is regulated by oxidants and the heavy metal cadmium at the level of transcription. We present evidence that the transcription factors involved in controlling the network of sulfur amino acid metabolism genes are also responsible for regulating GSH1 expression in response to cadmium. In particular the transcription factors Met-4, Met-31, and Met-32 are essential for cadmium-mediated regulation of gene expression, whereas the DNA-binding protein Cbf1 appears to play a negative role in controlling GSH1 expression.	Heriot Watt Univ, Dept Biol Sci, Edinburgh EH14 4AS, Midlothian, Scotland; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	Heriot Watt University; University of Oxford	Jamieson, DJ (corresponding author), Heriot Watt Univ, Dept Biol Sci, Edinburgh EH14 4AS, Midlothian, Scotland.	d.j.jamieson@hw.ac.uk	Kent, Nicholas/A-4503-2010	Kent, Nicholas/0000-0002-4114-1307				Blaiseau PL, 1998, EMBO J, V17, P6327, DOI 10.1093/emboj/17.21.6327; Blaiseau PL, 1997, MOL CELL BIOL, V17, P3640, DOI 10.1128/MCB.17.7.3640; Brennan RJ, 1996, MUTAT RES-FUND MOL M, V356, P171, DOI 10.1016/0027-5107(96)00051-6; COLLINSON LP, 1992, J GEN MICROBIOL, V138, P329, DOI 10.1099/00221287-138-2-329; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; ELSKENS MT, 1991, J GEN MICROBIOL, V137, P637, DOI 10.1099/00221287-137-3-637; Gietz R.D., 1994, MOL GENETICS YEAST P, P121; GLAESER H, 1991, CURR GENET, V19, P207, DOI 10.1007/BF00336488; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; Grant CM, 1996, CURR GENET, V29, P511, DOI 10.1007/BF02426954; Grant CM, 1996, MOL MICROBIOL, V21, P171, DOI 10.1046/j.1365-2958.1996.6351340.x; HIETER P, 1985, CELL, V42, P913, DOI 10.1016/0092-8674(85)90287-9; IZAWA S, 1995, FEBS LETT, V368, P73, DOI 10.1016/0014-5793(95)00603-7; Jamieson D. J., 1997, OXIDATIVE STRESS MOL, P91; Jamieson DJ, 1998, YEAST, V14, P1511, DOI 10.1002/(SICI)1097-0061(199812)14:16<1511::AID-YEA356>3.3.CO;2-J; JAMIESON DJ, 1995, REDOX REP, V1, P89, DOI 10.1080/13510002.1995.11746964; JAMIESON DJ, 1994, MICROBIOL-UK, V140, P3277, DOI 10.1099/13500872-140-12-3277; JAMIESON DJ, 1992, J BACTERIOL, V174, P6678, DOI 10.1128/JB.174.20.6678-6681.1992; KENT NA, 1994, MOL CELL BIOL, V14, P5229, DOI 10.1128/MCB.14.8.5229; KISTLER M, 1986, MUTAT RES, V173, P117, DOI 10.1016/0165-7992(86)90087-4; Kuras L, 1997, EMBO J, V16, P2441, DOI 10.1093/emboj/16.9.2441; Kuras L, 1996, EMBO J, V15, P2519, DOI 10.1002/j.1460-2075.1996.tb00609.x; LIU XF, 1994, MOL CELL BIOL, V14, P7037, DOI 10.1128/MCB.14.11.7037; Maris AF, 2000, CURR GENET, V37, P175, DOI 10.1007/s002940050516; Mehdi K, 1997, MICROBIOL-UK, V143, P1885, DOI 10.1099/00221287-143-6-1885; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MELLOR J, 1991, NUCLEIC ACIDS RES, V19, P2961, DOI 10.1093/nar/19.11.2961; Miyake T, 1999, YEAST, V15, P1449, DOI 10.1002/(SICI)1097-0061(199910)15:14<1449::AID-YEA469>3.0.CO;2-S; Rose M. D., 1990, METHODS YEAST GENETI, P155; SANTORO N, 1997, YEAST STRESS RESPONS, P171; Stephen DWS, 1997, MOL MICROBIOL, V23, P203, DOI 10.1046/j.1365-2958.1997.2081572.x; STEPHEN DWS, 1995, MOL MICROBIOL, V16, P415, DOI 10.1111/j.1365-2958.1995.tb02407.x; Stephen DWS, 1996, FEMS MICROBIOL LETT, V141, P207, DOI 10.1111/j.1574-6968.1996.tb08386.x; THOMAS D, 1992, MOL CELL BIOL, V12, P1719, DOI 10.1128/MCB.12.4.1719; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WEMMIE A, 1994, J BIOL CHEM, V269, P14690; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832	38	73	73	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32611	32616		10.1074/jbc.M004167200	http://dx.doi.org/10.1074/jbc.M004167200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10921921	hybrid			2022-12-27	WOS:000090003800034
J	Keyhani, N; Rodgers, ME; Demeler, B; Hansen, JC; Roseman, S				Keyhani, N; Rodgers, ME; Demeler, B; Hansen, JC; Roseman, S			Analytical sedimentation of the IIA(Chb) and IIBChb proteins of the Escherichia coli N,N '-Diacetylchitobiose phosphotransferase system - Demonstration of a model phosphotransfer transition state complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCUS-AUREUS; PHOSPHOENOL-PYRUVATE; BACTERIA; REVEALS	The phosphoenolpyruvate:glycose transferase system (PTS) is a prototypic signaling system responsible for the vectorial uptake and phosphorylation of carbohydrate substrates, The accompanying papers describe the proteins and product of the Escherichia coli N,N-diacetylchitobiose ((GlcNAc)(2)) PTS-mediated permease. Unlike most PTS transporters, the Chb system is composed of two soluble proteins, IIA(Chb) and IIBChb, and one transmembrane receptor (IICChb), The oligomeric states of PTS permease proteins and phosphoproteins have been difficult to determine. Using analytical ultracentrifugation, both dephospho and phosphorylated IIA(Chb) are shown to exist as stable dimers, whereas IIBChb, phos-pho-IIBChb and the mutant Cys10SerIIB(Chb) are monomers, The mutant protein Cys10SerIIB(Chb) is unable to accept phosphate from phospho-IIA(Chb) but forms a stable higher order complex with phospho-IIA(Chb) (but not with dephospho-IIA(Chb)). The stoichiometry of proteins in the purified complex was determined to be 1:1, indicating that two molecules of Cys10SerIIB(Chb) are associated with one phospho-IIA(Chb) dimer in the complex. The complex appears to be a transition state analogue in the phosphotransfer reaction between the proteins. A model is presented that describes the concerted assembly and disassembly of IIA(Chb)-IIBChb complexes contingent on phosphorylation-dependent conformational changes, especially of IIA(Chb).	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, McCollum Pratt Inst, Baltimore, MD 21218 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA	Johns Hopkins University; Johns Hopkins University; University of Texas System; University of Texas Health San Antonio	Roseman, S (corresponding author), Johns Hopkins Univ, Dept Biol, Mudd Hall,Rm 214,3400 N Charles St, Baltimore, MD 21218 USA.		Keyhani, Nemat O/I-8150-2013	Demeler, Borries/0000-0002-2414-9518	NIGMS NIH HHS [GM38759] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038759, R01GM038759] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AB E, 1994, PROTEIN SCI, V3, P282; Chauvin F, 1996, RES MICROBIOL, V147, P471, DOI 10.1016/0923-2508(96)84001-0; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; Demeler B, 1998, BIOPHYS J, V74, P444, DOI 10.1016/S0006-3495(98)77802-6; Demeler B, 1997, BIOPHYS J, V72, P397, DOI 10.1016/S0006-3495(97)78680-6; DEUTSCHER J, 1982, BIOCHEMISTRY-US, V21, P4867, DOI 10.1021/bi00263a006; HAYS JB, 1973, J BIOL CHEM, V248, P941; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Keyhani NO, 2000, J BIOL CHEM, V275, P33102, DOI 10.1074/jbc.M001045200; Keyhani NO, 2000, J BIOL CHEM, V275, P33091, DOI 10.1074/jbc.M001044200; Keyhani NO, 2000, J BIOL CHEM, V275, P33084, DOI 10.1074/jbc.M001043200; Keyhani NO, 2000, J BIOL CHEM, V275, P33068, DOI 10.1074/jbc.M001041200; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; Park JK, 2000, J BIOL CHEM, V275, P33077, DOI 10.1074/jbc.M001042200; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; RALSTON GB, 1993, INTRO ANAL ULTRACENT, P5; Sliz P, 1997, STRUCTURE, V5, P775, DOI 10.1016/S0969-2126(97)00232-3; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; vanMontfort RLM, 1997, STRUCTURE, V5, P217, DOI 10.1016/S0969-2126(97)00180-9	20	12	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33110	33115		10.1074/jbc.M001717200	http://dx.doi.org/10.1074/jbc.M001717200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10913122	hybrid			2022-12-27	WOS:000090003800099
J	Klarlund, JK; Tsiaras, W; Holik, JJ; Chawla, A; Czech, MP				Klarlund, JK; Tsiaras, W; Holik, JJ; Chawla, A; Czech, MP			Distinct polyphosphoinositide binding selectivities for pleckstrin homology domains of GRP1-like proteins based on diglycine versus triglycine motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; ADP-RIBOSYLATION FACTOR-6; PH DOMAIN; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; PHOSPHOINOSITIDE BINDING; TYROSINE KINASE; PLASMA-MEMBRANE; CYTOHESIN-1; TRANSLOCATION; SPECIFICITY	GRP1 and the related proteins ARNO and cytohesin-1 are ARF exchange factors that contain a pleckstrin homology (PH) domain thought to target these proteins to cell membranes through binding polyphosphoinositides, Here we show the PH domains of all three proteins exhibit relatively high affinity for dioctanoyl phosphatidylinositol 3,4,5-triphosphate (PtdIns(3,4,5)P-3), with K-D values of 0.05, 1.6 and 1.0 muM for GRP1, ARNO, and cytohesin-1, respectively. However, the GRP1 PH domain was unique among these proteins in its striking selectivity for PtdIns(3,4,5)P-3 versus phosphatidylinositol 4,5-diphosphate (PtdIns(4,5)P-2), for which it exhibits about 650-fold lower apparent affinity. Addition of a glycine to the Gly(274)-Gly(275) motif in GRP1 greatly increased its binding affinity for PtdIns(4,5)P-2 with little effect on its binding to PtdIns(3,4,5)P-3, while deletion of a single glycine in the corresponding triglycine motif of the ARNO PH domain markedly reduced its binding affinity for PtdIns(4,5)P-2 but not for PtdIns(3,4,5)P-3. In intact cells, the hemagglutinin epitope-tagged PH domain of GRP1 was recruited to ruffles in the cell surface in response to insulin, as were full-length GRP1 and cytohesin-1, but the PH domain of cytohesin-1 was not. These data indicate that the unique diglycine motif in the GRP1 PH domain, as opposed to the triglycine in ARNO and cytohesin-1, directs its remarkable PtdIns(3,4,5)P-3 binding selectivity.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Czech, MP (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.	michael.czech@umassmed.edu		Tsiaras, William/0000-0002-4080-4762	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030648] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30648] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Blomberg N, 1999, TRENDS BIOCHEM SCI, V24, P441, DOI 10.1016/S0968-0004(99)01472-3; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; Fushman D, 1998, J BIOL CHEM, V273, P2835, DOI 10.1074/jbc.273.5.2835; Gray A, 1999, BIOCHEM J, V344, P929, DOI 10.1042/0264-6021:3440929; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Hyvonen M, 1997, EMBO J, V16, P3396, DOI 10.1093/emboj/16.12.3396; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Kim HS, 1998, FEBS LETT, V433, P312, DOI 10.1016/S0014-5793(98)00937-5; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; Langille SE, 1999, J BIOL CHEM, V274, P27099, DOI 10.1074/jbc.274.38.27099; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; O'Rourke AM, 1998, IMMUNOGENETICS, V48, P354, DOI 10.1007/s002510050444; Oatey PB, 1999, BIOCHEM J, V344, P511, DOI 10.1042/0264-6021:3440511; Ogasawara M, 2000, J BIOL CHEM, V275, P3221, DOI 10.1074/jbc.275.5.3221; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Venkateswarlu K, 1999, J CELL SCI, V112, P1957; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yao LB, 1999, J BIOL CHEM, V274, P19752, DOI 10.1074/jbc.274.28.19752; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; Zheng J, 1997, J BIOL CHEM, V272, P30340, DOI 10.1074/jbc.272.48.30340	34	112	115	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32816	32821		10.1074/jbc.M002435200	http://dx.doi.org/10.1074/jbc.M002435200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10913124	hybrid			2022-12-27	WOS:000090003800061
J	Windfuhr, M; Manegold, A; Muhlenhoff, M; Eckhardt, M; Gerardy-Schahn, R				Windfuhr, M; Manegold, A; Muhlenhoff, M; Eckhardt, M; Gerardy-Schahn, R			Molecular defects that cause loss of polysialic acid in the complementation group 2A10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; GOLGI VESICLE MEMBRANES; CENTRAL-NERVOUS-SYSTEM; N-CAM; MUTANT DEFICIENT; NCAM-H; EXPRESSION; POLYSIALYLTRANSFERASES; SIALYLTRANSFERASES; IDENTIFICATION	Polysialic acid (PSA) is a dynamically regulated posttranslational modification of the neural cell adhesion molecule (NCAM), which modulates NCAM binding functions. PSA biosynthesis is catalyzed by two polysialyltransferases, ST8SiaII and ST8SiaIV. The catalytic mechanisms of these enzymes are unknown. In. Chinese hamster ovary cells, ST8SiaIV is responsible for PSA expression. In the complementation group 2A10, the ST8SiaIV gene is disrupted. Investigating the molecular defects in this complementation group, seven clones with missense mutations in ST8SiaIV were found. Mutations cause replacement of amino acids that are highly conserved in alpha2,8-sialyltransferases. To verify the physiological relevance of identified mutations, identical amino acid substitutions were introduced into epitope-tagged variants of hamster ST8SiaIV and murine ST8SiaII and recombinant proteins were tested in vivo and in vitro. None of these constructs reconstituted PSA synthesis in 2A10 cells, although the proteins were expressed and with the exception of the cysteine variants ST8SiaIV-C356F and ST8SiaII-C371F correctly targeted to the Golgi apparatus. Interestingly, two mutations (ST8SiaIV-R277G and -M333V and the corresponding mutants ST8SiaII-R292G and -M348V) could be partially rescued if tested in vitro. Although these mutants were negative for autopolysialylation, partial reconstitution of both auto- and NCAM polysialylation was achieved in the presence of NCAM. The data presented in this study suggest a functional link between auto- and NCAM polysialylation.	Hannover Med Sch, Inst Med Mikrobiol, D-30625 Hannover, Germany; Univ Bonn, Inst Physiol Chem, D-53115 Bonn, Germany	Hannover Medical School; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Bonn	Gerardy-Schahn, R (corresponding author), Hannover Med Sch, Inst Med Mikrobiol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	gerardy@rgs.mikrobio.mh-hannover.de						Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; Close BE, 2000, J BIOL CHEM, V275, P4484, DOI 10.1074/jbc.275.6.4484; Close BE, 1998, J BIOL CHEM, V273, P34586, DOI 10.1074/jbc.273.51.34586; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; Datta AK, 1998, J BIOL CHEM, V273, P9608, DOI 10.1074/jbc.273.16.9608; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; DOHERTY P, 1990, NEURON, V5, P209, DOI 10.1016/0896-6273(90)90310-C; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; FigarellaBranger D, 1996, J CLIN ONCOL, V14, P2066, DOI 10.1200/JCO.1996.14.7.2066; FREI T, 1992, J CELL BIOL, V118, P177, DOI 10.1083/jcb.118.1.177; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; GERARDYSCHAHN R, 1995, MOL MICROBIOL, V16, P441, DOI 10.1111/j.1365-2958.1995.tb02409.x; GERARDYSCHAHN R, 1994, INT J CANCER, P27; Geremia RA, 1997, GLYCOBIOLOGY, V7, pR5; Gluer S, 1998, BRIT J CANCER, V78, P106, DOI 10.1038/bjc.1998.450; Goridis C, 1992, Semin Cell Biol, V3, P189; Hildebrandt H, 1998, CANCER RES, V58, P779; Hildebrandt H, 1998, J NEUROCHEM, V71, P2339; Hu HY, 1996, NEURON, V16, P735, DOI 10.1016/S0896-6273(00)80094-X; KIBBELAAR RE, 1989, J PATHOL, V159, P23, DOI 10.1002/path.1711590108; Kiselyov VV, 1997, J BIOL CHEM, V272, P10125; Kiss JZ, 1997, CURR OPIN NEUROBIOL, V7, P640, DOI 10.1016/S0959-4388(97)80083-9; KISS JZ, 1994, EMBO J, V13, P5284, DOI 10.1002/j.1460-2075.1994.tb06862.x; Kojima N, 1997, J BIOCHEM-TOKYO, V122, P1265; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lantuejoul S, 1998, AM J SURG PATHOL, V22, P1267, DOI 10.1097/00000478-199810000-00012; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MOREMEN KW, 1986, J BIOL CHEM, V261, P945; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; Muhlenhoff M, 1996, EMBO J, V15, P6943, DOI 10.1002/j.1460-2075.1996.tb01086.x; Muhlenhoff M, 1998, CURR OPIN STRUC BIOL, V8, P558, DOI 10.1016/S0959-440X(98)80144-9; Muller D, 1996, NEURON, V17, P413, DOI 10.1016/S0896-6273(00)80174-9; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; Redies C, 1996, DEV BIOL, V180, P413, DOI 10.1006/dbio.1996.0315; Ronn LCB, 1998, EXP GERONTOL, V33, P853, DOI 10.1016/S0531-5565(98)00040-0; ROTH J, 1988, AM J PATHOL, V133, P227; Rutishauser U, 1996, CURR OPIN CELL BIOL, V8, P679, DOI 10.1016/S0955-0674(96)80109-8; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKI T, 1993, NEUROSCI RES, V17, P265, DOI 10.1016/0168-0102(93)90111-3; SEKI T, 1993, J NEUROSCI, V13, P2351, DOI 10.1523/JNEUROSCI.13-06-02351.1993; Sevigny MB, 1998, GLYCOBIOLOGY, V8, P857, DOI 10.1093/glycob/8.9.857; TEASDALE RD, 1994, GLYCOBIOLOGY, V4, P917, DOI 10.1093/glycob/4.6.917; Theodosis DT, 1999, J NEUROSCI, V19, P10228; Tsuji S, 1996, J BIOCHEM-TOKYO, V120, P1; Tsuji S, 1996, GLYCOBIOLOGY, V6, pR5; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Walsh FS, 1997, ANNU REV CELL DEV BI, V13, P425, DOI 10.1146/annurev.cellbio.13.1.425; Walsh FS, 1996, CURR OPIN CELL BIOL, V8, P707, DOI 10.1016/S0955-0674(96)80113-X; WEISZ OA, 1993, J CELL BIOL, V122, P1185, DOI 10.1083/jcb.122.6.1185; YOSHIDA Y, 1995, J BIOL CHEM, V270, P14628, DOI 10.1074/jbc.270.24.14628	54	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32861	32870		10.1074/jbc.M003507200	http://dx.doi.org/10.1074/jbc.M003507200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10921918	hybrid			2022-12-27	WOS:000090003800067
J	Moaddel, M; Falls, LA; Farrell, DH				Moaddel, M; Falls, LA; Farrell, DH			The role of gamma A/gamma ' fibrinogen in plasma factor XIII activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CHAIN; CROSS-LINKING; SUBUNIT STRUCTURES; HEPARIN-ANTITHROMBIN; THROMBIN; TRANSGLUTAMINASE; RESISTANCE; PLATELETS; SULFATION; FIBRINOLYSIS	Factor XIII zymogen activation is a complex series of events that involve fibrinogen acting in several different roles. This report focuses on the role of fibrinogen as a cofactor in factor MII activation by thrombin. We demonstrate that fibrinogen has two distinct activities that lead to an increased rate of factor XIII activation. First, the thrombin proteolytic activity is increased by fibrin. The cleavage rates of both a small chromogenic substrate and the factor XIII activation peptide are increased in the presence of either the major fibrin isoform, gamma A/gamma A fibrin, or a minor variant form, gamma A/gamma' fibrin. This enhancement of thrombin activity by fibrin is independent of fibrin polymerization and requires only cleavage of the fibrinopeptides. Subsequently, gamma A/gamma' fibrinogen accelerates plasma factor XIII activation by a non-proteolytic mechanism. This increased rate of activation results in a slightly more rapid cross-linking of fibrin gamma A and gamma' chains and a significantly more rapid cross-linking of fibrin alpha chain multimers. Together, these results show that although both forms of fibrin increase the rate of activation peptide cleavage by thrombin, gamma A/gamma' fibrinogen also increases the rate of factor XIII activation in a non-proteolytic manner. A revised model of factor XIII activation is presented below.	Oregon Hlth Sci Univ, Sch Dent, Dept Oral Mol Biol, Portland, OR 97201 USA; Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA	Oregon Health & Science University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Farrell, DH (corresponding author), Oregon Hlth Sci Univ, Sch Dent, Dept Oral Mol Biol, Portland, OR 97201 USA.				NHLBI NIH HHS [R29HL53997, K02HL04215] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL053997, K02HL004215] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOHN H, 1972, ANN NY ACAD SCI, V202, P256, DOI 10.1111/j.1749-6632.1972.tb16339.x; CARRELL NA, 1989, J BIOL CHEM, V264, P551; CHUNG DW, 1984, BIOCHEMISTRY-US, V23, P4232, DOI 10.1021/bi00313a033; CHUNG SI, 1972, ANN NY ACAD SCI, V202, P240, DOI 10.1111/j.1749-6632.1972.tb16338.x; CHUNG SI, 1974, J BIOL CHEM, V249, P940; CREDO RB, 1978, P NATL ACAD SCI USA, V75, P4234, DOI 10.1073/pnas.75.9.4234; Falls LA, 1997, J BIOL CHEM, V272, P14251, DOI 10.1074/jbc.272.22.14251; FARRELL DH, 1991, BIOCHEMISTRY-US, V30, P9414, DOI 10.1021/bi00103a004; FARRELL DH, 1994, J BIOL CHEM, V269, P226; FINLAYSON JS, 1963, BIOCHEMISTRY-US, V2, P42, DOI 10.1021/bi00901a010; FORNACE AJ, 1984, J BIOL CHEM, V259, P2826; FRANCIS CW, 1980, J BIOL CHEM, V255, P5599; HALL CE, 1959, J BIOPHYS BIOCHEM CY, V5, P11, DOI 10.1083/jcb.5.1.11; HIROSE S, 1988, J BIOL CHEM, V263, P7426; HOGG PJ, 1989, P NATL ACAD SCI USA, V86, P3619, DOI 10.1073/pnas.86.10.3619; HORNYAK TJ, 1992, BIOCHEMISTRY-US, V31, P423, DOI 10.1021/bi00117a017; HORTIN GL, 1989, BIOCHEM INT, V19, P1355; IKEMATSU S, 1981, J LAB CLIN MED, V97, P662; JANUS TJ, 1983, BIOCHEMISTRY-US, V22, P6269, DOI 10.1021/bi00295a035; KUNICKI TJ, 1985, BLOOD, V66, P808; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKI K, 1948, SCIENCE, V108, P280, DOI 10.1126/science.108.2802.280; Lewis KB, 1997, BIOCHEMISTRY-US, V36, P995, DOI 10.1021/bi961636z; LEWIS SD, 1985, BIOCHEMISTRY-US, V24, P6772, DOI 10.1021/bi00345a007; LOEWY AG, 1961, J BIOL CHEM, V236, P2634; LORAND L, 1993, METHOD ENZYMOL, V222, P22; Lorand L, 1998, P NATL ACAD SCI USA, V95, P537, DOI 10.1073/pnas.95.2.537; LORAND L, 1962, NATURE, V195, P911, DOI 10.1038/195911b0; Meh DA, 1996, J BIOL CHEM, V271, P23121, DOI 10.1074/jbc.271.38.23121; RADEK JT, 1993, BIOCHEMISTRY-US, V32, P3527, DOI 10.1021/bi00065a002; REED GL, 1992, THROMB HAEMOSTASIS, V68, P315; SCHWARTZ ML, 1971, J BIOL CHEM, V246, P5851; SCHWARTZ ML, 1971, J CLIN INVEST, V50, P1506, DOI 10.1172/JCI106636; SCHWARTZ ML, 1973, J BIOL CHEM, V248, P1395; SHAINOFF JR, 1962, J EXP MED, V116, P687, DOI 10.1084/jem.116.5.687; SIEBENLIST KR, 1994, J BIOL CHEM, V269, P28414; Siebenlist KR, 1996, BIOCHEMISTRY-US, V35, P10448, DOI 10.1021/bi9606206; SLAUGHTER TF, 1992, ANAL BIOCHEM, V205, P166, DOI 10.1016/0003-2697(92)90594-W; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; WOLFENSTEINTODEL C, 1980, P NATL ACAD SCI-BIOL, V77, P5069, DOI 10.1073/pnas.77.9.5069; YEE VC, 1995, THROMB RES, V78, P389, DOI 10.1016/0049-3848(95)00072-Y	41	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32135	32140		10.1074/jbc.M000496200	http://dx.doi.org/10.1074/jbc.M000496200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10913112	hybrid			2022-12-27	WOS:000089858900080
J	Taylor, WP; Sheflyan, GY; Woodard, RW				Taylor, WP; Sheflyan, GY; Woodard, RW			A single point mutation in 3-deoxy-D-manno-octulosonate-8-phosphate synthase is responsible for temperature sensitivity in a mutant strain of Salmonella typhimurium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID 8-PHOSPHATE SYNTHASE; PUTATIVE REACTION INTERMEDIATE; ESCHERICHIA-COLI; LIPID-A; 3-DEOXY-D-MANNO-2-OCTULOSONATE-8-PHOSPHATE SYNTHASE; BIOCHEMICAL-CHARACTERIZATION; CATALYTIC MECHANISM; KDO8P SYNTHASE; RNA-POLYMERASE; LETHAL MUTANT	Salmonella typhimurium mutants conditionally deficient in 3-deoxy-D-manno-octulosonate-8-phosphate (KDO8P) synthase activity play a central role in our understanding of lipopolysaccharide function in enteric bacteria. The detailed characterization of KDO8P synthase from such a mutant, however, has not been previously reported. To address this issue KDO8P synthase from S. typhimurium AG701 and from a related temperature-sensitive strain (S. typhimurium AG701i50) have been overexpressed in Escherichia coli and purified to homogeneity. The enzyme from the temperature-sensitive strain has a single proline to serine substitution at position 145, leading to an increase in K-m for both substrates, D-arabinose B-phosphate and phosphoenolpyruvate, Analytical gel filtration and native polyacrylamide gel electrophoresis indicate that this enzyme also has an altered oligomeric state. These observations are rationalized through an examination of the structure of E. coli KDO8P synthase, which has 93% sequence identity to the enzyme from S. typhimurium.	Univ Michigan, Coll Pharm, Interdept Program Med Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Woodard, RW (corresponding author), Univ Michigan, Coll Pharm, Interdept Program Med Chem, 428 Church St, Ann Arbor, MI 48109 USA.			Woodard, Ronald/0000-0002-7472-3653	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053069] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53069] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAASOV T, 1993, EUR J BIOCHEM, V217, P991, DOI 10.1111/j.1432-1033.1993.tb18330.x; Brabetz W, 1997, EUR J BIOCHEM, V244, P66, DOI 10.1111/j.1432-1033.1997.00066.x; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; DOONG RL, 1991, PLANT CELL ENVIRON, V14, P113, DOI 10.1111/j.1365-3040.1991.tb01377.x; DOTSON GD, 1995, J BIOL CHEM, V270, P13698, DOI 10.1074/jbc.270.23.13698; DOTSON GD, 1993, BIOCHEMISTRY-US, V32, P12392, DOI 10.1021/bi00097a017; DSouza FW, 1997, BIOORG MED CHEM LETT, V7, P2457, DOI 10.1016/S0960-894X(97)10019-1; Duewel HS, 1999, BIOCHEM BIOPH RES CO, V263, P346, DOI 10.1006/bbrc.1999.1361; DUGGLEBY RG, 1995, METHOD ENZYMOL, V249, P61; GHALAMBOR MA, 1966, J BIOL CHEM, V241, P3216; HANSENHAGGE T, 1985, EUR J BIOCHEM, V148, P21, DOI 10.1111/j.1432-1033.1985.tb08801.x; HEDSTROM L, 1988, BIOCHEM BIOPH RES CO, V157, P816, DOI 10.1016/S0006-291X(88)80322-X; KOHEN A, 1993, BIOORG MED CHEM LETT, V3, P1577, DOI 10.1016/S0960-894X(00)80021-9; LEVIN DH, 1959, J BIOL CHEM, V234, P2532; Radaev S, 2000, J BIOL CHEM, V275, P9476, DOI 10.1074/jbc.275.13.9476; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RICK PD, 1982, J BACTERIOL, V150, P447, DOI 10.1128/JB.150.2.447-455.1982; RICK PD, 1977, J BIOL CHEM, V252, P4895; RICK PD, 1972, P NATL ACAD SCI USA, V69, P3756, DOI 10.1073/pnas.69.12.3756; RIETSCHEL ET, 1987, SURFACE STRUCTURES M, P1; Sheflyan GY, 1999, BIOCHEMISTRY-US, V38, P14320, DOI 10.1021/bi9829884; Sheflyan GY, 1998, J AM CHEM SOC, V120, P11027, DOI 10.1021/ja9816281; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VOLK WA, 1960, BIOCHIM BIOPHYS ACTA, V37, P365, DOI 10.1016/0006-3002(60)90253-5; Walsh AG, 1999, FEMS MICROBIOL LETT, V173, P27, DOI 10.1111/j.1574-6968.1999.tb13480.x; WOISETSCHLAGER M, 1986, J BACTERIOL, V168, P437, DOI 10.1128/jb.168.1.437-439.1986	29	9	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32141	32146		10.1074/jbc.M001900200	http://dx.doi.org/10.1074/jbc.M001900200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10913123	hybrid			2022-12-27	WOS:000089858900081
J	Dey, R; Barrientos, A; Moraes, CT				Dey, R; Barrientos, A; Moraes, CT			Functional constraints of nuclear-mitochondrial DNA interactions in xenomitochondrial rodent cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS; RAPID EVOLUTION; SKELETAL-MUSCLE; MAMMALIAN-CELLS; SOMATIC-CELLS; HYBRID-CELLS; SEQUENCE; MUTATION; VERTEBRATES; EXPRESSION	The co-evolution of nuclear and mitochondrial genomes in vertebrates led to more than 100 specific interactions that are crucial for an optimized ATP generation. These interactions have been examined by introducing rat mtDNA into mouse cells devoid of mito chondrial DNA (mtDNA). When mtDNA-less cells derived from the common mouse (Mus musculus domesticus) were fused to cytoplasts prepared from Mus musculus, Mus spretus, or rat (Rattus norvegicus), a comparable number of respiring clones could be obtained. Mouse xenomitochondrial cybrids harboring rat mtDNA had a slower growth rate in medium containing galactose as the carbon source, suggesting a defect in oxidative phosphorylation. These clones respired approximately 50% less than the parental mouse cells or xenomitochondrial cybrids harboring Mus spretus mtDNA. The activities of respiratory complexes I and IV were approximately 50% lower, but mitochondrial protein synthesis was unaffected. The defects in complexes I and IV were associated with decreased steady-state levels of respective subunits suggesting problems in assembly. We also showed that the presence of 10% mouse mtDNA co-existing with rat mtDNA was sufficient to restore respiration to normal levels, Our results suggest that evolutionary distance alone is not a precise predictor of nuclear-mitochondrial interactions as previously suggested for primates.	Univ Miami, Sch Med, Dept Neurol, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA	University of Miami; University of Miami	Moraes, CT (corresponding author), Univ Miami, Sch Med, Dept Neurol, 1501 NW 9th Ave, Miami, FL 33136 USA.	cmoraes@med.miami.edu	Moraes, Carlos/AAT-3818-2021		NIGMS NIH HHS [GM55766] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI J, 1993, J MOL EVOL, V36, P270, DOI 10.1007/BF00160483; Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; ATTARDI B, 1972, P NATL ACAD SCI USA, V69, P129, DOI 10.1073/pnas.69.1.129; Barrientos A, 1998, J BIOL CHEM, V273, P14210, DOI 10.1074/jbc.273.23.14210; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; BOULET L, 1992, AM J HUM GENET, V51, P1187; BROWN WM, 1980, P NATL ACAD SCI-BIOL, V77, P3605, DOI 10.1073/pnas.77.6.3605; BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967; Burton RS, 1999, AM ZOOL, V39, P451; CATZEFLIS FM, 1992, TRENDS ECOL EVOL, V7, P122, DOI 10.1016/0169-5347(92)90146-3; CHALINE J, 1994, TRANSPLANT INT, V7, P216; Chomyn A, 1996, Methods Enzymol, V264, P197, DOI 10.1016/S0076-6879(96)64020-8; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; CLARK MA, 1982, NATURE, V295, P605, DOI 10.1038/295605a0; CLAYTON DA, 1971, NATURE, V234, P560, DOI 10.1038/234560a0; DAWID IB, 1974, GENETICS, V78, P459; DEFRANCESCO L, 1980, P NATL ACAD SCI-BIOL, V77, P4079, DOI 10.1073/pnas.77.7.4079; Dey R, 2000, J BIOL CHEM, V275, P7087, DOI 10.1074/jbc.275.10.7087; DiMauro S, 1999, J CHILD NEUROL, V14, pS23, DOI 10.1177/0883073899014001051; DITTA G, 1976, SOMAT CELL GENET, V2, P331, DOI 10.1007/BF01538838; Flynn L. J., 1985, EVOLUTIONARY RELATIO, P589; GADALETA G, 1989, J MOL EVOL, V28, P497, DOI 10.1007/BF02602930; GILES RE, 1980, SOMAT CELL GENET, V6, P543, DOI 10.1007/BF01539155; GRAVES JAM, 1984, CAN J GENET CYTOL, V26, P557; HAYASHI JI, 1982, EXP CELL RES, V138, P261, DOI 10.1016/0014-4827(82)90175-6; HAYASHI JI, 1986, CANCER RES, V46, P4001; HAYASHI JI, 1983, EXP CELL RES, V148, P258, DOI 10.1016/0014-4827(83)90206-9; HAYASHI JI, 1989, CANCER RES, V49, P4715; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HAYASHI JI, 1985, EXP CELL RES, V160, P387, DOI 10.1016/0014-4827(85)90185-5; HOLMES EC, 1991, J MOL EVOL, V33, P209, DOI 10.1007/BF02100671; Inoue K, 1997, BIOCHEM BIOPH RES CO, V239, P257, DOI 10.1006/bbrc.1997.7446; IWAKURA Y, 1985, CELL, V43, P777, DOI 10.1016/0092-8674(85)90251-X; JUKES TH, 1995, J MOL EVOL, V40, P537, DOI 10.1007/BF00166622; Kenyon L, 1997, P NATL ACAD SCI USA, V94, P9131, DOI 10.1073/pnas.94.17.9131; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Lanza RP, 1999, NAT MED, V5, P975, DOI 10.1038/12404; Manfred G, 1999, J BIOL CHEM, V274, P9386, DOI 10.1074/jbc.274.14.9386; MORAES CT, 1992, AM J HUM GENET, V50, P934; Moraes CT, 1999, MOL BIOL CELL, V10, P3345, DOI 10.1091/mbc.10.10.3345; MORAIS R, 1980, BIOCHEM BIOPH RES CO, V94, P71, DOI 10.1016/S0006-291X(80)80189-6; Robinson B H, 1996, Methods Enzymol, V264, P454, DOI 10.1016/S0076-6879(96)64041-5; ROSAMOND J, 1982, BIOCHEM J, V202, P1; SHAY JW, 1990, ANTICANCER RES, V10, P279; SHE JX, 1990, BIOL J LINN SOC, V41, P83, DOI 10.1111/j.1095-8312.1990.tb00823.x; SIBLEY CG, 1987, J MOL EVOL, V26, P99, DOI 10.1007/BF02111285; SOLUS JF, 1984, EXP CELL RES, V151, P299, DOI 10.1016/0014-4827(84)90380-X; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; Thyagarajan B, 1996, J BIOL CHEM, V271, P27536, DOI 10.1074/jbc.271.44.27536; TONSGARD JH, 1990, BIOCHEM J, V270, P511, DOI 10.1042/bj2700511; Trounce I, 1996, SOMAT CELL MOLEC GEN, V22, P81, DOI 10.1007/BF02374379; Trounce I, 1999, AM J HUM GENET, V65, pA431; WEIDE LG, 1982, SOMAT CELL GENET, V8, P15, DOI 10.1007/BF01538647; ZIEGLER ML, 1981, SOMAT CELL GENET, V7, P73, DOI 10.1007/BF01544749; ZUCKERMAN SH, 1986, SOMAT CELL MOLEC GEN, V12, P449, DOI 10.1007/BF01539916	55	87	88	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31520	31527		10.1074/jbc.M004053200	http://dx.doi.org/10.1074/jbc.M004053200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10908562	hybrid			2022-12-27	WOS:000089762700107
J	He, YC; Crouch, EC; Rust, K; Spaite, E; Brody, SL				He, YC; Crouch, EC; Rust, K; Spaite, E; Brody, SL			Proximal promoter of the surfactant protein D gene - Regulatory roles of AP-1, forkhead box, and GT box binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION-FACTOR-I; SP-A GENE; CELL-SPECIFIC EXPRESSION; COLLAGEN-LIKE DOMAIN; DNA-BINDING; B GENE; 5'-FLANKING REGION; MAMMALIAN LECTIN; LUNG; FAMILY	Surfactant protein D (SP-D) plays roles in pulmonary host defense and surfactant homeostasis and is increased following lung injury, Because AP-1 proteins regulate cellular responses to diverse environmental stimuli, we hypothesized that the conserved AP-1 motif (at -109) and flanking sequences in the human SP-D promoter contribute to the regulation of SP-D expression. The AP-1 sequence specifically bound to fra-1, junD, and junB in H441 lung adenocarcinoma nuclear extracts. Mutagenesis of the AP-1 motif in a chloramphenicol acetyltransferase reporter construct containing 285 base pairs of upstream sequence nearly abolished promoter activity, and co-transfection of junD significantly increased wild type but not mutant pro meter activity. The sequence immediately downstream of the AP-1 element contained a binding site for HNF-5 (FOXA), and simultaneous mutation of this site (fox-d) and an upstream FoxA binding site (-277, fox-u) caused a 4-fold reduction in chloramphenicol acetyltransferase activity. Immediately upstream of the AP-l-binding site, we identified a GT box-containing positive regulatory element, Despite finding regions of limited homology to the thyroid transcription factor 1-binding site, SP-D promoter activity did not require thyroid transcription factor 1, Thus, transcriptional regulation of SP-D gene expression involves complex interactions with ubiquitous and lineage dependent factors consistent with more generalized roles in innate immunity.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Crouch, EC (corresponding author), Barnes Jewish Hosp N, Dept Pathol & Immunol, Surg Pathol Mailstop 90-31-649,216 S Kingshighway, St Louis, MO 63110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044015, P01HL029594, R01HL056244, R29HL056244] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-56244, HL-44015, HL-29594] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BINGLE CD, 1995, BIOCHEM J, V308, P197, DOI 10.1042/bj3080197; BINGLE CD, 1993, BIOCHEM J, V295, P227, DOI 10.1042/bj2950227; BOHINSKI RJ, 1993, J BIOL CHEM, V268, P11160; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; Braun H, 1998, J BIOL CHEM, V273, P9821, DOI 10.1074/jbc.273.16.9821; Bravieri R, 1997, NUCLEIC ACIDS RES, V25, P2888, DOI 10.1093/nar/25.14.2888; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; Crouch EC, 1998, AM J RESP CELL MOL, V19, P177, DOI 10.1165/ajrcmb.19.2.140; Crowe AJ, 1999, J BIOL CHEM, V274, P25113, DOI 10.1074/jbc.274.35.25113; Dulkerian SJ, 1996, AM J RESP CELL MOL, V15, P781, DOI 10.1165/ajrcmb.15.6.8969273; Eggleton P, 1999, CURR OPIN IMMUNOL, V11, P28, DOI 10.1016/S0952-7915(99)80006-5; GAO E, 1993, J BIOL CHEM, V268, P19697; Gao EW, 1997, J BIOL CHEM, V272, P23398, DOI 10.1074/jbc.272.37.23398; Gotoh T, 1997, J BIOL CHEM, V272, P3694, DOI 10.1074/jbc.272.6.3694; Goytisolo FA, 1996, EMBO J, V15, P3421, DOI 10.1002/j.1460-2075.1996.tb00708.x; GREGORI C, 1994, NUCLEIC ACIDS RES, V22, P1242, DOI 10.1093/nar/22.7.1242; Hackett BP, 1996, ANNU REV PHYSIOL, V58, P51, DOI 10.1146/annurev.physiol.58.1.51; HROMAS R, 1995, CRIT REV ONCOL HEMAT, V20, P129, DOI 10.1016/1040-8428(94)00151-I; KAWASAKI N, 1994, BIOCHEM BIOPH RES CO, V198, P597, DOI 10.1006/bbrc.1994.1087; Kawasaki N, 1998, J BIOCHEM, V124, P1188, DOI 10.1093/oxfordjournals.jbchem.a022237; Kelly SE, 1996, J BIOL CHEM, V271, P6881, DOI 10.1074/jbc.271.12.6881; KLAMPFER L, 1994, MOL CELL BIOL, V14, P6561, DOI 10.1128/MCB.14.10.6561; Korfhagen TR, 1998, BBA-MOL BASIS DIS, V1408, P296, DOI 10.1016/S0925-4439(98)00075-1; Korfhagen TR, 1998, J BIOL CHEM, V273, P28438, DOI 10.1074/jbc.273.43.28438; Kumar AS, 1997, J BIOL CHEM, V272, P20764, DOI 10.1074/jbc.272.33.20764; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Lawson PR, 1999, AM J RESP CELL MOL, V20, P953, DOI 10.1165/ajrcmb.20.5.3343; LIOU LS, 1994, J IMMUNOL, V153, P173; Madsen J, 2000, J IMMUNOL, V164, P5866, DOI 10.4049/jimmunol.164.11.5866; Magdaleno SM, 1997, AM J PHYSIOL-LUNG C, V272, pL1142, DOI 10.1152/ajplung.1997.272.6.L1142; Martin ML, 1996, MOL CELL BIOL, V16, P2110; McIntosh JC, 1996, AM J RESP CELL MOL, V15, P509, DOI 10.1165/ajrcmb.15.4.8879185; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; McWhinney CD, 1996, DNA CELL BIOL, V15, P519, DOI 10.1089/dna.1996.15.519; Miura N, 1998, GENOMICS, V50, P346, DOI 10.1006/geno.1998.5288; Noti JD, 1996, MOL CELL BIOL, V16, P2940; Perl AKT, 1999, CLIN GENET, V56, P14, DOI 10.1034/j.1399-0004.1999.560103.x; PERSSON A, 1996, AM J RESPIR CELL MOL, V153, P109; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; QIAN XB, 1995, MOL CELL BIOL, V15, P1364; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; Rust K, 1996, AM J RESP CELL MOL, V14, P121, DOI 10.1165/ajrcmb.14.2.8630261; RYSECK RP, 1991, ONCOGENE, V6, P533; SAWAYA PL, 1993, MOL CELL BIOL, V13, P3860, DOI 10.1128/MCB.13.7.3860; SAWAYA PL, 1994, J BIOL CHEM, V269, P22211; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sever-Chroneos Z, 1999, AM J PHYSIOL-LUNG C, V277, pL79, DOI 10.1152/ajplung.1999.277.1.L79; Shaw-White JR, 1999, J BIOL CHEM, V274, P2658, DOI 10.1074/jbc.274.5.2658; Toonen RFG, 1996, BIOCHEM J, V316, P467, DOI 10.1042/bj3160467; Wani MA, 1999, GENOMICS, V60, P78, DOI 10.1006/geno.1999.5888; Whitsett JA, 1998, BBA-MOL BASIS DIS, V1408, P303, DOI 10.1016/S0925-4439(98)00076-3; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; Young PP, 1997, MOL ENDOCRINOL, V11, P1082, DOI 10.1210/me.11.8.1082; Zhang LQ, 1997, BBA-GENE STRUCT EXPR, V1350, P359, DOI 10.1016/S0167-4781(96)00180-7	57	48	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31051	31060		10.1074/jbc.M003499200	http://dx.doi.org/10.1074/jbc.M003499200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10915785	hybrid			2022-12-27	WOS:000089762700045
J	Nosjean, O; Ferro, M; Coge, F; Beauverger, P; Henlin, JM; Lefoulon, F; Fauchere, JL; Delagrange, P; Canet, E; Boutin, JA				Nosjean, O; Ferro, M; Coge, F; Beauverger, P; Henlin, JM; Lefoulon, F; Fauchere, JL; Delagrange, P; Canet, E; Boutin, JA			Identification of the melatonin-binding site MT3 as the quinone reductase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NAD(P)H-QUINONE REDUCTASE; DT-DIAPHORASE; MOUSE-LIVER; OXIDOREDUCTASE; SEQUENCE; RECEPTOR; GENE; LOCALIZATION; PURIFICATION; DERIVATIVES	The regulation of the circadian rhythm is relayed from the central nervous system to the periphery by melatonin, a hormone synthesized at night in the pineal gland. Besides two melatonin G-coupled receptors, mt, and MT2, the existence of a novel putative melatonin receptor, MT3, was hypothesized from the observation of a binding site in both central. and peripheral hamster tissues with an original binding profile and a very rapid kinetics of ligand exchange compared with mt(1) and MT2. In this report, we present the purification of MT3 from Syrian hamster kidney and its identification as the hamster homologue of the human quinone reductase 2 (QR(2), EC 1.6.99.2), Our purification strategy included the use of an affinity chromatography step which was crucial in purifying MT3 to homogeneity. The protein was sequenced by tandem mass spectrometry and shown to align with 95% identity with human QR(2). After transfection of CHO-K1 cells with the human QR(2) gene, not only did the QR(2) enzymatic activity appear, but also the melatonin-binding sites with MT3 characteristics, both being below the limit of detection in the native cells. We further confronted inhibition data from MT3 binding and QR(2) enzymatic activity obtained from samples of Syrian hamster kidney or QR(2)-overexpressing Chinese hamster ovary cells, and observed an overall good correlation of the data, In summary, our results provide the identification of the melatonin-binding site MT3 as the quinone reductase QR(2) and open perspectives as to the function of this enzyme, known so far mainly for its detoxifying properties.	Inst Rech Servier, F-78290 Croissy Sur Seine, France; CEA, Lab Chim Prot, F-38000 Grenoble, France; Technol Servier, F-45007 Orleans, France; Inst Rech Servier, F-92150 Suresnes, France; Inst Rech Int Servier, F-92415 Courbevoie, France	Servier; Institut de Recherches Internationales Servier; CEA; Servier; Servier; Institut de Recherches Internationales Servier; Servier; Institut de Recherches Internationales Servier	Boutin, JA (corresponding author), Inst Rech Servier, 125 Chemin de Ronde, F-78290 Croissy Sur Seine, France.	jaboutin@netgrs.com	Boutin, Jean Albert/W-9103-2019; FERRO, Myriam/O-6588-2014	Boutin, Jean Albert/0000-0003-0068-7204; FERRO, Myriam/0000-0002-4222-6847				CHEN SU, 1994, PROTEIN SCI, V3, P1296, DOI 10.1002/pro.5560030816; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DEPREUX P, 1994, J MED CHEM, V37, P3231, DOI 10.1021/jm00046a006; DUBOCOVICH ML, 1995, TRENDS PHARMACOL SCI, V16, P50, DOI 10.1016/S0165-6147(00)88978-6; DUBOCOVICH ML, 1998, IUPHAR COMPENDIUM RE, P187; DUNCAN MJ, 1988, ENDOCRINOLOGY, V122, P1825, DOI 10.1210/endo-122-5-1825; Ferry G, 2000, J BIOL CHEM, V275, P8794, DOI 10.1074/jbc.275.12.8794; Foster CE, 1999, BIOCHEMISTRY-US, V38, P9881, DOI 10.1021/bi990799v; FRIEDLOS F, 1992, BIOCHEM PHARMACOL, V44, P25, DOI 10.1016/0006-2952(92)90033-F; Helenius A, 1979, Methods Enzymol, V56, P734; JAISWAL AK, 1994, J BIOL CHEM, V269, P14502; JAISWAL AK, 1990, BIOCHEMISTRY-US, V29, P1899, DOI 10.1021/bi00459a034; JAISWAL AK, 1988, J BIOL CHEM, V263, P13572; Kodama T, 1997, NEPHROL DIAL TRANSPL, V12, P1453, DOI 10.1093/ndt/12.7.1453; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI RB, 1995, P NATL ACAD SCI USA, V92, P8846, DOI 10.1073/pnas.92.19.8846; LIAO S, 1962, J BIOL CHEM, V237, P2981; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Molinari EJ, 1996, EUR J PHARMACOL, V301, P159, DOI 10.1016/0014-2999(95)00870-5; Paul P, 1999, J PHARMACOL EXP THER, V290, P334; PICKERING DS, 1990, EUR J PHARMACOL, V175, P71, DOI 10.1016/0014-2999(90)90154-X; Poeggeler Burkhard, 1999, P421; POWELL MF, 1982, P NATL ACAD SCI-BIOL, V79, P4604, DOI 10.1073/pnas.79.15.4604; PROCHASKA HJ, 1986, J BIOL CHEM, V261, P1372; REPPERT SM, 1995, P NATL ACAD SCI USA, V92, P8734, DOI 10.1073/pnas.92.19.8734; REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8; ROY D, 1988, J BIOL CHEM, V263, P3646; Zhao QJ, 1997, P NATL ACAD SCI USA, V94, P1669, DOI 10.1073/pnas.94.5.1669	28	425	451	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31311	31317		10.1074/jbc.M005141200	http://dx.doi.org/10.1074/jbc.M005141200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10913150	hybrid			2022-12-27	WOS:000089762700080
J	Yuasa, K; Kotera, J; Fujishige, K; Michibata, H; Sasaki, T; Omori, K				Yuasa, K; Kotera, J; Fujishige, K; Michibata, H; Sasaki, T; Omori, K			Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-SPECIFIC PHOSPHODIESTERASE; CGMP-SPECIFIC PHOSPHODIESTERASE; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; DEPENDENT PROTEIN-KINASE; N-TERMINAL DOMAIN; MOLECULAR-CLONING; SPLICE VARIANTS; MESSENGER-RNA; MEMBRANE ASSOCIATION; GENE-EXPRESSION	cDNAs encoding a novel phosphodiesterase, phosphodiesterase 11A (PDE11A), were isolated by a combination of reverse transcriptase-polymerase chain reaction using degenerate oligonucleotide primers and rapid amplification of cDNA ends, Their catalytic domain was identical to that of PDE11A1 (490 amino acids) reported during the course of this study. However, the cDNAs we isolated had N termini distinct from PDE11A1, indicating two novel N-terminal variants of PDE11A, PDE11A3 cDNA encoded a 684-amino acid protein including one complete and one incomplete GAF domain in the N-terminal region. PDE11A4 was composed of 934 amino acids including two complete GAF domains and shared 630 C-terminal amino acids with PDE11A3 but had a distinct N terminus containing the putative phosphorylation sites for cAMP- and cGMP dependent protein kinases, PDE11A3 transcripts were specifically expressed in testis, whereas PDE11A4 transcripts were particularly abundant in prostate. Recombinant PDE11A4 expressed in COS-7 cells hydrolyzed cAMP and cGMP with K-m values of 3.0 and 1.4 mu M, respectively, and the V-max value with cAMP was almost twice that with cGMP. Although PDE11A3 showed the same Ii, values as PDE11A4, the relative V-max values of PDE11A3 were ap proximately one-sixth of those of PDE11A4. PDE11A4, but not PDE11A3, was phosphorylated by both cAMP- and cGMP-dependent protein kinases in vitro, Thus, the PDE11A gene undergoes tissue-specific alternative splicing that generates structurally and functionally distinct gene products.	Tanabe Seiyaku Co Ltd, Discovery Res Lab, Toda, Saitama 3358505, Japan	Mitsubishi Tanabe Pharma Corporation	Omori, K (corresponding author), Tanabe Seiyaku Co Ltd, Discovery Res Lab, 2-50 Kawagishi 2 Chome, Toda, Saitama 3358505, Japan.							Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; BANG YJ, 1994, P NATL ACAD SCI USA, V91, P5330, DOI 10.1073/pnas.91.12.5330; BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; Bolger GB, 1996, J BIOL CHEM, V271, P1065, DOI 10.1074/jbc.271.2.1065; Burns F, 1996, Adv Pharmacol, V36, P29, DOI 10.1016/S1054-3589(08)60575-X; Cox ME, 1999, CANCER RES, V59, P3821; Degerman E, 1997, J BIOL CHEM, V272, P6823, DOI 10.1074/jbc.272.11.6823; Fawcett L, 2000, P NATL ACAD SCI USA, V97, P3702, DOI 10.1073/pnas.050585197; Fisher DA, 1998, BIOCHEM BIOPH RES CO, V246, P570, DOI 10.1006/bbrc.1998.8684; Fisher DA, 1998, J BIOL CHEM, V273, P15559, DOI 10.1074/jbc.273.25.15559; FLORIO VA, 1994, BIOCHEMISTRY-US, V33, P8948, DOI 10.1021/bi00196a012; Fujishige K, 1999, EUR J BIOCHEM, V266, P1118, DOI 10.1046/j.1432-1327.1999.00963.x; Fujishige K, 1999, J BIOL CHEM, V274, P18438, DOI 10.1074/jbc.274.26.18438; Gautier-Courteille C, 1998, ENDOCRINOLOGY, V139, P2588, DOI 10.1210/en.139.5.2588; Goto T, 1999, INT J UROL, V6, P314, DOI 10.1046/j.1442-2042.1999.00069.x; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; Guh JH, 1998, MOL PHARMACOL, V53, P467, DOI 10.1124/mol.53.3.467; Han P, 1997, J BIOL CHEM, V272, P16152, DOI 10.1074/jbc.272.26.16152; Hayashi M, 1998, BIOCHEM BIOPH RES CO, V250, P751, DOI 10.1006/bbrc.1998.9379; Huston E, 1997, BIOCHEM J, V328, P549, DOI 10.1042/bj3280549; Huston E, 1996, J BIOL CHEM, V271, P31334, DOI 10.1074/jbc.271.49.31334; Korsa I, 1997, J BACTERIOL, V179, P41, DOI 10.1128/jb.179.1.41-45.1997; Kotera J, 1998, J BIOL CHEM, V273, P26982, DOI 10.1074/jbc.273.41.26982; Kotera J, 1999, BIOCHEM BIOPH RES CO, V261, P551, DOI 10.1006/bbrc.1999.1013; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lin CS, 2000, BIOCHEM BIOPH RES CO, V268, P628, DOI 10.1006/bbrc.2000.2187; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MACPHEE CH, 1988, J BIOL CHEM, V263, P10353; McAllisterLucas LM, 1995, J BIOL CHEM, V270, P30671, DOI 10.1074/jbc.270.51.30671; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; MCPHEE I, 1995, BIOCHEM J, V310, P965, DOI 10.1042/bj3100965; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; OConnell JC, 1996, BIOCHEM J, V318, P255, DOI 10.1042/bj3180255; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; REINHARDT RR, 1995, J CLIN INVEST, V95, P1528, DOI 10.1172/JCI117825; REPASKE DR, 1992, J BIOL CHEM, V267, P18683; Rosman GJ, 1997, GENE, V191, P89, DOI 10.1016/S0378-1119(97)00046-2; SAEKI T, 1994, J PHARMACOL EXP THER, V284, P25; Salanova M, 1999, ENDOCRINOLOGY, V140, P2297, DOI 10.1210/en.140.5.2297; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SCOTLAND G, 1995, BIOCHEM J, V308, P673, DOI 10.1042/bj3080673; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; SETTE C, 1994, J BIOL CHEM, V269, P9245; SHAKUR Y, 1993, BIOCHEM J, V292, P677, DOI 10.1042/bj2920677; Snyder PB, 1999, CELL SIGNAL, V11, P535, DOI 10.1016/S0898-6568(99)00027-3; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; Soderling SH, 1998, P NATL ACAD SCI USA, V95, P8991, DOI 10.1073/pnas.95.15.8991; Soderling SH, 1998, J BIOL CHEM, V273, P15553, DOI 10.1074/jbc.273.25.15553; TAKEDA M, 1995, UROLOGY, V45, P440, DOI 10.1016/S0090-4295(99)80013-2; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; Turko IV, 1996, J BIOL CHEM, V271, P22240, DOI 10.1074/jbc.271.36.22240; Turko IV, 1998, BIOCHEM J, V329, P505; Vemulapalli S, 1996, J CARDIOVASC PHARM, V28, P862, DOI 10.1097/00005344-199612000-00018; Vijayaraghavan S, 1997, J BIOL CHEM, V272, P4747, DOI 10.1074/jbc.272.8.4747; Wang X, 1997, J NEUROCHEM, V68, P443; WEYAND I, 1994, NATURE, V368, P859, DOI 10.1038/368859a0; Wiesner B, 1998, J CELL BIOL, V142, P473, DOI 10.1083/jcb.142.2.473; YAN C, 1994, J NEUROSCI, V14, P973; Yan C, 1996, J BIOL CHEM, V271, P25699, DOI 10.1074/jbc.271.41.25699; Yanaka N, 1998, EUR J BIOCHEM, V255, P391, DOI 10.1046/j.1432-1327.1998.2550391.x; YANG Q, 1994, BIOCHEM BIOPH RES CO, V205, P1850, DOI 10.1006/bbrc.1994.2886; Yuasa K, 1999, J BIOL CHEM, V274, P37429, DOI 10.1074/jbc.274.52.37429; Yuasa K, 2000, J BIOL CHEM, V275, P4897, DOI 10.1074/jbc.275.7.4897	65	112	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31469	31479		10.1074/jbc.M003041200	http://dx.doi.org/10.1074/jbc.M003041200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906126	hybrid			2022-12-27	WOS:000089762700101
J	Xu, LH; Yang, XH; Bradham, CA; Brenner, DA; Baldwin, AS; Craven, RJ; Cance, WG				Xu, LH; Yang, XH; Bradham, CA; Brenner, DA; Baldwin, AS; Craven, RJ; Cance, WG			The focal adhesion kinase suppresses transformation-associated, anchorage-independent apoptosis in human breast cancer cells - Involvement of death receptor-related signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; TUMOR-CELLS; EXPRESSION; OVEREXPRESSION; PP125(FAK); INHIBITION; CASPASES; SURVIVAL; GROWTH; SRC	The focal adhesion kinase (FAK) is a mediator of cell-extracellular matrix signaling events and is overexpressed in tumor cells. In order to rapidly down-regulate FAK function in normal and transformed mammary cells, we have used adenoviral gene transduction of the carboxyl-terminal domain of FAK (FAK-CD). Transduction of adenovirus containing FAH-CD in breast cancer cells caused loss of adhesion, degradation of p125(FAK), and induced apoptosis. Furthermore, breast tumor cells that were viable without matrix attachment also underwent apoptosis upon interruption of FAK function, demonstrating that FAK is a survival signal in breast tumor cells even in the absence of matrix signaling. In addition, both anchorage-dependent and anchorage-independent apoptotic signaling required Fas-associated death domain and caspase-8, suggesting that a death receptor-mediated apoptotic pathway is involved. Finally, FAK-CD had no effect on adhesion or viability in normal mammary cells, despite the loss of tyrosine phosphorylation of p125(FAK). These results indicate that FAK-mediated signaling is required for both cell adhesion and anchorage-independent survival and the disruption of FAK function involves the Fas-associated death domain and caspase-8 apoptotic pathway.	Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Surg, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Cance, WG (corresponding author), Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, CB 7210, Chapel Hill, NC 27599 USA.		Bradham, Cynthia/GXV-9373-2022	Brenner, David/0000-0003-2573-525X	NATIONAL CANCER INSTITUTE [R01CA065910] Funding Source: NIH RePORTER; NCI NIH HHS [CA65910] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; BROOKS SC, 1973, J BIOL CHEM, V248, P6251; Cary LA, 1996, J CELL SCI, V109, P1787; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; FERNANDES RS, 1996, LEUKEMIA, V10, P17; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Han NM, 1997, ANN SURG ONCOL, V4, P264, DOI 10.1007/BF02306620; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HOFFMAN B, 1994, ONCOGENE, V9, P1807; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1998, J CELL BIOL, V143, P547; Kumar R, 1996, CLIN CANCER RES, V2, P1215; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; McGill G, 1997, J CELL BIOL, V138, P901, DOI 10.1083/jcb.138.4.901; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nolan K, 1999, MOL CELL BIOL, V19, P6120; OWENS LV, 1995, CANCER RES, V55, P2752; Owens LV, 1996, ANN SURG ONCOL, V3, P100, DOI 10.1007/BF02409059; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; SOULE HD, 1990, CANCER RES, V50, P6075; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Withers BE, 1996, CANCER BIOCHEM BIOPH, V15, P127; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Xu LH, 1998, CELL GROWTH DIFFER, V9, P999; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413	45	174	178	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30597	30604		10.1074/jbc.M910027199	http://dx.doi.org/10.1074/jbc.M910027199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10899173	hybrid			2022-12-27	WOS:000089577900093
J	Chernukhin, IV; Shamsuddin, S; Robinson, AF; Carne, AF; Paul, A; El-Kady, AI; Lobanenkov, VV; Klenova, EM				Chernukhin, IV; Shamsuddin, S; Robinson, AF; Carne, AF; Paul, A; El-Kady, AI; Lobanenkov, VV; Klenova, EM			Physical and functional interaction between two pluripotent proteins, the Y-box DNA/RNA-binding factor, YB-1, and the multivalent zinc finger factor, CTCF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC GENE; TRANSCRIPTION FACTOR YB-1; HUMAN POLYOMAVIRUS JC; NUCLEAR FACTOR; 5'-FLANKING SEQUENCE; PRECURSOR PROMOTER; MESSENGER-RNA; DNA-SEQUENCE; EXPRESSION; CELLS	CTCF is a unique, highly conserved, and ubiquitously expressed 11 zinc finger (ZF) transcriptional factor with multiple DNA site specificities. It is able to bind to varying target sequences to perform different regulatory roles, including promoter activation or repression, creating hormone-responsive gene silencing elements, and functional block of enhancer-promoter interactions. Because different sets of ZFs are utilized to recognize different CTCF target DNA sites, each of the diverse DNA.CTCF complexes might engage different essential protein partners to define distinct functional readouts. To identify such proteins, we developed an affinity chromatography method based on matrix-immobilized purified recombinant CTCF. This approach resulted in isolation of several CTCF protein partners. One of these was identified as the multifunctional Y-box DNA/RNA-binding factor, YB-1, known to be involved in transcription, replication, and RNA processing. We examined CTCF/YB-1 interaction by reciprocal immunoprecipitation experiments with anti-CTCF and anti-YB-l antibodies, and found that CTCF and YB-1 form complexes in vivo. We show that the bacterially expressed ZF domain of CTCF is fully sufficient to retain YB-1 in vitro. To assess possible functional significance of CTCF/YB-1 binding, we employed the very first identified by us, negatively regulated, target for CTCF (c-myc oncogene promoter) as a model in co-transfection assays with both CTCF and YB-1 expression vectors. Although expression of YB-1 alone had no effect, co-expression with CTCF resulted in a marked enhancement of CTCF-driven c-myc transcriptional repression. Thus our findings demonstrate, for the first time, the biological relevance of the CTCF/YB-1 interaction.	Univ Oxford, Dept Biochem, Genet Lab, Oxford OX1 3QU, England; Inst Canc Res, Haddow Labs, Surrey, England; NIAID, Sect Mol Pathol, Immunopathol Lab, NIH, Bethesda, MD 20892 USA	University of Oxford; University of London; Institute of Cancer Research - UK; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Klenova, EM (corresponding author), Univ Oxford, Dept Biochem, Genet Lab, S Parks Rd, Oxford OX1 3QU, England.	klenovae@bioch.ox.ac.uk	Shamsuddin, Shaharum/A-7907-2011; Lobanenkov, Victor V./AGQ-8903-2022; Lobanenkov, Victor/ABD-5710-2021; Elkady, Ayman/J-5738-2012	Shamsuddin, Shaharum/0000-0001-9997-7740; Lobanenkov, Victor/0000-0001-6665-3635				Ansari SA, 1999, J GEN VIROL, V80, P2629, DOI 10.1099/0022-1317-80-10-2629; ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; ASSELIN C, 1989, ONCOGENE, V4, P549; Awad TA, 1999, J BIOL CHEM, V274, P27092, DOI 10.1074/jbc.274.38.27092; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Bell AC, 1999, CURR OPIN GENET DEV, V9, P191, DOI 10.1016/S0959-437X(99)80029-X; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; Boulikas T, 1996, ANTICANCER RES, V16, P225; Burcin M, 1997, MOL CELL BIOL, V17, P1281, DOI 10.1128/MCB.17.3.1281; Chen CY, 2000, GENE DEV, V14, P1236; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; Duh JL, 1995, J BIOL CHEM, V270, P30499, DOI 10.1074/jbc.270.51.30499; Englert C, 1998, TRENDS BIOCHEM SCI, V23, P389, DOI 10.1016/S0968-0004(98)01277-8; Fearon ER, 1999, CURR BIOL, V9, pR62, DOI 10.1016/S0960-9822(99)80012-8; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; Filippova GN, 1998, GENE CHROMOSOME CANC, V22, P26, DOI 10.1002/(SICI)1098-2264(199805)22:1<26::AID-GCC4>3.0.CO;2-9; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; GRANT CE, 1993, MOL CELL BIOL, V13, P4186, DOI 10.1128/MCB.13.7.4186; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P4915, DOI 10.1093/nar/19.18.4915; Ise T, 1999, CANCER RES, V59, P342; Kamura T, 1999, CANCER, V85, P2450, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U; Kanduri C, 2000, CURR BIOL, V10, P853, DOI 10.1016/S0960-9822(00)00597-2; Kanduri C, 2000, CURR BIOL, V10, P449, DOI 10.1016/S0960-9822(00)00442-5; KASHANCHI F, 1994, J VIROL, V68, P561, DOI 10.1128/JVI.68.1.561-565.1994; Klenova EM, 1997, NUCLEIC ACIDS RES, V25, P466, DOI 10.1093/nar/25.3.466; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; Ladomery M, 1997, BIOESSAYS, V19, P903, DOI 10.1002/bies.950191010; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; Li WW, 1997, MOL CELL BIOL, V17, P61, DOI 10.1128/MCB.17.1.61; LOBANENKOV VV, 1986, EUR J BIOCHEM, V159, P181, DOI 10.1111/j.1432-1033.1986.tb09850.x; LOBANENKOV VV, 1989, DOKL AKAD NAUK SSSR+, V309, P741; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; LOBANENKOV VV, 1989, GENE REGULATION AIDS, P45; MAREU KB, 1992, ANNU REV BIOCHEM, V61, P809; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; Montani V, 1998, ENDOCRINOLOGY, V139, P280, DOI 10.1210/en.139.1.280; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Ohmori M, 1996, MOL ENDOCRINOL, V10, P76, DOI 10.1210/me.10.1.76; PATTERSON SD, 1995, ELECTROPHORESIS, V16, P1791, DOI 10.1002/elps.11501601299; PLUMB MA, 1986, NUCLEIC ACIDS RES, V14, P7675, DOI 10.1093/nar/14.19.7675; Potter M, 1997, CURR TOP MICROBIOL, V224, P1; QUITSCHKE WW, 1994, J BIOL CHEM, V269, P21229; Raj GV, 1996, J VIROL, V70, P5944, DOI 10.1128/JVI.70.9.5944-5953.1996; SABATH DE, 1990, J BIOL CHEM, V265, P12671; Safak M, 1999, J VIROL, V73, P10146, DOI 10.1128/JVI.73.12.10146-10157.1999; Saitoh N, 2000, EMBO J, V19, P2315, DOI 10.1093/emboj/19.10.2315; Sawaya BE, 1998, J GEN VIROL, V79, P239, DOI 10.1099/0022-1317-79-2-239; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shibao K, 1999, INT J CANCER, V83, P732; SHIU RP, 1993, CLIN CHEM, V39, P353; Sommerville J, 1996, CHROMOSOMA, V104, P469, DOI 10.1007/s004120050139; Sommerville J, 1996, FASEB J, V10, P435, DOI 10.1096/fasebj.10.4.8647342; SPENCER CA, 1991, ADV CANCER RES, V56, P1; Swamynathan SK, 2000, BIOCHEM J, V348, P297, DOI 10.1042/0264-6021:3480297; Swamynathan SK, 1998, FASEB J, V12, P515, DOI 10.1096/fasebj.12.7.515; Szabo PE, 2000, CURR BIOL, V10, P607, DOI 10.1016/S0960-9822(00)00489-9; TEVOSYAN S G, 1991, Molekulyarnaya Biologiya (Moscow), V25, P1013; TOWATARI M, 1995, J BIOL CHEM, V270, P4101, DOI 10.1074/jbc.270.8.4101; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; Vostrov AA, 1997, J BIOL CHEM, V272, P33353, DOI 10.1074/jbc.272.52.33353; Wolffe AP, 1996, INT J BIOCHEM CELL B, V28, P247, DOI 10.1016/1357-2725(95)00141-7; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; WOLFFE AP, 1994, DEV GENET, V15, P463, DOI 10.1002/dvg.1020150604; Yang YX, 1999, J NEUROCHEM, V73, P2286, DOI 10.1046/j.1471-4159.1999.0732286.x; Zou YM, 1997, DEVELOPMENT, V124, P793; ZOU YM, 1995, MOL CELL BIOL, V15, P2972	70	83	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29915	29921		10.1074/jbc.M001538200	http://dx.doi.org/10.1074/jbc.M001538200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10906122	hybrid			2022-12-27	WOS:000089439800100
J	Medina, I; Krapivinsky, G; Arnold, S; Kovoor, P; Krapivinsky, L; Clapham, DE				Medina, I; Krapivinsky, G; Arnold, S; Kovoor, P; Krapivinsky, L; Clapham, DE			A switch mechanism for G ss gamma activation of I-KACh	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFIER POTASSIUM CHANNELS; RECTIFYING K+ CHANNELS; G-BETA-GAMMA; INWARD RECTIFIER; FUNCTIONAL EXPRESSION; G-PROTEINS; SUBUNITS; ACETYLCHOLINE; LOCALIZATION; BINDING	G protein-gated inwardly rectifying potassium (GIRK) channels are a family of K+-selective ion channels that slow the firing rate of neurons and cardiac myocytes. GIRK channels are directly bound and activated by the G protein G beta gamma subunit. As heterotetramers, they comprise the GIRK1 and the GIRK2, -8, or -4 subunits. Here we show that GIRK1 but not the GIRK4 subunit is phosphorylated when heterologously expressed. We found also that phosphatase PP2A dephosphorylation of a protein in the excised patch abrogates channel activation by G beta gamma. Experiments with the truncated molecule demonstrated that the GIRK1 C-terminal is critical for both channel phosphorylation and channel regulation by protein phosphorylation, but the critical phosphorylation sites were not located on the C terminus. These data provide evidence for a novel switch mechanism in which protein phosphorylation enables G beta gamma gating of the channel complex.	Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Clapham, DE (corresponding author), Childrens Hosp, Howard Hughes Med Inst, 1309 Enders,320 Longwood Ave, Boston, MA 02115 USA.		Clapham, David/S-1123-2019; Clapham, David/R-5974-2019; Medina, Igor/O-5532-2016	Clapham, David/0000-0002-4459-9428; Medina, Igor/0000-0001-6839-5414; Arnold, Susanne/0000-0003-2667-5156				Corey S, 1998, J BIOL CHEM, V273, P5271, DOI 10.1074/jbc.273.9.5271; Dissmann E, 1996, BIOCHEM BIOPH RES CO, V223, P474, DOI 10.1006/bbrc.1996.0918; DUPRAT F, 1995, BIOCHEM BIOPH RES CO, V212, P657, DOI 10.1006/bbrc.1995.2019; HARTZELL HC, 1977, J PHYSIOL-LONDON, V271, P817, DOI 10.1113/jphysiol.1977.sp012027; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; Jelacic TM, 1999, J MEMBRANE BIOL, V169, P123, DOI 10.1007/s002329900524; Kennedy ME, 1999, J BIOL CHEM, V274, P2571, DOI 10.1074/jbc.274.4.2571; Kim D, 1997, AM J PHYSIOL-HEART C, V272, pH195, DOI 10.1152/ajpheart.1997.272.1.H195; Kim D, 2000, J GEN PHYSIOL, V115, P287, DOI 10.1085/jgp.115.3.287; KIM D, 1991, J PHYSIOL-LONDON, V437, P133, DOI 10.1113/jphysiol.1991.sp018588; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LOEWI O., 1926, PFLUGER S ARCH GES PHYSIOL, V214, P678, DOI 10.1007/BF01741946; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Mullner C, 2000, J GEN PHYSIOL, V115, P547, DOI 10.1085/jgp.115.5.547; NELSON DA, 1992, J BIOL CHEM, V267, P14928; Nishikawa K, 1998, J BIOL CHEM, V273, P23126, DOI 10.1074/jbc.273.36.23126; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; Sui JL, 1996, J GEN PHYSIOL, V108, P381, DOI 10.1085/jgp.108.5.381; Wickman K, 1998, NEURON, V20, P103, DOI 10.1016/S0896-6273(00)80438-9; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0	25	49	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29709	29716		10.1074/jbc.M004989200	http://dx.doi.org/10.1074/jbc.M004989200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10900209	hybrid			2022-12-27	WOS:000089439800071
J	Higashimoto, Y; Saito, S; Tong, XH; Hong, A; Sakaguchi, K; Appella, E; Anderson, CW				Higashimoto, Y; Saito, S; Tong, XH; Hong, A; Sakaguchi, K; Appella, E; Anderson, CW			Human p53 is phosphorylated on serines 6 and 9 in response to DNA damage-inducing agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-I; PROTEIN; GENE; EXPRESSION; PHOSPHOSERINE; MUTATIONS; ANALOGS; SIGNALS; ISOFORM; GROWTH	To characterize the sites in human p53 that become phosphorylated in response to DNA damage, we have developed polyclonal antibodies that recognize p53 only when it is phosphorylated at specific sites. Several attempts to generate an antibody to p53 phosphorylated at Ser(6) using a phosphoserine-containing peptide as an immunogen were unsuccessful; however, phosphorylation-specific antibodies were produced by using the phosphoserine mimetic, L-2-amino-4-phosphono-4,4-di-fluorobutanoicacid (F(2)Pab), in place of phosphoserine. Fmoc-F(2)Pab was prepared by an improved synthesis and chemically incorporated using solid phase peptide synthesis, Affinity-purified antibodies elicited by immunizing rabbits with an F(2)Pab peptide coupled to keyhole limpet hemocyanin recognized a p53(1-39) peptide phosphorylated only at Ser(6) but not the unphosphorylated peptide or the same peptide phosphorylated at Ser(9), Ser(15), Ser(20), Ser(33), or Ser(37). Untreated A549 cells exhibited a background of constitutive phosphorylation at Ser(6) that increased approximately 10-fold upon exposure to either ionizing radiation or UV light. Similar results were obtained for Sers using antibodies raised against a conventional phosphopeptide. Ser(9) was phosphorylated by casein kinase 1 in vitro in a phosphoserine 6-dependent manner. Our data identify two additional DNA damage-induced phosphorylations in human p53 and show that F(2)Pab-derivatized peptides can be used to develop phosphorylation site-specific polyclonal antibodies.	NCI, NIH, Bethesda, MD 20892 USA; AnaSpec Inc, San Jose, CA 95131 USA; Kyushu Univ, Fac Sci, Dept Chem, Fukuoka 8128581, Japan; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kyushu University; United States Department of Energy (DOE); Brookhaven National Laboratory	Appella, E (corresponding author), NCI, NIH, Bethesda, MD 20892 USA.			Higashimoto, Yuichiro/0000-0003-1382-8598; Sakaguchi, Kazuyasu/0000-0002-8434-4171	NATIONAL CANCER INSTITUTE [Z01BC005599, ZIABC005599] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson Carl W., 1994, Seminars in Cell Biology, V5, P427, DOI 10.1006/scel.1994.1050; APPELLA E, 2000, IN PRESS PATHOL BIOL; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Berkowitz DB, 1996, J ORG CHEM, V61, P4666, DOI 10.1021/jo9604752; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CARR AM, 1995, TRENDS CELL BIOL, V5, P32, DOI 10.1016/S0962-8924(00)88934-5; CHEN L, 1995, BIOCHEM BIOPH RES CO, V216, P976, DOI 10.1006/bbrc.1995.2716; Christenson E, 1997, Recent Results Cancer Res, V143, P263; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; DOVER R, 1994, J CELL SCI, V107, P1181; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; Herrlich P, 1997, BIOL CHEM, V378, P1217; Hollstein M, 1998, MUTAT RES-FUND MOL M, V405, P145, DOI 10.1016/S0027-5107(98)00131-6; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Longenecker KL, 1996, J MOL BIOL, V257, P618, DOI 10.1006/jmbi.1996.0189; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MIYOSHI K, 1995, PEPTIDE CHEM, V33, P25; OTAKA A, 1995, TETRAHEDRON LETT, V36, P927, DOI 10.1016/0040-4039(94)02374-K; Prives C, 1999, J PATHOL, V187, P112; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; YEARGIN J, 1995, CURR BIOL, V5, P423, DOI 10.1016/S0960-9822(95)00083-2	32	104	111	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23199	23203		10.1074/jbc.M002674200	http://dx.doi.org/10.1074/jbc.M002674200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10930428	hybrid			2022-12-27	WOS:000088419400082
J	Feinberg, H; Torgersen, D; Drickamer, K; Weis, WI				Feinberg, H; Torgersen, D; Drickamer, K; Weis, WI			Mechanism of pH-dependent N-acetylgalactosamine binding by a functional mimic of the hepatocyte asialoglycoprotein receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; ANIMAL LECTINS; PROTEIN; RAT; SYSTEM	Efficient release of ligands from the Ca2+-dependent carbohydrate-recognition domain (CRD) of the hepatic asialoglycoprotein receptor at endosomal pH requires a small set of conserved amino acids that includes a critical histidine residue. When these residues are incorporated at corresponding positions in an homologous galactose-binding derivative of serum mannose-binding protein, the:pH dependence of ligand binding becomes more like that of the receptor. The modified CRD displays 40-fold preferential binding to N-acetylgalactosamine compared with galactose, making it a good functional mimic of the asialoglycoprotein receptor. In the crystal structure of the modified CRD bound to N-acetylgalactosamine, the histidine (His(202)) contacts the 2-acetamido; methyl group and also participates in a network of interactions involving Asp(212), Arg(216), and Tyr(218) that-positions a water molecule in a hydrogen bond with the sugar amide group. These interactions appear to produce the preference for N-acetylgalactosamine over galactose and are also likely to influence the pK(a) of His(202). Protonation of His(202) would disrupt its interaction with an asparagine that serves as a ligand for Ca2+ and sugar. The structure of the modified CRD without sugar displays several different conformations that may represent structures of intermediates in the release of Ca2+ and sugar ligands caused by protonation of His(202).	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA; Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England	Stanford University; University of Oxford	Weis, WI (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Fairchild Bldg,299 Campus Dr W, Stanford, CA 94305 USA.	bill.weis@stanford.edu	Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150	NIGMS NIH HHS [GM50565] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAVIL AJ, 1992, P NATL ACAD SCI USA, V89, P753, DOI 10.1073/pnas.89.2.753; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; Feinberg H, 2000, J BIOL CHEM, V275, P21539, DOI 10.1074/jbc.M002366200; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; IOBST ST, 1994, J BIOL CHEM, V269, P15512; Iobst ST, 1996, J BIOL CHEM, V271, P6686, DOI 10.1074/jbc.271.12.6686; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kolatkar AR, 1996, J BIOL CHEM, V271, P6679, DOI 10.1074/jbc.271.12.6679; Kolatkar AR, 1998, J BIOL CHEM, V273, P19502, DOI 10.1074/jbc.273.31.19502; LOEWENTHAL R, 1992, J MOL BIOL, V224, P759, DOI 10.1016/0022-2836(92)90560-7; Meier M, 2000, J MOL BIOL, V300, P857, DOI 10.1006/jmbi.2000.3853; Ng KKS, 1998, BIOCHEMISTRY-US, V37, P17965, DOI 10.1021/bi981972a; Ng KKS, 1997, BIOCHEMISTRY-US, V36, P979, DOI 10.1021/bi962564e; Ng KKS, 1998, BIOCHEMISTRY-US, V37, P17977, DOI 10.1021/bi9819733; Ng KKS, 1996, J BIOL CHEM, V271, P663, DOI 10.1074/jbc.271.2.663; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Wragg S, 1999, J BIOL CHEM, V274, P35400, DOI 10.1074/jbc.274.50.35400	25	45	58	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35176	35184		10.1074/jbc.M005557200	http://dx.doi.org/10.1074/jbc.M005557200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10931846	hybrid			2022-12-27	WOS:000165422800048
J	Roth, G; Kotzka, J; Kremer, L; Lehr, S; Lohaus, C; Meyer, HE; Krone, W; Muller-Wieland, D				Roth, G; Kotzka, J; Kremer, L; Lehr, S; Lohaus, C; Meyer, HE; Krone, W; Muller-Wieland, D			MAP kinases Erk1/2 phosphorylate sterol regulatory element-binding protein (SREBP)-1a at serine 117 in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; AMINO-ACID-SEQUENCES; SIGNAL-TRANSDUCTION; HEPG2 CELLS; TRANSCRIPTION; PATHWAY; ACTIVATION; PEPTIDES; INSULIN; SREBP	Sterol regulatory element-binding protein (SREBP)-1a is a transcription factor sensing cellular cholesterol levels and integrating gene regulatory signals mediated by MAP kinase cascades, Here we report the identification of serine 117 in SREBP-1a as the major phosphorylation site of the MAP kinases Erk1/2. This site was identified by nanoelectrospray mass spectrometry and peptide sequencing of recombinant fusion proteins phosphorylated by Erk1/2 in vitro. Serine 117 was verified as the major phosphorylation site by in vitro mutagenesis, Mutation of serine 117 to alanine abolished Erk2-mediated phosphorylation in vitro and the MAP kinase-related transcriptional activation of SREBP-1a by insulin and platelet-derived growth factor in vivo. Our data indicate that the MAP kinase-mediated effects on SREBP-1a-regulated target genes are linked to this phosphorylation site.	Univ Cologne, Klin & Poliklin Innere Med Klin 2, D-50924 Cologne, Germany; Ruhr Univ Bochum, Prot Strukturlab, D-50924 Cologne, Germany	University of Cologne; Ruhr University Bochum	Muller-Wieland, D (corresponding author), Univ Cologne, Klin & Poliklin Innere Med Klin 2, D-50924 Cologne, Germany.	dirk.mueller-wieland@medizin.uni-koeln.de		Kotzka, Jorg/0000-0003-1173-9372				Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Ericsson J, 1998, J BIOL CHEM, V273, P17865, DOI 10.1074/jbc.273.28.17865; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; Kotzka J, 2000, J LIPID RES, V41, P99; Kotzka J, 1998, BIOCHEM BIOPH RES CO, V249, P375, DOI 10.1006/bbrc.1998.9161; Kumar A, 1998, J BIOL CHEM, V273, P15742, DOI 10.1074/jbc.273.25.15742; LLOYD DB, 1995, J BIOL CHEM, V270, P25812, DOI 10.1074/jbc.270.43.25812; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Meier CA, 1997, EUR J ENDOCRINOL, V136, P271, DOI 10.1530/eje.0.1360271; MEYER HE, 1991, METHOD ENZYMOL, V201, P206; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SATO R, 1994, J BIOL CHEM, V269, P17267; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; STOPECK AT, 1993, J BIOL CHEM, V268, P17489; Streicher R, 1996, J BIOL CHEM, V271, P7128, DOI 10.1074/jbc.271.12.7128; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020	24	131	136	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33302	33307		10.1074/jbc.M005425200	http://dx.doi.org/10.1074/jbc.M005425200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10915800	hybrid			2022-12-27	WOS:000090104600020
J	Seroz, T; Perez, C; Bergmann, E; Bradsher, J; Egly, JM				Seroz, T; Perez, C; Bergmann, E; Bradsher, J; Egly, JM			p44/SSL1, the regulatory subunit of the XPD/RAD3 helicase, plays a crucial role in the transcriptional activity of TFIIH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; NUCLEOTIDE EXCISION-REPAIR; DNA-REPAIR; XERODERMA-PIGMENTOSUM; SACCHAROMYCES-CEREVISIAE; COCKAYNE-SYNDROME; OPEN COMPLEX; PROTEIN; MUTATIONS; GENE	In order to unravel the mechanism that regulates transcription of protein-coding genes, we investigated the function of the p44 subunit of TFIIH, a basal transcription factor that is also involved in DNA repair. We have shown previously that mutations in the C terminus of the XPD helicase, another subunit of TFIIH, prevent its regulation by p44 (Coin, F., Bergmann, E,, Tremeau-Bravard, A, and Egly, J. M. (1999) EMBO 18, 1357-1366). By using a site-directed mutagenesis approach within the p44 region from amino acids 66 to 200, we indicate how a decrease in the interaction between p44 and XPD results in a decrease of the XPD helicase activity and leads to a defect in the first steps of the transcription reaction, namely the first phosphodiester bond formation and promoter clearance. We thus provide some explanation for the transcriptional defect found in SSL1 mutated yeast (Wang, Z,, Buratowski, S., Svejstrup, J. Q,, Feaver, W. J.. Wu, X., Kornberg, R. D., Donahue, T, F., and Friedberg, E. C, (1995) Mol. Cell. Biol. 15, 2288-2293). Moreover, this study shows how the activity of the the cyclin-dependent kinase-activating kinase associated with TFIIH complex in stimulating transcription is mediated in part by p44/XPD interaction.	ULP, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Egly, JM (corresponding author), ULP, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, BP 163,CU Strasbourg, F-67404 Illkirch Graffenstaden, France.	egly@igbmc.u-strasbg.fr			NIGMS NIH HHS [F32 GM20174-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM020174] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL L, 1994, P NATL ACAD SCI USA, V91, P3926, DOI 10.1073/pnas.91.9.3926; Bootsma D., 1998, GENETIC BASIS HUMAN, P245; Bradsher J, 2000, J BIOL CHEM, V275, P2532, DOI 10.1074/jbc.275.4.2532; Burglen L, 1997, AM J HUM GENET, V60, P72; Cleaver JE, 1999, HUM MUTAT, V14, P9, DOI 10.1002/(SICI)1098-1004(1999)14:1<9::AID-HUMU2>3.3.CO;2-Y; Coin F, 1998, NAT GENET, V20, P184, DOI 10.1038/2491; Coin F, 1999, EMBO J, V18, P1357, DOI 10.1093/emboj/18.5.1357; de Boer J, 1999, CANCER RES, V59, P3489; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; Evans E, 1997, EMBO J, V16, P625, DOI 10.1093/emboj/16.3.625; Evans E, 1997, EMBO J, V16, P6559, DOI 10.1093/emboj/16.21.6559; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; Frit P, 1999, BIOCHIMIE, V81, P27, DOI 10.1016/S0300-9084(99)80035-2; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; Iyer N, 1996, BIOCHEMISTRY-US, V35, P2157, DOI 10.1021/bi9524124; Lee BS, 2000, MOL CELL BIOL, V20, P2436, DOI 10.1128/MCB.20.7.2436-2445.2000; Lehmann AR, 1998, BIOESSAYS, V20, P146, DOI 10.1002/(SICI)1521-1878(199802)20:2<146::AID-BIES7>3.3.CO;2-5; Maines S, 1998, GENETICS, V150, P963; Moreland RJ, 1999, J BIOL CHEM, V274, P22127, DOI 10.1074/jbc.274.32.22127; Mu D, 1997, J BIOL CHEM, V272, P28971, DOI 10.1074/jbc.272.46.28971; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; ROY R, 1994, J BIOL CHEM, V269, P9826; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; Sung P, 1996, J BIOL CHEM, V271, P10821, DOI 10.1074/jbc.271.18.10821; Taylor EM, 1997, P NATL ACAD SCI USA, V94, P8658, DOI 10.1073/pnas.94.16.8658; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; Vermeulen W, 1997, BIOCHEM SOC T, V25, P309, DOI 10.1042/bst0250309; VERMEULEN W, 1994, COLD SPRING HARB SYM, V59, P317, DOI 10.1101/SQB.1994.059.01.036; WANG ZG, 1995, MOL CELL BIOL, V15, P2288; YOON H, 1992, GENE DEV, V6, P2463, DOI 10.1101/gad.6.12b.2463	36	33	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33260	33266		10.1074/jbc.M004764200	http://dx.doi.org/10.1074/jbc.M004764200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10924514	hybrid			2022-12-27	WOS:000090104600014
J	Csordas, G; Santra, M; Reed, CC; Eichstetter, I; McQuillan, DJ; Gross, D; Nugent, MA; Hajnoczky, G; Iozzo, RV				Csordas, G; Santra, M; Reed, CC; Eichstetter, I; McQuillan, DJ; Gross, D; Nugent, MA; Hajnoczky, G; Iozzo, RV			Sustained down-regulation of the epidermal growth factor receptor by decorin - A mechanism for controlling tumor growth in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH PROTEOGLYCANS; DROSOPHILA EGF RECEPTOR; CELL-GROWTH; ACTIVATION; COLLAGEN; SIGNAL; LIGAND; FAMILY; SUPPRESSION; STIMULATION	The small leucine-rich proteoglycan decorin interacts with the epidermal growth factor receptor (EGFR) and triggers a signaling cascade that leads to elevation of endogenous p21 and growth suppression. We demonstrate that decorin causes a sustained down-regulation of the EGFR. Upon stable expression of decorin, the EGFR number is reduced by similar to 40%, without changes in EGFR expression. However, EGFR phosphorylation is nearly completely abolished. Concurrently, decorin attenuates the EGFR-mediated mobilization of intracellular calcium and blocks the growth of tumor xenografts by down-regulating the EGFR kinase in vivo. Thus, decorin acts as an autocrine and paracrine regulator of tumor growth and could be utilized as an effective anticancer agent.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, JAH, Philadelphia, PA 19107 USA; LifeCell Corp, Branchburg, NJ 08876 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Cell Biol & Signaling Program, Philadelphia, PA 19107 USA	Jefferson University; Boston University; Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, JAH, Rm 249,1020 Locust St, Philadelphia, PA 19107 USA.		Iozzo, Renato/AAS-1980-2020	Nugent, Matthew/0000-0002-8630-4712; Csordas, Gyorgy/0000-0003-3156-1460; Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [CA47282, CA39481] Funding Source: Medline; NEI NIH HHS [EY11004] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039481, R01CA047282] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011004] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Berridge M, 1999, CURR BIOL, V9, pR157, DOI 10.1016/S0960-9822(99)80101-8; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Conrad H. E., 1998, HEPARIN BINDING PROT; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FILMUS J, 1987, MOL CELL BIOL, V7, P251, DOI 10.1128/MCB.7.1.251; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; Ghiglione C, 1999, CELL, V96, P847, DOI 10.1016/S0092-8674(00)80594-2; Iozzo RV, 1999, P NATL ACAD SCI USA, V96, P3092, DOI 10.1073/pnas.96.6.3092; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; Musacchio M, 1996, DEV BIOL, V178, P63, DOI 10.1006/dbio.1996.0198; Nash MA, 1999, CANCER RES, V59, P6192; NUGENT MA, 1989, CANCER RES, V49, P3884; Patel S, 1998, J BIOL CHEM, V273, P3121, DOI 10.1074/jbc.273.6.3121; Perrimon N, 1997, CELL, V89, P13, DOI 10.1016/S0092-8674(00)80177-4; Perrimon N, 1999, CELL, V97, P13, DOI 10.1016/S0092-8674(00)80710-2; QUI Y, 1998, NATURE, V393, P83; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; SANTRA M, 2000, J BIOL CHEM     0814; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; Weiss FU, 1997, CURR OPIN GENET DEV, V7, P80, DOI 10.1016/S0959-437X(97)80113-X; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369	44	191	206	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32879	32887		10.1074/jbc.M005609200	http://dx.doi.org/10.1074/jbc.M005609200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10913155	hybrid			2022-12-27	WOS:000090003800069
J	Gibbons, HS; Lin, S; Cotter, RJ; Raetz, CRH				Gibbons, HS; Lin, S; Cotter, RJ; Raetz, CRH			Oxygen requirement for the biosynthesis of the S-2-hydroxymyristate moiety in Salmonella typhimurium lipid A - Function of LpxO, a new Fe2+/alpha-ketoglutarate-dependent dioxygenase homologue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINYL BETA-HYDROXYLASE; ESCHERICHIA-COLI; BACTERIAL VIRULENCE; PSEUDOMONAS-AERUGINOSA; POLYMYXIN RESISTANCE; GENE-EXPRESSION; REGULATED GENES; PHOP REGULON; IN-VIVO; LIPOPOLYSACCHARIDES	Lipid A molecules of certain Gram-negative bacteria, including Salmonella typhimurium and Pseudomonas aeruginosa, may contain secondary S-2-hydroxyacyl chains. S. typhimurium has recently been shown to synthesize its S-2-hydroxymyristate-modified lipid A in a PhoP/PhoQ-dependent manner, suggesting a possible role for the 2-OH group in pathogenesis, We postulated that 2-hydroxylation might be catalyzed by a novel dioxygenase. Lipid A was extracted from a PhoP-constitutive mutant of S. typhimurium grown in the presence or absence of O-2. Under anaerobic conditions, no 2-hydroxymyristate-containing lipid A was formed. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry of lipid A from cells grown in the presence of O-18(2) confirmed the direct incorporation of molecular oxygen into 2-hydroxyacyl-modified lipid A. Using several well characterized dioxygenase protein sequences as probes, tBLASTn searches revealed unassigned open reading frame(s) with similarity to mammalian aspartyl/asparaginyl beta -hydroxylases in bacteria known to make 2-hydroxyacylated lipid A molecules. The S. typhimurium aspartyl/asparaginyl beta -hydroxylase homologue (designated lpxO) was cloned into pBluescriptSK and expressed in Escherichia coli K-12, which does not contain lpxO. Analysis of the resulting construct revealed that lpxO expression is sufficient to induce O-2-dependent formation of 2-hydroxymyristate-modified lipid A in E. coli. LpxO very likely is a novel Fe2+/alpha -ketoglutarate-dependent dioxygenase that catalyzes the hydroxylation of lipid A (or of a key precursor). The S. typhimurium lpxO gene encodes a polypeptide of 302 amino acids with predicted membrane-anchoring sequences at both ends. We hypothesize that 2-hydroxymyristate chains released from lipopolysaccharide inside infected macrophages might be converted to 2-hydroxymyristoyl coenzyme A, a well characterized, potent inhibitor of protein N-myristoyl transferase.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Middle Atlantic Mass Spectrometry Lab, Baltimore, MD 21205 USA	Duke University; Johns Hopkins University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, POB 3711, Durham, NC 27710 USA.	raetz@biochem.duke.edu		Gibbons, Henry/0000-0002-5603-8679	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054882, R01GM051310] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07184-23, GM-54882, GM-51310] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BELDEN WJ, 1994, INFECT IMMUN, V62, P5095, DOI 10.1128/IAI.62.11.5095-5101.1994; Beutler B, 2000, CURR OPIN MICROBIOL, V3, P23, DOI 10.1016/S1369-5274(99)00046-6; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRYN K, 1978, EUR J BIOCHEM, V86, P311, DOI 10.1111/j.1432-1033.1978.tb12312.x; CHRIST WJ, 1994, J AM CHEM SOC, V116, P3637, DOI 10.1021/ja00087a075; Clementz T, 1997, J BIOL CHEM, V272, P10353; CLERESCI LS, 1989, STANDARD METHODS EXA; DINARELLO CA, 1991, BLOOD, V77, P1627; Eichhorn E, 1997, J BIOL CHEM, V272, P23031, DOI 10.1074/jbc.272.37.23031; Ernst RK, 1999, J INFECT DIS, V179, pS326, DOI 10.1086/513850; Ernst RK, 1999, SCIENCE, V286, P1561, DOI 10.1126/science.286.5444.1561; ERWIN AL, 1990, J BIOL CHEM, V265, P16444; ERWIN AL, 1992, BACTERIAL ENDOTOXIC, V1, P405; FIELDS PI, 1989, SCIENCE, V243, P1059, DOI 10.1126/science.2646710; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; Garcia-del Portillo F, 1999, TRENDS MICROBIOL, V7, P467, DOI 10.1016/S0966-842X(99)01618-2; GOLDMAN RC, 1988, J BIOL CHEM, V263, P5217; Groisman EA, 1998, BIOESSAYS, V20, P96, DOI 10.1002/(SICI)1521-1878(199801)20:1<96::AID-BIES13>3.0.CO;2-3; GROISMAN EA, 1989, P NATL ACAD SCI USA, V86, P7077, DOI 10.1073/pnas.86.18.7077; Groisman EA, 1997, J BACTERIOL, V179, P7040, DOI 10.1128/jb.179.22.7040-7045.1997; GRONKE RS, 1989, P NATL ACAD SCI USA, V86, P3609, DOI 10.1073/pnas.86.10.3609; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; HANCOCK IC, 1970, BIOCHIM BIOPHYS ACTA, V202, P389, DOI 10.1016/0005-2760(70)90204-3; Hegg EL, 1999, BIOCHEMISTRY-US, V38, P16714, DOI 10.1021/bi991796l; Hegg EL, 1997, EUR J BIOCHEM, V250, P625, DOI 10.1111/j.1432-1033.1997.t01-1-00625.x; Heithoff DM, 1999, SCIENCE, V284, P967, DOI 10.1126/science.284.5416.967; Heithoff DM, 1997, P NATL ACAD SCI USA, V94, P934, DOI 10.1073/pnas.94.3.934; HOLME E, 1975, BIOCHEMISTRY-US, V14, P4999, DOI 10.1021/bi00693a033; HUMPHREYS GO, 1972, J GEN MICROBIOL, V71, P221, DOI 10.1099/00221287-71-2-221; JIA S, 1994, P NATL ACAD SCI USA, V91, P7227, DOI 10.1073/pnas.91.15.7227; JIA S, 1992, J BIOL CHEM, V267, P14322; Jones BD, 1996, ANNU REV IMMUNOL, V14, P533, DOI 10.1146/annurev.immunol.14.1.533; Katz SS, 1999, J BIOL CHEM, V274, P36579, DOI 10.1074/jbc.274.51.36579; KAWAHARA K, 1979, BIOCHIM BIOPHYS ACTA, V572, P1; KAWAI Y, 1982, J BACTERIOL, V151, P996, DOI 10.1128/JB.151.2.996-1005.1982; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Lindgren SW, 1996, P NATL ACAD SCI USA, V93, P4197, DOI 10.1073/pnas.93.9.4197; MAHAN MJ, 1995, P NATL ACAD SCI USA, V92, P669, DOI 10.1073/pnas.92.3.669; MAHAN MJ, 1993, SCIENCE, V259, P686, DOI 10.1126/science.8430319; MEADE HM, 1982, J BACTERIOL, V149, P114, DOI 10.1128/JB.149.1.114-122.1982; Miller J. H., 1972, EXPT MOL GENETICS, P439; MILLER SI, 1990, J BACTERIOL, V172, P2485, DOI 10.1128/jb.172.5.2485-2490.1990; Monack DM, 1996, P NATL ACAD SCI USA, V93, P9833, DOI 10.1073/pnas.93.18.9833; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; MUNFORD RS, 1986, SCIENCE, V234, P203, DOI 10.1126/science.3529396; Nikaido H., 1996, ESCHERICHIA COLI SAL, P29; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; Odegaard TJ, 1997, J BIOL CHEM, V272, P19688, DOI 10.1074/jbc.272.32.19688; PAIGE LA, 1990, BIOCHEMISTRY-US, V29, P10566, DOI 10.1021/bi00498a021; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RAETZ CRH, 1973, J BIOL CHEM, V248, P1098; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; Reissbrodt R, 1997, J BACTERIOL, V179, P4538, DOI 10.1128/jb.179.14.4538-4544.1997; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; RichterDahlfors A, 1997, J EXP MED, V186, P569, DOI 10.1084/jem.186.4.569; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sanderson KE, 1996, ESCHERICHIA COLI SAL, V2, P1903; Schofield CJ, 1999, CURR OPIN STRUC BIOL, V9, P722, DOI 10.1016/S0959-440X(99)00036-6; Soncini FC, 1996, J BACTERIOL, V178, P5092, DOI 10.1128/jb.178.17.5092-5099.1996; STENFLO J, 1989, P NATL ACAD SCI USA, V86, P444, DOI 10.1073/pnas.86.2.444; THORNBURG LD, 1993, BIOCHEMISTRY-US, V32, P14034, DOI 10.1021/bi00213a037; Valegard K, 1998, NATURE, V394, P805, DOI 10.1038/29575; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; WELCH DF, 1991, CLIN MICROBIOL REV, V4, P422, DOI 10.1128/CMR.4.4.422-438.1991; Zahringer U, 1995, Prog Clin Biol Res, V392, P113; Zahringer U, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P93; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	76	126	129	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32940	32949		10.1074/jbc.M005779200	http://dx.doi.org/10.1074/jbc.M005779200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10903325	hybrid			2022-12-27	WOS:000090003800078
J	Huang, CS; Zhang, Z; Ding, M; Li, JX; Ye, JP; Leonard, SS; Shen, HM; Butterworth, L; Lu, YJ; Costa, M; Rojanasakul, Y; Castranova, V; Vallyathan, V; Shin, XL				Huang, CS; Zhang, Z; Ding, M; Li, JX; Ye, JP; Leonard, SS; Shen, HM; Butterworth, L; Lu, YJ; Costa, M; Rojanasakul, Y; Castranova, V; Vallyathan, V; Shin, XL			Vanadate induces p53 transactivation through hydrogen peroxide and causes apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; TUMOR-NECROSIS-FACTOR; MORPHOLOGICAL TRANSFORMATION; AMMONIUM METAVANADATE; ACTIVATOR PROTEIN-1; SIGNAL-TRANSDUCTION; RADICAL GENERATION; GENE-EXPRESSION; P38 KINASE; GROWTH	Vanadium is a metal widely distributed in the environment. Although vanadate-containing compounds exert potent toxic effects on a wide variety of biological systems, the mechanisms controlling vanadate-induced adverse effects remain to be elucidated. The present study investigated the vanadate-induced p53 activation and involvement of reactive oxygen species (ROS) in p53 activation as well as the role of p53 in apoptosis induction by vanadate. Exposure of mouse epidermal JB6 cells to vanadate led to transactivation of p53 activity in a time- and dose-dependent manner. It also caused mitochondrial damage, apoptosis, and generated ROS. Scavenging of vanadate-induced H2O2 by N-acetyl-L-cysteine (a general antioxidant) or catalase (a specific H2O2 inhibitor), or the chelation of vanadate by deferoxamine, resulted in inhibition of p53 activation and cell mitochondrial damage. In contract, an increase in H2O2 generation in response to superoxide dismutase or NADPH enhanced these effects caused by vanadate. Furthermore, vanadate-induced apoptosis occurred in cells expressing wild-type p53 (p53+/+) but was very weak in p53-deficient (p53-/-) cells. These results demonstrate that vanadate induces p53 activation mainly through H2O2 generation, and this activation is required for vanadate-induced apoptosis.	NIOSH, Hlth Effects Lab Div, Morgantown, WV 26505 USA; NYU, Sch Med, Nelson Inst Environm Med, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; W Virginia Univ, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); New York University; New York University; West Virginia University	Shin, XL (corresponding author), NIOSH, Hlth Effects Lab Div, Morgantown, WV 26505 USA.	xas0@cdc.gov	Ye, Jianping/N-1998-2017; SHEN, Han-Ming/B-5942-2011; Zhang, Zhuo/B-8601-2012; costa, max/H-1754-2012	Ye, Jianping/0000-0003-3875-365X; SHEN, Han-Ming/0000-0001-7369-5227; Huang, Chuanshu/0000-0003-4133-5096; Rojanasakul, Yon/0000-0002-8839-6462				Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; ALLEN PD, 1993, BLOOD REV, V7, P63, DOI 10.1016/0268-960X(93)90025-Y; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; Chen ZP, 1996, BIOCHEM MOL BIOL INT, V38, P607; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COHEN MD, 1992, MUTAT RES, V269, P141, DOI 10.1016/0027-5107(92)90169-3; Ding M, 1999, CARCINOGENESIS, V20, P663, DOI 10.1093/carcin/20.4.663; EDINGTON SM, 1993, BIOTECHNOLOGY, V11, P787; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; GOUGEON ML, 1993, SCIENCE, V260, P1269, DOI 10.1126/science.8098552; HARVEY M, 1993, ONCOGENE, V8, P2457; HENNET T, 1993, CANCER RES, V53, P1456; Huang CS, 1998, CANCER RES, V58, P4102; Huang CS, 1998, INT J ONCOL, V13, P711; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang CS, 1999, CARCINOGENESIS, V20, P237, DOI 10.1093/carcin/20.2.237; Huang CS, 1997, J BIOL CHEM, V272, P4187, DOI 10.1074/jbc.272.7.4187; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1997, P NATL ACAD SCI USA, V94, P11957, DOI 10.1073/pnas.94.22.11957; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; Meek DW, 1997, BIOCHEM SOC T, V25, P416, DOI 10.1042/bst0250416; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NORDEEN SK, 1976, J BIOL CHEM, V251, P7295; NRIAGU JO, 1988, NATURE, V333, P134, DOI 10.1038/333134a0; PARFETT CLJ, 1995, FOOD CHEM TOXICOL, V33, P301, DOI 10.1016/0278-6915(94)00141-A; Petit PX, 1996, FEBS LETT, V396, P7, DOI 10.1016/0014-5793(96)00988-X; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RAFF MC, 1992, SCIENCE, V356, P397; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHEU CW, 1992, FOOD CHEM TOXICOL, V30, P307, DOI 10.1016/0278-6915(92)90008-9; SHI XL, 1992, FREE RADICAL RES COM, V17, P369, DOI 10.3109/10715769209083141; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Ye JP, 1999, MOL CELL BIOCHEM, V202, P9, DOI 10.1023/A:1007078915585; Ye JP, 1999, J BIOL CHEM, V274, P34974, DOI 10.1074/jbc.274.49.34974; YIN XF, 1992, MOL CELL BIOCHEM, V115, P85	48	147	151	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32516	32522		10.1074/jbc.M005366200	http://dx.doi.org/10.1074/jbc.M005366200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10922372	hybrid, Green Submitted			2022-12-27	WOS:000090003800020
J	Keyhani, NO; Li, XB; Roseman, S				Keyhani, NO; Li, XB; Roseman, S			Chitin catabolism in the marine bacterium Vibrio furnissii - Identification and molecular cloning of a chitoporin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAFFINOSE PLASMID PRSD2; GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI; PHOSPHOTRANSFERASE SYSTEM; SUGAR-TRANSPORT; OUTER-MEMBRANE; DIFFUSION CHANNELS; RECEPTOR PROTEIN; ENTERIC BACTERIA; CASCADE	Chitin catabolism by the marine bacterium Vibrio furnissii involves many genes and proteins, including two unique periplasmic hydrolases, a chitodextrinase and a beta -N-acetylglucosaminidase (Keyhani, N. O., and Roseman, S, (1996) J. Biol; Chem. 271, 33414-33424 and 33425-33432). A specific chitoporin in the outer membrane may be required for these glycosidases to be accessible to extracellular chitooligosaccharides, (GlcN-Ac)(n), that are produced by chitinases. We report here the identification and molecular cloning of such a porin. An outer membrane protein, OMP (apparent molecular mass 40 kDa) was expressed when V, furnissii was induced by (GlcNAc)(n), n = 2-6, but not by GlcNAc or other sugars. Based on the N-terminal sequence of OMP, oligonucleotides were synthesized and used to clone the gene, chiP. The deduced amino acid sequence of ChiP is similar to several bacterial porins; OMP is a processed form of Chip. In Escherichia coli, two recombinant proteins were observed, corresponding to processed and unprocessed forms of ChiP, A null mutant of chiP was constructed in V. furnissii. In contrast to the parental strain, the mutant did not grow on (GlcNAc), and transported a nonmetabolizable analogue of (GlcNAc), at a reduced rate. These results imply that ChiP is a specific chitoporin.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, McCollum Pratt Inst, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Roseman, S (corresponding author), Johns Hopkins Univ, Dept Biol, Mudd Hall,Rm 214,3400 N Charles St, Baltimore, MD 21218 USA.		Keyhani, Nemat O/I-8150-2013		NIGMS NIH HHS [GM51215] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen C, 1998, EUR J BIOCHEM, V254, P679, DOI 10.1046/j.1432-1327.1998.2540679.x; AUSUBEL FM, 1996, CURRENT PROTOCOLS MO, V1; BASSLER BL, 1991, J BIOL CHEM, V266, P24268; BASSLER BL, 1991, J BIOL CHEM, V266, P24276; BENZ R, 1988, ANNU REV MICROBIOL, V42, P359, DOI 10.1146/annurev.mi.42.100188.002043; Bouma CL, 1996, J BIOL CHEM, V271, P33457, DOI 10.1074/jbc.271.52.33457; Bouma CL, 1996, J BIOL CHEM, V271, P33468, DOI 10.1074/jbc.271.52.33468; Chitlaru E, 1996, J BIOL CHEM, V271, P33433, DOI 10.1074/jbc.271.52.33433; FILIP C, 1973, J BACTERIOL, V115, P717, DOI 10.1128/JB.115.3.717-722.1973; FORST S, 1988, J BACTERIOL, V170, P5080, DOI 10.1128/jb.170.11.5080-5085.1988; GEHRING K, 1991, J BACTERIOL, V173, P1873, DOI 10.1128/jb.173.6.1873-1878.1991; HOROWITZ ST, 1957, J AM CHEM SOC, V79, P5046, DOI 10.1021/ja01575a059; Keyhani N, 2000, J BIOL CHEM, V275, P33110, DOI 10.1074/jbc.M001717200; Keyhani NO, 2000, J BIOL CHEM, V275, P33102, DOI 10.1074/jbc.M001045200; Keyhani NO, 2000, J BIOL CHEM, V275, P33091, DOI 10.1074/jbc.M001044200; Keyhani NO, 2000, J BIOL CHEM, V275, P33084, DOI 10.1074/jbc.M001043200; Keyhani NO, 1996, J BIOL CHEM, V271, P33425, DOI 10.1074/jbc.271.52.33425; Keyhani NO, 1996, J BIOL CHEM, V271, P33414, DOI 10.1074/jbc.271.52.33414; Keyhani NO, 1996, J BIOL CHEM, V271, P33409, DOI 10.1074/jbc.271.52.33409; LUCKEY M, 1980, BIOCHEM BIOPH RES CO, V93, P166, DOI 10.1016/S0006-291X(80)80261-0; LUCKEY M, 1980, P NATL ACAD SCI-BIOL, V77, P167, DOI 10.1073/pnas.77.1.167; MCCARTER LL, 1987, J BACTERIOL, V169, P3441, DOI 10.1128/jb.169.8.3441-3449.1987; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; MILTON DL, 1992, J BACTERIOL, V174, P7235, DOI 10.1128/jb.174.22.7235-7244.1992; NIKAIDO H, 1994, J BIOL CHEM, V269, P3905; NIKAIDO H, 1981, J GEN PHYSIOL, V77, P121, DOI 10.1085/jgp.77.2.121; NIKAIDO H, 1992, MOL MICROBIOL, V6, P435, DOI 10.1111/j.1365-2958.1992.tb01487.x; Osborn M J, 1974, Methods Enzymol, V31, P642; Park JK, 2000, J BIOL CHEM, V275, P33077, DOI 10.1074/jbc.M001042200; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; SCHMID K, 1991, MOL MICROBIOL, V5, P941, DOI 10.1111/j.1365-2958.1991.tb00769.x; Schulz GE, 1996, CURR OPIN STRUC BIOL, V6, P485, DOI 10.1016/S0959-440X(96)80113-8; SELVARAJ G, 1984, GENE, V32, P235, DOI 10.1016/0378-1119(84)90051-9; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; STOCK JB, 1982, J BIOL CHEM, V257, P4543; Ulmke C, 1997, J BACTERIOL, V179, P5783, DOI 10.1128/jb.179.18.5783-5788.1997; Wang LX, 1995, CARBOHYDR LETT, V1, P185; WANG YF, 1997, J MOL BIOL, V272, P57; WAYGOOD EB, 1979, ANAL BIOCHEM, V95, P293, DOI 10.1016/0003-2697(79)90219-7; YU C, 1993, J BIOL CHEM, V268, P9405; YU C, 1991, J BIOL CHEM, V266, P24260	43	60	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33068	33076		10.1074/jbc.M001041200	http://dx.doi.org/10.1074/jbc.M001041200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10913115	hybrid			2022-12-27	WOS:000090003800094
J	Marini, I; Moschini, R; Del Corso, A; Mura, U				Marini, I; Moschini, R; Del Corso, A; Mura, U			Complete protection by alpha-crystallin of lens sorbitol dehydrogenase undergoing thermal stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONE-LIKE ACTIVITY; HEAT-SHOCK-PROTEIN; MOLECULAR CHAPERONE; B-CRYSTALLIN; DENATURATION; SYSTEM	Sorbitol dehydrogenase (L-iditol:NAD(+) 2-oxidoreductase, E.C. 1.1.1.14) (SDH) was significantly protected from thermally induced inactivation and aggregation by bovine lens cu-crystallin, An alpha -crystallin/SDH ratio as low as 1:2 in weight was sufficient to preserve the transparency of the enzyme solution kept for at least 2 h at 55 degreesC, Moreover, an alpha -crystallin/SDH ratio of 5:1 (w/w) was sufficient to preserve the enzyme activity fully at 55 degreesC for at least 40 min. The protection by alpha -crystallin of SDH activity was essentially unaffected by high ionic strength (i.e. 0.5 M NaCl). On the other hand, the transparency of the protein solution was lost at a high salt concentration because of the precipitation of the alpha -crystallin/SDH adduct, Magnesium and calcium ions present at millimolar concentrations antagonized the protective action exerted by alpha -crystallin against the thermally induced inactivation and aggregation of SDH, The lack of protection of alpha -crystallin against the inactivation of SDH induced at 55 degreesC by thiol blocking agents or EDTA together with the additive effect of NADH in stabilizing the enzyme in the presence of rw-crystallin suggest that functional groups involved in catalysis are freely accessible in SDH while interacting with alpha -crystallin. Two different adducts between alpha -crystallin and SDH were isolated by gel filtration chromatography, One adduct was characterized by a high M-r of approximately 800,000 and carried exclusively inactive SDH, A second adduct, carrying active SDH, had a size consistent with an interaction of the enzyme with monomers or low M,aggregates of alpha -crystallin. Even though it had a reduced efficiency with respect to alpha -crystallin, bovine serum albumin was shown to mimic the chaperone-like activity of alpha -crystallin in protecting SDH from thermal denaturation. These findings suggest that the multimeric structural organization of alpha -crystallin may not be a necessary requirement for the stabilization of the enzyme activity.	Univ Pisa, Dipartimento Fisiol & Biochim, Biochim Lab, I-56100 Pisa, Italy	University of Pisa	Mura, U (corresponding author), Univ Pisa, Dipartimento Fisiol & Biochim, Biochim Lab, Via S Maria 55, I-56100 Pisa, Italy.		Moschini, Roberta/AAL-8338-2020	Moschini, Roberta/0000-0001-5227-2348; DEL CORSO, ANTONELLA/0000-0003-3165-6128				BOELENS WC, 1995, MOL BIOL REP, V21, P75, DOI 10.1007/BF00986495; BOYLE D, 1994, EXP EYE RES, V58, P9, DOI 10.1006/exer.1994.1190; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARVER JA, 1994, BBA-PROTEIN STRUCT M, V1204, P195, DOI 10.1016/0167-4838(94)90009-4; CARVER JA, 1995, BBA-PROTEIN STRUCT M, V1252, P251, DOI 10.1016/0167-4838(95)00146-L; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; Derham BK, 1997, BBA-GEN SUBJECTS, V1336, P187, DOI 10.1016/S0304-4165(97)00029-9; Head MW, 1996, J CELL SCI, V109, P1029; HESS JF, 1998, MOL VIS, V15, P4; Hook DWA, 1998, INT J BIOL MACROMOL, V22, P295, DOI 10.1016/S0141-8130(98)00027-0; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1992, AM J PATHOL, V140, P345; JEFFERY J, 1988, ADV ENZYMOL RAMB, V61, P47; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P201, DOI 10.1016/0304-4165(91)90062-L; Koretz JF, 1998, INT J BIOL MACROMOL, V22, P283, DOI 10.1016/S0141-8130(98)00026-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Marini I, 1997, ARCH BIOCHEM BIOPHYS, V340, P383, DOI 10.1006/abbi.1997.9882; MARINI I, 1995, BIOCHEM BIOPH RES CO, V212, P413, DOI 10.1006/bbrc.1995.1985; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MERCK KB, 1993, J BIOL CHEM, V268, P1046; Muchowski PJ, 1998, P NATL ACAD SCI USA, V95, P1004, DOI 10.1073/pnas.95.3.1004; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; Raman B, 1997, J BIOL CHEM, V272, P23559, DOI 10.1074/jbc.272.38.23559; RAMAN B, 1994, J BIOL CHEM, V269, P27264; RAO PV, 1993, BIOCHEM BIOPH RES CO, V190, P786, DOI 10.1006/bbrc.1993.1118; Smulders RHPH, 1998, INT J BIOL MACROMOL, V22, P187, DOI 10.1016/S0141-8130(98)00016-6; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; vanNoort JM, 1996, J MOL MED-JMM, V74, P285, DOI 10.1007/s001090050030; WANG KY, 1994, J BIOL CHEM, V269, P13601; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	32	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32559	32565		10.1074/jbc.M006133200	http://dx.doi.org/10.1074/jbc.M006133200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10930418	hybrid			2022-12-27	WOS:000090003800026
J	Fan, XM; Brass, LF; Poncz, M; Spitz, F; Maire, P; Manning, DR				Fan, XM; Brass, LF; Poncz, M; Spitz, F; Maire, P; Manning, DR			The alpha subunits of G(z) and G(i) interact with the eyes absent transcription cofactor Eya2, preventing its interaction with the six class of homeodomain-containing proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; NUCLEOTIDE EXCHANGE FACTOR; GTPASE-ACTIVATING PROTEIN; HETEROTRIMERIC G-PROTEINS; CYCLIC-AMP ACCUMULATION; SERUM RESPONSE FACTOR; NF-KAPPA-B; BINDING PROTEIN; DROSOPHILA EYE; SF9 CELLS	Yeast two-hybrid techniques were used to identify possible effecters for the heterotrimeric G protein G, in human bone marrow cells. Eya2, a human homologue of the Drosophila Eya transcription co-activator, was identified. Eya2 interacts with activated G alpha(z), and at feast one other member of the G alpha(i) family, G alpha(i2),. Interactions were confirmed in mammalian two-hybrid and glutathione S-transferase fusion protein pull-down assays. Regions of Eya2-mediating interaction were mapped to the C-terminal Eya consensus domain. Eya2 is an intrinsically cytosolic protein that is translocated to the nucleus by members of the Six homeodomain-containing family of proteins. Activated G alpha(z) and G alpha(i2) prevent Eya2 translocation and inhibit Six/Eya2-mediated activation of a reporter gene controlled through the MEF3/TATA promoter. Although G proteins are known to regulate the activity of numerous transcription factors, this regulation is normally achieved indirectly via one or more intermediates. We show here a novel functional regulation of a co-activator directly by G protein subunits.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Paris 05, Inst Cochin Genet Mol, INSERM, U129, F-75014 Paris, France	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Manning, DR (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 3620 Hamilton Walk, Philadelphia, PA 19104 USA.		Maire, Pascal/E-6339-2016	Maire, Pascal/0000-0001-7795-0029	NHLBI NIH HHS [HL45181] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045181] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alberts AS, 1998, J BIOL CHEM, V273, P8616, DOI 10.1074/jbc.273.15.8616; Barr AJ, 1997, J BIOL CHEM, V272, P2223; BERVEN LA, 1995, J BIOL CHEM, V270, P25893, DOI 10.1074/jbc.270.43.25893; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; BONINI NM, 1995, CURR OPIN GENET DEV, V5, P507, DOI 10.1016/0959-437X(95)90056-M; Borsani G, 1999, HUM MOL GENET, V8, P11, DOI 10.1093/hmg/8.1.11; Boucher CA, 1996, GENOMICS, V33, P140, DOI 10.1006/geno.1996.0172; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; Chen LT, 1999, J BIOL CHEM, V274, P26931, DOI 10.1074/jbc.274.38.26931; Chen R, 1997, CELL, V91, P893, DOI 10.1016/S0092-8674(00)80481-X; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; Coso OA, 1996, J BIOL CHEM, V271, P3963; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Crouch MF, 2000, CELL SIGNAL, V12, P153, DOI 10.1016/S0898-6568(99)00080-7; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; Fishburn CS, 2000, P NATL ACAD SCI USA, V97, P1085, DOI 10.1073/pnas.97.3.1085; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Garcia DE, 1998, J NEUROSCI, V18, P9163; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; HALLAK H, 1994, J BIOL CHEM, V269, P4571; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Harhammer R, 1996, FEBS LETT, V399, P211, DOI 10.1016/S0014-5793(96)01327-0; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HIDE M, 1991, MOL PHARMACOL, V40, P473; HINTON DR, 1990, J NEUROSCI, V10, P2763; Jeong SW, 1998, NEURON, V21, P1201, DOI 10.1016/S0896-6273(00)80636-4; Johanson SO, 1996, NEUROCHEM RES, V21, P779, DOI 10.1007/BF02532300; JONES DT, 1987, J BIOL CHEM, V262, P14241; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; Lin P, 2000, P NATL ACAD SCI USA, V97, P674, DOI 10.1073/pnas.97.2.674; Luo Y, 1999, J BIOL CHEM, V274, P10685, DOI 10.1074/jbc.274.16.10685; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Meng JW, 1999, J BIOL CHEM, V274, P36663, DOI 10.1074/jbc.274.51.36663; MOCHIZUKI N, 1995, FEBS LETT, V373, P155, DOI 10.1016/0014-5793(95)01031-9; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Ohto H, 1999, MOL CELL BIOL, V19, P6815; Pignoni F, 1997, CELL, V91, P881, DOI 10.1016/S0092-8674(00)80480-8; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Pryciak PM, 1996, MOL CELL BIOL, V16, P2614; PUMIGLIA KM, 1995, J BIOL CHEM, V270, P14251, DOI 10.1074/jbc.270.24.14251; Ram PT, 2000, SCIENCE, V287, P142, DOI 10.1126/science.287.5450.142; Shahrestanifar M, 1999, J BIOL CHEM, V274, P3828, DOI 10.1074/jbc.274.6.3828; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Spitz F, 1998, P NATL ACAD SCI USA, V95, P14220, DOI 10.1073/pnas.95.24.14220; Vorobiov D, 2000, J BIOL CHEM, V275, P4166, DOI 10.1074/jbc.275.6.4166; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; Xu PX, 1997, DEVELOPMENT, V124, P219; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246; ZIGMAN JM, 1994, ENDOCRINOLOGY, V135, P31, DOI 10.1210/en.135.1.31; Zimmerman JE, 1997, GENOME RES, V7, P128, DOI 10.1101/gr.7.2.128	63	48	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32129	32134		10.1074/jbc.M004577200	http://dx.doi.org/10.1074/jbc.M004577200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10906137	hybrid			2022-12-27	WOS:000089858900079
J	Gadda, G; Banerjee, A; Dangott, LJ; Fitzpatrick, PF				Gadda, G; Banerjee, A; Dangott, LJ; Fitzpatrick, PF			Identification of a cysteine residue in the active site of nitroalkane oxidase by modification with N-ethylmaleimide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROOROTATE DEHYDROGENASE-A; FAD-CONTAINING FORM; FUSARIUM-OXYSPORUM; 2-NITROPROPANE DIOXYGENASE; FLAVIN; ENZYME; PRINCIPLE; MECHANISM	The flavoprotein nitroalkane oxidase catalyzes the oxidative denitrification of primary or secondary nitroalkanes to the corresponding aldehydes or ketones with production of hydrogen peroxide and nitrite. The enzyme is irreversibly inactivated by treatment with N-ethylmaleimide at pH 7. The inactivation is time-dependent and shows first-order kinetics for three half-lives. The second-order rate constant for inactivation is 3.4 +/- 0.06 M-1 min-l. The competitive inhibitor valerate protects the enzyme from inactivation, indicating an active site-directed modification. Comparison of tryptic maps of enzyme treated with N-[ethyl-1-C-14]maleimide in the absence and presence of valerate shows a single radioactive peptide differentially labeled in the unprotected enzyme. The sequence of this peptide was determined to be LLNEVMCYPLFDGGNIGLR using Edman degradation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. The cysteine residue was identified as the site of alkylation by ion trap mass spectrometry.	2128 TAMU, Dept Biochem & Biophys, College Stn, TX 77843 USA; 2128 TAMU, Dept Chem, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University System; Texas A&M University College Station	Fitzpatrick, PF (corresponding author), 2128 TAMU, Dept Biochem & Biophys, College Stn, TX 77843 USA.		Gadda, Giovanni/M-2354-2016	Gadda, Giovanni/0000-0002-7508-4195	NIGMS NIH HHS [GM 58698] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNASCONI CF, 1992, ADV PHYS ORG CHEM, V27, P119; Bjornberg O, 1997, BIOCHEMISTRY-US, V36, P16197, DOI 10.1021/bi971628y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Davis Richard A., 1993, P599; Edmondson RD, 1996, J AM SOC MASS SPECTR, V7, P995, DOI 10.1016/1044-0305(96)00027-X; Edmondson RD, 1997, ANAL CHEM, V69, P2862, DOI 10.1021/ac9700989; Gadda G, 1997, J BIOL CHEM, V272, P5563, DOI 10.1074/jbc.272.9.5563; Gadda G, 2000, BIOCHEMISTRY-US, V39, P1400, DOI 10.1021/bi9922547; Gadda G, 1998, BIOCHEMISTRY-US, V37, P6154, DOI 10.1021/bi973085y; Gadda G, 1999, ARCH BIOCHEM BIOPHYS, V363, P309, DOI 10.1006/abbi.1998.1081; Gadda G, 2000, BIOCHEMISTRY-US, V39, P1406, DOI 10.1021/bi992255z; Gadda G, 2000, BIOCHEMISTRY-US, V39, P1162, DOI 10.1021/bi9921743; Gorlatova N, 1998, APPL ENVIRON MICROB, V64, P1029; Heasley CJ, 1996, BIOCHEM BIOPH RES CO, V225, P6, DOI 10.1006/bbrc.1996.1122; Jencks W. P., 1976, HDB BIOCH MOL BIOL, P305; KIDO T, 1984, AGR BIOL CHEM TOKYO, V48, P2549, DOI 10.1080/00021369.1984.10866530; KIDO T, 1978, J BACTERIOL, V133, P53, DOI 10.1128/JB.133.1.53-58.1978; PORTER DJT, 1972, Z NATURFORSCH PT B, VB 27, P1052; PORTER DJT, 1977, J BIOL CHEM, V252, P4361; QUINN DM, 1991, ENZYME MECH ISOTOPE, P73; Riordan J.F., 1967, METHOD ENZYMOL, V11, P541; Rowland P, 1998, PROTEIN SCI, V7, P1269, DOI 10.1002/pro.5560070601	22	12	12	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31891	31895		10.1074/jbc.M003679200	http://dx.doi.org/10.1074/jbc.M003679200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10913134	hybrid			2022-12-27	WOS:000089858900049
J	Guagliardi, A; Cerchia, L; Moracci, M; Rossi, M				Guagliardi, A; Cerchia, L; Moracci, M; Rossi, M			The chromosomal protein Sso7d of the crenarchaeon Sulfolobus solfataricus rescues aggregated proteins in an ATP hydrolysis-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; IN-VITRO; MOLECULAR CHAPERONE; ARCHAEAL PROTEIN; IDENTIFICATION; REPLICATION; DOMAIN; HSP70; SAC7D	In this work, we show that the nonspecific DNA-binding protein Sso7d from the crenarchaeon Sulfolobus solfataricus displays a cation-dependent ATPase activity with a pH optimum around neutrality and a temperature optimum of 70 degrees C. Measurements of tryptophan fluorescence and experiments that used 1-anilinonaphthalene-8-sulfonic acid as probe demonstrated that ATP hydrolysis induces a conformational change in the molecule and that the binding of the nucleotide triggers the ATP hydrolysis-induced conformation of the protein to return to the native conformation. We found that Sso7d rescues previously aggregated proteins in an ATP hydrolysis-dependent manner; the native conformation of Sso7d forms a complex with the aggregates, while the ATP hydrolysis-induced conformation is incapable of this interaction. Sso7d is believed to be the first protein isolated from an archaeon capable of rescuing aggregates.	Univ Naples Federico II, Dipartimento Chim Organ & Biol, I-80134 Naples, Italy; CNR, Ist Biochim Prot & Enzimol, I-80125 Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR)	Guagliardi, A (corresponding author), Univ Naples Federico II, Dipartimento Chim Organ & Biol, Via Mezzocannone 16, I-80134 Naples, Italy.	guaglia@unina.it	Moracci, Marco/B-8444-2015	Moracci, Marco/0000-0002-9846-2531; Cerchia, Laura/0000-0002-7633-7932				Agback P, 1998, NAT STRUCT BIOL, V5, P579, DOI 10.1038/836; Ball LJ, 1997, EMBO J, V16, P2473, DOI 10.1093/emboj/16.9.2473; BAUMANN H, 1994, NAT STRUCT BIOL, V1, P808, DOI 10.1038/nsb1194-808; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CARDAMONE M, 1992, BIOCHEM J, V282, P589, DOI 10.1042/bj2820589; Cerchia L, 2000, EXTREMOPHILES, V4, P1, DOI 10.1007/s007920050131; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; EDMONDSON SP, 1995, BIOCHEMISTRY-US, V34, P13289, DOI 10.1021/bi00041a004; Gao YG, 1998, NAT STRUCT BIOL, V5, P782, DOI 10.1038/1822; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; GUAGLIARDI A, 1994, BIOCATALYSIS, V11, P181, DOI 10.3109/10242429409034387; GUAGLIARDI A, 1995, J BIOL CHEM, V270, P28126; Guagliardi A, 1997, J MOL BIOL, V267, P841, DOI 10.1006/jmbi.1996.0873; GUAGLIARDI A, 1994, PROTEIN SCI, V3, P1436, DOI 10.1002/pro.5560030910; HWANG DS, 1990, J BIOL CHEM, V265, P19244; Jakob U, 1996, J BIOL CHEM, V271, P10035, DOI 10.1074/jbc.271.17.10035; Knapp S, 1998, PROTEINS, V31, P309, DOI 10.1002/(SICI)1097-0134(19980515)31:3<309::AID-PROT7>3.0.CO;2-D; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; LIBEREK K, 1988, P NATL ACAD SCI USA, V85, P6632, DOI 10.1073/pnas.85.18.6632; Lopez-Garcia P, 1998, NUCLEIC ACIDS RES, V26, P2322, DOI 10.1093/nar/26.10.2322; Lundback T, 1998, J MOL BIOL, V276, P775, DOI 10.1006/jmbi.1997.1558; Moracci M, 1996, PROTEIN ENG, V9, P1191, DOI 10.1093/protein/9.12.1191; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Robinson H, 1998, NATURE, V392, P202, DOI 10.1038/32455; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Takahashi M, 1996, EUR J BIOCHEM, V242, P20, DOI 10.1111/j.1432-1033.1996.0020r.x; WHEELIS ML, 1992, P NATL ACAD SCI USA, V89, P2930, DOI 10.1073/pnas.89.7.2930	31	21	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31813	31818		10.1074/jbc.M002122200	http://dx.doi.org/10.1074/jbc.M002122200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10908560	hybrid			2022-12-27	WOS:000089858900039
J	Marcinkiewicz, C; Taooka, Y; Yokosaki, Y; Calvete, JJ; Marcinkiewicz, MM; Lobb, RR; Niewiarowski, S; Sheppard, D				Marcinkiewicz, C; Taooka, Y; Yokosaki, Y; Calvete, JJ; Marcinkiewicz, MM; Lobb, RR; Niewiarowski, S; Sheppard, D			Inhibitory effects of MLDG-containing heterodimeric disintegrins reveal distinct structural requirements for interaction of the integrin alpha 9 ss 1 with VCAM-1, tenascin-C, and osteopontin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; BINDING-SITE; ALPHA(9)BETA(1) INTEGRIN; NEUTROPHIL MIGRATION; GLYCOPROTEIN IB; TERMINAL DOMAIN; VIPER VENOMS; III REPEAT; RGD; PROTEINS	The integrin alpha 9 beta 1 is expressed on epithelial cells, smooth muscle cells, skeletal muscle, and neutrophils and recognizes at least three distinct ligands: vascular cell adhesion molecule 1 (VCAM-1), tenascin-C, and osteopontin. The alpha 9 subunit is structurally similar to the integrin alpha 4 subunit, and alpha 9 beta 1 and alpha 4 beta 1 both recognize VCAM-1 as a ligand. We therefore examined whether the disintegrin EC3, which we have recently shown specifically inhibits the binding of alpha 4 integrins to ligands, would also be a functional inhibitor of alpha 9 beta 1. EC3 and a novel heterodimeric disintegrin that we identified, EC6, both were potent inhibitors of alpha 9 beta 1-mediated adhesion to VCAM-1 and of neutrophil migration across tumor necrosis factor-activated endothelial cells. A peptide containing a novel MLDG motif shared by both of these disintegrins also inhibited alpha 9 beta 1- and alpha 4 beta 1-mediated adhesion to VCAM-1. Surprisingly though, concentrations of EC3 that completely inhibited adhesion of alpha 9-transfected cells to VCAM-1 had little or no effect on adhesion to either of the other alpha 9 beta 1 ligands, osteopontin and tenascin-C. Furthermore, peptides AEIDGIEL and SV-VYGLR, which we have previously shown inhibit binding of alpha 9 beta 1-expressing cells to tenascin-C and osteopontin, respectively, had no effect on adhesion to VCAM-1. These data suggest that there are structurally distinct requirements for interactions of the alpha 9 beta 1 integrin with VCAM-1 and the extracellular matrix ligands osteopontin and tenascin-C.	Univ Calif San Francisco, Lung Biol Ctr, Ctr Environm & Occupat Hlth, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Temple Univ, Sch Med, Dept Physiol, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA; Natl Hiroshima Hosp, Dept Internal Med, Higashihiroshima 7390041, Japan; Natl Hiroshima Hosp, Dept Lab Med, Higashihiroshima 7390041, Japan; CSIC, Inst Biomed, E-46010 Valencia, Spain; Biogen Inc, Cambridge, MA 02142 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); Biogen	Sheppard, D (corresponding author), Univ Calif San Francisco, Lung Biol Ctr, Ctr Environm & Occupat Hlth, Cardiovasc Res Inst, Box 0854, San Francisco, CA 94143 USA.	deans@itsa.ucsf.edu	Calvete, Juan J/K-9619-2014; Calvete, Juan/P-2555-2019	Calvete, Juan J/0000-0001-5026-3122; Calvete, Juan/0000-0001-5026-3122	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047412, R37HL053949, R01HL053949, R01HL033259] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL/AI33259, HL47412, HL53949] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BJARNASON JB, 1994, PHARMACOL THERAPEUT, V62, P325, DOI 10.1016/0163-7258(94)90049-3; Brando C, 2000, BIOCHEM BIOPH RES CO, V267, P413, DOI 10.1006/bbrc.1999.1897; COOPER D, 1995, P NATL ACAD SCI USA, V92, P3978, DOI 10.1073/pnas.92.9.3978; Dickeson SK, 1999, J BIOL CHEM, V274, P32182, DOI 10.1074/jbc.274.45.32182; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; Fujimura Y, 1996, THROMB HAEMOSTASIS, V76, P633; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; GRESHAM HD, 1986, J IMMUNOL, V137, P868; HUANG TF, 1987, J BIOL CHEM, V262, P16157; Kamiguti AS, 1997, J BIOL CHEM, V272, P32599, DOI 10.1074/jbc.272.51.32599; KENT SJ, 1995, J NEUROIMMUNOL, V58, P1, DOI 10.1016/0165-5728(94)00165-K; King SL, 1997, J BIOL CHEM, V272, P28518, DOI 10.1074/jbc.272.45.28518; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Marcinkiewicz C, 1999, BIOCHEMISTRY-US, V38, P13302, DOI 10.1021/bi9906930; Marcinkiewicz C, 1999, J BIOL CHEM, V274, P12468, DOI 10.1074/jbc.274.18.12468; Marcinkiewicz C, 1997, BLOOD, V90, P1565, DOI 10.1182/blood.V90.4.1565.1565_1565_1575; McLane MA, 1998, P SOC EXP BIOL MED, V219, P109, DOI 10.3181/00379727-219-44322; MCLANE MA, 1994, BIOCHEM J, V301, P289; MUSIAL J, 1990, CIRCULATION, V82, P261, DOI 10.1161/01.CIR.82.1.261; NIEWIAROWSKI S, 1994, SEMIN HEMATOL, V31, P289; PALMER EL, 1993, J CELL BIOL, V123, P1289, DOI 10.1083/jcb.123.5.1289; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; RAHMAN S, 1995, BIOCHEM J, V312, P223, DOI 10.1042/bj3120223; Shang T, 1999, J LEUKOCYTE BIOL, V66, P809, DOI 10.1002/jlb.66.5.809; Smith LL, 1998, EXP CELL RES, V242, P351, DOI 10.1006/excr.1998.4108; Smith LL, 1996, J BIOL CHEM, V271, P28485, DOI 10.1074/jbc.271.45.28485; Tan L, 1999, BLOOD, V93, P2605, DOI 10.1182/blood.V93.8.2605.408k18_2605_2616; Taooka Y, 1999, J CELL BIOL, V145, P413, DOI 10.1083/jcb.145.2.413; TRIPANILOMBARDO V, 1985, J CLIN INVEST, V76, P1950; Wang A, 1996, AM J RESP CELL MOL, V15, P664, DOI 10.1165/ajrcmb.15.5.8918373; YEDNOCK TA, 1995, J BIOL CHEM, V270, P28740, DOI 10.1074/jbc.270.48.28740; YOKOSAKI Y, 1994, J BIOL CHEM, V269, P26691; Yokosaki Y, 1998, J BIOL CHEM, V273, P11423, DOI 10.1074/jbc.273.19.11423; Yokosaki Y, 1999, J BIOL CHEM, V274, P36328, DOI 10.1074/jbc.274.51.36328	34	56	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31930	31937		10.1074/jbc.M003209200	http://dx.doi.org/10.1074/jbc.M003209200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10926928	hybrid			2022-12-27	WOS:000089858900054
J	Jiang, XJ; Wang, XD				Jiang, XJ; Wang, XD			Cytochrome c promotes caspase-9 activation by inducing nucleotide binding to Apaf-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEGANS CED-4; APOPTOSIS; OLIGOMERIZATION; PROCASPASE-9; DATP; REQUIREMENT; PATHWAYS; HOMOLOG; COMPLEX; DEATH	We report here the biochemical analysis of the reconstituted de novo procaspase-9 activation using highly purified cytochrome c, recombinant apoptotic protease-activating factor-1 (Apaf-1), and recombinant procaspase-9. Using a nucleotide binding assay, we found that Apaf-1 alone bound dATP poorly and the nucleotide binding to Apaf-1 was significantly stimulated by cytochrome c, The binding of dATP to Apaf-1 induces the formation of a multimeric Apaf-1 cytochrome c complex, apoptosome. Procaspase-9 also synergistically promotes dATP binding to Apaf-1 in a cytochrome c-dependent manner, The dATP bound to apoptosome remained as dATP, not dADP. A nonhydrolyzable ATP analog, AD-PCP (beta,gamma-methylene adenosine 5'-triphosphate), was able to support apoptosome formation and caspase activation in place of dATP or ATP. These data indicate that the key event in Apaf-1-mediated caspase-9 activation is cytochrome c-induced dATP binding to Apaf-1.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Wang, XD (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Wang, Xiaodong/0000-0001-9885-356X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057158] Funding Source: NIH RePORTER; NIGMS NIH HHS [GMRO1-57158] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chen FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/science.287.5457.1485; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MATTSSON JP, 1994, J BIOL CHEM, V269, P24979; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; SKOOG L, 1974, J BIOL CHEM, V249, P6434; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	21	387	408	3	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31199	31203		10.1074/jbc.C000405200	http://dx.doi.org/10.1074/jbc.C000405200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10940292	hybrid			2022-12-27	WOS:000089762700064
J	Vigers, GPA; Dripps, DJ; Edwards, CK; Brandhuber, BJ				Vigers, GPA; Dripps, DJ; Edwards, CK; Brandhuber, BJ			X-ray crystal structure of a small antagonist peptide bound to interleukin-1 receptor type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-1 RECEPTOR; IDENTIFICATION; PROTEIN; REFINEMENT; MODELS; FAMILY; SITE	Interleukin (IL-1)alpha and IL-1 beta are important mediators of inflammation. The binding of IL-l to interleukin-l receptor (IL-1R) type 1 is the initial step in IL-1 signal transduction and therefore is a tempting target for antiinflammatory therapeutics. To advance our understanding of IL-1R1 binding interactions, we have determined the structure of the extracellular domains of IL-1R1 bound to a 21-amino acid IL-1 antagonist peptide at 3.0-Angstrom resolution. The antagonist peptide binds to the domain 1/2 junction of the receptor, which is a conserved binding site for IL-1 beta and IL-1 receptor antagonist (IL-1ra). This co-crystal structure also reveals that considerable flexibility is present in IL-1R1 because the carboxyl-terminal domain of the receptor is rotated almost 170 degrees relative to the first two domains of the receptor compared with the previously solved IL-1R1 ligand structures. The structure shows an unexpected binding mode for the peptide and may contribute to the design of smaller IL-1R antagonists.	Amgen Inc, Dept Inflammat Res, Boulder, CO 80301 USA	Amgen	Vigers, GPA (corresponding author), Array BioPharma Inc, 1885 33rd St, Boulder, CO 80301 USA.	gvigers@arraybiopharma.com		Vigers, Guy/0000-0003-4451-8453				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Born TL, 2000, J BIOL CHEM, V275, P29946, DOI 10.1074/jbc.M004077200; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; Cullinan EB, 1998, J IMMUNOL, V161, P5614; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DRIPPS DJ, 1991, J BIOL CHEM, V266, P10331; EISENBERG SP, 1991, P NATL ACAD SCI USA, V88, P5232, DOI 10.1073/pnas.88.12.5232; EVANS RJ, 1995, J BIOL CHEM, V270, P11477, DOI 10.1074/jbc.270.19.11477; Horai R, 2000, J EXP MED, V191, P313, DOI 10.1084/jem.191.2.313; Hoshino K, 1999, J IMMUNOL, V162, P5041; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1997, ACTA CRYSTALLOGR D, V53, P179, DOI 10.1107/S0907444996012279; LABRIOLATOMPKINS E, 1991, P NATL ACAD SCI USA, V88, P11182, DOI 10.1073/pnas.88.24.11182; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Nicklin MJH, 2000, J EXP MED, V191, P303, DOI 10.1084/jem.191.2.303; OTWINOWSKI Z, 1993, DATA COLLECTION PROC; PRIESTLE JP, 1989, P NATL ACAD SCI USA, V86, P9667, DOI 10.1073/pnas.86.24.9667; Schreuder H, 1997, NATURE, V386, P194, DOI 10.1038/386194a0; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; Vigers GPA, 1997, NATURE, V386, P190, DOI 10.1038/386190a0; VIGERS GPK, 1994, J BIOL CHEM, V269, P12874; Yanofsky SD, 1996, P NATL ACAD SCI USA, V93, P7381, DOI 10.1073/pnas.93.14.7381	24	43	51	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36927	36933		10.1074/jbc.M006071200	http://dx.doi.org/10.1074/jbc.M006071200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10903327	hybrid			2022-12-27	WOS:000165577700068
J	Heikkinen, J; Risteli, M; Wang, CG; Latvala, J; Rossi, M; Valtavaara, M; Myllyla, R				Heikkinen, J; Risteli, M; Wang, CG; Latvala, J; Rossi, M; Valtavaara, M; Myllyla, R			Lysyl hydroxylase 3 is a multifunctional protein possessing collagen glucosyltransferase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOFORM; CLONING; SPECIFICITY; ANTIBODIES; EXPRESSION; ENZYME; GENE	Lysyl hydroxylase (EC 1.14.11.4) and glucosyltransferase (EC 2.4.1.66) are enzymes involved in post-translational modifications during collagen biosynthesis, We reveal in this paper that the protein produced by the cDNA for human lysyl hydroxylase isoform 3 (LH3) has both lysyl hydroxylase and glucosyltransferase (GGT) activities. The other known lysyl hydroxylase isoforms, LH1, LH2a, and LH2b, have no GGT activity, Furthermore,: antibodies recognizing the amino acid sequence of human LH3 and those against a highly purified chicken GGT partially inhibited the GGT activity. Similarly, a partial inhibition was observed when these antibodies were tested against GGT extracted from human skin fibroblasts. In vitro mutagenesis experiments demonstrate that the amino acids involved in the GGT active site differ from those required for LH3 activity.	Oulu Univ, Dept Biochem, FIN-90014 Oulu, Finland	Finland National Institute for Health & Welfare; University of Oulu	Heikkinen, J (corresponding author), Oulu Univ, Dept Biochem, POB 3000, FIN-90014 Oulu, Finland.		Wang, Chunguang/AAE-7054-2020; Wang, Chunguang/AAE-6997-2020	Wang, Chunguang/0000-0001-5569-321X; 				AUSUBEL FM, 1988, CURRENT PROCOLS MOL; HAUTALA T, 1992, GENOMICS, V13, P62, DOI 10.1016/0888-7543(92)90202-4; HOYHTYA M, 1984, EUR J BIOCHEM, V141, P477, DOI 10.1111/j.1432-1033.1984.tb08217.x; KADLER K, 1994, PROTEIN PROFILE, V1, P545; KADLER K, 1994, PROTEIN PROFILE, V1, P525; KELLOKUMPU S, 1994, J BIOL CHEM, V269, P30524; Kielty Cay M., 1993, P103; Kivirikko K I, 1979, Int Rev Connect Tissue Res, V8, P23; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; KIVIRIKKOKI, 1992, POST TRANSLATIONAL M, P1; Krol BJ, 1996, J INVEST DERMATOL, V106, P11, DOI 10.1111/1523-1747.ep12326956; MYLLYLA R, 1977, BIOCHIM BIOPHYS ACTA, V480, P113, DOI 10.1016/0005-2744(77)90326-6; MYLLYLA R, 1981, BIOCHIM BIOPHYS ACTA, V658, P299, DOI 10.1016/0005-2744(81)90300-4; MYLLYLA R, 1976, EUR J BIOCHEM, V70, P225, DOI 10.1111/j.1432-1033.1976.tb10973.x; MYLLYLA R, 1975, EUR J BIOCHEM, V52, P401, DOI 10.1111/j.1432-1033.1975.tb04008.x; Passoja K, 1998, P NATL ACAD SCI USA, V95, P10482, DOI 10.1073/pnas.95.18.10482; Pirskanen A, 1996, J BIOL CHEM, V271, P9398, DOI 10.1074/jbc.271.16.9398; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Ruotsalainen H, 1999, MATRIX BIOL, V18, P325, DOI 10.1016/S0945-053X(99)00016-5; Valtavaara M, 1997, J BIOL CHEM, V272, P6831, DOI 10.1074/jbc.272.11.6831; Valtavaara M, 1998, J BIOL CHEM, V273, P12881, DOI 10.1074/jbc.273.21.12881; Valtavaara M., 1999, ACTA U OULUENSIS A, V334, P1; Wang CG, 2000, DNA CELL BIOL, V19, P71, DOI 10.1089/104454900314582; Yeowell HN, 1999, MATRIX BIOL, V18, P179, DOI 10.1016/S0945-053X(99)00013-X	24	100	105	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36158	36163		10.1074/jbc.M006203200	http://dx.doi.org/10.1074/jbc.M006203200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10934207	hybrid			2022-12-27	WOS:000165382000073
J	Kao, SY; Lemoine, FJ; Marriott, SJ				Kao, SY; Lemoine, FJ; Marriott, SJ			Suppression of DNA repair by human T cell leukemia virus type 1 Tax is rescued by a functional p53 signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; WILD-TYPE P53; NUCLEAR ANTIGEN; HTLV-I; POLYMERASE-DELTA; HUMAN FIBROBLASTS; TUMOR-SUPPRESSOR; PROTEIN; EXPRESSION; GENE	The Tax protein of human T cell leukemia virus type 1 is a viral transactivator and transforming protein. Tax is known to suppress cellular nucleotide excision repair (NER), and this activity has been proposed to play an important role in Tax transformation. In this study we have investigated the mechanism by which Tax suppresses NER with specific focus on the previously characterized ability of Tax to inhibit p53 function. Suppression of NER by Tax was rescued by overexpression of wild-type p53; however, a p53 transactivation-incompetent mutant did not restore NER activity. The cyclin-dependent kinase inhibitor p21, a major transcriptional target of p53, plays an important role in regulating DNA replication and repair. Overexpression of p21 reversed Tax-induced suppression of NER; however, a p21 C-terminal mutant that lacks the proliferating cell nuclear antigen binding domain did not restore NER activity. Thus, p53 and its downstream effector p21 can inhibit Tax-mediated suppression of DNA repair. These results imply that the inactivation of p53 function by Tax contributes to Tax suppression of DNA repair.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Cell & Mol Biol Program, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Marriott, SJ (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, 1 Baylor Plaza, Houston, TX 77030 USA.	susanm@bcm.tmc.edu			NCI NIH HHS [CA-77371, CA-09197] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077371] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; BRAVO R, 1980, EXP CELL RES, V127, P249, DOI 10.1016/0014-4827(80)90430-9; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; Ford JM, 1998, CANCER RES, V58, P599; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P283; Gartenhaus RB, 1995, LEUKEMIA, V9, P2082; GESSAIN A, 1985, LANCET, V2, P407; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Kao SY, 2000, ONCOGENE, V19, P2240, DOI 10.1038/sj.onc.1203559; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; KAO SY, 2000, RES ADV VIROL, V1, P1; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LOEB LA, 1991, CANCER RES, V51, P3075; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Lydy SL, 1998, VIROLOGY, V250, P60, DOI 10.1006/viro.1998.9378; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; MATSUOKA S, 1994, J BIOL CHEM, V269, P11030; McDonald E, 1996, CANCER RES, V56, P2250; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; Mozzherin DJ, 1997, P NATL ACAD SCI USA, V94, P6126, DOI 10.1073/pnas.94.12.6126; Mozzherin DJ, 1996, J BIOL CHEM, V271, P31711, DOI 10.1074/jbc.271.49.31711; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REID RL, 1993, ONCOGENE, V8, P3029; Ressler S, 1997, J VIROL, V71, P1181, DOI 10.1128/JVI.71.2.1181-1190.1997; SAGGIORO D, 1994, LEUKEMIA LYMPHOMA, V12, P281; SANDS AT, 1995, P NATL ACAD SCI USA, V92, P8517, DOI 10.1073/pnas.92.18.8517; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; SMITH ML, 1995, ONCOGENE, V10, P1053; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	46	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35926	35931		10.1074/jbc.M004397200	http://dx.doi.org/10.1074/jbc.M004397200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10931836	hybrid			2022-12-27	WOS:000165382000042
J	Sawaya, BE; Khalili, K; Gordon, J; Taube, R; Amini, S				Sawaya, BE; Khalili, K; Gordon, J; Taube, R; Amini, S			Cooperative interaction between HIV-1 regulatory proteins Tat and Vpr modulates transcription of the viral genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CELL-CYCLE ARREST; NUCLEAR-LOCALIZATION; TYPE-1 VPR; INDEPENDENT TRANSACTIVATION; MUTATIONAL ANALYSIS; IN-VITRO; P-TEFB; BINDING; RNA	The virion-associated protein of human immunodeficiency virus, type 1 (HIV-1), Vpr, is a small protein with 96 amino acid residues that has the ability to modulate transcription of HIV-1 long terminal repeat (LTR) promoter activity and affects several cellular functions. In this study we have employed molecular approaches to further investigate the mechanism by which Vpr exerts its regulatory effect upon the LTR. We show that by structural and functional interaction with Tat, a potent viral regulatory protein, Vpr synergistically enhances the transcriptional activity of the HIV-1 LTR, Because Tat utilizes cyclin T1 and its partner, CDK9 to elevate the level of transcription from the LTR, we examined the cooperativity between Vpr, Tat, and cyclin T1/CDK9 on viral gene transcription. Results from co-transfection studies indicated superactivation of LTR by Tat and cyclin T1/CDK9 in the presence of wild type Vpr. This activation was not observed with the R73S mutant of Vpr, which contains arginine to serine transition at residue 73, Interestingly, expression of R73S mutant in cells exerts a negative effect on the observed superactivation of the LTR by Tat, cyclin T1/CDK9, and wild type Vpr, Results from protein-protein interaction studies indicated that Vpr is associated with both Tat and cyclin T1 in cells expressing these proteins. Use of deletion mutant proteins in binding studies revealed that the binding sites for Tat and Vpr within cyclin T1 are distinct and that association of these two viral proteins with cyclin T1 is independent from each other. These observations suggest a working model on the cooperative interaction of Vpr with viral and cellular proteins and its involvement in control of viral gene transcription and replication. Moreover identification of R73S mutant of Vpr provides a new therapeutic avenue for controlling HIV-1 gene transcription and replication in the infected cells.	Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19122 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Microbiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Immunol, San Francisco, CA 94143 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Amini, S (corresponding author), Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, 1900 N 12th St,015-96, Philadelphia, PA 19122 USA.		TAUBE, RAN/F-2029-2012	TAUBE, RAN/0000-0002-2062-4537				Agostini I, 1996, J MOL BIOL, V261, P599, DOI 10.1006/jmbi.1996.0485; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P601; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; Cole Ruth, 1997, P117; DIMARZIO P, 1995, J VIROL, V69, P7909, DOI 10.1128/JVI.69.12.7909-7916.1995; Efthymiadis A, 1998, J BIOL CHEM, V273, P1623, DOI 10.1074/jbc.273.3.1623; Emerman M, 1996, CURR BIOL, V6, P1096, DOI 10.1016/S0960-9822(02)00676-0; Endo S, 1989, Virus Genes, V3, P99; Felzien LK, 1998, P NATL ACAD SCI USA, V95, P5281, DOI 10.1073/pnas.95.9.5281; Fujinaga K, 1999, P NATL ACAD SCI USA, V96, P1285, DOI 10.1073/pnas.96.4.1285; Fujinaga K, 1998, J VIROL, V72, P7154, DOI 10.1128/JVI.72.9.7154-7159.1998; Gallia GL, 1999, P NATL ACAD SCI USA, V96, P11572, DOI 10.1073/pnas.96.20.11572; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; Gold MO, 1998, J VIROL, V72, P4448, DOI 10.1128/JVI.72.5.4448-4453.1998; Gummuluru S, 1999, J VIROL, V73, P5422, DOI 10.1128/JVI.73.7.5422-5430.1999; HARRICH D, 1990, EMBO J, V9, P4417, DOI 10.1002/j.1460-2075.1990.tb07892.x; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; Hrimech M, 1999, J VIROL, V73, P4101, DOI 10.1128/JVI.73.5.4101-4109.1999; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; MAHALINGAM S, 1995, VIROLOGY, V212, P331, DOI 10.1006/viro.1995.1490; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; RE F, 1995, J VIROL, V69, P6859, DOI 10.1128/JVI.69.11.6859-6864.1995; Sawaya BE, 1999, GENE THER, V6, P947, DOI 10.1038/sj.gt.3300907; Sawaya BE, 2000, J VIROL, V74, P4877, DOI 10.1128/JVI.74.10.4877-4881.2000; Sawaya BE, 1998, J BIOL CHEM, V273, P20052, DOI 10.1074/jbc.273.32.20052; Shilatifard A, 1998, FASEB J, V12, P1437, DOI 10.1096/fasebj.12.14.1437; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAYLOR JP, 1994, J VIROL, V68, P3971, DOI 10.1128/JVI.68.6.3971-3981.1994; TAYLOR JP, 1992, EMBO J, V11, P3395, DOI 10.1002/j.1460-2075.1992.tb05418.x; WANG LL, 1995, J BIOL CHEM, V270, P25564, DOI 10.1074/jbc.270.43.25564; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Xiao H, 1997, MOL CELL BIOL, V17, P6898, DOI 10.1128/MCB.17.12.6898; Yong Voon Wee, 1997, P157; Zhang SG, 1998, GENE, V212, P157, DOI 10.1016/S0378-1119(98)00178-4; Zhao YQ, 1996, J VIROL, V70, P5821, DOI 10.1128/JVI.70.9.5821-5826.1996; Zhou Y, 1998, VIROLOGY, V242, P414, DOI 10.1006/viro.1998.9028; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	39	97	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35209	35214		10.1074/jbc.M005197200	http://dx.doi.org/10.1074/jbc.M005197200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10931842	hybrid			2022-12-27	WOS:000165422800052
J	Stone, SJ; Vance, JE				Stone, SJ; Vance, JE			Phosphatidylserine synthase-1 and-2 are localized to mitochondria-associated membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE; HAMSTER OVARY CELLS; ENDOPLASMIC-RETICULUM; RAT-LIVER; TRANSMEMBRANE PROTEINS; BIOSYNTHETIC-ENZYMES; GENETIC-EVIDENCE; CONTACT SITES; MOUSE-LIVER; CLONING	We report the subcellular localization of enzymes involved in phosphatidylserine biosynthesis in mammalian cells, Several lines of evidence suggest that phosphatidylserine synthase-l (PSS1) is highly enriched in mitochondria-associated membranes (MAM) and is largely excluded from the bulk of the endoplasmic reticulum (ER). Taking advantage of the substrate specificity of PSS1, we showed that (i) MAM contain choline exchange activity, whereas this activity is very low in the bulk of the ER, (ii) serine exchange activity is inhibited by choline to a much greater extent in MAM than in ER, and (iii) MAM use phosphatidylcholine and phosphatidylethanolamine as substrates for phosphatidylserine biosynthesis, whereas the ER utilizes only phosphatidylethanolamine. According to immunoblotting of proteins from both CHO-K1 cells and murine liver, PSS1 is localized to MAM, and in hepatoma cells stably expressing PSS1 this protein is highly enriched in MAM. Since the ER contains serine and ethanolamine exchange activities, we had predicted that PSS2 would account for the serine exchange activity in the ER. Unexpectedly, using immunoblotting experiments, we found that (i) PSS2 of CRO-K1 cells is present only in MAM and (ii) PSS2 is restricted to MAM of McArdle cells expressing recombinant PSS2. These data leave open the question of which enzyme imparts PSS activity to the ER and suggest that a third isoform of PSS might be located in the ER.	Univ Alberta, Dept Med, Heritage Med Res Ctr 332, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth, Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Vance, JE (corresponding author), Univ Alberta, Dept Med, Heritage Med Res Ctr 332, Edmonton, AB T6G 2S2, Canada.							ARDAIL D, 1993, J BIOL CHEM, V268, P25985; ARDAIL D, 1991, J BIOL CHEM, V266, P7978; Baksh S, 1995, J BIOL CHEM, V270, P31338, DOI 10.1074/jbc.270.52.31338; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CROZE EM, 1984, J CELL PHYSIOL, V119, P46, DOI 10.1002/jcp.1041190109; CUI Z, 1993, J BIOL CHEM, V268, P16655; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KUGE O, 1986, J BIOL CHEM, V261, P5795; KUGE O, 1991, J BIOL CHEM, V266, P24184; Kuge O, 1997, J BIOL CHEM, V272, P19133, DOI 10.1074/jbc.272.31.19133; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; RUSINOL AE, 1994, J BIOL CHEM, V269, P27494; Saito K, 1996, FEBS LETT, V395, P262, DOI 10.1016/0014-5793(96)01049-6; Saito K, 1998, J BIOL CHEM, V273, P17199, DOI 10.1074/jbc.273.27.17199; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SHIAO YJ, 1995, J BIOL CHEM, V270, P11190, DOI 10.1074/jbc.270.19.11190; Stone SJ, 1999, BIOCHEM J, V342, P57, DOI 10.1042/0264-6021:3420057; Stone SJ, 1998, J BIOL CHEM, V273, P7293, DOI 10.1074/jbc.273.13.7293; Vance DE, 1997, BBA-LIPID LIPID MET, V1348, P142, DOI 10.1016/S0005-2760(97)00108-2; Vance JE, 1998, TRENDS BIOCHEM SCI, V23, P423, DOI 10.1016/S0968-0004(98)01297-3; VANCE JE, 1988, J BIOL CHEM, V263, P5898; VANCE JE, 1990, J BIOL CHEM, V265, P7248; Vidugiriene J, 1999, J BIOL CHEM, V274, P15203, DOI 10.1074/jbc.274.21.15203; VOELKER DR, 1986, J BIOL CHEM, V261, P1002	24	253	257	4	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34534	34540		10.1074/jbc.M002865200	http://dx.doi.org/10.1074/jbc.M002865200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10938271	hybrid			2022-12-27	WOS:000165095300073
J	Tait, SWG; Reid, EB; Greaves, DR; Wileman, TE; Powell, PP				Tait, SWG; Reid, EB; Greaves, DR; Wileman, TE; Powell, PP			Mechanism of inactivation of NF-kappa B by a viral homologue of I kappa B alpha - Signal-induced release of I kappa B alpha results in binding of the viral homologue to NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFRICAN SWINE FEVER; UBIQUITIN-PROTEASOME PATHWAY; TRANSCRIPTIONAL ACTIVATION; INDUCED DEGRADATION; VIRUS; APOPTOSIS; COMPLEX; PHOSPHORYLATION; INHIBITION; PROTEINS	Activation of the nuclear factor kappaB plays a key role in viral pathogenesis, resulting in inflammation and modulation of the immune response. We have previously shown that A238L, an open reading frame from African swine fever virus (ASFV), encoding a protein with 40% homology to porcine I kappaB alpha exerts a potent anti-inflammatory effect in host, macrophages, where it down-regulates NF-kappaB-dependent gene transcription and proinflammatory cytokine production. This paper reveals the mechanism of suppression of NF-kappaB activity by A238Lp. A238Lp is synthesized throughout infection as two molecular mass forms of 28 and 32 kDa, and vaccinia-mediated expression of A238L demonstrated that both proteins are produced from a single gene. Significantly, the higher 32-kDa form of A238L, but not the 28-kDa form, interacts directly with RelA, the 65-kDa subunit of NF-kappaB, indicating that the binding is dependent on a posttranslational modification. Immunoprecipitation analysis shows the NF-kappaB p65-A238L p32 heterodimer is a separate complex from NF-kappaB-I kappaB alpha, and it resides in the cytoplasm. Moreover, we show that ASFV infection stimulates the NF kappaB signal transduction pathway, which results in the rapid degradation of endogenous I kappaB alpha, although both forms of A238Lp are resistant to stimulus-induced degradation. Using the proteasome inhibitor MG132, we show that when degradation of I kappaB alpha is inhibited, A238Lp binding to NF-kappaB p65 is reduced. The results suggest that the virus exploits its activation of the NF-kappaB pathway to enable its own I kappaB homologue to bind to NF-kappaB p65. Last, we show that synthesis of I kappaB alpha is increased during ASFV infection, indicating RelA-independent transcription of the I kappaB alpha gene.	Inst Anim Hlth, Dept Pathol & Immunol, BBSRC, Pirbright GU24 0NF, Surrey, England; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; University of Oxford	Powell, PP (corresponding author), Inst Anim Hlth, Dept Immunol, Ash Rd, Pirbright GU24 0NF, Surrey, England.	penny.powell@bbsrc.ac.uk		Tait, Stephen/0000-0001-7697-132X; Greaves, David/0000-0003-2856-9410; Powell, Penny/0000-0002-5347-0490				Alcami A, 1998, SEMIN VIROL, V8, P419, DOI 10.1006/smvy.1997.0143; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Chacon MR, 1995, VIROLOGY, V214, P670, DOI 10.1006/viro.1995.0083; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Conboy IM, 1999, P NATL ACAD SCI USA, V96, P6324, DOI 10.1073/pnas.96.11.6324; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Krajcsi P, 1998, J GEN VIROL, V79, P1323, DOI 10.1099/0022-1317-79-6-1323; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Mebus C. A., 1987, African swine fever, P21; Miskin JE, 1998, SCIENCE, V281, P562, DOI 10.1126/science.281.5376.562; Oura CAL, 1998, J GEN VIROL, V79, P1427, DOI 10.1099/0022-1317-79-6-1427; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; Powell PP, 1996, J VIROL, V70, P8527, DOI 10.1128/JVI.70.12.8527-8533.1996; Revilla Y, 1997, VIROLOGY, V228, P400, DOI 10.1006/viro.1996.8395; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Rouiller I, 1998, J VIROL, V72, P2373, DOI 10.1128/JVI.72.3.2373-2387.1998; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SUTTER G, 1995, FEBS LETT, V371, P9, DOI 10.1016/0014-5793(95)00843-X; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; WECHSLER AS, 1994, J IMMUNOL, V153, P2515; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Wilkinson P. J., 1989, Virus infections of porcines., P17; Wong HR, 1999, CELL STRESS CHAPERON, V4, P1; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; YANEZ RJ, 1995, VIROLOGY, V208, P249, DOI 10.1006/viro.1995.1149; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	43	73	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34656	34664		10.1074/jbc.M000320200	http://dx.doi.org/10.1074/jbc.M000320200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10934190	hybrid			2022-12-27	WOS:000165095300089
J	Xiao, GT; Harhaj, EW; Sun, SC				Xiao, GT; Harhaj, EW; Sun, SC			Domain-specific interaction with the I kappa B kinase (IKK) regulatory subunit IKK gamma is an essential step in tax-mediated activation of IKK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; HTLV-I; TRANSACTIVATOR TAX; TRANSCRIPTIONAL ACTIVATOR; DNA-BINDING; TRANSFORMING PROTEIN; 21-BASE-PAIR REPEATS; BZIP PROTEINS; CREB BINDING	The human T-cell leukemia virus type 1 Tax oncoprotein deregulates the NF-kappaB signaling pathway by persistently stimulating a key signal transducer, the I kappaB kinase (IKK). Tax physically associates with the IKK regulatory subunit, IKK gamma, although the underlying biochemical mechanism and functional significance remain unclear. We show that the Tax-IKK gamma interaction requires two homologous leucine zipper domains located within IKK gamma. These leucine zipper domains are unique for the presence of a conserved upstream region that is essential for Tax binding. Site-directed mutagenesis analysis revealed that a leucine-repeat region of Tax is important for IKK gamma binding. Interestingly, all the Tax mutants defective in IKK gamma binding failed to engage the IKK complex or stimulate IKK activity, and these functional defects can be rescued by fusing the Tax mutants to IKK gamma These results provide mechanistic insights into how Tax specifically targets and functionally activates the cellular kinase IKK.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Microbiol & Immunol, 500 Univ Dr, Hershey, PA 17033 USA.	sxs70@psu.edu			NCI NIH HHS [1 R01 CA68471] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068471] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADYA N, 1995, J VIROL, V69, P1834, DOI 10.1128/JVI.69.3.1834-1841.1995; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; Frishman D, 1996, PROTEIN ENG, V9, P133, DOI 10.1093/protein/9.2.133; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRILLI M, 1993, INT REV CYTOL, V143, P1; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Harhaj EW, 1998, J BIOL CHEM, V273, P25185, DOI 10.1074/jbc.273.39.25185; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 1998, CANCER J SCI AM, V4, pS92; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li J, 1998, J BIOL CHEM, V273, P30736, DOI 10.1074/jbc.273.46.30736; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Moitra J, 1997, BIOCHEMISTRY-US, V36, P12567, DOI 10.1021/bi971424h; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Nicot C, 1998, J VIROL, V72, P6777, DOI 10.1128/JVI.72.8.6777-6784.1998; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Ressler S, 1996, FEMS MICROBIOL LETT, V140, P99, DOI 10.1016/0378-1097(96)00166-8; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudolph D, 2000, GENE DEV, V14, P854; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Sun SC, 1996, MOL CELL BIOL, V16, P1058; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; YIN MJ, 1995, J VIROL, V69, P3420, DOI 10.1128/JVI.69.6.3420-3432.1995; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zandi E, 1999, MOL CELL BIOL, V19, P4547; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	67	87	88	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34060	34067		10.1074/jbc.M002970200	http://dx.doi.org/10.1074/jbc.M002970200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10906125	hybrid			2022-12-27	WOS:000165095300011
J	Angell, JE; Lindner, DJ; Shapiro, PS; Hofmann, ER; Kalvakolanu, DV				Angell, JE; Lindner, DJ; Shapiro, PS; Hofmann, ER; Kalvakolanu, DV			Identification of GRIM-19, a novel cell death-regulatory gene induced by the interferon-beta and retinoic acid combination, using a genetic approach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; DNA FRAGMENTATION; GTP-BINDING; IFN-GAMMA; TNF-ALPHA; APOPTOSIS; PROTEIN; EXPRESSION; CANCER; PML	We show here that the combination of interferon-beta (TFN-beta) and all-trans-retinoic acid (RA) induces the death of tumor cells. To understand the molecular basis for synergistic growth-suppressive action and to identify the gene products that participate in this process, me have employed an antisense knock-out technique. This approach permits the isolation of cell death-associated genes based on their selective inactivation by over-expression of antisense cDNAs, Because the antisense mRNA inactivates gene expression of death-specific genes, transfected cells survive in the presence death inducers. Several Genes associated with Retinoid-IFN-induced Mortality (GRIM) were identified using this approach. Here me report, the isolation of a novel GRIM gene, GRIM-19. This 552-base pair cDNA encodes a 16-kDa protein. Antisense expression of GRIM-19 confers a strong resistance against IFN/RA-induced death by reducing the intracellular levels of GRIM-19 protein. Overexpression of GRIM-19 enhances cell death in response to IFN/RA. GRIM-IS is primarily a nuclear protein whose expression is induced by the IFN/RA combination. Together, our studies identify a novel cell death-regulatory molecule.	Univ Maryland, Sch Med, Greenbaum Canc Ctr, BRB, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Mol & Cellular Biol Program, Baltimore, MD 21201 USA; Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Kalvakolanu, DV (corresponding author), Univ Maryland, Sch Med, Greenbaum Canc Ctr, BRB, 9th Floor,655 W Baltimore St, Baltimore, MD 21201 USA.		Lindner, Daniel/ABB-5440-2020		NATIONAL CANCER INSTITUTE [R01CA078282, R01CA071401] Funding Source: NIH RePORTER; NCI NIH HHS [CA78282, CA71401] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boehm U, 1998, J IMMUNOL, V161, P6715; BORDEN EC, 1995, J NATL CANCER I, V87, P257, DOI 10.1093/jnci/87.4.257; Carlow DA, 1998, J IMMUNOL, V161, P2348; Chelbi-Alix MK, 1998, J VIROL, V72, P1043, DOI 10.1128/JVI.72.2.1043-1051.1998; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; COHEN GM, 1992, BIOCHEM J, V286, P331, DOI 10.1042/bj2860331; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Faria TN, 1999, J BIOL CHEM, V274, P26783, DOI 10.1074/jbc.274.38.26783; Gao AC, 1999, PROSTATE, V38, P46, DOI 10.1002/(SICI)1097-0045(19990101)38:1<46::AID-PROS6>3.0.CO;2-9; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; GILLY M, 1992, J IMMUNOL, V148, P3275; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GOLDSTEIN D, 1986, CANCER RES, V46, P4315; Gongora C, 1997, J BIOL CHEM, V272, P19457, DOI 10.1074/jbc.272.31.19457; Harlow E., 1988, ANTIBODIES LAB MANUA; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Hofman ER, 1998, MOL CELL BIOL, V18, P6493, DOI 10.1128/MCB.18.11.6493; Hong Waun Ki, 1994, P597; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kalvakolanu DV, 2000, HISTOL HISTOPATHOL, V15, P523, DOI 10.14670/HH-15.523; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Lin RJ, 1999, TRENDS GENET, V15, P179, DOI 10.1016/S0168-9525(99)01710-2; Lindner DJ, 1997, CLIN CANCER RES, V3, P931; LOVE JM, 1994, CURR OPIN CELL BIOL, V6, P825, DOI 10.1016/0955-0674(94)90051-5; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Matikainen S, 1997, CELL GROWTH DIFFER, V8, P687; MOORE DM, 1994, SEMIN HEMATOL, V31, P31; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; RICHTER MF, 1995, J BIOL CHEM, V270, P13512, DOI 10.1074/jbc.270.22.13512; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980; SEN GC, 1997, TRANSCRIPTIONAL REGU; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SORACE JM, 1995, J LEUKOCYTE BIOL, V58, P477, DOI 10.1002/jlb.58.4.477; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Stennicke HR, 2000, BBA-PROTEIN STRUCT M, V1477, P299, DOI 10.1016/S0167-4838(99)00281-2; STUDZINSKI GP, 1995, UNPUB PRACTICAL APPR; Taylor GA, 2000, P NATL ACAD SCI USA, V97, P751, DOI 10.1073/pnas.97.2.751; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; Wang ZG, 1998, SCIENCE, V279, P1547; Xiao WH, 1997, J BIOL CHEM, V272, P9742, DOI 10.1074/jbc.272.15.9742; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D	50	173	206	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33416	33426		10.1074/jbc.M003929200	http://dx.doi.org/10.1074/jbc.M003929200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10924506	hybrid			2022-12-27	WOS:000090104600035
J	Burkhardt, M; Glazova, M; Gambaryan, S; Vollkommer, T; Butt, E; Bader, B; Heermeier, K; Lincoln, TM; Walter, U; Palmetshofer, A				Burkhardt, M; Glazova, M; Gambaryan, S; Vollkommer, T; Butt, E; Bader, B; Heermeier, K; Lincoln, TM; Walter, U; Palmetshofer, A			KT5823 inhibits cGMP-dependent protein kinase activity in vitro but not in intact human platelets and rat mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASODILATOR-STIMULATED PHOSPHOPROTEIN; SMOOTH-MUSCLE CELLS; TRANSMEMBRANE CONDUCTANCE REGULATOR; CYCLIC-GMP; NITRIC-OXIDE; IN-VITRO; NEUTROPHIL MIGRATION; K+ CHANNEL; PHOSPHORYLATION; CAMP	Many signal transduction pathways are mediated by the second messengers cGMP and cAMP, cGMP- and cAMP-dependent protein kinases (cGK and PHA), phosphodiesterases, and ion channels. To distinguish among the different cGMP effecters, inhibitors of cGK and PKA have been developed including the K-252 compound KT5823 and the isoquinolinesulfonamide H89, KT5823, an in vitro inhibitor of cGK, has also been used in numerous studies with intact cells to implicate or rule out the involvement of this protein kinase in a given cellular response, However, the efficacy and specificity of KT5823 as cGK inhibitor in intact cells or tissues have never been demonstrated. Here, we analyzed the effects of both KT5823 and H89 on cyclic-nucleotide-mediated phosphorylation of vasodilator-stimulated phosphoprotein (VASP) in intact human platelets and rat mesangial cells. These two cell types both express high levels of cGK. KT5823 inhibited purified cGK, However, with both intact human platelets and rat mesangial cells, KT5823 failed to inhibit cGK-mediated serine 157 and serine 239 phosphorylation of VASP induced by nitric oxide, atrial natriuretic peptide, or the membrane-permeant cGMP analog 8-pCPT-cGMP, KT5823 enhanced 8-pCPT-cGMP-stimulated VASP phosphorylation in platelets and did not inhibit forskolin-stimulated VASP phosphorylation in either platelets or mesangial cells, In contrast H89, an inhibitor of both PKA. and cGK, clearly inhibited 8-pCPT-cGMP and forskolin-stimulated VASP phosphorylation in the two cell types. The data indicate that KT5823 inhibits purified cGK but does not affect a cGK-mediated response in the two different cell types expressing cGK I. These observations indicate that data that interpret the effects of KT5823 in intact cells as the major or only criteria supporting the involvement of cGK clearly need to be reconsidered.	Med Univ Klin, Inst Klin Biochem & Pathobiochem, D-97080 Wurzburg, Germany; Med Univ Klin, Div Nephrol, D-97080 Wurzburg, Germany; Russian Acad Sci, Sechenov Evolutionary Physiol & Biochem Inst, St Petersburg 194223, Russia; Univ Alabama Birmingham, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Wurzburg; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Wurzburg; Russian Academy of Sciences; Sechenov Institute of Evolutionary Physiology & Biochemistry; University of Alabama System; University of Alabama Birmingham	Palmetshofer, A (corresponding author), Med Univ Klin, Inst Klin Biochem & Pathobiochem, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	palme@klin-biochem.uni-wuerzburg.de	Glazova, Margarita V/J-9938-2018; Glazova, Margarita/AAN-7567-2020; Glazova, Margarita/Q-8597-2016; Gambaryan, Stepan/I-3940-2016; Walter, ulrich/W-2478-2017	Glazova, Margarita V/0000-0001-6617-3404; Glazova, Margarita/0000-0001-6617-3404; Glazova, Margarita/0000-0001-6617-3404; Gambaryan, Stepan/0000-0002-1470-0791; Walter, ulrich/0000-0001-6784-2307; Bader, Benjamin/0000-0002-5299-396X				AbdAlla S, 1996, EUR J BIOCHEM, V241, P498, DOI 10.1111/j.1432-1033.1996.00498.x; Alioua A, 1998, J BIOL CHEM, V273, P32950, DOI 10.1074/jbc.273.49.32950; Aszodi A, 1999, EMBO J, V18, P37, DOI 10.1093/emboj/18.1.37; Browning DD, 1999, J BIOL CHEM, V274, P537, DOI 10.1074/jbc.274.1.537; BUTT E, 1992, BIOCHEM PHARMACOL, V43, P2591, DOI 10.1016/0006-2952(92)90148-C; Butt E, 1995, BRIT J PHARMACOL, V116, P3110, DOI 10.1111/j.1476-5381.1995.tb15112.x; BUTT E, 1994, EUR J PHARM-MOLEC PH, V269, P265, DOI 10.1016/0922-4106(94)90095-7; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; BUTT E, 1993, NEUROCHEM RES, V18, P27, DOI 10.1007/BF00966920; BUTT E, 1994, J BIOL CHEM, V269, P14509; BUTTERWORTH PJ, 1972, BIOCHIM BIOPHYS ACTA, V289, P251, DOI 10.1016/0005-2744(72)90074-5; Chiche JD, 1998, J BIOL CHEM, V273, P34263, DOI 10.1074/jbc.273.51.34263; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Cohen DM, 1997, COMP BIOCHEM PHYS A, V117, P291, DOI 10.1016/S0300-9629(96)00266-6; CORNWELL TL, 1994, AM J PHYSIOL, V267, P1; DARVISH N, 1995, AM J PHYSIOL-RENAL, V268, pF323, DOI 10.1152/ajprenal.1995.268.2.F323; DIXON M, 1972, BIOCHEM J, V129, P197, DOI 10.1042/bj1290197; DRAIJER R, 1995, CIRC RES, V77, P897, DOI 10.1161/01.RES.77.5.897; EIGENTHALER M, 1993, J BIOL CHEM, V268, P13526; EIGENTHALER M, 1992, EUR J BIOCHEM, V205, P471, DOI 10.1111/j.1432-1033.1992.tb16803.x; Elferink JGR, 1998, EUR J PHARMACOL, V350, P285, DOI 10.1016/S0014-2999(98)00265-9; Firestein BL, 1998, J NEUROCHEM, V71, P1846; Foster D C, 1999, Rev Physiol Biochem Pharmacol, V135, P1, DOI 10.1007/BFb0033668; Fukao M, 1999, J BIOL CHEM, V274, P10927, DOI 10.1074/jbc.274.16.10927; Fukumoto S, 1999, CIRC RES, V85, P985; FUKUSHIMA T, 1994, AM J RESP CELL MOL, V10, P65, DOI 10.1165/ajrcmb.10.1.8292382; GLASS DB, 1986, J BIOL CHEM, V261, P2166; Hauser W, 1999, P NATL ACAD SCI USA, V96, P8120, DOI 10.1073/pnas.96.14.8120; HIDAKA H, 1992, ANNU REV PHARMACOL, V32, P377, DOI 10.1146/annurev.pharmtox.32.1.377; HIRSCH J, 1995, PFLUG ARCH EUR J PHY, V429, P338, DOI 10.1007/BF00374148; Hirsch JR, 1999, J PHYSIOL-LONDON, V519, P645, DOI 10.1111/j.1469-7793.1999.0645n.x; HOLTHOFER H, 1995, APMIS, V103, P354; Jiang LH, 2000, J BIOL CHEM, V275, P6135, DOI 10.1074/jbc.275.9.6135; JOYCE NC, 1986, J CYCLIC NUCL PROT, V11, P191; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KEMP BE, 1988, METHOD ENZYMOL, V159, P173; Koesling D, 1999, Rev Physiol Biochem Pharmacol, V135, P41, DOI 10.1007/BFb0033669; Komalavilas P, 1999, J BIOL CHEM, V274, P34301, DOI 10.1074/jbc.274.48.34301; Komalavilas P, 1996, J BIOL CHEM, V271, P21933, DOI 10.1074/jbc.271.36.21933; KramerGuth A, 1996, KIDNEY INT, V49, P1250, DOI 10.1038/ki.1996.179; KREISBERG JI, 1983, KIDNEY INT, V23, P439, DOI 10.1038/ki.1983.40; Lincoln T M, 1995, Adv Pharmacol, V34, P305; Lincoln TM, 1998, ACTA PHYSIOL SCAND, V164, P507, DOI 10.1111/j.1365-201X.1998.tb10700.x; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; Massberg S, 1999, J EXP MED, V189, P1255, DOI 10.1084/jem.189.8.1255; Pfeifer A, 1999, Rev Physiol Biochem Pharmacol, V135, P105, DOI 10.1007/BFb0033671; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; Smolenski A, 1998, N-S ARCH PHARMACOL, V358, P134, DOI 10.1007/PL00005234; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; Syrovets T, 1997, BLOOD, V89, P4574, DOI 10.1182/blood.V89.12.4574; TIEN XY, 1994, J BIOL CHEM, V269, P51; VanUffelen BE, 1996, BIOCHEM BIOPH RES CO, V226, P21, DOI 10.1006/bbrc.1996.1305; WAHLER GM, 1995, AM J PHYSIOL-CELL PH, V268, pC45, DOI 10.1152/ajpcell.1995.268.1.C45; WALTER U, 1980, J BIOL CHEM, V255, P3757; Walter U, 1989, REV PHYSL BIOCH PHAR, V113, P41; WYATT TA, 1991, RES COMMUN CHEM PATH, V74, P3; WYATT TA, 1991, J BIOL CHEM, V266, P21274; Yu SM, 1997, CIRCULATION, V95, P1269	60	98	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33536	33541		10.1074/jbc.M005670200	http://dx.doi.org/10.1074/jbc.M005670200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10922374	hybrid			2022-12-27	WOS:000090104600051
J	Thangaraju, M; Kaufmann, SH; Couch, FJ				Thangaraju, M; Kaufmann, SH; Couch, FJ			BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERACT IN-VIVO; TUMOR-SUPPRESSOR; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVATION; SUSCEPTIBILITY GENE; SIGNALING PATHWAYS; CARCINOMA CELLS; FAS; EXPRESSION; PROTEIN	The BRCA1 tumor suppressor gene has previously been implicated in induction of high levels of apoptosis in osteocarcinoma cell lines. Overexpression of BRCA1 was shown to induce an apoptotic signaling pathway involving the c-Jun N-terminal kinase (JNK), but the signaling steps upstream and downstream of JNK were not delineated. To better understand the role of BRCA1 in apoptosis, we examined the effect of wild-type and C-terminal-truncated dominant negative BRCA1 on breast and ovarian cancer cell lines subjected to a number of different pro-apoptotic stimuli, including growth factor withdrawal, substratum detachment, ionizing radiation, and treatment with anticancer agents. All of these treatments were found to induce substantial levels of apoptosis in the presence of wild-type BRCA1, whereas dominant negative BRCA1 truncation mutants diminished the apoptotic response. Subsequent mapping of the apoptotic pathway induced by growth factor withdrawal demonstrated that BRCA1 enhanced signaling through a pathway that sequentially involved H-Ras, MEKK4, JNK, Fas ligand/Fas interactions, and caspase-9 activation. In addition, the pathway functioned independently of the p53 tumor suppressor. These data suggest that BRCA1 is an important modulator of the response to cellular stress and that loss of this apoptotic potential due to BRCA1 mutations may contribute to tumor development.	Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Pharmacol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Couch, FJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, 1001 Guggenheim Bldg,200 1st St SW, Rochester, MN 55905 USA.			Kaufmann, Scott/0000-0002-4900-7145	NCI NIH HHS [CA78878, R01 CA069008, CA69008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069008, R29CA078878] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbott DW, 1998, J NATL CANCER I, V90, P978, DOI 10.1093/jnci/90.13.978; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Brugarolas J, 1997, NAT MED, V3, P721, DOI 10.1038/nm0797-721; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; Conover CA, 1998, EXP CELL RES, V238, P439, DOI 10.1006/excr.1997.3861; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; EASTON DF, 1993, AM J HUM GENET, V52, P678; FAN SJ, 1995, CANCER RES, V55, P1649; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Feunteun J, 1996, BBA-REV CANCER, V1242, P177, DOI 10.1016/0304-419X(95)00016-9; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; Joneson T, 1999, MOL CELL BIOL, V19, P5892; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kottke TJ, 1999, J BIOL CHEM, V274, P15927, DOI 10.1074/jbc.274.22.15927; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Nishina H, 1997, J EXP MED, V186, P941, DOI 10.1084/jem.186.6.941; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Rao VN, 1996, ONCOGENE, V12, P523; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Shao NS, 1996, ONCOGENE, V13, P1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Thomas JE, 1996, J BIOL CHEM, V271, P28630, DOI 10.1074/jbc.271.45.28630; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Tomlinson GE, 1998, CANCER RES, V58, P3237; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	64	121	132	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33487	33496		10.1074/jbc.M005824200	http://dx.doi.org/10.1074/jbc.M005824200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10938285	hybrid			2022-12-27	WOS:000090104600044
J	Bruehl, RE; Bertozzi, CR; Rosen, SD				Bruehl, RE; Bertozzi, CR; Rosen, SD			Minimal sulfated carbohydrates for recognition by L-selectin and the MECA-79 antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH ENDOTHELIAL VENULES; SIALYL-LEWIS-X; LEUKOCYTE ADHESION MOLECULE; LYMPHOCYTE HOMING RECEPTOR; MANNOSE-BINDING PROTEIN; MAJOR CAPPING GROUP; P-SELECTIN; CELL-ADHESION; LINKED OLIGOSACCHARIDES; VASCULAR ADDRESSIN	Sulfated forms of sialyl-Le(X) containing Gal-B-SQ, or GlcNAc-6-SO4 have been implicated as potential recognition determinants on high endothelial venule ligands for L-selectin, The optimal configuration of sulfate esters on the N-acetyllactosamine (Gal beta1-->4GlcNAc) core of sulfosialyl-le(X), however, remains unsettled. Using a panel of sulfated lactose (Gal beta1-->4Glc) neoglycolipids as substrates in direct binding assays, we found that 6',6-disulfolactose was the preferred structure for L-selectin, although significant binding to 6'- and 6-sulfolactose was observed as well. Binding was EDTA-sensitive and blocked by L-selectin-specific monoclonal antibodies. Surprisingly, 6',6-disulfolactose was poorly recognized by MECA-79, a carbohydrate- and sulfate-dependent monoclonal antibody that binds competitively to L-selectin ligands. Instead, MECA-79 bound preferentially to 6-sulfolactose. The difference in preferred substrates between L-selectin and MECA-79 may explain the variable activity of MECA-79 as an inhibitor of lymphocyte adhesion to high endothelial venules in lymphoid organs. Our results suggest that both Gal-6-SO4 and GlcNAc-6SO(4) may contribute to L-selectin recognition, either as components of sulfosialyl-le(X) capping groups or in internal structures. By contrast, only GlcNAc-6-SO4 appears to contribute to MECA-79 binding.	Univ Calif San Francisco, Dept Anat, Program Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Program Biomed Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Rosen, SD (corresponding author), Univ Calif San Francisco, Dept Anat, Program Immunol, San Francisco, CA 94143 USA.			Rosen, Steven/0000-0002-6245-701X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023547, R01GM059907] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37GM23547, R01GM59907-01, R01GM5741] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; Berg EL, 1998, AM J PATHOL, V152, P469; BERTOZZI CR, 1995, BIOCHEMISTRY-US, V34, P14271, DOI 10.1021/bi00044a001; BERTOZZI CR, 1995, CHEM BIOL, V2, P703, DOI 10.1016/1074-5521(95)90096-9; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; BRANDLEY BK, 1993, GLYCOBIOLOGY, V3, P633, DOI 10.1093/glycob/3.6.633; Capon C, 1997, J BIOL CHEM, V272, P31957, DOI 10.1074/jbc.272.51.31957; Clark RA, 1998, J CELL BIOL, V140, P721, DOI 10.1083/jcb.140.3.721; CROMMIE D, 1995, J BIOL CHEM, V270, P22614, DOI 10.1074/jbc.270.38.22614; DASGUPTA F, 1994, EXPERT OPIN INV DRUG, V3, P709; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; Fukuda M, 1999, J CELL BIOL, V147, P467, DOI 10.1083/jcb.147.3.467; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; Galustian C, 1997, BIOCHEM BIOPH RES CO, V240, P748, DOI 10.1006/bbrc.1997.7737; Galustian C, 1999, J BIOL CHEM, V274, P18213, DOI 10.1074/jbc.274.26.18213; GEOFFROY JS, 1989, J CELL BIOL, V109, P2463, DOI 10.1083/jcb.109.5.2463; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; GREEN PJ, 1995, GLYCOBIOLOGY, V5, P29, DOI 10.1093/glycob/5.1.29; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4820, DOI 10.1021/bi00182a010; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; IMAI Y, 1993, NATURE, V361, P555; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kim YJ, 1999, AM J PATHOL, V155, P461, DOI 10.1016/S0002-9440(10)65142-5; Kimura N, 1999, P NATL ACAD SCI USA, V96, P4530, DOI 10.1073/pnas.96.8.4530; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; Knibbs RN, 1996, J CELL BIOL, V133, P911, DOI 10.1083/jcb.133.4.911; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; Koenig A, 1997, GLYCOBIOLOGY, V7, P79, DOI 10.1093/glycob/7.1.79; LARKIN M, 1992, J BIOL CHEM, V267, P13661; LASKY LA, 1992, COLD SPRING HARB SYM, V57, P259, DOI 10.1101/SQB.1992.057.01.031; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; Malhotra R, 1996, BIOCHEM J, V320, P589, DOI 10.1042/bj3200589; Malhotra R, 1996, BIOCHEM J, V314, P297, DOI 10.1042/bj3140297; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; MANNORI G, 1995, CANCER RES, V55, P4425; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MICHIE SA, 1993, AM J PATHOL, V143, P1688; Mitsuoka C, 1997, BIOCHEM BIOPH RES CO, V230, P546, DOI 10.1006/bbrc.1996.6012; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; NELSON RM, 1993, BLOOD, V82, P3253; Ng KKS, 1998, BIOCHEMISTRY-US, V37, P17965, DOI 10.1021/bi981972a; Ng KKS, 1997, BIOCHEMISTRY-US, V36, P979, DOI 10.1021/bi962564e; Ng KKS, 1998, BIOCHEMISTRY-US, V37, P17977, DOI 10.1021/bi9819733; PICKFORD LB, 1989, J NEUROCYTOL, V18, P465, DOI 10.1007/BF01474543; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; PURI KD, 1995, J CELL BIOL, V131, P261, DOI 10.1083/jcb.131.1.261; ROSEN SD, 1985, SCIENCE, V228, P1005, DOI 10.1126/science.4001928; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; Rosen SD, 1999, AM J PATHOL, V155, P1013, DOI 10.1016/S0002-9440(10)65201-7; Sanders WJ, 1999, J BIOL CHEM, V274, P5271, DOI 10.1074/jbc.274.9.5271; Sanders WJ, 1996, BIOCHEMISTRY-US, V35, P14862, DOI 10.1021/bi9613640; Sassetti C, 1998, J EXP MED, V187, P1965, DOI 10.1084/jem.187.12.1965; SCUDDER PR, 1994, GLYCOBIOLOGY, V4, P929, DOI 10.1093/glycob/4.6.929; Shailubhai K, 1997, GLYCOBIOLOGY, V7, P305; Simanek EE, 1998, CHEM REV, V98, P833, DOI 10.1021/cr940226i; Singer MS, 1996, J IMMUNOL METHODS, V196, P153, DOI 10.1016/0022-1759(96)00106-8; Spevak W, 1996, J ORG CHEM, V61, P3417, DOI 10.1021/jo9522522; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; Tangemann K, 1999, J EXP MED, V190, P935, DOI 10.1084/jem.190.7.935; Tsuboi S, 1996, J BIOL CHEM, V271, P27213, DOI 10.1074/jbc.271.44.27213; Tu L, 1999, J EXP MED, V189, P241, DOI 10.1084/jem.189.2.241; Uchimura K, 1998, J BIOCHEM-TOKYO, V124, P670, DOI 10.1093/oxfordjournals.jbchem.a022164; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; Yoshino K, 1997, J MED CHEM, V40, P455, DOI 10.1021/jm9605290; YUEN CT, 1994, J BIOL CHEM, V269, P1595; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003; Zakrzewicz A, 1997, BLOOD, V89, P3228, DOI 10.1182/blood.V89.9.3228	73	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32642	32648		10.1074/jbc.M001703200	http://dx.doi.org/10.1074/jbc.M001703200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10938267	hybrid			2022-12-27	WOS:000090003800038
J	Ong, LL; Lim, APC; Er, CPN; Kuznetsov, SA; Yu, H				Ong, LL; Lim, APC; Er, CPN; Kuznetsov, SA; Yu, H			Kinectin-kinesin binding domains and their effects on organelle motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNEIN SUPERFAMILY PROTEINS; CYTOPLASMIC DYNEIN; HEAVY-CHAIN; IN-VIVO; MEMBRANOUS ORGANELLES; ANTEROGRADE MOTOR; AXONAL-TRANSPORT; MONOMERIC MOTOR; GOLGI-COMPLEX; TAIL DOMAIN	Intracellular organelle motility involves motor proteins that move along microtubules or actin filaments. One of these motor proteins, kinesin, was proposed to bind to kinectin on membrane organelles during movement. Whether kinectin is the kinesin receptor on organelles with a role in organelle motility has been controversial. We have characterized the sites of interaction between human kinectin and conventional kinesin using in vivo and in vitro assays. The kinectin-binding domain on the kinesin tail partially overlaps its head-binding domain and the myosin-Va binding domain. The kinesin-binding domain on kinectin resides near the COOH terminus and enhances the microtubule-stimulated kinesin-ATPase activity, and the overexpression of the kinectin-kinesin binding domains inhibited kinesin-dependent organelle motility in vivo, These data, when combined with other studies, suggest a role for kinectin in organelle motility.	Natl Univ Singapore, Fac Med, NUMI, Singapore 117597, Singapore; Univ Rostock, Fachbereich Biowissensch, Inst Zellbiol & Biosystemtechnn, D-18055 Rostock, Germany	National University of Singapore; University of Rostock	Yu, H (corresponding author), Natl Univ Singapore, Fac Med, NUMI, Block MD11,03-02 Clin Res Ctr,10 Med Dr, Singapore 117597, Singapore.		Yu, Hanry/C-7375-2011; Yu, Hanry/C-1031-2013; Yu, Hanry/L-6050-2019	Yu, Hanry/0000-0002-0339-3685; Yu, Hanry/0000-0002-0339-3685				AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; Beck KA, 1998, BBA-MOL CELL RES, V1404, P153, DOI 10.1016/S0167-4889(98)00054-8; Bi GQ, 1997, J CELL BIOL, V138, P999, DOI 10.1083/jcb.138.5.999; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Burkhardt JK, 1996, TRENDS CELL BIOL, V6, P127, DOI 10.1016/0962-8924(96)20002-9; Burkhardt JK, 1998, BBA-MOL CELL RES, V1404, P113, DOI 10.1016/S0167-4889(98)00052-4; Coy DL, 1999, NAT CELL BIOL, V1, P288, DOI 10.1038/13001; De Matteis MA, 1998, CURR OPIN CELL BIOL, V10, P542, DOI 10.1016/S0955-0674(98)80071-9; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Friedman DS, 1999, NAT CELL BIOL, V1, P293, DOI 10.1038/13008; FUTTERER A, 1995, MOL BIOL CELL, V6, P161; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; Hirokawa N, 1998, CURR OPIN CELL BIOL, V10, P60, DOI 10.1016/S0955-0674(98)80087-2; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Huang JD, 1999, NATURE, V397, P267, DOI 10.1038/16722; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kirchner J, 1999, BIOL CHEM, V380, P915, DOI 10.1515/BC.1999.113; Kirchner J, 1999, EMBO J, V18, P4404, DOI 10.1093/emboj/18.16.4404; KONDO S, 1994, J CELL BIOL, V125, P1095, DOI 10.1083/jcb.125.5.1095; Kraemer J, 1999, EUR J CELL BIOL, V78, P265, DOI 10.1016/S0171-9335(99)80060-0; Kumar J, 1998, J BIOL CHEM, V273, P31738, DOI 10.1074/jbc.273.48.31738; KUMAR J, 1995, SCIENCE, V267, P1834, DOI 10.1126/science.7892610; KUZNETSOV SA, 1989, J BIOL CHEM, V264, P589; KUZNETSOV SA, 1986, P NATL ACAD SCI USA, V83, P8530, DOI 10.1073/pnas.83.22.8530; KUZNETSOV SA, 2000, IN PRESS METHODS MOL; LACEY ML, 1994, CELL MOTIL CYTOSKEL, V28, P205, DOI 10.1002/cm.970280304; LANGFORD GM, 1995, CURR OPIN CELL BIOL, V7, P82, DOI 10.1016/0955-0674(95)80048-4; LEE KD, 1995, J BIOL CHEM, V270, P5600, DOI 10.1074/jbc.270.10.5600; Leung E, 1996, IMMUNOL CELL BIOL, V74, P421, DOI 10.1038/icb.1996.72; Lindesmith L, 1997, J BIOL CHEM, V272, P22929, DOI 10.1074/jbc.272.36.22929; NAKATA T, 1995, J CELL BIOL, V131, P1039, DOI 10.1083/jcb.131.4.1039; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; NODA Y, 1995, J CELL BIOL, V129, P157, DOI 10.1083/jcb.129.1.157; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; PORTER ME, 1987, J BIOL CHEM, V262, P2794; Rogers SL, 1998, CURR BIOL, V8, P161, DOI 10.1016/S0960-9822(98)70063-6; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNAPP BJ, 1989, P NATL ACAD SCI USA, V86, P1548, DOI 10.1073/pnas.86.5.1548; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; SEKINE Y, 1994, J CELL BIOL, V127, P187, DOI 10.1083/jcb.127.1.187; Sheetz MP, 1996, SEMIN CELL DEV BIOL, V7, P329, DOI 10.1006/scdb.1996.0042; SKOUFIAS DA, 1994, J BIOL CHEM, V269, P1477; Tabb JS, 1998, J CELL SCI, V111, P3221; TOYOSHIMA I, 1992, J CELL BIOL, V118, P1121, DOI 10.1083/jcb.118.5.1121; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; VALLEE RB, 1988, NATURE, V332, P561, DOI 10.1038/332561a0; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; Wu XF, 1998, J CELL BIOL, V143, P1899, DOI 10.1083/jcb.143.7.1899; Xia CH, 1998, GENOMICS, V52, P209, DOI 10.1006/geno.1998.5427; YU H, 1995, MOL BIOL CELL, V6, P171, DOI 10.1091/mbc.6.2.171; YU H, 1992, J BIOL CHEM, V267, P20457	53	46	48	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32854	32860		10.1074/jbc.M005650200	http://dx.doi.org/10.1074/jbc.M005650200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10913441	hybrid			2022-12-27	WOS:000090003800066
J	Negroiu, G; Dwek, RA; Petrescu, SM				Negroiu, G; Dwek, RA; Petrescu, SM			Folding and maturation of tyrosinase-related protein-1 are regulated by the post-translational formation of disulfide bonds and by N-glycan processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; BROWN LOCUS; MELANOMA-CELLS; INFLUENZA HEMAGGLUTININ; SECRETORY PROTEINS; QUALITY-CONTROL; CALNEXIN; DITHIOTHREITOL; ISOMERASE; MOUSE	In this study we have explored the endoplasmic reticulum associated events accompanying the maturation of the tyrosinase-related protein-1 (TRP-1) nascent chain synthesized in mouse melanoma cells. We show that TRP-1 folding process occurs much more rapidly than for tyrosinase, a highly homologous protein, being completed post-translationally by the formation of critical disulfide bonds. In cells pretreated with dithiothreitol (DTT), unfolded TRP-1 is retained in the endoplasmic reticulum by a prolonged interaction with calnexin and BiP before being targeted for degradation. The TRP-1 chain was able to fold into DTT-resistant conformations both in the presence or absence of Lu-glucosidase inhibitors, but folding occurred through different pathways. During the normal folding pathway, TRP-1 interacts with calnexin. In the presence of a-glucosidase inhibitors, the interaction with calnexin is prevented, with TRP-1 folding being assisted by Dip. In this case, the process has similar kinetics to that of untreated TRP-1 and yields a compact form insensitive to DTT as well. However, this form has different thermal denaturation properties than the native conformation. We conclude that disulfide bridge burring is crucial for the TRP-1 export. This suggests that although various folding pathways may complete this process, the native form may be acquired only through the normal unperturbed pathway.	Romanian Acad, Inst Biochem, Bucharest 77700 17, Romania; Univ Oxford, Dept Biochem, Oxford Glycobiol Inst, Oxford OX1 3QU, England	Romanian Academy of Sciences; Institute of Biochemistry, Bucharest; University of Oxford	Petrescu, SM (corresponding author), Romanian Acad, Inst Biochem, Splaiul Independentei 296, Bucharest 77700 17, Romania.		Petrescu, Stefana/AAJ-9505-2021; Negroiu, Gabriela/G-4649-2016; Petrescu, Stefana M/I-9240-2012; Negroiu, Gabriela/AAO-3980-2020	Petrescu, Stefana/0000-0002-4047-0811; Petrescu, Stefana M/0000-0002-4047-0811; Negroiu, Gabriela/0000-0003-3712-7681				ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; AROCA P, 1993, J BIOL CHEM, V268, P25650; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; Branza-Nichita N, 2000, J BIOL CHEM, V275, P8169, DOI 10.1074/jbc.275.11.8169; Branza-Nichita N, 1999, BIOCHEM BIOPH RES CO, V261, P720, DOI 10.1006/bbrc.1999.1030; DAVIS C G, 1990, New Biologist, V2, P410; DER JE, 1993, BRIT J CANCER, V67, P47, DOI 10.1038/bjc.1993.8; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; FENG W, 1995, J BIOL CHEM, V270, P11851, DOI 10.1074/jbc.270.20.11851; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Gelman MS, 1996, J BIOL CHEM, V271, P10709, DOI 10.1074/jbc.271.18.10709; GUNTHER R, 1993, J BIOL CHEM, V268, P7728; Halaban R, 2000, P NATL ACAD SCI USA, V97, P5889, DOI 10.1073/pnas.97.11.5889; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; HEARING VJ, 1993, PIGMENTATION PIGMENT, P3; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hebert DN, 1997, J CELL BIOL, V139, P613, DOI 10.1083/jcb.139.3.613; HOUGHTON AN, 1994, J EXP MED, V180, P1, DOI 10.1084/jem.180.1.1; HOUGHTON AN, 1987, J EXP MED, V165, P812, DOI 10.1084/jem.165.3.812; JACKSON IJ, 1988, P NATL ACAD SCI USA, V85, P4392, DOI 10.1073/pnas.85.12.4392; King R., 1995, METABOLIC MOL BASES, P4353; Kobayashi T, 1998, J BIOL CHEM, V273, P31801, DOI 10.1074/jbc.273.48.31801; LEITZGEN K, 1998, CHEMTRACTS BIOCH MOL, V11, P423; LODISH HF, 1993, J BIOL CHEM, V268, P20598; LOSCH A, 1995, J BIOL CHEM, V270, P11543, DOI 10.1074/jbc.270.19.11543; McGinnes LW, 1996, VIROLOGY, V224, P465, DOI 10.1006/viro.1996.0553; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; MULLER G, 1988, EMBO J, V7, P2723, DOI 10.1002/j.1460-2075.1988.tb03126.x; Muresan Z, 1998, MOL ENDOCRINOL, V12, P458, DOI 10.1210/me.12.3.458; Negroiu G, 1999, BIOCHEM J, V344, P659, DOI 10.1042/0264-6021:3440659; Negroiu G, 1999, CELL MOL BIOL, V45, P1001; ORLOW SJ, 1994, J INVEST DERMATOL, V103, P196, DOI 10.1111/1523-1747.ep12392743; Petrescu SM, 1997, J BIOL CHEM, V272, P15796, DOI 10.1074/jbc.272.25.15796; Petrescu SM, 2000, BIOCHEMISTRY-US, V39, P5229, DOI 10.1021/bi000107z; Singh V, 2000, J BIOL CHEM, V275, P11765, DOI 10.1074/jbc.275.16.11765; SKOWRONEK NH, 1998, CELL, V92, P747; SPRITZ RA, 1991, AM J HUM GENET, V48, P318; Spritz Richard A., 1994, V22, P1; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; Toyofuku K, 1999, J BIOCHEM, V125, P82, DOI 10.1093/oxfordjournals.jbchem.a022272; Trombetta ES, 1998, CURR OPIN STRUC BIOL, V8, P587, DOI 10.1016/S0959-440X(98)80148-6; VIJAYASARADHI S, 1991, EXP CELL RES, V196, P233, DOI 10.1016/0014-4827(91)90256-T; VIJAYASARADHI S, 1990, J EXP MED, V171, P1375, DOI 10.1084/jem.171.4.1375; WEY J, 1996, P NATL ACAD SCI USA, V93, P5269; ZDARSKY E, 1990, GENETICS, V126, P443; Zhang JX, 1997, MOL BIOL CELL, V8, P1943, DOI 10.1091/mbc.8.10.1943	48	44	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32200	32207		10.1074/jbc.M005186200	http://dx.doi.org/10.1074/jbc.M005186200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10915799	hybrid			2022-12-27	WOS:000089858900089
J	Saeki, K; Suzuki, H; Tsuneoka, M; Maeda, M; Iwamoto, R; Hasuwa, H; Shida, S; Takahashi, T; Sakaguchi, M; Endo, T; Miura, Y; Mekada, E; Mihara, K				Saeki, K; Suzuki, H; Tsuneoka, M; Maeda, M; Iwamoto, R; Hasuwa, H; Shida, S; Takahashi, T; Sakaguchi, M; Endo, T; Miura, Y; Mekada, E; Mihara, K			Identification of mammalian TOM22 as a subunit of the preprotein translocase of the mitochondrial outer membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; INTERMEMBRANE-SPACE DOMAIN; DIPHTHERIA-TOXIN RECEPTOR; PROTEIN IMPORT RECEPTOR; PRECURSOR PROTEINS; INNER MEMBRANE; TARGETING SEQUENCES; BINDING-SITE; COMPLEX; YEAST	A mitochondrial outer membrane protein of similar to 22 kDa (1C9-2) was purified from Vero cells assessing immunoreactivity with a monoclonal antibody, and the cDNA was cloned based on the partial amino acid sequence of the trypsin-digested fragments. 1C9-2 had 19-20% sequence identity to fungal Tom22, a component of the preprotein translocase of the outer membrane (the TOM complex) with receptor and organizer functions. Despite such a low sequence identity, both shared a remarkable structural similarity in the hydrophobicity profile, membrane topology in the Ncyt-Cin orientation through a transmembrane domain in the middle of the molecule, and the abundant acidic amino acid residues in the N-terminal domain. The antibodies against 1C9-2 inhibited the import of a matrix-targeted preprotein into isolated mitochondria. Blue native polyacrylamide gel electrophoresis of digitonin-solubilized outer membranes revealed that 1C9-2 is firmly associated with TOM40 in the similar to 400-kDa complex, with a size and composition similar to those of the fungal TOM core complex. Furthermore, 1C9-2 complemented the defects of growth and mitochondrial protein import in Delta tom22 yeast cells. Taken together, these results demonstrate that 1C9-2 is a functional homologue of fungal Tom22 and functions as a component of the TOM complex.	Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128582, Japan; Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan; Nagoya Univ, Fac Sci, Dept Chem, Nagoya, Aichi 4648602, Japan	Kyushu University; Kurume University; Nagoya University	Mihara, K (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128582, Japan.	mihara@cell.med.kyushu-u.ac.jp	Hasuwa, Hidetoshi/B-1083-2009; Miura, Yoshiki/U-8875-2019	Miura, Yoshiki/0000-0002-7596-0482; Mekada, Eisuke/0000-0001-8858-4781				Ahting U, 1999, J CELL BIOL, V147, P959, DOI 10.1083/jcb.147.5.959; Armstrong LC, 1997, J BIOL CHEM, V272, P6510, DOI 10.1074/jbc.272.10.6510; Bauer MF, 2000, TRENDS CELL BIOL, V10, P25, DOI 10.1016/S0962-8924(99)01684-0; Bolliger L, 1995, EMBO J, V14, P6318, DOI 10.1002/j.1460-2075.1995.tb00322.x; Court DA, 1996, MOL CELL BIOL, V16, P4035; Davis AJ, 1998, MOL BIOL CELL, V9, P2577, DOI 10.1091/mbc.9.9.2577; Dekker PJT, 1998, MOL CELL BIOL, V18, P6515, DOI 10.1128/MCB.18.11.6515; Dekker PJT, 1996, BIOL CHEM, V377, P535; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; Endres M, 1999, EMBO J, V18, P3214, DOI 10.1093/emboj/18.12.3214; GOPING IS, 1995, FEBS LETT, V373, P45; HACHIYA N, 1994, EMBO J, V13, P5146, DOI 10.1002/j.1460-2075.1994.tb06844.x; HACHIYA N, 1993, EMBO J, V12, P1579, DOI 10.1002/j.1460-2075.1993.tb05802.x; Hanson B, 1996, EUR J BIOCHEM, V235, P750, DOI 10.1111/j.1432-1033.1996.t01-1-00750.x; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; HONLINGER A, 1995, MOL CELL BIOL, V15, P3382; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; Ishihara N, 1998, J BIOCHEM-TOKYO, V123, P722; Iwahashi J, 1997, J BIOL CHEM, V272, P18467, DOI 10.1074/jbc.272.29.18467; IWAMOTO R, 1991, J BIOL CHEM, V266, P20463; Jansch L, 1998, J BIOL CHEM, V273, P17251, DOI 10.1074/jbc.273.27.17251; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; Kerscher O, 2000, MOL BIOL CELL, V11, P103, DOI 10.1091/mbc.11.1.103; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Koehler CM, 1999, P NATL ACAD SCI USA, V96, P2141, DOI 10.1073/pnas.96.5.2141; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; Leuenberger D, 1999, EMBO J, V18, P4816, DOI 10.1093/emboj/18.17.4816; Lill R, 1996, CURR OPIN CELL BIOL, V8, P505, DOI 10.1016/S0955-0674(96)80028-7; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; MATSUMOTO T, 1986, J BIOCHEM-TOKYO, V100, P1359, DOI 10.1093/oxfordjournals.jbchem.a121842; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MAYER A, 1995, EMBO J, V14, P4204, DOI 10.1002/j.1460-2075.1995.tb00094.x; MEIJER M, 1996, ADV MOL CEL, V17, P127; MEKADA E, 1988, J CELL BIOL, V107, P511, DOI 10.1083/jcb.107.2.511; Mihara K, 1996, TRENDS CELL BIOL, V6, P104, DOI 10.1016/0962-8924(96)81000-2; Moczko M, 1997, MOL CELL BIOL, V17, P6574, DOI 10.1128/MCB.17.11.6574; Mori M, 1998, BBA-MOL CELL RES, V1403, P12, DOI 10.1016/S0167-4889(98)00021-4; Nakai M, 1995, J BIOL CHEM, V270, P30571, DOI 10.1074/jbc.270.51.30571; Nargang FE, 1998, MOL CELL BIOL, V18, P3173, DOI 10.1128/MCB.18.6.3173; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Nuttall SD, 1997, DNA CELL BIOL, V16, P1067, DOI 10.1089/dna.1997.16.1067; Omura T, 1998, J BIOCHEM-TOKYO, V123, P1010; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; Rapaport D, 1997, J BIOL CHEM, V272, P18725, DOI 10.1074/jbc.272.30.18725; Rassow J, 1999, J MOL BIOL, V286, P105, DOI 10.1006/jmbi.1998.2455; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schatz G, 1997, NATURE, V388, P121, DOI 10.1038/40510; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SEKI N, 1995, FEBS LETT, V375, P307, DOI 10.1016/0014-5793(95)01229-8; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; van Wilpe S, 1999, NATURE, V401, P485, DOI 10.1038/46802; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6	57	38	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31996	32002		10.1074/jbc.M004794200	http://dx.doi.org/10.1074/jbc.M004794200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10900208	hybrid			2022-12-27	WOS:000089858900062
J	Smith, JK; Poteet-Smith, CE; Lannigan, DA; Freed, TA; Zoltoski, AJ; Sturgill, TW				Smith, JK; Poteet-Smith, CE; Lannigan, DA; Freed, TA; Zoltoski, AJ; Sturgill, TW			Creation of a stress-activated p90 ribosomal S6 kinase - The carboxyl-terminal tail of the MAPK-activated protein kinases dictates the signal transduction pathway in which they function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MONOCLONAL-ANTIBODIES; IN-VIVO; SUBSTRATE-SPECIFICITY; DOCKING SITE; PHOSPHORYLATION; INHIBITOR; DOMAIN; IDENTIFICATION; TRANSCRIPTION; CASCADE	Mitogen-activated protein kinase-activated protein kinases (MAPKAPKs) lie immediately downstream of the mitogen-activated protein kinases (MAPKs), extracellular signal-regulated kinase (ERK), and p38 MAPK, Although the family of MAPKAPKs shares sequence similarity, it demonstrates selectivity for the upstream activator. Here we demonstrate that each of the ERK- and p38 MAPK-regulated MAPKAPKs contains a MAPK docking site positioned distally to the residue(s) phosphorylated by MAPKs. The isolated MAPK docking sites show specificity for the upstream activator similar to that reported for the full-length proteins. Moreover, replacement of the ERK docking site of p90 ribosomal S6 kinase with the p38 MAPK docking site of MAPKAPK2 converts p90 ribosomal S6 kinase into a stress-activated kinase in vivo, It is apparent that mechanisms controlling events downstream of the proline-directed MAPKs involve specific MAPK docking sites within the carboxyl termini of the MAPKAPKs that determine the cascade in which the MAPKAPK functions.	Univ Virginia, Hlth Sci Ctr, Markey Ctr Cell Signaling, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Howard Hughes Med Inst, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Med, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Virginia; Howard Hughes Medical Institute; University of Virginia; University of Virginia; University of Virginia	Smith, JK (corresponding author), Univ Virginia, Hlth Sci Ctr, Markey Ctr Cell Signaling, Box 800577, Charlottesville, VA 22908 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041077] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41077] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams PD, 1999, MOL CELL BIOL, V19, P1068; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Poteet-Smith CE, 1999, J BIOL CHEM, V274, P22135, DOI 10.1074/jbc.274.32.22135; SCIMECA JC, 1992, J BIOL CHEM, V267, P17369; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; Traish AM, 1996, STEROIDS, V61, P549, DOI 10.1016/S0039-128X(96)00109-2; TRAISH AM, 1995, STEROIDS, V60, P467, DOI 10.1016/0039-128X(95)00061-T; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900	22	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31588	31593		10.1074/jbc.M005892200	http://dx.doi.org/10.1074/jbc.M005892200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10922375	hybrid			2022-12-27	WOS:000089858900007
J	von Poser, C; Zhang, JZ; Mineo, C; Ding, W; Ying, YS; Sudhof, TC; Anderson, RGW				von Poser, C; Zhang, JZ; Mineo, C; Ding, W; Ying, YS; Sudhof, TC; Anderson, RGW			Synaptotagmin regulation of coated pit assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; LOW-DENSITY LIPOPROTEIN; PROTEIN-KINASE-C; C2B DOMAIN; TRANSMITTER RELEASE; ANTIBODY INJECTION; SYNAPTIC VESICLES; CLATHRIN LATTICES; MAMMALIAN-CELLS; CA2+ CHANNELS	Synaptotagmins bind clathrin AP-2 with high affinity via their second C-2 domain, which indicates they are involved in coated pit function. We now report that expression of synaptotagmins lacking either the second C-2 domain or the entire cytoplasmic region potently inhibit endocytosis. Inhibition was dependent on two intramembrane cysteine residues that were found to be essential for synaptotagmin oligomerization. Cells expressing the wild-type, but not the mutant, truncated synaptotagmin fragment had a reduced number of clathrin-coated pits. These results suggest that the formation of synaptotagmin multimers is an important step in the regulation of coated pit assembly.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Anderson, RGW (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	anders06@utsw.swmed.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKUSJARVI G, 1987, MOL CELL BIOL, V7, P549, DOI 10.1128/MCB.7.1.549; Anderson R G, 1986, Methods Enzymol, V129, P201; ANDERSON RGW, 1977, NATURE, V270, P695, DOI 10.1038/270695a0; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; Chapman ER, 1996, BIOCHEM BIOPH RES CO, V225, P326, DOI 10.1006/bbrc.1996.1174; Damer CK, 1996, J NEUROCHEM, V67, P1661; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DELALUNA S, 1988, GENE, V62, P121; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Haucke V, 1999, SCIENCE, V285, P1268, DOI 10.1126/science.285.5431.1268; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; IACOPETTA BJ, 1988, CELL, V54, P485, DOI 10.1016/0092-8674(88)90069-4; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; Kee Y, 1996, J NEUROSCI, V16, P1975; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; Kim K, 1997, P NATL ACAD SCI USA, V94, P14782, DOI 10.1073/pnas.94.26.14782; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; MAHAFFEY DT, 1989, J CELL BIOL, V108, P1615, DOI 10.1083/jcb.108.5.1615; MIKOSHIBA K, 1995, P NATL ACAD SCI USA, V92, P10703, DOI 10.1073/pnas.92.23.10703; MILLER K, 1991, CELL, V65, P621, DOI 10.1016/0092-8674(91)90094-F; Mochida S, 1996, NEURON, V17, P781, DOI 10.1016/S0896-6273(00)80209-3; MOORE MS, 1987, SCIENCE, V236, P558, DOI 10.1126/science.2883727; PEELER JS, 1993, J CELL BIOL, V120, P47, DOI 10.1083/jcb.120.1.47; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; Reist NE, 1998, J NEUROSCI, V18, P7662; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Rettig J, 1997, J NEUROSCI, V17, P6647; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; Schivell AE, 1996, J BIOL CHEM, V271, P27770, DOI 10.1074/jbc.271.44.27770; SEAMAN MNJ, 1993, J CELL BIOL, V123, P1093, DOI 10.1083/jcb.123.5.1093; Sheng ZH, 1997, P NATL ACAD SCI USA, V94, P5405, DOI 10.1073/pnas.94.10.5405; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; Traub LM, 1996, J CELL BIOL, V135, P1801, DOI 10.1083/jcb.135.6.1801; ULLRICH B, 1994, NEURON, V13, P1281, DOI 10.1016/0896-6273(94)90415-4; VALLEE RB, 1993, CIBA F SYMP, V176, P185; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	59	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30916	30924		10.1074/jbc.M005559200	http://dx.doi.org/10.1074/jbc.M005559200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906143	hybrid			2022-12-27	WOS:000089762700028
J	Bankhead, T; Segall, AM				Bankhead, T; Segall, AM			Characterization of a mutation of bacteriophage lambda integrase - Putative role in core binding and strand exchange for a conserved residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; ATTACHMENT SITES; DNA; TOPOISOMERASE; PROTEIN; ATTL; FLEXIBILITY; MECHANISM; COMPLEXES; SYNAPSE	Site-specific recombination is involved in processes ranging from resolution of bacterial chromosome dimers to adeno-associated viral integration and is a versatile tool for mammalian genetics. The bacteriophage h-encoded site-specific recombinase integrase (Int) is one of the best studied site-specific recombinases and mediates recombination via four distinct pathways. We have characterized a mutant version of lambda Int, IntT236I; this mutant can perform the bent-L pathway only, whereas the corresponding IntT236A mutant can perform bent-L, excision and integration pathways. Experiments with both IntT236I and IntT236A show that the hydroxyl group of threonine is necessary for wild-type recombination. Substitution of the threonine by serine leads to nearly complete rescue of the mutant phenotypes. In addition, our data show that the IntT236I mutant is defective partially due to obstructive steric interactions. Comparisons of crystal structures reveal that the threonine at residue 236 may play an important role in stabilizing recombination intermediates through solvent-mediated protein-DNA interactions at the core-binding sites and that the hydroxyl group is important for effective cleavage and Holliday junction formation. Our data also indicate that Int contacts the core sites differently in intermediates assembled in excisive versus bent-L recombination.	San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; San Diego State Univ, Inst Mol Biol, San Diego, CA 92182 USA	California State University System; San Diego State University; California State University System; San Diego State University	Segall, AM (corresponding author), San Diego State Univ, Dept Biol, San Diego, CA 92182 USA.		Bankhead, Troy/V-9033-2019	Bankhead, Troy/0000-0002-4336-0298; Segall, Anca/0000-0002-8454-5248	NIGMS NIH HHS [GM52487] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURGIN AB, 1995, CURR BIOL, V5, P1312, DOI 10.1016/S0960-9822(95)00258-2; Cao YH, 1999, J MOL BIOL, V289, P517, DOI 10.1006/jmbi.1999.2793; Cassell G, 2000, J MOL BIOL, V299, P1193, DOI 10.1006/jmbi.2000.3828; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; CRAIG NL, 1983, CELL, V35, P795, DOI 10.1016/0092-8674(83)90112-5; DIEDERICH L, 1994, BIOTECHNIQUES, V16, P916; Gopaul DN, 1998, EMBO J, V17, P4175, DOI 10.1093/emboj/17.14.4175; Guo F, 1999, P NATL ACAD SCI USA, V96, P7143, DOI 10.1073/pnas.96.13.7143; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; Hallet B, 1999, MOL CELL, V4, P949, DOI 10.1016/S1097-2765(00)80224-5; HAN YPW, 1994, J MOL BIOL, V235, P908, DOI 10.1006/jmbi.1994.1048; Hickman AB, 1997, CELL, V89, P227, DOI 10.1016/S0092-8674(00)80202-0; Jessop L, 2000, J BACTERIOL, V182, P1024, DOI 10.1128/JB.182.4.1024-1034.2000; KIM S, 1992, SCIENCE, V256, P198, DOI 10.1126/science.1533056; KIM SH, 1990, CELL, V63, P773, DOI 10.1016/0092-8674(90)90143-3; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; NAGARAJA R, 1990, J BACTERIOL, V172, P6540, DOI 10.1128/jb.172.11.6540-6550.1990; Neidhardt F. C. E. A., 1996, ESCHERICHIA COLI SAL; Nunes-Duby SE, 1998, NUCLEIC ACIDS RES, V26, P391, DOI 10.1093/nar/26.2.391; SEGALL AM, 1993, EMBO J, V12, P4567, DOI 10.1002/j.1460-2075.1993.tb06145.x; Segall AM, 1998, J BIOL CHEM, V273, P24258, DOI 10.1074/jbc.273.37.24258; Segall AM, 1996, GENES CELLS, V1, P453, DOI 10.1046/j.1365-2443.1996.d01-254.x; SEGALL AM, 1994, EMBO J, V13, P4536, DOI 10.1002/j.1460-2075.1994.tb06775.x; Shuman S, 1998, MOL CELL, V1, P741, DOI 10.1016/S1097-2765(00)80073-8; Subramanya HS, 1997, EMBO J, V16, P5178, DOI 10.1093/emboj/16.17.5178; Tirumalai RS, 1998, J MOL BIOL, V279, P513, DOI 10.1006/jmbi.1998.1786; WHANG I, 1994, MOL CELL BIOL, V14, P7492, DOI 10.1128/MCB.14.11.7492; Wittschieben J, 1997, NUCLEIC ACIDS RES, V25, P3001, DOI 10.1093/nar/25.15.3001	30	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36949	36956		10.1074/jbc.M004679200	http://dx.doi.org/10.1074/jbc.M004679200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10938278	hybrid			2022-12-27	WOS:000165577700071
J	Otsuka, M; Kato, N; Lan, KH; Yoshida, H; Kato, J; Goto, T; Shiratori, Y; Omata, M				Otsuka, M; Kato, N; Lan, KH; Yoshida, H; Kato, J; Goto, T; Shiratori, Y; Omata, M			Hepatitis C virus core protein enhances p53 function through augmentation of DNA binding affinity and transcriptional ability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; POLYMERASE CHAIN-REACTION; PROGRAMMED CELL-DEATH; NON-B-HEPATITIS; HEPATOCELLULAR-CARCINOMA; TUMOR-SUPPRESSOR; NON-A; X PROTEIN; T-ANTIGEN; IN-VIVO	Hepatitis C virus (HCV) causes a persistent infection, chronic hepatitis, and hepatocellular carcinoma. Since there are several reports indicating that some viruses influence the tumor suppressor p53 function, we determined the effects of MCV proteins on p53 function and its mechanism determined by use of a reporter assay. Among seven HCV proteins investigated (core, NS2, NS3, NS4A, NS4B, NS5A, and NS5B), only core protein augmented the transcriptional activity of p53 and increased the expression of p21(waf1) protein, which is a major target of p53. Core protein increased both DNA-binding affinity of p53 in electrophoretic morbidity shift assay and transcriptional ability of p53 itself in a reporter assay. The direct interaction between core protein and C terminus of p53 was also shown by glutathione S-transferase fusion protein binding assay. In addition, core protein interacted with hTAF(II)28, a component of the transcriptional factor complex in vivo and in vitro. These results suggest that HCV core protein interacts with p53 and modulates p53-dependent promoter activities during HCV infection.	Univ Tokyo, Fac Med, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo	Kato, N (corresponding author), Univ Tokyo, Fac Med, Dept Gastroenterol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		Otsuka, Motoyuki/H-9067-2019	Otsuka, Motoyuki/0000-0003-2869-2881				BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; CHANG SC, 1994, BIOCHEM BIOPH RES CO, V205, P1284, DOI 10.1006/bbrc.1994.2804; Chen WP, 1996, J VIROL, V70, P4849, DOI 10.1128/JVI.70.7.4849-4853.1996; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; Devireddy LR, 1999, J VIROL, V73, P3778, DOI 10.1128/JVI.73.5.3778-3788.1999; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Edamoto Y, 1996, CANCER, V77, P1787; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; Honda K, 1998, BRIT J CANCER, V77, P776, DOI 10.1038/bjc.1998.126; Hsieh TY, 1998, J BIOL CHEM, V273, P17651, DOI 10.1074/jbc.273.28.17651; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KATO N, 1993, BIOCHEM BIOPH RES CO, V192, P800, DOI 10.1006/bbrc.1993.1485; KATO N, 1990, J CLIN INVEST, V86, P1764, DOI 10.1172/JCI114903; Kato N, 1997, J VIROL, V71, P8856, DOI 10.1128/JVI.71.11.8856-8859.1997; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lu W, 1999, VIROLOGY, V264, P134, DOI 10.1006/viro.1999.9979; Matsumoto M, 1997, J VIROL, V71, P1301, DOI 10.1128/JVI.71.2.1301-1309.1997; McCormack SJ, 1997, ONCOGENE, V15, P265, DOI 10.1038/sj.onc.1201186; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Megyeri K, 1999, VIROLOGY, V259, P74, DOI 10.1006/viro.1999.9757; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; MICHELLE EDM, 1998, J VIROL, V72, P3146; MILLER RH, 1990, P NATL ACAD SCI USA, V87, P2057, DOI 10.1073/pnas.87.6.2057; Muganda P, 1998, CELL MOL BIOL, V44, P321; Muller-Tiemann BF, 1998, P NATL ACAD SCI USA, V95, P6079, DOI 10.1073/pnas.95.11.6079; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; Murono S, 1999, HISTOPATHOLOGY, V34, P432; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NOSE H, 1993, CANCER, V72, P355, DOI 10.1002/1097-0142(19930715)72:2<355::AID-CNCR2820720208>3.0.CO;2-W; ODA T, 1992, CANCER RES, V52, P3674; Ohashi M, 1999, GUT, V44, P366, DOI 10.1136/gut.44.3.366; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Prost S, 1998, J BIOL CHEM, V273, P33327, DOI 10.1074/jbc.273.50.33327; Qin LF, 1998, INT J CANCER, V79, P424, DOI 10.1002/(SICI)1097-0215(19980821)79:4<424::AID-IJC19>3.0.CO;2-4; RAVAGGI A, 1994, J HEPATOL, V20, P833, DOI 10.1016/S0168-8278(05)80157-6; RAY RB, 1995, VIRUS RES, V37, P209, DOI 10.1016/0168-1702(95)00034-N; Ray RB, 1997, J BIOL CHEM, V272, P10983; Ray RB, 1998, GENE, V208, P331, DOI 10.1016/S0378-1119(98)00030-4; ROGER JAG, 1996, VIROLOGY, V218, P23; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sheppard HM, 1999, MOL CELL BIOL, V19, P2746; SHIH CM, 1995, J VIROL, V69, P1160, DOI 10.1128/JVI.69.2.1160-1171.1995; SHIRATORI Y, 1995, HEPATOLOGY, V22, P1027, DOI 10.1002/hep.1840220403; TAKANO S, 1995, HEPATOLOGY, V21, P650; TANJI Y, 1995, J VIROL, V69, P1575, DOI 10.1128/JVI.69.3.1575-1581.1995; Taylor DR, 1999, SCIENCE, V285, P107, DOI 10.1126/science.285.5424.107; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Togo G, 1996, CANCER RES, V56, P5620; Tsuchihara K, 1999, VIROLOGY, V258, P100, DOI 10.1006/viro.1999.9694; Uchida T, 1996, INT J CANCER, V67, P892; WANG XW, 1995, CANCER RES, V55, P6012; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Yasui K, 1998, J VIROL, V72, P6048, DOI 10.1128/JVI.72.7.6048-6055.1998	73	134	140	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34122	34130		10.1074/jbc.M000578200	http://dx.doi.org/10.1074/jbc.M000578200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10924497	hybrid			2022-12-27	WOS:000165095300020
J	Brewer, G				Brewer, G			Regulation of c-myc mRNA decay in vitro by a phorbol ester-inducible, ribosome-associated component in differentiating megakaryoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE ERYTHROLEUKEMIA-CELLS; MESSENGER-RNA TURNOVER; IN-VITRO; GENE-EXPRESSION; BINDING-PROTEIN; CODING REGION; POSTTRANSCRIPTIONAL REGULATION; STABILITY INVITRO; MAMMALIAN-CELLS; LEUKEMIA-CELLS	The R562 leukemia cell line is bipotential for erythroid and megakaryoblastic differentiation. The phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) activates a genetic program of gene expression in these cells leading to their differentiation into megakaryoblasts, a platelet precursor. Thus, K562 cells offer a means to examine early changes in gene expression necessary for megakaryoblastic commitment and differentiation. An essential requirement for differentiation of many hematopoietic cell types is the down-regulation of c-myc expression, because its constitutive expression blocks differentiation. TPA-induced differentiation of K562 cells causes rapid down-regulation of c-myc expression, due in part to an mRNA decay rate that is 4-fold faster compared with dividing cells. A cell-free mRNA decay system reconstitutes TPA-induced destabilization of c-myc mRNA, but it requires at least two components for reconstitution. One component fractionates to the post-ribosomal supernatant from either untreated or treated cells. This component is sensitive to cycloheximide and micrococcal nuclease. The other component is polysome-associated and is induced or activated by TPA. Although in dividing cells c-myc mRNA decays via a sequential pathway involving removal of the poly(A) tract followed by degradation of the mRNA body, TPA activates a deadenylation-independent pathway. The cell-free mRNA decay system reconstitutes this alternate decay pathway as well.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Brewer, G (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, 675 Hoes Lane, Piscataway, NJ 08854 USA.				NCI NIH HHS [CA52243] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALITALO R, 1990, LEUKEMIA RES, V14, P501, DOI 10.1016/0145-2126(90)90002-Q; Bashkirov VI, 1997, J CELL BIOL, V136, P761, DOI 10.1083/jcb.136.4.761; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; Brewer G, 1999, J BIOL CHEM, V274, P16174, DOI 10.1074/jbc.274.23.16174; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1990, METHOD ENZYMOL, V181, P202; Brewer G, 1998, J BIOL CHEM, V273, P34770, DOI 10.1074/jbc.273.52.34770; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; BREWER G, 1992, PROMEGA NOTES, V40, P11; COLAMONICI OR, 1986, MOL CELL BIOL, V6, P1847, DOI 10.1128/MCB.6.5.1847; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; Couttet P, 1997, P NATL ACAD SCI USA, V94, P5628, DOI 10.1073/pnas.94.11.5628; Dang CV, 1999, MOL CELL BIOL, V19, P1; Davidson E. H., 1986, GENE ACTIVITY EARLY; DEAN A, 1983, P NATL ACAD SCI-BIOL, V80, P5515, DOI 10.1073/pnas.80.18.5515; DeMarchi S, 1997, NUMER FUNC ANAL OPT, V18, P65, DOI 10.1080/01630569708816747; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; Doyle GAR, 1998, NUCLEIC ACIDS RES, V26, P5036, DOI 10.1093/nar/26.22.5036; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Gallouzi IE, 1998, MOL CELL BIOL, V18, P3956, DOI 10.1128/MCB.18.7.3956; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Hilleren P, 1999, RNA, V5, P711, DOI 10.1017/S1355838299990519; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; KUME TU, 1988, J MOL BIOL, V202, P779, DOI 10.1016/0022-2836(88)90558-X; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LACHMAN HM, 1985, P NATL ACAD SCI USA, V82, P5323, DOI 10.1073/pnas.82.16.5323; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; Lee CH, 1998, J BIOL CHEM, V273, P25261, DOI 10.1074/jbc.273.39.25261; Leeds P, 1997, ONCOGENE, V14, P1279, DOI 10.1038/sj.onc.1201093; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUMELSKY NL, 1991, MOL CELL BIOL, V11, P3528, DOI 10.1128/MCB.11.7.3528; MORELLO D, 1993, ONCOGENE, V8, P1921; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; RATNER L, 1985, NUCLEIC ACIDS RES, V13, P5007, DOI 10.1093/nar/13.14.5007; ROSS J, 1986, MOL CELL BIOL, V6, P4362, DOI 10.1128/MCB.6.12.4362; ROSS J, 1995, MICROBIOL REV, V59, P16; RuizEchevarria MJ, 1996, TRENDS BIOCHEM SCI, V21, P433, DOI 10.1016/S0968-0004(96)10055-4; SIEBERT PD, 1985, J BIOL CHEM, V260, P3868; SWARTWOUT SG, 1987, MOL CELL BIOL, V7, P2052, DOI 10.1128/MCB.7.6.2052; SWARTWOUT SG, 1989, MOL CELL BIOL, V9, P288, DOI 10.1128/MCB.9.1.288; WISDOM R, 1990, J BIOL CHEM, V265, P19015; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; Yeilding NM, 1997, MOL CELL BIOL, V17, P2698, DOI 10.1128/MCB.17.5.2698; Yeilding NM, 1996, MOL CELL BIOL, V16, P3511; Zelus BD, 1996, J VIROL, V70, P2411, DOI 10.1128/JVI.70.4.2411-2419.1996; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	52	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33336	33345		10.1074/jbc.M006145200	http://dx.doi.org/10.1074/jbc.M006145200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10931849	hybrid			2022-12-27	WOS:000090104600025
J	Fisher, CA; Narayanaswami, V; Ryan, RO				Fisher, CA; Narayanaswami, V; Ryan, RO			The lipid-associated conformation of the low density lipoprotein receptor binding domain of human apolipoprotein E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; LDL RECEPTOR; ALZHEIMERS-DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; AQUEOUS-SOLUTION; PROTEIN	Apolipoprotein E (apoE) is a 34-kDa exchangeable apolipoprotein that regulates metabolism of plasma lipoproteins by functioning as a ligand for members of the LDL receptor family, The receptor-binding region localizes to the vicinity of residues 130-150 within its independently folded 22-kDa N-terminal domain. In the absence of lipid, this domain exists as a receptor-inactive, globular four-helix bundle. Receptor recognition properties of this domain are manifest upon lipid association, which is accompanied by a conformational change in the protein. Fluorescence resonance energy transfer has been used to monitor helix repositioning, which accompanies lipid association of the apoE N-terminal domain. Site-directed mutagenesis was used to replace naturally occurring Trp residues with phenylalanine, creating a Trp-null apoE3 N-terminal domain (residues 1-183), Subsequently, tyrosine residues in helix 2, helix 3, or helix 4 were converted to Trp, generating single Trp mutant proteins. The lone cysteine at position 112 was covalently modified with N-iodoacetyl-N'-(5-Sulfo-1-naphthyl)ethylenediamine, which serves as an energy acceptor from excited tryptophan residues. Fluorescence resonance energy transfer analysis of apoE N-terminal domain variants in phospholipid disc complexes suggests that the helix bundle opens to adopt a partially extended conformation. A model is presented that depicts a tandem arrangement of the receptor-binding region of the protein in the disc complex, corresponding to its low density lipoprotein receptor-active conformation.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada	University of Alberta	Ryan, RO (corresponding author), Childrens Hosp Oakland, Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.			Narayanaswami, Vasanthy/0000-0001-7088-4057	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL064159, R01HL064159] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64159] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; Blacklow SC, 1996, NAT STRUCT BIOL, V3, P758, DOI 10.1038/nsb0996-758; DEPAUW M, 1995, BIOCHEMISTRY-US, V34, P10953, DOI 10.1021/bi00034a030; Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; Fisher CA, 1999, J LIPID RES, V40, P93; Fisher CA, 1997, BIOCHEM CELL BIOL, V75, P45, DOI 10.1139/bcb-75-1-45; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P303; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; North CL, 1999, BIOCHEMISTRY-US, V38, P3926, DOI 10.1021/bi9821622; PITAS RE, 1980, J BIOL CHEM, V255, P5454; Poirier J, 1995, ANN MED, V27, P663, DOI 10.3109/07853899509019253; Raussens V, 1998, J BIOL CHEM, V273, P25825, DOI 10.1074/jbc.273.40.25825; Riddell DR, 1997, J BIOL CHEM, V272, P89; SELVIN PR, 1995, METHOD ENZYMOL, V246, P300; Swarnakar S, 1998, J BIOL CHEM, V273, P12140, DOI 10.1074/jbc.273.20.12140; THUREN T, 1991, J BIOL CHEM, V266, P4853; WEISGRABER KH, 1994, CURR OPIN STRUC BIOL, V4, P507, DOI 10.1016/S0959-440X(94)90212-7; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WEISGRABER KH, 1992, HIGH DENSITY LIPOPRO, V3, P175; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194	24	66	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33601	33606		10.1074/jbc.M002643200	http://dx.doi.org/10.1074/jbc.M002643200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10906325	hybrid			2022-12-27	WOS:000090104600060
J	Mikusova, K; Yagi, T; Stern, R; McNeil, MR; Besra, GS; Crick, DC; Brennan, PJ				Mikusova, K; Yagi, T; Stern, R; McNeil, MR; Besra, GS; Crick, DC; Brennan, PJ			Biosynthesis of the galactan component of the mycobacterial cell wall	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GALACTOPYRANOSE MUTASE; ESCHERICHIA-COLI; TUBERCULOSIS; GALACTOFURANOSE; IDENTIFICATION; GENE; ARABINOGALACTAN; OLIGOSACCHARIDE; CHROMATOGRAPHY; TUNICAMYCIN	The structural core of the cell walls of Mycobacterium spp. consists of peptidoglycan bound by a Linker unit (-alpha -L-Rhap-(1-->3)-D-GlcNAc-P-) to a galactofuran, which in turn is attached to arabinofuran and mycolic acids. The sequence of reactions leading to the biogenesis of this complex starts with the formation of the Linker unit on a polyprenyl-P to produce polyprenyl-P-P-GlcNAc-Rha (Mikusova, K., Mikus, M., Besra, G. S., Hancock, I., and Brennan, P. J. (1996) J. Biol. Chem. 271, 7820-7828), me now establish that formation of the galactofuran takes place on this intermediate with UDP-Galf as the Galf donor presented in the form of UDP-Galp and UDP-Galp mutase (the glf gene product) and is catalyzed by galactofuranosyl transferases, one of which, the Mycobacterium tuberculosis H37Rv3808c gene product, has been identified. Evidence is also presented for the growth of the arabinofuran on this polyprenyl-P-P-linker unit-galactan intermediate catalyzed by unidentified arabinosyl transferases, with decaprenyl-P-Araf or B-P-ribosyl-PP as the Araf donor, The product of these steps, the lipid-linked-LU-galaetan-arabinan has been partially characterized in terms of its heterogeneity, size, and composition. Biosynthesis of the major components of mycobacterial cell walls is proving to be extremely complex. However, partial definition of arabinogalactan synthesis, the site of action of several major anti-tuberculosis drugs, facilitates the present day thrust for new drugs to counteract multiple drug-resistant tuberculosis.	Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA	Colorado State University	Brennan, PJ (corresponding author), Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA.	pbrennan@cvmbs.colostate.edu	Yagi, Tetsuya/J-3303-2012; McNeil, Michael/G-3325-2019; Mikusova, Katarina/I-3622-2014; Crick, Dean/H-8251-2017	Crick, Dean/0000-0001-9281-7058; Besra, Gurdyal/0000-0002-5605-0395; Mikusova, Katarina/0000-0002-0100-4877	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033706, R37AI018357, R22AI018357, U19AI038087, R01AI018357] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-38087, AI-33706, AI-18357] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANGUS WW, 1972, ARCH BIOCHEM BIOPHYS, V151, P483, DOI 10.1016/0003-9861(72)90525-5; [Anonymous], CURRENT OPINION ANTI; Belanger AE, 1996, P NATL ACAD SCI USA, V93, P11919, DOI 10.1073/pnas.93.21.11919; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Breton C, 1998, J BIOCHEM, V123, P1000; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; DAFFE M, 1990, J BIOL CHEM, V265, P6734; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; FOLCH J, 1957, J BIOL CHEM, V226, P497; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; HUNTER SW, 1986, J BIOL CHEM, V261, P2345; Koplin R, 1997, J BIOL CHEM, V272, P4121, DOI 10.1074/jbc.272.7.4121; KUO SC, 1974, BIOCHEM BIOPH RES CO, V58, P287, DOI 10.1016/0006-291X(74)90925-5; Lee R, 1996, ANAL BIOCHEM, V242, P1, DOI 10.1006/abio.1996.0419; LEE RE, 1995, J AM CHEM SOC, V117, P11829, DOI 10.1021/ja00153a002; LIND T, 1993, J BIOL CHEM, V268, P20705; LUCAS JJ, 1975, J BIOL CHEM, V250, P1992; Ma YF, 1997, MICROBIOL-SGM, V143, P937, DOI 10.1099/00221287-143-3-937; MCNEELY TB, 1990, J IMMUNOL, V144, P2745; MCNEIL M, 1990, J BIOL CHEM, V265, P18200; Mikusova K, 1996, J BIOL CHEM, V271, P7820, DOI 10.1074/jbc.271.13.7820; Nassau PM, 1996, J BACTERIOL, V178, P1047, DOI 10.1128/jb.178.4.1047-1052.1996; Ramaswamy S., 1998, Tubercle and Lung Disease, V79, P3, DOI 10.1054/tuld.1998.0002; RUSH JS, 1993, J BIOL CHEM, V268, P13110; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; Scherman MS, 1996, J BIOL CHEM, V271, P29652, DOI 10.1074/jbc.271.47.29652; Stern RJ, 1999, MICROBIOL-UK, V145, P663, DOI 10.1099/13500872-145-3-663; TAKATSUKI A, 1975, AGR BIOL CHEM TOKYO, V39, P2089, DOI 10.1080/00021369.1975.10861914; TAKAYAMA K, 1973, BIOCHIM BIOPHYS ACTA, V136, P217; WARD JB, 1977, FEBS LETT, V78, P151, DOI 10.1016/0014-5793(77)80294-9; Weston A, 1998, TUBERCLE LUNG DIS, V78, P123, DOI 10.1016/S0962-8479(98)80005-1; WHITFIELD C, 1995, TRENDS MICROBIOL, V3, P178, DOI 10.1016/S0966-842X(00)88917-9	34	105	110	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33890	33897		10.1074/jbc.M006875200	http://dx.doi.org/10.1074/jbc.M006875200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10934214	hybrid			2022-12-27	WOS:000090104600098
J	Miller, MA; McGowan, SE; Gantt, KR; Champion, M; Novick, SL; Andersen, KA; Bacchi, CJ; Yarlett, N; Britigan, BE; Wilson, ME				Miller, MA; McGowan, SE; Gantt, KR; Champion, M; Novick, SL; Andersen, KA; Bacchi, CJ; Yarlett, N; Britigan, BE; Wilson, ME			Inducible resistance to oxidant stress in the protozoan Leishmania chagasi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-BRUCEI-RHODESIENSE; HEAT-SHOCK PROTEIN-70; ALPHA-DIFLUOROMETHYLORNITHINE; TRYPANOTHIONE REDUCTASE; MAJOR PROMASTIGOTES; DONOVANI-CHAGASI; DEVELOPMENTAL MODIFICATION; SURFACE LIPOPHOSPHOGLYCAN; INTRACELLULAR SURVIVAL; LIPID-PEROXIDATION	Leishmania sp, protozoa are introduced into a mammalian skin by a sandfly vector, whereupon they en counter increased temperature and toxic oxidants generated during phagocytosis, We studied the effects of 37 degreesC "heat shock" or sublethal menadione, which generates superoxide and hydrogen peroxide, on Leishmania chagasi virulence. Both heat and menadione caused parasites to become more resistant to H2O2-mediated toxicity. Peroxide resistance was also induced as promastigotes developed in culture from logarithmic to their virulent stationary phase form. Peroxide resistance was not associated with an increase in reduced thiols (trypanothione and glutathione) or increased activity of ornithine decarboxylase, which is rate-limiting in trypanothione synthesis. Membrane lipophosphoglycan increased in size as parasites developed to stationary phase but not after environmental exposures. Instead, parasites underwent a heat shock response upon exposure to heat or sublethal menadione, detected by increased levels of HSP70. Transfection of promastigotes with L, chagasi HSP70 caused a heat inducible increase in resistance to peroxide, implying it is involved in antioxidant defense. We conclude that leishmania have redundant mechanisms for resisting toxic oxidants, Some are induced during developmental change and others are induced in response to environmental stress.	Univ Iowa, Vet Affairs Med Ctr, Iowa City, IA 52242 USA; Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA; Univ Iowa, Interdisciplinary Immunol Program, Iowa City, IA 52242 USA; Pace Univ, Haskins Labs, New York, NY 10038 USA; Pace Univ, Dept Biol, New York, NY 10038 USA; Pace Univ, Dept Chem, New York, NY 10038 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa; University of Iowa; University of Iowa; Pace University; Pace University; Pace University	Wilson, ME (corresponding author), Univ Iowa, Vet Affairs Med Ctr, Iowa City, IA 52242 USA.	mary-wilson@uiowa.edu	Yarlett, Nigel/B-3523-2009	Wilson, Mary/0000-0001-8680-7275; Champion, Matthew M./0000-0001-5927-5277; McGowan, Stephen/0000-0003-3084-1962	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034954, R21AI032135, R01AI032135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK052550] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34954, AI32135] Funding Source: Medline; NIDDK NIH HHS [DK/AI52550] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andersen KA, 1996, AM J TROP MED HYG, V54, P471, DOI 10.4269/ajtmh.1996.54.471; ARGAMAN M, 1994, MOL BIOCHEM PARASIT, V64, P95, DOI 10.1016/0166-6851(94)90138-4; BACCHI CJ, 1993, BIOCHEM PHARMACOL, V46, P471, DOI 10.1016/0006-2952(93)90524-Z; BACCHI CJ, 1981, J PROTOZOOL, V28, P20, DOI 10.1111/j.1550-7408.1981.tb02798.x; Beaucamp N, 1998, FEBS LETT, V441, P215, DOI 10.1016/S0014-5793(98)01553-1; BERENS RL, 1976, J PARASITOL, V62, P360, DOI 10.2307/3279142; BROWN T, 2000, CURRENT PROTOCOLS MO; CHAN J, 1989, P NATL ACAD SCI USA, V86, P2453, DOI 10.1073/pnas.86.7.2453; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chong KY, 1998, J MOL CELL CARDIOL, V30, P599, DOI 10.1006/jmcc.1997.0623; COONS T, 1990, MOL BIOCHEM PARASIT, V39, P77, DOI 10.1016/0166-6851(90)90010-J; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; CUNNINGHAM ML, 1995, EUR J BIOCHEM, V230, P460, DOI 10.1111/j.1432-1033.1995.tb20583.x; DAVIES CR, 1990, PARASITOLOGY, V101, P337, DOI 10.1017/S0031182000060522; DAVIS LS, 1991, CURRENT PROTOCOLS IM; DEANDRADE CR, 1992, J CLIN MICROBIOL, V30, P330, DOI 10.1128/JCM.30.2.330-335.1992; DESCOTEAUX A, 1991, J IMMUNOL, V146, P2747; DESCOTEAUX A, 1992, J IMMUNOL, V149, P3008; Desjardins M, 1997, J EXP MED, V185, P2061, DOI 10.1084/jem.185.12.2061; DONATI YRA, 1990, BIOCHEM PHARMACOL, V40, P2571, DOI 10.1016/0006-2952(90)90573-4; Dumas C, 1997, EMBO J, V16, P2590, DOI 10.1093/emboj/16.10.2590; FAIRLAMB AH, 1987, MOL BIOCHEM PARASIT, V24, P185, DOI 10.1016/0166-6851(87)90105-8; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; Freeman ML, 1999, FREE RADICAL BIO MED, V26, P737, DOI 10.1016/S0891-5849(98)00258-5; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Ha HC, 1998, P NATL ACAD SCI USA, V95, P11140, DOI 10.1073/pnas.95.19.11140; HANSON S, 1992, J BIOL CHEM, V267, P2350; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; ISMAIL SO, 1994, INFECT IMMUN, V62, P657, DOI 10.1128/IAI.62.2.657-664.1994; JAATTELA M, 1993, J EXP MED, V177, P231, DOI 10.1084/jem.177.1.231; Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772; LATHIGRA RB, 1991, CURR TOP MICROBIOL, V167, P125; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; LESSE AJ, 1990, J IMMUNOL METHODS, V126, P109, DOI 10.1016/0022-1759(90)90018-Q; Levick MP, 1998, MOL BIOCHEM PARASIT, V96, P125, DOI 10.1016/S0166-6851(98)00122-4; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; MCCONVILLE MJ, 1992, EMBO J, V11, P3593, DOI 10.1002/j.1460-2075.1992.tb05443.x; McGonigle S, 1998, PARASITOL TODAY, V14, P139, DOI 10.1016/S0169-4758(97)01211-8; MCNEELY TB, 1990, J IMMUNOL, V144, P2745; MEISTER A, 1994, J BIOL CHEM, V269, P9397; Membrillo-Hernandez J, 1999, J BIOL CHEM, V274, P748, DOI 10.1074/jbc.274.2.748; Mukhopadhyay R, 1996, P NATL ACAD SCI USA, V93, P10383, DOI 10.1073/pnas.93.19.10383; MURRAY HW, 1981, J EXP MED, V153, P1690, DOI 10.1084/jem.153.6.1690; MURRAY HW, 1986, ANNU REV MED, V37, P61; MURRAY HW, 1985, J IMMUNOL, V134, P1619; PEARSON RD, 1982, J IMMUNOL, V129, P1282; PEARSON RD, 1983, J IMMUNOL, V131, P1994; PHILLIPS MA, 1987, MOL BIOCHEM PARASIT, V22, P9, DOI 10.1016/0166-6851(87)90064-8; PLUMIER JCL, 1995, J CLIN INVEST, V95, P1854, DOI 10.1172/JCI117865; Pompella A, 1997, INT J VITAM NUTR RES, V67, P289; PUENTES SM, 1988, J EXP MED, V167, P887, DOI 10.1084/jem.167.3.887; RAMAMOORTHY R, 1992, J BIOL CHEM, V267, P1888; RYAN KA, 1993, GENE, V131, P145, DOI 10.1016/0378-1119(93)90684-U; SACKS DL, 1990, MOL BIOCHEM PARASIT, V42, P225, DOI 10.1016/0166-6851(90)90165-I; SACKS DL, 1995, J EXP MED, V181, P685, DOI 10.1084/jem.181.2.685; SIMON MM, 1995, J CLIN INVEST, V95, P926, DOI 10.1172/JCI117800; Smith VP, 1998, EXP PARASITOL, V88, P103, DOI 10.1006/expr.1998.4209; Su CY, 1999, BIOCHEM BIOPH RES CO, V265, P279, DOI 10.1006/bbrc.1999.1649; Tovar J, 1998, P NATL ACAD SCI USA, V95, P5311, DOI 10.1073/pnas.95.9.5311; TURCO SJ, 1984, J BIOL CHEM, V259, P3883; Webb JR, 1998, INFECT IMMUN, V66, P3279, DOI 10.1128/IAI.66.7.3279-3289.1998; WILSON ME, 1994, INFECT IMMUN, V62, P5133, DOI 10.1128/IAI.62.11.5133-5141.1994; YARLETT N, 1991, EXP PARASITOL, V72, P205, DOI 10.1016/0014-4894(91)90138-M; ZARLEY JH, 1991, J CLIN INVEST, V88, P1511, DOI 10.1172/JCI115461	65	84	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33883	33889		10.1074/jbc.M003671200	http://dx.doi.org/10.1074/jbc.M003671200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10931831	hybrid			2022-12-27	WOS:000090104600097
J	Siess, DC; Vedder, CT; Merksen, LS; Tanaka, T; Freed, AC; McCoy, SL; Heinrich, MC; Deffebach, ME; Bennett, RM; Hefeneider, SH				Siess, DC; Vedder, CT; Merksen, LS; Tanaka, T; Freed, AC; McCoy, SL; Heinrich, MC; Deffebach, ME; Bennett, RM; Hefeneider, SH			A human gene coding for a membrane-associated nucleic acid-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SYSTEMIC LUPUS-ERYTHEMATOSUS; CELL-SURFACE MOLECULES; ANTI-DNA ANTIBODIES; RING FINGER DOMAIN; ZINC-FINGER; PLASMID DNA; RECEPTOR; OLIGODEOXYNUCLEOTIDES; FAMILY	Studies to clone a cell-surface DNA-binding protein involved in the binding and internalization of extracellular DNA have led to the isolation of a gene for a membrane-associated nucleic acid-binding protein (MNAB). The full-length cDNA is 4.3 kilobases with an open reading frame of 3576 base pairs encoding a protein of similar to 130 kDa (GenBank accession numbers AF255303 and AF255304), The MNAB gene is on human chromosome 9 with wide expression in normal tissues and tumor cells. A C3HC4 RING finger and a CCCH zinc finger have been identified in the amino-terminal half of the protein. MNAB bound DNA (K-D similar to4 nM) and mutagenesis of a single conserved amino acid in the zinc finger reduced DNA binding by 50%. A potential transmembrane domain exists near the carboxyl terminus, Antibodies against the amino terminal half of the protein immunoprecipitated a protein of molecular mass similar to 150 kDa and reacted with cell surfaces. The MNAB protein is membrane-associated and primarily localized to the perinuclear space, probably to the endoplasmic reticulum or trans-Golgi network, Characterization of the MNAB protein as a cell-surface DNA-binding protein, critical in binding and internalization of extracellular DNA, awaits confirmation of its localization to cell surfaces.	Vet Affairs Med Ctr, Dept Immunol, Portland, OR 97201 USA; Vet Affairs Med Ctr, Dept Pulmonol, Portland, OR 97201 USA; Vet Affairs Med Ctr, Dept Hematol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA; Targeted Gene Delivery Inc, Portland, OR 97201 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Oregon Health & Science University	Hefeneider, SH (corresponding author), Vet Affairs Med Ctr, Dept Immunol, R&D18,3710 SW US Vet Hosp Rd, Portland, OR 97201 USA.	Hefeneid@OHSU.edu	Heinrich, Michael/AAC-6745-2019	Bennett, Robert/0000-0002-7526-3425; Heinrich, Michael/0000-0003-3790-0478	NCI NIH HHS [R43 CA78140] Funding Source: Medline; NIAMS NIH HHS [R1AR3429B] Funding Source: Medline; NIDCD NIH HHS [R01 DC03573] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R43CA078140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Akhtar S, 1996, ANTISENSE NUCLEIC A, V6, P197, DOI 10.1089/oli.1.1996.6.197; BELTINGER C, 1995, J CLIN INVEST, V95, P1814, DOI 10.1172/JCI117860; Benimetskaya L, 1997, NAT MED, V3, P414, DOI 10.1038/nm0497-414; Bennett R M, 1993, Antisense Res Dev, V3, P235; BENNETT RM, 1991, CLIN EXP IMMUNOL, V86, P374; BENNETT RM, 1992, CLIN EXP IMMUNOL, V90, P428; BENNETT RM, 1987, J EXP MED, V166, P850, DOI 10.1084/jem.166.4.850; BENNETT RM, 1986, LANCET, V1, P186; BENNETT RM, 1983, J CLIN INVEST, V71, P611, DOI 10.1172/JCI110807; BENNETT RM, 1985, J CLIN INVEST, V76, P2182, DOI 10.1172/JCI112226; Bohle B, 1999, EUR J IMMUNOL, V29, P2344, DOI 10.1002/(SICI)1521-4141(199907)29:07<2344::AID-IMMU2344>3.0.CO;2-R; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Deml L, 1999, CLIN CHEM LAB MED, V37, P199, DOI 10.1515/CCLM.1999.037; Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617; EHRLICH M, 1976, BIOCHIM BIOPHYS ACTA, V454, P397, DOI 10.1016/0005-2787(76)90266-5; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; EMLEN W, 1988, AM J PATHOL, V133, P54; Feltquate DM, 1998, J CELL BIOCHEM, P304; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Freimark BD, 1998, J IMMUNOL, V160, P4580; GASPARRO FP, 1990, PHOTOCHEM PHOTOBIOL, V52, P315, DOI 10.1111/j.1751-1097.1990.tb04187.x; Hartmann G, 1999, P NATL ACAD SCI USA, V96, P9305, DOI 10.1073/pnas.96.16.9305; Hawley P, 1996, ANTISENSE NUCLEIC A, V6, P185, DOI 10.1089/oli.1.1996.6.185; HEFENEIDER SH, 1992, CLIN IMMUNOL IMMUNOP, V63, P245, DOI 10.1016/0090-1229(92)90229-H; HEFENEIDER SH, 1992, LUPUS, V1, P167, DOI 10.1177/096120339200100308; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KABAKOV AE, 1991, CLIN EXP IMMUNOL, V83, P359; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KAWABATA K, 1995, PHARMACEUT RES, V12, P825, DOI 10.1023/A:1016248701505; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lai WS, 1999, MOL CELL BIOL, V19, P4311; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Manzel L, 1999, ANTISENSE NUCLEIC A, V9, P459, DOI 10.1089/oli.1.1999.9.459; McCoy SL, 2000, J IMMUNOL METHODS, V241, P141, DOI 10.1016/S0022-1759(00)00205-2; MISHIMA K, 1993, J BIOL CHEM, V268, P8801; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; NORMENT AM, 1988, EMBO J, V7, P3433, DOI 10.1002/j.1460-2075.1988.tb03217.x; PRABHAKAR BS, 1990, J CLIN INVEST, V86, P1301, DOI 10.1172/JCI114838; RAZ E, 1993, EUR J IMMUNOL, V23, P383, DOI 10.1002/eji.1830230213; REDDY BA, 1991, NUCLEIC ACIDS RES, V19, P6330, DOI 10.1093/nar/19.22.6330; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; RIEBER M, 1989, BIOCHEM BIOPH RES CO, V159, P1441, DOI 10.1016/0006-291X(89)92271-7; Robinson HL, 1999, INT J MOL MED, V4, P549; RUSSELL JL, 1980, J IMMUNOL, V125, P2328; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SCHWARTZ DA, 1997, AM J RESP CRIT CARE, V144, pA501; Siemienski K, 1997, GENE, V195, P35, DOI 10.1016/S0378-1119(97)00147-9; Sparwasser T, 1997, EUR J IMMUNOL, V27, P1671, DOI 10.1002/eji.1830270712; STEIN CA, 1993, BIOCHEMISTRY-US, V32, P4855, DOI 10.1021/bi00069a022; Takagi T, 1998, BIOCHEM BIOPH RES CO, V245, P729, DOI 10.1006/bbrc.1998.8521; Tsan MF, 1997, P ASSOC AM PHYSICIAN, V109, P409; Worthington MT, 1996, P NATL ACAD SCI USA, V93, P13754, DOI 10.1073/pnas.93.24.13754; YAKUBOV L, 1991, NUCLEIC ACIDS RES S, V24, P311; YAKUBOV LA, 1989, P NATL ACAD SCI USA, V86, P6454, DOI 10.1073/pnas.86.17.6454; Yew NS, 1999, HUM GENE THER, V10, P223, DOI 10.1089/10430349950019011; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	67	38	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33655	33662		10.1074/jbc.M004461200	http://dx.doi.org/10.1074/jbc.M004461200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10938276	hybrid			2022-12-27	WOS:000090104600067
J	Lehtonen, S; Ora, A; Olkkonen, VM; Geng, L; Zerial, M; Somlo, S; Lehtonen, E				Lehtonen, S; Ora, A; Olkkonen, VM; Geng, L; Zerial, M; Somlo, S; Lehtonen, E			In vivo interaction of the adapter protein CD2-associated protein with the type 2 polycystic kidney disease protein, polycystin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PKD1 GENE-PRODUCT; IDENTIFICATION; EXPRESSION; CHANNEL; ENCODES; DOMAINS; MICE	We identified a developmentally regulated gene from mouse kidney whose expression is up-regulated in metanephrogenic mesenchyme cells when they are induced to differentiate to epithelial cells during kidney organogenesis. The deduced 70.5-kDa protein, originally named METS-1 (mesenchyme-to-epithelium transition protein with SH3 domains), has since been cloned as a CD2-associated protein (CD2AP). CD2AP is strongly expressed in glomerular podocytes, and the absence of CD2AP in mice results in congenital nephrotic syndrome. We have found that METS-1/CD2AP thereafter referred to as CD2AP) is expressed at lower levels in renal tubular epithelial cells in the adult kidney, particularly in distal nephron segments. Independent yeast two-hybrid screens using the COOH-terminal region of either CD2AP or polycystin-2 as bait identified the COOH termini of polycystin-2 and CD2AP, respectively, as strong interacting partners. This interaction was confirmed in cultured cells by eo-immunoprecipitation of endogenous polycystin-2 with endogenous CD2AP and vice versa. CD2AP shows a diffuse reticular cytoplasmic and perinuclear pattern of distribution, similar to polycystin-2, in cultured cells, and the two proteins co-localize by indirect double immunofluorescence microscopy. CD2AP is an adapter molecule that associates with a variety of membrane proteins to organize the cytoskeleton around a polarized site. Such a function fits well with that hypothesized for the polycystin proteins in renal tubular epithelial cells, and the present findings suggest that CD2AP has a role in polycystin-2 function.	Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, FIN-00290 Helsinki, Finland; Natl Publ Hlth Inst, Dept Biochem, FIN-00300 Helsinki, Finland; European Mol Biol Lab, D-6900 Heidelberg, Germany; Yale Univ, Sch Med, Nephrol Sect, New Haven, CT 06520 USA	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Finland National Institute for Health & Welfare; European Molecular Biology Laboratory (EMBL); Yale University	Somlo, S (corresponding author), Yale Univ, Sch Med, Nephrol Sect, 295 Congress Ave, New Haven, CT 06519 USA.		Lehtonen, Sanna/GRJ-3642-2022; ora, ari/P-5180-2015; Lehtonen, Sanna/AAE-4545-2020; Lehtonen, Eero/AGJ-4027-2022	Lehtonen, Sanna/0000-0003-4189-2415; Olkkonen, Vesa/0000-0001-5553-7997; Lehtonen, Eero/0000-0002-8218-635X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK057328] Funding Source: NIH RePORTER; NIDDK NIH HHS [P50 DK057328, P50DK57328] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnould T, 1999, MOL CELL BIOL, V19, P3423; Barasch J, 1999, CELL, V99, P377, DOI 10.1016/S0092-8674(00)81524-X; BURN TC, 1995, HUM MOL GENET, V4, P575, DOI 10.1093/hmg/4.4.575; Cai ZQ, 1999, J BIOL CHEM, V274, P28557, DOI 10.1074/jbc.274.40.28557; CALVET JP, 1993, KIDNEY INT, V43, P101, DOI 10.1038/ki.1993.17; Charron AJ, 2000, J CELL BIOL, V149, P111, DOI 10.1083/jcb.149.1.111; Chen XZ, 1999, NATURE, V401, P383, DOI 10.1038/43907; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; Emmons SW, 1999, NATURE, V401, P339, DOI 10.1038/43810; Foggensteiner L, 2000, J AM SOC NEPHROL, V11, P814, DOI 10.1681/ASN.V115814; Gallagher AR, 2000, P NATL ACAD SCI USA, V97, P4017, DOI 10.1073/pnas.97.8.4017; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; Grantham JJ, 1997, CONTRIB NEPHROL, V122, P1; Guillaume R, 2000, MECH DEVELOP, V93, P179, DOI 10.1016/S0925-4773(00)00257-4; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Huan YH, 1999, J CLIN INVEST, V104, P1459, DOI 10.1172/JCI5111; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; Jansson S, 1997, J CELL PHYSIOL, V173, P147, DOI 10.1002/(SICI)1097-4652(199711)173:2<147::AID-JCP13>3.0.CO;2-D; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; Kirsch KH, 1999, P NATL ACAD SCI USA, V96, P6211, DOI 10.1073/pnas.96.11.6211; Lehtonen S, 1999, INT J DEV BIOL, V43, P425; Lehtonen S, 1998, INT J DEV BIOL, V42, P775; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Markowitz GS, 1999, AM J PHYSIOL-RENAL, V277, pF17, DOI 10.1152/ajprenal.1999.277.1.F17; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; MORTON CJ, 1994, CURR BIOL, V4, P615, DOI 10.1016/S0960-9822(00)00134-2; Nomura H, 1998, J BIOL CHEM, V273, P25967, DOI 10.1074/jbc.273.40.25967; Obermuller N, 1999, AM J PHYSIOL-RENAL, V277, pF914, DOI 10.1152/ajprenal.1999.277.6.F914; ORA A, 1995, J BIOL CHEM, V270, P26060, DOI 10.1074/jbc.270.44.26060; Parnell SC, 1998, BIOCHEM BIOPH RES CO, V251, P625, DOI 10.1006/bbrc.1998.9514; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PETERS DJM, 1992, CONTRIB NEPHROL, V97, P128; Qian F, 1996, CELL, V87, P979, DOI 10.1016/S0092-8674(00)81793-6; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Saxen L., 1987, ORGANOGENESIS KIDNEY; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Torres VE, 1998, CURR OPIN NEPHROL HY, V7, P159, DOI 10.1097/00041552-199803000-00004; Tsiokas L, 1999, P NATL ACAD SCI USA, V96, P3934, DOI 10.1073/pnas.96.7.3934; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Veldhuisen B, 1999, EUR J HUM GENET, V7, P860, DOI 10.1038/sj.ejhg.5200383; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARD CJ, 1994, CELL, V77, P881; Wilson PD, 1999, EXP NEPHROL, V7, P114; Wilson PD, 1999, LAB INVEST, V79, P1311; Wu GQ, 2000, NAT GENET, V24, P75, DOI 10.1038/71724; Wu GQ, 1998, GENOMICS, V54, P564, DOI 10.1006/geno.1998.5618; Wu GQ, 1997, GENOMICS, V45, P220, DOI 10.1006/geno.1997.4920; Wu GQ, 1998, CELL, V93, P177, DOI 10.1016/S0092-8674(00)81570-6	50	78	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32888	32893		10.1074/jbc.M006624200	http://dx.doi.org/10.1074/jbc.M006624200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10913159	hybrid			2022-12-27	WOS:000090003800070
J	Litvak, V; Tian, D; Shaul, YD; Lev, S				Litvak, V; Tian, D; Shaul, YD; Lev, S			Targeting of PYK2 to focal adhesions as a cellular mechanism for convergence between integrins and G protein-coupled receptor signaling cascades	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; TYROSINE KINASE; ACTIN CYTOSKELETON; CARDIAC MYOCYTES; ANGIOTENSIN-II; EGF RECEPTOR; PHOSPHORYLATION; ACTIVATION; IDENTIFICATION; ASSOCIATION	The non-receptor tyrosine kinase PYK2 appears to function at a point of convergence of integrins and certain G protein-coupled receptor (GPCR) signaling cascades. In this study, we provide evidence that translocation of PYK2 to focal adhesions is triggered both by cell adhesion to extracellular matrix proteins and by activation of the histamine GPCR. By using different mutants of PYK2 as green fluorescent fusion proteins, we show that the translocation of PYK2 to focal adhesions is not dependent on its catalytic activity but rather is mediated by its carboxyl-terminal domain. Translocation of PYK2 to focal adhesions was attributed to enhanced tyrosine phosphorylation of PYK2 and its association with the focal adhesion proteins paxillin and p130(Cas). Translocation of PYK2 to focal adhesions, as well as its tyrosine phosphorylation in response to histamine treatment, was abolished in the presence of protein kinase C inhibitors or cytochalasin D treatment, whereas activation of protein kinase C by phorbol ester resulted in focal adhesion targeting of PYR2 and its tyrosine phosphorylation in an integrin-clustering dependent manner. Overexpression of a wild-type PYK2 enhanced ERK activation in response to histamine, whereas a kinase-deficient mutant substantially inhibited this response. Furthermore, inhibition of PYK2 translocation to focal adhesions abolished ERK activation in response to histamine treatment. These results suggest that PYK2 apparently links between GPCRs and focal adhesion-dependent ERK activation and can provide the molecular basis underlying PYK2 function at a point of convergence between signaling pathways triggered by extracellular matrix proteins and certain GPCR agonists.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Lev, S (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.		Lev, Sima/AAP-7880-2020; Shaul, Yoav/AAY-7011-2020	Lev, Sima/0000-0002-2108-3330; 				Andreev J, 1999, MOL CELL BIOL, V19, P2338; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Bootman MD, 1996, BIOCHEM J, V314, P347, DOI 10.1042/bj3140347; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Giancotti FG, 2000, NAT CELL BIOL, V2, pE13, DOI 10.1038/71397; Gismondi A, 1997, J IMMUNOL, V159, P4729; GRINNELL F, 1986, EXP CELL RES, V162, P449, DOI 10.1016/0014-4827(86)90349-6; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Haimovich B, 1996, BLOOD, V87, P152, DOI 10.1182/blood.V87.1.152.bloodjournal871152; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Johnson JA, 1996, CIRC RES, V79, P1086, DOI 10.1161/01.RES.79.6.1086; Lakkakorpi PT, 1999, J BIOL CHEM, V274, P4900, DOI 10.1074/jbc.274.8.4900; Lev S, 1999, MOL CELL BIOL, V19, P2278; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LI J, 1996, BLOOD, P417; Ma EA, 1997, EUR J IMMUNOL, V27, P329, DOI 10.1002/eji.1830270147; Ohba T, 1998, BIOCHEM J, V330, P1249, DOI 10.1042/bj3301249; Rodriguez-Fernandez JL, 1999, BIOESSAYS, V21, P1069, DOI 10.1002/(SICI)1521-1878(199912)22:1<1069::AID-BIES13>3.0.CO;2-C; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SanchezMateos P, 1996, SEMIN CANCER BIOL, V7, P99, DOI 10.1006/scbi.1996.0015; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SCHLAEPFER DD, 1994, NATURE, V372, P786; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; Soltoff SP, 1998, J BIOL CHEM, V273, P2653, DOI 10.1074/jbc.273.5.2653; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VAN BT, 1995, NATURE, V376, P781; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; WOODS A, 1992, J CELL SCI, V101, P277; Xiong WC, 1998, J CELL SCI, V111, P1981; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417; ZACHARY I, 1993, J BIOL CHEM, V268, P22060	50	69	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32736	32746		10.1074/jbc.M004200200	http://dx.doi.org/10.1074/jbc.M004200200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10915788	hybrid			2022-12-27	WOS:000090003800051
J	Sakamoto, I; Kishida, S; Fukui, A; Kishida, M; Yamamoto, H; Hino, S; Michiue, T; Takada, S; Asashima, M; Kikuchi, A				Sakamoto, I; Kishida, S; Fukui, A; Kishida, M; Yamamoto, H; Hino, S; Michiue, T; Takada, S; Asashima, M; Kikuchi, A			A novel beta-catenin-binding protein inhibits beta-catenin-dependent Tcf activation and axis formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WNT SIGNALING PATHWAY; GLYCOGEN-SYNTHASE KINASE-3-BETA; TRANSCRIPTION FACTOR TCF; MOUSE FUSED LOCUS; F-BOX PROTEIN; NEGATIVE REGULATOR; XENOPUS EMBRYOS; FUNCTIONAL INTERACTION; PHOSPHATASE 2A; COMPLEX	beta -Catenin is efficiently phosphorylated by glycogen synthase kinase-3 beta in the Axin complex in the cytoplasm, resulting in the down-regulation. In response to Wnt, beta -catenin is stabilized and translocated into the nucleus where it stimulates gene expression through Tcf/Lef, Here we report a novel protein, designated Duplin (for axis duplication inhibitor), which negatively regulates the function of beta -catenin in the nucleus. Duplin was located in the nucleus. Duplin bound directly to the Armadillo repeats of beta -catenin, thereby inhibiting the binding of Tcf to beta -catenin. It did not affect the stability of beta -catenin but inhibited Wnt- or beta -catenin-dependent Tcf activation. Furthermore, expression of Duplin in Xenopus embryos inhibited the axis formation and beta -catenin-dependent axis duplication, and prevented the beta -catenin's ability to rescue ventralizing phenotypes induced by ultraviolet light irradiation. Thus, Duplin is a nuclear protein that inhibits beta -catenin signaling.	Kyoto Univ, Fac Sci, Ctr Mol & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan; Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; PRESTO, Japan Sci & Technol Corp, Hiroshima 7348551, Japan; Univ Tokyo, Dept Life Sci Biol, Meguro Ku, Tokyo 1538902, Japan; Univ Tokyo, CREST Project, Meguro Ku, Tokyo 1538902, Japan; Japan Sci & Technol Corp, ERATO, Kondoh Differentiat Signaling Project, Kyoto 6068305, Japan	Kyoto University; Hiroshima University; Japan Science & Technology Agency (JST); University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo; Japan Science & Technology Agency (JST)	Kikuchi, A (corresponding author), Kyoto Univ, Fac Sci, Ctr Mol & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan.	akikuchi@mcai.med.hiroshima-u.ac.jp	Fukui, Akimasa/F-5284-2011	kishida, shosei/0000-0003-0405-851X; Takada, Shinji/0000-0003-4125-6056				Bauer A, 1998, P NATL ACAD SCI USA, V95, P14787, DOI 10.1073/pnas.95.25.14787; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Brannon M, 1999, DEVELOPMENT, V126, P3159; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Dale TC, 1998, BIOCHEM J, V329, P209; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GLUECKSOHNSCHOENHEIMER S, 1949, J EXP ZOOL, V110, P47, DOI 10.1002/jez.1401100105; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; HURT EC, 1993, FEBS LETT, V325, P76, DOI 10.1016/0014-5793(93)81417-X; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; Kikuchi A, 1999, CELL SIGNAL, V11, P777, DOI 10.1016/S0898-6568(99)00054-6; Kikuchi A, 1999, CYTOKINE GROWTH F R, V10, P255, DOI 10.1016/S1359-6101(99)00017-9; Kishida M, 1999, ONCOGENE, V18, P979, DOI 10.1038/sj.onc.1202388; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; Maniatis T., 1982, MOL CLONING; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 1998, BIOESSAYS, V20, P536, DOI 10.1002/(SICI)1521-1878(199807)20:7<536::AID-BIES4>3.3.CO;2-U; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Okazaki M, 1996, CANCER RES, V56, P2387; PERRY WL, 1995, GENETICS, V141, P321; Pizzuti A, 1996, HUM MOL GENET, V5, P953, DOI 10.1093/hmg/5.7.953; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; SCHARF SR, 1980, DEV BIOL, V79, P181, DOI 10.1016/0012-1606(80)90082-2; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Shibamoto S, 1998, GENES CELLS, V3, P659; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tian Q, 1999, DEVELOPMENT, V126, P3371; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	56	84	86	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32871	32878		10.1074/jbc.M004089200	http://dx.doi.org/10.1074/jbc.M004089200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10921920	hybrid			2022-12-27	WOS:000090003800068
J	Igarashi, J; Michel, T				Igarashi, J; Michel, T			Agonist-modulated targeting of the EDG-1 receptor to plasmalemmal caveolae - eNOS activation by sphingosine 1-phosphate and the role of caveolin-1 in sphingolipid signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; PROTEIN-COUPLED RECEPTOR; HUMAN ENDOTHELIAL-CELLS; LYSOPHOSPHATIDIC ACID; MOLECULAR-CLONING; CARDIAC MYOCYTES; DUAL ACYLATION; KINASE PATHWAY; SPHINGOSINE-1-PHOSPHATE; MEMBRANE	Plasmalemmal caveolae are membrane microdomains that are specifically enriched in sphingolipids and contain a wide array of signaling proteins, including the endothelial isoform of nitric-oxide synthase (eNOS). EDG-1 is a G protein-coupled receptor for sphingosine 1-phosphate (S1P) that is expressed in endothelial cells and has been implicated in diverse vascular signal transduction pathways. We analyzed the subcellular distribution of EDG-1 in COS-7 cells transiently transfected with cDNA constructs encoding epitope-tagged EDG-1. Subcellular fractionation of cell lysates resolved by ultracentrifugation in discontinuous sucrose gradients revealed that similar to 55% of the EDG-1 protein was recovered in fractions enriched in caveolin-1, a resident protein of caveolae, Co-immunoprecipitation experiments showed that EDG-1 could be specifically precipitated by antibodies directed against caveolin-1 and vice versa. The targeting of EDG-1 to caveolae-enriched fractions was markedly increased (from 51 +/- 11% to 93 +/- 14%) by treatment of transfected cells with S1P (5 mu M, 60 min). In co-transfection experiments expressing EDG-1 and eNOS cDNAs in COS-7 cells, we found that S1P treatment significantly and specifically increased nitric-oxide synthase activity, with an EC50 of 30 nM S1P. Overexpression of transfected caveolin-1 cDNA together with EDG-1 and eNOS markedly diminished S1P-mediated eNOS activation; caveolin overexpression also attenuated agonist-induced phosphorylation of EDG-1 receptor by >90%. These results suggest that the interaction of the EDG-1 receptor with caveolin may serve to inhibit signaling through the S1P pathway, even as the targeting of EDG-1 to caveolae facilitates the interactions of this receptor with ligands and effecters that are also targeted to caveolae. The agonist-modulated targeting of EDG-1 to caveolae and its dynamic inhibitory interactions with caveolin identify new points for regulation of sphingolipid-dependent signaling in the vascular wall.	Harvard Univ, Brigham & Womens Hosp, Div Cardiovasc, Sch Med, Boston, MA 02115 USA; Vet Affairs Boston Healthcare Syst, W Roxbury, MA 02132 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Michel, T (corresponding author), Harvard Univ, Brigham & Womens Hosp, Div Cardiovasc, Sch Med, 75 Francis St,Thorn Bldg,Rm 1210A, Boston, MA 02115 USA.	michel@calvin.bwh.harvard.edu						Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Feron O, 1998, BIOCHEMISTRY-US, V37, P193, DOI 10.1021/bi972307p; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; HLA T, 1990, J BIOL CHEM, V265, P9308; Hla T, 1999, BIOCHEM PHARMACOL, V58, P201; Igarashi J, 1999, P NATL ACAD SCI USA, V96, P12583, DOI 10.1073/pnas.96.22.12583; Ishizaka N, 1998, HYPERTENSION, V32, P459, DOI 10.1161/01.HYP.32.3.459; KU DD, 1993, AM J PHYSIOL, V265, pH586, DOI 10.1152/ajpheart.1993.265.2.H586; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; Lee H, 2000, AM J PHYSIOL-CELL PH, V278, pC612, DOI 10.1152/ajpcell.2000.278.3.C612; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272; Lee MJ, 1998, J BIOL CHEM, V273, P22105, DOI 10.1074/jbc.273.34.22105; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Liu CH, 1999, MOL BIOL CELL, V10, P1179, DOI 10.1091/mbc.10.4.1179; Liu J, 1999, J BIOL CHEM, V274, P15781, DOI 10.1074/jbc.274.22.15781; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; ROBINSON LJ, 1995, P NATL ACAD SCI USA, V92, P11776, DOI 10.1073/pnas.92.25.11776; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Sekiguchi K, 1999, CIRC RES, V85, P1000; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stamler, 1996, METHODS NITRIC OXIDE, P249; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499; Yamazaki Y, 2000, BIOCHEM BIOPH RES CO, V268, P583, DOI 10.1006/bbrc.2000.2162; Yatomi Y, 1997, J BIOCHEM, V121, P969	44	136	139	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32363	32370		10.1074/jbc.M003075200	http://dx.doi.org/10.1074/jbc.M003075200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10921915	hybrid			2022-12-27	WOS:000089858900110
J	Taniguchi, N; Taniura, H; Niinobe, M; Takayama, C; Tominaga-Yoshino, K; Ogura, A; Yoshikawa, K				Taniguchi, N; Taniura, H; Niinobe, M; Takayama, C; Tominaga-Yoshino, K; Ogura, A; Yoshikawa, K			The postmitotic growth suppressor necdin interacts with a calcium-binding protein (NEFA) in neuronal cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRADER-WILLI-SYNDROME; NUCLEAR-PROTEIN; MOLECULAR-CLONING; CELL-GROWTH; GENE; NUCLEOBINDIN; MOUSE; DIFFERENTIATION; EXPRESSION; APOPTOSIS	Necdin, a growth suppressor expressed predominantly in postmitotic neurons, interacts with viral oncoproteins and cellular transcription factors E2F1 and p53. In search of other cellular targets of necdin, we screened cDNA libraries from neurally differentiated murine embryonal carcinoma P19 cells and adult rat brain by the yeast two-hybrid assay. We isolated cDNAs encoding partial sequences of mouse NEFA and rat nucleobindin (CALNUC), which are Ca2+-binding proteins possessing similar domain structures. Necdin interacted with NEFA via a domain encompassing two EF hand motifs, which had Ca2+ binding activity as determined by Ca-45(2+) overlay. NEFA was widely distributed in mouse organs, whereas necdin was expressed predominantly in the brain and skeletal muscle. In mouse brain in vivo, NEFA was localized in neuronal perikarya and dendrites. By immunoelectron microscopy, NEFA was localized to the cisternae of the endoplasmic reticulum and nuclear envelope in brain neurons. NEFA-green fluorescent protein (GFP) fusion protein expressed in neuroblastoma N1E-115 cells was retained in the cytoplasm and partly secreted into the culture medium. Necdin enhanced the cytoplasmic retention of NEFA-GFP and potentiated the effect of NEFA-GFP on caffeine-evoked elevation of cytosolic Ca2+ levels. Thus, necdin and NEFA might be involved in Ca2+ homeostasis in neuronal cytoplasm.	Osaka Univ, Inst Prot Res, Div Regulat Macromol Funct, Suita, Osaka 5650871, Japan; Hokkaido Univ, Sch Med, Dept Mol Neuroanat, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Osaka Univ, Grad Sch Sci, Dept Biol, Toyonaka, Osaka 5600043, Japan	Osaka University; Hokkaido University; Osaka University	Yoshikawa, K (corresponding author), Osaka Univ, Inst Prot Res, Div Regulat Macromol Funct, Yamadaoka 3-2, Suita, Osaka 5650871, Japan.		Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				AIZAWA T, 1992, DEV BRAIN RES, V68, P265, DOI 10.1016/0165-3806(92)90069-9; Azuma-Hara N, 1999, EXP CELL RES, V251, P442, DOI 10.1006/excr.1999.4593; Ballif BA, 1996, P NATL ACAD SCI USA, V93, P5544, DOI 10.1073/pnas.93.11.5544; BARNIKOLWATANABE S, 1994, BIOL CHEM H-S, V375, P497, DOI 10.1515/bchm3.1994.375.8.497; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; Gerard M, 1999, NAT GENET, V23, P199, DOI 10.1038/13828; Gill RM, 2000, J CELL BIOL, V148, P1187, DOI 10.1083/jcb.148.6.1187; HAYASHI Y, 1995, BIOCHEM BIOPH RES CO, V213, P317, DOI 10.1006/bbrc.1995.2132; Jay P, 1997, NAT GENET, V17, P357, DOI 10.1038/ng1197-357; KANAI Y, 1992, IMMUNOL LETT, V32, P43; Kawano J, 2000, EUR J CELL BIOL, V79, P208, DOI 10.1078/S0171-9335(04)70024-2; Koizumi S, 1999, J BIOL CHEM, V274, P33327, DOI 10.1074/jbc.274.47.33327; Kroll KA, 1999, BIOCHEM BIOPH RES CO, V260, P1, DOI 10.1006/bbrc.1999.0867; KUDO Y, 1986, BRIT J PHARMACOL, V89, P191, DOI 10.1111/j.1476-5381.1986.tb11135.x; Lin P, 1998, J CELL BIOL, V141, P1515, DOI 10.1083/jcb.141.7.1515; MacDonald HR, 1997, HUM MOL GENET, V6, P1873, DOI 10.1093/hmg/6.11.1873; Malviya AN, 1998, CELL, V92, P17, DOI 10.1016/S0092-8674(00)80895-8; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V178, P291, DOI 10.1016/0006-291X(91)91812-Q; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MCBURNEY MW, 1988, J NEUROSCI, V8, P1063; MIURA K, 1992, BIOCHEM BIOPH RES CO, V187, P375, DOI 10.1016/S0006-291X(05)81503-7; MIURA K, 1994, BIOCHEM BIOPH RES CO, V199, P1388, DOI 10.1006/bbrc.1994.1384; MOCHIZUKI N, 1995, FEBS LETT, V373, P155, DOI 10.1016/0014-5793(95)01031-9; Nakada Y, 1998, GENE, V213, P65, DOI 10.1016/S0378-1119(98)00206-6; Niinobe M, 2000, DEV NEUROSCI-BASEL, V22, P310, DOI 10.1159/000017455; Otte S, 1999, MECH DEVELOP, V86, P155, DOI 10.1016/S0925-4773(99)00103-3; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sutcliffe JS, 1997, LANCET, V350, P1520, DOI 10.1016/S0140-6736(05)63943-8; Taniura H, 1999, J BIOL CHEM, V274, P16242, DOI 10.1074/jbc.274.23.16242; Taniura H, 1998, J BIOL CHEM, V273, P720, DOI 10.1074/jbc.273.2.720; Uetsuki T, 1996, J BIOL CHEM, V271, P918, DOI 10.1074/jbc.271.2.918; Wendel M, 1998, J CELL BIOL, V141, P839, DOI 10.1083/jcb.141.3.839	33	77	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31674	31681		10.1074/jbc.M005103200	http://dx.doi.org/10.1074/jbc.M005103200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10915798	hybrid			2022-12-27	WOS:000089858900020
J	Drum, CL; Yan, SZ; Sarac, R; Mabuchi, Y; Beckingham, K; Bohm, A; Grabarek, Z; Tang, WJ				Drum, CL; Yan, SZ; Sarac, R; Mabuchi, Y; Beckingham, K; Bohm, A; Grabarek, Z; Tang, WJ			An extended conformation of calmodulin induces interactions between the structural domains of adenylyl cyclase from Bacillus anthracis to promote catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCITATION-ENERGY TRANSFER; SITE-DIRECTED MUTAGENESIS; BORDETELLA-PERTUSSIS; POINT MUTATIONS; 2 SERIES; CRYSTAL-STRUCTURE; EUKARYOTIC CELLS; PEPTIDE COMPLEX; CALCIUM-BINDING; CA2+ BINDING	The edema factor exotoxin produced by Bacillus anthracis fs an adenylyl cyclase that is activated by calmodulin (CaM) at resting state calcium concentrations in infected cells. A C-terminal 60-kDa fragment corresponding to the catalytic domain of edema factor (EF3) was cloned, overexpressed in Escherichia coli, and purified. The N-terminal 43-kDa domain (EF3-N) of EF3, the sole domain of edema factor homologous to adenylyl cyclases from Bordetella pertussis and Pseudomonas aeruginosa, is highly resistant to protease digestion. The C-terminal 160-amino acid domain (EF3-C) of EF3 is sensitive to proteolysis in the absence of CaM. The addition of CaM protects EF3-C from being digested by proteases. EF3-N and EF3-C were expressed separately, and both fragments were required to reconstitute full CaM-sensitive enzyme activity. Fluorescence resonance energy transfer experiments using a double-labeled CaM molecule were performed and indicated that CaM adopts an extended conformation upon binding to EF3. This contrasts sharply with the compact conformation adopted by CaM upon binding myosin light chain kinase and CaM-dependent protein kinase type II. Mutations in each of the four calcium binding sites of CaM were examined for their effect on EF3 activation. Sites 3 and 4 were found critical for the activation, and neither the N- nor the C-terminal domain of CaM alone was capable of activating EF3. A genetic screen probing loss-of-function mutations of EF3 and site-directed mutations based on the:homology of the edema factor family revealed a conserved pair of aspartate residues and an arginine that: are important for catalysis. Similar residues are essential for di-metal-mediated catalysis in mammalian adenylyl cyclases and a family of DNA polymerases and nucleotidyltransferases. This suggests that edema factor may utilize a similar catalytic mechanism.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Boston Biomed Res Inst, Watertown, MA 02472 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77251 USA	University of Chicago; Boston Biomedical Research Institute; Rice University	Tang, WJ (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, 947 E 58th St,MC0926, Chicago, IL 60637 USA.	wtang@uchicago.edu	Drum, Chester/A-6089-2015	Drum, Chester/0000-0001-6327-4584; Tang, Wei-Jen/0000-0002-8267-8995; Grabarek, Zenon/0000-0002-3636-5701	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041637] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053459] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R44DA005778, R43DA005778] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41637] Funding Source: Medline; NIDA NIH HHS [DA05778] Funding Source: Medline; NIGMS NIH HHS [GM53459] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1609, DOI 10.1093/nar/27.7.1609; AU DC, 1989, BIOCHEMISTRY-US, V28, P2772, DOI 10.1021/bi00433a005; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; DOMENIGHINI M, 1995, HANDB NAT T, V8, P59; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Fairclough R H, 1978, Methods Enzymol, V48, P347; GAO ZH, 1993, J BIOL CHEM, V268, P20096; GLASER P, 1989, EMBO J, V8, P967, DOI 10.1002/j.1460-2075.1989.tb03459.x; GLASER P, 1991, EMBO J, V10, P1683, DOI 10.1002/j.1460-2075.1991.tb07692.x; Hanna P, 1998, CURR TOP MICROBIOL, V225, P13; Huber PAJ, 1996, BIOCHEM J, V316, P413, DOI 10.1042/bj3160413; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; LABRUYERE E, 1990, BIOCHEMISTRY-US, V29, P4922, DOI 10.1021/bi00472a024; Leppla S. H., 1995, Bacterial toxins and virulence factors in disease., P543; LEPPLA SH, 1984, ADV CYCLIC NUCL PROT, V17, P189; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; MAUNE JF, 1992, BIOCHEMISTRY-US, V31, P7779, DOI 10.1021/bi00149a006; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEANS AR, 1988, RECENT PROG HORM RES, V44, P223; Mock M, 1993, Trends Microbiol, V1, P187, DOI 10.1016/0966-842X(93)90089-A; MUNIER H, 1993, J BIOL CHEM, V268, P1695; MUNIER H, 1992, J BIOL CHEM, V267, P9816; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; REDDY P, 1989, NUCLEIC ACIDS RES, V17, P10473, DOI 10.1093/nar/17.24.10473; STAROVASNIK MA, 1992, PROTEIN SCI, V1, P245; Steitz TA, 1998, NATURE, V391, P231, DOI 10.1038/34542; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Tan RY, 1996, J BIOL CHEM, V271, P7479, DOI 10.1074/jbc.271.13.7479; Tang WJ, 1998, MOL PHARMACOL, V54, P231, DOI 10.1124/mol.54.2.231; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAO T, 1983, BIOCHEMISTRY-US, V22, P3059, DOI 10.1021/bi00282a006; TAO T, 1979, BIOCHEMISTRY-US, V18, P2759, DOI 10.1021/bi00580a011; TAO T, 1981, BIOCHEMISTRY-US, V20, P5051, DOI 10.1021/bi00520a035; TAYLOR DA, 1991, J BIOL CHEM, V266, P21375; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; TREWHELLA J, 1990, BIOCHEMISTRY-US, V29, P9316, DOI 10.1021/bi00492a003; XIA ZG, 1990, J BIOL CHEM, V265, P6517; Yahr TL, 1998, P NATL ACAD SCI USA, V95, P13899, DOI 10.1073/pnas.95.23.13899; Yan SZ, 1997, J BIOL CHEM, V272, P12342, DOI 10.1074/jbc.272.19.12342; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758	47	59	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36334	36340		10.1074/jbc.M004778200	http://dx.doi.org/10.1074/jbc.M004778200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10926933	hybrid			2022-12-27	WOS:000165382000097
J	Gaines, P; Geiger, JN; Knudsen, G; Seshasayee, D; Wojchowski, DM				Gaines, P; Geiger, JN; Knudsen, G; Seshasayee, D; Wojchowski, DM			GATA-1-and FOG-dependent activation of megakaryocytic alpha IIB gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; CREB-BINDING-PROTEIN; PLATELET GLYCOPROTEIN-IIB; ZINC-FINGER PROTEIN; DNA-BINDING; ERYTHROID-DIFFERENTIATION; 5'-FLANKING REGION; KRUPPEL FAMILY; MICE LACKING; GPIIB GENE	FOG is a multitype zinc finger protein that is essential for megakaryopoiesis, binds to the amino-terminal finger of GATA-1, and modulates the transcription of GATA-1 target genes. Presently investigated are effects of FOG and GATA-1 on the transcription of the megakaryocytic integrin gene, alpha IIb. In GATA-1-deficient FDCER cells (in the presence of endogenous FOG), ectopically expressed GATA-1 activated transcription 3-10-fold both from alpha IIb templates and the endogenous alpha IIb gene. The increased expression of FOG increased reporter construct transcription 30-fold overall. Unexpectedly, alpha IIb gene transcription also was stimulated efficiently upon the ectopic expression in of FOG per se. This occurred in the absence of any detectable expression of GATA-1 and was observed in multiple independent sublines for both the endogenous alpha IIb gene and transfected constructs yet proved to depend largely upon conserved GATA elements 457 and 55 base pairs upstream from the transcriptional start site, In 293 cells, FOG plus GATA-1 but not FOG alone only moderately stimulated alpha IIb transcription, and no direct interactions of FOG with the alpha IIb promoter were detectable Thus, FOG acts in concert with GATA-1 to stimulate alpha IIb expression but also can act via a GATA-1-independent route, which is proposed to involve additional hematopoietic-restricted cofactors (possibly GATA-2).	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Wojchowski, DM (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, 115 William L Henning Bldg, University Pk, PA 16802 USA.	dmw1@psu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009749, R01HL044491] Funding Source: NIH RePORTER; NHLBI NIH HHS [F32 HL09749, R01 HL44491] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702; BARON MH, 1994, MOL CELL BIOL, V14, P3108, DOI 10.1128/MCB.14.5.3108; Bastian LS, 1996, J BIOL CHEM, V271, P18554, DOI 10.1074/jbc.271.31.18554; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; BLOCK KL, 1994, BLOOD, V84, P3385; Cortes M, 1999, CURR OPIN IMMUNOL, V11, P167, DOI 10.1016/S0952-7915(99)80028-4; Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; Deconinck AE, 2000, DEVELOPMENT, V127, P2031; DENARIER E, 1993, BIOCHEM BIOPH RES CO, V195, P1360, DOI 10.1006/bbrc.1993.2193; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; Doubeikovski A, 1997, J BIOL CHEM, V272, P24300, DOI 10.1074/jbc.272.39.24300; Fox AH, 1998, J BIOL CHEM, V273, P33595, DOI 10.1074/jbc.273.50.33595; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Gstaiger M, 1996, EMBO J, V15, P2781, DOI 10.1002/j.1460-2075.1996.tb00638.x; HASHIMOTO Y, 1995, J BIOL CHEM, V270, P24532, DOI 10.1074/jbc.270.41.24532; HEIDENREICH R, 1990, BIOCHEMISTRY-US, V29, P1232, DOI 10.1021/bi00457a020; Hung HL, 1999, MOL CELL BIOL, V19, P3496; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Kelley CM, 1998, CURR BIOL, V8, P508, DOI 10.1016/S0960-9822(98)70202-7; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MARTIN F, 1993, J BIOL CHEM, V268, P21606; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Minami T, 1998, EUR J BIOCHEM, V258, P879, DOI 10.1046/j.1432-1327.1998.2580879.x; Morgan B, 1997, EMBO J, V16, P2004, DOI 10.1093/emboj/16.8.2004; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PHILLIPS DR, 1988, BLOOD, V71, P831; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; Prandini MH, 1996, BLOOD, V88, P2062, DOI 10.1182/blood.V88.6.2062.bloodjournal8862062; QUELLE DE, 1991, P NATL ACAD SCI USA, V88, P4801, DOI 10.1073/pnas.88.11.4801; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Seshasayee D, 2000, J BIOL CHEM, V275, P22969, DOI 10.1074/jbc.M002931200; Seshasayee D, 1998, MOL CELL BIOL, V18, P3278, DOI 10.1128/MCB.18.6.3278; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Tsang AP, 1998, GENE DEV, V12, P1176, DOI 10.1101/gad.12.8.1176; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Yamaguchi Y, 1999, BLOOD, V94, P1429, DOI 10.1182/blood.V94.4.1429.416k13_1429_1439; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; ZON LI, 1993, BLOOD, V81, P3234	58	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34114	34121		10.1074/jbc.M006017200	http://dx.doi.org/10.1074/jbc.M006017200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10926935	hybrid			2022-12-27	WOS:000165095300019
J	Hashimoto, Y; Niikura, T; Ito, Y; Nishimoto, I				Hashimoto, Y; Niikura, T; Ito, Y; Nishimoto, I			Multiple mechanisms underlie neurotoxicity by different types of Alzheimer's disease mutations of amyloid precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY CEREBRAL-HEMORRHAGE; CEREBELLAR GRANULE NEURONS; APOPTOTIC CELL-DEATH; HIPPOCAMPAL-NEURONS; OXIDATIVE STRESS; BETA-PROTEIN; MITOCHONDRIAL DYSFUNCTION; GENE-EXPRESSION; PC12 CELLS; IN-VITRO	We examined a neuronal cell system in which single-cell expression of either familial Alzheimer's disease (FAD) gene V642I-APP or K595N/M596L-APP (NL-APP) in an inducible plasmid was controlled without affecting transfection efficiency. This system revealed that (i) low expression of both mutants exerted toxicity sensitive to both Ac-DEVD-CHO (DEVD) and glutathione ethyl ester (GEE), whereas wild-type APP (wtAPP) only at higher expression levels caused GEE/DEVD-resistant death to lesser degrees; (ii) toxicity by the V642I mutation was entirely GEE/DEVD sensitive; and (iii) toxicity by higher expression of NL-APP was GEE/DEVD resistant. The GEE/DEVD-sensitive death was sensitive to pertussis toxin and was due to G(o)-interacting His(657)-Lys(676) domain. The GEE/DEVD-resistant death was due to C-terminal Met(677)-Asn(695). APP mutants lacking either domain unraveled elaborate intracellular cross-talk between these domains. EB18Q-APP, responsible for non-AD type of a human disease, only exerted GEE/DEVD-resistant death at higher expression. Therefore, (i) different FAD mutations in APP cause neuronal cell death through different cytoplasmic domains via different sets of mechanisms; (ii) expression levels of FAD genes are critical in activating specific death mechanisms; and (iii) toxicity by low expression of both mutants most likely reflects the pathogenetic mechanism of FAD.	Keio Univ, Sch Med, Dept Pharmacol, Tokyo 160, Japan; Keio Univ, Sch Med, Dept Neurosci, Tokyo 160, Japan	Keio University; Keio University	Niikura, T (corresponding author), Keio Univ, Sch Med, Dept Pharmacol, Tokyo 160, Japan.		Hashimoto, Yuichi/N-1508-2015	Hashimoto, Yuichi/0000-0001-5863-3618				Brouillet E, 1999, J NEUROSCI, V19, P1717; Bursztajn S, 1998, J NEUROSCI, V18, P9790; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CARRACEDO J, 1995, EUR J IMMUNOL, V25, P3094, DOI 10.1002/eji.1830251116; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Farkas I, 1998, NEUROSCIENCE, V86, P903, DOI 10.1016/S0306-4522(98)00108-0; FERNANDEZMADRID I, 1991, ANN NEUROL, V30, P730, DOI 10.1002/ana.410300516; Fu WM, 1998, NEUROBIOL DIS, V5, P229, DOI 10.1006/nbdi.1998.0192; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Giambarella U, 1997, EMBO J, V16, P4897, DOI 10.1093/emboj/16.16.4897; GSCHWIND M, 1995, J NEUROCHEM, V65, P292; HAAN J, 1992, CLIN NEUROL NEUROSUR, V94, P317, DOI 10.1016/0303-8467(92)90181-2; HARRIS ME, 1995, EXP NEUROL, V131, P193, DOI 10.1016/0014-4886(95)90041-1; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Lin SZ, 1997, BRAIN RES, V771, P184, DOI 10.1016/S0006-8993(97)00763-4; LOCKHART BP, 1994, J NEUROSCI RES, V39, P494, DOI 10.1002/jnr.490390416; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; Luo JJ, 1999, J NEUROSCI RES, V55, P629, DOI 10.1002/(SICI)1097-4547(19990301)55:5<629::AID-JNR10>3.0.CO;2-Y; MAATSCHIEMAN MLC, 1994, ACTA NEUROPATHOL, V88, P371; MANELLI AM, 1995, BRAIN RES BULL, V38, P569, DOI 10.1016/0361-9230(95)02034-X; Mark RJ, 1997, BRAIN RES, V756, P205, DOI 10.1016/S0006-8993(97)00196-0; Miranda S, 2000, PROG NEUROBIOL, V62, P633, DOI 10.1016/S0301-0082(00)00015-0; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; Nishimura I, 1998, J NEUROSCI, V18, P2387, DOI 10.1523/jneurosci.18-07-02387.1998; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Okamoto T, 1996, EMBO J, V15, P3769, DOI 10.1002/j.1460-2075.1996.tb00750.x; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; Okazawa M, 1998, J BIOL CHEM, V273, P12584, DOI 10.1074/jbc.273.20.12584; Pike CJ, 1997, J NEUROCHEM, V69, P1601; PLATIKA D, 1985, P NATL ACAD SCI USA, V82, P3499, DOI 10.1073/pnas.82.10.3499; RAMIREZ R, 1994, J EXP MED, V180, P1147, DOI 10.1084/jem.180.3.1147; Sharma K, 1998, BIOCHEM BIOPH RES CO, V242, P134, DOI 10.1006/bbrc.1997.7933; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Vinters HV, 1998, ACTA NEUROPATHOL, V95, P235, DOI 10.1007/s004010050793; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349; Yamatsuji T, 1996, EMBO J, V15, P498, DOI 10.1002/j.1460-2075.1996.tb00382.x; YAN GM, 1995, J NEUROCHEM, V65, P2425; Yin DL, 1997, NEUROSCI RES, V29, P121, DOI 10.1016/S0168-0102(97)00080-1; Zhao B, 1997, J NEUROSCI RES, V47, P253	45	55	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34541	34551		10.1074/jbc.M005332200	http://dx.doi.org/10.1074/jbc.M005332200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10934205	hybrid			2022-12-27	WOS:000165095300074
J	Yamashita, T; Terakita, A; Shichida, Y				Yamashita, T; Terakita, A; Shichida, Y			Distinct roles of the second and third cytoplasmic loops of bovine rhodopsin in G protein activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECONSTITUTED PHOSPHOLIPID-VESICLES; BETA-ADRENERGIC RECEPTORS; GTP-BINDING PROTEIN; CONNECTING HELIX-C; NEUROTRANSMITTER RECEPTORS; TRANSDUCIN ACTIVATION; ADENYLATE-CYCLASE; MECHANISMS; MUTANTS; SITES	In contrast to the extensive studies of light-induced conformational changes in rhodopsin, the cytoplasmic architecture of rhodopsin related to the G protein activation and the selective recognition of G protein subtype is still unclear. Here, we prepared a set of bovine rhodopsin mutants whose cytoplasmic loops were replaced by those of other ligand-binding receptors, and we compared their ability for G protein activation in order to obtain a cine to the roles of the second and third cytoplasmic loops of rhodopsin. The mutants bearing the third loop of four other G(o)-coupled receptors belonging to the rhodopsin superfamily showed significant G(o) activation, indicating that the third loop of rhodopsin possibly has a putative site(s) related to the interaction of G protein and that it is simply exchangeable with those of other G(o)-coupled receptors. The mutants bearing the second loop of other receptors, however, had little ability for G protein activation, suggesting that the second loop of rhodopsin contains a specific region essential for rhodopsin to be a G protein-activating form. Systematic chimeric and point mutational studies indicate that three amino acids (Glu(134), Val(138) and Cys(140)) in the N-terminal region of the second loop of rhodopsin are crucial for efficient G protein activation. These results suggest that the second and third cytoplasmic loops of bovine rhodopsin have distinct roles in G protein activation and subtype specificity.	Kyoto Univ, Grad Sch Sci, Dept Biophys, Kyoto 6068502, Japan; Japan Sci & Technol Corp, CREST, Kyoto 6068502, Japan	Kyoto University; Japan Science & Technology Agency (JST)	Shichida, Y (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Biophys, Kyoto 6068502, Japan.			Terakita, Akihisa/0000-0002-8379-8913				Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; ARCHARYA S, 1997, J BIOL CHEM, V272, P6519; ASANO T, 1984, J BIOL CHEM, V259, P9351; Dunham TD, 1999, J BIOL CHEM, V274, P1683, DOI 10.1074/jbc.274.3.1683; Eason MG, 1996, J BIOL CHEM, V271, P12826, DOI 10.1074/jbc.271.22.12826; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; FRYXELL KJ, 1991, J MOL EVOL, V33, P367, DOI 10.1007/BF02102867; FRYXELL KJ, 1995, J MOL EVOL, V41, P85, DOI 10.1007/BF00174044; IWABE N, 1993, THESIS KYUSHU U JAPA; KANAHO Y, 1984, J BIOL CHEM, V259, P7378; KATADA T, 1994, METHOD ENZYMOL, V237, P131; Kojima D, 1997, J BIOL CHEM, V272, P22979, DOI 10.1074/jbc.272.37.22979; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; Krebs A, 1998, J MOL BIOL, V282, P991, DOI 10.1006/jmbi.1998.2070; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Liu J, 1996, J BIOL CHEM, V271, P8772, DOI 10.1074/jbc.271.15.8772; Marin EP, 2000, J BIOL CHEM, V275, P1930, DOI 10.1074/jbc.275.3.1930; Nagata T, 1997, BIOCHEMISTRY-US, V36, P6164, DOI 10.1021/bi962920t; Peng YW, 1997, P NATL ACAD SCI USA, V94, P1995, DOI 10.1073/pnas.94.5.1995; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P8804, DOI 10.1021/bi00027a032; RUBENSTEIN RC, 1991, BIOCHEMISTRY-US, V30, P10769, DOI 10.1021/bi00108a023; Sakmar TP, 1998, PROG NUCLEIC ACID RE, V59, P1; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; SHI W, 1995, J BIOL CHEM, V270, P2112, DOI 10.1074/jbc.270.5.2112; Shichida Y, 1998, CELL MOL LIFE SCI, V54, P1299, DOI 10.1007/s000180050256; Siebert F, 1995, ISRAEL J CHEM, V35, P309; Tachibanaki S, 1997, BIOCHEMISTRY-US, V36, P14173, DOI 10.1021/bi970932o; TAKAGI Y, 1995, J BIOL CHEM, V270, P10072, DOI 10.1074/jbc.270.17.10072; Terakita A, 1998, FEBS LETT, V439, P110, DOI 10.1016/S0014-5793(98)01340-4; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; WEISS ER, 1988, J BIOL CHEM, V263, P6150; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; WESSLINGRESNICK M, 1987, BIOCHEMISTRY-US, V26, P4316, DOI 10.1021/bi00388a020; WONG SKF, 1994, J BIOL CHEM, V269, P18968; Yang K, 1996, BIOCHEMISTRY-US, V35, P12464, DOI 10.1021/bi960848t; YOSHIZAWA T, 1982, METHOD ENZYMOL, V81, P333; Zeng FY, 1999, J BIOL CHEM, V274, P16629, DOI 10.1074/jbc.274.23.16629	43	66	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34272	34279		10.1074/jbc.M002954200	http://dx.doi.org/10.1074/jbc.M002954200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10930404	hybrid			2022-12-27	WOS:000165095300039
J	Enke, DK; Kaldis, P; Solomon, MJ				Enke, DK; Kaldis, P; Solomon, MJ			Kinetic analysis of the cyclin-dependent kinase-activating kinase (Cak1p) from budding yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; CATALYTIC SUBUNIT; SACCHAROMYCES-CEREVISIAE; TYROSINE KINASE; CDC28 MUTATION; MAP KINASE; MECHANISM; BINDING; COMPLEMENTATION; COMPLEX	Cak1p, the Cyclin-dependent kinase-activating kinase from budding yeast, is an unusual protein kinase that lacks many of the highly conserved motifs observed among members of the protein kinase superfamily, Cak1p phosphorylates and activates Cdc28p, the major cyclin-dependent kinase (CDK) in yeast, and is thereby required for passage through the yeast cell cycle. In this paper, me explore the kinetics of CDK phosphorylation by Cak1p, and me examine the role of the catalytic step in the reaction mechanism. Cak1p proceeds by a sequential reaction mechanism, binding to both ATP and CDK2 with reasonable affinities, exhibiting Ii, values of 7.2 and 0.6 muM, respectively. Interestingly, these values are approximately the same as the K-M values, indicating that the binding of substrates is fast with respect to catalysis and that the most likely reaction mechanism is rapid equilibrium random. Cak1p is a slow enzyme, with a catalytic rate of only 4.3 min(-1). The absence of a burst phase indicates that product release is not rate-limiting. This result, and a solvent isotope effect, suggests that a catalytic step is rate-limiting.	Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University	Solomon, MJ (corresponding author), Yale Univ, Sch Med, Dept Mol Biophys & Biochem, 266 Whitney Ave, New Haven, CT 06520 USA.		Kaldis, Philipp/G-2714-2010	Kaldis, Philipp/0000-0002-7247-7591	NIGMS NIH HHS [GM47830] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047830] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; Boerner RJ, 1995, BIOCHEMISTRY-US, V34, P16419, DOI 10.1021/bi00050a024; Burke JR, 1998, J BIOL CHEM, V273, P12041, DOI 10.1074/jbc.273.20.12041; Chun KT, 1997, MOL GEN GENET, V256, P365, DOI 10.1007/s004380050580; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; Enke DA, 1999, J BIOL CHEM, V274, P1949, DOI 10.1074/jbc.274.4.1949; ERNEUX C, 1983, J BIOL CHEM, V258, P4137; Espinoza FH, 1996, SCIENCE, V273, P1714, DOI 10.1126/science.273.5282.1714; Grant BD, 1996, BIOCHEMISTRY-US, V35, P2022, DOI 10.1021/bi952144+; Hemmer W, 1997, J BIOL CHEM, V272, P16946, DOI 10.1074/jbc.272.27.16946; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; Kaldis P, 1998, MOL BIOL CELL, V9, P2545, DOI 10.1091/mbc.9.9.2545; KONG CT, 1988, BIOCHEMISTRY-US, V27, P4795, DOI 10.1021/bi00413a032; Konstantinidis AK, 1998, J BIOL CHEM, V273, P26506, DOI 10.1074/jbc.273.41.26506; KWIATKOWSKI AP, 1990, BIOCHEMISTRY-US, V29, P153, DOI 10.1021/bi00453a019; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; Lew J, 1997, BIOCHEMISTRY-US, V36, P6717, DOI 10.1021/bi963164u; LoGrasso PV, 1997, BIOCHEMISTRY-US, V36, P10422, DOI 10.1021/bi9706778; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; POSNER I, 1992, J BIOL CHEM, V267, P20638; Rudolph F B, 1979, Methods Enzymol, V63, P138; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0; VIOLA RE, 1982, BIOCHEMISTRY-US, V21, P1295, DOI 10.1021/bi00535a029; Wagner M, 1997, EMBO J, V16, P1305, DOI 10.1093/emboj/16.6.1305; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; YOON MY, 1987, BIOCHEMISTRY-US, V26, P4118, DOI 10.1021/bi00387a056; YUAN CJ, 1990, J BIOL CHEM, V265, P16205	32	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33267	33271		10.1074/jbc.M004748200	http://dx.doi.org/10.1074/jbc.M004748200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10934199	hybrid			2022-12-27	WOS:000090104600015
J	Guo, NH; Kawamoto, S				Guo, NH; Kawamoto, S			An intronic downstream enhancer promotes 3 ' splice site usage of a neural cell-specific exon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; TRACT-BINDING-PROTEIN; VERTEBRATE NONMUSCLE MYOSIN; ALTERNATIVE EXON; SR-PROTEINS; DEVELOPMENTAL CONSEQUENCES; SEQUENCE ELEMENTS; PREMESSENGER RNA; FACTOR U2AF(35); CHAIN-B	The human nonmuscle myosin heavy chain B gene contains a 30-nucleotide alternative exon, N30, that is included in the mRNA from neural cells but is skipped in all other cells. We have previously identified an intronic distal downstream enhancer (IDDE) region that is required for neural cell-specific inclusion of N30, In this study, me investigated the mechanism by which the IDDE promotes N30 exon usage. In vitro splicing analysis using neural cell nuclear extracts and two-exon pre-mRNA substrates, which consist of the N30 exon and either the upstream (E5) or downstream (E6) exon, demonstrates that the IDDE activates upstream E5-N30 splicing by facilitating early prespliceosome complex formation. The IDDE has no effect on N30-E6 splicing where the IDDE resides. Inspection of splice site consensus sequences shows that a polypyrimidine (Py) tract preceding N30 is suboptimal for U2AF binding. Optimizing the Py tract completely relieves the requirement for the IDDE in E5-N30 splicing in vitro. In transfected cells, the wild-type minigene transcripts, which consist of three exons, E5, N30, and E6, undergo neural cell-specific and IDDE-dependent alternative splicing of N30, Optimizing the Py tract in minigenes also completely relieves the requirement for the IDDE in N30 inclusion. Furthermore, overexpression of the truncated U2AF65, which contains the arginine and serine dipeptide-rich domain and linker domain, but lacks the RNA binding domain, selectively inhibits the IDDE-mediated N30 inclusion in mRNA from the wild-type minigene in a dominant negative fashion. These results support the hypothesis that the IDDE facilitates the recognition of the 3' splice site preceding N30 by a network of protein-protein interactions implicated in the recruitment of U2AF to a suboptimal Py tract.	NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Kawamoto, S (corresponding author), NHLBI, Mol Cardiol Lab, NIH, Bldg 10,Rm 8N202,10 Ctr Dr,MSC 1762, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL004225] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ashiya M, 1997, RNA, V3, P996; AUSUBEL FM, 1990, CURR PROTOCOLS MOL B, V2; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; BLACK DL, 1992, CELL, V69, P795, DOI 10.1016/0092-8674(92)90291-J; BLACK DL, 1991, GENE DEV, V5, P389, DOI 10.1101/gad.5.3.389; Carlo T, 1996, RNA, V2, P342; Chan RCC, 1997, MOL CELL BIOL, V17, P4667, DOI 10.1128/MCB.17.8.4667; Chou MY, 1999, MOL CELL BIOL, V19, P69; DelGatto F, 1997, MOL CELL BIOL, V17, P5106, DOI 10.1128/MCB.17.9.5106; DOMINSKI Z, 1992, MOL CELL BIOL, V12, P2108, DOI 10.1128/MCB.12.5.2108; DOMINSKI Z, 1991, MOL CELL BIOL, V11, P6075, DOI 10.1128/MCB.11.12.6075; Fleckner J, 1997, GENE DEV, V11, P1864, DOI 10.1101/gad.11.14.1864; FU XD, 1995, RNA, V1, P663; Gallego ME, 1997, EMBO J, V16, P1772, DOI 10.1093/emboj/16.7.1772; Hedjran F, 1997, P NATL ACAD SCI USA, V94, P12343, DOI 10.1073/pnas.94.23.12343; HOFFMAN BE, 1992, GENE DEV, V6, P2554, DOI 10.1101/gad.6.12b.2554; HUH GS, 1994, GENE DEV, V8, P1561, DOI 10.1101/gad.8.13.1561; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; ITOH K, 1995, J BIOL CHEM, V270, P14533, DOI 10.1074/jbc.270.24.14533; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; Jensen KB, 2000, NEURON, V25, P359, DOI 10.1016/S0896-6273(00)80900-9; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; KUO HC, 1991, SCIENCE, V251, P1045, DOI 10.1126/science.1825520; LAVIGUEUR A, 1993, GENE DEV, V7, P2405, DOI 10.1101/gad.7.12a.2405; Lim LP, 1998, MOL CELL BIOL, V18, P3900, DOI 10.1128/MCB.18.7.3900; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; LYNCH KW, 1995, GENE DEV, V9, P284, DOI 10.1101/gad.9.3.284; MacDougall C, 1995, DEV BIOL, V172, P353, DOI 10.1006/dbio.1995.8047; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; Modafferi EF, 1997, MOL CELL BIOL, V17, P6537, DOI 10.1128/MCB.17.11.6537; MULLIGAN GJ, 1992, J BIOL CHEM, V267, P25480; Pato MD, 1996, J BIOL CHEM, V271, P2689, DOI 10.1074/jbc.271.5.2689; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; RUSKIN B, 1990, METHOD ENZYMOL, V181, P180; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; SIRANDPUGNET P, 1995, NUCLEIC ACIDS RES, V23, P3501, DOI 10.1093/nar/23.17.3501; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Stamm S, 1999, MOL BRAIN RES, V64, P108, DOI 10.1016/S0169-328X(98)00313-1; STAMM S, 1994, NUCLEIC ACIDS RES, V22, P1515, DOI 10.1093/nar/22.9.1515; Standiford DM, 1997, GENETICS, V147, P725; TACKE R, 1991, GENE DEV, V5, P1416, DOI 10.1101/gad.5.8.1416; TAKAHASHI M, 1992, J BIOL CHEM, V267, P17864; Tronchere H, 1997, NATURE, V388, P397, DOI 10.1038/41137; Uren D, 2000, J CLIN INVEST, V105, P663, DOI 10.1172/JCI8199; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; Vogel J, 1997, NUCLEIC ACIDS RES, V25, P2030, DOI 10.1093/nar/25.10.2030; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; Wu Q, 1999, MOL CELL BIOL, V19, P3225; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	57	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33641	33649		10.1074/jbc.M005597200	http://dx.doi.org/10.1074/jbc.M005597200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10931847	hybrid			2022-12-27	WOS:000090104600065
J	Mikkelsen, MD; Hansen, CH; Wittstock, U; Halkier, BA				Mikkelsen, MD; Hansen, CH; Wittstock, U; Halkier, BA			Cytochrome P450CYP79B2 from Arabidopsis catalyzes the conversion of tryptophan to indole-3-acetaldoxime, a precursor of indole glucosinolates and indole-3-acetic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OILSEED RAPE LEAVES; ESCHERICHIA-COLI; CYANOGENIC GLUCOSIDES; CHINESE-CABBAGE; AMINO-ACID; BIOSYNTHESIS; ENZYME; EXPRESSION; PLANTS; METABOLISM	Glucosinolates are natural plant products known as flavor compounds, cancer-preventing agents, and biopesticides. We report cloning and characterization of the cytochrome P450 CYP79B2 from Arabidopsis, Heterologous expression of CYP79B2 in Escherichia coli shows that CYP79B2 catalyzes the conversion of tryptophan to indole-3-acetaldoxime. Recombinant CYP79B2 has a K-m of 21 muM and a V-max of 7.78 nmol/h/ml culture. Inhibitor studies show that CYP79B2 is different from a previously described enzyme activity that converts tryptophan to indole-3-acetaldoxime (Ludwig-Muller, J., and Hilgenberg, W, (1990) Phytochemistry, 29, 1397-1400). CYP79B2 is wound-inducible and expressed in leaves, stem, flowers, and roots, with the highest expression in roots. Arabidopsis overexpressing CYP79B2 has increased levels of indole glucosinolates, which strongly indicates that CYP79B2 is involved in indole glucosinolate biosynthesis, Our data show that oxime production by CYP79s is not restricted to those amino acids that are precursors for cyanogenic glucosides, Our data are consistent with the hypothesis that indole glucosinolates have evolved from cyanogenesis, Indole-3-acetaldoxime is a precursor of the plant hormone indole-3-acetic acid, which suggests that CYP79B2 might function in biosynthesis of indole-3-acetic acid. Identification of CYP79B2 provides an important tool for modification of the indole glucosinolate content to improve nutritional value and pest resistance.	Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, DK-1871 Frederiksberg C, Denmark; Royal Vet & Agr Univ, Ctr Mol Plant Physiol Pl, DK-1871 Frederiksberg C, Denmark	University of Copenhagen; University of Copenhagen	Halkier, BA (corresponding author), Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, Thorvaldsensvej 40, DK-1871 Frederiksberg C, Denmark.	halkier@biobase.dk	Halkier, Barbara A/H-3196-2014	Halkier, Barbara A/0000-0002-3742-702X; Wittstock, Ute/0000-0002-0914-8453				Andersen MD, 2000, J BIOL CHEM, V275, P1966, DOI 10.1074/jbc.275.3.1966; Bak S, 1999, PLANT J, V20, P663, DOI 10.1046/j.1365-313X.1999.00642.x; Bak S, 1998, PLANT MOL BIOL, V38, P725, DOI 10.1023/A:1006064202774; Barnes HJ, 1996, METHOD ENZYMOL, V272, P3, DOI 10.1016/S0076-6879(96)72003-7; Bartel Bonnie, 1997, Annu Rev Plant Physiol Plant Mol Biol, V48, P51, DOI 10.1146/annurev.arplant.48.1.51; BENNETT R, 1993, PLANT PHYSIOL, V102, P1307, DOI 10.1104/pp.102.4.1307; Bennett RN, 1996, PLANT CELL ENVIRON, V19, P801, DOI 10.1111/j.1365-3040.1996.tb00417.x; Bennett RN, 1997, PHYTOCHEMISTRY, V45, P59, DOI 10.1016/S0031-9422(96)00787-X; BENNETT RN, 1995, PLANT PHYSIOL, V109, P299, DOI 10.1104/pp.109.1.299; BODNARYK RP, 1994, PHYTOCHEMISTRY, V35, P301, DOI 10.1016/S0031-9422(00)94752-6; BODNARYK RP, 1992, PHYTOCHEMISTRY, V31, P2671, DOI 10.1016/0031-9422(92)83609-3; BUCHNER R, 1987, P50; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; DOUGHTY KJ, 1995, PHYTOCHEMISTRY, V38, P347, DOI 10.1016/0031-9422(94)00653-B; Du LC, 1996, PLANT PHYSIOL, V111, P831, DOI 10.1104/pp.111.3.831; Du LC, 1995, P NATL ACAD SCI USA, V92, P12505, DOI 10.1073/pnas.92.26.12505; Ettlinger M.G., 1968, RECENT ADV PHYTOCHEM, V1, P59; GILLAM EMJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P123, DOI 10.1006/abbi.1993.1401; GROSSBERGER D, 1987, NUCLEIC ACIDS RES, V15, P6737, DOI 10.1093/nar/15.16.6737; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; Halkier BA, 1999, NATURALLY OCCURRING GLYCOSIDES, P193; HALKIER BA, 1995, ARCH BIOCHEM BIOPHYS, V322, P369, DOI 10.1006/abbi.1995.1477; HAUGHN GW, 1991, PLANT PHYSIOL, V97, P217, DOI 10.1104/pp.97.1.217; HELMLINGER J, 1987, PHYTOCHEMISTRY, V26, P615, DOI 10.1016/S0031-9422(00)84751-2; HELMLINGER J, 1985, PHYTOCHEMISTRY, V24, P2497, DOI 10.1016/S0031-9422(00)80654-8; JEFFERSON RA, 1987, EMBO J, V6, P3901; JENKINS CM, 1994, J BIOL CHEM, V269, P27401; Joshi CP, 1997, PLANT MOL BIOL, V35, P993, DOI 10.1023/A:1005816823636; LUDWIGMULLER J, 1988, PHYSIOL PLANTARUM, V74, P240, DOI 10.1111/j.1399-3054.1988.tb00627.x; LUDWIGMULLER J, 1990, PHYSIOL PLANTARUM, V79, P311; Martin T., 1992, GUS protocols: using the GUS gene as a reporter of gene expression., P23; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Nelson DR, 1999, ARCH BIOCHEM BIOPHYS, V369, P1, DOI 10.1006/abbi.1999.1352; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; Nielsen JS, 1999, ARCH BIOCHEM BIOPHYS, V368, P121, DOI 10.1006/abbi.1999.1258; Normanly J, 1999, CURR OPIN PLANT BIOL, V2, P207, DOI 10.1016/S1369-5266(99)80037-5; RADWANSKI ER, 1995, PLANT CELL, V7, P921, DOI 10.1105/tpc.7.7.921; RAJAGOPAL R, 1972, PLANTA, V103, P45, DOI 10.1007/BF00394605; RAUSCH T, 1985, J CHROMATOGR, V318, P95, DOI 10.1016/S0021-9673(01)90667-3; Rodman J.E., 1981, PHYTOCHEMISTRY ANGIO, P43; Rodman JE, 1998, AM J BOT, V85, P997, DOI 10.2307/2446366; Saupe SG, 1981, PHYTOCHEMISTRY ANGIO, P80; SIBBESEN O, 1995, J BIOL CHEM, V270, P3506, DOI 10.1074/jbc.270.8.3506; Sorensen H., 1990, CANOLA RAPESEED PROD, P149; TATE WP, 1992, BIOCHEMISTRY-US, V31, P2443, DOI 10.1021/bi00124a001; TOPFER R, 1987, NUCLEIC ACIDS RES, V15, P5890, DOI 10.1093/nar/15.14.5890; WENJUN S, 1983, NUCLEIC ACIDS RES, V17, P8385; Wittstock U, 2000, J BIOL CHEM, V275, P14659, DOI 10.1074/jbc.275.19.14659; ZAMBRYSKI P, 1983, EMBO J, V2, P2143, DOI 10.1002/j.1460-2075.1983.tb01715.x	49	318	345	7	56	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33712	33717		10.1074/jbc.M001667200	http://dx.doi.org/10.1074/jbc.M001667200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10922360	hybrid			2022-12-27	WOS:000090104600074
J	Ding, VW; Chen, RH; McCormick, F				Ding, VW; Chen, RH; McCormick, F			Differential regulation of glycogen synthase kinase 3 beta by insulin and Wnt signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; INTEGRIN-LINKED KINASE; RABBIT SKELETAL-MUSCLE; BETA-CATENIN; PROTEIN-KINASE; INTACT-CELLS; FUNCTIONAL INTERACTION; PHOSPHORYLASE-KINASE; XENOPUS EMBRYOS; COLON-CARCINOMA	Glycogen synthase kinase 3 beta (GSK3 beta) is a key component in many biological processes including insulin and Wnt signaling. Since the activation of each signaling pathway results in a decrease in GSK3 beta activity, we examined the specificity of their downstream effects in the same cell type. Insulin induces an increased activity of glycogen synthase but has no influence on the protein level of beta -catenin. In contrast, Wnt increases the cytosolic pool of beta -catenin but not glycogen synthase activity. We found that, unlike insulin, neither the phosphorylation status of the serine9 residue of GSK3 beta nor the activity of protein kinase B is regulated by Wnt. Although the decrease in GSK3 beta activity is required, GSK3 beta may not be the limiting component for Wnt signaling in the cells that we examined. Our results suggest that the axin-conductin complexed GSK3 beta may be dedicated to Wnt rather than insulin signaling. Insulin and Wnt pathways regulate GSK3 beta through different mechanisms, and therefore lead to distinct downstream events.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	McCormick, F (corresponding author), Univ Calif San Francisco, Canc Res Inst, 2340 Sutter St,Box 0128, San Francisco, CA 94115 USA.							Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; Bullions Linda C., 1998, Current Opinion in Oncology, V10, P81, DOI 10.1097/00001622-199801000-00013; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chen RH, 2000, J BIOL CHEM, V275, P17894, DOI 10.1074/jbc.M905336199; CHENG K, 1983, MOL CELL BIOCHEM, V56, P183; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DICKENS M, 1992, BIOCHEM J, V287, P201, DOI 10.1042/bj2870201; EldarFinkelman H, 1996, P NATL ACAD SCI USA, V93, P10228, DOI 10.1073/pnas.93.19.10228; EMBI N, 1980, EUR J BIOCHEM, V107, P519, DOI 10.1111/j.1432-1033.1980.tb06059.x; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; GOODE N, 1992, J BIOL CHEM, V267, P16878; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HOOPER JE, 1994, NATURE, V372, P461, DOI 10.1038/372461a0; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Markuns JF, 1999, J BIOL CHEM, V274, P24896, DOI 10.1074/jbc.274.35.24896; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Papkoff J, 1998, BIOCHEM BIOPH RES CO, V247, P851, DOI 10.1006/bbrc.1998.8888; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Proud CG, 1997, BIOCHEM J, V328, P329; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Ruel L, 1999, J BIOL CHEM, V274, P21790, DOI 10.1074/jbc.274.31.21790; RYLATT DB, 1980, EUR J BIOCHEM, V107, P529; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Semenov MV, 1997, GENOMICS, V42, P302, DOI 10.1006/geno.1997.4713; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Staal FJT, 1999, INT IMMUNOL, V11, P317, DOI 10.1093/intimm/11.3.317; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; Welsh GI, 1996, TRENDS CELL BIOL, V6, P274, DOI 10.1016/0962-8924(96)10023-4; Welsh GI, 1997, ANAL BIOCHEM, V244, P16, DOI 10.1006/abio.1996.9838; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; WOODGETT JR, 1993, BIOCHEM SOC T, V21, P905, DOI 10.1042/bst0210905; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Yuan HD, 1999, J BIOL CHEM, V274, P30419, DOI 10.1074/jbc.274.43.30419	53	358	366	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32475	32481		10.1074/jbc.M005342200	http://dx.doi.org/10.1074/jbc.M005342200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10913153	hybrid			2022-12-27	WOS:000090003800015
J	Huxford, T; Malek, S; Ghosh, G				Huxford, T; Malek, S; Ghosh, G			Preparation and crystallization of dynamic NF-kappa B center dot I kappa B complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ANGSTROM-RESOLUTION; ENVELOPE GLYCOPROTEIN; P50/P65 HETERODIMER; RIBOSOMAL-SUBUNIT; DNA-BINDING; HOMODIMER; EXPRESSION; PROTEINS; BETA	The formation of single, well-diffracting crystals is a requirement for any molecular structure determination by x-ray crystallography. Crystallization of biological macromolecules can represent a significant obstacle when the subject exhibits internal flexibility or indiscriminate self-association. In such cases, the removal of inherently flexible regions and the addition of stabilizing ligands can improve the probability of crystal formation and ordered growth. We have applied these principles in order to form crystals of the Rel homology region of transcription factor NF-kappaB in complex with its inhibitors I kappaB alpha and I kappaB beta. None of these molecules crystallizes in the absence of a binding partner. Recombinant overexpression of truncated I kappaB alpha required selection of the correct start site. NF-kappaB .I kappaB alpha complex crystals formed under relatively stringent conditions. NF-kappaB .I kappaB beta complex crystals were formed by analogy to NF-kappaB .I kappaB alpha, although some modifications in purification and complex formation were necessary due to differences between the inhibitors.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92037 USA	University of California System; University of California San Diego	Ghosh, G (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, Mail Code 0359,9500 Gilman Dr, La Jolla, CA 92037 USA.			Huxford, Tom/0000-0002-1939-7373; Malek, Shiva/0000-0002-9526-7968	NCI NIH HHS [5POCA23100-16, CA78749] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023100, R01CA078749] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Ban N, 1999, NATURE, V400, P841, DOI 10.1038/23641; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; Chen FE, 1999, PROTEIN ENG, V12, P423, DOI 10.1093/protein/12.5.423; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; Clemons WM, 1999, NATURE, V400, P833, DOI 10.1038/23631; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; FURLONG J, 1992, NUCLEIC ACIDS RES, V20, P4668, DOI 10.1093/nar/20.17.4668; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Grimes JM, 1998, NATURE, V395, P470, DOI 10.1038/26694; Huang DB, 1997, STRUCTURE, V5, P1427, DOI 10.1016/S0969-2126(97)00293-1; Huxford T, 1999, COLD SPRING HARB SYM, V64, P533, DOI 10.1101/sqb.1999.64.533; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kwong PD, 1999, J BIOL CHEM, V274, P4115, DOI 10.1074/jbc.274.7.4115; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LOOMAN AC, 1987, EMBO J, V6, P2489, DOI 10.1002/j.1460-2075.1987.tb02530.x; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; McKinsey TA, 1997, J BIOL CHEM, V272, P22377, DOI 10.1074/jbc.272.36.22377; McPherson A., 1999, CRYSTALLIZATION BIOL; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Phelps CB, 2000, J BIOL CHEM, V275, P29840, DOI 10.1074/jbc.M004899200; Reinisch KM, 2000, NATURE, V404, P960, DOI 10.1038/35010041; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Thanaraj TA, 1996, PROTEIN SCI, V5, P1594, DOI 10.1002/pro.5560050814; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944	36	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32800	32806		10.1074/jbc.M006037200	http://dx.doi.org/10.1074/jbc.M006037200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10906335	hybrid			2022-12-27	WOS:000090003800059
J	Marshall, NF; Dahmus, ME				Marshall, NF; Dahmus, ME			C-terminal domain phosphatase sensitivity of RNA polymerase II in early elongation complexes on the HIV-1 and adenovirus 2 major late templates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPT RELEASE FACTOR; FACTOR P-TEFB; IN-VITRO; PROTEIN PHOSPHATASE; TAT TRANSACTIVATION; PURIFICATION; KINASE; ACTIVATION; INITIATION; DROSOPHILA	The fate of RNA polymerase II in early elongation complexes is under the control of factors that regulate and respond to the phosphorylation state of the C-terminal domain (CTD). Phosphorylation of the CTD protects early elongation complexes from negative transcription elongation factors such as NELF, DSIF, and factor 2. To understand the relationship between transcript elongation and the sensitivity of RNA polymerase IIO to dephosphorylation, elongation complexes at defined positions on the Ad2-ML and human immunodeficiency virus type 1 (HIV-1) templates were purified, and their sensitivity to CTD phosphatase was determined. Purified elongation complexes treated with 1% Sarkosyl and paused at U-14/G(16) on an HIV-1 template and at G(11) on the Ad2-ML template are equally sensitive to dephosphorylation by CTD phosphatase. Multiple elongation complexes paused at more promoter distal sites are more resistant to dephosphorylation than are U-14/G(16) and G(11) complexes. The HIV-1 long terminal repeat and adenovirus 2 major late promoter do not appear to differentially influence the CTD phosphatase sensitivity of stringently washed complexes. Subsequent elongation by 1% Sarkosyl-washed U-14/G(16) complexes is unaffected by prior CTD phosphatase treatment. This result is consistent with the hypothesis that CTD phosphatase requires the presence of specific elongation factors to propagate a negative effect on transcript elongation. The action of CTD phosphatase on elongation complexes is inhibited by HIV-1 Tat protein, This observation is consistent with the idea that Tat suppression of CTD phosphatase plays a role in transactivation.	Univ Calif Davis, Sect Mol & Cellular Biol, Div Biol Sci, Davis, CA 95616 USA	University of California System; University of California Davis	Dahmus, ME (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, Div Biol Sci, Davis, CA 95616 USA.	medahmus@ucdavis.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018952, R01GM033300] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18952, GM-33300] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Archambault J, 1998, J BIOL CHEM, V273, P27593, DOI 10.1074/jbc.273.42.27593; Archambault J, 1997, P NATL ACAD SCI USA, V94, P14300, DOI 10.1073/pnas.94.26.14300; Bieniasz PD, 1999, P NATL ACAD SCI USA, V96, P7791, DOI 10.1073/pnas.96.14.7791; Chambers RS, 1996, J BIOL CHEM, V271, P24498, DOI 10.1074/jbc.271.40.24498; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; Chen D, 1999, MOL CELL BIOL, V19, P2863; Chen D, 1999, P NATL ACAD SCI USA, V96, P13468, DOI 10.1073/pnas.96.23.13468; Cho H, 1999, GENE DEV, V13, P1540, DOI 10.1101/gad.13.12.1540; Chun RF, 1996, J BIOL CHEM, V271, P27888, DOI 10.1074/jbc.271.44.27888; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GarciaMartinez LF, 1997, EMBO J, V16, P2836, DOI 10.1093/emboj/16.10.2836; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; LASPIA MF, 1993, J MOL BIOL, V232, P732, DOI 10.1006/jmbi.1993.1427; Lehman AL, 2000, J BIOL CHEM, V275, P14923, DOI 10.1074/jbc.275.20.14923; Liu MY, 1998, J BIOL CHEM, V273, P25541, DOI 10.1074/jbc.273.40.25541; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; Marshall NF, 1998, J BIOL CHEM, V273, P31726, DOI 10.1074/jbc.273.48.31726; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Morrison DJ, 1999, NUCLEIC ACIDS RES, V27, P1251, DOI 10.1093/nar/27.5.1251; O'Keeffe B, 2000, J BIOL CHEM, V275, P279, DOI 10.1074/jbc.275.1.279; Okamoto H, 1996, P NATL ACAD SCI USA, V93, P11575, DOI 10.1073/pnas.93.21.11575; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; Peng JM, 1998, J BIOL CHEM, V273, P13855, DOI 10.1074/jbc.273.22.13855; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Pessler F, 1998, J BIOL CHEM, V273, P5375, DOI 10.1074/jbc.273.9.5375; Pessler F, 1997, MOL CELL BIOL, V17, P3786, DOI 10.1128/MCB.17.7.3786; Samkurashvili I, 1998, MOL CELL BIOL, V18, P5343, DOI 10.1128/MCB.18.9.5343; Shilatifard A, 1998, FASEB J, V12, P1437, DOI 10.1096/fasebj.12.14.1437; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Xie Z, 1997, J BIOL CHEM, V272, P31902, DOI 10.1074/jbc.272.50.31902; Xie Z, 1996, J BIOL CHEM, V271, P11043, DOI 10.1074/jbc.271.19.11043; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yang XZ, 1996, J VIROL, V70, P4576, DOI 10.1128/JVI.70.7.4576-4584.1996; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; ZHOU QA, 1995, EMBO J, V14, P321, DOI 10.1002/j.1460-2075.1995.tb07006.x; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	47	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32430	32437		10.1074/jbc.M005898200	http://dx.doi.org/10.1074/jbc.M005898200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10938286	hybrid			2022-12-27	WOS:000090003800009
J	Mochida, Y; Takeda, K; Saitoh, M; Nishitoh, H; Amagasa, T; Ninomiya-Tsuji, J; Matsumoto, K; Ichijo, H				Mochida, Y; Takeda, K; Saitoh, M; Nishitoh, H; Amagasa, T; Ninomiya-Tsuji, J; Matsumoto, K; Ichijo, H			ASK1 inhibits interleukin-1-induced NF-kappa B activity through disruption of TRAF6-TAK1 interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATING KINASE-1; TERMINAL KINASE; APOPTOSIS; PATHWAYS; MITOGEN; INDUCTION; BETA; TRANSDUCTION; CASCADES	Apoptosis signal-regulating kinase 1 (ASK1) is a mem ber of the MAPKKK family in the JNK and p38 mitogen-activated protein kinase cascades and critically involved in stress- and cytokine-induced apoptosis. The transcription factor nuclear factor-kappaB (NF-kappaB) is a pivotal regulator of immune and inflammatory responses and exerts anti-apoptotic roles in various cells. Here we show that ASK1 directly interacts with transforming growth factor-beta -activated kinase 1 (TAK1), another MAPKKK that has been identified as a signaling intermediate in the interleukin 1 (IL-1)-induced NF-kappaB pathway as well as the transforming growth factor-beta superfamily-induced JNK/p38 pathway. Overexpression of ASK1 inhibits IL-1-, TRAF6-, or TAK1-induced, but not NF-kappaB-inducing kinase-induced, NF-kappaB activation. ASK1 dissociates TAK1 but not NF-kappaB-inducing kinase from TRAF6. Moreover, IL-1-induced complex formation of endogenous TAK1 and TRAF6 was blocked by ASK1 overexpression. It thus appears that the inhibition of NF-kappaB by ASK1 may result at least in part from the disruption of the TRAF6 . TAK1 complex formation in the IL-1 signaling pathway. These results provide a new insight in the mode of action of MAPKKK family members; two distinct MAPRKKKs in the same MAP kinase cascades directly interact and exert opposite effects in another signaling pathway, NF-kappaB.	Tokyo Med & Dent Univ, Dept Hard Tissue Engn, Div Biomatrix, Grad Sch,Lab Cell Signalling,Bunkyo Ku, Tokyo 1138549, Japan; Tokyo Med & Dent Univ, Dept Maxillofacial Reconstruct & Funct, Div Maxillofacial & Neck Reconstruct, Grad Sch,Bunkyo Ku, Tokyo 1138549, Japan; Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Chikusa Ku, Nagoya, Aichi 46401, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Nagoya University	Ichijo, H (corresponding author), Tokyo Med & Dent Univ, Dept Hard Tissue Engn, Div Biomatrix, Grad Sch,Lab Cell Signalling,Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.	ichijo.csi@tmd.ac.jp		Ichijo, Hidenori/0000-0002-5005-6438; Mochida, Yoshiyuki/0000-0002-2115-4303; Nishitoh, Hideki/0000-0002-8652-4109; Takeda, Kohsuke/0000-0002-8359-8399; Ninomiya-Tsuji, Jun/0000-0002-5584-0176				BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; Funato N, 1998, LAB INVEST, V78, P477; Ghosh S, 1999, IMMUNOL RES, V19, P183, DOI 10.1007/BF02786486; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Kanamoto T, 2000, MOL CELL BIOL, V20, P196, DOI 10.1128/MCB.20.1.196-204.2000; Kashiwada M, 1998, J EXP MED, V187, P237, DOI 10.1084/jem.187.2.237; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nakahara S, 1999, J NEUROPATH EXP NEUR, V58, P442, DOI 10.1097/00005072-199905000-00003; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; NISHIDA E, 1992, INT REV CYTOL, V138, P211, DOI 10.1016/S0074-7696(08)61589-2; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sakurai H, 1998, BIOCHEM BIOPH RES CO, V243, P545, DOI 10.1006/bbrc.1998.8124; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takeda K, 2000, J BIOL CHEM, V275, P9805, DOI 10.1074/jbc.275.13.9805; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	39	45	47	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32747	32752		10.1074/jbc.M003042200	http://dx.doi.org/10.1074/jbc.M003042200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10921914	hybrid			2022-12-27	WOS:000090003800052
J	Baldwin, TA; Gogela-Spehar, M; Ostergaard, HL				Baldwin, TA; Gogela-Spehar, M; Ostergaard, HL			Specific isoforms of the resident endoplasmic reticulum protein glucosidase II associate with the CD45 protein-tyrosine phosphatase via a lectin-like interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELLS; LINKED OLIGOSACCHARIDES; CALNEXIN; GLYCOPROTEIN; CALRETICULIN; SUBSTRATE; RECOGNITION; EXPRESSION; GALECTIN-1; APOPTOSIS	We have previously demonstrated that CD45 physically associates with the endoplasmic reticulum processing enzyme glucosidase II (GII). GII consists of the catalytic alpha-chain and an associated beta-chain. To gain insight into the basis of the association between CD45 and GII, we examined the biochemical requirements for the interaction. We show that the alpha-subunit is essential for the interaction. Interestingly, only a higher molecular weight form of GII alpha! is capable of associating with CD45 in a competitive situation where multiple GII alpha isoforms are expressed. Further, transfection studies demonstrate that only isoforms containing the alternatively spliced sequence Box Al are capable of binding CD45, although all isoforms are catalytically active, The interaction between CD45 and GII is dependent on the active site of GII, is mediated through the carbohydrate on CD45, and can be inhibited with mannose. Taken together, these results suggest that GII alpha acts as a lectin and binds to CD45 in an exon-dependent manner. This lectin activity of GIT may be a novel mechanism for the regulation of CD45 biology and play a role in immune function, possibly by regulating CD45 glycosylation.	Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2S2, Canada	University of Alberta	Ostergaard, HL (corresponding author), Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2S2, Canada.							Arendt CW, 1999, GLYCOBIOLOGY, V9, P277, DOI 10.1093/glycob/9.3.277; Arendt CW, 1997, J BIOL CHEM, V272, P13117, DOI 10.1074/jbc.272.20.13117; ARENDT CW, 1995, J BIOL CHEM, V270, P2313; Arendt CW, 2000, GLYCOBIOLOGY, V10, P487, DOI 10.1093/glycob/10.5.487; Ashwell JD, 1999, IMMUNOL TODAY, V20, P412, DOI 10.1016/S0167-5699(99)01505-4; BEGOVAC PC, 1994, J BIOL CHEM, V269, P31793; Flura T, 1997, GLYCOBIOLOGY, V7, P617, DOI 10.1093/glycob/7.5.617; GRINNA LS, 1980, J BIOL CHEM, V255, P2255; Hagen FK, 1999, J BIOL CHEM, V274, P6797, DOI 10.1074/jbc.274.10.6797; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; KAUSHAL GP, 1990, J BIOL CHEM, V265, P16271; LUCOCQ JM, 1986, J CELL BIOL, V102, P2137, DOI 10.1083/jcb.102.6.2137; Ma JY, 1996, J BIOL CHEM, V271, P7758, DOI 10.1074/jbc.271.13.7758; ORA A, 1995, J BIOL CHEM, V270, P26060, DOI 10.1074/jbc.270.44.26060; Pace KE, 1999, J IMMUNOL, V163, P3801; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; PULIDO R, 1992, EUR J IMMUNOL, V22, P463, DOI 10.1002/eji.1830220226; Rodan AR, 1996, EMBO J, V15, P6921, DOI 10.1002/j.1460-2075.1996.tb01084.x; SGROI D, 1995, P NATL ACAD SCI USA, V92, P4026, DOI 10.1073/pnas.92.9.4026; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; THOMAS ML, 1988, IMMUNOL TODAY, V9, P320, DOI 10.1016/0167-5699(88)91326-6; Thomas ML, 1999, IMMUNOL TODAY, V20, P406, DOI 10.1016/S0167-5699(99)01506-6; Trombetta ES, 1996, J BIOL CHEM, V271, P27509, DOI 10.1074/jbc.271.44.27509; TROPEA JE, 1989, BIOCHEMISTRY-US, V28, P2027, DOI 10.1021/bi00431a010; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; Uemura K, 1996, J BIOL CHEM, V271, P4581; Wada I, 1997, EMBO J, V16, P5420, DOI 10.1093/emboj/16.17.5420; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3	33	15	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32071	32076		10.1074/jbc.M003088200	http://dx.doi.org/10.1074/jbc.M003088200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10921916	hybrid			2022-12-27	WOS:000089858900072
J	Ikeda, Y; Koizumi, N; Kusano, T; Sano, H				Ikeda, Y; Koizumi, N; Kusano, T; Sano, H			Specific binding of a 14-3-3 protein to autophosphorylated WPK4, an SNF1-related wheat protein kinase, and to WPK4-phosphorylated nitrate reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITOR PROTEIN; PHOSPHORYLATION; 14-3-3-PROTEINS; TRANSCRIPTS; INTERACT; SUCROSE; HOMOLOG; LEAVES; PLANTS; LIGHT	WPK4 is a wheat protein kinase related to the yeast protein kinase SNF1, which plays a role in catabolite repression. To identify proteins involved in signal transduction through WPK4, we performed yeast two-hybrid screens and isolated two cDNA clones designated as TaWIN1 and TaWIN2. Both encode 14-3-3 proteins that, upon autophosphorylation, bind the C-terminal regulatory domain of WPK4. Mutational analysis through amino acid substitution revealed that TaWIN1 and TaWIN2 primarily bind WPK4 through phosphoserines at the positions 388 and 418, both located in the C-terminal region. Mutations in the conserved residues of the TaWIN1 amphipathic groove impaired the ability of TaWIN1 to bind to WPK4. A screen for in vitro phosphorylation of proteins involved in nutrient metabolism revealed a putative WPK4 substrate, nitrate reductase; its hinge 1 region was efficiently phosphorylated by WPK4. Subsequent far Western blots showed that it specifically bound TaWIN1. Since nitrate reductase has been shown to be inactivated by phosphorylation upon 14-3-3 binding, the present findings strongly suggest that WPK4 is the protein kinase responsible for controlling the nitrogen metabolic pathway, assembling the nitrate reductase and 14-3-3 complex through its phosphorylation specificity.	Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Nara 6300101, Japan	Nara Institute of Science & Technology	Sano, H (corresponding author), Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Nara 6300101, Japan.		Ikeda, Yoshihisa/B-4614-2013					BACHMANN M, 1995, PLANT PHYSIOL, V108, P1083, DOI 10.1104/pp.108.3.1083; Bachmann M, 1996, FEBS LETT, V387, P127, DOI 10.1016/0014-5793(96)00478-4; Bhalerao RP, 1999, P NATL ACAD SCI USA, V96, P5322, DOI 10.1073/pnas.96.9.5322; Bouly JP, 1999, PLANT J, V18, P541, DOI 10.1046/j.1365-313X.1999.00476.x; Camoni L, 1998, FEBS LETT, V430, P381, DOI 10.1016/S0014-5793(98)00696-6; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; CRAWFORD NM, 1995, PLANT CELL, V7, P859, DOI 10.1105/tpc.7.7.859; Douglas P, 1997, BIOCHEM J, V325, P101, DOI 10.1042/bj3250101; Douglas P, 1995, FEBS LETT, V377, P113, DOI 10.1016/0014-5793(95)01300-8; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Finnie C, 1999, PLANT MOL BIOL, V40, P545, DOI 10.1023/A:1006211014713; Halford NG, 1998, PLANT MOL BIOL, V37, P735, DOI 10.1023/A:1006024231305; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Ikeda Y, 1999, PLANT PHYSIOL, V121, P813, DOI 10.1104/pp.121.3.813; Kaiser WM, 1999, PHYSIOL PLANTARUM, V105, P385, DOI 10.1034/j.1399-3054.1999.105225.x; Kinoshita T, 1999, EMBO J, V18, P5548, DOI 10.1093/emboj/18.20.5548; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; LU GH, 1994, PLANT CELL, V6, P501, DOI 10.1105/tpc.6.4.501; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; Purcell PC, 1998, PLANT J, V14, P195, DOI 10.1046/j.1365-313X.1998.00108.x; SANO H, 1994, P NATL ACAD SCI USA, V91, P2582, DOI 10.1073/pnas.91.7.2582; Schultz TF, 1998, PLANT CELL, V10, P837, DOI 10.1105/tpc.10.5.837; Shi JR, 1999, PLANT CELL, V11, P2393, DOI 10.1105/tpc.11.12.2393; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	24	58	67	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31695	31700		10.1074/jbc.M004892200	http://dx.doi.org/10.1074/jbc.M004892200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10918058	hybrid			2022-12-27	WOS:000089858900023
J	Kumar, S; Lee, IH; Plamann, M				Kumar, S; Lee, IH; Plamann, M			Cytoplasmic dynein ATPase activity is regulated by dynactin-dependent phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-RELATED PROTEIN; MICROTUBULE-ASSOCIATED PROTEINS; LIGHT-CHAIN; NUCLEAR-DISTRIBUTION; HEAVY-CHAIN; ASPERGILLUS-NIDULANS; INTERMEDIATE-CHAIN; NEUROSPORA-CRASSA; MITOTIC SPINDLE; MOTOR PROTEINS	Cytoplasmic dynein is a microtubule-associated motor that utilizes ATP hydrolysis to conduct minus-end directed transport of various organelles. Dynactin is a multisubunit complex that has been proposed to both link dynein with cargo and activate dynein motor function. The mechanisms by which dynactin regulates dynein activity are not clear. In this study, we examine the role of dynactin in regulating dynein ATPase activity. We show that dynein-microtubule binding and ATP-dependent release of dynein from microtubules are reduced in dynactin null mutants, Delta ro-3 (p150(Glued)) and Delta ro-4 (Arp1), relative to wild-type. The dynein-microtubule binding activity, but not the ATP-dependent release of dynein from microtubules, is restored by in vitro mixing of extracts from dynein and dynactin mutants. Dynein produced in a Delta ro-3 mutant has similar to 8-fold reduced ATPase activity relative to dynein isolated from wildtype. However, dynein ATPase activity from wild-type is not reduced when dynactin is separated from dynein, suggesting that dynein produced in a dynactin mutant is inactivated. Treatment of dynein isolated from the Delta ro-3 mutant with lambda protein phosphatase restores the ATPase activity to near wild-type levels. The reduced dynein ATPase activity observed in dynactin null mutants is mainly due to altered affinity for ATP. Radiolabeling experiments revealed that low molecular mass proteins, particularly 20- and 8-kDa proteins, that immunoprecipitate with dynein heavy chain are hyperphosphorylated in the dynactin mutant and dephosphorylated upon A protein phosphatase treatment. The results suggest that cytoplasmic dynein ATPase activity is regulated by dynactin-dependent phosphorylation of dynein light chains.	Univ Missouri, Sch Biol Sci, Kansas City, MO 64110 USA	University of Missouri System; University of Missouri Kansas City	Plamann, M (corresponding author), Univ Missouri, Sch Biol Sci, 5100 Rockhill Rd, Kansas City, MO 64110 USA.	plamannm@umkc.edu			NIGMS NIH HHS [GM51217] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM051217, R01GM051217] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allan V, 1996, CURR BIOL, V6, P630, DOI 10.1016/S0960-9822(09)00434-5; BARKALOW K, 1994, J CELL BIOL, V126, P727, DOI 10.1083/jcb.126.3.727; Beckwith SM, 1998, J CELL BIOL, V143, P1239, DOI 10.1083/jcb.143.5.1239; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Bowman AB, 1999, J CELL BIOL, V146, P165; Bruno KS, 1996, P NATL ACAD SCI USA, V93, P4775, DOI 10.1073/pnas.93.10.4775; CLARK SW, 1994, J CELL BIOL, V127, P129, DOI 10.1083/jcb.127.1.129; Davis R.H., 1970, METHODS ENZYMOL, V17, P79, DOI [10.1016/0076-6879(71)17168-6, DOI 10.1016/0076-6879(71)17168-6]; Dickman MB, 1999, FUNGAL GENET BIOL, V26, P99, DOI 10.1006/fgbi.1999.1118; DILLMAN JF, 1994, J CELL BIOL, V127, P1671, DOI 10.1083/jcb.127.6.1671; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Eckley DM, 1999, J CELL BIOL, V147, P307, DOI 10.1083/jcb.147.2.307; ESHEL D, 1993, P NATL ACAD SCI USA, V90, P11172, DOI 10.1073/pnas.90.23.11172; Farshori P, 1997, BIOCHEM BIOPH RES CO, V232, P810, DOI 10.1006/bbrc.1997.6379; Gee MA, 1997, NATURE, V390, P636, DOI 10.1038/37663; Habura A, 1999, J BIOL CHEM, V274, P15447, DOI 10.1074/jbc.274.22.15447; HAMASAKI T, 1991, P NATL ACAD SCI USA, V88, P7918, DOI 10.1073/pnas.88.18.7918; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Holleran EA, 1996, J CELL BIOL, V135, P1815, DOI 10.1083/jcb.135.6.1815; Holleran EA, 1998, INT REV CYTOL, V182, P69, DOI 10.1016/S0074-7696(08)62168-3; Holleran EA, 1998, TRENDS CELL BIOL, V8, P26, DOI 10.1016/S0962-8924(97)01195-1; HOLZBAUR ELF, 1991, NATURE, V351, P579, DOI 10.1038/351579a0; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; Huang CYF, 1999, J BIOL CHEM, V274, P14262, DOI 10.1074/jbc.274.20.14262; Inaba K, 1999, BIOCHEM BIOPH RES CO, V256, P177, DOI 10.1006/bbrc.1999.0309; KARKI S, 1995, J BIOL CHEM, V131, P385; King SJ, 2000, NAT CELL BIOL, V2, P20, DOI 10.1038/71338; King SJ, 1999, MOL BIOL CELL, V10, p248A; King SM, 1996, J BIOL CHEM, V271, P19358, DOI 10.1074/jbc.271.32.19358; KING SM, 1995, J BIOL CHEM, V270, P11445, DOI 10.1074/jbc.270.19.11445; King SM, 1996, J BIOL CHEM, V271, P32281, DOI 10.1074/jbc.271.50.32281; King SM, 1998, BIOCHEMISTRY-US, V37, P15033, DOI 10.1021/bi9810813; Koonce MP, 1997, J BIOL CHEM, V272, P19714, DOI 10.1074/jbc.272.32.19714; Kumar S, 2000, BIOCHIMIE, V82, P229, DOI 10.1016/S0300-9084(00)00206-6; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LI YY, 1993, P NATL ACAD SCI USA, V90, P10096, DOI 10.1073/pnas.90.21.10096; LIN SXH, 1994, J CELL BIOL, V127, P1009, DOI 10.1083/jcb.127.4.1009; LIN SXH, 1993, J CELL SCI, V105, P579; MCGRAIL M, 1995, J CELL BIOL, V131, P411, DOI 10.1083/jcb.131.2.411; Minke PF, 1999, MOL MICROBIOL, V32, P1065, DOI 10.1046/j.1365-2958.1999.01421.x; MUHUA L, 1994, CELL, V78, P669, DOI 10.1016/0092-8674(94)90531-2; PASCHAL BM, 1991, METHOD ENZYMOL, V196, P181; Pazour GJ, 1999, MOL BIOL CELL, V10, P3507, DOI 10.1091/mbc.10.10.3507; PLAMANN M, 1994, J CELL BIOL, V127, P139, DOI 10.1083/jcb.127.1.139; Reese EL, 1999, MOL BIOL CELL, V10, p250A; Runnegar MT, 1999, BIOCHEM J, V342, P1, DOI 10.1042/0264-6021:3420001; Schafer DA, 1999, ANNU REV CELL DEV BI, V15, P341, DOI 10.1146/annurev.cellbio.15.1.341; SCHAFER DA, 1994, J CELL BIOL, V126, P403, DOI 10.1083/jcb.126.2.403; Schroer TA, 1996, SEMIN CELL DEV BIOL, V7, P321, DOI 10.1006/scdb.1996.0041; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; Seiler S, 1999, CURR BIOL, V9, P779, DOI 10.1016/S0960-9822(99)80360-1; SLOBODA RD, 1976, BIOCHEMISTRY-US, V15, P4497, DOI 10.1021/bi00665a026; Sloboda RD, 1998, PROTEIN EXPRES PURIF, V13, P205, DOI 10.1006/prep.1998.0902; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Tai AW, 1999, MOL BIOL CELL, V10, p368A; Tinsley JH, 1998, MOL GEN GENET, V259, P601, DOI 10.1007/s004380050853; Tinsley JH, 1996, MOL BIOL CELL, V7, P731, DOI 10.1091/mbc.7.5.731; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; WATERMANSTORER CM, 1995, P NATL ACAD SCI USA, V92, P1634, DOI 10.1073/pnas.92.5.1634; WEBER A, 1994, J CELL BIOL, V127, P1627, DOI 10.1083/jcb.127.6.1627; Wu HW, 1999, MOL BIOL CELL, V10, p369A; XIANG X, 1994, P NATL ACAD SCI USA, V91, P2100, DOI 10.1073/pnas.91.6.2100	63	35	37	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31798	31804		10.1074/jbc.M000449200	http://dx.doi.org/10.1074/jbc.M000449200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10921911	hybrid			2022-12-27	WOS:000089858900037
J	Wu, XS; Edwards, HD; Sather, WA				Wu, XS; Edwards, HD; Sather, WA			Side chain orientation in the selectivity filter of a voltage-gated Ca2+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTEINE ACCESSIBILITY METHOD; RAT PHEOCHROMOCYTOMA CELLS; K+ CHANNEL; ION PERMEATION; POTASSIUM CHANNEL; CALCIUM CHANNELS; BINDING-SITES; SUBSTITUTED CYSTEINES; LINING RESIDUES	Four glutamate residues (EEEE locus) are essential for ion selectivity in voltage-gated Ca2+ channels, with ion-specific differences in binding to the locus providing the basis of selectivity. Whether side chain carboxylates or alternatively main chain carbonyls of these glutamates project into the pore to form the ion-binding locus has been uncertain. We have addressed this question by examining effects of sulfhydryl-modifying agents (methanethiosulfonates) on 20 cysteine-substituted mutant forms of an L-type Ca2+ channel. Sulfhydryl modifiers partially blocked whole oocyte Ba2+ currents carried by wild type channels, but this block was largely reversed with washout. In contrast, each of the four EEEE locus glutamate --> cysteine mutants (6 position) was persistently blocked by sulfhydryl modifiers, indicating covalent attachment of a modifying group to the side chain of the substituted cysteine. Cysteine substitutions at positions immediately adjacent to the EEEE locus glutamates (+/-1 positions) were also generally susceptible to sulfhydryl modification. Sulfhydryl modifiers had lesser effects on channels substituted one position further from the EEEE locus (+/-2 positions). These results indicate that the carboxylate-bearing side chains of the EEEE locus glutamates and their immediate neighbors project into the water-filled lumen of the pore to form an ion-binding locus. Thus the structure of the Ca2+ channel selectivity filter differs substantially from that of ancestral K+ channels.	Univ Colorado, Hlth Sci Ctr, Ctr Neurosci, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Neurosci, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sather, WA (corresponding author), Univ Colorado, Hlth Sci Ctr, Ctr Neurosci, Dept Pharmacol, Box B-138,4200 E 9th Ave, Denver, CO 80262 USA.			Sather, William/0000-0003-1482-8055	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035245] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35245] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akabas MH, 1998, BIOCHEMISTRY-US, V37, P12233, DOI 10.1021/bi980969o; AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1994, J BIOL CHEM, V269, P14865; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; Beck C, 1999, NEURON, V22, P559, DOI 10.1016/S0896-6273(00)80710-2; Chen XH, 1997, J BIOL CHEM, V272, P30002, DOI 10.1074/jbc.272.48.30002; Chen XH, 1996, J GEN PHYSIOL, V108, P363, DOI 10.1085/jgp.108.5.363; CHIAMVIMONVAT N, 1995, CIRC RES, V76, P325, DOI 10.1161/01.RES.76.3.325; Chiamvimonvat N, 1996, NEURON, V16, P1037, DOI 10.1016/S0896-6273(00)80127-0; Chiamvimonvat N, 1996, J PHYSIOL-LONDON, V491, P51, DOI 10.1113/jphysiol.1996.sp021195; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Egan TM, 1998, J NEUROSCI, V18, P2350; ELLINOR PT, 1995, NEURON, V15, P1121, DOI 10.1016/0896-6273(95)90100-0; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; Fahlke C, 1997, NATURE, V390, P529, DOI 10.1038/37391; FALKE JJ, 1994, Q REV BIOPHYS, V27, P219, DOI 10.1017/S0033583500003012; Fearon IM, 1999, J PHYSIOL-LONDON, V514, P629, DOI 10.1111/j.1469-7793.1999.629ad.x; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HILLE B, 1992, IONIC CHANNELS EXCIT, P525; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; Horenstein J, 1998, MOL PHARMACOL, V53, P870; Hu H, 1997, CIRC RES, V81, P742; Jiang YX, 2000, J GEN PHYSIOL, V115, P269, DOI 10.1085/jgp.115.3.269; Karlin A, 1998, METHOD ENZYMOL, V293, P123; KIM MS, 1993, FEBS LETT, V318, P145, DOI 10.1016/0014-5793(93)80009-J; Klockner U, 1996, J BIOL CHEM, V271, P22293; Krovetz HS, 1997, BIOPHYS J, V72, P117, DOI 10.1016/S0006-3495(97)78651-X; Kuner T, 1996, NEURON, V17, P343, DOI 10.1016/S0896-6273(00)80165-8; KUO CC, 1993, J PHYSIOL-LONDON, V466, P629; KUO CC, 1993, J PHYSIOL-LONDON, V466, P657; KURZ LL, 1995, BIOPHYS J, V68, P900, DOI 10.1016/S0006-3495(95)80266-3; LANSMAN JB, 1986, J GEN PHYSIOL, V88, P321, DOI 10.1085/jgp.88.3.321; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; Loussouarn G, 2000, J BIOL CHEM, V275, P1137, DOI 10.1074/jbc.275.2.1137; LU Q, 1995, SCIENCE, V268, P304, DOI 10.1126/science.7716526; Lu T, 1999, NEURON, V22, P571, DOI 10.1016/S0896-6273(00)80711-4; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; MCCLESKEY EW, 1985, P NATL ACAD SCI USA, V82, P7149, DOI 10.1073/pnas.82.20.7149; MIKALA G, 1993, FEBS LETT, V335, P265, DOI 10.1016/0014-5793(93)80743-E; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; PASCUAL JM, 1995, NEURON, V14, P1055, DOI 10.1016/0896-6273(95)90344-5; ROOT MJ, 1994, SCIENCE, V265, P1852, DOI 10.1126/science.7522344; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SCHAUER CK, 1987, J AM CHEM SOC, V109, P3646, DOI 10.1021/ja00246a022; Seal RP, 2000, NEURON, V25, P695, DOI 10.1016/S0896-6273(00)81071-5; Sun ZP, 1996, NEURON, V16, P141, DOI 10.1016/S0896-6273(00)80031-8; TANG SQ, 1993, J BIOL CHEM, V268, P13026; Tsushima RG, 1997, J GEN PHYSIOL, V109, P463, DOI 10.1085/jgp.109.4.463; Wang KW, 1996, NEURON, V16, P571, DOI 10.1016/S0896-6273(00)80076-8; Williamson AV, 1999, BIOPHYS J, V77, P2575, DOI 10.1016/S0006-3495(99)77092-X; XU M, 1993, J BIOL CHEM, V268, P21505; Yamagishi T, 1997, BIOPHYS J, V73, P195, DOI 10.1016/S0006-3495(97)78060-3; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0	56	36	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31778	31785		10.1074/jbc.M004829200	http://dx.doi.org/10.1074/jbc.M004829200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10934200	hybrid			2022-12-27	WOS:000089858900034
J	McAllister, KA; Peery, RB; Meier, TI; Fischl, AS; Zhao, G				McAllister, KA; Peery, RB; Meier, TI; Fischl, AS; Zhao, G			Biochemical and molecular analyses of the Streptococcus pneumoniae acyl carrier protein synthase, an enzyme essential for fatty acid biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; ESCHERICHIA-COLI K-12; COENZYME-A; POLYKETIDE SYNTHASE; BACILLUS-SUBTILIS; PDXJ OPERON; GENES; PURIFICATION; STREPTOMYCES; CLUSTER	Acyl carrier protein synthase (AcpS) is an essential enzyme in the biosynthesis of fatty acids in all bacteria. AcpS catalyzes the transfer of 4'-phosphopantetheine from coenzyme A (CoA) to apo-ACP, thus converting apo-ACP to holo-ACP that serves as an acyl carrier for the biosynthesis of fatty acids and lipids. To further understand the physiological role of AcpS, we identified, cloned, and expressed the acpS and acpP genes of Streptococcus pneumoniae and purified both products to homogeneity. Both acpS and acpP form operons with the genes whose functions are required for other cellular metabolism. The acpS gene complements an Escherichia coli mutant defective in the production of AcpS and appears to be essential for the growth of S. pneumoniae. Gel filtration and cross-linking analyses establish that purified AcpS exists as a homotrimer. AcpS activity was significantly stimulated by apo-ACP at concentrations over 10 mu M and slightly inhibited at concentrations of 5-10 mu M. Double reciprocal analysis of initial velocities of AcpS at various concentrations of CoA or apo-ACP indicated a random or compulsory ordered bi bi type of reaction mechanism. Further analysis of the inhibition kinetics of the product (3',5'-ADP) suggested that it is competitive with respect to CoA but mixed (competitive and noncompetitive) with respect to apo-ACP. Finally, apo-ACP bound tightly to AcpS in the absence of CoA, but CoA failed to do so in the absence of apo-ACP. Together, these results suggest that AcpS may be allosterically regulated by apo ACP and probably proceeds by an ordered reaction mechanism with the first formation of the AcpS-apo-ACP complex and the subsequent transfer of 4'-phosphopantetheine to the apo-ACP of the complex.	Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA	Eli Lilly	Zhao, G (corresponding author), Eli Lilly & Co, Lilly Res Labs, DC 0438, Indianapolis, IN 46285 USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Baltz RH, 1998, MICROB DRUG RESIST, V4, P1, DOI 10.1089/mdr.1998.4.1; BALTZ RH, 1997, 37 ICAAC INT C ANT A, P391; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carreras CW, 1997, BIOCHEMISTRY-US, V36, P11757, DOI 10.1021/bi971350+; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; COOPER CL, 1987, BIOCHEMISTRY-US, V26, P2740, DOI 10.1021/bi00384a013; COPELAND RA, 1996, ENZYMES PRACTICAL IN; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; CROSBY J, 1995, BBA-PROTEIN STRUCT M, V1251, P32, DOI 10.1016/0167-4838(95)00053-W; ELOVSON J, 1968, J BIOL CHEM, V243, P3603; Flugel RS, 2000, J BIOL CHEM, V275, P959, DOI 10.1074/jbc.275.2.959; Gehring AM, 1997, CHEM BIOL, V4, P17, DOI 10.1016/S1074-5521(97)90233-7; Heath RJ, 1996, J BIOL CHEM, V271, P1833, DOI 10.1074/jbc.271.4.1833; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; JACKOWSKI S, 1984, J BACTERIOL, V158, P115, DOI 10.1128/JB.158.1.115-120.1984; JACKOWSKI S, 1986, J BACTERIOL, V166, P866, DOI 10.1128/jb.166.3.866-871.1986; JACKOWSKI S, 1981, J BACTERIOL, V148, P926, DOI 10.1128/JB.148.3.926-932.1981; JACKOWSKI S, 1983, J BIOL CHEM, V258, P5186; Kalman S, 1999, NAT GENET, V21, P385, DOI 10.1038/7716; KEATING DH, 1995, J BIOL CHEM, V270, P22229, DOI 10.1074/jbc.270.38.22229; KUBITSCHEK HE, 1986, J BACTERIOL, V168, P1466, DOI 10.1128/jb.168.3.1466-1467.1986; Kullik I, 1998, GENE, V219, P9, DOI 10.1016/S0378-1119(98)00404-1; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Kutchma AJ, 1999, J BACTERIOL, V181, P5498, DOI 10.1128/JB.181.17.5498-5504.1999; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM HM, 1992, J BACTERIOL, V174, P1554, DOI 10.1128/jb.174.5.1554-1567.1992; Lambalot RH, 1997, METHOD ENZYMOL, V279, P254; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; LAMBALOT RH, 1995, J BIOL CHEM, V270, P24658, DOI 10.1074/jbc.270.42.24658; LLOYD RG, 1996, ESCHERICHIA COLI SAL, P2336; MAJERUS PW, 1965, P NATL ACAD SCI USA, V53, P410, DOI 10.1073/pnas.53.2.410; Morbidoni HR, 1996, J BACTERIOL, V178, P4794, DOI 10.1128/jb.178.16.4794-4800.1996; Quadri LEN, 1998, BIOCHEMISTRY-US, V37, P1585, DOI 10.1021/bi9719861; RAWLINGS M, 1992, J BIOL CHEM, V267, P5751; ROCK CO, 1979, J BIOL CHEM, V254, P9778; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; Shen ZW, 1996, J BACTERIOL, V178, P571, DOI 10.1128/jb.178.2.571-573.1996; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; TAKIFF HE, 1992, J BACTERIOL, V174, P1544, DOI 10.1128/jb.174.5.1544-1553.1992; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Tropf S, 1998, CHEM BIOL, V5, P135, DOI 10.1016/S1074-5521(98)90058-8; VALLARI DS, 1988, J BACTERIOL, V170, P3961, DOI 10.1128/jb.170.9.3961-3966.1988; VALLARI DS, 1987, J BIOL CHEM, V262, P2468; Zhao GS, 1999, MICROBIOL-UK, V145, P791, DOI 10.1099/13500872-145-4-791; Zhou P, 1999, CHEM BIOL, V6, P577, DOI 10.1016/S1074-5521(99)80090-8	47	30	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30864	30872		10.1074/jbc.M004475200	http://dx.doi.org/10.1074/jbc.M004475200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10903317	hybrid			2022-12-27	WOS:000089762700021
J	Watanabe, T; Inoue, R; Kimura, N; Furukawa, K				Watanabe, T; Inoue, R; Kimura, N; Furukawa, K			Versatile transcription of biphenyl catabolic bph operon in Pseudomonas pseudoalcaligenes KF707	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP STRAIN KKS102; GRAM-NEGATIVE BACTERIA; RHODOCOCCUS SP M5; NUCLEOTIDE-SEQUENCE; ENCODING BIPHENYL; CHLOROBIPHENYL DEGRADATION; TRANSPOSON MUTAGENESIS; FUNCTIONAL-ANALYSIS; SOIL BACTERIA; GENE-CLUSTER	Pseudomonas pseudoalcaligenes KF707 possesses a chromosomally encoded bph gene cluster responsible for the catabolism of biphenyl/polychlorinated biphenyls. The gene cluster consists of (orf0)bphA1A-2(orf3)bphA3A4BCX0X1X2X3D. We studied the role of orf0 and transcription in the KF707 bph operon, Primer extension analyses revealed that at least as many as six transcriptional initiation sites exist upstream of orf0, bphA1, bphX0, bphX1, and bphD, including two upstream of bphD. The orf0-disruptant failed to grow on biphenyl but accumulated large amounts of the biphenyl ring meta-cleavage yellow compound (2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoate). Western blot analysis revealed that ORF0 protein is inducibly expressed in KF707 in the presence of biphenyl. Gel shift assay revealed that ORFO directly binds to the orf0 operator region, This binding was greatly enhanced by addition of the biphenyl ring meta-cleavage yellow compound. These results indicated that orf0, bphA1A2(orf3)bphA3A4BC and bphX0X1X2X3D are independently transcribed, and that ORFO protein belonging to the GntR family is involved in the regulation of the bph operon in KF707 and is absolutely required for the expression of orf0 and bphX0X1X2X3D.	Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Appl Microbiol Lab, Fukuoka 8128581, Japan	Kyushu University	Furukawa, K (corresponding author), Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Appl Microbiol Lab, Hakozaki 6-10-1, Fukuoka 8128581, Japan.	kfurukaw@agr.kyushu-u.ac.jp	KENSUKE, FURUKAWA/R-3105-2019; Kimura, Nobutada/D-5399-2017	Kimura, Nobutada/0000-0003-1483-0024				ALLISON SL, 1990, J BACTERIOL, V172, P5470, DOI 10.1128/jb.172.9.5470-5476.1990; Arai H, 1999, MOL MICROBIOL, V33, P1132, DOI 10.1046/j.1365-2958.1999.01554.x; Ausubel FM, 1994, CURRENT PROTOCOLS MO; ERICKSON BD, 1992, J BACTERIOL, V174, P2903, DOI 10.1128/JB.174.9.2903-2912.1992; FUJITA Y, 1987, P NATL ACAD SCI USA, V84, P4524, DOI 10.1073/pnas.84.13.4524; FUJITA Y, 1990, FEBS LETT, V267, P71, DOI 10.1016/0014-5793(90)80290-Y; FURUKAWA K, 1987, J BACTERIOL, V169, P427, DOI 10.1128/jb.169.1.427-429.1987; FURUKAWA K, 1991, GENE, V98, P21; FURUKAWA K, 1986, J BACTERIOL, V166, P392, DOI 10.1128/jb.166.2.392-398.1986; Habig W H, 1981, Methods Enzymol, V77, P398; HAYASE N, 1990, J BACTERIOL, V172, P1160, DOI 10.1128/jb.172.2.1160-1164.1990; HAYDON DJ, 1991, FEMS MICROBIOL LETT, V79, P291, DOI 10.1016/0378-1097(91)90101-F; HOFER B, 1994, GENE, V144, P9, DOI 10.1016/0378-1119(94)90196-1; HOFER B, 1993, GENE, V130, P47, DOI 10.1016/0378-1119(93)90345-4; IMAJOHOHMI S, 1994, KOUPEPUTIDOKOUTAI JI, P47; KIKUCHI Y, 1994, J BACTERIOL, V176, P1689, DOI 10.1128/jb.176.6.1689-1694.1994; KIKUCHI Y, 1994, J BACTERIOL, V176, P4269, DOI 10.1128/jb.176.14.4269-4276.1994; Kim E, 1996, APPL ENVIRON MICROB, V62, P262, DOI 10.1128/AEM.62.1.262-265.1996; KIM E, 1995, J BACTERIOL, V177, P3095, DOI 10.1128/jb.177.11.3095-3103.1995; KIMBARA K, 1989, J BACTERIOL, V171, P2740, DOI 10.1128/jb.171.5.2740-2747.1989; Kimura N, 1997, J BACTERIOL, V179, P3936, DOI 10.1128/jb.179.12.3936-3943.1997; Labbe D, 1997, J BACTERIOL, V179, P2772, DOI 10.1128/jb.179.8.2772-2776.1997; Lau PCK, 1996, GENE, V171, P53, DOI 10.1016/0378-1119(96)00025-X; Masai E, 1997, GENE, V187, P141, DOI 10.1016/S0378-1119(96)00748-2; MASAI E, 1995, APPL ENVIRON MICROB, V61, P2079, DOI 10.1128/AEM.61.6.2079-2085.1995; Merlin C, 1999, PLASMID, V41, P40, DOI 10.1006/plas.1998.1375; Merlin C, 1997, MOL GEN GENET, V253, P499; Mouz S, 1999, MOL GEN GENET, V262, P790, DOI 10.1007/s004380051142; Nishi A, 2000, J BACTERIOL, V182, P1949, DOI 10.1128/JB.182.7.1949-1955.2000; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHINGLER V, 1992, J BACTERIOL, V174, P711, DOI 10.1128/jb.174.3.711-724.1992; SIMON R, 1989, GENE, V80, P161, DOI 10.1016/0378-1119(89)90262-X; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SPRINGAEL D, 1993, J BACTERIOL, V175, P1674, DOI 10.1128/JB.175.6.1674-1681.1993; TAIRA K, 1992, J BIOL CHEM, V267, P4844; WANG Y, 1995, GENE, V164, P117, DOI 10.1016/0378-1119(95)00448-F; YOSHIDA K, 1995, MOL GEN GENET, V248, P583, DOI 10.1007/BF02423454	37	41	45	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31016	31023		10.1074/jbc.M003023200	http://dx.doi.org/10.1074/jbc.M003023200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10900199	hybrid			2022-12-27	WOS:000089762700041
J	Yorimitsu, T; Asai, Y; Sato, K; Homma, M				Yorimitsu, T; Asai, Y; Sato, K; Homma, M			Intermolecular cross-linking between the periplasmic Loop(3-4) regions of PomA, a component of the Na+-driven flagellar motor of Vibrio alginolyticus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE CHANNEL COMPONENTS; ESCHERICHIA-COLI; SCANNING MUTAGENESIS; AMILORIDE ANALOG; POLAR; PHENAMIL; MOTILITY; PROTEIN; FORCE; MUTATIONS	PomA and PomB form a complex that conducts sodium ions and generates the torque for the Na+-driven polar flagellar motor of Vibrio alginolyticus, PomA has four transmembrane segments. One periplasmic loop (loop,,) connects segments 1 and 2, and another (loop(3-4)), in which cysteine-scanning mutagenesis had been carried out, connects segments 3 and 4, When PomA with an introduced Cys residue (Cys-PomA) in the C-terminal periplasmic loop (loop(3-4)) was examined without exposure to a reducing reagent, a 43-kDa band was observed, whereas only a 25-kDa band, which corresponds to monomeric PomA, was observed under reducing conditions, The intensity of the 43-kDa band was enhanced in most mutants by the oxidizing reagent CuCl2. The 43-kDa band was strongest in the P172C mutant. The motility of the P172C mutant was severely reduced, and P172C showed a dominant-negative effect, whereas substitution of Pro with Ala, Ile, or Ser at this position did not affect motility, In the presence of DTT, the ability to swim was partially restored; and the amount of 43-kDa protein was reduced. These results suggest that the disulfide cross-link disturbs the Reaction of PomA, When the mutated Cys residue was modified with N-ethyhmaleimide, only the 25-kDa PomA band was labeled, demonstrating that the 43-kDa form is a cross-linked homodimer and suggesting that the loops,4 of adjacent subunits of PomA are close to each other in the assembled motor. We propose that this loop region is important for dimer formation and motor function.	Nagoya Univ, Div Biol Sci, Grad Sch Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University	Homma, M (corresponding author), Nagoya Univ, Div Biol Sci, Grad Sch Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan.							Aizawa SI, 1996, MOL MICROBIOL, V19, P1, DOI 10.1046/j.1365-2958.1996.344874.x; Asai Y, 2000, J BACTERIOL, V182, P1001, DOI 10.1128/JB.182.4.1001-1007.2000; Asai Y, 1997, J BACTERIOL, V179, P5104, DOI 10.1128/jb.179.16.5104-5110.1997; Asai Y, 1999, J BACTERIOL, V181, P6332, DOI 10.1128/JB.181.20.6332-6338.1999; BLAIR DF, 1990, CELL, V60, P439, DOI 10.1016/0092-8674(90)90595-6; BLAIR DF, 1995, ANNU REV MICROBIOL, V49, P489, DOI 10.1146/annurev.mi.49.100195.002421; BLAIR DF, 1988, SCIENCE, V242, P1678, DOI 10.1126/science.2849208; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; Furuno M, 1999, MICROBIOL IMMUNOL, V43, P39, DOI 10.1111/j.1348-0421.1999.tb02370.x; Hase CC, 1999, P NATL ACAD SCI USA, V96, P3183, DOI 10.1073/pnas.96.6.3183; Homma M, 1996, MICROBIOL-UK, V142, P2777, DOI 10.1099/13500872-142-10-2777; IMAE Y, 1989, J BIOENERG BIOMEMBR, V21, P705, DOI 10.1007/BF00762688; Jaques S, 1999, P NATL ACAD SCI USA, V96, P5740, DOI 10.1073/pnas.96.10.5740; Kimura T, 1998, BIOCHEMISTRY-US, V37, P5475, DOI 10.1021/bi973188g; Kojima S, 1999, J BACTERIOL, V181, P1927, DOI 10.1128/JB.181.6.1927-1930.1999; Kojima S, 1999, MICROBIOL-UK, V145, P1759, DOI 10.1099/13500872-145-7-1759; Kojima S, 1997, J MOL BIOL, V265, P310, DOI 10.1006/jmbi.1996.0732; Kojima S, 2000, J BACTERIOL, V182, P3314, DOI 10.1128/JB.182.11.3314-3318.2000; Kojima S, 1999, J MOL BIOL, V285, P1537, DOI 10.1006/jmbi.1998.2377; Kubo Y, 1998, FEBS LETT, V435, P69, DOI 10.1016/S0014-5793(98)01038-2; MANSON MD, 1977, P NATL ACAD SCI USA, V74, P3060, DOI 10.1073/pnas.74.7.3060; MCCARTER LL, 1994, J BACTERIOL, V176, P5988, DOI 10.1128/jb.176.19.5988-5998.1994; MCCARTER LL, 1994, J BACTERIOL, V176, P4219, DOI 10.1128/jb.176.14.4219-4225.1994; MURAMOTO K, 1994, J BIOL CHEM, V269, P3374; Okunishi I, 1996, J BACTERIOL, V178, P2409, DOI 10.1128/jb.178.8.2409-2415.1996; PerezGarcia MT, 1996, P NATL ACAD SCI USA, V93, P300, DOI 10.1073/pnas.93.1.300; Sato K, 2000, J BIOL CHEM, V275, P5718, DOI 10.1074/jbc.275.8.5718; Sato K, 2000, J BIOL CHEM, V275, P20223, DOI 10.1074/jbc.M002236200; SHARP LL, 1995, BIOCHEMISTRY-US, V34, P9166, DOI 10.1021/bi00028a028; STOLZ B, 1991, J BACTERIOL, V173, P7033, DOI 10.1128/jb.173.21.7033-7037.1991; Tang H, 1996, J MOL BIOL, V261, P209, DOI 10.1006/jmbi.1996.0453; WILSON ML, 1990, J BACTERIOL, V172, P3932, DOI 10.1128/jb.172.7.3932-3939.1990; Yorimitsu T, 1999, J BACTERIOL, V181, P5103, DOI 10.1128/JB.181.16.5103-5106.1999	33	15	15	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31387	31391		10.1074/jbc.M000848200	http://dx.doi.org/10.1074/jbc.M000848200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10900193	hybrid			2022-12-27	WOS:000089762700090
J	Cheng, LY; Rossi, F; Fang, WZ; Mori, T; Cobrinik, D				Cheng, LY; Rossi, F; Fang, WZ; Mori, T; Cobrinik, D			Cdk2-dependent phosphorylation and functional inactivation of the pRB-related p130 protein in pRB(-), p16(INK4A)(+) tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							E2F TRANSCRIPTION FACTORS; RETINOBLASTOMA GENE-PRODUCT; CYCLIN-DEPENDENT KINASES; S-PHASE ENTRY; HISTONE DEACETYLASE; IN-VIVO; GROWTH SUPPRESSION; NUCLEAR-PROTEIN; MAMMALIAN-CELLS; FAMILY MEMBERS	The retinoblastoma family proteins pRB, p107, and p130 are phosphorylated and released from E2Fs in the late G(1) phase of the cell cycle. This phosphorylation is thought to contribute to the derepression of E2F-responsive genes and to be mediated, in part, by Cdk4 and Cdk6. Evidence that Cdk4/6 activity is inhibited by p16(INK4A) in most pRB(-) cells suggests that p107 and p130 may be underphosphorylated and remain associated with E2Fs during G(1)-S progression in cells that lack pRB. To examine this, we evaluated the cell cycle-dependent phosphorylation and E2F binding abilities of p107 and p130 in pRB(-), p16(+) Saos-2 osteosarcoma cells. p130, but not p107, was phosphorylated and released from E2F-4 in late G(1) and S phase cells, although p130 phosphorylation differed qualitatively in these and other pRB(-), p16(+) cells as compared with pRB(+), p16(-) cell types. p130 phosphorylation occurred in the absence of cyclin D-Cdk4/6 complexes, coincided with cyclin E- and Cdk2-associated kinase activity, and was prevented by expression of dominant negative Cdk2. Moreover, dominant negative Cdk2 prevented the dissociation of endogenous p130-E2F-4 complexes and inhibited E2F-4-dependent transcription. These findings show that p130 can be phosphorylated and functionally inactivated in a Cdk2-dependent process, and they highlight the involvement of distinct Cdks in the regulation of different pRB family proteins.	Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Inst Canc Genet, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Cobrinik, D (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, 630 W 168th St, New York, NY 10032 USA.							Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chesnut JD, 1996, J IMMUNOL METHODS, V193, P17, DOI 10.1016/0022-1759(96)00032-4; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; Chow KNB, 1996, MOL CELL BIOL, V16, P7173; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Cobrinik D, 1996, CURR TOP MICROBIOL, V208, P31; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; Dong F, 1998, J BIOL CHEM, V273, P6190, DOI 10.1074/jbc.273.11.6190; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Helin K, 1997, P NATL ACAD SCI USA, V94, P6933, DOI 10.1073/pnas.94.13.6933; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hofmann F, 1996, GENE DEV, V10, P851, DOI 10.1101/gad.10.7.851; Hoshikawa Y, 1998, P NATL ACAD SCI USA, V95, P8574, DOI 10.1073/pnas.95.15.8574; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; LeCouter JE, 1998, MOL CELL BIOL, V18, P7455, DOI 10.1128/MCB.18.12.7455; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, ONCOGENE, V10, P2125; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magae J, 1996, J CELL SCI, V109, P1717; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MAYOL X, 1993, ONCOGENE, V8, P2561; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Muller H, 1997, MOL CELL BIOL, V17, P5508; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Mulligan GJ, 1998, MOL CELL BIOL, V18, P206, DOI 10.1128/MCB.18.1.206; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Philips A, 1998, ONCOGENE, V16, P1373, DOI 10.1038/sj.onc.1201655; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; QIN XQ, 1995, MOL CELL BIOL, V15, P742; Reed SI, 1997, CANCER SURV, V29, P7; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Starostik P, 1996, MOL CELL BIOL, V16, P3606; Stiegler P, 1998, CANCER RES, V58, P5049; Strober BE, 1996, MOL CELL BIOL, V16, P1576; TAM SW, 1994, ONCOGENE, V9, P2663; TAM SW, 1994, CANCER RES, V54, P5816; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; TSAI LH, 1993, ONCOGENE, V8, P1593; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; YEAGER T, 1995, CANCER RES, V55, P493; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; ZHANG YH, 1995, ONCOGENE, V10, P2085; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	109	38	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30317	30325		10.1074/jbc.M005707200	http://dx.doi.org/10.1074/jbc.M005707200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10906146	hybrid			2022-12-27	WOS:000089577900056
J	Wu, GK; Lee, WH; Chen, PL				Wu, GK; Lee, WH; Chen, PL			NBS1 and TRF1 colocalize at promyelocytic leukemia bodies during late S/G(2) phases in immortalized telomerase-negative cells - Implication of NBS1 in alternative lengthening of telomeres	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIJMEGEN BREAKAGE SYNDROME; DOUBLE-STRAND BREAKS; DNA-DAMAGE RESPONSE; SYNDROME PROTEIN; IN-VITRO; MRE11; REPAIR; COMPLEX; RAD50; RECOMBINATION	Nijmegen breakage syndrome, a chromosomal instability disorder, is characterized in part by cellular hypersensitivity to ionizing radiation. The NBS1 gene product, p95 (NBS1 or nibrin) forms a complex with Rad50 and Mre11. Cells deficient in the formation of this complex are defective in DNA double-strand break repair, cell cycle checkpoint control, and telomere length maintenance. How the NBS1 complex is involved in telomere length maintenance remains unclear. Here we show that the C-terminal region of NBS1 interacts directly with a telomere repeat binding factor, TRF1, by both yeast two-hybrid and in vivo DNA-coimmunoprecipitation assays. NBS1 and Mre11 colocalize with TRF1 at promyelocytic leukemia (PML) nuclear bodies in immortalized telomerase-negative cell lines, but rarely in telomerase-positive cell lines. The translocation of NBS1 to PML bodies occurs specifically during late S to G(2) phases of the cell cycle and coincides with active DNA synthesis in these NBS1-containing PML bodies. These results suggest that NBS1 may be involved in alternative lengthening of telomeres in telomerase-negative immortalized cells.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Chen, PL (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.				NATIONAL CANCER INSTITUTE [P01CA081020, R01CA085605] Funding Source: NIH RePORTER; NCI NIH HHS [CA85605, CA81020] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Colgin LM, 1999, CURR OPIN GENET DEV, V9, P97, DOI 10.1016/S0959-437X(99)80014-8; DETKE S, 1979, P NATL ACAD SCI USA, V76, P4995, DOI 10.1073/pnas.76.10.4995; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; Dong ZW, 1999, J BIOL CHEM, V274, P19513, DOI 10.1074/jbc.274.28.19513; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Featherstone C, 1998, CURR BIOL, V8, pR622, DOI 10.1016/S0960-9822(98)70392-6; Furuse M, 1998, EMBO J, V17, P6412, DOI 10.1093/emboj/17.21.6412; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Le S, 1999, GENETICS, V152, P143; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Moreau S, 1999, MOL CELL BIOL, V19, P556; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Prescott J, 1997, GENE DEV, V11, P528, DOI 10.1101/gad.11.4.528; Prescott JC, 1999, CURR OPIN GENET DEV, V9, P368, DOI 10.1016/S0959-437X(99)80055-0; RAYMOND WE, 1993, NUCLEIC ACIDS RES, V21, P3851, DOI 10.1093/nar/21.16.3851; Reddel RR, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1254; Shore D, 1998, SCIENCE, V281, P1818, DOI 10.1126/science.281.5384.1818; TOBEY RA, 1990, P NATL ACAD SCI USA, V87, P5104, DOI 10.1073/pnas.87.13.5104; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Usui T, 1998, CELL, V95, P705, DOI 10.1016/S0092-8674(00)81640-2; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Yeager TR, 1999, CANCER RES, V59, P4175; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	34	176	182	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30618	30622		10.1074/jbc.C000390200	http://dx.doi.org/10.1074/jbc.C000390200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10913111	hybrid			2022-12-27	WOS:000089577900096
J	Minambres, B; Olivera, ER; Jensen, RA; Luengo, JM				Minambres, B; Olivera, ER; Jensen, RA; Luengo, JM			A new class of glutamate dehydrogenases (GDH) - Biochemical and genetic characterization of the first member, the AMP-requiring NAD-specific GDH of Streptomyces clavuligerus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-LACTAM; CEPHALOSPORIN PRODUCTION; PYROCOCCUS-FURIOSUS; SEQUENCE ALIGNMENT; CLAVULANIC ACID; PURIFICATION; ENZYME; EVOLUTION; SYNTHETASE; MECHANISM	A new class of glutamate dehydrogenase (GDH) is reported. The GDH of Streptomyces clavuligerus was purified to homogeneity and characterized. It has a native molecular mass of 1,100 kDa and exists as an alpha (6) oligomeric structure composed of 183-kDa subunits, GDH, which requires AMP as an essential activator, shows a maximal rate of catalysis in 100 mM phosphate buffer, pH 7.0, at 30 degreesC. Under these conditions, GDH displayed hyperbolic behavior toward ammonia (K-m, 33 mM) and sigmoidal responses to changes in alpha -ketoglutarate (S-0.5 1.3 mM; n(H) 1.50) and NADH (S-0.5 20 mum; n(H) 1.52) concentrations. Aspartate and asparagine were found to be allosteric activators. This enzyme is inhibited by an excess of NADH or NH4+, by some tricarboxylic acid cycle intermediates and by ATP, This GDH seems to be a catabolic enzyme as indicated by the following: (i) it is NAD-specific; (ii) it shows a high value of K-m for ammonia; and (iii) when S. clavuligerus was cultured in minimal medium containing glutamate as the sole source of carbon and nitrogen, a 5-fold increase in specific activity of GDH was detected compared with cultures provided with glycerol and ammonia. GDH has 1,651 amino acids, and it is encoded by a DNA fragment of 4,953 base pairs (gdh gene), It shows strong sequence similarity to proteins encoded by unidentified open reading frames present in the genomes of species belonging to the genera Mycobacterium, Rickettsia, Pseudomonas, Vibrio, Shewanella, and Caulobacter, suggesting that it has a broad distribution. The GDH of S, clavuligerus is the first member of a class of GDHs included in a subfamily of GDHs (large GDHs) whose catalytic requirements and evolutionary implications are described and discussed.	Univ Leon, Dept Bioquim & Biol Mol, Fac Vet, E-24007 Leon, Spain; Los Alamos Natl Lab, Biosci Div, Los Alamos, NM 87545 USA	Universidad de Leon; United States Department of Energy (DOE); Los Alamos National Laboratory	Luengo, JM (corresponding author), Univ Leon, Dept Bioquim & Biol Mol, Fac Vet, E-24007 Leon, Spain.	dbbjlr@unileon.es	Olivera, Elias Rodriguez/Q-1166-2019; OLIVERA, ELIAS RODRIGUEZ/H-6385-2016; Luengo, Jose M./E-1935-2016	Olivera, Elias Rodriguez/0000-0003-2315-8524; OLIVERA, ELIAS RODRIGUEZ/0000-0003-2315-8524; Luengo, Jose M./0000-0002-4984-6256; Minambres Rodriguez, Baltasar/0000-0003-4590-4911				ABEYSINGHE LSB, 1993, THESIS U SHEFFIELD W; AHARONOWITZ Y, 1977, ARCH MICROBIOL, V115, P169, DOI 10.1007/BF00406371; AHARONOWITZ Y, 1979, CAN J MICROBIOL, V25, P61, DOI 10.1139/m79-010; AHARONOWITZ Y, 1978, ANTIMICROB AGENTS CH, V14, P159, DOI 10.1128/AAC.14.2.159; AHARONOWITZ Y, 1980, ARCH MICROBIOL, V125, P137, DOI 10.1007/BF00403210; ANDERSON BM, 1993, ARCH BIOCHEM BIOPHYS, V300, P483, DOI 10.1006/abbi.1993.1065; Bachmann BO, 1998, P NATL ACAD SCI USA, V95, P9082, DOI 10.1073/pnas.95.16.9082; BAKER PJ, 1995, STRUCTURE, V3, P693, DOI 10.1016/S0969-2126(01)00204-0; BAKER PJ, 1992, PROTEINS, V12, P75, DOI 10.1002/prot.340120109; BALDWIN JE, 1988, NAT PROD REP, V5, P129, DOI 10.1039/np9880500129; BARKER HA, 1981, ANNU REV BIOCHEM, V50, P23, DOI 10.1146/annurev.bi.50.070181.000323; BASCARAN V, 1989, J GEN MICROBIOL, V135, P2465; Beaman Blaine L., 1995, P379; BENACHENHOULAHFA N, 1993, J MOL EVOL, V36, P335; BONETE MJ, 1990, BIOCHIM BIOPHYS ACTA, V1041, P305, DOI 10.1016/0167-4838(90)90289-R; Bonete MJ, 1996, BBA-GEN SUBJECTS, V1289, P14, DOI 10.1016/0304-4165(95)00134-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANA AF, 1986, ARCH MICROBIOL, V146, P46, DOI 10.1007/BF00690157; BRANA AF, 1986, J GEN MICROBIOL, V132, P1305; BRITTON KL, 1993, J MOL BIOL, V234, P938, DOI 10.1006/jmbi.1993.1647; Britton KL, 1998, J BIOL CHEM, V273, P9023, DOI 10.1074/jbc.273.15.9023; BRITTON KL, 1992, EUR J BIOCHEM, V209, P851, DOI 10.1111/j.1432-1033.1992.tb17357.x; Britton KL, 1999, J MOL BIOL, V293, P1121, DOI 10.1006/jmbi.1999.3205; Brown JR, 1997, MICROBIOL MOL BIOL R, V61, P456, DOI 10.1128/.61.4.456-502.1997; CONSALVI V, 1991, EUR J BIOCHEM, V196, P459, DOI 10.1111/j.1432-1033.1991.tb15837.x; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DEMAIN AL, 1982, TRENDS ANTIBIOTIC RE, P233; Di Fraia R, 2000, EUR J BIOCHEM, V267, P121, DOI 10.1046/j.1432-1327.2000.00972.x; DUNCAN PA, 1992, APPL ENVIRON MICROB, V58, P4032, DOI 10.1128/AEM.58.12.4032-4037.1992; FAHIEN LA, 1970, METHODS ENZYMOLOGY B, V17, P839; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FITCH WM, 1971, SYST ZOOL, V20, P406, DOI 10.2307/2412116; Galtier N, 1996, COMPUT APPL BIOSCI, V12, P543; HALL T, 2000, BIOEDIT BIOL SEQUENC; HAMMER BA, 1988, ARCH MICROBIOL, V150, P460, DOI 10.1007/BF00422287; HIGGENS CE, 1974, J ANTIBIOT, V27, P298, DOI 10.7164/antibiotics.27.298; HUDSON RC, 1993, COMP BIOCHEM PHYS B, V106, P767, DOI 10.1016/0305-0491(93)90031-Y; JAHNS T, 1993, J GEN MICROBIOL, V139, P775, DOI 10.1099/00221287-139-4-775; JENSEN RA, 1976, ANNU REV MICROBIOL, V30, P409, DOI 10.1146/annurev.mi.30.100176.002205; Jensen RA, 1996, J BACTERIOL, V178, P2161, DOI 10.1128/jb.178.8.2161-2171.1996; KINNAIRD JH, 1983, GENE, V26, P253, DOI 10.1016/0378-1119(83)90195-6; Knapp S, 1997, J MOL BIOL, V267, P916, DOI 10.1006/jmbi.1996.0900; KREMECKOVA H, 1992, J GEN MICROBIOL, V138, P1587, DOI 10.1099/00221287-138-8-1587; LASCU I, 1977, BIOCHIM BIOPHYS ACTA, V482, P251, DOI 10.1016/0005-2744(77)90239-X; LEJOHN HB, 1967, BIOCHEM BIOPH RES CO, V28, P96, DOI 10.1016/0006-291X(67)90412-3; MAULIK P, 1986, EUR J BIOCHEM, V155, P595, DOI 10.1111/j.1432-1033.1986.tb09530.x; MEERS JL, 1970, J GEN MICROBIOL, V64, P187, DOI 10.1099/00221287-64-2-187; MERRICK MJ, 1995, MICROBIOL REV, V59, P604, DOI 10.1128/MMBR.59.4.604-622.1995; Miller PW, 1998, PLANT MOL BIOL, V37, P243, DOI 10.1023/A:1005921018137; Minambres B, 2000, BIOCHEM BIOPH RES CO, V272, P477, DOI 10.1006/bbrc.2000.2709; MINAMBRES B, 1992, J ANTIBIOT, V45, P269, DOI 10.7164/antibiotics.45.269; Mosher RH, 1999, ANTIMICROB AGENTS CH, V43, P1215, DOI 10.1128/AAC.43.5.1215; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NAKATANI Y, 1988, NUCLEIC ACIDS RES, V16, P6237, DOI 10.1093/nar/16.13.6237; *NOM COMM IUB, 1992, ENZ NOM; Olivera ER, 1998, P NATL ACAD SCI USA, V95, P6419, DOI 10.1073/pnas.95.11.6419; PAMULA F, 1992, J GEN MICROBIOL, V138, P1935, DOI 10.1099/00221287-138-9-1935; PEREZPOMARES F, 1999, BIOCHIM BIOPHYS ACTA, V426, P513; Peterson PE, 1999, STRUCTURE, V7, P769, DOI 10.1016/S0969-2126(99)80101-4; READING C, 1977, ANTIMICROB AGENTS CH, V11, P852, DOI 10.1128/AAC.11.5.852; REITZER LJ, 1987, CELLULAR MOL BIOL, V1, P302; RICE DW, 1985, J MOL BIOL, V181, P147, DOI 10.1016/0022-2836(85)90334-1; Saitou N, 1996, METHOD ENZYMOL, V266, P427; SCHMIDT E, 1974, METHOD ENZYMAT AN, V2, P650; Stackebrandt E, 1997, INT J SYST BACTERIOL, V47, P479, DOI 10.1099/00207713-47-2-479; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VERONESE FM, 1975, BIOCHIM BIOPHYS ACTA, V377, P217, DOI 10.1016/0005-2744(75)90304-6; VINING LC, 1987, APPL MICROBIOL BIOT, V27, P240; WEBER K, 1969, J BIOL CHEM, V244, P4406; YAMAMOTO I, 1987, J GEN MICROBIOL, V133, P2773; YIP KSP, 1995, STRUCTURE, V3, P1147, DOI 10.1016/S0969-2126(01)00251-9	71	58	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39529	39542		10.1074/jbc.M005136200	http://dx.doi.org/10.1074/jbc.M005136200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10924516	hybrid			2022-12-27	WOS:000165953100080
J	Gao, ZY; Reavey-Cantwell, J; Young, RA; Jegier, P; Wolf, BA				Gao, ZY; Reavey-Cantwell, J; Young, RA; Jegier, P; Wolf, BA			Synaptotagmin III/VII isoforms mediate Ca2+-induced insulin secretion in pancreatic islet beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EATON MYASTHENIC SYNDROME; GATED CALCIUM CHANNELS; FIRST C-2 DOMAIN; ARACHIDONIC-ACID; MYOINOSITOL 1,4,5-TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; INTRACELLULAR CA-2+; CA2+ OSCILLATIONS; SYNDROME ANTIGEN; PROTEIN-KINASE	Synaptotagmins (Syt) play important roles in Ca2+-induced neuroexocytosis, Insulin secretion of the pancreatic beta -cell is dependent on an increase in intracellular Ca2+; however, Syt involvement in insulin exocytosis is poorly understood. Reverse transcriptase-polymerase chain reaction studies showed the presence of Syt isoforms III, IV, V, and VII in rat pancreatic islets, whereas Syt isoforms I, II, III, TV,V,VII, and VIII were present in insulin-secreting beta TC3 cell. Syt III and VII proteins were identified in rat islets and beta TC3 and RINm5F beta -cells by immunoblotting, Confocal microscopy showed that Syt III and VII co-localized with insulin-containing secretory granules, Two-fold overexpression of Syt III in RINm5F beta -cell (Syt III cell) was achieved by stable transfection, which conferred greater Ca2+ sensitivity for exocytosis, and resulted in increased insulin secretion. Glyceraldehyde + carbachol-induced insulin secretion in Syt III cells was 2.5-fold higher than control empty vector cells, whereas potassium-induced secretion was 6-fold higher. In permeabilized Syt III cells, Ca2+-induced and mastoparan-induced insulin secretion was also increased. In Syt VII-overexpressing RINm5F beta -cells, there was amplification of carbachol-induced insulin secretion in intact cells and of Ca2+-induced and mastoparan-induced insulin secretion in permeabilized cells. In conclusion, Syt III/VII are located in insulin-containing secretory granules, and we suggest that Syt III/VII may be the Ca2+ sensor or one of the Ca2+ sensors for insulin exocytosis of the beta -cell.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Wolf, BA (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 230 John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK019525, R01DK043354, P01DK049814] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49814, DK43354, DK19525] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aspinwall CA, 1999, J BIOL CHEM, V274, P6360, DOI 10.1074/jbc.274.10.6360; Brown H, 2000, DIABETES, V49, P383, DOI 10.2337/diabetes.49.3.383; Butz S, 1999, J BIOL CHEM, V274, P18290, DOI 10.1074/jbc.274.26.18290; Charvin N, 1997, EMBO J, V16, P4591, DOI 10.1093/emboj/16.15.4591; Chen M, 1996, ENDOCRINOLOGY, V137, P2901, DOI 10.1210/en.137.7.2901; Daniel S, 1999, DIABETES, V48, P1686, DOI 10.2337/diabetes.48.9.1686; DAVID P, 1993, NEUROMUSCULAR DISORD, V3, P451, DOI 10.1016/0960-8966(93)90095-2; Davis AF, 1999, NEURON, V24, P363, DOI 10.1016/S0896-6273(00)80850-8; Easom RA, 1999, DIABETES, V48, P675, DOI 10.2337/diabetes.48.4.675; Gao Z, 1999, DIABETES, V48, P1535, DOI 10.2337/diabetes.48.8.1535; Gao ZY, 1998, EUR J NEUROSCI, V10, P2416, DOI 10.1046/j.1460-9568.1998.00252.x; Gao ZY, 1996, DIABETES, V45, P854, DOI 10.2337/diabetes.45.7.854; Harbeck MC, 1996, DIABETES, V45, P711, DOI 10.2337/diabetes.45.6.711; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; HELLMAN B, 1992, BIOCHIM BIOPHYS ACTA, V1113, P295, DOI 10.1016/0304-4157(92)90003-S; Henquin JC, 1998, DIABETES METAB, V24, P30; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; Komatsu M, 1997, DIABETES, V46, P1928, DOI 10.2337/diabetes.46.12.1928; Konrad RJ, 1996, J BIOL CHEM, V271, P24179, DOI 10.1074/jbc.271.39.24179; KONRAD RJ, 1995, J BIOL CHEM, V270, P12869, DOI 10.1074/jbc.270.21.12869; KONRAD RJ, 1992, BIOCHEM J, V287, P283, DOI 10.1042/bj2870283; KONRAD RJ, 1994, BIOCHEMISTRY-US, V33, P13284, DOI 10.1021/bi00249a015; Lang JC, 1997, EMBO J, V16, P5837, DOI 10.1093/emboj/16.19.5837; Lang JC, 1999, EUR J BIOCHEM, V259, P3, DOI 10.1046/j.1432-1327.1999.00043.x; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; LEVEQUE C, 1994, J BIOL CHEM, V269, P6306; LITTLETON JT, 1995, TRENDS NEUROSCI, V18, P177; Major CD, 1999, DIABETES, V48, P1372, DOI 10.2337/diabetes.48.7.1372; MARTINMOUTOT N, 1993, J PHYSIOLOGY-PARIS, V87, P37, DOI 10.1016/0928-4257(93)90022-L; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Mizuta M, 1997, DIABETES, V46, P2002, DOI 10.2337/diabetes.46.12.2002; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; OCONNOR VM, 1993, FEBS LETT, V326, P255, DOI 10.1016/0014-5793(93)81802-7; POLONSKY KS, 1995, DIABETES, V44, P705, DOI 10.2337/diabetes.44.6.705; Pouli AE, 1998, BIOCHEM J, V333, P193, DOI 10.1042/bj3330193; PRENTKI M, 1984, EXPERIENTIA, V40, P1052, DOI 10.1007/BF01971451; Prentki M, 1997, DIABETOLOGIA, V40, pS32, DOI 10.1007/s001250051395; RASMUSSEN H, 1995, ENDOCR REV, V16, P649, DOI 10.1210/er.16.5.649; Sampo B, 2000, P NATL ACAD SCI USA, V97, P3666, DOI 10.1073/pnas.97.7.3666; Seagar M, 1999, PHILOS T ROY SOC B, V354, P289, DOI 10.1098/rstb.1999.0380; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sugita S, 2000, BIOCHEMISTRY-US, V39, P2940, DOI 10.1021/bi9920984; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Tobi D, 1998, RECEPTOR CHANNEL, V6, P89; TURK J, 1987, PROG LIPID RES, V26, P125, DOI 10.1016/0163-7827(87)90010-5; ULLRICH B, 1995, NEUROPHARMACOLOGY, V34, P1371, DOI 10.1016/0028-3908(95)00132-P; ULLRICH B, 1994, NEURON, V13, P1281, DOI 10.1016/0896-6273(94)90415-4; Vance CL, 1999, NEUROSCIENCE, V90, P665, DOI 10.1016/S0306-4522(98)00420-5; Wheeler MB, 1996, ENDOCRINOLOGY, V137, P1340, DOI 10.1210/en.137.4.1340; Wiser O, 1999, P NATL ACAD SCI USA, V96, P248, DOI 10.1073/pnas.96.1.248; WOLF BA, 1985, BIOCHEM J, V227, P965, DOI 10.1042/bj2270965; WOLF BA, 1988, AM J PHYSIOL, V254, pE121, DOI 10.1152/ajpendo.1988.254.2.E121; WOLF BA, 1986, J BIOL CHEM, V261, P3501; WOLLHEIM CB, 1978, J CLIN INVEST, V62, P451, DOI 10.1172/JCI109146; Xu GG, 1999, J BIOL CHEM, V274, P18067, DOI 10.1074/jbc.274.25.18067	56	87	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36079	36085		10.1074/jbc.M004284200	http://dx.doi.org/10.1074/jbc.M004284200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10938083	hybrid			2022-12-27	WOS:000165382000063
J	Oleszewski, M; Gutwein, P; von der Lieth, W; Rauch, U; Altevogt, P				Oleszewski, M; Gutwein, P; von der Lieth, W; Rauch, U; Altevogt, P			Characterization of the L1-neurocan-binding site - Implications for L1-L1 homophilic binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; CHONDROITIN SULFATE PROTEOGLYCANS; NEURITE OUTGROWTH; NERVOUS-TISSUE; N-CAM; NEUROCAN BINDING; L1; BRAIN; EXPRESSION; MUTATIONS	The L1 adhesion molecule is a 200-220-kDa membrane glycoprotein of the Ig superfamily implicated in important neural processes including neuronal cell migration, axon outgrowth, learning, and memory formation. L1 supports hemophilic L1-L1 binding that involves several Ig domains but can also bind with high affinity to the proteoglycan neurocan, it has been reported that neurocan can block hemophilic binding; however, the mechanism of inhibition and the precise binding sites in both molecules have not been determined. By using fusion proteins, site-directed mutagenesis, and peptide blocking experiments, we have characterized the neurocan-binding site in the first Ig-like domain of human L1, Results from molecular modeling suggest that the sequences involved in neurocan binding are localized on the surface of the first Ig domain and largely overlap with the G-F-C beta -strands proposed to interact with the fourth Ig domain during hemophilic binding. This suggests that neurocan may sterically hinder a proper alignment of LI domains. We find that the C-terminal portion of neurocan is sufficient to mediate binding to the first Ig domain of L1, and we suggest that the sushi domain cooperates with a glycosaminoglycan side chain in forming the binding site for L1.	German Canc Res Ctr, Tumor Immunol Programme, D-69120 Heidelberg, Germany; German Canc Res Ctr, Cent Spectroscop Div, D-69120 Heidelberg, Germany; Univ Lund, Dept Expt Pathol, Univ Hosp, S-22185 Lund, Sweden	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Lund University; Skane University Hospital	Altevogt, P (corresponding author), German Canc Res Ctr, Tumor Immunol Programme, G0100,Neuenheimer Feld 280, D-69120 Heidelberg, Germany.							APPEL F, 1993, J NEUROSCI, V13, P4764; Bateman A, 1996, EMBO J, V15, P6050, DOI 10.1002/j.1460-2075.1996.tb00993.x; Beer S, 1999, J CELL SCI, V112, P2667; Brummendorf T, 1998, CURR OPIN NEUROBIOL, V8, P87, DOI 10.1016/S0959-4388(98)80012-3; De Angelis E, 1999, EMBO J, V18, P4744, DOI 10.1093/emboj/18.17.4744; Ebeling O, 1996, EUR J IMMUNOL, V26, P2508, DOI 10.1002/eji.1830261035; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; Fukuda T, 1997, J COMP NEUROL, V382, P141; Grumet M, 1996, PERSPECT DEV NEUROBI, V3, P319; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; GRUMET M, 1994, J BIOL CHEM, V269, P12142; Haspel J, 2000, J NEUROBIOL, V42, P287, DOI 10.1002/(SICI)1097-4695(20000215)42:3<287::AID-NEU1>3.3.CO;2-O; Herndon ME, 1999, GLYCOBIOLOGY, V9, P143, DOI 10.1093/glycob/9.2.143; Hortsch M, 1996, NEURON, V17, P587, DOI 10.1016/S0896-6273(00)80192-0; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; Kamiguchi H, 1998, ANNU REV NEUROSCI, V21, P97, DOI 10.1146/annurev.neuro.21.1.97; Kenwrick S, 1998, BIOESSAYS, V20, P668, DOI 10.1002/(SICI)1521-1878(199808)20:8<668::AID-BIES10>3.0.CO;2-X; Lilien J, 1999, J NEUROSCI RES, V58, P727, DOI 10.1002/(SICI)1097-4547(19991215)58:6<727::AID-JNR1>3.0.CO;2-7; LINDSTROMDINNETZ I, 1995, EUR J BIOCHEM, V230, P920, DOI 10.1111/j.1432-1033.1995.tb20637.x; Margolis RK, 1996, PERSPECT DEV NEUROBI, V3, P273; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; MARGOLIS RU, 1975, BIOCHEMISTRY-US, V14, P85, DOI 10.1021/bi00672a014; MIAO HQ, 1995, J CELL PHYSIOL, V164, P482, DOI 10.1002/jcp.1041640306; Milev P, 1996, J BIOL CHEM, V271, P15716, DOI 10.1074/jbc.271.26.15716; Nolte C, 1999, CELL TISSUE RES, V298, P261, DOI 10.1007/s004419900063; OAKLEY RA, 1991, DEV BIOL, V147, P187, DOI 10.1016/S0012-1606(05)80017-X; Oleszewski M, 1999, J BIOL CHEM, V274, P24602, DOI 10.1074/jbc.274.35.24602; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; OOHIRA A, 1991, J NEUROSCI, V11, P822; OOHIRA A, 1994, NEUROSCI RES, V20, P195, DOI 10.1016/0168-0102(94)90088-4; Pancook JD, 1997, J IMMUNOL, V158, P4413; PERRIS R, 1991, DEVELOPMENT, V111, P583; PINDZOLA RR, 1993, DEV BIOL, V156, P34, DOI 10.1006/dbio.1993.1057; Rauch U, 1997, J BIOL CHEM, V272, P26905, DOI 10.1074/jbc.272.43.26905; RAUCH U, 1991, J BIOL CHEM, V266, P14785; Retzler C, 1996, J BIOL CHEM, V271, P27304, DOI 10.1074/jbc.271.44.27304; ROSENTHAL A, 1992, NAT GENET, V2, P107, DOI 10.1038/ng1092-107; Schachner M, 1997, CURR OPIN CELL BIOL, V9, P627, DOI 10.1016/S0955-0674(97)80115-9; Schaefer AW, 1999, J BIOL CHEM, V274, P37965, DOI 10.1074/jbc.274.53.37965; SCHUCH U, 1989, NEURON, V3, P13, DOI 10.1016/0896-6273(89)90111-6; Schwartz NB, 1999, PROG NUCLEIC ACID RE, V62, P177; Su XD, 1998, SCIENCE, V281, P991, DOI 10.1126/science.281.5379.991; Takeda Y, 1996, J NEUROCHEM, V66, P2338; Talts U, 2000, EXP CELL RES, V259, P378, DOI 10.1006/excr.2000.4987; UJITA M, 1994, J BIOL CHEM, V269, P27603; VITS L, 1994, NAT GENET, V7, P408, DOI 10.1038/ng0794-408; Yang BL, 2000, J BIOL CHEM, V275, P21255, DOI 10.1074/jbc.M001443200	47	39	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34478	34485		10.1074/jbc.M004147200	http://dx.doi.org/10.1074/jbc.M004147200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10934197	hybrid			2022-12-27	WOS:000165095300065
J	Farzan, M; Vasilieva, N; Schnitzler, CE; Chung, S; Robinson, J; Gerard, NP; Gerard, C; Choe, H; Sodroski, J				Farzan, M; Vasilieva, N; Schnitzler, CE; Chung, S; Robinson, J; Gerard, NP; Gerard, C; Choe, H; Sodroski, J			A tyrosine-sulfated peptide based on the N terminus of CCR5 interacts with a CD4-enhanced epitope of the HIV-1 gp120 envelope glycoprotein and inhibits HIV-1 entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CD4 BINDING-SITE; GENETIC RESTRICTION; INFECTION; RECEPTOR; CORECEPTOR; ANTIBODY; 7-TRANSMEMBRANE; INDIVIDUALS; AIDS	The sequential association of the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein gp120 with CD4 and a seven-transmembrane segment coreceptor such as CC RB or CXCR4 initiates entry of the virus into its target cell. The N terminus of CCR5, which contains several sulfated tyrosines, plays a critical role in the CD4-dependent association of gp120 with CCR5 and in viral entry. Here we demonstrate that a tyrosine-sulfated peptide based on the N terminus of CCR5, but not its unsulfated analogue, inhibits infection of macrophages and peripheral blood mononuclear cells by CCR5-dependent, but not CXCR4-dependent, HIV-1 isolates. The sulfated peptide also inhibited the association of CCR5-expressing cells with gp120-soluble CD4 complexes and, less efficiently, with MIP-1 alpha. Moreover, this peptide inhibited the precipitation of gp120 by 48d and 23e antibodies, which recognize CD4-inducible gp120 epitopes, but not by several other antibodies that recognize proximal epitopes, The ability of the sulfated peptide to block 48d association with gp120 was dependent in part on seven tropism-determining residues in the third variable (V3) and fourth conserved (C4) domains of gp120, These data underscore the important role of the N-terminal sulfate moieties of CCR5 in the entry of R5 HIV-1 isolates and Localize a critical contact between gp120 and CCR5.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Sch Publ Hlth, Dept Canc Biol, Boston, MA 02115 USA; Childrens Hosp, Dept Pediat, Perlmutter Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Beth Israel Hosp, Dept Med, Boston, MA 02115 USA; Tulane Univ, Med Ctr, Dept Pediat, New Orleans, LA 70112 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Tulane University	Farzan, M (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 4 Binney St, Boston, MA 02115 USA.		Schnitzler, Christine/G-8733-2013	Farzan, Michael/0000-0002-2990-5319; Schnitzler, Christine/0000-0002-5001-6524	NIAID NIH HHS [AI28691, R01 AI043891, AI41851, AI43891] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043891, R01AI041851, P30AI028691] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBAS CF, 1993, J MOL BIOL, V230, P812, DOI 10.1006/jmbi.1993.1203; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Carrillo A, 1996, J VIROL, V70, P1301, DOI 10.1128/JVI.70.2.1301-1309.1996; Choe H, 1998, J VIROL, V72, P6113, DOI 10.1128/JVI.72.7.6113-6118.1998; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; Cormier EG, 2000, P NATL ACAD SCI USA, V97, P5762, DOI 10.1073/pnas.97.11.5762; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1997, NATURE, V388, P296, DOI 10.1038/40894; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1998, J VIROL, V72, P279, DOI 10.1128/JVI.72.1.279-285.1998; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; Farzan M, 1997, J EXP MED, V186, P405, DOI 10.1084/jem.186.3.405; Farzan M, 1998, J VIROL, V72, P1160, DOI 10.1128/JVI.72.2.1160-1164.1998; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FREED EO, 1995, J BIOL CHEM, V270, P23883, DOI 10.1074/jbc.270.41.23883; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; Horuk R, 1998, J BIOL CHEM, V273, P386, DOI 10.1074/jbc.273.1.386; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Mirzabekov T, 1999, J BIOL CHEM, V274, P28745, DOI 10.1074/jbc.274.40.28745; Moore JP, 1996, J VIROL, V70, P1863, DOI 10.1128/JVI.70.3.1863-1872.1996; POSNER MR, 1993, J ACQ IMMUN DEF SYND, V6, P7; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; ROBEN P, 1994, J VIROL, V68, P4821, DOI 10.1128/JVI.68.8.4821-4828.1994; Ross TM, 1998, J VIROL, V72, P1918, DOI 10.1128/JVI.72.3.1918-1924.1998; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1997, J BIOL CHEM, V272, P24934, DOI 10.1074/jbc.272.40.24934; SULLIVAN N, 1993, J VIROL, V67, P3674, DOI 10.1128/JVI.67.6.3674-3679.1993; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Winkler C, 1998, SCIENCE, V279, P389, DOI 10.1126/science.279.5349.389; WU L, 1996, NATURE, V184, P179; WYATT R, 1993, J VIROL, V67, P4557, DOI 10.1128/JVI.67.8.4557-4565.1993	38	134	147	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33516	33521		10.1074/jbc.M007228200	http://dx.doi.org/10.1074/jbc.M007228200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10938094	hybrid			2022-12-27	WOS:000090104600048
J	Friesen, RHE; Knol, J; Poolman, B				Friesen, RHE; Knol, J; Poolman, B			Quaternary structure of the lactose transport protein of Streptococcus thermophilus in the detergent-solubilized and membrane-reconstituted state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PERMEASE; LIPOSOMES; MOLECULES; MONOMER; BINDING; FAMILY; DOMAIN	The quaternary structure of LacS, the lactose transporter of Streptococcus thermophilus, has been determined for the detergent-solubilized and the membrane-reconstituted state of the protein. The quaternary structure of the n-dodecyl-beta -D-maltoside-solubilized state was studied using a combination of sedimentation velocity and equilibrium centrifugation analysis. From these measurements it followed that the detergent-solubilized LacS undergoes reversible self-association with a monomer to dimer mode of association. The association constants were 5.4 +/- 3.6 and 4.4 +/- 1.0 ml mg(-1) as determined from the velocity and equilibrium sedimentation measurements, respectively. The experiments did not indicate significant changes in the shape of the protein-detergent complex or the amount of detergent bound in going from the monomeric to dimeric state of LacS. Importantly, a single Cys mutant of LacS is labeled by 2-(4'-maleimidylanilino)naphthalene-6-sulfonic acid in a substrate-dependent manner, indicating that the detergent-solubilized protein exhibits ligand binding activity. The quaternary structure of membrane-reconstituted LacS was determined by freeze-fracture electron microscopy analysis. Recent developments in the analysis of freeze-fracture images (Eskandari, S, P,, Wright, E, Ri,, Freman, M., Starace, D, M,, and Zampighi, G. A. (1998) Proc. Natl. Acad, Sci, U, S, A. 95, 11235-11240) allowed us to directly correlate the cross-sectional area of the transmembrane segment to a dimeric state of the functionally membrane-reconstituted LacS protein. The cross-sectional area of the LacS protein was calibrated using the membrane-reconstituted transmembrane domain of the mannitol transporter enzyme II, an intramembrane particle for which the cross-sectional area was obtained from maps of two-dimensional crystals. The consequences of the determined quaternary structure for the transport function and regulation of LacS are discussed.	Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands	University of Groningen	Poolman, B (corresponding author), Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.		Knol, Jan/AAL-6487-2020; Poolman, Bert/D-1882-2012; Knol, Jan/A-2178-2010	Knol, Jan/0000-0002-2103-5961; Knol, Jan/0000-0002-2103-5961				AMBUDKAR SV, 1990, J BIOL CHEM, V265, P12287; AQUILA H, 1987, FEBS LETT, V212, P1, DOI 10.1016/0014-5793(87)81546-6; ARISAKA F, 1979, J MOL BIOL, V134, P41, DOI 10.1016/0022-2836(79)90413-3; Cann J. R., 1970, INTERACTING MACROMOL; CASASSA EF, 1964, ADV PROTEIN CHEM, V19, P287, DOI 10.1016/S0065-3233(08)60191-6; CHEN CC, 1986, P NATL ACAD SCI USA, V83, P2652, DOI 10.1073/pnas.83.8.2652; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; COSTELLO MJ, 1983, J MICROSC-OXFORD, V125, P125; Eskandari S, 1998, P NATL ACAD SCI USA, V95, P11235, DOI 10.1073/pnas.95.19.11235; GRASBERGER B, 1986, P NATL ACAD SCI USA, V83, P6258, DOI 10.1073/pnas.83.17.6258; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Knol J, 1998, BIOCHEMISTRY-US, V37, P16410, DOI 10.1021/bi981596u; Knol J, 1996, J BIOL CHEM, V271, P15358, DOI 10.1074/jbc.271.26.15358; Koning RI, 1999, J MOL BIOL, V287, P845, DOI 10.1006/jmbi.1999.2650; Lamm O., 1929, ARK MAT ASTR FYS, V21B, P1; LEACH SJ, 1960, J AM CHEM SOC, V82, P4790, DOI 10.1021/ja01503a008; LEMAIRE M, 1983, BIOCHIM BIOPHYS ACTA, V722, P150, DOI 10.1016/0005-2728(83)90168-8; LIAO DI, 1991, BIOCHEMISTRY-US, V30, P9583, DOI 10.1021/bi00104a004; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOLLER JV, 1993, J BIOL CHEM, V268, P18659; NICHOL LW, 1964, PROTEINS; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Poolman B, 1996, MOL MICROBIOL, V19, P911, DOI 10.1046/j.1365-2958.1996.397949.x; Pourcher T, 1996, BIOCHEMISTRY-US, V35, P4161, DOI 10.1021/bi9527496; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P213, DOI 10.1016/0010-4655(82)90173-4; ROARK DE, 1969, ANN NY ACAD SCI, V164, P245, DOI 10.1111/j.1749-6632.1969.tb14043.x; SAHINTOTH M, 1994, P NATL ACAD SCI USA, V91, P5421, DOI 10.1073/pnas.91.12.5421; SCHUBERT D, 1994, PROG COLL POL SCI S, V94, P14; Spooner PJR, 2000, BIOPHYS J, V79, P756, DOI 10.1016/S0006-3495(00)76333-8; Spooner PJR, 1999, BIOCHEMISTRY-US, V38, P9634, DOI 10.1021/bi990745l; TANFORD C, 1974, BIOCHEMISTRY-US, V13, P2369, DOI 10.1021/bi00708a021; Veenhoff LM, 1999, J BIOL CHEM, V274, P33244, DOI 10.1074/jbc.274.47.33244; VERKLEIJ AJ, 1978, BIOCHIM BIOPHYS ACTA, V515, P303, DOI 10.1016/0304-4157(78)90017-5; WAGNER R, 1989, EUR J BIOCHEM, V182, P165, DOI 10.1111/j.1432-1033.1989.tb14813.x; WRIGHT JK, 1983, FEBS LETT, V162, P11; WU JH, 1994, PROTEIN SCI, V3, P2294, DOI 10.1002/pro.5560031214	36	38	38	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33527	33535		10.1074/jbc.M004066200	http://dx.doi.org/10.1074/jbc.M004066200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10921919	Green Published, hybrid			2022-12-27	WOS:000090104600050
J	Du, J; Alsayed, YM; Xin, F; Ackerman, SJ; Platanias, LC				Du, J; Alsayed, YM; Xin, F; Ackerman, SJ; Platanias, LC			Engagement of the CrkL adapter in interleukin-5 signaling in eosinophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-5 RECEPTOR-ALPHA; COLONY-STIMULATING FACTOR; MAP KINASE ACTIVATION; EXCHANGE FACTOR C3G; MYELOID CELL-LINE; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; CYTOPLASMIC DOMAIN; GROWTH-FACTOR; SUBUNIT GENE	Interleukin-5 (IL-5) drives the terminal differentiation of myeloid progenitors to the eosinophil lineage; blocks eosinophil apoptosis; and primes eosinophils for enhanced functional activities in allergic, parasitic, and other eosinophil-associated diseases. Here we describe a novel signaling pathway activated by the IL-5 receptor in eosinophils involving the CrkL adapter protein. We determined whether IL-5 induces activation of CrkL, and STAT5 in eosinophils using both the human eosinophil-differentiated AML14.3D10 cell line and purified peripheral blood eosinophils from normal donors. Stimulation of AML14.3D10 cells or blood eosinophils with IL-5 induced rapid tyrosine phosphorylation of the CrkL adapter and STAT5 and the association of CrkL and STAT5 in vivo as evidenced by the detection of STAT5 in anti-CrkL immunoprecipitates. The resulting CrkL.STAT5 complexes translocated to the nucleus and bound STAT5 consensus DNA-binding sites present in the promoters of IL-5-regulated genes, as shown in gel mobility and antibody supershift assays. IL-5 also induced marked activity of an 8X-GAS (interferon gamma -activated site)-luciferase reporter construct in transient transfections of AML14.3D10 eosinophils, demonstrating that these complexes play a functional role in IL-5 signaling. CrkT, was also found to interact, via its N-terminal SH3 domain, with C3G, a guanine exchange factor for the small G-protein Rap1, which was also rapidly activated in an IL-5-dependent manner in these cells, establishing that CrkL mediates downstream activation of at least two signaling cascades in IL-5-stimulated eosinophils. Thus, the CrkL adapter plays an important role in IL-5 signaling in the eosinophil, acting as a nuclear adapter for STAT5 and as an upstream regulator of the C3G-Rap1 signaling pathway.	Univ Illinois, Coll Med A312, Dept Biochem & Mol Biol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Med, Hematol Oncol Sect, Chicago, IL 60612 USA; W Side Vet Affairs Med Ctr, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Ackerman, SJ (corresponding author), Univ Illinois, Coll Med A312, Dept Biochem & Mol Biol, 1819 W Polk St,MC536, Chicago, IL 60612 USA.				NCI NIH HHS [CA77816] Funding Source: Medline; NIAID NIH HHS [AI33043, AI25230] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077816] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033043, R01AI025230] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adachi T, 1999, J IMMUNOL, V162, P1496; Adachi T, 1999, J IMMUNOL, V163, P939; Adachi T, 1998, AM J PHYSIOL-CELL PH, V275, pC623, DOI 10.1152/ajpcell.1998.275.3.C623; Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; ALAM R, 1995, INT ARCH ALLERGY IMM, V107, P226, DOI 10.1159/000236985; Alsayed Y, 2000, J IMMUNOL, V164, P1800, DOI 10.4049/jimmunol.164.4.1800; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Arai A, 1999, BLOOD, V93, P3713, DOI 10.1182/blood.V93.11.3713.411a36_3713_3722; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; Baumann MA, 1997, METHODS, V11, P88, DOI 10.1006/meth.1996.0392; Baumann MA, 1998, STEM CELLS, V16, P16, DOI 10.1002/stem.160016; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Bracke M, 1998, J IMMUNOL, V161, P6768; Caldenhoven E, 1998, STEM CELLS, V16, P397, DOI 10.1002/stem.160397; Cameron L, 2000, J IMMUNOL, V164, P1538, DOI 10.4049/jimmunol.164.3.1538; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; Dijkers PF, 1999, ONCOGENE, V18, P3334, DOI 10.1038/sj.onc.1202678; Fish EN, 1999, J BIOL CHEM, V274, P571, DOI 10.1074/jbc.274.2.571; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; GALLI SJ, 1994, CL ALLER IM, V2, P255; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; Heaney C, 1997, BLOOD, V89, P297, DOI 10.1182/blood.V89.1.297.297_297_306; HER E, 1991, J CLIN INVEST, V88, P1982, DOI 10.1172/JCI115524; Horie S, 1996, J ALLERGY CLIN IMMUN, V98, P371, DOI 10.1016/S0091-6749(96)70161-6; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Huston MM, 1996, J IMMUNOL, V156, P1392; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; Koenderman L, 1996, EUR RESPIR J, V9, pS119; Kopf M, 1996, IMMUNITY, V4, P15, DOI 10.1016/S1074-7613(00)80294-0; Kouro T, 1996, INT IMMUNOL, V8, P237, DOI 10.1093/intimm/8.2.237; Koval AP, 1998, J BIOL CHEM, V273, P14780, DOI 10.1074/jbc.273.24.14780; Lopez A F, 1992, Immunol Ser, V57, P549; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MILTENYI S, 1990, CYTOMETRY, V11, P231, DOI 10.1002/cyto.990110203; MIYAJIMA A, 1993, BLOOD, V82, P1960; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; Nosaka Y, 1999, J BIOL CHEM, V274, P30154, DOI 10.1074/jbc.274.42.30154; Oda A, 1998, BLOOD, V92, P443, DOI 10.1182/blood.V92.2.443.414k25_443_451; Ogata N, 1997, INT ARCH ALLERGY IMM, V114, P24, DOI 10.1159/000237712; Ogata N, 1998, BLOOD, V91, P2264, DOI 10.1182/blood.V91.7.2264.2264_2264_2271; Ozaki K, 1998, BLOOD, V92, P4652; PAUL CC, 1994, J LEUKOCYTE BIOL, V56, P74, DOI 10.1002/jlb.56.1.74; Paul CC, 1997, AM J HEMATOL, V56, P79, DOI 10.1002/(SICI)1096-8652(199710)56:2<79::AID-AJH2>3.0.CO;2-Y; PAUL CC, 1995, BLOOD, V86, P3737, DOI 10.1182/blood.V86.10.3737.bloodjournal86103737; PAUL CC, 1993, BLOOD, V81, P1193; PAZDRAK K, 1995, J IMMUNOL, V155, P397; Pazdrak K, 1997, J EXP MED, V186, P561, DOI 10.1084/jem.186.4.561; PAZDRAK K, 1995, J EXP MED, V181, P1827, DOI 10.1084/jem.181.5.1827; Pazdrak K, 1998, J EXP MED, V188, P421, DOI 10.1084/jem.188.3.421; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Rhodes J, 2000, EXP HEMATOL, V28, P305, DOI 10.1016/S0301-472X(99)00148-4; Ribon V, 1996, MOL CELL BIOL, V16, P45; Robinson DS, 1999, INT ARCH ALLERGY IMM, V118, P98, DOI 10.1159/000024039; Sanderson C J, 1990, Immunol Ser, V49, P231; SANDERSON CJ, 1991, INT ARCH ALLER A IMM, V94, P122, DOI 10.1159/000235342; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; Sehmi R, 1997, J CLIN INVEST, V100, P2466, DOI 10.1172/JCI119789; SILBERSTEIN DS, 1989, HEMATOL ONCOL CLIN N, V3, P511, DOI 10.1016/S0889-8588(18)30545-8; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; Sun Z, 1996, CURR TOP MICROBIOL, V211, P173; SUN ZJ, 1995, J BIOL CHEM, V270, P1462, DOI 10.1074/jbc.270.3.1462; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; TAKAKI S, 1993, J EXP MED, V177, P1523, DOI 10.1084/jem.177.6.1523; TAKATSU K, 1994, ADV IMMUNOL, V57, P145, DOI 10.1016/S0065-2776(08)60673-2; TAKATSU K, 1988, IMMUNOL REV, V102, P107, DOI 10.1111/j.1600-065X.1988.tb00743.x; TAKATSU K, 1992, ANN NY ACAD SCI, V651, P241; Tavernier J, 2000, BLOOD, V95, P1600, DOI 10.1182/blood.V95.5.1600.005k22_1600_1607; TAVERNIER J, 1995, AGENT ACTION SUPPL, V46, P23; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TENHOEVE J, 1993, ONCOGENE, V8, P2469; TOMINAGA A, 1991, J EXP MED, V173, P429, DOI 10.1084/jem.173.2.429; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; VanderBruggen T, 1996, CLIN EXP ALLERGY, V26, P880, DOI 10.1046/j.1365-2222.1996.d01-391.x; VANDERBRUGGEN T, 1995, BLOOD, V85, P1442, DOI 10.1182/blood.V85.6.1442.bloodjournal8561442; vanDijk TB, 1997, FEBS LETT, V412, P161, DOI 10.1016/S0014-5793(97)00768-0; Ward AC, 2000, BLOOD, V95, P19; YAMAGUCHI Y, 1988, J EXP MED, V167, P43, DOI 10.1084/jem.167.1.43; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737; YAMAGUCHI Y, 1991, BLOOD, V78, P2542; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zimmermann N, 2000, J IMMUNOL, V164, P1055, DOI 10.4049/jimmunol.164.2.1055; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	85	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33167	33175		10.1074/jbc.M003655200	http://dx.doi.org/10.1074/jbc.M003655200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10926930	hybrid			2022-12-27	WOS:000090003800106
J	Hebert, SS; Daviau, A; Grondin, G; Latreille, M; Aubin, RA; Blouin, R				Hebert, SS; Daviau, A; Grondin, G; Latreille, M; Aubin, RA; Blouin, R			The mixed lineage kinase DLK is oligomerized by tissue transglutaminase during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUN NH2-TERMINAL KINASE; PROTEIN-KINASE; CALPHOSTIN-C; SIGNAL-TRANSDUCTION; CELL-DEATH; ZPK GENE; MOLECULAR-CLONING; BINDING-PROTEINS; GOLGI-APPARATUS; EMERGING ROLES	Current evidence suggests that the mixed lineage kinase family member dual leucine zipper-bearing kinase (DLK) might play a significant role in the regulation of cell growth and differentiation, particularly during the process of tissue remodeling. To further explore this working model, we have investigated the regulation of host and recombinant DLK in NIH3T3 and COS-1 cells undergoing apoptosis, Using calphostin C, a potent and selective inhibitor of protein kinase C and a recognized apoptosis inducer for various cell types, we demonstrate, by immunoblot analysis, that DLK protein levels are rapidly and dramatically down-regulated during the early phases of apoptosis, Down-regulation in calphostin C-treated cells was also accompanied by the appearance of SDS- and mercaptoethanol-resistant high molecular weight DLK immunoreactive oligomers, Experiments aimed at elucidating the mechanism(s) underlying DLK oligomerization revealed that the tissue transglutaminase (tTG) inhibitor monodansylcadaverine antagonized the effects of calphostin C almost completely, thereby suggesting the involvement of a tTG-catalyzed reaction as the root cause of DLK downregulation and accumulation as high molecular weight species. In support of this notion, we also show that DLK can serve as a substrate for tTG-dependent cross-linking in vitro and that this covalent post-translational modification leads to the functional inactivation of DLK, Taken together, these observations suggest that transglutamination and oligomerization may constitute a relevant physiological mechanism for the regulation of DLK activity.	Univ Sherbrooke, Dept Biol, Fac Sci, Ctr Rech Mecanismes Express Genet, Sherbrooke, PQ J1K 2R1, Canada; Sante Canada, Program Prod Therapeut, Bur Prod Biol & Radiopharmaceut, Div Serv Rech Biotechnol, Ottawa, ON K1A 0L2, Canada	University of Sherbrooke	Blouin, R (corresponding author), Univ Sherbrooke, Dept Biol, Fac Sci, Ctr Rech Mecanismes Express Genet, 2500 Blvd Univ, Sherbrooke, PQ J1K 2R1, Canada.	rblouin@courrier.usherb.ca	Hébert, Sébastien S./Q-2729-2017	Latreille, Mathieu/0000-0001-8542-749X; Hebert, Sebastien/0000-0002-0391-9325				Alonso M, 1998, EUR J CELL BIOL, V76, P93, DOI 10.1016/S0171-9335(98)80021-6; Autuori F, 1998, Adv Biochem Eng Biotechnol, V62, P129, DOI 10.1007/BFb0102308; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bergeron P, 1997, BIOCHEM BIOPH RES CO, V231, P153, DOI 10.1006/bbrc.1997.6073; Blouin R, 1996, DNA CELL BIOL, V15, P631, DOI 10.1089/dna.1996.15.631; BROWN WJ, 1989, METHOD CELL BIOL, V31, P553; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; Cockcroft S, 1999, CHEM PHYS LIPIDS, V98, P23, DOI 10.1016/S0009-3084(99)00015-8; CORDELLAMIELE E, 1990, J BIOL CHEM, V265, P17180; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Donaldson JG, 2000, CELL, V101, P693, DOI 10.1016/S0092-8674(00)80881-8; DOROW DS, 1995, EUR J BIOCHEM, V234, P492, DOI 10.1111/j.1432-1033.1995.492_b.x; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; Douziech M, 1999, J HISTOCHEM CYTOCHEM, V47, P1287, DOI 10.1177/002215549904701008; Douziech M, 1998, BIOCHEM BIOPH RES CO, V249, P927, DOI 10.1006/bbrc.1998.9249; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; EZOE K, 1994, ONCOGENE, V9, P935; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Frutos S, 1999, J BIOL CHEM, V274, P10765, DOI 10.1074/jbc.274.16.10765; GALLO KA, 1994, J BIOL CHEM, V269, P15092; GERMAIN L, 2000, IN PRESS J INVEST DE; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; GORDGE PC, 1994, CELL SIGNAL, V6, P871, DOI 10.1016/0898-6568(94)90020-5; Hirai S, 1996, ONCOGENE, V12, P641; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; IKEMOTO H, 1995, J NEUROSURG, V83, P1008, DOI 10.3171/jns.1995.83.6.1008; ING YL, 1994, ONCOGENE, V9, P1745; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jarpe MB, 1998, ONCOGENE, V17, P1475, DOI 10.1038/sj.onc.1202183; KATOH M, 1995, ONCOGENE, V10, P1447; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Matsui N, 1996, BIOCHEM BIOPH RES CO, V229, P571, DOI 10.1006/bbrc.1996.1845; Mayne GC, 1998, J BIOL CHEM, V273, P24115, DOI 10.1074/jbc.273.37.24115; Melino G, 1998, FEBS LETT, V430, P59, DOI 10.1016/S0014-5793(98)00521-3; Melino G, 1997, EXP CELL RES, V235, P55, DOI 10.1006/excr.1997.3656; Merritt SE, 1999, J BIOL CHEM, V274, P10195, DOI 10.1074/jbc.274.15.10195; Nadeau A, 1997, J HISTOCHEM CYTOCHEM, V45, P107, DOI 10.1177/002215549704500114; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Oliverio S, 1999, J BIOL CHEM, V274, P34123, DOI 10.1074/jbc.274.48.34123; Ozaki I, 1999, J BIOL CHEM, V274, P5310, DOI 10.1074/jbc.274.9.5310; Patrick GN, 1998, J BIOL CHEM, V273, P24057, DOI 10.1074/jbc.273.37.24057; Piredda L, 1999, FASEB J, V13, P355, DOI 10.1096/fasebj.13.2.355; Pollack IF, 1997, J NEURO-ONCOL, V31, P255, DOI 10.1023/A:1005729626354; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Rasmussen RK, 1998, BIOCHEM J, V335, P119, DOI 10.1042/bj3350119; Reddy UR, 1999, ONCOGENE, V18, P4474, DOI 10.1038/sj.onc.1202813; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613, DOI 10.1006/bbrc.1994.1972; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sakuma H, 1997, J BIOL CHEM, V272, P28622, DOI 10.1074/jbc.272.45.28622; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Thomazy VA, 1999, CELL DEATH DIFFER, V6, P146, DOI 10.1038/sj.cdd.4400464; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Zhang HF, 1999, EXP CELL RES, V247, P133, DOI 10.1006/excr.1998.4329; Zhu DM, 1998, CLIN CANCER RES, V4, P2967	63	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32482	32490		10.1074/jbc.M006528200	http://dx.doi.org/10.1074/jbc.M006528200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10922377	hybrid			2022-12-27	WOS:000090003800016
J	Keyhani, NO; Wang, LX; Lee, YC; Roseman, S				Keyhani, NO; Wang, LX; Lee, YC; Roseman, S			The chitin disaccharide, N,N '-diacetylchitobiose, is catabolized by Escherichia coli and is transported/phosphorylated by the Phosphoenolpyruvate : Glycose phosphotransferase system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIUM VIBRIO-FURNISSII; MARINE-BACTERIA; MOLECULAR-CLONING; SUGAR-TRANSPORT; PROTEIN FAMILY; HUMAN SERUM; CEL OPERON; SEQUENCE; OLIGOSACCHARIDES; CHITOTRIOSIDASE	We have previously reported that wild type strains of Escherichia coli grow on the chitin disaccharide N,N'-diacetylchitobiose, (GlcNAc)(2), as the sole source of carbon (Keyhani, N. O., and Roseman, S. (1997) Proc. Natl. Acad Sci., U.S. A. 94, 14367-14371). A nonhydrolyzable analogue of (GlcNAc)(2), methyl beta -N, N'-[H-3]diacetyl-thiochitobioside ([H-3]Me-TCB), was used to characterize the disaccharide transport process, which was found to be mediated by the phosphoenolpyruvate:glycose phosphotransferase system (PTS). Here and in the accompanying papers (Keyhani, N. O., Boudker, O., and Roseman, S. (2000) J. Biol. Chem. 275, 33091-33101; Keyhani, N. O., Bacia, K., and Roseman, S. (2000) J. Biol. Chem. 275, 33102-33109; Keyhani, N. O., Rodgers, M., Demeler, B., Hansen, J., and Roseman, S. (2000) J. Biol. Chem. 275, 33110-33115), we report that transport of [H-3]Me-TCB and (GlcNAc), involves a specific PTS Enzyme II complex, requires Enzyme I and HPr of the PTS, and results in the accumulation of the sugar derivative as a phosphate ester. The phosphoryl group is linked to the C-6 position of the GlcNAc residue at the nonreducing end of the disaccharide. The [H-3]Me-TCB uptake system was induced only by (GlcNAc)(n), n = 2 or 3. The apparent K-m of transport was 50-100 muM, and effective inhibitors of uptake included (GlcNAc),, n = 2 or 3, cellobiose, and other PTS sugars, ie. glucose and GlcNAc. Presumably the PTS sugars inhibit by competing for PTS components. Kinetic properties of the transport system are described.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, McCollum Pratt Inst, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Roseman, S (corresponding author), Johns Hopkins Univ, Dept Biol, Mudd Hall,Rm 214,3400 N Charles St, Baltimore, MD 21218 USA.		Wang, Lai-Xi/E-8755-2019; wang, xl/Y-8251-2019; Keyhani, Nemat O/I-8150-2013; Wang, Lai-Xi/E-8790-2019	Wang, Lai-Xi/0000-0003-4293-5819	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009970, R37DK009970] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038759, R37GM038759] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 009970] Funding Source: Medline; NIGMS NIH HHS [GM38759] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASSLER BL, 1991, J BIOL CHEM, V266, P24268; BASSLER BL, 1991, J BIOL CHEM, V266, P24276; BERLIN WK, 1995, TRENDS GLYCOSCI GLYC, V7, P101; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BOOT RG, 1995, J BIOL CHEM, V270, P26252, DOI 10.1074/jbc.270.44.26252; Bouma CL, 1996, J BIOL CHEM, V271, P33457, DOI 10.1074/jbc.271.52.33457; Bouma CL, 1996, J BIOL CHEM, V271, P33468, DOI 10.1074/jbc.271.52.33468; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; ESCOTT GM, 1995, INFECT IMMUN, V63, P4770, DOI 10.1128/IAI.63.12.4770-4773.1995; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; HOROWITZ ST, 1957, J AM CHEM SOC, V79, P5046, DOI 10.1021/ja01575a059; Hu B, 1996, J BIOL CHEM, V271, P19415, DOI 10.1074/jbc.271.32.19415; JEUNIAUX C, 1961, NATURE, V192, P135, DOI 10.1038/192135a0; Keyhani N, 2000, J BIOL CHEM, V275, P33110, DOI 10.1074/jbc.M001717200; Keyhani NO, 2000, J BIOL CHEM, V275, P33102, DOI 10.1074/jbc.M001045200; Keyhani NO, 2000, J BIOL CHEM, V275, P33091, DOI 10.1074/jbc.M001044200; Keyhani NO, 2000, J BIOL CHEM, V275, P33068, DOI 10.1074/jbc.M001041200; Keyhani NO, 1996, J BIOL CHEM, V271, P33409, DOI 10.1074/jbc.271.52.33409; Keyhani NO, 1997, P NATL ACAD SCI USA, V94, P14367, DOI 10.1073/pnas.94.26.14367; KRANTZ MJ, 1976, ANAL BIOCHEM, V71, P318, DOI 10.1016/0003-2697(76)90044-0; KRICKER M, 1987, GENETICS, V115, P419; LAI XK, 1993, J BACTERIOL, V175, P6441, DOI 10.1128/jb.175.20.6441-6450.1993; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDBLAD G, 1979, EUR J BIOCHEM, V100, P455, DOI 10.1111/j.1432-1033.1979.tb04188.x; OVERDIJK B, 1994, GLYCOBIOLOGY, V4, P797, DOI 10.1093/glycob/4.6.797; PALUH JL, 1986, NUCLEIC ACIDS RES, V14, P7851, DOI 10.1093/nar/14.20.7851; Park JK, 2000, J BIOL CHEM, V275, P33077, DOI 10.1074/jbc.M001042200; PARKER LL, 1990, GENETICS, V124, P455; RENKEMA GH, 1995, J BIOL CHEM, V270, P2198, DOI 10.1074/jbc.270.5.2198; Segel IH, 1976, BIOCH CALCULATIONS, P214; Thompson J, 1999, J BACTERIOL, V181, P7339, DOI 10.1128/JB.181.23.7339-7345.1999; WAYGOOD EB, 1979, ANAL BIOCHEM, V95, P293, DOI 10.1016/0003-2697(79)90219-7; YU C, 1993, J BIOL CHEM, V268, P9405; YU C, 1991, J BIOL CHEM, V266, P24260	34	44	48	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33084	33090		10.1074/jbc.M001043200	http://dx.doi.org/10.1074/jbc.M001043200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10913117	hybrid			2022-12-27	WOS:000090003800096
J	Raddatz, R; Wilson, AE; Artymyshyn, R; Bonini, JA; Borowsky, B; Boteju, LW; Zhou, SQ; Kouranova, EV; Nagorny, R; Guevarra, MS; Dai, M; Lerman, GS; Vaysse, PJ; Branchek, TA; Gerald, C; Forray, C; Adham, N				Raddatz, R; Wilson, AE; Artymyshyn, R; Bonini, JA; Borowsky, B; Boteju, LW; Zhou, SQ; Kouranova, EV; Nagorny, R; Guevarra, MS; Dai, M; Lerman, GS; Vaysse, PJ; Branchek, TA; Gerald, C; Forray, C; Adham, N			Identification and characterization of two neuromedin U receptors differentially expressed in peripheral tissues and the central nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE SPINAL-CORD; XENOPUS OOCYTES; GASTROINTESTINAL-TRACT; SEROTONIN RECEPTORS; RAT; IMMUNOREACTIVITY; PRECURSOR; CLONING; GALANIN; BRAIN	Two structurally related, G-protein-coupled receptors were identified as receptors for the neuropeptide, neuromedin U, This peptide is found in highest levels in the gut and genitourinary system where it potently contracts smooth muscle but is also expressed in the spinal cord and discrete regions of the brain. Binding sites for neuromedin U have been characterized in rat uterus, however, little is known about the activity of this peptide in the regions of the central nervous system where it is expressed. The receptors characterized in this report are activated by neuromedin U at nanomolar potency in heterologous expression systems and bind radiolabeled neuromedin U with high affinity. Localization of the receptor RNA by quantitative reverse transcription-polymerase chain reaction in a variety of human tissues shows distinct expression patterns for the two receptors, NMU1 is expressed predominantly in peripheral tissues, whereas NMU2 is more highly expressed in the central nervous system. Identification of neuromedin U receptor subtypes will greatly aid in the determination of the physiological roles of this peptide.	Synapt Pharmaceut Corp, Paramus, NJ 07652 USA		Raddatz, R (corresponding author), Synapt Pharmaceut Corp, 215 Coll Rd, Paramus, NJ 07652 USA.		Adham, Nika/N-4376-2017	Adham, Nika/0000-0002-2773-2522				AUSTIN C, 1995, J MOL ENDOCRINOL, V14, P157, DOI 10.1677/jme.0.0140157; BALLESTA J, 1988, NEUROSCIENCE, V25, P797, DOI 10.1016/0306-4522(88)90037-1; BENITOORFILA MA, 1991, EUR J PHARMACOL, V193, P329, DOI 10.1016/0014-2999(91)90147-I; BROWN DR, 1988, EUR J PHARMACOL, V155, P159, DOI 10.1016/0014-2999(88)90415-3; CIMINI V, 1993, CELL TISSUE RES, V272, P137, DOI 10.1007/BF00323579; DOMIN J, 1989, J BIOL CHEM, V264, P20881; DOMIN J, 1990, CELL TISSUE RES, V260, P131, DOI 10.1007/BF00297498; DOMIN J, 1987, PEPTIDES, V8, P779, DOI 10.1016/0196-9781(87)90058-1; Fujii R, 2000, J BIOL CHEM, V275, P21068, DOI 10.1074/jbc.M001546200; GARDINER SM, 1990, AM J PHYSIOL, V258, pR32, DOI 10.1152/ajpregu.1990.258.1.R32; GUNDERSEN CB, 1983, PROC R SOC SER B-BIO, V219, P103, DOI 10.1098/rspb.1983.0062; HASHIMOTO T, 1991, CHEM PHARM BULL, V39, P2319; HONZAWA M, 1987, NEUROSCIENCE, V23, P1103, DOI 10.1016/0306-4522(87)90185-0; LO G, 1992, MOL ENDOCRINOL, V6, P1538, DOI 10.1210/me.6.10.1538; MAGGI CA, 1990, BRIT J PHARMACOL, V99, P186, DOI 10.1111/j.1476-5381.1990.tb14675.x; MALENDOWICZ LK, 1994, HISTOL HISTOPATHOL, V9, P591; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MINAMINO N, 1985, PEPTIDES, V6, P245, DOI 10.1016/0196-9781(85)90381-X; MINAMINO N, 1985, BIOCHEM BIOPH RES CO, V130, P1078, DOI 10.1016/0006-291X(85)91726-7; NANDHA KA, 1993, BIOMED RES-TOKYO, V14, P71; NANDHA KA, 1993, ENDOCRINOLOGY, V133, P482, DOI 10.1210/en.133.2.482; QUICK MW, 1994, METH NEUROSCI, V19, P261; SAKURA N, 1991, CHEM PHARM BULL, V39, P2016; Smith KE, 1997, J BIOL CHEM, V272, P24612, DOI 10.1074/jbc.272.39.24612; STEEL JH, 1988, ENDOCRINOLOGY, V122, P270, DOI 10.1210/endo-122-1-270; SUMI S, 1987, LIFE SCI, V41, P1585, DOI 10.1016/0024-3205(87)90725-9; Szekeres PG, 2000, J BIOL CHEM, V275, P20247, DOI 10.1074/jbc.C000244200; TAKAHASHI T, 1987, P NATL ACAD SCI USA, V84, P5063, DOI 10.1073/pnas.84.14.5063	28	164	182	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32452	32459		10.1074/jbc.M004613200	http://dx.doi.org/10.1074/jbc.M004613200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10899166	hybrid			2022-12-27	WOS:000090003800012
J	Lee, HY; Suh, YA; Robinson, MJ; Clifford, JL; Hong, WK; Woodgett, JR; Cobb, MH; Mangelsdorf, DJ; Kurie, JM				Lee, HY; Suh, YA; Robinson, MJ; Clifford, JL; Hong, WK; Woodgett, JR; Cobb, MH; Mangelsdorf, DJ; Kurie, JM			Stress pathway activation induces phosphorylation of retinoid X receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PROTEIN-KINASE PATHWAY; N-TERMINAL KINASE; C-JUN; EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION; ESTROGEN-RECEPTOR; CARCINOMA-CELLS; UP-REGULATION; RXR-ALPHA	Cellular stresses inhibit retinoid signaling, but the molecular basis for this phenomenon has not been revealed. Here, we present evidence that retinoid X receptor (RXR) is a substrate for both mitogen-activated protein kinase kinase-4 (MKR4/SEK1) and its downstream mediator c-Jun N-terminal kinase (JNK). MKK4/SEK1 and JNK recognized distinct features on RXR in the DE and AB regions, respectively. Phosphorylation by MKK4/SEK1 had profound effects on the biochemical properties of RXR, inhibiting the expression of genes activated by RXR-retinoic acid receptor complexes. Tyr-249 in the RXR DE region was required for the inhibitory effect of MKK4/SEK1. These effects were significantly reduced in MKK4/SEK1-null cells, indicating that MKK4/SEK1 is required for the suppression of retinoid signaling by stress. Findings presented here demonstrate that MKK4/SEK1 can directly modulate transcription by phosphorylating RXR, a novel MKK4/SEK1 substrate.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M4X 1K9, Canada	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Kurie, JM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	jmkurie@audumla.mdacc.tmc.edu	Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797; Cobb, Melanie/0000-0003-0833-5473; Lee, Ho-Young/0000-0001-7556-9312; Mangelsdorf, David/0000-0002-4355-0796	NATIONAL CANCER INSTITUTE [P50CA070907, R29CA067353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056498] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA70907, R29 CA67353] Funding Source: Medline; NIGMS NIH HHS [GM56498] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam-Stitah S, 1999, J BIOL CHEM, V274, P18932, DOI 10.1074/jbc.274.27.18932; ANDREATTAVANLEYEN S, 1994, J CELL PHYSIOL, V160, P265, DOI 10.1002/jcp.1041600208; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; Camp HS, 1999, ENDOCRINOLOGY, V140, P392, DOI 10.1210/en.140.1.392; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Geisen C, 1997, CANCER RES, V57, P1460; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; HILLIARD GM, 1994, BIOCHEMISTRY-US, V33, P4300, DOI 10.1021/bi00180a026; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KIM YH, 1995, CANCER RES, V55, P5603; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lee HY, 1996, CELL GROWTH DIFFER, V7, P997; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; MILLER LA, 1993, CANCER RES, V53, P2527; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Rogatsky I, 1998, P NATL ACAD SCI USA, V95, P2050, DOI 10.1073/pnas.95.5.2050; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Shea CR, 1991, PHYSL BIOCH MOL BIOL, V2, P910; Solomon C, 1999, J CLIN INVEST, V103, P1729, DOI 10.1172/JCI6871; Swantek JL, 1999, J BIOL CHEM, V274, P11667, DOI 10.1074/jbc.274.17.11667; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; Wang ZQ, 1999, NAT MED, V5, P418, DOI 10.1038/7417; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Woodgett JR, 1996, CANCER SURV, V27, P127; Xu XC, 1999, CANCER RES, V59, P2477; Xu XC, 1997, JNCI-J NATL CANCER I, V89, P624, DOI 10.1093/jnci/89.9.624; Xu XC, 1997, CANCER RES, V57, P4992; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	44	79	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32193	32199		10.1074/jbc.M005490200	http://dx.doi.org/10.1074/jbc.M005490200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10938283	hybrid			2022-12-27	WOS:000089858900088
J	Park, OK; Schaefer, LK; Wang, WL; Schaefer, TS				Park, OK; Schaefer, LK; Wang, WL; Schaefer, TS			Dimer stability as a determinant of differential DNA binding activity of Stat3 isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVITY; CONSTITUTIVE ACTIVATION; SIGNAL TRANSDUCERS; CELLS; INTERFERON; RECEPTOR; PROTEIN; SRC; TRANSFORMATION; CYTOKINES	Stat3 alpha and Stat3 beta are two Stat3 isoforms with marked quantitative differences in their DNA binding activities. To examine the molecular basis of the differential DNA binding activities, we measured DNA binding strength and dimer stability, two possible mechanisms responsible for these differences. Stat3 alpha and Stat3 beta showed no difference in DNA binding strength, i.e. they had similar association and dissociation rates for DNA binding However, competition analyses performed with dissociating reagents including an anti-phosphotyrosine antibody, SH2 domain protein, and a phosphopeptide demonstrated that Stat3 beta dimers are more stable than Stat3 alpha dimers. We report here that dimer stability of activated forms plays a critical role in determining DNA binding activity of Stat3 isoforms. We found that C-terminal deletions of Stat3 alpha increased both DNA binding activity and dimer stability of Stat3 alpha. Our findings suggest that the acidic C-terminal region of Stat3 alpha does not interfere with the DNA binding of activated Stat3 alpha dimers, but destabilizes the dimeric forms of Stat3 alpha. We propose that dimer stability described in vitro may be the underlying mechanism of in vivo stability of activated Stat3 proteins, regulating dephosphorylation of tyrosine 705.	KLESL, Kumho Life & Environm Sci Lab, Puk Gu, Kwangju 500480, South Korea; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; AI duPont Hosp Children, Dept Clin & Med Sci, Wilmington, DE 19803 USA	University of Texas System; UTMD Anderson Cancer Center; Nemours Alfred I. duPont Hospital for Children	Park, OK (corresponding author), KLESL, Kumho Life & Environm Sci Lab, Puk Gu, 1 Oryong Dong, Kwangju 500480, South Korea.							ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Ihle JN, 1998, ANN NY ACAD SCI, V865, P1, DOI 10.1111/j.1749-6632.1998.tb11157.x; IMPROTA T, 1994, P NATL ACAD SCI USA, V91, P4776, DOI 10.1073/pnas.91.11.4776; IVASHKIV LB, 1995, IMMUNITY, V3, P1, DOI 10.1016/1074-7613(95)90152-3; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Ni Z, 2000, CANCER RES, V60, P1225; Niu GL, 1999, CANCER RES, V59, P5059; Park OK, 1996, P NATL ACAD SCI USA, V93, P13704, DOI 10.1073/pnas.93.24.13704; Schaefer LK, 1999, BIOCHEM BIOPH RES CO, V266, P481, DOI 10.1006/bbrc.1999.1853; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; Schindler C, 1999, EXP CELL RES, V253, P7, DOI 10.1006/excr.1999.4670; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Shuai K, 1996, MOL CELL BIOL, V16, P4932; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Strehlow I, 1998, J BIOL CHEM, V273, P28049, DOI 10.1074/jbc.273.43.28049; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; Xia Z, 1998, CANCER RES, V58, P3173; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang XK, 1999, MOL CELL BIOL, V19, P7138	36	44	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32244	32249		10.1074/jbc.M005082200	http://dx.doi.org/10.1074/jbc.M005082200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10915797	hybrid			2022-12-27	WOS:000089858900095
J	Sargueil, B; McKenna, J; Burke, JM				Sargueil, B; McKenna, J; Burke, JM			Analysis of the functional role of a G center dot A sheared base pair by in vitro genetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOZYME-SUBSTRATE COMPLEX; TERTIARY STRUCTURE FORMATION; RINGSPOT VIRUS SATELLITE; YELLOW MOTTLE VIRUS; HAIRPIN RIBOZYME; HAMMERHEAD RIBOZYME; IN-VITRO; JUNCTION CONFORMATION; SECONDARY STRUCTURE; EFFICIENT CLEAVAGE	A classical genetic strategy has been combined with an in vitro selection method to search for functional interactions between the two domains of the hairpin ribozyme, G(21) is located within internal loop B; it is proposed to form a sheared base pair with A(43) across loop B and to bind a Mg2+ ion, Both nucleotides are important for ribozyme function, and G.A sheared base pairs are a very widespread motif in structured RNA. We took advantage of its presence in the hairpin ribozyme to study its functional role. Pseudorevertants, in which the loss of G(21) was compensated by mutations at other positions, were isolated by in vitro selection. The vast majority of G(21) revertants contained substitutions within domain A, pointing to functional communication between specific sites within the two domains of the hairpin ribozyme. The possibility of a direct or redundant contacts is supported by electrophoretic mobility shift studies showing that a complex formed between domain B of the ribozyme and the substrate was disrupted and restored by base substitutions that have analogous effects on catalytic activity. The functional significance of this complex, the role of the nucleotides involved, and the basis for magnesium ion requirement is discussed.	CNRS, Ctr Genet Mol, F-91190 Gif Sur Yvette, France; Univ Vermont, Dept Microbiol & Mol Genet, Markey Ctr Mol Genet, Burlington, VT 05405 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Vermont	Sargueil, B (corresponding author), CNRS, Ctr Genet Mol, Ave Terrasse, F-91190 Gif Sur Yvette, France.	sargueil@smigiris.cgm.cnrs-gif.fr	, John/AAB-5945-2021	sargueil, bruno/0000-0003-4483-355X				ANDERSON P, 1994, NUCLEIC ACIDS RES, V22, P1096, DOI 10.1093/nar/22.6.1096; Been MD, 1997, EUR J BIOCHEM, V247, P741, DOI 10.1111/j.1432-1033.1997.00741.x; BERZALHERRANZ A, 1992, GENE DEV, V6, P129, DOI 10.1101/gad.6.1.129; BERZALHERRANZ A, 1993, EMBO J, V12, P2567, DOI 10.1002/j.1460-2075.1993.tb05912.x; BURKE JM, 1996, NUCL ACIDS MOL BIOL, V10, P129; BUTCHER SE, 1994, BIOCHEMISTRY-US, V33, P992, DOI 10.1021/bi00170a018; BUTCHER SE, 1994, J MOL BIOL, V244, P52, DOI 10.1006/jmbi.1994.1703; BUTCHER SE, 1995, J BIOL CHEM, V270, P29648; Butcher SE, 2000, BIOCHEMISTRY-US, V39, P2174, DOI 10.1021/bi9923454; Butcher SE, 1999, NAT STRUCT BIOL, V6, P212; Cai ZP, 1996, BIOCHEMISTRY-US, V35, P6026, DOI 10.1021/bi952985g; CHOWRIRA BM, 1992, NUCLEIC ACIDS RES, V20, P2835, DOI 10.1093/nar/20.11.2835; DEYOUNG MB, 1995, BIOCHEMISTRY-US, V34, P15785, DOI 10.1021/bi00048a024; Earnshaw DJ, 1997, J MOL BIOL, V274, P197, DOI 10.1006/jmbi.1997.1405; Esteban JA, 1998, P NATL ACAD SCI USA, V95, P6091, DOI 10.1073/pnas.95.11.6091; Esteban JA, 1997, J BIOL CHEM, V272, P13629, DOI 10.1074/jbc.272.21.13629; Fedor MJ, 2000, J MOL BIOL, V297, P269, DOI 10.1006/jmbi.2000.3560; FEDOR MJ, 1990, P NATL ACAD SCI USA, V87, P1668, DOI 10.1073/pnas.87.5.1668; Feig A. L., 1999, RNA WORLD, P287; FELDSTEIN PA, 1993, NUCLEIC ACIDS RES, V21, P1991, DOI 10.1093/nar/21.8.1991; FU DJ, 1993, BIOCHEMISTRY-US, V32, P10629, DOI 10.1021/bi00091a013; FU DJ, 1992, BIOCHEMISTRY-US, V31, P10941, DOI 10.1021/bi00160a001; GRASBY JA, 1995, BIOCHEMISTRY-US, V34, P4068, DOI 10.1021/bi00012a025; GREEN R, 1991, Methods (Orlando), V2, P75, DOI 10.1016/S1046-2023(05)80127-6; HAMPEL A, 1990, NUCLEIC ACIDS RES, V18, P299, DOI 10.1093/nar/18.2.299; Hampel A, 1997, CHEM BIOL, V4, P513, DOI 10.1016/S1074-5521(97)90323-9; Hampel KJ, 1998, BIOCHEMISTRY-US, V37, P14672, DOI 10.1021/bi981083n; JOSEPH S, 1993, J BIOL CHEM, V268, P24515; JOSEPH S, 1993, GENE DEV, V7, P130, DOI 10.1101/gad.7.1.130; KOMATSU Y, 1995, J MOL BIOL, V252, P296, DOI 10.1006/jmbi.1995.0497; Leontis NB, 1998, RNA, V4, P1134, DOI 10.1017/S1355838298980566; MCKAY DB, 1999, RNA WORLD, P265; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; Murchie AIH, 1998, MOL CELL, V1, P873, DOI 10.1016/S1097-2765(00)80086-6; Murray JB, 2000, MOL CELL, V5, P279, DOI 10.1016/S1097-2765(00)80423-2; Murray JB, 1998, CHEM BIOL, V5, P587, DOI 10.1016/S1074-5521(98)90116-8; Nesbitt S, 1997, CHEM BIOL, V4, P619, DOI 10.1016/S1074-5521(97)90247-7; Nesbitt SM, 1999, J MOL BIOL, V286, P1009, DOI 10.1006/jmbi.1999.2543; Pinard R, 1999, J MOL BIOL, V287, P239, DOI 10.1006/jmbi.1999.2626; Pinard R, 1999, BIOCHEMISTRY-US, V38, P16035, DOI 10.1021/bi992024s; PLEY HW, 1994, NATURE, V372, P111, DOI 10.1038/372111a0; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; Rastogi T, 1998, J MOL BIOL, V277, P215, DOI 10.1006/jmbi.1997.1623; RUBINO L, 1990, J GEN VIROL, V71, P1897, DOI 10.1099/0022-1317-71-9-1897; Ryder SP, 1999, J MOL BIOL, V291, P295, DOI 10.1006/jmbi.1999.2959; SANTALUCIA J, 1993, BIOCHEMISTRY-US, V32, P12612, DOI 10.1021/bi00210a009; SANTALUCIA J, 1992, SCIENCE, V256, P217, DOI 10.1126/science.1373521; SARGUEIL B, 1995, BIOCHEMISTRY-US, V34, P7739, DOI 10.1021/bi00023a021; Sargueil B, 1997, Methods Mol Biol, V74, P289; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; Schmidt S, 1996, NUCLEIC ACIDS RES, V24, P573, DOI 10.1093/nar/24.4.573; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; Siwkowski A, 1998, BIOTECHNIQUES, V24, P278, DOI 10.2144/98242st05; Siwkowski A, 1997, BIOCHEMISTRY-US, V36, P3930, DOI 10.1021/bi9628735; SZEWCZAK AA, 1993, P NATL ACAD SCI USA, V90, P9581, DOI 10.1073/pnas.90.20.9581; Thomson JB, 1999, RNA, V5, P180, DOI 10.1017/S1355838299981670; WALTER AE, 1994, BIOCHEMISTRY-US, V33, P11349, DOI 10.1021/bi00203a033; Walter F, 1998, BIOCHEMISTRY-US, V37, P14195, DOI 10.1021/bi981513+; Walter F, 1998, BIOCHEMISTRY-US, V37, P17629, DOI 10.1021/bi9821115; Walter NG, 1998, CURR OPIN CHEM BIOL, V2, P24, DOI 10.1016/S1367-5931(98)80032-X; Walter NG, 1997, RNA, V3, P392; Walter NG, 1998, EMBO J, V17, P2378, DOI 10.1093/emboj/17.8.2378; Walter NG, 2000, J MOL BIOL, V298, P539, DOI 10.1006/jmbi.2000.3691; Wang SL, 1999, BIOCHEMISTRY-US, V38, P14363, DOI 10.1021/bi9913202; WIMBERLY B, 1994, NAT STRUCT BIOL, V1, P820, DOI 10.1038/nsb1194-820; WIMBERLY B, 1993, BIOCHEMISTRY-US, V32, P1078, DOI 10.1021/bi00055a013; Young KJ, 1999, J MOL BIOL, V288, P853, DOI 10.1006/jmbi.1999.2748; Young KJ, 1997, NUCLEIC ACIDS RES, V25, P3760, DOI 10.1093/nar/25.19.3760	68	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32157	32166		10.1074/jbc.M005591200	http://dx.doi.org/10.1074/jbc.M005591200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10906144	hybrid			2022-12-27	WOS:000089858900083
J	Krauss, M; Korr, D; Herrmann, A; Hucho, F				Krauss, M; Korr, D; Herrmann, A; Hucho, F			Binding properties of agonists and antagonists to distinct allosteric states of the nicotinic acetylcholine receptor are incompatible with a concerted model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-SUBUNIT; NONCOMPETITIVE INHIBITORS; H-3 CHLORPROMAZINE; ION-CHANNEL; ETHIDIUM BINDING; ALPHA-SUBUNIT; AMINO-ACIDS; M2 DOMAIN; SITE; QUINACRINE	Recent work has shown that the nicotinic acetylcholine receptor (nAChR) can be fixed in distinct conformations by chemical cross-licking with glutardialdehyde, which abolishes allosteric transitions in the protein. Here, two conformations that resemble the desensitized and the resting states were compared with respect to their affinities for different classes of ligands. The same ligands were tested for their ability to convert the nAChR from a conformation with low affinity to a conformation with high affinity for acetylcholine. As expected, agonists were found to bind with higher affinity to the desensitized state-like conformation and to induce a shift of the nAChR to this high affinity state. In contrast, although most antagonists tested bound preferentially to the desensitized receptor as well they failed to induce a change of the affinity for acetylcholine. These observations sharply contradict basic predictions of the concerted model, including the postulate of a preformed equilibrium between the different states of the nAChR in the absence of agonist. With a similar approach we could show that the non-competitive inhibitor ethidium is displaced in a non-allosteric manner by other well characterized channel blockers from the cross-linked nAChR. These results require revision of current models for the mechanisms underlying noncompetitive antagonism at the nAChR.	Free Univ Berlin, AG Neurochem, Inst Biochem, D-14195 Berlin, Germany; Humboldt Univ, Inst Biol Biophys, D-10115 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin	Hucho, F (corresponding author), Free Univ Berlin, AG Neurochem, Inst Biochem, Thielallee 63, D-14195 Berlin, Germany.	hucho@chemie.fu-berlin.de		Krauss, Michael/0000-0003-1010-9723				Arias HR, 1997, BBA-LIPID LIPID MET, V1347, P9, DOI 10.1016/S0005-2760(97)00045-3; Arias HR, 1996, MOL MEMBR BIOL, V13, P1; ARIAS HR, 1993, BIOCHEMISTRY-US, V32, P6237, DOI 10.1021/bi00075a017; AUERBACH A, 1983, BIOPHYS J, V42, P1, DOI 10.1016/S0006-3495(83)84362-8; Auerbach A, 1996, J PHYSIOL-LONDON, V494, P155, DOI 10.1113/jphysiol.1996.sp021482; BERTRAND D, 1992, P NATL ACAD SCI USA, V89, P1261, DOI 10.1073/pnas.89.4.1261; Bixel MG, 2000, EUR J BIOCHEM, V267, P110, DOI 10.1046/j.1432-1327.2000.00971.x; BLANTON M, 1988, MOL PHARMACOL, V33, P634; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; Chen J, 1998, BIOPHYS J, V75, P218, DOI 10.1016/S0006-3495(98)77508-3; Chiara DC, 1997, J BIOL CHEM, V272, P32940, DOI 10.1074/jbc.272.52.32940; CZAJKOWSKI C, 1991, J BIOL CHEM, V266, P22603; FILATOV GN, 1995, MOL PHARMACOL, V48, P379; Gallagher MJ, 1999, MOL PHARMACOL, V56, P300, DOI 10.1124/mol.56.2.300; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; GIRAUDAT J, 1987, BIOCHEMISTRY-US, V26, P2410, DOI 10.1021/bi00383a003; GIRAUDAT J, 1989, FEBS LETT, V253, P190, DOI 10.1016/0014-5793(89)80957-3; HAMILL OP, 1981, NATURE, V294, P462, DOI 10.1038/294462a0; HARTIG PR, 1979, BIOCHEMISTRY-US, V18, P1146, DOI 10.1021/bi00574a004; HERZ JM, 1992, BIOPHYS J, V62, P74, DOI 10.1016/S0006-3495(92)81784-8; HERZ JM, 1991, J BIOL CHEM, V266, P16691; HERZ JM, 1987, J BIOL CHEM, V262, P7238; HUCHO F, 1986, FEBS LETT, V205, P137, DOI 10.1016/0014-5793(86)80881-X; Hucho F, 1996, EUR J BIOCHEM, V239, P539, DOI 10.1111/j.1432-1033.1996.0539u.x; JACKSON MB, 1984, P NATL ACAD SCI-BIOL, V81, P3901, DOI 10.1073/pnas.81.12.3901; Johnson DA, 1996, BIOCHEMISTRY-US, V35, P6330, DOI 10.1021/bi960123p; JOHNSON DA, 1994, BIOCHEMISTRY-US, V33, P9070, DOI 10.1021/bi00197a007; KARLIN A, 1967, J THEOR BIOL, V16, P306, DOI 10.1016/0022-5193(67)90011-2; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KATZ B, 1957, J PHYSIOL-LONDON, V138, P63, DOI 10.1113/jphysiol.1957.sp005838; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; LABARCA C, 1995, NATURE, V376, P514, DOI 10.1038/376514a0; Lurtz MM, 1997, BIOCHEMISTRY-US, V36, P2068, DOI 10.1021/bi962547p; MACHOLD J, 1995, P NATL ACAD SCI USA, V92, P7282, DOI 10.1073/pnas.92.16.7282; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MOORE MA, 1995, BBA-BIOMEMBRANES, V1235, P336, DOI 10.1016/0005-2736(95)80022-8; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; OBERTHUR W, 1988, J PROTEIN CHEM, V7, P141, DOI 10.1007/BF01025243; OBERTHUR W, 1986, EMBO J, V5, P1815, DOI 10.1002/j.1460-2075.1986.tb04431.x; PALMA AL, 1991, J MEMBRANE BIOL, V122, P143, DOI 10.1007/BF01872637; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; Prince RJ, 1999, J BIOL CHEM, V274, P19623, DOI 10.1074/jbc.274.28.19623; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; Saez-Briones P, 1999, EUR J BIOCHEM, V265, P902, DOI 10.1046/j.1432-1327.1999.00787.x; SCHIEBLER W, 1978, EUR J BIOCHEM, V85, P55, DOI 10.1111/j.1432-1033.1978.tb12211.x; STERZ R, 1982, EUR J PHARMACOL, V80, P393, DOI 10.1016/0014-2999(82)90085-1; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; Watty A, 1997, P NATL ACAD SCI USA, V94, P8202, DOI 10.1073/pnas.94.15.8202; [No title captured]	50	16	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30196	30201		10.1074/jbc.M001782200	http://dx.doi.org/10.1074/jbc.M001782200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10900197	hybrid			2022-12-27	WOS:000089577900040
J	Leibiger, B; Wahlander, K; Berggren, PO; Leibiger, IB				Leibiger, B; Wahlander, K; Berggren, PO; Leibiger, IB			Glucose-stimulated insulin biosynthesis depends on insulin-stimulated insulin gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; RECEPTOR; TRANSLATION; EXPRESSION; PROTEINS	Glucose stimulation of pancreatic p-cells leads to insulin secretion as well as up-regulation of insulin biosynthesis. The acute elevation in pro-insulin levels is thought to be exclusively because of the activation of translation of pre existing prepro-insulin mRNA. Glucose-stimulated insulin gene transcription is believed to be a long term effect and should therefore not contribute to the acute elevation in pro-insulin levels. We have recently shown that glucose activates insulin gene transcription within minutes and that secreted insulin is one of the key factors triggering this process in an autocrine manner. We now provide evidence that 50% of the glucose-stimulated, acute pro-insulin biosynthesis within 30 min results from up-regulated insulin gene transcription. Our data led us to propose that glucose elevates pro-insulin levels by stimulating both transcriptional and post-transcriptional/post-translational events to an equal extent. Whereas the stimulatory effect on transcription is mediated by insulin secreted in response to glucose, glucose directly stimulates the post-transcriptional/post-translational processes.	Karolinska Inst, Dept Mol Med, Rolf Luft Ctr Diabet Res, Karolinska Hosp L102, S-17176 Stockholm, Sweden	Karolinska Institutet	Berggren, PO (corresponding author), Karolinska Inst, Dept Mol Med, Rolf Luft Ctr Diabet Res, Karolinska Hosp L102, S-17176 Stockholm, Sweden.			Berggren, Per-Olof/0000-0001-8991-413X				Aspinwall CA, 1999, J BIOL CHEM, V274, P6360, DOI 10.1074/jbc.274.10.6360; EFRAT S, 1991, J BIOL CHEM, V266, P11141; GUEST PC, 1991, BIOCHEM J, V274, P73, DOI 10.1042/bj2740073; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; Leibiger B, 1998, P NATL ACAD SCI USA, V95, P9307, DOI 10.1073/pnas.95.16.9307; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; LERNMARK A, 1974, DIABETOLOGIA, V10, P431, DOI 10.1007/BF01221634; MALAISSE WJ, 1977, HORM RES, V8, P203; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; Proud CG, 1997, BIOCHEM J, V328, P329; Rhodes Christopher J., 1996, P27; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Xu G, 1998, J BIOL CHEM, V273, P4485, DOI 10.1074/jbc.273.8.4485; Xu GG, 1998, DIABETES, V47, P1243, DOI 10.2337/diabetes.47.8.1243	17	62	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30153	30156		10.1074/jbc.M005216200	http://dx.doi.org/10.1074/jbc.M005216200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10913151	hybrid			2022-12-27	WOS:000089577900034
J	Yoo, SH; Lewis, MS				Yoo, SH; Lewis, MS			Interaction of chromogranin B and the near N-temninal region of chromogranin B with an intraluminal loop peptide of the inositol 1,4,5-trisphosphate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY VESICLE MEMBRANE; PH-DEPENDENT INTERACTION; DISULFIDE-BONDED LOOP; TRISPHOSPHATE RECEPTOR; BINDING REGION; CONFORMATIONAL CHANGE; INTRACELLULAR STORES; CA2+ MOBILIZATION; CALCIUM RELEASE; MATRIX PROTEINS	Given the interaction of the inositol 1,4,5-trisphosphate receptor (IP3R) with chromogranins A (CGA) and B (CGB), two major Ca2+ storage proteins of secretory granules that have been shown to be IP3-sensitive intracellular Ca2+ store of neuroendocrine cells, we have investigated the potential interaction of the intraluminal loop regions of the IP3R with both intact CGB and the conserved near N-terminal region of CGB. The interaction studies carried out with CGB and glutathione S-transferase fusion proteins of intraluminal loop regions of bovine type 1 IP3R showed that CGB interacts with intraluminal loop 3-2 (the second loop formed between transmembrane regions 5 and 6) of the IP3R at both pH 5.5 and 7.5. Analytical ultracentrifugation studies also indicated-that CGB interacts with the same intraluminal loop region of the IP3R and the interaction was much stronger than that between CGA and the loop. Moreover, the conserved near N-terminal region of CGB also interacted with the intraluminal loop region of the IP3R. The CGB interaction with the IP3R intraluminal loop peptide at pH 7.5 showed a Delta G(0) value of -8.1 kcal/ mol at 37 degrees C for a 1:1 stoichiometry, indicating a K-d of similar to 1.9 mu M. These results give insight into the molecular organization of the IP3-sensitive Ca2+ store.	Korea Adv Inst Sci & Technol, Biomed Res Ctr, Natl Creat Res Initiat Ctr Secretory Granule Res, Taejon 305701, South Korea; NIH, Div Bioengn & Phys Sci, Off Res Serv, Bethesda, MD 20892 USA	Korea Advanced Institute of Science & Technology (KAIST); National Institutes of Health (NIH) - USA	Yoo, SH (corresponding author), Korea Adv Inst Sci & Technol, Biomed Res Ctr, Natl Creat Res Initiat Ctr Secretory Granule Res, Taejon 305701, South Korea.				OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [Z01OD010184] Funding Source: NIH RePORTER	OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BAUER JW, 1991, BIOCHIM BIOPHYS ACTA, V1089, P124, DOI 10.1016/0167-4781(91)90094-3; BENEDUM UM, 1987, EMBO J, V6, P1203, DOI 10.1002/j.1460-2075.1987.tb02355.x; BLONDEL O, 1994, P NATL ACAD SCI USA, V91, P7777, DOI 10.1073/pnas.91.16.7777; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; BULENDA D, 1985, BIOCHEMISTRY-US, V24, P7760, DOI 10.1021/bi00347a039; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; HUTTON JC, 1989, DIABETOLOGIA, V32, P271, DOI 10.1007/BF00265542; IACANGELO AL, 1995, REGUL PEPTIDES, V58, P65, DOI 10.1016/0167-0115(95)00069-N; JOSEPH SK, 1995, J BIOL CHEM, V270, P23310, DOI 10.1074/jbc.270.40.23310; Kang YK, 1997, FEBS LETT, V404, P87, DOI 10.1016/S0014-5793(97)00099-9; Kromer A, 1998, J CELL BIOL, V140, P1331, DOI 10.1083/jcb.140.6.1331; LEWIS MS, 1994, MODERN ANAL ULTRACEN, P94; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; MUALLEM S, 1989, J BIOL CHEM, V264, P205; Nguyen T, 1998, NATURE, V395, P908, DOI 10.1038/27686; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; POHL TM, 1990, FEBS LETT, V262, P219, DOI 10.1016/0014-5793(90)80194-N; REIFFEN FU, 1986, FEBS LETT, V195, P327, DOI 10.1016/0014-5793(86)80187-9; Srivastava M, 1999, P NATL ACAD SCI USA, V96, P13783, DOI 10.1073/pnas.96.24.13783; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; Thiele C, 1998, J BIOL CHEM, V273, P1223, DOI 10.1074/jbc.273.2.1223; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7; YAMADA N, 1994, BIOCHEM J, V302, P781, DOI 10.1042/bj3020781; YOO SH, 1995, BIOCHEMISTRY-US, V34, P8680, DOI 10.1021/bi00027a017; Yoo SH, 2000, J BIOL CHEM, V275, P12553, DOI 10.1074/jbc.275.17.12553; YOO SH, 1992, J BIOL CHEM, V267, P11236; YOO SH, 1994, J BIOL CHEM, V269, P12001; Yoo SH, 1996, J BIOL CHEM, V271, P17041, DOI 10.1074/jbc.271.29.17041; Yoo SH, 1996, J BIOL CHEM, V271, P1558; YOO SH, 1995, J BIOL CHEM, V270, P12578, DOI 10.1074/jbc.270.21.12578; Yoo SH, 1997, FEBS LETT, V406, P259, DOI 10.1016/S0014-5793(97)00276-7; YOO SH, 1991, J BIOL CHEM, V266, P7740; YOO SH, 1990, J BIOL CHEM, V265, P13446; YOO SH, 1993, BIOCHEMISTRY-US, V32, P8213, DOI 10.1021/bi00083a023; Yoo SH, 1998, FEBS LETT, V427, P55, DOI 10.1016/S0014-5793(98)00393-7; YOO SH, 1995, BIOCHEMISTRY-US, V34, P632, DOI 10.1021/bi00002a030; YOO SH, 1993, BIOCHIM BIOPHYS ACTA, V1179, P239, DOI 10.1016/0167-4889(93)90078-4	47	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30293	30300		10.1074/jbc.M001204200	http://dx.doi.org/10.1074/jbc.M001204200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10906121	hybrid			2022-12-27	WOS:000089577900053
J	Antonin, W; Meyer, HA; Hartmann, E				Antonin, W; Meyer, HA; Hartmann, E			Interactions between Spc2p and other components of the endoplasmic reticulum translocation sites of the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL PEPTIDASE ACTIVITY; PROTEIN-TRANSPORT; ER MEMBRANE; COMPLEX; SEC11; GENE; SUBUNITS; DISTINCT; HOMOLOG; MUTANT	In yeast, the endoplasmic reticulum membrane proteins Sec11p and Spc3p are essential for the cleavage of signal peptides of nascent polypeptide chains during their passage through translocation sites. Genetic and biochemical experiments demonstrate that Sec11p and Spc3p are tightly associated with two other proteins, Spc1p and Spc2p, whose functions are largely unknown. Using anti-Spc2p antibodies, we show here that this heterotetrameric complex associates with Sbh1p and Sbh2p, the beta -subunits of the Sec61p complex and the Ssh1p complex respectively. Depletion of Spc2p decreased the enzymatic activity of the SPC in vitro, led to a loss of Spc1p, and led to a down-regulation of the amount of Sec11p and Spc3p in the endoplasmic reticulum. Moreover, the deletion of Spc2p also decreased the expression level of Sbh2p. These data implicate that Spc2p not only enhances the enzymatic activity of the SPC but also facilitates the interactions between different components of the translocation site.	Univ Gottingen, Biochem Abt 2, Zentrum Biochem & Mol Zellbiol, D-37073 Gottingen, Germany	University of Gottingen	Hartmann, E (corresponding author), Univ Gottingen, Biochem Abt 2, Zentrum Biochem & Mol Zellbiol, Heinrich Duker Weg 12, D-37073 Gottingen, Germany.		Antonin, Wolfram/P-3648-2019; Hartmann, Enno/C-5687-2013; Antonin, Wolfram/A-8656-2014	Antonin, Wolfram/0000-0003-4669-379X; Antonin, Wolfram/0000-0003-4669-379X				Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; ESNAULT Y, 1993, EMBO J, V12, P4083, DOI 10.1002/j.1460-2075.1993.tb06092.x; Fang H, 1996, J BIOL CHEM, V271, P16460, DOI 10.1074/jbc.271.28.16460; Fang H, 1997, J BIOL CHEM, V272, P13152, DOI 10.1074/jbc.272.20.13152; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; Johnson CH, 1999, YEAST, V15, P799, DOI 10.1002/(SICI)1097-0061(19990630)15:9&lt;799::AID-YEA419&gt;3.0.CO;2-N; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; Kalies KU, 1996, J BIOL CHEM, V271, P3925; Kalies KU, 1998, J CELL BIOL, V141, P887, DOI 10.1083/jcb.141.4.887; LIVELY MO, 1983, J BIOL CHEM, V258, P9488; Meyer HA, 1997, J BIOL CHEM, V272, P13159, DOI 10.1074/jbc.272.20.13159; Mullins C, 1996, J BIOL CHEM, V271, P29094, DOI 10.1074/jbc.271.46.29094; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIKORSKI RS, 1989, GENETICS, V122, P19; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VanValkenburgh C, 1999, J BIOL CHEM, V274, P11519, DOI 10.1074/jbc.274.17.11519; WALTER P, 1983, METHOD ENZYMOL, V96, P84; YADEAU JT, 1991, P NATL ACAD SCI USA, V88, P517, DOI 10.1073/pnas.88.2.517; ZWIZINSKI C, 1980, J BIOL CHEM, V255, P7973	26	20	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34068	34072		10.1074/jbc.M006126200	http://dx.doi.org/10.1074/jbc.M006126200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10921929	Green Published, hybrid			2022-12-27	WOS:000165095300012
J	Hosseinpour, F; Wikvall, K				Hosseinpour, F; Wikvall, K			Porcine microsomal vitamin D-3 25-hydroxylase (CYP2D25) - Catalytic properties, tissue distribution, and comparison with human CYP2D6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LIVER CYTOCHROME-P-450; MESSENGER-RNA; PIG-LIVER; EXPRESSION; ACID; PURIFICATION; MITOCHONDRIA; CLONING; CDNA; 26-HYDROXYLATION	The metabolic activation of the prohormone vitamin D-3 requires a 25-hydroxylation that has been reported to be catalyzed by both mitochondrial CYP27A and a microsomal vitamin D-3 25-hydroxylase in the liver. CYP27A has been extensively studied, but its role as a physiologically important vitamin D-3 25-hydroxylase has been questioned. The present: paper reports that the microsomal vitamin D-3 25-hydroxylase, purified from pig liver, converted vitamin D-3 into 25-hydroxyvitamin D-3 in substrate concentrations which are within the physiological range (apparent K-m = 0.1 muM). The enzyme 25-hydroxylated vitamin D-3, 1 alpha -hydroxyvitamin D-3 and vitamin D-2 and also converted tolterodine, a substrate for human CYP2D6, into its 5-hydroxymethyl metabolite. Tolterodine inhibited the microsomal 25-hydroxylation, whereas quinidine, an inhibitor of CYP2D6, did not markedly inhibit the reaction. The primary structure of the microsomal vitamin D-3 25-hydroxylase, designated CYP2D25, shows 77% identity with that of human CYP2D6, Northern blot and reverse transcription-polymerase chain reaction experiments revealed that CYP2D25 mRNA is expressed in higher levels in liver than in kidney and in small amounts in adrenals, brain, heart, intestine, Lung, muscle, spleen, and thymus, Experiments with human liver microsomes and recombinantly expressed CYP2D6 strongly indicate that the microsomal 25-hydroxylation of vitamin D-3 in human Liver is catalyzed by an enzyme different from CYP2D6.	Uppsala Univ, Dept Pharmaceut Biosci, Div Biochem, S-75123 Uppsala, Sweden	Uppsala University	Hosseinpour, F (corresponding author), Uppsala Univ, Dept Pharmaceut Biosci, Div Biochem, Box 578, S-75123 Uppsala, Sweden.	fardin.hosseinpour@farmbio.uu.se						ANDERSSON S, 1983, J BIOL CHEM, V258, P6777; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AXEN E, 1992, BIOCHEM J, V287, P725, DOI 10.1042/bj2870725; AXEN E, 1994, J STEROID BIOCHEM, V51, P97, DOI 10.1016/0960-0760(94)90120-1; AXEN E, 1994, P NATL ACAD SCI USA, V91, P10014, DOI 10.1073/pnas.91.21.10014; BERGMAN T, 1990, BIOCHEM J, V270, P345, DOI 10.1042/bj2700345; Bjorkhem I., 1995, METABOLIC MOL BASES, P2073; DAHLBACK H, 1988, BIOCHEM J, V252, P207, DOI 10.1042/bj2520207; DAHLBACKSJOBERG H, 1993, BIOCHEM J, V293, P203, DOI 10.1042/bj2930203; Gonzalez FJ, 1996, CYTOCHROMES P450S ME, P183; GOTOH O, 1992, J BIOL CHEM, V267, P83; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P391, DOI 10.1021/tx00022a001; GUENGERICH FP, 1992, FASEB J, V6, P745, DOI 10.1096/fasebj.6.2.1537465; GUO YD, 1993, P NATL ACAD SCI USA, V90, P8668, DOI 10.1073/pnas.90.18.8668; Hakkola J, 1996, BIOCHEM PHARMACOL, V52, P379, DOI 10.1016/0006-2952(96)00216-X; HAYASHI S, 1986, J BIOCHEM-TOKYO, V99, P1753, DOI 10.1093/oxfordjournals.jbchem.a135653; Hiroi T, 1998, BBA-GEN SUBJECTS, V1380, P305, DOI 10.1016/S0304-4165(97)00157-8; HOLMBERG I, 1986, SCAND J CLIN LAB INV, V46, P785, DOI 10.3109/00365518609084051; HOLMES RP, 1983, J AM COLL NUTR, V2, P173; INABA T, 1985, DRUG METAB DISPOS, V13, P443; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewis D.F.V., 1996, CYTOCHROME P450 STRU; Lo Guidice JM, 1997, BIOCHEM BIOPH RES CO, V241, P79, DOI 10.1006/bbrc.1997.7775; MCLAUGHLIN MP, 1999, REGRESSPLUS VERSION; Pikuleva IA, 1997, ARCH BIOCHEM BIOPHYS, V343, P123, DOI 10.1006/abbi.1997.0142; Postlind H, 1998, DRUG METAB DISPOS, V26, P289; Postlind H, 1997, BIOCHEM BIOPH RES CO, V241, P491, DOI 10.1006/bbrc.1997.7551; POSTLIND H, 1988, BIOCHEM J, V253, P549, DOI 10.1042/bj2530549; Rosen H, 1998, J BIOL CHEM, V273, P14805, DOI 10.1074/jbc.273.24.14805; SAAREM K, 1984, J BIOL CHEM, V259, P936; Smith G, 1998, BIOCHEM J, V331, P783, DOI 10.1042/bj3310783; SU P, 1990, DNA CELL BIOL, V9, P657, DOI 10.1089/dna.1990.9.657; Thompson CM, 1998, ARCH BIOCHEM BIOPHYS, V359, P115, DOI 10.1006/abbi.1998.0892; USUI E, 1990, FEBS LETT, V262, P135, DOI 10.1016/0014-5793(90)80172-F; WIKVALL K, 1984, J BIOL CHEM, V259, P3800; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337	37	71	74	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34650	34655		10.1074/jbc.M004185200	http://dx.doi.org/10.1074/jbc.M004185200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10924511	hybrid, Green Submitted			2022-12-27	WOS:000165095300088
J	Mintz-Weber, CS; Johnson, JP				Mintz-Weber, CS; Johnson, JP			Identification of the elements regulating the expression of the cell adhesion molecule MCAM/MUC18 - Loss of AP-2 is not required for MCAM expression in melanoma cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER; GENE-TRANSCRIPTION; TUMOR-GROWTH; GLYCOPROTEIN; PROGRESSION; METASTASIS; MUC18/MCAM; BASAL; ACTS; CAMP	The cell adhesion molecule melonoma cell adhesion molecule (MCAM)/MUC18/CD146 is specifically up-regulated on tumors of neuroectodermal origin and in animal models confers metastatic capacity to human melanoma cells, To identify critical regions regulating MCAM expression in melanomas, 1 kilobase of the MCAM 5' region was analyzed for promoter activity and transcription factor binding in 1 glioma, 1 carcinoma, and 4 melanoma cell lines. The minimal MCAM promoter (-106/+22 base pair (bp)) consists of 4 Sp-l sites, two AP-2 elements, one cAMP responsive element, and the initiator surrounding the transcriptional start site. Analysis of mutated constructs indicated that the cAMP-responsive element is a major transcriptional activator in the majority of cell Lines. Site-directed mutagenesis revealed that, in AP-2 expressing cells, the AP-2 site within the core promoter (-23 bp) has an inhibitory influence on MCAM expression while the AP-2 sites at -131 and -302 bp are activating. Functional AP-2 was observed in both MCAM positive and MCAM negative melanoma cell lines indicating that expression of MCAM does not require loss of this transcription factor. Furthermore, all MCAM: constructs were strongly expressed in MCAM negative as well as MCAM positive cells, indicating that the expression of this gene is not controlled solely by the presence of transactivating factors binding to the investigated region.	Univ Munich, Inst Immunol, D-80336 Munich, Germany	University of Munich	Johnson, JP (corresponding author), Univ Munich, Inst Immunol, Goethestr 31, D-80336 Munich, Germany.							Bani MR, 1996, CANCER RES, V56, P3075; BUCK CA, 1995, MOL BASIS CANC, P175; Chen AP, 1996, J BIOL CHEM, V271, P25994, DOI 10.1074/jbc.271.42.25994; Chen TT, 1997, MOL CELL BIOL, V17, P3056, DOI 10.1128/MCB.17.6.3056; HOLZMANN B, 1987, INT J CANCER, V39, P466, DOI 10.1002/ijc.2910390410; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; Johnson JP, 1999, CANCER METAST REV, V18, P345, DOI 10.1023/A:1006304806799; Johnson JP, 1997, INT J CANCER, V73, P769; Karlen S, 1999, J INVEST DERMATOL, V113, P711, DOI 10.1046/j.1523-1747.1999.00746.x; KIM KS, 1993, J BIOL CHEM, V268, P15689; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEHMANN JM, 1987, CANCER RES, V47, P841; MEDCALF RL, 1990, J BIOL CHEM, V265, P14618; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Rummel MM, 1996, CANCER RES, V56, P2218; Schlagbauer-Wadl H, 1999, INT J CANCER, V81, P951, DOI 10.1002/(SICI)1097-0215(19990611)81:6<951::AID-IJC18>3.0.CO;2-V; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SERS C, 1993, P NATL ACAD SCI USA, V90, P8514, DOI 10.1073/pnas.90.18.8514; Shih C, 1997, CANCER RES, V57, P1116; Shih IM, 1997, AM J PATHOL, V151, P745; SHIH IM, 1994, CANCER RES, V54, P2514; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Xie SH, 1997, CANCER RES, V57, P2295; Xie SH, 1997, ONCOGENE, V15, P2069, DOI 10.1038/sj.onc.1201358	25	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34672	34680		10.1074/jbc.M003812200	http://dx.doi.org/10.1074/jbc.M003812200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10938273	hybrid			2022-12-27	WOS:000165095300091
J	Watada, H; Mirmira, RG; Leung, J; German, MS				Watada, H; Mirmira, RG; Leung, J; German, MS			Transcriptional and translational regulation of beta-cell differentiation factor Nkx6.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; INSULIN GENE; MICE LACKING; PANCREAS; BINDING; HOMEODOMAIN; INITIATION; ENTRY; CONTAINS; AGENESIS	In the mature pancreas, the homeodomain transcription factor Nkx6.1 is uniquely restricted to beta -cells, Nkx6.1 also is expressed in developing beta -cells and plays an essential role in their differentiation. Among cell Lines, both beta- and alpha -cell lines express nkx6.1 mRNA; but no protein can be detected in the alpha -cell lines, suggesting that post-transcriptional regulation contributes to the restriction of Nkx6.1 to beta -cells. To investigate the regulator of Nkx6.1 expression, we outlined the structure of the mouse nkx6.1 gene, and we identified regions that direct cell type-specific expression. The nkx6.1 gene has a long 5'-untranslated region (5'-UTR) downstream of a cluster of transcription start sites, nkx6.1 gene sequences from -5.6 to +1.0 kilobase pairs have specific promoter activity in beta -cell Lines but not in NIH3T3 cells. This activity is dependent on sequences located at about -800 base pairs and on the 5'-UTR. Electrophoretic mobility shift assays demonstrate that homeodomain transcription factors PDX1 and Nkx2.2 can bind to the sequence element located at -800 base pairs. In addition, dicistronic assays establish that the 5'-UTR region functions as a potent internal ribosomal entry site, providing cell type-specific regulation of translation. These data demonstrate that complex regulation of both Nkx6.1 transcription and translation provides the specificity of expression required during pancreas development.	Univ Calif San Francisco, Hormone Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	German, MS (corresponding author), Univ Calif San Francisco, Hormone Res Inst, 513 Parnassus Ave, San Francisco, CA 94143 USA.		Mirmira, Raghavendra G/AAD-7592-2020	Mirmira, Raghavendra G/0000-0002-5013-6075; Watada, Hirotaka/0000-0001-5961-1816	NIDDK NIH HHS [DK30255, DK31371, R01 DK021344] Funding Source: Medline; PHS HHS [K08] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021344] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Bernstein J, 1997, J BIOL CHEM, V272, P9356; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; GERMAN MS, 1992, MOL CELL BIOL, V12, P1777, DOI 10.1128/MCB.12.4.1777; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; Harrison KA, 1999, NAT GENET, V23, P71, DOI 10.1038/12674; Jacquemin P, 2000, MOL CELL BIOL, V20, P4445, DOI 10.1128/MCB.20.12.4445-4454.2000; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Lannoy VJ, 1998, J BIOL CHEM, V273, P13552, DOI 10.1074/jbc.273.22.13552; Li H, 1999, NAT GENET, V23, P67; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Mirmira RG, 2000, J BIOL CHEM, V275, P14743, DOI 10.1074/jbc.275.19.14743; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Oster A, 1998, J HISTOCHEM CYTOCHEM, V46, P707, DOI 10.1177/002215549804600602; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; RUDNICK A, 1994, P NATL ACAD SCI USA, V91, P12203, DOI 10.1073/pnas.91.25.12203; SAMBROOK J, 1989, MOL CLONING, V1, P7; Sander M, 1997, J MOL MED, V75, P327, DOI 10.1007/s001090050118; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; Schwitzgebel VM, 2000, DEVELOPMENT, V127, P3533; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Sussel L, 1998, DEVELOPMENT, V125, P2213; Teerink H, 1995, BBA-GENE STRUCT EXPR, V1264, P403, DOI 10.1016/0167-4781(95)00185-9; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; Watada H, 2000, P NATL ACAD SCI USA, V97, P9443, DOI 10.1073/pnas.97.17.9443; Ye X, 1997, MOL CELL BIOL, V17, P1714, DOI 10.1128/MCB.17.3.1714	35	56	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34224	34230		10.1074/jbc.M004981200	http://dx.doi.org/10.1074/jbc.M004981200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10938085	hybrid			2022-12-27	WOS:000165095300032
J	Vancompernolle, K; Boonefaes, T; Mann, M; Fiers, W; Grooten, J				Vancompernolle, K; Boonefaes, T; Mann, M; Fiers, W; Grooten, J			Tumor necrosis factor-induced microtubule stabilization mediated by hyperphosphorylated oncoprotein 18 promotes cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; DESTABILIZING ACTIVITY; FACTOR RECEPTOR; INTACT-CELLS; PHOSPHORYLATION; STATHMIN; GENE; DYNAMICS; IDENTIFICATION; PHOSPHOPROTEIN	Tumor necrosis factor (TNF)-induced cell death in the fibrosarcoma cell line L929 occurs independently of caspase activation and cytochrome c release. However, it is dependent on mitochondria and is characterized by increased production of reactive oxygen intermediates that are essential to the death process. To identify signaling molecules involved in this TNF-induced, reactive oxygen intermediate-dependent cell death pathway, we performed a comparative study by two-dimensional gel electrophoresis of phosphoproteins from a mitochondria-enriched fraction derived from TNF-treated and control cells. TNF induced rapid and persistent phosphorylation of the phosphorylation-responsive regulator of the microtubule (MT) dynamics, oncoprotein 18 (Op18). By using induced overexpression of wild type Op18 and phosphorylation site-deficient mutants S25A/S38A and S16A/S63A in L929 cells, we show that TNF-induced phosphorylation on each of the four Ser residues of Op18 promotes cell death and that Ser(16) and Ser(63) are the primary sites, This hyperphosphorylation of Op18 is known to completely turn off its NPT-destabilizing activity. As a result, TNF treatment of L929 cells induced elongated and extremely tangled microtubules. These TNF-induced changes to the MT network were also observed in cells overexpressing wild type Op18 and, to a lesser extent, in cells overexpressing the S25A/S38A mutant. No changes in the MT network were observed upon TNF treatment of cells overexpressing the S16A/S63A mutant, and these cells were desensitized to TNF-induced cell death. These findings indicate that TNF-induced MT stabilization is mediated by hyperphosphorylation of Op18 and that this promotes cell death. The data suggest that Op18 and the MT network play a functional role in transduction of the cell death signal to the mitochondria.	State Univ Ghent, Dept Mol Biol, B-9000 Ghent, Belgium; Flanders Interuniv Inst Biotechnol, B-9000 Ghent, Belgium; European Mol Biol Lab, Prot & Peptide Grp, D-69117 Heidelberg, Germany	Ghent University; European Molecular Biology Laboratory (EMBL)	Vancompernolle, K (corresponding author), State Univ Ghent, Dept Mol Biol, KL Ledeganckstr 35, B-9000 Ghent, Belgium.		Mann, Matthias/A-3454-2013	Mann, Matthias/0000-0003-1292-4799				Ahn J, 1999, ONCOGENE, V18, P5954, DOI 10.1038/sj.onc.1202986; Ameyar M, 1999, ONCOGENE, V18, P5464, DOI 10.1038/sj.onc.1202919; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BERETTA L, 1993, J BIOL CHEM, V268, P20076; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bieche I, 1998, BRIT J CANCER, V78, P701, DOI 10.1038/bjc.1998.565; BRATTSAND G, 1993, LEUKEMIA, V7, P569; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; De Vos K, 1998, J BIOL CHEM, V273, P9673, DOI 10.1074/jbc.273.16.9673; DiPaolo G, 1997, FEBS LETT, V416, P149, DOI 10.1016/S0014-5793(97)01188-5; DOYE V, 1989, J BIOL CHEM, V264, P12134; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Goossens V, 1999, BIOFACTORS, V10, P145, DOI 10.1002/biof.5520100210; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Gradin HM, 1998, J CELL BIOL, V140, P131, DOI 10.1083/jcb.140.1.131; GROOTEN J, 1993, CYTOKINE, V5, P546, DOI 10.1016/S1043-4666(05)80003-1; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; GUY GR, 1991, J BIOL CHEM, V266, P14343; GUY GR, 1992, J BIOL CHEM, V267, P1846; Hanash SM, 1998, ELECTROPHORESIS, V19, P2004, DOI 10.1002/elps.1150191119; Hehner SP, 1998, J BIOL CHEM, V273, P18117, DOI 10.1074/jbc.273.29.18117; Horwitz SB, 1997, J BIOL CHEM, V272, P8129, DOI 10.1074/jbc.272.13.8129; Howell B, 1999, J CELL SCI, V112, P3713; HUG H, 1988, MOL CELL BIOL, V8, P3065, DOI 10.1128/MCB.8.8.3065; Jeha S, 1996, CANCER RES, V56, P1445; Larsson N, 1997, MOL CELL BIOL, V17, P5530, DOI 10.1128/MCB.17.9.5530; Lawler S, 1998, CURR BIOL, V8, pR212, DOI 10.1016/S0960-9822(98)70128-9; Li YB, 1998, MOL BRAIN RES, V55, P277, DOI 10.1016/S0169-328X(98)00008-4; LLEONART R, 1990, BIO-TECHNOL, V8, P1263, DOI 10.1038/nbt1290-1263; Lovric J, 1998, J BIOL CHEM, V273, P22848; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	37	28	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33876	33882		10.1074/jbc.M004785200	http://dx.doi.org/10.1074/jbc.M004785200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10913145	hybrid			2022-12-27	WOS:000090104600096
J	Bofill-Cardona, E; Kudlacek, O; Yang, Q; Ahorn, H; Freissmuth, M; Nanoff, C				Bofill-Cardona, E; Kudlacek, O; Yang, Q; Ahorn, H; Freissmuth, M; Nanoff, C			Binding of calmodulin to the D-2-dopamine receptor reduces receptor signaling by arresting the G protein activation switch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F LOOP REGION; DOPAMINE-RECEPTORS; A(1)-ADENOSINE RECEPTOR; REGULATORY PROTEINS; ADENYLYL-CYCLASE; ALPHA-SUBUNITS; BRAIN-REGIONS; BETA-SUBUNIT; RAT-BRAIN; EXPRESSION	Signaling by D-2-dopamine receptors in neurons likely proceeds in the presence of Ca2+ oscillations. We describe here the biochemical basis for a cross-talk between intracellular Ca2+ and the D-2 receptor. By activation of calmodulin (CaM), Ca2+ directly inhibits the D-2 receptor; this conclusion is based on the following observations: (i) The receptor contains a CaM-binding motif in the NH2-terminal end of the third loop, a domain involved in activating G(i/o). A peptide fragment encompassing this domain (D2N) bound dansylated CaM in a Ca2+-dependent manner (K-D similar to 0.1 muM). (ii) Activation of purified G alpha (il) by D2N, and D-2 receptor-promoted GTP gammaS (guanosine 5'-(3-O-thio)triphosphate) binding in membranes was suppressed by Ca2+/CaM (IC50 similar to 0.1 muM), (iii) If Ca2+ influx was elicited in D-2 receptor-expressing HEK293 cells, agonist-dependent inhibition of cAMP formation decreased. This effect was not seen with other G(i)-coupled receptors (A(1)-adenosine and Mel(1A)-melatonin receptor). (iv) The D-2 receptor was retained by immobilized CaM and radiolabeled CaM was co-immunoprecipitated with the receptor. Specifically, inhibition by CaM does not result from uncoupling the D-2 receptor from its cognate G protein(s); rather, CaM directly targets the D-2 receptor to block the receptor-operated G protein activation switch.	Univ Vienna, Inst Pharmacol, A-1090 Vienna, Austria; Boehringer Ingelheim Austria GMBH, A-1120 Vienna, Austria	University of Vienna; Boehringer Ingelheim	Nanoff, C (corresponding author), Univ Vienna, Inst Pharmacol, Wahringer Str 13A, A-1090 Vienna, Austria.	christian.nanoff@univie.ac.at		Freissmuth, Michael/0000-0001-9398-1765; Kudlacek, Oliver/0000-0002-3086-8551; nanoff, christian/0000-0002-8857-2470				Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; Bahia DS, 1998, BIOCHEMISTRY-US, V37, P11555, DOI 10.1021/bi980284o; BOUNDY VA, 1993, MOL PHARMACOL, V43, P666; Brydon L, 1999, MOL ENDOCRINOL, V13, P2025, DOI 10.1210/me.13.12.2025; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; Hohenegger M, 1996, MOL PHARMACOL, V49, P73; Holler C, 1999, CELL MOL LIFE SCI, V55, P257, DOI 10.1007/s000180050288; Huff RM, 1996, CELL SIGNAL, V8, P453, DOI 10.1016/S0898-6568(96)00074-5; Jackson VN, 1999, MOL PHARMACOL, V55, P195, DOI 10.1124/mol.55.2.195; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P3; Liu MY, 1997, J BIOL CHEM, V272, P18801, DOI 10.1074/jbc.272.30.18801; MONS N, 1994, MOL BRAIN RES, V22, P236, DOI 10.1016/0169-328X(94)90052-3; MORI A, 1994, BRAIN RES, V654, P177, DOI 10.1016/0006-8993(94)91587-3; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; Nakajima Y, 1999, J BIOL CHEM, V274, P27573, DOI 10.1074/jbc.274.39.27573; Nanoff C, 1997, NEUROPHARMACOLOGY, V36, P1211, DOI 10.1016/S0028-3908(97)00135-4; Nishi A, 1997, J NEUROSCI, V17, P8147; O'Connor V, 1999, SCIENCE, V286, P1180, DOI 10.1126/science.286.5442.1180; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; POLLI JW, 1994, J NEUROSCI, V14, P1251, DOI 10.1523/JNEUROSCI.14-03-01251.1994; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Roka F, 1999, MOL PHARMACOL, V56, P1014, DOI 10.1124/mol.56.5.1014; SELZER E, 1993, P NATL ACAD SCI USA, V90, P1609, DOI 10.1073/pnas.90.4.1609; SURMEIER DJ, 1993, TRENDS NEUROSCI, V16, P299, DOI 10.1016/0166-2236(93)90103-S; TAYLOR JM, 1994, J BIOL CHEM, V269, P27618; VOSS T, 1993, J BIOL CHEM, V268, P4637; Waldhoer M, 1998, MOL PHARMACOL, V53, P808; Waldhoer M, 1999, J BIOL CHEM, V274, P30571, DOI 10.1074/jbc.274.43.30571; Wang DX, 1999, J BIOL CHEM, V274, P22081, DOI 10.1074/jbc.274.31.22081; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Wu GY, 1998, J BIOL CHEM, V273, P7197, DOI 10.1074/jbc.273.13.7197; YAN C, 1994, J NEUROSCI, V14, P973; Yang K, 1996, BIOCHEMISTRY-US, V35, P12464, DOI 10.1021/bi960848t; Zawarynski P, 1998, FEBS LETT, V441, P383, DOI 10.1016/S0014-5793(98)01588-9	38	113	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32672	32680		10.1074/jbc.M002780200	http://dx.doi.org/10.1074/jbc.M002780200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10926927	hybrid			2022-12-27	WOS:000090003800042
J	Cambillau, C; Claverie, JM				Cambillau, C; Claverie, JM			Structural and genomic correlates of hyperthermostability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PYROCOCCUS-FURIOSUS; THERMOSTABILITY; RESOLUTION; STABILITY; SEQUENCE; ENZYMES; DNA	While most organisms grow at temperatures ranging between 20 and 50 degreesC, many archaea and a few bacteria have been found capable of withstanding temperatures close to 100 degreesC, or beyond, such as Pyrococcus or Aquifer Here we report the results of two independent large scale unbiased approaches to identify global protein properties correlating with an extreme thermophile lifestyle. First, we performed a comparative proteome analyses using 30 complete genome sequences from the three kingdoms. A large difference between the proportions of charged versus polar (noncharged) amino acids was found to be a signature of all hyperthermophilic organisms. Second, we analyzed the water accessible surfaces of 189 protein structures belonging to mesophiles or hyperthermophiles. We found that the surfaces of hyperthermophilic proteins exhibited the shift already observed at the genomic level, i.e, a proportion of solvent accessible charged residues strongly increased at the expense of polar residues. The biophysical requirements for the presence of charged residues at the protein surface, allowing protein stabilization through ion bonds, is therefore clearly imprinted and detectable in all genome sequences available to date.	CNRS UPR 9039, F-13402 Marseille 20, France; CNRS UMR 1889, F-13402 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS)	Cambillau, C (corresponding author), CNRS UPR 9039, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	cambillau@afmb.cnrs-mrs.fr	Claverie, Jean-Michel/AAG-4889-2019; Claverie, Jean Michel/Z-2183-2019	Claverie, Jean-Michel/0000-0003-1424-0315; 				Audic S, 1998, P NATL ACAD SCI USA, V95, P10026, DOI 10.1073/pnas.95.17.10026; BOHM G, 1994, INT J PEPT PROT RES, V43, P97; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Choi IG, 1997, EXTREMOPHILES, V1, P125, DOI 10.1007/s007920050025; CONNOLLY ML, 1983, SCIENCE, V306, P287; Danson MJ, 1998, TRENDS MICROBIOL, V6, P307, DOI 10.1016/S0966-842X(98)01316-X; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; Goldman A, 1995, STRUCTURE, V3, P1277, DOI 10.1016/S0969-2126(01)00263-5; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kawarabayasi Y, 1999, DNA Res, V6, P83, DOI 10.1093/dnares/6.2.83; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; KOROLEV S, 1995, P NATL ACAD SCI USA, V92, P9264, DOI 10.1073/pnas.92.20.9264; Lo Leggio L, 1999, PROTEINS, V36, P295; Maes D, 1999, PROTEINS, V37, P441, DOI 10.1002/(SICI)1097-0134(19991115)37:3<441::AID-PROT11>3.3.CO;2-Z; Pace CN, 2000, NAT STRUCT BIOL, V7, P345, DOI 10.1038/75100; PACE N, 2000, STRUCTURE LOND; Perl D, 2000, NAT STRUCT BIOL, V7, P380; Russell RJM, 1997, BIOCHEMISTRY-US, V36, P9983, DOI 10.1021/bi9705321; Scheraga HA, 1998, J BIOMOL STRUCT DYN, V16, P447, DOI 10.1080/07391102.1998.10508260; Tekaia F, 1999, GENOME RES, V9, P550; Thompson MJ, 1999, J MOL BIOL, V290, P595, DOI 10.1006/jmbi.1999.2889; Vogt G, 1997, J MOL BIOL, V269, P631, DOI 10.1006/jmbi.1997.1042; YIP KSP, 1995, STRUCTURE, V3, P1147, DOI 10.1016/S0969-2126(01)00251-9	23	230	237	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32383	32386		10.1074/jbc.C000497200	http://dx.doi.org/10.1074/jbc.C000497200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10940293	hybrid			2022-12-27	WOS:000090003800002
J	Schmidt, M; Frings, M; Mono, ML; Guo, YJ; Weernink, PAO; Evellin, S; Han, L; Jakobs, KH				Schmidt, M; Frings, M; Mono, ML; Guo, YJ; Weernink, PAO; Evellin, S; Han, L; Jakobs, KH			G protein-coupled receptor-induced sensitization of phospholipase C stimulation by receptor tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTORS; GROWTH-FACTOR RECEPTOR; HETEROLOGOUS POTENTIATION; SPHINGOSINE KINASE; INSULIN-RECEPTOR; EGF RECEPTOR; INHIBITION; ISOZYMES; GAMMA	Activation of stably expressed M-2 and M-3 muscarinic acetylcholine receptors (mAChRs) as well as of endogenously expressed lysophosphatidic acid and purinergic receptors in HEK-293 cells can induce a long lasting potentiation of phospholipase C (PLC) stimulation by these and other G protein-coupled receptors (GPCRs), Here, we report that GPCRs can induce an up-regulation of PLC stimulation by receptor tyrosine kinases (RTKs) as well and provide essential mechanistic characteristics of this sensitization process. Pretreatment of HEK-293 cells for 2 min with carbachol, a mAChR agonist, lysophosphatidic acid, or ATP, followed by agonist washout, strongly increased (by 23-fold) maximal PLC stimulation (measured greater than or equal to 40 min later) by epidermal growth factor and platelet-derived growth factor, but not insulin, and largely enhanced PLC sensitivity to these RTK agonists, The up-regulation of RTK-induced PLC stimulation was cycloheximide-insensitive and was observed for up to similar to 90 min after removal of the GPCR agonist, Sensitization of receptor-induced PLC stimulation caused by prior M-2 mAChR activation was fully prevented by pertussis toxin and strongly reduced by expression of G beta gamma scavengers. Furthermore, inhibition of conventional protein kinase C (PKC) isoenzymes and chelation of intracellular Ca2+ suppressed the sensitization process, while overexpression of PKC-alpha, but not PKC-beta1, further enhanced the M-2 mAChR-induced sensitization of PLC stimulation. None of these treatments affected acute PLC stimulation by either GPCR or RTK agonists, Taken together, short term activation of GPCRs can induce a strong and long lasting sensitization of PLC stimulation by RTKs, a process apparently involving G(i)-derived G beta gammas as well as increases in intracellular Ca2+ and activation of a PKC isoenzyme, most likely PKC-alpha.	Univ Essen Gesamthsch Klinikum, Inst Pharmakol, D-45122 Essen, Germany	University of Duisburg Essen	Schmidt, M (corresponding author), Univ Essen Gesamthsch Klinikum, Inst Pharmakol, Hufelandstr 55, D-45122 Essen, Germany.		Schmidt, Martina/C-5339-2018	Schmidt, Martina/0000-0003-3075-0630				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; CHILVERS ER, 1991, BIOCHEM J, V275, P373, DOI 10.1042/bj2750373; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; Gautam N, 1998, CELL SIGNAL, V10, P447, DOI 10.1016/S0898-6568(98)00006-0; Heringdorf DM, 1999, FEBS LETT, V461, P217, DOI 10.1016/S0014-5793(99)01463-5; Heringdorf DMZ, 1998, EMBO J, V17, P2830, DOI 10.1093/emboj/17.10.2830; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; Kayali AG, 1998, J BIOL CHEM, V273, P13808, DOI 10.1074/jbc.273.22.13808; KELLERER M, 1991, BIOCHEM BIOPH RES CO, V181, P566, DOI 10.1016/0006-291X(91)91227-4; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOVALENKO M, 1994, CANCER RES, V54, P6106; Krudewig R, 2000, J NEUROCHEM, V74, P1721, DOI 10.1046/j.1471-4159.2000.0741721.x; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; SALTIEL AR, 1996, AM J PHYSIOL, V270, P375; Schmidt M, 1996, MOL PHARMACOL, V50, P1038; SCHMIDT M, 1995, N-S ARCH PHARMACOL, V352, P469, DOI 10.1007/BF00169379; SCHMIDT M, 1995, J BIOL CHEM, V270, P19949, DOI 10.1074/jbc.270.34.19949; Schmidt M, 1998, MOL PHARMACOL, V53, P1139; SCHMIDT M, 1994, EUR J BIOCHEM, V225, P667, DOI 10.1111/j.1432-1033.1994.00667.x; Schmidt M, 1999, J BIOL CHEM, V274, P14648, DOI 10.1074/jbc.274.21.14648; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; VanEppsFung M, 1997, ENDOCRINOLOGY, V138, P5170, DOI 10.1210/en.138.12.5170; Voss M, 1999, J BIOL CHEM, V274, P34691, DOI 10.1074/jbc.274.49.34691; Whitehead JP, 2000, CURR OPIN CELL BIOL, V12, P222, DOI 10.1016/S0955-0674(99)00079-4; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	32	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32603	32610		10.1074/jbc.M004784200	http://dx.doi.org/10.1074/jbc.M004784200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10908568	hybrid			2022-12-27	WOS:000090003800033
J	Kang, J; Kim, T; Ko, YG; Rho, SB; Park, SG; Kim, MJ; Kwon, HJ; Kim, S				Kang, J; Kim, T; Ko, YG; Rho, SB; Park, SG; Kim, MJ; Kwon, HJ; Kim, S			Heat shock protein 90 mediates protein-protein interactions between human aminoacyl-tRNA synthetases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; MOLECULAR CHAPERONE; NUCLEOTIDE-SEQUENCE; COMPLEX; HSP90; FAMILY; CYTOKINE; GENE; ATP; IDENTIFICATION	Heat shock protein 90 (hsp90) is a molecular chaperone responsible for protein folding and maturation in vivo. Interaction of hsp90 with human glutamyl-prolyl-tRNA synthetase (EPRS) was found by genetic screening, co-immunoprecipitation, and in vitro binding experiments. This interaction was sensitive to the hsp90 inhibitor, geldanamycin, and also ATP, suggesting that the chaperone activity of hsp90 is required for interaction with EPRS. Interaction of EPRS with hsp90 was targeted to the region of three tandem repeats linking the two catalytic domains of EPRS that is also responsible for the interaction with isoleucyl-tRNA synthetase (IRS), Interaction of EPRS and IRS also depended on the activity of hsp90, implying that their association was mediated by hsp90. EPRS and IRS form a macromolecular protein complex with at least six other tRNA synthetases and three cofactors, hsp90 preferentially binds to most of the complex-forming enzymes rather than those that are not found in the complex. In addition, inactivation of hsp90 interfered with the in vivo incorporation of the nascent aminoacyl-tRNA synthetases into the multi-ARS complex. Thus, hsp90 appears to mediate protein-protein interactions of mammalian tRNA synthetases.	Sungkyunkwan Univ, Ctr ARS Network, Natl Creat Res Initiat Ctr, Jangan Gu, Suwon 440746, Kyunggido, South Korea; Sejong Univ, Dept Biosci & Biotechnol, Kwangjin Gu, Seoul 143747, South Korea	Sungkyunkwan University (SKKU); Sejong University	Kim, S (corresponding author), Sungkyunkwan Univ, Ctr ARS Network, Natl Creat Res Initiat Ctr, Jangan Gu, 300 Chunchundong, Suwon 440746, Kyunggido, South Korea.	shkim@yurim.skku.ac.kr	Kim, Sunghoon/AAE-8314-2020; 권, 호정/AAS-3642-2021					Bijlmakers MJJE, 2000, MOL BIOL CELL, V11, P1585, DOI 10.1091/mbc.11.5.1585; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Cerini C, 1997, EUR J BIOCHEM, V244, P176, DOI 10.1111/j.1432-1033.1997.00176.x; CIRAKOGLU B, 1985, FEBS LETT, V183, P185; Cruciat CM, 1999, EMBO J, V18, P5226, DOI 10.1093/emboj/18.19.5226; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; FARRELLY FW, 1984, J BIOL CHEM, V259, P5745; FETT R, 1991, J BIOL CHEM, V266, P1448; FROLOVA LY, 1991, GENE, V109, P291, DOI 10.1016/0378-1119(91)90624-K; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Grimaud R, 1998, J BACTERIOL, V180, P1148, DOI 10.1128/JB.180.5.1148-1153.1998; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HSIEH SL, 1991, BIOCHEM J, V278, P809, DOI 10.1042/bj2780809; KELLERMAYER MSZ, 1995, BIOCHEM BIOPH RES CO, V211, P166, DOI 10.1006/bbrc.1995.1792; Kleeman TA, 1997, J BIOL CHEM, V272, P14420, DOI 10.1074/jbc.272.22.14420; KRONE PH, 1994, BIOCHEM BIOPH RES CO, V204, P746, DOI 10.1006/bbrc.1994.2522; Liu XD, 1999, J BIOL CHEM, V274, P26654, DOI 10.1074/jbc.274.38.26654; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; MINAMI Y, 1994, MOL CELL BIOL, V14, P1459, DOI 10.1128/MCB.14.2.1459; MIRANDE M, 1982, EMBO J, V1, P733, DOI 10.1002/j.1460-2075.1982.tb01238.x; MOORE SK, 1989, J BIOL CHEM, V264, P5343; NEMOTO T, 1995, EUR J BIOCHEM, V233, P1, DOI 10.1111/j.1432-1033.1995.001_1.x; NORCUM MT, 1989, J BIOL CHEM, V264, P15043; Norcum MT, 1998, PROTEIN SCI, V7, P79, DOI 10.1002/pro.5560070108; Park SG, 1999, J BIOL CHEM, V274, P16673, DOI 10.1074/jbc.274.24.16673; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Quevillon S, 1996, FEBS LETT, V395, P63, DOI 10.1016/0014-5793(96)01005-8; Quevillon S, 1999, J MOL BIOL, V285, P183, DOI 10.1006/jmbi.1998.2316; Quevillon S, 1997, J BIOL CHEM, V272, P32573, DOI 10.1074/jbc.272.51.32573; REBBE NF, 1987, GENE, V53, P235, DOI 10.1016/0378-1119(87)90012-6; Rho SB, 1996, P NATL ACAD SCI USA, V93, P10128, DOI 10.1073/pnas.93.19.10128; Rho SB, 1999, P NATL ACAD SCI USA, V96, P4488, DOI 10.1073/pnas.96.8.4488; Rho SB, 1998, J BIOL CHEM, V273, P11267, DOI 10.1074/jbc.273.18.11267; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Schulte TW, 1998, CELL STRESS CHAPERON, V3, P100, DOI 10.1379/1466-1268(1998)003<0100:ARBTTN>2.3.CO;2; SHIBA K, 1994, J BIOL CHEM, V269, P30049; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; TSUI FWL, 1987, NUCLEIC ACIDS RES, V15, P3349, DOI 10.1093/nar/15.8.3349; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	42	29	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31682	31688		10.1074/jbc.M909965199	http://dx.doi.org/10.1074/jbc.M909965199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10913161	hybrid			2022-12-27	WOS:000089858900021
J	Todorov, AG; Einicker-Lamas, M; de Castro, SL; Oliveira, MM; Guilherme, A				Todorov, AG; Einicker-Lamas, M; de Castro, SL; Oliveira, MM; Guilherme, A			Activation of host cell phosphatidylinositol 3-kinases by Trypanosoma cruzi infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; C2 DOMAIN; INVASION; KINASE; MACROPHAGES; CALCIUM; PRODUCTS; PATHWAYS	Trypanosoma cruzi, the causative agent of Chagas' disease in humans, is an intracellular protozoan parasite with the ability to invade a wide variety of mammalian cells by a unique and remarkable process in cell biology that is poorly understood. Here we present evidence suggesting a role for the host phosphatidylinositol (PI) S-kinases during T. cruzi invasion. The PI 3-kinase inhibitor wortmannin marked inhibited T. cruzi infection when macrophages were pretreated for 20 min at 37 degrees C before inoculation. Infection of macrophages with T. cruzi markedly stimulated the formation of the lipid products of the phosphatidylinositol (PI) 3-kinases, PI 3-phospate, PI 3,4-biphosphate, and PI 3,4,5-triphosphate, but not PI 4-phosphate or PI 4,5-biphosphate. This activation was inhibited by wortmannin. Infection with T. cruzi also stimulated a marked increase in the in vitro lipid kinase activities that are present in the immunoprecipitates of anti-p85 subunit of class I PI 3-kinase and anti-phosphotyrosine. In addition, T. cruzi invasion also activated lipid kinase activity found in immunoprecipitates of class II and class III PI 3-kinases. These data demonstrate that T. cruzi invasion into macrophages strongly activates separated PI 3-kinase isoforms. Furthermore, the inhibition of the class I and class III PI 3-kinase activities abolishes the parasite entry into macrophages. These findings suggest a prominent role for the host PI 3-kinase activities during the T. cruzi infection process.	Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21941900 Rio De Janeiro, Brazil; Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Dept Ultraestrutura & Biol Celular, BR-21045900 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Fundacao Oswaldo Cruz	Guilherme, A (corresponding author), Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA.	Adilson.Guilherme@umassmed.edu	Castro, Solange L/K-9342-2015					ANDREWS NW, 1983, GENES ANTIGENS PARAS, P37; Arcaro A, 1998, J BIOL CHEM, V273, P33082, DOI 10.1074/jbc.273.49.33082; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown RA, 1999, J BIOL CHEM, V274, P14529, DOI 10.1074/jbc.274.21.14529; BURLEIGH BA, 1995, ANNU REV MICROBIOL, V49, P175, DOI 10.1146/annurev.mi.49.100195.001135; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; Forney JR, 1999, INFECT IMMUN, V67, P844, DOI 10.1128/IAI.67.2.844-852.1999; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; GUILHERME A, 1991, BIOCHEMISTRY-US, V30, P5700, DOI 10.1021/bi00237a010; Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Malaquias AT, 1999, ACTA TROP, V73, P93, DOI 10.1016/S0001-706X(99)00016-9; MING M, 1995, CELL, V82, P287, DOI 10.1016/0092-8674(95)90316-X; MORENO SNJ, 1994, J EXP MED, V180, P1535, DOI 10.1084/jem.180.4.1535; *NAT I ALL INF DIS, 1996, COUNCIL NEWS, V5, P1; Ono F, 1998, J BIOL CHEM, V273, P7731, DOI 10.1074/jbc.273.13.7731; Ruta S, 1996, PARASITOL RES, V82, P481, DOI 10.1007/s004360050149; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Turner SJ, 1998, J BIOL CHEM, V273, P25987, DOI 10.1074/jbc.273.40.25987; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; VIEIRA MCF, 1994, BIOCHEM BIOPH RES CO, V203, P967, DOI 10.1006/bbrc.1994.2276; Villalta F, 1998, BIOCHEM BIOPH RES CO, V249, P247, DOI 10.1006/bbrc.1998.9127; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; WHO, 2000, WEEKLY EPIDEMIOL REC, V894, DOI [10.1016/S0140-6736(57)91352-1, DOI 10.1016/S0140-6736(57)91352-1]; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129; Zhang J, 1998, J BIOL CHEM, V273, P14081, DOI 10.1074/jbc.273.23.14081	31	44	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32182	32186		10.1074/jbc.M909440199	http://dx.doi.org/10.1074/jbc.M909440199			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10913160	hybrid			2022-12-27	WOS:000089858900086
J	Belandia, B; Parker, MG				Belandia, B; Parker, MG			Functional interaction between the p160 coactivator proteins and the transcriptional enhancer factor family of transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR COACTIVATOR-1; DNA-BINDING DOMAIN; M-CAT ELEMENTS; FACTOR-I; NUCLEAR-RECEPTOR; HISTONE ACETYLTRANSFERASE; MEDIATED TRANSACTIVATIONS; ACTIVATION FUNCTION; ESTROGEN-RECEPTOR; GENE-EXPRESSION	SRC1, initially identified as a nuclear receptor coactivator, was found to interact with a member of the transcriptional enhancer factor (TEF) family of transcription factors, TEF-4, The interaction, which occurs in both intact cells and in a cell-free system, is mediated by the highly conserved basic helix-loop-helix/Per-Arnt-Sim (bHLH-PAS) domain present in the N-terminal region of SRC1. Moreover, all three members of the p160 family of nuclear receptor coactivators, SRC1, TIF2, and RAGS, are able to potentiate transcription from a TEF response element in transient transfection experiments, and this activation requires the presence of the bHLH-PAS domain. These results suggest that the p160 proteins could be bona fide coactivators of the TEF family of transcription factors.	Imperial Canc Res Fund, Mol Endocrinol Lab, London WC2A 3PX, England	Cancer Research UK; University of London; Queen Mary University London	Parker, MG (corresponding author), Imperial Canc Res Fund, Mol Endocrinol Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Belandia, Borja/H-1509-2015	Belandia, Borja/0000-0003-2448-206X				Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Bray S, 1999, CURR BIOL, V9, pR245, DOI 10.1016/S0960-9822(99)80154-7; BURGLIN TR, 1991, CELL, V66, P11, DOI 10.1016/0092-8674(91)90132-I; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Carson JA, 1996, AM J PHYSIOL-CELL PH, V270, pC1624, DOI 10.1152/ajpcell.1996.270.6.C1624; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen SL, 2000, GENE DEV, V14, P1209; Crews ST, 1999, CURR OPIN GENET DEV, V9, P580, DOI 10.1016/S0959-437X(99)00003-9; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; Glass CK, 2000, GENE DEV, V14, P121; Gupta MP, 1997, MOL CELL BIOL, V17, P3924, DOI 10.1128/MCB.17.7.3924; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HWANG JJ, 1993, EMBO J, V12, P2337, DOI 10.1002/j.1460-2075.1993.tb05888.x; Ikeda M, 1999, MOL CELL ENDOCRINOL, V147, P103, DOI 10.1016/S0303-7207(98)00211-1; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; Jacquemin P, 1996, J BIOL CHEM, V271, P21775, DOI 10.1074/jbc.271.36.21775; Jacquemin P, 1997, J BIOL CHEM, V272, P12928, DOI 10.1074/jbc.272.20.12928; Jiang SW, 1999, MOL ENDOCRINOL, V13, P879, DOI 10.1210/me.13.6.879; Jiang SW, 1996, J BIOL CHEM, V271, P9510, DOI 10.1074/jbc.271.16.9510; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; KARIYA K, 1993, J BIOL CHEM, V268, P26658; Kim HJ, 1998, J BIOL CHEM, V273, P28564, DOI 10.1074/jbc.273.44.28564; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Lahooti H, 1995, J STEROID BIOCHEM, V55, P305, DOI 10.1016/0960-0760(95)00188-3; Larkin SB, 1996, MOL CELL BIOL, V16, P3742; LEDOUARIN B, 1995, NUCLEIC ACIDS RES, V23, P876, DOI 10.1093/nar/23.5.876; Lee SK, 1999, MOL ENDOCRINOL, V13, P1924, DOI 10.1210/me.13.11.1924; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MELIN F, 1993, EMBO J, V12, P4657, DOI 10.1002/j.1460-2075.1993.tb06154.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Montano MM, 1997, MOL ENDOCRINOL, V11, P330, DOI 10.1210/me.11.3.330; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Peterson CL, 2000, J CELL BIOCHEM, V78, P179, DOI 10.1002/(SICI)1097-4644(20000801)78:2<179::AID-JCB1>3.0.CO;2-E; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Vaudin P, 1999, DEVELOPMENT, V126, P4807; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; YASUNAMI M, 1995, J BIOL CHEM, V270, P18649, DOI 10.1074/jbc.270.31.18649	50	97	97	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30801	30805		10.1074/jbc.C000484200	http://dx.doi.org/10.1074/jbc.C000484200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10934189	hybrid			2022-12-27	WOS:000089762700011
J	Santana, MA; Pedraza-Alva, G; Olivares-Zavaleta, N; Madrid-Marina, V; Horejsi, V; Burakoff, SJ; Rosenstein, Y				Santana, MA; Pedraza-Alva, G; Olivares-Zavaleta, N; Madrid-Marina, V; Horejsi, V; Burakoff, SJ; Rosenstein, Y			CD43-mediated signals induce DNA binding activity of AP-1, NF-AT, and NF kappa B transcription factors in human T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH SYNDROME; CELL ACTIVATION; PROTEIN-KINASE; NUCLEAR FACTOR; SURFACE SIALOGLYCOPROTEIN; CD43 LEUKOSIALIN; GENE-EXPRESSION; CYCLOSPORINE-A; CROSS-LINKING; IL-2 GENE	Although numerous reports document a role for CD43 in T cell signaling, the direct participation of this molecule in cell activation has been questioned. In this study we show that CD43 ligation on human normal peripheral T cells was sufficient to induce interleukin-2, CD69, and CD40-L gene expression, without requiring signals provided by additional receptor molecules. This response was partially inhibited by cyclosporin A and staurosporine, suggesting the participation of both the Ca2+ and the protein kinase C pathways in CD43 signaling. Consistent with the transient CD43-dependent intracellular Ca2+ peaks reported by others, signals generated through the CD43 molecule resulted in the induction of NF-AT DNA binding activity. CD43-dependent signals resulted also in AP-1 and NF kappa B activation, probably as a result of protein kinase C involvement. AP-1 complexes bound to the AP-1 sequence contained c-Jun, and those bound to the NF-AT-AP-1 composite site contained c-Jun and Fos. NF kappa B complexes containing p65 could be found as early as 1 h after CD43 crosslinking, suggesting that CD43 participates in early events of T cell activation. The induction of the interleukin-a, CD69, and CD-40L genes and the participation of AP-1, NF-AT, and NF kappa B in the CD43-mediated signaling cascade implicate an important role for this molecule in the regulation of gene expression and cell function.	Univ Nacl Autonoma Mexico, Inst Biotecnol, Cuernavaca 62250, Morelos, Mexico; Inst Nacl Salud Publ, Ctr Invest Enfermedades Infecciosas, Dept Inmunol Viral, Cuernavaca 62508, Morelos, Mexico; Acad Sci Czech Republ, Inst Mol Genet, CR-14220 Prague, Czech Republic; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Universidad Nacional Autonoma de Mexico; Instituto Nacional de Salud Publica; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Rosenstein, Y (corresponding author), Univ Nacl Autonoma Mexico, Inst Biotecnol, Apartado Postal 510-3, Cuernavaca 62250, Morelos, Mexico.		Santana, M. Angélica/F-3593-2019; Horejsi, Vaclav/G-3113-2014	Santana, M. Angélica/0000-0001-8373-7873; Horejsi, Vaclav/0000-0003-4925-0142				AlberolaIla J, 1997, ANNU REV IMMUNOL, V15, P125, DOI 10.1146/annurev.immunol.15.1.125; ALVARADO M, 1995, EUR J IMMUNOL, V25, P1051, DOI 10.1002/eji.1830250429; AXELSSON B, 1988, J IMMUNOL, V141, P2912; Babina M, 1997, EUR J IMMUNOL, V27, P1147, DOI 10.1002/eji.1830270515; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown TJ, 1996, J BIOL CHEM, V271, P27686, DOI 10.1074/jbc.271.44.27686; Castellanos MD, 1997, J IMMUNOL, V159, P5463; Chen SQ, 1997, P NATL ACAD SCI USA, V94, P3172, DOI 10.1073/pnas.94.7.3172; Corinti S, 1999, J IMMUNOL, V162, P6331; CYSTER JG, 1991, EMBO J, V10, P893, DOI 10.1002/j.1460-2075.1991.tb08022.x; CYSTER JG, 1992, EUR J IMMUNOL, V22, P2565, DOI 10.1002/eji.1830221015; delPozo MA, 1997, J CELL BIOL, V137, P493; DESMET W, 1993, IMMUNOLOGY, V79, P46; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Ellies LG, 1996, BLOOD, V88, P1725, DOI 10.1182/blood.V88.5.1725.bloodjournal8851725; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; Ghosh P, 1996, J BIOL CHEM, V271, P7700, DOI 10.1074/jbc.271.13.7700; GIORDANENGO V, 1995, BLOOD, V86, P2302, DOI 10.1182/blood.V86.6.2302.bloodjournal8662302; Grassl C, 1999, J AM SOC NEPHROL, V10, P1466; Harrington LE, 2000, J EXP MED, V191, P1241, DOI 10.1084/jem.191.7.1241; Huang TT, 1999, MOL CELL ENDOCRINOL, V152, P21, DOI 10.1016/S0303-7207(99)00067-2; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Jones A.M., 1994, BRIT J MANAGE, V5, P153, DOI DOI 10.1111/J.1467-8551.1994.TB00075.X; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LOPEZCABRERA M, 1995, J BIOL CHEM, V270, P21545, DOI 10.1074/jbc.270.37.21545; MANJUNATH N, 1993, J IMMUNOL, V151, P1528; MANJUNATH N, 1995, NATURE, V377, P535, DOI 10.1038/377535a0; MENTZER SJ, 1987, J EXP MED, V165, P1383, DOI 10.1084/jem.165.5.1383; Mondino A, 1996, J IMMUNOL, V157, P2048; MURPHY TL, 1995, MOL CELL BIOL, V15, P5258; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OSTERBERG JR, 1998, IMMUNOL TODAY, V19, P546; PADILLANORIEGA L, 1993, J CLIN MICROBIOL, V31, P622, DOI 10.1128/JCM.31.3.622-628.1993; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; PARK JK, 1991, NATURE, V350, P706, DOI 10.1038/350706a0; Pedraza-Alva G, 1998, J BIOL CHEM, V273, P14218, DOI 10.1074/jbc.273.23.14218; PEDRAZAALVA G, 1994, J BIOL CHEM, V269, P6978; PedrazaAlva G, 1996, J BIOL CHEM, V271, P27564, DOI 10.1074/jbc.271.44.27564; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; REMOLDODONNELL E, 1986, J BIOL CHEM, V261, P7526; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; Rosenstein Y, 1999, IMMUNOL RES, V20, P89, DOI 10.1007/BF02786465; SANCHEZMATEOS P, 1995, BLOOD, V86, P2228, DOI 10.1182/blood.V86.6.2228.bloodjournal8662228; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHELLEY CS, 1989, P NATL ACAD SCI USA, V86, P2819, DOI 10.1073/pnas.86.8.2819; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SPERLING AI, 1995, J EXP MED, V182, P139, DOI 10.1084/jem.182.1.139; Srivastava S, 1999, J CLIN INVEST, V104, P503, DOI 10.1172/JCI7094; STEFANOVA I, 1988, FOLIA BIOL-PRAGUE, V34, P255; Stockl J, 1996, J EXP MED, V184, P1769, DOI 10.1084/jem.184.5.1769; Stockton BM, 1998, IMMUNITY, V8, P373, DOI 10.1016/S1074-7613(00)80542-7; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Timmerman LA, 1997, J IMMUNOL, V159, P2735; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Tsytsykova AV, 1996, J BIOL CHEM, V271, P3763; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WONG RCK, 1990, J IMMUNOL, V144, P1455	69	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31460	31468		10.1074/jbc.M005231200	http://dx.doi.org/10.1074/jbc.M005231200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10908570	hybrid			2022-12-27	WOS:000089762700100
J	Takeuchi, S; Takayama, Y; Ogawa, A; Tamura, K; Okada, M				Takeuchi, S; Takayama, Y; Ogawa, A; Tamura, K; Okada, M			Transmembrane phosphoprotein Cbp positively regulates the activity of the carboxyl-terminal Src kinase, Csk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; T-CELL ACTIVATION; NEGATIVE REGULATION; FAMILY KINASES; C-SRC; SUPPRESSION; MEMBRANES; P50(CSK); RAFTS	Csk (carboxyl-terminal Src kinase) is a cytoplasmic tyrosine kinase that phosphorylates a critical tyrosine residue in each of the Src family kinases (SFKs) to inhibit their activities. Recently, we identified a transmembrane protein, Cbp (Csk-binding protein), that, when phosphorylated, can recruit Csk to the membrane where the SFKs are located. The Cbp-mediated relocation of Csk to the membrane may play a role in turning off the signaling events initiated by SFKs, To further characterize the Csk-Cbp interaction, we have generated a reconstituted system using soluble, highly purified proteins. Csk and phosphorylated Cbp were co-purified as a large protein complex consisting of at least four Csk-Cbp units. The addition of the phosphorylated, but not nonphosphorylated, Cbp to an in vitro assay stimulated Csk activity toward Src. Csk was also activated by a phosphopeptide containing the tyrosine in Cbp that binds to Csk (Tyr-314), Kinetic analysis revealed that Cbp or the phosphopeptide induced up to a g-fold reduction in the K-m for Src, indicating that the Csk Cbp complex has a greater affinity for Src than free Csk. These findings suggest that Cbp is involved in the regulation of SFKs not only by relocating Csk to the membrane but also by directly activating Csk.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan	Osaka University	Okada, M (corresponding author), Osaka Univ, Inst Prot Res, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Takayama, Yoshiharu/M-8826-2019; Takayama, Yoshiharu/E-3662-2010	Takayama, Yoshiharu/0000-0003-4532-7114; Takayama, Yoshiharu/0000-0003-4532-7114				Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; CLOUTIER JF, 1995, MOL CELL BIOL, V15, P5937; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sun GQ, 1999, ARCH BIOCHEM BIOPHYS, V367, P167, DOI 10.1006/abbi.1999.1253; Thomas ML, 1999, IMMUNOL TODAY, V20, P406, DOI 10.1016/S0167-5699(99)01506-6; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	19	128	135	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29183	29186		10.1074/jbc.C000326200	http://dx.doi.org/10.1074/jbc.C000326200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10918051	hybrid			2022-12-27	WOS:000089439800002
J	Chao, SH; Fujinaga, K; Marion, JE; Taube, R; Sausville, EA; Senderowicz, AM; Peterlin, BM; Price, DH				Chao, SH; Fujinaga, K; Marion, JE; Taube, R; Sausville, EA; Senderowicz, AM; Peterlin, BM; Price, DH			Flavopiridol inhibits P-TEFb and blocks HIV-1 replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; BREAST-CARCINOMA CELLS; IN-VITRO; ELONGATION COMPLEXES; TAT TRANSACTIVATION; KINASE-ACTIVITY; TRANSCRIPTION; PROTEIN; ACTIVATION; PHOSPHATASE	Flavopiridol (L86-8275, HMR1275) is a cyclin-dependent kinase (Cdk) inhibitor that is in clinical trials as a cancer treatment because of its antiproliferative properties. We found that the flavonoid potently inhibited transcription by RNA polymerase II in vitro by blocking the transition into productive elongation, a step controlled by P-TEFb, The ability of P-TEFb to phosphorylate the carboxyl-terminal domain of the large subunit of RNA polymerase II was inhibited by flavopiridol with a K-i of 3 nM. Interestingly, the drug was not competitive with ATP. P-TEFb composed of Cdk9 and cyclin T1 is a required cellular cofactor for the human immunodeficiency virus (HIV-1) transactivator, Tat, Consistent with its ability to inhibit P-TEFb, flavopiridol blocked Tat transactivation of the viral promoter in vitro. Furthermore, flavopiridol blocked HIV-1 replication in both single-round and viral spread assays with an IC50 of less than 10 nM.	Univ Iowa, Program Mol Biol, Iowa City, IA 52242 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; NCI, Dev Therapeut Program, Clin Trials Unit, Div Canc Treatment & Diag,NIH, Bethesda, MD 20892 USA	University of Iowa; University of Iowa; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Senderowicz, AM (corresponding author), Univ Iowa, Program Mol Biol, Iowa City, IA 52242 USA.		Price, David H/F-6173-2010; TAUBE, RAN/F-2029-2012	TAUBE, RAN/0000-0002-2062-4537; Price, David/0000-0002-5597-385X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043691] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000701] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035500] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43691] Funding Source: Medline; NIGMS NIH HHS [GM35500] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bieniasz PD, 1999, MOL CELL BIOL, V19, P4592, DOI 10.1128/mcb.19.7.4592; Carlson B, 1999, CANCER RES, V59, P4634; Carlson BA, 1996, CANCER RES, V56, P2973; Cho H, 1999, GENE DEV, V13, P1540, DOI 10.1101/gad.13.12.1540; Cleland W W, 1979, Methods Enzymol, V63, P103; DE AWJ, 1996, P NATL ACAD SCI USA, V93, P2735; Fackler OT, 1997, EUR J BIOCHEM, V247, P843, DOI 10.1111/j.1432-1033.1997.00843.x; Flores OL, 1999, P NATL ACAD SCI USA, V96, P7208, DOI 10.1073/pnas.96.13.7208; Fu TJ, 1999, J BIOL CHEM, V274, P34527, DOI 10.1074/jbc.274.49.34527; Garber ME, 1999, CURR OPIN IMMUNOL, V11, P460, DOI 10.1016/S0952-7915(99)80077-6; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; Garriga J, 1998, ONCOGENE, V17, P3093, DOI 10.1038/sj.onc.1202548; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; LOSIEWICZ MD, 1994, BIOCHEM BIOPH RES CO, V201, P589, DOI 10.1006/bbrc.1994.1742; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; Marshall NF, 1998, J BIOL CHEM, V273, P31726, DOI 10.1074/jbc.273.48.31726; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Peng J, 1998, COLD SPRING HARB SYM, V63, P365, DOI 10.1101/sqb.1998.63.365; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Senderowicz AM, 2000, JNCI-J NATL CANCER I, V92, P376, DOI 10.1093/jnci/92.5.376; Senderowicz AM, 1998, J CLIN ONCOL, V16, P2986, DOI 10.1200/JCO.1998.16.9.2986; Taube R, 1999, VIROLOGY, V264, P245, DOI 10.1006/viro.1999.9944; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Wu-Baer F, 1998, J MOL BIOL, V277, P179, DOI 10.1006/jmbi.1997.1601; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	30	404	438	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28345	28348		10.1074/jbc.C000446200	http://dx.doi.org/10.1074/jbc.C000446200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10906320	hybrid			2022-12-27	WOS:000089330700002
J	Meyermans, H; Morreel, K; Lapierre, C; Pollet, B; De Bruyn, A; Busson, R; Herdewijn, P; Devreese, B; Van Beeumen, J; Marita, JM; Ralph, J; Chen, CY; Burggraeve, B; Van Montagu, M; Messens, E; Boerjan, W				Meyermans, H; Morreel, K; Lapierre, C; Pollet, B; De Bruyn, A; Busson, R; Herdewijn, P; Devreese, B; Van Beeumen, J; Marita, JM; Ralph, J; Chen, CY; Burggraeve, B; Van Montagu, M; Messens, E; Boerjan, W			Modifications in lignin and accumulation of phenolic glucosides in poplar xylem upon down-regulation of caffeoyl-coenzyme A O-methyltransferase, an enzyme involved in lignin biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VANILLA-PLANIFOLIA ANDR; PHENYLPROPANOID METABOLISM; SUBSTRATE SPECIFICITIES; SUSPENSION-CULTURES; TRANSGENIC POPLARS; MAIZE LIGNIN; ACID; EXPRESSION; SYRINGYL; METHYLATION	Caffeoyl-coenzyme A O-methyltransferase (CCoAOMT) methylates, in vitro, caffeoyl-CoA and 5-hydroxyferuloyl-CoA, two possible precursors in monolignol biosynthesis in vivo. To clarify the in vivo role of CCoAOMT in lignin biosynthesis, transgenic poplars with 10% residual CCoAOMT protein levels in the stem xylem were generated. Upon analysis of the xylem, the affected transgenic lines had a 12% reduced Klason lignin content, an 11% increased syringyl/guaiacyl ratio in the noncondensed lignin fraction, and an increase in lignin-attached p-hydroxybenzoate but otherwise a lignin composition similar to that of wild type. Stem xylem of the CCoAOMT-down-regulated lines had a pink-red coloration, which coincided with an enhanced fluorescence of mature vessel cell walls. The reduced production of CCoAOMT caused an accumulation of O-3-beta -D-glucopyranosyl-caffeic acid, O-4-beta -D-glucopyranosyl-vanillic acid, and O-4-beta -D-glucopyranosyl-sinapic acid (GSA), as authenticated by H-1 NMR Feeding experiments showed that O-3-beta -D-glucopyranosyl-caffeic acid and GSA are storage or detoxification products of caffeic and sinapic acid, respectively. The observation that down-regulation of CCoAOMT decreases lignin amount whereas GSA accumulates to 10% of soluble phenolics indicates that endogenously produced sinapic acid is not a major precursor in syringyl lignin biosynthesis. Our in vivo results support the recently obtained in vitro enzymatic data that suggest that the route hom caffeic acid to sinapic acid is not used for lignin biosynthesis.	State Univ Ghent VIB, Dept Plantengenet, B-9000 Ghent, Belgium; State Univ Ghent VIB, Vakgrp Mol Genet, B-9000 Ghent, Belgium; Inst Natl Agron Paris Grignon, Chim Biol Lab, F-78850 Thiverval Grignon, France; Univ Ghent, Vakgrp Organ Scheikunde, B-9000 Ghent, Belgium; Univ Ghent, Vakgrp Biochem Fysiol & Microbiol, B-9000 Ghent, Belgium; Katholieke Univ Leuven, Lab Med Scheikunde, B-3000 Louvain, Belgium; USDA ARS, US Dairy Forage Res Ctr, Madison, WI 53706 USA	Flanders Institute for Biotechnology (VIB); Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University; AgroParisTech; Ghent University; Ghent University; KU Leuven; United States Department of Agriculture (USDA)	Boerjan, W (corresponding author), State Univ Ghent VIB, Dept Plantengenet, KL Ledeganckstr 35, B-9000 Ghent, Belgium.	woboe@gengenp.rug.ac.be	Lapierre, Catherine/AAD-9209-2020; Devreese, Bart/K-2841-2019; Boerjan, Wout/Y-4158-2019; Ralph, John/C-3161-2009; Devreese, Bart/B-2011-2009	Devreese, Bart/0000-0002-9764-2581; Boerjan, Wout/0000-0003-1495-510X; Ralph, John/0000-0002-6093-4521; Devreese, Bart/0000-0002-9764-2581; Lapierre, Catherine/0000-0002-6757-1524; Herdewijn, Piet/0000-0003-3589-8503				Allina SM, 1998, PLANT PHYSIOL, V116, P743, DOI 10.1104/pp.116.2.743; ATANASSOVA R, 1995, PLANT J, V8, P465, DOI 10.1046/j.1365-313X.1995.8040465.x; Baucher M, 1998, CRIT REV PLANT SCI, V17, P125, DOI 10.1016/S0735-2689(98)00360-8; BECKER D, 1990, NUCLEIC ACIDS RES, V18, P203, DOI 10.1093/nar/18.1.203; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; BJORKMAN A, 1956, SVENSK PAPPERSTIDN, V59, P447; Boudet AM, 1998, TRENDS PLANT SCI, V3, P67, DOI 10.1016/S1360-1385(97)01176-X; Braun S., 1998, 150 MORE BASIC NMR E; CHAPPLE CCS, 1992, PLANT CELL, V4, P1413, DOI 10.1105/tpc.4.11.1413; Chen CuiYing, 1999, Plant Physiology, V120, P635; Chen CY, 2000, PLANT PHYSIOL, V123, P853, DOI 10.1104/pp.123.3.853; Chen F, 1999, PLANTA, V207, P597, DOI 10.1007/s004250050523; Christensen JH, 2000, FOR SCI, V64, P227; DEBRUYN A, 1977, B SOC CHIM BELG, V86, P259; FUNK C, 1990, PLANT PHYSIOL, V94, P95, DOI 10.1104/pp.94.1.95; FUNK C, 1992, PLANT PHYSIOL, V99, P256, DOI 10.1104/pp.99.1.256; Grabber JH, 1996, PHYTOCHEMISTRY, V43, P1189, DOI 10.1016/S0031-9422(96)00431-1; GRAND C, 1983, PLANTA, V158, P225, DOI 10.1007/BF01075258; Higuchi T., 1985, BIOSYNTHESIS BIODEGR; Hu WJ, 1999, NAT BIOTECHNOL, V17, P808, DOI 10.1038/11758; Humphreys JM, 1999, P NATL ACAD SCI USA, V96, P10045, DOI 10.1073/pnas.96.18.10045; IBRAHIM RK, 1977, Z PFLANZENPHYSIOL, V85, P253, DOI 10.1016/S0044-328X(77)80251-1; IIYAMA K, 1994, PLANT PHYSIOL, V104, P315, DOI 10.1104/pp.104.2.315; Inoue K, 1998, PLANT PHYSIOL, V117, P761, DOI 10.1104/pp.117.3.761; KAY R, 1987, SCIENCE, V236, P1299, DOI 10.1126/science.236.4806.1299; Kooter JM, 1999, TRENDS PLANT SCI, V4, P340, DOI 10.1016/S1360-1385(99)01467-3; Lapierre C, 1999, PLANT PHYSIOL, V119, P153, DOI 10.1104/pp.119.1.153; LAPIERRE C, 1986, HOLZFORSCHUNG, V40, P113, DOI 10.1515/hfsg.1986.40.2.113; LEPLE JC, 1992, PLANT CELL REP, V11, P137, DOI 10.1007/BF00232166; Li LG, 2000, J BIOL CHEM, V275, P6537, DOI 10.1074/jbc.275.9.6537; LOSCHER R, 1994, PLANT PHYSIOL, V106, P271, DOI 10.1104/pp.106.1.271; Lu FC, 1999, J AGR FOOD CHEM, V47, P1988, DOI 10.1021/jf981140j; Matsui N, 2000, PLANTA, V210, P831, DOI 10.1007/s004250050686; MATSUI N, 1994, HOLZFORSCHUNG, V48, P375, DOI 10.1515/hfsg.1994.48.5.375; Maury S, 1999, PLANT PHYSIOL, V121, P215, DOI 10.1104/pp.121.1.215; MAVANDAD M, 1990, PLANT PHYSIOL, V94, P671, DOI 10.1104/pp.94.2.671; Meng H, 1998, PLANT MOL BIOL, V38, P513, DOI 10.1023/A:1006071708728; Monties B., 1989, METHODS PLANT BIOCH, VVolume 1, P113; Nakamura Y, 1978, CELL CHEM TECHNOL, V12, P199; Osakabe K, 1999, P NATL ACAD SCI USA, V96, P8955, DOI 10.1073/pnas.96.16.8955; PAKUSCH AE, 1991, PLANT PHYSIOL, V95, P137, DOI 10.1104/pp.95.1.137; Piquemal J, 1998, PLANT J, V13, P71, DOI 10.1046/j.1365-313X.1998.00014.x; Ralph J, 1997, SCIENCE, V277, P235, DOI 10.1126/science.277.5323.235; RALPH J, 1994, J AM CHEM SOC, V116, P9448, DOI 10.1021/ja00100a006; Rolando C., 1992, METHODS LIGNIN CHEM, P334, DOI DOI 10.1007/978-3-642-74065-7_23; Saka S., 1985, BIOSYNTHESIS BIODEGR, P51; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHNITZLER JP, 1992, PLANTA, V188, P594, DOI 10.1007/BF00197054; THIEME H, 1969, PHARMAZIE, V24, P292; Tsai CJ, 1998, PLANT PHYSIOL, V117, P101, DOI 10.1104/pp.117.1.101; Vander Mijnsbrugge K, 2000, PLANTA, V210, P589; VanDoorsselaere J, 1995, PLANT J, V8, P855, DOI 10.1046/j.1365-313X.1995.8060855.x; VICKERY ML, 1981, SECONDARY PLANT META, P32; Waterhouse PM, 1999, TRENDS PLANT SCI, V4, P452, DOI 10.1016/S1360-1385(99)01493-4; Whetten RW, 1998, ANNU REV PLANT PHYS, V49, P585, DOI 10.1146/annurev.arplant.49.1.585; YE ZH, 1994, PLANT CELL, V6, P1427, DOI 10.1105/tpc.6.10.1427; Zhong RQ, 1998, PLANT CELL, V10, P2033, DOI 10.1105/tpc.10.12.2033; [No title captured]	58	193	235	4	65	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36899	36909		10.1074/jbc.M006915200	http://dx.doi.org/10.1074/jbc.M006915200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10934215	hybrid, Green Accepted, Green Published			2022-12-27	WOS:000165577700065
J	Hurt, CM; Feng, FY; Kobilka, B				Hurt, CM; Feng, FY; Kobilka, B			Cell-type specific targeting of the alpha(2c)-andrenoceptor - Evidence for the organization of receptor microdomains during neuronal differentiation of PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA(2)-ADRENERGIC RECEPTORS; ALPHA(2A)-ADRENERGIC RECEPTOR; POSTSYNAPTIC LOCALIZATION; SECRETORY PATHWAY; QUALITY-CONTROL; PROTEIN-KINASE; NERVOUS-SYSTEM; SUBTYPE-C; MICE; DESENSITIZATION	We have previously shown differences in the intracellular targeting of alpha 2a (alpha (2A))- and alpha 2c (alpha (2C))-adrenoreceptors expressed in the same cell line (von Zastrow, M,, Link, Rt, Daunt, D., Barsh, G,, and Kobilka, B. (1993) J. Biol. Chem, 268, 763-766; Daunt, D. A., Hurt, C., Hein, L., Kallio, J., Feng, F., and Kobilka, B, K, (1997) Mot Pharmacol, 51, 711-720), alpha (2A)-Adrenoreceptors reside primarily in the plasma membrane in HEK 293 cells, while co-expressed alpha (2C)-adrenoreceptors are found mainly in an intracellular compartment, Since Lu,,-adrenoreceptors:are expressed primarily in the brain, we compared the intracellular targeting of alpha (2C)-adrenoreceptors in two:neuroendocrine cell lines with the targeting in three epithelial cell lines and one fibroblast cell line. In transiently transfected COS7 cells, and in stably transfected normal rat kidney cells, Madin-Darby canine kidney cells, and Rat1 fibroblasts, a significant proportion of alpha (2C)-adrenoreceptor detected by immunocytochemistry co-localized with markers for both the endoplasmic reticulum and the cis/medial Golgi compartments. In contrast, both PC12 cells and AtT20 cells efficiently targeted Lu,,-adrenoreceptors to the plasma membrane. Ligand binding and Western blot analyses indicate that intracellular receptor in normal rat kidney cells is functional and undergoes normal post-translational processing. In PC12 cells the expressed alpha (2C)-adrenoreceptors become concentrated in neurite outgrowths in discrete regions of the plasma membrane having a high density of F-actin following treatment with nerve growth factor. These findings provide evidence for cell-type specific factors that facilitate the targeting the G protein-coupled receptors to the plasma membrane.	Stanford Univ, Howard Hughes Med Inst, Sch Med, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	Kobilka, B (corresponding author), Stanford Univ, Howard Hughes Med Inst, Sch Med, Stanford, CA 94305 USA.			Kobilka, Brian/0000-0001-5958-3990	PHS HHS [G07365] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; Allison DW, 1998, J NEUROSCI, V18, P2423; Altman JD, 1999, MOL PHARMACOL, V56, P154, DOI 10.1124/mol.56.1.154; APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; Daunt DA, 1997, MOL PHARMACOL, V51, P711, DOI 10.1124/mol.51.5.711; EASON MG, 1992, J BIOL CHEM, V267, P25473; FLORDELLIS CS, 1995, J BIOL CHEM, V270, P3491, DOI 10.1074/jbc.270.8.3491; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hein L, 1999, NATURE, V402, P181, DOI 10.1038/46040; HEIN L, 1994, J BIOL CHEM, V269, P27719; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Holkeri H, 1998, FEBS LETT, V429, P162, DOI 10.1016/S0014-5793(98)00586-9; KIRSCH J, 1995, J NEUROSCI, V15, P4148; KUROSE H, 1994, J BIOL CHEM, V269, P10093; Lee A, 1998, J COMP NEUROL, V394, P218; Lee A, 1998, NEUROSCIENCE, V84, P1085, DOI 10.1016/S0306-4522(97)00578-2; Link RE, 1996, SCIENCE, V273, P803, DOI 10.1126/science.273.5276.803; MacDonald E, 1997, TRENDS PHARMACOL SCI, V18, P211; MacMillan L B, 1998, Adv Pharmacol, V42, P493; MacMillan LB, 1996, SCIENCE, V273, P801, DOI 10.1126/science.273.5276.801; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; Sallinen J, 1999, MOL PSYCHIATR, V4, P443, DOI 10.1038/sj.mp.4000543; Sallinen J, 1998, J NEUROSCI, V18, P3035; VON ZM, 1993, J BIOL CHEM, V268, P763; Wozniak M, 1996, J BIOL CHEM, V271, P5017; Yu R, 1997, MOL PHARMACOL, V51, P785, DOI 10.1124/mol.51.5.785; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	28	44	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35424	35431		10.1074/jbc.M006241200	http://dx.doi.org/10.1074/jbc.M006241200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10906149	hybrid			2022-12-27	WOS:000165422800079
J	Rebhun, JF; Castro, AF; Quilliam, LA				Rebhun, JF; Castro, AF; Quilliam, LA			Identification of guanine nucleotide exchange factors (GEFs) for the Rap1 GTPase - Regulation of MR-GEF by M-Ras-GTP interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER CELLS; BINDING-PROTEIN; ENCODING KRIT1; MAP KINASE; FAMILY; ACTIVATION; DOMAIN; GENE; PATHWAY; TRANSFORMATION	Although the Ras subfamily of GTPases consists of similar to 20 members, only a limited number of guanine nucleotide exchange factors (GEFs) that couple extracellular stimuli to Ras protein activation have been identified. Furthermore, no novel downstream effecters have been identified for the M-Ras/R-Ras3 GTPase. Here we report the identification and characterization of three Ras family GEFs that are most abundantly expressed in brain. Two of these GEFs, MR-GEF (M-Ras-regulated GEF, KIAA0277) and PDZ-GEF (KIAA0313) bound specifically to nucleotide-free Rap1 and Rap1/Rap2, respectively. Both proteins functioned as Rap1 GEFs in vivo. A third GEF, GRP3 (KIAA0846), activated both Ras and Rap1 and shared significant sequence homology with the calcium- and diacylglycerol-activated GEFs, GRP1 and GRP2, Similarly to previously identified Rap GEFs, C3G and Smg GDS, each of the newly identified exchange factors promoted the activation of Elk-1 in the LNCaP prostate tumor cell line where B-Raf can couple Rap1 to the extracellular receptor-activated kinase cascade. MR-GEF and PDZ-GEF both contain a region immediately N-terminal to their catalytic domains that share sequence homology with Ras-associating or Ral-GDS/AF6 homology (RA) domains. By searching for in vitro interaction with Ras-GTP proteins, PDZ-GEF specifically bound to Rap1A- and Rap2B-GTP, whereas MR-GEF bound to M-Ras-GTP. C-terminally truncated MR-GEF, lacking the GEF catalytic domain, retained its ability to bind M-Ras-GTP, suggesting that the RA domain is important for this interaction. Co-immunoprecipitation studies confirmed the interaction of M-Ras-GTP with MR-GEF in vivo, In addition, a constitutively active M-Ras(71L) mutant inhibited the ability of MR-GEF to promote Rap1A activation in a dose-dependent manner. These data suggest that M-Ras may inhibit Rap1 in order to elicit its biological effects.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Quilliam, LA (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr,MS-4075, Indianapolis, IN 46202 USA.		Quilliam, Lawrence/B-6447-2015; Quilliam, Lawrence/Q-4987-2019; Rebhun, John F/H-7235-2019	Rebhun, John F/0000-0002-0764-5210				BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Chen TS, 1999, CANCER RES, V59, P213; CHUANG TH, 1994, BIOCHEM J, V303, P761, DOI 10.1042/bj3030761; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Dodelet VC, 1999, J BIOL CHEM, V274, P31941, DOI 10.1074/jbc.274.45.31941; EHINU JO, 1998, SCIENCE, V280, P1082; Ehrhardt GRA, 1999, BLOOD, V94, P2433, DOI 10.1182/blood.V94.7.2433.419k31_2433_2444; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Ichiba T, 1999, FEBS LETT, V457, P85, DOI 10.1016/S0014-5793(99)01012-1; Iouzalen N, 1998, BIOCHEM BIOPH RES CO, V250, P359, DOI 10.1006/bbrc.1998.9336; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Laberge-le Couteulx S, 1999, NAT GENET, V23, P189, DOI 10.1038/13815; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; Liao YH, 1999, J BIOL CHEM, V274, P37815, DOI 10.1074/jbc.274.53.37815; Linnemann T, 1999, J BIOL CHEM, V274, P13556, DOI 10.1074/jbc.274.19.13556; Louahed J, 1999, BLOOD, V94, P1701, DOI 10.1182/blood.V94.5.1701.417k29_1701_1710; Lu YM, 1999, J BIOL CHEM, V274, P10047, DOI 10.1074/jbc.274.15.10047; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Matsubara K, 1999, ONCOGENE, V18, P1303, DOI 10.1038/sj.onc.1202425; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; Matsumoto K, 1997, ONCOGENE, V15, P2409, DOI 10.1038/sj.onc.1201416; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Ohtsuka T, 1999, BIOCHEM BIOPH RES CO, V265, P38, DOI 10.1006/bbrc.1999.1619; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Pham N, 2000, CURR BIOL, V10, P555, DOI 10.1016/S0960-9822(00)00473-5; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Ponting CP, 1999, J MOL MED, V77, P695, DOI 10.1007/s001099900054; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Rebhun JF, 2000, J BIOL CHEM, V275, P13406, DOI 10.1074/jbc.C000085200; Sahoo T, 1999, HUM MOL GENET, V8, P2325, DOI 10.1093/hmg/8.12.2325; Serebriiskii I, 1997, ONCOGENE, V15, P1043, DOI 10.1038/sj.onc.1201268; SHAH GV, 1994, ENDOCRINOLOGY, V134, P596, DOI 10.1210/en.134.2.596; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; Vetter IR, 1999, FEBS LETT, V451, P175, DOI 10.1016/S0014-5793(99)00555-4; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wittinghofer A, 1998, BIOL CHEM, V379, P933; Wojcik J, 1999, BIOCHEM BIOPH RES CO, V259, P113, DOI 10.1006/bbrc.1999.0727; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	57	119	124	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34901	34908		10.1074/jbc.M005327200	http://dx.doi.org/10.1074/jbc.M005327200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10934204	hybrid			2022-12-27	WOS:000165422800013
J	Sharma, M; Zarnegar, M; Li, XY; Lim, B; Sun, ZJ				Sharma, M; Zarnegar, M; Li, XY; Lim, B; Sun, ZJ			Androgen receptor interacts with a novel MYST protein, HBO1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-BINDING DOMAINS; HUMAN PROSTATE CELLS; ZINC-FINGER PROTEIN; HEAT-SHOCK PROTEINS; TRANSCRIPTIONAL ACTIVATION; ESTROGEN-RECEPTOR; GLUCOCORTICOID RECEPTOR; DNA-BINDING; HUMAN GENES; COACTIVATOR	The androgen receptor (AR), a member of the nuclear receptor superfamily, plays a central role in male sexual differentiation and prostate cell proliferation. Results of-treating prostate cancer by androgen ablation indicate that signals mediated through AR are critical for the growth of these tumors. Like other nuclear receptors, AR exerts its transcriptional function by binding to cis-elements upstream of promoters and interacting with. other transcriptional factors (e.g. activators, repressors and modulators). To determine the mechanism of AR-regulated transcription, we used the yeast two-hybrid system to identify AR-associated proteins. One of the proteins we identified is identical to the human origin recognition complex-interacting protein termed HBO1. A ligand-enhanced interaction between AR and HBO1 was further confirmed in vivo and in vitro. Immunofluorescence experiments showed that HBO1 is a nuclear:protein,:and Northern blot analysis revealed that it is ubiquitously expressed, with the highest levels present inhuman testis. HBO1 belongs to the MYST family, which is characterized by a highly conserved C2HC zinc finger and a putative histone acetyltransferase domain. Surprisingly, two yeast members of the MYST family, SAS2: and SAS3, have been shown to function as transcription silencers, despite the presence of the histone acetyltransferase domain. Using a GAL4 DNA-binding domain assay, we mapped a transcriptional repression domain within the N-terminal region of HBO1. Transient transfection experiments revealed that HBO1 specifically repressed AR-mediated transcription in both CV-1 and PC-3 cells. These results indicate that HBO1 is a new AR-interacting protein capable of modulating AR activity. It could play a significant role in regulating AR-dependent genes in normal and prostate cancer cells.	Stanford Univ, Dept Surg & Genet, Sch Med, Liem Sioe Liong Mol Biol Lab, Stanford, CA 94305 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA	Stanford University; Harvard University; Beth Israel Deaconess Medical Center	Sun, ZJ (corresponding author), Stanford Univ, Dept Surg & Genet, Sch Med, Liem Sioe Liong Mol Biol Lab, R135,Edwards Bldg, Stanford, CA 94305 USA.	zsun@stanford.edu			NATIONAL CANCER INSTITUTE [R29CA070297, R01CA070297, R01CA087767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047636] Funding Source: NIH RePORTER; NCI NIH HHS [CA70297, R01 CA070297-09, R01 CA070297-11A2, R01 CA087767-03, R01 CA087767-02, R01 CA070297-10, R01 CA070297-12, R01 CA087767, R01 CA070297, R01 CA070297-08] Funding Source: Medline; NIDDK NIH HHS [DK47636] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ayer DE, 1996, MOL CELL BIOL, V16, P5772; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Bellefroid EJ, 1996, CELL, V87, P1191, DOI 10.1016/S0092-8674(00)81815-2; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Champagne N, 1999, J BIOL CHEM, V274, P28528, DOI 10.1074/jbc.274.40.28528; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; EhrenhoferMurray AE, 1997, GENETICS, V145, P923; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HEIDENBERG HB, 1995, J UROLOGY, V154, P414, DOI 10.1016/S0022-5347(01)67065-4; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hsiao PW, 1999, J BIOL CHEM, V274, P22373, DOI 10.1074/jbc.274.32.22373; Hsiao PW, 1999, J BIOL CHEM, V274, P20229, DOI 10.1074/jbc.274.29.20229; Iizuka M, 1999, J BIOL CHEM, V274, P23027, DOI 10.1074/jbc.274.33.23027; ISAACS JT, 1987, UROL RES, V15, P133; James P, 1996, GENETICS, V144, P1425; Jenster G, 1999, SEMIN ONCOL, V26, P407; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; Kasten MM, 1996, MOL CELL BIOL, V16, P4215; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; MINER JN, 1991, CELL GROWTH DIFFER, V2, P525; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Monden T, 1997, J BIOL CHEM, V272, P29834, DOI 10.1074/jbc.272.47.29834; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Navone NM, 1997, CLIN CANCER RES, V3, P2493; ONATE SA, 1995, SCIENCE, V270, P1354; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SCHOWALTER DB, 1991, J BIOL CHEM, V266, P21165; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; SIMENTAL JA, 1992, J STEROID BIOCHEM, V43, P37, DOI 10.1016/0960-0760(92)90185-L; STERNECK E, 1992, EMBO J, V11, P115, DOI 10.1002/j.1460-2075.1992.tb05034.x; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Sun ZJ, 1999, CANCER-AM CANCER SOC, V86, P689, DOI 10.1002/(SICI)1097-0142(19990815)86:4<689::AID-CNCR19>3.0.CO;2-P; Sun ZJ, 1997, NUCLEIC ACIDS RES, V25, P3318, DOI 10.1093/nar/25.16.3318; Takechi S, 1999, BIOCHEM BIOPH RES CO, V266, P405, DOI 10.1006/bbrc.1999.1836; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; TRAPMAN J, 1988, BIOCHEM BIOPH RES CO, V153, P241, DOI 10.1016/S0006-291X(88)81214-2; VELDSCHOLTE J, 1992, BIOCHEMISTRY-US, V31, P742, DOI 10.1021/bi00147a029; Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; ZHOU ZX, 1994, RECENT PROG HORM RES, V49, P249; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	59	104	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35200	35208		10.1074/jbc.M004838200	http://dx.doi.org/10.1074/jbc.M004838200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10930412	hybrid			2022-12-27	WOS:000165422800051
J	Cheng, AY; Kaldis, P; Solomon, MJ				Cheng, AY; Kaldis, P; Solomon, MJ			Dephosphorylation of human cyclin-dependent kinases by protein phosphatase type 2C alpha and beta 2 isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK-ACTIVATING KINASE; SERINE-THREONINE PHOSPHATASE; TRANSCRIPTION FACTOR TFIIH; RABBIT SKELETAL-MUSCLE; CELL-CYCLE; MESSENGER-RNA; SCHIZOSACCHAROMYCES-POMBE; MOLECULAR-CLONING; BUDDING YEAST; MAP KINASE	We previously reported that the activating phosphorylation on cyclin-dependent kinases in yeast (Gdc28p) and in humans (Cdk2) is removed by type 2C protein phosphatases. In this study, we characterize this PP2C-like activity in HeLa cell extract and determine that it is due to PP2C beta2, a novel PP2C beta isoform, and to PP2C alpha. PP2C alpha and PP2C beta2 co-purified with Mg2+-dependent Cdk2/Cdk6 phosphatase activity in DEAE-Sepharose, Superdex-200, and Mono Q chromatographies. Moreover, purified recombinant PP2C alpha and PP2C beta2 proteins efficiently dephosphorylated monomeric Cdk2/Cdk6 in vitro. The dephosphorylation of Cdk2 and Cdk6 by PP2C isoforms was inhibited by the binding of cyclins. We found that the PP2C-like activity in HeLa cell extract, partially purified HeLa PP2C alpha and PP2C beta2 isoforms, and the recombinant PP2Cs exhibited a comparable substrate preference for a phosphothreonine containing substrate, consistent with the conservation of threonine residues at the site of activating phosphorylation in CDKs.	Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University	Solomon, MJ (corresponding author), Yale Univ, Sch Med, Dept Mol Biophys & Biochem, 333 Cedar St, New Haven, CT 06520 USA.	Mark.Solomon@yale.edu	Kaldis, Philipp/G-2714-2010	Kaldis, Philipp/0000-0002-7247-7591	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047830] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47830] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adamczewski JP, 1996, EMBO J, V15, P1877, DOI 10.1002/j.1460-2075.1996.tb00538.x; BOOHER R, 1986, MOL CELL BIOL, V6, P3523, DOI 10.1128/MCB.6.10.3523; Cheng AY, 1999, GENE DEV, V13, P2946, DOI 10.1101/gad.13.22.2946; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; CLARKE PR, 1991, ADV PROT PHOSPHATASE, V6, P187; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Das AK, 1996, EMBO J, V15, P6798, DOI 10.1002/j.1460-2075.1996.tb01071.x; Davies SP, 1995, FEBS LETT, V377, P421, DOI 10.1016/0014-5793(95)01368-7; DEANA AD, 1990, BIOCHIM BIOPHYS ACTA, V1051, P199, DOI 10.1016/0167-4889(90)90194-I; Espinoza FH, 1996, SCIENCE, V273, P1714, DOI 10.1126/science.273.5282.1714; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; Guthridge MA, 1997, MOL CELL BIOL, V17, P5485, DOI 10.1128/MCB.17.9.5485; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; HARPER JW, 1993, CELL, V75, P805; Hishiya A, 1999, J BIOL CHEM, V274, P26705, DOI 10.1074/jbc.274.38.26705; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kaldis P, 2000, EUR J BIOCHEM, V267, P4213, DOI 10.1046/j.1432-1327.2000.01455.x; Kaldis P, 2000, J BIOL CHEM, V275, P32578, DOI 10.1074/jbc.M003212200; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; Kaldis P, 1998, J CELL SCI, V111, P3585; Kaldis P, 1998, MOL BIOL CELL, V9, P2545, DOI 10.1091/mbc.9.9.2545; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kitani T, 1999, J BIOCHEM-TOKYO, V125, P1022, DOI 10.1093/oxfordjournals.jbchem.a022381; KREK W, 1992, NEW BIOL, V4, P323; Kusuda K, 1998, BIOCHEM J, V332, P243, DOI 10.1042/bj3320243; Labes M, 1998, MOL CELL NEUROSCI, V12, P29, DOI 10.1006/mcne.1998.0692; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MANN DJ, 1992, BIOCHIM BIOPHYS ACTA, V1130, P100, DOI 10.1016/0167-4781(92)90471-B; Marley AE, 1996, BIOCHEM J, V320, P801, DOI 10.1042/bj3200801; Marley AE, 1998, FEBS LETT, V431, P121, DOI 10.1016/S0014-5793(98)00708-X; MCGOWAN CH, 1987, EUR J BIOCHEM, V166, P713, DOI 10.1111/j.1432-1033.1987.tb13570.x; MCGOWAN CH, 1988, METHOD ENZYMOL, V159, P416; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; Morgan DO, 1996, CURR OPIN CELL BIOL, V8, P767, DOI 10.1016/S0955-0674(96)80076-7; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Murray MV, 1999, GENE DEV, V13, P87, DOI 10.1101/gad.13.1.87; Nguyen AN, 1999, GENE DEV, V13, P1653, DOI 10.1101/gad.13.13.1653; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SHIOZAKI K, 1995, EMBO J, V14, P492, DOI 10.1002/j.1460-2075.1995.tb07025.x; SHIOZAKI K, 1994, MOL CELL BIOL, V14, P3742, DOI 10.1128/MCB.14.6.3742; Solomon M J, 1998, Results Probl Cell Differ, V22, P79; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; Stark MJR, 1996, YEAST, V12, P1647, DOI 10.1002/(SICI)1097-0061(199612)12:16<1647::AID-YEA71>3.0.CO;2-Q; Strovel ET, 2000, J BIOL CHEM, V275, P2399, DOI 10.1074/jbc.275.4.2399; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; TAMURA S, 1989, P NATL ACAD SCI USA, V86, P1796, DOI 10.1073/pnas.86.6.1796; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0; Tong Y, 1998, J BIOL CHEM, V273, P35282, DOI 10.1074/jbc.273.52.35282; Travis SM, 1997, P NATL ACAD SCI USA, V94, P11055, DOI 10.1073/pnas.94.20.11055; Travis SM, 1997, FEBS LETT, V412, P415, DOI 10.1016/S0014-5793(97)00837-5; WENK J, 1992, FEBS LETT, V297, P135, DOI 10.1016/0014-5793(92)80344-G	63	79	85	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34744	34749		10.1074/jbc.M006210200	http://dx.doi.org/10.1074/jbc.M006210200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10934208	hybrid			2022-12-27	WOS:000165095300099
J	Jiang, Y; Qian, WJ; Hawes, JW; Walsh, JP				Jiang, Y; Qian, WJ; Hawes, JW; Walsh, JP			A domain with homology to neuronal calcium sensors is required for calcium-dependent activation of diacylglycerol kinase alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EF-HAND MOTIFS; PHOSPHATIDIC-ACID; 3-DIMENSIONAL STRUCTURE; BOVINE NEUROCALCIN; BINDING PROTEINS; ESCHERICHIA-COLI; HUMAN-PLATELETS; 2ND MESSENGERS; RAT-BRAIN; EXPRESSION	Diacylglycerol kinases (DGKs) phosphorylate diacylglycerol produced during stimulus-induced phosphoinositide turnover and attenuate protein kinase C activation. Diacylglycerol kinase alpha is an 82-kDa DGK isoform that is activated in vitro by Ca2+. The DGK alpha regulatory region includes tandem C1 protein kinase C homology domains and Ca2+-binding EF hand motifs, It also contains an N-terminal recoverin homology (RVH) domain that is related to the N termini of the recoverin family of neuronal calcium sensors. To probe the structural basis of Ca2+ regulation, we expressed a series of DGK alpha deletions spanning its regulatory domain in COS-l cells. Deletion of the RVH domain resulted in loss of Ca2+-dependent activation. Further deletion of the EF hands resulted in a constitutively active enzyme, suggesting that sequences in or near the EF hands are sufficient for autoinhibition, Binding of Ca2+ to the EF hands protected sites within both the RVH domain and EF hands from trypsin cleavage and increased the phenyl-Sepharose binding of a recombinant DGK alpha fragment that included both the RVH domain and EF hands. These observations suggested that Ca2+ elicits a concerted conformational change of these two domains. A cationic amphiphile, octadecyltrimethylammonium chloride, also activated DGK alpha. As with Ca2+, this activation required the RVH domain. However, this agent did not protect the EF hands and RVH domain from trypsin cleavage. These findings indicate that the EF hands and RVH domain act as a functional unit during Ca2+-induced DGK alpha activation.	Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Walsh, JP (corresponding author), Richard L Roudebush Vet Affairs Med Ctr, Sect Endocrinol & Metab 111E, 1481 W 10th St, Indianapolis, IN 46202 USA.	jpwalsh@iupui.edu						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AMES BN, 1960, J BIOL CHEM, V235, P769; Ames JB, 1999, J BIOL CHEM, V274, P19329, DOI 10.1074/jbc.274.27.19329; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; BISHOP WR, 1986, J BIOL CHEM, V261, P6993; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braunewell KH, 1999, CELL TISSUE RES, V295, P1, DOI 10.1007/s004410051207; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLINT JH, 1975, J CHEM SOC FARAD T 1, V71, P1327, DOI 10.1039/f19757101327; DELAAGE M, 1967, BIOCHEM BIOPH RES CO, V28, P390, DOI 10.1016/0006-291X(67)90323-3; Erickson RW, 1999, J BIOL CHEM, V274, P22243, DOI 10.1074/jbc.274.32.22243; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; Flores I, 1996, J BIOL CHEM, V271, P10334, DOI 10.1074/jbc.271.17.10334; GOTO K, 1994, P NATL ACAD SCI USA, V91, P13042, DOI 10.1073/pnas.91.26.13042; GOTO K, 1992, MOL BRAIN RES, V16, P75, DOI 10.1016/0169-328X(92)90196-I; Hurley JH, 1997, PROTEIN SCI, V6, P477; Jiang Y, 2000, BIOCHEM PHARMACOL, V59, P763, DOI 10.1016/S0006-2952(99)00395-0; KANOH H, 1993, CELL SIGNAL, V5, P495, DOI 10.1016/0898-6568(93)90045-N; KATO M, 1990, J BIOL CHEM, V265, P794; Landar A, 1998, BIOCHEMISTRY-US, V37, P17429, DOI 10.1021/bi9817921; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; Matsuda S, 1998, J BIOL CHEM, V273, P20223, DOI 10.1074/jbc.273.32.20223; Montgomery RB, 1997, BIOCHEM BIOPH RES CO, V232, P111, DOI 10.1006/bbrc.1997.6237; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Rudnicka-Nawrot M, 1998, BIOCHEMISTRY-US, V37, P248, DOI 10.1021/bi972306x; SAKANE F, 1991, J BIOL CHEM, V266, P7096; Sakane F, 1997, INT J BIOCHEM CELL B, V29, P1139, DOI 10.1016/S1357-2725(97)00037-X; SAKANE F, 1991, BIOCHEM BIOPH RES CO, V181, P1015, DOI 10.1016/0006-291X(91)92038-L; Sakane F, 1996, BIOCHEM J, V318, P583, DOI 10.1042/bj3180583; SAKANE F, 1989, FEBS LETT, V255, P409, DOI 10.1016/0014-5793(89)81134-2; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Sciorra VA, 1996, J BIOL CHEM, V271, P14226, DOI 10.1074/jbc.271.24.14226; SIPOS T, 1970, BIOCHEMISTRY-US, V9, P2766, DOI 10.1021/bi00816a003; Tachibanaki S, 2000, J BIOL CHEM, V275, P3313, DOI 10.1074/jbc.275.5.3313; TENG DHF, 1994, J BIOL CHEM, V269, P31900; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Vijay-Kumar S, 1999, NAT STRUCT BIOL, V6, P80; WALSH JP, 1992, METHOD ENZYMOL, V209, P153; WALSH JP, 1986, J BIOL CHEM, V261, P6239; WALSH JP, 1995, J BIOL CHEM, V270, P28647, DOI 10.1074/jbc.270.48.28647; YADA Y, 1990, J BIOL CHEM, V265, P19237; Yamada K, 1997, BIOCHEM J, V321, P59, DOI 10.1042/bj3210059; YAMADA K, 1988, BIOCHEM J, V255, P601; YAMADA K, 1993, BIOCHIM BIOPHYS ACTA, V1169, P211; ZOZULYA S, 1995, METHOD ENZYMOL, V250, P383	46	48	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34092	34099		10.1074/jbc.M004914200	http://dx.doi.org/10.1074/jbc.M004914200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10918059	hybrid			2022-12-27	WOS:000165095300016
J	Membrillo-Hernandez, J; Echave, P; Cabiscol, E; Tamarit, J; Ros, J; Lin, ECC				Membrillo-Hernandez, J; Echave, P; Cabiscol, E; Tamarit, J; Ros, J; Lin, ECC			Evolution of the adhE gene product of Escherichia coli from a functional reductase to a dehydrogenase - Genetic and biochemical studies of the mutant proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERMENTATIVE ALCOHOL-DEHYDROGENASE; ENCODING ETHANOL OXIDOREDUCTASE; PROPANEDIOL OXIDOREDUCTASE; ZYMOMONAS-MOBILIS; OXIDATIVE STRESS; ENZYMES; L-1,2-PROPANEDIOL; SEQUENCE; CLONING; FUCOSE	The multifunctional AdhE protein of Escherichia coli (encoded by the adhE gene) physiologically catalyzes the sequential reduction of acetyl-CoA to acetaldehyde and then to ethanol under fermentative conditions. The NH2-terminal region of the AdhE protein is highly homologous to aldehyde:NAD(+) oxidoreductases, whereas the COOH-terminal region is homologous to a family of Fe2+-dependent ethanol:NAD(+) oxidoreductases. This fusion protein also functions as a pyruvate formate lyase deactivase. E. coli cannot grow aerobically on ethanol as the sole carbon and energy source because of inadequate rate of adhE transcription and the vulnerability of the AdhE protein to metal-catalyzed oxidation. In this study, we characterized 16 independent two-step mutants with acquired and improved aerobic growth ability on ethanol, The AdhE proteins in these mutants catalyzed the sequential oxidation of ethanol to acetaldehyde and to acetyl-CoA All first stage mutants grew on ethanol with a doubling time of about 240 min. Sequence analysis of a randomly chosen mutant revealed an Ala-267 --> Thr substitution in the acetaldehyde:NAD(+) oxidoreductase domain of AdhE. All second stage mutants grew on ethanol with a doubling time of about 90 min, and all of them produced an AdhE(E568K)(A267T/), Purified AdhE(A267T) and AdhE(A267T/E568K) showed highly elevated acetaldehyde dehydrogenase activities. It therefore appears that when AdhE catalyzes the two sequential reactions in the counter-physiological direction, acetaldehyde dehydrogenation is the rate-limiting step. Both mutant proteins were more thermosensitive than the wild-type protein, but AdhE(A267T/E568K) was more thermal stable than AdhE(A267T). Since both mutant enzymes exhibited similar kinetic properties, the second mutation probably conferred an increased growth rate on ethanol by stabilizing AdhE(A267T).	Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Lleida 25198, Spain; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Universitat de Lleida; Harvard University; Harvard Medical School	Ros, J (corresponding author), Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Lleida 25198, Spain.		Membrillo-Hernández, Jorge/AAN-4996-2021; Tamarit, Jordi/C-6316-2008; Cabiscol, Elisa/A-4584-2009; Ros, Joaquim/A-7507-2010; ROS, Joaquim/ABG-7487-2020	Membrillo-Hernández, Jorge/0000-0001-7650-8116; Tamarit, Jordi/0000-0003-3227-6928; Cabiscol, Elisa/0000-0003-2795-7999; ROS, Joaquim/0000-0003-0901-8648	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040993] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40993] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLYN MKB, 1996, ESCHERICHIA COLI SAL, P1715; BORONAT A, 1981, BIOCHIM BIOPHYS ACTA, V672, P98, DOI 10.1016/0304-4165(81)90283-X; BORONAT A, 1979, J BACTERIOL, V140, P320, DOI 10.1128/JB.140.2.320-326.1979; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P134; CABISCOL E, 1994, J BIOL CHEM, V269, P6592; CHEN YM, 1991, J BACTERIOL, V173, P8009, DOI 10.1128/jb.173.24.8009-8013.1991; CHEN YM, 1989, J BACTERIOL, V171, P6097, DOI 10.1128/jb.171.11.6097-6105.1989; CLARK D, 1980, J BACTERIOL, V141, P177, DOI 10.1128/JB.141.1.177-183.1980; CLARK DP, 1980, J BACTERIOL, V144, P179, DOI 10.1128/JB.144.1.179-184.1980; CLARK DP, 1989, FEMS MICROBIOL LETT, V63, P223, DOI 10.1111/j.1574-6968.1989.tb03398.x; COCKS GT, 1974, J BACTERIOL, V118, P83, DOI 10.1128/JB.118.1.83-88.1974; CONWAY T, 1989, J BACTERIOL, V171, P3754, DOI 10.1128/jb.171.7.3754-3759.1989; CUNNINGHAM PR, 1986, MOL GEN GENET, V205, P487, DOI 10.1007/BF00338087; GOODLOVE PE, 1989, GENE, V85, P209, DOI 10.1016/0378-1119(89)90483-6; Gupta S, 2000, FEMS MICROBIOL LETT, V182, P51, DOI 10.1111/j.1574-6968.2000.tb08872.x; KESSLER D, 1992, J BIOL CHEM, V267, P18073; KESSLER D, 1991, FEBS LETT, V281, P59, DOI 10.1016/0014-5793(91)80358-A; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONARDO MR, 1993, J BACTERIOL, V175, P870, DOI 10.1128/JB.175.3.870-878.1993; Leonardo MR, 1996, J BACTERIOL, V178, P6013, DOI 10.1128/jb.178.20.6013-6018.1996; LEVINE RL, 1984, METHOD ENZYMOL, V107, P370; Lu Z, 1998, J BIOL CHEM, V273, P8308, DOI 10.1074/jbc.273.14.8308; LURZ R, 1979, ARCH MICROBIOL, V120, P255, DOI 10.1007/BF00423073; MCPHEDRAN P, 1961, J BACTERIOL, V81, P852, DOI 10.1128/JB.81.6.852-857.1961; Membrillo-Hernandez J, 1999, J BACTERIOL, V181, P7390; Membrillo-Hernandez J, 1999, J BACTERIOL, V181, P7571; MILLER JG, 1972, SHORT COURSE BACTERI; RACKER E, 1955, METHOD ENZYMOL, V1, P500, DOI 10.1016/0076-6879(55)01084-7; Rosenthal B, 1997, J BACTERIOL, V179, P3736, DOI 10.1128/jb.179.11.3736-3745.1997; Sambrook J., 2002, MOL CLONING LAB MANU; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SMITH LT, 1980, ARCH BIOCHEM BIOPHYS, V203, P663, DOI 10.1016/0003-9861(80)90224-6; SRIDHARA S, 1969, J BACTERIOL, V98, P87, DOI 10.1128/JB.98.1.87-95.1969; Tamarit J, 1998, J BIOL CHEM, V273, P3027, DOI 10.1074/jbc.273.5.3027; Wood W. A., 1961, BACTERIA	35	69	88	3	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33869	33875		10.1074/jbc.M005464200	http://dx.doi.org/10.1074/jbc.M005464200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10922373	Green Submitted, hybrid, Green Published			2022-12-27	WOS:000090104600095
J	Suzuki, M; Yoshida, S; Adman, ET; Blank, A; Loeb, LA				Suzuki, M; Yoshida, S; Adman, ET; Blank, A; Loeb, LA			Thermus aquaticus DNA polymerase I mutants with altered fidelity - Interacting mutations in the O-helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLENOW FRAGMENT; CRYSTAL-STRUCTURE; ACTIVE-SITE; REPLICATION; ERRORS; MUTAGENESIS; RESOLUTION; COMPLEX; PROGRAM	Phe(667) in the conserved O-helix of Thermus aquaticus (Taq) DNA polymerase I (pol I) is known to be important for discrimination against dideoxy-NTPs. We show here that Phe(667) is also important for base selection fidelity. In a forward mutation assay at high polymerase concentration, wild type pol I catalyzed frequent A --> T and G --> T transversions and -1 frameshifts at nonreiterated sites involving loss of a purine immediately downstream of a pyrimidine, The mutants F667L and A661E,I665T, F667L exhibited large decreases in A --> T and G --> T transversions, and the triple mutant displayed reduction in the aforementioned -1 frameshifts as well. Kinetic analysis showed that the F667L and A661E,I665T, F667L polymerases discriminated against synthesis of A:A mispairs more effectively and catalyzed less extension of A:A mispairs than the wild type enzyme. These data indicate that Phe(667) functions in maintaining the error frequency and spectrum, and the catalytic efficiency, of wild type pol I. We also found that the strong general mutator activity conferred by the single A661E substitution was entirely suppressed in the A661E, I665T,F667L polymerase, exemplifying how interactions among O-helix residues can contribute to fidelity. We discuss the mutator and anti-mutator mutations in light of recently obtained three-dimensional structures of T, aquaticus pol I.	Univ Washington, Dept Pathol, Joseph Gottstein Mem Canc Res Lab, Seattle, WA 98195 USA; Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Nagoya Univ, Sch Med, Dis Mechanism & Control Res Inst, Nagoya, Aichi 4668550, Japan	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Nagoya University	Loeb, LA (corresponding author), Univ Washington, Dept Pathol, Joseph Gottstein Mem Canc Res Lab, Box 357705, Seattle, WA 98195 USA.	laloeb@u.washington.edu	Suzuki, Motoshi/I-7246-2014	Suzuki, Motoshi/0000-0003-0682-5006	NATIONAL CANCER INSTITUTE [R01CA078885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG001751] Funding Source: NIH RePORTER; NCI NIH HHS [CA78885] Funding Source: Medline; NIA NIH HHS [AG01751] Funding Source: Medline; NIEHS NIH HHS [P30 ES07033] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; Astatke M, 1998, J MOL BIOL, V278, P147, DOI 10.1006/jmbi.1998.1672; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Bell JB, 1997, J BIOL CHEM, V272, P7345, DOI 10.1074/jbc.272.11.7345; BERNSTEIN FC, 1977, EUR J BIOCHEM, V80, P319, DOI 10.1111/j.1432-1033.1977.tb11885.x; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; FEIG DI, 1994, P NATL ACAD SCI USA, V91, P6609, DOI 10.1073/pnas.91.14.6609; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; HUANG MM, 1992, NUCLEIC ACIDS RES, V20, P4567, DOI 10.1093/nar/20.17.4567; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOYCE CM, 1992, J BIOL CHEM, V267, P24485; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KORNBERG A, 1992, DNA REPLICATION, P498; KOROLEV S, 1995, P NATL ACAD SCI USA, V92, P9264, DOI 10.1073/pnas.92.20.9264; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Li Y, 1999, P NATL ACAD SCI USA, V96, P9491, DOI 10.1073/pnas.96.17.9491; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; LOEB LA, 1982, ANNU REV BIOCHEM, V51, P429, DOI 10.1146/annurev.bi.51.070182.002241; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067; MIZRAHI V, 1986, P NATL ACAD SCI USA, V83, P231, DOI 10.1073/pnas.83.2.231; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; Suzuki M, 1996, P NATL ACAD SCI USA, V93, P9670, DOI 10.1073/pnas.93.18.9670; Suzuki M, 1997, J BIOL CHEM, V272, P11228; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027	34	59	65	5	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32728	32735		10.1074/jbc.M000097200	http://dx.doi.org/10.1074/jbc.M000097200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10906120	hybrid			2022-12-27	WOS:000090003800050
J	Bell, SD; Jackson, SP				Bell, SD; Jackson, SP			Mechanism of autoregulation by an archaeal transcriptional repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE PROMOTER ELEMENT; RNA-POLYMERASE-II; DNA-BINDING; PREINITIATION COMPLEX; FACTOR REQUIREMENTS; TATA-BOX; PROTEIN; EUKARYOTES; SHIBATAE	The basal transcription machinery of archaea corresponds to the core components of the eucaryal RNA polymerase II apparatus. Thus, archaea possess a complex multi-subunit RNA polymerase, a TATA box-binding protein and a protein termed transcription factor B (TFB), which is a homologue of eucaryal transcription factor IIB (TFIIB). Intriguingly, archaeal genome sequencing projects have revealed the existence of homologues of bacterial transcriptional regulators. To investigate the mechanism of transcriptional regulation in archaea we have studied one such molecule, Lrs14, a Sulfolobus solfataricus P2 homologue of the bacterial leucine-responsive regulatory protein, Lrp. We find that purified Lrs14 specifically represses the transcription of its own gene in a reconstituted in vitro transcription system. Furthermore, we show that Lrs14 binding sites overlap the basal promoter elements of the Lrs14 promoter and reveal that binding of Lrs14 to these sites prevents promoter recognition by TATA box-binding protein and TFB.	Inst Canc & Dev Biol, Wellcome Trust, Cambridge CB2 1QR, England; Inst Canc & Dev Biol, CRC, Cambridge CB2 1QR, England; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England	Wellcome Trust Sanger Institute; University of Cambridge	Jackson, SP (corresponding author), Inst Canc & Dev Biol, Wellcome Trust, Tennis Court Rd, Cambridge CB2 1QR, England.		Dry, Kate/I-2328-2014; Jackson, Stephen Philip/R-4548-2019	Jackson, Stephen Philip/0000-0001-9317-7937; Bell, Stephen/0000-0002-8474-6592				Aravind L, 1999, NUCLEIC ACIDS RES, V27, P4658, DOI 10.1093/nar/27.23.4658; Bell SD, 2000, J BIOL CHEM, V275, P12934, DOI 10.1074/jbc.275.17.12934; Bell SD, 1999, MOL CELL, V4, P971, DOI 10.1016/S1097-2765(00)80226-9; Bell SD, 1998, P NATL ACAD SCI USA, V95, P15218, DOI 10.1073/pnas.95.26.15218; Bell SD, 1998, TRENDS MICROBIOL, V6, P222, DOI 10.1016/S0966-842X(98)01281-5; Bell SD, 1999, P NATL ACAD SCI USA, V96, P13662, DOI 10.1073/pnas.96.24.13662; Burke TW, 1998, COLD SPRING HARB SYM, V63, P75, DOI 10.1101/sqb.1998.63.75; Kosa PF, 1997, P NATL ACAD SCI USA, V94, P6042, DOI 10.1073/pnas.94.12.6042; Kyrpides NC, 1999, P NATL ACAD SCI USA, V96, P8545, DOI 10.1073/pnas.96.15.8545; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; Napoli A, 1999, J BACTERIOL, V181, P1474, DOI 10.1128/JB.181.5.1474-1480.1999; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Qureshi SA, 1997, EMBO J, V16, P2927, DOI 10.1093/emboj/16.10.2927; Qureshi SA, 1998, MOL CELL, V1, P389, DOI 10.1016/S1097-2765(00)80039-8; ROWLANDS T, 1994, SCIENCE, V264, P1326, DOI 10.1126/science.8191287; Sambrook J., 2002, MOL CLONING LAB MANU; Smale ST, 1998, COLD SPRING HARB SYM, V63, P21, DOI 10.1101/sqb.1998.63.21; Soppa J, 1999, MOL MICROBIOL, V31, P1295, DOI 10.1046/j.1365-2958.1999.01273.x; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088	20	79	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31624	31629		10.1074/jbc.M005422200	http://dx.doi.org/10.1074/jbc.M005422200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10900210	hybrid			2022-12-27	WOS:000089858900012
J	Blain, SW; Massague, J				Blain, SW; Massague, J			Different sensitivity of the transforming growth factor-ss cell cycle arrest pathway to c-Myc and IMDM-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA; TGF-BETA; TRANSCRIPTIONAL ACTIVITY; MAMMALIAN-CELLS; I RECEPTORS; MDM2; PROTEINS; REPRESSION; ACTIVATION; P15(INK4B)	Recently, the oncoprotein MDM-2 was implicated in the transforming growth factor-beta (TGF-beta) growth inhibitory pathway by the finding that prolonged, constitutive expression of MDM-2 in mink lung epithelial cells could overcome the antiproliferative effect of TGF-beta (Sun, P., Dong, P., Dal, K., Hannon, G. J., and Beach, D. (1998) Science 282, 2270-2272). However, using Mv1Lu cells conditionally expressing MDM-2, we found that MDM-2 does not overcome TGF-beta-mediated growth arrest. No detectable changes were observed in various TGF-beta responses, including cell cycle arrest, activation of transcriptional reporters, and TGF-beta-dependent Smad2/3 nuclear accumulation. This finding was in direct contrast to the effect of forcing c-Myc expression, a bona fide member of the TGF-beta growth inhibitory pathway, which renders cells refractory to TGF-beta-induced cell cycle arrest. Our results suggest that an MDM-2-dependent increase in cell cycle progression may allow the acquisition of additional mutations over time and that these alterations then allow cells to evade a TGF-beta-mediated growth arrest. Our conclusion is that, whereas c-Mye down-regulation by TGF-beta is a required event in the cell cycle arrest response of epithelial cells, MDM-2 is not a direct participant in the normal TGF-beta antiproliferative response.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Massague, J (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, POB 116,1275 York Ave, New York, NY 10021 USA.			Massague, Joan/0000-0001-9324-8408				ALEXANDROW MG, 1995, CANCER RES, V55, P1452; AMATI B, 1994, CURR OPIN GENET DEV, P4; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Connell-Crowley L, 1998, CURR BIOL, V8, P65, DOI 10.1016/S0960-9822(98)70021-1; Dang CV, 1999, MOL CELL BIOL, V19, P1; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Iavarone A, 1997, NATURE, V387, P417; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MALLIRI A, 1996, CELL GROWTH DIFFER, V7, P12991; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; Polyak K, 1996, BBA-REV CANCER, V1242, P185, DOI 10.1016/0304-419X(95)00009-5; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yam CH, 1999, CANCER RES, V59, P5075; Yap DBS, 1999, ONCOGENE, V18, P7681, DOI 10.1038/sj.onc.1202954; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	32	20	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32066	32070		10.1074/jbc.M006496200	http://dx.doi.org/10.1074/jbc.M006496200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10906337	hybrid			2022-12-27	WOS:000089858900071
J	Maccarrone, M; Lorenzon, T; Bari, M; Melino, G; Finazzi-Agro, A				Maccarrone, M; Lorenzon, T; Bari, M; Melino, G; Finazzi-Agro, A			Anandamide induces apoptosis in human cells via vanilloid receptors - Evidence for a protective role of cannabinoid receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; MESENTERIC VASODILATION; CB2 RECEPTORS; GLIOMA-CELLS; DELTA(9)-TETRAHYDROCANNABINOL; DEGRADATION; INDUCTION; CALCIUM; AGONIST; NEURONS	The endocannabinoid anandamide (AEA) is shown to induce apoptotic bodies formation and DNA fragmentation, hallmarks of programmed cell death, in human neuroblastoma CHP100 and lymphoma U937 cells. RNA and protein synthesis inhibitors like actinomycin D and cycloheximide reduced to one-fifth the number of apoptotic bodies induced by AEA, whereas the AEA transporter inhibitor AM404 or the AEA hydrolase inhibitor ATFMK significantly increased the number of dying cells. Furthermore, specific antagonists of cannabinoid or vanilloid receptors potentiated or inhibited cell death induced by AEA, respectively. Other endocannabinoids such as 2-arachidonoylglycerol, linoleoylethanolamide, oleoylethanolamide, and palmitoylethanolamide did not promote cell death under the same experimental conditions. The formation of apoptotic bodies induced by AEA was paralleled by increases in intracellular calcium (3-fold over the controls), mitochondrial uncoupling (6-fold), and cytochrome c release (3-fold). The intracellular calcium chelator EGTA-AM reduced the number of apoptotic bodies to 40% of the controls, and electrotransferred anti-cytochrome c monoclonal antibodies fully prevented apoptosis induced by AEA, Moreover, 5-lipoxygenase inhibitors 5,8,11,14-eicosatetraynoic acid and MK886, cyclooxygenase inhibitor indomethacin, caspase-3 and caspase-9 inhibitors Z-DEVD-FMK and Z-LEHD-FMK, but not nitric oxide synthase inhibitor Nw-nitro-L-arginine methyl ester, significantly reduced the cell death-inducing effect of AEA. The data presented indicate a protective role of cannabinoid receptors against apoptosis induced by AEA via vanilloid receptors.	Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy	University of Rome Tor Vergata	Finazzi-Agro, A (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Via Tor Vergata 135, I-00133 Rome, Italy.	Finazzi@uniroma2.it						Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; Ara G, 1996, PROSTAG LEUKOTR ESS, V54, P3, DOI 10.1016/S0952-3278(96)90075-7; Basavarajappa BS, 1999, J NEUROCHEM, V72, P522, DOI 10.1046/j.1471-4159.1999.0720522.x; Biro T, 1998, MOL BRAIN RES, V56, P89, DOI 10.1016/S0169-328X(98)00033-3; Chan GCK, 1998, J NEUROSCI, V18, P5322, DOI 10.1523/JNEUROSCI.18-14-05322.1998; Datta K, 1998, J BIOL CHEM, V273, P28163, DOI 10.1074/jbc.273.43.28163; De Petrocellis L, 1998, P NATL ACAD SCI USA, V95, P8375, DOI 10.1073/pnas.95.14.8375; Derocq JM, 1998, FEBS LETT, V425, P419, DOI 10.1016/S0014-5793(98)00275-0; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; Deutsch DG, 1997, J CLIN INVEST, V100, P1538, DOI 10.1172/JCI119677; Di Marzo V, 1998, NATURE, V396, P636, DOI 10.1038/25267; Di Marzo V, 1999, EUR J BIOCHEM, V264, P258, DOI 10.1046/j.1432-1327.1999.00631.x; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432-1033.1995.tb20780.x; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Goparaju SK, 1998, FEBS LETT, V422, P69, DOI 10.1016/S0014-5793(97)01603-7; Jarai Z, 1999, P NATL ACAD SCI USA, V96, P14136, DOI 10.1073/pnas.96.24.14136; KOUTEK B, 1994, J BIOL CHEM, V269, P22937; Maccarrone M, 2000, J BIOL CHEM, V275, P13484, DOI 10.1074/jbc.275.18.13484; Maccarrone M, 2000, FEBS LETT, V468, P176, DOI 10.1016/S0014-5793(00)01223-0; Maccarrone M, 1996, EUR J BIOCHEM, V241, P297, DOI 10.1111/j.1432-1033.1996.0297t.x; MACCARRONE M, 1992, EUR J BIOCHEM, V205, P995, DOI 10.1111/j.1432-1033.1992.tb16866.x; Maccarrone M, 1997, CELL DEATH DIFFER, V4, P396, DOI 10.1038/sj.cdd.4400255; Maccarrone M, 2000, LANCET, V355, P1326, DOI 10.1016/S0140-6736(00)02115-2; Maccarrone M, 1998, J BIOL CHEM, V273, P32332, DOI 10.1074/jbc.273.48.32332; Macho A, 1999, CELL DEATH DIFFER, V6, P155, DOI 10.1038/sj.cdd.4400465; MAKI A, 1992, FASEB J, V6, P919, DOI 10.1096/fasebj.6.3.1740241; Neame SJ, 1998, J CELL BIOL, V142, P1583, DOI 10.1083/jcb.142.6.1583; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; Piomelli D, 1999, P NATL ACAD SCI USA, V96, P5802, DOI 10.1073/pnas.96.10.5802; Pop E, 1999, CURR OPIN CHEM BIOL, V3, P418, DOI 10.1016/S1367-5931(99)80062-3; Ruiz L, 1999, FEBS LETT, V458, P400, DOI 10.1016/S0014-5793(99)01073-X; Saito M, 1999, NEUROCHEM RES, V24, P1107, DOI 10.1023/A:1020704218574; Sanchez C, 1998, FEBS LETT, V436, P6, DOI 10.1016/S0014-5793(98)01085-0; Sarker KP, 2000, FEBS LETT, V472, P39, DOI 10.1016/S0014-5793(00)01425-3; SCHWARZ H, 1994, J NEUROIMMUNOL, V55, P107, DOI 10.1016/0165-5728(94)90152-X; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; Smart D, 2000, TRENDS PHARMACOL SCI, V21, P134, DOI 10.1016/S0165-6147(00)01459-0; SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671; Sugimoto T, 1999, BRAIN RES, V818, P147, DOI 10.1016/S0006-8993(98)01227-X; Ushmorov A, 1999, BLOOD, V93, P2342, DOI 10.1182/blood.V93.7.2342.407k09_2342_2352; van Leyen K, 1998, NATURE, V395, P392, DOI 10.1038/26500; Vanags DM, 1997, CELL DEATH DIFFER, V4, P479, DOI 10.1038/sj.cdd.4400269; VANDENBERGHE PA, 1990, J IMMUNOL METHODS, V127, P197, DOI 10.1016/0022-1759(90)90069-8; Wagner JA, 1999, HYPERTENSION, V33, P429, DOI 10.1161/01.HYP.33.1.429; Walker JM, 1999, P NATL ACAD SCI USA, V96, P12198, DOI 10.1073/pnas.96.21.12198; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	50	283	293	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31938	31945		10.1074/jbc.M005722200	http://dx.doi.org/10.1074/jbc.M005722200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10913156	hybrid			2022-12-27	WOS:000089858900055
J	Miyakawa, Y; Drachman, JG; Gallis, B; Kaushansky, A; Kaushansky, K				Miyakawa, Y; Drachman, JG; Gallis, B; Kaushansky, A; Kaushansky, K			A structure-function analysis of serine/threonine phosphorylation of the thrombopoietin receptor, c-Mpl	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BLOOD-PLATELETS; PROTEIN-TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; ACTIVATION; KINASE; CELLS; IDENTIFICATION; PROLIFERATION; PATHWAY; DOMAIN	Thrombopoietin (TPO), the critical regulator of platelet production, acts by binding to its cell surface receptor, c-Mpl. Numerous studies have shown that TPO binding leads to JAK2 kinase activation and Tyr phosphorylation of c-Mpl and several intracellular signaling intermediates, events vital for the biological activity of the hormone. In contrast, virtually nothing is known of the role of Ser or Thr phosphorylation of c-Mpl. By using phosphoamino acid analysis we found that Ser residues of c-Mpl were constitutively phosphorylated in receptor-bearing cells, levels that were increased following exposure of cells to TPO. To identify which residues were modified, and to determine the functional consequences of their phosphorylation, we generated a series of Ser to Ala mutations of a truncated c-Mpl receptor (T69) capable of supporting TPO-induced cell growth. Of the eight Ser within T69 we found that at least four are phosphorylated in TPO-stimulated cells. The mutation of each of these residues alone had minimal effects on TPO-induced proliferation, but substitution of all of the phosphoserine residues with Ala reduced the capacity of the receptor to support cell growth by over 50%. Additionally, the Ser at cytoplasmic position 18 is not detectably phosphorylated. However, the mutation of Ser-18 to Ala nearly abrogates TPO-induced proliferation and co-precipitation of JAK2 with Mpl. This study provides the first systematic analysis of the role of Ser residues in c-Mpl signaling.	Univ Washington, Sch Med, Div Hematol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Div Cardiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Kaushansky, K (corresponding author), Univ Washington, Sch Med, Div Hematol, 1959 NE Pacific St, Seattle, WA 98195 USA.	kkaushan@u.washington.edu	Kaushansky, Alexis/U-6695-2019		NATIONAL CANCER INSTITUTE [R01CA031615] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064228] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049855] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA31615] Funding Source: Medline; NHLBI NIH HHS [1RO1HL64228] Funding Source: Medline; NIDDK NIH HHS [R01 DK49855] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexander WS, 1996, BLOOD, V87, P2162, DOI 10.1182/blood.V87.6.2162.bloodjournal8762162; BEYAERT R, 1995, J BIOL CHEM, V270, P23293, DOI 10.1074/jbc.270.40.23293; CHEN JC, 1995, BLOOD, V86, P4054, DOI 10.1182/blood.V86.11.4054.bloodjournal86114054; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; Dorsch M, 1997, J EXP MED, V186, P1947, DOI 10.1084/jem.186.12.1947; Drachman JG, 1999, J BIOL CHEM, V274, P13480, DOI 10.1074/jbc.274.19.13480; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAUSHANSKY K, 1995, BLOOD, V86, P419, DOI 10.1182/blood.V86.2.419.bloodjournal862419; LIU L, 1995, J BIOL CHEM, V270, P22422, DOI 10.1074/jbc.270.38.22422; Luoh SM, 2000, MOL CELL BIOL, V20, P507, DOI 10.1128/MCB.20.2.507-515.2000; MIYAKAWA Y, 1995, BLOOD, V86, P23, DOI 10.1182/blood.V86.1.23.bloodjournal86123; Miyakawa Y, 1996, BLOOD, V87, P439, DOI 10.1182/blood.V87.2.439.bloodjournal872439; MU SX, 1995, BLOOD, V86, P4532, DOI 10.1182/blood.V86.12.4532.bloodjournal86124532; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Oda A, 1996, BLOOD, V88, P1330, DOI 10.1182/blood.V88.4.1330.bloodjournal8841330; RAO P, 1995, J BIOL CHEM, V270, P6886, DOI 10.1074/jbc.270.12.6886; Rojnuckarin P, 1999, BLOOD, V94, P1273, DOI 10.1182/blood.V94.4.1273.416k04_1273_1282; Sawyer ST, 1996, J BIOL CHEM, V271, P32430, DOI 10.1074/jbc.271.50.32430; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; Solar GP, 1998, BLOOD, V92, P4, DOI 10.1182/blood.V92.1.4.413k38_4_10; Stomski FC, 1999, BLOOD, V94, P1933; Van Linden AA, 2000, J BIOL CHEM, V275, P6996, DOI 10.1074/jbc.275.10.6996; Zhang LR, 1997, J BIOL CHEM, V272, P14762, DOI 10.1074/jbc.272.23.14762	25	19	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32214	32219		10.1074/jbc.M005080200	http://dx.doi.org/10.1074/jbc.M005080200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10918061	hybrid			2022-12-27	WOS:000089858900091
J	Schwarz, DA; Barry, G; Eliasof, SD; Petroski, RE; Conlon, PJ; Maki, RA				Schwarz, DA; Barry, G; Eliasof, SD; Petroski, RE; Conlon, PJ; Maki, RA			Characterization of gamma-aminobutyric acid receptor GABA(B(1e)), a GABA(B(1)) splice variant encoding a truncated receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; LIGAND-BINDING; EXTRACELLULAR DOMAIN; TERMINAL DOMAIN; GABA-RECEPTORS; EXPRESSION; GABA(B)R1; AGONIST; IDENTIFICATION; SELECTIVITY	We have identified a splice variant encoding only the extracellular ligand-binding domain of the gamma-aminobutyric acid B (GABA(B)) receptor subunit GABA(B(1a)). This isoform, which we have named GABA(B(1e)), is detected in both rats and humans, While GABA(B(1e)) is a minor component of the total pool of GABA(B(1)) transcripts detected in the central nervous system, it is the primary isoform found in all peripheral tissues examined. When expressed in a heterologous system, the truncated receptor is both secreted and membrane associated. However, GABA(B(1e)) lacks the ability to bind the radiolabeled antagonist [H-3]CGP 54626A, activate G-protein coupled inwardly rectifying potassium channels, or inhibit forskolin-induced cAMP production when it is expressed alone or together with GABA(B(2)). Interestingly, when co-expressed with GABA(B(2)), not only does the truncated receptor heterodimerize with GABA(B(2)), he association is of sufficient avidity to disrupt the normal GABA(B(1a))/GABA(B(2)) association. Despite this strong interaction, GABA(B(1e)) fails to disrupt G-protein coupled inwardly rectifying potassium activation by the full-length heterodimer pair of GABA(B(1a))/GABA(B(2)).	Neurocrine Biosci Inc, San Diego, CA 92121 USA	Neurocrine Biosciences	Schwarz, DA (corresponding author), Neurocrine Biosci Inc, 10555 Sci Ctr Dr, San Diego, CA 92121 USA.		Barry, Guy/C-1188-2011	Barry, Guy/0000-0001-6404-086X				Benke D, 1999, J BIOL CHEM, V274, P27323, DOI 10.1074/jbc.274.38.27323; Bettler B, 1998, CURR OPIN NEUROBIOL, V8, P345, DOI 10.1016/S0959-4388(98)80059-7; BOWERY NG, 1981, EUR J PHARMACOL, V71, P53, DOI 10.1016/0014-2999(81)90386-1; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Couve A, 1998, J BIOL CHEM, V273, P26361, DOI 10.1074/jbc.273.41.26361; Galvez T, 1999, J BIOL CHEM, V274, P13362, DOI 10.1074/jbc.274.19.13362; Han GM, 1999, J BIOL CHEM, V274, P10008, DOI 10.1074/jbc.274.15.10008; Hawrot E, 1998, FEBS LETT, V432, P103, DOI 10.1016/S0014-5793(98)00794-7; Hoon MA, 1999, CELL, V96, P541, DOI 10.1016/S0092-8674(00)80658-3; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Kaupmann K, 1998, P NATL ACAD SCI USA, V95, P14991, DOI 10.1073/pnas.95.25.14991; KERR DI, 1995, PHARMACOL THERAPEUT, V6, P187; KERR DIB, 1993, EUR J PHARMACOL, V236, P239, DOI 10.1016/0014-2999(93)90594-8; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; Malitschek B, 1999, MOL PHARMACOL, V56, P448, DOI 10.1124/mol.56.2.448; Martin SC, 1999, MOL CELL NEUROSCI, V13, P180, DOI 10.1006/mcne.1999.0741; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; Ng GYK, 1999, J BIOL CHEM, V274, P7607, DOI 10.1074/jbc.274.12.7607; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; ONG J, 1990, LIFE SCI, V46, P1489, DOI 10.1016/0024-3205(90)90421-M; Peters HC, 1998, NEUROGENETICS, V2, P47, DOI 10.1007/s100480050051; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354	28	91	97	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32174	32181		10.1074/jbc.M005333200	http://dx.doi.org/10.1074/jbc.M005333200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10906333	hybrid			2022-12-27	WOS:000089858900085
J	Takeshita, A; Watanabe, A; Takada, Y; Hanazawa, S				Takeshita, A; Watanabe, A; Takada, Y; Hanazawa, S			Selective stimulation by ceramide of the expression of the a isoform of retinoic acid and retinoid X receptors in osteoblastic cells - A role of sphingosine 1-phosphate-mediated AP-1 in the ligand-dependent transcriptional activity of these receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT JE; PROTEIN-KINASE; CHLORAMPHENICOL ACETYLTRANSFERASE; NEUTRAL SPHINGOMYELINASE; INTERLEUKIN-6 SYNTHESIS; GENE-EXPRESSION; MC3T3-E1 CELLS; ACTIVATION; ALPHA; BETA	Recent studies have demonstrated that sphingosine l-phosphate (SPP) plays a functional role as a signaling molecule in gene expression in several kinds of cells. The present study demonstrates selective expression by ceramide of retinoic acid receptor-alpha (RAR-alpha) and retinoic X receptor-alpha (RXR-alpha) in osteoblastic MC3T3-E1 cells and a functional role of SPP-mediated AP-1 in the signaling mechanism of ligand-dependent transcriptional activity of heterodimers of these receptors in the cells. C-2- and C-6-ceramides selectively stimulated the expression of RAR-alpha and RXR-alpha genes, but not that of beta and gamma isoform genes of RAR and RXR, in the cells. The C-2-ceramide-induced stimulation was clearly inhibited by DL-threo-dihydrosphingosine, an inhibitor of sphingosine kinase. SPP also selectively stimulated the expression of both receptors and increased the specific binding of the nuclear proteins to direct repeat 5 (DR-S), a consensus sequence of RAR-RXR. In addition, SPP markedly stimulated transient chloramphenicol acetyltransferase (CAT) activity of retinoic acid-dependent transcriptional activity in the cells transfected with a DR-B-CAT reporter gene. The SPP stimulation was activation protein-1 (AP-l)-dependent, because the SPP stimulatory action toward these nuclear gene expressions and the transient CAT activity were inhibited by antisense c-fos and c-jun oligonucleotides. We observed that SPP actually stimulated AP-1 transcriptional activity in the cells. This study suggests an important role of SPP-mediated AP-1 in the selective expression of RAR-a! and RXR-alpha in osteoblastic cells via the sphingosine pathway.	Meikai Univ, Sch Dent, Dept Oral Microbiol, Sakado, Saitama 3500283, Japan; Snow Brand Milk Prod Co Ltd, Tech Res Inst, Kawagoe, Saitama 3501165, Japan	Meikai University; Snow Brand Milk Products Co., Ltd.	Hanazawa, S (corresponding author), Kyushu Univ, Fac Dent Sci, Div Oral Infect Dis & Immunol, Higashi Ku, Maidashi 3-1-1, Fukuoka 8128582, Japan.	hanazawa@dent.kyushu-u.ac.jp						Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNETTE E, 1992, NUCLEIC ACIDS RES, V20, P1151, DOI 10.1093/nar/20.5.1151; Chen Y, 1996, J BIOL CHEM, V271, P31602, DOI 10.1074/jbc.271.49.31602; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HANAZAWA S, 1994, J BIOL CHEM, V269, P21379; HANAZAWA S, 1993, J BIOL CHEM, V268, P9526; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Kanety H, 1996, J BIOL CHEM, V271, P9895, DOI 10.1074/jbc.271.17.9895; Kastner P, 1997, DEVELOPMENT, V124, P313; Kitajima I, 1996, BONE, V19, P263, DOI 10.1016/8756-3282(96)00181-0; Kozawa O, 1997, J BIOL CHEM, V272, P25099, DOI 10.1074/jbc.272.40.25099; Kozawa O, 1997, FEBS LETT, V418, P149, DOI 10.1016/S0014-5793(97)01366-5; LIU R, 1995, BIOCHEM BIOPH RES CO, P676; LOHNES D, 1994, DEVELOPMENT, V120, P2723; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; Luo JM, 1996, MECH DEVELOP, V55, P33, DOI 10.1016/0925-4773(95)00488-2; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Maniatis T., 1982, MOL CLONING; Manji SS, 1998, J CELL PHYSIOL, V176, P1; MURRAY IA, 1991, NUCLEIC ACIDS RES, V19, P6648; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; ROBERTS AB, 1984, RETINOIDS, V2, P28; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHUTZE S, 1995, IMMUNOBIOLOGY, V193, P193, DOI 10.1016/S0171-2985(11)80543-7; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; SU Y, 1994, J BIOL CHEM, V269, P16512; Takeda H, 1998, FEBS LETT, V422, P255, DOI 10.1016/S0014-5793(98)00005-2; TAKESHITA A, 1995, J IMMUNOL, V155, P419; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; Yasuda H, 1999, BONE, V25, P109, DOI 10.1016/S8756-3282(99)00121-0	38	18	19	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32220	32226		10.1074/jbc.M002569200	http://dx.doi.org/10.1074/jbc.M002569200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10915783	hybrid			2022-12-27	WOS:000089858900092
J	Zhang, XQ; Arvan, P				Zhang, XQ; Arvan, P			Cell type-dependent differences in thyroid peroxidase cell surface expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-LEVEL EXPRESSION; EPITHELIAL-CELLS; HASHIMOTOS-THYROIDITIS; INTRACELLULAR TRAFFICKING; ENDOPLASMIC-RETICULUM; HUMAN THYROPEROXIDASE; AUTOANTIBODY BINDING; MICROSOMAL ANTIGEN; ENZYMATIC-ACTIVITY; EUKARYOTIC CELLS	Recently, it has been suggested that only similar to 2% of human thyroid peroxidase (hTPO(933)) reaches the surface of stably transfected (Chinese hamster ovary) cells, most being degraded intracellularly, and this might be representative of thyroid peroxidase (TPO) behavior in thyrocytes (Fayadat, L,, Siffroi-Fernandez, S., Lanet, J,, and Franc, J.-L, (2000) J. Biol. Chem. 275, 15948-15954), In agreement, in stably transfected Madin-Darby canine kidney clones, nonpermeabilized cells exhibit wild-type hTPO(933) immunofluorescence (apically) on <10% of that found in permeabilized cells, where an endoplasmic reticulum pattern is observed. Further, a C-terminally truncated, membrane-anchorless hTPO(848) is also retained in the endoplasmic reticulum of stably transfected Madin-Darby canine kidney cells. However, by contrast, in Chinese hamster ovary cells after transient transfection, hTPO(933) immunofluorescence is detected equally well in nonpermeabilized and permeabilized cells, indicating that a large portion of hTPO(933) is present at the cell surface; furthermore, hTPO(933) is efficiently secreted. Further, using an antiserum not crossreacting with rat TPO, we find by immunofluorescence that in stable clones of PC Cl3 (rat) thyrocytes, considerably more (similar to 50%) of the cells exhibit hTPO(933) at the cell surface. However, cell surface biotinylation and endoglycosidase H digestion assays appear to under-represent the extent of hTPO(933) transport, presumably because protein folding limits both Golgi carbohydrate modification and accessibility of lysines in the extracellular domain. We conclude that cell type-specific factors may facilitate stable expression of TPO at the cell surface of thyrocytes.	Albert Einstein Coll Med, Div Endocrinol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Arvan, P (corresponding author), Albert Einstein Coll Med, Div Endocrinol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	arvan@aecom.yu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040344, R01DK040344] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 40344] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALQUIER C, 1989, AUTOIMMUNITY, V3, P113, DOI 10.3109/08916938909019960; BARTLES JR, 1988, TRENDS BIOCHEM SCI, V13, P181, DOI 10.1016/0968-0004(88)90147-8; Bikker H, 1997, J CLIN ENDOCR METAB, V82, P649, DOI 10.1210/jc.82.2.649; BJORKMAN U, 1978, ENDOCRINOLOGY, V102, P460, DOI 10.1210/endo-102-2-460; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; Castle AM, 1997, J CELL BIOL, V138, P45, DOI 10.1083/jcb.138.1.45; CHIOVATO L, 1985, J CLIN ENDOCR METAB, V61, P12, DOI 10.1210/jcem-61-1-12; CHIOVATO L, 1988, ENDOCRINOLOGY, V123, P1140, DOI 10.1210/endo-123-2-1140; COLOMER V, 1994, EMBO J, V13, P3711, DOI 10.1002/j.1460-2075.1994.tb06680.x; CZARNOCKA B, 1986, J ENDOCRINOL INVEST, V9, P135, DOI 10.1007/BF03348084; EKHOLM R, 1981, MOL CELL ENDOCRINOL, V24, P141, DOI 10.1016/0303-7207(81)90056-3; Fayadat L, 1998, ENDOCRINOLOGY, V139, P4277, DOI 10.1210/en.139.10.4277; Fayadat L, 2000, ENDOCRINOLOGY, V141, P959, DOI 10.1210/en.141.3.959; Fayadat L, 2000, J BIOL CHEM, V275, P15948, DOI 10.1074/jbc.M905763199; Fayadat L, 1999, J BIOL CHEM, V274, P10533, DOI 10.1074/jbc.274.15.10533; FINKE R, 1990, J CLIN ENDOCR METAB, V71, P53, DOI 10.1210/jcem-71-1-53; FINKE R, 1992, MOL CELL ENDOCRINOL, V84, P73, DOI 10.1016/0303-7207(92)90073-F; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; FOTI D, 1990, MOL ENDOCRINOL, V4, P786, DOI 10.1210/mend-4-5-786; FOTI D, 1990, ENDOCRINOLOGY, V126, P2983, DOI 10.1210/endo-126-6-2983; GIRAUD A, 1992, J ENDOCRINOL, V132, P317, DOI 10.1677/joe.0.1320317; Gorr SU, 1999, AM J PHYSIOL-CELL PH, V277, pC121, DOI 10.1152/ajpcell.1999.277.1.C121; GOTTARDI CJ, 1995, AM J PHYSIOL-RENAL, V268, pF285, DOI 10.1152/ajprenal.1995.268.2.F285; Guo J, 1998, ENDOCRINOLOGY, V139, P999, DOI 10.1210/en.139.3.999; HATA J, 1989, BIOCHEM BIOPH RES CO, V164, P1268, DOI 10.1016/0006-291X(89)91806-8; Huang XF, 1997, J BIOL CHEM, V272, P27598, DOI 10.1074/jbc.272.44.27598; Jones FG, 1996, J MOL ENDOCRINOL, V17, P165, DOI 10.1677/jme.0.0170165; KAUFMAN KD, 1989, J CLIN INVEST, V84, P394, DOI 10.1172/JCI114179; KAUFMAN KD, 1991, MOL CELL ENDOCRINOL, V78, P107; KISO Y, 1992, AUTOIMMUNITY, V12, P259, DOI 10.3109/08916939209148468; KOTANI T, 1987, ENDOCRINOL JAPON, V34, P407; KULIAWAT R, 1995, J BIOL CHEM, V270, P2478, DOI 10.1074/jbc.270.6.2478; LONG Y, 1991, EUR J BIOCHEM, V202, P501, DOI 10.1111/j.1432-1033.1991.tb16401.x; MAGNUSSON RP, 1987, MOL ENDOCRINOL, V1, P856, DOI 10.1210/mend-1-11-856; MARINOVICH M, 1995, BIOCHEM BIOPH RES CO, V212, P602, DOI 10.1006/bbrc.1995.2012; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MCLACHLAN SM, 1992, ENDOCR REV, V13, P192, DOI 10.1210/er.13.2.192; MOURA EG, 1991, ACTA ENDOCRINOL-COP, V124, P107, DOI 10.1530/acta.0.1240107; NIEPOMNISZCZE H, 1975, METABOLISM, V24, P57, DOI 10.1016/0026-0495(75)90007-4; NILSSON M, 1987, MOL CELL ENDOCRINOL, V53, P177, DOI 10.1016/0303-7207(87)90172-9; OFVERHOLM T, 1985, MOL CELL ENDOCRINOL, V40, P1, DOI 10.1016/0303-7207(85)90151-0; Oyarce AM, 2000, J BIOL CHEM, V275, P3270, DOI 10.1074/jbc.275.5.3270; Penel C, 1998, J CELL PHYSIOL, V174, P160, DOI 10.1002/(SICI)1097-4652(199802)174:2<160::AID-JCP3>3.0.CO;2-M; PINCHERA A, 1987, ACTA ENDOCRINOL-COP, V115, P57; Rasmussen AK, 1999, AUTOIMMUNITY, V29, P323, DOI 10.3109/08916939908994752; RAWITCH AB, 1992, ARCH BIOCHEM BIOPHYS, V297, P321, DOI 10.1016/0003-9861(92)90679-Q; Roush DL, 1998, J BIOL CHEM, V273, P26862, DOI 10.1074/jbc.273.41.26862; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; STRUM J M, 1970, Journal of Cell Biology, V44, P655, DOI 10.1083/jcb.44.3.655; WATANABE K, 1991, ENDOCRINOL JAPON, V38, P89; ZURZOLO C, 1993, J CELL BIOL, V121, P1031, DOI 10.1083/jcb.121.5.1031; ZURZOLO C, 1992, J CELL BIOL, V117, P551, DOI 10.1083/jcb.117.3.551	52	11	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31946	31953		10.1074/jbc.M003559200	http://dx.doi.org/10.1074/jbc.M003559200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10924504	hybrid			2022-12-27	WOS:000089858900056
J	Chou, KM; Kukhanova, M; Cheng, YC				Chou, KM; Kukhanova, M; Cheng, YC			A novel action of human apurinic/apyrimidinic endonuclease - Excision of L-configuration deoxyribonucleoside analogs from the 3 ' termini of DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APURINIC ENDONUCLEASE; L-DIOXOLANE-CYTIDINE; IN-VITRO; CYTOSINE-ARABINOSIDE; NUCLEOSIDE ANALOGS; ANTITUMOR-ACTIVITY; PROTEIN APE/REF-1; BINDING ACTIVITY; AP-ENDONUCLEASE; NUCLEAR-PROTEIN	beta-L-Dioxolane-cytidine (L-OddC, BCH-4556, Troxacitabine) is a novel unnatural stereochemical nucleoside analog that is under phase II clinical study for cancer treatment. This nucleoside analog could be phosphorylated and subsequently incorporated into the 3' terminus of DNA. The cytotoxicity of L-OddC was correlated with the amount of L-OddCMP in DNA, which depends on the incorporation by DNA polymerases and the removal by exonucleases. Here we reported the purification and identification of the major enzyme that could preferentially remove L-OddCMP compared with dCMP from the 3' termini of DNA in human cells. Surprisingly, this enzyme was found to be apurinic/apyrimidinic endonuclease (APE1) (1), a well characterized DNA base excision repair protein, APE1 preferred to remove L- over D-configuration nucleosides from 3' termini of DNA. The efficiency of removal of these deoxycytidine analogs were as follows: L-OddC > beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine > beta-L-2',3'-dideoxycytidine > beta-L-2',3'-dideoxy-3'-thiocytidine > beta-D-2',3'-dideoxycytidine > beta-D-2',2'-difluorodeoxycytidine > beta-D-8'-deoxycytidine greater than or equal to beta-D-arabinofuranosylcytosine. This report is the first demonstration that an exonuclease can preferentially excise L-configuration nucleoside analogs. This discovery suggests that APE1 could be critical for the activity of L-OddC or other L-nucleoside analogs and may play additional important roles in cells that were not previously known.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Cheng, YC (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, Sterling Hall Med,B315,333 Cedar St, New Haven, CT 06520 USA.				NCI NIH HHS [CA 63477] Funding Source: Medline; NIAID NIH HHS [AI 39204] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA063477, R01CA063477] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBRUZZESE JL, 1991, J CLIN ONCOL, V9, P491, DOI 10.1200/JCO.1991.9.3.491; BARZILAY G, 1995, BIOESSAYS, V17, P713, DOI 10.1002/bies.950170808; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Chaudhry MA, 1999, BIOCHEM PHARMACOL, V57, P531, DOI 10.1016/S0006-2952(98)00327-X; CHEN DS, 1993, RADIAT RES, V135, P405, DOI 10.2307/3578882; COHEN SS, 1977, CANCER-AM CANCER SOC, V40, P509, DOI 10.1002/1097-0142(197707)40:1+<509::AID-CNCR2820400717>3.0.CO;2-8; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DEVINENI D, 1995, CLIN PHARMACOKINET, V28, P351, DOI 10.2165/00003088-199528050-00002; Dutschman GE, 1998, ANTIMICROB AGENTS CH, V42, P1799, DOI 10.1128/AAC.42.7.1799; Fritz G, 1999, ONCOGENE, V18, P1033, DOI 10.1038/sj.onc.1202394; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; GOSSELIN G, 1994, ANTIMICROB AGENTS CH, V38, P1292, DOI 10.1128/AAC.38.6.1292; Grindey G B, 1990, Cancer Invest, V8, P313, DOI 10.3109/07357909009017602; Grove KL, 1996, CANCER RES, V56, P4187; GROVE KL, 1995, CANCER RES, V55, P3008; HERTEL LW, 1990, CANCER RES, V50, P4417; HIDDEMANN W, 1991, ANN HEMATOL, V62, P119, DOI 10.1007/BF01702925; Izumi T, 1998, CARCINOGENESIS, V19, P525, DOI 10.1093/carcin/19.3.525; Kadhim SA, 1997, CANCER RES, V57, P4803; Kukhanova M, 2000, NUCLEOS NUCLEOT NUCL, V19, P435, DOI 10.1080/15257770008033019; KUKHANOVA M, 1995, J BIOL CHEM, V270, P23055, DOI 10.1074/jbc.270.39.23055; Lamartine J, 1997, CYTOGENET CELL GENET, V78, P31, DOI 10.1159/000134621; Lin TS, 1996, J MED CHEM, V39, P1757, DOI 10.1021/jm950836q; LONGLEY MJ, 1993, METHOD ENZYMOL, V218, P587; Ludwig DL, 1998, MUTAT RES-DNA REPAIR, V409, P17, DOI 10.1016/S0921-8777(98)00039-1; LUND B, 1993, CANCER TREAT REV, V19, P45, DOI 10.1016/0305-7372(93)90026-N; Marty J., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P123; Mazur DJ, 1999, J BIOL CHEM, V274, P19655, DOI 10.1074/jbc.274.28.19655; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; Moore LE, 1997, CANCER CHEMOTH PHARM, V39, P532, DOI 10.1007/s002800050609; Nakagawa Y, 1997, ACTA MED OKAYAMA, V51, P195; PATNAIK A, 2000, P AM ASSOC CANC RES, V41, P815; Pelicano H, 2000, MOL PHARMACOL, V57, P1051; Perrino Fred W., 1999, Cell Biochemistry and Biophysics, V30, P331, DOI 10.1007/BF02738118; PERRINO FW, 1994, J BIOL CHEM, V269, P16357; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P1087, DOI 10.1093/nar/19.5.1087; Rothwell DG, 1997, ONCOL RES, V9, P275; RUTH JL, 1981, MOL PHARMACOL, V20, P415; SHELTON MJ, 1993, ANN PHARMACOTHER, V27, P480; SKALSKI V, 1995, BIOCHEM PHARMACOL, V50, P815, DOI 10.1016/0006-2952(95)00205-E; SKALSKI V, 1993, J BIOL CHEM, V268, P23234; TABOR CW, 1976, ANNU REV BIOCHEM, V45, P285, DOI 10.1146/annurev.bi.45.070176.001441; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Xanthoudakis S, 1996, P NATL ACAD SCI USA, V93, P8919, DOI 10.1073/pnas.93.17.8919; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Yacoub A, 1997, CANCER RES, V57, P5457; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997	48	100	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31009	31015		10.1074/jbc.M004082200	http://dx.doi.org/10.1074/jbc.M004082200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906132	hybrid			2022-12-27	WOS:000089762700040
J	Pei, L				Pei, L			Activation of mitogen-activated protein kinase cascade regulates pituitary tumor-transforming gene transactivation function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; MAP KINASES; SUBSTRATE RECOGNITION; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; HUMAN HOMOLOG; S6 KINASE; C-MYC; IDENTIFICATION	Pituitary tumor-transforming gene (PTTG) is a recently characterized oncogene that can act as a transcriptional activator. In this study, we have characterized the transactivation domain of PTTG. Transient transfection of fusion constructs containing GAL4 DNA-binding domain and different parts of PTTG indicated the transactivation domain of PTTG is located between amino acids 119 and 164. Mitogen-activated protein (MAP) kinase cascade is important in the regulation of cell growth, apoptosis, and differentiation. Therefore, we have explored the possibility that this kinase cascade plays a role in regulating PTTG transactivation function. Activation of the MAP kinase cascade by epidermal growth factor or an expression vector for a constitutively active form of the MAP kinase kinase (MEK1) led to stimulation of PTTG transactivation activity. We showed that PTTG is phosphorylated in vitro on Ser(162) by MAP kinase and that this phosphorylation site plays an essential role in PTTG transactivation function. We demonstrated that PTTG interacts directly with MEK1 through a putative SH3 domain-binding site located between amino acids 51 and 54 and that this interaction is crucial for PTTG transactivation function. In addition, we showed that activation of MAP kinase phosphorylation cascade resulted in nuclear translocation of PTTG. Together, our data establish that a growth factor-stimulated MAP kinase plays an important role in modulating PTTG function.	Univ Calif Los Angeles, Cedars Sinai Med Ctr, Div Endocrinol & Metab, Sch Med, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Pei, L (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Div Endocrinol & Metab, Sch Med, 8700 Beverly Blvd,D2019, Los Angeles, CA 90048 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK056608, K08DK002346] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-56608, DK-02346] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Chien WW, 2000, J BIOL CHEM, V275, P19422, DOI 10.1074/jbc.M910105199; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Dang A, 1998, J BIOL CHEM, V273, P19909, DOI 10.1074/jbc.273.31.19909; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORENO S, 1990, NATURE, V374, P131; NAGAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207; Papin C, 1996, ONCOGENE, V12, P2213; Pei L, 1998, J BIOL CHEM, V273, P5219, DOI 10.1074/jbc.273.9.5219; Pei L, 1999, J BIOL CHEM, V274, P3151, DOI 10.1074/jbc.274.5.3151; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Ramos-Morales F, 2000, ONCOGENE, V19, P403, DOI 10.1038/sj.onc.1203320; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Saez C, 1999, ONCOGENE, V18, P5473, DOI 10.1038/sj.onc.1202914; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SETH A, 1991, J BIOL CHEM, V266, P23521; SETH A, 1992, J BIOL CHEM, V267, P24796; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVER PA, 1988, GENE DEV, V2, P707, DOI 10.1101/gad.2.6.707; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	52	62	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31191	31198		10.1074/jbc.M002451200	http://dx.doi.org/10.1074/jbc.M002451200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906323	hybrid			2022-12-27	WOS:000089762700063
J	Villemain, JL; Ma, YJ; Giedroc, DP; Morrical, SW				Villemain, JL; Ma, YJ; Giedroc, DP; Morrical, SW			Mutations in the N-terminal cooperativity domain of gene 32 protein alter properties of the T4 DNA replication and recombination systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; NUCLEIC-ACID COMPLEXES; BINDING-PROTEIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; POLYMERASE HOLOENZYME; BACTERIOPHAGE-T4; PURIFICATION; MECHANISM; DISSOCIATION	The gene 32 protein (gp32) of bacteriophage T4 is the essential single-stranded DNA (ssDNA)-binding protein required for phage DNA replication and recombination, gp32 binds ssDNA with high affinity and cooperativity, forming contiguous clusters that optimally configure the ssDNA for recognition by DNA polymerase or recombination enzymes. The precise roles of gp32 affinity and cooperativity in promoting replication and recombination have yet to be defined, however. Previous work established that the N-terminal "B-domain" of gp32 is essential for cooperativity and that point mutations at Arg(4) and Lys(3) positions have varying and dramatic effects on gp32-ssDNA interactions. Therefore, we examined the effects of six different gp32 B-domain mutants on T4 in vitro systems for DNA synthesis and homologous pairing, We find that the B-domain is essential for gp32's stimulation of these reactions. The stimulatory efficacy of gp32 B-domain mutants generally correlates with the hierarchy of relative ssDNA binding affinities, i.e, wild-type gp32 approximate to R4K > K3A approximate to R4Q > R4T > R4G much greater than gp32-B. However, the functional defect of a particular mutant is often greater than can be explained simply by its ability to saturate the ssDNA at equilibrium, suggesting additional defects in the proper assembly and activity of DNA polymerase and recombinase complexes on ssDNA, which may derive from a decreased lifetime of gp32-ssDNA clusters.	Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	University of Vermont; Texas A&M University System; Texas A&M University College Station	Morrical, SW (corresponding author), Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA.	smorrica@zoo.uvm.edu	Giedroc, David/A-8608-2018	Giedroc, David/0000-0002-2342-1620	NIGMS NIH HHS [GM48847, GM42569] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM042569, R01GM042569, R56GM048847, R01GM048847] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; BITTNER M, 1979, J BIOL CHEM, V254, P9565; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Bochkarev A, 1999, EMBO J, V18, P4498, DOI 10.1093/emboj/18.16.4498; CHA TA, 1989, J BIOL CHEM, V264, P12220; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; DOTTO GP, 1981, P NATL ACAD SCI-BIOL, V78, P5421, DOI 10.1073/pnas.78.9.5421; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; GIEDROC DP, 1986, P NATL ACAD SCI USA, V83, P8452, DOI 10.1073/pnas.83.22.8452; GIEDROC DP, 1990, J BIOL CHEM, V265, P11444; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; HURLEY JM, 1993, J MOL BIOL, V229, P398, DOI 10.1006/jmbi.1993.1042; JIANG H, 1993, J BIOL CHEM, V268, P7904; Karpel R.L., 1990, BIOL NONSPECIFIC DNA, P103; KODADEK T, 1988, J BIOL CHEM, V263, P9427; KODADEK T, 1990, J BIOL CHEM, V265, P20966; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; KOWALCZYKOWSKI SC, 1990, LANDOLTBORNSTEIN NUM, P244; Lefebvre SD, 1997, J MOL BIOL, V272, P312, DOI 10.1006/jmbi.1997.1264; LOHMAN TM, 1986, J MOL BIOL, V187, P603, DOI 10.1016/0022-2836(86)90338-4; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1984, BIOCHEMISTRY-US, V23, P4665, DOI 10.1021/bi00315a023; MILLER H, 1987, METHOD ENZYMOL, V152, P145; Morrical SW, 1996, J BIOL CHEM, V271, P20198, DOI 10.1074/jbc.271.33.20198; MORRIS CF, 1979, J BIOL CHEM, V254, P6787; NEWPORT JW, 1981, J MOL BIOL, V145, P105, DOI 10.1016/0022-2836(81)90336-3; QIU HW, 1994, J BIOL CHEM, V269, P2773; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; Sweezy MA, 1997, J MOL BIOL, V266, P927, DOI 10.1006/jmbi.1996.0829; VILLEMAIN JL, 1993, BIOCHEMISTRY-US, V32, P11235, DOI 10.1021/bi00092a038; Villemain JL, 1996, BIOCHEMISTRY-US, V35, P14395, DOI 10.1021/bi961482n; Villemain JL, 1996, J BIOL CHEM, V271, P27623, DOI 10.1074/jbc.271.44.27623; Webster G, 1997, FEBS LETT, V411, P313, DOI 10.1016/S0014-5793(97)00747-3; WILLIAMS KR, 1994, MOL BIOL BACTERIOP T, V4, P301; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7; Yang C, 1997, NAT STRUCT BIOL, V4, P153, DOI 10.1038/nsb0297-153	39	11	22	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31496	31504		10.1074/jbc.M002902200	http://dx.doi.org/10.1074/jbc.M002902200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906124	hybrid			2022-12-27	WOS:000089762700104
J	Fan, MY; Goodwin, M; Vu, T; Brantley-Finley, C; Gaarde, WA; Chambers, TC				Fan, MY; Goodwin, M; Vu, T; Brantley-Finley, C; Gaarde, WA; Chambers, TC			Vinblastine-induced phosphorylation of Bcl-2 and Bcl-X-L is mediated by JNK and occurs in parallel with inactivation of the Raf-1/MEK/ERK cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PATHWAY; RAF-1/BCL-2 PHOSPHORYLATION; CANCER CELLS; APOPTOSIS; DEATH; ACTIVATION; RAF-1	Microtubule-damaging agents arrest cells at G(2)/M and induce apoptosis in association with phosphorylation of the anti-apoptotic proteins Bcl-2 and Bcl-X-L. Because microtubule inhibitors activate JNK, we sought to determine whether JNK was responsible for Bcl-2/Bcl-X-L phosphorylation in KB-3 cells treated with vinblastine. Two major endogenous forms of JNK, p46(JNK1) and p54(JNK2), were present in KB-3 cells, and both isoforms were activated by vinblastine as determined by Mono Q chromatography. We used antisense oligonucleotides (AS) to specifically inhibit their expression. A combination of AS-JNK1 with AS-JNK2 inhibited by 80% vinblastine-induced phosphorylation of two known JNK substrates, c-Jun and ATF-2. In addition, AS-JNK1/2 inhibited vinblastine-induced phosphorylation of Bcl-2 by 85% and that of Bcl-X-L by 65%. Stable expression of the JNK scaffold protein JIP-1 blocked vinblastine-induced phosphorylation of c-Jun and ATF-2, but did not affect Bcl-2/Bcl-X-L phosphorylation, confirming a bifurcation in JNK signaling involving both nuclear and non-nuclear substrates. Vinblastine-induced phosphorylation of Raf-1 was unaffected by AS-JNK1/2 and was associated with loss of activity for MEK substrate in vitro and inactivation of ERK in vivo. These results provide evidence for a direct role of the JNK pathway in apoptotic regulation through Bcl-2/ Bcl-X-L phosphorylation.	Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA; ISIS Pharmaceut Inc, Dept Mol Pharmacol, Carlsbad, CA 92008 USA	University of Arkansas System; University of Arkansas Medical Sciences; Isis Pharmaceuticals Inc	Chambers, TC (corresponding author), Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Mail Slot 516,4301 W Markham St, Little Rock, AR 72205 USA.	chamberstimothyc@exchange.uams.edu			NCI NIH HHS [CA-75577] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075577] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attalla H, 1998, BIOCHEM BIOPH RES CO, V247, P616, DOI 10.1006/bbrc.1998.8870; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Blagosklonny MV, 1999, LEUKEMIA, V13, P1028, DOI 10.1038/sj.leu.2401449; Blagosklonny MV, 1997, CANCER RES, V57, P130; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; Haskell CM., 1995, CANC TREATMENT, P78; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Rowinsky E. K., 1998, CHEMOTHERAPY SOURCE, P387; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Stone AA, 2000, EXP CELL RES, V254, P110, DOI 10.1006/excr.1999.4731; Torres K, 1998, CANCER RES, V58, P3620; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Wartmann M, 1997, J BIOL CHEM, V272, P3915, DOI 10.1074/jbc.272.7.3915; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469	29	264	276	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					29980	29985		10.1074/jbc.M003776200	http://dx.doi.org/10.1074/jbc.M003776200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10913135	hybrid			2022-12-27	WOS:000089577900010
J	Inoue, S; Lin, SL; Inoue, Y				Inoue, S; Lin, SL; Inoue, Y			Chemical analysis of the developmental pattern of polysialylation in chicken brain - Expression of only an extended form of polysialyl chains during embryogenesis and the presence of disialyl residues in both embryonic and adult chicken brains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; PERFORMANCE LIQUID-CHROMATOGRAPHY; ANION-EXCHANGE CHROMATOGRAPHY; CENTRAL-NERVOUS-SYSTEM; 2-KETO-3-DEOXY-D-GLYCERO-D-GALACTONONONIC ACID; 2 POLYSIALYLTRANSFERASES; CARBOHYDRATE UNITS; RAT BRAIN; GLYCOPROTEINS; STX	Recent studies have demonstrated the involvement of two polysialyltransferases in neural cell adhesion molecule (N-CAM) polysialylation. The availability of cDNAs encoding these enzymes facilitated studies on polysialylation of N-CAM. However, there is a dearth of detailed structural information on the degree of polymerization (DP), DP ranges, and the influence of embryogenesis on the DP. It is also unclear how many polysialic acid (polySia) chains are attached to a single core N-glycan. In this paper we applied new, efficient, and sensitive high pressure liquid chromatography methods to qualitatively and quantitatively analyze the polySia structures expressed on embryonic and adult chicken brain N-CAM. Our studies resulted in the following new findings. 1) The DP of the polySia chains was invariably 40-50 throughout developmental stages from embryonic day 5 to 21 after fertilization. In contrast, glycopeptides containing polySia with shorter DPs, ranging from 15 to 35, were isolated from adult brain. 2) Chemical evidence showed glycan chains abundant in Neu5Ac alpha 2,8Neu5Ac were expressed during all developmental stages including adult. 3) Levels of both di- and polySia were found to show distinctive changes during embryonic development.	Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan	Academia Sinica - Taiwan	Inoue, Y (corresponding author), Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan.	syinoue@gate.sinica.edu.tw			NHLBI NIH HHS [NHRI-GT-EX89B805P] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; ASHWELL G, 1994, ANAL BIOCHEM, V222, P495, DOI 10.1006/abio.1994.1523; BITTERSUERMANN D, 1987, IMMUNOL RES, V6, P225, DOI 10.1007/BF02935517; BONFANTI L, 1992, NEUROSCIENCE, V49, P419, DOI 10.1016/0306-4522(92)90107-D; Chaplin M. F., 1994, CARBOHYDRATE ANAL PR, P27; Close BE, 2000, J BIOL CHEM, V275, P4484, DOI 10.1074/jbc.275.6.4484; Close BE, 1998, J BIOL CHEM, V273, P34586, DOI 10.1074/jbc.273.51.34586; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; FINNE J, 1982, J BIOL CHEM, V257, P1966; FINNE J, 1983, LANCET, V2, P355; FINNE J, 1983, BIOCHEM BIOPH RES CO, V112, P482, DOI 10.1016/0006-291X(83)91490-0; FINNE J, 1987, J IMMUNOL, V138, P4402; Funakoshi Y, 1997, GLYCOBIOLOGY, V7, P195, DOI 10.1093/glycob/7.2.195; HARA S, 1987, ANAL BIOCHEM, V164, P138, DOI 10.1016/0003-2697(87)90377-0; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HOFFMAN S, 1982, J BIOL CHEM, V257, P7720; INOUE S, 1986, J BIOL CHEM, V261, P5256; Inoue S, 1996, J BIOL CHEM, V271, P24341, DOI 10.1074/jbc.271.40.24341; Inoue Y, 1999, PURE APPL CHEM, V71, P789, DOI 10.1351/pac199971050789; KITAJIMA K, 1992, ANAL BIOCHEM, V205, P244, DOI 10.1016/0003-2697(92)90430-F; KITAZUME S, 1994, J BIOL CHEM, V269, P22712; Kojima N, 1996, J BIOL CHEM, V271, P22058, DOI 10.1074/jbc.271.36.22058; Kojima N, 1997, J BIOCHEM-TOKYO, V122, P1265; Kudo M, 1998, GLYCOBIOLOGY, V8, P771, DOI 10.1093/glycob/8.8.771; Kudo M, 1996, J BIOL CHEM, V271, P32667, DOI 10.1074/jbc.271.51.32667; Lin SL, 1999, GLYCOBIOLOGY, V9, P807, DOI 10.1093/glycob/9.8.807; LIVINGSTON BD, 1988, J BIOL CHEM, V263, P9443; MANZI AE, 1994, J BIOL CHEM, V269, P23617; MCCOY RD, 1985, J BIOL CHEM, V260, P2695; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; NOMOTO H, 1982, ARCH BIOCHEM BIOPHYS, V218, P335, DOI 10.1016/0003-9861(82)90352-6; OKA S, 1995, J BIOL CHEM, V270, P19357, DOI 10.1074/jbc.270.33.19357; Ong E, 1998, GLYCOBIOLOGY, V8, P415, DOI 10.1093/glycob/8.4.415; RUTISHAUSER U, 1992, DEVELOPMENT, P99; Rutishauser U, 1996, CURR OPIN CELL BIOL, V8, P679, DOI 10.1016/S0955-0674(96)80109-8; Sato C, 1999, ANAL BIOCHEM, V266, P102, DOI 10.1006/abio.1998.2921; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; SEKI T, 1993, NEUROSCI RES, V17, P265, DOI 10.1016/0168-0102(93)90111-3; Sevigny MB, 1998, GLYCOBIOLOGY, V8, P857, DOI 10.1093/glycob/8.9.857; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; VIMR ER, 1984, P NATL ACAD SCI-BIOL, V81, P1971, DOI 10.1073/pnas.81.7.1971; Wood GK, 1997, MOL BRAIN RES, V51, P69, DOI 10.1016/S0169-328X(97)00209-X; YOSHIDA Y, 1995, J BIOL CHEM, V270, P14628, DOI 10.1074/jbc.270.24.14628; Zhang Y, 1999, J BIOL CHEM, V274, P6183, DOI 10.1074/jbc.274.10.6183; Zhang Y, 1997, ANAL BIOCHEM, V250, P245, DOI 10.1006/abio.1997.2225; ZUBER C, 1992, J BIOL CHEM, V267, P9965	47	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					29968	29979		10.1074/jbc.M004150200	http://dx.doi.org/10.1074/jbc.M004150200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10908565	hybrid			2022-12-27	WOS:000089577900009
J	Dufner, P; Marra, G; Raschle, M; Jiricny, J				Dufner, P; Marra, G; Raschle, M; Jiricny, J			Mismatch recognition and DNA-dependent stimulation of the ATPase activity of hMutS alpha is abolished by a single mutation in the hMSH6 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREVISIAE MSH2-MSH6 COMPLEX; SACCHAROMYCES-CEREVISIAE; SLIDING CLAMP; PROTEIN BINDS; MUTS-BETA; REPAIR; MSH6; HETERODIMER; SPECIFICITY; HYDROLYSIS	The most abundant mismatch binding factor in human cells, hMutS alpha, is a heterodimer of hMSH2 and hMSH6, two homologues of the bacterial MutS protein. The C-terminal portions of all MutS homologues contain an ATP binding motif and are highly conserved throughout evolution. Although the N termini are generally divergent, they too contain short conserved sequence elements. A phenylalanine --> alanine substitution within one such motif, GXFY(X)(5)DA, has been shown to abolish the mismatch binding activity of the MutS protein of Thermus aquaticus (Malkov, V. A, Biswas, I., Camerini-Otero, R, D., and Hsieh, P, (1997) J. Biol. Chem. 272, 23811-23817); We introduced an identical mutation into one or both subunits of hMutS alpha The Phe --> Ala substitution in hMSH2 had no effect on the biological activity of the heterodimer. In contrast, the in vitro mismatch binding and mismatch repair functions of hMutS alpha were severely attenuated when the hMSH6 subunit was mutated. Moreover, this variant heterodimer also displayed a general DNA binding defect. Correspondingly, its ATPase activity could not be stimulated by either heteroduplex or homoduplex DNA Thus the N-terminal portion of hMSH6 appears to impart on hMutS alpha: not only the specificity for recognition and binding of mismatched substrates but also the ability to bind to homoduplex DNA.	Univ Zurich, Inst Med Radiobiol, CH-8008 Zurich, Switzerland; Paul Scherrer Inst, CH-8008 Zurich, Switzerland	University of Zurich; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Jiricny, J (corresponding author), Univ Zurich, Inst Med Radiobiol, August Forel Str 7, CH-8008 Zurich, Switzerland.	jiricny@imr.unizh.ch						Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Alani E, 1996, MOL CELL BIOL, V16, P5604; BISHOP DK, 1989, P NATL ACAD SCI USA, V86, P3713, DOI 10.1073/pnas.86.10.3713; Biswas I, 2000, BIOCHEM J, V347, P881, DOI 10.1042/0264-6021:3470881; Bjornson KP, 2000, BIOCHEMISTRY-US, V39, P3176, DOI 10.1021/bi992286u; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; Bowers J, 1999, J BIOL CHEM, V274, P16115, DOI 10.1074/jbc.274.23.16115; Clark AB, 1999, NUCLEIC ACIDS RES, V27, P736, DOI 10.1093/nar/27.3.736; CROUSE G, 1997, DNA DAMAGE REPAIR, V1, P411; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HUGHES MJ, 1992, J BIOL CHEM, V267, P23876; Iaccarino I, 1996, CURR BIOL, V6, P484, DOI 10.1016/S0960-9822(02)00516-X; Iaccarino I, 2000, J BIOL CHEM, V275, P2080, DOI 10.1074/jbc.275.3.2080; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; JIRICNY J, 1988, NUCLEIC ACIDS RES, V16, P7843, DOI 10.1093/nar/16.16.7843; JIRICNY J, 1988, P NATL ACAD SCI USA, V85, P8860, DOI 10.1073/pnas.85.23.8860; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; KRAMER B, 1984, CELL, V38, P879, DOI 10.1016/0092-8674(84)90283-6; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; Malkov VA, 1997, J BIOL CHEM, V272, P23811, DOI 10.1074/jbc.272.38.23811; Marra G, 1998, P NATL ACAD SCI USA, V95, P8568, DOI 10.1073/pnas.95.15.8568; Marsischky GT, 1999, J BIOL CHEM, V274, P26668, DOI 10.1074/jbc.274.38.26668; Ni TT, 1999, MOL CELL, V4, P439, DOI 10.1016/S1097-2765(00)80346-9; OHMOLOVA G, 2000, NATURE, V407, P703; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; Studamire B, 1998, MOL CELL BIOL, V18, P7590, DOI 10.1128/MCB.18.12.7590; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829	37	65	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36550	36555		10.1074/jbc.M005987200	http://dx.doi.org/10.1074/jbc.M005987200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10938287	Green Accepted, hybrid			2022-12-27	WOS:000165577700014
J	Talts, JF; Sasaki, T; Miosge, N; Gohring, W; Mann, K; Mayne, R; Timpl, R				Talts, JF; Sasaki, T; Miosge, N; Gohring, W; Mann, K; Mayne, R; Timpl, R			Structural and functional analysis of the recombinant G domain of the laminin alpha 4 chain and its proteolytic processing in tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEINS; SITE-DIRECTED MUTAGENESIS; GLYCOSAMINOGLYCAN MODIFICATION; DYSTROGLYCAN BINDING; MYCOBACTERIUM-LEPRAE; SULFATIDE-BINDING; ENDOTHELIAL-CELLS; DEPENDENT BINDING; GROWTH-FACTOR; A CHAIN	The C-terminal G domains of laminin a chains have been implicated in various cellular and other interactions. The G domain of the alpha4 chain was now produced in transfected mammalian cells as two tandem arrays of LG modules, alpha 4LG1-3 and alpha 4LG4-5. The recombinant fragments Were shown to fold into globular structures and could be distinguished by specific antibodies. Both fragments were able to bind to heparin, sulfatides, and the microfibrillar fibulin-1 and fibulin-2. They were, however, poor substrates for cell adhesion and had only a low affinity;for the alpha -dystroglycan receptor when compared with: the G domains of the laminin alpha1 and alpha2 chains. Yet antibodies to alpha 4LG1-3 but not to alpha 4LG4-5 clearly inhibited alpha (6)beta (1) integrin-mediated cell adhesion to laminin-8, indicating the participation of alpha 4LG1-3 in a cell-adhesive structure of higher complexity. Proteolytic: processing within a link region between the alpha 4LG3 and alpha 4LG4 modules was shown to occur during recombinant production and in endothelial and Schwann cell culture. Cleavage could be attributed to three different peptide bonds and is accompanied by the release of the alpha 4LG4-5 segment. Immunohistology demonstrated abundant staining of alpha 4LG1-3 in vessel walls, adipose, and perineural tissue. No significant staining was found for alpha 4LG4-5 indicating their loss from tissues. Immunogold staining demonstrated an association of the alpha4 chain primarily with microfibrillar regions rather than with basement membranes, while laminin alpha2 chains appear primarily associated with various basement membranes.	Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Gottingen, Ctr Anat, D-37075 Gottingen, Germany; Univ Gottingen, Dept Histol, D-37075 Gottingen, Germany; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	Max Planck Society; University of Gottingen; University of Gottingen; University of Alabama System; University of Alabama Birmingham	Timpl, R (corresponding author), Max Planck Inst Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.		Miosge, Nicolai/E-3244-2010; Mann, Karlheinz/C-4254-2008	Talts, Jan/0000-0001-5777-5411				Andac Z, 1999, J MOL BIOL, V287, P253, DOI 10.1006/jmbi.1999.2606; ARATANI Y, 1988, J BIOL CHEM, V263, P16163; AUMAILLEY M, 1991, EXP CELL RES, V196, P177, DOI 10.1016/0014-4827(91)90248-S; AUMAILLEY M, 1989, EXP CELL RES, V181, P463, DOI 10.1016/0014-4827(89)90103-1; AUMAILLEY M, 1989, EUR J BIOCHEM, V184, P241, DOI 10.1111/j.1432-1033.1989.tb15013.x; AUMAILLEY M, 1990, FEBS LETT, V262, P82, DOI 10.1016/0014-5793(90)80159-G; AUMAILLEY M, 1996, LAMININS, P127; BRANCACCIO A, 1995, FEBS LETT, V368, P139, DOI 10.1016/0014-5793(95)00628-M; BURGESON RE, 1996, LAMININS, P65; DENTZMANNR, 1990, EUR J BIOCH, V191, P513; Durbeej M, 1998, CURR OPIN CELL BIOL, V10, P594, DOI 10.1016/S0955-0674(98)80034-3; EKBLOM P, 1996, LAMININS; ENGEL J, 1994, METHOD ENZYMOL, V245, P469; Friedrich MVK, 1999, J MOL BIOL, V294, P259, DOI 10.1006/jmbi.1999.3259; Frieser M, 1997, EUR J BIOCHEM, V246, P727, DOI 10.1111/j.1432-1033.1997.t01-1-00727.x; Geberhiwot T, 1999, EXP CELL RES, V253, P723, DOI 10.1006/excr.1999.4653; Gesemann M, 1998, J BIOL CHEM, V273, P600, DOI 10.1074/jbc.273.1.600; Gohring W, 1998, EUR J BIOCHEM, V255, P60, DOI 10.1046/j.1432-1327.1998.2550060.x; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; IIVANAINEN A, 1995, FEBS LETT, V365, P183, DOI 10.1016/0014-5793(95)00462-I; Iivanainen A, 1997, J BIOL CHEM, V272, P27862, DOI 10.1074/jbc.272.44.27862; Kohfeldt E, 1998, J MOL BIOL, V282, P99, DOI 10.1006/jmbi.1998.2004; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; Kortesmaa J, 2000, J BIOL CHEM, V275, P14853, DOI 10.1074/jbc.275.20.14853; Liu JG, 1996, MATRIX BIOL, V15, P433, DOI 10.1016/S0945-053X(96)90162-6; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Miosge N, 2000, J HISTOCHEM CYTOCHEM, V48, P229, DOI 10.1177/002215540004800208; Miosge N, 1999, LAB INVEST, V79, P1591; Niimi T, 1997, MATRIX BIOL, V16, P223, DOI 10.1016/S0945-053X(97)90011-1; OTT U, 1982, EUR J BIOCHEM, V123, P63, DOI 10.1111/j.1432-1033.1982.tb06499.x; PAN TC, 1993, EUR J BIOCHEM, V215, P733, DOI 10.1111/j.1432-1033.1993.tb18086.x; Rambukkana A, 1998, SCIENCE, V282, P2076, DOI 10.1126/science.282.5396.2076; Rambukkana A, 1997, CELL, V88, P811, DOI 10.1016/S0092-8674(00)81927-3; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; Richards A, 1996, EUR J BIOCHEM, V238, P813, DOI 10.1111/j.1432-1033.1996.0813w.x; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; Sasaki T, 1996, J CELL SCI, V109, P2895; Sasaki T, 1999, FEBS LETT, V460, P280, DOI 10.1016/S0014-5793(99)01362-9; Sasaki T, 1998, FEBS LETT, V435, P169, DOI 10.1016/S0014-5793(98)01063-1; SASAKI T, 1995, J MOL BIOL, V254, P892, DOI 10.1006/jmbi.1995.0664; SASAKI T, 1995, J MOL BIOL, V245, P241, DOI 10.1006/jmbi.1994.0020; Sasaki T, 1999, GUIDEBOOK EXTRACELLU, P434; SCHULZE B, 1995, EUR J BIOCHEM, V231, P551, DOI 10.1111/j.1432-1033.1995.tb20731.x; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; Talts JF, 1999, FEBS LETT, V458, P319, DOI 10.1016/S0014-5793(99)01180-1; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; Talts JF, 1998, FEBS LETT, V426, P71, DOI 10.1016/S0014-5793(98)00312-3; TARABOLETTI G, 1990, J BIOL CHEM, V265, P12253; TIMPL R, 1987, METHOD ENZYMOL, V145, P363; TIMPL R, 1982, METHOD ENZYMOL, V82, P472; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432; TOKIDA Y, 1990, J BIOL CHEM, V265, P18123	52	126	133	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35192	35199		10.1074/jbc.M003261200	http://dx.doi.org/10.1074/jbc.M003261200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10934193	hybrid			2022-12-27	WOS:000165422800050
J	Jin, SH; Zhai, B; Qiu, ZL; Wu, JR; Lane, MD; Liao, K				Jin, SH; Zhai, B; Qiu, ZL; Wu, JR; Lane, MD; Liao, K			c-Crk, a substrate of the insulin-like growth factor-1 receptor tyrosine kinase, functions as an early signal mediator in the adipocyte differentiation process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-3 DOMAIN; 3T3-L1 PREADIPOCYTES; GENE-EXPRESSION; FACTOR-I; ADIPOSE CONVERSION; SH3 DOMAIN; CELL LINE; PROTEIN; ENHANCER; TRANSCRIPTION	Differentiation of 3T3-L1 preadipocytes into adipocytes is induced by a combination of inducers, including a glucocorticoid, an agent that elevates cellular cAMP, and a ligand of the insulin-like growth factor-1 receptor. Previous studies have implicated protein-tyrosine phosphatase (PTPase) HA2, a homologue of PTPase 1B, in the signaling cascade initiated by the differentiation inducers. Vanadate, a potent PTPase inhibitor, blocks adipocyte differentiation at an early stage in the program, but has no effect on the mitotic clonal expansion required for differentiation. Exposure of preadipocytes to vanadate along with the inducing agents led to the accumulation of pp35, a phosphotyrosyl protein that is a substrate for PTPase HA2. pp35 was purified to homogeneity and shown by amino acid sequence and mass analyses of tryptic peptides to be c-Crk, a known cytoplasmic target of the insulin-like growth factor-1 receptor tyrosine kinase. Transfection of 3T3-L1 preadipocytes with a c-Crk antisense RNA expression vector markedly reduced c-Crk levels and prevented differentiation into adipocytes. Studies with C3G, a protein that binds to the SH3 domain in c-Crk, showed that phosphorylation of c-Crk rendered the SH3 domain inaccessible to C3G. Taken together, these findings indicate that locking c-Crk in the phosphorylated state with vanadate prevents its participation in the signaling system that initiates adipocyte differentiation.	Chinese Acad Sci, Shanghai Inst Biochem, Shanghai Life Sci Res Ctr, Shanghai 200031, Peoples R China; Chinese Acad Sci, Shanghai Inst Biochem, State Lab Mol Biol, Shanghai 200031, Peoples R China; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Johns Hopkins University	Liao, K (corresponding author), Chinese Acad Sci, Shanghai Inst Biochem, Shanghai Life Sci Res Ctr, 320 Yueyang Rd, Shanghai 200031, Peoples R China.							AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; Anafi M, 1996, J BIOL CHEM, V271, P21365, DOI 10.1074/jbc.271.35.21365; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BERNLOHR DA, 1985, J BIOL CHEM, V260, P5563; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAVES RA, 1992, J CELL BIOCHEM, V49, P219, DOI 10.1002/jcb.240490303; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; Hwang CS, 1997, ANNU REV CELL DEV BI, V13, P231, DOI 10.1146/annurev.cellbio.13.1.231; Hwang CS, 1996, P NATL ACAD SCI USA, V93, P873, DOI 10.1073/pnas.93.2.873; Kiyokawa E, 1997, CRIT REV ONCOGENESIS, V8, P329, DOI 10.1615/CritRevOncog.v8.i4.30; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Koval AP, 1998, BIOCHEM J, V330, P923; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAO K, 1995, J BIOL CHEM, V270, P12123, DOI 10.1074/jbc.270.20.12123; LIAO K, 1991, J BIOL CHEM, V266, P6544; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; Loftus TM, 1997, CURR OPIN GENET DEV, V7, P603, DOI 10.1016/S0959-437X(97)80006-8; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MACKALL JC, 1976, J BIOL CHEM, V251, P6462; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; Modan-Moses D, 1998, BIOCHEM J, V333, P825, DOI 10.1042/bj3330825; OGAWA S, 1994, ONCOGENE, V9, P1669; Okada S, 1998, EMBO J, V17, P2554, DOI 10.1093/emboj/17.9.2554; PETAL YM, 1999, P NATL ACAD SCI USA, V96, P1279; REED BC, 1980, P NATL ACAD SCI-BIOL, V77, P285, DOI 10.1073/pnas.77.1.285; REED BC, 1981, J BIOL CHEM, V256, P3917; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RONNETT GV, 1984, J BIOL CHEM, V259, P4566; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; Rosen O M, 1979, Recent Prog Horm Res, V35, P477; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VASSEURCOGNET M, 1993, CURR OPIN GENET DEV, V3, P238, DOI 10.1016/0959-437X(93)90029-O	52	43	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34344	34352		10.1074/jbc.M004927200	http://dx.doi.org/10.1074/jbc.M004927200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10926934	hybrid			2022-12-27	WOS:000165095300048
J	Silles, E; Mazon, MJ; Gevaert, K; Goethals, M; Vandekerckhove, J; Leber, R; Sandoval, IV				Silles, E; Mazon, MJ; Gevaert, K; Goethals, M; Vandekerckhove, J; Leber, R; Sandoval, IV			Targeting of aminopeptidase I to the yeast vacuole ts mediated by Ssa1p, a cytosolic member of the 70-kDa stress protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CYTOPLASM; PATHWAY; HSP70; IDENTIFICATION; TRANSLOCATION; PRESEQUENCE; AUTOPHAGY; TRANSPORT; MECHANISM	The two cytosolic members of the highly conserved 70-kDa stress protein family, Ssa1p and Ssa2p, were specifically retained by the prepro-NH2 extension of the vacuolar aminopeptidase I precursor (pAPI) conjugated to agarose (Sulfolink). A temperature-sensitive mutant strain a1(ts)a234 (ssa1(ts) ssa2 ssa3 ssa4), when incubated at the restrictive temperature, was able to assemble the API precursor into dodecamers, but failed to pack pAPI into vesicles and to convert it into mature API (mAPI), a process that occurs in the vacuole. Altogether these results indicate that Ssa1p mediates the targeting of pAPI to the vacuole.	Univ Autonoma Madrid, Fac Ciencias, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; Univ Autonoma Madrid, Fac Ciencias, CSIC, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain; State Univ Ghent VIB, Dept Biochem, B-9000 Ghent, Belgium	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Flanders Institute for Biotechnology (VIB); Ghent University	Sandoval, IV (corresponding author), Univ Autonoma Madrid, Fac Ciencias, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.	isandoval@cbm.uam.es	Gevaert, Kris/AAE-4212-2019; Calpena, María Jesús Mazón/E-9168-2016; Gevaert, Kris/H-3637-2013; Gevaert, Kris/D-6489-2017	Gevaert, Kris/0000-0002-4237-0283; Calpena, María Jesús Mazón/0000-0003-4151-4051; Gevaert, Kris/0000-0002-4237-0283; Gevaert, Kris/0000-0002-4237-0283; Leber, Regina/0000-0001-5306-5834				ARNOLD CE, 1994, J BIOL CHEM, V269, P30412; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Becker J, 1996, MOL CELL BIOL, V16, P4378; Endo T, 1996, J BIOL CHEM, V271, P4161; Gevaert K, 1998, ELECTROPHORESIS, V19, P909, DOI 10.1002/elps.1150190606; Griffin PR, 1995, RAPID COMMUN MASS SP, V9, P1546, DOI 10.1002/rcm.1290091515; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kim J, 1997, J CELL BIOL, V137, P609, DOI 10.1083/jcb.137.3.609; Kim S, 1998, P NATL ACAD SCI USA, V95, P12860, DOI 10.1073/pnas.95.22.12860; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; Liu Y, 1996, EMBO J, V15, P6750, DOI 10.1002/j.1460-2075.1996.tb01064.x; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Martinez E, 1997, J MOL BIOL, V267, P1124, DOI 10.1006/jmbi.1997.0925; Martinez E, 1999, MOL MICROBIOL, V33, P52, DOI 10.1046/j.1365-2958.1999.01446.x; McClellan AJ, 1998, MOL BIOL CELL, V9, P3533, DOI 10.1091/mbc.9.12.3533; Oda MN, 1996, J CELL BIOL, V132, P999, DOI 10.1083/jcb.132.6.999; Sambrook J., 2002, MOL CLONING LAB MANU; Satyanarayana C, 2000, FEBS LETT, V470, P232, DOI 10.1016/S0014-5793(00)01324-7; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; Scott SV, 1997, J CELL BIOL, V138, P37, DOI 10.1083/jcb.138.1.37; Scott SV, 1995, J CELL BIOL, V131, P1727, DOI 10.1083/jcb.131.6.1727; SEGUIREAL B, 1995, EMBO J, V14, P5476, DOI 10.1002/j.1460-2075.1995.tb00234.x; Sherman F, 1986, LAB COURSE MANUAL ME; SIKORSKI RS, 1989, GENETICS, V122, P19; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Unno K, 1997, BIOL PHARM BULL, V20, P1240; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310	29	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34054	34059		10.1074/jbc.M003514200	http://dx.doi.org/10.1074/jbc.M003514200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10903313	hybrid			2022-12-27	WOS:000165095300010
J	Firulli, BA; Hadzic, DB; McDaid, JR; Firulli, AB				Firulli, BA; Hadzic, DB; McDaid, JR; Firulli, AB			The basic helix-loop-helix transcription factors dHAND and eHAND exhibit dimerization characteristics that suggest complex regulation of function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; CARDIAC MORPHOGENESIS; 2-HYBRID SYSTEM; EXPRESSION; E2A; PROTEINS; IDENTIFICATION; SELECTION; ENHANCER; SUBCLASS	dHAND and eHAND are basic helix-loop-helix (bHLH) transcription factors expressed during embryogenesis and are required for the proper development of cardiac and extraembryonic tissues. RAND genes, like the myogenic bHLH genes, are classified as class B bHLH genes, which are expressed in a tissue-restricted pattern and function by forming heterodimers with class A bHLH proteins. Myogenic bHLH genes are shown not to form homodimers efficiently, suggesting that their activity is dependent on their E-protein partners. To identify Hips (HAND-interacting proteins) that regulate the activity of the RAND genes, we screened an 9.5-10.5-day-old mouse embryonic yeast two-hybrid library with eHAND. Several HIPs held high sequence identity to eHAND, indicating that eHAND could form and function as a homodimer. Based on the high degree of amino acid identity between eHAND and dHAND, it is possible that dHAND could also form homodimers and heterodimers with eHAND, We show using yeast and mammalian two-hybrid assays as well as biochemical pull-down assays that eHAND and dHAND are capable of forming both HAND homo- and heterodimers in vivo. To investigate whether HAND genes form heterodimers with other biologically relevant bHLH proteins, we tested and show HAND heterodimerization with the recently identified Hairy-related transcription factors, HRT1-3, This finding is exciting, because both HRT and HAND genes are coexpressed in the developing heart and limb and both have been implicated in establishing tissue boundaries and pattern formation. Moreover, competition gel shift analysis demonstrates that dHAND and eHAND can negatively regulate the DNA binding of MyoD/E12 heterodimers in a manner similar to MISTI and Id proteins, suggesting a possible transcriptional inhibitory role for HAND genes. Taken together, these results show that dHAND and eHAND can form homo- and heterodimer combinations with multiple bHLH partners and that this broad dimerization profile reflects the mechanisms by which HAND genes regulate transcription.	Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Firulli, AB (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Physiol, 7703 Floyd Curl Dr,7703, San Antonio, TX 78229 USA.			/0000-0001-6687-8949	NHLBI NIH HHS [R01 HL061677, R01 HL061677-03, R01 HLA61677-01A1] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061677] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; Charite J, 2000, DEVELOPMENT, V127, P2461; CROSS JC, 1995, DEVELOPMENT, V121, P2513; CSERJESI P, 1995, DEV BIOL, V170, P664, DOI 10.1006/dbio.1995.1245; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Fernandez-Teran M, 2000, DEVELOPMENT, V127, P2133; Firulli AB, 1998, NAT GENET, V18, P266, DOI 10.1038/ng0398-266; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; James P, 1996, GENETICS, V144, P1425; Kokubo H, 1999, BIOCHEM BIOPH RES CO, V260, P459, DOI 10.1006/bbrc.1999.0880; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; LEMCERCIER C, 1998, EMBO J, V17, P1412; Lewis AL, 1999, J BIOL CHEM, V274, P14188, DOI 10.1074/jbc.274.20.14188; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Molkentin JD, 1996, MOL CELL BIOL, V16, P3814; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; Nakagawa O, 1999, DEV BIOL, V216, P72, DOI 10.1006/dbio.1999.9454; NEUMAN T, 1993, EUR J NEUROSCI, V5, P311, DOI 10.1111/j.1460-9568.1993.tb00498.x; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Rhodes KJ, 1996, J NEUROSCI, V16, P4846; Riley P, 1998, NAT GENET, V18, P271, DOI 10.1038/ng0398-271; Scott IC, 2000, MOL CELL BIOL, V20, P530, DOI 10.1128/MCB.20.2.530-541.2000; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; Srivastava D, 1997, NAT GENET, V16, P154, DOI 10.1038/ng0697-154; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; STAUDINGER J, 1993, J BIOL CHEM, V268, P4608; Steidl C, 2000, GENOMICS, V66, P195, DOI 10.1006/geno.2000.6200; WRITGHT WE, 1991, MOL CELL BIOL, V11, P4101; XIN XQ, 1993, J IMMUNOL, V151, P5398; Yelon D, 2000, DEVELOPMENT, V127, P2573	35	79	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33567	33573		10.1074/jbc.M005888200	http://dx.doi.org/10.1074/jbc.M005888200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10924525	Green Accepted, hybrid			2022-12-27	WOS:000090104600056
J	Brehelin, C; Mouaheb, N; Verdoucq, L; Lancelin, JM; Meyer, Y				Brehelin, C; Mouaheb, N; Verdoucq, L; Lancelin, JM; Meyer, Y			Characterization of determinants for the specificity of Arabidopsis thioredoxins h in yeast complementation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; IN-VIVO; PLANT THIOREDOXINS; GLUTAREDOXINS; REDUCTASE; PATHWAY; MUTANT; CELLS; NMR	The disruption of the two thioredoxin genes in Saccharomyces cerevisiae leads to a complex phenotype, including the inability to use methionine sulfoxide as sulfur source, modified cell cycle parameters, reduced H2O2 tolerance, and inability to use sulfate as sulfur source. Expression of one of the multiple Arabidopsis thaliana thioredoxins h in this mutant complements only some aspects of the phenotype, depending on the expressed thioredoxin: AtTRX2 or AtTRX3 induce methionine sulfoxide assimilation and restore a normal cell cycle. In addition AtTRX2 also confers growth on sulfate but no H2O2 tolerance, In contrast, AtTRX3 does not confer growth on sulfate but induces H2O2 tolerance. We have constructed hybrid proteins between these two thioredoxins and show that all information necessary for sulfate assimilation is present in the C-terminal part of AtTRX2, whereas some information needed for H2O2 tolerance is located in the N-terminal part of AtTRX3. In addition, mutation of the atypical redox active site WCPPC to the classical site WCGPC restores some growth on sulfate. All these data suggest that the multiple Arabidopsis thioredoxins h originate from a totipotent ancestor with all the determinants necessary for interaction with the different thioredoxin target proteins. After duplications each member evolved by losing or masking some of the determinants.	Univ Perpignan, UMR CNRS 5096, Lab Genome & Dev Plantes, F-66860 Perpignan, France; Univ Lyon 1, Lab Resonance Magnet Nucl Biomol, CNRS, F-69622 Villeurbanne, France; Ecole Super Chim Phys & Elect, F-69622 Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS); Universite Perpignan Via Domitia; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Meyer, Y (corresponding author), Univ Perpignan, UMR CNRS 5096, Lab Genome & Dev Plantes, 52 Av Villeneuve, F-66860 Perpignan, France.	ymeyer@univ-perp.fr	Lancelin, Jean-marc/AAC-5686-2019	Brehelin, Claire/0000-0002-1889-9582; Verdoucq, Lionel/0000-0001-8238-3700				CHEREST H, 1992, GENETICS, V130, P51; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P15810, DOI 10.1021/bi971504l; COLE GM, 1990, MOL CELL BIOL, V10, P510, DOI 10.1128/MCB.10.2.510; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; FORMANKAY JD, 1992, J BIOMOL NMR, V2, P431, DOI 10.1007/BF02192807; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jacquot JP, 1997, NEW PHYTOL, V136, P543, DOI 10.1046/j.1469-8137.1997.00784.x; Jaramillo JL, 1998, PLANT J, V15, P155, DOI 10.1046/j.1365-313X.1998.00176.x; Jeong JS, 1999, BIOCHEMISTRY-US, V38, P776, DOI 10.1021/bi9817818; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee J, 1999, J BIOL CHEM, V274, P4537, DOI 10.1074/jbc.274.8.4537; Lillig CH, 1999, J BIOL CHEM, V274, P7695, DOI 10.1074/jbc.274.12.7695; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; Meyer Y, 1999, TRENDS PLANT SCI, V4, P388, DOI 10.1016/S1360-1385(99)01475-2; Mittard V, 1997, EUR J BIOCHEM, V243, P374, DOI 10.1111/j.1432-1033.1997.0374a.x; Mouaheb N, 1998, P NATL ACAD SCI USA, V95, P3312, DOI 10.1073/pnas.95.6.3312; MULLER EGD, 1992, YEAST, V8, P117, DOI 10.1002/yea.320080206; MULLER EGD, 1991, J BIOL CHEM, V266, P9194; Muller EGD, 1996, MOL BIOL CELL, V7, P1805, DOI 10.1091/mbc.7.11.1805; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; Qin J, 1996, STRUCTURE, V4, P613, DOI 10.1016/S0969-2126(96)00065-2; RIVERAMADRID R, 1995, P NATL ACAD SCI USA, V92, P5620, DOI 10.1073/pnas.92.12.5620; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sherman F, 1979, METHODS YEAST GENETI; Verdoucq L, 1999, J BIOL CHEM, V274, P19714, DOI 10.1074/jbc.274.28.19714	29	36	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31641	31647		10.1074/jbc.M002916200	http://dx.doi.org/10.1074/jbc.M002916200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10906327	hybrid, Green Published			2022-12-27	WOS:000089858900015
J	Kapus, A; Di Ciano, C; Sun, JG; Zhan, X; Kim, L; Wong, TW; Rotstein, OD				Kapus, A; Di Ciano, C; Sun, JG; Zhan, X; Kim, L; Wong, TW; Rotstein, OD			Cell volume-dependent phosphorylation of proteins of the cortical cytoskeleton and cell-cell contact sites - The role of Fyn and FER kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC FAMILY KINASES; CADHERIN CATENIN COMPLEX; HAMSTER OVARY CELLS; TYROSINE PHOSPHORYLATION; BETA-CATENIN; BINDING PROTEIN; GROWTH-FACTOR; ADHERENS JUNCTIONS; SIGNAL TRANSDUCER; OSMOTIC-STRESS	Cell volume affects diverse functions including cytoskeletal organization, but the underlying signaling pathways remained undefined. We have shown previously that shrinkage induces Fyn-dependent tyrosine phosphorylation of the cortical actin-binding protein, cortactin, Because FER kinase was implicated in the direct phosphorylation of cortactin, we investigated the osmotic responsiveness of FER and its relationship to Fyn and cortactin. Shrinkage increased FER activity and tyrosine phosphorylation, These effects were abolished by the Src family inhibitor PP2 and strongly mitigated in Fyn-deficient but not in Src-deficient cells. FER overexpression caused cortactin phosphorylation that was further enhanced by hypertonicity. Exchange of tyrosine residues 421, 466, and 482 for phenylalanine prevented cortactin phosphorylation by hypertonicity and strongly decreased it upon FER overexpression, suggesting that FER targets primarily the same osmo-sensitive tyrosines, Because constituents of the cell-cell contacts are substrates of Fyn and FER, we investigated the effect of shrinkage on the adherens junctions. Hypertonicity provoked Fyn-dependent tyrosine phosphorylation in beta-catenin, alpha-catenin, and p120(Cas) and caused the dissociation of beta-catenin from the contacts, This process was delayed in Fyn-deficient or PP2-treated cells. Thus, FER is a volume-sensitive kinase downstream from Fyn, and the Fyn/FER pathway may contribute to the cell size-dependent reorganization of the cytoskeleton and the cell-cell contacts.	Toronto Gen Hosp, Dept Surg, Toronto, ON M5G 1L7, Canada; Univ Toronto, Toronto, ON M5G 1L7, Canada; Amer Red Cross, Jerome H Holland Lab, Dept Expt Pathol, Rockville, MD 20855 USA; NIDDK, NIH, Bethesda, MD 20892 USA; Bristol Myers Squibb Co, Pharmaceut Res Inst, Princeton, NJ 08543 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; American Red Cross; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Bristol-Myers Squibb	Kapus, A (corresponding author), Toronto Gen Hosp, Dept Surg, Rm CCRW 2-850,101 Coll St, Toronto, ON M5G 1L7, Canada.							Abe J, 1999, J BIOL CHEM, V274, P21003, DOI 10.1074/jbc.274.30.21003; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bode JG, 1999, J BIOL CHEM, V274, P30222, DOI 10.1074/jbc.274.42.30222; Calautti E, 1998, J CELL BIOL, V141, P1449, DOI 10.1083/jcb.141.6.1449; Clerk A, 1997, FEBS LETT, V403, P23, DOI 10.1016/S0014-5793(97)00020-3; Craig AWB, 1999, J BIOL CHEM, V274, P19934, DOI 10.1074/jbc.274.28.19934; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; Garcia JGN, 1999, AM J PHYSIOL-LUNG C, V276, pL989, DOI 10.1152/ajplung.1999.276.6.L989; Gatsios P, 1998, J BIOL CHEM, V273, P22962, DOI 10.1074/jbc.273.36.22962; Gloushankova NA, 1997, P NATL ACAD SCI USA, V94, P879, DOI 10.1073/pnas.94.3.879; Gloushankova NA, 1998, P NATL ACAD SCI USA, V95, P4362, DOI 10.1073/pnas.95.8.4362; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hansen K, 1997, BIOCHEM BIOPH RES CO, V241, P355, DOI 10.1006/bbrc.1997.7743; Herring TL, 1999, J MEMBRANE BIOL, V171, P151, DOI 10.1007/s002329900567; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P19248, DOI 10.1074/jbc.272.31.19248; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; KAPUS A, 1994, J BIOL CHEM, V269, P23544; Katsube T, 1998, J BIOL CHEM, V273, P29672, DOI 10.1074/jbc.273.45.29672; Kim L, 1998, J BIOL CHEM, V273, P23542, DOI 10.1074/jbc.273.36.23542; KIM L, 1995, MOL CELL BIOL, V15, P4553; Klein JD, 1995, AM J PHYSIOL-CELL PH, V269, pC1524, DOI 10.1152/ajpcell.1995.269.6.C1524; Krump E, 1997, J BIOL CHEM, V272, P17303, DOI 10.1074/jbc.272.28.17303; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Levenberg S, 1998, CELL ADHES COMMUN, V6, P161, DOI 10.3109/15419069809004473; Liu JL, 1999, ONCOGENE, V18, P6700, DOI 10.1038/sj.onc.1203050; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; Patel AS, 1998, ONCOGENE, V16, P3227, DOI 10.1038/sj.onc.1201850; Priel-Halachmi S, 2000, J BIOL CHEM, V275, P28902, DOI 10.1074/jbc.M003402200; Ragsdale GK, 1997, BIOPHYS J, V73, P2798, DOI 10.1016/S0006-3495(97)78309-7; Rivero F, 1996, J CELL SCI, V109, P2679; Rizoli SB, 2000, AM J PHYSIOL-CELL PH, V279, pC619, DOI 10.1152/ajpcell.2000.279.3.C619; Roig J, 2000, J BIOL CHEM, V275, P16933, DOI 10.1074/jbc.M001627200; Rosato R, 1998, MOL CELL BIOL, V18, P5762, DOI 10.1128/MCB.18.10.5762; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; SARTOR O, 1993, J BIOL CHEM, V268, P21014; Smithgall TE, 1998, CRIT REV ONCOGENESIS, V9, P43, DOI 10.1615/CritRevOncog.v9.i1.40; Szaszi K, 1997, J BIOL CHEM, V272, P16670, DOI 10.1074/jbc.272.26.16670; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; WANG YM, 2000, BIOCHEM J, V346, P209; Weed SA, 1998, J CELL SCI, V111, P2433; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Yates KE, 1996, STEM CELLS, V14, P714, DOI 10.1002/stem.140714; Zischka H, 1999, EMBO J, V18, P4241, DOI 10.1093/emboj/18.15.4241	58	72	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32289	32298		10.1074/jbc.M003172200	http://dx.doi.org/10.1074/jbc.M003172200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10921917	hybrid			2022-12-27	WOS:000089858900101
J	Liu, KY; Li, LM; Cohen, SN				Liu, KY; Li, LM; Cohen, SN			Antisense RNA-mediated deficiency of the calpain protease, nCL-4, in NIH3T3 cells is associated with neoplastic transformation and tumorigenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC CALPAIN; TUMOR-SUPPRESSOR GENES; DRUG-INDUCED APOPTOSIS; DYSTROPHY TYPE 2A; PHYSIOLOGICAL-FUNCTION; PROTEOLYTIC-ENZYME; MOLECULAR-CLONING; SKELETAL-MUSCLE; DIGESTIVE-TRACT; FAMILY MEMBERS	We previously have described the use of an antisense RNA strategy termed random homozygous knock-out (RHKO) to identify negative regulators of cell proliferation, Here we report the discovery that RHKO-mediated deficiency of the nCL-4 calpain protease results in cellular transformation of and tumorigenesis by murine NIH3T3 fibroblasts. We isolated cell clones able to form colonies on 0.5% soft agar and found that these cells generated tumors when injected subcutaneously into nude mice. The gene inactivated by RHKO was identified as nCL-4 by genomic library screening, transcript analysis, and DNA sequencing. Anchorage-independent growth, as indicated by colony formation on soft agar, was reversed by reversal of antisense-mediated homozygous inactivation, but continued haplo-insufficiency of nCL-4 resulting from insertional mutagenesis of one nCL-4 allele was associated with persistent tumorigenesis. nCL-4 cDNA expressed in naive 3T3 cells in the antisense, but not sense, direction under control of the cytomegalovirus early promoter reproduced the anchorage-independent growth effects of RHKO. Our results implicate deficiency of the nCL-4 calpain protease in neoplastic transformation.	Stanford Univ, Sch Med, Med Ctr, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Cohen, SN (corresponding author), Stanford Univ, Sch Med, Med Ctr, Dept Genet, Rm M320, Stanford, CA 94305 USA.	sncohen@stanford.edu			NCI NIH HHS [CA09302] Funding Source: Medline; NHGRI NIH HHS [HG 00044-04] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Baghdiguian S, 1999, NAT MED, V5, P503, DOI 10.1038/8385; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; Busquets S, 2000, BBA-GEN SUBJECTS, V1475, P5, DOI 10.1016/S0304-4165(00)00050-7; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Choi YH, 1997, J BIOL CHEM, V272, P28479, DOI 10.1074/jbc.272.45.28479; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; Debiasi RL, 1999, J VIROL, V73, P695, DOI 10.1128/JVI.73.1.695-701.1999; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Gonen H, 1997, FEBS LETT, V406, P17, DOI 10.1016/S0014-5793(97)00225-1; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Jang JS, 1999, ONCOGENE, V18, P1789, DOI 10.1038/sj.onc.1202497; Jang JS, 1999, INT J MOL MED, V4, P487; Kimura Y, 1998, NAT MED, V4, P915, DOI 10.1038/nm0898-915; Kinbara K, 1998, BIOCHEM PHARMACOL, V56, P415; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kulkarni S, 1999, J BIOL CHEM, V274, P21265, DOI 10.1074/jbc.274.30.21265; Kusakawa G, 2000, J BIOL CHEM, V275, P17166, DOI 10.1074/jbc.M907757199; Lee HJ, 1998, BIOL CHEM, V379, P175, DOI 10.1515/bchm.1998.379.2.175; Lee HJ, 1999, ARCH BIOCHEM BIOPHYS, V362, P22, DOI 10.1006/abbi.1998.1021; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Liu KY, 1999, MOL CELL BIOL, V19, P3696; LUPTON SD, 1991, MOL CELL BIOL, V11, P3374, DOI 10.1128/MCB.11.6.3374; NAKAMURA M, 1992, EXP CELL RES, V200, P513, DOI 10.1016/0014-4827(92)90203-K; Ono Y, 1998, BIOCHEM BIOPH RES CO, V245, P289, DOI 10.1006/bbrc.1998.8085; Ono Y, 1998, J BIOL CHEM, V273, P17073, DOI 10.1074/jbc.273.27.17073; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; Patel YM, 1999, P NATL ACAD SCI USA, V96, P1279, DOI 10.1073/pnas.96.4.1279; Penna D, 1999, J IMMUNOL, V163, P50; Ray SK, 1999, BRAIN RES, V829, P18, DOI 10.1016/S0006-8993(99)01290-1; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; Ruiz-Vela A, 1999, EMBO J, V18, P4988, DOI 10.1093/emboj/18.18.4988; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Shibata MA, 1999, EMBO J, V18, P2692, DOI 10.1093/emboj/18.10.2692; Shields DC, 1999, P NATL ACAD SCI USA, V96, P11486, DOI 10.1073/pnas.96.20.11486; Shinagawa T, 2000, EMBO J, V19, P2280, DOI 10.1093/emboj/19.10.2280; SORIMACHI H, 1994, FEBS LETT, V343, P1, DOI 10.1016/0014-5793(94)80595-4; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; SORIMACHI H, 1993, J BIOL CHEM, V268, P19476; SUZUKI K, 1995, BIOL CHEM H-S, V376, P523; Tagawa K, 2000, HUM MOL GENET, V9, P1393, DOI 10.1093/hmg/9.9.1393; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Tidball JG, 2000, INT J BIOCHEM CELL B, V32, P1, DOI 10.1016/S1357-2725(99)00095-3; Ueki K, 1999, CANCER RES, V59, P5995; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Wood DE, 1999, J BIOL CHEM, V274, P8309, DOI 10.1074/jbc.274.12.8309; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Xie WQ, 1998, P NATL ACAD SCI USA, V95, P1595, DOI 10.1073/pnas.95.4.1595; Yoshikawa Y, 2000, JPN J CANCER RES, V91, P459, DOI 10.1111/j.1349-7006.2000.tb00967.x; Zhang WL, 1997, ONCOGENE, V14, P255, DOI 10.1038/sj.onc.1200841	61	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31093	31098		10.1074/jbc.M005451200	http://dx.doi.org/10.1074/jbc.M005451200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906334	hybrid			2022-12-27	WOS:000089762700050
J	Ohnishi, K; Shimizu, T; Karasuyama, H; Melchers, F				Ohnishi, K; Shimizu, T; Karasuyama, H; Melchers, F			The identification of a nonclassical cadherin expressed during B cell development and its interaction with surrogate light chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE BONE-MARROW; MU HEAVY-CHAIN; LYMPHOCYTE-B; ALLELIC EXCLUSION; EPITHELIAL-CELLS; PRO-B; GENE; SURFACE; ADHESION; SUPERFAMILY	A 130-kDa glycoprotein (p130) has been found to be associated with surrogate light chain on pro- and pre-B I cells. Using peptide sequences obtained from purified p130 we have cloned its gene. The gene encodes a typical cadherin type 1 membrane protein with six extracellular cadherin domains tone pseudo domain) but lacking the catenin-binding site in its cytoplasmic part. Even without this catenin-binding site, p130 mediates Ca2+- dependent homotypic adhesion of cells. The interaction of p130 with surrogate light chain is confirmed by cotransfection and co-immunoprecipitation experiments. The expression of p130 is biphasic during the B cell development. Reverse transcriptase-polymerase chain reaction and flow cytometric analyses revealed that it is expressed on B220(+)c-Kit(+) pro-B and pre-B-I cells as well as on B220(+)CD25(-)IgM(+) immature and mature B cells but not on B220(+)CD25(+) pre-B-II cells. It is also expressed in fetal liver, at low levels in myeloid cells, and strongly in intestinal epithelial cells. In the spleen, p130-expressing cells are mainly localized in the marginal zone. We call this B lineage-, intestine-, liver- and leukocyte-expressed gene BILL-cadherin. The possible functions of BILL cadherin in B cell development are discussed.	Basel Inst Immunol, CH-4005 Basel, Switzerland; Tokyo Metropolitan Inst Med Sci, Dept Immunol, Tokyo 1138613, Japan	Tokyo Metropolitan Institute of Medical Science	Ohnishi, K (corresponding author), Natl Inst Infect Dis, Dept Immunol, Tokyo 1628640, Japan.		Karasuyama, Hajime/A-7966-2011	Karasuyama, Hajime/0000-0003-0689-0836				BAUER SR, 1986, J IMMUNOL, V136, P4695; BERNDORFF D, 1994, J CELL BIOL, V125, P1353, DOI 10.1083/jcb.125.6.1353; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; Chen XJ, 1997, INT IMMUNOL, V9, P27, DOI 10.1093/intimm/9.1.27; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cowin P, 1996, CURR OPIN CELL BIOL, V8, P56, DOI 10.1016/S0955-0674(96)80049-4; DANTZIG AH, 1994, SCIENCE, V264, P430, DOI 10.1126/science.8153632; DAVIDSON WF, 1988, J EXP MED, V168, P389, DOI 10.1084/jem.168.1.389; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GRAWUNDER U, 1995, IMMUNITY, V3, P601, DOI 10.1016/1074-7613(95)90131-0; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; JACOBSEN K, 1990, EUR J IMMUNOL, V20, P2395, DOI 10.1002/eji.1830201106; KARASUYAMA H, 1993, J EXP MED, V178, P469, DOI 10.1084/jem.178.2.469; KARASUYAMA H, 1994, CELL, V77, P133, DOI 10.1016/0092-8674(94)90241-0; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; Karecla PI, 1996, J BIOL CHEM, V271, P30909, DOI 10.1074/jbc.271.48.30909; KARECLA PI, 1995, EUR J IMMUNOL, V25, P852, DOI 10.1002/eji.1830250333; Kincade P W, 1993, Curr Top Microbiol Immunol, V184, P215; Kincade P W, 1991, Semin Immunol, V3, P379; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; Kreft B, 1997, J CELL BIOL, V136, P1109, DOI 10.1083/jcb.136.5.1109; LEPTIN M, 1985, EUR J IMMUNOL, V15, P131, DOI 10.1002/eji.1830150206; Loffert D, 1996, IMMUNITY, V4, P133, DOI 10.1016/S1074-7613(00)80678-0; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Melchers F, 1999, SEMIN IMMUNOL, V11, P307, DOI 10.1006/smim.1999.0187; MELCHERS F, 1993, IMMUNOL TODAY, V14, P60, DOI 10.1016/0167-5699(93)90060-X; MELCHERS F, 1995, CURR OPIN IMMUNOL, V7, P214, DOI 10.1016/0952-7915(95)80006-9; Melchers F, 1999, P NATL ACAD SCI USA, V96, P2571, DOI 10.1073/pnas.96.6.2571; Minegishi Y, 1999, P NATL ACAD SCI USA, V96, P3041, DOI 10.1073/pnas.96.6.3041; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; NISHIKAWA SI, 1988, EUR J IMMUNOL, V18, P1767, DOI 10.1002/eji.1830181117; Ogawa M, 1998, EXP HEMATOL, V26, P478; OHNISHI K, 1994, J BIOL CHEM, V269, P28347; Oliver AM, 1997, EUR J IMMUNOL, V27, P2366, DOI 10.1002/eji.1830270935; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Osmond D G, 1990, Semin Immunol, V2, P173; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; RANSCHT B, 1994, CURR OPIN CELL BIOL, V6, P740, DOI 10.1016/0955-0674(94)90102-3; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROLINK A, 1993, EUR J IMMUNOL, V23, P1284, DOI 10.1002/eji.1830230614; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; Sambrook J., 2002, MOL CLONING LAB MANU; Sanz E, 1996, J EXP MED, V183, P2693, DOI 10.1084/jem.183.6.2693; Senzaki K, 1999, CELL, V99, P635, DOI 10.1016/S0092-8674(00)81552-4; SHAPIRO L, 1995, P NATL ACAD SCI USA, V92, P6793, DOI 10.1073/pnas.92.15.6793; SHINJO F, 1994, INT IMMUNOL, V6, P393, DOI 10.1093/intimm/6.3.393; SPRENT J, 1973, CELL IMMUNOL, V7, P10, DOI 10.1016/0008-8749(73)90180-9; SPRINGER TA, 1981, J BIOL CHEM, V256, P3833; STEVENS SK, 1982, J IMMUNOL, V128, P844; SUDO T, 1989, J EXP MED, V170, P333, DOI 10.1084/jem.170.1.333; Sugino H, 2000, GENOMICS, V63, P75, DOI 10.1006/geno.1999.6066; Suzuki ST, 1996, J CELL SCI, V109, P2609; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; TAKEMORI T, 1987, EMBO J, V6, P951, DOI 10.1002/j.1460-2075.1987.tb04844.x; THOMSON RB, 1995, J BIOL CHEM, V270, P17594, DOI 10.1074/jbc.270.29.17594; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Uemura T, 1998, CELL, V93, P1095, DOI 10.1016/S0092-8674(00)81452-X; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; WAGNER G, 1995, SCIENCE, V267, P342, DOI 10.1126/science.7824932; WALLNY HJ, 1995, EUR J IMMUNOL, V25, P1262, DOI 10.1002/eji.1830250520; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WINKLER TH, 1995, EUR J IMMUNOL, V25, P446, DOI 10.1002/eji.1830250221; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8	65	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31134	31144		10.1074/jbc.M005901200	http://dx.doi.org/10.1074/jbc.M005901200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906147	hybrid			2022-12-27	WOS:000089762700056
J	Potter, LR; Hunter, T				Potter, LR; Hunter, T			Activation of protein kinase C stimulates the dephosphorylation of natriuretic peptide receptor-B at a single serine residue - A possible mechanism of heterologous desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED MOUSE ASTROCYTES; CYCLIC-GMP RESPONSES; GUANYLYL CYCLASE-A; SMOOTH-MUSCLE; ADENINE-NUCLEOTIDES; CGMP ACCUMULATION; PHOSPHORYLATION; SYSTEM; CELLS; PLASMA	The binding of atrial natriuretic peptide and C-type natriuretic peptide (CNP) to the guanylyl cyclase-linked natriuretic peptide receptors A and B (NPR-A and -B), respectively, stimulates increases in intracellular cGMP concentrations. The vasoactive peptides vasopressin, angiotensin II, and endothelin inhibit natriuretic peptide-dependent cGMP elevations by activating protein kinase C (PKC). Recently, we identified six in vivo phosphorylation sites for NPR-A and five sites for NPR-B and demonstrated that the phosphorylation of these sites is required for ligand-dependent receptor activation. Here, we show that phorbol 12-myristate 13-acetate, a direct activator of PKC, causes the dephosphorylation and desensitization of NPR-B. In contrast to the CNP-dependent desensitization process, which results in coordinate dephosphorylation of all five sites in the receptor, phorbol la-myristate 13-acetate treatment causes the dephosphorylation of only one site, which we have identified as Ser(523). The conversion of this residue to alanine or glutamate did not reduce the amount of mature receptor protein as indicated by detergent-dependent guanylyl cyclase activities or Western blot analysis but completely blocked the ability of PKC to induce the dephosphorylation and desensitization of NPR-B, Thus, in contrast to previous reports suggesting that PKC directly phosphorylates and inhibits guanylyl cyclase linked natriuretic peptide receptors, we show that PRC-dependent dephosphorylation of NPR-B at Ser523 provides a possible molecular explanation for how presser hormones inhibit CNP signaling.	Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA	Salk Institute	Potter, LR (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, Gortner Lab 356, 1479 Gortner Ave, St Paul, MN 55108 USA.	Potter@tc.umn.edu			NCI NIH HHS [CA39780, CA14195, F32 CA067452, CA-67452] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA067452, P30CA014195, R35CA039780] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; APPEL RG, 1992, AM J PHYSIOL, V262, pF911, DOI 10.1152/ajprenal.1992.262.6.F911; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; CHANG CH, 1990, BIOCHIM BIOPHYS ACTA, V1052, P159, DOI 10.1016/0167-4889(90)90071-K; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1992, J BIOL CHEM, V267, P18589; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; Chrisman TD, 1999, J BIOL CHEM, V274, P4293, DOI 10.1074/jbc.274.7.4293; CHRISMAN TD, 1993, J BIOL CHEM, V268, P3698; Crook RB, 1997, BIOCHEM J, V324, P49, DOI 10.1042/bj3240049; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; DUDA T, 1995, BIOCHEM BIOPH RES CO, V209, P286, DOI 10.1006/bbrc.1995.1501; DUDA T, 1990, MOL CELL BIOCHEM, V93, P179; Forssmann WG, 1998, HISTOCHEM CELL BIOL, V110, P335, DOI 10.1007/s004180050295; Foster DC, 1998, J BIOL CHEM, V273, P16311, DOI 10.1074/jbc.273.26.16311; Fowkes RC, 2000, J ENDOCRINOL, V166, P195, DOI 10.1677/joe.0.1660195; FURUYA M, 1995, ANN NY ACAD SCI, V748, P517; HAGIWARA H, 1994, J BIOL CHEM, V269, P10729; Hagiwara H, 1996, AM J PHYSIOL-CELL PH, V270, pC1311, DOI 10.1152/ajpcell.1996.270.5.C1311; HANEDA M, 1991, KIDNEY INT, V40, P188, DOI 10.1038/ki.1991.199; HOLLIDAY LS, 1995, J BIOL CHEM, V270, P18983, DOI 10.1074/jbc.270.32.18983; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; Itoh H, 1997, ANN NY ACAD SCI, V811, P533, DOI 10.1111/j.1749-6632.1997.tb52037.x; IWATA T, 1991, J BIOCHEM-TOKYO, V110, P35, DOI 10.1093/oxfordjournals.jbchem.a123539; JAISWAL RK, 1992, BIOCHEM BIOPH RES CO, V182, P395, DOI 10.1016/S0006-291X(05)80158-5; Kitano K, 1996, J IMMUNOL METHODS, V194, P147, DOI 10.1016/0022-1759(96)00075-0; KOLLER KJ, 1993, J BIOL CHEM, V268, P5997; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; KUROSE H, 1987, FEBS LETT, V219, P375, DOI 10.1016/0014-5793(87)80256-9; LAROSE L, 1992, MOL CELL BIOCHEM, V115, P203, DOI 10.1007/BF00230332; LEFKOWITZ RJ, 1986, CURR TOP CELL REGUL, V28, P209; Levin ER, 1998, NEW ENGL J MED, V339, P321; LOWE DG, 1992, BIOCHEMISTRY-US, V31, P10421, DOI 10.1021/bi00158a001; Maack T, 1996, KIDNEY INT, V49, P1732, DOI 10.1038/ki.1996.257; Matsukawa N, 1999, P NATL ACAD SCI USA, V96, P7403, DOI 10.1073/pnas.96.13.7403; MCARDLE CA, 1993, ENDOCRINOLOGY, V132, P2065, DOI 10.1210/en.132.5.2065; NAMBI P, 1986, P NATL ACAD SCI USA, V83, P8492, DOI 10.1073/pnas.83.22.8492; Oliver PM, 1997, P NATL ACAD SCI USA, V94, P14730, DOI 10.1073/pnas.94.26.14730; OMAHONEY JV, 1994, DNA CELL BIOL, V13, P1227, DOI 10.1089/dna.1994.13.1227; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; Potter LR, 1998, J BIOL CHEM, V273, P15533, DOI 10.1074/jbc.273.25.15533; POTTER LR, 1992, J BIOL CHEM, V267, P14531; Potter LR, 1998, BIOCHEMISTRY-US, V37, P2422, DOI 10.1021/bi972303k; POTTER LR, 1994, J BIOL CHEM, V269, P14636; Potter LR, 1999, MOL BIOL CELL, V10, P1811, DOI 10.1091/mbc.10.6.1811; Potter LR, 1999, METHODS, V19, P506, DOI 10.1006/meth.1999.0893; Potter LR, 1998, MOL CELL BIOL, V18, P2164, DOI 10.1128/MCB.18.4.2164; Richards AM, 1996, HEART, V76, P36, DOI 10.1136/hrt.76.3_Suppl_3.36; SHARMA R K, 1989, Steroids, V53, P437, DOI 10.1016/0039-128X(89)90024-X; SHINOMIYA M, 1994, BIOCHEM BIOPH RES CO, V205, P1051, DOI 10.1006/bbrc.1994.2772; STINGO AJ, 1992, AM J PHYSIOL, V263, pH1318, DOI 10.1152/ajpheart.1992.263.4.H1318; Suda M, 1998, P NATL ACAD SCI USA, V95, P2337, DOI 10.1073/pnas.95.5.2337; SUGA S, 1992, J CLIN INVEST, V90, P1145, DOI 10.1172/JCI115933; SUGA SI, 1992, ENDOCRINOLOGY, V130, P229, DOI 10.1210/en.130.1.229; Tsang D, 1997, REGUL PEPTIDES, V70, P91, DOI 10.1016/S0167-0115(97)00013-X; Yasoda A, 1998, J BIOL CHEM, V273, P11695, DOI 10.1074/jbc.273.19.11695; YASUNARI K, 1992, HYPERTENSION, V19, P314, DOI 10.1161/01.HYP.19.4.314; Yeung VTF, 1996, J NEUROSCI RES, V46, P686, DOI 10.1002/(SICI)1097-4547(19961215)46:6<686::AID-JNR6>3.0.CO;2-B; YEUNG VTF, 1992, FEBS LETT, V308, P301, DOI 10.1016/0014-5793(92)81298-Z	61	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31099	31106		10.1074/jbc.M005506200	http://dx.doi.org/10.1074/jbc.M005506200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10915802	hybrid			2022-12-27	WOS:000089762700051
J	Bai, LC; Merchant, JL				Bai, LC; Merchant, JL			Transcription factor ZBP-89 cooperates with histone acetyltransferase p300 during butyrate activation of p21(waf1) transcription in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; ZINC-FINGER PROTEIN; GENE PROMOTER; GROWTH-INHIBITION; BINDING PROTEIN; DNA-BINDING; SP1; DIFFERENTIATION; ACETYLATION; EXPRESSION	Inducible p53-independent regulation of the cyclin-dependent kinase inhibitor p21(waf1) transcription is mediated through proximal GC-rich sites. Prior studies have shown that Sp1, Sp3, and the histone acetylase co-activator p300 are components of the complexes binding to these sites. Although Sp1 and Sp3 collaborate with p300, a direct interaction between Sp1 and p300 does not occur. This study sought to determine whether ZBP-89 rather than Sp1 is the direct target of p300 during butyrate induction of p21(waf1). ZBP-89 (BFCOL1, BERF-1, ZNF 148) is a Kruppel-type zinc finger transcription factor that binds to GC-rich elements and represses or activates known target genes. Adenoviral-mediated expression of ZBP-89 in HT-29 cells revealed that ZBP-89 potentiates butyrate induction of endogenous p21(waf1) gene expression. Further, cotransfection of a ZBP-89 expression vector with a 2.3-kilobase p21(waf1) reporter recapitulated the potentiation by butyrate. DNase I foot-printing analysis of the human p21(waf1) promoter with recombinant ZBP-89 identified a binding site at -245 to -215. Electrophoretic mobility shift assays confirmed that both recombinant and endogenous ZBP-89 and Sp1 bind to this element. The potentiation was abolished in the presence of adenoviral protein E1A. Deletion of the N-terminal domain of ZBP-89 abolished the potentiation mediated by butyrate treatment. This same deletion mutant abolished the ZBP-89 interaction with p300. Cotransfection of p300 with ZBP-89 stimulated the p21(waf1) promoter in the absence of butyrate, p300 co-precipitated with ZBP-89 but not with Sp1, whereas ZBP-89 co-precipitated with Sp1. Together, these findings demonstrate that ZBP-89 also plays a critical role in butyrate activation of the p21(waf)1 promoter and reveals preferential cooperation of this four-zinc finger transcription factor with p300.	Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Physiol, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Merchant, JL (corresponding author), 1150 W Med Dr,MSRB 1,3510, Ann Arbor, MI 48109 USA.		Merchant, Juanita/AAF-8277-2019	Merchant, Juanita/0000-0002-6559-8184	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034533, R01DK045729, R56DK055732, R37DK045729, R01DK055732] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-55732, DK-34533, DK-45729] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aoki K, 1999, MOL MED, V5, P224, DOI 10.1007/BF03402119; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Ausubel FM., 2006, ENZYMATIC MANIPULATI; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BARNARD JA, 1993, CELL GROWTH DIFFER, V4, P495; Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Eckner R, 1996, BIOL CHEM, V377, P685; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; Hasegawa T, 1999, BIOCHEM BIOPH RES CO, V256, P249, DOI 10.1006/bbrc.1999.0275; Hasegawa T, 1997, J BIOL CHEM, V272, P4915, DOI 10.1074/jbc.272.8.4915; Hollander MC, 1997, J BIOL CHEM, V272, P13731, DOI 10.1074/jbc.272.21.13731; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; Kung AL, 2000, GENE DEV, V14, P272; Law DJ, 1998, MAMM GENOME, V9, P165, DOI 10.1007/s003359900711; Law GL, 1998, J BIOL CHEM, V273, P19955, DOI 10.1074/jbc.273.32.19955; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; Merchant JL, 1996, MOL CELL BIOL, V16, P6644; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Muraoka M, 1996, ONCOGENE, V12, P1565; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Parks CL, 1997, J VIROL, V71, P9600, DOI 10.1128/JVI.71.12.9600-9607.1997; Passantino R, 1998, J BIOL CHEM, V273, P484, DOI 10.1074/jbc.273.1.484; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Reizis B, 1999, J EXP MED, V189, P1669, DOI 10.1084/jem.189.10.1669; Remington MC, 1997, BIOCHEM BIOPH RES CO, V237, P230, DOI 10.1006/bbrc.1997.7119; Siavoshian S, 2000, GUT, V46, P507, DOI 10.1136/gut.46.4.507; Sowa Y, 1999, CANCER RES, V59, P4266; Taniuchi T, 1997, BIOCHEM BIOPH RES CO, V233, P154, DOI 10.1006/bbrc.1997.6310; WANG YK, 1993, MOL CELL BIOL, V13, P5691, DOI 10.1128/MCB.13.9.5691; Wieczorek E, 2000, J BIOL CHEM, V275, P12879, DOI 10.1074/jbc.275.17.12879; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Xiao HY, 1997, BIOCHEM BIOPH RES CO, V237, P457, DOI 10.1006/bbrc.1997.7158; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Ye S, 1999, FEBS LETT, V450, P268, DOI 10.1016/S0014-5793(99)00509-8; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	51	97	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30725	30733		10.1074/jbc.M004249200	http://dx.doi.org/10.1074/jbc.M004249200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10899165	hybrid			2022-12-27	WOS:000089577900110
J	Comer, FI; Hart, GW				Comer, FI; Hart, GW			O-glycosylation of nuclear and cytosolic proteins - Dynamic interplay between O-GlcNAc and O-phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							LINKED N-ACETYLGLUCOSAMINE; RNA-POLYMERASE-II; IN-VIVO; TETRATRICOPEPTIDE REPEATS; CYTOPLASMIC PROTEINS; INSULIN-RESISTANCE; ALZHEIMERS-DISEASE; GLUCOSE-TRANSPORT; SKELETAL-MUSCLE; TERMINAL DOMAIN		Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Univ Alabama, Dept Biochem & Mol Genet, Grad Program, Birmingham, AL 35294 USA	Johns Hopkins University; University of Alabama System; University of Alabama Birmingham	Hart, GW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.			Hart, Gerald/0000-0001-7812-4351	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD013563, R01HD013563] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA042486] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42486] Funding Source: Medline; NICHD NIH HHS [HD 13563] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AKIMOTO Y, 2000, IN PRESS DIABETOLOGI; Alonso AD, 1996, NAT MED, V2, P783, DOI 10.1038/nm0796-783; Arnold CS, 1996, J BIOL CHEM, V271, P28741, DOI 10.1074/jbc.271.46.28741; BAGLIA FA, 1983, P NATL ACAD SCI-BIOL, V80, P2285, DOI 10.1073/pnas.80.8.2285; Baron AD, 1995, J CLIN INVEST, V96, P2792, DOI 10.1172/JCI118349; CHOU CF, 1993, J BIOL CHEM, V268, P4465; CHOU CF, 1992, J BIOL CHEM, V267, P3901; CHOU TY, 1995, P NATL ACAD SCI USA, V92, P4417, DOI 10.1073/pnas.92.10.4417; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; COHEN PTW, 1993, BIOCHEM SOC T, V21, P884, DOI 10.1042/bst0210884; Cole RN, 1999, J NEUROCHEM, V73, P418, DOI 10.1046/j.1471-4159.1999.0730418.x; Comer FI, 1999, BBA-GEN SUBJECTS, V1473, P161, DOI 10.1016/S0304-4165(99)00176-2; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DATTA B, 1989, J BIOL CHEM, V264, P20620; Dong DLY, 1996, J BIOL CHEM, V271, P20845, DOI 10.1074/jbc.271.34.20845; DONG DLY, 1994, J BIOL CHEM, V269, P19321; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; Furukawa Kiyoshi, 1992, Current Opinion in Biotechnology, V3, P554, DOI 10.1016/0958-1669(92)90085-W; Greis KD, 1996, ANAL BIOCHEM, V234, P38, DOI 10.1006/abio.1996.0047; Griffith LS, 1999, EUR J BIOCHEM, V262, P824, DOI 10.1046/j.1432-1327.1999.00439.x; GRIFFITH LS, 1995, J NEUROSCI RES, V41, P270, DOI 10.1002/jnr.490410214; Haltiwanger RS, 1998, J BIOL CHEM, V273, P3611, DOI 10.1074/jbc.273.6.3611; Haltiwanger RS, 1997, BIOCHEM BIOPH RES CO, V231, P237, DOI 10.1006/bbrc.1997.6110; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P1; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Hanover JA, 1999, ARCH BIOCHEM BIOPHYS, V362, P38, DOI 10.1006/abbi.1998.1016; HANOVER JA, 1987, J BIOL CHEM, V262, P9887; HART GW, 1995, ADV EXP MED BIOL, V376, P115; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; Haurum JS, 1999, J EXP MED, V190, P145, DOI 10.1084/jem.190.1.145; Hebert LF, 1996, J CLIN INVEST, V98, P930, DOI 10.1172/JCI118876; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; HORSCH M, 1991, EUR J BIOCHEM, V197, P815, DOI 10.1111/j.1432-1033.1991.tb15976.x; HUBERT J, 1989, CELL DIFFER DEV, V27, P69, DOI 10.1016/0922-3371(89)90737-5; ISHIBASHI M, 1974, VIROLOGY, V58, P345, DOI 10.1016/0042-6822(74)90070-1; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; Jung E, 1998, EUR J BIOCHEM, V253, P517, DOI 10.1046/j.1432-1327.1998.2530517.x; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KELLY WG, 1993, J BIOL CHEM, V268, P10416; KREBS EG, 1993, BIOSCIENCE REP, V13, P127, DOI 10.1007/BF01149958; Kreppel LK, 1999, J BIOL CHEM, V274, P32015, DOI 10.1074/jbc.274.45.32015; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; Lefebvre T, 1999, BBA-GEN SUBJECTS, V1472, P71, DOI 10.1016/S0304-4165(99)00105-1; LIN TS, 1980, EUR J BIOCHEM, V106, P341, DOI 10.1111/j.1432-1033.1980.tb04580.x; Lubas WA, 2000, J BIOL CHEM, V275, P10983, DOI 10.1074/jbc.275.15.10983; Lubas WA, 1997, J BIOL CHEM, V272, P9316; MARSHALL S, 2000, IN PRESS DIABETES AN, V13; Medina L, 1998, GLYCOBIOLOGY, V8, P383, DOI 10.1093/glycob/8.4.383; Milczarek GJ, 1996, LIFE SCI, V60, P1, DOI 10.1016/S0024-3205(96)00479-1; Miller MW, 1999, ARCH BIOCHEM BIOPHYS, V367, P51, DOI 10.1006/abbi.1999.1237; MULLIS KG, 1990, J VIROL, V64, P5317, DOI 10.1128/JVI.64.11.5317-5323.1990; Proudfoot N, 2000, TRENDS BIOCHEM SCI, V25, P290, DOI 10.1016/S0968-0004(00)01591-7; ROBINSON KA, 1993, DIABETES, V42, P1333, DOI 10.2337/diabetes.42.9.1333; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; Roos MD, 1998, P ASSOC AM PHYSICIAN, V110, P422; Roquemore EP, 1996, BIOCHEMISTRY-US, V35, P3578, DOI 10.1021/bi951918j; Selzer J, 1996, J BIOL CHEM, V271, P25173, DOI 10.1074/jbc.271.41.25173; Shafi R, 2000, P NATL ACAD SCI USA, V97, P5735, DOI 10.1073/pnas.100471497; Shaw P, 1996, ONCOGENE, V12, P921; Simanek EE, 1998, J AM CHEM SOC, V120, P11567, DOI 10.1021/ja982312w; SNOW DM, 1996, MOL BIOL CELL, V6, P357; Thornton TM, 1999, TRENDS PLANT SCI, V4, P424, DOI 10.1016/S1360-1385(99)01485-5; TORRES CR, 1984, J BIOL CHEM, V259, P3308; Yao PJ, 1998, J NEUROSCI, V18, P2399; Yki-Jarvinen H, 1998, METABOLISM, V47, P449, DOI 10.1016/S0026-0495(98)90058-0; ZHIVKOV V, 1975, COMP BIOCHEM PHYS B, V51, P421, DOI 10.1016/0305-0491(75)90032-2	68	306	323	3	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29179	29182		10.1074/jbc.R000010200	http://dx.doi.org/10.1074/jbc.R000010200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10924527	hybrid			2022-12-27	WOS:000089439800001
J	Weimar, T; Bukowski, R; Young, NM				Weimar, T; Bukowski, R; Young, NM			The conformation of the T-antigen disaccharide found to Maclura pomifera agglutinin in aqueous solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; CARBOHYDRATE SPECIFICITY; LECTIN; NMR; SPECTROSCOPY; COMPLEX	The complex of Maclura pomifera agglutinin with the T-antigen disaccharide (beta -D-Gal-(1-->3)-alpha -D-GalNAc-(1-->O)- Me) was investigated by NMR spectroscopy in aqueous solution Intramolecular transferred nuclear Overhauser enhancement (NOE) effects between the monosaccharide moieties were used to derive the Ligand conformation in the lectin-bound state. Ligand protons in contact with the protein were identified by saturation transfer difference experiments and intermolecular transferred NOE effects. It is demonstrated that structural differences exist for the ligand-lectin complex in aqueous solution as compared with the previously published crystal structure (Lee,X, Thompson, A, Zhiming, Z., Ton-that, H., Biesterfeldt, J., Ogata, C., Xu, L., Johnston, R. A Z., and Young, N. M. (1998) J. Biol: Chem 273, 6312-6318). Tn order to accommodate the O-methyl group of the disaccharide, the amino acid side chain of Tyr-122 has to rotate from its position in the crystal The NMR data are in accord with two conformational families at the beta-(1-->3)glycosidic linkage in the solution complex with interglycosidic angles phi/psi = 45/-65 degrees and -65/ -18 degrees. These differ from the bound conformation of the ligand in the crystal (phi/psi = 39/-8 degrees) and are not highly populated by the ligand in the free state. The reason for the structural, differences at the beta-(1-->)glycosidic linkage are hydrogen bonds that stabilize the relative orientation of the monosaccharide units in the crystal. Our results demonstrate that the crystallization of a protein-carbohydrate complex car interfere with the delicate process of carbohydrate recognition in solution.	Med Univ Lubeck, Inst Chem, D-23538 Lubeck, Germany; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	University of Lubeck; National Research Council Canada	Weimar, T (corresponding author), Med Univ Lubeck, Inst Chem, Ratzeburger Allee 160, D-23538 Lubeck, Germany.							Feeney R E, 1978, Adv Protein Chem, V32, P191, DOI 10.1016/S0065-3233(08)60576-8; Friedenreich V., 1930, THOMSEN HEMAGGLUTINA; GEEN H, 1991, J MAGN RESON, V93, P93, DOI 10.1016/0022-2364(91)90034-Q; Haselhorst T, 1999, BIOCHEMISTRY-US, V38, P6449, DOI 10.1021/bi982984z; Lee X, 1998, J BIOL CHEM, V273, P6312, DOI 10.1074/jbc.273.11.6312; Mayer M, 1999, ANGEW CHEM INT EDIT, V38, P1784, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q; NI F, 1994, PROG NUCL MAG RES SP, V26, P517, DOI 10.1016/0079-6565(94)90000-0; PERLMAN ME, 1994, BIOCHEMISTRY-US, V33, P7547, DOI 10.1021/bi00190a007; PETERS T, 1993, CARBOHYD RES, V238, P49, DOI 10.1016/0008-6215(93)87005-D; Peters T, 1996, CURR OPIN STRUC BIOL, V6, P710, DOI 10.1016/S0959-440X(96)80039-X; Poveda A, 1997, J MOL GRAPH MODEL, V15, P9, DOI 10.1016/S1093-3263(97)00012-0; Ravishankar R, 1997, CURR SCI INDIA, V72, P855; Sankaranarayanan R, 1996, NAT STRUCT BIOL, V3, P596, DOI 10.1038/nsb0796-596; SARKAR M, 1981, ARCH BIOCHEM BIOPHYS, V209, P204, DOI 10.1016/0003-9861(81)90273-3; SCHERF T, 1993, BIOPHYS J, V64, P754, DOI 10.1016/S0006-3495(93)81436-X; SPRINGER GF, 1995, CRIT REV ONCOGENESIS, V6, P57, DOI 10.1615/CritRevOncog.v6.i1.50; STUIKEPRILL R, 1990, EUR J BIOCHEM, V194, P903, DOI 10.1111/j.1432-1033.1990.tb19485.x; THOMSEN OLUF, 1927, ZEITSCHR IMMUNITATSFORSCH U EXP THERAP, V52, P85; Transue TR, 1997, NAT STRUCT BIOL, V4, P779, DOI 10.1038/nsb1097-779; VERMA M, 1994, GLYCOCONJUGATE J, V11, P172, DOI 10.1007/BF00731215; Vincent SJF, 1997, P NATL ACAD SCI USA, V94, P4383, DOI 10.1073/pnas.94.9.4383; YOUNG NM, 1989, ARCH BIOCHEM BIOPHYS, V270, P596, DOI 10.1016/0003-9861(89)90542-0	22	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37006	37010		10.1074/jbc.M005092200	http://dx.doi.org/10.1074/jbc.M005092200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10913148	hybrid			2022-12-27	WOS:000165577700078
J	Bolesch, DG; Keasling, JD				Bolesch, DG; Keasling, JD			Polyphosphate binding and chain length recognition of Escherichia coli exopolyphosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPIONIBACTERIUM-SHERMANII; KINASE; GLUCOKINASE; MECHANISM; PROTEINS; ACTIN; GENE	Exopolyphosphatase of Escherichia coli (PPX) is a highly processive enzyme demonstrating the ability to recognize polyphosphates of specific lengths. The mechanisms responsible for the processivity and polymer length recognition of the enzyme were investigated in relation to the manner in which polyphosphate is bound to the enzyme. Multiple polyphosphate binding sites were identified on distant portions of the enzyme and were determined to be responsible for the polymer length recognition of the enzyme. In addition, two independently folded domains were identified. The N-terminal domain contained a quasi-processive polyphosphatase active site belonging to the sugar kinase/actin/hsp70 superfamily. The C-terminal domain contained a single polyphosphate binding site and was responsible for nearly all of the PPX affinity for polyphosphate. This domain was also found to confer a highly processive mode of action to PPX. Collectively; these results cc-ere used to describe the interaction of polyphosphate with PPX.	Univ Calif Berkeley, Dept Chem Engn, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Bolesch, DG (corresponding author), Chiron Corp, 4560 Horton St,M-200, Emeryville, CA 94608 USA.		Keasling, Jay D/J-9162-2012	Keasling, Jay D/0000-0003-4170-6088	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008352] Funding Source: NIH RePORTER; NIGMS NIH HHS [2T32GM08352] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN KH, 1990, J BIOL CHEM, V265, P11734; AKIYAMA M, 1993, J BIOL CHEM, V268, P633; AKIYAMA M, 1992, J BIOL CHEM, V267, P22556; BOLESCH DG, 1997, THESIS U CALIFORNIA; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; Brandrup J., 1989, POLYM HDB, V3rd ed.; Cashel M, 1987, ESCHERICHIA COLI SAL, P1410; CLARK JE, 1987, ANAL BIOCHEM, V161, P280, DOI 10.1016/0003-2697(87)90452-0; CROOKE E, 1994, J BIOL CHEM, V269, P6290; KEASLING JD, 1993, P NATL ACAD SCI USA, V90, P7029, DOI 10.1073/pnas.90.15.7029; KORNBERG A, 1995, J BACTERIOL, V177, P491, DOI 10.1128/jb.177.3.491-496.1995; Kulaev IS, 1979, BIOCH INORGANIC POLY; PEPIN CA, 1987, J BIOL CHEM, V262, P5223; PEPIN CA, 1986, J BIOL CHEM, V261, P4476; Rao NN, 1996, J BACTERIOL, V178, P1394, DOI 10.1128/jb.178.5.1394-1400.1996; REIZER J, 1993, TRENDS BIOCHEM SCI, V18, P247, DOI 10.1016/0968-0004(93)90172-J; REUSCH RN, 1988, P NATL ACAD SCI USA, V85, P4176, DOI 10.1073/pnas.85.12.4176; ROBINSON NA, 1984, BIOCHEM INT, V8, P757; SPRIA B, 1995, J BACTERIOL, V177, P4053; STRAUSS UP, 1953, J AM CHEM SOC, V75, P3935, DOI 10.1021/ja01112a017; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60	21	28	29	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33814	33819		10.1074/jbc.M002039200	http://dx.doi.org/10.1074/jbc.M002039200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10922361	hybrid			2022-12-27	WOS:000090104600088
J	Hardeland, U; Bentele, M; Jiricny, J; Schar, P				Hardeland, U; Bentele, M; Jiricny, J; Schar, P			Separating substrate recognition from base hydrolysis in human thymine DNA glycosylase by mutational analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-CELLS; CRYSTAL-STRUCTURE; NUCLEAR EXTRACTS; G/T MISMATCH; G.T MISPAIRS; HELA-CELLS; URACIL; 3,N-4-ETHENOCYTOSINE; KINETICS	Human thymine DNA glycosylase (TDG) was discovered as an enzyme that can initiate base excision repair at sites of 5-methylcytosine- or cytosine deamination in DNA by its ability to release thymine or uracil from G.T and G.U mismatches. Crystal structure analysis of an Escherichia coli homologue identified conserved amino acid residues that are critical for its substrate recognition/interaction and base hydrolysis functions. Guided by this revelation, we performed a mutational study of structure function relationships with the human TDG. Substitution of the postulated catalytic site asparagine with alanine (N140A) resulted in an enzyme that bound mismatched substrates but was unable to catalyze base removal. Mutation of Met-269 in a motif with a postulated role in protein-substrate interaction selectively inactivated stable binding of the enzyme to mismatched substrates but not so its glycosylase activity. These results establish that the structure function model postulated for the E. coli enzyme is largely applicable to the human TDG. We further provide evidence for G.U being the preferred substrate of TDG, not only at the mismatch recognition step of the reaction but also in base hydrolysis, and for the importance of stable complementary strand interactions by TDG to compensate for its comparably poor hydrolytic potential.	Univ Zurich, Inst Med Radiobiol, CH-8008 Zurich, Switzerland; Paul Scherrer Inst, CH-8008 Zurich, Switzerland	University of Zurich; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Schar, P (corresponding author), Univ Zurich, Inst Med Radiobiol, August Forel Str 7, CH-8008 Zurich, Switzerland.		Schär, Primo/G-5967-2012	Schär, Primo/0000-0003-1843-6147				Barrett TE, 1999, EMBO J, V18, P6599, DOI 10.1093/emboj/18.23.6599; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; EHRLICH M, 1990, MUTAT RES, V238, P277, DOI 10.1016/0165-1110(90)90019-8; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; Hang B, 1998, P NATL ACAD SCI USA, V95, P13561, DOI 10.1073/pnas.95.23.13561; INGRAHAM HA, 1986, BIOCHEMISTRY-US, V25, P3225, DOI 10.1021/bi00359a022; Kinsella AR, 1997, BRIT J CANCER, V75, P935, DOI 10.1038/bjc.1997.164; MAJOR PP, 1982, CANCER RES, V42, P3005; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; NEDDERMANN P, 1994, P NATL ACAD SCI USA, V91, P1642, DOI 10.1073/pnas.91.5.1642; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Saparbaev M, 1998, P NATL ACAD SCI USA, V95, P8508, DOI 10.1073/pnas.95.15.8508; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Um S, 1998, J BIOL CHEM, V273, P20728, DOI 10.1074/jbc.273.33.20728; Waters TR, 1998, J BIOL CHEM, V273, P20007, DOI 10.1074/jbc.273.32.20007; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0; Zhu B, 2000, P NATL ACAD SCI USA, V97, P5135, DOI 10.1073/pnas.100107597	20	109	109	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33449	33456		10.1074/jbc.M005095200	http://dx.doi.org/10.1074/jbc.M005095200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10938281	hybrid, Green Accepted			2022-12-27	WOS:000090104600039
J	Shao, JY; Sheng, HM; Inoue, H; Morrow, JD; DuBois, RN				Shao, JY; Sheng, HM; Inoue, H; Morrow, JD; DuBois, RN			Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEROXIDE SYNTHASE-2 GENE; INTESTINAL EPITHELIAL-CELLS; PROTEIN-KINASE PATHWAY; GROWTH-FACTOR-ALPHA; N-TERMINAL KINASE; COLORECTAL-CANCER; ASPIRIN USE; POSTTRANSCRIPTIONAL REGULATION; TRANSCRIPTIONAL REGULATION; INHIBITOR SUPPRESSES	Cyclooxygenase-2 (COX-2) is not normally expressed in the human large intestine, but its levels are increased in the majority of human colorectal carcinomas, Here we investigate the regulation of constitutive COX-2 expression and prostaglandin production in human colorectal carcinoma cells. Both COX-2 mRNA and protein were expressed in well differentiated HCA-7, Moser, LS-174, and HT-29 cells, albeit at different levels. COX-2 expression was not detected in several poorly differentiated colon cancer cell lines including DLD-1, Transcriptional regulation played a key role for the expression of COX-2 in human colon carcinoma cells, and both the nuclear factor for interleukin-6 regulatory element and the cAMP-response element were responsible for regulation of COX-2 transcription. COX-2 mRNA was more stable in HCA-7 cells than in the other cell lines tested. Both transcriptional and post-transcriptional regulation of COX-2 involved the MAP kinase pathway. Modulation of the Akt/protein kinase B or Rho B signaling pathways altered the levels of COX-2 expression. Furthermore, COX-2 protein is degraded through ubiquitin proteolysis, and its half-life was similar to3.5-8 h, HCA-7 cells produced significant quantities of prostaglandin E-2 and other prostaglandins. Moser and LS-174 cells also generated prostaglandins, but levels were significantly lower than that observed in HCA-7 cells.	Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Vet Affairs Med Ctr,Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Vet Affairs Med Ctr,Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Vet Affairs Med Ctr,Dept Cell Biol, Nashville, TN 37232 USA; Natl Cardiovasc Ctr, Res Inst, Dept Pharmacol, Suita, Osaka 5658565, Japan	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; National Cerebral & Cardiovascular Center - Japan	DuBois, RN (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med GI, MCN C-2104,1161 21st Ave S, Nashville, TN 37232 USA.		DuBois, Raymond N./AAX-8869-2020		NCI NIH HHS [CA-77839] Funding Source: Medline; NIDDK NIH HHS [DK-48831, DK-47297] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047297, R37DK047297, R01DK048831] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Chapple KS, 2000, AM J PATHOL, V156, P545, DOI 10.1016/S0002-9440(10)64759-1; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAVIS RJ, 1995, HUM MOL GENET, V4, P2355, DOI 10.1093/hmg/4.12.2355; delPeso L, 1997, SCIENCE, V278, P687; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; GIOVANNUCCI E, 1994, ANN INTERN MED, V121, P241, DOI 10.7326/0003-4819-121-4-199408150-00001; Goldman AP, 1998, CARCINOGENESIS, V19, P2195, DOI 10.1093/carcin/19.12.2195; GREENBERG ER, 1993, JNCI-J NATL CANCER I, V85, P912, DOI 10.1093/jnci/85.11.912; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; Haas AL, 1997, FASEB J, V11, P1053, DOI 10.1096/fasebj.11.13.9367340; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kawamori T, 1998, CANCER RES, V58, P409; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Masferrer JL, 2000, CANCER RES, V60, P1306; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; Mestre JR, 1997, CANCER RES, V57, P2890; Nakatsugi S, 1997, JPN J CANCER RES, V88, P1117, DOI 10.1111/j.1349-7006.1997.tb00337.x; Nishimura G, 1999, JPN J CANCER RES, V90, P1152, DOI 10.1111/j.1349-7006.1999.tb00690.x; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PELEG II, 1994, ARCH INTERN MED, V154, P394, DOI 10.1001/archinte.154.4.394; Reddy ST, 2000, J BIOL CHEM, V275, P3107, DOI 10.1074/jbc.275.5.3107; Rioux N, 1998, CANCER RES, V58, P5354; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; Rolfe M, 1997, J MOL MED-JMM, V75, P5, DOI 10.1007/s001090050081; SANO H, 1995, CANCER RES, V55, P3785; Shao JY, 1999, CARCINOGENESIS, V20, P185, DOI 10.1093/carcin/20.2.185; Sheng GG, 1997, GASTROENTEROLOGY, V113, P1883, DOI 10.1016/S0016-5085(97)70007-6; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 2000, J BIOL CHEM, V275, P6628, DOI 10.1074/jbc.275.9.6628; Sheng HM, 1998, J BIOL CHEM, V273, P22120, DOI 10.1074/jbc.273.34.22120; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Shiff SJ, 1999, J EXP MED, V190, P445, DOI 10.1084/jem.190.4.445; Subbaramaiah K, 1998, J BIOL CHEM, V273, P32943, DOI 10.1074/jbc.273.49.32943; Subbaramaiah K, 1996, CANCER RES, V56, P4424; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; THUN MJ, 1993, CANCER RES, V53, P1322; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Watanabe K, 1999, CANCER RES, V59, P5093; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zhang F, 1998, J BIOL CHEM, V273, P2424, DOI 10.1074/jbc.273.4.2424; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	57	238	246	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33951	33956		10.1074/jbc.M002324200	http://dx.doi.org/10.1074/jbc.M002324200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10930401	hybrid			2022-12-27	WOS:000090104600106
J	Chung, SW; Kang, BY; Kim, SH; Pak, YK; Cho, D; Trinchieri, G; Kim, TS				Chung, SW; Kang, BY; Kim, SH; Pak, YK; Cho, D; Trinchieri, G; Kim, TS			Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; MONOCYTE-DERIVED MACROPHAGES; BLOOD MONONUCLEAR-CELLS; IL-12 PRODUCTION; GENE-EXPRESSION; PPAR-GAMMA; TRANSCRIPTION FACTOR; ESTROGEN-RECEPTOR; INTERFERON-GAMMA; DENDRITIC CELLS	Lipopolysaccharide (LPS) increases the production of interleukin-12 (IL-12) from mouse macrophages via a kappaB site within the IL-12 p40 promoter. In this study, we found that oxidized low density lipoprotein (oxLDL) inhibited this LPS-stimulated production of IL-12 in a dose-dependent manner while native LDL did not. OxLDL inhibited p40 promoter activation in monocytic RAW264.7 cells transiently transfected with p40 promoter/reporter constructs, and the repressive effect mapped to a region in the p40 promoter containing a binding site for nuclear factor-kappaB (NF-kappaB) (p40-kappaB), Activation of macrophages by LPS in the presence of oxLDL resulted in markedly reduced binding to the kappaB site, as demonstrated by the electrophoretic mobility shift assays. In contrast, native LDL did not inhibit the IL-12 p40 promoter activation and NF-kappaB binding to the kappaB sites, suggesting that oxidative modification of LDL was crucial for the inhibition of NF-kappaB-mediated IL-12 production. 9-Hydroxyoctadecadienoic acid, a major oxidized lipid component of oxLDL, significantly inhibited IL-12 production in LPS-stimulated mouse macrophages and also suppressed NF-kappaB-mediated activation in IL-12 p40 promoter. The NF-kappaB components p50 and p65 directly bound peroxisome proliferator-activated receptor-gamma (PPAP-gamma) in vitro, In cotransfections of CV-1 and HeLa cells, PPAR-gamma inhibited the NF-kappaB transactivation in an oxLDL-dependent manner. From these results, we propose that oxLDL-mediated suppression of the IL-12 production from LPS-activated mouse macrophages may, at least in part, involve both inhibition of the NF-kappaB-DNA interactions and physical interactions between NF-kappaB and PPAR-gamma.	Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea; Natl Inst Hlth, Div Metab Dis, Seoul 122701, South Korea; Seoul Natl Univ, Coll Med, Canc Res Ctr, Seoul 110799, South Korea; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	Chonnam National University; Korea Centers for Disease Control & Prevention (KCDC); Korea National Institute of Health (KNIH); Korea CDC Center for Biomedical Science; Seoul National University (SNU); The Wistar Institute	Kim, TS (corresponding author), Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea.	taekim@chonnam.chonnam.ac.kr	Pak, Youngmi Kim/AAI-1091-2020; Trinchieri, Giorgio/F-9369-2015	Pak, Youngmi Kim/0000-0001-7424-3484; Trinchieri, Giorgio/0000-0001-5892-7464				Benjamin D, 1996, J IMMUNOL, V156, P1626; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; Caspi NR, 1998, CLIN IMMUNOL IMMUNOP, V88, P4, DOI 10.1006/clin.1998.4540; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Constantinescu CS, 1998, IMMUNOL LETT, V62, P25, DOI 10.1016/S0165-2478(98)00025-X; D'Ambrosio D, 1998, J CLIN INVEST, V101, P252, DOI 10.1172/JCI1050; DeKruyff R, 1998, J IMMUNOL, V160, P2231; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FONG LG, 1991, J LIPID RES, V32, P1899; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; Gri G, 1998, J BIOL CHEM, V273, P6431, DOI 10.1074/jbc.273.11.6431; HAMILTON TA, 1990, J IMMUNOL, V144, P2343; HAMILTON TA, 1995, J CLIN INVEST, V95, P2020, DOI 10.1172/JCI117887; Han JH, 1997, J BIOL CHEM, V272, P21654, DOI 10.1074/jbc.272.34.21654; HOFF HF, 1992, J BIOL CHEM, V267, P602; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; JOUGASAKI M, 1992, CIRC RES, V71, P614, DOI 10.1161/01.RES.71.3.614; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; Kang KF, 1996, J IMMUNOL, V156, P1402; Kim CH, 1995, J INFLAMM, V45, P312; Kim TS, 1997, J IMMUNOL, V158, P4137; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; Koch F, 1996, J EXP MED, V184, P741, DOI 10.1084/jem.184.2.741; KU G, 1992, J BIOL CHEM, V267, P14183; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEHR HA, 1993, LAB INVEST, V68, P388; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; LIPTON BA, 1995, J LIPID RES, V36, P2232; Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147; MALDEN LT, 1991, J BIOL CHEM, V266, P13901; McDyer JF, 1998, J ALLERGY CLIN IMMUN, V102, P11; Moller DR, 1997, IMMUNOLOGY, V91, P197, DOI 10.1046/j.1365-2567.1997.00246.x; Moller DR, 1997, J IMMUNOL, V159, P5157; Moore DD, 1995, GLOB MOB SURV; MURPHY TL, 1995, MOL CELL BIOL, V15, P5258; Na SY, 1999, J BIOL CHEM, V274, P7674, DOI 10.1074/jbc.274.12.7674; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Ohlsson BG, 1996, J CLIN INVEST, V98, P78, DOI 10.1172/JCI118780; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; PaninaBordignon P, 1997, J CLIN INVEST, V100, P1513, DOI 10.1172/JCI119674; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; RALDWIN AS, 1996, ANNU REV IMMUNOL, V14, P649; RAY A, 1994, J BIOL CHEM, V269, P12940; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHUH J, 1978, P NATL ACAD SCI USA, V75, P3173, DOI 10.1073/pnas.75.7.3173; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; STERN AS, 1990, P NATL ACAD SCI USA, V87, P6808, DOI 10.1073/pnas.87.17.6808; THOMAS CE, 1994, J LIPID RES, V35, P417; Tone Y, 1996, EUR J IMMUNOL, V26, P1222, DOI 10.1002/eji.1830260606; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Trinchieri G, 1998, Int Rev Immunol, V16, P365, DOI 10.3109/08830189809043002; Uyemura K, 1996, J CLIN INVEST, V97, P2130, DOI 10.1172/JCI118650; WYSOCKA M, 1995, EUR J IMMUNOL, V25, P672, DOI 10.1002/eji.1830250307; Yoshimoto T, 1996, J IMMUNOL, V156, P1082	64	305	317	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32681	32687		10.1074/jbc.M002577200	http://dx.doi.org/10.1074/jbc.M002577200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10934192	hybrid			2022-12-27	WOS:000090003800043
J	Uliel, L; Weisman-Shomer, P; Oren-Jazans, H; Newcomb, T; Loeb, LA; Fry, M				Uliel, L; Weisman-Shomer, P; Oren-Jazans, H; Newcomb, T; Loeb, LA; Fry, M			Human Ku antigen tightly binds and stabilizes a tetrahelical form of the fragile X syndrome d(CGG)(n) expanded sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; HUMAN FMR1 GENE; QUADRUPLEX TELOMERIC DNA; SYNTHESIS IN-VITRO; TRIPLET REPEATS; AUTOANTIGEN-KU; HELA-CELLS; TRINUCLEOTIDE REPEATS; DELAYED REPLICATION; HAIRPIN STRUCTURES	Hairpin and tetrahelical structures of a d(CGG)(n) sequence in the FMR1 gene have been implicated in its expansion in fragile X syndrome. The identification of tetraplex d(CGG)(n) destabilizing proteins (Fry, M., and Loeb, L. A.(1999) J. Biol. Chem. 274, 12797-12803; Weisman-Shomer, P., Naot, Y., and Fry, M. (2000) J. Biol. Chem. 275, 2231-2238) suggested that proteins might modulate d(CGG), folding and aggregation. We assayed human TK-6 lymphoblastoid cell extracts for d(CGG)(n) oligomer binding proteins. The principal binding protein was identified as Ku antigen by its partial amino acid sequence and antigenicity. The purified 88/75-kDa heterodimeric Ku bound with similar affinities (K-d similar to1.8-10.2 x 10(-9) mol/liter) to double-stranded d(CGG)(8).d(CCG)(8), hairpin d(CGG)(8), single-stranded d(CII)(8), or tetraplex structures of telomeric or IgG switch region sequences. However,Ku associated more tightly with bimolecular G'2 tetraplex d(CGG)(8) (K-d similar to0.35 x 10(-9) mol/liter). Binding to Ku protected G'2 d(CGG)(8) against nuclease digestion and impeded its unwinding by the tetraplex destabilizing protein qTBP42, Stabilization of d(CGG)(n) tetraplex domains in FMR1 by Ku or other proteins might promote d(CGG) expansion and FMR1 silencing.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Biochem Unit, IL-31096 Haifa, Israel; Univ Washington, Dept Pathol, Gottstein Med Canc Res Lab, Seattle, WA 98195 USA	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; University of Washington; University of Washington Seattle	Fry, M (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Biochem Unit, POB 9649, IL-31096 Haifa, Israel.				NCI NIH HHS [P01-CA-47852] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bailey DB, 1995, MENTAL RETARDATION D, V1, P238; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; Bianchi A, 1999, J BIOL CHEM, V274, P21223, DOI 10.1074/jbc.274.30.21223; BLIER PR, 1993, J BIOL CHEM, V268, P7594; CAO QP, 1994, BIOCHEMISTRY-US, V33, P8548, DOI 10.1021/bi00194a021; CHEN FM, 1995, J BIOL CHEM, V270, P23090, DOI 10.1074/jbc.270.39.23090; CHEN XA, 1995, P NATL ACAD SCI USA, V92, P5199, DOI 10.1073/pnas.92.11.5199; Chung U, 1996, J BIOL CHEM, V271, P8593, DOI 10.1074/jbc.271.15.8593; Cooper MP, 2000, GENE DEV, V14, P907; Deissler H, 1997, J BIOL CHEM, V272, P16761, DOI 10.1074/jbc.272.27.16761; Deissler H, 1996, J BIOL CHEM, V271, P4327; DIETRICH A, 1991, NUCLEIC ACIDS RES, V19, P2567, DOI 10.1093/nar/19.10.2567; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; Erlitzki R, 1997, J BIOL CHEM, V272, P15881, DOI 10.1074/jbc.272.25.15881; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GACY AM, 1995, CELL, V81, P533; GENERSCH E, 1995, EMBO J, V14, P791, DOI 10.1002/j.1460-2075.1995.tb07057.x; GRIFFITH AJ, 1992, MOL BIOL REP, V16, P91, DOI 10.1007/BF00419754; HANSEN RS, 1992, HUM MOL GENET, V1, P571, DOI 10.1093/hmg/1.8.571; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; Hansen RS, 1997, P NATL ACAD SCI USA, V94, P4587, DOI 10.1073/pnas.94.9.4587; HEITZ D, 1991, SCIENCE, V251, P1236, DOI 10.1126/science.2006411; Ji JP, 1996, NUCLEIC ACIDS RES, V24, P2835, DOI 10.1093/nar/24.14.2835; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; KETTANI A, 1995, J MOL BIOL, V254, P638, DOI 10.1006/jmbi.1995.0644; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; Lieber MR, 1997, CURR OPIN GENET DEV, V7, P99, DOI 10.1016/S0959-437X(97)80116-5; Malter HE, 1997, NAT GENET, V15, P165, DOI 10.1038/ng0297-165; Mariappan SVS, 1996, NUCLEIC ACIDS RES, V24, P784, DOI 10.1093/nar/24.4.784; MAY G, 1991, J BIOL CHEM, V266, P3052; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MITAS M, 1995, BIOCHEMISTRY-US, V34, P12803, DOI 10.1021/bi00039a041; Muller-Hartmann H, 2000, J BIOL CHEM, V275, P6447, DOI 10.1074/jbc.275.9.6447; NADEL Y, 1995, J BIOL CHEM, V270, P28970, DOI 10.1074/jbc.270.48.28970; NAKAHORI Y, 1991, NUCLEIC ACIDS RES, V19, P4355, DOI 10.1093/nar/19.16.4355; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Sarig G, 1997, J BIOL CHEM, V272, P4474, DOI 10.1074/jbc.272.7.4474; STUIVER MH, 1990, J EXP MED, V172, P1049, DOI 10.1084/jem.172.4.1049; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; SUTHERLAND GR, 1977, SCIENCE, V197, P265, DOI 10.1126/science.877551; Torrance H, 1998, J BIOL CHEM, V273, P20810, DOI 10.1074/jbc.273.33.20810; TOTH EC, 1993, NUCLEIC ACIDS RES, V21, P3257, DOI 10.1093/nar/21.14.3257; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VISHWANATHA JK, 1990, BIOCHEMISTRY-US, V29, P8753, DOI 10.1021/bi00489a036; Weisman-Shomer P, 2000, J BIOL CHEM, V275, P2231, DOI 10.1074/jbc.275.3.2231; WEISMANSHOMER P, 1993, J BIOL CHEM, V268, P3306; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; YANOYANAGISAWA H, 1995, NUCLEIC ACIDS RES, V23, P2654, DOI 10.1093/nar/23.14.2654; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2; ZHANG WW, 1993, BIOCHEM J, V293, P769, DOI 10.1042/bj2930769; Zhao YF, 1996, J BIOMOL STRUCT DYN, V14, P235, DOI 10.1080/07391102.1996.10508113	59	21	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33134	33141		10.1074/jbc.M005542200	http://dx.doi.org/10.1074/jbc.M005542200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10924524	hybrid			2022-12-27	WOS:000090003800102
J	Mast, AE; Stadanlick, JE; Lockett, JM; Dietzen, DJ; Hasty, KA; Hall, CL				Mast, AE; Stadanlick, JE; Lockett, JM; Dietzen, DJ; Hasty, KA; Hall, CL			Tissue factor pathway inhibitor binds to platelet thrombospondin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; ANTITHROMBIN-III; FACTOR-XA; COAGULATION INHIBITOR; FACTOR-VIIA; IN-VITRO; SECRETE THROMBOSPONDIN; CARBOXY-TERMINUS; HEPARIN; RECEPTOR	Tissue factor pathway inhibitor (TFPI) is a Kunitz-type serine proteinase inhibitor that down-regulates tissue factor-initiated blood coagulation. The most biologically active pool of TFPI is associated with the vascular endothelium, however, the biochemical mechanisms responsible for its cellular binding are not entirely defined. Proposed cellular binding sites for TFPI include nonspecific association with cell surface glycosaminoglycans and binding to glycosyl phosphatidylinositol-anchored proteins. Here, we report that TFPI binds specifically and saturably to thrombospondin-l (TSP-1) purified from platelet alpha-granules with an apparent K-D of similar to 7.5 nM. Binding is inhibited by polyclonal antibodies against TFPI and partially inhibited by the B-7 monoclonal anti-TSP-l antibody. TFPI bound to immobilized TSP-1 remains an active proteinase inhibitor. Additionally, in solution phase assays measuring TFPI inhibition of factor VIIa/tissue factor catalytic activity, the rate of factor Xa generation was decreased 55% in the presence of TSP-1 compared with TFPI alone. Binding experiments done in the presence of heparin and with altered forms of TFPI suggest that the basic C-terminal region of TFPI is required for TSP-1 binding. The data provide a mechanism for the recruitment and localization of TFPI to extravascular surfaces within a bleeding wound, where it can efficiently down-regulate the procoagulant activity of tissue factor and allow subsequent aspects of platelet-mediated healing to proceed.	Univ Tennessee, Res Serv, Dept Vet Affairs, Memphis, TN 38104 USA; Univ Tennessee, Pathol Serv, Dept Vet Affairs, Memphis, TN 38104 USA; Univ Tennessee, Dept Pathol, Memphis, TN 38104 USA; Univ Tennessee, Dept Anat, Memphis, TN 38104 USA; Univ Memphis, Dept Biomed Engn, Memphis, TN 38152 USA	University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Memphis	Mast, AE (corresponding author), VA Hosp, Res Serv 151, 1030 Jefferson Ave, Memphis, TN 38104 USA.	alan@pathology.utmem.edu						AMERI A, 1992, BLOOD, V79, P3219; BAENZIGER NL, 1972, J BIOL CHEM, V247, P2723; Baugh RJ, 1998, J BIOL CHEM, V273, P4378, DOI 10.1074/jbc.273.8.4378; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; BROZE GJ, 1994, BLOOD COAGUL FIBRIN, V5, P551; BROZE GJ, 1993, BLOOD, V82, P1679; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; CREASEY AA, 1993, J CLIN INVEST, V91, P2850, DOI 10.1172/JCI116529; de Jonge E, 2000, BLOOD, V95, P1124, DOI 10.1182/blood.V95.4.1124.002k20_1124_1129; DiPietro LA, 1996, AM J PATHOL, V148, P1851; DIXIT VM, 1984, J BIOL CHEM, V259, P100; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; Hansen JB, 1996, THROMB HAEMOSTASIS, V76, P703; Hansen JB, 1997, THROMB RES, V85, P413, DOI 10.1016/S0049-3848(97)00029-7; Huang ZF, 1997, BLOOD, V90, P944, DOI 10.1182/blood.V90.3.944.944_944_951; JAFFE EA, 1985, BLOOD, V65, P79; JAFFE EA, 1983, P NATL ACAD SCI-BIOL, V80, P998, DOI 10.1073/pnas.80.4.998; Jesty J, 1996, BLOOD, V87, P2301, DOI 10.1182/blood.V87.6.2301.bloodjournal8762301; KONDO S, 1987, THROMB RES, V46, P325, DOI 10.1016/0049-3848(87)90294-5; LAHAV J, 1984, EUR J BIOCHEM, V145, P151, DOI 10.1111/j.1432-1033.1984.tb08534.x; LAWLER J, 1989, BLOOD, V74, P2022; LAWLER J, 1982, J BIOL CHEM, V257, P2257; LAWLER J, 1983, J BIOL CHEM, V258, P2098; Lawler J, 1998, J CLIN INVEST, V101, P982, DOI 10.1172/JCI1684; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER JW, 1981, THROMB RES, V22, P267, DOI 10.1016/0049-3848(81)90119-5; LAWSON JH, 1993, J BIOL CHEM, V268, P767; LINDHOUT T, 1994, BIOCHEM J, V297, P131, DOI 10.1042/bj2970131; Lupu C, 1997, ARTERIOSCL THROM VAS, V17, P2964, DOI 10.1161/01.ATV.17.11.2964; Mast AE, 1997, BIOCHEM J, V327, P577; MOSHER DF, 1982, J CELL BIOL, V93, P343, DOI 10.1083/jcb.93.2.343; NOVOTNY WF, 1988, BLOOD, V72, P2020; NOVOTNY WF, 1991, BLOOD, V78, P387; Ott I, 2000, ARTERIOSCL THROM VAS, V20, P874, DOI 10.1161/01.ATV.20.3.874; Pendurthi UR, 1999, BLOOD, V94, P579, DOI 10.1182/blood.V94.2.579.414k23_579_586; POLVERINI PJ, 1995, FASEB J, V9, pA272; RAUGI GJ, 1987, J INVEST DERMATOL, V89, P551, DOI 10.1111/1523-1747.ep12461198; SANDSET PM, 1988, THROMB RES, V50, P803, DOI 10.1016/0049-3848(88)90340-4; SANTORO SA, 1987, METHOD ENZYMOL, V144, P438; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; Sevinsky JR, 1996, J CELL BIOL, V133, P293, DOI 10.1083/jcb.133.2.293; SILVERSTEIN RL, 1984, J CLIN INVEST, V74, P1625, DOI 10.1172/JCI111578; SUGIHARA K, 1992, BLOOD, V80, P2634; VALENTIN S, 1993, BLOOD COAGUL FIBRIN, V4, P713, DOI 10.1097/00001721-199304050-00007; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; WARSHAWSKY I, 1995, J CLIN INVEST, V95, P1773, DOI 10.1172/JCI117855; WESSELSCHMIDT R, 1992, BLOOD, V79, P2004; WESSELSCHMIDT R, 1993, BLOOD COAGUL FIBRIN, V4, P661, DOI 10.1097/00001721-199304050-00001; Wojtukiewicz MZ, 1999, THROMB HAEMOSTASIS, V82, P1659	50	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31715	31721		10.1074/jbc.M006595200	http://dx.doi.org/10.1074/jbc.M006595200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10922378	hybrid			2022-12-27	WOS:000089858900026
J	Yamazaki, N; Shinohara, Y; Kajimoto, K; Shindo, M; Terada, H				Yamazaki, N; Shinohara, Y; Kajimoto, K; Shindo, M; Terada, H			Novel expression of equivocal messages containing both regions of choline/ethanolamine kinase and muscle type carnitine palmitoyltransferase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; MESSENGER-RNAS; DNA-SEQUENCE; GENE; IDENTIFICATION; COMPLEMENTARY; ACETYLCHOLINE; TRANSPORTER; TISSUE; CPT1B	For characterization of the detailed gene structure of human muscle type carnitine palmitoyltransferase I (M-CPTI), we analyzed the 5'-upstream region of the M-CPTI transcripts. As a result, we found a cDNA clone containing a nucleotide sequence unexpected from the reported M-CPTI gene structure in the upstream region of its 5' end. Comparison of this nucleotide sequence with that of genomic DNA showed that this sequence was derived from the 3'-untranslated region of the gene encoding choline/ethanolamine kinase-beta (CK/EK-beta) located upstream of the M-CPTI gene. Southern blot analysis showed that there was no other region homologous to the CK/EK-beta gene in the whole human genome. Thus, the overlapping transcript was concluded to be produced from the functional genes of CK/EK-beta and M-CPTI. Furthermore, cDNAs containing both exons of these genes were detected by the polymerase chain reaction using the cDNA of human heart M-CPTI obtained by specific reverse transcription from its S'-untranslated region as a template. From these results, the production and organization of these overlapping transcripts are discussed.	Univ Tokushima, Fac Pharmaceut Sci, Tokushima 7708505, Japan	Tokushima University	Terada, H (corresponding author), Univ Tokushima, Fac Pharmaceut Sci, Shomachi 1, Tokushima 7708505, Japan.	hterada@ph.tokushima-u.ac.jp	Shindo, Mitsuru/ABN-5203-2022; Kajimoto, Kazuaki/A-3799-2012; Kajimoto, Kazuaki/L-6418-2018; Yamazaki, N/K-7420-2019	Kajimoto, Kazuaki/0000-0002-1636-4154; Shindo, Mitsuru/0000-0002-0588-8075				Aoyama C, 1998, BBA-LIPID LIPID MET, V1393, P179, DOI 10.1016/S0005-2760(98)00062-9; Aoyama C, 1998, BBA-LIPID LIPID MET, V1390, P1, DOI 10.1016/S0005-2760(97)00177-X; Aoyama C, 2000, J LIPID RES, V41, P452; BEJANIN S, 1994, J BIOL CHEM, V269, P21944; Britton CH, 1997, GENOMICS, V40, P209, DOI 10.1006/geno.1996.4539; Chen Z, 1996, TRENDS GENET, V12, P87, DOI 10.1016/0168-9525(96)81412-0; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; ERICKSON JD, 1994, J BIOL CHEM, V269, P21929; HOSHIMARU M, 1987, J BIOL CHEM, V262, P14625; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; NORMARK S, 1983, ANNU REV GENET, V17, P499, DOI 10.1146/annurev.ge.17.120183.002435; Sambrook J., 1989, MOL CLONING, pA1; vanderLeij FR, 1997, BBA-GENE STRUCT EXPR, V1352, P123, DOI 10.1016/S0167-4781(97)00037-7; WANG B, 1988, J BIOL CHEM, V263, P15841; Wang DC, 1998, GENOMICS, V48, P314, DOI 10.1006/geno.1997.5184; WILLIAMS T, 1986, NATURE, V322, P275, DOI 10.1038/322275a0; Yamazaki N, 1997, FEBS LETT, V409, P401, DOI 10.1016/S0014-5793(97)00561-9; YAMAZAKI N, 1995, FEBS LETT, V363, P41, DOI 10.1016/0014-5793(95)00277-G; Yamazaki N, 1996, BBA-GENE STRUCT EXPR, V1307, P157, DOI 10.1016/0167-4781(96)00069-3; Yu GS, 1998, J BIOL CHEM, V273, P32901, DOI 10.1074/jbc.273.49.32901	22	17	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31739	31746		10.1074/jbc.M006322200	http://dx.doi.org/10.1074/jbc.M006322200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10918069	hybrid			2022-12-27	WOS:000089858900029
J	Evans, BN; Rosenblatt, MI; Mnayer, LO; Oliver, KR; Dickerson, IM				Evans, BN; Rosenblatt, MI; Mnayer, LO; Oliver, KR; Dickerson, IM			CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; CENTRAL-NERVOUS-SYSTEM; ANTISENSE RNA; RAT; BRAIN; IDENTIFICATION; ACTIVATION; DOMAIN	It is becoming clear that receptors that initiate signal transduction by interacting with G-proteins do not function as monomers, but often require accessory proteins for function. Some of these accessory proteins are chaperones, required for correct transport of the receptor to the cell surface, but the function of many accessory proteins remains unknown, We determined the role of an accessory protein for the receptor for calcitonin gene-related peptide (CGRP), a potent vasodilator neuropeptide. me have previously shown that this accessory protein, the CGRP-receptor component protein (RCP), is expressed in CGRP responsive tissues and that RCP protein expression correlates with the biological efficacy of CGRP in vivo, However, the function of RCP has remained elusive. In this study stable cell lines were made that express antisense RCP RNA, and CGRP- and adrenomedullin-mediated signal transduction were greatly reduced, However, the loss of RCP did not effect CGRP binding or receptor density, indicating that RCP did not behave as a chaperone but was instead coupling the CGRP receptor to downstream effecters. A candidate CGRP receptor named calcitonin receptor-like receptor (CRLR) has been identified, and in this study RCP co-immunoprecipitated with CRLR indicating that these two proteins interact directly. Since CGRP and adrenomedullin can both signal through CRLR, which has been previously shown to require a chaperone protein for function, we now propose that a functional CGRP or adrenomedullin receptor consists of at least three proteins: the receptor (CRLR), the chaperone protein (RAMP), and RCP that couples the receptor to the cellular signal transduction pathway.	Univ Miami, Sch Med, Dept Physiol & Biophys, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA; Univ Miami, Sch Med, Neurosci Program, Miami, FL 33101 USA; Merck Sharp & Dohme Res Labs, Ctr Res Neurosci, Harlow CM20 2QR, Essex, England	University of Miami; University of Miami; University of Miami; Merck & Company	Dickerson, IM (corresponding author), Univ Miami, Sch Med, Dept Physiol & Biophys, POB 016430, Miami, FL 33101 USA.			Dickerson, Ian/0000-0002-2480-0606	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052328] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52328, R01 DK052328] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aiyar N, 1996, J BIOL CHEM, V271, P11325, DOI 10.1074/jbc.271.19.11325; Battastini AMO, 1998, INT J BIOCHEM CELL B, V30, P669, DOI 10.1016/S1357-2725(98)00022-3; Buhlmann N, 1999, ENDOCRINOLOGY, V140, P2883, DOI 10.1210/en.140.6.2883; CHANG CP, 1993, NEURON, V11, P1187, DOI 10.1016/0896-6273(93)90230-O; CHATTERJEE TK, 1991, MOL PHARMACOL, V39, P798; EDVINSSON L, 1987, J CEREBR BLOOD F MET, V7, P720, DOI 10.1038/jcbfm.1987.126; EGUCHI Y, 1991, ANNU REV BIOCHEM, V60, P631, DOI 10.1146/annurev.bi.60.070191.003215; FLUHMANN B, 1995, BIOCHEM BIOPH RES CO, V206, P341, DOI 10.1006/bbrc.1995.1047; GREEN PJ, 1986, ANNU REV BIOCHEM, V55, P569, DOI 10.1146/annurev.bi.55.070186.003033; Han ZQ, 1997, J MOL ENDOCRINOL, V18, P267, DOI 10.1677/jme.0.0180267; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; JOHNSON RA, 1994, METHOD ENZYMOL, V238, P56; Kato A, 1998, J BIOL CHEM, V273, P23969, DOI 10.1074/jbc.273.37.23969; Knight YE, 1999, NEUROPEPTIDES, V33, P41, DOI 10.1054/npep.1999.0009; Luebke AE, 1996, P NATL ACAD SCI USA, V93, P3455, DOI 10.1073/pnas.93.8.3455; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Menard DP, 1996, J NEUROSCI, V16, P2342; Naghashpour M, 2000, AM J PHYSIOL-CELL PH, V278, pC561, DOI 10.1152/ajpcell.2000.278.3.C561; Naghashpour M, 1997, ENDOCRINOLOGY, V138, P4207, DOI 10.1210/en.138.10.4207; NELSON MT, 1990, NATURE, V344, P770, DOI 10.1038/344770a0; Oliver KR, 1999, MOL BRAIN RES, V66, P205, DOI 10.1016/S0169-328X(99)00036-4; Oliver KR, 1998, MOL BRAIN RES, V57, P149, DOI 10.1016/S0169-328X(98)00052-7; POYNER DR, 1992, BRIT J PHARMACOL, V105, P441, DOI 10.1111/j.1476-5381.1992.tb14272.x; Roche KW, 1999, J BIOL CHEM, V274, P25953, DOI 10.1074/jbc.274.36.25953; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Rosenblatt MI, 1997, PEPTIDES, V18, P567, DOI 10.1016/S0196-9781(97)00055-7; Rosenblatt MI, 2000, INVEST OPHTH VIS SCI, V41, P1159; Sarkar A, 1997, J NEUROCHEM, V69, P455; VANVALEN F, 1990, NEUROSCI LETT, V119, P195, DOI 10.1016/0304-3940(90)90832-T; YUN HY, 1993, ARCH BIOCHEM BIOPHYS, V301, P77, DOI 10.1006/abbi.1993.1117	30	258	283	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31438	31443		10.1074/jbc.M005604200	http://dx.doi.org/10.1074/jbc.M005604200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10903324	hybrid			2022-12-27	WOS:000089762700097
J	Hall, RK; Yamasaki, T; Kucera, T; Waltner-Law, M; O'Brien, R; Granner, DK				Hall, RK; Yamasaki, T; Kucera, T; Waltner-Law, M; O'Brien, R; Granner, DK			Regulation of phosphoenolpyruvate carboxykinase and insulin-like growth factor-binding protein-1 gene expression by insulin - The role of winged helix/forkhead proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; AGE-1 PI3 KINASE; CAENORHABDITIS-ELEGANS; RESPONSE SEQUENCE; AMINOTRANSFERASE GENE; SIGNALING PATHWAY; NUCLEAR FACTOR-3; FAMILY MEMBER; FACTOR FKHR; PROMOTER	Winged helix/forkhead (Fox) transcription factors have been implicated in the regulation of a number of insulin-responsive genes. The insulin response elements (IREs) of the phosphoenolpyruvate carboxykinase (PEPCK) and insulin-like growth factor-binding protein-1 (IGFBP-1) genes bind members of the FKHR and HNF3 subclasses of Fox proteins. Previous mutational analyses of the PEPCK and IGFBP-1 IREs revealed mutations which do not affect the binding of HNF3 proteins to these elements but do eliminate the ability of the IREs to mediate an insulin response. This dissociation of binding and function provided compelling evidence that HNF3 proteins, per se, are not insulin response proteins. The same approach was used here to determine if FKHRL1, a member of the FKHR subclass of Fox proteins, binds to the PEPCK and IGFBP-1 IREs in a manner that correlates with the ability of these elements to mediate an insulin response. Overexpression of FKHRL1 stimulates transcription from transfected reporter constructs that contain a multimerized PEPCK IRE or an IGFBP-1 IRE and this stimulation is repressed by insulin. There is a direct correlation between the ability of mutant versions of the PEPCK and IGFBP-1 IREs to bind FKHRL1 and their ability to mediate FRHRL1-induced transcription when FKHRL1 is overexpressed. However, under conditions where FKHRL1 is not overexpressed, there is a lack of correlation between FKHRL1 binding to mutant versions of the PEPCK and IGFBP-1 IREs and the ability of these elements to mediate an insulin response. Therefore, the PEPCK and IGFBP-1 IREs mediate FKHRL1-induced transcription and its inhibition by insulin when this protein is overexpressed, but at the normal cellular concentration of FKHRL1 the insulin response mediated by these elements must involve another protein.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA	Vanderbilt University	Granner, DK (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, 707 Light Hall, Nashville, TN 37232 USA.							Beurton F, 1999, BIOCHEM J, V343, P687, DOI 10.1042/0264-6021:3430687; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CHEN M, 1994, J LIPID RES, V35, P1918; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; GANSS R, 1994, MOL ENDOCRINOL, V8, P895, DOI 10.1210/me.8.7.895; GOSWAMI R, 1994, ENDOCRINOLOGY, V134, P736, DOI 10.1210/en.134.2.736; GOTTLIEB S, 1994, GENETICS, V137, P107; GRANNER D, 1991, RECENT PROG HORM RES, V47, P319; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; HALL RK, 1992, MOL CELL BIOL, V12, P5527, DOI 10.1128/MCB.12.12.5527; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; Paradis S, 1999, GENE DEV, V13, P1438, DOI 10.1101/gad.13.11.1438; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Powell David R., 1995, Progress in Growth Factor Research, V6, P93, DOI 10.1016/0955-2235(95)00034-8; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; Sugiyama T, 1998, MOL ENDOCRINOL, V12, P1487, DOI 10.1210/me.12.10.1487; SUWANICKUL A, 1993, J BIOL CHEM, V268, P17063; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tissenbaum HA, 1998, GENETICS, V148, P703; Tomizawa M, 2000, J BIOL CHEM, V275, P7289, DOI 10.1074/jbc.275.10.7289; UNTERMAN TG, 1994, BIOCHEM BIOPH RES CO, V203, P1835, DOI 10.1006/bbrc.1994.2401; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794	38	232	240	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30169	30175		10.1074/jbc.M004898200	http://dx.doi.org/10.1074/jbc.M004898200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10913147	hybrid			2022-12-27	WOS:000089577900037
J	Levkowitz, G; Oved, S; Klapper, LN; Harari, D; Lavi, S; Sela, M; Yarden, Y				Levkowitz, G; Oved, S; Klapper, LN; Harari, D; Lavi, S; Sela, M; Yarden, Y			c-Cbl is a suppressor of the Neu oncogene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; DROSOPHILA EGF RECEPTOR; HUMAN BREAST-CANCER; ERBB RECEPTORS; SIGNAL-TRANSDUCTION; TRANSGENIC MICE; MAMMARY-TUMORS; MONOCLONAL-ANTIBODIES; DOWN-REGULATION	A rodent oncogenic mutant of the Neu receptor tyrosine kinase is a useful experimental model because overexpression of:the respective receptor, namely HER2/ErbB-2 in human malignancies is associated with relatively aggressive diseases. Here we show that the oncogenic form of Neu is constitutively associated with the product of the c-cbl proto-oncogene and is part of a large complex that includes the phosphoinositide 3-kinase and Shc. Ectopic expression of c-Cbl, a ubiquitin-protein isopeptide ligase specific to activated tyrosine kinases, causes rapid removal of Neu from the cell surface-and severely reduces signaling downstream of oncogenic Neu. c-Cbl-induced down-regulation of Neu involves covalent attachment of ubiquitin molecules and requires the carboxyl-terminal domain of Neu. The negative effect of c-Cbl is antagonized by v-Cbl, a virus-encoded oncogenic truncated form of c-Cbl. In an in vivo model, infection of a Neu-transformed neuroblastoma with: a c-Cbl-encoding retrovirus caused enhanced down-regulation of Neu and correlated with tumor retardation. Our results implicate c-Cbl in negative regulation of Neu and offer a potential target for treatment of HER2/ErbB-2-positive human malignancies.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.	yosef.yarden@weizmann.ac.il	Levkowitz, Gil/AAB-9441-2019; YARDEN, YOSEF/K-1467-2012	Levkowitz, Gil/0000-0002-3896-1881; 	NATIONAL CANCER INSTITUTE [R37CA072981, R01CA072981] Funding Source: NIH RePORTER; NCI NIH HHS [CA-72981] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Baselga J, 1997, Oncology (Williston Park), V11, P43; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Baulida J, 1996, J BIOL CHEM, V271, P5251; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; Bol D, 1998, MOL CARCINOGEN, V21, P2, DOI 10.1002/(SICI)1098-2744(199801)21:1<2::AID-MC2>3.3.CO;2-7; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DiGiovanna MP, 1998, ONCOGENE, V17, P1877, DOI 10.1038/sj.onc.1202091; Ettenberg S A, 1999, Mol Cell Biol Res Commun, V2, P111, DOI 10.1006/mcbr.1999.0157; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GILBOA L, 1995, J BIOL CHEM, V270, P7061, DOI 10.1074/jbc.270.13.7061; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HURWITZ E, 1995, P NATL ACAD SCI USA, V92, P3353, DOI 10.1073/pnas.92.8.3353; JALLAL B, 1992, J BIOL CHEM, V267, P4357; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; KASPRZYK PG, 1992, CANCER RES, V52, P2771; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; Klapper LN, 1999, P NATL ACAD SCI USA, V96, P4995, DOI 10.1073/pnas.96.9.4995; Klapper LN, 2000, ADV CANCER RES, V77, P25; Klapper LN, 2000, CANCER RES, V60, P3384; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Levkowitz G, 1996, ONCOGENE, V12, P1117; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; LONARDO F, 1990, New Biologist, V2, P992; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; Magnifico A, 1998, FEBS LETT, V422, P129, DOI 10.1016/S0014-5793(97)01612-8; MAIER LA, 1991, CANCER RES, V51, P5361; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Muller WJ, 1998, BIOCHEM SOC SYMP, P149; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1992, J BIOL CHEM, V267, P12266; Perrimon N, 1997, CELL, V89, P13, DOI 10.1016/S0092-8674(00)80177-4; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SEGATTO O, 1993, ONCOGENE, V8, P2105; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON D, 1998, P AN M AM SOC CLIN, V17, P98; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; SORKIN A, 1993, ONCOGENE, V8, P3021; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Thien CBF, 1998, IMMUNOL CELL BIOL, V76, P473, DOI 10.1046/j.1440-1711.1998.00768.x; Trebak M, 1998, CELL IMMUNOL, V188, P151, DOI 10.1006/cimm.1998.1348; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1998, BBA-REV CANCER, V1377, pM25, DOI 10.1016/S0304-419X(97)00032-2; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Waterman H, 1998, J BIOL CHEM, V273, P13819, DOI 10.1074/jbc.273.22.13819; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	79	64	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35532	35539		10.1074/jbc.M002661200	http://dx.doi.org/10.1074/jbc.M002661200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10940298	hybrid			2022-12-27	WOS:000165422800092
J	Boopathi, E; Anandatheerthavarada, HK; Bhagwat, SV; Biswas, G; Fang, JK; Avadhani, NG				Boopathi, E; Anandatheerthavarada, HK; Bhagwat, SV; Biswas, G; Fang, JK; Avadhani, NG			Accumulation of mitochondrial P450MT2, NH2-terminal truncated cytochrome P4501A1 in rat brain during chronic treatment with beta-naphthoflavone - A role in the metabolism of neuroactive drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C6 CELL-LINE; MULTIPLE FORMS; INDUCTION; SYSTEM; IDENTIFICATION; ADRENODOXIN; EXPRESSION; PROTEINS; BINDING; LIVER	The biochemical and molecular characteristics of cytochrome P4501A1 targeted to rat brain mitochondria was studied to determine the generality of the targeting mechanism previously described for mitochondrial cytochrome P450MT2 (P450MT2) from rat liver. In rat brain and C6 glioma cells chronically exposed to beta -naphoflavone (BNF), P450MT2 content reached 50 and 95% of the total cellular pool, respectively. P450MT2 from 10 days of BNF-treated rat brain was purified to over 85% purity using hydrophobic chromatography followed by adrenodoxin affinity binding. Purified brain P450MT2 consisted of two distinct molecular species with NH2 termini identical to liver mitochondrial forms. These results confirm the specificity of endoprotease-processing sites. The purified P450MT2 showed a preference for adrenodoxin + adrenodoxin reductase electron donor system and exhibited high erythromycin N-demethylation activity. Brain mitoplasts from 10-day BNF-treated rats and also purified P450MT2 exhibited high N-demethylation activities for a number of neuroactive drugs, including trycyclic anti-depressants, anti-convulsants, and opiates. At 10 days of BNF treatment, the mitochondrial metabolism of these neuroactive drugs represented about 85% of the total tissue activity. These results provide new insights on the role of P450MT2 in modulating the pharmacological potencies of different neuroactive drugs in chronically exposed individuals.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Avadhani, NG (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA.	narayan@vet.upenn.edu		Ettickan, Boopathi/0000-0001-9431-7719	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034883] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34883, R01 GM034883] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDYA S, 1994, ARCH BIOCHEM BIOPHYS, V310, P82, DOI 10.1006/abbi.1994.1143; ADDYA S, 1991, BIOCHEMISTRY-US, V30, P8323, DOI 10.1021/bi00098a007; Addya S, 1997, J CELL BIOL, V139, P589, DOI 10.1083/jcb.139.3.589; Anandatheerthavarada HK, 1999, J BIOL CHEM, V274, P6617, DOI 10.1074/jbc.274.10.6617; ANANDATHEERTHAVARADA HK, 1990, BRAIN RES, V536, P339, DOI 10.1016/0006-8993(90)90047-F; Anandatheerthavarada HK, 1998, BIOCHEMISTRY-US, V37, P1150, DOI 10.1021/bi972046j; ANANDATHEERTHAVARADA HK, 1993, BIOCHEM BIOPH RES CO, V194, P312, DOI 10.1006/bbrc.1993.1821; Anandatheerthavarada HK, 1997, ARCH BIOCHEM BIOPHYS, V339, P136, DOI 10.1006/abbi.1996.9855; BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370; Bergh AF, 1996, MOL CELL BIOCHEM, V162, P31; Bhagwat SV, 1999, J BIOL CHEM, V274, P24014, DOI 10.1074/jbc.274.34.24014; Bhagwat SV, 1999, TOXICOL APPL PHARM, V156, P231, DOI 10.1006/taap.1999.8646; BHAGWAT SV, 1995, ARCH BIOCHEM BIOPHYS, V320, P73, DOI 10.1006/abbi.1995.1344; BHAMRE S, 1993, ARCH BIOCHEM BIOPHYS, V339, P136; BHAT NK, 1982, BIOCHEMISTRY-US, V21, P2452, DOI 10.1021/bi00539a026; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIAN WR, 1990, BIOCHEMISTRY-US, V29, P11280, DOI 10.1021/bi00503a018; BURKE MD, 1985, BIOCHEM PHARMACOL, V34, P3337, DOI 10.1016/0006-2952(85)90355-7; CLARK BJ, 1991, J BIOL CHEM, V266, P5898; COGHLAN VM, 1991, J BIOL CHEM, V266, P18606; Egashira T, 1999, JPN J PHARMACOL, V81, P115, DOI 10.1254/jjp.81.115; GENG J, 1993, BIOCHEM BIOPH RES CO, V197, P1179, DOI 10.1006/bbrc.1993.2601; Geng J, 1997, BRAIN RES, V774, P11, DOI 10.1016/S0006-8993(97)81681-2; GENG J, 1995, J NEUROCHEM, V65, P554; Geng J, 1998, BRAIN RES, V784, P276, DOI 10.1016/S0006-8993(97)01346-2; GONZALEZ FJ, 1990, PHARMACOL THERAPEUT, V45, P1, DOI 10.1016/0163-7258(90)90006-N; HANUKOGLU I, 1981, J BIOL CHEM, V256, P4321, DOI 10.1016/S0021-9258(19)69436-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOEPER J, 1993, GASTROENTEROLOGY, V104, P203, DOI 10.1016/0016-5085(93)90853-5; MATSUBARA T, 1976, ANAL BIOCHEM, V75, P596, DOI 10.1016/0003-2697(76)90114-7; NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416; NEBERT DW, 1991, MOL ENDOCRINOL, V5, P1203, DOI 10.1210/mend-5-9-1203; NIRANJAN BG, 1984, J BIOL CHEM, V259, P2495; OKEY AB, 1986, CLIN BIOCHEM, V19, P132, DOI 10.1016/S0009-9120(86)80060-1; Parkinson A, 1996, TOXICOL PATHOL, V24, P45, DOI 10.1177/019262339602400107; RAZA H, 1988, J BIOL CHEM, V263, P9533; RIZZOLO LJ, 1985, J CELL BIOL, V101, P1351, DOI 10.1083/jcb.101.4.1351; Robin Marie-Anne, 1997, Journal of Hepatology, V26, P23, DOI 10.1016/S0168-8278(97)82329-X; SHAYIQ RM, 1991, METHOD ENZYMOL, V206, P587; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; SOURKES TL, 1981, BASIC NEUROCHEMISTRY, P737; Strobel HW, 1997, DRUG METAB REV, V29, P1079, DOI 10.3109/03602539709002244; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WADA A, 1992, J BIOL CHEM, V267, P22877	44	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34415	34423		10.1074/jbc.M004431200	http://dx.doi.org/10.1074/jbc.M004431200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10915793	Green Accepted, hybrid			2022-12-27	WOS:000165095300057
J	Enyeart, JA; Xu, L; Enyeart, JJ				Enyeart, JA; Xu, L; Enyeart, JJ			A bovine adrenocortical Kv1.4 K+ channel whose expression is potently inhibited by ACTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL-CORTICAL CELLS; GATED TRANSIENT CURRENTS; ZONA-FASCICULATA CELLS; POTASSIUM CHANNEL; CALCIUM-CHANNEL; ANGIOTENSIN-II; CYCLIC-AMP; TRANSCRIPTION; HORMONE; STEROIDOGENESIS	We have cloned a bovine adrenal cortical (bKv1.4) KC channel cDNA whose expression is rapidly inhibited by adrenocorticotropic hormone (ACTH). The 4386-nucleotide cDNA is homologous to other voltage-gated, rapidly inactivating Kv1.4 channels, and includes a 1986-nucleotide coding region and large 5'- and 3'-untranslated regions. Bovine Kv1.4-specific mRNA from adrenal zona fasciculata (AZF) cells was rapidly and potently reduced by ACTH, with a t(1/2) of approximately 1 h and an IC50 of 1.2 pM. The membrane-permeable cAMP analog 8-pcpt-cAMP also reduced bKv1.4 mRNA expression with kinetics similar to that observed with ACTH. Reduction of bKv1.4 mRNA expression by ACTH and 8-pcpt-cAMP was only partially inhibited by the selective protein kinase A antagonist H-89. Consistent with their effect on bKv1.4 mRNA, ACTH and 8-pcpt-cAMP both dramatically reduced the expression of bKv1.4-associated A-type current measured over 72 h. These results demonstrate that bovine AZF cells synthesize a Kv1.4-type channel whose expression is inhibited at the pretranslational level by ACTH and 8-pcpt-cAMP by a mechanism that is partially dependent on the activation of protein kinase A. The rapid, potent reduction of bKv1.4 mRNA produced by ACTH and 8-pcpt-cAMP indicates that the expression of this K+ channel is under tonic inhibitory control of the hypothalamic-pituitary-adrenal axis. The basic electrical properties of AZF cells might be tightly regulated at the transcriptional level by the normal diurnal pattern of ACTH secretion, and altered during bouts of stress by the enhanced release of this pituitary peptide. Under conditions of prolonged stress or adrenal insufficiency, persistent ACTH-induced changes in the electrical properties of AZF cells could be coupled to parallel changes in cortisol secretion.	Ohio State Univ, Coll Med, Dept Neurosci, Columbus, OH 43210 USA	Ohio State University	Enyeart, JJ (corresponding author), Ohio State Univ, Coll Med, Dept Neurosci, 5190 Graves Hall,333 W 10th Ave, Columbus, OH 43210 USA.	enyeart.1@osu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047875] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK47875] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen ML, 1998, P NATL ACAD SCI USA, V95, P7693, DOI 10.1073/pnas.95.13.7693; BARBARA JG, 1995, J PHYSIOL-LONDON, V488, P609, DOI 10.1113/jphysiol.1995.sp020994; BONDY P K, 1985, P816; CATALANO RD, 1986, J CLIN ENDOCR METAB, V62, P300, DOI 10.1210/jcem-62-2-300; CHANDY KG, 1994, LIGAND VOLTAGE GATED, P1; DAVIS IJ, 1994, MOL CELL BIOL, V14, P3469, DOI 10.1128/MCB.14.5.3469; Enyeart JJ, 1996, MOL CELL ENDOCRINOL, V124, P97, DOI 10.1016/S0303-7207(96)03938-X; Enyeart JJ, 1997, J GEN PHYSIOL, V110, P679, DOI 10.1085/jgp.110.6.679; Enyeart JJ, 1998, J MEMBRANE BIOL, V164, P139; ENYEART JJ, 1993, MOL ENDOCRINOL, V7, P1031, DOI 10.1210/me.7.8.1031; Enyeart JJ, 1996, J GEN PHYSIOL, V108, P251, DOI 10.1085/jgp.108.4.251; GARCIAGUZMAN M, 1994, FEBS LETT, V354, P173, DOI 10.1016/0014-5793(94)01117-6; GARCIAGUZMAN M, 1992, FEBS LETT, V308, P283, DOI 10.1016/0014-5793(92)81294-V; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIDAKA H, 1991, METHOD ENZYMOL, V201, P328; Hille B., 1992, IONIC CHANNELS EXCIT; KOJIMA I, 1986, J BIOL CHEM, V261, P9832; KOJIMA I, 1985, J BIOL CHEM, V260, P9171; LYMANGROVER JR, 1982, ENDOCRINOLOGY, V110, P462, DOI 10.1210/endo-110-2-462; MARTY A, 1985, J PHYSIOL-LONDON, V367, P117, DOI 10.1113/jphysiol.1985.sp015817; MLINAR B, 1993, J BIOL CHEM, V268, P8640; MLINAR B, 1993, J GEN PHYSIOL, V102, P239, DOI 10.1085/jgp.102.2.239; MLINAR B, 1993, J GEN PHYSIOL, V102, P217, DOI 10.1085/jgp.102.2.217; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MORI Y, 1993, J BIOL CHEM, V268, P26482; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; MOYLE WR, 1973, J BIOL CHEM, V248, P2409; Parker KL, 1995, VITAM HORM, V51, P339, DOI 10.1016/S0083-6729(08)61044-4; QUINN SJ, 1988, ANNU REV PHYSIOL, V50, P409, DOI 10.1146/annurev.ph.50.030188.002205; RAIKHINSTEIN M, 1994, BBA-MOL CELL RES, V1220, P329, DOI 10.1016/0167-4889(94)90157-0; SALA GB, 1979, J BIOL CHEM, V254, P3861; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; VELAN B, 1995, CURRENT PROTOCOLS BI, V1; VELDHUIS JD, 1990, J CLIN ENDOCR METAB, V71, P452, DOI 10.1210/jcem-71-2-452; WILSON TE, 1993, MOL CELL BIOL, V13, P861, DOI 10.1128/MCB.13.2.861; Wymore RS, 1996, J BIOL CHEM, V271, P15629, DOI 10.1074/jbc.271.26.15629; Yamazaki T, 1998, ENDOCRINOLOGY, V139, P4765, DOI 10.1210/en.139.12.4765; Zazopoulos E, 1997, NATURE, V390, P311, DOI 10.1038/36899; ZUBER MX, 1986, J BIOL CHEM, V261, P2475	43	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34640	34649		10.1074/jbc.M004214200	http://dx.doi.org/10.1074/jbc.M004214200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10913143	hybrid			2022-12-27	WOS:000165095300087
J	Hayashi, M; Yamada, H; Mitamura, T; Horii, T; Yamamoto, A; Moriyama, Y				Hayashi, M; Yamada, H; Mitamura, T; Horii, T; Yamamoto, A; Moriyama, Y			Vacuolar H+-ATPase localized in plasma membranes of malaria parasite cells, Plasmodium falciparum, is involved in regional acidification of parasitized erythrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASES; INFECTED ERYTHROCYTES; SYNCHRONIZED CULTURES; LACTATE PRODUCTION; CHLOROQUINE; SUBUNIT; BAFILOMYCINS; COMPARTMENT; EXPRESSION; MOLECULES	Recent biochemical studies involving 2',7'-bis-(2-carboxyethyl)-5,6 -carboxylfluorescein (BCECF)-labeled saponin-permeabilized and parasitized erythrocytes indicated that malaria parasite cells maintain the resting cytoplasmic pH at about 7.3, and treatment with vacuolar proton-pump inhibitors reduces the resting pH to 6.7, suggesting proton extrusion from the parasite cells via vacuolar H+-ATPase (Saliba, K. J., and Kirk, K. (1999) J, Biol. Chem, 274, 33213-33219), In the present study, we investigated the localization of vacuolar H+-ATPase in Plasmodium falciparum cells infecting erythrocytes, Antibodies against vacuolar H+-ATPase subunit A and B specifically immunostained the infecting parasite cells and recognized a single 67- and 55-kDa polypeptide, respectively. Immunoelectron microscopy indicated that the immunological counterpart of V-ATPase subunits A and B is localized at the plasma membrane, small clear vesicles, and food vacuoles, a lower extent being detected at the parasitophorus vacuolar membrane of the parasite cells. We measured the cytoplasmic pH of both infected erythrocytes and invading malaria parasite cells by microfluorimetry using BCECF fluorescence. It was found that a restricted area of the erythrocyte cytoplasm near a parasite cell is slightly acidic, being about pH 6.9. The pH increased to pH 7.3 upon the addition of either concanamycin B or bafilomycin A(1), specific inhibitors of vacuolar H+-ATPase. Simultaneously, the cytoplasmic pH of the infecting parasite cell decreased from pH 7.3 to 7.1. Neither vanadate at 0.5 mM, an inhibitor of P-type H+-ATPase, nor ethylisopropylamiloride at 0.2 mM, an inhibitor of Na+/H+-exchanger, affected the cytoplasmic pH of erythrocytes or infecting parasite cells. These results constitute direct evidence that plasma membrane vacuolar H+-ATPase is responsible for active exclusion of protons from the parasite cells.	Okayama Univ, Fac Pharmaceut Sci, Dept Biochem, Okayama 7008530, Japan; Osaka Univ, Inst Microbial Dis, Suita, Osaka 5650871, Japan; Kansai Med Univ, Dept Physiol, Osaka 5708506, Japan	Okayama University; Osaka University; Kansai Medical University	Moriyama, Y (corresponding author), Okayama Univ, Fac Pharmaceut Sci, Dept Biochem, 3-1-1 Tsushima Naka, Okayama 7008530, Japan.	moriyama@pheasant.pharm.okayama-u.ac.jp	Yamada, Hiroshi/AGZ-4497-2022; YAMADA, Hiroshi/B-2251-2011	Yamada, Hiroshi/0000-0002-9328-3446; YAMADA, Hiroshi/0000-0002-9328-3446; Horii, Toshihiro/0000-0002-3000-2045				ATKINSON CT, 1990, BLOOD CELLS, V16, P351; Blackman MJ, 1998, J BIOL CHEM, V273, P23398, DOI 10.1074/jbc.273.36.23398; BOSIA A, 1993, J CELL PHYSIOL, V154, P527, DOI 10.1002/jcp.1041540311; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRAY PG, 1992, BIOCHEM PHARMACOL, V43, P1219, DOI 10.1016/0006-2952(92)90495-5; CHOI I, 1988, MOL BIOCHEM PARASIT, V31, P71, DOI 10.1016/0166-6851(88)90146-6; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; FUKUI Y, 1992, J HISTOCHEM CYTOCHEM, V40, P73, DOI 10.1177/40.1.1729355; Haldar K, 1996, TRENDS CELL BIOL, V6, P398, DOI 10.1016/0962-8924(96)10032-5; ITO K, 1995, J ANTIBIOT, V48, P488, DOI 10.7164/antibiotics.48.488; JENSEN JB, 1979, EXP PARASITOL, V48, P36, DOI 10.1016/0014-4894(79)90052-3; KARCZ SR, 1994, MOL BIOCHEM PARASIT, V65, P123, DOI 10.1016/0166-6851(94)90121-X; KARCZ SR, 1993, MOL BIOCHEM PARASIT, V58, P333, DOI 10.1016/0166-6851(93)90056-4; KELLENBERGER E, 1987, J HISTOCHEM CYTOCHEM, V35, P959, DOI 10.1177/35.9.3302020; KRISHNA S, 1993, J CELL BIOL, V120, P385, DOI 10.1083/jcb.120.2.385; KROGSTAD DJ, 1985, J CELL BIOL, V101, P2302, DOI 10.1083/jcb.101.6.2302; Lingelbach K, 1998, J CELL SCI, V111, P1467; MIKKELSEN RB, 1982, J CELL BIOL, V93, P685, DOI 10.1083/jcb.93.3.685; MIKKELSEN RB, 1986, MOL BIOCHEM PARASIT, V21, P83, DOI 10.1016/0166-6851(86)90082-4; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; MORIYAMA Y, 1989, BIOCHIM BIOPHYS ACTA, V980, P241, DOI 10.1016/0005-2736(89)90405-7; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; PFALLER MA, 1982, EXP PARASITOL, V54, P391, DOI 10.1016/0014-4894(82)90048-0; Saliba KJ, 1999, J BIOL CHEM, V274, P33213, DOI 10.1074/jbc.274.47.33213; SASAKI T, 1994, CELL TISSUE RES, V278, P265, DOI 10.1007/s004410050216; SHERMAN IW, 1979, MICROBIOL REV, V43, P453, DOI 10.1128/MMBR.43.4.453-495.1979; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; TAKADA T, 1992, HISTOCHEMISTRY, V98, P183, DOI 10.1007/BF00315877; Tomochika K, 1997, FEBS LETT, V404, P61, DOI 10.1016/S0014-5793(97)00090-2; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; UYAMA T, 1994, J EXP ZOOL, V270, P148, DOI 10.1002/jez.1402700204; VANDERJAGT DL, 1990, MOL BIOCHEM PARASIT, V42, P277, DOI 10.1016/0166-6851(90)90171-H; Ward GE, 1997, PARASITOL TODAY, V13, P57, DOI 10.1016/S0169-4758(96)10080-6; WHITE NJ, 1998, MALARIA PARASITE BIO, P371; Wieczorek H, 1999, BIOESSAYS, V21, P637, DOI 10.1002/(SICI)1521-1878(199908)21:8<637::AID-BIES3>3.3.CO;2-N; Woodrow CJ, 1999, J BIOL CHEM, V274, P7272, DOI 10.1074/jbc.274.11.7272; Wunsch S, 1998, J CELL BIOL, V140, P335, DOI 10.1083/jcb.140.2.335; YAMAMOTO A, 1994, J HISTOCHEM CYTOCHEM, V42, P1463, DOI 10.1177/42.11.7930528; YAYON A, 1984, EMBO J, V3, P2695, DOI 10.1002/j.1460-2075.1984.tb02195.x; ZOLG JW, 1984, IN VITRO CELL DEV B, V20, P205, DOI 10.1007/BF02618189	41	92	93	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34353	34358		10.1074/jbc.M003323200	http://dx.doi.org/10.1074/jbc.M003323200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10915784	hybrid			2022-12-27	WOS:000165095300049
J	Choudhury, A; Singh, RK; Moniaux, N; El-Metwally, TH; Aubert, JP; Batra, SK				Choudhury, A; Singh, RK; Moniaux, N; El-Metwally, TH; Aubert, JP; Batra, SK			Retinoic acid-dependent transforming growth factor-beta 2-mediated induction of MUC4 mucin expression in human pancreatic tumor cells follows retinoic acid receptor-alpha signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER-CELLS; GENE-EXPRESSION; FACTOR-BETA; CHROMOSOMAL LOCALIZATION; MOLECULAR-CLONING; EPITHELIAL-CELLS; CYSTIC-FIBROSIS; GENOMIC ORGANIZATION; SIALOMUCIN COMPLEX; COMPLEMENTARY-DNA	The MUC4 mucin is considered as the homologue of rat sialomucin complex (SMC, rat Muc4) due to its similar structural organization. Like SMC, MUC4 may also exist as two subunits: a mucin type unit known as MUC4 alpha and a growth factor-like transmembrane subunit, MUC4 beta. The expression of MUC4 in normal human pancreas is not detectable, but it is highly expressed in pancreatic tumor cells. In the present study, we investigated the regulation of MUC4 expression in human pancreatic tumor cells CD18/HPAF, exhibiting a high level of MUC4 transcripts and protein, When these cells were adapted to grow in the serum-free medium (CD18/HPAF-SF), the MUC4 expression was undetectable. Among several serum constituents, all-trans-retinoic acid (RA) induced the expression of MUC4 transcripts in a concentration- and time-dependent manner, The RA-mediated increase in the level of the MUC4 transcript coincided with an increased expression of transforming growth factor-beta2 (TGF-beta2) transcript. The antagonist of the retinoic acid receptor (RAR)-alpha (Ro41-5253) abrogated the expression of MUC4 and TGF-beta2 induced by RA. The exogenous addition of TGF-beta2 also increased the MUC4 expression. The TGF-P-neutralizing antibody blocked the RA-induced as well as TGF-beta2-mediated MUC4 expression. In conclusion, induction of MUC4 expression in pancreatic carcinoma by RA is mediated through the RAR-alpha signaling pathway, and TGF-beta2 may serve as an interim mediator of this regulated expression.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Nebraska Med Ctr 984525, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; INSERM, U377, F-59045 Lille, France	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Institut National de la Sante et de la Recherche Medicale (Inserm)	Batra, SK (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Nebraska Med Ctr 984525, Omaha, NE 68198 USA.		El-Metwally, Tarek H./AAH-2054-2020; Moniaux, Nicolas/Y-3243-2018	El-Metwally, Tarek H./0000-0001-9040-6642; Moniaux, Nicolas/0000-0001-9718-1386	NATIONAL CANCER INSTITUTE [R01CA072781, R29CA072781, R01CA078590] Funding Source: NIH RePORTER; NCI NIH HHS [CA72781, CA 78590] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; ARTEAGA CL, 1988, CANCER RES, V48, P3898; Ashley DM, 1998, CANCER RES, V58, P302; AUBERT JP, 1991, AM J RESP CELL MOL, V5, P178, DOI 10.1165/ajrcmb/5.2.178; AUDIE JP, 1995, HUM REPROD, V10, P98, DOI 10.1093/humrep/10.1.98; AUDIE JP, 1993, J HISTOCHEM CYTOCHEM, V41, P1479, DOI 10.1177/41.10.8245407; BALAGUE C, 1994, GASTROENTEROLOGY, V106, P1054, DOI 10.1016/0016-5085(94)90767-6; BASCOM CC, 1989, MOL CELL BIOL, V9, P5508, DOI 10.1128/MCB.9.12.5508; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; Bernacki SH, 1999, AM J RESP CELL MOL, V20, P595, DOI 10.1165/ajrcmb.20.4.3442; Bobek LA, 1996, GENOMICS, V31, P277, DOI 10.1006/geno.1996.0049; Borchers MT, 1999, AM J PHYSIOL-LUNG C, V276, pL549, DOI 10.1152/ajplung.1999.276.4.L549; BRAND NJ, 1990, NUCLEIC ACIDS RES, V18, P6799, DOI 10.1093/nar/18.23.6799; Buisine MP, 1998, BIOCHEM J, V332, P729, DOI 10.1042/bj3320729; Buisine MP, 1999, AM J RESP CELL MOL, V20, P209, DOI 10.1165/ajrcmb.20.2.3259; CARRATO C, 1994, GASTROENTEROLOGY, V107, P160, DOI 10.1016/0016-5085(94)90073-6; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; CHANG SK, 1994, GASTROENTEROLOGY, V107, P28, DOI 10.1016/0016-5085(94)90057-4; Choudhury A, 2000, J BIOCHEM-TOKYO, V128, P233, DOI 10.1093/oxfordjournals.jbchem.a022746; CHOUDHURY A, 2001, IN PRESS TERATOGENES, V21; Copin MC, 2000, INT J CANCER, V86, P162, DOI 10.1002/(SICI)1097-0215(20000415)86:2<162::AID-IJC3>3.3.CO;2-I; DAHIYA R, 1993, CANCER RES, V53, P1437; Debailleul V, 1998, J BIOL CHEM, V273, P881, DOI 10.1074/jbc.273.2.881; DEMARTIN R, 1987, EMBO J, V6, P3673, DOI 10.1002/j.1460-2075.1987.tb02700.x; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; Desseyn JL, 1997, J BIOL CHEM, V272, P16873, DOI 10.1074/jbc.272.27.16873; DUFOSSE J, 1993, BIOCHEM J, V293, P329, DOI 10.1042/bj2930329; FINKBEINER WE, 1993, AM J RESP CELL MOL, V9, P547, DOI 10.1165/ajrcmb/9.5.547; FRIESS H, 1993, CANCER RES, V53, P2704; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Gipson IK, 1999, BIOL REPROD, V60, P58, DOI 10.1095/biolreprod60.1.58; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; Gray TE, 1996, AM J RESP CELL MOL, V14, P104, DOI 10.1165/ajrcmb.14.1.8534481; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1994, J BIOL CHEM, V269, P2440; Guzman K, 1996, AM J PHYSIOL-LUNG C, V270, pL846, DOI 10.1152/ajplung.1996.270.5.L846; Guzman K, 1995, BIOCHEM BIOPH RES CO, V217, P412, DOI 10.1006/bbrc.1995.2792; HO JJL, 1994, PANCREAS, V9, P674; HO SB, 1993, CANCER RES, V53, P641; HOLLINGSWORTH MA, 1994, INT J CANCER, V57, P198, DOI 10.1002/ijc.2910570212; Issing WJ, 1996, ANTICANCER RES, V16, P2373; KELLY D, 1990, CYTOTECHNOLOGY, V4, P227, DOI 10.1007/BF00563783; KELLY D, 1992, DEV BIOL, V153, P172, DOI 10.1016/0012-1606(92)90102-M; Kelly DL, 1999, ANTICANCER RES, V19, P4791; Kim YS, 1999, ANN ONCOL, V10, P51, DOI 10.1023/A:1008332602541; KIM YW, 1989, PANCREAS, V4, P353, DOI 10.1097/00006676-198906000-00013; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; Koo JS, 1999, BIOCHEM J, V338, P351, DOI 10.1042/0264-6021:3380351; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LAN MS, 1990, J BIOL CHEM, V265, P15294; Lapensee L, 1997, FERTIL STERIL, V68, P702, DOI 10.1016/S0015-0282(97)00317-8; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; Li DC, 1997, J PATHOL, V181, P305; Li JD, 1997, P NATL ACAD SCI USA, V94, P967, DOI 10.1073/pnas.94.3.967; Moniaux N, 2000, EUR J BIOCHEM, V267, P4536, DOI 10.1046/j.1432-1327.2000.01504.x; Moniaux N, 1999, BIOCHEM J, V338, P325, DOI 10.1042/0264-6021:3380325; Nollet S, 1998, BIOCHEM J, V332, P739, DOI 10.1042/bj3320739; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; Price-Schiavi SA, 1998, J BIOL CHEM, V273, P35228, DOI 10.1074/jbc.273.52.35228; Price-Schiavi SA, 2000, J BIOL CHEM, V275, P17800, DOI 10.1074/jbc.275.23.17800; RANCHALIS JE, 1987, BIOCHEM BIOPH RES CO, V148, P783, DOI 10.1016/0006-291X(87)90944-2; Reid CJ, 1997, MOL MED, V3, P403; Reid CJ, 1998, GUT, V42, P220, DOI 10.1136/gut.42.2.220; Rossi EA, 1996, J BIOL CHEM, V271, P33476, DOI 10.1074/jbc.271.52.33476; Shankar V, 1997, AM J RESP CELL MOL, V16, P232, DOI 10.1165/ajrcmb.16.3.9070607; SIDDIKI J, 1987, P NATL ACAD SCI USA, V84, P6060; STEINER MS, 1992, MOL ENDOCRINOL, V6, P15, DOI 10.1210/me.6.1.15; TASHIRO Y, 1994, HUM PATHOL, V25, P364, DOI 10.1016/0046-8177(94)90144-9; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; Vandenhaute B, 1997, J HEPATOL, V27, P1057, DOI 10.1016/S0168-8278(97)80150-X; Williams SJ, 1999, CANCER RES, V59, P4083; YONEZAWA S, 1991, BIOCHEM J, V276, P599, DOI 10.1042/bj2760599; Yoon JH, 1997, AM J RESP CELL MOL, V16, P724, DOI 10.1165/ajrcmb.16.6.9191474	74	62	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33929	33936		10.1074/jbc.M005115200	http://dx.doi.org/10.1074/jbc.M005115200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10938282	hybrid			2022-12-27	WOS:000090104600103
J	Grange, M; Sette, C; Cuomo, M; Conti, M; Lagarde, M; Prigent, AF; Nemoz, G				Grange, M; Sette, C; Cuomo, M; Conti, M; Lagarde, M; Prigent, AF; Nemoz, G			The cAMP-specific phosphodiesterase PDE4D3 is regulated by phosphatidic acid binding - Consequences for cAMP signaling pathway and characterization of a phosphatidic acid binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; DEPENDENT PROTEIN-KINASE; BLOOD MONONUCLEAR-CELLS; EPIDERMAL GROWTH-FACTOR; PHOSPHOLIPASE-D; RAT THYMOCYTES; POTENTIAL ROLE; TUMOR-CELLS; ACTIVATION; PHOSPHORYLATION	Hormones and growth factors induce in many cell types the production of phosphatidic acid (PA), which has been proposed to play a role as a second messenger. We have previously shown in an acellular system that PA selectively stimulates certain isoforms of type 4 cAMP-phosphodiesterases (PDE4), Here we studied the effect of endogenous PA on PDE activity of transiently transfected MA10 cells overexpressing the PA-sensitive isoform PDE4D3, Cell treatment with inhibitors of PA degradation, including propranolol, induced an accumulation of endogenous PA accompanied by a stimulation of PDE activity and a significant decrease in both cAMP levels and protein kinase A activity. Furthermore, in FRTL5 cells, which natively express PDE4D3, pretreatment with compounds inducing PA accumulation prevented both cAMP increase and cAMP-responsive element-binding protein phosphorylation triggered by thyroid-stimulating hormone. To determine the mechanism of PDE stimulation by PA, endogenous phospholipids were labeled by preincubating MA10 cells overexpressing PDE4D3 with [P-32]orthophosphate. Immunoprecipitation experiments showed that PA was specifically bound to PDE4D3, supporting the hypothesis that PDE4D3 activation occurs through direct binding of PA to the protein. PA binding site on PDE4D3 was characterized by engineering deletions of selected regions in the N-terminal regulatory domain of the enzyme, Deletion of amino acid residues 31-59 suppressed both PA-activating effect and PA binding, suggesting that this region rich in basic and hydrophobic residues contains the PA binding site. These observations strongly suggest that endogenous PA can modulate cAMP levels in intact cells, through a direct activation of PDE4D3.	Inst Natl Sci Appl, Lab Biochim & Pharmacol, INSERM U352, F-69621 Villeurbanne, France; Univ Roma Tor Vergata, Dept Publ Hlth & Cell Biol, I-00173 Rome, Italy; Univ Rome La Sapienza, Dept Histol & Med Embryol, I-00161 Rome, Italy; Stanford Univ, Med Ctr, Div Human Reprod, Stanford, CA 94305 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National des Sciences Appliquees de Lyon - INSA Lyon; University of Rome Tor Vergata; Sapienza University Rome; Stanford University	Nemoz, G (corresponding author), Inst Natl Sci Appl, Lab Biochim & Pharmacol, INSERM U352, Bat 406, F-69621 Villeurbanne, France.		Sette, Claudio/S-4307-2019	Sette, Claudio/0000-0003-2864-8266				Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; Beard MB, 2000, J BIOL CHEM, V275, P10349, DOI 10.1074/jbc.275.14.10349; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOARDER MR, 1994, TRENDS PHARMACOL SCI, V15, P57, DOI 10.1016/0165-6147(94)90111-2; CAMPAGNE MMV, 1990, J BIOL CHEM, V265, P5840; Cockcroft S, 1996, CHEM PHYS LIPIDS, V80, P59, DOI 10.1016/0009-3084(96)02546-7; Colley WC, 1997, BIOCHEM J, V326, P745, DOI 10.1042/bj3260745; CONTI M, 1995, ENDOCR REV, V16, P370, DOI 10.1210/er.16.3.370; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; ElBawab S, 1997, EUR J BIOCHEM, V247, P1151, DOI 10.1111/j.1432-1033.1997.01151.x; English D, 1996, CELL SIGNAL, V8, P341, DOI 10.1016/0898-6568(95)00076-3; ESSAYAN DM, 1994, J IMMUNOL, V153, P3408; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Flores I, 1996, J BIOL CHEM, V271, P10334, DOI 10.1074/jbc.271.17.10334; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Grange Muriel, 1998, Cell Biochemistry and Biophysics, V29, P1, DOI 10.1007/BF02737825; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; Hoffmann R, 1998, BIOCHEM J, V333, P139, DOI 10.1042/bj3330139; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; HOWE R, 1966, NATURE, V210, P1336, DOI 10.1038/2101336a0; IACOVELLI L, 1993, J BIOL CHEM, V268, P20402; IGARASHI K, 1995, J BIOL CHEM, V270, P29075, DOI 10.1074/jbc.270.49.29075; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; JIN SLC, 1992, J BIOL CHEM, V267, P18929; JONES GA, 1993, J BIOL CHEM, V268, P20845; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KASZKIN M, 1992, CANCER RES, V52, P5627; LAURITZEN L, 1994, MOL CELL ENDOCRINOL, V104, P229, DOI 10.1016/0303-7207(94)90125-2; LAVIE Y, 1990, FEBS LETT, V277, P7, DOI 10.1016/0014-5793(90)80796-L; Lim J, 1999, J BIOL CHEM, V274, P19677, DOI 10.1074/jbc.274.28.19677; Liu HG, 1999, J BIOL CHEM, V274, P10557, DOI 10.1074/jbc.274.15.10557; MARCOZ P, 1993, BIOCHIM BIOPHYS ACTA, V1176, P129, DOI 10.1016/0167-4889(93)90187-T; MARCOZ P, 1993, MOL PHARMACOL, V44, P1027; MATSUMOTO H, 1989, BIOCHEM BIOPH RES CO, V158, P105, DOI 10.1016/S0006-291X(89)80183-4; MESKINI N, 1995, EUR J BIOCHEM, V233, P907, DOI 10.1111/j.1432-1033.1995.907_3.x; MORITZ A, 1992, J BIOL CHEM, V267, P7207; NAKAMURA K, 1984, ANAL BIOCHEM, V142, P406, DOI 10.1016/0003-2697(84)90484-6; Naro F, 1999, MOL BIOL CELL, V10, P4355, DOI 10.1091/mbc.10.12.4355; Nemoz G, 1997, MOL PHARMACOL, V51, P242, DOI 10.1124/mol.51.2.242; Oki N, 2000, J BIOL CHEM, V275, P10831, DOI 10.1074/jbc.275.15.10831; PERRY DK, 1992, J IMMUNOL, V149, P2749; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; Sambrook J., 1989, MOL CLONING, pA1; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; SETTE C, 1994, J BIOL CHEM, V269, P9245; SETTE C, 1994, J BIOL CHEM, V269, P18271; Siddhanta A, 1998, J BIOL CHEM, V273, P17995, DOI 10.1074/jbc.273.29.17995; SOZZANI S, 1992, J BIOL CHEM, V267, P20481; SWINNEN JV, 1991, J BIOL CHEM, V266, P14383; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; YAMAKI M, 1993, KIDNEY INT, V43, P1286, DOI 10.1038/ki.1993.181; Zakaroff-Girard A, 1999, J LEUKOCYTE BIOL, V65, P381, DOI 10.1002/jlb.65.3.381	57	95	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33379	33387		10.1074/jbc.M006329200	http://dx.doi.org/10.1074/jbc.M006329200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10938092	hybrid			2022-12-27	WOS:000090104600030
J	Wang, D; Westerheide, SD; Hanson, JL; Baldwin, AS				Wang, D; Westerheide, SD; Hanson, JL; Baldwin, AS			Tumor necrosis factor alpha-induced phosphorylation of RelA/p65 on Ser(529) is controlled by casein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DNA-BINDING; TRANSCRIPTIONAL ACTIVITY; CONSTITUTIVE PHOSPHORYLATION; TRANSACTIVATION DOMAIN; FAMILY MEMBERS; GROWTH-FACTOR; P65 SUBUNIT; PEST DOMAIN; IN-VIVO	Nuclear factor kappaB (NF-kappaB)/Rel transcription factors are key regulators of a variety of genes involved in immune and inflammatory responses, growth, differentiation, apoptosis, and development. In unstimulated cells, NF-kappaB/Rel proteins are sequestered in the cytoplasm by I kappaB inhibitor proteins. Many extracellular stimuli, such as tumor necrosis factor alpha (TNF alpha), cause rapid phosphorylation of I kappaB at N-terminal serine residues leading to ubiquitination and degradation of the inhibitor. Subsequently, NF-kappaB proteins translocate to the nucleus and activate gene expression through KB response elements. TNF alpha, as well as certain other stimuli, also induces the phosphorylation of the NP-kappaB proteins. Previously, we have shown that TNF alpha induces RelA/p65 phosphorylation at serine 529 and that this inducible phosphorylation increases NF-kappaB transcriptional activity on an exogenously supplied reporter (1). In this report, we demonstrate that casein kinase II (CKII) interacts with p65 in vivo and can phosphorylate p65 at serine 529 in vitro. A CKII inhibitor (PD144795) inhibited TNF alpha -induced p65 phosphorylation in vivo. Furthermore, our results indicate that the association between I kappaB alpha and p65 inhibits p65 phosphorylation by CKII and that degradation of I kappaB alpha allows CKII to phosphorylate p65 to increase NF-kappaB transactivation potential. These data may explain the ability of CKII to modulate cell growth and demonstrate a mechanism whereby CKII can function in an inducible manner.	Univ N Carolina, Dept Biol, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Baldwin, AS (corresponding author), Univ N Carolina, Dept Biol, Curriculum Genet & Mol Biol, CB 3280, Chapel Hill, NC 27599 USA.				NATIONAL CANCER INSTITUTE [R01CA072771] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI035098, R01AI035098] Funding Source: NIH RePORTER; NCI NIH HHS [CA72771] Funding Source: Medline; NIAID NIH HHS [AI35098] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; CHENWU JLP, 1988, MOL CELL BIOL, V8, P4981, DOI 10.1128/MCB.8.11.4981; Chu ZL, 1996, MOL CELL BIOL, V16, P5974; Cogswell PC, 1997, J EXP MED, V185, P491, DOI 10.1084/jem.185.3.491; Critchfield JW, 1997, P NATL ACAD SCI USA, V94, P6110, DOI 10.1073/pnas.94.12.6110; Critchfield JW, 1996, AIDS RES HUM RETROV, V12, P39, DOI 10.1089/aid.1996.12.39; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIEHL JA, 1995, J BIOL CHEM, V270, P2703, DOI 10.1074/jbc.270.6.2703; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore TD, 1996, ONCOGENE, V13, P1367; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HAYASHI T, 1993, J BIOL CHEM, V268, P26790; Heilker R, 1999, EUR J BIOCHEM, V259, P253, DOI 10.1046/j.1432-1327.1999.00028.x; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; LI CCH, 1994, BIOCHEM J, V303, P499, DOI 10.1042/bj3030499; LI CCH, 1994, J BIOL CHEM, V269, P30089; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; Lin RT, 1996, MOL CELL BIOL, V16, P1401; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; Mayo MW, 2000, BBA-REV CANCER, V1470, pM55, DOI 10.1016/S0304-419X(00)00002-0; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; OSTROWSKI J, 1991, J BIOL CHEM, V266, P12722; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Sharma HW, 1996, ANTICANCER RES, V16, P589; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; TUAZON PT, 1991, ADV 2 MESSENGER PHOS, V23, P123; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Vilk G, 1999, J BIOL CHEM, V274, P14406, DOI 10.1074/jbc.274.20.14406; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yoza BK, 1996, J BIOL CHEM, V271, P18306, DOI 10.1074/jbc.271.31.18306; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	62	364	374	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32592	32597		10.1074/jbc.M001358200	http://dx.doi.org/10.1074/jbc.M001358200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10938077	Green Published, hybrid			2022-12-27	WOS:000090003800031
J	Datta, R; Oki, E; Endo, K; Biedermann, V; Ren, J; Kufe, D				Datta, R; Oki, E; Endo, K; Biedermann, V; Ren, J; Kufe, D			XIAP regulates DNA damage-induced apoptosis downstream of caspase-9 cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; PROTEIN-KINASE; LEUKEMIA-CELLS; ACTIVATION; MITOCHONDRIA; INHIBITORS; INDUCTION; PATHWAY; DEATH; IAP	The IAP (inhibitor of apoptosis) family of anti-apoptotic proteins regulates programmed cell death. Of the six known human IAP-related proteins, XIAP is the most potent inhibitor. To study the mechanistic effects of XIAP on DNA damage-induced apoptosis, we prepared U-937 cells that stably overexpress XIAP. The results demonstrate that XIAP inhibits apoptosis induced by 1-[beta-D-arabinofuranosyl]cytosine (ara-C) and other genotoxic agents. XIAP had no detectable effect on ara-C-induced release of mitochondrial cytochrome c and attenuated cleavage of procaspase-9. In addition, we show that ara-C induces the association of XIAP with the cleaved fragments of caspase-9 and thereby inhibition of caspase-9 activity. The results also demonstrate that ara-C induces cleavage of procaspase-3 by a caspase-8-dependent mechanism and that XIAP inhibits caspase-3 activity. These results demonstrate that XIAP functions downstream of procaspase-9 cleavage as an inhibitor of both proteolytically processed caspase-9 and -3 in the cellular response to genotoxic stress.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Datta, R (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.				NCI NIH HHS [CA29431] Funding Source: Medline; NIGMS NIH HHS [GM58200] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029431] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058200] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; DATTA R, 1995, CELL GROWTH DIFFER, V6, P363; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; FRAM RJ, 1982, CANCER RES, V42, P4050; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; GUNJI H, 1991, CANCER RES, V51, P741; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HALL EJ, 1988, AM J CLIN ONCOL-CANC, V11, P220, DOI 10.1097/00000421-198806000-00003; Hauser HP, 1998, J CELL BIOL, V141, P1415, DOI 10.1083/jcb.141.6.1415; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kojima H, 1998, J BIOL CHEM, V273, P16647, DOI 10.1074/jbc.273.27.16647; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; ROBERTSON MJ, 1995, LEUKEMIA LYMPHOMA, V17, P51, DOI 10.3109/10428199509051703; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	40	81	87	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31733	31738		10.1074/jbc.M910231199	http://dx.doi.org/10.1074/jbc.M910231199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10930419	hybrid			2022-12-27	WOS:000089858900028
J	Hu, YK; Eisses, JF; Kaplan, JH				Hu, YK; Eisses, JF; Kaplan, JH			Expression of an active Na,K-ATPase with an alpha-subunit lacking all twenty-three native cysteine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ADENOSINE-TRIPHOSPHATASE; SULFHYDRYL-GROUPS; H+-ATPASE; TRANSPORT; ISOZYMES; ISOFORM; PROTEIN	We have constructed a mutant Na,K-ATPase alpha 1-subunit with all native cysteine residues replaced. Using the baculovirus system, this cysteine-less alpha 1-subunit and wild-type beta 1-subunit were expressed in High Five cells. After 3 days of infection, cells were fractionated, and endoplasmic reticulum. Golgis apparatus, and plasma membranes were isolated. The molecular activity of the cysteine-less mutant in the plasma membranes was close to the wild-type protein (8223 min(-1) versus 6655 min(-1)). Cation and ATP activation of Na,K-ATPase activities revealed that replacing all 23 cysteines resulted in only a 50% reduction of K-m for Na+, a 2-fold increase in K-m for K+, and no changes inK(m) for ATP. The distribution of alpha-subunits among the membranes showed a high percentage of cysteine-less protein in the endoplasmic reticulum and Golgi apparatus compared with the wild-type protein. Furthermore, the cellular stability of the alpha beta assembly appeared reduced in the cysteine-less mutant. Cells harvested after more than 3 days of infection showed extensive degradation of the cysteine-less alpha-subunit, which is not observed with the wild-type enzyme. Thus the Na,K-ATPase contains no cysteine residues that are critical for function, but the folding and/or assembly pathway of this enzyme is affected by total cysteine substitution.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Kaplan, JH (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, L224,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.			Kaplan, Jack/0000-0002-7048-6574	NIGMS NIH HHS [GM39500] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039500] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANNER BM, 1990, BIOCHEM BIOPH RES CO, V167, P1115, DOI 10.1016/0006-291X(90)90638-4; Beggah A, 1996, J BIOL CHEM, V271, P20895, DOI 10.1074/jbc.271.34.20895; BLANCO G, 1995, BIOCHEMISTRY-US, V34, P9897, DOI 10.1021/bi00031a011; Blanco G, 1999, BIOCHEMISTRY-US, V38, P13661, DOI 10.1021/bi991207b; CANESSA CM, 1992, EMBO J, V11, P1681, DOI 10.1002/j.1460-2075.1992.tb05218.x; CASEY JR, 1995, J BIOL CHEM, V270, P8521, DOI 10.1074/jbc.270.15.8521; DETOMASO AW, 1993, J BIOL CHEM, V268, P1470; ESMANN M, 1982, BIOCHIM BIOPHYS ACTA, V688, P251, DOI 10.1016/0005-2736(82)90601-0; FAHN S, 1966, J BIOL CHEM, V241, P1890; Gatto C, 1999, J BIOL CHEM, V274, P24995, DOI 10.1074/jbc.274.35.24995; GEERING K, 1987, J CELL BIOL, V105, P2613, DOI 10.1083/jcb.105.6.2613; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hu YK, 2000, J BIOL CHEM, V275, P19185, DOI 10.1074/jbc.M000641200; KAPLAN JH, 1985, ARCH BIOCHEM BIOPHYS, V237, P386, DOI 10.1016/0003-9861(85)90290-5; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Mahanty SK, 1996, J BIOL CHEM, V271, P367, DOI 10.1074/jbc.271.1.367; PATZELTWENCZLER R, 1981, EUR J BIOCHEM, V114, P79; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; PETROV VV, 1995, J BIOL CHEM, V270, P28535, DOI 10.1074/jbc.270.48.28535; POST RL, 1975, J BIOL CHEM, V250, P691; SCHULTHEIS PJ, 1993, BIOCHEMISTRY-US, V32, P544, DOI 10.1021/bi00053a020; Shi HLG, 2000, BBA-BIOMEMBRANES, V1464, P177, DOI 10.1016/S0005-2736(99)00245-X; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; VANIWAARDEN PR, 1991, BIOCHEMISTRY-US, V30, P9595, DOI 10.1021/bi00104a005; Wang SG, 1998, J BIOL CHEM, V273, P29400, DOI 10.1074/jbc.273.45.29400; Woo AL, 1999, J MEMBRANE BIOL, V169, P39, DOI 10.1007/PL00005899	30	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30734	30739		10.1074/jbc.M003737200	http://dx.doi.org/10.1074/jbc.M003737200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10906129	hybrid			2022-12-27	WOS:000089577900111
J	Hua, SM; Inesi, G				Hua, SM; Inesi, G			Distinct topologies of mono- and decavanadate binding and photo-oxidative cleavage in the sarcoplasmic reticulum ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; CHEMICAL MECHANISM; TRANSITION-STATE; VANADATE; PHOSPHATE; CA-2+-ATPASE; PHOTOCLEAVAGE; CA2+-ATPASE; PROTEINS; VESICLES	UV irradiation of the sarcoplasmic reticulum (SR) ATPase in the presence of vanadate cleaves the enzyme at either of two different sites. Under conditions favoring the presence of monovanadate, and in the presence of Ca2+, ADP, and Mg2+ cleavage results in two fragments of 71- and 38-kDa electrophoretic mobility. On the other hand, under conditions permitting formation of decavanadate, and in the absence of Ca2+ and ADP, cleavage results in two fragments of 88- and 21-kDa electrophoretic mobility. The amino terminus resulting from cleavage is blocked and resistant to Edman degradation. However, the initial photo-oxidation product can be reduced with (NaBH4)-H-3, resulting in incorporation of radioactive H-3 label. Extensive digestion of the labeled protein with trypsin then yields labeled peptides that are specific for the each of the photo-oxidation conditions, and can be sequenced after purification. Collection of the Edman reaction fractional products reveals the radioactive label and demonstrates that Thr(353) is the residue oxidized by monovanadate at the phosphorylation site (i.e. Asp(351)). Correct positioning of monovanadate at the phosphorylation site requires binding of Mg2+ and ADP to the Ca2+-dependent conformation of the enzyme. Subsequent hydrolytic cleavage is likely assisted by the neighboring Asp(601), and yields the 71- and 38-kDa fragments. On the other hand, Ser(186) (and possibly the following three residues: Val(187), Ile(188) and Lys(189)) is the residue that is photo-oxidized by de cavanadate in the absence of ADP. Hydrolytic cleavage of the oxidized product at this site is likely assisted by neighboring acidic residues, and yields the 88- and 21-kDa fragments. The bound decavanadate, which we find to produce steric interference with TNP-AMP binding, must therefore extend to the A domain (i.e. small cytosolic loop) in order to oxidize Ser(186). This protein conformation is only obtained in the absence of Ca2+.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 113, Japan	University System of Maryland; University of Maryland Baltimore; University of Tokyo	Inesi, G (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA.	ginesi@umaryland.edu		Toyoshima, Chikashi/0000-0001-9640-0778	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027867] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL27867] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AURELIANO M, 1994, BBA-MOL CELL RES, V1221, P259, DOI 10.1016/0167-4889(94)90249-6; BASTIDE F, 1973, J BIOL CHEM, V248, P8485; CREMO CR, 1989, J BIOL CHEM, V264, P6608; DEGANI C, 1973, J BIOL CHEM, V248, P8222; DUPONT Y, 1982, FEBS LETT, V139, P237, DOI 10.1016/0014-5793(82)80860-0; DUX L, 1983, J BIOL CHEM, V258, P2599; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; Goldshleger R, 1999, J BIOL CHEM, V274, P16213, DOI 10.1074/jbc.274.23.16213; Grammer JC, 1996, BIOCHEMISTRY-US, V35, P15582, DOI 10.1021/bi961901g; GRAMMER JC, 1988, BIOCHEMISTRY-US, V27, P8408, DOI 10.1021/bi00422a017; Hua SM, 1999, BIOPHYS J, V77, P2217, DOI 10.1016/S0006-3495(99)77062-1; INESI G, 1980, J BIOL CHEM, V255, P6040; Ko YH, 1999, J BIOL CHEM, V274, P28853, DOI 10.1074/jbc.274.41.28853; Ko YH, 1997, J BIOL CHEM, V272, P18875, DOI 10.1074/jbc.272.30.18875; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCINTOSH DB, 1992, J BIOL CHEM, V267, P5301; MOLNAR E, 1991, BIOCHIM BIOPHYS ACTA, V1068, P17, DOI 10.1016/0005-2736(91)90056-E; MUHLRAD A, 1995, MET IONS BIOL SYST, V31, P211; NAKAMOTO RK, 1984, J BIOL CHEM, V259, P2961; PICK U, 1982, J BIOL CHEM, V257, P6111; TAYLOR KA, 1986, J MOL BIOL, V187, P417, DOI 10.1016/0022-2836(86)90442-0; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; VEGH M, 1990, BIOCHIM BIOPHYS ACTA, V1023, P168, DOI 10.1016/0005-2736(90)90411-G; WATANABE T, 1982, J BIOL CHEM, V257, P1510; WEBER K, 1969, J BIOL CHEM, V244, P4406; Young HS, 1997, BIOPHYS J, V72, P2545, DOI 10.1016/S0006-3495(97)78898-2	27	42	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30546	30550		10.1074/jbc.M003218200	http://dx.doi.org/10.1074/jbc.M003218200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10906127	hybrid			2022-12-27	WOS:000089577900086
J	Wei, Y; Guffanti, AA; Ito, M; Krulwich, TA				Wei, Y; Guffanti, AA; Ito, M; Krulwich, TA			Bacillus subtilis YqkI is a novel malic/Na(+)-lactate antiporter that enhances growth on malate at low protonmotive force	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTIC-ACID BACTERIA; MALOLACTIC FERMENTATION; ESCHERICHIA-COLI; NA+/H+ ANTIPORTER; PH HOMEOSTASIS; SACCHAROMYCES-CEREVISIAE; LACTOBACILLUS-PLANTARUM; ENERGY TRANSDUCTION; MOTIVE FORCE; FIRMUS OF4	Bacillus subtilis yheL encodes a Na(+)/H(+) antiporter, whereas its paralogue, yqkI, encodes a novel antiporter that achieves a simultaneous Na(+)/R(+) and malolactate antiport. B. subtilis yufR, a control in some experiments, encodes a Na(+)/malate symporter. YqkI complemented a malate transport mutant of Escherichia coli if Na(+) and lactate were present. YheL conferred Na(+) uptake capacity on everted membrane vesicles from an antiporter-deficient E. coli mutant that was consistent with a secondary Na(+)/H(+) antiport, but YqkI-dependent Na(+) uptake depended on intravesicular malate and extravesicular lactate. YqkI-dependent lactate uptake depended on intravesicular malate and extravesicular Na(+). YqkI mediated an electroneutral exchange, which is proposed to be a malic(-2)-2H(+) (or fully protonated malate)/Na(+)-lactate(-1) antiport, Because the composite YqkI-mediated exchanges could be driven by gradients of the malate-lactate pair, this transporter could play a role in growth of B. subtilis on malate at low protonmotive force. A mutant with a disruption of yqkI exhibited an abrupt arrest in the mid-logarithmic phase of growth on malate when low concentrations of protonophore were present. Thus growth of B. subtilis to high density on a putatively nonfermentative dicarboxylic acid substrate depends on a malolactate exchange at suboptimal protonmotive force.	Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Krulwich, TA (corresponding author), Mt Sinai Sch Med, Dept Biochem & Mol Biol, Box 1020,1 Gustave L Levy Pl, New York, NY 10029 USA.	terry.krulwich@mssm.edu	ITO, MASAHIRO/H-1960-2013	ITO, MASAHIRO/0000-0002-4976-762X	NIGMS NIH HHS [GM52837, GM28454] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028454] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe K, 1996, J BIOL CHEM, V271, P3079, DOI 10.1074/jbc.271.6.3079; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMBUDKAR SV, 1984, J BIOL CHEM, V259, P6142; ANANTHARAM V, 1989, J BIOL CHEM, V264, P7244; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bandell M, 1997, J BIOL CHEM, V272, P18140, DOI 10.1074/jbc.272.29.18140; Bony M, 1997, FEBS LETT, V410, P452, DOI 10.1016/S0014-5793(97)00637-6; CASPRITZ G, 1983, J BIOL CHEM, V258, P4907; DAVIS CR, 1988, AM J ENOL VITICULT, V39, P137; DENAYROLLES M, 1994, FEMS MICROBIOL LETT, V116, P79, DOI 10.1016/0378-1097(94)90111-2; Dimroth P, 1997, BBA-BIOENERGETICS, V1318, P11, DOI 10.1016/S0005-2728(96)00127-2; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; Guffanti AA, 1998, J BIOL CHEM, V273, P26447, DOI 10.1074/jbc.273.41.26447; GUFFANTI AA, 1987, J BACTERIOL, V169, P4469, DOI 10.1128/jb.169.10.4469-4478.1987; HAROLD FM, 1986, VITAL FORCE STUDY BI, P57; HENICKKLING T, 1995, J APPL BACTERIOL, V79, pS29; Higuchi T, 1997, J BACTERIOL, V179, P3362, DOI 10.1128/JB.179.10.3362-3364.1997; Ito M, 1999, J BACTERIOL, V181, P2394, DOI 10.1128/JB.181.8.2394-2402.1999; Ito M, 1997, J BACTERIOL, V179, P3851, DOI 10.1128/jb.179.12.3851-3857.1997; IVEY DM, 1991, J BIOL CHEM, V266, P23483; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; Kakinuma Y, 1998, MICROBIOL MOL BIOL R, V62, P1021, DOI 10.1128/MMBR.62.4.1021-1045.1998; Kawai S, 1997, J BACTERIOL, V179, P4056, DOI 10.1128/jb.179.12.4056-4060.1997; Konings WN, 1997, ANTON LEEUW INT J G, V71, P117, DOI 10.1023/A:1000143525601; KRULWICH TA, 1994, J EXP BIOL, V196, P457; Krulwich TA, 1999, NOVART FDN SYMP, V221, P167; KUNKEE RE, 1991, FEMS MICROBIOL LETT, V88, P55, DOI 10.1016/0168-6445(91)90006-4; Labarre C, 1996, APPL ENVIRON MICROB, V62, P1274, DOI 10.1128/AEM.62.4.1274-1282.1996; LLOKEMA JS, 1995, J BIOENERG BIOMEMBR, V27, P467; LO TCY, 1972, J BIOL CHEM, V247, P6323; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACNAB RM, 1987, BIOPHYS J, V52, P637, DOI 10.1016/S0006-3495(87)83255-1; MOLENAAR D, 1993, J BACTERIOL, V175, P2864, DOI 10.1128/JB.175.10.2864-2870.1993; OLSEN EB, 1991, J BACTERIOL, V173, P6199, DOI 10.1128/jb.173.19.6199-6206.1991; Padan E, 2000, BACTERIAL STRESS RESPONSES, P117; PADAN E, 1994, BBA-BIOENERGETICS, V1185, P129, DOI 10.1016/0005-2728(94)90204-6; Padan E., 1996, HDB BIOL PHYS, V2, P501; PINNER E, 1993, J BIOL CHEM, V268, P1729; POOLMAN B, 1991, J BACTERIOL, V173, P6030, DOI 10.1128/jb.173.19.6030-6037.1991; REIZER J, 1994, BBA-REV BIOMEMBRANES, V1197, P133, DOI 10.1016/0304-4157(94)90003-5; Takami H, 2000, EXTREMOPHILES, V4, P19, DOI 10.1007/s007920050133; Volschenk H, 1997, NAT BIOTECHNOL, V15, P253, DOI 10.1038/nbt0397-253; Wang W, 2000, J BACTERIOL, V182, P2088, DOI 10.1128/JB.182.8.2088-2095.2000; WEST IC, 1974, BIOCHEM J, V144, P87, DOI 10.1042/bj1440087	44	62	67	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30287	30292		10.1074/jbc.M001112200	http://dx.doi.org/10.1074/jbc.M001112200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10903309	hybrid			2022-12-27	WOS:000089577900052
J	Lee, VT; Tam, C; Schneewind, O				Lee, VT; Tam, C; Schneewind, O			LcrV, a substrate for Yersinia enterocolitica type III secretion, is required for toxin targeting into the cytosol of HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-CALCIUM RESPONSE; PROTEIN-TYROSINE-PHOSPHATASE; V-ANTIGEN; YOP SECRETION; MAMMALIAN-CELLS; TRANSCRIPTIONAL ACTIVATOR; NEGATIVE REGULATION; VIRULENCE PLASMID; LOW-CA2+ RESPONSE; EUKARYOTIC CELLS	Pathogenic Yersinia species employ type III machines to transport virulence factors across the bacterial envelope. Some substrates for the type III machinery are secreted into the extracellular medium, whereas others are targeted into the cytosol of host cells. We found that during infection of tissue culture cells, yersiniae secrete small amounts of LcrV into the extracellular medium. Knockout mutations of lcrV abolish Yersinia targeting and reduce expression of the lcrGVHyopBD operon. In contrast, a block in LcrV secretion does not affect targeting, but results in premature expression and secretion of Yop proteins into the extracellular medium. LcrV-mediated activation of the type III pathway is thought to occur by sequestration of the regulatory factor LcrG, presumably via the formation of LcrV LcrG complexes. These results suggest that intrabacterial LcrV regulates the expression and targeting of Yop proteins during Yersinia infection, whereas secreted LcrV is required to ensure specificity of Yop injection into eukaryotic cells.	Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Schneewind, O (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.			Lee, Vincent T./0000-0002-3593-0318	NIAID NIH HHS [AI 42797] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042797] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAOUI A, 1994, J BACTERIOL, V176, P4534, DOI 10.1128/JB.176.15.4534-4542.1994; ALLAOUI A, 1995, MOL MICROBIOL, V18, P343, DOI 10.1111/j.1365-2958.1995.mmi_18020343.x; Anderson DM, 1999, MOL MICROBIOL, V31, P1139, DOI 10.1046/j.1365-2958.1999.01254.x; BERGMAN T, 1994, J BACTERIOL, V176, P2619, DOI 10.1128/JB.176.9.2619-2626.1994; BERGMAN T, 1991, J BACTERIOL, V173, P1607, DOI 10.1128/jb.173.5.1607-1616.1991; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; Boland A, 1996, EMBO J, V15, P5191, DOI 10.1002/j.1460-2075.1996.tb00904.x; Boyd AP, 1998, MOL MICROBIOL, V27, P425, DOI 10.1046/j.1365-2958.1998.00691.x; BURROWS TW, 1956, BRIT J EXP PATHOL, V37, P481; BURROWS TW, 1958, BRIT J EXP PATHOL, V39, P278; Cheng LW, 1997, MOL MICROBIOL, V24, P757, DOI 10.1046/j.1365-2958.1997.3831750.x; CORNELIS G, 1975, J GEN MICROBIOL, V87, P285, DOI 10.1099/00221287-87-2-285; CORNELIS G, 1989, J BACTERIOL, V171, P254, DOI 10.1128/jb.171.1.254-262.1989; Cornelis GR, 1998, MICROBIOL MOL BIOL R, V62, P1315, DOI 10.1128/MMBR.62.4.1315-1352.1998; Cornelis GR, 1998, J BACTERIOL, V180, P5495, DOI 10.1128/JB.180.21.5495-5504.1998; Cornelis GR, 1997, MOL MICROBIOL, V23, P861, DOI 10.1046/j.1365-2958.1997.2731623.x; Fields KA, 1999, INFECT IMMUN, V67, P5395, DOI 10.1128/IAI.67.10.5395-5408.1999; GALYOV EE, 1993, NATURE, V361, P730, DOI 10.1038/361730a0; GOGUEN JD, 1984, J BACTERIOL, V160, P842, DOI 10.1128/JB.160.3.842-848.1984; Hakansson S, 1996, MOL MICROBIOL, V20, P593, DOI 10.1046/j.1365-2958.1996.5251051.x; Hill J, 1997, INFECT IMMUN, V65, P4476, DOI 10.1128/IAI.65.11.4476-4482.1997; HOE NP, 1993, J BACTERIOL, V175, P7901, DOI 10.1128/JB.175.24.7901-7909.1993; HOE NP, 1992, J BACTERIOL, V174, P4275, DOI 10.1128/JB.174.13.4275-4286.1992; Iriarte M, 1998, MOL MICROBIOL, V29, P915, DOI 10.1046/j.1365-2958.1998.00992.x; Lee VT, 1998, MOL MICROBIOL, V28, P593, DOI 10.1046/j.1365-2958.1998.00822.x; Lee VT, 1999, MOL MICROBIOL, V31, P1619, DOI 10.1046/j.1365-2958.1999.01270.x; Lee VT, 1999, IMMUNOL REV, V168, P241, DOI 10.1111/j.1600-065X.1999.tb01296.x; MICHIELS T, 1991, J BACTERIOL, V173, P4994, DOI 10.1128/jb.173.16.4994-5009.1991; MICHIELS T, 1990, INFECT IMMUN, V58, P2840, DOI 10.1128/IAI.58.9.2840-2849.1990; MICHIELS T, 1991, J BACTERIOL, V173, P1677, DOI 10.1128/jb.173.5.1677-1685.1991; Mills SD, 1997, P NATL ACAD SCI USA, V94, P12638, DOI 10.1073/pnas.94.23.12638; NAKAJIMA R, 1995, INFECT IMMUN, V63, P3021, DOI 10.1128/IAI.63.8.3021-3029.1995; Nilles ML, 1997, J BACTERIOL, V179, P1307, DOI 10.1128/jb.179.4.1307-1316.1997; Nilles ML, 1998, J BACTERIOL, V180, P3410, DOI 10.1128/JB.180.13.3410-3420.1998; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; PERSSON C, 1995, MOL MICROBIOL, V18, P135, DOI 10.1111/j.1365-2958.1995.mmi_18010135.x; Pettersson J, 1999, MOL MICROBIOL, V32, P961, DOI 10.1046/j.1365-2958.1999.01408.x; Pettersson J, 1996, SCIENCE, V273, P1231, DOI 10.1126/science.273.5279.1231; PRICE SB, 1989, J BACTERIOL, V171, P5646, DOI 10.1128/jb.171.10.5646-5653.1989; REISS B, 1984, EMBO J, V3, P3317, DOI 10.1002/j.1460-2075.1984.tb02297.x; ROSQVIST R, 1991, INFECT IMMUN, V59, P4562, DOI 10.1128/IAI.59.12.4562-4569.1991; ROSQVIST R, 1994, EMBO J, V13, P964, DOI 10.1002/j.1460-2075.1994.tb06341.x; ROSQVIST R, 1988, INFECT IMMUN, V56, P2139, DOI 10.1128/IAI.56.8.2139-2143.1988; ROSQVIST R, 1990, MOL MICROBIOL, V4, P657, DOI 10.1111/j.1365-2958.1990.tb00635.x; Sarker MR, 1998, J BACTERIOL, V180, P1207, DOI 10.1128/JB.180.5.1207-1214.1998; Sarker MR, 1998, INFECT IMMUN, V66, P2976, DOI 10.1128/IAI.66.6.2976-2979.1998; SKRZYPEK E, 1993, J BACTERIOL, V175, P3520, DOI 10.1128/jb.175.11.3520-3528.1993; Stainier I, 1997, MOL MICROBIOL, V26, P833, DOI 10.1046/j.1365-2958.1997.6281995.x; STRALEY SC, 1993, MOL MICROBIOL, V8, P1005, DOI 10.1111/j.1365-2958.1993.tb01644.x; UNE T, 1984, J IMMUNOL, V133, P2226; WATTIAU P, 1994, J BACTERIOL, V176, P3878, DOI 10.1128/JB.176.13.3878-3884.1994; Welkos S, 1998, MICROB PATHOGENESIS, V24, P185, DOI 10.1006/mpat.1997.0188; Williams AW, 1998, J BACTERIOL, V180, P350, DOI 10.1128/JB.180.2.350-358.1998; YOTHER J, 1986, J BACTERIOL, V165, P443, DOI 10.1128/jb.165.2.443-447.1986	54	67	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36869	36875		10.1074/jbc.M002467200	http://dx.doi.org/10.1074/jbc.M002467200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10930402	hybrid			2022-12-27	WOS:000165577700061
J	Poso, D; Sessions, RB; Lorch, M; Clarke, AR				Poso, D; Sessions, RB; Lorch, M; Clarke, AR			Progressive stabilization of intermediate and transition states in protein folding reactions by introducing surface hydrophobic residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENGINEERING PROCEDURE; AMINO-ACIDS; BARNASE; ENZYME; PROPENSITIES; BACKBONE; DYNAMICS; TOPOLOGY; SOLVENT; CD2	It can be argued from the principle of solvent exclusion that the introduction of hydrophobic residues onto the surface of a protein wildrophobic surface mutations. This effect is slightly moderated in the folded state presumably by the perturbation of van der Waals' contacl not destabilize the folded state because the nonpolar side chain will be at least as exposed in ocal electrostatic interactions that have a greater influence in this fully compact structure. The fact that in all but one case we find that stabilization of the rapidly collapsthe unfolded state as it is when the protein chain is folded. A comparison of the folding pathway of wild type and 11 site-directed mutants of CD2.d1 shows this to be true. In fact, owing to partial burial of nonpolar groups as folding proceeds, we find that the rapidly formed intermediate state and, to a greater extent, the transition state are generally stabilized by hyts and/or led intermediate is accompanied by a faster acquisition of the folded state refutes the argument that I states are generally "off pathway" conformations or ensembles that lead to the inhibition of otherwise more rapid folding trajectories.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Clarke, AR (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Univ Walk, Bristol BS8 1TD, Avon, England.			Sessions, Richard/0000-0003-0320-0895				Baldwin RL, 1996, FOLD DES, V1, pR1, DOI 10.1016/S1359-0278(96)00003-X; Clarke AR, 1997, CURR OPIN BIOTECH, V8, P400, DOI 10.1016/S0958-1669(97)80060-2; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; CREIGHTON TE, 1994, NAT STRUCT BIOL, V1, P135, DOI 10.1038/nsb0394-135; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; Fersht AR, 1997, CURR OPIN STRUC BIOL, V7, P3, DOI 10.1016/S0959-440X(97)80002-4; Gu H, 1999, PROTEIN SCI, V8, P2734; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; KIM CWA, 1993, NATURE, V362, P267, DOI 10.1038/362267a0; LESSER GJ, 1990, PROTEINS, V8, P6, DOI 10.1002/prot.340080104; LEVITT M, 1976, J MOL BIOL, V104, P59, DOI 10.1016/0022-2836(76)90004-8; Lorch M, 1999, BIOCHEMISTRY-US, V38, P1377, DOI 10.1021/bi9817820; MATOUSCHEK A, 1992, J MOL BIOL, V224, P819, DOI 10.1016/0022-2836(92)90564-Z; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; NAKAI K, 1988, PROTEIN ENG, V2, P93, DOI 10.1093/protein/2.2.93; NOZAKI Y, 1971, J BIOL CHEM, V246, P2211; Oliveberg M, 1998, ACCOUNTS CHEM RES, V31, P765, DOI 10.1021/ar970089m; PAKULA AA, 1990, NATURE, V344, P363, DOI 10.1038/344363a0; Parker MJ, 1997, BIOCHEMISTRY-US, V36, P13396, DOI 10.1021/bi971294c; PARKER MJ, 1995, J MOL BIOL, V253, P771, DOI 10.1006/jmbi.1995.0590; Parker MJ, 1997, BIOCHEMISTRY-US, V36, P5786, DOI 10.1021/bi9629283; Parker MJ, 1998, NAT STRUCT BIOL, V5, P194, DOI 10.1038/nsb0398-194; Roder H, 1997, CURR OPIN STRUC BIOL, V7, P15, DOI 10.1016/S0959-440X(97)80004-8; ROSE GD, 1985, SCIENCE, V229, P834, DOI 10.1126/science.4023714; Schindler T, 1998, PROTEINS, V30, P401, DOI 10.1002/(SICI)1097-0134(19980301)30:4<401::AID-PROT7>3.3.CO;2-G; SERRANO L, 1992, J MOL BIOL, V224, P805, DOI 10.1016/0022-2836(92)90563-Y; SERRANO L, 1992, J MOL BIOL, V224, P783, DOI 10.1016/0022-2836(92)90562-X; SHRAKE A, 1973, J MOL BIOL, V79, P351, DOI 10.1016/0022-2836(73)90011-9; SIMTH CK, 1994, BIOCHEMISTRY-US, V33, P5510	31	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35723	35726		10.1074/jbc.M001747200	http://dx.doi.org/10.1074/jbc.M001747200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10938078	hybrid			2022-12-27	WOS:000165382000013
J	Fukasawa, M; Nishijima, M; Itabe, H; Takano, T; Hanada, K				Fukasawa, M; Nishijima, M; Itabe, H; Takano, T; Hanada, K			Reduction of sphingomyelin level without accumulation of ceramide iu Chinese hamster ovary cells affects detergent-resistant membrane domains and enhances cellular cholesterol efflux to methyl-beta-cyclodextrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; ANCHORED PROTEIN; ENDOPLASMIC-RETICULUM; CULTURED FIBROBLASTS; TRANSPORT; DEGRADATION; VESICLES; BIOSYNTHESIS; INSOLUBILITY; TRAFFICKING	We examined the effects of reduction of sphingomyelin level on cholesterol behavior in cells using 2 types of Chinese hamster ovary cell mutants deficient in sphingomyelin synthesis: LY-A strain defective in intracellular trafficking of ceramide for sphingomyelin synthesis, and LP-B strain defective in the enzyme catalyzing the initial step of sphingolipid biosynthesis. Although the sphingomyelin content in LY-A and LY-B cells was similar to 40 and similar to 15% respectively, of the wild-type level without accumulation of ceramide, these mutant cells were almost identical in cholesterol content and also in plasma membrane cholesterol level to the wild-type cells. However, density gradient fractionation analysis of Triton X-100-treated lysates of cells prelabeled with [H-3]cholesterol showed that the [H-3]cholesterol level in the low-density floating fraction was lower in sphingomyelin-deficient cells than in wild-type cells. When cells mere exposed to methyl-beta -cyclodextrin, cholesterol was more efficiently fluxed from sphingomyelin-deficient cells than wild-type cells. These results suggest that the steady state level of cholesterol at the plasma membrane is little affected by the sphingomyelin levels in Chinese hamster ovary cells, but that sphingomyelin levels play an important role in the retention of cholesterol in the plasma membrane against efflux to extracellular cholesterol-acceptors, due to interaction between sphingomyelin and cholesterol in detergent-resistant membrane domains.	Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Tokyo 1628640, Japan; Teikyo Univ, Fac Pharmaceut Sci, Dept Microbiol & Mol Pathol, Sagamiko, Kanagawa 1990195, Japan	National Institute of Infectious Diseases (NIID); Teikyo University	Hanada, K (corresponding author), Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.		板部板部, 洋之/ABC-7746-2020	Hanada, Kentaro/0000-0003-1383-2781				Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BITTMAN R, 1994, BIOCHEMISTRY-US, V33, P11776, DOI 10.1021/bi00205a013; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; DAHL NK, 1992, J BIOL CHEM, V267, P4889; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; DEMEL RA, 1977, BIOCHIM BIOPHYS ACTA, V465, P1, DOI 10.1016/0005-2736(77)90350-9; Fielding CJ, 1997, J LIPID RES, V38, P1503; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; Fukasawa M, 1999, J CELL BIOL, V144, P673, DOI 10.1083/jcb.144.4.673; GUPTA AK, 1991, J LIPID RES, V32, P125; HANADA K, 1993, J BIOL CHEM, V268, P13820; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; Hanada K, 1998, J BIOL CHEM, V273, P33787, DOI 10.1074/jbc.273.50.33787; HARMALA AS, 1993, BIOCHIM BIOPHYS ACTA, V1210, P97, DOI 10.1016/0005-2760(93)90054-D; HEIDER JG, 1978, J LIPID RES, V19, P514; Ito J, 2000, J LIPID RES, V41, P894; KAN CC, 1991, BIOCHEMISTRY-US, V30, P7759, DOI 10.1021/bi00245a013; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; KRIEGER M, 1983, ANAL BIOCHEM, V135, P383, DOI 10.1016/0003-2697(83)90700-5; KUDEHODKAR BJ, 1983, ATHEROSCLEROSIS, V46, P353; Liscum L, 1999, BBA-MOL CELL BIOL L, V1438, P19, DOI 10.1016/S1388-1981(99)00043-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Naslavsky N, 1999, J BIOL CHEM, V274, P20763, DOI 10.1074/jbc.274.30.20763; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Ohvo H, 1997, BBA-LIPID LIPID MET, V1349, P131, DOI 10.1016/S0005-2760(97)00126-4; Ostermeyer AG, 1999, J BIOL CHEM, V274, P34459, DOI 10.1074/jbc.274.48.34459; PORN MI, 1995, BIOCHEM J, V308, P269; PORN MI, 1993, J LIPID RES, V34, P1385; Ramstedt B, 1999, BIOPHYS J, V76, P908, DOI 10.1016/S0006-3495(99)77254-1; RIDGWAY ND, 1995, BBA-LIPID LIPID MET, V1256, P39, DOI 10.1016/0005-2760(95)00009-2; Rothblat GH, 1999, J LIPID RES, V40, P781; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SLOTTE JP, 1990, BIOCHIM BIOPHYS ACTA, V1030, P251, DOI 10.1016/0005-2736(90)90301-4; SLOTTE JP, 1989, BIOCHIM BIOPHYS ACTA, V985, P90, DOI 10.1016/0005-2736(89)90108-9; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; STEIN O, 1992, BIOCHIM BIOPHYS ACTA, V1126, P291, DOI 10.1016/0005-2760(92)90243-O; Stevens VL, 1997, J BIOL CHEM, V272, P18020, DOI 10.1074/jbc.272.29.18020; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; VANBLITTERSWIJK WJ, 1987, BIOCHEMISTRY-US, V26, P1746, DOI 10.1021/bi00380a038; WATTENBERG BW, 1983, J BIOL CHEM, V258, P2284; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026; YEAGLE PL, 1986, J BIOL CHEM, V261, P8175	48	92	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34028	34034		10.1074/jbc.M005151200	http://dx.doi.org/10.1074/jbc.M005151200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10930414	hybrid			2022-12-27	WOS:000165095300006
J	Leu, FP; Hingorani, MM; Turner, J; O'Donnell, M				Leu, FP; Hingorani, MM; Turner, J; O'Donnell, M			The delta subunit of DNA polymerase III holoenzyme serves as a sliding clamp unloader in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL REPLICATION MACHINE; LAGGING-STRAND REPLICATION; CELL NUCLEAR ANTIGEN; ACCESSORY PROTEINS; ATP HYDROLYSIS; ALPHA-SUBUNIT; BETA-SUBUNIT; PCNA; PURIFICATION; COMPLEX	In Escherichia coli, the circular beta sliding clamp facilitates processive DNA replication by tethering the polymerase to primer-template DNA. When synthesis is complete, polymerase dissociates from beta and DNA and cycles to a new start site, a primed template loaded with beta. DNA polymerase cycles frequently during lagging strand replication while synthesizing l-a-kilobase Okazaki fragments. The clamps left behind remain stable on DNA (t(1/2) similar to 115 min) and must be removed rapidly for reuse at numerous primed sites on the lagging strand. Here we show that delta, a single subunit of DNA polymerase III holoenzyme, opens beta and slips it off DNA (k(unloading) = 0.011 s(-1)) at a rate similar to that of the multisubunit gamma complex clamp loader by itself (0.015 s(-1)) or within polymerase (pol) III* (0.0065 s(-1)). Moreover, unlike gamma complex and pol III*, delta does not require ATP to catalyze clamp unloading. Quantitation of gamma complex subunits (gamma, delta, delta', chi, psi) in E. coli cells reveals an excess of delta, free from gamma complex and pol III*. Since pol III* and gamma complex occur in much lower quantities and perform several DNA metabolic functions in replication and repair, the delta subunit probably aids beta clamp recycling during DNA replication.	Rockefeller Univ, New York, NY 10021 USA; Howard Hughes Med Inst, Lab DNA Reprod, New York, NY 10021 USA; Cornell Univ, Dept Pharmacol, Joan & Sanford I Weill Grad Sch Med Sci, New York, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute; Cornell University	O'Donnell, M (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.				NIGMS NIH HHS [GM 38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; BURGERS PMJ, 1981, P NATL ACAD SCI-BIOL, V78, P5391, DOI 10.1073/pnas.78.9.5391; Cai JS, 1997, J BIOL CHEM, V272, P18974, DOI 10.1074/jbc.272.30.18974; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FAY PJ, 1981, J BIOL CHEM, V256, P976; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HELMSTETTER CE, 1996, ESCHERICHIA COLI SAL, P1627; Hingorani MM, 1999, EMBO J, V18, P5131, DOI 10.1093/emboj/18.18.5131; Hingorani MM, 2000, CURR BIOL, V10, pR25, DOI 10.1016/S0960-9822(99)00252-3; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; HUANG CC, 1981, J BIOL CHEM, V256, P4087; Kelman Z, 1998, EMBO J, V17, P2436, DOI 10.1093/emboj/17.8.2436; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; KELMAN Z, 1995, THESIS CORNELL U; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KORNBERG T, 1972, J BIOL CHEM, V247, P5369; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; Lemon KP, 1998, SCIENCE, V282, P1516, DOI 10.1126/science.282.5393.1516; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; MAKI H, 1985, J BIOL CHEM, V260, P2987; MAKI S, 1988, J BIOL CHEM, V263, P6555; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; Moarefi I, 2000, J MOL BIOL, V296, P1215, DOI 10.1006/jmbi.1999.3511; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1991, J BIOL CHEM, V266, P21681; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; RUSH J, 1989, J BIOL CHEM, V264, P10943; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; Soumillion P, 1998, BIOCHEMISTRY-US, V37, P1819, DOI 10.1021/bi972526a; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TINKER LF, 1994, DIABETES SPECTRUM, V7, P225; TINKER RL, 1994, EMBO J, V13, P5330, DOI 10.1002/j.1460-2075.1994.tb06867.x; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; WU YH, 1984, J BIOL CHEM, V259, P2117; XIAO H, 1995, J BIOL CHEM, V270, P13378, DOI 10.1074/jbc.270.22.13378; XIAO H, 1993, J BIOL CHEM, V268, P11773; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; Young MC, 1996, J MOL BIOL, V264, P440, DOI 10.1006/jmbi.1996.0652; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	65	70	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34609	34618		10.1074/jbc.M005495200	http://dx.doi.org/10.1074/jbc.M005495200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10924523	hybrid			2022-12-27	WOS:000165095300083
J	Tamura, K; Chen, YQE; Lopez-Ilasaca, M; Daviet, L; Tamura, N; Ishigami, T; Akishita, M; Takasaki, I; Tokita, Y; Pratt, RE; Horiuchi, M; Dzau, VJ; Umemura, S				Tamura, K; Chen, YQE; Lopez-Ilasaca, M; Daviet, L; Tamura, N; Ishigami, T; Akishita, M; Takasaki, I; Tokita, Y; Pratt, RE; Horiuchi, M; Dzau, VJ; Umemura, S			Molecular mechanism of fibronectin gene activation by cyclic stretch in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CARDIAC MYOCYTES; GROWTH-FACTOR-BETA; ANGIOTENSIN-II; COLLAGEN-SYNTHESIS; PRESSURE-OVERLOAD; RECEPTOR SUBTYPES; IN-VITRO; EXPRESSION; STRAIN; TRANSCRIPTION	Fibronectin plays an important role in vascular remodeling. A functional interaction between mechanical stimuli and locally produced vasoactive agents is suggested to be crucial for vascular remodeling. We examined the effect of mechanical stretch on fibronectin gene expression in vascular smooth muscle cells and the role of vascular angiotensin II in the regulation of the fibronectin gene in response to stretch. Cyclic stretch induced an increase in vascular fibronectin mRNA levels that was inhibited by actinomycin D and CV11974, an angiotensin II type 1 receptor antagonist; cycloheximide and PD123319, an angiotensin II type 2 receptor antagonist, did not affect the induction. In transfection experiments, fibronectin promoter activity was stimulated by stretch and inhibited by CV11974 but not by PD123319, DNA-protein binding experiments revealed that cyclic stretch enhanced nuclear binding to the AP-1 site, which was partially supershifted by antibody to c-Jun. Site-directed mutation of the AP-1 site significantly decreased the cyclic stretch-mediated activation of fibronectin promoter. Furthermore, antisense c-jun oligo nucleotides decreased the stretch-induced stimulation of the fibronectin promoter activity and the mRNA expression. These results suggest that cyclic stretch stimulates vascular fibronectin gene expression mainly via the activation of AP-1 through the angiotensin II type 1 receptor.	Yokohama City Univ, Sch Med, Dept Internal Med 2, Yokohama, Kanagawa 236, Japan; Yokohama City Univ, Sch Med, Dept Dermatol, Yokohama, Kanagawa 236, Japan; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Fujisawa Municipal Hosp, Dept Med, Div Renal, Fujisawa, Kanagawa 251, Japan	Yokohama City University; Yokohama City University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Tamura, K (corresponding author), Yokohama City Univ, Sch Med, Dept Internal Med 2, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.	tamukou@med.yokohama-cu.ac.jp						BENES AJ, 1985, J CELL SCI, V75, P35; BOOZ GW, 1992, ENDOCRINOLOGY, V130, P3641, DOI 10.1210/en.130.6.3641; BOWLUS CL, 1991, J BIOL CHEM, V266, P1122; Cheng GC, 1997, CIRC RES, V80, P28, DOI 10.1161/01.RES.80.1.28; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GILBERT JA, 1994, J BIOMECH, V27, P1169, DOI 10.1016/0021-9290(94)90057-4; GREEN LM, 1984, J IMMUNOL METHODS, V70, P257, DOI 10.1016/0022-1759(84)90190-X; Haller H, 1996, CIRC RES, V79, P765, DOI 10.1161/01.RES.79.4.765; Hamaguchi A, 1999, HYPERTENSION, V34, P126, DOI 10.1161/01.HYP.34.1.126; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; IKEDA U, 1995, CIRCULATION, V92, P2683, DOI 10.1161/01.CIR.92.9.2683; KAGAMI S, 1994, J CLIN INVEST, V93, P2431, DOI 10.1172/JCI117251; KATO H, 1991, J HYPERTENS, V9, P17; Kijima K, 1996, CIRC RES, V79, P887, DOI 10.1161/01.RES.79.4.887; KIM SK, 1995, CIRCULATION, V92, P88, DOI 10.1161/01.CIR.92.1.88; KINUGAWA K, 1993, EUR J PHARMACOL, V235, P313, DOI 10.1016/0014-2999(93)90153-9; Li Q, 1998, J VASC RES, V35, P93, DOI 10.1159/000025570; LOKUTA AJ, 1994, J BIOL CHEM, V269, P4832; Mercurius KO, 1998, CIRC RES, V82, P548, DOI 10.1161/01.RES.82.5.548; NODA M, 1993, BIOCHEM PHARMACOL, V46, P311; Nyui N, 1997, BIOCHEM BIOPH RES CO, V235, P36, DOI 10.1006/bbrc.1997.6706; RuizOrtega M, 1997, KIDNEY INT, V52, P1497, DOI 10.1038/ki.1997.480; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SHIOTA N, 1992, HYPERTENSION, V20, P168, DOI 10.1161/01.HYP.20.2.168; SUDHIR K, 1993, J CLIN INVEST, V92, P3003, DOI 10.1172/JCI116923; SUZUKI M, 1995, MOL CELL BIOL, V15, P5423; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; TAKASAKI I, 1990, J BIOL CHEM, V265, P21935; Tamura K, 1998, KIDNEY INT, V54, P382, DOI 10.1046/j.1523-1755.1998.00025.x; Tamura K, 1999, J HYPERTENS, V17, P81, DOI 10.1097/00004872-199917010-00013; Tamura K, 1998, J BIOL CHEM, V273, P26487, DOI 10.1074/jbc.273.41.26487; Tamura K, 1996, HYPERTENSION, V27, P1216, DOI 10.1161/01.HYP.27.6.1216; vonHarsdorf R, 1997, J CLIN INVEST, V100, P1294, DOI 10.1172/JCI119643; Wilson E, 1998, HYPERTENSION, V31, P170, DOI 10.1161/01.HYP.31.1.170; WILSON E, 1995, J CLIN INVEST, V96, P2364, DOI 10.1172/JCI118293; YAMAZAKI T, 1995, CIRC RES, V77, P258, DOI 10.1161/01.RES.77.2.258	37	42	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34619	34627		10.1074/jbc.M004421200	http://dx.doi.org/10.1074/jbc.M004421200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10930408	hybrid			2022-12-27	WOS:000165095300084
J	Mwanjewe, J; Martinez, R; Agrawal, P; Samson, SE; Coughlin, MD; Brassard, P; Grover, AK				Mwanjewe, J; Martinez, R; Agrawal, P; Samson, SE; Coughlin, MD; Brassard, P; Grover, AK			On the Ca2+ dependence of non-transferrin-bound iron uptake in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; SUBCELLULAR-LOCALIZATION; MEMBRANE-VESICLES; HELA-CELLS; RAT-LIVER; TRANSPORT; EXPRESSION; SYSTEM	Non-transferrin-bound iron (NTBI) uptake has been reported to follow two pathways, Ca2+-dependent and Ca2+-independent (Wright, T. L., Brissot, P,, Ma, W, L,, and Weisiger, R. A. (1986) J. Biol. Chern, 261, 10909-10914; Sturrock, k, Alexander, J,, Lamb, J,, Craven, C, M., and Kaplan, J, (1990) J, Biol. Chem. 265, 3139-3145). Studies reporting the two pathways have ignored the weak interactions of Ca2+ with the chelator nitrilotriacetate (NTA) and the reducing agent ascorbate. These studies used a constant ratio of total Fe2+ to NTA with and without Ca2+, We observed Ca2+ activation of NTBI uptake in PC12 cells with the characteristics reported for other cells upon using 1 mM ascorbate and a constant ratio of total Fe2+ to NTA with or without Ca2+. However, Ca2+ did not affect NTBI uptake in solutions without NTA. We then determined conditional stability constants for NTA binding to Ca2+ and Fe2+ by potentiometry under conditions of NTBI uptake experiments (pH, ionic strength, temperature, ascorbate, total Fe2+, and total Ca2+ concentrations). In solutions based on these constants and taking Ca2+ chelation into account, Ca2+ did not affect NTBI uptake over a range of free Fe2+ concentrations. Thus, the Ca2+ activation of NTBI uptake observed using the constant total Fe2+ to NTA ratio was because of Ca2+-NTA chelation rather than an activation of the NTBI transporter itself, It is suggested that the previously reported Ca2+ dependence of NTBI uptake be re-evaluated.	McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Chem, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University; McMaster University	Grover, AK (corresponding author), McMaster Univ, Dept Med, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.							AHNERTHILGER G, 1987, J NEUROCHEM, V49, P764, DOI 10.1111/j.1471-4159.1987.tb00959.x; Baker E, 1998, BBA-GEN SUBJECTS, V1380, P21, DOI 10.1016/S0304-4165(97)00120-7; BARISANI D, 1995, AM J PHYSIOL-GASTR L, V269, pG570, DOI 10.1152/ajpgi.1995.269.4.G570; Bouron A, 1999, N-S ARCH PHARMACOL, V359, P370, DOI 10.1007/PL00005363; Canonne-Hergaux F, 1999, BLOOD, V93, P4406, DOI 10.1182/blood.V93.12.4406.412k21_4406_4417; DIAMOND J, 1992, J NEUROSCI, V12, P1467; Garrick MD, 1999, BBA-MOL CELL RES, V1449, P125, DOI 10.1016/S0167-4889(99)00006-3; GUSTAFSON RL, 1963, J PHYS CHEM-US, V67, P576, DOI 10.1021/j100797a008; INMAN RS, 1993, J BIOL CHEM, V268, P8521; Keller D, 2000, NEUROREPORT, V11, P65, DOI 10.1097/00001756-200001170-00013; Kim S, 1999, J BIOL CHEM, V274, P33035, DOI 10.1074/jbc.274.46.33035; LAMB JE, 1983, J BIOL CHEM, V258, P8751; Liu HL, 1997, J BIOL CHEM, V272, P6038, DOI 10.1074/jbc.272.9.6038; MARTELL AE, 1999, CRITICAL STABILITY C, V5, P62; NAKAGAWA G, 1980, B CHEM SOC JPN, V53, P1303, DOI 10.1246/bcsj.53.1303; Parkes JG, 1997, TOXICOLOGY, V117, P141, DOI 10.1016/S0300-483X(96)03566-4; RANDELL EW, 1994, J BIOL CHEM, V269, P16046; Richert R, 1997, RRD MACROMOL RES, V2, P1; STREMMEL W, 1987, EUR J CLIN INVEST, V17, P136, DOI 10.1111/j.1365-2362.1987.tb02393.x; STURROCK A, 1990, J BIOL CHEM, V265, P3139; Wessling-Resnick M, 1999, CRIT REV BIOCHEM MOL, V34, P285, DOI 10.1080/10409239991209318; WRIGHT TL, 1990, HEPATOLOGY, V12, P498, DOI 10.1002/hep.1840120309; WRIGHT TL, 1986, J BIOL CHEM, V261, P909; YUCHI A, 1983, ANAL CHIM ACTA, V149, P209, DOI 10.1016/S0003-2670(00)83177-3	24	11	11	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33512	33515		10.1074/jbc.M005435200	http://dx.doi.org/10.1074/jbc.M005435200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10906140	hybrid			2022-12-27	WOS:000090104600047
J	Zhao, X; Creuzenet, C; Belanger, M; Egbosimba, E; Li, JJ; Lam, JS				Zhao, X; Creuzenet, C; Belanger, M; Egbosimba, E; Li, JJ; Lam, JS			WbpO, a UDP-N-acetyl-D-galactosamine dehydrogenase from Pseudomonas aeruginosa serotype O6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; ESCHERICHIA-COLI; CAPSULAR POLYSACCHARIDE; GLUCOSE-DEHYDROGENASE; MOLECULAR CHARACTERIZATION; ALCOHOL-DEHYDROGENASE; CIRCULAR-DICHROISM; BACILLUS-SUBTILIS; SOMATIC ANTIGENS; VI ANTIGEN	WbpO is associated with E-band lipopolysaccharide biosynthesis in Pseudomonas aeruginosa serotype O6, This protein is thought to catalyze the enzymatic conversion of UDP-N-acetyl-D-galactosamine (UDP-GalNAc) to UDP-N-acetyl-D-galactosaminuronic acid (UDP-Gal-NAcA). WbpO was overexpressed with a C-terminal hexahistidine tag. The soluble form Of expressed WbpO (WbpO(Sol)) exhibited a secondary structure with 29.2% cy-helix and 20.1% beta -strand. However, no enzymatic activity could be detected using either high performance anion exchange chromatography or capillary electrophoresis-mass spectrometry analysis, An insoluble form of expressed WbpO was purified in the presence of guanidine hydrochloride by immobilized metal ion affinity chromatography, After refolding, this preparation of WbpO (designated as WbpO(Rf))exhibited stable secondary structure at pH 7.5 to 8.2, and it was enzymatically active. Capillary electrophoresis-mass spectrometry and tandem mass spectrometry analysis showed that WbpO(Rf) catalyzed the conversion of UDP-GalNAc to UDP-GalNAcA. 26 and 22% of the substrate could be converted to UDP-GalNAcA in the presence of NAD(+) and NADP(+) as the cofactors, respectively. The K-m values of WbpO(Rf) for UDP-GalNAc, NAD(+), and NADP(+) were 7.79, 0.65, and 0.44 mM, respectively, WbpO, can also catalyze the conversion of UDP-GlcNAc to UDP-GlcNAcA. In conclusion, this is the first report of the overexpression, purification, and biochemical characterization of an NAD(+)/NADP(+)-dependent UDP-GalNAc dehydrogenase, Our results also complete the biosynthetic pathway for GalNAcA that is part of the O-antigen of P. aeruginosa serotype O6 lipopolysaccharide.	Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	University of Guelph; National Research Council Canada	Lam, JS (corresponding author), Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Belanger M, 1999, MICROBIOL-UK, V145, P3505, DOI 10.1099/00221287-145-12-3505; Bert F, 1996, J ANTIMICROB CHEMOTH, V37, P809, DOI 10.1093/jac/37.4.809; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Burrows LL, 1999, J BACTERIOL, V181, P973, DOI 10.1128/JB.181.3.973-980.1999; Burrows LL, 1997, J BACTERIOL, V179, P1482, DOI 10.1128/jb.179.5.1482-1489.1997; CASEY JP, 1972, J AM CHEM SOC, V94, P6141, DOI 10.1021/ja00772a036; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Creuzenet C, 2000, J BIOL CHEM, V275, P19060, DOI 10.1074/jbc.M001171200; Dahan D, 1996, FEBS LETT, V392, P304, DOI 10.1016/0014-5793(96)00841-1; DEKIEVIT TR, 1995, MOL MICROBIOL, V16, P565; GUISEZ Y, 1993, PROTEIN EXPRES PURIF, V4, P240, DOI 10.1006/prep.1993.1031; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Haseley SR, 1997, EUR J BIOCHEM, V244, P761, DOI 10.1111/j.1432-1033.1997.00761.x; HASHIMOTO Y, 1993, J BACTERIOL, V175, P4456, DOI 10.1128/JB.175.14.4456-4465.1993; HENNESSEY JP, 1981, BIOCHEMISTRY-US, V20, P1085, DOI 10.1021/bi00508a007; HILT W, 1991, BIOCHIM BIOPHYS ACTA, V1076, P298, DOI 10.1016/0167-4838(91)90281-4; Holzinger A, 1996, BIOTECHNIQUES, V20, P804; HUANG JZ, 1995, MOL MICROBIOL, V16, P977, DOI 10.1111/j.1365-2958.1995.tb02323.x; HUFF JP, 1990, BIOTECHNIQUES, V9, P570; *INT UN BIOCH NOM, 1979, ENZ NOM, P19; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KAHN PC, 1968, J AM CHEM SOC, V90, P4168, DOI 10.1021/ja01017a051; KAWAMURA T, 1982, METHOD ENZYMOL, V83, P519; KAWAMURA T, 1985, J BIOCHEM-TOKYO, V98, P105, DOI 10.1093/oxfordjournals.jbchem.a135248; Kawarabayasi Y, 1998, DNA Res, V5, P147, DOI 10.1093/dnares/5.2.147; KAYA S, 1989, J BIOCHEM, V105, P35, DOI 10.1093/oxfordjournals.jbchem.a122613; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; KNIREL YA, 1994, EUR J BIOCHEM, V221, P239, DOI 10.1111/j.1432-1033.1994.tb18734.x; KNIREL YA, 1987, EUR J BIOCHEM, V166, P189, DOI 10.1111/j.1432-1033.1987.tb13501.x; KNIREL YA, 1990, CRIT REV MICROBIOL, V17, P273, DOI 10.3109/10408419009105729; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT JB, 1996, ORGANIC STRUCTURAL S, P295; LILJEBJELKE K, 1995, ANAL BIOCHEM, V225, P296, DOI 10.1006/abio.1995.1158; LIN WS, 1994, J BACTERIOL, V176, P7005, DOI 10.1128/JB.176.22.7005-7016.1994; Matheron C, 1999, APPL ENVIRON MICROB, V65, P1941; Missiakas D, 1997, J BACTERIOL, V179, P2465, DOI 10.1128/jb.179.8.2465-2471.1997; OGASAHARA K, 1976, J BIOCHEM-TOKYO, V79, P819, DOI 10.1093/oxfordjournals.jbchem.a131135; ORGAMBIDE G, 1991, J BIOL CHEM, V266, P8312; Parolis H, 1997, CARBOHYD RES, V303, P319, DOI 10.1016/S0008-6215(97)00178-X; PAULY HE, 1975, H-S Z PHYSIOL CHEM, V356, P1613, DOI 10.1515/bchm2.1975.356.2.1613; Pier GB, 1996, SCIENCE, V271, P64, DOI 10.1126/science.271.5245.64; PITT TL, 1988, EUR J CLIN MICROBIOL, V7, P238, DOI 10.1007/BF01963095; REDDY GP, 1993, ANAL BIOCHEM, V214, P106, DOI 10.1006/abio.1993.1463; Reddy GP, 1998, EUR J BIOCHEM, V255, P279, DOI 10.1046/j.1432-1327.1998.2550279.x; REEN RK, 1993, BIOCHEM PHARMACOL, V46, P229, DOI 10.1016/0006-2952(93)90408-O; Robertson D, 1996, BIOCHEM J, V313, P311, DOI 10.1042/bj3130311; Rocchetta HL, 1999, MICROBIOL MOL BIOL R, V63, P523, DOI 10.1128/MMBR.63.3.523-553.1999; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; Rost B, 1996, METHOD ENZYMOL, V266, P525; Sambrook J., 1989, MOL CLONING LAB MANU, pA2; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; Shashkov AS, 1998, CARBOHYD RES, V306, P297, DOI 10.1016/S0008-6215(97)10048-9; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stanislavsky ES, 1997, FEMS MICROBIOL REV, V21, P243, DOI 10.1016/S0168-6445(97)00059-4; Todaka T, 2000, ARCH BIOCHEM BIOPHYS, V374, P189, DOI 10.1006/abbi.1999.1450; Trivic S, 1998, J ENZYM INHIB, V13, P57, DOI 10.3109/14756369809035827; Vachee A, 1997, PATHOL BIOL, V45, P357; WAXIN H, 1993, RES MICROBIOL, V144, P363, DOI 10.1016/0923-2508(93)90193-6; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2	64	22	27	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33252	33259		10.1074/jbc.M004191200	http://dx.doi.org/10.1074/jbc.M004191200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10931835	hybrid			2022-12-27	WOS:000090104600013
J	Kokame, K; Agarwala, KL; Kato, H; Miyata, T				Kokame, K; Agarwala, KL; Kato, H; Miyata, T			Herp, a new ubiquitin-like membrane protein induced by endoplasmic reticulum stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ENDOTHELIAL-CELLS; TRANSCRIPTION FACTOR; TRANSMEMBRANE PROTEIN; RESPONSE ELEMENT; MESSENGER-RNA; QUALITY-CONTROL; ER; HOMOCYSTEINE; RETENTION; PATHWAY	Hyperhomocysteinemia, a risk factor for vascular disease, injures endothelial cells through undefined mechanisms. We previously identified several homocysteine-responsive genes in cultured human vascular endothelial cells, including the endoplasmic reticulum (ER)-resident molecular chaperone GRP78/BiP. Here, we demonstrate that homocysteine induces the ER stress response and leads to the expression of a novel protein, Herp, containing a ubiquitin-like domain at the N terminus. mRNA expression of Herp was strongly upregulated by inducers of ER stress, including mercaptoethanol, tunicamycin, A23187, and thapsigargin. The ER stress-dependent induction of Herp was also observed at the protein level. Immunochemical analyses using Herp-specific antibodies indicated that Herp is a 54-kDa, membrane-associated ER protein. Herp is the first integral membrane protein regulated by the ER stress response pathway. Both the N and C termini face the cytoplasmic side of the ER; this membrane topology makes it unlikely that Herp acts as a molecular chaperone for proteins in the ER, in contrast to GRP78 and other ER stress-responsive proteins. Herp may, therefore, play an unknown role in the cellular survival response to stress.	Natl Cardiovasc Ctr, Res Inst, Suita, Osaka 5658565, Japan	National Cerebral & Cardiovascular Center - Japan	Kokame, K (corresponding author), Natl Cardiovasc Ctr, Res Inst, 5-7-1 Fujishirodai, Suita, Osaka 5658565, Japan.			Kokame, Koichi/0000-0002-9654-6299				AGARWALA KL, 1994, BIOCHEMISTRY-US, V33, P5167, DOI 10.1021/bi00183a021; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; Brower CS, 1999, J BIOL CHEM, V274, P13629, DOI 10.1074/jbc.274.19.13629; BUCHMAN TG, 1990, SURGERY, V108, P559; Chapman RE, 1997, CURR BIOL, V7, P850, DOI 10.1016/S0960-9822(06)00373-3; Cosson P, 1998, EMBO J, V17, P6863, DOI 10.1093/emboj/17.23.6863; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; DELAHUNTY MD, 1993, J BIOL CHEM, V268, P12017; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; Duell PB, 1997, CURR OPIN LIPIDOL, V8, P28, DOI 10.1097/00041433-199702000-00007; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Hodges M, 1998, CURR BIOL, V8, pR749, DOI 10.1016/S0960-9822(07)00477-0; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kawahara T, 1997, MOL BIOL CELL, V8, P1845, DOI 10.1091/mbc.8.10.1845; Kokame K, 1996, J BIOL CHEM, V271, P29659, DOI 10.1074/jbc.271.47.29659; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lentz S R, 1998, Curr Opin Hematol, V5, P343, DOI 10.1097/00062752-199809000-00007; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Mori K, 2000, P NATL ACAD SCI USA, V97, P4660, DOI 10.1073/pnas.050010197; Mori K, 1998, J BIOL CHEM, V273, P9912, DOI 10.1074/jbc.273.16.9912; MORI K, 1993, CELL, V74, P743; Mori K, 1996, GENES CELLS, V1, P803, DOI 10.1046/j.1365-2443.1996.d01-274.x; Mudd S.H., 1995, METABOLIC MOL BASES, V1, P1279; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; Outinen PA, 1998, BIOCHEM J, V332, P213, DOI 10.1042/bj3320213; Outinen PA, 1999, BLOOD, V94, P959, DOI 10.1182/blood.V94.3.959.415k20_959_967; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Sato M, 1996, J CELL BIOL, V134, P279, DOI 10.1083/jcb.134.2.279; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Tanaka K, 1998, MOL CELLS, V8, P503; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; van Laar T, 2000, FEBS LETT, V469, P123, DOI 10.1016/S0014-5793(00)01253-9; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741	50	249	256	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32846	32853		10.1074/jbc.M002063200	http://dx.doi.org/10.1074/jbc.M002063200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10922362	hybrid			2022-12-27	WOS:000090003800065
J	Soutourina, J; Plateau, P; Blanquet, S				Soutourina, J; Plateau, P; Blanquet, S			Metabolism of D-aminoacyl-tRNAs in Escherichia coli and Saccharomyces cerevisiae cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; RIBONUCLEIC-ACID SYNTHETASE; D-ASPARTATE; TRYPTOPHAN SYNTHASE; SERINE RACEMASE; GENE; PURIFICATION; PERMEASE; REPRESSION; SEQUENCE	In Escherichia coli, tyrosyl-tRNA synthetase is known to esterify tRNA(Tyr) with tyrosine. Resulting D-Tyr-tRNA(Tyr) can be hydrolyzed by a D-Tyr-tRNA(Tyr) deacylase, By monitoring E. coli growth in liquid medium, we systematically searched for other D-amino acids, the toxicity of which might be exacerbated by the inactivation of the gene encoding D-Tyr-tRNA(Tyr) deacylase, In addition to the already documented case of D-tyrosine, positive responses were obtained with D-tryptophan, D-aspartate, D-serine, and D-glutamine. In agreement with this observation, production of D-Asp-tRNA(Asp) and D-Trp-tRNA(Typ) by aspartyl-tRNA synthetase and tryptophanyl-tRNA synthetase, respectively, was established in vitro. Furthermore, the two D-aminoacylated tRNAs behaved as substrates of purified E. coli D-Tyr-tRNA(Tyr) deacylase. These results indicate that an unexpected high number of D-amino acids can impair the bacterium growth through the accumulation of D-aminoacyl-tRNA(Tyr) molecules and that D-Tyr-tRNA(Tyr) deacylase has a specificity broad enough to recycle any of these molecules. The same strategy of screening was applied using Saccharomyces cerevisiae, the tyrosyl-tRNA synthetase of which also produces D-Tyr-tRNA(Tyr), and which, like E. coli, possesses a D-Tyr-tRNATyr deacylase activity. In this case, inhibition of growth by the various 19 D-amino acids was followed on solid medium. Two isogenic strains containing or not the deacylase were compared. Toxic effects of D-tyrosine and D-leucine were reinforced upon deprivation of the deacylase, This observation suggests that, in yeast, at least two D-amino acids succeed in being transferred onto tRNAs and that, like in E. coli, the resulting two D-aminoacyl-tRNAs are substrates of a same D-aminoacyl-tRNA deacylase.	Ecole Polytech, CNRS, UMR 7654, Biochim Lab, F-91128 Palaiseau, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut Polytechnique de Paris	Plateau, P (corresponding author), Ecole Polytech, CNRS, UMR 7654, Biochim Lab, F-91128 Palaiseau, France.	plateau@coli.polytechnique.fr	Soutourina, Julie/F-8305-2014	Soutourina, Julie/0000-0001-5218-2350				ADAMS AEM, 1989, GENETICS, V121, P675; AHMED SA, 1986, BIOCHEMISTRY-US, V25, P4233, DOI 10.1021/bi00363a010; BATURINA ID, 1972, FEBS LETT, V22, P235, DOI 10.1016/0014-5793(72)80053-X; BERGMANN F, 1961, J BIOL CHEM, V236, P1735; BLANQUET S, 1974, EUR J BIOCHEM, V44, P343, DOI 10.1111/j.1432-1033.1974.tb03491.x; BLOOM FR, 1975, J BACTERIOL, V121, P1078, DOI 10.1128/JB.121.3.1078-1084.1975; CALENDAR R, 1966, BIOCHEMISTRY-US, V5, P1690, DOI 10.1021/bi00869a034; CALENDAR R, 1967, J MOL BIOL, V26, P39, DOI 10.1016/0022-2836(67)90259-8; CAPARROS M, 1991, RES MICROBIOL, V142, P345, DOI 10.1016/0923-2508(91)90050-K; Capparos M, 1992, J BACTERIOL, V174, P5549; CHAMPNEY WS, 1970, J BACTERIOL, V104, P107, DOI 10.1128/JB.104.1.107-116.1970; COSLOY SD, 1973, J BACTERIOL, V114, P685, DOI 10.1128/JB.114.2.685-694.1973; ERIANI G, 1990, NUCLEIC ACIDS RES, V18, P7109, DOI 10.1093/nar/18.23.7109; FISHER GH, 1992, NEUROSCI LETT, V143, P215, DOI 10.1016/0304-3940(92)90268-C; FLOSSDORF J, 1973, EUR J BIOCHEM, V36, P534, DOI 10.1111/j.1432-1033.1973.tb02940.x; FLOSSDORF J, 1976, EUR J BIOCHEM, V66, P147, DOI 10.1111/j.1432-1033.1976.tb10435.x; FRANKLIN FCH, 1976, MOL GEN GENET, V149, P229, DOI 10.1007/BF00332894; Friedman M, 1999, J AGR FOOD CHEM, V47, P3457, DOI 10.1021/jf990080u; FRIEDMAN M, 1991, ADV EXP MED BIOL, V289, P447; GARTLAND WJ, 1966, P NATL ACAD SCI USA, V55, P948, DOI 10.1073/pnas.55.4.948; GRENSON M, 1983, EUR J BIOCHEM, V133, P141, DOI 10.1111/j.1432-1033.1983.tb07439.x; GRENSON M, 1983, EUR J BIOCHEM, V133, P135, DOI 10.1111/j.1432-1033.1983.tb07438.x; HALL CV, 1981, J BACTERIOL, V148, P941, DOI 10.1128/JB.148.3.941-949.1981; HARRIS CL, 1981, J BACTERIOL, V145, P1031, DOI 10.1128/JB.145.2.1031-1035.1981; HELENE C, 1971, J MOL BIOL, V58, P349, DOI 10.1016/0022-2836(71)90251-8; HIREL PH, 1988, BIOCHIMIE, V70, P773, DOI 10.1016/0300-9084(88)90107-1; Jack RW, 1998, CHIMIA, V52, P48; JAUNIAUX JC, 1990, EUR J BIOCHEM, V190, P39, DOI 10.1111/j.1432-1033.1990.tb15542.x; JENSEN RA, 1972, ARCH MIKROBIOL, V87, P173, DOI 10.1007/BF00424998; KANZAKI H, 1987, EUR J BIOCHEM, V163, P105, DOI 10.1111/j.1432-1033.1987.tb10742.x; KUHN J, 1974, BIOCHIM BIOPHYS ACTA, V332, P298, DOI 10.1016/0005-2736(74)90382-4; KUMAGAI H, 1970, BIOCHEM BIOPH RES CO, V39, P796, DOI 10.1016/0006-291X(70)90393-1; LEPORE GC, 1975, EUR J BIOCHEM, V56, P369, DOI 10.1111/j.1432-1033.1975.tb02242.x; LINDAHL T, 1966, P NATL ACAD SCI USA, V55, P941, DOI 10.1073/pnas.55.4.941; MAN EH, 1987, J NEUROCHEM, V48, P510, DOI 10.1111/j.1471-4159.1987.tb04122.x; MARTIN F, 1993, J MOL BIOL, V234, P965, DOI 10.1006/jmbi.1993.1651; MCFALL E, 1987, ESCHERICHIA COLI SAL, P1520; MEINNEL T, 1988, NUCLEIC ACIDS RES, V16, P8095, DOI 10.1093/nar/16.16.8095; METZLER DE, 1954, J AM CHEM SOC, V76, P648, DOI 10.1021/ja01632a004; MILES EW, 1986, BIOCHEMISTRY-US, V25, P4240, DOI 10.1021/bi00363a011; MILLER HI, 1980, CELL, V20, P711, DOI 10.1016/0092-8674(80)90317-7; Miller J.H., 1992, SHORT COURSE BACTERI, P150; OHNISHI E, 1962, J BIOL CHEM, V237, P138; OLSIEWSKI PJ, 1980, J BIOL CHEM, V255, P4487; OWENS SL, 1968, J MOL BIOL, V38, P145, DOI 10.1016/0022-2836(68)90137-X; OWENS SL, 1970, J BIOL CHEM, V245, P5515; Park J. T., 1987, ESCHERICHIA COLI SAL, P663; PEYPOUX F, 1985, EUR J BIOCHEM, V153, P335, DOI 10.1111/j.1432-1033.1985.tb09307.x; RYTKA J, 1975, J BACTERIOL, V121, P562, DOI 10.1128/JB.121.2.562-570.1975; Schell MJ, 1997, P NATL ACAD SCI USA, V94, P2013, DOI 10.1073/pnas.94.5.2013; SCHMITT JH, 1968, ANAL BIOCHEM, V23, P433, DOI 10.1016/0003-2697(68)90235-2; SHOJI J, 1976, J ANTIBIOT, V29, P1275, DOI 10.7164/antibiotics.29.1275; SIVONEN K, 1992, CHEM RES TOXICOL, V5, P464, DOI 10.1021/tx00028a003; Soutourina J, 1999, J BIOL CHEM, V274, P19109, DOI 10.1074/jbc.274.27.19109; Soutourina J, 2000, J BIOL CHEM, V275, P11626, DOI 10.1074/jbc.275.16.11626; TSURUOKA T, 1984, J BACTERIOL, V160, P889, DOI 10.1128/JB.160.3.889-894.1984; WILD J, 1981, MOL GEN GENET, V181, P373, DOI 10.1007/BF00425614; Wolosker H, 1999, P NATL ACAD SCI USA, V96, P13409, DOI 10.1073/pnas.96.23.13409; Wolosker H, 1999, P NATL ACAD SCI USA, V96, P721, DOI 10.1073/pnas.96.2.721; WOODWARD JR, 1980, BIOCHEM J, V192, P659, DOI 10.1042/bj1920659; ZENK MH, 1965, BIOCHEM Z, V342, P54	61	106	116	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32535	32542		10.1074/jbc.M005166200	http://dx.doi.org/10.1074/jbc.M005166200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10918062	hybrid			2022-12-27	WOS:000090003800023
J	Bing, ZY; Huang, JYH; Liao, WSL				Bing, ZY; Huang, JYH; Liao, WSL			NF kappa B interacts with serum amyloid A3 enhancer factor to synergistically activate mouse serum amyloid A3 gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ACUTE-PHASE RESPONSE; CELL-ADHESION MOLECULE-1; DNA-BINDING ACTIVITY; IFN-BETA GENE; GLUCOCORTICOID RECEPTOR; HEPATOMA-CELLS; FAMILY MEMBERS; NUCLEAR FACTOR; FACTOR LSF	We had previously identified a distal regulatory element (DRE) in the mouse serum amyloid A3 (SAA3) promoter that functions as a cytokine-inducible transcription enhancer. Within this DRE, three functional elements interact with CCAAT/enhancer-binding protein (C/EBP) and SAA3 enhancer factor (SEF) transcription factors. In this study, we show that cotransfection of the SEF expression plasmid with an SAA3/luciferase reporter resulted in 3-5-fold activation of the SAA3 promoter. When SEF-transfected cells were further stimulated with conditioned medium or interleukin-l, SAA3 promoter activity was dramatically increased, suggesting that SEF may cooperate functionally with other interleukin-l-inducible transcription factors to synergistically up-regulate SAA3 gene transcription. Indeed, cotransfection of SEF and NF kappa Bp65 expression DNAs resulted in synergistic activation of the SAA3 promoter. Intriguingly, no consensus NF kappa B-binding site was found in the SAA3 promoter region; rather a putative NF kappa B-binding sequence with 3-base pair mismatches was identified in the DRE, When this sequence was used in an electrophoretic mobility shift assay, it interacted with NF kappa Bp50, albeit with binding affinities that were several hundredfold lower than that with the consensus NF kappa B probe. Functional cooperation between SEF and NF kappa B was further strengthened by the finding that SEF and NF kappa B formed stable cytokine-inducible protein-protein complexes. Finally, despite its weak binding, mutation of this NF kappa B-binding site nevertheless dramatically reduced both NF kappa Bp65- and cytokine-mediated induction of SAA3 promoter. Therefore, the molecular basis for the functional synergy between SEF and NF kappa B may, in part, be the ability of SEF to recruit NF kappa B through physical interactions that lead to enhancement or stabilization of NF kappa B binding to the SAA3 promoter element.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Program Genes & Dev, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Liao, WSL (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Program Genes & Dev, Box 117,1515 Holcombe Blvd, Houston, TX 77030 USA.				NIAMS NIH HHS [AR38858] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR038858, R01AR038858] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akira S, 1997, ADV IMMUNOL, V65, P1, DOI 10.1016/S0065-2776(08)60740-3; AOUDJIT F, 1994, INT J CANCER, V58, P543, DOI 10.1002/ijc.2910580416; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Bing ZY, 1999, J BIOL CHEM, V274, P24649, DOI 10.1074/jbc.274.35.24649; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; DARLINGTON GJ, 1986, J CELL BIOL, V103, P787, DOI 10.1083/jcb.103.3.787; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Franzoso G, 1996, EMBO J, V15, P3403, DOI 10.1002/j.1460-2075.1996.tb00706.x; GRILLI M, 1993, INT REV CYTOL, V143, P1; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; HOFFMAN JS, 1982, J BIOL CHEM, V257, P510; HUANG HC, 1990, GENE DEV, V4, P287, DOI 10.1101/gad.4.2.287; HUANG JH, 1990, MOL CELL BIOL, V10, P3619, DOI 10.1128/MCB.10.7.3619; HUANG JH, 1994, MOL CELL BIOL, V14, P4475, DOI 10.1128/MCB.14.7.4475; Huang JYH, 1999, J INTERF CYTOK RES, V19, P1403, DOI 10.1089/107999099312867; JOSHIBARVE SS, 1993, J BIOL CHEM, V268, P18018; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; Li L, 1999, BIOCHEM BIOPH RES CO, V264, P395, DOI 10.1006/bbrc.1999.1527; LI X, 1992, NUCLEIC ACIDS RES, V20, P4765, DOI 10.1093/nar/20.18.4765; LI XX, 1990, MOL CELL BIOL, V10, P6624, DOI 10.1128/MCB.10.12.6624; LI XX, 1991, J BIOL CHEM, V266, P15192; LIM LC, 1992, MOL CELL BIOL, V12, P828, DOI 10.1128/MCB.12.2.828; LOWELL CA, 1986, J BIOL CHEM, V261, P8442; LOWELL CA, 1986, J BIOL CHEM, V261, P8453; LU SY, 1994, MOL CELL BIOL, V14, P6253, DOI 10.1128/MCB.14.9.6253; MAIZEL AL, 1981, J IMMUNOL, V127, P1058; MALIM MH, 1989, J VIROL, V63, P3213, DOI 10.1128/JVI.63.8.3213-3219.1989; MESSER G, 1990, Cytokine, V2, P389, DOI 10.1016/1043-4666(90)90046-V; MORROW JF, 1981, P NATL ACAD SCI-BIOL, V78, P4718, DOI 10.1073/pnas.78.8.4718; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Ren YS, 1999, J BIOL CHEM, V274, P37154, DOI 10.1074/jbc.274.52.37154; Romerio F, 1997, J VIROL, V71, P9375, DOI 10.1128/JVI.71.12.9375-9382.1997; Ruocco MR, 1996, J BIOL CHEM, V271, P22479, DOI 10.1074/jbc.271.37.22479; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; STEARMAN RS, 1986, NUCLEIC ACIDS RES, V14, P797, DOI 10.1093/nar/14.2.797; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; SUNDSETH R, 1992, J BIOL CHEM, V267, P7845; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; VANDIJK MA, 1995, MECH DEVELOP, V52, P99, DOI 10.1016/0925-4773(95)00394-G; Volker JL, 1997, GENE DEV, V11, P1435, DOI 10.1101/gad.11.11.1435; WU FK, 1988, EMBO J, V7, P2117, DOI 10.1002/j.1460-2075.1988.tb03051.x; Yie JM, 1997, MOL CELL BIOL, V17, P3649, DOI 10.1128/MCB.17.7.3649; Yu Y, 1997, NATURE, V385, P552, DOI 10.1038/385552a0; Zambrano N, 1998, J BIOL CHEM, V273, P20128, DOI 10.1074/jbc.273.32.20128	61	26	29	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31616	31623		10.1074/jbc.M005378200	http://dx.doi.org/10.1074/jbc.M005378200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10899169	hybrid			2022-12-27	WOS:000089858900011
J	Kim, JE; Kim, SJ; Lee, BH; Park, RW; Kim, KS; Kim, IS				Kim, JE; Kim, SJ; Lee, BH; Park, RW; Kim, KS; Kim, IS			Identification of motifs for cell adhesion within the repeated domains of transforming growth factor-beta-induced gene, beta ig-h3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE COLLAGEN ALPHA-1(IV)531-543; ALPHA(3)BETA(1) INTEGRIN; FASCICLIN-I; PEPTIDE; PROTEIN; MOLECULE; BINDING; ALPHA-3A-BETA-1; CHONDROCYTES; RECOGNITION	beta ig-h3 is a transforming growth factor-beta-inducible cell adhesion molecule that has four characteristic homologous repeated domains. We made recombinant beta ig-h3 proteins, which were highly active in mediating human corneal epithelial (HCE) cell adhesion and spreading. The 2nd and the 4th repeated domains were sufficient to mediate HCE cell adhesion, A sequence analysis showed that aspartic acid (Asp) and isoleucine (Ile) of the 2nd and the 4th domains are highly conserved in many fasciclin 1 homologous (fas-l) domains, Substitution mutational study identified these two amino acids are essential for cell adhesion. Synthetic peptides containing Asp and Re, NKDIL and EPDIM derived from the 2nd and the 4th domains, respectively, almost completely blocked cell adhesion mediated by not only wild type beta ig-h3 but also each of the 2nd and the 4th domains. These peptides alone were fully active in mediating cell adhesion. In addition, we demonstrated the functional receptor for beta ig-h3 is alpha(3)beta(1) integrin. These results, therefore, establish the essential motifs within the 2nd and the 4th domains of beta ig-h3, which interact with alpha(3)beta(1) integrin to mediate HCE cell adhesion to beta ig-h3 and suggest that other proteins containing Asp-ne in their fas-l domains could possibly function as cell adhesion molecules.	Kyungpook Natl Univ, Sch Med, Dept Biochem, Jung Gu, Taegu 700422, South Korea; Kyungpook Natl Univ, Sch Med, Biomol Engn Ctr, Taegu 700422, South Korea; Dongguk Univ, Sch Med, Dept Biochem, Kyungju 780714, South Korea; Keimyung Univ, Sch Med, Dept Ophthalmol, Taegu 700310, South Korea	Kyungpook National University; Kyungpook National University; Dongguk University; Keimyung University	Kim, IS (corresponding author), Kyungpook Natl Univ, Sch Med, Dept Biochem, Jung Gu, 101 Dongindong, Taegu 700422, South Korea.	iskim@kyungpook.ac.kr	김, 인산/I-8988-2014					DEDHAR S, 1992, J BIOL CHEM, V267, P18908; DELWEL GO, 1994, MOL BIOL CELL, V5, P203, DOI 10.1091/mbc.5.2.203; Dieudonne SC, 2000, J CELL BIOCHEM, V76, P231, DOI 10.1002/(SICI)1097-4644(20000201)76:2<231::AID-JCB7>3.0.CO;2-X; DIPERSIO CM, 1995, J CELL SCI, V108, P2321; EBEL JA, 1997, MOL BIOL INTELLIGENC, P1; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; GEHLSEN KR, 1992, J CELL BIOL, V117, P449, DOI 10.1083/jcb.117.2.449; Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239; HUBER O, 1994, EMBO J, V13, P4212, DOI 10.1002/j.1460-2075.1994.tb06741.x; Kawamoto T, 1998, BBA-GENE STRUCT EXPR, V1395, P288, DOI 10.1016/S0167-4781(97)00172-3; Kim IS, 1996, MOL CELL BIOL, V16, P4003; Kim JE, 2000, J CELL BIOCHEM, V77, P169, DOI 10.1002/(SICI)1097-4644(20000501)77:2<169::AID-JCB1>3.0.CO;2-L; Krutzsch HC, 1999, J BIOL CHEM, V274, P24080, DOI 10.1074/jbc.274.34.24080; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LEBARON RG, 1995, J INVEST DERMATOL, V104, P844, DOI 10.1111/1523-1747.ep12607024; Lee EH, 2000, INVEST OPHTH VIS SCI, V41, P1840; MILES AJ, 1994, J BIOL CHEM, V269, P30939; MILES AJ, 1995, J BIOL CHEM, V270, P29047, DOI 10.1074/jbc.270.49.29047; Munier FL, 1997, NAT GENET, V15, P247, DOI 10.1038/ng0397-247; OBrien ER, 1996, ARTERIOSCL THROM VAS, V16, P576, DOI 10.1161/01.ATV.16.4.576; Ohno S, 1999, BBA-MOL CELL RES, V1451, P196, DOI 10.1016/S0167-4889(99)00093-2; Rawe IM, 1997, INVEST OPHTH VIS SCI, V38, P893; SKONIER J, 1994, DNA CELL BIOL, V13, P571, DOI 10.1089/dna.1994.13.571; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; WANG WC, 1993, J BIOL CHEM, V268, P1448; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651	26	235	249	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30907	30915		10.1074/jbc.M002752200	http://dx.doi.org/10.1074/jbc.M002752200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906123	hybrid			2022-12-27	WOS:000089762700027
J	Hemming, SA; Jansma, DB; Macgregor, PF; Goryachev, A; Friesen, JD; Edwards, AM				Hemming, SA; Jansma, DB; Macgregor, PF; Goryachev, A; Friesen, JD; Edwards, AM			RNA polymerase II subunit Rpb9 regulates transcription elongation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; TFIIS; VIABILITY; MOTIF	RNA polymerase II lacking the Rpb9 subunit uses alternate transcription initiation sites in vitro and in vivo and is unable to respond to the transcription elongation factor TFIIS in vitro. Here, we show that RPB9 has a synthetic phenotype with the TFIIS gene. Disruption of RPB9 in yeast also resulted in sensitivity to 6-azauracil, which is a phenotype linked to defects in transcription elongation. Expression of the TFIIS gene on a high-copy plasmid partially suppressed the 6-azauracil sensitivity of Delta rpb9 cells. We set out to determine the relevant cellular role of yeast RpbS by assessing the ability of 20 different site-directed and deletion mutants of RPB9 to complement the initiation and elongation defects of Delta rpb9 cells in vivo. RpbS is composed of two zinc ribbons.' The N-terminal zinc ribbon restored the wild-type pattern of initiation start sites, but was unable to complement the growth defects associated with defects in elongation. Most of the site-directed mutants complemented the elongation-specific growth phenotypes and reconstituted the normal pattern of transcription initiation: sites. The anti-correlation between the growth defects of cells disrupted for RPB9 and the selection of transcription:start sites suggests that this is not the primary cellular role for RpbS. Genome-wide transcription profiling of Delta rpb9 cells revealed only a few changes, predominantly in genes related to metabolism.	Univ Toronto, Banting & Best Dept Med Res, Charles H Best Inst, Toronto, ON M5G 1L6, Canada	University of Toronto	Edwards, AM (corresponding author), Univ Toronto, Banting & Best Dept Med Res, Charles H Best Inst, 112 Coll St, Toronto, ON M5G 1L6, Canada.		Goryachev, Andrew B/A-6553-2013	Goryachev, Andrew B/0000-0002-1332-4819; Edwards, Aled/0000-0002-4782-6016				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Awrey DE, 1997, J BIOL CHEM, V272, P14747, DOI 10.1074/jbc.272.23.14747; CARLES C, 1991, J BIOL CHEM, V266, P24092; Chedin S, 1998, GENE DEV, V12, P3857, DOI 10.1101/gad.12.24.3857; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; Fu JH, 1999, CELL, V98, P799, DOI 10.1016/S0092-8674(00)81514-7; FURTERGRAVES EM, 1994, NUCLEIC ACIDS RES, V22, P4932, DOI 10.1093/nar/22.23.4932; HARRISON DA, 1992, MOL CELL BIOL, V12, P928, DOI 10.1128/MCB.12.3.928; Hemming SA, 2000, J BIOL CHEM, V275, P2288, DOI 10.1074/jbc.275.4.2288; HULL MW, 1995, GENE DEV, V9, P481, DOI 10.1101/gad.9.4.481; NOGI Y, 1993, MOL CELL BIOL, V13, P114, DOI 10.1128/MCB.13.1.114; Poglitsch CL, 1999, CELL, V98, P791, DOI 10.1016/S0092-8674(00)81513-5; QIAN XQ, 1993, NATURE, V365, P277, DOI 10.1038/365277a0; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; Sun ZW, 1996, NUCLEIC ACIDS RES, V24, P2560, DOI 10.1093/nar/24.13.2560; Wang B, 1998, STRUCTURE, V6, P555, DOI 10.1016/S0969-2126(98)00058-6; WOYCHIK NA, 1990, J BIOL CHEM, V265, P17816; WOYCHIK NA, 1991, J BIOL CHEM, V266, P19053; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	22	75	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35506	35511		10.1074/jbc.M004721200	http://dx.doi.org/10.1074/jbc.M004721200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10938084	hybrid			2022-12-27	WOS:000165422800089
J	Hummel, HS; Gillespie, RD; Swindle, J				Hummel, HS; Gillespie, RD; Swindle, J			Mutational analysis of 3 ' splice site selection during trans-splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; BRUCEI PROVIDES EVIDENCE; TRYPANOSOMA-CRUZI; MAMMALIAN INTRONS; SECONDARY STRUCTURE; BRANCH POINT; T-BRUCEI; VSG GENE; U5 SNRNP; SEQUENCE	trans-Splicing is essential for mRNA maturation in trypanosomatids. A conserved AG dinucleotide serves as the 3' splice acceptor site, and analysis of native processing sites suggests that selection of this site is determined according to a 5'-3' scanning model. A series of stable gene replacement lines were generated that carried point mutations at or near the 3' splice site within the intergenic region separating CUB2.65, the calmodulin-ubiquitin associated gene, and FUS1, the ubiquitin fusion gene of Trypanosoma cruzi. In one stable line, the elimination of the native 3' splice acceptor site led to the accumulation of Y-branched splicing intermediates, which served as templates for mapping the first trans-splicing branch points in T. cruzi, In other lines, point mutations shifted the position of the first consensus AG dinucleotide either upstream or downstream of the wild-type 3' splice acceptor site in this intergenic region, Consistent with the scanning model, the first AG dinucleotide downstream of the branch points was used as the predominant 3' splice acceptor site. In: all of the stable lines, the point mutations affected splicing efficiency in this region.	Univ Tennessee, Dept Immunol & Microbiol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Swindle, J (corresponding author), Univ Tennessee, Dept Immunol & Microbiol, 858 Madison Ave, Memphis, TN 38163 USA.	jswindle@IDRI.org			NIAID NIH HHS [AI26578] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026578] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Achsel T, 1998, MOL CELL BIOL, V18, P6756, DOI 10.1128/MCB.18.11.6756; AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; AJIOKA J, 1993, MOL BIOCHEM PARASIT, V57, P127, DOI 10.1016/0166-6851(93)90250-2; Brys A, 1996, RNA, V2, P707; CamargO E. P., 1964, Revista do Instituto de Medicina Tropical de Sao Paulo, V6, P93; Chen SY, 2000, P NATL ACAD SCI USA, V97, P593, DOI 10.1073/pnas.97.2.593; Chua K, 1999, NATURE, V402, P207, DOI 10.1038/46086; DELANGE T, 1984, NUCLEIC ACIDS RES, V12, P4431, DOI 10.1093/nar/12.11.4431; DESHLER JO, 1991, GENE DEV, V5, P1252, DOI 10.1101/gad.5.7.1252; FRANK D, 1992, MOL CELL BIOL, V12, P5197, DOI 10.1128/MCB.12.11.5197; FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8; FU XY, 1988, MOL CELL BIOL, V8, P3582, DOI 10.1128/MCB.8.9.3582; GILLESPIE RD, 1993, MOL BIOCHEM PARASIT, V60, P281, DOI 10.1016/0166-6851(93)90139-O; GONZALEZ A, 1985, NUCLEIC ACIDS RES, V13, P5789, DOI 10.1093/nar/13.16.5789; HARIHARAN S, 1993, MOL BIOCHEM PARASIT, V57, P15, DOI 10.1016/0166-6851(93)90240-X; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; HODGES PE, 1995, YEAST, V11, P337; HUANG J, 1991, EMBO J, V10, P3877, DOI 10.1002/j.1460-2075.1991.tb04957.x; HUG M, 1994, MOL CELL BIOL, V14, P7428, DOI 10.1128/MCB.14.11.7428; JAISHANKAR S, 1996, MICROBIOLOGY IMMUNOL; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; KOOTER JM, 1987, CELL, V51, P261, DOI 10.1016/0092-8674(87)90153-X; LANG KM, 1983, SCIENCE, V220, P1351, DOI 10.1126/science.6304877; LANGFORD CJ, 1984, CELL, V36, P645, DOI 10.1016/0092-8674(84)90344-1; LEBOWITZ JH, 1993, GENE DEV, V7, P996, DOI 10.1101/gad.7.6.996; Lucke S, 1997, EMBO J, V16, P4433, DOI 10.1093/emboj/16.14.4433; Luukkonen BGM, 1997, EMBO J, V16, P779, DOI 10.1093/emboj/16.4.779; MATTHEWS KR, 1994, GENE DEV, V8, P491, DOI 10.1101/gad.8.4.491; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MUHICH ML, 1988, MOL CELL BIOL, V8, P3837, DOI 10.1128/MCB.8.9.3837; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; PADGETT RA, 1984, SCIENCE, V225, P898, DOI 10.1126/science.6206566; PATZELT E, 1989, MOL CELL BIOL, V9, P4291, DOI 10.1128/MCB.9.10.4291; PERRY K, 1991, EXPERIENTIA, V47, P118, DOI 10.1007/BF01945412; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHEA C, 1987, CELL, V50, P603, DOI 10.1016/0092-8674(87)90033-X; Siatecka M, 1999, GENE DEV, V13, P1983, DOI 10.1101/gad.13.15.1983; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; SMITH CWJ, 1993, MOL CELL BIOL, V13, P4939, DOI 10.1128/MCB.13.8.4939; SOLNICK D, 1985, CELL, V43, P667, DOI 10.1016/0092-8674(85)90239-9; Spritz R A, 1983, Prog Clin Biol Res, V134, P77; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; SWINDLE J, 1988, EMBO J, V7, P1121, DOI 10.1002/j.1460-2075.1988.tb02921.x; TEIGELKAMP S, 1995, EMBO J, V14, P2602, DOI 10.1002/j.1460-2075.1995.tb07258.x; THOMASHOW LS, 1983, CELL, V32, P35, DOI 10.1016/0092-8674(83)90494-4; ULFENDAHL PJ, 1989, NUCLEIC ACIDS RES, V17, P925, DOI 10.1093/nar/17.3.925; UMEN JG, 1995, GENE DEV, V9, P855, DOI 10.1101/gad.9.7.855; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; Wu SP, 1999, NATURE, V402, P832, DOI 10.1038/45590; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; Zorio DAR, 1999, NATURE, V402, P835, DOI 10.1038/45597; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	56	20	20	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35522	35531		10.1074/jbc.M002424200	http://dx.doi.org/10.1074/jbc.M002424200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10938269	hybrid			2022-12-27	WOS:000165422800091
J	Dean, YD; McGreal, EP; Akatsu, H; Gasque, P				Dean, YD; McGreal, EP; Akatsu, H; Gasque, P			Molecular and cellular properties of the rat AA4 antigen, a C-type lectin-like receptor with structural homology to thrombomodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC STEM-CELLS; ENDOTHELIAL-CELLS; APOPTOTIC BODIES; PHAGOCYTIC-CELLS; CDNA CLONING; YOLK-SAC; IN-VITRO; SURFACE; C1Q; EXPRESSION	The murine fetal stem cell marker AA4 has recently been cloned and is known to be the homolog of the human phagocytic Clq receptor involved in host defense. We herein report the molecular cloning and the cellular expression pattern of the rat AA4 antigen. Modular architecture analysis indicated that the rat AA4 is a member of C-type lectin-like family and, interestingly, displays similar domain composition and organization to thrombomodulin. Northern blot and reverse transcriptase-polymerase chain reaction analyses indicated that rat AA4 was encoded by a single transcript of 7 kilobases expressed constitutively in all tissues. In situ hybridization showed that AA4 was expressed predominantly by pneumocytes and vascular endothelial cells. Using an affinity purified polyclonal antibody raised against a rat AA4-Fc fusion protein, AA4 was identified as a glycosylated protein of 100 kDa expressed by endothelial cells > platelets > NK cells and monocytes (ED1+ cells). The staining was associated to the cell surface and intracytoplasmic vesicles. Conversely, erythrocytes, T and B lymphocytes, neutrophils, and macrophages (ED2+ cells) were consistently negative for AA4. As expected, the macrophage cell line NR8383 expressed weak levels of AA4. Taken together, our results support the idea that AA4/C1qRp is involved in some cell-cell interactions.	Univ Wales Coll Med, Brain Inflammat & Immun Grp, Dept Med Biochem, Heath Hosp, Cardiff CF14 4XN, S Glam, Wales; Choju Med Inst, Toyohashi, Aichi 4418124, Japan	Cardiff University	Gasque, P (corresponding author), Univ Wales Coll Med, Brain Inflammat & Immun Grp, Dept Med Biochem, Heath Hosp, Tenovus Bldg, Cardiff CF14 4XN, S Glam, Wales.							Akatsu H, 1997, MICROBIOL IMMUNOL, V41, P575, DOI 10.1111/j.1348-0421.1997.tb01894.x; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; Conway EM, 1997, BLOOD, V89, P652, DOI 10.1182/blood.V89.2.652; Conway EM, 1999, BLOOD, V93, P3442, DOI 10.1182/blood.V93.10.3442.410k17_3442_3450; Coulouarn Y, 1998, P NATL ACAD SCI USA, V95, P15803, DOI 10.1073/pnas.95.26.15803; DITTMAN WA, 1990, BLOOD, V75, P329; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Eggleton P, 2000, CLIN EXP IMMUNOL, V120, P406, DOI 10.1046/j.1365-2249.2000.01218.x; Eggleton P, 1998, TRENDS CELL BIOL, V8, P428, DOI 10.1016/S0962-8924(98)01373-7; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; Esmon CT, 2000, BBA-PROTEIN STRUCT M, V1477, P349, DOI 10.1016/S0167-4838(99)00266-6; Franc NC, 1999, CURR OPIN IMMUNOL, V11, P47, DOI 10.1016/S0952-7915(99)80009-0; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; GODIN I, 1995, P NATL ACAD SCI USA, V92, P773, DOI 10.1073/pnas.92.3.773; GUAN E, 1994, J IMMUNOL, V152, P4005; Hess KL, 1997, EXP CELL RES, V236, P404, DOI 10.1006/excr.1997.3745; Holmgren L, 1999, BLOOD, V93, P3956, DOI 10.1182/blood.V93.11.3956.411k05_3956_3963; HUANG H, 1993, P NATL ACAD SCI USA, V90, P10110, DOI 10.1073/pnas.90.21.10110; JORDAN CT, 1995, EXP HEMATOL, V23, P1011; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Korb LC, 1997, J IMMUNOL, V158, P4525; Lafay M, 1998, THROMB HAEMOSTASIS, V79, P848, DOI 10.1055/s-0037-1615076; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Marcos MAR, 1997, J IMMUNOL, V158, P2627; Matsushita Y, 1998, CANCER LETT, V127, P195, DOI 10.1016/S0304-3835(98)00038-X; MCKEARN JP, 1984, J IMMUNOL, V132, P332; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; Mevorach D, 1998, J EXP MED, V188, P387, DOI 10.1084/jem.188.2.387; Nepomuceno RR, 1997, IMMUNITY, V6, P119, DOI 10.1016/S1074-7613(00)80419-7; Nepomuceno RR, 1998, J IMMUNOL, V160, P1929; Nepomuceno RR, 1999, J IMMUNOL, V162, P3583; Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129; Norsworthy PJ, 1999, MAMM GENOME, V10, P789, DOI 10.1007/s003359901093; Oka K, 1998, P NATL ACAD SCI USA, V95, P9535, DOI 10.1073/pnas.95.16.9535; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; Petrenko O, 1999, IMMUNITY, V10, P691, DOI 10.1016/S1074-7613(00)80068-0; Potocnik AJ, 1997, P NATL ACAD SCI USA, V94, P10295, DOI 10.1073/pnas.94.19.10295; Ray RJ, 1996, EUR J IMMUNOL, V26, P1504, DOI 10.1002/eji.1830260715; Singhrao SK, 1999, LAB INVEST, V79, P1247; Stahl PD, 1998, CURR OPIN IMMUNOL, V10, P50, DOI 10.1016/S0952-7915(98)80031-9; Tenner AJ, 1998, IMMUNOBIOLOGY, V199, P250, DOI 10.1016/S0171-2985(98)80031-4; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Zhang YM, 1998, J CLIN INVEST, V101, P1301, DOI 10.1172/JCI925	45	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34382	34392		10.1074/jbc.M006229200	http://dx.doi.org/10.1074/jbc.M006229200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10934210	hybrid			2022-12-27	WOS:000165095300053
J	Reunanen, N; Foschi, M; Han, JH; Kahari, VM				Reunanen, N; Foschi, M; Han, JH; Kahari, VM			Activation of extracellular signal-regulated kinase 1/2 inhibits type I collagen expression by human skin fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; MESSENGER-RNA LEVELS; GENE-EXPRESSION; PROTEIN-KINASE; GROWTH-FACTOR; GRANULATION-TISSUE; OKADAIC ACID; MAP-KINASES; CELLS; TRANSFORMATION	Treatment with the lipid second messenger, ceramide, activates extracellular signal-regulated kinase-1/2 (ERK1/2), c-Jun N-terminal kinase, and p38 in human skin fibroblasts and induces their collagenase-1 expression (Reunanen, N., Westermarck, J., Hakkinen, L., Holmstrom, T. H, Elo, T., Eriksson, J. E., and Kahari, V.-M. (1998) J. Biol. Chem. 213, 5137-5145). Here we show that C-2-ceramide inhibits expression of type I and III collagen mRNAs in dermal fibroblasts, suppresses pro alpha2(I) collagen promoter activity, and reduces stability of type I collagen mRNAs. The down-regulatory effect of C-2-ceramide on type I collagen mRNA levels was abrogated by protein kinase C inhibitors H7, staurosporine, and Re-31-8220 and potently inhibited by a combination of MEK1,2 inhibitor PD98059 and p38 inhibitor 8B203580. Activation of ERK1/2 by adenovirus-mediated expression of constitutively active MEK1 resulted in marked down-regulation of type I collagen mRNA levels and production in fibroblasts, whereas activation of p38 by constitutively active MAPK kinase-3b and MAPK kinase-6b slightly up-regulated type I collagen expression. These results identify the ERK1/2 signaling cascade as a potent negative regulatory pathway with respect to type I collagen expression in fibroblasts, suggesting that it mediates inhibition of collagen production in response to mitogenic stimulation and transformation.	Univ Turku, Turku Ctr Biotechnol, FIN-20520 Turku, Finland; Abo Akad Univ, FIN-20520 Turku, Finland; Univ Turku, Dept Med Biochem, FIN-20520 Turku, Finland; Univ Turku, Dept Dermatol, FIN-20520 Turku, Finland; Univ Florence, Dept Med, I-50134 Florence, Italy; Scripps Res Inst, Dept Immunol, San Diego, CA 92121 USA	University of Turku; Abo Akademi University; University of Turku; University of Turku; University of Florence; Scripps Research Institute	Kahari, VM (corresponding author), Univ Turku, Turku Ctr Biotechnol, Tykistokatu 6B, FIN-20520 Turku, Finland.	veli-matti.kahari@utu.fi	Han, J/G-4671-2010; Kähäri, Veli-Matti/E-5144-2011; Kahari, Veli-Matti/T-4925-2019	Kähäri, Veli-Matti/0000-0003-2421-9368; Kahari, Veli-Matti/0000-0003-2421-9368				Ahonen M, 1998, CANCER RES, V58, P2310; Andreu T, 1998, J BIOL CHEM, V273, P13848, DOI 10.1074/jbc.273.22.13848; BOAST S, 1990, J BIOL CHEM, V265, P13351; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Davis BH, 1996, J BIOL CHEM, V271, P11039, DOI 10.1074/jbc.271.19.11039; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Gebken J, 1999, J BIOCHEM, V126, P676, DOI 10.1093/oxfordjournals.jbchem.a022502; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GOLDSTEIN RH, 1990, J BIOL CHEM, V265, P13623; HAMALAINEN L, 1985, J BIOL CHEM, V260, P720; Johansson N, 2000, J CELL SCI, V113, P227; KAHARI VM, 1984, BIOCHIM BIOPHYS ACTA, V781, P183, DOI 10.1016/0167-4781(84)90136-2; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; LAATO M, 1987, BIOCHEM J, V247, P385, DOI 10.1042/bj2470385; Laine P, 2000, BIOCHEM J, V349, P19, DOI 10.1042/0264-6021:3490019; MAKELA JK, 1990, BIOCHIM BIOPHYS ACTA, V1049, P171, DOI 10.1016/0167-4781(90)90037-3; MAKELA JK, 1988, NUCLEIC ACIDS RES, V16, P349, DOI 10.1093/nar/16.1.349; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; OKA H, 1995, CANCER RES, V55, P4182; Palcy S, 1999, BIOCHEM J, V343, P21, DOI 10.1042/0264-6021:3430021; POSTLETHWAITE AE, 1992, J CLIN INVEST, V90, P1479, DOI 10.1172/JCI116015; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; SANDBERG M, 1989, MATRIX, V9, P82, DOI 10.1016/S0934-8832(89)80025-3; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Simon C, 1998, CANCER RES, V58, P1135; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; SLACK JL, 1992, MOL CELL BIOL, V12, P4714, DOI 10.1128/MCB.12.10.4714; Svegliati-Baroni G, 1999, HEPATOLOGY, V29, P1743, DOI 10.1002/hep.510290632; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; WESTERMARCK J, 1995, J INVEST DERMATOL, V105, P197, DOI 10.1111/1523-1747.ep12317114; WESTERMARCK J, 1995, BIOCHEM J, V308, P995, DOI 10.1042/bj3080995; Westermarck J, 1998, MATRIX BIOL, V17, P547, DOI 10.1016/S0945-053X(98)90107-X; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233	40	53	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34634	34639		10.1074/jbc.C000175200	http://dx.doi.org/10.1074/jbc.C000175200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10926924	hybrid			2022-12-27	WOS:000165095300086
J	Bhatt, RR; Ferrell, JE				Bhatt, RR; Ferrell, JE			Cloning and characterization of Xenopus Rsk2, the predominant p90 Rsk isozyme in oocytes and eggs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RIBOSOMAL S6 KINASE; MAP KINASE; MEIOTIC MATURATION; SIGNAL-TRANSDUCTION; PHORBOL ESTER; INHIBITORY KINASE; METAPHASE ARREST; ONCOGENE PRODUCT; DOCKING SITE	The 90-kDa ribosomal S6 kinases, the p90 Rsks, are a family of intracellular serine/threonine protein kinases distinguished by two distinct kinase domains. Rsks are activated downstream of the ERK1 (p44) and ERK2 (p42) mitogen-activated protein (MAP) kinases in diverse biological contexts, including progression through meiotic and mitotic M phases in Xenopus oocytes and cycling Xenopus egg extracts, and are critical for the M phase functions of Xenopus p42 MAPK, Here we report the cloning and biochemical characterization of Xenopus Rsk2. Xenopus Rsk1 and Rsk2 are specifically recognized by commercially available RSK1 and RSK2 antisera on immunoblots, but both Rsk1 and Rsk2 are immunoprecipitated by RSK1, RSK2, and RSK3 sera. Rsk2 is about 20-fold more abundant than the previously described Xenopus Rsk1 protein; their concentrations are approximately 120 and 5 nM, respectively. Rsk2, like Rsk1, forms a heteromeric complex with p42 MAP kinase. This interaction depends on sequences at the extreme C terminus of Rsk2 and can be disrupted by a synthetic peptide derived from the C-terminal 20 amino acids of Rsk2. Finally, we demonstrate that p42 MAP kinase can activate recombinant Rsk2 in vitro to a specific activity comparable to that found in Rsk2 that has been activated maximally in vivo, These findings underscore the importance of the Rsk2 isozyme in the M phase functions of p42 MAP kinase and provide tools for further examining Rsk2 function.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Ferrell, JE (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.	ferrell@cmgm.stanford.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM016415] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM16415, GM46383] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bhatt RR, 1999, SCIENCE, V286, P1362, DOI 10.1126/science.286.5443.1362; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; BLENIS J, 1985, P NATL ACAD SCI USA, V82, P7621, DOI 10.1073/pnas.82.22.7621; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Bruning JC, 2000, P NATL ACAD SCI USA, V97, P2462, DOI 10.1073/pnas.97.6.2462; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Cross DAE, 1998, EXP CELL RES, V241, P12, DOI 10.1006/excr.1998.4023; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; ERIKSON E, 1985, P NATL ACAD SCI USA, V82, P742, DOI 10.1073/pnas.82.3.742; ERIKSON E, 1986, J BIOL CHEM, V261, P350; ERIKSON E, 1991, J BIOL CHEM, V266, P5249; ERIKSON E, 1991, METHOD ENZYMOL, V200, P252; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; Ferrell JE, 1999, BIOESSAYS, V21, P866, DOI 10.1002/(SICI)1521-1878(199910)21:10<866::AID-BIES9>3.0.CO;2-1; Ferrell JE, 1999, BIOESSAYS, V21, P833, DOI 10.1002/(SICI)1521-1878(199910)21:10<833::AID-BIES5>3.0.CO;2-P; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; Ferrell JE, 1997, J BIOL CHEM, V272, P19008, DOI 10.1074/jbc.272.30.19008; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Fisher DL, 1999, DEVELOPMENT, V126, P4537; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; Gavin AC, 1999, MOL BIOL CELL, V10, P2971, DOI 10.1091/mbc.10.9.2971; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; Gotoh Y, 1995, Prog Cell Cycle Res, V1, P287; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; Gross SD, 2000, CURR BIOL, V10, P430, DOI 10.1016/S0960-9822(00)00425-5; Gross SD, 1999, SCIENCE, V286, P1365, DOI 10.1126/science.286.5443.1365; GROVE JR, 1993, BIOCHEMISTRY-US, V32, P7727, DOI 10.1021/bi00081a018; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; Huang CYF, 1996, EMBO J, V15, P2169, DOI 10.1002/j.1460-2075.1996.tb00570.x; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KOSAKO H, 1994, J BIOL CHEM, V269, P28354; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MOLLER DE, 1994, AM J PHYSL 1, V299, pC351; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Murakami MS, 1998, DEVELOPMENT, V125, P237; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Sagata N, 1997, BIOESSAYS, V19, P13, DOI 10.1002/bies.950190105; Schwab MS, 1999, MOL CELL BIOL, V19, P2485; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TABARINI D, 1985, P NATL ACAD SCI USA, V82, P4369, DOI 10.1073/pnas.82.13.4369; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Verlhac MH, 1996, DEVELOPMENT, V122, P815; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353	73	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32983	32990		10.1074/jbc.M006386200	http://dx.doi.org/10.1074/jbc.M006386200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10934212	hybrid			2022-12-27	WOS:000090003800083
J	Hiller, O; Lichte, A; Oberpichler, A; Kocourek, A; Tschesche, H				Hiller, O; Lichte, A; Oberpichler, A; Kocourek, A; Tschesche, H			Matrix metalloproteinases collagenase-2, macrophage elastase, collagenase-3, and membrane type 1-matrix metalloproteinase impair clotting by degradation of fibrinogen and factor XII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT CATALYTIC DOMAIN; AMINO-ACID-SEQUENCE; BETA-FACTOR-XIIA; BLOOD-COAGULATION; BREAST CARCINOMAS; MATRILYSIN MMP-7; ACTIVATION; GELATINASE; NEOVASCULARIZATION; STROMELYSIN-1	The effects of plasma proteins on controlling the activity of matrix metalloproteinases (MMPs, matrixins) have been the focus of numerous studies, although only a few have examined the influence of matrixins on plasma proteins. Recently, it has been shown that MMPs may play a role in the degradation of fibrin, We have now investigated the role of collagenase-a (MMP-8), macrophage elastase (MMP-12), collagenase-3 (MMP-13), and membrane type 1-matrix metalloproteinase (MT1-MMP, MMMP-14) in the degradation of fibrinogen and Factor XII of the plasma clotting system. Our data demonstrate that the catalytic domains of MMP-8, MMP-12, MMP-13, and MMP-14 can proteolytically process fibrinogen and, with the exception of MMP-8, also inactivate Factor XII (Hageman factor). We have identified the amino termini of the major protein fragments. Cleavage of fibrinogen occurred in all chains and resulted in significantly impaired clotting. Moreover, rapid proteolytic inactivation of Factor XII (Hageman factor) by MMP-18, MMP-13, and MMP-14 was noted. These results support the hypothesis of an impaired thrombolytic potential of MMP-degraded Factor MI in vivo. MMP-induced degradation of fibrinogen supports a plasmin-independent fibrinolysis mechanism. Consequently, degradation of these proteins may be important in inflammation, atherosclerosis, and angiogenesis, all of which are known to be influenced by MMP activity.	Univ Bielefeld, Fac Chem, Dept Biochem, D-33615 Bielefeld, Germany	University of Bielefeld	Tschesche, H (corresponding author), Univ Bielefeld, Fac Chem, Dept Biochem, D-33615 Bielefeld, Germany.	harald.tschesche@uni-bielefeld.de						BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; Bini A, 1999, BIOCHEMISTRY-US, V38, P13928, DOI 10.1021/bi991096g; Bini A, 1996, BIOCHEMISTRY-US, V35, P13056, DOI 10.1021/bi960730c; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; Butenas S, 1999, BLOOD, V94, P2169, DOI 10.1182/blood.V94.7.2169.419k22_2169_2178; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; COOL DE, 1985, J BIOL CHEM, V260, P3666; Cornelius LA, 1998, J IMMUNOL, V161, P6845; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; DIEKMANN O, 1994, BRAZ J MED BIOL RES, V27, P1865; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; FELDINGHABERMANN B, 1992, J BIOL CHEM, V267, P5070; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; FUJIKAWA K, 1983, J BIOL CHEM, V258, P924; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Gorkun OV, 1997, BLOOD, V89, P4407, DOI 10.1182/blood.V89.12.4407; Henschen-Edman AH, 1999, HAEMOSTASIS, V29, P179; Herrick S, 1999, INT J BIOCHEM CELL B, V31, P741, DOI 10.1016/S1357-2725(99)00032-1; HERTFELDER HJ, 1994, EUR J CLIN CHEM CLIN, V32, P441; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; Imai S, 1998, J BONE JOINT SURG BR, V80B, P701, DOI 10.1302/0301-620X.80B4.7952; JOCHUM M, 1984, ADV EXP MED BIOL, V167, P391; Johnson LL, 1998, CURR OPIN CHEM BIOL, V2, P466, DOI 10.1016/S1367-5931(98)80122-1; KLEINE T, 1993, BIOCHEMISTRY-US, V32, P14125, DOI 10.1021/bi00214a008; KLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186; KNAUPER V, 1990, FEBS LETT, V263, P355, DOI 10.1016/0014-5793(90)81412-H; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LEWALLE JM, 1995, J CELL PHYSIOL, V165, P475, DOI 10.1002/jcp.1041650305; Lichte A, 1996, FEBS LETT, V397, P277, DOI 10.1016/S0014-5793(96)01206-9; Liotta L A, 1990, Semin Cancer Biol, V1, P99; MACHEIN U, 1997, CELLULAR PEPTIDASE I, P97; Mann KG, 1999, THROMB HAEMOSTASIS, V82, P165; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCMULLEN BA, 1985, J BIOL CHEM, V260, P5328; MOORE WM, 1986, BIOCHEMISTRY-US, V25, P5189, DOI 10.1021/bi00366a031; MURPHY G, 1992, J BIOL CHEM, V267, P9612; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NAGASE H, INHIBITORS METALLOPR; Patterson BC, 1997, J BIOL CHEM, V272, P28823, DOI 10.1074/jbc.272.46.28823; REINKE H, 1991, ADV LIF SCI, P55; SCHETTLER A, 1991, EUR J BIOCHEM, V197, P197, DOI 10.1111/j.1432-1033.1991.tb15899.x; TRIEBEL S, 1992, FEBS LETT, V314, P386, DOI 10.1016/0014-5793(92)81511-J; WEBER K, 1969, J BIOL CHEM, V244, P4406; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Willmroth F, 1998, IMMUNOBIOLOGY, V198, P375, DOI 10.1016/S0171-2985(98)80046-6; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Yong VW, 1998, TRENDS NEUROSCI, V21, P75	53	102	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33008	33013		10.1074/jbc.M001836200	http://dx.doi.org/10.1074/jbc.M001836200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10930399	hybrid			2022-12-27	WOS:000090003800086
J	Komoto, J; Huang, YF; Gomi, T; Ogawa, H; Takata, Y; Fujioka, M; Takusagawa, F				Komoto, J; Huang, YF; Gomi, T; Ogawa, H; Takata, Y; Fujioka, M; Takusagawa, F			Effects of site-directed mutagenesis on structure and function of recombinant rat liver S-adenosylhomocysteine hydrolase - Crystal structure of D244E mutant enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME BINDING; MECHANISM; 2'-DEOXYADENOSINE; INACTIVATION; ACID; CDNA	A site-directed mutagenesis, D244E, of S-adenosylhomocysteine hydrolase (AdoHcyase) changes drastically the nature of the protein, especially the NAD(+) binding affinity. The mutant enzyme contained NADH rather than NAD(+) (Gomi, T., Takata, Y., Date, T., Fujioka, M., Aksamit, R. R., Backlund, P. S., and Cantoni, G. L. (1990) J. Biol. Chem. 265, 16102-16107). In contrast to the site-directed mutagenesis study, the crystal structures of human and rat AdoHcyase recently determined have shown that the carboxyl group of Asp-244 points in a direction opposite to the bound NAD molecule and does not participate in any hydrogen bonds with the NAD molecule. To explain the discrepancy between the mutagenesis study and the x-ray studies, we have determined the crystal structure of the recombinant rat-liver D244E mutant enzyme to 2.8-Angstrom resolution. The D244E mutation changes the enzyme structure from the open to the closed conformation by means of a similar to 17 degrees rotation of the individual catalytic domains around the molecular hinge sections, The D244E mutation shifts the catalytic reaction from a reversible to an irreversible fashion. The large affinity difference between NAD(+) and NADH is mainly due to the enzyme conformation, but not to the binding-site geometry; an NAD(+) in the open conformation is readily released from the enzyme, whereas an NADH in the closed conformation is trapped and cannot leave the enzyme. A catalytic mechanism of AdoHcyase has been proposed on the basis of the crystal structures of the wild-type and D244E enzymes.	Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA; Toyama Med & Pharmaceut Univ, Fac Med, Dept Biochem, Sugitani, Toyama 9300194, Japan	University of Kansas; University of Toyama	Takusagawa, F (corresponding author), Univ Kansas, Dept Mol Biosci, 3042 Haworth Hall, Lawrence, KS 66045 USA.				NIGMS NIH HHS [GM37233] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELES RH, 1982, BIOCHEMISTRY-US, V21, P5557, DOI 10.1021/bi00265a027; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1993, XPLOR 3 1 SYSTEM XRA; CHIANG PK, 1979, TRANSMETHYLATION, P165; FERSHT AR, 1987, TRENDS BIOCHEM SCI, V12, P301, DOI 10.1016/0968-0004(87)90146-0; FUJIOKA M, 1981, J BIOL CHEM, V256, P1631; GOMI T, 1989, BIOCHIM BIOPHYS ACTA, V994, P172, DOI 10.1016/0167-4838(89)90157-X; GOMI T, 1989, J BIOL CHEM, V264, P16138; GOMI T, 1984, BIOCHIM BIOPHYS ACTA, V785, P177, DOI 10.1016/0167-4838(84)90141-9; GOMI T, 1990, J BIOL CHEM, V265, P16102; HERSHFIELD MS, 1979, J BIOL CHEM, V254, P22; Hu YB, 1999, BIOCHEMISTRY-US, V38, P8323, DOI 10.1021/bi990332k; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; OGAWA H, 1987, P NATL ACAD SCI USA, V84, P719, DOI 10.1073/pnas.84.3.719; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PALMER JL, 1979, J BIOL CHEM, V254, P1217; PALMER JL, 1976, J BIOL CHEM, V251, P5817; RICHARDS HH, 1978, J BIOL CHEM, V253, P4476; Turner MA, 1998, NAT STRUCT BIOL, V5, P369, DOI 10.1038/nsb0598-369	20	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32147	32156		10.1074/jbc.M003725200	http://dx.doi.org/10.1074/jbc.M003725200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10913437	hybrid			2022-12-27	WOS:000089858900082
J	Duplus, E; Glorian, M; Forest, C				Duplus, E; Glorian, M; Forest, C			Fatty acid regulation of gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PROLIFERATOR-ACTIVATED RECEPTOR; PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; CARNITINE PALMITOYLTRANSFERASE-I; ELEMENT-BINDING PROTEIN-1; ADIPOSE CELL-DIFFERENTIATION; COA DESATURASE-1 GENE; RAT HEPATOCYTES; AP2 GENE; LINE INS-1; PPAR-GAMMA		CNRS, INSERM, Unit 530, F-92190 Meudon, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Forest, C (corresponding author), CNRS, INSERM, Unit 530, 9 Rue Jules Hetzel, F-92190 Meudon, France.		; DUPLUS, Eric/F-2969-2013	Forest, Claude/0000-0003-3401-8148; GLORIAN, Martine/0000-0002-4502-3543; DUPLUS, Eric/0000-0003-1954-4836				Abumrad N, 1998, J LIPID RES, V39, P2309; ALLMAN DW, 1969, J LIPID RES, V6, P51; AMRI EZ, 1991, J LIPID RES, V32, P1457; AMRI EZ, 1991, J LIPID RES, V32, P1449; ANTRASFERRY J, 1995, EUR J BIOCHEM, V234, P390, DOI 10.1111/j.1432-1033.1995.390_b.x; ANTRASFERRY J, 1994, BIOCHEM BIOPH RES CO, V203, P385, DOI 10.1006/bbrc.1994.2194; AssimacopoulosJeannet F, 1997, J BIOL CHEM, V272, P1659, DOI 10.1074/jbc.272.3.1659; Bastie C, 1999, J BIOL CHEM, V274, P21920, DOI 10.1074/jbc.274.31.21920; BERTHOU L, 1995, EUR J BIOCHEM, V232, P179, DOI 10.1111/j.1432-1033.1995.tb20797.x; Black PN, 2000, J NUTR, V130, p305S, DOI 10.1093/jn/130.2.305S; BLAKE WL, 1990, J NUTR, V120, P1727, DOI 10.1093/jn/120.12.1727; CAVE WT, 1991, FASEB J, V5, P2160, DOI 10.1096/fasebj.5.8.1673664; Chatelain F, 1996, EUR J BIOCHEM, V235, P789, DOI 10.1111/j.1432-1033.1996.00789.x; Cho HP, 1999, J BIOL CHEM, V274, P471, DOI 10.1074/jbc.274.1.471; Cho HP, 1999, J BIOL CHEM, V274, P37335, DOI 10.1074/jbc.274.52.37335; Choi JY, 1996, J BIOL CHEM, V271, P3581; CLARKE SD, 1994, ANNU REV NUTR, V14, P83, DOI 10.1146/annurev.nu.14.070194.000503; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Forest C, 1997, PROSTAG LEUKOTR ESS, V57, P47, DOI 10.1016/S0952-3278(97)90492-0; Foretz M, 1999, BIOCHEM J, V341, P371, DOI 10.1042/0264-6021:3410371; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GLORIAN M, 1999, CHEM PHYS LIPIDS, V101, P141; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GRIMALDI PA, 1992, P NATL ACAD SCI USA, V89, P10930, DOI 10.1073/pnas.89.22.10930; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Jump DB, 1999, LIPIDS, V34, pS209, DOI 10.1007/BF02562292; JUMP DB, 1993, P NATL ACAD SCI USA, V90, P8454, DOI 10.1073/pnas.90.18.8454; Jump DB, 1999, ANNU REV NUTR, V19, P63, DOI 10.1146/annurev.nutr.19.1.63; KAIKAUS RM, 1993, J BIOL CHEM, V268, P26866; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; LANDSCHULZ KT, 1994, BIOCHEM BIOPH RES CO, V200, P763, DOI 10.1006/bbrc.1994.1516; Mater MK, 1999, J BIOL CHEM, V274, P32725, DOI 10.1074/jbc.274.46.32725; MeunierDurmort C, 1996, BIOCHEM J, V319, P483, DOI 10.1042/bj3190483; MIKKELSEN L, 1993, BIOCHIM BIOPHYS ACTA, V1166, P99, DOI 10.1016/0005-2760(93)90289-L; Niot I, 1997, BIOCHIMIE, V79, P129, DOI 10.1016/S0300-9084(97)81504-0; NTAMBI JM, 1992, J BIOL CHEM, V267, P10925; Pan DA, 2000, J LIPID RES, V41, P742; Pegorier J P, 1998, Curr Opin Clin Nutr Metab Care, V1, P329, DOI 10.1097/00075197-199807000-00003; Raclot T, 1997, J LIPID RES, V38, P1963; Ren B, 1997, J BIOL CHEM, V272, P26827, DOI 10.1074/jbc.272.43.26827; Ren B, 1996, J BIOL CHEM, V271, P17167, DOI 10.1074/jbc.271.29.17167; RESHEFF L, 1970, J BIOL CHEM, V245, P5979; Roche E, 1999, DIABETES, V48, P2007, DOI 10.2337/diabetes.48.10.2007; Sessler AM, 1998, J NUTR, V128, P923, DOI 10.1093/jn/128.6.923; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Thurmond DC, 1998, J BIOL CHEM, V273, P15373, DOI 10.1074/jbc.273.25.15373; Tobin KAR, 2000, MOL ENDOCRINOL, V14, P741, DOI 10.1210/me.14.5.741; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Wahli W, 1999, ADV EXP MED BIOL, V447, P199; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537; Xu J, 1999, J BIOL CHEM, V274, P23577, DOI 10.1074/jbc.274.33.23577; Yahagi N, 1999, J BIOL CHEM, V274, P35840, DOI 10.1074/jbc.274.50.35840	57	264	282	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30749	30752		10.1074/jbc.R000015200	http://dx.doi.org/10.1074/jbc.R000015200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10934217	hybrid			2022-12-27	WOS:000089762700002
J	Yao, TT; Cohen, RE				Yao, TT; Cohen, RE			Cyclization of polyubiquitin by the E2-25K ubiquitin conjugating enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL HYDROLASES; DEUBIQUITINATING ENZYMES; MULTIUBIQUITIN CHAINS; DEPENDENT PROTEOLYSIS; PROTEIN-DEGRADATION; IN-VIVO; SPECIFICITY; PROTEASOME; ISOPEPTIDASE; MECHANISM	For most substrates of ubiquitin (Ub)-dependent degradation, recognition by the proteasome is mediated by a covalently attached signal assembled hom multiple ubiquitins linked to each other via the C terminus of one Ub and the E-amine of Lys(48) Of another Uh. Among Ub-conjugating enzymes, E2-25K is unique in its ability to synthesize in vitro unanchored Lys(48)-linked poly-Uh chains from mono- or poly-Uh, E1, and ATP; thus, E2-25K has distinct binding sites for donor and acceptor (poly)Ub. During studies of chain assembly by E2-25K we observed that Lys(48)-linked tri-Ub was efficiently converted to a new species that upon SDS-polyacrylamide gel electrophoresis migrated between linear di-Ub and tri-Ub. Analysis of this product by mass spectrometry and tryptic digestion showed that it was a cyclic form of tri-Ub. Cyclization of tri-Ub requires E1, E2-25K ATP, and that the Linear substrate has a free Gly(76) C terminus on the proximal end Ub and a Lys48 Side chain available on the distal end Ub. E2-25K similarly can catalyze the cyclization of longer poly-Uh chains, including tetra- and penta-Ub. Although cyclic tri-Ub resists hydrolysis by the PA700 or isopeptidase T deubiquitinating enzymes, it can be disassembled to Ub monomers by isopeptidase(s) in a red blood cell extract. Thus, if cyclic poly-Uh forms in vivo, it will not accumulate as a deadend product.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa	Cohen, RE (corresponding author), Univ Iowa, Dept Biochem, 51 Newton Rd, Iowa City, IA 52242 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037666] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37666] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerik AY, 1997, EMBO J, V16, P4826; Ausubel FM., 2006, ENZYMATIC MANIPULATI; Beal RE, 1998, BIOCHEMISTRY-US, V37, P2925, DOI 10.1021/bi972514p; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1991, J BIOL CHEM, V266, P15698; COOK WJ, 1994, J MOL BIOL, V236, P601, DOI 10.1006/jmbi.1994.1169; COOK WJ, 1992, J BIOL CHEM, V267, P16467; COX MJ, 1986, ARCH BIOCHEM BIOPHYS, V250, P400, DOI 10.1016/0003-9861(86)90742-3; Dang LC, 1998, BIOCHEMISTRY-US, V37, P1868, DOI 10.1021/bi9723360; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Dubiel W, 1999, CURR BIOL, V9, pR554, DOI 10.1016/S0960-9822(99)80353-4; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1985, J BIOL CHEM, V260, P2464; Haas AL, 1997, FASEB J, V11, P1257; Haldeman MT, 1997, BIOCHEMISTRY-US, V36, P10526, DOI 10.1021/bi970750u; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Johnston SC, 1999, EMBO J, V18, P3877, DOI 10.1093/emboj/18.14.3877; Kalchman MA, 1996, J BIOL CHEM, V271, P19385, DOI 10.1074/jbc.271.32.19385; Lam YA, 1997, J BIOL CHEM, V272, P28438, DOI 10.1074/jbc.272.45.28438; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Larsen CN, 1996, BIOCHEMISTRY-US, V35, P6735, DOI 10.1021/bi960099f; Larsen CN, 1998, BIOCHEMISTRY-US, V37, P3358, DOI 10.1021/bi972274d; Mastrandrea LD, 1998, BIOCHEMISTRY-US, V37, P9784, DOI 10.1021/bi9800911; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; PICKART CM, 1986, J BIOL CHEM, V261, P210; PICKART CM, 1992, J BIOL CHEM, V267, P14418; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Piotrowski J, 1997, J BIOL CHEM, V272, P23712, DOI 10.1074/jbc.272.38.23712; Shaeffer JR, 1997, BLOOD, V90, P1300, DOI 10.1182/blood.V90.3.1300.1300_1300_1308; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; VANNOCKER S, 1993, J BIOL CHEM, V268, P24766; vanNocker S, 1996, P NATL ACAD SCI USA, V93, P856, DOI 10.1073/pnas.93.2.856; WILKINSON KD, 1981, J BIOL CHEM, V256, P9235; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; XU W, 1999, THESIS U IOWA	40	19	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36862	36868		10.1074/jbc.M006050200	http://dx.doi.org/10.1074/jbc.M006050200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10906148	hybrid			2022-12-27	WOS:000165577700060
J	Stevanin, TM; Ioannidis, N; Mills, CE; Kim, SO; Hughes, MN; Poole, RK				Stevanin, TM; Ioannidis, N; Mills, CE; Kim, SO; Hughes, MN; Poole, RK			Flavohemoglobin hmp affords inducible protection for Escherichia coli respiration, catalyzed by cytochromes bo ' or bd, from nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVOHAEMOGLOBIN HMP; OXIDATIVE-STRESS; C-OXIDASE; OXYGEN-AFFINITY; NITROSATIVE STRESS; IN-VIVO; BINDING; NO; INHIBITION; MECHANISM	Respiration of Escherichia coli catalyzed either by cytochrome bo' or bd is sensitive to micromolar extracellular NO; extensive, transient inhibition of respiration increases as dissolved oxygen tension in the medium decreases. At low oxygen concentrations (25-33 muM), the duration of inhibition of respiration by 9 muM NO is increased by mutation of either oxidase. Respiration of an hmp mutant defective in flavohemoglobin (Hmp) synthesis is extremely NO-sensitive (I(50) about 0.8 muM); conversely, cells pre-grown with sodium nitroprusside or overexpressing plasmid-borne hmp(+) are insensitive to 60 muM NO and have elevated levels of immunologically detectable Hmp. Purified Hmp consumes O(2), at a rate that,is instantaneously and extensively (>10-fold) stimulated by MO due to NO oxygenase activity but, in the absence of NO, limp does not contribute measurably to cell oxygen consumption. Cyanide binds to Hmp (K(d) 3 muM). Concentrations of KCN (100 muM) that do not significantly inhibit cell respiration markedly suppress the protection of respiration from NO afforded by Hmp and abolish NO oxygenase activity of purified Hmp, The results demonstrate the role of limp in protecting respiration from NO stress and are discussed in relation to the energy metabolism off. coli in natural O(2)-depleted environments.	Univ Sheffield, Krebs Inst Biomolec Res, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Natl Ctr Sci Res Demokritos, Aghia Paraskevi 15310, Greece; Kings Coll London, Dept Chem, London WC2R 2LS, England	University of Sheffield; National Centre of Scientific Research "Demokritos"; University of London; King's College London	Poole, RK (corresponding author), Univ Sheffield, Krebs Inst Biomolec Res, Dept Mol Biol & Biotechnol, Firth Court,Western Bank, Sheffield S10 2TN, S Yorkshire, England.	r.poole@sheffield.ac.uk	Ioannidis, Nikolaos/AFS-4799-2022	Ioannidis, Nikolaos/0000-0002-2528-5271				Bolognesi M, 1999, J MOL BIOL, V291, P637, DOI 10.1006/jmbi.1999.2975; Bonner F. T., 1988, COMMENTS INORG CHEM, V7, P215, DOI DOI 10.1080/02603598808072309; Bonner F.T., 2010, CHEMINFORM, V28, DOI [10.1002/chin.199715245, DOI 10.1002/CHIN.199715245]; BRUDVIG GW, 1980, BIOCHEMISTRY-US, V19, P5275, DOI 10.1021/bi00564a020; Butler CS, 1997, BIOCHEMISTRY-US, V36, P16259, DOI 10.1021/bi971481a; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; Cooper CE, 1999, BBA-BIOENERGETICS, V1411, P290, DOI 10.1016/S0005-2728(99)00021-3; Crawford MJ, 1998, J BIOL CHEM, V273, P12543, DOI 10.1074/jbc.273.20.12543; DEGROOTE MA, 1995, CLIN INFECT DIS, V21, pS162, DOI 10.1093/clinids/21.Supplement_2.S162; Dmello R, 1996, MICROBIOL-UK, V142, P755, DOI 10.1099/00221287-142-4-755; DMELLO R, 1995, J BACTERIOL, V177, P867, DOI 10.1128/jb.177.3.867-870.1995; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Gardner PR, 1998, J BIOL CHEM, V273, P26528, DOI 10.1074/jbc.273.41.26528; Gaston B, 1999, BBA-BIOENERGETICS, V1411, P323, DOI 10.1016/S0005-2728(99)00023-7; Gennis R. B., 1996, ESCHERICHIA COLI SAL, P217; Giuffre A, 1999, P NATL ACAD SCI USA, V96, P14718, DOI 10.1073/pnas.96.26.14718; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; Guest John R., 1996, P317; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; Hori H, 1996, J BIOL CHEM, V271, P9254, DOI 10.1074/jbc.271.16.9254; Hu YM, 1999, J BACTERIOL, V181, P3486, DOI 10.1128/JB.181.11.3486-3493.1999; HUBBARD JAM, 1983, FEBS LETT, V164, P241, DOI 10.1016/0014-5793(83)80293-2; HUBBARD JAM, 1985, MICROBIAL GAS METABO, P231; Hughes MN, 1999, BBA-BIOENERGETICS, V1411, P263, DOI 10.1016/S0005-2728(99)00019-5; IOANNIDIS N, 1992, BIOCHEM J, V288, P649, DOI 10.1042/bj2880649; JI XB, 1988, APPL ENVIRON MICROB, V54, P1791, DOI 10.1128/AEM.54.7.1791-1794.1988; Kalnenieks U, 1998, FEMS MICROBIOL LETT, V168, P91; Kim SO, 1999, FEBS LETT, V445, P389, DOI 10.1016/S0014-5793(99)00157-X; Maloy SR., 1996, GENETIC ANAL PATHOGE; Membrillo-Hernandez J, 1998, MOL MICROBIOL, V29, P1101, DOI 10.1046/j.1365-2958.1998.01000.x; Membrillo-Hernandez J, 1999, J BIOL CHEM, V274, P748, DOI 10.1074/jbc.274.2.748; MembrilloHernandez J, 1996, FEBS LETT, V382, P141, DOI 10.1016/0014-5793(96)00154-8; Millar AH, 1996, FEBS LETT, V398, P155, DOI 10.1016/S0014-5793(96)01230-6; Murad F, 1999, BIOSCIENCE REP, V19, P133, DOI 10.1023/A:1020265417394; Nagata K, 1998, J BIOL CHEM, V273, P14071, DOI 10.1074/jbc.273.23.14071; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993, DOI 10.1073/pnas.90.21.9993; Poole R.K., 2000, SPECTROPHOTOMETRY SP, P1; Poole RK, 1996, J BACTERIOL, V178, P5487, DOI 10.1128/jb.178.18.5487-5492.1996; Poole RK, 2000, MOL MICROBIOL, V36, P775, DOI 10.1046/j.1365-2958.2000.01889.x; Poole RK, 1997, MICROBIOL-SGM, V143, P1557, DOI 10.1099/00221287-143-5-1557; POOLE RK, 1989, J GEN MICROBIOL, V135, P1865; POOLE RK, 1994, P ROY SOC B-BIOL SCI, V255, P251, DOI 10.1098/rspb.1994.0036; Poole RK, 2000, ADV MICROB PHYSIOL, V43, P165, DOI 10.1016/S0065-2911(00)43005-5; Poole RK, 1996, MICROBIOL-SGM, V142, P1141, DOI 10.1099/13500872-142-5-1141; POOLE RK, 1987, ESCHERICHIA COLI SAL, P170; RENART J, 1984, METHOD ENZYMOL, V104, P455; Rudolph J, 1996, J ATMOS CHEM, V23, P275, DOI 10.1007/BF00055157; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOEDON G, 1995, CLIN INFECT DIS, V21, pS152, DOI 10.1093/clinids/21.Supplement_2.S152; Soballe B, 1998, MICROBIOL-UK, V144, P361, DOI 10.1099/00221287-144-2-361; Stubauer G, 1998, BIOCHEM BIOPH RES CO, V245, P459, DOI 10.1006/bbrc.1998.8457; Torres J, 1998, J BIOENERG BIOMEMBR, V30, P63, DOI 10.1023/A:1020559528124; Torres J, 1999, BBA-BIOENERGETICS, V1411, P310, DOI 10.1016/S0005-2728(99)00022-5; VASUDEVAN SG, 1991, MOL GEN GENET, V226, P49, DOI 10.1007/BF00273586; Watmough NJ, 1999, BBA-BIOENERGETICS, V1411, P456, DOI 10.1016/S0005-2728(99)00032-8; Wu GH, 2000, J BIOL CHEM, V275, P4679, DOI 10.1074/jbc.275.7.4679; Yoshimura T, 1995, MCBU, P217; Yu H, 1997, FEBS LETT, V409, P161, DOI 10.1016/S0014-5793(97)00494-8	59	130	135	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35868	35875		10.1074/jbc.M002471200	http://dx.doi.org/10.1074/jbc.M002471200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10915782	hybrid			2022-12-27	WOS:000165382000034
J	Eberhardy, SR; D'Cunha, CA; Farnham, PJ				Eberhardy, SR; D'Cunha, CA; Farnham, PJ			Direct examination of histone acetylation on Myc target genes using chromatin immunoprecipitation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE PROMOTER; C-MYC; TRANSGENIC MICE; CELL-CYCLE; ORNITHINE DECARBOXYLASE; DEACETYLASE INHIBITOR; GROWTH-REGULATION; BINDING PROTEIN; TRANSCRIPTION; EXPRESSION	Overexpression of c-Myc can lead to altered transcriptional regulation of cellular genes and to neoplastic transformation. Although DNA binding is clearly required, the mechanism by which recruitment of c-Myc to target promoters results in transcriptional activation is highly debated. Much of this controversy comes from the difficulty in clearly defining a true Myc target gene. We have previously determined that cad is a bona fide Myc target gene and thus now use the cad promoter as a model to study Myc function. Others have shown that Myc can interact indirectly with histone acetylases and have suggested that Myc mediates transcriptional activation by causing an increase in the levels of acetylated histones on target promoters. To directly test this model, we employed a chromatin immunoprecipitation assay to examine the levels of acetylated histones on the cad promoter. Although Myc was bound to the cad promoter in S phase but not in G(0) phase, we found high levels of acetylated histones on the promoter in both stages. We also examined acetylated histones on the cad promoter before and after differentiation of U937 cells. Although the levels of c-Myc bound to the cad promoter were greatly reduced after differentiation, we saw high levels of acetylated histones on the cad promoter both before and after differentiation. Finally, we found that a 30-fold change in binding of N-Myc to the telomerase promoter did not result in a concomitant change in histone acetylation. Thus, recruitment of a Myc family member to a target promoter does not necessarily influence the amount of acetylated histones at that promoter. Further investigations are in progress to define the role of Myc in transcriptional activation.	Univ Wisconsin, Sch Med, Mcardle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Farnham, PJ (corresponding author), Univ Wisconsin, Sch Med, Mcardle Lab Canc Res, Madison, WI 53706 USA.	farnham@oncology.wisc.edu		Farnham, Peggy/0000-0003-4469-7914	NCI NIH HHS [CA45240, CA09135] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA045240, R01CA045240] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Fry CJ, 1999, J BIOL CHEM, V274, P15883, DOI 10.1074/jbc.274.22.15883; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Herrera JE, 1999, MOL CELL BIOL, V19, P3466; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Jones RM, 1996, MOL CELL BIOL, V16, P4754; KACZMAREK L, 1987, J CELL PHYSIOL, V132, P545, DOI 10.1002/jcp.1041320318; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Larsson LG, 1997, ONCOGENE, V15, P737, DOI 10.1038/sj.onc.1201390; Lukas ER, 1999, MOL CARCINOGEN, V25, P295, DOI 10.1002/(SICI)1098-2744(199908)25:4<295::AID-MC8>3.0.CO;2-9; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; ONEILL LP, 1995, EMBO J, V14, P3946, DOI 10.1002/j.1460-2075.1995.tb00066.x; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; Pinaud S, 1998, J MOL BIOL, V280, P785, DOI 10.1006/jmbi.1998.1905; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; SANDGREN EP, 1989, ONCOGENE, V4, P715; Shetty S, 1999, BIOCHEM J, V339, P751, DOI 10.1042/0264-6021:3390751; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Takahashi Y, 2000, GENE DEV, V14, P804; VanLint C, 1996, GENE EXPRESSION, V5, P245; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5	47	83	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33798	33805		10.1074/jbc.M005154200	http://dx.doi.org/10.1074/jbc.M005154200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10931841	hybrid			2022-12-27	WOS:000090104600086
J	Commins, SP; Watson, PM; Levin, N; Beiler, RJ; Gettys, TW				Commins, SP; Watson, PM; Levin, N; Beiler, RJ; Gettys, TW			Central leptin regulates the UCP1 and ob genes in brown and white adipose tissue via different beta-adrenoceptor subtypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(3)-ADRENERGIC RECEPTOR GENE; SYMPATHETIC NERVOUS-SYSTEM; MESSENGER-RNA LEVELS; ADRENERGIC-RECEPTOR; UNCOUPLING PROTEIN; BETA-3-ADRENERGIC RECEPTOR; MOLECULAR-CLONING; C57BL/6 MICE; OB/OB MICE; OBESE GENE	The three known subtypes of beta -adrenoreceptors (beta (1)-AR, beta (2)-AR, and beta (3)-AR) are differentially expressed in brown and white adipose tissue and mediate peripheral responses to central modulation of sympathetic outflow by leptin, To assess the relative roles of the P-AR subtypes in mediating leptin's effects on adipocyte gene expression, mice with a targeted disruption of the beta (3)-adrenoreceptor gene (beta (3)-AR KO) were treated with vehicle or the beta (1)/beta (2)-AR selective antagonist, propranolol (20 mug/g body weight/day) prior to intracerebroventricular (ICV) injections of leptin (0.1 mug/g body weight/day). Leptin produced a 3-fold increase in UCP1 mRNA in brown adipose tissue of wild type (FVB/NJ) and beta (3)-AR KO mice. The response was unaltered by propranolol in wild type mice, but was completely blocked by this antagonist in beta (3)-AR KO mice. In contrast, ICV leptin had no effect on leptin mRNA in either epididymal or retroperitoneal white adipose tissue (WAT) from beta (3)-AR KOs, Moreover, propranolol did not block the ability of exogenous leptin to reduce leptin mRNA in either WAT depot site of wild type mice. These results demonstrate that the beta (3)-AR is required for leptin-mediated regulation of ob mRNA expression in WAT, but is interchangeable with the beta (1)/beta (2)-ARs in mediating leptin's effect on UCP1 mRNA expression in brown adipose tissue.	Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Div Gastroenterol & Hepatol, Charleston, SC 29425 USA; Amgen Inc, Thousand Oaks, CA 91320 USA	Medical University of South Carolina; Medical University of South Carolina; Amgen	Gettys, TW (corresponding author), Med Univ S Carolina, Dept Med, 916-G Clin Sci Bldg,96 Jonathan Lucas St, Charleston, SC 29425 USA.		Gettys, Thomas W/N-1964-2017	Gettys, Thomas W/0000-0001-7125-7995	NIDDK NIH HHS [DK 53981] Funding Source: Medline; NIGMS NIH HHS [GM08716] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053981] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atgie C, 1997, AM J PHYSIOL-CELL PH, V273, pC1136, DOI 10.1152/ajpcell.1997.273.4.C1136; BLOOM JD, 1992, J MED CHEM, V35, P3081, DOI 10.1021/jm00094a025; Boss O, 1999, BIOCHEM BIOPH RES CO, V261, P870, DOI 10.1006/bbrc.1999.1145; BOUILLAUD F, 1984, J BIOL CHEM, V259, P1583; BRAY GA, 1971, PHYSIOL REV, V51, P598, DOI 10.1152/physrev.1971.51.3.598; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chaudhry A, 1999, AM J PHYSIOL-REG I, V277, pR147, DOI 10.1152/ajpregu.1999.277.1.R147; COLLINS S, 1994, MOL ENDOCRINOL, V8, P518, DOI 10.1210/me.8.4.518; Collins S, 1996, NATURE, V380, P677, DOI 10.1038/380677a0; Commins SP, 1999, ENDOCRINOLOGY, V140, P292, DOI 10.1210/en.140.1.292; Commins SP, 1999, ENDOCRINOLOGY, V140, P4772, DOI 10.1210/en.140.10.4772; Deng CJ, 1997, ENDOCRINOLOGY, V138, P548, DOI 10.1210/en.138.2.548; DOOLEY DJ, 1986, EUR J PHARMACOL, V130, P137, DOI 10.1016/0014-2999(86)90193-7; Elias CF, 1998, NEURON, V21, P1375, DOI 10.1016/S0896-6273(00)80656-X; Elmquist JK, 1998, P NATL ACAD SCI USA, V95, P741, DOI 10.1073/pnas.95.2.741; Evans BA, 1999, FEBS LETT, V444, P149, DOI 10.1016/S0014-5793(99)00049-6; FEVE B, 1991, J BIOL CHEM, V266, P20329; FEVE B, 1990, J BIOL CHEM, V265, P16343; Galitzky J, 1997, BRIT J PHARMACOL, V122, P1244, DOI 10.1038/sj.bjp.0701523; GETTYS TW, 1991, J BIOL CHEM, V266, P15949; Gettys TW, 1997, ENDOCRINOLOGY, V138, P2697, DOI 10.1210/en.138.7.2697; Gettys TW, 1996, ENDOCRINOLOGY, V137, P4054, DOI 10.1210/en.137.9.4054; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; GRANNEMAN JG, 1991, MOL PHARMACOL, V40, P895; GRANNEMAN JG, 1993, MOL PHARMACOL, V44, P264; GRANNEMAN JG, 1995, CELL SIGNAL, V7, P9, DOI 10.1016/0898-6568(94)00066-K; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Haynes WG, 1997, J CLIN INVEST, V100, P270, DOI 10.1172/JCI119532; Hwa JJ, 1997, AM J PHYSIOL-REG I, V272, pR1204, DOI 10.1152/ajpregu.1997.272.4.R1204; Hwa JJ, 1996, HORM METAB RES, V28, P659, DOI 10.1055/s-2007-979873; Konkar AA, 2000, MOL PHARMACOL, V57, P252; Kutoh E, 1997, LIFE SCI, V62, P445, DOI 10.1016/S0024-3205(97)01138-7; LAFONTAN M, 1993, J LIPID RES, V34, P1057; Levin N, 1996, P NATL ACAD SCI USA, V93, P1726, DOI 10.1073/pnas.93.4.1726; Lollmann B, 1997, BIOCHEM BIOPH RES CO, V238, P648, DOI 10.1006/bbrc.1997.7205; Mizuno A, 1998, ENDOCRINOLOGY, V139, P3863, DOI 10.1210/en.139.9.3863; MUZZIN P, 1991, J BIOL CHEM, V266, P24053; Niijima A, 1999, NEUROSCI LETT, V262, P125, DOI 10.1016/S0304-3940(99)00054-3; Nisoli E, 1996, MOL PHARMACOL, V49, P7; Pelleymounter MA, 2000, J PHARMACOL EXP THER, V293, P799; Preitner F, 1998, BRIT J PHARMACOL, V124, P1684, DOI 10.1038/sj.bjp.0702007; Revelli JP, 1997, J CLIN INVEST, V100, P1098, DOI 10.1172/JCI119620; RODBELL M, 1964, J BIOL CHEM, V239, P375; ROHLFS EM, 1995, J BIOL CHEM, V270, P10723, DOI 10.1074/jbc.270.18.10723; Sarmiento U, 1997, LAB INVEST, V77, P243; Scarpace PJ, 1998, AM J PHYSIOL-ENDOC M, V275, pE259, DOI 10.1152/ajpendo.1998.275.2.E259; Scarpace PJ, 1997, AM J PHYSIOL-ENDOC M, V273, pE226, DOI 10.1152/ajpendo.1997.273.1.E226; Siegrist-Kaiser CA, 1997, J CLIN INVEST, V100, P2858, DOI 10.1172/JCI119834; SUSULIC VS, 1995, J BIOL CHEM, V270, P29483, DOI 10.1074/jbc.270.49.29483; TATE KM, 1991, EUR J BIOCHEM, V196, P357, DOI 10.1111/j.1432-1033.1991.tb15824.x; Wang MY, 1999, J BIOL CHEM, V274, P17541, DOI 10.1074/jbc.274.25.17541; Wang ZW, 1999, P NATL ACAD SCI USA, V96, P10373, DOI 10.1073/pnas.96.18.10373; ZHAO J, 1994, AM J PHYSIOL-CELL PH, V267, pC969, DOI 10.1152/ajpcell.1994.267.4.C969; Zhao J, 1998, AM J PHYSIOL-REG I, V275, pR2002, DOI 10.1152/ajpregu.1998.275.6.R2002; Zhao J, 1997, J BIOL CHEM, V272, P32847, DOI 10.1074/jbc.272.52.32847	55	89	90	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33059	33067		10.1074/jbc.M006328200	http://dx.doi.org/10.1074/jbc.M006328200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10938091	hybrid			2022-12-27	WOS:000090003800093
J	Tang, HL; Wong-Staal, F				Tang, HL; Wong-Staal, F			Specific interaction between RNA helicase A and Tap, two cellular proteins that bind to the constitutive transport element of type D retrovirus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNAL; MESSENGER-RNA; CYTOPLASMIC FIBRILS; CRM1; CTE; IDENTIFICATION; RAT8P/DBP5P; SPLICEOSOME; INHIBITION; SEQUENCES	Constitutive transport element (CTE) facilitates retroviral RNA export by interacting with the cellular RNA export machinery. Two cellular proteins, RNA helicase A (RHA) and Tip-associated protein (Tap) were identified as binding to CTE and were proposed to function as CTE co-factors (1, a), Here, we report that these two CTE-binding proteins interact with each other in vitro and in vivo. The in vitro binding of RHA to Tap is direct and independent of either CTE or the nuclear transport domain of RHA. The removal of the first 60 amino acids of Tap significantly diminishes the binding to RHA. The activity of this Tap mutant to enhance CTE-mediated gene expression is also markedly reduced. A transdominant mutant of Tap inhibited RHA-mediated up-regulation of CTE function in mammalian cells. The nuclear transport domain of RHA also interfered with Tap-mediated transactivation of the CTE function in quail cells, in which the function of CTE is dependent on the expression of a functional human Tap cDNA.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Wong-Staal, F (corresponding author), Univ Calif San Diego, Dept Biol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	fwongstaal@ucsd.edu	Tang, Hengli/F-2085-2014		NIGMS NIH HHS [GM56089] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bachi A, 2000, RNA, V6, P136, DOI 10.1017/S1355838200991994; Bear J, 1999, MOL CELL BIOL, V19, P6306; Braun IC, 1999, EMBO J, V18, P1953, DOI 10.1093/emboj/18.7.1953; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; CULLEN BR, 1983, P NATL ACAD SCI-BIOL, V80, P2946, DOI 10.1073/pnas.80.10.2946; Ernst RK, 1997, MOL CELL BIOL, V17, P135, DOI 10.1128/MCB.17.1.135; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; Hodge CA, 1999, EMBO J, V18, P5778, DOI 10.1093/emboj/18.20.5778; Huang YQ, 1999, EMBO J, V18, P1642, DOI 10.1093/emboj/18.6.1642; Kang YB, 1999, GENE DEV, V13, P1126, DOI 10.1101/gad.13.9.1126; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; Li JZ, 1999, P NATL ACAD SCI USA, V96, P709, DOI 10.1073/pnas.96.2.709; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; Ohno M, 1996, GENE DEV, V10, P997, DOI 10.1101/gad.10.8.997; ONO W, 1994, MOL CELL BIOL, V14, P7611, DOI 10.1128/MCB.14.11.7611; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Pasquinelli AE, 1997, P NATL ACAD SCI USA, V94, P14394, DOI 10.1073/pnas.94.26.14394; Pasquinelli AE, 1997, EMBO J, V16, P7500, DOI 10.1093/emboj/16.24.7500; Saavedra C, 1997, CURR BIOL, V7, P619, DOI 10.1016/S0960-9822(06)00288-0; Schmitt C, 1999, EMBO J, V18, P4332, DOI 10.1093/emboj/18.15.4332; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Snay-Hodge CA, 1998, EMBO J, V17, P2663, DOI 10.1093/emboj/17.9.2663; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Strahm Y, 1999, EMBO J, V18, P5761, DOI 10.1093/emboj/18.20.5761; Tabernero C, 1996, J VIROL, V70, P5998, DOI 10.1128/JVI.70.9.5998-6011.1996; Tang H, 1999, MOL CELL BIOL, V19, P3540; Tang HL, 1997, VIROLOGY, V228, P333, DOI 10.1006/viro.1996.8407; Tang HL, 1997, SCIENCE, V276, P1412, DOI 10.1126/science.276.5317.1412; Tseng SSL, 1998, EMBO J, V17, P2651, DOI 10.1093/emboj/17.9.2651; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; Westberg C, 2000, J BIOL CHEM, V275, P21396, DOI 10.1074/jbc.M909887199; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Yoon DW, 1997, IMMUNITY, V6, P571, DOI 10.1016/S1074-7613(00)80345-3; Zhang SS, 1999, J CELL SCI, V112, P1055; ZOLOTUKHIN AS, 1994, J VIROL, V68, P7944, DOI 10.1128/JVI.68.12.7944-7952.1994	39	33	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32694	32700		10.1074/jbc.M003933200	http://dx.doi.org/10.1074/jbc.M003933200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10924507	hybrid			2022-12-27	WOS:000090003800045
J	Edwards, JC; Kapadia, S				Edwards, JC; Kapadia, S			Regulation of the bovine kidney microsomal chloride channel p64 by p59(fyn), a Src family tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; SH3 DOMAINS; SUBCELLULAR-DISTRIBUTION; PROTEIN; EXPRESSION; ACTIVATION; BINDING; CELLS; PURIFICATION; ASSOCIATION	p64 is a chloride channel of intracellular membranes which is present in regulated secretory vesicles. Mechanisms by which the p64 channel could be regulated are largely unknown. p59(fyn) is a non-receptor tyrosine kinase of the Src family that has been implicated in a variety of intracellular signaling events. The N-terminal portion of p64 has several potential binding sites for Src family SH2 domains. In this paper, we demonstrate that p64 becomes tyrosine phosphorylated when co-expressed with p59(fyn) in HeLa cells. We show that co-expression of p64 with p59(fyn) renders p64 a ligand for the SH2 domain of p59(fyn) and this SH2 binding is eliminated by treating p64 with alkaline phosphatase. Using site-directed mutagenesis, we find that tyrosine 33 in the p64 sequence is necessary for SH2 binding. We also characterized p64-p59(fyn) interactions using native material from bovine kidney. We found that a small fraction of native kidney p64 can bind Fyn SH2 in vitro. Immunoprecipitation of p64 from solubilized kidney membranes yields a kinase activity with the same mobility by SDS-polyacrylamide gel electrophoresis as authentic bovine p59(fyn), Finally, we demonstrate that co-expression of p64 and p59(fyn) in HeLa cells results in enhanced p64-associated chloride channel activity.	St Louis Vet Affairs Med Ctr, Renal Div 657 111JC, St Louis, MO 63106 USA; St Louis Univ, Dept Med, Div Renal, St Louis, MO 63106 USA	Saint Louis University	Edwards, JC (corresponding author), St Louis Vet Affairs Med Ctr, Renal Div 657 111JC, 915 N Grand Ave, St Louis, MO 63106 USA.	John.Edwards3@med.va.gov			NIAMS NIH HHS [AR44838] Funding Source: Medline; NIDDK NIH HHS [DK46212] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046212] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; ARMITAGE P, 1971, STATISTICAL METHODS, P189; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; Chellaiah M, 1996, ENDOCRINOLOGY, V137, P2432, DOI 10.1210/en.137.6.2432; COURTNEIDGE SA, 1993, DEVELOPMENT, P57; Duncan RR, 1997, J BIOL CHEM, V272, P23880, DOI 10.1074/jbc.272.38.23880; Edwards JC, 1998, J MEMBRANE BIOL, V163, P119; Edwards JC, 1999, AM J PHYSIOL-RENAL, V276, pF398, DOI 10.1152/ajprenal.1999.276.3.F398; Fernandez-Salas E, 1999, J BIOL CHEM, V274, P36488, DOI 10.1074/jbc.274.51.36488; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Heiss NS, 1997, GENOMICS, V45, P224, DOI 10.1006/geno.1997.4922; KEFALAS P, 1995, INT J BIOCHEM CELL B, V27, P551, DOI 10.1016/1357-2725(95)00024-J; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; LANDRY D, 1993, J BIOL CHEM, V268, P14948; LANDRY DW, 1989, SCIENCE, V244, P1469, DOI 10.1126/science.2472007; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; Nishizawa T, 2000, J BIOL CHEM, V275, P11164, DOI 10.1074/jbc.275.15.11164; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Qian ZJ, 1999, J BIOL CHEM, V274, P1621, DOI 10.1074/jbc.274.3.1621; Redhead C, 1997, MOL BIOL CELL, V8, P691, DOI 10.1091/mbc.8.4.691; Resh MD, 1998, INT J BIOCHEM CELL B, V30, P1159, DOI 10.1016/S1357-2725(98)00089-2; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; Schlesinger PH, 1997, J BIOL CHEM, V272, P18636, DOI 10.1074/jbc.272.30.18636; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SIEGELBAUM SA, 1994, CURR BIOL, V4, P242, DOI 10.1016/S0960-9822(00)00054-3; Sobko A, 1998, EMBO J, V17, P4723, DOI 10.1093/emboj/17.16.4723; Staub O, 1997, CURR OPIN NEPHROL HY, V6, P447, DOI 10.1097/00041552-199709000-00007; Tang H, 1999, J BIOL CHEM, V274, P12401, DOI 10.1074/jbc.274.18.12401; Tulk BM, 1998, AM J PHYSIOL-RENAL, V274, pF1140, DOI 10.1152/ajprenal.1998.274.6.F1140; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	39	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31826	31832		10.1074/jbc.M005275200	http://dx.doi.org/10.1074/jbc.M005275200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10930415	hybrid			2022-12-27	WOS:000089858900041
J	Gross, C; Kelleher, M; Iyer, VR; Brown, PO; Winge, DR				Gross, C; Kelleher, M; Iyer, VR; Brown, PO; Winge, DR			Identification of the copper regulon in Saccharomyces cerevisiae by DNA microarrays	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR MAC1; GENE-EXPRESSION; MOLECULAR CHARACTERIZATION; SUPEROXIDE-DISMUTASE; METALLOTHIONEIN GENE; PHYSIOLOGICAL-ROLE; TRANSPORT PROTEIN; BINDING PROTEIN; YEAST COPPER; IRON UPTAKE	In Saccharomyces cerevisiae, copper ions regulate gene expression through the two transcriptional activators, Ace1 and Mad. Ace1 mediates copper-induced gene expression in cells exposed to stressful levels of copper salts, whereas Mad activates a subset of genes under copper-deficient conditions. DNA microarray hybridization experiments revealed a limited set of yeast genes differentially expressed under growth conditions of excess copper or copper deficiency. Mad activates the expression of six S. cerevisiae genes, including CTR1, CTR3, FRE1, FRE7, YFR055w, and YJL217w, Two of the last three newly identified Mad target genes have no known function; the third, YFR055w, is homologous to cystathionine gamma-lyase encoded by CYS3. Several genes that are differentially expressed in cells containing a constitutively active Mad, designated Mac1(up1), are not direct targets of Mad. Induction or repression of these genes is likely a secondary effect of cells because of constitutive Mad activity. Elevated copper levels induced the expression of the metallothioneins CUP1 and CRS5 and two genes, FET3 and FTR1, in the iron uptake system. Copper-induced FET3 and FTR1 expression arises from an indirect copper effect on cellular iron pools.	Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Hlth Sci Ctr, Dept Biochem, Salt Lake City, UT 84132 USA; Stanford Univ, Sch Med, Dept Biochem, Howard Hughes Med Inst, Stanford, CA 94305 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Stanford University	Winge, DR (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA.	dennis.winge@hsc.utah.edu	Winge, Dennis/G-3611-2010		NCI NIH HHS [5P30-CA 42014, CA61286] Funding Source: Medline; NHGRI NIH HHS [HG00983] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061286, P30CA042014] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000983] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Askwith CC, 1996, MOL MICROBIOL, V20, P27, DOI 10.1111/j.1365-2958.1996.tb02485.x; BACHHAWAT N, 1995, J BIOL CHEM, V270, P25087, DOI 10.1074/jbc.270.42.25087; BAKERBRACHMANN C, 1998, YEAST, V14, P115; BUCHMAN C, 1989, MOL CELL BIOL, V9, P4091, DOI 10.1128/MCB.9.9.4091; BUCHMAN C, 1990, MOL CELL BIOL, V10, P4778, DOI 10.1128/MCB.10.9.4778; CULOTTA VC, 1994, J BIOL CHEM, V269, P25295; CULOTTA VC, 1995, J BIOL CHEM, V270, P29991; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dix D, 1997, J BIOL CHEM, V272, P11770, DOI 10.1074/jbc.272.18.11770; FOGEL S, 1982, P NATL ACAD SCI-BIOL, V79, P5342, DOI 10.1073/pnas.79.17.5342; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; Georgatsou E, 1997, J BIOL CHEM, V272, P13786, DOI 10.1074/jbc.272.21.13786; GRALLA EB, 1991, P NATL ACAD SCI USA, V88, P8558, DOI 10.1073/pnas.88.19.8558; HAMER DH, 1985, SCIENCE, V228, P685, DOI 10.1126/science.3887570; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; Jensen LT, 1996, J BIOL CHEM, V271, P18514, DOI 10.1074/jbc.271.31.18514; Jensen LT, 1998, J BIOL CHEM, V273, P23805, DOI 10.1074/jbc.273.37.23805; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; KAMPFENKEL K, 1995, J BIOL CHEM, V270, P28479, DOI 10.1074/jbc.270.47.28479; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Labbe S, 1999, J BIOL CHEM, V274, P36252, DOI 10.1074/jbc.274.51.36252; Lesuisse E, 1996, J BIOL CHEM, V271, P13578, DOI 10.1074/jbc.271.23.13578; Liu XF, 1997, J BIOL CHEM, V272, P11763, DOI 10.1074/jbc.272.18.11763; Martins LJ, 1998, J BIOL CHEM, V273, P23716, DOI 10.1074/jbc.273.37.23716; McDaniels CPJ, 1999, J BIOL CHEM, V274, P26962, DOI 10.1074/jbc.274.38.26962; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Ono B, 1999, YEAST, V15, P1365, DOI 10.1002/(SICI)1097-0061(19990930)15:13<1365::AID-YEA468>3.0.CO;2-U; Serpe M, 1999, J BIOL CHEM, V274, P29211, DOI 10.1074/jbc.274.41.29211; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; Winge DR, 1998, CURR OPIN CHEM BIOL, V2, P216, DOI 10.1016/S1367-5931(98)80063-X; Winge DR, 1998, PROG NUCLEIC ACID RE, V58, P165; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030; YamaguchiIwai Y, 1997, J BIOL CHEM, V272, P17711, DOI 10.1074/jbc.272.28.17711; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Zhao H, 1998, J BIOL CHEM, V273, P28713, DOI 10.1074/jbc.273.44.28713; Zhu ZW, 1998, J BIOL CHEM, V273, P1277, DOI 10.1074/jbc.273.3.1277	41	141	151	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32310	32316		10.1074/jbc.M005946200	http://dx.doi.org/10.1074/jbc.M005946200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10922376	hybrid			2022-12-27	WOS:000089858900103
J	Holliday, LS; Lu, M; Lee, BS; Nelson, RD; Solivan, S; Zhang, L; Gluck, SL				Holliday, LS; Lu, M; Lee, BS; Nelson, RD; Solivan, S; Zhang, L; Gluck, SL			The amino-terminal domain of the B subunit of vacuolar H+-ATPase contains a filamentous actin binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOCLASTS; EXPRESSION; KIDNEY; ACIDIFICATION; ASSOCIATION; RESORPTION; ISOFORM; MYOSIN; MOUSE; MICE	Vacuolar H+-ATPase (V-ATPase) binds actin filaments with high affinity (K-d = 55 nM; Lee, B. S., Gluck, S. L., and Holliday, L. S. (1999) J. Biol. Chem. 274, 29164-29171). We have proposed that this interaction is an important mechanism controlling transport of V-ATPase from the cytoplasm to the plasma membrane of osteoclasts. Here we show that both the B1 (kidney) and B2 (brain) isoforms of the B subunit of V-ATPase contain a microfilament binding site in their amino-terminal domain. In pelleting assays containing actin filaments and partially disrupted V-ATPase, B subunits were found in greater abundance in actin pellets than were other V-ATPase subunits, suggesting that the B subunit contained an F-actin binding site. In overlay assays, biotinylated actin filaments also bound to the B subunit. A fusion protein containing the amino-terminal half of B1 subunit bound actin filaments tightly, but fusion proteins containing the carboxyl-terminal half of B1 subunit, or the full-length E subunit, did not bind F-actin. Fusion proteins containing the amino-terminal 106 amino acids of the B1 isoform or the amino-terminal 112 amino acids of the 112 isoform bound filamentous actin with K-d values of 130 and 190 nM, respectively, and approached saturation at 1 mel of fusion protein/mol of filamentous actin. The B1 and B2 amino-terminal fusion proteins competed with V-ATPase for binding to filamentous actin. In summary, binding sites for F-actin are present in the aminoterminal domains of both isoforms of the B subunit, and likely are responsible for the interaction between V-ATPase and actin filaments in vivo.	Univ Florida, Coll Med, Dept Med, Div Nephrol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; Univ Utah, Dept Pediat, Salt Lake City, UT 84132 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Washington University (WUSTL); Utah System of Higher Education; University of Utah	Holliday, LS (corresponding author), Univ Florida, Coll Med, Dept Med, Div Nephrol, 1600 Archer Rd,Campus Box 100224, Gainesville, FL 32610 USA.		Lee, Beth S/E-9578-2010; Holliday, Lexie/GYQ-4972-2022	Lee, Beth S/0000-0002-1468-6387; Holliday, Lexie/0000-0002-0844-1965	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038848, R01DK052131] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK52131, R01 DK38848] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AbuAmer Y, 1997, J CELL BIOL, V137, P247, DOI 10.1083/jcb.137.1.247; BASTANI B, 1991, J CLIN INVEST, V88, P126, DOI 10.1172/JCI115268; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; Boekema EJ, 1999, NATURE, V401, P37, DOI 10.1038/43369; Breton S, 2000, J BIOL CHEM, V275, P18219, DOI 10.1074/jbc.M909857199; Breton S, 1996, NAT MED, V2, P470, DOI 10.1038/nm0496-470; BROWN D, 1987, J CELL BIOL, V105, P1636; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Forgac M, 2000, J EXP BIOL, V203, P71; Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131; GLUCK S, 1987, J BIOL CHEM, V262, P15780; Gluck S L, 1993, Int Rev Cytol, V137C, P105; Gluck SL, 1996, ANNU REV PHYSIOL, V58, P427, DOI 10.1146/annurev.physiol.58.1.427; HEMKEN P, 1992, J BIOL CHEM, V267, P9948; HOLLIDAY LS, 1995, J BIOL CHEM, V270, P18983, DOI 10.1074/jbc.270.32.18983; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; Lee BS, 1999, J BIOL CHEM, V274, P29164, DOI 10.1074/jbc.274.41.29164; Lee BS, 1999, J BONE MINER RES, V14, P2127, DOI 10.1359/jbmr.1999.14.12.2127; LEE BS, 1996, AM J PHYSIOL, V39, pC382; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; Luna EJ, 1998, METHOD ENZYMOL, V298, P32, DOI 10.1016/S0076-6879(98)98006-5; MARKS SC, 1985, J HERED, V76, P171, DOI 10.1093/oxfordjournals.jhered.a110059; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Nakamura I, 1997, FEBS LETT, V401, P207, DOI 10.1016/S0014-5793(96)01454-8; Nelson N, 2000, J EXP BIOL, V203, P89; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; Sambrook J., 1989, MOL CLONING LAB MANU, V3, P18; SATO M, 1990, CELL MOTIL CYTOSKEL, V17, P250, DOI 10.1002/cm.970170311; Scimeca JC, 2000, BONE, V26, P207, DOI 10.1016/S8756-3282(99)00278-1; Skinner MA, 1999, J HISTOCHEM CYTOCHEM, V47, P1247, DOI 10.1177/002215549904701004; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TISHER CC, 1991, CONTRIB NEPHROL, V95, P168; VAANANEN HK, 1990, J CELL BIOL, V111, P1305, DOI 10.1083/jcb.111.3.1305; Wax MB, 1997, P NATL ACAD SCI USA, V94, P6752, DOI 10.1073/pnas.94.13.6752; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Zhang N, 1999, ONCOGENE, V18, P2273, DOI 10.1038/sj.onc.1202545	39	151	156	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32331	32337		10.1074/jbc.M004795200	http://dx.doi.org/10.1074/jbc.M004795200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10915794	hybrid			2022-12-27	WOS:000089858900106
J	Inbar, O; Liefshitz, B; Bitan, G; Kupiec, M				Inbar, O; Liefshitz, B; Bitan, G; Kupiec, M			The relationship between homology length and crossing over during the repair of a broken chromosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAK; SACCHAROMYCES-CEREVISIAE MSH2; GENE CONVERSION TRACTS; YEAST MATING TYPE; MISMATCH-REPAIR; MITOTIC RECOMBINATION; DNA; PROTEINS; RESOLUTION; BINDS	Homologous recombination can result in the transfer of genetic information from one DNA molecule to another (gene conversion). These events are often accompanied by a reciprocal exchange between the interacting molecules (termed "crossing over"). This association suggests that the two types of events could be mechanistically related. We have analyzed the repair, by homologous recombination, of a broken chromosome in yeast. We show that gene conversion can be uncoupled from crossing over when the length of homology of the interacting substrates is below a certain threshold. In addition, a minimal length of homology on each broken chromosomal arm is needed for crossing over. We also show that the coupling between gene conversion and crossing over is affected by the mismatch repair system; mutations in the MSH2 or MSH6 genes cause an increase in the crossing over observed for short alleles. Our results provide a mechanism to explain how chromosomal recombinational repair can take place without altering the stability of the genome.	Tel Aviv Univ, Dept Mol Microbiol & Biotechnol, IL-69978 Ramat Aviv, Israel	Tel Aviv University	Kupiec, M (corresponding author), Tel Aviv Univ, Dept Mol Microbiol & Biotechnol, IL-69978 Ramat Aviv, Israel.		Bitan, Gal/U-2204-2019	Bitan, Gal/0000-0001-7046-3754				AGUILERA A, 1989, GENETICS, V123, P683; ALANI E, 1994, GENETICS, V137, P19; Alani E, 1996, MOL CELL BIOL, V16, P5604; BELMAAZA A, 1994, MUTAT RES, V314, P199, DOI 10.1016/0921-8777(94)90065-5; BENNETT CB, 1993, P NATL ACAD SCI USA, V90, P5613, DOI 10.1073/pnas.90.12.5613; Chen WL, 1998, MOL CELL BIOL, V18, P6525, DOI 10.1128/MCB.18.11.6525; Datta A, 1996, MOL CELL BIOL, V16, P1085; Datta A, 1997, P NATL ACAD SCI USA, V94, P9757, DOI 10.1073/pnas.94.18.9757; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; FUJITANI Y, 1995, GENETICS, V140, P797; HABER JE, 1993, P NATL ACAD SCI USA, V90, P3363, DOI 10.1073/pnas.90.8.3363; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; Iaccarino I, 1996, CURR BIOL, V6, P484, DOI 10.1016/S0960-9822(02)00516-X; Inbar O, 1999, MOL CELL BIOL, V19, P4134; JINKSROBERTSON S, 1993, MOL CELL BIOL, V13, P3937, DOI 10.1128/MCB.13.7.3937; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; KLAR AJS, 1984, NATURE, V310, P744, DOI 10.1038/310744a0; LICHTEN M, 1989, GENETICS, V123, P261; Marsischky GT, 1999, J BIOL CHEM, V274, P7200, DOI 10.1074/jbc.274.11.7200; MCGILL CB, 1993, CURR GENET, V23, P305, DOI 10.1007/BF00310891; MESELSON MS, 1975, P NATL ACAD SCI USA, V72, P358, DOI 10.1073/pnas.72.1.358; NASMYTH KA, 1982, ANNU REV GENET, V16, P439, DOI 10.1146/annurev.ge.16.120182.002255; NASSIF N, 1994, MOL CELL BIOL, V14, P1613, DOI 10.1128/MCB.14.3.1613; NICKOLOFF JA, 1990, MOL CELL BIOL, V10, P1174, DOI 10.1128/MCB.10.3.1174; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; Paques F, 1997, MOL CELL BIOL, V17, P6765, DOI 10.1128/MCB.17.11.6765; Paques F, 1998, MOL CELL BIOL, V18, P2045, DOI 10.1128/MCB.18.4.2045; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; Porter G, 1996, GENETICS, V143, P755; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; SWEETSER DB, 1994, MOL CELL BIOL, V14, P3863, DOI 10.1128/MCB.14.6.3863; SZOSTAK JW, 1983, CELL, V3, P725; Weng YS, 1998, GENETICS, V148, P59; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; ZENVIRTH D, 1992, EMBO J, V11, P3441, DOI 10.1002/j.1460-2075.1992.tb05423.x	39	56	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30833	30838		10.1074/jbc.C000133200	http://dx.doi.org/10.1074/jbc.C000133200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10924495	hybrid			2022-12-27	WOS:000089762700016
J	Overgaard, MT; Haaning, J; Boldt, HB; Olsen, IM; Laursen, LS; Christiansen, M; Gleich, GJ; Sottrup-Jensen, L; Conover, CA; Oxvig, C				Overgaard, MT; Haaning, J; Boldt, HB; Olsen, IM; Laursen, LS; Christiansen, M; Gleich, GJ; Sottrup-Jensen, L; Conover, CA; Oxvig, C			Expression of recombinant human pregnancy-associated plasma protein-A and identification of the proform of eosinophil major basic protein as its physiological inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR BINDING PROTEIN-4; MESSENGER-RIBONUCLEIC-ACID; MATRIX METALLOPROTEINASES; HUMAN FIBROBLASTS; CYSTEINE SWITCH; DOWN-SYNDROME; PAPP-A; SERUM; PRECURSOR; PURIFICATION	Pregnancy-associated plasma protein-A (PAPP-A), originally known from human pregnancy serum, has recently been demonstrated to be a metzincin superfamily metalloproteinase involved in normal and pathological insulin-like growth factor (IGF) physiology. PAPP-A specifically cleaves IGF-binding protein (LGFBP)-4, one of six antagonists of IGF action, which results in release of IGF bound to IGFBP-4. IGFBP-4 is the only known PAPP-A substrate. Its cleavage by PAPP-A uniquely depends on the presence of IGF. We here report mammalian expression and purification of recombinant 1547-residue PAPP-A (rPAPP-A). The recombinant protein is secreted as a homodimer of about 400 kDa composed of two 200-kDa disulfide-bound subunits. Antigenically and functionally, rPAPP-A behaves like the native protein. In human pregnancy, PAPP-A is known to circulate as a 500-kDa disulfide-bound 2:2 complex with the proform of eosinophil major basic protein (proMBP), PAPP-A/proMBP. A comparison between rPAPP-A and pregnancy serum PAPP-A/proMBP complex surprisingly reveals a difference greater than 100-fold in proteolytic activity, showing that proMBP functions as a proteinase inhibitor in vivo. We find that polyclonal antibodies against PAPP-A abrogate all detectable IGFBP-4 proteolytic activity in pregnancy serum, pointing at PAPP-A as the dominating, if not the only, IGFBP-4 proteinase present in the circulation. We further show that pregnancy serum and plasma contain traces (<1%) of uncomplexed PAPP-A with a much higher specific activity than the PAPP-A/proMBP complex. The measurable activity of the PAPP-A/proMBP complex probably results from the presence of a minor subpopulation of partly inhibited PAPP-A that exists in a 2:1 complex with proMBP. Inhibition of PAPP-A by proMBP represents a novel inhibitory mechanism with the enzyme irreversibly bound to its inhibitor by disulfide bonds.	Aarhus Univ, Dept Mol & Struct Biol, DK-8000 Aarhus C, Denmark; Statens Serum Inst, Dept Clin Biochem, DK-2300 Copenhagen S, Denmark; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Endocrine Res Unit, Rochester, MN 55905 USA	Aarhus University; Statens Serum Institut; Mayo Clinic; Mayo Clinic	Oxvig, C (corresponding author), Aarhus Univ, Dept Mol & Struct Biol, Sci Pk,Gustav Wieds Vej 10C, DK-8000 Aarhus C, Denmark.	co@mbio.aau.dk	Christiansen, Michael/B-4588-2009; Overgaard, Michael Toft/E-1354-2011	Christiansen, Michael/0000-0003-4713-755X; Overgaard, Michael Toft/0000-0002-1423-2481; Laursen, Lisbeth Schmidt/0000-0002-8676-5869; Oxvig, Claus/0000-0002-4715-9719				Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BARKER RL, 1991, J CLIN INVEST, V88, P798, DOI 10.1172/JCI115379; BARKER RL, 1988, J EXP MED, V168, P1493, DOI 10.1084/jem.168.4.1493; BISCHOF P, 1979, ARCH GYNECOL, V227, P315, DOI 10.1007/BF02109920; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; BONNO M, 1994, LAB INVEST, V71, P560; Byun D, 2000, J CLIN ENDOCR METAB, V85, P373, DOI 10.1210/jc.85.1.373; Christiansen M, 1999, PRENATAL DIAG, V19, P905, DOI 10.1002/(SICI)1097-0223(199910)19:10<905::AID-PD658>3.0.CO;2-Q; Conover CA, 1999, J CLIN ENDOCR METAB, V84, P4742, DOI 10.1210/jc.84.12.4742; CONOVER CA, 1993, J CLIN INVEST, V91, P1129, DOI 10.1172/JCI116272; DAVEY MW, 1983, ANAL BIOCHEM, V131, P18, DOI 10.1016/0003-2697(83)90130-6; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; FOLKERSEN J, 1981, AM J OBSTET GYNECOL, V139, P910, DOI 10.1016/0002-9378(81)90957-1; Fowlkes JL, 1997, TRENDS ENDOCRIN MET, V8, P299, DOI 10.1016/S1043-2760(97)00112-4; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Haaning J, 1996, EUR J BIOCHEM, V237, P159, DOI 10.1111/j.1432-1033.1996.0159n.x; KRISTENSEN T, 1994, BIOCHEMISTRY-US, V33, P1592, DOI 10.1021/bi00172a040; Kubler B, 1998, ENDOCRINOLOGY, V139, P1556, DOI 10.1210/en.139.4.1556; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence JB, 1999, GROWTH HORM IGF RES, V9, P25, DOI 10.1054/ghir.1998.0083; Lawrence JB, 1999, P NATL ACAD SCI USA, V96, P3149, DOI 10.1073/pnas.96.6.3149; LIN TM, 1974, AM J OBSTET GYNECOL, V118, P223, DOI 10.1016/0002-9378(74)90553-5; Loechel F, 1999, J BIOL CHEM, V274, P13427, DOI 10.1074/jbc.274.19.13427; MCGROGAN M, 1988, J EXP MED, V168, P2295, DOI 10.1084/jem.168.6.2295; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Overgaard MT, 1999, BIOL REPROD, V61, P1083, DOI 10.1095/biolreprod61.4.1083; OXVIG C, 1994, FEBS LETT, V341, P213, DOI 10.1016/0014-5793(94)80459-1; OXVIG C, 1994, BIOCHEM MOL BIOL INT, V33, P329; OXVIG C, 1995, J BIOL CHEM, V270, P13645, DOI 10.1074/jbc.270.23.13645; OXVIG C, 1993, J BIOL CHEM, V268, P12243; OXVIG C, 1994, BBA-GEN SUBJECTS, V1201, P415, DOI 10.1016/0304-4165(94)90071-X; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Popken-Harris P, 1998, BLOOD, V92, P623, DOI 10.1182/blood.V92.2.623.414k32_623_631; Qin QP, 1997, CLIN CHEM, V43, P2323; Qin XZ, 1998, J BIOL CHEM, V273, P23509, DOI 10.1074/jbc.273.36.23509; Rajaram S, 1997, ENDOCR REV, V18, P801, DOI 10.1210/er.18.6.801; SINOSICH MJ, 1990, ELECTROPHORESIS, V11, P70, DOI 10.1002/elps.1150110115; SOTTRUPJENSEN L, 1993, BIOCHEM MOL BIOL INT, V30, P789; SOTTRUPJENSEN L, 1995, ANAL BIOCHEM, V225, P187, DOI 10.1006/abio.1995.1137; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; Tsukuba T, 1998, J BIOL CHEM, V273, P35260, DOI 10.1074/jbc.273.52.35260; WESTERGAARD JG, 1983, PLACENTA, V4, P13, DOI 10.1016/S0143-4004(83)80013-7	43	154	169	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31128	31133		10.1074/jbc.M001384200	http://dx.doi.org/10.1074/jbc.M001384200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10913121	hybrid			2022-12-27	WOS:000089762700055
J	Ducros, V; Charnock, SJ; Derewenda, U; Derewenda, ZS; Dauter, Z; Dupont, C; Shareck, F; Morosoli, R; Kluepfel, D; Davies, GJ				Ducros, V; Charnock, SJ; Derewenda, U; Derewenda, ZS; Dauter, Z; Dupont, C; Shareck, F; Morosoli, R; Kluepfel, D; Davies, GJ			Substrate specificity in glycoside hydrolase family 10 - Structural and kinetic analysis of the streptomyces lividans xylanase 10A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; CRYSTAL-STRUCTURE; ACTIVE-SITE; ENZYME INTERMEDIATE; ANGSTROM RESOLUTION; MACROMOLECULAR STRUCTURES; THERMOASCUS-AURANTIACUS; BETA-1,4-GLYCANASE CEX; CATALYTIC INTERMEDIATE; MOLECULAR REPLACEMENT	Endoxylanases are a group of enzymes that hydrolyze the beta-1,4-linked xylose backbone of xylans. They are predominantly found in two discrete sequence families known as glycoside hydrolase families 10 and 11. The Streptomyces lividans xylanase Xyl10A is a family 10 enzyme, the native structure of which has previously been determined by x-ray crystallography at a 2.6 Angstrom resolution (Derewenda, U., Swenson, L., Green, R., Wei, Y., Morosoli, R., Shareck, F., Kluepfel, D., and Derewenda, Z. S. (1994) J. Biol. Chem. 269, 20811-20814). Here, we report the native structure of Xyl10A refined at a resolution of 1.2 Angstrom which reveals many features such as the rare occurrence of a discretely disordered disulfide bond between residues Cys-168 and Cys-201. In order to investigate substrate binding and specificity in glycoside hydrolase family 10, the covalent xylobiosyl enzyme and the covalent cellobiosyl enzyme intermediates of Xyl10A were trapped through the use of appropriate 2-fluoroglycosides. The Lu-linked intermediate with the nucleophile, Glu-236, is in a C-4(1) chair conformation as previously observed in the family 10 enzyme Cex from Cellulomonas fimi (Notenboom, V., Birsan, C., Warren, R. A. J., Withers, S. G., and Rose, D. R. (1998) Biochemistry 37, 4751-4758). The different interactions of Xyl10A with the xylobiosyl and cellobiosyl moieties, notably conformational changes in the -2 and -1 subsites, together with the observed kinetics on a range of aryl glycosides, shed new light on substrate specificity in glycoside hydrolase family 10.	Univ York, Dept Chem, Struct Biol Lab, York YO10 5DD, N Yorkshire, England; Univ Virginia, Ctr Hlth Sci, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22906 USA; Brookhaven Natl Lab, Upton, NY 11973 USA; Univ Quebec, Inst Armand Frappier, INRS, Inst Microbiol & Biotechnol, Laval, PQ H7V 1B7, Canada	University of York - UK; University of Virginia; United States Department of Energy (DOE); Brookhaven National Laboratory; University of Quebec; Institut national de la recherche scientifique (INRS)	Davies, GJ (corresponding author), Univ York, Dept Chem, Struct Biol Lab, York YO10 5DD, N Yorkshire, England.		Davies, Gideon J/A-9042-2011	Davies, Gideon J/0000-0002-7343-776X				Andrews SR, 2000, J BIOL CHEM, V275, P23027, DOI 10.1074/jbc.M000128200; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Burmeister WP, 1997, STRUCTURE, V5, P663, DOI 10.1016/S0969-2126(97)00221-9; Charnock SJ, 1998, J BIOL CHEM, V273, P32187, DOI 10.1074/jbc.273.48.32187; DAVIES G, 1997, COMPREHENSIVE BIOL C, V1, P119; Davies GJ, 1998, BIOCHEMISTRY-US, V37, P11707, DOI 10.1021/bi981315i; DEREWENDA U, 1994, J BIOL CHEM, V269, P20811; DOMINGUEZ R, 1995, NAT STRUCT BIOL, V2, P569, DOI 10.1038/nsb0795-569; GILKES NR, 1991, MICROBIOL REV, V55, P303, DOI 10.1128/MMBR.55.2.303-315.1991; HARRIS GW, 1994, STRUCTURE, V2, P1107, DOI 10.1016/S0969-2126(94)00112-X; Heightman TD, 1999, ANGEW CHEM INT EDIT, V38, P750, DOI 10.1002/(SICI)1521-3773(19990315)38:6<750::AID-ANIE750>3.0.CO;2-6; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Henrissat B, 1998, FEBS LETT, V425, P352, DOI 10.1016/S0014-5793(98)00265-8; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Hilge M, 1998, STRUCTURE, V6, P1433, DOI 10.1016/S0969-2126(98)00142-7; JENKINS J, 1995, FEBS LETT, V362, P281, DOI 10.1016/0014-5793(95)00252-5; JONES KL, 1949, J BACTERIOL, V57, P141, DOI 10.1128/JB.57.2.141-145.1949; KLEYWEGT GJ, 1994, ESF CCP4 NEWSLETTER, V31, P9; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Laskowski R. A., 1993, J APPL CRYSTALLOGR, V26, P282; Lo Leggio L, 1999, PROTEINS, V36, P295; Lovry O.H., 1951, J BIOL CHEM, V193, P265; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; MONDOU F, 1986, GENE, V49, P323, DOI 10.1016/0378-1119(86)90368-9; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Namchuk MN, 1995, BIOCHEMISTRY-US, V34, P16194, DOI 10.1021/bi00049a035; Natesh R, 1999, J MOL BIOL, V288, P999, DOI 10.1006/jmbi.1999.2727; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Notenboom V, 1998, NAT STRUCT BIOL, V5, P812, DOI 10.1038/1852; Notenboom V, 1998, BIOCHEMISTRY-US, V37, P4751, DOI 10.1021/bi9729211; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; Roberge M, 1997, BIOCHEMISTRY-US, V36, P7769, DOI 10.1021/bi9703296; Roberge M, 1997, PROTEIN ENG, V10, P399, DOI 10.1093/protein/10.4.399; Sabini E, 2000, ACTA CRYSTALLOGR D, V56, P3, DOI 10.1107/S0907444999013943; Sabini E, 1999, CHEM BIOL, V6, P483, DOI 10.1016/S1074-5521(99)80066-0; Schmidt A, 1998, PROTEIN SCI, V7, P2081, DOI 10.1002/pro.5560071004; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Sidhu G, 1999, BIOCHEMISTRY-US, V38, P5346, DOI 10.1021/bi982946f; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; Sulzenbacher G, 1997, BIOCHEMISTRY-US, V36, P16032, DOI 10.1021/bi972407v; Sulzenbacher G, 1999, BIOCHEMISTRY-US, V38, P4826, DOI 10.1021/bi982648i; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WHITE A, 1994, BIOCHEMISTRY-US, V33, P12546, DOI 10.1021/bi00208a003; White A, 1996, NAT STRUCT BIOL, V3, P149, DOI 10.1038/nsb0296-149; WITHERS SG, 1987, J AM CHEM SOC, V109, P7530, DOI 10.1021/ja00258a047	55	74	74	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23020	23026		10.1074/jbc.275.30.23020	http://dx.doi.org/10.1074/jbc.275.30.23020			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10930426	hybrid			2022-12-27	WOS:000088419400057
J	Lewis, RJ; Nielsen, KJ; Craik, DJ; Loughnan, ML; Adams, DA; Sharpe, IA; Luchian, T; Adams, DJ; Bond, T; Thomas, L; Jones, A; Matheson, JL; Drinkwater, R; Andrews, PR; Alewood, PF				Lewis, RJ; Nielsen, KJ; Craik, DJ; Loughnan, ML; Adams, DA; Sharpe, IA; Luchian, T; Adams, DJ; Bond, T; Thomas, L; Jones, A; Matheson, JL; Drinkwater, R; Andrews, PR; Alewood, PF			Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TYPE; CA2+ CHANNELS; BETA-SUBUNIT; SYNAPTIC TRANSMISSION; PERIPHERAL NEURONS; FUNCTIONAL ASSAY; ALPHA-CONOTOXIN; GVIA; RAT; ANTAGONISTS	omega -Conotoxins selective for N-type calcium channels are useful in the management of severe pain. In an attempt to expand the therapeutic potential of this class, four new omega -conotoxins (CVIA-D) have been discovered in the venom of the piscivorous cone snail, Conus catus, using assay-guided fractionation and gene cloning. Compared with other omega -conotoxins, CVID has a novel loop 4 sequence and the highest selectivity for N-type over P/Q-type calcium channels in radioligand binding assays. CVIA-D also inhibited contractions of electrically stimulated rat vas deferens. In electrophysiological studies, omega -conotoxins CVID and MVIIA had similar potencies to inhibit current through central (alpha (1B-d)) and peripheral (alpha (1B-b)) splice variants of the rat N-type calcium channels when coexpressed with rat beta (3) in Xenopus oocytes, However, the potency of CVID and MVIIA increased when alpha (1B-d) and alpha (1B-b) were expressed in the absence of rat beta (3), an effect most pronounced for CVID at alpha (1B-d) (up to 540-fold) and least pronounced for MVIIA at alpha (1B-d) (3-fold). The novel selectivity of CVID may have therapeutic implications. H-1 NMR studies reveal that CMD possesses a combination of unique structural features, including two hydrogen bonds that stabilize loop 2 and place loop 2 proximal to loop 4, creating a globular surface that is rigid and well defined.	Univ Queensland, Inst Mol Biosci, Ctr Drug Design & Dev, 3D Ctr, Brisbane, Qld 4072, Australia; Univ Queensland, Dept Physiol & Pharmacol, Brisbane, Qld 4072, Australia; Univ Queensland, CSIRO Trop Agr, Brisbane, Qld 4072, Australia; Univ Queensland, Queensland Agr Biotechnol Ctr, QDPI, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland; Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of Queensland; University of Queensland	Lewis, RJ (corresponding author), Univ Queensland, Inst Mol Biosci, Ctr Drug Design & Dev, 3D Ctr, Brisbane, Qld 4072, Australia.		Milne, Trudy J/G-2630-2011; Lewis, Richard/T-8763-2019; Adams, David John/K-3578-2019; Lewis, Richard J/E-8674-2013; Adams, David/J-9125-2014; Craik, David/B-1695-2010; Loughnan, Marion/B-4508-2009	Lewis, Richard/0000-0003-3470-923X; Adams, David John/0000-0002-7030-2288; Lewis, Richard J/0000-0003-3470-923X; Adams, David/0000-0002-7030-2288; Craik, David/0000-0003-0007-6796; Alewood, Paul/0000-0001-7454-6522; Luchian, Tudor/0000-0002-9388-7266				Adams DJ, 1999, DRUG DEVELOP RES, V46, P219; Atkinson RA, 2000, BIOCHEMISTRY-US, V39, P3908, DOI 10.1021/bi992651h; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; BOOT JR, 1994, EUR J PHARMACOL, V258, P155, DOI 10.1016/0014-2999(94)90069-8; Brunger A. T., 1992, SYSTEM XRAY CRYSTALL; BRUNGER AT, 1986, P NATL ACAD SCI USA, V83, P3801, DOI 10.1073/pnas.83.11.3801; COLLEDGE CJ, 1992, TOXICON, V30, P1111, DOI 10.1016/0041-0101(92)90056-B; CRUZ LJ, 1986, J BIOL CHEM, V261, P6230; Currie KPM, 1997, J NEUROSCI, V17, P4570; DAVIS JH, 1993, BIOCHEMISTRY-US, V32, P7396, DOI 10.1021/bi00080a009; ELLINOR PT, 1994, NATURE, V372, P272, DOI 10.1038/372272a0; Flinn JP, 1999, EUR J BIOCHEM, V262, P447, DOI 10.1046/j.1432-1327.1999.00383.x; Gehrmann J, 1998, J MOL BIOL, V278, P401, DOI 10.1006/jmbi.1998.1701; HILLYARD DR, 1992, NEURON, V9, P69, DOI 10.1016/0896-6273(92)90221-X; KRISTIPATI R, 1994, MOL CELL NEUROSCI, V5, P219, DOI 10.1006/mcne.1994.1026; Lew MJ, 1997, J BIOL CHEM, V272, P12014, DOI 10.1074/jbc.272.18.12014; Lin ZX, 1999, J NEUROSCI, V19, P5322; Lin ZX, 1997, NEURON, V18, P153, DOI 10.1016/S0896-6273(01)80054-4; LUDRIGSEN S, 1992, J BIOMOL NMR, V2, P227; Ludwig A, 1997, J NEUROSCI, V17, P1339; MAGGI CA, 1988, N-S ARCH PHARMACOL, V338, P107, DOI 10.1007/BF00174856; MALMBERG AB, 1995, PAIN, V60, P83, DOI 10.1016/0304-3959(94)00094-U; McDonough SI, 1996, J NEUROSCI, V16, P2612; McIntosh J M, 1999, Methods Enzymol, V294, P605; MILJANICH GP, 1995, ANNU REV PHARMACOL, V35, P707, DOI 10.1146/annurev.pa.35.040195.003423; Moreno H, 1997, P NATL ACAD SCI USA, V94, P14042, DOI 10.1073/pnas.94.25.14042; NADASDI L, 1995, BIOCHEMISTRY-US, V34, P8076, DOI 10.1021/bi00025a013; Nielsen KJ, 1999, J MED CHEM, V42, P415, DOI 10.1021/jm981052q; Nielsen KJ, 1999, J MOL BIOL, V289, P1405, DOI 10.1006/jmbi.1999.2817; Nielsen KJ, 1999, BIOCHEMISTRY-US, V38, P6741, DOI 10.1021/bi982980u; Nielsen KJ, 1996, J MOL BIOL, V263, P297, DOI 10.1006/jmbi.1996.0576; Nielsen KJ, 2000, J MOL RECOGNIT, V13, P55, DOI 10.1002/(SICI)1099-1352(200003/04)13:2<55::AID-JMR488>3.0.CO;2-O; OLIVERA BM, 1984, BIOCHEMISTRY-US, V23, P5087, DOI 10.1021/bi00317a001; OLIVERA BM, 1987, BIOCHEMISTRY-US, V26, P2086, DOI 10.1021/bi00382a004; OLIVERA BM, 1985, SCIENCE, V230, P1338, DOI 10.1126/science.4071055; Penn RD, 2000, PAIN, V85, P291, DOI 10.1016/S0304-3959(99)00254-7; PriceCarter M, 1996, BIOCHEMISTRY-US, V35, P15547, DOI 10.1021/bi9615755; RAMILO CA, 1992, BIOCHEMISTRY-US, V31, P9919, DOI 10.1021/bi00156a009; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Scanlon MJ, 1997, STRUCTURE, V5, P1585, DOI 10.1016/S0969-2126(97)00307-9; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Scott VES, 1996, J BIOL CHEM, V271, P3207, DOI 10.1074/jbc.271.6.3207; SEABROOK GR, 1989, BRIT J PHARMACOL, V97, P1125, DOI 10.1111/j.1476-5381.1989.tb12570.x; Smith AB, 1996, NEUROSCIENCE, V70, P817, DOI 10.1016/S0306-4522(96)83018-1; SMITH MT, 2000, AUST SOC CLIN EXP PH, V7, P50; STEIN EG, 1996, J MAGN RESON, V124, P1554; Stocker JW, 1997, J NEUROSCI, V17, P3002; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; Wang YX, 1998, N-S ARCH PHARMACOL, V357, P159, DOI 10.1007/PL00005150; WETENBROEK RE, 1998, J NEUROSCI, V18, P6319; Wheeler DB, 1996, J NEUROSCI, V16, P2226; WITCHER DR, 1993, NEUROPHARMACOLOGY, V32, P1127, DOI 10.1016/0028-3908(93)90007-P; WOODWARD SR, 1990, EMBO J, V9, P1015, DOI 10.1002/j.1460-2075.1990.tb08204.x; Wright CE, 1996, BRIT J PHARMACOL, V119, P49, DOI 10.1111/j.1476-5381.1996.tb15676.x; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P1; YAMADA K, 1994, NEUROPHARMACOLOGY, V33, P251, DOI 10.1016/0028-3908(94)90016-7; Zamponi GW, 1996, J NEUROSCI, V16, P2430	59	188	205	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35335	35344		10.1074/jbc.M002252200	http://dx.doi.org/10.1074/jbc.M002252200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10938268	Green Published, Green Accepted, hybrid			2022-12-27	WOS:000165422800068
J	Anwar, A; Ali, N; Tanveer, R; Siddiqui, A				Anwar, A; Ali, N; Tanveer, R; Siddiqui, A			Demonstration of functional requirement of polypyrimidine tract-binding protein by SELEX RNA during hepatitis C virus internal ribosome entry site-mediated translation initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' NONCODING REGION; HEPATOCELLULAR-CARCINOMA; 3'-UNTRANSLATED REGION; 5'-UNTRANSLATED REGION; 5'-NONCODING REGION; PICORNAVIRUS RNA; GENOME; POLIOVIRUS; ELEMENT; REPLICATION	Polypyrimidine tract-binding protein (PTB) has been previously shown to physically interact with the hepatitis C virus (HCV) RNA genome at its 5'- and 3'-noncoding regions, Using high affinity SELEX RNA molecules, we present evidence for the functional requirement of PTB during HCV internal ribosome entry site (IRES)-controlled translation initiation. This study was carried out in rabbit reticulocyte translation lysates in which the HCV IRES-driven reporter RNA was introduced along with the PTB-specific SELEX RNA molecules. The SELEX RNAs specifically inhibited the HCV IRES function in the context of mono- and dicistronic mRNAs. The cap-dependent translation of a reporter (chloramphenicol acetyltransferase) RNA or naturally capped brome mosaic virus RNA, however, was not affected by the presence of SELEX during in vitro translation assays. The SELEX-mediated inhibition of the HCV IRES is shown to be relieved by the addition of recombinant human PTB in an add-back experiment. The in vivo requirement of PTB was further confirmed by cotransfection of Huh7 cells with reporter RNA and PTB-specific SELEX RNA. The HCV IRES activity was inhibited by the SELEX RNA in these cells, but not by an unrelated control RNA. Together, these results demonstrate the functional requirement of cellular PTB in HCV translation and further support the feasible use of SELEX RNA strategy in demonstrating the functional relevance of cellular protein(s) in complex biological processes.	Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Siddiqui, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Microbiol, B172,4200 E 9th Ave, Denver, CO 80262 USA.	Aleem.Siddiqui@UCHSC.edu		Ali, Naushad/0000-0002-0058-7396				Ali N, 2000, J BIOL CHEM, V275, P27531; ALI N, 1995, J VIROL, V69, P6367, DOI 10.1128/JVI.69.10.6367-6375.1995; Ali N, 1997, P NATL ACAD SCI USA, V94, P2249, DOI 10.1073/pnas.94.6.2249; Barton DJ, 1996, METHOD ENZYMOL, V275, P35; Belsham GJ, 1996, MICROBIOL REV, V60, P499, DOI 10.1128/MMBR.60.3.499-511.1996; Buratti E, 1998, NUCLEIC ACIDS RES, V26, P3179, DOI 10.1093/nar/26.13.3179; Chen H, 1996, METHOD ENZYMOL, V275, P503; Conte MR, 2000, EMBO J, V19, P3132, DOI 10.1093/emboj/19.12.3132; Das S, 1998, J VIROL, V72, P5638, DOI 10.1128/JVI.72.7.5638-5647.1998; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FUKUSHI S, 1994, BIOCHEM BIOPH RES CO, V199, P425, DOI 10.1006/bbrc.1994.1246; Gamarnik AV, 1998, GENE DEV, V12, P2293, DOI 10.1101/gad.12.15.2293; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; Gontarek RR, 1999, NUCLEIC ACIDS RES, V27, P1457, DOI 10.1093/nar/27.6.1457; Gosert R, 2000, MOL CELL BIOL, V20, P1583, DOI 10.1128/MCB.20.5.1583-1595.2000; Hahm B, 1998, FEBS LETT, V425, P401, DOI 10.1016/S0014-5793(98)00269-5; Hahn B, 1998, J VIROL, V72, P8782, DOI 10.1128/JVI.72.11.8782-8788.1998; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; Honda M, 1996, VIROLOGY, V222, P31, DOI 10.1006/viro.1996.0395; HOUGHTON M, 1996, FIELDS VIROLOGY, P1035; Isoyama T, 1999, J GEN VIROL, V80, P2319, DOI 10.1099/0022-1317-80-9-2319; Ito T, 1999, VIROLOGY, V254, P288, DOI 10.1006/viro.1998.9541; Ito T, 1998, J VIROL, V72, P8789, DOI 10.1128/JVI.72.11.8789-8796.1998; Ito T, 1997, J VIROL, V71, P8698, DOI 10.1128/JVI.71.11.8698-8706.1997; Kaminski A, 1995, RNA, V1, P924; Kamoshita N, 1997, VIROLOGY, V233, P9, DOI 10.1006/viro.1997.8600; Kieft JS, 1999, J MOL BIOL, V292, P513, DOI 10.1006/jmbi.1999.3095; Kolykhalov AA, 1996, J VIROL, V70, P3363, DOI 10.1128/JVI.70.6.3363-3371.1996; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Lu HH, 1996, P NATL ACAD SCI USA, V93, P1412, DOI 10.1073/pnas.93.4.1412; Perez I, 1997, BIOCHEMISTRY-US, V36, P11881, DOI 10.1021/bi9711745; REYNOLDS JE, 1995, EMBO J, V14, P6010, DOI 10.1002/j.1460-2075.1995.tb00289.x; RIJNBRAND R, 1995, FEBS LETT, V365, P115, DOI 10.1016/0014-5793(95)00458-L; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; Sickinger S, 1999, BIOL CHEM, V380, P1217, DOI 10.1515/BC.1999.154; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; Sizova DV, 1998, J VIROL, V72, P4775, DOI 10.1128/JVI.72.6.4775-4782.1998; Spangberg K, 1999, J GEN VIROL, V80, P1371, DOI 10.1099/0022-1317-80-6-1371; Tsuchihara K, 1997, J VIROL, V71, P6720, DOI 10.1128/JVI.71.9.6720-6726.1997; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501; WANG CY, 1994, J VIROL, V68, P7301, DOI 10.1128/JVI.68.11.7301-7307.1994; WANG CY, 1995, RNA, V1, P526; WANG CY, 1993, J VIROL, V67, P3338, DOI 10.1128/JVI.67.6.3338-3344.1993	45	71	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34231	34235		10.1074/jbc.M006343200	http://dx.doi.org/10.1074/jbc.M006343200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10938288	hybrid			2022-12-27	WOS:000165095300033
J	Morrison, DL; Yee, A; Paddon, HB; Vilimek, D; Aebersold, R; Pelech, SL				Morrison, DL; Yee, A; Paddon, HB; Vilimek, D; Aebersold, R; Pelech, SL			Regulation of the meiosis-inhibited protein kinase, a p38(MAPK) isoform, during meiosis and following fertilization of seastar oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA STAR OOCYTES; TYROSINE PHOSPHORYLATION; SUBSTRATE-SPECIFICITY; MAP KINASE; RIBOSOMAL-S6 KINASES; M-PHASE; ACTIVATION; MATURATION; PURIFICATION; CLONING	A p38(MAPK) homolog Mipk (meiosis-inhibited protein kinase) was cloned from seastar oocytes. This 40-kDa protein shares approximately 65% amino acid identity with mammalian p38-alpha isoforms. Mipk was one of the major tyrosine-phosphorylated proteins in immature oocytes arrested at the G(2)/M transition of meiosis I. The tyrosine phosphorylation of Mipk was increased in response to anisomycin, heat, and osmotic shock of oocytes. During 1-methyladenine-induced oocyte maturation, Mipk underwent tyrosine dephosphorylation and remained dephosphorylated in mature oocytes and during the early mitotic cell divisions until approximately 12 h after fertilization. At the time of differentiation and acquisition of G phases in the developing embryos, Mipk was rephosphorylated on tyrosine. In oocytes that were microinjected with Mipk antisense oligonucleotides and subsequently were allowed to mature and become fertilized, differentiation was blocked. Because MipK antisense oligonucleotides and a dominant-negative (K62R)Mipk when microinjected into immature oocytes failed to induce germinal vesicle breakdown, inhibition of Mipk function was not sufficient by itself to cause oocyte maturation. These findings point to a putative role for Mipk in cell cycle control as a G-phase-promoting factor.	Univ British Columbia, Dept Med, Vancouver, BC V6T 1Z3, Canada; Kinetek Pharmaceut Inc, Vancouver, BC V6P 6P2, Canada; Univ Washington, Dept Biotechnol, Seattle, WA 98105 USA	University of British Columbia; University of Washington; University of Washington Seattle	Pelech, SL (corresponding author), Univ British Columbia, Dept Med, 2nd Floor,2211 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.							Abrieu A, 1997, MOL BIOL CELL, V8, P249, DOI 10.1091/mbc.8.2.249; ALI SA, 1995, BIOTECHNIQUES, V18, P746; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Charlton LA, 1999, J CELL BIOCHEM, V75, P310; Chenchik A, 1996, BIOTECHNIQUES, V21, P526; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; DOREE M, 1994, FASEB J, V8, P1114, DOI 10.1096/fasebj.8.14.7958616; FRASER A, 1981, CAN J ZOOL, V59, P1700, DOI 10.1139/z81-234; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; GUERRIER P, 1977, MOL CELL ENDOCRINOL, V7, P137, DOI 10.1016/0303-7207(77)90063-6; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAN JH, 1993, J BIOL CHEM, V268, P25009; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; KALVAKOLANU DVR, 1991, BIOTECHNIQUES, V10, P176; Kishimoto T, 1996, TRENDS BIOCHEM SCI, V21, P35, DOI 10.1016/0968-0004(96)80885-1; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; KURODA S, 1995, J BIOL CHEM, V270, P2460, DOI 10.1074/jbc.270.6.2460; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lefebvre DL, 1999, J CELL BIOCHEM, V75, P272; Masui Y, 1979, Int Rev Cytol, V57, P185, DOI 10.1016/S0074-7696(08)61464-3; MEIJER L, 1987, BIOCHEMISTRY-US, V26, P7968, DOI 10.1021/bi00398a063; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; Murray A, 1993, CELL CYCLE INTRO; PELECH SL, 1987, BIOCHEMISTRY-US, V26, P7960, DOI 10.1021/bi00398a062; PELECH SL, 1988, DEV BIOL, V130, P28, DOI 10.1016/0012-1606(88)90410-1; PELECH SL, 1995, MAP KINASE DEPENDENT, V1, P33; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; Sadler KC, 1998, DEV BIOL, V197, P25, DOI 10.1006/dbio.1998.8869; Sagata N, 1996, TRENDS CELL BIOL, V6, P22, DOI 10.1016/0962-8924(96)81034-8; Sambrook J., 1989, MOL CLONING, pA1; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SANGHERA JS, 1991, BIOCHIM BIOPHYS ACTA, V1095, P153, DOI 10.1016/0167-4889(91)90078-C; SANGHERA JS, 1992, BIOCHEM J, V283, P829, DOI 10.1042/bj2830829; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; Stapleton G, 1998, DEV BIOL, V193, P36, DOI 10.1006/dbio.1997.8791; Suzanne M, 1999, GENE DEV, V13, P1464, DOI 10.1101/gad.13.11.1464; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; WATTS JD, 1994, J BIOL CHEM, V269, P29520; XU Z, 1993, DEV GENET, V14, P424, DOI 10.1002/dvg.1020140604; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723	45	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34236	34244		10.1074/jbc.M004656200	http://dx.doi.org/10.1074/jbc.M004656200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10906138	hybrid			2022-12-27	WOS:000165095300034
J	Tyzack, JK; Wang, XM; Belsham, GJ; Proud, CG				Tyzack, JK; Wang, XM; Belsham, GJ; Proud, CG			ABC50 interacts with eukaryotic initiation factor 2 and associates with the ribosome in an ATP-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; T-CELL ACTIVATION; POLYPEPTIDE-CHAIN INITIATION; PROTEIN-SYNTHESIS INITIATION; BINDING CASSETTE PROTEIN; TRANSFER-RNA-SYNTHETASES; ELONGATION FACTOR-III; EIF-2-ALPHA KINASE; BETA-SUBUNIT; TRANSLATIONAL CONTROL	Eukaryotic initiation factor 2 (eIF2) plays a key role in the process of translation initiation and in its control. Here we demonstrate that highly purified mammalian eIF2 contains an additional polypeptide of apparent molecular mass of 110 kDa, This polypeptide co-purified with eIF2 through five different chromatography procedures. A cDNA clone encoding the polypeptide was isolated, and its sequence closely matched that of a protein previously termed ABC50, a member of the ATP-binding cassette (ABC) family of proteins. Antibodies to ABC50 co-immunoprecipitated eIF2 and vice versa, indicating that the two proteins interact. The presence of ABC50 had no effect upon the ability of eIF2 to bind GDP but markedly enhanced the association of methionyl-tRNA with the factor. Unlike the majority of ABC proteins, which are membrane-associated transporters, ABC50 associates with the ribosome and co-sediments in sucrose gradients with the 40 and 60 S ribosomal subunits, The association of ABC50 with ribosomal subunits was increased by ATP and decreased by ADP, ABC50 is related to GCN20 and eEF3, two yeast ABC proteins that are not membrane-associated transporters and are instead implicated in mRNA translation and/or its control. Thus, these data identify ABC50 as a third ABC protein with a likely function in mRNA translation, which associates with eIF2 and with ribosomes.	Univ Dundee, Dundee DD1 5EH, Scotland; AFRC, Inst Anim Hlth, Woking GU24 0NF, Surrey, England	University of Dundee; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Pirbright Institute	Proud, CG (corresponding author), Univ Dundee, MSI WTB Complex, Dundee DD1 5EH, Scotland.	c.g.proud@dundee.ac.uk	Belsham, Graham/J-3132-2019; Belsham, Graham J./H-8589-2019	Belsham, Graham/0000-0003-1187-4873; Belsham, Graham J./0000-0003-1187-4873; Proud, Christopher/0000-0003-0704-6442				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AUSABEL F, 1995, CURRENT PROTOCOLS MO; BELFIELD GP, 1995, J MOL EVOL, V41, P376, DOI 10.1007/BF01215185; BELFIELD GP, 1993, MOL MICROBIOL, V9, P411, DOI 10.1111/j.1365-2958.1993.tb01702.x; BENNE R, 1976, J BIOL CHEM, V251, P7675; BOAL TR, 1993, BIOCHIM BIOPHYS ACTA, V1176, P257, DOI 10.1016/0167-4889(93)90053-R; BOMMER UA, 1991, BIOCHIMIE, V73, P1007, DOI 10.1016/0300-9084(91)90142-N; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; CLEMENS MJ, 1987, J BIOL CHEM, V262, P767; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; COHEN RB, 1990, EMBO J, V9, P3831, DOI 10.1002/j.1460-2075.1990.tb07601.x; Das S, 1997, J BIOL CHEM, V272, P31712, DOI 10.1074/jbc.272.50.31712; DEALDANA CRV, 1995, EMBO J, V14, P3184, DOI 10.1002/j.1460-2075.1995.tb07321.x; DHOLAKIA JN, 1989, J BIOL CHEM, V264, P20638; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; EVERSON WV, 1989, AM J PHYSIOL, V256, pC18, DOI 10.1152/ajpcell.1989.256.1.C18; FLYNN A, 1993, BIOCHIM BIOPHYS ACTA, V1174, P117, DOI 10.1016/0167-4781(93)90105-M; HANNIG EM, 1993, MOL CELL BIOL, V13, P506, DOI 10.1128/MCB.13.1.506; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harlow E., 1989, ANTIBODIES LAB MANUA; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; JEDLICKA P, 1991, J BIOL CHEM, V266, P15663; Kimball SR, 1998, J BIOL CHEM, V273, P3039, DOI 10.1074/jbc.273.5.3039; KIMBALL SR, 1991, J BIOL CHEM, V266, P1969; MAO XH, 1992, J BIOL CHEM, V267, P20444; Marton MJ, 1997, MOL CELL BIOL, V17, P4474, DOI 10.1128/MCB.17.8.4474; MARTON MJ, 1993, MOL CELL BIOL, V13, P3541, DOI 10.1128/MCB.13.6.3541; OLDFIELD S, 1992, EUR J BIOCHEM, V208, P73, DOI 10.1111/j.1432-1033.1992.tb17160.x; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; POLLARD JW, 1989, EUR J BIOCHEM, V182, P1, DOI 10.1111/j.1432-1033.1989.tb14793.x; PRICE N, 1994, BIOCHIMIE, V76, P748, DOI 10.1016/0300-9084(94)90079-5; PRICE NT, 1994, BBA-GENE STRUCT EXPR, V1217, P207, DOI 10.1016/0167-4781(94)90037-X; PRICE NT, 1989, BIOCHIM BIOPHYS ACTA, V1008, P177, DOI 10.1016/0167-4781(80)90005-6; Price NT, 1996, BIOCHEM J, V318, P631, DOI 10.1042/bj3180631; PROUD CG, 1982, FEBS LETT, V143, P55, DOI 10.1016/0014-5793(82)80273-1; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; Redpath NT, 1996, J BIOL CHEM, V271, P17547, DOI 10.1074/jbc.271.29.17547; Richard M, 1998, GENOMICS, V53, P137, DOI 10.1006/geno.1998.5480; SAFER B, 1975, J BIOL CHEM, V250, P9067; Santoyo J, 1997, J BIOL CHEM, V272, P12544, DOI 10.1074/jbc.272.19.12544; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Smith V, 1996, SCIENCE, V274, P2069, DOI 10.1126/science.274.5295.2069; Sood R, 2000, GENETICS, V154, P787; Sood R, 1997, FASEB J, V11, pA1232; THOMAS NSB, 1985, J BIOL CHEM, V260, P9860; Welsh GI, 1996, J BIOL CHEM, V271, P11410, DOI 10.1074/jbc.271.19.11410; WETTENHALL RE, 1974, BIOCHIM BIOPHYS ACTA, V349, P214, DOI 10.1016/0005-2787(74)90082-3; WONG ST, 1982, J BIOL CHEM, V257, P5231	50	94	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34131	34139		10.1074/jbc.M002868200	http://dx.doi.org/10.1074/jbc.M002868200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10931828	hybrid			2022-12-27	WOS:000165095300021
J	Cid, E; Gomis, RR; Geremia, RA; Guinovart, JJ; Ferrer, JC				Cid, E; Gomis, RR; Geremia, RA; Guinovart, JJ; Ferrer, JC			Identification of two essential glutamic acid residues in glycogen synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DIABETES-MELLITUS; ALPHA-MANNOSYLTRANSFERASE; PHOSPHORYLATION SITES; SEQUENCE SIMILARITIES; CDNA CLONING; PROTEIN; LIVER; GLYCOSYLTRANSFERASES; GENE; CLASSIFICATION	The detailed catalytic mechanism by which glycosyltransferases catalyze the transfer of a glycosyl residue from a donor sugar to an acceptor is not known, Through the multiple alignment of all known eukaryotic glycogen synthases we have found an invariant 17-amino acid stretch enclosed within the most conserved region of the members of this family. This peptide includes an E-X-7-E motif, which is highly conserved in four families of retaining glycosyltransferases. Site-directed mutagenesis was performed in human muscle glycogen synthase to analyze the roles of the two conserved Glu residues (Glu-510 and Glu-518) of the motif. Proteins were transiently expressed in COS-l cells as fusions to green fluorescence protein. The E510A and E518A mutant proteins retained the ability to translocate from the nucleus to the cytosol in response to glucose and to bind to intracellular glycogen. Although the E518A variant had approximately 6% of the catalytic activity shown by the green fluorescence protein-human muscle glycogen synthase fusion protein, the E510A mutation inactivated the enzyme. These results led us to conclude that the E-X-7-E motif is part of the active site of eukaryotic glycogen synthases and that both conserved Glu residues are involved in catalysis. We propose that Glu-510 may function as the nucleophile and Glu-518 as the general acid/base catalyst.	Univ Barcelona, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Univ Grenoble 1, CNRS, Ctr Rech Macromol Vegetales, F-38041 Grenoble, France	University of Barcelona; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Ferrer, JC (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Marti I Franques 1, E-08028 Barcelona, Spain.	ferrer@sun.bq.ub.es	Geremia, Roberto A/A-7972-2010; Cid, Emili/F-7207-2016; Ferrer, Joan C./AAP-2145-2021; Gomis, Roger R/E-9788-2016	Cid, Emili/0000-0002-5025-352X; Gomis, Roger R/0000-0001-6473-2858; Ferrer, Joan C./0000-0003-1212-5161				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Baba O, 1993, Kokubyo Gakkai Zasshi, V60, P264; BAI G, 1990, J BIOL CHEM, V265, P7843; BAK JF, 1992, DIABETOLOGIA, V35, P777; Bollen M, 1998, BIOCHEM J, V336, P19, DOI 10.1042/bj3360019; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNER MF, 1989, P NATL ACAD SCI USA, V86, P1443, DOI 10.1073/pnas.86.5.1443; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Campbell JA, 1998, BIOCHEM J, V329, P719, DOI 10.1042/bj3290719; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; CHAN TM, 1976, ANAL BIOCHEM, V71, P96, DOI 10.1016/0003-2697(76)90014-2; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; DAVIES G, 1998, GLYCOSYL TRANSFER, P119; FARKAS I, 1991, J BIOL CHEM, V266, P15602; FARKAS I, 1990, J BIOL CHEM, V265, P20879; Ferrer JC, 1997, FEBS LETT, V415, P249, DOI 10.1016/S0014-5793(97)01136-8; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Geremia RA, 1999, MOL GEN GENET, V261, P933, DOI 10.1007/s004380051040; Geremia RA, 1996, BIOCHEM J, V318, P133, DOI 10.1042/bj3180133; Kapitonov D, 1999, GLYCOBIOLOGY, V9, P961, DOI 10.1093/glycob/9.10.961; KASLOW HR, 1985, J BIOL CHEM, V260, P9953; KASLOW HR, 1984, FEBS LETT, V172, P294, DOI 10.1016/0014-5793(84)81144-8; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMESLEVARLOOT L, 1990, BIOCHIMIE, V72, P555, DOI 10.1016/0300-9084(90)90120-6; Ly HD, 1999, ANNU REV BIOCHEM, V68, P487, DOI 10.1146/annurev.biochem.68.1.487; MAHRENHOLZ AM, 1988, J BIOL CHEM, V263, P10561; Nichols DJ, 2000, BIOCHEMISTRY-US, V39, P7820, DOI 10.1021/bi000407g; NUTTALL FQ, 1994, ARCH BIOCHEM BIOPHYS, V311, P443, DOI 10.1006/abbi.1994.1260; Orho M, 1998, J CLIN INVEST, V102, P507, DOI 10.1172/JCI2890; Pellegri G, 1996, MOL BRAIN RES, V38, P191, DOI 10.1016/0169-328X(95)00305-C; Petroni EA, 1996, J BACTERIOL, V178, P4814, DOI 10.1128/jb.178.16.4814-4821.1996; ROACH PJ, 1991, ADV ENZYME REGUL, V31, P101, DOI 10.1016/0065-2571(91)90011-A; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SKURAT AV, 1994, J BIOL CHEM, V269, P25534; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THORBURN AW, 1991, J CLIN INVEST, V87, P489, DOI 10.1172/JCI115022; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VRIELINK A, 1994, EMBO J, V13, P3413, DOI 10.1002/j.1460-2075.1994.tb06646.x; ZHANG WM, 1989, FASEB J, V3, P2532, DOI 10.1096/fasebj.3.13.2509275; ZHANG WM, 1993, ARCH BIOCHEM BIOPHYS, V304, P219, DOI 10.1006/abbi.1993.1342	46	55	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33614	33621		10.1074/jbc.M005358200	http://dx.doi.org/10.1074/jbc.M005358200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10924520	hybrid			2022-12-27	WOS:000090104600062
J	Urban, S; Zieseniss, S; Werder, M; Hauser, H; Budzinski, R; Engelmann, B				Urban, S; Zieseniss, S; Werder, M; Hauser, H; Budzinski, R; Engelmann, B			Scavenger receptor BI transfers major lipoprotein-associated phospholipids into the cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; SR-BI; SELECTIVE UPTAKE; PLASMA-MEMBRANE; HUMAN PLATELETS; ADRENAL-GLAND; CHOLESTEROL; PHOSPHATIDYLCHOLINE; SPHINGOMYELIN; CAVEOLAE	The phospholipids of lipoproteins can be transferred to cells by an endocytosis-independent uptake pathway. We analyzed the role of scavenger receptor BI (SR-BI) for the selective cellular phospholipid import. Human monocytes rapidly acquired the pyrene (py)-labeled phospholipids sphingomyelin (SM), phosphatidylcholine, and phosphatidylethanolamine from different donors (low and high density lipoproteins (LDL, HDL), lipid vesicles). The anti-SR-BI antibody directed against the extracellular loop of the membrane protein lowered the cellular import of the phospholipids by 40-80%. The phospholipid transfer from the lipid vesicles into the monocytes was suppressed by LDL, I-IDL, and apoprotein AI, Transfection of BHK cells with the cDNA for human SR-BI enhanced the cellular import of the vesicle-derived py-phospholipids by 5-6-fold. In the case of the LDL donors, transfer of py-SM to the transfected cells was stimulated to a greater extent than the uptake of the other py-phospholipids. Similar differences were not observed when the vesicles and HDL were used as phospholipid donors, The concentration of LDL required for the half-maximal phospholipid import was close to the previously reported apparent dissociation constant for LDL binding to SR-BI, The low activation energy of the SR-BI-mediated py-phospholipid import indicated that the transfer occurs entirely in a hydrophobic environment, Disruption of cell membrane caveolae by cyclodextrin treatment reduced the SR-BI-catalyzed incorporation of py-SM, suggesting that intact caveolae are necessary for the phospholipid uptake. In conclusion, SR-BI mediates the selective import of the major lipoprotein-associated phospholipids into the cells, the transfer efficiency being dependent on the structure of the donor lipoprotein.	Univ Munich, Inst Physiol, D-80336 Munich, Germany; ETH Zurich, Inst Biochem, CH-8092 Zurich, Switzerland; Boehringer Ingelheim Pharma KG, D-88397 Biberach, Germany	University of Munich; Swiss Federal Institutes of Technology Domain; ETH Zurich; Boehringer Ingelheim	Engelmann, B (corresponding author), Univ Munich, Inst Physiol, Schillerstr 44, D-80336 Munich, Germany.							Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Acton S, 1999, ARTERIOSCL THROM VAS, V19, P1734, DOI 10.1161/01.ATV.19.7.1734; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; Bevers EM, 1999, BBA-MOL CELL BIOL L, V1439, P317, DOI 10.1016/S1388-1981(99)00110-9; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN RE, 1991, SUBCELLULAR BIOCH, P333; Dobner P, 1998, AM J PHYSIOL-ENDOC M, V275, pE777, DOI 10.1152/ajpendo.1998.275.5.E777; Downes CP, 1998, CURR BIOL, V8, pR865, DOI 10.1016/S0960-9822(07)00546-5; Engelmann B, 1998, J BIOL CHEM, V273, P27800, DOI 10.1074/jbc.273.43.27800; Engelmann B, 1996, BIOCHEM J, V315, P781, DOI 10.1042/bj3150781; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Graf GA, 1999, J BIOL CHEM, V274, P12043, DOI 10.1074/jbc.274.17.12043; Hauser H, 1998, BIOCHEMISTRY-US, V37, P17843, DOI 10.1021/bi982404y; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; MOLOTKOVSKY JG, 1982, EUR J BIOCHEM, V122, P573; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; Murphy HC, 1997, BIOCHEM BIOPH RES CO, V234, P733, DOI 10.1006/bbrc.1997.6634; Rhainds D, 1999, EUR J BIOCHEM, V261, P227, DOI 10.1046/j.1432-1327.1999.00264.x; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; SOMMER A, 1992, J BIOL CHEM, V267, P24217; Swarnakar S, 1999, J BIOL CHEM, V274, P29733, DOI 10.1074/jbc.274.42.29733; Ueda Y, 1999, J BIOL CHEM, V274, P7165, DOI 10.1074/jbc.274.11.7165; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; Wang PY, 1999, J BIOL CHEM, V274, P23235, DOI 10.1074/jbc.274.33.23235; Zwaal RFA, 1998, BBA-REV BIOMEMBRANES, V1376, P433, DOI 10.1016/S0304-4157(98)00018-5	28	68	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33409	33415		10.1074/jbc.M004031200	http://dx.doi.org/10.1074/jbc.M004031200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10938082	hybrid			2022-12-27	WOS:000090104600034
J	Ikeda, Y; Sugawara, A; Taniyama, Y; Uruno, A; Igarashi, K; Arima, S; Ito, S; Takeuchi, K				Ikeda, Y; Sugawara, A; Taniyama, Y; Uruno, A; Igarashi, K; Arima, S; Ito, S; Takeuchi, K			Suppression of rat thromboxane synthase gene transcription by peroxisome proliferator-activated receptor gamma in macrophages via an interaction with NRF2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PPAR-GAMMA; SMALL MAF; DIFFERENTIAL EXPRESSION; DIABETIC NEPHROPATHY; ENDOTHELIAL-CELLS; HEME OXYGENASE-1; OXIDATIVE STRESS; PROTEINS; FAMILY	We have studied the transcription regulation of the rat thromboxane synthase (TXS) gene by peroxisome proliferator-activated receptor gamma (PPAR gamma) in macrophages, The transcription activity of a cloned 8'-flanking region (1.6 kilobases) of the rat TXS gene (5'FL-TXS) was examined by luciferase reporter gene assay. TXS mRNA expression and the transcription activity of 5'FL-TXS were inhibited by PPAR gamma ligands, 15-deoxy-(12,14)-prostaglandin J(2) (PGJ(2)), and the thiazolidinedione troglitazone (TRO) in a dose-dependent manner. Overexpression of PPAR gamma also significantly suppressed transcription, and further addition of PGJ(2) or TRO augmented the suppression. Deletion analysis showed that the element responsible for the PPAR gamma effect is located in a region containing the nuclear factor E2 (NF-EB)/AP-1 site (-98/-88), which was indicated to be the major promoter of the TXS gene. By electrophoretic mobility shift assay using the NF-E2/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 (NF-EB-related factor 2). Moreover, the complex was decreased with PGJ(2), TRO, or in vitro translated PPAR gamma. The transcription suppression by PPAR gamma was confirmed using this truncated NRF2-binding element (-98/-88) by the reporter gene assay. Finally, a direct interaction between PPAR gamma and NRF2 was confirmed by glutathione S-transferase pull-down assay. In conclusion, the NRF2-binding site (-98/-88) is the major promoter of 5'FL-TXS which can be suppressed by activated PPAR gamma via a protein-protein interaction with NRF2 in macrophages.	Tohoku Univ, Grad Sch Med, Dept Med,Mol Biol Unit, Div Nephol Endocrinol & Vasc Med,Aoba Ku, Sendai, Miyagi 9808574, Japan; Hiroshima Univ, Dept Biochem, Sch Med, Hiroshima 7348551, Japan	Tohoku University; Hiroshima University	Takeuchi, K (corresponding author), Tohoku Univ, Grad Sch Med, Dept Med,Mol Biol Unit, Div Nephol Endocrinol & Vasc Med,Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	kazut2i@mail.cc.tohoku.ac.jp	Uruno, Akira/U-1812-2019; Uruno, Akira/ABF-3988-2020; Ito, Sadayoshi/A-3933-2015	Igarashi, Kazuhiko/0000-0002-2470-2475; Sugawara, Akira/0000-0003-4511-8101; Ito, Sadayoshi/0000-0002-5092-3626				Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; BERKES EA, 1995, KIDNEY INT, V48, P1344, DOI 10.1038/ki.1995.420; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; Delerive P, 1999, CIRC RES, V85, P394, DOI 10.1161/01.RES.85.5.394; Deveaux S, 1997, EMBO J, V16, P5654, DOI 10.1093/emboj/16.18.5654; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Giustina A, 1998, DIABETES, V47, P423, DOI 10.2337/diabetes.47.3.423; HORA K, 1990, NEPHRON, V56, P297, DOI 10.1159/000186157; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; IGARASHI K, 1995, P NATL ACAD SCI USA, V92, P7445, DOI 10.1073/pnas.92.16.7445; Igarashi K, 1998, J BIOL CHEM, V273, P11783, DOI 10.1074/jbc.273.19.11783; Ikeda Y, 1999, BIOCHEM BIOPH RES CO, V262, P494, DOI 10.1006/bbrc.1999.1226; Imano E, 1998, DIABETES CARE, V21, P2135, DOI 10.2337/diacare.21.12.2135; Ishii T, 1999, FREE RADICAL RES, V31, P351, DOI 10.1080/10715769900300921; Itoh K, 1999, FREE RADICAL RES, V31, P319, DOI 10.1080/10715769900300881; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; LEBLANC BP, 1995, GENE DEV, V9, P1811, DOI 10.1101/gad.9.15.1811; Lee KD, 1996, BIOCHEM J, V319, P783, DOI 10.1042/bj3190783; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Marx N, 1998, CIRC RES, V83, P1097, DOI 10.1161/01.RES.83.11.1097; Marx N, 1998, AM J PATHOL, V153, P17, DOI 10.1016/S0002-9440(10)65540-X; MEHTA JL, 1988, P NATL ACAD SCI USA, V85, P4511, DOI 10.1073/pnas.85.12.4511; NEEDLEMAN P, 1977, SCIENCE, V195, P409, DOI 10.1126/science.831285; NUSING R, 1990, EICOSANOIDS, V3, P175; OGIHARA T, 1995, AM J HYPERTENS, V8, P316, DOI 10.1016/0895-7061(95)96214-5; OHASHI K, 1992, J BIOL CHEM, V267, P789; Oyake T, 1996, MOL CELL BIOL, V16, P6083; REMUZZI G, 1985, J CLIN INVEST, V75, P94, DOI 10.1172/JCI111703; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; SHIMADA K, 1994, J BIOL CHEM, V269, P18275; Shinohara E, 1998, ATHEROSCLEROSIS, V136, P275, DOI 10.1016/S0021-9150(97)00220-7; STAHL RAK, 1990, KIDNEY INT, V38, P273, DOI 10.1038/ki.1990.196; Sugawara A, 1999, HYPERTENSION, V34, P363; SUGAWARA A, 1995, ENDOCRINOLOGY, V136, P1766, DOI 10.1210/en.136.4.1766; Takahashi N, 1998, BIOCHEM BIOPH RES CO, V244, P489, DOI 10.1006/bbrc.1998.8283; Takeuchi K, 1997, CYTOGENET CELL GENET, V76, P47, DOI 10.1159/000134513; Takeuchi K, 1996, J CLIN ENDOCR METAB, V81, P4496, DOI 10.1210/jc.81.12.4496; Toki T, 1997, ONCOGENE, V14, P1901, DOI 10.1038/sj.onc.1201024; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Tsutsumi E, 1997, PROSTAG OTH LIPID M, V53, P423, DOI 10.1016/S0090-6980(97)00059-2; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Zhang LQ, 1997, GENOMICS, V45, P519, DOI 10.1006/geno.1997.4982; ZHANG LQ, 1993, BIOCHEM BIOPH RES CO, V194, P741, DOI 10.1006/bbrc.1993.1884; Zucker TP, 1998, CIRCULATION, V97, P589	47	85	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33142	33150		10.1074/jbc.M002319200	http://dx.doi.org/10.1074/jbc.M002319200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10930400	hybrid			2022-12-27	WOS:000090003800103
J	Birch, OM; Hewitson, KS; Fuhrmann, M; Burgdorf, K; Baldwin, JE; Roach, PL; Shaw, NM				Birch, OM; Hewitson, KS; Fuhrmann, M; Burgdorf, K; Baldwin, JE; Roach, PL; Shaw, NM			MioC is an FMN-binding protein that is essential for Escherichia coli biotin synthase activity in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE; GENE-CLUSTER; REPLICATION; FLAVODOXIN; TRANSCRIPTION; DETHIOBIOTIN; MECHANISM; SEQUENCE; SULFUR; INITIATION	Biotin synthase is required for the conversion of dethiobiotin to biotin and requires a number of accessory proteins and small molecule cofactors for activity in vitro. We have previously identified two of these proteins as flavodoxin and ferredoxin (flavodoxin) NADP(+) reductase. We now report the identification of MioC as a third essential protein, together with its cloning, purification, and characterization. Purified MioC has a UV-visible spectrum characteristic of a flavoprotein and contains flavin mononucleotide. The presence of flavin mononucleotide and the primary sequence similarity to flavodoxin suggest that. MioC may function as an electron transport protein. The role of MioC in the biotin synthase reaction is discussed, and the structure and function of MioC is compared with that of flavodoxin.	Lonza AG, Biotechnol Res, CH-3930 Visp, Switzerland; Univ Oxford, Dyson Perrins Lab, Oxford OX1 3QY, England; Univ Southampton, Dept Chem, Southampton SO17 1BJ, Hants, England	Lonza Group; University of Oxford; University of Southampton	Shaw, NM (corresponding author), Lonza AG, Biotechnol Res, CH-3930 Visp, Switzerland.		Roach, Peter/C-6248-2013; Roach, Peter/AAW-7071-2021					ASAI T, 1991, JPN J GENET, V66, P85, DOI 10.1266/jjg.66.85; Bates DB, 1997, P NATL ACAD SCI USA, V94, P12497, DOI 10.1073/pnas.94.23.12497; Becker A, 1999, NAT STRUCT BIOL, V6, P969; BIRCH OM, 1995, J BIOL CHEM, V270, P19158, DOI 10.1074/jbc.270.32.19158; BIRCH OM, 1994, Patent No. 08023; Bui BTS, 1998, FEBS LETT, V440, P226, DOI 10.1016/S0014-5793(98)01464-1; BURLAND V, 1993, GENOMICS, V16, P551, DOI 10.1006/geno.1993.1230; Escalettes F, 1999, J AM CHEM SOC, V121, P3571, DOI 10.1021/ja9811748; FLINT DH, 1997, METHOD ENZYMOL, V279, P356; Gibson KJ, 1999, BIOCHEM BIOPH RES CO, V254, P632, DOI 10.1006/bbrc.1998.9991; GRANDORI R, 1994, PROTEIN SCI, V3, P2185, DOI 10.1002/pro.5560031204; Guianvarc'h D, 1997, BIOCHEM BIOPH RES CO, V236, P402, DOI 10.1006/bbrc.1997.6952; HUGHES GJ, 1990, BIOCHEM J, V271, P641, DOI 10.1042/bj2710641; IFUKU O, 1994, EUR J BIOCHEM, V224, P173, DOI 10.1111/j.1432-1033.1994.tb20009.x; LOBNEROLESEN A, 1992, NUCLEIC ACIDS RES, V20, P3029, DOI 10.1093/nar/20.12.3029; LOBNEROLESEN A, 1987, J BACTERIOL, V169, P2835, DOI 10.1128/jb.169.6.2835-2842.1987; McIver L, 1998, EUR J BIOCHEM, V257, P577, DOI 10.1046/j.1432-1327.1998.2570577.x; Mejean A, 1995, BIOCHEM BIOPH RES CO, V217, P1231, DOI 10.1006/bbrc.1995.2900; MULLIEZ E, 1999, IRON METABOLISM; Nakamura M, 1999, J BIOCHEM, V126, P10, DOI 10.1093/oxfordjournals.jbchem.a022409; OGAWA T, 1994, J BACTERIOL, V176, P1609, DOI 10.1128/jb.176.6.1609-1615.1994; OHSHIRO T, 1994, BIOSCI BIOTECH BIOCH, V58, P1738, DOI 10.1271/bbb.58.1738; OSBORNE C, 1991, J BACTERIOL, V173, P1729, DOI 10.1128/jb.173.5.1729-1737.1991; Sambrook J., 2002, MOL CLONING LAB MANU; Sanyal I, 1996, ARCH BIOCHEM BIOPHYS, V326, P48, DOI 10.1006/abbi.1996.0045; Shaw NM, 1998, BIOCHEM J, V330, P1079; Takahashi Y, 1999, J BIOCHEM, V126, P917, DOI 10.1093/oxfordjournals.jbchem.a022535; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	28	25	27	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32277	32280		10.1074/jbc.M004497200	http://dx.doi.org/10.1074/jbc.M004497200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10913144	hybrid			2022-12-27	WOS:000089858900099
J	Wang, XJ; Ching, YP; Lam, WH; Qi, Z; Zhang, MJ; Wang, JH				Wang, XJ; Ching, YP; Lam, WH; Qi, Z; Zhang, MJ; Wang, JH			Identification of a common protein association region in the neuronal Cdk5 activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; BOVINE BRAIN; CDC2-LIKE KINASE; P35(-/-) MICE; TAU-PROTEIN; P35; DIFFERENTIATION; DISRUPTION; DEFECTS; SUBUNIT	Cyclin-dependent protein kinase 5 (CdkB) depends on the association with neuronal CdkB activator (Nck5a) for kinase activity. A variety of cellular proteins have been shown to undergo high affinity association with Nck5a, including three novel proteins, C42, C48, and C53 found by a yeast two-hybrid screen (Ching, Y. P., Qi, Z., and Wang, J. H. (2000) Gene 242, 285-294). The three proteins show competitive binding to Nck5a suggesting that they bind at a common site. The binding site has been mapped to a region of 26 amino acid residues (residues 145 to 170) at the N-terminal boundary of the kinase activation domain of Nck5a. This region of Nck5a contains an amphipathic a-helix whose hydrophobic face is involved in Cdk5 activation (Chin, K. T., Ohki, S, Tang, D., Cheng, H. C., Wang, J. H., and Zhang, M. (1999) J. Biol. Chem. 274, 7120-7127). Several lines of evidence suggest that Nck5a interacts with the binding proteins at the hydrophilic face of the amphipathic cu-helix. First, the Nck5a-(145-170) peptide can bind CdkB and Nck5a-binding proteins simultaneously. Second, the association of Nck5a-(145-170) to C48 can be markedly reduced by high ionic strength whereas the interaction between Nck5a and CdkB is not affected. Third, substitution of Glu(157) by glutamine in Nck5a-(145-170) abolishes the peptide's ability to bind to the three Nck5a-binding proteins without diminishing its Cdk5 binding activity.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore	Hong Kong University of Science & Technology; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Wang, JH (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China.	jerwang@ust.hk	Ching, Yick Pang/C-4244-2009	Zhang, Mingjie/0000-0001-9404-0190; CHING, Yick Pang/0000-0002-6461-8358				Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Chin KT, 1999, J BIOL CHEM, V274, P7120, DOI 10.1074/jbc.274.11.7120; Ching YP, 2000, GENE, V242, P285, DOI 10.1016/S0378-1119(99)00499-0; Chou KC, 1999, BIOCHEM BIOPH RES CO, V259, P420, DOI 10.1006/bbrc.1999.0792; Gilmore EC, 1998, J NEUROSCI, V18, P6370; HAYES TE, 1991, NEW BIOL, V3, P259; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; Kwon YT, 2000, CURR BIOL, V10, P363, DOI 10.1016/S0960-9822(00)00411-5; Kwon YT, 1998, J COMP NEUROL, V395, P510, DOI 10.1002/(SICI)1096-9861(19980615)395:4<510::AID-CNE7>3.0.CO;2-4; Kwon YT, 1999, J COMP NEUROL, V415, P218, DOI 10.1002/(SICI)1096-9861(19991213)415:2<218::AID-CNE6>3.0.CO;2-F; Lee KY, 1996, J BIOL CHEM, V271, P1538, DOI 10.1074/jbc.271.3.1538; Lee KY, 1997, J BIOL CHEM, V272, P5622, DOI 10.1074/jbc.272.9.5622; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MIYAJIMA M, 1995, NEUROREPORT, V6, P1130, DOI 10.1097/00001756-199505300-00014; Moorthamer M, 1999, FEBS LETT, V446, P343, DOI 10.1016/S0014-5793(99)00248-3; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; NUGENT JHA, 1991, J CELL SCI, V99, P669; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Paglini G, 1998, J NEUROSCI, V18, P9858; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Qi Z, 1998, J BIOL CHEM, V273, P2329, DOI 10.1074/jbc.273.4.2329; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Tang DM, 1997, J BIOL CHEM, V272, P12318, DOI 10.1074/jbc.272.19.12318; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	32	36	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31763	31769		10.1074/jbc.M004358200	http://dx.doi.org/10.1074/jbc.M004358200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10915792	hybrid			2022-12-27	WOS:000089858900032
J	Lazarowski, ER; Boucher, RC; Harden, TK				Lazarowski, ER; Boucher, RC; Harden, TK			Constitutive release of ATP and evidence for major contribution of ecto-nucleotide pyrophosphatase and nucleoside diphosphokinase to extracellular nucleotide concentrations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-VOLUME REGULATION; MOLECULAR-CLONING; EPITHELIAL-CELLS; AIRWAY EPITHELIA; CYSTIC-FIBROSIS; RECEPTOR; RAT; MECHANISM; UTP; STIMULATION	Nucleotides are important extracellular signaling molecules, At least five mammalian P2Y receptors exist that are specifically activated by ATP, UTP, ADP, or UDP, Although the existence of ectoenzymes that metabolize extracellular nucleotides is well established, the relative flux of ATP and UTP through their extracellular metabolic products remains undefined. Therefore, we have studied the kinetics of accumulation and metabolism of endogenous ATP in the extracellular medium of four different cell lines. ATP concentrations reached a maximum immediately after change of medium and decreased thereafter with a single exponential decay (t1/2 similar to 30-40 min). ATP levels did not fall to zero but attained a base-line concentration that was independent of the medium volume and of the initial ATP concentration, Although the base line concentration of ATP remained stable for up to 12 h, [gamma-P-32]ATP added to resting cells as a radiotracer was completely degraded within 120 min, indicating that steady state reflected a basal rate of ATP release balanced by ATP hydrolysis (20-200 fmol x min(-1) x cell(-6)). High performance liquid chromatography analysis revealed that the gamma-phosphate of ATP was rapidly, although transiently, transferred during steady state to species subsequently identified as UTP and GTP, indicating the existence of both ecto-nucleoside diphosphokinase activity and the accumulation of endogenous UDP and GDP, Conversely, addition of [gamma-P-32]UTP, resting cells resulted in transient formation of [gamma-P-32]ATP, indicating phosphorylation of endogenous ADP by nucleoside diphosphokinase, The final P-32-products of [gamma-P-32]ATP metabolism were [P-32]orthophosphoric acid and a P-32-labeled species that was further purified and identified as [P-32]inorganic pyrophosphate, In C6 cells, the formation of [P-32]pyrophosphate from [gamma-P-32]ATP at steady state exceeded by 3-fold that of [P-32]orthophosphate. These results illustrate for the first time a constitutive release of ATP and other nucleotides and reveal the existence of a complex extracellular metabolic pathway for released nucleotides, In addition to the existence of an ecto-ATPase activity, our results suggest a major scavenger role of ecto-ATP pyrophosphatase and a transphosphorylating activity of nucleoside diphosphokinase.	Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Lazarowski, ER (corresponding author), Univ N Carolina, Sch Med, Dept Med, CB 7248,7017 Thurston Bowles Bldg, Chapel Hill, NC 27599 USA.				NHLBI NIH HHS [HL34322] Funding Source: Medline; NIGMS NIH HHS [GM38213] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034322] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038213] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267; Bogdanov YD, 1998, BRIT J PHARMACOL, V124, P428, DOI 10.1038/sj.bjp.0701880; Boucher RC, 1999, J PHYSIOL-LONDON, V516, P631, DOI 10.1111/j.1469-7793.1999.0631u.x; Brown J, 2000, LAB INVEST, V80, P37, DOI 10.1038/labinvest.3780006; BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1; BURNSTOCK G, 1998, P2 NUCLEOTIDE RECEPT, P3; Communi D, 1997, J BIOL CHEM, V272, P31969, DOI 10.1074/jbc.272.51.31969; DAVIS CW, 1992, AM J PHYSIOL, V262, pC1313, DOI 10.1152/ajpcell.1992.262.5.C1313; Evans RJ, 1998, P2 NUCLEOTIDE RECEPT, P43; Feranchak AP, 1998, J BIOL CHEM, V273, P14906, DOI 10.1074/jbc.273.24.14906; Ferguson DR, 1997, J PHYSIOL-LONDON, V505, P503, DOI 10.1111/j.1469-7793.1997.503bb.x; Fredholm BB, 1997, TRENDS PHARMACOL SCI, V18, P79, DOI 10.1016/S0165-6147(96)01038-3; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; Grobben B, 1999, J NEUROCHEM, V72, P826, DOI 10.1046/j.1471-4159.1999.0720826.x; Grygorczyk R, 1997, AM J PHYSIOL-CELL PH, V272, pC1058; Hamada K, 1998, J BIOL CHEM, V273, P6334, DOI 10.1074/jbc.273.11.6334; HARDEN TK, 1998, P2 NUCLEOTIDE RECEPT, P109; HASSESSIAN H, 1993, BRIT J PHARMACOL, V109, P466, DOI 10.1111/j.1476-5381.1993.tb13592.x; Hazama A, 1999, J GEN PHYSIOL, V114, P525, DOI 10.1085/jgp.114.4.525; King BF, 1998, TRENDS PHARMACOL SCI, V19, P506, DOI 10.1016/S0165-6147(98)01271-1; Korngreen A, 1996, J PHYSIOL-LONDON, V497, P53, DOI 10.1113/jphysiol.1996.sp021749; Lazarowski ER, 1996, BRIT J PHARMACOL, V117, P203, DOI 10.1111/j.1476-5381.1996.tb15175.x; Lazarowski ER, 1997, J BIOL CHEM, V272, P20402, DOI 10.1074/jbc.272.33.20402; Lazarowski ER, 1999, BRIT J PHARMACOL, V127, P1272, DOI 10.1038/sj.bjp.0702654; LAZAROWSKI ER, 1995, BRIT J PHARMACOL, V116, P1619, DOI 10.1111/j.1476-5381.1995.tb16382.x; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; LAZAROWSKI ER, 2000, ECTO ATPASES RELATED, P283; LETHEM MI, 1993, AM J RESP CELL MOL, V9, P315, DOI 10.1165/ajrcmb/9.3.315; Mitchell CH, 1998, P NATL ACAD SCI USA, V95, P7174, DOI 10.1073/pnas.95.12.7174; Roman RM, 1997, J BIOL CHEM, V272, P21970, DOI 10.1074/jbc.272.35.21970; Saiag B, 1995, ENDOTHELIUM, V2, P279, DOI 10.3109/10623329509024644; Schlosser SF, 1996, P NATL ACAD SCI USA, V93, P9948, DOI 10.1073/pnas.93.18.9948; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Todorov LD, 1996, J PHYSIOL-LONDON, V496, P731, DOI 10.1113/jphysiol.1996.sp021723; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; VILLALON M, 1989, BIOPHYS J, V56, P1255, DOI 10.1016/S0006-3495(89)82772-9; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Watt WC, 1998, J BIOL CHEM, V273, P14053, DOI 10.1074/jbc.273.22.14053; Webb TE, 1998, J NEUROCHEM, V71, P1348; Zimmermann H, 1996, DRUG DEVELOP RES, V39, P337, DOI 10.1002/(SICI)1098-2299(199611/12)39:3/4<337::AID-DDR15>3.0.CO;2-Z; [No title captured]	41	262	266	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31061	31068		10.1074/jbc.M003255200	http://dx.doi.org/10.1074/jbc.M003255200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10913128	hybrid, Green Published			2022-12-27	WOS:000089762700046
J	Park, PW; Reizes, O; Bernfield, M				Park, PW; Reizes, O; Bernfield, M			Cell surface heparan sulfate proteoglycans: Selective regulators of ligand-receptor encounters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							FIBROBLAST-GROWTH-FACTOR; SYNDECAN-1 ECTODOMAIN; CYTOPLASMIC DOMAINS; MAST-CELLS; DROSOPHILA; BINDING; PROTEIN; HOMOLOG; ACTIVATION; MIGRATION		Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School	Bernfield, M (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, 300 Longwood Ave,Enders-9, Boston, MA 02115 USA.		Reizes, Ofer/ABA-4179-2021	Reizes, Ofer/0000-0003-0075-6871; Park, Pyong Woo/0000-0002-7979-4979	NCI NIH HHS [CA 28735] Funding Source: Medline; NHLBI NIH HHS [HL 56398] Funding Source: Medline; NICHD NIH HHS [HD 06763] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD006763, R01HD006763] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA028735] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056398] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexander CM, 2000, NAT GENET, V25, P329, DOI 10.1038/77108; Andrade RB, 1999, ORG LETT, V1, P1811, DOI 10.1021/ol991071+; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Baciu PC, 2000, J CELL SCI, V113, P315; Beiman M, 1996, GENE DEV, V10, P2993, DOI 10.1101/gad.10.23.2993; Benevolenskaya EV, 1998, MOL GEN GENET, V260, P131, DOI 10.1007/s004380050879; Berman B, 1999, J BIOL CHEM, V274, P36132, DOI 10.1074/jbc.274.51.36132; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Conrad H. E., 1998, HEPARIN BINDING PROT; Couchman JR, 1996, J CELL BIOCHEM, V61, P578, DOI 10.1002/(SICI)1097-4644(19960616)61:4<578::AID-JCB11>3.0.CO;2-C; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Fan GP, 2000, FEBS LETT, V467, P7, DOI 10.1016/S0014-5793(00)01111-X; Feyzi E, 1997, J BIOL CHEM, V272, P5518, DOI 10.1074/jbc.272.9.5518; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Grootjans JJ, 2000, J BIOL CHEM, V275, P19933, DOI 10.1074/jbc.M002459200; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; Hata Y, 1996, J NEUROSCI, V16, P2488; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Ishiguro K, 2000, J BIOL CHEM, V275, P5249, DOI 10.1074/jbc.275.8.5249; JALKANEN M, 1987, J CELL BIOL, V105, P3087, DOI 10.1083/jcb.105.6.3087; Kainulainen V, 1998, J BIOL CHEM, V273, P11563, DOI 10.1074/jbc.273.19.11563; KATO M, 1995, MOL BIOL CELL, V6, P559, DOI 10.1091/mbc.6.5.559; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; Kinnunen T, 1998, J BIOL CHEM, V273, P10702, DOI 10.1074/jbc.273.17.10702; KLAMBT C, 1992, GENE DEV, V6, P1668, DOI 10.1101/gad.6.9.1668; Lander AD, 1998, MATRIX BIOL, V17, P465, DOI 10.1016/S0945-053X(98)90093-2; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lin XH, 1999, DEVELOPMENT, V126, P3715; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; MALI M, 1994, J BIOL CHEM, V269, P27795; Oh ES, 1997, ARCH BIOCHEM BIOPHYS, V344, P67, DOI 10.1006/abbi.1997.0180; Ott VL, 1998, J BIOL CHEM, V273, P35291, DOI 10.1074/jbc.273.52.35291; Park PW, 2000, J BIOL CHEM, V275, P3057, DOI 10.1074/jbc.275.5.3057; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; Pye DA, 1999, J BIOL CHEM, V274, P13456, DOI 10.1074/jbc.274.19.13456; RAPRAEGER AC, 1995, CHEM BIOL, V2, P645, DOI 10.1016/1074-5521(95)90025-X; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Ringvall M, 2000, J BIOL CHEM, V275, P25926, DOI 10.1074/jbc.C000359200; Rostand KS, 1997, INFECT IMMUN, V65, P1; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; Sen J, 1998, CELL, V95, P471, DOI 10.1016/S0092-8674(00)81615-3; SPRING J, 1994, P NATL ACAD SCI USA, V91, P3334, DOI 10.1073/pnas.91.8.3334; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; Stringer SE, 1997, J BIOL CHEM, V272, P20508, DOI 10.1074/jbc.272.33.20508; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; Sutherland D, 1996, CELL, V87, P1091, DOI 10.1016/S0092-8674(00)81803-6; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Toyoda H, 2000, J BIOL CHEM, V275, P21856, DOI 10.1074/jbc.M003540200; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Venkataraman G, 1999, SCIENCE, V286, P537, DOI 10.1126/science.286.5439.537; Woods A, 2000, J BIOL CHEM, V275, P24233, DOI 10.1074/jbc.R000001200; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451	64	295	301	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					29923	29926		10.1074/jbc.R000008200	http://dx.doi.org/10.1074/jbc.R000008200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10931855	hybrid			2022-12-27	WOS:000089577900001
J	Shaikh, AC; Sadowski, PD				Shaikh, AC; Sadowski, PD			Trans complementation of variant Cre proteins for defects in cleavage and synapsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; FLP RECOMBINASE; SACCHAROMYCES-CEREVISIAE; INTEGRASE FAMILY; 2-MU-M PLASMID; DNA; MECHANISM; TYROSINE; RESIDUE; CIRCLE	The Cre recombinase is a member of the integrase family of conservative site-specific recombinases. These proteins share five conserved catalytic residues, one of which is a tyrosine that acts as the nucleophile to attack the scissile phosphodiester bond in the DNA target. Recombination by the Cre recombinase takes place in a supramolecular structure called a synapse that consists of four molecules of Cre bound to two DNA target sequences called lox sites. The synapse is held together by an intricate network of protein-protein interactions. They bend the two sites into square planar structure that resembles a Holliday intermediate. We have studied three mutant Cre proteins that appear to have defects in synapsis (Cre A36V, Cre T41F, and Cre G314R). We found that they were unable to carry out strand cleavage but that cleavage occurred if they were mixed with a cleavage-defective Cre protein that lacks the catalytic nucleophilic tyrosine residue. The three variant proteins could also be complemented for the formation of a novel structure ("complexV"), which may be a cleaved synaptic intermediate. We suggest that these three mutant proteins have a defect in DNA bending and discuss the relationship between bending, synapsis, and cleavage.	Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto	Sadowski, PD (corresponding author), Univ Toronto, Dept Mol & Med Genet, Med Sci Bldg, Toronto, ON M5S 1A8, Canada.							ABREMSKI K, 1983, CELL, V32, P1301, DOI 10.1016/0092-8674(83)90311-2; ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; ANDREWS BJ, 1987, J MOL BIOL, V193, P345, DOI 10.1016/0022-2836(87)90223-3; AUSTIN S, 1981, CELL, V25, P729, DOI 10.1016/0092-8674(81)90180-X; Cao YH, 1999, J MOL BIOL, V289, P517, DOI 10.1006/jmbi.1999.2793; CHEN JW, 1992, GENE, V119, P37; CHEN JW, 1991, J MOL BIOL, V218, P107, DOI 10.1016/0022-2836(91)90877-9; CRAIG NL, 1988, ANNU REV GENET, V22, P77; DIXON JE, 1995, MOL MICROBIOL, V18, P449, DOI 10.1111/j.1365-2958.1995.mmi_18030449.x; Esposito D, 1997, NUCLEIC ACIDS RES, V25, P3605, DOI 10.1093/nar/25.18.3605; EVANS BR, 1990, J BIOL CHEM, V265, P18504; Gopaul Deshmukh N., 1999, Current Opinion in Structural Biology, V9, P14, DOI 10.1016/S0959-440X(99)80003-7; Gopaul DN, 1998, EMBO J, V17, P4175, DOI 10.1093/emboj/17.14.4175; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P3274, DOI 10.1128/MCB.5.11.3274; Guo F, 1999, P NATL ACAD SCI USA, V96, P7143, DOI 10.1073/pnas.96.13.7143; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; HOESS R, 1987, P NATL ACAD SCI USA, V84, P6840, DOI 10.1073/pnas.84.19.6840; HOESS R, 1990, J MOL BIOL, V216, P873, DOI 10.1016/S0022-2836(99)80007-2; HOESS RH, 1990, NUCLEIC ACIDS MOL BI, V4, P99; HOESS RH, 1990, STRUCTURE METHODS, V1, P203; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LEE J, 1994, EMBO J, V13, P5346, DOI 10.1002/j.1460-2075.1994.tb06869.x; Nunes-Duby SE, 1998, NUCLEIC ACIDS RES, V26, P391, DOI 10.1093/nar/26.2.391; SADOWSKI PD, 1993, FASEB J, V7, P760, DOI 10.1096/fasebj.7.9.8392474; SADOWSKI PD, 1995, PROG NUCLEIC ACID RE, V51, P53, DOI 10.1016/S0079-6603(08)60876-4; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWARTZ CJE, 1989, J MOL BIOL, V205, P647, DOI 10.1016/0022-2836(89)90310-0; Shaikh AC, 2000, J MOL BIOL, V302, P27, DOI 10.1006/jmbi.2000.3967; Shaikh AC, 1997, J BIOL CHEM, V272, P5695, DOI 10.1074/jbc.272.9.5695; SHAIKH AC, 2000, THESIS U TORONTO; SHAIKH AC, 1997, THESIS U TORONTO; WIERZBICKI A, 1987, J MOL BIOL, V195, P785, DOI 10.1016/0022-2836(87)90484-0	33	8	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30186	30195		10.1074/jbc.M005256200	http://dx.doi.org/10.1074/jbc.M005256200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10903322	hybrid			2022-12-27	WOS:000089577900039
J	Wynn, RM; Chuang, JL; Cote, CD; Chuang, DT				Wynn, RM; Chuang, JL; Cote, CD; Chuang, DT			Tetrameric assembly and conservation in the ATP-binding domain of rat branched-chain alpha-ketoacid dehydrogenase kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYRUP-URINE-DISEASE; PROTEIN-KINASES; DIHYDROLIPOYL ACETYLTRANSFERASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; LIPOYL DOMAIN; COMPLEX; EXPRESSION; LIVER; DECARBOXYLASE	We showed previously that the rat branched-chain alpha-ketoacid dehydrogenase (BCKD) kinase is capable of autophosphorylation. However, despite its sequence similarity to bacterial histidine protein kinases, BCKD kinase does not function as a histidine protein kinase. In the present study, we report that the rat BCKD kinase exists as a homotetramer of M-r = 185,000, based on results of gel filtration and dynamic light scattering. This is in contrast to the related mammalian pyruvate dehydrogenase kinase isozymes that occur as homodimers. The tetrameric assembly of BCKD kinase was confirmed by the presence of four 5' -adenylyl-imidodiphosphate-binding sites (K-D = 4.1 x 10(-6) M) per molecule of the kinase. Incubation of the BCKD kinase with increasing concentrations of urea resulted in dissociation of the tetramer to dimers and eventually to monomers as separated on a sucrose density gradient. Both tetramers and dimers, but not the monomer, maintained the conformation capable of binding ATP and undergoing autophosphorylation. BCKD kinase depends on a fully lipoylated transacylase for maximal activity, but the interaction between the kinase and the transacylase is impeded in the presence of high salt concentrations. Alterations of conserved residues in the ATP-binding domain led to a marked reduction or complete loss in the catalytic efficiency of the BCKD kinase. The results indicate that BCKD kinase, similar to pyruvate dehydrogenase kinase isozymes, belongs to the superfamily of ATPase/kinase.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Wynn, RM (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Wynn, Richard/0000-0002-1879-2136	NIDDK NIH HHS [DK-26758] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026758] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AFTRING RP, 1988, AM J PHYSIOL, V254, pE292, DOI 10.1152/ajpendo.1988.254.3.E292; Bilwes AM, 1999, CELL, V96, P131, DOI 10.1016/S0092-8674(00)80966-6; BLOCK KP, 1985, BIOCHEM J, V232, P593, DOI 10.1042/bj2320593; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; Bowker-Kinley M, 1999, BIOCHEM J, V344, P47, DOI 10.1042/0264-6021:3440047; CHUANG JL, 1995, J CLIN INVEST, V95, P954, DOI 10.1172/JCI117804; Chuang JL, 2000, METHOD ENZYMOL, V324, P413; DAMUNI Z, 1984, P NATL ACAD SCI-BIOL, V81, P4335, DOI 10.1073/pnas.81.14.4335; DAVIE JR, 1995, J BIOL CHEM, V270, P19861, DOI 10.1074/jbc.270.34.19861; GRIFFIN TA, 1990, J BIOL CHEM, V265, P12104; HARRIS RA, 1995, ADV ENZYME REGUL, V35, P147, DOI 10.1016/0065-2571(94)00020-4; HARRIS RA, 1986, ADV ENZYME REGUL, V25, P219, DOI 10.1016/0065-2571(86)90016-6; Lee, 1991, CHEM BIOCH FLAVOENZY, V2, P109; LIU SJ, 1995, J BIOL CHEM, V270, P793, DOI 10.1074/jbc.270.2.793; MacColl R, 1998, BIOCHEMISTRY-US, V37, P417, DOI 10.1021/bi971453s; MENDOZA JA, 1991, J BIOL CHEM, V266, P13587; MILLER RH, 1988, J BIOL CHEM, V263, P3454; PAUL HS, 1982, J BIOL CHEM, V257, P4875; POPOV KM, 1992, J BIOL CHEM, V267, P13127; POPOV KM, 1993, J BIOL CHEM, V268, P26602; RADKE GA, 1993, BIOCHEM BIOPH RES CO, V190, P982, DOI 10.1006/bbrc.1993.1146; Ravindran S, 1996, J BIOL CHEM, V271, P653, DOI 10.1074/jbc.271.2.653; ROCHE TE, 1996, ALPHA KETO ACID DEHY, P33; SHIMOMURA Y, 1990, ARCH BIOCHEM BIOPHYS, V283, P293, DOI 10.1016/0003-9861(90)90645-F; SILVERMAN RB, 1995, METHOD ENZYMOL, V249, P240; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WYNN RM, 1992, J BIOL CHEM, V267, P12400; Wynn RM, 1998, J BIOL CHEM, V273, P13110, DOI 10.1074/jbc.273.21.13110; YEAMAN SJ, 1989, BIOCHEM J, V257, P625, DOI 10.1042/bj2570625	29	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30512	30519		10.1074/jbc.M005075200	http://dx.doi.org/10.1074/jbc.M005075200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10903321	hybrid			2022-12-27	WOS:000089577900081
J	Oei, SL; Ziegler, M				Oei, SL; Ziegler, M			ATP for the DNA ligation step in base excision repair is generated from poly(ADP-ribose)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II-DEPENDENT TRANSCRIPTION; POLYMERASE-BETA; LIGASE-III; MAMMALIAN-CELLS; STRAND BREAKS; DAMAGED CELLS; XRCC1; IDENTIFICATION; PROTEIN; GENE	In mammalian cells, the base excision repair (BER) pathway is the main route to counteract the mutagenic effects of DNA lesions. DNA nicks induce, among others, DNA polymerase activities and the synthesis of poly(ADP-ribose). It is shown here that poly(ADP-ribose) serves as an energy source for the final and rate-limiting step of BER, DNA ligation. This conclusion was drawn from experiments in which the fate of [P-32]poly(ADP-ribose) or [P-32]NAD added to HeLa nuclear extracts was systematically followed. ATP was synthesized from poly(ADP-ribose) in a pathway that strictly depended on nick-induced DNA synthesis. NAD was used for the synthesis of poly(ADP-ribose), which, in turn, was converted to ATP by pyrophosphorylytic cleavage utilizing the pyrophosphate generated from dNTPs during DNA synthesis. The adenylyl moiety was then preferentially used to adenylate DNA ligase III, from which it was transferred to the 5'-phosphoryl end of the nicked DNA. Finally, ligation to the 3'-OH end resulted in the release of AMP. When using NAD, but not poly(ADP-ribose), in the presence of 3-aminobenzamide, the entire process was blocked, confirming poly(ADP-ribosyl)ation to be the essential initial step. Thus, poly(ADP-ribose) polymerase-1, DNA polymerase beta, and ligase III interact with x-ray repair cross-complementing protein-1 within the BER complex, which ensures that ATP is generated and specifically used for DNA ligation.	Free Univ Berlin, Inst Biochem, D-14195 Berlin, Germany	Free University of Berlin	Oei, SL (corresponding author), Free Univ Berlin, Inst Biochem, Thielallee 63, D-14195 Berlin, Germany.			Ziegler, Mathias/0000-0001-6961-2396				ALVAREZGONZALEZ R, 1989, MUTAT RES, V218, P67, DOI 10.1016/0921-8777(89)90012-8; [Anonymous], 1985, DNA REPAIR; BENJAMIN RC, 1980, J BIOL CHEM, V255, P502; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; Cappelli E, 1997, J BIOL CHEM, V272, P23970, DOI 10.1074/jbc.272.38.23970; CREISSEN D, 1982, NATURE, V296, P271, DOI 10.1038/296271a0; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dantzer F, 1999, BIOCHIMIE, V81, P69, DOI 10.1016/S0300-9084(99)80040-6; DAS SK, 1986, BIOCHEM BIOPH RES CO, V137, P1153, DOI 10.1016/0006-291X(86)90346-3; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; DING RC, 1992, J BIOL CHEM, V267, P12804; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; Griesenbeck J, 1997, BIOCHEMISTRY-US, V36, P7297, DOI 10.1021/bi962710g; Hagen T, 1997, BBA-PROTEIN STRUCT M, V1340, P7, DOI 10.1016/S0167-4838(97)00021-6; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Lin WS, 1997, J BIOL CHEM, V272, P11895, DOI 10.1074/jbc.272.18.11895; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Mackey ZB, 1999, J BIOL CHEM, V274, P21679, DOI 10.1074/jbc.274.31.21679; Maruta H, 1997, BIOCHEM BIOPH RES CO, V236, P265, DOI 10.1006/bbrc.1997.6910; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; Oei SL, 1998, J BIOL CHEM, V273, P31644, DOI 10.1074/jbc.273.48.31644; Oei SL, 1998, BIOCHEMISTRY-US, V37, P1465, DOI 10.1021/bi9727390; OGATA N, 1981, J BIOL CHEM, V256, P4135; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SIMS JL, 1983, BIOCHEMISTRY-US, V22, P5188, DOI 10.1021/bi00291a019; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Tebbs RS, 1999, DEV BIOL, V208, P513, DOI 10.1006/dbio.1999.9232; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; Tomkinson AE, 1997, BIOESSAYS, V19, P893, DOI 10.1002/bies.950191009; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6	35	124	128	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23234	23239		10.1074/jbc.M002429200	http://dx.doi.org/10.1074/jbc.M002429200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10930429	hybrid			2022-12-27	WOS:000088419400087
J	Nehring, RB; Horikawa, HPM; El Far, O; Kneussel, M; Brandstatter, JH; Stamm, S; Wischmeyer, E; Betz, H; Karschin, A				Nehring, RB; Horikawa, HPM; El Far, O; Kneussel, M; Brandstatter, JH; Stamm, S; Wischmeyer, E; Betz, H; Karschin, A			The metabotropic GABA(B) receptor directly interacts with the activating transcription factor 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM-MEMORY; GAMMA-AMINOBUTYRIC-ACID; DNA-BINDING PROTEINS; NEGATIVELY REGULATE TRANSCRIPTION; RECTIFYING K+ CHANNELS; GLUTAMATE RECEPTORS; NUCLEOCYTOPLASMIC TRANSPORT; SYNAPTIC TRANSMISSION; HIPPOCAMPAL-NEURONS; LEUCINE ZIPPER	G protein-coupled receptors regulate gene expression by cellular signaling cascades that target transcription factors and their recognition by specific DNA sequences, In the central nervous system, heteromeric metabotropic gamma -aminobutyric acid type B (GABA(B)) receptors through adenylyl cyclase regulate cAMP levels, which may control transcription factor binding to the cAMP response element. Using yeast-two hybrid screens of rat brain libraries, we now demonstrate that GABA(B) receptors are engaged in a direct and specific interaction with the activating transcription factor 4 (ATF-4), a member of the cAMP response element-binding protein/ATF family. As confirmed by pull-down assays, ATF-4 associates via its conserved basic leucine zipper domain with the C termini of both GABA(B) receptor (GABA(B)R) 1 and GABA(B)R2 at a site which serves to assemble these receptor subunits in heterodimeric complexes. Confocal fluorescence microscopy shows that GABA(B)R and ATF-4 are strongly coclustered in the soma and at the dendritic membrane surface of both cultured hippocampal neurons as well as retinal amacrine cells in vivo. In oocyte coexpression assays short term signaling of GABA(B)Rs via G proteins was only marginally affected by the presence of the transcription factor, but ATF-4 was moderately stimulated in response to receptor activation in in vivo reporter assays. Thus, inhibitory metabotropic GABA(B)Rs may regulate activity-dependent gene expression via a direct interaction with ATF-4.	Max Planck Inst Biophys Chem, Dept Mol Neurobiol Signal Transduct, D-37070 Gottingen, Germany; Max Planck Inst Brain Res, D-60528 Frankfurt, Germany; Max Planck Inst Neurobiol, Res Grp Neuron Spec Splicing, D-82152 Martinsried, Germany	Max Planck Society; Max Planck Society; Max Planck Society	Karschin, A (corresponding author), Max Planck Inst Biophys Chem, Dept Mol Neurobiol Signal Transduct, D-37070 Gottingen, Germany.	akarsch@gwdg.de	Far, Oussama El/D-4225-2017; EL FAR, Oussama/P-9915-2019	Far, Oussama El/0000-0002-7473-8345; EL FAR, Oussama/0000-0002-7473-8345; Kneussel, Matthias/0000-0003-4900-366X				Abel T, 1998, SCIENCE, V279, P338, DOI 10.1126/science.279.5349.338; Abel T, 1998, BRAIN RES REV, V26, P360, DOI 10.1016/S0165-0173(97)00050-7; Angenstein F, 1998, P NATL ACAD SCI USA, V95, P15078, DOI 10.1073/pnas.95.25.15078; Ashery U, 1999, EUR J CELL BIOL, V78, P525, DOI 10.1016/S0171-9335(99)80017-X; Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; Barthel F, 1996, NEUROSCIENCE, V70, P417, DOI 10.1016/0306-4522(95)00380-0; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; Bettler B, 1998, CURR OPIN NEUROBIOL, V8, P345, DOI 10.1016/S0959-4388(98)80059-7; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Carew TJ, 1996, NEURON, V16, P5, DOI 10.1016/S0896-6273(00)80016-1; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Couve A, 1998, J BIOL CHEM, V273, P26361, DOI 10.1074/jbc.273.41.26361; Crino P, 1998, P NATL ACAD SCI USA, V95, P2313, DOI 10.1073/pnas.95.5.2313; DAVIES CH, 1991, NATURE, V349, P609, DOI 10.1038/349609a0; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HEIDELBERGER R, 1991, P NATL ACAD SCI USA, V88, P7135, DOI 10.1073/pnas.88.16.7135; Heuss C, 1999, NAT NEUROSCI, V2, P1070, DOI 10.1038/15996; Hevers W, 1998, MOL NEUROBIOL, V18, P35, DOI 10.1007/BF02741459; HURST HC, 1994, PROTEIN PROFILE, V1, P123; Isomoto S, 1998, BIOCHEM BIOPH RES CO, V253, P10, DOI 10.1006/bbrc.1998.9706; Johnston GAR, 1996, TRENDS PHARMACOL SCI, V17, P319, DOI 10.1016/S0165-6147(96)10038-9; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kammerer RA, 1999, BIOCHEMISTRY-US, V38, P13263, DOI 10.1021/bi991018t; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Kaupmann K, 1998, P NATL ACAD SCI USA, V95, P14991, DOI 10.1073/pnas.95.25.14991; KERR DIB, 1995, PHARMACOL THERAPEUT, V67, P187, DOI 10.1016/0163-7258(95)00016-A; Klein U, 1997, J BIOL CHEM, V272, P19099, DOI 10.1074/jbc.272.31.19099; Koulen P, 1998, EUR J NEUROSCI, V10, P1446, DOI 10.1046/j.1460-9568.1998.00156.x; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Liang GS, 1997, J BIOL CHEM, V272, P24088, DOI 10.1074/jbc.272.38.24088; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; MIELNICKI LM, 1991, NUCLEIC ACIDS RES, V19, P6332, DOI 10.1093/nar/19.22.6332; MINTZ IM, 1993, NEURON, V10, P889, DOI 10.1016/0896-6273(93)90204-5; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; Ng GYK, 1999, J BIOL CHEM, V274, P7607, DOI 10.1074/jbc.274.12.7607; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Persico AM, 1996, REV NEUROSCIENCE, V7, P233; Pfaff T, 1999, EUR J NEUROSCI, V11, P2874, DOI 10.1046/j.1460-9568.1999.00704.x; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; SCHOLZ KP, 1991, J PHYSIOL-LONDON, V444, P669, DOI 10.1113/jphysiol.1991.sp018900; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; Sodickson DL, 1996, J NEUROSCI, V16, P6374; TSUJIMOTO A, 1991, J VIROL, V65, P1420, DOI 10.1128/JVI.65.3.1420-1426.1991; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Wischmeyer E, 1997, MOL CELL NEUROSCI, V9, P194, DOI 10.1006/mcne.1997.0614; WOJCIK WJ, 1984, MOL PHARMACOL, V25, P24; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473	64	102	111	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35185	35191		10.1074/jbc.M002727200	http://dx.doi.org/10.1074/jbc.M002727200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10924501	hybrid, Green Published			2022-12-27	WOS:000165422800049
J	Koza, RA; Hohmann, SM; Guerra, C; Rossmeisl, M; Kozak, LP				Koza, RA; Hohmann, SM; Guerra, C; Rossmeisl, M; Kozak, LP			Synergistic gene interactions control the induction of the mitochondrial uncoupling protein (Ucp1) gene in white fat tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; DIET-INDUCED OBESITY; MESSENGER-RNA; ADULT HUMANS; MICE; ADIPOCYTES; EXPRESSION; PHEOCHROMOCYTOMA; SUSCEPTIBILITY; AGONIST	Among a selected group of mouse strains susceptible to dietary obesity, those with an enhanced capacity for Ucp1 and brown adipocyte induction in white fat preferentially lost body weight following adrenergic stimulation. Eased on the generality of this mechanism for reducing obesity, a genetic analysis was initiated to identify genes that control brown adipocyte induction in white fat depots in mice, Quantitative trait locus (QTL) analysis was performed using the variations of retroperitoneal fat Ucp1 mRNA expression in progeny of genetic crosses between the A/J and C57BL/6J parental strains and selected AXE recombinant inbred strains. Three A/J-derived loci on chromosomes 2, 3, and 8 and one C57BL/6J locus on chromosome 19 were linked to Ucp1 induction in retroperitoneal fat. Although A/J-derived alleles seemed to contribute to elevated Ucp1 expression, the C57BL/6J allele on chromosome 19 increased Ucp1 mRNA to levels higher than parental values. Thus, novel patterns of C57BL/6J and A/J recombinant genotypes among the four mapped loci resulted in a transgressive variation of Ucp1 phenotypes, Although the extent, of the interchromosomal interactions have not been fully explored, strong synergistic interactions occur between a C57BL/6J allele on chromosome 19 and an A/J allele on chromosome a In addition to selective synergistic interactions between loci, variations in recessive and dominant effects also contribute to the final levels of Ucp1 expression.	Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Kozak, LP (corresponding author), Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.	Kozaklp@pbrc.edu	Rossmeisl, Martin/C-1892-2012; Guerra, Carmen/K-5852-2014; Rossmeisl, Martin/CAF-0060-2022	Rossmeisl, Martin/0000-0001-8534-4002; Rossmeisl, Martin/0000-0001-8534-4002; Guerra, Carmen/0000-0002-3891-046X				Champigny O, 1996, J LIPID RES, V37, P1907; CHAMPIGNY O, 1991, P NATL ACAD SCI USA, V88, P10774, DOI 10.1073/pnas.88.23.10774; CHEVERUD JM, 1995, GENETICS, V139, P1455; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Collins S, 1997, ENDOCRINOLOGY, V138, P405, DOI 10.1210/en.138.1.405; COUSIN B, 1992, J CELL SCI, V103, P931; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; Digby JE, 1998, DIABETES, V47, P138, DOI 10.2337/diabetes.47.1.138; Doerge RW, 1996, GENETICS, V142, P285; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fijneman RJA, 1996, NAT GENET, V14, P465, DOI 10.1038/ng1296-465; FRANKEL WN, 1995, MAMM GENOME, V6, P830, DOI 10.1007/BF00292431; GARRUTI G, 1992, INT J OBESITY, V16, P383; Ghorbani M, 1997, BIOCHEM PHARMACOL, V54, P121, DOI 10.1016/S0006-2952(97)00162-7; Guerra C, 1998, J CLIN INVEST, V102, P412, DOI 10.1172/JCI3155; HIMMSHAGEN J, 1994, AM J PHYSIOL, V266, pR1371, DOI 10.1152/ajpregu.1994.266.4.R1371; Kopecky J, 1995, J CLIN INVEST, V96, P2914, DOI 10.1172/JCI118363; Kopecky J, 1996, AM J PHYSIOL-ENDOC M, V270, pE768, DOI 10.1152/ajpendo.1996.270.5.E768; LANDER ES, 1989, GENETICS, V121, P185; Lean M. E. J., 1986, BROWN ADIPOSE TISSUE, P339; LEAN MEJ, 1986, INT J OBESITY, V10, P219; LEAN MEJ, 1986, CLIN SCI, V71, P291, DOI 10.1042/cs0710291; LONCAR D, 1988, J ULTRA MOL STRUCT R, V101, P199, DOI 10.1016/0889-1605(88)90010-9; Manly KF, 1999, MAMM GENOME, V10, P327, DOI 10.1007/s003359900997; MARTINEZ O, 1992, THEOR APPL GENET, V88, P349; MCMILLAN I, 1974, HEREDITY, V32, P349, DOI 10.1038/hdy.1974.43; NEDERGAARD J, 1986, BROWN ADIPOSE TISSUE, P153; RICQUIER D, 1982, J CLIN ENDOCR METAB, V54, P803; ROTHWELL NJ, 1979, NATURE, V281, P31, DOI 10.1038/281031a0; SURWIT RS, 1988, DIABETES, V37, P1163, DOI 10.2337/diabetes.37.9.1163; vanWezel T, 1996, NAT GENET, V14, P468, DOI 10.1038/ng1296-468; YOUNG P, 1984, FEBS LETT, V167, P10, DOI 10.1016/0014-5793(84)80822-4	33	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34486	34492		10.1074/jbc.M002136200	http://dx.doi.org/10.1074/jbc.M002136200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10931824	hybrid			2022-12-27	WOS:000165095300066
J	Seiffert, D; Bradley, JD; Rominger, CM; Rominger, DH; Yang, FD; Meredith, JE; Tang, Q; Roach, AH; Thompson, LA; Spitz, SM; Higaki, JN; Prakash, SR; Combs, AP; Copeland, RA; Arneric, SP; Hartig, PR; Robertson, DW; Cordell, B; Stern, AM; Olson, RE; Zaczek, R				Seiffert, D; Bradley, JD; Rominger, CM; Rominger, DH; Yang, FD; Meredith, JE; Tang, Q; Roach, AH; Thompson, LA; Spitz, SM; Higaki, JN; Prakash, SR; Combs, AP; Copeland, RA; Arneric, SP; Hartig, PR; Robertson, DW; Cordell, B; Stern, AM; Olson, RE; Zaczek, R			Presenilin-1 and-2 are molecular targets for gamma-secretase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; BETA-SECRETASE; CLEAVAGE; DEFICIENCY; COMPLEX	Presenilins are integral membrane protein involved in the production of amyloid beta -protein, Mutations of the presenilin-1 and -2 gene are associated with familial Alzheimer's disease and are thought to alter gamma -secretase cleavage of the beta -amyloid precursor protein, leading to increased production of longer and more amyloidogenic forms of A beta, the 4-kDa beta -peptide, Here, we show that radiolabeled gamma -secretase inhibitors bind to mammalian cell membranes, and a benzophenone analog specifically photocross-links three major membrane polypeptides. A positive correlation is observed among these compounds for inhibition of cellular A beta formation, inhibition of membrane binding and cross-linking. Immunological techniques establish N- and C-terminal fragments of presenilin-1 as specifically cross-linked polypeptides, Furthermore, binding of gamma -secretase inhibitors to embryonic membranes derived fi om presenilin-1 knockout embryos is reduced in a gene dose-dependent manner. In addition, C-terminal fragments of presenilin-2 are specifically cross-linked. Taken together, these results indicate that potent and selective gamma -secretase inhibitors block A beta formation by binding to presenilin-1 and -2.	DuPont Pharmaceut Co, Expt Stn, Wilmington, DE 19880 USA; Scios Inc, Sunnyvale, CA 94086 USA	DuPont; Scios	Seiffert, D (corresponding author), DuPont Pharmaceut Co, Expt Stn, POB 80400, Wilmington, DE 19880 USA.			Stern, Andrew/0000-0002-8437-2957				BECKETT RP, 1993, SYNLETT, P137; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Czech C, 2000, PROG NEUROBIOL, V60, P363, DOI 10.1016/S0301-0082(99)00033-7; De Strooper B, 1999, NATURE, V402, P471, DOI 10.1038/44973; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; Harlow E., 1999, USING ANTIBODIES LAB; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Higaki JN, 1999, J MED CHEM, V42, P3889, DOI 10.1021/jm990009f; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; HUSSAIN I, 1999, MOL CELL NEUROSCI; KEEN M, 1999, RECEPTOR BINDING TEC, P106; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Moore CL, 1999, EXPERT OPIN THER PAT, V9, P135, DOI 10.1517/13543776.9.2.135; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	24	287	345	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34086	34091		10.1074/jbc.M005430200	http://dx.doi.org/10.1074/jbc.M005430200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10915801	hybrid			2022-12-27	WOS:000165095300015
J	Kueltzo, LA; Normand, N; O'Hare, P; Middaugh, CR				Kueltzo, LA; Normand, N; O'Hare, P; Middaugh, CR			Conformational lability of herpesvirus protein VP22	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; HIV-1 TAT PROTEIN; MOLTEN GLOBULE STATE; CIRCULAR-DICHROISM; INTERCELLULAR TRAFFICKING; SECONDARY STRUCTURE; MEMBRANE-INSERTION; FUSION PROTEINS; I TAT; DELIVERY	The herpesvirus protein VP22 traffics between cells, being exported from expressing cells in a non-Golgi-dependent manner and localizing in the nuclei of surrounding cells. This transport is retained in certain VP22 fusion proteins, making VP22 a candidate for use in macromolecular drug delivery. In an effort to understand the physical basis for this activity, we have initiated structural studies of VP22.C1, the C-terminal half of VP22, which possesses the full transport activity of the native protein. CD and Fourier transform infrared analyses indicate a secondary structure consisting of approximately 30% alpha -helix, 17% beta -sheet, and 51% disordered and turn structure. Unfolding studies conducted by CD, differential scanning calorimetry, and fluorescence reveal a series of discrete structural transitions in the range of 20-60 degreesC, CD and fluorescence studies of interactions between VP22.C1 and divalent cations and model polyanions indicate that Mg2+, Zn2+, oligonucleotides, and heparin interact with the protein, causing changes in secondary structure and thermal stability. Additionally, the interaction of VP22.C1 with model lipids was examined. Fluorescence titrations of the protein with trans-parinaric acid at various temperatures suggest the binding of one to two molecules of parinaric acid to VP22.C1 at temperatures >40 degreesC, suggesting the possibility of conformation dependent membrane interaction under physiological conditions.	Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66047 USA; Marie Curie Res Inst, Oxford RH8 0TL, Surrey, England	University of Kansas	Middaugh, CR (corresponding author), Univ Kansas, Dept Pharmaceut Chem, 2095 Constant Ave, Lawrence, KS 66047 USA.	middaugh@ukans.edu		O'Hare, Peter/0000-0003-4508-5602; Kueltzo, Lisa/0000-0001-7157-320X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008359] Funding Source: NIH RePORTER; NIGMS NIH HHS [2 T32 GM08359-11] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; BARRICK D, 1993, PROTEIN SCI, V2, P869, DOI 10.1002/pro.5560020601; BAYER P, 1995, J MOL BIOL, V247, P529, DOI 10.1016/S0022-2836(05)80133-0; BYCHKOVA VE, 1992, BIOCHEMISTRY-US, V31, P7566, DOI 10.1021/bi00148a018; BYCHKOVA VE, 1988, FEBS LETT, V238, P231, DOI 10.1016/0014-5793(88)80485-X; COLLINS D, 1994, BIOCHEMISTRY-US, V33, P4521, DOI 10.1021/bi00181a012; Conrad H. E., 1998, HEPARIN BINDING PROT; COPELAND RA, 1991, ARCH BIOCHEM BIOPHYS, V289, P53, DOI 10.1016/0003-9861(91)90441-K; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Dilber MS, 1999, GENE THER, V6, P12, DOI 10.1038/sj.gt.3300838; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Elliott G, 1998, J VIROL, V72, P6448, DOI 10.1128/JVI.72.8.6448-6455.1998; Elliott G, 1999, GENE THER, V6, P149, DOI 10.1038/sj.gt.3300850; Elliott G, 1996, VIROLOGY, V226, P140, DOI 10.1006/viro.1996.0638; ELLIOTT GD, 1992, J GEN VIROL, V73, P723, DOI 10.1099/0022-1317-73-3-723; Fischer PM, 2000, J PEPT RES, V55, P163, DOI 10.1034/j.1399-3011.2000.00163.x; Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HAUGLAND RP, 1996, HDB FLUORESCENT PROB, P297; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; Kuchler K, 1990, CURR OPIN CELL BIOL, V2, P617, DOI 10.1016/0955-0674(90)90102-K; Linemeyer DL, 1990, GROWTH FACTORS, V3, P287, DOI 10.3109/08977199009003671; MACH H, 1995, BIOCHEMISTRY-US, V34, P9913, DOI 10.1021/bi00031a013; MACH H, 1993, BIOCHEMISTRY-US, V32, P7703, DOI 10.1021/bi00081a015; MACH H, 1994, ANAL BIOCHEM, V222, P323, DOI 10.1006/abio.1994.1499; Mach H, 1995, Methods Mol Biol, V40, P91; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; MIDDAUGH CR, 1995, PROTEIN STABILITY FO, V40, P137; MIDDAUGH CR, 1993, CURR OPIN INVEST DR, V2, P991; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; ORTEGA S, 1991, J BIOL CHEM, V266, P5842; Phelan A, 1998, NAT BIOTECHNOL, V16, P440, DOI 10.1038/nbt0598-440; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Rubartelli A, 1998, IMMUNOL TODAY, V19, P543, DOI 10.1016/S0167-5699(98)01351-6; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; Rubartelli A., 1997, UNUSUAL SECRETORY PA, P87, DOI [10.1007/978-3-662-22581-3_3, DOI 10.1007/978-3-662-22581-3_3]; Rusnati M, 1999, J BIOL CHEM, V274, P28198, DOI 10.1074/jbc.274.40.28198; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SKLAR LA, 1976, J SUPRAMOL STR CELL, V4, P449, DOI 10.1002/jss.400040404; SKLAR LA, 1977, BIOCHEMISTRY-US, V16, P813, DOI 10.1021/bi00624a001; Soulages JL, 1998, BIOCHEMISTRY-US, V37, P10203, DOI 10.1021/bi980622l; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Stolowich NJ, 1997, BIOCHEMISTRY-US, V36, P1719, DOI 10.1021/bi962317a; SUSI H, 1986, METHOD ENZYMOL, V130, P290; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; Vecsey-Semjen B, 1999, BIOCHEMISTRY-US, V38, P4296, DOI 10.1021/bi982472k; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; WIEDLOCHA A, 1992, EMBO J, V11, P4835, DOI 10.1002/j.1460-2075.1992.tb05589.x	50	31	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33213	33221		10.1074/jbc.M002476200	http://dx.doi.org/10.1074/jbc.M002476200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10913125	hybrid			2022-12-27	WOS:000090104600008
J	Zhang, L; Spratt, SK; Liu, Q; Johnstone, B; Qi, H; Raschke, EE; Jamieson, AC; Rebar, EJ; Wolffe, AP; Case, CC				Zhang, L; Spratt, SK; Liu, Q; Johnstone, B; Qi, H; Raschke, EE; Jamieson, AC; Rebar, EJ; Wolffe, AP; Case, CC			Synthetic zinc finger transcription factor action at an endogenous chromosomal site - Activation of the human erythropoietin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; RIBOSOMAL-RNA GENES; FACTOR ACCESS; FACTOR-IIIA; IN-VIVO; 5S RNA; XENOPUS OOCYTE; POSITIVE ROLE; HISTONE H1; CHROMATIN	We have targeted the activation of an endogenous chromosomal locus including the human erythropoietin gene using synthetic transcription factors. These transcription factors are targeted to particular DNA sequences in the 5'-flanking region of the erythropoietin gene through engineering of a zinc finger DNA binding domain. The DNA binding domain is linked to a VP16 transcriptional activation domain. We find that these synthetic transcription factors invariably activate transiently transfected templates in which sequences within the 5' flank of the erythropoietin gene are fused to a luciferase reporter. The efficiency of activation under these circumstances at a defined site is dependent on DNA binding affinity. In contrast, only a subset of these same zinc finger proteins is able to activate the endogenous chromosomal locus. The activity of these proteins is influenced by their capacity to gain access to their recognition elements within the chromatin infrastructure, Zinc finger transcription factors will provide a powerful tool to probe the determinants of chromatin accessibility and remodeling within endogenous chromosomal loci.	Sangamo Biosci Inc, Point Richmond Tech Ctr, Richmond, CA 94804 USA	Sangamo Therapeutics, Inc.	Wolffe, AP (corresponding author), Sangamo Biosci Inc, Point Richmond Tech Ctr, 501 Canal Blvd,Suite A100, Richmond, CA 94804 USA.							ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Beerli RR, 1998, P NATL ACAD SCI USA, V95, P14628, DOI 10.1073/pnas.95.25.14628; Beerli RR, 2000, P NATL ACAD SCI USA, V97, P1495, DOI 10.1073/pnas.040552697; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; Chan WK, 1999, J BIOL CHEM, V274, P12115, DOI 10.1074/jbc.274.17.12115; CHIPEV CC, 1992, MOL CELL BIOL, V12, P45, DOI 10.1128/MCB.12.1.45; CHOO Y, 1994, NATURE, V372, P642, DOI 10.1038/372642a0; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; Crane-Robinson C, 1998, TRENDS GENET, V14, P477, DOI 10.1016/S0168-9525(98)01621-7; DESJARLAIS JR, 1992, PROTEINS, V12, P101, DOI 10.1002/prot.340120202; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DREW HR, 1984, J MOL BIOL, V176, P535, DOI 10.1016/0022-2836(84)90176-1; ENGLANDER EW, 1993, J BIOL CHEM, V268, P19565; ENGLANDER EW, 1995, J BIOL CHEM, V270, P10091, DOI 10.1074/jbc.270.17.10091; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; GOTTESFELD J, 1982, CELL, V28, P781, DOI 10.1016/0092-8674(82)90057-5; Greisman HA, 1997, SCIENCE, V275, P657, DOI 10.1126/science.275.5300.657; Gupta M, 1996, NUCLEIC ACIDS RES, V24, P4768, DOI 10.1093/nar/24.23.4768; HAYES JJ, 1992, P NATL ACAD SCI USA, V89, P1229, DOI 10.1073/pnas.89.4.1229; Hu B, 1997, MOL CELL BIOL, V17, P851, DOI 10.1128/MCB.17.2.851; Jamieson AC, 1996, P NATL ACAD SCI USA, V93, P12834, DOI 10.1073/pnas.93.23.12834; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; Kim JS, 1997, J BIOL CHEM, V272, P29795, DOI 10.1074/jbc.272.47.29795; Kim JS, 1997, P NATL ACAD SCI USA, V94, P3616, DOI 10.1073/pnas.94.8.3616; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Lee HJ, 1996, J BIOL CHEM, V271, P10405, DOI 10.1074/jbc.271.17.10405; Panetta G, 1998, J MOL BIOL, V282, P683, DOI 10.1006/jmbi.1998.2087; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; REEVES R, 1985, NUCLEIC ACIDS RES, V13, P3599, DOI 10.1093/nar/13.10.3599; RHODES D, 1985, EMBO J, V4, P3473, DOI 10.1002/j.1460-2075.1985.tb04106.x; Sera T, 1998, MOL CELL BIOL, V18, P3668, DOI 10.1128/MCB.18.7.3668; TREMETHICK D, 1990, J BIOL CHEM, V265, P5014; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; Tse C, 1998, P NATL ACAD SCI USA, V95, P12169, DOI 10.1073/pnas.95.21.12169; URA K, 1995, EMBO J, V14, P3752, DOI 10.1002/j.1460-2075.1995.tb00045.x; Vitolo JM, 2000, MOL CELL BIOL, V20, P2167, DOI 10.1128/MCB.20.6.2167-2175.2000; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; WU H, 1995, P NATL ACAD SCI USA, V92, P344, DOI 10.1073/pnas.92.2.344	39	150	198	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33850	33860		10.1074/jbc.M005341200	http://dx.doi.org/10.1074/jbc.M005341200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10913152	hybrid			2022-12-27	WOS:000090104600093
J	Keyhani, NO; Bacia, K; Roseman, S				Keyhani, NO; Bacia, K; Roseman, S			The transport/phosphorylation of N-N '-Diacetylchitobiose in Escherichia coli - Characterization of phospho-IIBChb and of a potential transition state analogue in the phosphotransfer reaction between the proteins IIA(Chb) and IIBChb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE; GLUCOSE-TRANSPORTER; CEL OPERON; INTERMEDIATE; SYSTEM; PHOSPHOCYSTEINE; PHOSPHOENOLPYRUVATE; CYSTEINE; VISUALIZATION; CATALYSIS	Enzyme II permeases of the phosphoenolpyruvate:glycose phosphotransferase system comprise one to five separately encoded polypeptides, but most contain similar domains (IIA RB, and IIC). The phosphoryl group is transferred from one domain to another, with histidine as the phosphoryl acceptor in IIA and cysteine as the acceptor in certain IIB domains. IIBChb is a phosphocarrier in the uptake/phosphorylation of the chitin disaccharide, (Glc-NAc)(2) by Escherichia coli and is unusual because it is separately encoded and soluble. Both the crystal and solution structures of a IIBChb mutant (C10S) have been reported. In the present studies, homogeneous phospho-IIBChb was isolated, and the phosphoryl-Cys linkage was established by Slp NMR spectroscopy. Rate constants for the hydrolysis of phospho-IIBChb plotted versus pH gave the same shape peak reported for the model compound, butyl thiophosphate, but was shifted about 4 pH units. Evidence is presented for a stable complex between homogeneous Cys10SerIIB(Chb) (which cannot be phosphorylated) and phospho-IIA(Chb) but not with IIA(Chb). The complex (a tetramer (3)) contains equimolar quantities of the two proteins and has been chemically cross-linked. It appears to be an analogue of the transition state complex in the reaction: phospho-IIA(Chb) + IIBChb <-> IIA(Chb) + phospho-IIBChb. This is apparently the first report of the isolation of a transition state analogue in a protein-protein phosphotransfer reaction.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, McCollum Pratt Inst, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Roseman, S (corresponding author), Johns Hopkins Univ, Dept Biol, Mudd Hall,Rm 214,3400 N Charles St, Baltimore, MD 21218 USA.		Keyhani, Nemat O/I-8150-2013		PHS HHS [38759] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AB E, 1994, PROTEIN SCI, V3, P282; CHO HJ, 1992, J AM CHEM SOC, V114, P7296, DOI 10.1021/ja00044a052; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; ERNI B, 1989, FEMS MICROBIOL LETT, V63, P13, DOI 10.1016/0168-6445(89)90004-1; Gemmecker G, 1997, BIOCHEMISTRY-US, V36, P7408, DOI 10.1021/bi963053v; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HERR EB, 1957, BIOCHIM BIOPHYS ACTA, V25, P219, DOI 10.1016/0006-3002(57)90456-0; Keyhani N, 2000, J BIOL CHEM, V275, P33110, DOI 10.1074/jbc.M001717200; Keyhani NO, 2000, J BIOL CHEM, V275, P33091, DOI 10.1074/jbc.M001044200; Keyhani NO, 2000, J BIOL CHEM, V275, P33084, DOI 10.1074/jbc.M001043200; Keyhani NO, 2000, J BIOL CHEM, V275, P33068, DOI 10.1074/jbc.M001041200; Keyhani NO, 1997, P NATL ACAD SCI USA, V94, P14367, DOI 10.1073/pnas.94.26.14367; MATHEIS G, 1984, INT J BIOCHEM, V16, P867, DOI 10.1016/0020-711X(84)90145-9; MEINS M, 1993, J BIOL CHEM, V268, P11604; Pannifer ADB, 1998, J BIOL CHEM, V273, P10454, DOI 10.1074/jbc.273.17.10454; Park JK, 2000, J BIOL CHEM, V275, P33077, DOI 10.1074/jbc.M001042200; PARKER LL, 1990, GENETICS, V124, P455; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5515, DOI 10.1021/bi00415a019; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5835, DOI 10.1021/bi00416a002; PAS HH, 1991, J BIOL CHEM, V266, P6690; POGGEVONSTRANDM.P, 1995, EUR J BIOCHEM, V233, P1166; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; vanMontfort RLM, 1997, STRUCTURE, V5, P217, DOI 10.1016/S0969-2126(97)00180-9; VANMONTFORT RLM, 1994, J MOL BIOL, V239, P588, DOI 10.1006/jmbi.1994.1399; VOGEL HJ, 1989, METHOD ENZYMOL, V177, P263; WEIGEL N, 1982, J BIOL CHEM, V257, P4477	27	17	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33102	33109		10.1074/jbc.M001045200	http://dx.doi.org/10.1074/jbc.M001045200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10913119	hybrid			2022-12-27	WOS:000090003800098
J	Ritz-Laser, B; Estreicher, A; Gauthier, B; Philippe, J				Ritz-Laser, B; Estreicher, A; Gauthier, B; Philippe, J			The paired homeodomain transcription factor Pax-2 is expressed in the endocrine pancreas and transactivates the glucagon gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC EXPRESSION; DNA-BINDING; ADHESION MOLECULE; WILMS-TUMOR; ELEMENT; DOMAIN; IDENTIFICATION; PROTEINS; KIDNEY; REGION	Glucagon gene expression is controlled by at least four DNA elements within the promoter; G2, G3, and G4 confer islet-specific expression, while G1 restricts glucagon transcription to Lu cells. Two islet-specific complexes are formed on G3, the insulin-responsive element of the glucagon gene; one of these corresponds to the paired homeodomain protein Pax-6, a major glucagon gene transactivator that plays a crucial role in alpha cell development. We describe here the identification of the second complex as Pax-2, another member of the paired box family. Pax-2 is known to be crucial for the development of the urogenital tract and of the central nervous system, but its presence in the endocrine pancreas has not been reported. We detected Pax-2 gene expression by RT-PCR; in islets, Pax-2 is present as two alternative splicing isoforms, Pax-2A and Pax-BE, whereas in the glucagon- and insulin-producing cell lines alpha TC1 and Min6, a distinct isoform, Pax-2D2, is found in addition to Pax-BE. Both islet-specific isoforms bind to the enhancer element G3 and to the alpha -specific promoter element G1 that also interacts with Pax-6. Pax-2A and Pax-BE dose-dependently activate transcription from the 63 and the G1 elements both in heterologous and in glucagon-producing cells. Our data indicate that Pax-a is the third paired domain protein present in the endocrine pancreas and that one of its roles may be the regulation of glucagon gene expression.	Ctr Med Univ Geneva, Diabet Unit, CH-1211 Geneva 4, Switzerland	University of Geneva	Ritz-Laser, B (corresponding author), Ctr Med Univ Geneva, Diabet Unit, CH-1211 Geneva 4, Switzerland.	Beate.Laser@medecine.unige.ch	Gauthier, Benoit R/C-3138-2017	Gauthier, Benoit R/0000-0001-8146-7486; Estreicher, Anne/0000-0001-6828-2508				ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; CHALEPAKIS G, 1994, DNA CELL BIOL, V13, P891, DOI 10.1089/dna.1994.13.891; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRESSLER GR, 1993, NATURE, V362, P65, DOI 10.1038/362065a0; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; DRUCKER DJ, 1987, J BIOL CHEM, V262, P15659; Eberhard D, 1999, CANCER RES, V59, p1716S; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; Favor J, 1996, P NATL ACAD SCI USA, V93, P13870, DOI 10.1073/pnas.93.24.13870; Fujitani Y, 1999, MOL CELL BIOL, V19, P8281; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; Havik B, 1999, BIOCHEM BIOPH RES CO, V266, P532, DOI 10.1006/bbrc.1999.1854; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; Holst BD, 1997, P NATL ACAD SCI USA, V94, P1465, DOI 10.1073/pnas.94.4.1465; Larsson LI, 1998, MECH DEVELOP, V79, P153, DOI 10.1016/S0925-4773(98)00182-8; Lechner MS, 1996, J BIOL CHEM, V271, P21088, DOI 10.1074/jbc.271.35.21088; MANSOURI A, 1994, J CELL SCI, P35; McConnell MJ, 1997, ONCOGENE, V14, P2689, DOI 10.1038/sj.onc.1201114; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; MOREL C, 1995, J BIOL CHEM, V270, P3046, DOI 10.1074/jbc.270.7.3039; NORNES HO, 1990, DEVELOPMENT, V109, P797; Pfeffer PL, 2000, DEVELOPMENT, V127, P1017; Phelps DE, 1996, J BIOL CHEM, V271, P7978, DOI 10.1074/jbc.271.14.7978; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PHILIPPE J, 1990, J BIOL CHEM, V265, P1465; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; PHILIPPE J, 1995, J BIOL CHEM, V270, P3039, DOI 10.1074/jbc.270.7.3039; POWERS AC, 1990, DIABETES, V39, P406, DOI 10.2337/diabetes.39.4.406; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; Ritz-Laser B, 1999, J BIOL CHEM, V274, P4124, DOI 10.1074/jbc.274.7.4124; ROTHENPIELER UW, 1993, DEVELOPMENT, V119, P711; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; SANYANUSIN P, 1995, NAT GENET, V9, P358, DOI 10.1038/ng0495-358; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; Sheng GJ, 1997, GENE DEV, V11, P1122, DOI 10.1101/gad.11.9.1122; Smith SB, 1999, MOL CELL BIOL, V19, P8272; Song DL, 1996, DEVELOPMENT, V122, P627; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Sun HM, 1997, P NATL ACAD SCI USA, V94, P5156, DOI 10.1073/pnas.94.10.5156; TAKAKI R, 1986, IN VITRO CELL DEV B, V22, P120; Tavassoli K, 1997, HUM GENET, V101, P371, DOI 10.1007/s004390050644; Terzic J, 1998, INT J DEV BIOL, V42, P701; Torres M, 1995, DEVELOPMENT, V121, P4057; Torres MA, 1996, DEVELOPMENT, V122, P3381; WARD TA, 1994, CELL GROWTH DIFFER, V5, P1015; Zhou YH, 2000, GENE, V245, P319, DOI 10.1016/S0378-1119(00)00019-6	53	36	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32708	32715		10.1074/jbc.M005704200	http://dx.doi.org/10.1074/jbc.M005704200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10938089	hybrid			2022-12-27	WOS:000090003800047
J	Chen, L; Smith, L; Johnson, MR; Wang, KS; Diasio, RB; Smith, JB				Chen, L; Smith, L; Johnson, MR; Wang, KS; Diasio, RB; Smith, JB			Activation of protein kinase C induces nuclear translocation of RFX1 and down-regulates c-myc via an intron 1 X box in undifferentiated leukemia HL-60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B VIRUS ENHANCER; DNA-BINDING PROTEIN; REPRESSION DOMAINS; HL60 CELLS; DIFFERENTIATION; TRANSCRIPTION; PROMOTER; EXPRESSION; BLOCK; GENE	Treatment of human promyelocytic leukemia cells (HL-60) with phorbol la-myristate 13-acetate (PMA) is known to decrease c-myc mRNA by blocking transcription elongation at sites near the first exon/intron border. Treatment of HL-60 cells with either PMA or bryostatin 1, which acutely activates protein kinase C (PKC), decreased the levels of myc mRNA and Myc protein. The inhibition of Myc synthesis accounted for the drop in Myc protein, because PMA treatment had no effect on Myc turnover. Treatment with PMA or bryostatin 1 increased nuclear protein binding to MIE1, a c-myc intron 1 element that defines an RFX1-binding X box. RFX1 antiserum supershifted MIE1-protein complexes. Increased MIE1 binding was independent of protein synthesis and abolished by a selective PKC inhibitor, which also prevented the effect of PMA on myc mRNA and protein levels and Myc synthesis. PMA treatment increased RFX1 in the nuclear fraction and decreased it in the cytosol without affecting total RFX1. Transfection of HL-60 cells with myc reporter gene constructs showed that the RFX1-binding X box was required for the downregulation of reporter gene expression by PMA. These findings suggest that nuclear translocation and binding of RFX1 to the X box cause the down-regulation of myc expression, which follows acute PKC activation in undifferentiated HL-60 cells.	Univ Alabama, Sch Med, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA; Univ Alabama, Sch Med, Ctr Comprehens Canc, Birmingham, AL 35294 USA; Univ Alabama, Sch Dent, Ctr Comprehens Canc, Birmingham, AL 35294 USA; Univ Alabama, Sch Dent, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Smith, JB (corresponding author), Univ Alabama, Sch Med, Dept Pharmacol & Toxicol, Volker Hall G133E,1670 Univ Blvd, Birmingham, AL 35294 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060383] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60383] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; BENLEVY R, 1989, MOL CELL BIOL, V9, P1804, DOI 10.1128/MCB.9.4.1804; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; Blake M, 1996, J VIROL, V70, P6060, DOI 10.1128/JVI.70.9.6060-6066.1996; Chen L, 2000, ARCH BIOCHEM BIOPHYS, V374, P306, DOI 10.1006/abbi.1999.1603; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; Dang CV, 1999, MOL CELL BIOL, V19, P1; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; Emery P, 1996, MOL CELL BIOL, V16, P4486; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Gajiwala KS, 2000, NATURE, V403, P916, DOI 10.1038/35002634; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Iwama A, 1999, MOL CELL BIOL, V19, P3940; Katan Y, 1997, NUCLEIC ACIDS RES, V25, P3621, DOI 10.1093/nar/25.18.3621; Katan-Khaykovich Y, 1998, J BIOL CHEM, V273, P24504, DOI 10.1074/jbc.273.38.24504; KRAFT AS, 1986, P NATL ACAD SCI USA, V83, P1334, DOI 10.1073/pnas.83.5.1334; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee HW, 1996, AM J PHYSIOL-CELL PH, V271, pC304, DOI 10.1152/ajpcell.1996.271.1.C304; Lee HW, 1996, J BIOL CHEM, V271, P20973, DOI 10.1074/jbc.271.35.20973; Lee HW, 1997, MOL PHARMACOL, V51, P439; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; OSTAPCHUK P, 1989, MOL CELL BIOL, V9, P2787, DOI 10.1128/MCB.9.7.2787; Pan QT, 1999, J BIOL CHEM, V274, P8437, DOI 10.1074/jbc.274.13.8437; REINHOLD W, 1995, MOL CELL BIOL, V15, P3041; REITH W, 1989, P NATL ACAD SCI USA, V86, P4200, DOI 10.1073/pnas.86.11.4200; SALEHI Z, 1988, J BIOL CHEM, V263, P1898; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; Simpson RU, 1998, J BIOL CHEM, V273, P19587, DOI 10.1074/jbc.273.31.19587; SIMPSON RU, 1989, J BIOL CHEM, V264, P19710; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; TONETTI DA, 1994, J BIOL CHEM, V269, P23230; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Westerheide SD, 1999, NUCLEIC ACIDS RES, V27, P1635, DOI 10.1093/nar/27.7.1635; YU BW, 1993, J BIOL CHEM, V268, P19586; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510; ZHANG XY, 1990, CANCER RES, V50, P6865; ZHANG XY, 1993, MOL CELL BIOL, V13, P6810, DOI 10.1128/MCB.13.11.6810	45	34	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32227	32233		10.1074/jbc.M002645200	http://dx.doi.org/10.1074/jbc.M002645200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10918054	hybrid			2022-12-27	WOS:000089858900093
J	Harborth, J; Weber, K; Osborn, M				Harborth, J; Weber, K; Osborn, M			GAS41, a highly conserved protein in eukaryotic nuclei, binds to NuMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC SPINDLE; SECONDARY-STRUCTURE; ACUTE-LEUKEMIA; COILED-COIL; PHOSPHORYLATION; APPARATUS; SEQUENCE; SITES; PREDICTION; INTERACTS	The yeast two-hybrid system was used to identify binding partners of NuMA, a component of the nuclear matrix in interphase cells. By using the C-terminal half of NuMA as bait, a human cDNA sequence coding for a 223-amino acid protein with a non-helical N-terminal domain and a C-terminal a-helical portion was identified and fully sequenced. It was identical to GAS41, a sequence amplified in human gliomas, The sequence of the homologous Drosophila protein was established, and the alignment for GAS41 from nine different species showed that GAS41 is a general eukaryotic protein found in species as diverse as Arabidopsis, Drosophila, Caenorhabditis elegans, yeast, and man. Northern blot analysis showed a single transcript in eight human tissues. A polyclonal antibody to GAS41 showed a dotted staining pattern in interphase nuclei and a uniform distribution in mitotic cells. A GFP-GAS41 fusion protein displayed equivalent patterns. In vitro GAS41 bound to the C-terminal part of the rod region of NuMA, as shown by dot overlay and by surface plasmon resonance measurements. The K-d of the complex was 2 x 10(-7) M. GAS41 is related to the AF-9 and ENL proteins, which are putative transcription factors found as fusion proteins in some acute leukemias. The NuMA/GAS41 interaction may provide a link between nuclear structure and gene expression.	Max Planck Inst Biophys Chem, Dept Biochem, D-37077 Gottingen, Germany	Max Planck Society	Harborth, J (corresponding author), Max Planck Inst Biophys Chem, Dept Biochem, Fassberg 11, D-37077 Gottingen, Germany.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COMPTON DA, 1995, J CELL SCI, V108, P621; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; FERAMISCO JR, 1980, J BIOL CHEM, V255, P4240; Fischer U, 1997, HUM MOL GENET, V6, P1817, DOI 10.1093/hmg/6.11.1817; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Gueth-Hallonet C, 1998, EXP CELL RES, V243, P434, DOI 10.1006/excr.1998.4178; Harborth J, 1999, EMBO J, V18, P1689, DOI 10.1093/emboj/18.6.1689; HARBORTH J, 1995, EMBO J, V14, P2447, DOI 10.1002/j.1460-2075.1995.tb07242.x; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; KALLAJOKI M, 1991, EMBO J, V10, P3351, DOI 10.1002/j.1460-2075.1991.tb04899.x; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LUDERUS MEE, 1994, MOL CELL BIOL, V14, P6297, DOI 10.1128/MCB.14.9.6297; LYDERSEN BK, 1980, CELL, V22, P489, DOI 10.1016/0092-8674(80)90359-1; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; NISHIKAWA K, 1983, BIOCHIM BIOPHYS ACTA, V748, P285, DOI 10.1016/0167-4838(83)90306-0; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SPARKS CA, 1995, J CELL SCI, V108, P3389; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; YANG CH, 1992, J CELL BIOL, V116, P1303, DOI 10.1083/jcb.116.6.1303; YANG CH, 1992, MOL BIOL CELL, V3, P1259, DOI 10.1091/mbc.3.11.1259	31	38	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31979	31985		10.1074/jbc.M000994200	http://dx.doi.org/10.1074/jbc.M000994200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10913114	hybrid, Green Published			2022-12-27	WOS:000089858900060
J	Kanda, K; Hu, HM; Zhang, L; Grandchamps, J; Boxer, LM				Kanda, K; Hu, HM; Zhang, L; Grandchamps, J; Boxer, LM			NF-kappa B activity is required for the deregulation of c-myc expression by the immunoglobulin heavy chain enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; VIRTUALLY IDENTICAL ENHANCERS; BURKITTS-LYMPHOMA CELLS; ALPHA PROTEOLYSIS; 3'-IGH ENHANCER; TRANSCRIPTION; PHOSPHORYLATION; IDENTIFICATION; ACTIVATION; DOWNSTREAM	The c-myc gene is translocated to one of the immunoglobulin genes in Burkitt's lymphoma resulting in deregulated expression of c-myc. Several enhancers have been shown to be important for expression of the immunoglobulin heavy chain gene. Four enhancer regions (murine-hypersensitive sites (MHS) 1, 2, 3, and 4) located 3' of the murine immunoglobulin heavy chain gene play a role in activating expression of the translocated c-myc gene. The enhancer regions also result in a shift in transcriptional initiation from the P2 promoter to P1 that is characteristic of the translocated c-myc allele. We found that the most 3' enhancer region (MHS4) activated the c-myc promoter by 46-fold in the Raji Burkitt's lymphoma cell line, and it was the most active enhancer in these cells. The addition of enhancer regions MHS1,2 and 3 to MHS4 increased c-myc transcription by an additional 3-fold and resulted in the full promoter shift from Pa to P1. By deletion analysis of enhancer region MHS4, we located a region that was critical for the transcriptional activity of MHS4. Electrophoretic mobility shift assay analysis revealed that NF-kappa B/Rel family members bound to this region. Mutation of the NF-kappa B binding site abolished both the enhancer activity and the promoter shift activity of MHS4. An active NF-kappa B site was also identified in the human HS4 enhancer. Inhibition of c-myc promoter activity driven by the immunoglobulin enhancers was observed with expression of a super-repressor I kappa B alpha construct. These results indicate that the NF-kappa B/Rel transcription factors play an important role in the deregulation of the translocated c-myc gene in Burkitt's lymphoma and suggest that interference with NF-kappa B function may represent a new approach to the treatment of Burkitt's lymphoma.	Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Ctr Mol Biol Med, Palo Alto, CA 94305 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Boxer, LM (corresponding author), Stanford Univ, Sch Med, Dept Med, S-161, Stanford, CA 94305 USA.				NCI NIH HHS [CA69322] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069322] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bergan R, 1996, BLOOD, V88, P731, DOI 10.1182/blood.V88.2.731.bloodjournal882731; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chauveau C, 1998, EUR J IMMUNOL, V28, P3048, DOI 10.1002/(SICI)1521-4141(199810)28:10<3048::AID-IMMU3048>3.0.CO;2-V; Chen CQ, 1997, J IMMUNOL, V159, P1310; COGNE M, 1994, CELL, V77, P737, DOI 10.1016/0092-8674(94)90057-4; DARIAVACH P, 1991, EUR J IMMUNOL, V21, P1499, DOI 10.1002/eji.1830210625; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; HUANG Y, 1995, MOL MED, V1, P647, DOI 10.1007/BF03401605; JI L, 1995, J BIOL CHEM, V270, P13392, DOI 10.1074/jbc.270.22.13392; JI L, 1994, MOL CELL BIOL, V14, P7967, DOI 10.1128/MCB.14.12.7967; KESSLER DJ, 1992, ONCOGENE, V7, P2447; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; Madisen L, 1998, MOL CELL BIOL, V18, P6281, DOI 10.1128/MCB.18.11.6281; MCMANAWAY ME, 1990, LANCET, V335, P808, DOI 10.1016/0140-6736(90)90934-W; Michaelson JS, 1996, J IMMUNOL, V156, P2828; MICHAELSON JS, 1995, NUCLEIC ACIDS RES, V23, P975, DOI 10.1093/nar/23.6.975; Mills FC, 1997, J EXP MED, V186, P845, DOI 10.1084/jem.186.6.845; Ong J, 1998, J IMMUNOL, V160, P4896; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; PETTERSSON S, 1990, NATURE, V344, P165, DOI 10.1038/344165a0; Pinaud E, 1997, EUR J IMMUNOL, V27, P2981, DOI 10.1002/eji.1830271134; Saleque S, 1997, J IMMUNOL, V158, P4780; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SHIRAMIZU B, 1991, BLOOD, V77, P1516; Smith JB, 1998, J NATL CANCER I, V90, P1146, DOI 10.1093/jnci/90.15.1146; Snapper CM, 1996, J IMMUNOL, V156, P183; STROBL LJ, 1993, ONCOGENE, V8, P1437; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; Tang H, 1999, IMMUNITY, V11, P517, DOI 10.1016/S1074-7613(00)80127-2; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Williams SA, 1997, ANN ONCOL, V8, P25, DOI 10.1023/A:1008289430541	36	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32338	32346		10.1074/jbc.M004148200	http://dx.doi.org/10.1074/jbc.M004148200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10931834	hybrid			2022-12-27	WOS:000089858900107
J	Liang, JS; Wu, XY; Fisher, EA; Ginsberg, HN				Liang, JS; Wu, XY; Fisher, EA; Ginsberg, HN			The amino-terminal domain of apolipoprotein B does not undergo retrograde translocation from the endoplasmic reticulum to the cytosol - Proteasomal degradation of nascent apolipoprotein B begins at the carboxyl terminus of the protein, while apolipoprotein B is still in its original, translocon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; HEP G2 CELLS; INTRACELLULAR DEGRADATION; CONTAINING LIPOPROTEINS; SECRETORY PROTEIN; ER DEGRADATION; PAUSE TRANSFER; MEMBRANE; UBIQUITIN; PATHWAY	We studied the sequential topology of the NH, and COOH termini of apoB during translocation by expressing, in Chinese hamster ovary (CHO) and HepG2 cells, an apoB42 construct with c-Myc and hemagglutinin (HA) tags at 2 and 41% (relative to apoB100) of its amino acid sequence. We conducted similar studies using monoclonal antibodies against the NH, and COOH termini of apoB100 in HepG2 cells. After radiolabeling, microsomes were immunoisolated from transfected CHO cells using anti-c-Mye or anti-HA antibodies. Throughout a 60-min chase in the presence of N-acetyl-leucylnorleucinal, more than 90% of microsomes were isolated by anti-HA antibodies, whereas less than 10% were isolated by anti-c-Mye antibodies. Proteinase K digestion of total microsomes consistently generated two fragments (similar to 70 and similar to 120 kDa) of apoB42 containing the NH, terminus throughout the chase; no fragments containing the COOH terminus were detected. Immunofluorescent studies of transfected CHO cells were consistent with results from the labeling studies. Essentially identical results were obtained from pulse-chase studies in both native and apoB42-transfected HepG2 cells. The present studies support a model in which, in the absence of adequate core lipid synthesis, there is partial translocation of apoB leading to cytosolic exposure, ubiquitination, and proteasomal degradation directly from the original translocation channel.	Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Mt Sinai Sch Med, Cardiovasc Inst, Lab Lipoprot Res, New York, NY 10029 USA	Columbia University; Icahn School of Medicine at Mount Sinai	Liang, JS (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Med, 630 W 168th St, New York, NY 10032 USA.	jl698@columbia.edu		Fisher, Edward/0000-0001-9802-143X	NHLBI NIH HHS [T32 HL07343, HL58541, HL55638] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007343, R01HL058541, R01HL055638] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; Corsi AK, 1996, J BIOL CHEM, V271, P30299, DOI 10.1074/jbc.271.48.30299; Cresswell P, 1997, CURR BIOL, V7, pR552, DOI 10.1016/S0960-9822(06)00279-X; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; DAVIS RA, 1989, J LIPID RES, V30, P1185; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DU EZ, 1994, J BIOL CHEM, V269, P24169; Du XB, 1998, J CELL BIOL, V141, P585, DOI 10.1083/jcb.141.3.585; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Huang XF, 1999, J LIPID RES, V40, P2212; Ingram MF, 1997, J BIOL CHEM, V272, P10279; Kivlen MH, 1997, J LIPID RES, V38, P1149; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; LIANG J, 1988, J BIOL CHEM, V273, P35216; Liao W, 1998, J BIOL CHEM, V273, P27225, DOI 10.1074/jbc.273.42.27225; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; Pease RJ, 1996, CURR OPIN LIPIDOL, V7, P132, DOI 10.1097/00041433-199606000-00004; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; Rusinol AE, 1998, J LIPID RES, V39, P1287; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; Shelness GS, 1999, J NUTR, V129, p456S, DOI 10.1093/jn/129.2.456S; SPARKS JD, 1992, J CLIN INVEST, V89, P1418, DOI 10.1172/JCI115731; STEINBERG D, 1989, CIRCULATION, V80, P719, DOI 10.1161/01.CIR.80.3.719; Suzuki T, 1998, J BIOL CHEM, V273, P10083, DOI 10.1074/jbc.273.17.10083; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Yao ZM, 1997, J LIPID RES, V38, P1937; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	42	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32003	32010		10.1074/jbc.M004646200	http://dx.doi.org/10.1074/jbc.M004646200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10922368	hybrid			2022-12-27	WOS:000089858900063
J	Liu, PS; Wang, PY; Michaely, P; Zhu, MF; Anderson, RGW				Liu, PS; Wang, PY; Michaely, P; Zhu, MF; Anderson, RGW			Presence of oxidized cholesterol in caveolae uncouples active platelet-derived growth factor receptors from tyrosine kinase substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; MEDIATED ENDOCYTOSIS; SIGNAL-TRANSDUCTION; BILAYER MEMBRANES; LIPID-MEMBRANES; CULTURED-CELLS; OXIDATION; ORGANIZATION; LOCALIZATION; MODULATION	Platelet-derived growth factor receptor beta (PDGFR beta) in fibroblasts is concentrated in caveolae where it controls the tyrosine phosphorylation of multiple proteins. Caveolae are enriched in cholesterol and sphingolipids, but the role of these lipids in PDGFR signal transduction is unknown. We report that introduction of cholest-4-en-3-one into caveolae membranes uncouples PDGFR autophosphorylation from tyrosine phosphorylation of neighboring proteins. Cholest-4-en-3-one appears to interfere with the normal interaction between PDGFR and its partners. The results suggest that tightly packed caveolae lipids form a membrane platform that functions as a lipid scaffold for organizing the molecular interactions of multiple signaling pathways.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Anderson, RGW (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Liu, Pingsheng/B-7124-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052016] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline; NIGMS NIH HHS [GM 52016] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; Claesson-Welsh Lena, 1994, Progress in Growth Factor Research, V5, P37, DOI 10.1016/0955-2235(94)90016-7; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; GAMBLE W, 1978, J LIPID RES, V19, P1068; Gil T, 1998, BBA-REV BIOMEMBRANES, V1376, P245, DOI 10.1016/S0304-4157(98)00022-7; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; LAU WF, 1995, EXPERIENTIA, V51, P731, DOI 10.1007/BF01941271; Liu PS, 1999, BIOCHEM BIOPH RES CO, V261, P695, DOI 10.1006/bbrc.1999.1082; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; LUU B, 1991, BIOCHIMIE, V73, P1317, DOI 10.1016/0300-9084(91)90095-I; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; OWICKI JC, 1978, P NATL ACAD SCI USA, V75, P1616, DOI 10.1073/pnas.75.4.1616; OWICKI JC, 1979, P NATL ACAD SCI USA, V76, P4750, DOI 10.1073/pnas.76.10.4750; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; SMITH RM, 1990, ENDOCRINOLOGY, V126, P1551, DOI 10.1210/endo-126-3-1551; TOMASKA L, 1993, J BIOL CHEM, V268, P5317; Verhagen JCD, 1996, J LIPID RES, V37, P1488; WOOD WG, 1995, BRAIN RES, V683, P36; YATES AJ, 1995, J NEURO-ONCOL, V24, P65, DOI 10.1007/BF01052661	36	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31648	31654		10.1074/jbc.M004599200	http://dx.doi.org/10.1074/jbc.M004599200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10918056	hybrid			2022-12-27	WOS:000089858900016
J	Solban, N; Jia, HP; Richard, S; Tremblay, S; Devlin, AM; Peng, JZ; Gossard, F; Guo, DF; Morel, G; Hamet, P; Lewanczuk, R; Tremblay, J				Solban, N; Jia, HP; Richard, S; Tremblay, S; Devlin, AM; Peng, JZ; Gossard, F; Guo, DF; Morel, G; Hamet, P; Lewanczuk, R; Tremblay, J			HCaRG, a novel calcium-regulated gene coding for a nuclear protein, is potentially involved in the regulation of cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR CALCIUM; CA2+-SENSING RECEPTOR; FUNCTIONAL EXPRESSION; TRANSCRIPTION FACTOR; HYPERTENSIVE RATS; MOLECULAR-CLONING; PARATHYROID CELLS; SENSING RECEPTOR; BLOOD-PRESSURE; RENIN-ACTIVITY	Since a negative calcium balance is present in spontaneously hypertensive rats, we searched for the gene(s) involved in this dysregulation. A cDNA library was constructed from the spontaneously hypertensive rat parathyroid gland, which is a key regulator of serum-ionized calcium. From seven overlapping DNA fragments, a 1100-base pair novel cDNA containing an open reading frame of 224 codons was reconstituted. This novel gene, named HCaRG (hypertension-related, calcium-regulated gene), was negatively regulated by extracellular calcium con centration, and its basal mRNA levels were higher in hypertensive animals. The deduced protein showed no transmembrane domain, 67% alpha-helix content, a mutated calcium-binding site (EF-hand motif), four putative "leucine zipper" moths, and a nuclear receptor-binding domain. At the subcellular level, HCaRG had a nuclear localization. We cloned the human homolog of this gene. Sequence comparison revealed 80% homology between rats and humans at the nucleotide and amino acid sequences. Tissue distribution showed a preponderance in the heart, stomach, jejunum, kidney (tubular fraction), liver, and adrenal gland (mainly in the medulla). HCaRG mRNA was significantly more expressed in adult than in fetal organs, and its levels were decreased in tumors and cancerous cell lines. We observed that after 60-min ischemia followed by reperfusion, HCaRG mRNA declined rapidly in contrast with an increase in c-myc mRNA. Its levels then rose steadily to exceed base Line at 48 h of reperfusion. HEK293 cells stably transfected with HCaRG exhibited much lower proliferation, as shown by cell count and [H-3]thymidine incorporation. Taken together, our results suggest that HCaRG is a nuclear protein potentially involved in the control of cell proliferation.	CHU Montreal, Hotel Dieu, Lab Cellular Biol Hypertens, Ctr Rech, Montreal, PQ H2W 1T8, Canada; Univ Alberta, Dept Endocrinol, Edmonton, AB T6G 2S2, Canada; Univ Lyon 1, F-69365 Lyon, France	Laval University; Universite de Montreal; University of Alberta; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Tremblay, J (corresponding author), CHU Montreal, Hotel Dieu, Lab Cellular Biol Hypertens, Ctr Rech, 3850 St Urbain St, Montreal, PQ H2W 1T8, Canada.		jia, jhp@mm8899/AAH-6611-2020; Cossette, Suzanne/I-8008-2016					Arthur JM, 1997, AM J PHYSIOL-RENAL, V273, pF129, DOI 10.1152/ajprenal.1997.273.1.F129; BACALLAO R, 1989, AM J PHYSIOL, V257, pF913, DOI 10.1152/ajprenal.1989.257.6.F913; BENISHIN CG, 1991, P NATL ACAD SCI USA, V88, P6372, DOI 10.1073/pnas.88.14.6372; Benishin CG, 1999, AM J HYPERTENS, V12, P1260, DOI 10.1016/S0895-7061(99)00173-9; BONVENTRE JV, 1995, EXP NEPHROL, V3, P159; Brown Edward M., 1996, American Journal of the Medical Sciences, V312, P99; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIRILLO M, 1989, AM J HYPERTENS, V2, P741, DOI 10.1093/ajh/2.10.741; Cohn David V., 1994, P107; DRUEKE T, 1994, AM J MED SCI S, V307, P96; ERNE P, 1989, HYPERTENSION, V14, P145, DOI 10.1161/01.HYP.14.2.145; FEINLEIB M, 1984, SCIENCE, V226, P384, DOI 10.1126/science.6494890; Franz C, 1998, J BIOL CHEM, V273, P18826, DOI 10.1074/jbc.273.30.18826; FRIED TA, 1984, AM J PHYSIOL, V247, pF568, DOI 10.1152/ajprenal.1984.247.4.F568; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; Gomez E, 1997, BIOL REPROD, V56, P1513, DOI 10.1095/biolreprod56.6.1513; HATTON DC, 1994, HYPERTENSION, V23, P513, DOI 10.1161/01.HYP.23.4.513; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Huang ZQ, 1999, J BIOL CHEM, V274, P7640, DOI 10.1074/jbc.274.12.7640; Kato A, 1997, NEPHRON, V75, P72, DOI 10.1159/000189502; KATO A, 1995, KIDNEY INT, V48, P1577, DOI 10.1038/ki.1995.450; KAY LE, 1991, BIOCHEMISTRY-US, V30, P4323, DOI 10.1021/bi00231a031; KIFOR O, 1992, J BONE MINER RES, V7, P1327; Kifor O, 1997, J BONE MINER RES, V12, P715, DOI 10.1359/jbmr.1997.12.5.715; Knuutila S, 1998, AM J PATHOL, V152, P1107; Kohn WD, 1997, J BIOL CHEM, V272, P2583, DOI 10.1074/jbc.272.5.2583; KUNES J, 1986, CLIN SCI, V70, P185, DOI 10.1042/cs0700185; LINSE S, 1993, PROTEIN SCI, V2, P985, DOI 10.1002/pro.5560020612; Lobie PE, 1999, EXP CELL RES, V246, P47, DOI 10.1006/excr.1998.4288; MCHAFFIE GS, 1995, BONE, V17, P11, DOI 10.1016/8756-3282(95)00131-V; Mckusick V.A., 1994, MENDELIAN INHERITANC; MOLITORIS BA, 1988, J MEMBRANE BIOL, V106, P233, DOI 10.1007/BF01872161; Mueller A, 1999, HISTOCHEM CELL BIOL, V111, P453, DOI 10.1007/s004180050381; Nakajima T, 1996, AM J PHYSIOL-RENAL, V271, pF846, DOI 10.1152/ajprenal.1996.271.4.F846; NYGREN P, 1988, BIOCHIM BIOPHYS ACTA, V968, P253, DOI 10.1016/0167-4889(88)90014-6; OKAZAKI T, 1992, J CLIN INVEST, V89, P1268, DOI 10.1172/JCI115711; Onyango I, 1999, EXP CELL RES, V247, P9, DOI 10.1006/excr.1998.4324; ORLOV SN, 1995, SEMIN NEPHROL, V15, P569; REID RE, 1981, J BIOL CHEM, V256, P2742; Resnick Lawrence M., 1995, P1169; RESNICK LM, 1987, AM J MED, V82, P16, DOI 10.1016/0002-9343(87)90267-1; RESNICK LM, 1983, NEW ENGL J MED, V309, P888, DOI 10.1056/NEJM198310133091504; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; SHAW GS, 1992, BIOCHEMISTRY-US, V31, P9572, DOI 10.1021/bi00155a009; SHAW GS, 1994, PROTEIN SCI, V3, P1010, DOI 10.1002/pro.5560030703; SOWERS JR, 1989, J LAB CLIN MED, V114, P338; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; WALLIN A, 1992, LAB INVEST, V66, P474; Wicki R, 1997, CELL CALCIUM, V22, P243, DOI 10.1016/S0143-4160(97)90063-4; WITZGALL R, 1993, MOL CELL BIOL, V13, P1933, DOI 10.1128/MCB.13.3.1933; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514	55	37	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32234	32243		10.1074/jbc.M001352200	http://dx.doi.org/10.1074/jbc.M001352200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10918053	hybrid			2022-12-27	WOS:000089858900094
J	Vaulont, S; Vasseur-Cognet, M; Kahn, A				Vaulont, S; Vasseur-Cognet, M; Kahn, A			Glucose regulation of gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PYRUVATE-KINASE GENE; FATTY-ACID SYNTHASE; UPSTREAM STIMULATORY FACTOR; ACTIVATED PROTEIN-KINASE; PANCREATIC BETA-CELLS; CARBOHYDRATE RESPONSE ELEMENT; PENTOSE-PHOSPHATE PATHWAY; LIPOGENIC ENZYME GENES; RAT HEPATOCYTES; S14 GENE		Univ Paris 05, INSERM U129, ICGM, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier	Vaulont, S (corresponding author), Univ Paris 05, INSERM U129, ICGM, 24 Rue Faubourg St Jacques, F-75014 Paris, France.	vaulont@cochin.inserm.fr	Vasseur, Mireille/L-6958-2017; Vaulont, Sophie/O-6732-2017	Vasseur, Mireille/0000-0001-6963-4114; 				Antoine B, 1997, J BIOL CHEM, V272, P17937, DOI 10.1074/jbc.272.29.17937; Ayala JE, 1999, DIABETES, V48, P1885, DOI 10.2337/diabetes.48.9.1885; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; Burcelin R, 2000, J BIOL CHEM, V275, P10930, DOI 10.1074/jbc.275.15.10930; Carlson M, 1998, CURR OPIN GENET DEV, V8, P560, DOI 10.1016/S0959-437X(98)80011-7; Casado M, 1999, J BIOL CHEM, V274, P2009, DOI 10.1074/jbc.274.4.2009; Chen YQ, 1998, J BIOL CHEM, V273, P8225, DOI 10.1074/jbc.273.14.8225; CUIF MH, 1993, J BIOL CHEM, V268, P13769; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; Daniel S, 1996, J BIOL CHEM, V271, P1385, DOI 10.1074/jbc.271.3.1385; Datta U, 1999, BBA-GENE STRUCT EXPR, V1447, P236, DOI 10.1016/S0167-4781(99)00158-X; Doiron B, 1996, J BIOL CHEM, V271, P5321, DOI 10.1074/jbc.271.10.5321; Ferber S, 2000, NAT MED, V6, P568, DOI 10.1038/75050; Fleischmann M, 2000, BIOCHEM J, V349, P13, DOI 10.1042/bj3490013; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Foretz M, 1998, J BIOL CHEM, V273, P14767, DOI 10.1074/jbc.273.24.14767; Fukuda H, 1999, FEBS LETT, V464, P113, DOI 10.1016/S0014-5793(99)01700-7; Fukuda H, 1999, FEBS LETT, V455, P165, DOI 10.1016/S0014-5793(99)00877-7; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; Gourdon L, 1999, FEBS LETT, V459, P9, DOI 10.1016/S0014-5793(99)01203-X; Goya L, 1999, J BIOL CHEM, V274, P24633, DOI 10.1074/jbc.274.35.24633; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; Guillam MT, 1998, P NATL ACAD SCI USA, V95, P12317, DOI 10.1073/pnas.95.21.12317; Guillemain G, 2000, J CELL SCI, V113, P841; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; GUZ Y, 1995, DEVELOPMENT, V121, P11; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Hani EH, 1999, J CLIN INVEST, V104, pR41, DOI 10.1172/JCI7469; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hasegawa J, 1999, J BIOL CHEM, V274, P1100, DOI 10.1074/jbc.274.2.1100; Johnston M, 1999, TRENDS GENET, V15, P29, DOI 10.1016/S0168-9525(98)01637-0; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Josefsen K, 1999, DIABETOLOGIA, V42, P195, DOI 10.1007/s001250051139; Kahn A, 2000, NAT MED, V6, P505, DOI 10.1038/74980; Kaytor EN, 1997, J BIOL CHEM, V272, P7525, DOI 10.1074/jbc.272.11.7525; Koo SH, 2000, J BIOL CHEM, V275, P5200, DOI 10.1074/jbc.275.7.5200; Leclerc I, 1998, FEBS LETT, V431, P180, DOI 10.1016/S0014-5793(98)00745-5; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; Lou DQ, 1999, J BIOL CHEM, V274, P28385, DOI 10.1074/jbc.274.40.28385; Macfarlane WM, 1999, J CLIN INVEST, V104, pR33, DOI 10.1172/JCI7449; MacFarlane WM, 1999, J BIOL CHEM, V274, P34059, DOI 10.1074/jbc.274.48.34059; Macfarlane WM, 1999, J BIOL CHEM, V274, P1011, DOI 10.1074/jbc.274.2.1011; MARIE S, 1993, J BIOL CHEM, V268, P23881; Massillon D, 1998, J BIOL CHEM, V273, P228, DOI 10.1074/jbc.273.1.228; Mater MK, 1999, J BIOL CHEM, V274, P32725, DOI 10.1074/jbc.274.46.32725; Moon YA, 1999, EXP MOL MED, V31, P108, DOI 10.1038/emm.1999.18; Moriizumi S, 1998, GENE EXPRESSION, V7, P103; Mourrieras F, 1997, BIOCHEM J, V326, P345, DOI 10.1042/bj3260345; Olson AL, 1996, ANNU REV NUTR, V16, P235, DOI 10.1146/annurev.nu.16.070196.001315; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Portois L, 1999, J BIOL CHEM, V274, P8181, DOI 10.1074/jbc.274.12.8181; Rafiq I, 2000, J BIOL CHEM, V275, P15977, DOI 10.1074/jbc.275.21.15977; Rafiq I, 1998, J BIOL CHEM, V273, P23241, DOI 10.1074/jbc.273.36.23241; Salt I, 1998, BIOCHEM J, V334, P177, DOI 10.1042/bj3340177; Salt IP, 1998, BIOCHEM J, V335, P533, DOI 10.1042/bj3350533; Santer R, 1997, NAT GENET, V17, P324, DOI 10.1038/ng1197-324; Sayeski PP, 1996, J BIOL CHEM, V271, P15237, DOI 10.1074/jbc.271.25.15237; Schafer D, 1997, FEBS LETT, V417, P325, DOI 10.1016/S0014-5793(97)01314-8; Scott DK, 1998, J BIOL CHEM, V273, P24145, DOI 10.1074/jbc.273.37.24145; Seijffers R, 1999, ENDOCRINOLOGY, V140, P3311, DOI 10.1210/en.140.7.3311; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; SHIH HM, 1992, J BIOL CHEM, V267, P13222; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Stoffers DA, 1998, J CLIN INVEST, V102, P232, DOI 10.1172/JCI2242; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Towle HC, 1997, ANNU REV NUTR, V17, P405, DOI 10.1146/annurev.nutr.17.1.405; Vallet VS, 1997, J BIOL CHEM, V272, P21944, DOI 10.1074/jbc.272.35.21944; Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; Viollet B, 1997, MOL CELL BIOL, V17, P4208, DOI 10.1128/MCB.17.8.4208; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; Wang JL, 1998, NATURE, V393, P684, DOI 10.1038/31474; Wu H, 1999, BIOCHEM J, V344, P813, DOI 10.1042/0264-6021:3440813; Xavier GD, 2000, P NATL ACAD SCI USA, V97, P4023, DOI 10.1073/pnas.97.8.4023; Yamada K, 1999, BIOCHEM BIOPH RES CO, V257, P44, DOI 10.1006/bbrc.1999.0410; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	81	212	221	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31555	31558		10.1074/jbc.R000016200	http://dx.doi.org/10.1074/jbc.R000016200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10934218	hybrid			2022-12-27	WOS:000089858900001
J	Amemiya-Kudo, M; Shimano, H; Yoshikawa, T; Yahagi, N; Hasty, AH; Okazaki, H; Tamura, Y; Shionoiri, F; Iizuka, Y; Ohashi, K; Osuga, J; Harada, K; Gotoda, T; Sato, R; Kimura, S; Ishibashi, S; Yamada, N				Amemiya-Kudo, M; Shimano, H; Yoshikawa, T; Yahagi, N; Hasty, AH; Okazaki, H; Tamura, Y; Shionoiri, F; Iizuka, Y; Ohashi, K; Osuga, J; Harada, K; Gotoda, T; Sato, R; Kimura, S; Ishibashi, S; Yamada, N			Promoter analysis of the mouse sterol regulatory element-binding protein-1c gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; SREBP-1C MESSENGER-RNA; TRANSGENIC MICE; CHOLESTEROL-SYNTHESIS; TRANSCRIPTION FACTOR; SYNTHASE PROMOTER; ADIPOSE-TISSUE; CULTURED-CELLS; NF-Y; EXPRESSION	Recent data suggest that sterol regulatory-binding protein (SREBP)-1c plays a key role in the transcriptional regulation of different lipogenic genes mediating lipid synthesis as a key regulator of fuel metabolism. SREBP-1c regulates its downstream genes by changing its own mRNA level, which led us to sequence and analyze the promoter region of the mouse SREBP-1c gene. A cluster of putative binding sites of several transcription factors composed of an NF-Y site, an E-box, a sterol-regulatory element 3, and an Spl site were located at -90 base pairs of the SREBP-1c promoter. Luciferase reporter gene assays indicated that this SRE complex is essential to the basal promoter activity and confers responsiveness to activation by nuclear SREBPs, Deletion and mutation analyses suggest that the NF-Y site and SRE3 in the SRE complex are responsible for SREBP activation, although the other sites were also involved in the basal activity. Gel mobility shift assays demonstrate that SREBP-1 binds to the SRE3, Taken together, these findings implicate a positive loop production of SREBP-1c through the SRE complex, possibly leading to the overshoot in induction of SREBP-1c and its downstream genes seen in the livers of refed mice. Furthermore, reporter assays using larger upstream fragments indicated another region that was inducible by addition of sterols. The presence of the SRE complex and a sterol-inducible region in the same promoter suggests a novel regulatory Link between cholesterol and fatty acid synthesis.	Univ Tsukuba, Inst Clin Med, Dept Internal Med, Tsukuba, Ibaraki 3058575, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Metab Dis, Fac Med, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo 1138655, Japan	University of Tsukuba; University of Tokyo; University of Tokyo	Shimano, H (corresponding author), Univ Tsukuba, Inst Clin Med, Dept Internal Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	shimano-tky@umin.ac.jp	Shimano, Hitoshi/AAI-5648-2020; Hasty, Alyssa/AAA-2757-2020; Yahagi, Naoya/D-2360-2014; Shimano, Hitoshi/V-1761-2019	Hasty, Alyssa/0000-0001-7302-8045; Yahagi, Naoya/0000-0002-1823-1865; Shimano, Hitoshi/0000-0002-5562-5572				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; GOODRIDGE AG, 1987, ANNU REV NUTR, V7, P157, DOI 10.1146/annurev.nu.07.070187.001105; Hasty AH, 2000, J BIOL CHEM, V275, P31069, DOI 10.1074/jbc.M003335200; HEINEMEYER T, 1999, NUCLEIC ACIDS RES, V26, P364; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; Kim HJ, 1999, J BIOL CHEM, V274, P25892, DOI 10.1074/jbc.274.36.25892; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Koo SH, 2000, J BIOL CHEM, V275, P5200, DOI 10.1074/jbc.275.7.5200; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Magana MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Soukas A, 2000, GENE DEV, V14, P963; Thewke DP, 1998, J BIOL CHEM, V273, P21402, DOI 10.1074/jbc.273.33.21402; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; WANG XD, 1993, J BIOL CHEM, V268, P14497; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537; Xiong SB, 2000, P NATL ACAD SCI USA, V97, P3948, DOI 10.1073/pnas.040574197; Xu J, 1999, J BIOL CHEM, V274, P23577, DOI 10.1074/jbc.274.33.23577; Yahagi N, 1999, J BIOL CHEM, V274, P35840, DOI 10.1074/jbc.274.50.35840	38	203	205	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31078	31085		10.1074/jbc.M005353200	http://dx.doi.org/10.1074/jbc.M005353200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10918064	hybrid			2022-12-27	WOS:000089762700048
J	Wallis, R; Dodd, RB				Wallis, R; Dodd, RB			Interaction of mannose-binding protein with associated serine proteases - Effects of naturally occurring mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RA-REACTIVE FACTOR; LECTIN ACTIVATION PATHWAY; HUMAN-COMPLEMENT; MANNAN-BINDING; BACTERICIDAL FACTOR; IMMUNE-SYSTEM; VERTEBRATES; COMPONENTS; SEQUENCE; DOMAIN	Mannose binding protein (MBP; mannose-binding lectin) forms part of the innate immune system. By binding directly to carbohydrates on the surfaces of potential microbial pathogens, MBP and MBP-associated serine proteases (MASPs) can replace antibodies and complement components C1q, C1r, and C1s of the classical complement pathway. In order to investigate the mechanisms of MASP activation by MBP, the cDNAs of rat MASP-1 and -2 have been isolated, and portions encompassing the N-terminal CUB and epidermal growth factor-like domains have been expressed and purified. Biophysical characterization of the purified proteins indicates that each truncated MASP is a Ca2+-independent homodimer in solution, in which the interacting modules include the N-terminal two domains. Binding studies reveal that both MASPs associate independently with rat MBP in a Ca2+-dependent manner through interactions involving the N-terminal three domains. The biophysical properties of the truncated MASPs indicate that the interactions with MBP leading to complement activation differ significantly from those between components C1q, C1r, and C1s of the classical pathway. Analysis of MASP binding by rat MBP containing naturally occurring mutations equivalent to those associated with human immunodeficiency indicates that binding to both truncated MASP-1 and MASP-2 proteins is defective in such mutants.	Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England	University of Oxford	Wallis, R (corresponding author), Univ Oxford, Dept Biochem, Glycobiol Inst, S Parks Rd, Oxford OX1 3QU, England.		Dodd, Roger/B-4917-2008	Wallis, Russell/0000-0002-8705-5295; Dodd, Roger/0000-0003-4268-1863				BUSBY TF, 1990, BIOCHEMISTRY-US, V29, P4613, DOI 10.1021/bi00471a016; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; Eftink MR, 1997, METHOD ENZYMOL, V278, P258; Endo Y, 1998, J IMMUNOL, V161, P4924; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; IOBST ST, 1994, J BIOL CHEM, V269, P15505; Ji X, 1997, P NATL ACAD SCI USA, V94, P6340, DOI 10.1073/pnas.94.12.6340; JI YH, 1993, J IMMUNOL, V150, P571; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P537, DOI 10.1016/0076-6879(90)85044-O; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; Lacroix M, 1997, BIOCHEMISTRY-US, V36, P6270, DOI 10.1021/bi962719i; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING LAB MANU; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; Matsushita M, 1998, CURR OPIN IMMUNOL, V10, P29, DOI 10.1016/S0952-7915(98)80027-7; REID KBM, 1983, BIOCHEM SOC T, V11, P1; Stover CM, 1999, J IMMUNOL, V163, P6848; Stover CM, 1999, J IMMUNOL, V162, P3481; TAKADA F, 1993, BIOCHEM BIOPH RES CO, V196, P1003, DOI 10.1006/bbrc.1993.2349; Takahashi M, 1999, INT IMMUNOL, V11, P859, DOI 10.1093/intimm/11.5.859; TAKAYAMA Y, 1994, J IMMUNOL, V152, P2308; Terai I, 1997, CLIN EXP IMMUNOL, V110, P317; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; THIELENS NM, 1990, J BIOL CHEM, V265, P14469; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; VALERA PF, 1997, J MOL BIOL, V274, P635; Wallis R, 1999, J BIOL CHEM, V274, P3580, DOI 10.1074/jbc.274.6.3580; Wallis R, 1999, J IMMUNOL, V163, P4953; Wallis R, 1997, BIOCHEM J, V325, P391, DOI 10.1042/bj3250391; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x	31	74	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30962	30969		10.1074/jbc.M004030200	http://dx.doi.org/10.1074/jbc.M004030200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10913141	hybrid			2022-12-27	WOS:000089762700034
J	Cabezon, E; Arechaga, I; Butler, PJG; Walker, JE				Cabezon, E; Arechaga, I; Butler, PJG; Walker, JE			Dimerization of bovine F-1-ATPase by binding the inhibitor protein, IF1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUNDARY ANALYSIS; ATP SYNTHASE; SUBUNIT	In mitochondria, the hydrolytic activity of ATP synthase is regulated by a natural inhibitor protein, IF1. The binding of IF1 to ATP synthase depends on pH values, and below neutrality, IF1 forms a stable complex with the enzyme. Bovine IF1 has two oligomeric states, dimer and tetramer, depending on pH values. At pH 6.5, where it is active, IF1 dimerizes by formation of an antiparallel alpha-helical coiled-coil in its C-terminal region. This arrangement places the inhibitory N-terminal regions in opposition, implying that active dimeric IF1 can bind two F-1 domains simultaneously. Evidence of dimerization of F-1-ATPase by binding to IF1 is provided by gel filtration chromatography, analytical ultracentrifugation, and electron microscopy. At present, it is not known whether IF1 can bring about the dimerization of the F1F0-ATPase complex.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; MRC Laboratory Molecular Biology	Walker, JE (corresponding author), MRC, Dunn Human Nutr Unit, Hills Rd, Cambridge CB2 2XY, England.		Cabezon, Elena/K-5874-2014; Arechaga, Ignacio/K-2198-2014	Arechaga, Ignacio/0000-0002-1342-9370; Cabezon, Elena/0000-0002-6177-5016; Walker, John/0000-0001-7929-2162				Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Cabezon E, 2000, J BIOL CHEM, V275, P25460, DOI 10.1074/jbc.M003859200; FABERGE AC, 1974, J MICROSC-PARIS, V20, P241; JACKSON PJ, 1988, FEBS LETT, V229, P224, DOI 10.1016/0014-5793(88)80832-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Orriss GL, 1998, STRUCT FOLD DES, V6, P831, DOI 10.1016/S0969-2126(98)00085-9; PANCHENKO MV, 1985, FEBS LETT, V184, P226, DOI 10.1016/0014-5793(85)80611-6; Philo JS, 2000, ANAL BIOCHEM, V279, P151, DOI 10.1006/abio.2000.4480; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Stafford WF, 1997, CURR OPIN BIOTECH, V8, P14, DOI 10.1016/S0958-1669(97)80152-8; STAFFORD WF, 1994, METHOD ENZYMOL, V240, P478; WALKER JE, 1994, CURR OPIN STRUC BIOL, V4, P912, DOI 10.1016/0959-440X(94)90274-7; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4	15	92	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28353	28355		10.1074/jbc.C000427200	http://dx.doi.org/10.1074/jbc.C000427200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10918052	hybrid			2022-12-27	WOS:000089330700004
J	Ali, BRS; Tjernberg, A; Chait, BT; Field, MC				Ali, BRS; Tjernberg, A; Chait, BT; Field, MC			A microsomal GTPase is required for glycopeptide export from the mammalian endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMANNOSE-TYPE OLIGOSACCHARIDES; QUALITY-CONTROL; SACCHAROMYCES-CEREVISIAE; GUANYLATE KINASE; SECRETORY PATHWAY; HEPG2 CELLS; PROTEIN; TRANSPORT; CYTOSOL; PROTEASOME	Bidirectional transport of proteins via the Sec61p translocon across the endoplasmic reticulum (ER) membrane is a recognized component of the ER quality control machinery. Following translocation and engagement by the luminal quality control system, misfolded and unassembled proteins are exported from the ER lumen back to the cytosol for degradation by the proteasome. Additionally, other ER contents, including oligosaccharides, oligopeptides, and glycopeptides, are efficiently exported from mammalian and yeast systems, indicating that bidirectional transport across ER membranes is a general eukaryotic phenomenon Glycopeptide and protein export from the ER in in vitro systems is both ATP- and cytosol-dependent. Using a well established system to study glycopeptide export and conventional liquid chromatography, we isolated a single polypeptide species of 23 kDa from rat Liver cytosol that was capable of fully supporting glycopeptide export from rat microsomes in the presence of an ATP-regenerating system. The protein was identified by mass spectrometric sequence analysis as guanylate kinase (GK), a housekeeping enzyme critical in the regulation of cellular GTP levels. We confirmed the ability of GK to substitute for complete cytosol by reconstitution of glycopeptide export from rat Liver microsomes using highly purified recombinant GK from Saccharomyces cerevisiae. Most significantly, we found that the GK (and hence the cytosolic component) requirement was fully bypassed by low micromolar concentrations of GDP or GTP. Similarly, export was inhibited by non-hydrolyzable analogues of GDP and GTP, indicating a requirement for GTP hydrolysis. Membrane integrity was fully maintained under assay conditions, as no ER luminal. proteins mere released. Competence for glycopeptide export was abolished by very mild protease treatment of microsomes, indicating the presence of an essential protein on the cytosolic face of the ER membrane. These data demonstrate that export of glycopeptide export is controlled by a microsomal GTPase and is independent of cytosolic protein factors.	Univ London Imperial Coll Sci Technol & Med, Dept Biochem, Wellcome Trust Labs Mol Parasitol, London SW7 2AY, England; Rockefeller Univ, Lab Biol Mass Spectrometry & Gaseous Ion Chem, New York, NY 10021 USA	Imperial College London; Rockefeller University	Field, MC (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biochem, Wellcome Trust Labs Mol Parasitol, Exhibit Rd, London SW7 2AY, England.		Field, Mark/AAD-6455-2021; Ali, Bassam/J-7014-2012	Field, Mark/0000-0002-4866-2885; Ali, Bassam R/0000-0003-1306-6618	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000862] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00862] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ali BRS, 2000, GLYCOBIOLOGY, V10, P383, DOI 10.1093/glycob/10.4.383; Bacik I, 1997, J EXP MED, V186, P479, DOI 10.1084/jem.186.4.479; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; Banhegyi G, 1999, J BIOL CHEM, V274, P12213, DOI 10.1074/jbc.274.18.12213; BERNINSONE P, 1994, J BIOL CHEM, V269, P207; BIEMANN K, 1992, ANNU REV BIOCHEM, V61, P977, DOI 10.1146/annurev.bi.61.070192.004553; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Brady WA, 1996, J BIOL CHEM, V271, P16734, DOI 10.1074/jbc.271.28.16734; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; Cacan R, 2000, GLYCOBIOLOGY, V10, P645, DOI 10.1093/glycob/10.7.645; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Fenyo D, 1998, ELECTROPHORESIS, V19, P998, DOI 10.1002/elps.1150190615; Gaut JR, 1993, CURR OPIN CELL BIOL, V5, P589, DOI 10.1016/0955-0674(93)90127-C; Gillece P, 2000, P NATL ACAD SCI USA, V97, P4609, DOI 10.1073/pnas.090083497; HALL SW, 1986, EUR J BIOCHEM, V161, P551, DOI 10.1111/j.1432-1033.1986.tb10477.x; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Imamura T, 1998, J BIOL CHEM, V273, P11183, DOI 10.1074/jbc.273.18.11183; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Lavoie C, 1996, J CELL SCI, V109, P1415; Li Y, 1996, J BIOL CHEM, V271, P28038, DOI 10.1074/jbc.271.45.28038; Moore SEH, 1999, TRENDS CELL BIOL, V9, P441, DOI 10.1016/S0962-8924(99)01648-7; Moore SEH, 1998, GLYCOBIOLOGY, V8, P373, DOI 10.1093/glycob/8.4.373; MOORE SEH, 1995, EMBO J, V14, P6034, DOI 10.1002/j.1460-2075.1995.tb00292.x; PAIEMENT J, 1983, J CELL BIOL, V96, P1791, DOI 10.1083/jcb.96.6.1791; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Qin J, 1998, RAPID COMMUN MASS SP, V12, P209, DOI 10.1002/(SICI)1097-0231(19980314)12:5<209::AID-RCM141>3.0.CO;2-S; ROELSE J, 1994, J EXP MED, V180, P1591, DOI 10.1084/jem.180.5.1591; ROMISCH K, 1992, P NATL ACAD SCI USA, V89, P7227, DOI 10.1073/pnas.89.15.7227; Romisch K, 1997, P NATL ACAD SCI USA, V94, P6730, DOI 10.1073/pnas.94.13.6730; SaintPol A, 1997, J CELL BIOL, V136, P45, DOI 10.1083/jcb.136.1.45; SCHUMACHER TNM, 1994, J EXP MED, V179, P533, DOI 10.1084/jem.179.2.533; Suzuki T, 1998, J BIOL CHEM, V273, P10083, DOI 10.1074/jbc.273.17.10083; WALTER P, 1979, P NATL ACAD SCI USA, V76, P1795, DOI 10.1073/pnas.76.4.1795; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wilbourn B, 1998, BIOCHEM J, V332, P111, DOI 10.1042/bj3320111; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	38	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33222	33230		10.1074/jbc.M003845200	http://dx.doi.org/10.1074/jbc.M003845200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10913137	Green Published, hybrid			2022-12-27	WOS:000090104600009
J	Johnson, TM; Williamson, NA; Scholz, G; Jaworowski, A; Wettenhall, REH; Dunn, AR; Cheng, HC				Johnson, TM; Williamson, NA; Scholz, G; Jaworowski, A; Wettenhall, REH; Dunn, AR; Cheng, HC			Modulation of the catalytic activity of the Src family tyrosine kinase Hck by autophosphorylation at a novel site in the unique domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PROTEIN-KINASE; SH2 DOMAIN; C-SRC; PHOSPHORYLATION; PEPTIDES; BINDING; SPECIFICITY; SUBSTRATE; P34CDC2	Autophosphorylation is a key event in the activation of protein kinases, In this study, we demonstrate that autophosphorylation of the recombinant Src family kinase Hck leads to a 20-fold increase in its specific enzymatic activity. Hck was found to autophosphorylate readily to a stoichiometry of 1.3 mol of phosphate per mol of enzyme, indicating that the kinase autophosphorylated at more than one site. Solid phase sequencing and two-dimensional mapping of the phosphopeptide fragments derived from the autophosphorylated enzyme revealed that the kinase can undergo autophosphorylation at the following two sites: (i) Tyr-388, which is located to the consensus autophosphorylation site commonly found in the activation loop of many protein kinases, and (ii) Tyr-29, which is located in the unique domain of Hck, lick purified from mouse bone marrow-derived macrophages could also autophosphorylate in vitro at both Tyr-388 and Tyr-29, indicating that naturally occurring Hck can also autophosphorylate at Tyr-29, Furthermore, Hck transiently expressed in human embryonic kidney 293T cells was found to be phosphorylated at Tyr-29 and Tyr-388, proving that lick can also undergo autophosphorylation at both sites in vivo. The recombinant enzyme carrying the mutation of TST-388 to Phe was also able to autophosphorylate at Tyr-29, albeit at a significantly slower rate. A a-fold increase in the specific enzymatic activity was seen with this mutant despite the stoichiometry of autophosphorylation only approaching 0.2 mol of phosphate per mol of enzyme. This indicates that autophosphorylation of Tyr-29 contributes significantly to the activation of Hck. Regulation of the catalytic activity by phosphorylation of Tyr-29 in the unique domain may represent a new mechanism of regulation of Src family tyrosine kinases.	Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia; Univ Melbourne, Dept Med, Parkville, Vic 3052, Australia; Ludwig Inst Canc Res, Melbourne Tumour Biol Branch, Melbourne, Vic 3050, Australia	University of Melbourne; University of Melbourne; Ludwig Institute for Cancer Research	Cheng, HC (corresponding author), Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia.	h.cheng@biochemistry.unimelb.edu.au	Williamson, Nicholas A/O-9812-2016	Williamson, Nicholas A/0000-0002-2173-3452; Scholz, Glen/0000-0003-2722-6344; jaworowski, anthony/0000-0002-3844-805X; Cheng, Heung-Chin/0000-0002-4965-7148				AEHERSOLD R, 1993, PRACTICAL GUIDE PEPT, P71; ALLEN G, 1981, SEQUENCING PROTEINS, P53; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CAMPBELL KS, 1995, EUR J IMMUNOL, V25, P2408, DOI 10.1002/eji.1830250842; CHENG HC, 1991, J BIOL CHEM, V266, P17919; CHENG HC, 1992, J BIOL CHEM, V267, P9248; COURTNEIDGE SA, 1994, PROTEIN KINASES, P212; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; GRACE TDC, 1962, NATURE, V195, P788, DOI 10.1038/195788a0; Harlow E., 1988, ANTIBODIES LAB MANUA, P298; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Johnson TM, 1997, J PEPT RES, V50, P365; LI CF, 1990, BIOCHEMISTRY-US, V29, P4535, DOI 10.1021/bi00471a005; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOAREFI I, 1997, NATURE, V385, P629; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; ROTH CW, 1983, J BIOL CHEM, V258, P768; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Sicilia RJ, 1998, J BIOL CHEM, V273, P16756, DOI 10.1074/jbc.273.27.16756; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; VAIRO G, 1985, BIOCHEM BIOPH RES CO, V132, P430, DOI 10.1016/0006-291X(85)91040-X; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; WETTENHALL REH, 1991, METHOD ENZYMOL, V201, P186; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	31	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33353	33364		10.1074/jbc.M002022200	http://dx.doi.org/10.1074/jbc.M002022200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10934191	hybrid			2022-12-27	WOS:000090104600027
J	Reinard, T; Janke, V; Willard, J; Buck, F; Jacobsen, HJ; Vockley, J				Reinard, T; Janke, V; Willard, J; Buck, F; Jacobsen, HJ; Vockley, J			Cloning of a gene for an acyl-CoA dehydrogenase from Pisum sativum L. and purification and characterization of its product as an isovaleryl-CoA dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; RAT-LIVER MITOCHONDRIA; MEDIUM-CHAIN; IDENTIFICATION; PROTEIN; PLANTS; CELLS	Isovaleryl-CoA dehydrogenase (IVD, EC 1.3.99.10) catalyzes the third step in the catabolism of leucine in mammals. Deficiency of this enzyme leads to the clinical disorder isovaleric acidemia. IVD has been purified and characterized from human and rat liver, and the x-ray crystallographic structure of purified recombinant human IVD has been reported. Nothing is known about IVD activity in plants, although cDNA clones from Arabidopsis thaliana and partial sequences from Gossypium hirsutum and Oryza sativa have been identified as putative IVDs based on sequence homology and immune cross-reactivity, In this report we describe the identification and characterization of an IVD from pea, purification of the enzyme using a novel and rapid auxin affinity chromatography matrix, and cloning of the corresponding gene. At the amino acid level, pea IVD is 60% similar to human and rat IVD, The specific activity and abundance of plant IVD was found to be significantly lower than for its human counterpart and exhibits developmental regulation. Substrate specificity of the plant enzyme is similar to the human TVD, and it crossreacts to anti-human IVD antibodies. Molecular modeling of the pea enzyme based on the structure of human IVD indicates a high degree of structural similarity among these enzymes. Glu-244, shown to function as the catalytic base in human IVD along with most of the amino acids that make up the acyl CoA binding pocket, is conserved in pea IVD, The genomic structure of the plant IVD gene consists of 13 exons and 12 introns, spanning approximately 4 kilobases, and the predicted RNA splicing sites exhibit the extended consensus sequence described for other plant genes.	Univ Hannover, LG Mol Genet, D-30419 Hannover, Germany; Mayo Clin & Mayo Fdn, Dept Med Genet, Rochester, MN 55905 USA; Univ Hamburg, Krankenhaus Eppendorf, Inst Zellbiochem & Klin Neurobiol, D-20246 Hamburg, Germany	Leibniz University Hannover; Mayo Clinic; University of Hamburg	Reinard, T (corresponding author), Univ Hannover, LG Mol Genet, Herrenhauser Str, D-30419 Hannover, Germany.		Vockley, Jerry/AAF-8523-2020; Vockley, Jerry/B-5210-2016	Vockley, Jerry/0000-0002-8180-6457; Vockley, Jerry/0000-0002-8180-6457	NIDDK NIH HHS [1RO1-DK45482] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045482] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson MD, 1998, PLANT PHYSIOL, V118, P1127, DOI 10.1104/pp.118.4.1127; Aubert S, 1996, FEBS LETT, V383, P175, DOI 10.1016/0014-5793(96)00244-X; Battaile KP, 1998, BBA-LIPID LIPID MET, V1390, P333, DOI 10.1016/S0005-2760(97)00185-9; Daschner K, 1999, PLANT MOL BIOL, V39, P1275; DOYLE JJ, 1990, FOCUS IDAHO, V122, P13; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; Finocchiaro G, 1988, Adv Neurol, V48, P221; Fujiki Yuki, 1997, Plant Physiology (Rockville), V114, P95; FULLMER CS, 1984, ANAL BIOCHEM, V142, P336, DOI 10.1016/0003-2697(84)90473-1; Hebsgaard SM, 1996, NUCLEIC ACIDS RES, V24, P3439, DOI 10.1093/nar/24.17.3439; Hooks MA, 1996, BIOCHEM J, V320, P607, DOI 10.1042/bj3200607; IKEDA Y, 1983, J BIOL CHEM, V258, P1066; IKEDA Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P662, DOI 10.1016/0003-9861(87)90072-5; IKEDA Y, 1983, J BIOL CHEM, V258, P1077; Mohsen AA, 1998, BIOCHEMISTRY-US, V37, P10325, DOI 10.1021/bi973096r; MOHSEN AWA, 1995, GENE, V160, P263, DOI 10.1016/0378-1119(95)00256-6; PARIMOO B, 1993, GENOMICS, V15, P582, DOI 10.1006/geno.1993.1111; REINARD T, 1995, J PLANT PHYSIOL, V147, P132, DOI 10.1016/S0176-1617(11)81425-2; Reinard T, 1998, PLANT CELL PHYSIOL, V39, P874, DOI 10.1093/oxfordjournals.pcp.a029447; Telford EAR, 1999, BBA-GENE STRUCT EXPR, V1446, P371, DOI 10.1016/S0167-4781(99)00102-5; Tiffany KA, 1997, BIOCHEMISTRY-US, V36, P8455, DOI 10.1021/bi970422u; VOCKLEY J, 2000, IN PRESS METHODS ENZ, V324	22	20	20	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33738	33743		10.1074/jbc.M004178200	http://dx.doi.org/10.1074/jbc.M004178200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10913142	hybrid			2022-12-27	WOS:000090104600077
J	Yamauchi, T; Yamauchi, N; Ueki, K; Sugiyama, T; Waki, H; Miki, H; Tobe, K; Matsuda, S; Tsushima, T; Yamamoto, T; Fujita, T; Taketani, Y; Fukayama, M; Kimura, S; Yazaki, Y; Nagai, R; Kadowaki, T				Yamauchi, T; Yamauchi, N; Ueki, K; Sugiyama, T; Waki, H; Miki, H; Tobe, K; Matsuda, S; Tsushima, T; Yamamoto, T; Fujita, T; Taketani, Y; Fukayama, M; Kimura, S; Yazaki, Y; Nagai, R; Kadowaki, T			Constitutive tyrosine phosphorylation of ErbB-2 via Jak2 by autocrine secretion of prolactin in human breast cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HER2/NEU-OVEREXPRESSING METASTATIC BREAST; RAS SIGNALING PATHWAY; GROWTH-HORMONE; NEU ONCOGENE; CARCINOMA-CELLS; FACTOR-RECEPTOR; EGF RECEPTOR; PROTEIN OVEREXPRESSION; MONOCLONAL-ANTIBODY; RECURRENT DISEASE	Overexpression of the oncogene for ErbB-2 is an unfavorable prognostic marker in human breast cancer. Its oncogenic potential appears to depend on the state of tyrosine phosphorylation, However, the mechanisms by which ErbB-2 is constitutively tyrosine-phospholylated in human breast cancer are poorly understood. We now show that human breast carcinoma samples with ErbB-2 overexpression have higher proliferative and metastatic activity in the presence of autocrine secretion of prolactin (PRL). By using a neutralizing antibody or dominant negative (DN) strategies or specific inhibitors, we also show that activation of Janus kinase Jak2 by autocrine secretion of PRL is one of the significant components of constitutive tyrosine phosphorylation of ErbB-2, its association with Grb2 and activation of mitogen-activated protein (MAP) kinase in human breast cancer cell lines that overexpress ErbB-2. Furthermore, the neutralizing anti-PRL antibody or erbB-2 antisense oligonucleotide or DN Jak2 or Jak2 inhibitor or DNRas or MAP kinase kinase inhibitor inhibits the proliferation of both untreated and PRL treated cells. Our results indicate that autocrine secretion of PRL stimulates tyrosine phosphorylation of ErbB-2 by Jak2, provides docking sites for Grb2 and stimulates Ras-MAP kinase cascade, thereby causing unrestricted cellular proliferation. The identification of this novel cross-talk between ErbB-2 and the autocrine growth stimulatory loop for PRL may provide new targets for therapeutic and preventive intervention of human breast cancer.	Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Grad Sch Med, Dept Pathol, Tokyo 113, Japan; Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Nagoya, Aichi 466, Japan; Tokyo Womens Med Coll, Dept Internal Med 2, Tokyo 162, Japan; Univ Tokyo, Inst Med Sci, Dept Oncol, Tokyo 108, Japan; Univ Tokyo, Grad Sch Med, Dept Obstet & Gynecol, Tokyo 113, Japan; Int Med Ctr Japan, Tokyo 162, Japan	University of Tokyo; University of Tokyo; Nagoya University; Tokyo Women's Medical University; University of Tokyo; University of Tokyo; National Center for Global Health & Medicine - Japan	Kadowaki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.		Waki, Hironori/AAE-3942-2020	Waki, Hironori/0000-0002-5302-9793				Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; Chu KC, 1996, JNCI-J NATL CANCER I, V88, P1571, DOI 10.1093/jnci/88.21.1571; Clark JW, 1996, INT J CANCER, V65, P186; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; COLOMER R, 1994, BRIT J CANCER, V70, P819, DOI 10.1038/bjc.1994.405; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; EPSTEIN RJ, 1992, P NATL ACAD SCI USA, V89, P10435, DOI 10.1073/pnas.89.21.10435; ERWIN RA, 1995, ENDOCRINOLOGY, V136, P3512, DOI 10.1210/en.136.8.3512; FUH G, 1995, J BIOL CHEM, V270, P13133, DOI 10.1074/jbc.270.22.13133; GINSBURG E, 1995, CANCER RES, V55, P2591; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; Hortobagyi GN, 1998, NEW ENGL J MED, V339, P974, DOI 10.1056/NEJM199810013391407; HUGHES JP, 1982, ENDOCRINOLOGY, V111, P827, DOI 10.1210/endo-111-3-827; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; JANES PW, 1994, ONCOGENE, V9, P3601; KADOWAKI T, 1987, BIOCHEM BIOPH RES CO, V144, P699, DOI 10.1016/S0006-291X(87)80021-9; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; LEMOINE NR, 1990, ONCOGENE, V5, P227; MAGUIRE HC, 1989, SEMIN ONCOL, V16, P148; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Ng ST, 1997, NAT MED, V3, P1141, DOI 10.1038/nm1097-1141; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PATERSON MC, 1991, CANCER RES, V51, P556; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; PRESS MF, 1993, CANCER RES, V53, P4960; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Reynolds C, 1997, ENDOCRINOLOGY, V138, P5555, DOI 10.1210/en.138.12.5555; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; SUDA Y, 1990, EMBO J, V9, P181, DOI 10.1002/j.1460-2075.1990.tb08094.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; Wennbo H, 1997, J CLIN INVEST, V100, P2744, DOI 10.1172/JCI119820; WIECHEN K, 1995, INT J CANCER, V63, P604, DOI 10.1002/ijc.2910630423; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; WRIGHT C, 1989, CANCER RES, V49, P2087; YAMAMOTO T, 1985, NATURE, V319, P220; Yamauchi N, 1996, INT J GYNECOL PATHOL, V15, P202, DOI 10.1097/00004347-199607000-00003; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yamauchi T, 1998, J BIOL CHEM, V273, P15719, DOI 10.1074/jbc.273.25.15719; ZOLL B, 1992, J CANCER RES CLIN, V118, P468, DOI 10.1007/BF01629432	57	86	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33937	33944		10.1074/jbc.M000743200	http://dx.doi.org/10.1074/jbc.M000743200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10938266	hybrid			2022-12-27	WOS:000090104600104
J	Hoover, DM; Rajashankar, KR; Blumenthal, R; Puri, A; Oppenheim, JJ; Chertov, O; Lubkowski, J				Hoover, DM; Rajashankar, KR; Blumenthal, R; Puri, A; Oppenheim, JJ; Chertov, O; Lubkowski, J			The structure of human beta-defensin-2 shows evidence of higher order oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PERMEABILIZATION; ANTIMICROBIAL PEPTIDES; DIFFRACTION DATA; HUMAN DEFENSINS; LIPID BILAYERS; OUTER-MEMBRANE; BETA-DEFENSINS; PROTEIN; CRYSTALLOGRAPHY; REFINEMENT	Defensins are small cationic peptides that are crucial components of innate immunity, serving as both antimicrobial agents and chemoattractant molecules. The specific mechanism of antimicrobial activity involves permeabilization of bacterial membranes. It has been postulated that individual monomers oligomerize to form a pore through anionic membranes, although the evidence is only indirect. Here, we report two high resolution x-ray structures of human beta -defensin-2 (hBD2). The phases were experimentally determined by the multiwavelength anomalous diffraction method, utilizing a novel, rapid method of derivatization with halide ions. Although the shape and charge distribution of the monomer are similar to those of other defensins, an additional alpha -helical region makes this protein topologically distinct from the mammalian alpha- and beta -defensin structures reported previously. hBD2 forms dimers topologically distinct from that of human neutrophil peptide-3. The quaternary octameric arrangement of hBD2 is conserved in two crystal forms. These structures provide the first detailed description of dimerization of beta -defensins, and we postulate that the mode of dimerization of hBD2 is representative of other beta -defensins. The structural and electrostatic properties of the hBD2 octamer support an electrostatic charge-based mechanism of membrane permeabilization by beta -defensins, rather than a mechanism based on formation of bilayer-spanning pores.	NCI, Macromol Crystallog Lab, Program Struct Biol, Frederick Canc Res & Dev Ctr,NIH, Frederick, MD 21702 USA; NCI, SAIC Frederick, Frederick Canc Res & Dev Ctr, NIH, Frederick, MD 21702 USA; Brookhaven Natl Lab, Upton, NY 11973 USA; NCI, Lab Expt & Computat Biol, Frederick Canc Res & Dev Ctr, NIH, Frederick, MD 21702 USA; NCI, Mol Immunoregulat Lab, Frederick Canc Res & Dev Ctr, NIH, Frederick, MD 21702 USA; NCI, Intramural Res Support Program, SAIC Frederick, Frederick Canc Res & Dev Ctr,NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; United States Department of Energy (DOE); Brookhaven National Laboratory; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Lubkowski, J (corresponding author), NCI, Macromol Crystallog Lab, Program Struct Biol, Frederick Canc Res & Dev Ctr,NIH, Frederick, MD 21702 USA.			Chertov, Oleg/0000-0002-0426-2521	NCI NIH HHS [N01-CO-56000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC009369, Z01BC008303] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bechinger B, 1997, J MEMBRANE BIOL, V156, P197, DOI 10.1007/s002329900201; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chertov O, 1996, J BIOL CHEM, V271, P2935, DOI 10.1074/jbc.271.6.2935; COCIANCICH S, 1993, J BIOL CHEM, V268, P19239; Cohen GH, 1997, J APPL CRYSTALLOGR, V30, P1160, DOI 10.1107/S0021889897006729; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Dauter Z, 2000, ACTA CRYSTALLOGR D, V56, P232, DOI 10.1107/S0907444999016352; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FOGH RH, 1990, J BIOL CHEM, V265, P13016; FUJII G, 1993, PROTEIN SCI, V2, P1301, DOI 10.1002/pro.5560020813; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; GALVEZ A, 1991, J BACTERIOL, V173, P886, DOI 10.1128/jb.173.2.886-892.1991; Ganz T, 1998, CURR OPIN IMMUNOL, V10, P41, DOI 10.1016/S0952-7915(98)80029-0; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hristova K, 1997, J BIOL CHEM, V272, P24224, DOI 10.1074/jbc.272.39.24224; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; Lehrer RI, 1996, ANN NY ACAD SCI, V797, P228, DOI 10.1111/j.1749-6632.1996.tb52963.x; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; Ludtke SJ, 1996, BIOCHEMISTRY-US, V35, P13723, DOI 10.1021/bi9620621; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OTWINOWSKI Z, 1991, P CCP4 STUD WEEK DAR; PALLAGHY PK, 1995, BIOCHEMISTRY-US, V34, P3782, DOI 10.1021/bi00011a036; Rana F, 1989, Prog Clin Biol Res, V292, P77; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Torres AM, 1999, BIOCHEM J, V341, P785, DOI 10.1042/0264-6021:3410785; VAARA M, 1992, MICROBIOL REV, V56, P395, DOI 10.1128/MMBR.56.3.395-411.1992; VILJANEN P, 1988, INFECT IMMUN, V56, P2324, DOI 10.1128/IAI.56.9.2324-2329.1988; WALKER JM, 1996, PROTEIN PROTOCOLS HD; WHITE SH, 1995, CURR OPIN STRUC BIOL, V5, P521, DOI 10.1016/0959-440X(95)80038-7; WIMLEY WC, 1994, PROTEIN SCI, V3, P1362, DOI 10.1002/pro.5560030902; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525	40	261	281	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32911	32918		10.1074/jbc.M006098200	http://dx.doi.org/10.1074/jbc.M006098200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10906336	hybrid			2022-12-27	WOS:000090003800074
J	Keyhani, NO; Boudker, O; Roseman, S				Keyhani, NO; Boudker, O; Roseman, S			Isolation and characterization of IIA(Chb), a soluble protein of the enzyme II complex required for the transport/phosphorylation of N,N '-Diacetylchitobiose in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCING PROTEIN; SUGAR PHOSPHOTRANSFERASE SYSTEM; BACTERIAL PHOSPHOENOLPYRUVATE; PHOSPHOCARRIER PROTEIN; STAPHYLOCOCCUS-AUREUS; PHOSPHORYL TRANSFER; NMR TECHNIQUES; IIIGLC; TRANSPORT; SEQUENCE	N,N'-Diacetylchitobiose is transported/phosphorylated in Escherichia coli by the (GlcNAc)(2)-specific Enzyme II permease of the phosphoenolpyruvate:glycose phosphotransferase system. IIA(Chb), one protein of the Enzyme II complex, was cloned and purified to homogeneity. IIA(Chb) and phospho-IIA(Chb) form stable homodimers (3). Phospho-IIA(Chb) behaves as a typical epsilon2-N (i.e. N-3) phospho-His protein. However, the rate constants for hydrolysis of phospho-IIA(Chb) at pH 8.0 unexpectedly increased 7-fold between 25 and 37 degreesC and increased similar to 4-fold with decreasing protein concentration at 37 degreesC (but not 25 degreesC), The data were explained by thermal denaturation studies using CD spectroscopy. IIA(Chb) and phospho-IIA(Chb) exhibit virtually identical spectra at 25 degreesC (similar to 80% alpha -helix), but phospho-IIA(Chb) loses about 30% of its helicity at 37 degreesC, whereas IIA(Chb) shows only a slight change. Furthermore, the T-m for thermal denaturation of IIA(Chb) Wag 54 degreesC, only slightly affected by concentration, whereas the T-m for phospho-IIA(Chb) was much lower, ranging from 40 to 46 degreesC, depending on concentration. In addition, divalent cations (Mg2+, Cu2+, and Ni2+) have a dramatic and differential effect on the structure, depending on the state of phosphorylation of the protein. Thus, phosphorylation destabilizes IIA(Chb) at 37 degreesC, potentially affecting the monomer/dimer transition, which correlates with its chemical instability at this temperature. The physiological consequences of this phenomenon are briefly considered.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, McCollum Pratt Inst, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Roseman, S (corresponding author), Johns Hopkins Univ, Dept Biol, Mudd Hall,Rm 214,3400 N Charles St, Baltimore, MD 21218 USA.		Keyhani, Nemat O/I-8150-2013		NIGMS NIH HHS [GM38759] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038759, R37GM038759] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AB E, 1994, PROTEIN SCI, V3, P282; ANDERSON JW, 1992, BIOCHEM CELL BIOL, V70, P242, DOI 10.1139/o92-036; AUSUBEL FM, 1996, CURRENT PROTOCOLS MO, V1; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BUHR A, 1993, J BIOL CHEM, V268, P11599; DEUTSCHER J, 1982, BIOCHEMISTRY-US, V21, P4867, DOI 10.1021/bi00263a006; Feese MD, 1997, BIOCHEMISTRY-US, V36, P16087, DOI 10.1021/bi971999e; HALL BG, 1992, MOL BIOL EVOL, V9, P688; HAYS JB, 1973, J BIOL CHEM, V248, P941; JAENICKE L, 1974, ANAL BIOCHEM, V61, P623, DOI 10.1016/0003-2697(74)90429-1; Keyhani N, 2000, J BIOL CHEM, V275, P33110, DOI 10.1074/jbc.M001717200; Keyhani NO, 2000, J BIOL CHEM, V275, P33102, DOI 10.1074/jbc.M001045200; Keyhani NO, 2000, J BIOL CHEM, V275, P33084, DOI 10.1074/jbc.M001043200; Keyhani NO, 2000, J BIOL CHEM, V275, P33068, DOI 10.1074/jbc.M001041200; Keyhani NO, 1997, P NATL ACAD SCI USA, V94, P14367, DOI 10.1073/pnas.94.26.14367; KUNDIG W, 1964, P NATL ACAD SCI USA, V52, P1067, DOI 10.1073/pnas.52.4.1067; KUNDIG W, 1966, METHOD ENZYMOL, V9, P396; Park JK, 2000, J BIOL CHEM, V275, P33077, DOI 10.1074/jbc.M001042200; Pelton JG, 1996, J BIOL CHEM, V271, P33446, DOI 10.1074/jbc.271.52.33446; PELTON JG, 1992, BIOCHEMISTRY-US, V31, P5215, DOI 10.1021/bi00137a017; PELTON JG, 1991, BIOCHEMISTRY-US, V30, P10043, DOI 10.1021/bi00105a032; PELTON JG, 1993, PROTEIN SCI, V2, P543; PETTIGREW DW, 1994, PHOSPHATE IN MICROORGANISMS, P335; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; Sambrook J., 2002, MOL CLONING LAB MANU; Sliz P, 1997, STRUCTURE, V5, P775, DOI 10.1016/S0969-2126(97)00232-3; WAYGOOD EB, 1985, BIOCHEMISTRY-US, V24, P6938, DOI 10.1021/bi00345a028; WEIGEL N, 1982, J BIOL CHEM, V257, P4477; WORTHYLAKE D, 1991, P NATL ACAD SCI USA, V88, P10382, DOI 10.1073/pnas.88.23.10382	30	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33091	33101		10.1074/jbc.M001044200	http://dx.doi.org/10.1074/jbc.M001044200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10913118	hybrid			2022-12-27	WOS:000090003800097
J	Sawa, T; Akaike, T; Maeda, H				Sawa, T; Akaike, T; Maeda, H			Tyrosine nitration by peroxynitrite formed from nitric oxide and superoxide generated by xanthine oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS; URIC-ACID; OXYGEN RADICALS; PATHOGENESIS; DISMUTASE; OXIDATION; MYELOPEROXIDASE; INACTIVATION; INHIBITION	Peroxynitrite (ONOO-) is a potent nitrating and oxidizing agent that is formed by a rapid reaction of nitric oxide (NO) with superoxide anion (O-2(.)). It appears to be involved in the pathophysiology of many inflammatory and neurodegenerative diseases. It has recently been reported (Pfeiffer, S., and Mayer, B. (1998) J. Biol. Chem. 273, 27280-27285) that ONOO- generated at neutral pH from NO and O-2(.) (NO/O-2(.)) was substantially less efficient than preformed ONOO- at nitrating tyrosine. Here we re-evaluated tyrosine nitration by NO/O-2(.) with a shorter incubation period and a more sensitive electrochemical detection system. Appreciable amounts of nitrotyrosine were produced by ONOO- formed in situ (2.9 muM for 5 min; 10 nM/s) by NO/O-2(.) flux obtained from propylamine NONOate (CH3N[N(O)NO](-) (CH2)(3)NH2+CH3) and xanthine oxidase using pterin as a substrate in phosphate buffer (pH 7.0) containing 0.1 mM L-tyrosine. The yield of nitrotyrosine by this NO/O-2(.) flux was approximately 70% of that produced by the same flux of preformed ONOO(2.9 muM/5 min). When hypoxanthine was used as a substrate, tyrosine nitration by NO/O-2(.) was largely eliminated because of the inhibitory effect of uric acid produced during the oxidation of hypoxanthine. Tyrosine nitration caused by NO/O-2(.) was inhibited by the ONOO- scavenger ebselen and was enhanced 2-fold by NaHCO3, as would be expected, because CO2 promotes tyrosine nitration. The profile of nitrotyrosine and dityrosine formation produced by NO/O-2(.) flux (2.9 muM/5 min) was consistent with that produced by preformed ONOO-. Tyrosine nitration predominated compared with dityrosine formation caused by a low nanomolar flux of ONOO- at physiological concentrations of free tyrosine (<0.5 mM), In conclusion, our results show that NO generated with O-2(.) nitrates tyrosine with a reactivity and efficacy similar to those of chemically synthesized ONOO-, indicating that ONOO- can be a significant source of tyrosine nitration in physiological and pathological events in vivo.	Kumamoto Univ, Sch Med, Dept Microbiol, Kumamoto 8600811, Japan	Kumamoto University	Akaike, T (corresponding author), Kumamoto Univ, Sch Med, Dept Microbiol, Kumamoto 8600811, Japan.							Adler H, 1997, J EXP MED, V185, P1533, DOI 10.1084/jem.185.9.1533; AKAIKE T, 1990, J CLIN INVEST, V85, P739, DOI 10.1172/JCI114499; Akaike T, 1996, P NATL ACAD SCI USA, V93, P2448, DOI 10.1073/pnas.93.6.2448; Akaike T, 1996, METHOD ENZYMOL, V268, P211; AKAIKE T, 1993, BIOCHEMISTRY-US, V32, P827, DOI 10.1021/bi00054a013; Bagasra O, 1995, P NATL ACAD SCI USA, V92, P12041, DOI 10.1073/pnas.92.26.12041; Balavoine GGA, 1999, NITRIC OXIDE-BIOL CH, V3, P40, DOI 10.1006/niox.1999.0206; BECKER BF, 1991, CHEST, V100, pS176, DOI 10.1378/chest.100.3_Supplement.176S; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Brito C, 1999, J IMMUNOL, V162, P3356; Coddington JW, 1999, J AM CHEM SOC, V121, P2438, DOI 10.1021/ja982887t; Crow JP, 1999, METHOD ENZYMOL, V301, P151; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Eiserich JP, 1999, P NATL ACAD SCI USA, V96, P6365, DOI 10.1073/pnas.96.11.6365; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; Gaston B, 1999, BBA-BIOENERGETICS, V1411, P323, DOI 10.1016/S0005-2728(99)00023-7; Goldstein S, 2000, J BIOL CHEM, V275, P3031, DOI 10.1074/jbc.275.5.3031; Gow A, 1996, ARCH BIOCHEM BIOPHYS, V333, P42, DOI 10.1006/abbi.1996.0362; Haddad IY, 1996, AM J PHYSIOL-LUNG C, V270, pL281, DOI 10.1152/ajplung.1996.270.2.L281; Hooper DC, 1998, P NATL ACAD SCI USA, V95, P675, DOI 10.1073/pnas.95.2.675; Hooper DC, 1997, P NATL ACAD SCI USA, V94, P2528, DOI 10.1073/pnas.94.6.2528; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Ichimori K, 1999, J BIOL CHEM, V274, P7763, DOI 10.1074/jbc.274.12.7763; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; ISCHIROPOULOS H, 1995, AM J PHYSIOL-LUNG C, V269, pL158, DOI 10.1152/ajplung.1995.269.2.L158; Jourd'heuil D, 1999, ARCH BIOCHEM BIOPHYS, V365, P92, DOI 10.1006/abbi.1999.1143; Kamisaki Y, 1998, P NATL ACAD SCI USA, V95, P11584, DOI 10.1073/pnas.95.20.11584; Koppenol WH, 1996, METHOD ENZYMOL, V269, P296; Lee CI, 2000, J BIOL CHEM, V275, P9369, DOI 10.1074/jbc.275.13.9369; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433; Liu PT, 1997, AM J PHYSIOL-HEART C, V272, pH2327, DOI 10.1152/ajpheart.1997.272.5.H2327; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; MacMillan-Crow LA, 1998, BIOCHEMISTRY-US, V37, P1613, DOI 10.1021/bi971894b; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; Malencik DA, 1996, ANAL BIOCHEM, V242, P202, DOI 10.1006/abio.1996.0454; Masumoto H, 1996, CHEM RES TOXICOL, V9, P262, DOI 10.1021/tx950115u; McAndrew J, 1997, SEMIN PERINATOL, V21, P351, DOI 10.1016/S0146-0005(97)80002-X; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Moriel P, 1997, BIOCHEM BIOPH RES CO, V232, P332, DOI 10.1006/bbrc.1997.6287; ODA T, 1989, SCIENCE, V244, P974, DOI 10.1126/science.2543070; Pfeiffer S, 2000, J BIOL CHEM, V275, P6346, DOI 10.1074/jbc.275.9.6346; Pfeiffer S, 1998, J BIOL CHEM, V273, P27280, DOI 10.1074/jbc.273.42.27280; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; Sampson JB, 1998, ARCH BIOCHEM BIOPHYS, V356, P207, DOI 10.1006/abbi.1998.0772; Skinner KA, 1998, J BIOL CHEM, V273, P24491, DOI 10.1074/jbc.273.38.24491; VANDERVLIET A, 1995, ARCH BIOCHEM BIOPHYS, V319, P341, DOI 10.1006/abbi.1995.1303; Wang PH, 1996, J BIOL CHEM, V271, P29223, DOI 10.1074/jbc.271.46.29223; WHITE A, 1973, PRINCIPLES BIOCHEMIS	50	165	167	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32467	32474		10.1074/jbc.M910169199	http://dx.doi.org/10.1074/jbc.M910169199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10906338	hybrid			2022-12-27	WOS:000090003800014
J	Johnson, TR; Biggs, JR; Winbourn, SE; Kraft, AS				Johnson, TR; Biggs, JR; Winbourn, SE; Kraft, AS			Regulation of dual-specificity phosphatases M3/6 and hVH5 by phorbol esters - Analysis of a delta-like domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MAP KINASE; C-JUN; TYROSINE-PHOSPHATASE; SELECTIVELY DEPHOSPHORYLATES; CATALYTIC ACTIVATION; MOLECULAR-CLONING; INTERACTION MOTIF; PTP-SL; STRESS	Treatment of leukemic cells with phorbol 12-myristate 13-acetate (PMA) induces a short-lived phosphorylation and activation of stress-activated protein kinase (SAPK) and cellular differentiation. To investigate whether the rapid deactivation of SAPK results from dephosphorylation by dual-specificity phosphatases (DSPs), we studied regulation of the DSP hVH5 and its murine orthologue M3/6 in K562 human leukemia cells. PMA treatment rapidly induced hVH5 transcripts in these cells, and induced expression of M3/6 completely inhibited PMA-stimulated phosphorylation of SAPK, suggesting a feedback loop to control SAPK activity. Using both stable cell lines and transient transfection we demonstrate that activation of SAPK rapidly stimulated phosphorylation of M3/6. This phosphorylation did not regulate the half-life of total cellular M3/6. hVH5 and M3/6 shares with all sequenced mammalian DSPs an amino acid motif, XILPXLXL, located approximately 80 amino acids from the active site. The hVH5-M3/6 sequence, RILPHLYL, shares significant homology with the SAPK binding site of the c-Jun protein, called the delta domain. This motif was found to be important for DSP function, because deletion of RILPHLYL inhibits SAPK-mediated phosphorylation of M3/6, and deletion of this sequence or mutation of the Ln portion blocks the ability of this phosphatase to dephosphorylate SAPK.	Univ Colorado, Hlth Sci Ctr, Dept Med Oncol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Kraft, AS (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med Oncol, 4200 E 9th Ave, Denver, CO 80262 USA.				NATIONAL CANCER INSTITUTE [R01CA042533] Funding Source: NIH RePORTER; NCI NIH HHS [CA42533] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1994, J BIOL CHEM, V269, P11186; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; BAICHWAL UR, 1990, CELL, V16, P815; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; DAI TN, 1995, ONCOGENE, V10, P849; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dowd S, 1998, J CELL SCI, V111, P3389; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Grumont RJ, 1996, MOL CELL BIOL, V16, P2913; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; Haneda M, 1999, EUR J PHARMACOL, V365, P1, DOI 10.1016/S0014-2999(98)00857-7; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LOZZIO CB, 1975, BLOOD, V45, P332; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Rininsland F, 1997, P NATL ACAD SCI USA, V94, P5854, DOI 10.1073/pnas.94.11.5854; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Theodosiou A, 1999, ONCOGENE, V18, P6981, DOI 10.1038/sj.onc.1203185; Theodosiou AM, 1996, HUM MOL GENET, V5, P675, DOI 10.1093/hmg/5.5.675; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900	46	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31755	31762		10.1074/jbc.M004182200	http://dx.doi.org/10.1074/jbc.M004182200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10915787	hybrid			2022-12-27	WOS:000089858900031
J	Macdonald, JM; Haas, AL; London, RE				Macdonald, JM; Haas, AL; London, RE			Novel mechanism of surface catalysis of protein adduct formation - NMR studies of the acetylation of ubiquitin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLIMIDAZOLE; NONENZYMATIC GLYCOSYLATION; AMADORI REARRANGEMENT; GROWTH-HORMONE; AMINO-GROUPS; GLYCATION; SITES; IDENTIFICATION; HEMOGLOBIN; SPECIFICITY	Reactivity of surface lysyl residues of proteins with a broad range of chemical agents has been proposed to be dependent on the catalytic microenvironment of the residue. We have investigated the acetylation of wild type ubiquitin and of the UbH68N mutant to evaluate the potential contribution of His-68 to the reactivity of Lys-6, which is about 4 Angstrom distant. These studies were performed using [1-C-13]acetyl salicylate or [1,1'-C-13(2)]acetic anhydride, and the acetylated products were detected by two-dimensional heteronuclear multiple quantum coherence spectroscopy. The results demonstrate that His-68 makes a positive contribution to the rate of acetylation of Lys-6 by labeled aspirin. Additionally, a pair of transient resonances is observed after treatment of wild type ubiquitin with the labeled acetic anhydride but not upon treatment of the H68N mutant. These resonances are assigned to the acetylated His-68 residue. The loss of intensity of the acetylhistidine resonances is accompanied by an increase in intensity of the acetyl-lys-g peak, supporting the existence of a transacetylation process between the acetylhistidine 68 and lysine 6 residues located on the protein surface. Hence, this may be the first direct demonstration of a catalytic intermediate forming on the protein surface.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Medical College of Wisconsin	London, RE (corresponding author), NIEHS, Struct Biol Lab, NIH, MR-01,Box 12233, Res Triangle Pk, NC 27709 USA.		London, Robert E/F-7990-2019	London, Robert E/0000-0001-9108-8463	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050111, ZIAES050111] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ACHARYA AS, 1983, J BIOL CHEM, V258, P2296; ARGUELLO JM, 1990, BIOCHEMISTRY-US, V29, P5775, DOI 10.1021/bi00476a019; Bailey AJ, 1998, MECH AGEING DEV, V106, P1, DOI 10.1016/S0047-6374(98)00119-5; BALDWIN JS, 1995, BBA-PROTEIN STRUCT M, V1247, P60, DOI 10.1016/0167-4838(94)00202-R; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; DESATZ VB, 1981, INT J PEPT PROT RES, V18, P492; GERIG JT, 1981, ORG MAGN RESONANCE, V15, P158, DOI 10.1002/mrc.1270150210; HAYDEN PJ, 1991, BIOCHEMISTRY-US, V30, P5935, DOI 10.1021/bi00238a018; HIPKISS AR, 1995, FEBS LETT, V371, P81, DOI 10.1016/0014-5793(95)00849-5; IBERG N, 1986, J BIOL CHEM, V261, P3542; KALIMAN P, 1991, INT J PEPT PROT RES, V38, P38; KHALIFAH RG, 1979, BIOCHEMISTRY-US, V18, P391, DOI 10.1021/bi00569a025; KINNUNEN PM, 1988, BIOCHEMISTRY-US, V27, P7344, DOI 10.1021/bi00419a025; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Macdonald JM, 1999, BIOCHEM PHARMACOL, V57, P1233, DOI 10.1016/S0006-2952(99)00039-8; MIYATA T, 1994, BIOCHEMISTRY-US, V33, P12215, DOI 10.1021/bi00206a026; MOORE GJ, 1985, INT J PEPT PROT RES, V26, P469; NACHARAJU P, 1992, BIOCHEMISTRY-US, V31, P12673, DOI 10.1021/bi00165a018; NIGEN AM, 1973, J BIOL CHEM, V248, P3724; RIORDAN JF, 1965, BIOCHEMISTRY-US, V4, P1758, DOI 10.1021/bi00885a012; SHILTON BH, 1991, J BIOL CHEM, V266, P5587; SHILTON BH, 1993, EUR J BIOCHEM, V215, P567, DOI 10.1111/j.1432-1033.1993.tb18067.x; SVENSSON L A, 1986, Proteins Structure Function and Genetics, V1, P370, DOI 10.1002/prot.340010410; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; WALKER JE, 1976, FEBS LETT, V66, P173, DOI 10.1016/0014-5793(76)80496-6; WATKINS NG, 1985, J BIOL CHEM, V260, P629; WELSCH DJ, 1988, BIOCHEMISTRY-US, V27, P7513, DOI 10.1021/bi00419a050; WLODAWER A, 1983, BIOCHEMISTRY-US, V22, P2720, DOI 10.1021/bi00280a021; WUNDERLIN M, 1994, THESIS U KONSTANZ GE; Xu ASL, 1999, BBA-PROTEIN STRUCT M, V1432, P333, DOI 10.1016/S0167-4838(99)00094-1	31	16	16	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31908	31913		10.1074/jbc.M000684200	http://dx.doi.org/10.1074/jbc.M000684200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10906321	hybrid			2022-12-27	WOS:000089858900051
J	Nguyen, BP; Gil, SG; Carter, WG				Nguyen, BP; Gil, SG; Carter, WG			Deposition of laminin 5 by keratinocytes regulates integrin adhesion and signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL EPIDERMOLYSIS-BULLOSA; BASEMENT-MEMBRANE ADHESION; CELL-CELL ADHESION; DIFFICILE TOXIN-B; EXTRACELLULAR-MATRIX; PYLORIC ATRESIA; ALPHA-6-BETA-4 INTEGRIN; EPITHELIAL-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; DISTINCT FUNCTIONS	Deposition of laminin 5 over exposed dermal collagen in epidermal wounds is an early event in repair of the basement membrane. We report that deposition of laminin 5 onto collagen switches adhesion and signaling from collagen-dependent to laminin 5-dependent, Ligation of laminin 5 by integrin alpha(6)beta(4) activates phosphoinositide S-OH-kinase (PI3K) signaling. This activation allows for adhesion and spreading via integrin alpha(3)beta(1) on laminin 5 independent of RhoGTPase, a regulator of actin stress fibers. In contrast, adhesion and spreading on collagen via alpha(2)beta(1) is Rho-dependent and is inhibited by toxin B, a Rho inhibitor. Deposition of laminin 5 and ligation of alpha(6)beta(4) increases PI3K-dependent production of phosphoinositide di- and triphosphates, PI3K activity, and phosphorylation of downstream target protein c-Jun NH3-terminal kinase, Conversely, blocking laminin 5-deposition with brefeldin A, an inhibitor of vesicle transport, or with anti-laminin 5 monoclonal antibodies abolishes the PI3K-dependent spreading mediated by alpha(3)beta(1) and phosphorylation of c-Jun NH2-terminal kinase. Studies with keratinocytes lacking alpha(6)beta(4) or laminin 5 confirm that deposition of laminin 5 and ligation by alpha(6)beta(4) are required for PI3K-dependent spreading via alpha(3)beta(1). We suggest that deposition of laminin 5 onto the collagen substratum, as in wound repair, enables human foreskin keratinocytes to interact via alpha(6)beta(4) and to switch from a RhoGTPase-dependent adhesion on collagen to a PI3K-dependent adhesion and spreading mediated by integrin alpha(3)beta(1) on laminin 5.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Carter, WG (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.	wcarter@fhcrc.org			NCI NIH HHS [CA49259] Funding Source: Medline; NIAMS NIH HHS [AR21557] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR021557] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Barry ST, 1996, CELL ADHES COMMUN, V4, P387, DOI 10.3109/15419069709004456; BOYCE ST, 1985, J TISSUE CULTURE MET, V9, P83; Braga VMM, 1999, J CLIN PATHOL-MOL PA, V52, P197, DOI 10.1136/mp.52.4.197; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Brown TA, 1996, J INVEST DERMATOL, V107, P384, DOI 10.1111/1523-1747.ep12363370; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; Chen M, 1997, J BIOL CHEM, V272, P14516, DOI 10.1074/jbc.272.23.14516; DIPERSIO CM, 1995, J CELL SCI, V108, P2321; Farrelly N, 1999, J CELL BIOL, V144, P1337, DOI 10.1083/jcb.144.6.1337; Fuchs E, 1997, CURR OPIN GENET DEV, V7, P672, DOI 10.1016/S0959-437X(97)80016-0; GeorgesLabouesse E, 1996, NAT GENET, V13, P370, DOI 10.1038/ng0796-370; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; GIL SG, 1994, J INVEST DERMATOL, V103, pS31, DOI 10.1111/1523-1747.ep12398953; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Goldfinger LE, 1999, J CELL SCI, V112, P2615; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; Henry MD, 1999, CURR OPIN CELL BIOL, V11, P602, DOI 10.1016/S0955-0674(99)00024-1; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; JONES JCR, 1991, CELL REGUL, V2, P427, DOI 10.1091/mbc.2.6.427; JUST I, 1994, J BIOL CHEM, V269, P10706; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Kainulainen T, 1998, J HISTOCHEM CYTOCHEM, V46, P353, DOI 10.1177/002215549804600309; KIKKAWA Y, 1994, J BIOCHEM-TOKYO, V116, P862, DOI 10.1093/oxfordjournals.jbchem.a124608; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lampe PD, 1998, J CELL BIOL, V143, P1735, DOI 10.1083/jcb.143.6.1735; Lim KK, 1996, MAYO CLIN PROC, V71, P863, DOI 10.4065/71.9.863; Lo Surdo P, 1999, J BIOL CHEM, V274, P15678, DOI 10.1074/jbc.274.22.15678; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIYAZAKI K, 1993, P NATL ACAD SCI USA, V90, P11767, DOI 10.1073/pnas.90.24.11767; Niessen CM, 1996, J CELL SCI, V109, P1695; Pilcher BK, 1998, ARCH DERMATOL RES, V290, pS37, DOI 10.1007/PL00007452; Pilcher BK, 1999, ANN NY ACAD SCI, V878, P12, DOI 10.1111/j.1749-6632.1999.tb07671.x; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; Pulkkinen L, 1998, AM J HUM GENET, V63, P1376, DOI 10.1086/302116; Rabinovitz I, 1997, J CELL BIOL, V139, P1873, DOI 10.1083/jcb.139.7.1873; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; Rousselle P, 1997, J CELL BIOL, V138, P719, DOI 10.1083/jcb.138.3.719; RYAN MC, 1994, J BIOL CHEM, V269, P22779; Ryan MC, 1996, MATRIX BIOL, V15, P369, DOI 10.1016/S0945-053X(96)90157-2; Ryan MC, 1999, J CELL BIOL, V145, P1309, DOI 10.1083/jcb.145.6.1309; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; SONNENBERG A, 1991, J CELL BIOL, V113, P907, DOI 10.1083/jcb.113.4.907; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970; Sudbeck BD, 1997, J BIOL CHEM, V272, P22103, DOI 10.1074/jbc.272.35.22103; Takizawa Y, 1997, J INVEST DERMATOL, V108, P943, DOI 10.1111/1523-1747.ep12296240; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VIDAL F, 1995, NAT GENET, V10, P229, DOI 10.1038/ng0695-229; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; Xia YP, 1996, J CELL BIOL, V132, P727, DOI 10.1083/jcb.132.4.727; Zhang K, 1996, EXP CELL RES, V227, P309, DOI 10.1006/excr.1996.0280	60	136	139	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31896	31907		10.1074/jbc.M006379200	http://dx.doi.org/10.1074/jbc.M006379200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10926936	hybrid			2022-12-27	WOS:000089858900050
J	Qiu, WS; Zhuang, SH; von Lintig, FC; Boss, GR; Pilz, RB				Qiu, WS; Zhuang, SH; von Lintig, FC; Boss, GR; Pilz, RB			Cell type-specific regulation of B-Raf kinase by cAMP and 14-3-3 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; NIH 3T3 CELLS; NUCLEOTIDE-EXCHANGE FACTOR; MAP KINASE; CYCLIC-AMP; DEPENDENT ACTIVATION; PC12 CELLS; SIGNAL-TRANSDUCTION; DIFFERENTIAL REGULATION; BINDING PROTEINS	Cyclic AMP can either activate or inhibit the mitogen-activated protein kinase (MAPK) pathway in different cell types; MAPK activation has been observed in B-Raf-expressing cells and has been attributed to Rap1 activation with subsequent B-Raf activation, whereas MAPK inhibition has been observed in cells lacking B-Raf and has been attributed to cAMP-dependent protein kinase (protein kinase A)-mediated phosphorylation and inhibition of Raf-l kinase. We found that cAMP stimulated MAPK activity in CHO-K1 and PC12 cells but inhibited MAPK activity in C6 and NB2A cells. In all four cell types, cAMP activated Rap1, and the 95- and 68-kDa isoforms of B-Raf were expressed, cAMP activation or inhibition of MAPK correlated with activation or inhibition of endogenous and transfected B-Raf kinase. Although all cell types expressed similar amounts of 14-3-3 proteins, approximately B-fold less 14-3-3 was associated with B-Raf in cells in which cAMP was inhibitory than in cells in which cAMP was stimulatory. We found that the cell type-specific inhibition of B-Raf could be completely prevented by overexpression of 14-3-3 isoforms, whereas expression of a dominant negative 14-3-3 mutant resulted in partial loss of B-Raf activity. Our data suggest that 14-3-3 bound to B-Raf protects the enzyme from protein kinase A-mediated inhibition; the amount of 14-3-3 associated with B-Raf may explain the tissue-specific effects of cAMP on B-Raf kinase activity.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Pilz, RB (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.			Boss, Gerry/0000-0002-9758-8714	NATIONAL CANCER INSTITUTE [R21CA081115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055586] Funding Source: NIH RePORTER; NCI NIH HHS [R21-CA81115] Funding Source: Medline; NIGMS NIH HHS [R01 GM55586] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; AITKEN A, 1995, BIOCHEM SOC T, V23, P605, DOI 10.1042/bst0230605; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; Bos JL, 1997, FEBS LETT, V410, P59, DOI 10.1016/S0014-5793(97)00324-4; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; BRUNK CF, 1979, ANAL BIOCHEM, V92, P497, DOI 10.1016/0003-2697(79)90690-0; BUHL AM, 1994, P NATL ACAD SCI USA, V91, P9190, DOI 10.1073/pnas.91.19.9190; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; Bustin SA, 1999, DNA CELL BIOL, V18, P653, DOI 10.1089/104454999315060; CATLING AD, 1994, J BIOL CHEM, V269, P30014; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; Chen JH, 1998, P NATL ACAD SCI USA, V95, P2648, DOI 10.1073/pnas.95.5.2648; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; ENGLARO W, 1995, J BIOL CHEM, V270, P24315, DOI 10.1074/jbc.270.41.24315; ERHARDT P, 1995, MOL CELL BIOL, V15, P5524; EYCHENE A, 1995, ONCOGENE, V10, P1159; FAURE M, 1995, MOL BIOL CELL, V6, P1025, DOI 10.1091/mbc.6.8.1025; FAURE M, 1994, J BIOL CHEM, V269, P7851; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HAFNER S, 1994, MOL CELL BIOL, V14, P6606; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; HATA Y, 1991, J BIOL CHEM, V266, P6571; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Jaiswal RK, 1996, J BIOL CHEM, V271, P23626, DOI 10.1074/jbc.271.39.23626; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; MacNicol MC, 2000, J BIOL CHEM, V275, P3803, DOI 10.1074/jbc.275.6.3803; MacNicol MC, 1999, J BIOL CHEM, V274, P13193, DOI 10.1074/jbc.274.19.13193; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; MATOUSOVIC K, 1995, J CLIN INVEST, V96, P401, DOI 10.1172/JCI118049; McPherson RA, 1999, ONCOGENE, V18, P3862, DOI 10.1038/sj.onc.1202730; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Papin C, 1998, J BIOL CHEM, V273, P24939, DOI 10.1074/jbc.273.38.24939; PAPIN C, 1995, ONCOGENE, V10, P1647; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PERALDI P, 1995, FEBS LETT, V357, P290, DOI 10.1016/0014-5793(94)01376-C; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; Rommel C, 1996, ONCOGENE, V12, P609; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Seidel MG, 1999, J BIOL CHEM, V274, P25833, DOI 10.1074/jbc.274.36.25833; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; Sidovar MF, 2000, J BIOL CHEM, V275, P28688, DOI 10.1074/jbc.M909351199; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; Sprenkle AB, 1997, FEBS LETT, V403, P254, DOI 10.1016/S0014-5793(97)00062-8; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; Sugawara F, 1996, MOL PHARMACOL, V49, P447; Suhasini M, 1998, MOL CELL BIOL, V18, P6983, DOI 10.1128/MCB.18.12.6983; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; TOKER A, 1992, EUR J BIOCHEM, V206, P453, DOI 10.1111/j.1432-1033.1992.tb16946.x; Tsai RYL, 1997, BIOTECHNIQUES, V23, P794, DOI 10.2144/97235bm06; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Verheijen MHG, 1997, J BIOL CHEM, V272, P3423, DOI 10.1074/jbc.272.6.3423; von Lintig FC, 2000, ONCOGENE, V19, P4029, DOI 10.1038/sj.onc.1203741; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Xing HM, 2000, EMBO J, V19, P349, DOI 10.1093/emboj/19.3.349; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; Yao H, 1998, J BIOL CHEM, V273, P8240, DOI 10.1074/jbc.273.14.8240; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	89	87	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31921	31929		10.1074/jbc.M003327200	http://dx.doi.org/10.1074/jbc.M003327200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10931830	hybrid			2022-12-27	WOS:000089858900053
J	Bazzoni, G; Martinez-Estrada, OM; Mueller, F; Nelboeck, P; Schmid, G; Bartfai, T; Dejana, E; Brockhaus, M				Bazzoni, G; Martinez-Estrada, OM; Mueller, F; Nelboeck, P; Schmid, G; Bartfai, T; Dejana, E; Brockhaus, M			Hemophilic interaction of junctional adhesion molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; CRYSTAL-STRUCTURE; IMMUNOGLOBULIN SUPERFAMILY; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; SOLUBLE FORM; CD58 LFA-3; DIMERIZATION; CD2; RESOLUTION	Junctional adhesion molecule (JAM) is an integral membrane protein that belongs to the immunoglobulin superfamily, localizes at tight junctions, and regulates both paracellular permeability and leukocyte transmigration. To investigate molecular determinants of JAM function, the extracellular domain of murine JAM was produced as a recombinant soluble protein (rsJAM) in insect cells, rsJAM consisted in large part of noncovalent homodimers, as assessed by analytical ultracentrifugation, JAM dimers were also detected at the surface of Chinese hamster ovary cells transfected with murine JAM, as evaluated by cross-linking and immunoprecipitation. Furthermore, fluid-phase rsJAM bound dose-dependently solid-phase rsJAM, and such hemophilic binding was inhibited by anti-JAM Fab BV11, but not by Fab BV12, Interestingly, Fab BV11 exclusively bound rsJAM dimers (but not monomers) in solution, whereas Fab BV12 bound both dimers and monomers, Finally, we mapped the BV11 and BV12 epitopes to a largely overlapping sequence in proximity of the extracellular amino terminus of JAM, me hypothesize that rsJAM dimerization induces a BV11-positive conformation which in turn is critical for rsJAM hemophilic interactions. Dimerization and hemophilic binding may contribute to both adhesive function and junctional organization of JAM.	Ist Ric Farmacol Mario Negri, Lab Vasc Biol, I-20157 Milan, Italy; F Hoffmann La Roche & Co Ltd, Pharmaceut Res, CH-4070 Basel, Switzerland; F Hoffmann La Roche & Co Ltd, Chem Technol, CH-4070 Basel, Switzerland; F Hoffmann La Roche & Co Ltd, Cent Nervous Syst Dis, CH-4070 Basel, Switzerland; F Hoffmann La Roche & Co Ltd, Fermentat Technol, CH-4070 Basel, Switzerland; Univ Insubria, Dipartimento Sci Clin & Biol, I-21100 Varese, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Roche Holding; Roche Holding; Roche Holding; Roche Holding; University of Insubria	Bazzoni, G (corresponding author), Ist Ric Farmacol Mario Negri, Lab Vasc Biol, Via Eritrea 62, I-20157 Milan, Italy.		Martinez-Estrada, Ofelia M/V-4733-2017	Martinez-Estrada, Ofelia M/0000-0002-1814-1974; DEJANA, ELISABETTA/0000-0002-0007-0426				Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; BEDNARCZYK JL, 1994, J BIOL CHEM, V269, P8348; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; Casasnovas JM, 1998, P NATL ACAD SCI USA, V95, P4134, DOI 10.1073/pnas.95.8.4134; Chothia C, 1997, ANNU REV BIOCHEM, V66, P823, DOI 10.1146/annurev.biochem.66.1.823; Del Maschio A, 1999, J EXP MED, V190, P1351, DOI 10.1084/jem.190.9.1351; Dustin ML, 1996, J CELL BIOL, V132, P465, DOI 10.1083/jcb.132.3.465; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hunter I, 1996, BIOCHEM J, V320, P847, DOI 10.1042/bj3200847; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KORNECKI E, 1990, J BIOL CHEM, V265, P10042; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; Leahy DJ, 1997, ANNU REV CELL DEV BI, V13, P363, DOI 10.1146/annurev.cellbio.13.1.363; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; Malergue F, 1998, MOL IMMUNOL, V35, P1111, DOI 10.1016/S0161-5890(98)00102-3; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; MILLER J, 1995, J EXP MED, V182, P1231, DOI 10.1084/jem.182.5.1231; Ozaki H, 1999, J IMMUNOL, V163, P553; REILLY PL, 1995, J IMMUNOL, V155, P529; SCHUCK P, 1994, PROG COLL POL SCI S, V94, P1; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STUEBER D, 1990, IMMUNOL METHODS, V4, P122; VANDERMERWE PA, 1994, BIOCHEMISTRY-US, V33, P10149, DOI 10.1021/bi00199a043; Wang J, 1999, CELL, V97, P791, DOI 10.1016/S0092-8674(00)80790-4; WANG JM, 1994, J IMMUNOL METHODS, V171, P55, DOI 10.1016/0022-1759(94)90228-3; Williams LA, 1999, MOL IMMUNOL, V36, P1175, DOI 10.1016/S0161-5890(99)00122-4; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yauch RL, 1997, J EXP MED, V186, P1347, DOI 10.1084/jem.186.8.1347	31	124	133	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30970	30976		10.1074/jbc.M003946200	http://dx.doi.org/10.1074/jbc.M003946200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10913139	hybrid			2022-12-27	WOS:000089762700035
J	Huang, Y; Hamada, M; Maraia, RJ				Huang, Y; Hamada, M; Maraia, RJ			Isolation and cloning of four subunits of a fission yeast TFIIIC complex that includes an ortholog of the human regulatory protein TFIIIC beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; TATA-BINDING PROTEIN; TRANSCRIPTION FACTOR; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; DNA-BINDING; ACETYLTRANSFERASE ACTIVITY; S-POMBE; GENE; EXPRESSION	Eukaryotic tRNA genes are controlled by proximal and downstream elements that direct transcription by RNA polymerase (pol) III. Transcription factors (TFs) that reside near the initiation site are related in Saccharomyces cerevisiae and humans, while those that reside at or downstream of the B box share no recognizable sequence relatedness. Human TFIIIC beta is a transcriptional regulator that exhibits no homology to S. cerevisiae sequences on its own. We cloned an essential Schizosaccharomyces pombe gene that encodes a protein, Sfc6p, with homology to the S. cerevisiae TFIIIC subunit, TFC6p, that extends to human TFIIIC beta. We also isolated and cloned S. pombe homologs of three other TFIIIC subunits, Sfc3p, Sfc4p, and Sfc1p, the latter two of which are conserved from S. cerevisiae to humans, while the former shares homology with the S. cerevisiae B box-binding homolog only. Sfc6p is a component of a sequence-specific DNA-binding complex that also contains the B box-binding homolog, Sfc3p. Immunoprecipitation of Sfc3p further revealed that Sfc1p, Sfc3p, Sfc4p, and Sfc6p are associated in vivo and that the isolated Sfc3p complex is active for pol III-mediated transcription of a S. pombe tRNA gene in vitro. These results establish a link between the downstream pol III TFs in yeast and humans.	NICHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Maraia, RJ (corresponding author), 6 Ctr Dr,Rm 416, Bethesda, MD 20892 USA.	maraiar@mail.nih.gov	Maraia, Richard/ABC-1442-2020	Maraia, Richard/0000-0002-5209-0066	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000412] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000412] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arrebola R, 1998, MOL CELL BIOL, V18, P1; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; Baserga S., 1993, RNA WORLD, P359; Chedin S, 1998, COLD SPRING HARB SYM, V63, P381, DOI 10.1101/sqb.1998.63.381; Chen L, 1997, NUCLEIC ACIDS RES, V25, P1633, DOI 10.1093/nar/25.8.1633; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; Dang VD, 1999, MOL CELL BIOL, V19, P2351; Deprez E, 1999, MOL CELL BIOL, V19, P8042; Dumay H, 1999, J BIOL CHEM, V274, P33462, DOI 10.1074/jbc.274.47.33462; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; Flores A, 1999, P NATL ACAD SCI USA, V96, P7815, DOI 10.1073/pnas.96.14.7815; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; Geiduschek E.P., 1992, TRANSCRIPTIONAL REGU, P247; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; Hamada M, 2000, J BIOL CHEM, V275, P29076, DOI 10.1074/jbc.M003980200; Hsieh YJ, 1999, MOL CELL BIOL, V19, P4944; Hsieh YJ, 1999, MOL CELL BIOL, V19, P7697; Huet J, 1996, METHOD ENZYMOL, V273, P249; KANTERSMOLER G, 1994, BIOTECHNIQUES, V16, P798; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; Kassavetis GA, 1999, EMBO J, V18, P5042, DOI 10.1093/emboj/18.18.5042; KASSAVETIS GA, 1994, TRANSCRIPTION MECHAN, P107; KOVELMAN R, 1992, J BIOL CHEM, V267, P24446; Kundu TK, 1999, MOL CELL BIOL, V19, P1605; LAGNA G, 1994, MOL CELL BIOL, V14, P3053, DOI 10.1128/MCB.14.5.3053; LETOILE ND, 1994, P NATL ACAD SCI USA, V91, P1652, DOI 10.1073/pnas.91.5.1652; LOBO SM, 1994, TRANSCRIPTION MECH R, P127; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; Manaud N, 1998, MOL CELL BIOL, V18, P3191, DOI 10.1128/MCB.18.6.3191; MAO JI, 1980, CELL, V21, P509, DOI 10.1016/0092-8674(80)90488-2; MARCK C, 1993, P NATL ACAD SCI USA, V90, P4027, DOI 10.1073/pnas.90.9.4027; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; Moir RD, 1997, MOL CELL BIOL, V17, P7119, DOI 10.1128/MCB.17.12.7119; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NICHOLS M, 1990, METHOD ENZYMOL, V181, P377; Ohi R, 1996, GENE, V174, P315, DOI 10.1016/0378-1119(96)00085-6; PARSONS MC, 1992, J BIOL CHEM, V267, P2894; RAMEAU G, 1994, MOL CELL BIOL, V14, P822, DOI 10.1128/MCB.14.1.822; Rodicker F, 1999, GENE EXPRESSION, V8, P165; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Ruth J, 1996, EMBO J, V15, P1941, DOI 10.1002/j.1460-2075.1996.tb00545.x; Shen YH, 1996, MOL CELL BIOL, V16, P4163; SINN E, 1995, GENE DEV, V9, P675, DOI 10.1101/gad.9.6.675; SWANSON RN, 1991, P NATL ACAD SCI USA, V88, P4887, DOI 10.1073/pnas.88.11.4887; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; Wang ZX, 1997, GENE DEV, V11, P1315, DOI 10.1101/gad.11.10.1315; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WILLIS I, 1986, J BIOL CHEM, V261, P5878; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x	54	20	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31480	31487		10.1074/jbc.M004635200	http://dx.doi.org/10.1074/jbc.M004635200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906331	hybrid			2022-12-27	WOS:000089762700102
J	Mercado, A; Song, LY; Vazquez, N; Mount, DB; Gamba, G				Mercado, A; Song, LY; Vazquez, N; Mount, DB; Gamba, G			Functional comparison of the K+-Cl- cotransporters KCC1 and KCC4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PASSIVE K/CL TRANSPORT; SHEEP RED-CELLS; THICK ASCENDING LIMB; PROTEIN PHOSPHATASES; BASOLATERAL MEMBRANE; MOLECULAR-CLONING; CHLORIDE TRANSPORT; BUMETANIDE BINDING; HUMAN ERYTHROCYTES; N-ETHYLMALEIMIDE	The K+-Cl- cotransporters (KCCs) are members of the cation-chloride cotransporter gene family and fall into two phylogenetic subgroups: KCC2 paired with KCC4 and KCC1 paired with KCC3. We report a functional comparison in Xenopus oocytes of KCC1 and KCC4, widely expressed representatives of these two sub groups. KCC1 and KCC4 exhibit differential sensitivity to transport inhibitors, such that KCC4 is much less sensitive to bumetanide and furosemide. The efficacy of these anion inhibitors is critically dependent on the concentration of extracellular K+, with much higher inhibition in 50 mM K+ versus 2 mM K+. KCC4 is also uniquely sensitive to 10 mM barium and to 2 mM trichlormethiazide, Kinetic characterization reveals divergent affinities for K+ (K-m values of similar to 25.5 and 17.5 mM for KCC1 and KCC4, respectively), probably due to variation within the second transmembrane segment. Although the two isoforms have equivalent affinities for Cl-, they differ in the anion selectivity of K+ transport (Cl- > SCN- = Br- > PO4-3 > I- for KCC1 and Cl- > Br- > PO4-3 = I- > SCN- for KCC4). Both KCCs express minimal K+-C1- cotransport under isotonic conditions, with significant activation by cell swelling under hypotonic conditions. The cysteine-alkylating agent N-ethylmaleimide activates K+-Cl- cotransport in isotonic conditions but abrogates hypotonic activation, an unexpected dissociation of N-ethylmaleimide sensitivity and volume sensitivity. Although KCC4 is consistently more volume-sensitive, the hypotonic activation of both isoforms is critically dependent on protein phosphatase 1. Overall, the functional comparison of these cloned K+-Cl- cotransporters reveals important functional, pharmacological, and kinetic differences with both physio logical and mechanistic implications.	Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mol Physiol Unit, Mexico City 14000, DF, Mexico; Univ Nacl Autonoma Mexico, Inst Invest Biomed, Mexico City 14000, DF, Mexico; Vanderbilt Univ, Med Ctr, Dept Med, Div Nephrol & Hypertens, Nashville, TN 37232 USA	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; Universidad Nacional Autonoma de Mexico; Vanderbilt University	Gamba, G (corresponding author), Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mol Physiol Unit, Vasco Quiroga 15, Mexico City 14000, DF, Mexico.		Mercado, Adriana/AAR-6143-2021; Gamba, Gerardo/P-4873-2016	Mercado, Adriana/0000-0002-6881-0160; Gamba, Gerardo/0000-0002-4378-9043	NIDDK NIH HHS [R01 DK57708, K11 DK02328] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057708, K11DK002328] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adragna NC, 2000, AM J PHYSIOL-CELL PH, V278, pC381, DOI 10.1152/ajpcell.2000.278.2.C381; ADRAGNA NC, 1994, J MEMBRANE BIOL, V142, P195; Amlal H, 1996, AM J PHYSIOL-CELL PH, V271, pC455, DOI 10.1152/ajpcell.1996.271.2.C455; AMLAL H, 1994, AM J PHYSIOL-CELL PH, V267, pC1607, DOI 10.1152/ajpcell.1994.267.6.C1607; AVISON MJ, 1988, J MEMBRANE BIOL, V105, P197, DOI 10.1007/BF01870997; BAUER J, 1983, J MEMBRANE BIOL, V73, P257, DOI 10.1007/BF01870540; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Bize I, 1998, AM J PHYSIOL-CELL PH, V274, pC440, DOI 10.1152/ajpcell.1998.274.2.C440; Bize I, 1999, AM J PHYSIOL-CELL PH, V277, pC926, DOI 10.1152/ajpcell.1999.277.5.C926; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Cossins AR, 1997, J EXP BIOL, V200, P343; DELPIRE E, 1991, J GEN PHYSIOL, V97, P173, DOI 10.1085/jgp.97.2.173; DELPIRE E, 1992, J MEMBRANE BIOL, V126, P89; Di Stefano A, 1998, CELL PHYSIOL BIOCHEM, V8, P89, DOI 10.1159/000016273; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; ELLISON DH, 1985, AM J PHYSIOL, V248, pF638, DOI 10.1152/ajprenal.1985.248.5.F638; ENAN E, 1992, BIOCHEM PHARMACOL, V43, P177; Fahlke C, 1997, P NATL ACAD SCI USA, V94, P2729, DOI 10.1073/pnas.94.6.2729; Fahlke C, 1997, NATURE, V390, P529, DOI 10.1038/37391; Flatman PW, 1996, AM J PHYSIOL-CELL PH, V271, pC255, DOI 10.1152/ajpcell.1996.271.1.C255; GAMBA G, 1994, J BIOL CHEM, V269, P17713; Gamba G, 1999, KIDNEY INT, V56, P1606, DOI 10.1046/j.1523-1755.1999.00712.x; GARAY RP, 1988, MOL PHARMACOL, V33, P696; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; GREGER R, 1983, PFLUG ARCH EUR J PHY, V396, P325, DOI 10.1007/BF01063938; Harling H, 1997, EMBO J, V16, P5855, DOI 10.1093/emboj/16.19.5855; Hiki K, 1999, J BIOL CHEM, V274, P10661, DOI 10.1074/jbc.274.15.10661; Holtzman EJ, 1998, AM J PHYSIOL-RENAL, V275, pF550, DOI 10.1152/ajprenal.1998.275.4.F550; Isenring P, 1998, J BIOL CHEM, V273, P11295, DOI 10.1074/jbc.273.18.11295; Isenring P, 1998, J GEN PHYSIOL, V112, P549, DOI 10.1085/jgp.112.5.549; Isenring P, 1998, P NATL ACAD SCI USA, V95, P7179, DOI 10.1073/pnas.95.12.7179; Isenring P, 1997, J BIOL CHEM, V272, P24556, DOI 10.1074/jbc.272.39.24556; Isenring Paul, 1996, Journal of the American Society of Nephrology, V7, P1282; ISHIBASHI K, 1990, AM J PHYSIOL, V258, pF1569; Jacoby SC, 1999, AM J PHYSIOL-CELL PH, V277, pC684, DOI 10.1152/ajpcell.1999.277.4.C684; Jarolimek W, 1999, J NEUROSCI, V19, P4695; JENNINGS ML, 1991, J GEN PHYSIOL, V97, P799, DOI 10.1085/jgp.97.4.799; Ji HL, 1998, AM J PHYSIOL-CELL PH, V275, pC1182; KAJI DM, 1991, AM J PHYSIOL, V260, pC176, DOI 10.1152/ajpcell.1991.260.1.C176; Krarup T, 1996, AM J PHYSIOL-CELL PH, V270, pC898, DOI 10.1152/ajpcell.1996.270.3.C898; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; LAUF PK, 1992, AM J PHYSIOL, V263, pC917, DOI 10.1152/ajpcell.1992.263.5.C917; LAUF PK, 1991, AM J PHYSIOL, V260, pC503, DOI 10.1152/ajpcell.1991.260.3.C503; LAUF PK, 1995, AM J PHYSIOL-CELL PH, V269, pC1167, DOI 10.1152/ajpcell.1995.269.5.C1167; LAUF PK, 1987, J MEMBRANE BIOL, V98, P237, DOI 10.1007/BF01871186; LAUF PK, 1984, J MEMBRANE BIOL, V77, P57, DOI 10.1007/BF01871100; Li DL, 1998, AM J PHYSIOL-RENAL, V275, pF863, DOI 10.1152/ajprenal.1998.275.6.F863; Liapis H, 1998, AM J PHYSIOL-CELL PH, V275, pC1432, DOI 10.1152/ajpcell.1998.275.6.C1432; Moseley RH, 1999, AM J PHYSIOL-GASTR L, V276, pG185, DOI 10.1152/ajpgi.1999.276.1.G185; Mount DB, 1999, J BIOL CHEM, V274, P16355, DOI 10.1074/jbc.274.23.16355; Payne JA, 1996, J BIOL CHEM, V271, P16245, DOI 10.1074/jbc.271.27.16245; Payne JA, 1997, AM J PHYSIOL-CELL PH, V273, pC1516, DOI 10.1152/ajpcell.1997.273.5.C1516; PAYNE JA, 1990, AM J PHYSIOL, V259, pC819, DOI 10.1152/ajpcell.1990.259.5.C819; Pellegrino CM, 1998, BLOOD CELL MOL DIS, V24, P31, DOI 10.1006/bcmd.1998.0168; PERRY PB, 1993, AM J PHYSIOL, V265, pC763, DOI 10.1152/ajpcell.1993.265.3.C763; Race JE, 1999, AM J PHYSIOL-CELL PH, V277, pC1210, DOI 10.1152/ajpcell.1999.277.6.C1210; Rivera C, 1999, NATURE, V397, P251, DOI 10.1038/16697; ROSE BD, 1991, KIDNEY INT, V39, P336, DOI 10.1038/ki.1991.43; Scott DA, 1999, NAT GENET, V21, P440, DOI 10.1038/7783; STARKE LC, 1993, AM J PHYSIOL, V264, pC118, DOI 10.1152/ajpcell.1993.264.1.C118; Strange K, 2000, AM J PHYSIOL-CELL PH, V279, pC860, DOI 10.1152/ajpcell.2000.279.3.C860; Su WF, 1999, AM J PHYSIOL-CELL PH, V277, pC899, DOI 10.1152/ajpcell.1999.277.5.C899; Vandorpe DH, 1998, J BIOL CHEM, V273, P21542, DOI 10.1074/jbc.273.34.21542; WEILMASLANSKY E, 1994, AM J PHYSIOL-CELL PH, V267, pC932, DOI 10.1152/ajpcell.1994.267.4.C932; Yan GX, 1996, J PHYSIOL-LONDON, V490, P215, DOI 10.1113/jphysiol.1996.sp021137	65	140	147	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30326	30334		10.1074/jbc.M003112200	http://dx.doi.org/10.1074/jbc.M003112200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10913127	hybrid			2022-12-27	WOS:000089577900057
J	Uchida, T; Ishimori, K; Morishima, I				Uchida, T; Ishimori, K; Morishima, I			Unusual pressure effects on ligand rebinding to the human myoglobin leucine 29 mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VOLUME PROFILE ANALYSIS; SPERM WHALE MYOGLOBIN; CARBON-MONOXIDE; HYDROSTATIC-PRESSURE; FLASH-PHOTOLYSIS; LASER PHOTOLYSIS; BINDING-DYNAMICS; HEME POCKET; PROTEINS; SPECTRA	Using high pressure flash photolysis, we revealed that the side chain of Leu(29) controls the reaction volume of the ligand migration process in myoglobin, which is the primary factor for the unusual activation volume of ligand binding in some Leu(29) mutants. As we previously reported (Adachi, S., Sunohara, N., Ishimori, K., and Morishima, I. (1992) J. Biol. Chem. 267, 12614-12621), CO bimolecular rebinding in the L29A mutant was unexpectedly decelerated by pressurization, suggesting that the rate-determining step is switched to ligand migration. However, very slow CO bimolecular rebinding of the mutants implies that bond formation is still the rate-determining step. To gain further insights into effects of the side chain on ligand binding, we prepared some new Leu(29) mutants to measure the CO and O-2 rebinding reaction rates under high hydrostatic pressure. CO bimolecular rebinding in the mutants bearing Gly or Ser at position 29 was also decelerated upon pressurization, resulting in apparent positive activation volumes (Delta V-double dagger), as observed for O-2 binding. Based on the three-state model, we concluded that the increased space available to ligands in these mutants enhances the volume difference between the geminate and deoxy states (Delta V-32), which shifts the apparent activation volume to the positive side, and that the apparent positive activation volume is not due to contribution of the ligand migration process to the rate-determining step.	Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6068501, Japan	Kyoto University	Morishima, I (corresponding author), Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6068501, Japan.		Ishimori, Koichiro/AAQ-4434-2021; Uchida, Takeshi/A-6455-2017; Ishimori, Koichiro/S-1247-2016	Ishimori, Koichiro/0000-0002-5868-0462; Uchida, Takeshi/0000-0001-9270-8329; Ishimori, Koichiro/0000-0002-5868-0462				ADACHI S, 1992, J BIOL CHEM, V267, P12614; ADACHI S, 1989, J BIOL CHEM, V264, P18896; ALDEN RG, 1989, J BIOL CHEM, V264, P1933; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN, P193; BALNY C, 1989, BIOPHYS CHEM, V33, P237, DOI 10.1016/0301-4622(89)80025-0; CARVER TE, 1990, J BIOL CHEM, V265, P20007; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; FRAUENFELDER H, 1990, J PHYS CHEM-US, V94, P1024, DOI 10.1021/j100366a002; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; GIBSON QH, 1977, J BIOL CHEM, V252, P4098; GROSS M, 1994, EUR J BIOCHEM, V221, P617, DOI 10.1111/j.1432-1033.1994.tb18774.x; HARA K, 1988, REV SCI INSTRUM, V59, P2397, DOI 10.1063/1.1139917; HASINOFF BB, 1974, BIOCHEMISTRY-US, V13, P3111, DOI 10.1021/bi00712a017; HENRY ER, 1983, J MOL BIOL, V166, P443, DOI 10.1016/S0022-2836(83)80094-1; HEREMANS K, 1982, ANNU REV BIOPHYS BIO, V11, P1, DOI 10.1146/annurev.bb.11.060182.000245; HOA GHB, 1982, EUR J BIOCHEM, V124, P311; HOA GHB, 1989, BIOCHEMISTRY-US, V28, P651; JUNG C, 1995, EUR J BIOCHEM, V233, P600, DOI 10.1111/j.1432-1033.1995.600_2.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LAIRD BB, 1989, J CHEM PHYS, V90, P3274, DOI 10.1063/1.455881; LANGE R, 1994, BIOPHYS J, V66, P89, DOI 10.1016/S0006-3495(94)80772-6; Le Noble W.J., 1967, PROGR PHYS ORGANIC C, V5, P207; NEWMANN RC, 1973, J PHYS CHEM-US, V77, P2687; OGUNMOLA GB, 1977, P NATL ACAD SCI USA, V74, P1, DOI 10.1073/pnas.74.1.1; Olson JS, 1996, J BIOL CHEM, V271, P17593, DOI 10.1074/jbc.271.30.17593; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; PROJAHN HD, 1991, INORG CHEM, V30, P3288, DOI 10.1021/ic00017a014; PROJAHN HD, 1990, J AM CHEM SOC, V112, P17, DOI 10.1021/ja00157a005; Scott EE, 1997, BIOCHEMISTRY-US, V36, P11909, DOI 10.1021/bi970719s; SLICHTER CP, 1980, PHYS REV B, V22, P4097, DOI 10.1103/PhysRevB.22.4097; TAKANO T, 1977, J MOL BIOL, V110, P537, DOI 10.1016/S0022-2836(77)80111-3; TAUBE DJ, 1990, J AM CHEM SOC, V112, P6880, DOI 10.1021/ja00175a023; Uchida T, 1997, J BIOL CHEM, V272, P30108, DOI 10.1074/jbc.272.48.30108; UNNO M, 1991, BIOCHEMISTRY-US, V30, P10679, DOI 10.1021/bi00108a011; UNNO M, 1990, BIOCHEMISTRY-US, V29, P10199, DOI 10.1021/bi00496a007; UNNO M, 1994, BIOCHEMISTRY-US, V33, P9762, DOI 10.1021/bi00198a047; VANELDIK R, 1989, CHEM REV, V89, P549, DOI 10.1021/cr00093a005; VANELLDIK R, 1986, INORGANIC HIGH PRESS; VARADARAJAN R, 1989, BIOCHEMISTRY-US, V28, P3771, DOI 10.1021/bi00435a022; VARADARAJAN R, 1985, P NATL ACAD SCI USA, V82, P5681, DOI 10.1073/pnas.82.17.5681	42	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30309	30316		10.1074/jbc.M910287199	http://dx.doi.org/10.1074/jbc.M910287199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10906339	hybrid			2022-12-27	WOS:000089577900055
J	Hudder, A; Werner, R				Hudder, A; Werner, R			Analysis of a Charcot-Marie-Tooth disease mutation reveals an essential internal ribosome entry site element in the connexin-32 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; 5'-UNTRANSLATED REGION; TRANSLATION INITIATION; 5'-NONCODING SEQUENCES; C-MYC; EXPRESSION; BINDING; LEADER; SYSTEM; EIF4G	A mutation located in the 5'-untranslated region (5'-UTR) of the nerve-specific connexin-32 mRNA, previously found in a family with Charcot-Marie-Tooth disease (CMTX), was analyzed for its effect on the expression of a reporter gene (luciferase) in transgenic mice and in transfected cells. Whereas both mutant and wild-type genes appeared to be transcribed and spliced efficiently, no luciferase was detected from the mutant in either system, suggesting that the mutation affects translation of the mRNA When the 5'-UTR of nerve-specific connexin-32 mRNA was inserted between the two genes of a bicistronic vector and transfected into various cell Lines, expression of the second gene was significantly increased. Because the mutant did not facilitate translation of the second gene in the bicistronic mRNA system, this result suggested that the CMTX mutation abolished function of an internal ribosome entry site (IRES) in the 5'-UTR of the wild-type connexin-32 mRNA The CMTX phenotype of the mutant 5'-UTR further suggested that the wild-type IRES was essential for the translation of the connexin-32 mRNA in nerve cells, In addition, other sequence elements of the connexin-32 IRES were characterized by mutation analysis; A mutation in either of the first two elements investigated showed loss of IRES function, whereas mutation of a third element showed gain of function.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami	Werner, R (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, POB 016129, Miami, FL 33101 USA.		Hudder, Alice/A-9342-2009		NICHD NIH HHS [HD34152] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034152] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; Chappell SA, 2000, P NATL ACAD SCI USA, V97, P1536, DOI 10.1073/pnas.97.4.1536; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; FLAGIELLO L, 1999, HUM MUTAT, V195, P361; Gan WN, 1996, J BIOL CHEM, V271, P623, DOI 10.1074/jbc.271.2.623; HILL JR, 1992, J BIOL CHEM, V267, P21886; HOFFMAN MA, 1995, J VIROL, V65, P4867; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; IMATAKA H, 1994, J BIOL CHEM, V269, P20668; Ionasescu VV, 1996, NEUROLOGY, V47, P541, DOI 10.1212/WNL.47.2.541; JACKSON RJ, 1988, NATURE, V334, P292, DOI 10.1038/334292a0; Jackson RJ, 1995, RNA, V1, P985; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; Kim JG, 1998, MOL CELL NEUROSCI, V12, P119, DOI 10.1006/mcne.1998.0701; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Negulescu D, 1998, J BIOL CHEM, V273, P20109, DOI 10.1074/jbc.273.32.20109; NEUHAUS IM, 1995, GENE, V158, P257, DOI 10.1016/0378-1119(94)00899-4; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; PERICAKVANCE MA, 1995, HUM HERED, V45, P121, DOI 10.1159/000154272; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Robertson MEM, 1999, RNA, V5, P1167, DOI 10.1017/S1355838299990301; Sachs AB, 2000, CELL, V101, P243, DOI 10.1016/S0092-8674(00)80834-X; Schiavi A, 1999, FEBS LETT, V464, P118, DOI 10.1016/S0014-5793(99)01699-3; Witherell GW, 1995, VIROLOGY, V214, P660, DOI 10.1006/viro.1995.0081; YU W, 1994, P ROY SOC B-BIOL SCI, V255, P125, DOI 10.1098/rspb.1994.0018; Zhang J, 1999, VIROLOGY, V261, P263, DOI 10.1006/viro.1999.9879; ZUKER M, 1999, ALGORITHMS THERMODYN	32	78	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34586	34591		10.1074/jbc.M005199200	http://dx.doi.org/10.1074/jbc.M005199200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10931843	hybrid			2022-12-27	WOS:000165095300080
J	Koh, H; Lee, KH; Kim, D; Kim, S; Kim, JW; Chung, J				Koh, H; Lee, KH; Kim, D; Kim, S; Kim, JW; Chung, J			Inhibition of Akt and its anti-apoptotic activities by tumor necrosis factor-induced protein kinase C-related kinase 2 (PRK2) cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GLYCOGEN-SYNTHASE KINASE-3; PHOSPHATIDYLINOSITOL 3-KINASE; MOLECULAR-CLONING; SIGNAL-TRANSDUCTION; POTENTIAL EFFECTOR; IN-VITRO; ACTIVATION; PHOSPHORYLATION; INSULIN	Akt is stimulated by several growth factors and has a major anti-apoptotic role in the cell. Therefore, we hypothesized that a pathway leading to the inhibition of Akt might be utilized in the process of apoptosis. Accordingly, we used a yeast two-hybrid screening assay to identify the proteins that interact with and possibly inhibit Akt, We found that the C-terminal region of protein kinase C-related kinase 2 (PRK2), containing amino acids 862 to 908, specifically binds to Akt in yeast and mammalian cells. During early stages of apoptosis, the C-terminal region of PRK2 is cleaved from the inhibitory N-terminal region and can bind Akt, The protein-protein interaction between Akt and the PRK2 C-terminal region specifically down-modulates the protein kinase activities of Akt by inhibiting phosphorylation at threonine 308 and serine 473 of Akt, This inhibition of Abt leads to the inhibition of the downstream signaling of Akt in vivo. The PRK2 C-terminal fragment strongly inhibits the Akt-mediated phosphorylation of BAD, a pro-apoptotic Bcl-2 family protein, and blocks the anti-apoptotic activities of Akt in vivo. These results provide direct evidence that the products of protein cleavage during apoptosis inhibit pro-survival signalings, leading to the amplification of pro-apoptotic signalings in the cell.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Pai Chai Univ, Dept Biochem, Taejon 302735, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Pai Chai University	Chung, J (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, 373-1 Kusong Dong, Taejon 305701, South Korea.	jchung@mail.kaist.ac.kr	Koh, Hyoungjong/C-1615-2012	Koh, Hyongjong/0000-0003-2594-4799				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cryns VL, 1997, J BIOL CHEM, V272, P29449, DOI 10.1074/jbc.272.47.29449; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Francois F, 1999, J NEUROCHEM, V73, P1773, DOI 10.1046/j.1471-4159.1999.731773.x; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Hemmings BA, 1997, SCIENCE, V275, P1899, DOI 10.1126/science.275.5308.1899; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; Ozes ON, 1999, NATURE, V401, P82; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; Rho SB, 1996, P NATL ACAD SCI USA, V93, P10128, DOI 10.1073/pnas.93.19.10128; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	55	56	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34451	34458		10.1074/jbc.M001753200	http://dx.doi.org/10.1074/jbc.M001753200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10926925	hybrid			2022-12-27	WOS:000165095300061
J	Mao, AJ; Bechberger, J; Lidington, D; Galipeau, J; Laird, DW; Naus, CCG				Mao, AJ; Bechberger, J; Lidington, D; Galipeau, J; Laird, DW; Naus, CCG			Neuronal differentiation and growth control of neuro-2a cells after retroviral gene delivery of connexin43	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION PROTEIN; C6 GLIOMA-CELLS; GREEN FLUORESCENT PROTEIN; EMBRYONAL CARCINOMA-CELLS; MICE LACKING CONNEXIN43; HIGH-TITER; NERVOUS-SYSTEM; HELA-CELLS; IN-VITRO; EXPRESSION	Given the roles proposed for gap junctional intercellular communication in neuronal differentiation and growth control, we examined the effects of connexin43 (Cx43) expression in a neuroblastoma cell line. A vesicular stomatitis virus G protein (VSVG)-pseudotyped retrovector was engineered to co-express the green fluorescent protein (GFP) and Cx43 in the communication-deficient neuro-2a (N2a) cell line. The 293 GPG packaging cell line was used to produce VSVG-pseudotyped retrovectors coding for GFP, Cx43, or chimeric Cx43 GFP fusion protein. The titer of viral supernatant, as measured by flow cytometry for GFP fluorescence, was approximately 2.0 x 10(7) colony form units (CFU)/ml and was free of replication-competent retroviruses. After a 7-day treatment with retinoic acid (20 muM), N2a transformants (N2a-Cx43 and N2a-Cx43 GFP) maintained the expression of Cx43 and Cx43 GFP. Expression of both constructs resulted in functional coupling, as evidenced by electrophysiological and dye-injection analysis. Suppression of cell growth correlated with expression of both Cx43 or Cx43 GFP and retinoic acid treatment. Based on morphology and immunocytochemistry for neurofilament, no difference was observed in the differentiation of N2a cells compared with cells expressing Cx43 constructs. In conclusion, constitutive expression of Cx43 in N2a cells does not alter retinoic acid-induced neuronal differentiation but does enhance growth inhibition.	Univ Western Ontario, Dept Anat & Cell Biol, Child Hlth Res Inst, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Med Biophys, Child Hlth Res Inst, London, ON N6A 5C1, Canada; McGill Univ, Lady Davis Inst, McGill Ctr Translat Res Canc, Montreal, PQ H3T 1E2, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Lady Davis Institute; McGill University	Naus, CCG (corresponding author), Univ Western Ontario, Dept Anat & Cell Biol, Child Hlth Res Inst, Med Sci Bldg, London, ON N6A 5C1, Canada.		Laird, Dale w/E-4176-2015; Laird, Dale W/AAL-2407-2020; Galipeau, Jacques/R-9909-2019	Laird, Dale W/0000-0002-4568-3285; Galipeau, Jacques/0000-0002-9374-1996; Lidington, Darcy/0000-0001-7582-7924				AboodyGuterman KS, 1997, NEUROREPORT, V8, P3801, DOI 10.1097/00001756-199712010-00029; Bagley J, 1998, TRANSPLANTATION, V65, P1233, DOI 10.1097/00007890-199805150-00015; Bani-Yaghoub M, 1999, DEV GENET, V24, P69, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<69::AID-DVG8>3.0.CO;2-M; Bani-Yaghoub M, 1999, EXP NEUROL, V156, P16, DOI 10.1006/exnr.1998.6950; BaniYaghoub M, 1997, J NEUROSCI RES, V49, P19, DOI 10.1002/(SICI)1097-4547(19970701)49:1<19::AID-JNR3>3.0.CO;2-G; Belliveau DJ, 1997, DEV GENET, V21, P187, DOI 10.1002/(SICI)1520-6408(1997)21:3<187::AID-DVG2>3.0.CO;2-3; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; Bruzzone R, 1997, EUR J NEUROSCI, V9, P1, DOI 10.1111/j.1460-9568.1997.tb01346.x; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; Bukauskas FF, 2000, P NATL ACAD SCI USA, V97, P2556, DOI 10.1073/pnas.050588497; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; CEPEDA C, 1993, CEREB CORTEX, V3, P95, DOI 10.1093/cercor/3.2.95; COOK JE, 1995, MICROSC RES TECHNIQ, V31, P408, DOI 10.1002/jemt.1070310510; DERMIETZEL R, 1993, TRENDS NEUROSCI, V16, P186, DOI 10.1016/0166-2236(93)90151-B; Dudek F.E., 1983, BASIC MECHANISMS NEU, P31; EGHBALI B, 1991, P NATL ACAD SCI USA, V88, P10701, DOI 10.1073/pnas.88.23.10701; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; FREDERICK M, 1993, CURRENT PROTOCOLS MO; Galipeau J, 1999, CANCER RES, V59, P2384; HOLDER JW, 1993, CANCER RES, V53, P3475; Jordan K, 1999, MOL BIOL CELL, V10, P2033, DOI 10.1091/mbc.10.6.2033; Juneja SC, 1999, BIOL REPROD, V60, P1263, DOI 10.1095/biolreprod60.5.1263; Kandler Karl, 1995, Current Opinion in Neurobiology, V5, P98, DOI 10.1016/0959-4388(95)80093-X; LAIRD DW, 1990, J CELL SCI, V97, P109; LOEWENSTEIN WR, 1966, NATURE, V209, P1248, DOI 10.1038/2091248a0; MESNIL M, 1993, MOL CARCINOGEN, V7, P14, DOI 10.1002/mc.2940070103; MESNIL M, 1995, CANCER RES, V55, P629; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; Nadarajah B, 1996, J COMP NEUROL, V376, P326, DOI 10.1002/(SICI)1096-9861(19961209)376:2<326::AID-CNE13>3.0.CO;2-J; NAUS CCG, 1992, CELL MOL NEUROBIOL, V12, P163, DOI 10.1007/BF00713370; NAUS CCG, 1992, CANCER RES, V52, P4208; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; ROSE B, 1993, CARCINOGENESIS, V14, P1073, DOI 10.1093/carcin/14.5.1073; ROZENTAL R, 1995, DEV BIOL, V167, P350, DOI 10.1006/dbio.1995.1029; RUCH RJ, 1994, ANN CLIN LAB SCI, V24, P216; SPRAY DC, 1985, ANNU REV PHYSIOL, V47, P281, DOI 10.1146/annurev.ph.47.030185.001433; SPRAY DC, 1981, J GEN PHYSIOL, V77, P77, DOI 10.1085/jgp.77.1.77; VEENSTRA RD, 1992, CIRC RES, V71, P1277, DOI 10.1161/01.RES.71.5.1277; Wang LJ, 1996, EXP NEUROL, V139, P1, DOI 10.1006/exnr.1996.0074; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; ZHU D, 1991, P NATL ACAD SCI USA, V88, P1883, DOI 10.1073/pnas.88.5.1883; ZHU DG, 1992, P NATL ACAD SCI USA, V89, P10218, DOI 10.1073/pnas.89.21.10218	44	63	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34407	34414		10.1074/jbc.M003917200	http://dx.doi.org/10.1074/jbc.M003917200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10924505	hybrid			2022-12-27	WOS:000165095300056
J	Saito, S; Hiroi, Y; Zou, YZ; Aikawa, R; Toko, H; Shibasaki, F; Yazaki, Y; Nagai, R; Komuro, I				Saito, S; Hiroi, Y; Zou, YZ; Aikawa, R; Toko, H; Shibasaki, F; Yazaki, Y; Nagai, R; Komuro, I			beta-adrenergic pathway induces apoptosis through calcineurin activation in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGESTIVE-HEART-FAILURE; CYTOCHROME-C; CELL-DEATH; BAD PHOSPHORYLATION; RECEPTOR BLOCKADE; HYPERTROPHY; RELEASE; DISSOCIATION; MITOCHONDRIA; INVOLVEMENT	Apoptosis of cardiac myocytes is one of the causes of heart failure. Here we examine the mechanism by which the activation of beta -adrenergic receptor induces cardiomyocyte apoptosis. Terminal deoxynucleotide transferase-mediated dUTP nick end labeling and DNA ladder analyses revealed that isoproterenol (Iso) induced the apoptosis of cardiac myocytes of neonatal rats through an increase in intracellular Ca2+ levels. The Iso-induced cardiomyocyte apoptosis was strongly inhibited by the L-type Ca2+ channel antagonist nifedipine and by the calcineurin inhibitors cyclosporin A and FK506. Iso reduced the phosphorylation levels of the proapoptotic Bcl-2 family protein Bad and induced cytochrome c release from mitochondria to the cytosol through calcineurin activation. Infusion of Iso increased calcineurin activity by similar to3-fold in the hearts of wild-type mice but not in the hearts of transgenic mice that overexpress dominant negative mutants of calcineurin. Terminal deoxynucleotide transferase-mediated dUTP nick end labeling analysis revealed that infusion of Iso induced apoptosis of cardiac myocytes and that the number of apoptotic cardiomyocytes was significantly less in the hearts of the transgenic mice compared with the wild-type mice. These results suggest that calcineurin plays a critical role in Iso-induced apoptosis of cardiac myocytes, possibly through dephosphorylating Bad.	Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo 1138655, Japan; Tokyo Metropolitan Inst Med Sci, Tokyo 1138613, Japan	University of Tokyo; Tokyo Metropolitan Institute of Medical Science	Komuro, I (corresponding author), Chiba Univ, Sch Med, Dept Med 3, Chuo Ku, 1-8-1 Inohana, Chiba 2608677, Japan.							Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Ankarcrona M, 1996, FEBS LETT, V394, P321, DOI 10.1016/0014-5793(96)00959-3; Asai K, 1999, J CLIN INVEST, V104, P551, DOI 10.1172/JCI7418; BEAN BP, 1984, NATURE, V307, P371, DOI 10.1038/307371a0; Communal C, 1998, CIRCULATION, V98, P1329, DOI 10.1161/01.CIR.98.13.1329; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; De Windt LJ, 2000, CIRC RES, V86, P255, DOI 10.1161/01.RES.86.3.255; DEL PL, 1997, SCIENCE, V278, P687; DOUGHTY RN, 1994, J AM COLL CARDIOL, V23, P814, DOI 10.1016/0735-1097(94)90773-0; Geng YJ, 1999, CIRC RES, V84, P34; HASKING GJ, 1986, CIRCULATION, V73, P615, DOI 10.1161/01.CIR.73.4.615; Iwai-Kanai E, 1999, CIRCULATION, V100, P305, DOI 10.1161/01.CIR.100.3.305; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krown KA, 1996, J CLIN INVEST, V98, P2854, DOI 10.1172/JCI119114; Leri A, 1998, J CLIN INVEST, V101, P1326, DOI 10.1172/JCI316; Lotem J, 1999, P NATL ACAD SCI USA, V96, P12016, DOI 10.1073/pnas.96.21.12016; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; Newton GE, 1996, CIRCULATION, V94, P353, DOI 10.1161/01.CIR.94.3.353; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; RONA G, 1985, J MOL CELL CARDIOL, V17, P291, DOI 10.1016/S0022-2828(85)80130-9; Saraste A, 1997, CIRCULATION, V95, P320; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; SHEU SS, 1987, AM J PHYSIOL, V252, pH697, DOI 10.1152/ajpheart.1987.252.4.H697; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Shizukuda Y, 1998, AM J PHYSIOL-HEART C, V275, pH961, DOI 10.1152/ajpheart.1998.275.3.H961; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; SWEDBERG K, 1984, AM J CARDIOL, V54, P783, DOI 10.1016/S0002-9149(84)80208-8; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yoshikawa T, 1996, AM HEART J, V131, P329, DOI 10.1016/S0002-8703(96)90362-2; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	34	138	151	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34528	34533		10.1074/jbc.M002844200	http://dx.doi.org/10.1074/jbc.M002844200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10931827	hybrid			2022-12-27	WOS:000165095300072
J	Muehlenweg, B; Assfalg-Machleidt, I; Parrado, SG; Burgle, M; Creutzburg, S; Schmitt, M; Auerswald, EA; Machleidt, W; Magdolen, V				Muehlenweg, B; Assfalg-Machleidt, I; Parrado, SG; Burgle, M; Creutzburg, S; Schmitt, M; Auerswald, EA; Machleidt, W; Magdolen, V			A novel type of bifunctional inhibitor directed against proteolytic activity and receptor/ligand interaction - Cystatin with a urokinase receptor binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-CELL INVASION; EGG-WHITE CYSTATIN; CATHEPSIN-B; CHICKEN CYSTATIN; PROTEASE INHIBITORS; TERMINAL FRAGMENT; ESCHERICHIA-COLI; METASTASIS; EXPRESSION; PROGRESSION	Cancer invasion and metastasis is a process requiring a coordinated series of (anti-)adhesive, migratory, and pericellular proteolytic events involving various proteases such as urokinase-type plasminogen activator (uPA)/plasmin, cathepsins B and L, and matrix metalloproteases. Novel types of double-headed inhibitors directed to different tumor-associated proteolytic systems were generated by substitution of a loop in chicken cystatin, which is nonessential for cysteine protease inhibition, with uPA-derived peptides covering the human uPA receptor binding sequence uPA-(19-31), The inhibition constants of these hybrids toward cysteine proteases are similar to those of wild-type cystatin (K-i, papain (pm), 1.9-2.4; K-i, cathepsin B (nM), 1.0-1.7; K-i, cathepsin L (par), 0.12-0.61). FAGS analyses revealed that the hybrids compete for binding of uPA to the cell surface-associated uPA receptor (uPAR) expressed on human U937 cells. The simultaneous interaction of the hybrid molecules with papain and uPAR was analyzed by surface plasmon resonance. The measured K-D value of a papain-bound cystatin variant harboring the uPAR binding sequence of uPA (chCys-uPA-(19-31)) and soluble uPAR was 17 nM (K-D value for uPA/uPAR interaction, 5 nM). These results indicate that cystatins with a uPAR binding site are efficient inhibitors of cysteine proteases and uPA/uPAR interaction at the same time. Therefore, these compact and small bifunctional inhibitors may represent promising agents for the therapy of solid tumors.	Tech Univ Munich, Frauenklin, Klin Forschergrp, D-81675 Munich, Germany; Wilex Biotechnol, D-81675 Munich, Germany; Univ Munich, Chirurg Klin Innenstadt, Abt Klin Chem & Klin Biochem, D-80336 Munich, Germany; Univ Munich, Chirurg Klin Innenstadt, Adolf Butenandt Inst Physiol Chem Phys Biochem &, D-80336 Munich, Germany	Technical University of Munich; University of Munich; University of Munich	Muehlenweg, B (corresponding author), Tech Univ Munich, Frauenklin, Klin Forschergrp, Ismaninger Str 22, D-81675 Munich, Germany.							Alvarez-Fernandez M, 1999, J BIOL CHEM, V274, P19195, DOI 10.1074/jbc.274.27.19195; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; AUERSWALD EA, 1994, EUR J BIOCHEM, V224, P407, DOI 10.1111/j.1432-1033.1994.00407.x; Auerswald EA, 1996, EUR J BIOCHEM, V235, P534, DOI 10.1111/j.1432-1033.1996.00534.x; AUERSWALD EA, 1992, EUR J BIOCHEM, V209, P837, DOI 10.1111/j.1432-1033.1992.tb17355.x; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; BOKMAN AM, 1993, J BIOL CHEM, V268, P13858; Burgle M, 1997, BIOL CHEM, V378, P231, DOI 10.1515/bchm.1997.378.3-4.231; Coulibaly S, 1999, INT J CANCER, V83, P526, DOI 10.1002/(SICI)1097-0215(19991112)83:4<526::AID-IJC15>3.3.CO;2-D; Cox JL, 1999, MELANOMA RES, V9, P369, DOI 10.1097/00008390-199908000-00005; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; DeClerck YA, 1997, ADV EXP MED BIOL, V425, P89; ENGH RA, 1993, J MOL BIOL, V234, P1060, DOI 10.1006/jmbi.1993.1659; Foekens JA, 2000, CANCER RES, V60, P636; Frosch BA, 1999, APMIS, V107, P28, DOI 10.1111/j.1699-0463.1999.tb01523.x; Grasberger H, 1999, J BIOL CHEM, V274, P15046, DOI 10.1074/jbc.274.21.15046; Harbeck N, 2000, INT J BIOL MARKER, V15, P79, DOI 10.1177/172460080001500115; Kobayashi H, 1998, EUR J BIOCHEM, V253, P817, DOI 10.1046/j.1432-1327.1998.2530817.x; Kolkhorst V, 1998, J CANCER RES CLIN, V124, P598, DOI 10.1007/s004320050221; Kruger A, 2000, CANCER GENE THER, V7, P292, DOI 10.1038/sj.cgt.7700144; LU H, 1994, FEBS LETT, V356, P56, DOI 10.1016/0014-5793(94)01237-7; MACHLEIDT W, 1995, FEBS LETT, V361, P185, DOI 10.1016/0014-5793(95)00174-8; MACHLEIDT W, 1993, MONOGRAPHS INNOVATIO, P179; MAGDOLEN V, 1995, ELECTROPHORESIS, V16, P813, DOI 10.1002/elps.11501601134; McCarthy BJ, 1997, J MOL BIOL, V267, P561, DOI 10.1006/jmbi.1996.0909; Min HY, 1996, CANCER RES, V56, P2428; Monahan PE, 2000, GENE THER, V7, P24, DOI 10.1038/sj.gt.3301109; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; PADMANABHAN J, 1995, THROMB HAEMOSTASIS, V73, P829; Reuning U, 1998, INT J ONCOL, V13, P893; Schmitt M, 2000, FIBRINOLYSIS PROTEOL, V14, P114, DOI 10.1054/fipr.2000.0079; STRAUSS M, 1988, BIOL CHEM H-S, V369, P209; Thomssen C, 1995, CLIN CANCER RES, V1, P741; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Yan SQ, 1998, BIOL CHEM, V379, P113	36	34	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33562	33566		10.1074/jbc.C000383200	http://dx.doi.org/10.1074/jbc.C000383200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10913110	hybrid			2022-12-27	WOS:000090104600055
J	Spitaler, M; Villunger, A; Grunicke, H; Uberall, F				Spitaler, M; Villunger, A; Grunicke, H; Uberall, F			Unique structural and functional properties of the ATP-binding domain of atypical protein kinase C-iota	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROLYZING PHOSPHOLIPASE-C; DRUG-INDUCED APOPTOSIS; TYROSINE KINASE; CRYSTAL-STRUCTURE; INSULIN-RECEPTOR; IN-VIVO; CAENORHABDITIS-ELEGANS; EPITHELIAL-CELLS; DOWN-REGULATION; PKC-EPSILON	Atypical protein kinase C-iota (aPKC iota) plays an important role in mitogenic signaling, actin cytoskeleton organization, and cell survival. Apart from the differences in the regulatory domain, the catalytic domain of aPKC iota differs considerably from other known kinases, because it contains a modification within the glycine-rich loop motif (GXGXXG) that is found in the nucleotide-binding fold of virtually all nucleotide-binding proteins including PI(Cs, Ras, adenylate kinase, and the mitochondrial F1-ATPase, We have used site-directed mutagenesis and kinetic analysis to investigate whether these sequence differences affect the nucleotide binding properties and catalytic activity of aPKC iota. When lysine 274, a residue essential for ATP binding and activity conserved in most protein kinases, was replaced by arginine (K274R mutant), aPKC iota retained its normal kinase activity. This is in sharp contrast to results published for any other PKC or even distantly related kinases like phosphoinositide S-kinase gamma, where the same mutation completely abrogated the kinase activity. Furthermore, the sensitivity of aPKC iota for inhibition by GF109203X, a substance acting on the ATP-binding site, was not altered in the K274R mutant. In contrast, replacement of Lys-274 by tryptophan (K274W) completely abolished the kinase activity of PKC iota, In accordance with results obtained with other kinase-defective PKC mutants, in cultured cells aPKC iota -R274W acted in a dominant negative fashion on signal transduction pathways involving endogenous aPKC iota, whereas the effect of the catalytically active K274R mutant was identical to the wild type enzyme. In summary, aPKC iota differs from classical and novel PKCs also in the catalytic domain. This information could be of significant value for the development of specific inhibitors of aPKC iota as a key factor in central signaling pathways.	Univ Innsbruck, Inst Med Chem & Biochem, A-6020 Innsbruck, Austria	University of Innsbruck	Spitaler, M (corresponding author), Univ Innsbruck, Inst Med Chem & Biochem, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	martin.spitaler@uibk.ac.at		Spitaler, Martin/0000-0002-8833-638X				AHMAD S, 1993, MOL PHARMACOL, V43, P858; Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; Bandyopadhyay G, 1999, BIOCHEM J, V337, P461, DOI 10.1042/0264-6021:3370461; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Bjorkoy G, 1997, J BIOL CHEM, V272, P11557; BJORKOY G, 1995, J BIOL CHEM, V270, P21299; Chan CL, 1996, J BIOL CHEM, V271, P22619, DOI 10.1074/jbc.271.37.22619; CHIN JE, 1993, J BIOL CHEM, V268, P6338; CHOU CK, 1987, J BIOL CHEM, V262, P1842; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; Enke DA, 1999, J BIOL CHEM, V274, P1949, DOI 10.1074/jbc.274.4.1949; Gatti A, 1996, J BIOL CHEM, V271, P31718, DOI 10.1074/jbc.271.49.31718; Ghaffari-Tabrizi N, 1999, EUR J IMMUNOL, V29, P132; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; GRAVITT KR, 1994, BIOCHEM PHARMACOL, V48, P375, DOI 10.1016/0006-2952(94)90110-4; Guo Q, 1998, NAT MED, V4, P957, DOI 10.1038/nm0898-957; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; Kampfer S, 1998, EMBO J, V17, P4046, DOI 10.1093/emboj/17.14.4046; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Masso-Welch PA, 1998, EUR J CELL BIOL, V77, P48, DOI 10.1016/S0171-9335(98)80101-5; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; ODAWARA M, 1989, SCIENCE, V245, P66, DOI 10.1126/science.2544998; ORR JW, 1994, J BIOL CHEM, V269, P27715; Perletti GP, 1996, ONCOGENE, V12, P847; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; SchmitzPeiffer C, 1997, DIABETES, V46, P169, DOI 10.2337/diabetes.46.2.169; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; Stoyanova S, 1997, BIOCHEM J, V324, P489, DOI 10.1042/bj3240489; Tabuse Y, 1998, DEVELOPMENT, V125, P3607; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TONG L, 1989, NATURE, V337, P90, DOI 10.1038/337090a0; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Uberall F, 1999, J CELL BIOL, V144, P413, DOI 10.1083/jcb.144.3.413; Uberall F, 1997, J BIOL CHEM, V272, P4072, DOI 10.1074/jbc.272.7.4072; WEINMASTER G, 1986, EMBO J, V5, P69, DOI 10.1002/j.1460-2075.1986.tb04179.x; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; ZHAO L, 1994, ENDOCRINOLOGY, V135, P2504, DOI 10.1210/en.135.6.2504; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	53	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33289	33296		10.1074/jbc.M002742200	http://dx.doi.org/10.1074/jbc.M002742200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10906326	hybrid			2022-12-27	WOS:000090104600018
J	Abel, A; Wittau, N; Wieland, T; Schultz, G; Kalkbrenner, F				Abel, A; Wittau, N; Wieland, T; Schultz, G; Kalkbrenner, F			Cell cycle-dependent coupling of the vasopressin V-1a receptor to different G proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; GONADOTROPIN-RELEASING-HORMONE; HETEROTRIMERIC G-PROTEINS; PHOSPHOLIPASE-C ISOZYMES; BETA-GAMMA-SUBUNITS; ALPHA-SUBUNITS; RGS PROTEINS; MOLECULAR PHARMACOLOGY; FUNCTIONAL EXPRESSION; ARGININE-VASOPRESSIN	Arginine vasopressin (AVP) regulates biological processes by binding to G protein-coupled receptors. In Swiss 3T3 fibroblasts, expressing the V-1a subtype of vasopressin receptors, AVP mobilizes calcium from intracellular stores. In proliferating cells, the AVP-induced increase in intracellular calcium concentration ([Ca2+](i)) was mediated by G proteins of the G(q) family, which are insensitive to pertussis toxin (PTX) pretreatment of the cells. In quiescent cells, the AVP-induced increase in [Ca2+](i) was partially PTX-sensitive, suggesting an involvement of G. proteins. We confirmed this by photoaffinity labeling of G proteins in Swiss 3T3 cell membranes activated by AVP. In Swiss 3T3 cells arrested in the G(0)/G(1) phase of the cell cycle, the AVP-induced increase in [Ca2+](i) was also partially PTX-sensitive but was PTX-insensitive in cells arrested in other phases of the cell cycles. The blocking effect of PTX pretreatment in G(0)/G(1) cells was mimicked by microinjection of antisense oligonucleotides suppressing the expression of the G alpha (i3) subunits. These results were confirmed by microinjection of antibodies directed against the C terminus of G protein alpha -subunits. The data presented indicate that in Swiss 3T3 fibroblasts synchronized in the G(0)/G(1) phase of the cell cycle the V-1a receptor couples to G(q/11) and G(i3) to activate the phospholipase C-beta, leading to release of intracellular calcium.	Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pharmakol, D-14195 Berlin, Germany; Univ Hamburg, Krankenhaus Eppendorf, Abt Allgemeine Pharmakol, D-20246 Hamburg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Hamburg	Kalkbrenner, F (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pharmakol, Thielallee 69-73, D-14195 Berlin, Germany.	Frank.Kalkbrenner@bc.boehringeringelheim.com	Wieland, Thomas/Q-1506-2019; Wieland, Thomas/G-1772-2012	Wieland, Thomas/0000-0001-8262-8261; Wieland, Thomas/0000-0001-8262-8261				BAERTSCHI AJ, 1985, ENDOCRINOLOGY, V116, P499, DOI 10.1210/endo-116-2-499; Barberis C, 1999, DRUG NEWS PERSPECT, V12, P279, DOI 10.1358/dnp.1999.12.5.863621; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BIZZARRI C, 1994, ENDOCRINOLOGY, V134, P133, DOI 10.1210/en.134.1.133; Buckbinder L, 1997, P NATL ACAD SCI USA, V94, P7868, DOI 10.1073/pnas.94.15.7868; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CHAKRABORTY M, 1991, SCIENCE, V251, P1078, DOI 10.1126/science.1847755; COCKCROFT S, 1992, BIOCHEM J, V288, P1; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; Dippel E, 1996, P NATL ACAD SCI USA, V93, P1391, DOI 10.1073/pnas.93.4.1391; Dulin NO, 1999, MOL CELL BIOL, V19, P714; DUZIC E, 1992, J BIOL CHEM, V267, P9844; Exton JH, 1997, EUR J BIOCHEM, V243, P10, DOI 10.1111/j.1432-1033.1997.t01-1-00010.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; HOWL J, 1995, GEN PHARMACOL-VASC S, V26, P1143, DOI 10.1016/0306-3623(95)00016-T; Innamorati G, 1998, J BIOL CHEM, V273, P7155, DOI 10.1074/jbc.273.12.7155; JARD S, 1986, MOL PHARMACOL, V30, P171; JHON DY, 1993, J BIOL CHEM, V268, P6654; JIANG HP, 1994, J BIOL CHEM, V269, P7593; Kalkbrenner F, 1996, BBA-MOL CELL RES, V1314, P125, DOI 10.1016/S0167-4889(96)00072-9; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KIEHNE K, 1995, J CELL PHYSIOL, V162, P367, DOI 10.1002/jcp.1041620309; KOZASA T, 1993, P NATL ACAD SCI USA, V90, P9176, DOI 10.1073/pnas.90.19.9176; KRUSZYNSKI M, 1980, J MED CHEM, V23, P364, DOI 10.1021/jm00178a003; LEVY A, 1990, CLIN ENDOCRINOL, V33, P73, DOI 10.1111/j.1365-2265.1990.tb00467.x; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; LOLAIT SJ, 1995, P NATL ACAD SCI USA, V92, P6783, DOI 10.1073/pnas.92.15.6783; MILLAR JBA, 1990, J BIOL CHEM, V265, P19973; Neill JD, 1997, ENDOCRINOLOGY, V138, P843, DOI 10.1210/en.138.2.843; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; OFFERMANNS S, 1994, FEBS LETT, V349, P201, DOI 10.1016/0014-5793(94)00667-9; OFFERMANNS S, 1991, METHOD ENZYMOL, V195, P286; PARK DG, 1993, J BIOL CHEM, V268, P4573; ROZENGURT E, 1979, P NATL ACAD SCI USA, V76, P1284, DOI 10.1073/pnas.76.3.1284; SERRADEILLEGAL C, 1994, BIOCHEM PHARMACOL, V47, P633; SPICHER K, 1994, BIOCHEM BIOPH RES CO, V198, P906, DOI 10.1006/bbrc.1994.1129; Strakova Z, 1997, MOL PHARMACOL, V51, P217, DOI 10.1124/mol.51.2.217; SUGIMOTO T, 1994, J BIOL CHEM, V269, P27088; TAYLOR CW, 1988, BIOCHEM J, V249, P917, DOI 10.1042/bj2490917; THIBONNIER M, 1993, REGUL PEPTIDES, V45, P79, DOI 10.1016/0167-0115(93)90186-C; Thibonnier M, 1998, PROG BRAIN RES, V119, P147; THIBONNIER M, 1992, REGUL PEPTIDES, V38, P1, DOI 10.1016/0167-0115(92)90067-5; Thibonnier M, 1997, ENDOCRINOLOGY, V138, P4109, DOI 10.1210/en.138.10.4109; THIBONNIER M, 1994, J BIOL CHEM, V269, P3304; WANGE RL, 1991, J BIOL CHEM, V266, P11409; Wieland T, 1999, N-S ARCH PHARMACOL, V360, P14, DOI 10.1007/s002109900031; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zhang JS, 1996, J BIOL CHEM, V271, P15026, DOI 10.1074/jbc.271.25.15026; ZHU X, 1994, MOL PHARMACOL, V46, P460	53	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32543	32551		10.1074/jbc.M002171200	http://dx.doi.org/10.1074/jbc.M002171200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10931825	hybrid			2022-12-27	WOS:000090003800024
J	Gardner, PR; Gardner, AM; Martin, LA; Dou, Y; Li, TS; Olson, JS; Zhu, H; Riggs, AF				Gardner, PR; Gardner, AM; Martin, LA; Dou, Y; Li, TS; Olson, JS; Zhu, H; Riggs, AF			Nitric-oxide dioxygenase activity and function of flavohemoglobins - Sensitivity to nitric oxide and carbon monoxide inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-BINDING HEMOGLOBIN; COLI FLAVOHAEMOGLOBIN HMP; ESCHERICHIA-COLI; ALCALIGENES-EUTROPHUS; OXIDATIVE STRESS; GENE-EXPRESSION; MYCOBACTERIUM-TUBERCULOSIS; SUPEROXIDE-DISMUTASE; YEAST HEMOGLOBIN; IN-VITRO	Widely distributed flavohemoglobins (flavoHbs) function as NO dioxygenases and confer upon cells a resistance to NO toxicity. FlavoHbs from Saccharomyces cerevisiae, Alcaligenes eutrophus, and Escherichia coli share similar spectra, O-2, NO, and CO binding kinetics, and steady-state NO dioxygenation kinetics. Turnover numbers (V-max) for S. cerevisiae, A. eutrophus, and E. coli flavoHbs are 112, 290, and 365 NO heme(-1) s(-1), respectively, at 37 degrees C with 200 mu M O-2. The K-M values for NO are low and range from 0.1 to 0.25 mu M. V-max/K-M(NO) ratios of 900-2900 mu M-1 s(-1) indicate an extremely efficient dioxygenation mechanism. Approximate K-M values for O-2 range from 60 to 90 mu M. NO inhibits the dioxygenases at NO:O-2 ratios of greater than or equal to 1:100 and makes true K-M(O-2) values difficult to determine, High and roughly equal second order rate constants for O-2 and NO association with the reduced flavoHbs (17-50 mu M-1 s(-1)) and small NO dissociation rate constants suggest that NO inhibits the dioxygenase reaction by forming inactive flavoHbNO complexes. Carbon monoxide also binds reduced flavoHbs with high affinity and competitively inhibits NO dioxygenases with respect to O-2 (K-I(CO) = similar to 1 mu M). These results suggest that flavoHbs and related hemoglobins evolved as NO detoxifying components of nitrogen metabolism capable of discriminating O-2 from inhibitory NO and CO.	Childrens Hosp, Med Ctr, Div Crit Care Med, Cincinnati, OH 45229 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Rice Univ, WM Keck Ctr Computat Biol, Houston, TX 77005 USA; Univ Texas, Sch Biol Sci, Neurobiol Sect, Austin, TX 78712 USA	Cincinnati Children's Hospital Medical Center; Rice University; Rice University; University of Texas System; University of Texas Austin	Gardner, PR (corresponding author), Childrens Hosp, Med Ctr, Div Crit Care Med, Cincinnati, OH 45229 USA.			Gardner, Anne/0000-0001-7095-772X; Gardner, Paul/0000-0001-8189-0903; Olson, John/0000-0002-0760-5403	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035847, R01GM035649] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47020] Funding Source: Medline; NIGMS NIH HHS [GM35847, GM35649] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Appleby C A, 1978, Methods Enzymol, V52, P157; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPPELL JB, 1964, BIOCHEM J, V90, P225, DOI 10.1042/bj0900225; Couture M, 1999, P NATL ACAD SCI USA, V96, P11223, DOI 10.1073/pnas.96.20.11223; Cramm R, 1997, J BACTERIOL, V179, P6769, DOI 10.1128/jb.179.21.6769-6777.1997; CRAMM R, 1994, J BIOL CHEM, V269, P7349; Crawford MJ, 1998, J BIOL CHEM, V273, P12543, DOI 10.1074/jbc.273.20.12543; Crawford MJ, 1998, J BIOL CHEM, V273, P34028, DOI 10.1074/jbc.273.51.34028; CRAWFORD MJ, 1995, J BIOL CHEM, V270, P6991, DOI 10.1074/jbc.270.12.6991; CZAPSKI G, 1995, FREE RADICAL BIO MED, V19, P785, DOI 10.1016/0891-5849(95)00081-8; DICKERSON RE, 1969, STRUCTURE ACTION PRO, P44; DIKSHIT RP, 1992, ARCH BIOCHEM BIOPHYS, V293, P241, DOI 10.1016/0003-9861(92)90391-9; Doyle M P, 1985, J Free Radic Biol Med, V1, P145, DOI 10.1016/0748-5514(85)90019-4; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; Ermler U, 1995, EMBO J, V14, P6067, DOI 10.1002/j.1460-2075.1995.tb00297.x; ESCHENBRENNER M, 1994, BIOCHEM BIOPH RES CO, V198, P127, DOI 10.1006/bbrc.1994.1018; FAVEY S, 1995, MICROBIOL-UK, V141, P863, DOI 10.1099/13500872-141-4-863; Gardner AM, 2000, J BIOL CHEM, V275, P12581, DOI 10.1074/jbc.275.17.12581; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; GARDNER PR, 1993, J BIOL CHEM, V268, P12958; Gardner PR, 1997, J BIOL CHEM, V272, P25071, DOI 10.1074/jbc.272.40.25071; Gardner PR, 1998, J BIOL CHEM, V273, P26528, DOI 10.1074/jbc.273.41.26528; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Hardison R, 1999, AM SCI, V87, P126, DOI 10.1511/1999.20.809; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; Horvath I, 1998, THORAX, V53, P668, DOI 10.1136/thx.53.8.668; Hu YM, 1999, J BACTERIOL, V181, P3486, DOI 10.1128/JB.181.11.3486-3493.1999; Iijima M, 2000, CELL STRUCT FUNCT, V25, P47, DOI 10.1247/csf.25.47; IOANNIDIS N, 1992, BIOCHEM J, V288, P649, DOI 10.1042/bj2880649; IWAASA H, 1992, J MOL BIOL, V227, P948, DOI 10.1016/0022-2836(92)90236-D; KEELE BB, 1970, J BIOL CHEM, V245, P6176; KEILIN D, 1955, BIOCHEM J, V60, P310, DOI 10.1042/bj0600310; KEILIN D, 1953, NATURE, V172, P390, DOI 10.1038/172390a0; Kim SO, 1999, FEBS LETT, V445, P389, DOI 10.1016/S0014-5793(99)00157-X; Kurata S, 1996, J BIOCHEM-TOKYO, V120, P49; Labesse G, 1998, EUR J BIOCHEM, V253, P751, DOI 10.1046/j.1432-1327.1998.2530751.x; LaCelle M, 1996, J BACTERIOL, V178, P3803, DOI 10.1128/jb.178.13.3803-3808.1996; Lebioda L, 1999, NATURE, V401, P445, DOI 10.1038/46728; Liu LM, 2000, P NATL ACAD SCI USA, V97, P4672, DOI 10.1073/pnas.090083597; MCCARTER LL, 1994, J BACTERIOL, V176, P5988, DOI 10.1128/jb.176.19.5988-5998.1994; Membrillo-Hernandez J, 1997, FEMS MICROBIOL LETT, V155, P179, DOI 10.1111/j.1574-6968.1997.tb13875.x; Membrillo-Hernandez J, 1999, J BIOL CHEM, V274, P748, DOI 10.1074/jbc.274.2.748; MembrilloHernandez J, 1996, FEBS LETT, V382, P141, DOI 10.1016/0014-5793(96)00154-8; Minning DM, 1999, NATURE, V401, P497, DOI 10.1038/46822; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; ORII Y, 1992, BIOCHEM BIOPH RES CO, V187, P94, DOI 10.1016/S0006-291X(05)81463-9; OSHINO R, 1973, EUR J BIOCHEM, V39, P581, DOI 10.1111/j.1432-1033.1973.tb03157.x; PERUTZ MF, 1979, ANNU REV BIOCHEM, V48, P327, DOI 10.1146/annurev.bi.48.070179.001551; Poole RK, 1996, J BACTERIOL, V178, P5487, DOI 10.1128/jb.178.18.5487-5492.1996; POOLE RK, 1994, P ROY SOC B-BIOL SCI, V255, P251, DOI 10.1098/rspb.1994.0036; POOLE RK, 1994, ANTON LEEUW INT J G, V65, P289, DOI 10.1007/BF00872215; PROBST I, 1979, BIOCHIM BIOPHYS ACTA, V576, P471, DOI 10.1016/0005-2795(79)90422-7; PRYOR WA, 1995, AM J PHYSIOL, V268, P699; RIGGS AF, 1991, AM ZOOL, V31, P535; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; Ross J., 1982, PYRIDINE NUCLEOTIDE, P19; Takaya N, 1997, FEBS LETT, V414, P545, DOI 10.1016/S0014-5793(97)01069-7; Wan LL, 1998, P NATL ACAD SCI USA, V95, P12825, DOI 10.1073/pnas.95.22.12825; WITTENBERG JB, 1990, ANNU REV BIOPHYS BIO, V19, P217; WU H, 1923, J BIOCHEM-TOKYO, V2, P189; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5015, DOI 10.1073/pnas.89.11.5015	62	125	129	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31581	31587		10.1074/jbc.M004141200	http://dx.doi.org/10.1074/jbc.M004141200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10922365	hybrid			2022-12-27	WOS:000089858900006
J	Okano, J; Gaslightwala, I; Birnbaum, MJ; Rustgi, AK; Nakagawa, H				Okano, J; Gaslightwala, I; Birnbaum, MJ; Rustgi, AK; Nakagawa, H			Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; SERINE-THREONINE KINASE; HUMAN PANCREATIC-CANCER; NF-KAPPA-B; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; FACTOR RECEPTOR; ESOPHAGEAL-CARCINOMA; TRANSCRIPTION FACTOR; MOLECULAR-CLONING	Overexpression of epidermal growth factor receptor (EGFR) in certain cancers is well established. There is growing evidence that epidermal growth factor (EGF) activates Akt/protein kinase B (PKB) in a phosphoinositide 3-OH kinase (PI3K)-dependent manner, but it is not yet clear which Akt isoforms are involved in this signal transduction pathway. We investigated the functional regulation of three Akt isoforms, Akt1/PKB alpha, Akt2/PKB beta, and Akt3/PKB gamma, in esophageal cancer cells where EGFR is frequently overexpressed. Upon EGF simulation, phosphorylation of Akt1 at the Ser-473 residue was remarkably induced. This result was corroborated by in vitro Akt kinase assays using glycogen synthase kinase 3 beta as the substrate. PI3K inhibitors, wortmannin or LY294002, significantly blocked the Akt kinase activity induced by EGF. Akt2 activity was evaluated by electrophoretic mobility shift assays. Robust activation of Akt2 by EGF was observed in some cell lines in a PI3K-dependent manner. EGF-induced Akt3 activation was demonstrated by Ser-472 phosphorylation of Akt3 but in a restrictive fashion. In aggregate, EGF-mediated activation of Akt isoforms is overlapping and distinctive. The mechanism by which EGFR recruits the PI3K/Akt pathway was in part differentially regulated at the level of Ras but independent of heterodimerization of EGFR with either ErbB2 or ErbB3 based upon functional dissection of pathways in esophageal cancer cell lines.	Univ Penn, Div Gastroenterol, Philadelphia, PA 19104 USA; Univ Penn, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA; Univ Penn, Dept Genet, Philadelphia, PA 19104 USA	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Rustgi, AK (corresponding author), Univ Penn, Div Gastroenterol, 600A CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.			Birnbaum, Morris/0000-0001-9972-8680	NIDDK NIH HHS [DK53377] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053377] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Brodbeck D, 1999, J BIOL CHEM, V274, P9133, DOI 10.1074/jbc.274.14.9133; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Filippa N, 1999, MOL CELL BIOL, V19, P4989; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Friess H, 1999, WORLD J SURG, V23, P1010, DOI 10.1007/s002689900616; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Hardwick RH, 1997, EUR J SURG ONCOL, V23, P30, DOI 10.1016/S0748-7983(97)80139-4; Hayashi K, 1999, J CELL BIOL, V145, P727, DOI 10.1083/jcb.145.4.727; Huang GC, 1998, BIOCHEM J, V331, P113, DOI 10.1042/bj3310113; IIHARA K, 1993, CANCER, V71, P2902, DOI 10.1002/1097-0142(19930515)71:10<2902::AID-CNCR2820711004>3.0.CO;2-J; Islam M, 2000, EXP EYE RES, V70, P261, DOI 10.1006/exer.1999.0783; ITAKURA Y, 1994, CANCER, V74, P795, DOI 10.1002/1097-0142(19940801)74:3<795::AID-CNCR2820740303>3.0.CO;2-I; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; KIM HH, 1994, J BIOL CHEM, V269, P24747; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Konishi H, 1999, J BIOCHEM-TOKYO, V126, P1136, DOI 10.1093/oxfordjournals.jbchem.a022559; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lam KY, 1998, EUR J SURG ONCOL, V24, P431, DOI 10.1016/S0748-7983(98)92403-9; Lin JQ, 1999, CANCER RES, V59, P2891; Liu AX, 1998, CANCER RES, V58, P2973; Masure S, 1999, EUR J BIOCHEM, V265, P353, DOI 10.1046/j.1432-1327.1999.00774.x; Miwa W, 1996, BIOCHEM BIOPH RES CO, V225, P968, DOI 10.1006/bbrc.1996.1280; Morimoto AM, 2000, ONCOGENE, V19, P200, DOI 10.1038/sj.onc.1203288; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; NAKAGAWA H, 1995, CANCER-AM CANCER SOC, V76, P541, DOI 10.1002/1097-0142(19950815)76:4<541::AID-CNCR2820760402>3.0.CO;2-I; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Ozes ON, 1999, NATURE, V401, P82; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Sabbatini P, 1999, J BIOL CHEM, V274, P24263, DOI 10.1074/jbc.274.34.24263; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Summers SA, 1999, J BIOL CHEM, V274, P23858, DOI 10.1074/jbc.274.34.23858; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; Tanaka S, 1997, CANCER RES, V57, P28; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	69	178	181	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30934	30942		10.1074/jbc.M004112200	http://dx.doi.org/10.1074/jbc.M004112200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10908564	hybrid			2022-12-27	WOS:000089762700030
J	Bernier, SG; Haldar, S; Michel, T				Bernier, SG; Haldar, S; Michel, T			Bradykinin-regulated interactions of the mitogen-activated protein kinase pathway with the endothelial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; PHOSPHORYLATION; CELLS; TRANSLOCATION; CAVEOLAE; AKT; RECEPTORS; INHIBITOR; CASCADE	Activation of the bradykinin B2 receptor in endothelial cells initiates a complex array of cellular responses mediated by diverse signaling pathways, including stimulation of the mitogen-activated protein (MAP) kinase cascade and activation of the endothelial isoform of nitric-oxide synthase (eNOS). Several protein kinases have been implicated in eNOS regulation, but the role of MAP kinases remains less well understood. We explored the interactions between eNOS and components of the MAP kinase pathway in bovine aortic endothelial cells (BAEC), Using co-immunoprecipitation experiments, we isolated eNOS in a complex with the MAP kinases extracellular signal-regulated kinases 1 and 2 (ERK1/2) as well as the protein kinases Raf-1 and Akt. Within minutes of adding bradykinin to BAEC, the eNOS-Raf-1-ERK-Akt heteromeric complex dissociated, and it subsequently reassociated following more prolonged agonist stimulation. Bradykinin treatment of BAEC led to the activation of ERK, associated with an increase in phosphorylation of eNOS; phosphorylation of eNOS by ERK in vitro significantly reduced eNOS enzyme activity. Evidence for the direct phosphorylation of eNOS by MAP kinase in BAEC came from "back-phosphorylation" experiments using [gamma-P-32]ATP and ERK in vitro to phosphorylate eNOS isolated from cells previously treated with bradykinin or the MAP kinase inhibitor PD98059. The ERK-catalyzed in vitro P-32 phosphorylation of eNOS isolated from BAEC treated with bradykinin was significantly attenuated compared with untreated cells, indicating that bradykinin treatment led to the phosphorylation of ERK-sensitive sites in cells. Conversely, eNOS isolated from endothelial cells pretreated with the MAP kinase inhibitor PD98059 showed increased ERK-promoted phosphorylation in vitro. Taken together, our results suggest that bradykinin-induced activation of ERK leads to eNOS phosphorylation and enzyme inhibition, a process influenced by the reversible associations of members of the MAP kinase pathway with eNOS.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Vet Affairs Boston Healthcare Syst, W Roxbury, MA 02132 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Michel, T (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc, Thorn Bldg,Rm 1210A,75 Francis St, Boston, MA 02115 USA.							Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BALLIGAND JL, 1995, J BIOL CHEM, V270, P14582, DOI 10.1074/jbc.270.24.14582; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FLEMING I, 1995, CIRC RES, V76, P522, DOI 10.1161/01.RES.76.4.522; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Graness A, 1998, J BIOL CHEM, V273, P32016, DOI 10.1074/jbc.273.48.32016; HIRATA K, 1995, HYPERTENSION, V25, P180, DOI 10.1161/01.HYP.25.2.180; Jaffa AA, 1997, AM J PHYSIOL-RENAL, V273, pF916, DOI 10.1152/ajprenal.1997.273.6.F916; Kaplan AP, 1998, CLIN REV ALLERG IMMU, V16, P403, DOI 10.1007/BF02737659; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEE CM, 1995, J BIOL CHEM, V270, P27403, DOI 10.1074/jbc.270.46.27403; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Mombouli JV, 1999, J MOL CELL CARDIOL, V31, P61, DOI 10.1006/jmcc.1998.0844; MORGANBOYD R, 1987, AM J PHYSIOL, V253, pC588, DOI 10.1152/ajpcell.1987.253.4.C588; Naraba H, 1998, FEBS LETT, V435, P96, DOI 10.1016/S0014-5793(98)01045-X; Prabhakar P, 1998, J BIOL CHEM, V273, P27383, DOI 10.1074/jbc.273.42.27383; Robinson LJ, 1996, METHOD ENZYMOL, V268, P436; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; Sakamoto N, 1998, BRIT J PHARMACOL, V125, P283, DOI 10.1038/sj.bjp.0702060; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843	31	157	172	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30707	30715		10.1074/jbc.M005116200	http://dx.doi.org/10.1074/jbc.M005116200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10899167	hybrid			2022-12-27	WOS:000089577900108
J	Martemyanov, KA; Gudkov, AT				Martemyanov, KA; Gudkov, AT			Domain III of elongation factor G from Thermus thermophilus is essential for induction of GTP hydrolysis on the ribosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR EF-TU; CRYSTAL-STRUCTURE; GUANOSINE TRIPHOSPHATE; CONFORMATIONAL-CHANGES; PROTEIN-SYNTHESIS; TERNARY COMPLEX; TRANSFER-RNA; TRANSLOCATION; TRANSLATION; ACID	Two elongation factors (EF) EF-Tu and EF-G participate in the elongation phase during protein biosynthesis on the ribosome, Their functional cycles depend on GTP binding and its hydrolysis. The EF-Tu complexed with GTP and aminoacyl-tRNA delivers tRNA to the ribosome, whereas EF-G stimulates translocation, a process in which tRNA and mRNA movements occur in the ribosome. In the present paper we report that: (a) intrinsic GTPase activity of EF-G is influenced by excision of its-domain III; (b) the EF-G lacking domain III has a 10(3)-fold decreased GTPase activity on the ribosome, whereas its affinity for GTP is slightly decreased; and (c) the truncated EF-G does not stimulate translocation despite the physical presence of domain TV, which is also very important for translocation, By contrast, the interactions of the truncated factor with GDP and fusidic acid-dependent binding of EF-G GDP complex to the ribosome are nest influenced. These findings indicate an essential contribution of domain III to activation of GTP hydrolysis. These results also suggest conformational changes of the EF-G molecule in the course of its interaction with the ribosome that might be induced by GTP binding and hydrolysis.	Russian Acad Sci, Inst Prot Res, Pushchino 142292, Moscow Region, Russia	Russian Academy of Sciences	Gudkov, AT (corresponding author), Russian Acad Sci, Inst Prot Res, Pushchino 142292, Moscow Region, Russia.	gudkov@vega.protres.ru						AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; Agrawal RK, 1999, NAT STRUCT BIOL, V6, P643, DOI 10.1038/10695; Al-Karadaghi S, 1996, STRUCTURE, V4, P555, DOI 10.1016/S0969-2126(96)00061-5; ARAI KI, 1978, EUR J BIOCHEM, V92, P521, DOI 10.1111/j.1432-1033.1978.tb12774.x; BACA OG, 1976, BIOCHEMISTRY-US, V15, P4570, DOI 10.1021/bi00666a004; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BODLEY JW, 1970, J BIOL CHEM, V245, P5662; Bubunenko M G, 1990, Biomed Sci, V1, P127; Clark BFC, 1999, FEBS LETT, V452, P41, DOI 10.1016/S0014-5793(99)00562-1; Czworkowski J, 1997, BIOCHEMISTRY-US, V36, P10327, DOI 10.1021/bi970610k; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; GAVRILOVA LP, 1976, J MOL BIOL, V101, P537, DOI 10.1016/0022-2836(76)90243-6; GAVRILOVA LP, 1981, J MOL BIOL, V149, P69, DOI 10.1016/0022-2836(81)90260-6; GUDKOV AT, 1984, FEBS LETT, V176, P32, DOI 10.1016/0014-5793(84)80906-0; GUDKOV AT, 1989, BIOCHIMIE, V71, P779, DOI 10.1016/0300-9084(89)90040-0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOU Y, 1994, J BACTERIOL, V176, P7038, DOI 10.1128/JB.176.22.7038-7044.1994; KAWAKITA M, 1974, J BIOCHEM-TOKYO, V76, P801; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDER P, 1966, BIOCHEM BIOPH RES CO, V25, P233, DOI 10.1016/0006-291X(66)90586-9; Liljas A, 1996, CURR BIOL, V6, P247, DOI 10.1016/S0960-9822(02)00469-4; Martemyanov KA, 2000, PROTEIN EXPRES PURIF, V18, P257, DOI 10.1006/prep.1999.1178; Martemyanov KA, 1998, FEBS LETT, V434, P205, DOI 10.1016/S0014-5793(98)00982-X; Martemyanov KA, 1999, FEBS LETT, V452, P155, DOI 10.1016/S0014-5793(99)00635-3; Martemyanov KA, 1998, BIOCHEMISTRY-MOSCOW+, V63, P1216; MESTERS JR, 1994, J MOL BIOL, V242, P644, DOI 10.1006/jmbi.1994.1614; NEUHARD G, 1987, ESCHERICHIA COLI SAL, P445; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Nyborg J, 1996, TRENDS BIOCHEM SCI, V21, P81, DOI 10.1016/0968-0004(96)30008-X; Polekhina G, 1996, STRUCTURE, V4, P1141, DOI 10.1016/S0969-2126(96)00122-0; Rodnina MV, 1997, NATURE, V385, P37, DOI 10.1038/385037a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Spirin A, 1986, RIBOSOME STRUCTURE P; SPIRIN AS, 1985, PROG NUCLEIC ACID RE, V32, P75, DOI 10.1016/S0079-6603(08)60346-3; Stark H, 2000, CELL, V100, P301, DOI 10.1016/S0092-8674(00)80666-2; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WILLIE GR, 1975, BIOCHEMISTRY-US, V14, P1713, DOI 10.1021/bi00679a025; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8	39	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35820	35824		10.1074/jbc.M002656200	http://dx.doi.org/10.1074/jbc.M002656200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10940297	hybrid			2022-12-27	WOS:000165382000027
J	Daumer, KM; Khan, AU; Steinbeck, MJ				Daumer, KM; Khan, AU; Steinbeck, MJ			Chlorination of pyridinium compounds - Possible role of hypochlorite, N-chloramines, and chlorine in the oxidation of pyridinoline cross-links of articular cartilage collagen type II during acute inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; HUMAN-NEUTROPHILS; HYDROGEN-PEROXIDE; OXYGEN RADICALS; POLYMORPHONUCLEAR LEUKOCYTES; SELECTIVE DEGRADATION; CYTOCHEMICAL METHOD; MODIFIED HEMOGLOBIN; PHAGOCYTIC-CELLS; NADPH-OXIDASE	Reactive oxygen species produced by activated neutrophils and monocytes are thought to be involved in mediating the loss of collagen and other matrix proteins at sites of inflammation. To evaluate their potential to oxidize the pyridinoline (Pyd) cross links found in collagen types I and II, we reacted hydrogen peroxide (H2O2), hypochlorous acid/hypochlorite (HOCl/OCl-), and singlet oxygen (O-2((1)Deltag)) with the Pyd substitutes, pyridoxamine dihydrochloride and vitamin B-6, which share the same chemical structure and spectral properties of Pyd cross-links. Neither H2O2 (125-500 muM) nor O-2((1)Deltag) (10-25 muM) significantly changed the spectral properties of pyridoxamine or vitamin B-6. Reaction of HOCl/OCl- (12.5-50 muM) with pyridoxamine at pH 7.2 resulted in a concentration-dependent appearance of two new absorbance peaks and a decrease in fluorescence at 400 nm (excitation 325 nm). The new absorbance peaks correlated with the formation of an N-chloramine and the product of its subsequent reaction with pyridoxamine, In contrast, the extent to which HOCl reacted with vitamin B-6, which lacks a primary amine group, was variable at this pH. At lysosomal pH 5.5, Cl-2/HOCl/OCl- reacted with both pyridoxamine and vitamin B-6, Four of the chlorinated products of this reaction were identified by gas chromatography-mass spectrometry and included 3-chloropyridinium, an aldehyde, and several chlorinated products with disrupted rings, To evaluate the effects of Cl-2/HOCl/OCl- on Pyd cross-links in collagen, we exposed bone collagen type I and articular cartilage type II to HOCl. Treatment of either collagen type with HOCl at pH 5.0 or 7.2 resulted in the oxidation of amine groups and, for collagen type II, the specific decrease in Pyd cross-link fluorescence, suggesting that during inflammation both oxidations may be used by neutrophils and monocytes to promote the loss of matrix integrity.	Thomas Jefferson Univ, Dept Orthopaed Surg, Philadelphia, PA 19107 USA; NYU, Dept Chem, New York, NY 10003 USA	Jefferson University; New York University	Steinbeck, MJ (corresponding author), Thomas Jefferson Univ, Dept Orthopaed Surg, 1015 Walnut St,Curtis Bldg,Rm 324, Philadelphia, PA 19107 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008507, R29DE011082] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-08507, DE-11082, R29 DE011082-06] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; [Anonymous], 1985, SINGLET O2; BABIOR BM, 1984, BLOOD, V64, P959; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BAINTON DF, 1968, J CELL BIOL, V39, P299, DOI 10.1083/jcb.39.2.299; BERGER RR, 1966, FED PROC, V25, P840; BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2; BREALEY GJ, 1955, J AM CHEM SOC, V77, P4462, DOI 10.1021/ja01622a006; BRIGGS RT, 1975, J CELL BIOL, V67, P566, DOI 10.1083/jcb.67.3.566; BRODSKY B, 1982, METHOD ENZYMOL, V82, P127; CECH P, 1984, BLOOD, V63, P88; CERVERA J, 1988, FASEB J, V2, P2591, DOI 10.1096/fasebj.2.10.2898411; DAVIES JMS, 1993, FREE RADICAL BIO MED, V15, P637, DOI 10.1016/0891-5849(93)90167-S; DAVIES KJA, 1987, J BIOL CHEM, V262, P9914; Deby-Dupont G, 1998, BBA-GEN SUBJECTS, V1379, P61, DOI 10.1016/S0304-4165(97)00083-4; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; DOWNS AJ, 1973, COMPREHENSIVE INORGA, P1400; Eyre D.R., 1981, CHEM BIOL MINERALISE, P51; EYRE DR, 1980, SCIENCE, V207, P1315, DOI 10.1126/science.7355290; EYRE DR, 1984, ANNU REV BIOCHEM, V53, P717, DOI 10.1146/annurev.bi.53.070184.003441; Fredriksson M, 1998, J CLIN PERIODONTOL, V25, P394, DOI 10.1111/j.1600-051X.1998.tb02461.x; Fredriksson MI, 1999, J PERIODONTOL, V70, P1355, DOI 10.1902/jop.1999.70.11.1355; FUJIMOTO D, 1978, BIOCHEM BIOPH RES CO, V84, P52, DOI 10.1016/0006-291X(78)90261-9; GARTNER A, 1986, TOP CURR CHEM, V132, P1; GINIS I, 1990, BLOOD, V76, P1233; GIULIVI C, 1994, ARCH BIOCHEM BIOPHYS, V311, P329, DOI 10.1006/abbi.1994.1245; GREENWALD RA, 1986, INFLAMMATION, V10, P15, DOI 10.1007/BF00916037; GREENWALD RA, 1991, SEMIN ARTHRITIS RHEU, V20, P219, DOI 10.1016/0049-0172(91)90018-U; HALLIWELL B, 1995, ANN RHEUM DIS, V54, P505, DOI 10.1136/ard.54.6.505; HARLAN JM, 1985, BLOOD, V65, P513; HARRIS ED, 1988, INFLAMMATION BASIC P, P751; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Hazen SL, 1998, BIOCHEMISTRY-US, V37, P6864, DOI 10.1021/bi972449j; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; HELD AM, 1978, J AM CHEM SOC, V100, P5732, DOI 10.1021/ja00486a025; HENSON PM, 1987, J CLIN INVEST, V79, P669, DOI 10.1172/JCI112869; HORMEL SE, 1991, BIOCHIM BIOPHYS ACTA, V1078, P243, DOI 10.1016/0167-4838(91)90565-H; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; KHAN AU, 1994, P NATL ACAD SCI USA, V91, P12362, DOI 10.1073/pnas.91.26.12362; KHAN AU, 1963, J CHEM PHYS, V39, P2105, DOI 10.1063/1.1734588; Klebanoff SJ., 1988, INFLAMMATION BASIC P, P391; LATIMER WM, 1938, OXIDATION STATES ELE, P48; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LUKACS GL, 1990, J BIOL CHEM, V265, P21099; MCCORD JM, 1968, J BIOL CHEM, V243, P5753; PACIFICI RE, 1993, J BIOL CHEM, V268, P15405; PIEZ KA, 1984, EXTRACELLULAR MATRIX, P1; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; SALO DC, 1990, J BIOL CHEM, V265, P11919; SANANTONIO JD, 1994, J CELL BIOL, V125, P1179, DOI 10.1083/jcb.125.5.1179; SEGAL AW, 1978, LANCET, V2, P446; SEGAL AW, 1981, NATURE, V290, P406, DOI 10.1038/290406a0; SELVARAJ RJ, 1978, J INFECT DIS, V137, P481, DOI 10.1093/infdis/137.4.481; SNEED MC, 1954, COMPREHENSIVE INORGA, P152; STEINBECK MJ, 1991, J BIOL CHEM, V266, P16336; STEINBECK MJ, 1992, J BIOL CHEM, V267, P13425; STEINBECK MJ, 1993, J HISTOCHEM CYTOCHEM, V41, P1659, DOI 10.1177/41.11.8292156; Thomas E L, 1986, Methods Enzymol, V132, P569; THOMAS EL, 1983, J CLIN INVEST, V72, P441, DOI 10.1172/JCI110992; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; VATER CA, 1979, BIOCHEM J, V181, P639, DOI 10.1042/bj1810639; VISSERS MCM, 1986, BIOCHIM BIOPHYS ACTA, V889, P277, DOI 10.1016/0167-4889(86)90190-4; VISSERS MCM, 1991, ARCH BIOCHEM BIOPHYS, V285, P357, DOI 10.1016/0003-9861(91)90372-P; VISSERS MCM, 1991, ARCH BIOCHEM BIOPHYS, V285, P53, DOI 10.1016/0003-9861(91)90327-F; VISSERS MCM, 1985, BLOOD, V66, P161; WASSERMA.HH, 1972, J CHEM SOC CHEM COMM, P253, DOI 10.1039/c39720000253; WEISS SJ, 1982, LAB INVEST, V47, P5; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; WEISS SJ, 1983, SCIENCE, V222, P625, DOI 10.1126/science.6635660; WITKO V, 1992, J CLIN LAB ANAL, V6, P47, DOI 10.1002/jcla.1860060110; Woolley DE, 1997, ANN RHEUM DIS, V56, P151, DOI 10.1136/ard.56.3.151	71	52	53	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34681	34692		10.1074/jbc.M002003200	http://dx.doi.org/10.1074/jbc.M002003200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10940296	Green Accepted, hybrid			2022-12-27	WOS:000165095300092
J	Eastmond, PJ; Hooks, MA; Williams, D; Lange, P; Bechtold, N; Sarrobert, C; Nussaume, L; Graham, IA				Eastmond, PJ; Hooks, MA; Williams, D; Lange, P; Bechtold, N; Sarrobert, C; Nussaume, L; Graham, IA			Promoter trapping of a novel medium-chain acyl-CoA oxidase, which is induced transcriptionally during Arabidopsis seed germination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARRIER PROTEIN THIOESTERASE; PEROXISOMAL BETA-OXIDATION; MALATE SYNTHASE GENE; FATTY-ACIDS; DEVELOPMENTAL REGULATION; EXPRESSION; PLANTS; RECEPTOR; BIOSYNTHESIS; PURIFICATION	The first step of peroxisomal fatty acid beta -oxidation is catalyzed by a family of acyl-CoA oxidase isozymes with distinct fatty acyl-CoA chain-length specificities. Here we identify a new acyl-CoA oxidase gene from Arabidopsis (AtACX3) following the isolation of a promoter-trapped mutant in which beta -glucuronidase expression was initially detected in the root meristem. In acx3 mutant seedlings medium-chain acyl-CoA oxidase activity was reduced by 95%, whereas long- and short-chain activities were unchanged. Despite this reduction in activity lipid catabolism and seedling development were not perturbed. AtACX3 was cloned and expressed in Escherichia coli. The recombinant enzyme displayed medium-chain acyl-CoA substrate specificity. Analysis of beta -glucuronidase activity in acx3 revealed that, in addition to constitutive expression in the root axis, AtACX3 is also up-regulated strongly in the hypocotyl and cotyledons of germinating seedlings. This suggests that beta -oxidation is regulated predominantly at the level of transcription in germinating oilseeds. After the discovery of AtACX3, the Arabidopsis acyl-CoA oxidase gene family now comprises four isozymes with substrate specificities that encompass the full range of acyl-CoA chain lengths that exist in vivo.	Univ York, Dept Biol, Ctr Novel Agr Prod, York YO10 5YW, N Yorkshire, England; Univ Wales, Sch Biol Sci, Bangor LL57 2UW, Gwynedd, Wales; Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland; Inst Rech Agron, Genet & Ameliorat Plantes Stn, F-78026 Versailles, France; CEA Saclay, Dept Ecophysiol Vegetale & Microbiol, F-13108 St Paul Les Durance, France	University of York - UK; Bangor University; University of Glasgow; INRAE; CEA	Graham, IA (corresponding author), CNAP, Cent Sci Lab, York YO41 1LZ, N Yorkshire, England.	iag1@cnap.york.ac.uk	NUSSAUME, Laurent/AAB-8312-2020; NUSSAUME, Laurent/AAA-5980-2022	NUSSAUME, Laurent/0000-0002-9445-2563; Eastmond, Peter/0000-0003-4526-5136				Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BLACK PN, 1994, BBA-LIPID LIPID MET, V1210, P123, DOI 10.1016/0005-2760(94)90113-9; BOUCHEZ D, 1993, CR ACAD SCI III-VIE, V316, P1188; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broun P, 1998, PLANT J, V13, P201, DOI 10.1046/j.1365-313X.1998.00023.x; BROWSE J, 1986, ANAL BIOCHEM, V152, P141, DOI 10.1016/0003-2697(86)90132-6; CHU CH, 1994, BIOCHEM J, V302, P23, DOI 10.1042/bj3020023; DENYER K, 1988, PLANTA, V173, P172, DOI 10.1007/BF00403008; Do YY, 1997, ARCH BIOCHEM BIOPHYS, V344, P295, DOI 10.1006/abbi.1997.0212; Eastmond PJ, 2000, P NATL ACAD SCI USA, V97, P5669, DOI 10.1073/pnas.97.10.5669; Eastmond PJ, 2000, BIOCHEM SOC T, V28, P95, DOI 10.1042/bst0280095; Eccleston VS, 1998, PLANT CELL, V10, P613, DOI 10.1105/tpc.10.4.613; Eccleston VS, 1996, PLANTA, V198, P46, DOI 10.1007/BF00197585; FARMER EE, 1994, PLANT MOL BIOL, V26, P1423, DOI 10.1007/BF00016483; GERHARDT B, 1985, PHYTOCHEMISTRY, V24, P351, DOI 10.1016/S0031-9422(00)83551-7; GRAHAM IA, 1990, PLANT MOL BIOL, V15, P539, DOI 10.1007/BF00017829; GROSSI M, 1995, PLANT SCI, V105, P71, DOI 10.1016/0168-9452(94)04043-G; Hayashi H, 1998, J BIOL CHEM, V273, P8301, DOI 10.1074/jbc.273.14.8301; Hayashi H, 1999, J BIOL CHEM, V274, P12715, DOI 10.1074/jbc.274.18.12715; Hayashi M, 1998, PLANT CELL, V10, P183, DOI 10.1105/tpc.10.2.183; HOLTMAN WL, 1994, PLANT SCI, V99, P43, DOI 10.1016/0168-9452(94)90119-8; Hooks MA, 1999, PLANT J, V20, P1, DOI 10.1046/j.1365-313X.1999.00559.x; Hooks MA, 1996, BIOCHEM J, V320, P607, DOI 10.1042/bj3200607; Hooks MA, 1999, PLANTA, V207, P385, DOI 10.1007/s004250050496; HOOKS MA, 1995, PHYTOCHEMISTRY, V40, P657, DOI 10.1016/0031-9422(95)98169-H; HRYB DJ, 1979, BIOCHEM BIOPH RES CO, V87, P1200, DOI 10.1016/S0006-291X(79)80034-0; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; Karpichev IV, 1998, MOL CELL BIOL, V18, P6560, DOI 10.1128/MCB.18.11.6560; KAY R, 1987, SCIENCE, V236, P1299, DOI 10.1126/science.236.4806.1299; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KIM DJ, 1994, PLANT MOL BIOL, V26, P423, DOI 10.1007/BF00039551; KINDL H, 1987, BIOCH PLANTS, V9, P31; KIRSCH T, 1986, J BIOL CHEM, V261, P8570; Kleiter AE, 1998, PLANTA, V206, P125, DOI 10.1007/s004250050382; LANGE PR, 1998, ADV PLANT LIPID RES, P343; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Richmond TA, 1999, PLANT CELL, V11, P1911, DOI 10.1105/tpc.11.10.1911; SAMBROOK J, 1989, MOL CLONING LAB MANU, P320; Sarah CJ, 1996, MOL GEN GENET, V250, P153, DOI 10.1007/BF02174174; Takahashi H, 1997, PLANT J, V11, P993, DOI 10.1046/j.1365-313X.1997.11050993.x; Wasternack C, 1997, TRENDS PLANT SCI, V2, P302, DOI 10.1016/S1360-1385(97)89952-9; Wimmer C, 1998, PLANT J, V16, P453, DOI 10.1046/j.1365-313x.1998.00320.x; Wolf G, 1998, NUTR REV, V56, P61, DOI 10.1111/j.1753-4887.1998.tb01693.x; Zhang JZ, 1996, PLANT PHYSIOL, V110, P1069, DOI 10.1104/pp.110.4.1069	46	61	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34375	34381		10.1074/jbc.M004945200	http://dx.doi.org/10.1074/jbc.M004945200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10918060	Green Published, hybrid			2022-12-27	WOS:000165095300052
J	Lai, MM; Luo, HR; Burnett, PE; Hong, JJ; Snyder, SH				Lai, MM; Luo, HR; Burnett, PE; Hong, JJ; Snyder, SH			The calcineurin-binding protein cain is a negative regulator of synaptic vesicle endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED ENDOCYTOSIS; MAMMALIAN PROTEIN; NERVE-TERMINALS; T-CELLS; DYNAMIN; AMPHIPHYSIN; PHOSPHORYLATION; COMPLEXES; RELEASE; KINASE	During neurotransmitter release, exocytosed neurotransmitter vesicles are recycled by endocytosis, which involves the assembly of a complex of endocytic proteins. Assembly of endocytic proteins into a functional complex depends on their dephosphorylation by calcineurin, a calcium-sensitive protein phosphatase and the inhibitory target of immunosuppressive drugs cyclosporin A and FK506. Cain is a recently identified protein inhibitor of calcineurin. We now provide evidence that cain is a component of the endocytic protein complex. The proline-rich region of cain forms a stable association with the SH3 domain of amphiphysin 1. Using a transferrin uptake assay, we found that overexpression of cain in HEK293 cells blocks endocytosis as potently as expression of a dominant negative dynamin 1 construct. The use of other calcineurin inhibitors such as cyclosporin A and FK506 also blocks endocytosis. Since binding of cain to amphiphysin 1 does not affect amphiphysin's interaction with other endocytic proteins, our results suggest that cain negatively regulates synaptic vesicle endocytosis by inhibiting calcineurin activity, rather than sterically interfering with the assembly of the endocytic protein complex.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Snyder, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.				NIDA NIH HHS [DA-00074] Funding Source: Medline; NIGMS NIH HHS [GM-07309] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018501, R37MH018501] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P8351, DOI 10.1073/pnas.95.14.8351; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DEBELLO WM, 1993, CELL, V74, P947, DOI 10.1016/0092-8674(93)90716-4; DeCamilli P, 1996, NEURON, V16, P481, DOI 10.1016/S0896-6273(00)80068-9; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; Gijtenbeek JMM, 1999, J NEUROL, V246, P339, DOI 10.1007/s004150050360; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Lai MM, 1999, J BIOL CHEM, V274, P25963, DOI 10.1074/jbc.274.37.25963; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MENEGAUX F, 1994, TRANSPLANTATION, V58, P447, DOI 10.1097/00007890-199408270-00010; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; SMYTHE E, 1992, METHOD ENZYMOL, V219, P223; Snyder SH, 1998, NEURON, V21, P283, DOI 10.1016/S0896-6273(00)80538-3; Steiner JP, 1997, P NATL ACAD SCI USA, V94, P2019, DOI 10.1073/pnas.94.5.2019; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; Wijdicks EFM, 1996, NEUROLOGY, V47, P1523, DOI 10.1212/WNL.47.6.1523; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790	28	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34017	34020		10.1074/jbc.C000429200	http://dx.doi.org/10.1074/jbc.C000429200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10931822	hybrid			2022-12-27	WOS:000165095300003
J	Cuervo, AM; Gomes, AV; Barnes, JA; Dice, JF				Cuervo, AM; Gomes, AV; Barnes, JA; Dice, JF			Selective degradation of annexins by chaperone-mediated autophagy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER LYSOSOMES; CYTOSOLIC PROTEINS; BINDING-PROTEINS; PEPTIDE SEQUENCES; PROTEOLYSIS; PATHWAY; PURIFICATION; LOCALIZATION; MACROPHAGES; SUBSTRATE	Annexins are a family of proteins that bind phospholipids in a calcium-dependent manner. Analysis of the sequences of the different members of the annexin family revealed the presence of a pentapeptide biochemically related to KFERQ in some annexins but not in others. Such sequences have been proposed to be a targeting sequence for chaperone mediated autophagy, a lysosomal pathway of protein degradation that is activated in confluent cells in response to removal of serum growth factors. We demonstrate that annexins II and VI, which contain KFERQ-like sequences, are degraded more rapidly in response to serum withdrawal, while annexins V and XI, without such sequences, are degraded at the same rate in the presence and absence of serum. Using isolated lysosomes, only the annexins containing KFERQ-like sequences are degraded by chaperone mediated-autophagy. Annexins V and XI could associate with lysosomes but did not enter the lysosomes and were not proteolytic substrates. Furthermore, four annexins containing KFERQ-like sequences, annexins I, II, IV, and VI, are enriched in lysosomes with high chaperone-mediated autophagy activity as expected for substrate proteins. These results provide striking evidence for the importance of KFERQ motifs in substrates of chaperone-mediated autophagy.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA; Univ W Indies, Dept Preclin Sci, Champs Fleurs, Trinidad Tobago	Tufts University; University West Indies Mona Jamaica; University West Indies Saint Augustine	Dice, JF (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.	james.dice@tufts.edu		Cuervo, Ana Maria/0000-0002-0771-700X	NATIONAL INSTITUTE ON AGING [R01AG006116, R37AG006116] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Agarraberes FA, 1997, J CELL BIOL, V137, P825, DOI 10.1083/jcb.137.4.825; ANIENTO F, 1993, J BIOL CHEM, V268, P10463; Avila-Sakar AJ, 1998, BBA-PROTEIN STRUCT M, V1387, P103, DOI 10.1016/S0167-4838(98)00111-3; Bandorowicz-Pikula J, 1998, ACTA BIOCHIM POL, V45, P721; BARNES PJ, 1995, MOL MED TODAY, V1, P149, DOI 10.1016/S1357-4310(95)80093-X; Benz J, 1997, BIOL CHEM, V378, P177; BLUMENFELD N, 1994, J BIOL CHEM, V269, P9574; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; Cuervo AM, 1998, J MOL MED-JMM, V76, P6, DOI 10.1007/s109-1998-8099-y; Cuervo AM, 1999, KIDNEY INT, V55, P529, DOI 10.1046/j.1523-1755.1999.00268.x; Cuervo AM, 1997, J BIOL CHEM, V272, P5606, DOI 10.1074/jbc.272.9.5606; Cuervo AM, 1998, MOL BIOL CELL, V9, P1995, DOI 10.1091/mbc.9.8.1995; CUERVO AM, 1995, AM J PHYSIOL-CELL PH, V269, pC1200, DOI 10.1152/ajpcell.1995.269.5.C1200; Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501; CULARD JF, 1992, J INVEST DERMATOL, V98, P436, DOI 10.1111/1523-1747.ep12499850; DAVIES N, 1994, BBA-GENE STRUCT EXPR, V1218, P187, DOI 10.1016/0167-4781(94)90009-4; Diakonova M, 1997, J CELL SCI, V110, P1199; DICE J, 2000, IN PRESS LYSOSOMAL P; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; Dillon SR, 2000, J IMMUNOL, V164, P1322, DOI 10.4049/jimmunol.164.3.1322; Donato R., 1999, Cell Calcium, V26, P85, DOI 10.1054/ceca.1999.0079; Donnelly SR, 1997, CELL MOL LIFE SCI, V53, P533, DOI 10.1007/s000180050068; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; Gomes AV, 1995, BIOCHEM MOL BIOL INT, V37, P853; Hajjar KA, 1999, TRENDS CARDIOVAS MED, V9, P128, DOI 10.1016/S1050-1738(99)00020-1; Horst M, 1999, MOL BIOL CELL, V10, P2879, DOI 10.1091/mbc.10.9.2879; JACKLE S, 1994, J BIOL CHEM, V269, P1026; Kohler G, 1997, BIOCHEMISTRY-US, V36, P8189, DOI 10.1021/bi9703960; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu L, 1995, BIOCHEM MOL BIOL INT, V36, P373; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Moss S. E., 1992, ANNEXINS, P1; Movitz C, 1999, BBA-BIOMEMBRANES, V1416, P101, DOI 10.1016/S0005-2736(98)00212-0; OHSUMI Y, 1983, J BIOCHEM, V93, P547; Pittis MG, 1999, J LEUKOCYTE BIOL, V66, P845, DOI 10.1002/jlb.66.5.845; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rosengarth A, 1998, FEBS LETT, V438, P279, DOI 10.1016/S0014-5793(98)01318-0; Sable CL, 1999, BIOCHEM BIOPH RES CO, V258, P162, DOI 10.1006/bbrc.1999.0544; Silvestro L, 1999, BIOCHEMISTRY-US, V38, P113, DOI 10.1021/bi981289o; Speijer H, 1997, FEBS LETT, V402, P193, DOI 10.1016/S0014-5793(96)01527-X; TAKENAKA IM, 1995, J BIOL CHEM, V270, P19839, DOI 10.1074/jbc.270.34.19839; TERLECKY SR, 1993, J BIOL CHEM, V268, P23490; TERLECKY SR, 1992, J BIOL CHEM, V267, P9202; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vishwanatha JK, 1998, CLIN CANCER RES, V4, P2559; WALLACE RW, 1987, BIOCHEMISTRY-US, V26, P2766, DOI 10.1021/bi00384a017; WANG C, 1993, BIOCHEM J, V294, P69, DOI 10.1042/bj2940069; WATTIAUX R, 1978, J CELL BIOL, V78, P349, DOI 10.1083/jcb.78.2.349; WING SS, 1991, BIOCHEM J, V275, P165, DOI 10.1042/bj2750165; Wu FJ, 1999, BIOCHEMISTRY-US, V38, P792, DOI 10.1021/bi9819677; Zanotti G, 1998, BIOCHEM J, V329, P101, DOI 10.1042/bj3290101; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	52	62	63	2	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33329	33335		10.1074/jbc.M005655200	http://dx.doi.org/10.1074/jbc.M005655200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10938088	hybrid			2022-12-27	WOS:000090104600024
J	Jaitovitch-Groisman, I; Fotouhi-Ardakani, N; Schecter, RL; Woo, A; Alaoui-Jamali, MA; Batist, G				Jaitovitch-Groisman, I; Fotouhi-Ardakani, N; Schecter, RL; Woo, A; Alaoui-Jamali, MA; Batist, G			Modulation of glutathione S-transferase alpha by hepatitis B virus and the chemopreventive drug oltipraz	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-GENE-PRODUCT; PRIMARY HEPATOCELLULAR-CARCINOMA; NF-KAPPA-B; AFLATOXIN B-1; LIVER-CANCER; HUMAN HEPATOCYTES; HBX PROTEIN; EXPRESSION; DNA; RAT	Persistent infection by hepatitis B virus (HBV) and exposure to chemical carcinogens correlates with the prevalence of hepatocellular carcinoma in endemic areas. The precise nature of the interaction between these factors is not known, Glutathione S-transferases (GST) are responsible for the cellular metabolism and detoxification of a variety of cytotoxic and carcinogenic compounds by catalysis of their conjugation with glutathione. Diminished GST activity could enhance cellular sensitivity to chemical carcinogens. We have investigated GST isozyme expression in hepatocellular HepG2 cells and in an HBV-transfected subline. Total GST activity and selenium-independent glutathione peroxidase activity are significantly decreased in HBV transfected cells. On immunoblotting, HBV transfected cells demonstrate a significant decrease in the level of GST Alpha class. Cytotoxicity assays reveal that the HBV transfected cells are more sensitive to a wide range of compounds known to be detoxified by GST Alpha conjugation, Although no significant difference in protein half-life between the two cell lines was found, semiquantitative reverse transcription-polymerase chain reaction shows a reduced amount of GST Alpha mRNA in the transfected cells, Because the HBV x protein (HBx) seems to play a role in HBV transfection, we also demonstrated that expression of the HBx gene into HepG2 cells decreased the amount of GST Alpha protein, Transient transfection experiments using both rat and human GST Alpha (rGSTA5 and hGSTA1) promoters in HepG2 cells show a decreased CAT activity upon HBx expression, supporting a transcriptional regulation of both genes by HBx. This effect is independent of HBx interaction with Sp1. Treatment with oltipraz, an inducer of GST Alpha, partially overcomes the effect of HBx on both promoters. Promoter deletion studies indicate that oltipraz works through responsive elements distinct from AP1 or NF-kappaB transcription factors. Thus, REV infection alters phase II metabolizing enzymes via different mechanisms than those modulated by treatment with oltipraz.	McGill Univ, McGill Ctr Translat Res Canc, Lady Davis Inst, Dept Med,Sir Mortimer B Davis Jewish Hosp, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University	Batist, G (corresponding author), McGill Univ, McGill Ctr Translat Res Canc, Lady Davis Inst, Dept Med,Sir Mortimer B Davis Jewish Hosp, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	gbatist@onc.jgh.mcgill.ca						Alpert LC, 1997, CLIN CANCER RES, V3, P661; ANSHER SS, 1983, HEPATOLOGY, V3, P932; AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; BANNASCH P, 1995, CANCER RES, V55, P3318; Barsalou A, 1998, J BIOL CHEM, V273, P17138, DOI 10.1074/jbc.273.27.17138; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; BOLTON MG, 1991, CANCER RES, V51, P2410; Bosch FX, 1999, SEMIN LIVER DIS, V19, P271, DOI 10.1055/s-2007-1007117; BOWYER SM, 1987, P NATL ACAD SCI USA, V84, P847, DOI 10.1073/pnas.84.3.847; BOYER TD, 1987, HEPATOLOGY, V7, P843, DOI 10.1002/hep.1840070509; BRAVARD A, 1993, CARCINOGENESIS, V14, P21, DOI 10.1093/carcin/14.1.21; Chi WJ, 1998, CARCINOGENESIS, V19, P2133, DOI 10.1093/carcin/19.12.2133; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; COLES B, 1985, CARCINOGENESIS, V6, P693, DOI 10.1093/carcin/6.5.693; Cong YS, 1997, J BIOL CHEM, V272, P16482, DOI 10.1074/jbc.272.26.16482; DIILIO C, 1991, CARCINOGENESIS, V12, P1471; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; FEITELSON M, 1992, CLIN MICROBIOL REV, V5, P275, DOI 10.1128/CMR.5.3.275-301.1992; Feitelson MA, 1999, J CELL PHYSIOL, V181, P188; FERRY JA, 1997, CARCINOGENESIS, V18, P21113; Fotouhi-Ardakani N, 2000, MOL BIOL EVOL, V17, P331, DOI 10.1093/oxfordjournals.molbev.a026313; Galipeau J, 1999, CANCER RES, V59, P2384; Groisman IJ, 1999, CARCINOGENESIS, V20, P479, DOI 10.1093/carcin/20.3.479; HAYES JD, 1991, BIOCHEM J, V279, P385, DOI 10.1042/bj2790385; HAYES PC, 1991, GUT, V32, P1546, DOI 10.1136/gut.32.12.1546; HAYES PC, 1987, GLUTATHIONE S TRANSF, P175; HOWIE AF, 1990, CARCINOGENESIS, V11, P451, DOI 10.1093/carcin/11.3.451; HU KQ, 1990, P NATL ACAD SCI USA, V87, P7140, DOI 10.1073/pnas.87.18.7140; KANEKO S, 1988, J VIROL, V62, P3979, DOI 10.1128/JVI.62.11.3979-3984.1988; KENSLER TW, 1995, J CELL BIOCHEM, P101; KENSLER TW, 1987, CANCER RES, V47, P4271; Kessler FK, 1997, CARCINOGENESIS, V18, P107, DOI 10.1093/carcin/18.1.107; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kirby GM, 1996, TOXICOL PATHOL, V24, P458, DOI 10.1177/019262339602400408; KLONE A, 1990, CARCINOGENESIS, V11, P2179, DOI 10.1093/carcin/11.12.2179; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LANGOUET S, 1995, CANCER RES, V55, P5574; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; Lee YI, 1998, ONCOGENE, V16, P2367, DOI 10.1038/sj.onc.1201760; LIN JK, 1977, CANCER RES, V37, P4430; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MOREL F, 1993, CANCER RES, V53, P231; Nakamoto Y, 1998, J EXP MED, V188, P341, DOI 10.1084/jem.188.2.341; ODwyer PJ, 1997, CANCER RES, V57, P1050; Pulford DJ, 1996, BIOCHEM J, V318, P75, DOI 10.1042/bj3180075; ROBINSON WS, 1994, ANNU REV MED, V45, P297; ROSS RK, 1992, LANCET, V339, P943, DOI 10.1016/0140-6736(92)91528-G; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHECTER RL, 1993, CANCER RES, V53, P4900; SELLS MA, 1987, P NATL ACAD SCI USA, V84, P1005, DOI 10.1073/pnas.84.4.1005; Sohn S, 2000, MUTAT RES-DNA REPAIR, V460, P17, DOI 10.1016/S0921-8777(00)00010-0; STALKER MJ, 1994, HEPATOLOGY, V20, P149, DOI 10.1016/0270-9139(94)90147-3; STENBERG G, 1992, PROTEIN EXPRES PURIF, V3, P80, DOI 10.1016/1046-5928(92)90060-A; SUZUKI T, 1994, BIOCHEM BIOPH RES CO, V200, P1665, DOI 10.1006/bbrc.1994.1643; SWENSON DH, 1977, CANCER RES, V37, P172; TAKADA S, 1994, VIROLOGY, V205, P503, DOI 10.1006/viro.1994.1671; Tan MJ, 1999, J BIOL CHEM, V274, P12061, DOI 10.1074/jbc.274.17.12061; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501; UNSAL H, 1994, P NATL ACAD SCI USA, V91, P822, DOI 10.1073/pnas.91.2.822; WANG WL, 1991, CANCER RES, V51, P4971; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WARHOLM M, 1981, BIOCHEM BIOPH RES CO, V98, P512, DOI 10.1016/0006-291X(81)90870-6; WILD CP, 1993, ENVIRON HEALTH PERSP, V99, P115, DOI 10.2307/3431466; WOGAN GN, 1992, CANCER RES, V52, pS2114; WOLOSCHAK GE, 1995, MOL CARCINOGEN, V13, P44, DOI 10.1002/mc.2940130108; YAO KS, 1995, BIOCHEM PHARMACOL, V49, P275, DOI 10.1016/0006-2952(94)00544-V; ZHANG MH, 1991, HEPATOLOGY, V13, P316; Zhou TL, 1997, CANCER RES, V57, P2749; ZHU MH, 1993, INT J CANCER, V55, P571, DOI 10.1002/ijc.2910550409	71	22	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33395	33403		10.1074/jbc.M003754200	http://dx.doi.org/10.1074/jbc.M003754200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10934196	hybrid			2022-12-27	WOS:000090104600032
J	Kozak, KR; Rowlinson, SW; Marnett, LJ				Kozak, KR; Rowlinson, SW; Marnett, LJ			Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE NEUROBLASTOMA-CELLS; TIME-DEPENDENT INHIBITION; NITRIC-OXIDE SYNTHASE; SELECTIVE-INHIBITION; ENDOPEROXIDE SYNTHASE; ARACHIDONIC-ACID; CANNABINOID RECEPTOR; ACTIVE-SITE; H SYNTHASES; BIOSYNTHESIS	Cyclooxygenases (COX) play an important role in lipid signaling by oxygenating arachidonic acid to endoperoxide precursors of prostaglandins and thromboxane. Two cyclooxygenases exist which differ in tissue distribution and regulation but otherwise carry out identical chemical functions. The neutral arachidonate derivative, 2-arachidonylglycerol (2-AG), is one of two described endocannabinoids and appears to be a ligand for both the central (CB1) and peripheral (CB2) cannabinoid receptors. Here we report that 2-AG is a substrate for COX-2 and that it is metabolized as effectively as arachidonic acid. COX-2-mediated 2-AG oxygenation provides the novel lipid, prostaglandin H-2 glycerol ester (PGH(2)-G), in vitro and in cultured macrophages. PGH(2)-G produced by macrophages is a substrate for cellular PGD synthase, affording PGD(2)-G. Pharmacological studies reveal that macrophage production of PGD(2)-G from endogenous sources of 2-AG is calcium-dependent and mediated by diacylglycerol Lipase and COX-2. These results identify a distinct function for COX-2 in endocannabinoid metabolism and in the generation of a new family of prostaglandins derived from diacylglycerol and 2-AG.	Vanderbilt Univ, Sch Med, Dept Biochem, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Chem, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Marnett, LJ (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, Vanderbilt Ingram Canc Ctr, 221 Kirkland Hall, Nashville, TN 37232 USA.	marnett@toxicology.mc.vanderbilt.edu			NCI NIH HHS [CA47479, CA68484] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047479, P01CA068484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; Bisogno T, 1999, J NEUROCHEM, V72, P2113, DOI 10.1046/j.1471-4159.1999.0722113.x; Bisogno T, 1999, BIOCHEM BIOPH RES CO, V256, P377, DOI 10.1006/bbrc.1999.0254; Bisogno T, 1997, BIOCHEM J, V322, P671, DOI 10.1042/bj3220671; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; Burstein SH, 2000, PROSTAG OTH LIPID M, V61, P29, DOI 10.1016/S0090-6980(00)00053-8; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 1999, CURR MED CHEM, V6, P721; Di Marzo V, 1999, EUR J BIOCHEM, V264, P258, DOI 10.1046/j.1432-1327.1999.00631.x; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; EVETT GE, 1993, ARCH BIOCHEM BIOPHYS, V306, P169, DOI 10.1006/abbi.1993.1496; Felder CC, 1998, ANNU REV PHARMACOL, V38, P179, DOI 10.1146/annurev.pharmtox.38.1.179; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; Greig GM, 1997, MOL PHARMACOL, V52, P829, DOI 10.1124/mol.52.5.829; Guo QP, 1996, J BIOL CHEM, V271, P19134, DOI 10.1074/jbc.271.32.19134; HAMBERG M, 1973, P NATL ACAD SCI USA, V70, P899, DOI 10.1073/pnas.70.3.899; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Jeon YJ, 1996, MOL PHARMACOL, V50, P334; Kalgutkar AS, 2000, P NATL ACAD SCI USA, V97, P925, DOI 10.1073/pnas.97.2.925; Kalgutkar AS, 1998, J MED CHEM, V41, P4800, DOI 10.1021/jm980303s; KENNEDY BP, 1993, BIOCHEM BIOPH RES CO, V197, P494, DOI 10.1006/bbrc.1993.2506; Kiefer JR, 2000, NATURE, V405, P97, DOI 10.1038/35011103; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; Landino LM, 1996, P NATL ACAD SCI USA, V93, P15069, DOI 10.1073/pnas.93.26.15069; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; MacPherson JC, 1996, BBA-LIPID LIPID MET, V1303, P127, DOI 10.1016/0005-2760(96)00097-5; MARNETT LJ, 1984, MOL PHARMACOL, V26, P328; MARNETT LJ, 1997, BIOCHEMISTRY-US, V16, P4303; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Needleman P, 1997, J RHEUMATOL, V24, P6; ODENWALLER R, 1990, METHOD ENZYMOL, V187, P479; PINTO JC, 1994, MOL PHARMACOL, V46, P516; Rowlinson SW, 2000, J BIOL CHEM, V275, P6586, DOI 10.1074/jbc.275.9.6586; Rowlinson SW, 1999, J BIOL CHEM, V274, P23305, DOI 10.1074/jbc.274.33.23305; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; So OY, 1998, J BIOL CHEM, V273, P5801, DOI 10.1074/jbc.273.10.5801; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; Sugiura T, 2000, J BIOL CHEM, V275, P605, DOI 10.1074/jbc.275.1.605; Sugiura T, 1999, J BIOL CHEM, V274, P2794, DOI 10.1074/jbc.274.5.2794; SUTHERLAND CA, 1982, J BIOL CHEM, V257, P4006; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; Yu M, 1997, J BIOL CHEM, V272, P21181, DOI 10.1074/jbc.272.34.21181	46	307	316	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33744	33749		10.1074/jbc.M007088200	http://dx.doi.org/10.1074/jbc.M007088200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10931854	hybrid			2022-12-27	WOS:000090104600078
J	Marti, T; Hu, ZH; Pohl, NL; Shah, AN; Khosla, C				Marti, T; Hu, ZH; Pohl, NL; Shah, AN; Khosla, C			Cloning, nucleotide sequence, and heterologous expression of the biosynthetic gene cluster for R1128, a non-steroidal estrogen receptor antagonist - Insights into an unusual priming mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AROMATIC POLYKETIDE SYNTHASE; ACYL CARRIER PROTEIN; STREPTOMYCES-COELICOLOR A3(2); ENGINEERED BIOSYNTHESIS; BETA-KETOACYL; DEINOCOCCUS RADIODURANS; DEDUCED FUNCTIONS; ESCHERICHIA-COLI; PURIFICATION; STRAIN	R1128 substances are anthraquinone natural products that were previously reported as non-steroidal estrogen receptor antagonists with in vitro and in vivo potency approaching that of tamoxifen, From a biosynthetic viewpoint, these polyketides possess structurally interesting features such as an unusual primer unit that are absent in the well studied anthracyclic and tetracyclic natural products. The entire R1128 gene cluster was cloned and expressed in Streptomyces lividans, a genetically well developed heterologous host. In addition to R1128C, a novel optically active natural product, designated HU235, was isolated. Nucleotide sequence analysis of the biosynthetic gene cluster revealed genes encoding two ketosynthases, a chain length factor, an acyl transferase, three acetyl-CoA carboxylase subunits, two cyclases, two oxygenases, an amidase, and remarkably, two acyl carrier proteins. Feeding studies indicate that the unusual 4-methylvaleryl side chain of R1128C is derived from valine, Together with the absence of a dedicated ketoreductase, dehydratase, or enoylreductase within the R1128 gene cluster, this suggests a functional link between fatty acid biosynthesis and R1128 biosynthesis in the engineered host. Specifically, we propose that the R1128 synthase recruits four subunits from the endogenous fatty acid synthase during the biosynthesis of this family of pharmacologically significant natural products.	Stanford Univ, Dept Chem & Biochem, Stanford, CA 94305 USA; Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA	Stanford University; Stanford University	Khosla, C (corresponding author), Stanford Univ, Dept Chem & Biochem, Stanford, CA 94305 USA.	ck@chemeng.stanford.edu		Khosla, Chaitan/0000-0001-6529-495X	NCI NIH HHS [CA77248] Funding Source: Medline; NIGMS NIH HHS [1 F32 GM19540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bao WL, 1999, BIOCHEMISTRY-US, V38, P9752, DOI 10.1021/bi990751h; BARTEL PL, 1990, J BACTERIOL, V172, P4816, DOI 10.1128/jb.172.9.4816-4826.1990; BIBB MJ, 1994, GENE, V142, P31, DOI 10.1016/0378-1119(94)90351-4; BIERMAN M, 1992, GENE, V116, P43, DOI 10.1016/0378-1119(92)90627-2; BLACK LJ, 1994, J CLIN INVEST, V93, P63, DOI 10.1172/JCI116985; Carreras CW, 1998, BIOCHEMISTRY-US, V37, P2084, DOI 10.1021/bi972919+; Curnow AW, 1998, P NATL ACAD SCI USA, V95, P12838, DOI 10.1073/pnas.95.22.12838; DECKER H, 1995, J BACTERIOL, V177, P6126, DOI 10.1128/jb.177.21.6126-6136.1995; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; Dreier J, 2000, BIOCHEMISTRY-US, V39, P2088, DOI 10.1021/bi992121l; Dreier J, 1999, J BIOL CHEM, V274, P25108, DOI 10.1074/jbc.274.35.25108; FERNANDEZMORENO MA, 1992, J BIOL CHEM, V267, P19278; Gokhale RS, 2000, CURR OPIN CHEM BIOL, V4, P22, DOI 10.1016/S1367-5931(99)00046-0; GORNICKI P, 1993, J BACTERIOL, V175, P5268, DOI 10.1128/JB.175.16.5268-5272.1993; Gould SJ, 1998, J ANTIBIOT, V51, P50, DOI 10.7164/antibiotics.51.50; GRIMM A, 1994, GENE, V151, P1, DOI 10.1016/0378-1119(94)90625-4; Han L, 2000, MICROBIOL-UK, V146, P903, DOI 10.1099/00221287-146-4-903; Han L, 1998, J BACTERIOL, V180, P4481, DOI 10.1128/JB.180.17.4481-4486.1998; Hong ST, 1997, J BACTERIOL, V179, P470, DOI 10.1128/jb.179.2.470-476.1997; Hopwood D.A., 1985, GENETIC MANIPULATION; HORI Y, 1993, J ANTIBIOT, V46, P1055, DOI 10.7164/antibiotics.46.1055; HORI Y, 1993, J ANTIBIOT, V46, P1063, DOI 10.7164/antibiotics.46.1063; HORI Y, 1993, J ANTIBIOT, V46, P1069, DOI 10.7164/antibiotics.46.1069; Hutchinson CR, 1997, CHEM REV, V97, P2525, DOI 10.1021/cr960022x; KEDAR RP, 1994, LANCET, V343, P1318, DOI 10.1016/S0140-6736(94)92466-X; Khosla C, 1999, ANNU REV BIOCHEM, V68, P219, DOI 10.1146/annurev.biochem.68.1.219; LEGOUILL C, 1993, MOL GEN GENET, V240, P146, DOI 10.1007/BF00276894; Lomovskaya N, 1998, J BACTERIOL, V180, P2379, DOI 10.1128/JB.180.9.2379-2386.1998; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; MALPARTIDA F, 1984, NATURE, V309, P462, DOI 10.1038/309462a0; Maniatis T., 1982, MOL CLONING; MAYAUX JF, 1991, J BACTERIOL, V173, P6694, DOI 10.1128/jb.173.21.6694-6704.1991; MCDANIEL R, 1993, J AM CHEM SOC, V115, P11671, DOI 10.1021/ja00078a002; MCDANIEL R, 1994, J AM CHEM SOC, V116, P10855, DOI 10.1021/ja00103a001; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; MCDANIEL R, 1995, NATURE, V375, P549, DOI 10.1038/375549a0; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; REVILL WP, 1995, J BACTERIOL, V177, P3946, DOI 10.1128/jb.177.14.3946-3952.1995; RICHARDSON MT, 1999, COMPREHENSIVE NATURA, V1, P473; STRAUCH E, 1991, MOL MICROBIOL, V5, P289, DOI 10.1111/j.1365-2958.1991.tb02109.x; TSAY JT, 1992, J BIOL CHEM, V267, P6807; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571; YE JS, 1994, J BACTERIOL, V176, P6270, DOI 10.1128/jb.176.20.6270-6280.1994; Zawada RJX, 1997, J BIOL CHEM, V272, P16184, DOI 10.1074/jbc.272.26.16184; Zhang YX, 1999, MICROBIOL-SGM, V145, P2323, DOI 10.1099/00221287-145-9-2323; Ziermann R, 1999, BIOTECHNIQUES, V26, P106, DOI 10.2144/99261st05	46	80	84	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33443	33448		10.1074/jbc.M006766200	http://dx.doi.org/10.1074/jbc.M006766200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10931852	hybrid			2022-12-27	WOS:000090104600038
J	Beerli, RR; Schopfer, U; Dreier, B; Barbas, CF				Beerli, RR; Schopfer, U; Dreier, B; Barbas, CF			Chemically regulated zinc finger transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLLING GENE-EXPRESSION; RECEPTOR FUSION PROTEINS; MAMMALIAN-CELLS; ECDYSONE RECEPTOR; BINDING DOMAIN; LAC REPRESSOR; DNA; SYSTEM; COMPLEX; TRANSFORMATION	Ligand-dependent transcriptional regulators were generated by fusion of designed Cys(2)-His(2) zinc finger proteins and steroid hormone receptor ligand binding domains. To produce novel DNA binding domains, three-finger proteins binding specific 9-base pair sequences were constructed from modular building blocks. Fusion of these zinc finger proteins to a transcriptional activation domain and to modified ligand binding domains derived from either the estrogen or progesterone receptors yielded potent ligand-dependent transcriptional regulators. Together with optimized minimal promoters, these regulators provide 4-hydroxytamoxifen- or RU486-inducible expression systems with induction ratios of up to 3 orders of magnitude. These inducible expression systems are functionally independent, and each can be selectively switched on within the same cell. The potential use of zinc finger-steroid receptor fusion proteins for the regulation of natural promoters was also explored. A gene-specific six-finger protein binding an 18-base pair target sequence was converted into a ligand-dependent regulator by fusion with either two estrogen receptor ligand binding domains or one ecdysone receptor and one retinoid X receptor ligand binding domain. These single-chain receptor proteins undergo an intramolecular rearrangement, rather than intermolecular dimerization and are functional as monomers, Thus, the ability to engineer DNA binding specificities of zinc finger proteins enables the construction of ligand dependent transcriptional regulators with potential for the regulation of virtually any desired artificial or natural promoter. It is anticipated that the novel chemically regulated gene switches described herein will find many applications in applied and basic research, where the specific modulation of gene expression can be exploited.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Barbas, CF (corresponding author), Scripps Res Inst, Dept Mol Biol, BCC-550,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R01CA086258] Funding Source: NIH RePORTER; NCI NIH HHS [CA86258] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aumais JP, 1996, J BIOL CHEM, V271, P12568, DOI 10.1074/jbc.271.21.12568; BAIM SB, 1991, P NATL ACAD SCI USA, V88, P5072, DOI 10.1073/pnas.88.12.5072; Baron U, 1999, P NATL ACAD SCI USA, V96, P1013, DOI 10.1073/pnas.96.3.1013; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Beerli RR, 1998, P NATL ACAD SCI USA, V95, P14628, DOI 10.1073/pnas.95.25.14628; Beerli RR, 2000, P NATL ACAD SCI USA, V97, P1495, DOI 10.1073/pnas.040552697; BRASELMANN S, 1993, P NATL ACAD SCI USA, V90, P1657, DOI 10.1073/pnas.90.5.1657; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; CHRISTOPHERSON KS, 1992, P NATL ACAD SCI USA, V89, P6314, DOI 10.1073/pnas.89.14.6314; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Greisman HA, 1997, SCIENCE, V275, P657, DOI 10.1126/science.275.5300.657; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Kim JS, 1997, J BIOL CHEM, V272, P29795, DOI 10.1074/jbc.272.47.29795; LABOW MA, 1990, MOL CELL BIOL, V10, P3343, DOI 10.1128/MCB.10.7.3343; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Liu Q, 1997, P NATL ACAD SCI USA, V94, P5525, DOI 10.1073/pnas.94.11.5525; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; LOUVION JF, 1993, GENE, V131, P129, DOI 10.1016/0378-1119(93)90681-R; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; NAKANISHI K, 1992, STEROIDS, V57, P649, DOI 10.1016/0039-128X(92)90018-5; NELSON M, 1989, MOL CELL BIOL, V9, P384, DOI 10.1128/MCB.9.2.384; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Rivera VM, 1996, NAT MED, V2, P1028, DOI 10.1038/nm0996-1028; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Segal DJ, 2000, CURR OPIN CHEM BIOL, V4, P34, DOI 10.1016/S1367-5931(99)00048-4; Segal DJ, 1999, P NATL ACAD SCI USA, V96, P2758, DOI 10.1073/pnas.96.6.2758; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; Wang Y, 1997, GENE THER, V4, P432, DOI 10.1038/sj.gt.3300402; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; Whelan J, 1996, J STEROID BIOCHEM, V58, P3, DOI 10.1016/0960-0760(96)00010-6; WU H, 1995, P NATL ACAD SCI USA, V92, P344, DOI 10.1073/pnas.92.2.344; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0	47	100	117	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32617	32627		10.1074/jbc.M005108200	http://dx.doi.org/10.1074/jbc.M005108200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10924515	hybrid			2022-12-27	WOS:000090003800035
J	Munoz-Alonso, MJ; Guillemain, G; Kassis, N; Girard, J; Burnol, AF; Leturque, A				Munoz-Alonso, MJ; Guillemain, G; Kassis, N; Girard, J; Burnol, AF; Leturque, A			A novel cytosolic dual specificity phosphatase, interacting with glucokinase, increases glucose phosphorylation rate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; IN-VIVO PHOSPHORYLATION; REGULATORY PROTEIN; SACCHAROMYCES-CEREVISIAE; KINASE PHOSPHATASE; CATALYTIC ROLE; LIVER; GENE; HEXOKINASE-2; SITE	A novel protein was cloned from a rat liver cDNA library by interaction with the liver glucokinase. This protein contained 339 residues and possessed a canonical consensus sequence for a dual specificity phosphatase. The recombinant protein was able to dephosphorylate phosphotyrosyl and phosphosery/threonyl substrates. We called this protein the glucokinase-associated phosphatase (GKAP). The GKAP partially dephosphorylated the recombinant glucokinase previously phosphorylated, in vitro, by protein kinase A. The GKAP fused with green fluorescent protein was located in the cytosol, where glucokinase phosphorylates glucose, and not in the nucleus where the glucokinase is retained inactive by the glucokinase regulatory protein. More importantly, the GKAP accelerated the glucokinase activity in a dose-dependent manner and with a stoichiometry compatible with a physiological mechanism. This strongly suggested that the interaction between GKAP and glucokinase had a functional significance. The cloning of this novel protein with a dual specificity phosphatase activity allows the description of a possible new regulatory step in controlling the glycolysis flux.	INSERM U505, Inst Biomed Cordeliers, F-75006 Paris, France; CNRS, UPR 1524, F-92190 Meudon, France; CNRS, UPRESA 7059, Lab Physiopathol Nutr, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Leturque, A (corresponding author), INSERM U505, Inst Biomed Cordeliers, 15 Rue Ecole Med, F-75006 Paris, France.	leturque@infobiogen.fr	Leturque, Armelle/Q-9437-2017; Guillemain, Ghislaine/P-7740-2017; Burnol, Anne-Francoise/P-2181-2017	Leturque, Armelle/0000-0001-6570-6387; Guillemain, Ghislaine/0000-0002-8256-9545				ADAMS V, 1991, BIOCHEM MED METAB B, V45, P271, DOI 10.1016/0885-4505(91)90032-G; AGIUS L, 1995, BIOCHEM J, V309, P711, DOI 10.1042/bj3090711; ANTOINE B, 1992, EXP CELL RES, V200, P175, DOI 10.1016/S0014-4827(05)80086-2; AORA KK, 1990, J BIOL CHEM, V265, P6481; Behlke J, 1998, BIOCHEMISTRY-US, V37, P11989, DOI 10.1021/bi980914m; Brown KS, 1997, DIABETES, V46, P179, DOI 10.2337/diabetes.46.2.179; CHARLES RS, 1994, DIABETES, V43, P784, DOI 10.2337/diab.43.6.784; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; EKMAN P, 1988, ARCH BIOCHEM BIOPHYS, V261, P275, DOI 10.1016/0003-9861(88)90342-6; Fang TY, 1998, J BIOL CHEM, V273, P19548, DOI 10.1074/jbc.273.31.19548; Farrelly D, 1999, P NATL ACAD SCI USA, V96, P14511, DOI 10.1073/pnas.96.25.14511; Fernandez-Novell JM, 1999, FEBS LETT, V459, P211, DOI 10.1016/S0014-5793(99)01249-1; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GUAN K, 1992, P NATL ACAD SCI USA, V89, P12175, DOI 10.1073/pnas.89.24.12175; Heidrich K, 1997, BIOCHEMISTRY-US, V36, P1960, DOI 10.1021/bi9623643; Kasus-Jacobi A, 1998, J BIOL CHEM, V273, P26026, DOI 10.1074/jbc.273.40.26026; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRIEGEL TM, 1994, BIOCHEMISTRY-US, V33, P148, DOI 10.1021/bi00167a019; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; LIANG Y, 1991, J BIOL CHEM, V266, P6999; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; Martell KJ, 1998, MOL CELLS, V8, P2; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P4319; Randez-Gil F, 1998, MOL CELL BIOL, V18, P2940, DOI 10.1128/MCB.18.5.2940; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P179; VANSCHAFTINGEN E, 1994, FASEB J, V8, P414, DOI 10.1096/fasebj.8.6.8168691; XU LZ, 1995, J BIOL CHEM, V270, P9939, DOI 10.1074/jbc.270.17.9939; ZHENG CF, 1993, J BIOL CHEM, V268, P16116; ZHOU GC, 1994, J BIOL CHEM, V269, P28084	37	42	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32406	32412		10.1074/jbc.M000841200	http://dx.doi.org/10.1074/jbc.M000841200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10913113	hybrid			2022-12-27	WOS:000090003800006
J	Okano, S; Kanno, S; Nakajima, S; Yasui, A				Okano, S; Kanno, S; Nakajima, S; Yasui, A			Cellular responses and repair of single-strand breaks introduced by UV damage endonuclease in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFIED HUMAN PROTEINS; BASE EXCISION-REPAIR; YEAST SCHIZOSACCHAROMYCES-POMBE; DNA-REPAIR; APURINIC/APYRIMIDINIC SITES; PATHWAY; GENE; XRCC1; RECONSTITUTION; POLYMERASE	Although single-strand breaks (SSBs) occur frequently, the cellular responses and repair of SSB are not well understood. To address this, we established mammalian cell Lines expressing Neurospora crassa UV damage endonuclease (UVDE), which introduces a SSB with a 3'-OH immediately 5' to UV-induced cyclobutane pyrimidine dimers or 6-4 photoproducts and initiates an alternative excision repair process. Xeroderma pigmentosum group A cells expressing UVDE show UV resistance of almost the wild-type level. In these cells SSBs are produced upon UV irradiation and then efficiently repaired. The repair patch size is about seven nucleotides, and repair synthesis is decreased to 30% by aphidicolin, suggesting the involvement of a DNA polymerase delta/is an element of -dependent long-patch repair. Immediately after UV irradiation, cellular proteins are poly(ADP-ribosyl)ated. The UV resistance of the cells is decreased in the presence of 3-aminobenzamide, an inhibitor of poly(AI)P-ribose) polymerase. Expression of UVDE in XRCC1-defective EM9, a Chinese hamster ovary cell line, greatly sensitizes the host cells to UV, and addition of 3-aminobenzamide results in almost no further sensitization of the cells to UV. Thus, we show that XRCC1 and PARP are involved in the same pathway for the repair of SSBs.	Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Genet, Sendai, Miyagi 9808575, Japan	Tohoku University	Yasui, A (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Genet, Sendai, Miyagi 9808575, Japan.	ayasui@idac.tohoku.ac.jp	Kanno, Shin-ichiro/AAE-4549-2019					Alleva JL, 2000, BIOCHEMISTRY-US, V39, P2659, DOI 10.1021/bi992751n; ALVAREZGONZALEZ R, 1989, MUTAT RES, V218, P67, DOI 10.1016/0921-8777(89)90012-8; BENHUR E, 1984, RADIAT RES, V97, P546, DOI 10.2307/3576146; BOORSTEIN RJ, 1984, J CELL PHYSIOL, V120, P345, DOI 10.1002/jcp.1041200313; Bowman KK, 1997, MUTAT RES-DNA REPAIR, V385, P95, DOI 10.1016/S0921-8777(97)00029-3; BOWMAN KK, 1994, NUCLEIC ACIDS RES, V22, P3026, DOI 10.1093/nar/22.15.3026; Chatterjee S, 1998, CONT CANC RES, P487; FREYER GA, 1995, MOL CELL BIOL, V15, P4572; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Kanno S, 1999, NUCLEIC ACIDS RES, V27, P3096, DOI 10.1093/nar/27.15.3096; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; LEHMAN AR, 1981, DNA REPAIR LAB MANUA, P471; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MIYAMOTO I, 1992, J BIOL CHEM, V267, P12182; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Pascucci B, 1999, J BIOL CHEM, V274, P33696, DOI 10.1074/jbc.274.47.33696; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; POVIRK LF, 1977, NUCLEIC ACIDS RES, V4, P3573, DOI 10.1093/nar/4.10.3573; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shen NR, 1998, NUCLEIC ACIDS RES, V26, P1032, DOI 10.1093/nar/26.4.1032; SMITH CA, 1981, DNA REPAIR LABORAT B, V1, P289; Takao M, 1996, NUCLEIC ACIDS RES, V24, P1267, DOI 10.1093/nar/24.7.1267; Taylor RM, 2000, MOL CELL BIOL, V20, P735, DOI 10.1128/MCB.20.2.735-740.2000; Thompson LH, 2000, MUTAT RES-DNA REPAIR, V459, P1, DOI 10.1016/S0921-8777(99)00058-0; VALERIE K, 1987, CANCER RES, V47, P2967; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571; YAJIMA H, 1995, EMBO J, V14, P2393, DOI 10.1002/j.1460-2075.1995.tb07234.x; Yasuhira S, 1999, J BIOL CHEM, V274, P26822, DOI 10.1074/jbc.274.38.26822; Yasui A, 1998, BIOESSAYS, V20, P291, DOI 10.1002/(SICI)1521-1878(199804)20:4<291::AID-BIES5>3.0.CO;2-T; Yonemasu R, 1997, NUCLEIC ACIDS RES, V25, P1553, DOI 10.1093/nar/25.8.1553; Yoon JH, 1999, BIOCHEMISTRY-US, V38, P4809, DOI 10.1021/bi990105i	34	36	36	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32635	32641		10.1074/jbc.M004085200	http://dx.doi.org/10.1074/jbc.M004085200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10924509	hybrid			2022-12-27	WOS:000090003800037
J	Baglia, FA; Badellino, KO; Ho, DH; Dasari, VR; Walsh, PN				Baglia, FA; Badellino, KO; Ho, DH; Dasari, VR; Walsh, PN			A binding site for the kringle II domain of prothrombin in the Apple 1 domain of factor XI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-XI; MOLECULAR-WEIGHT KININOGEN; BLOOD-COAGULATION; FUNCTIONAL-CHARACTERIZATION; HAGEMAN-FACTOR; HEAVY-CHAIN; ACTIVATION; THROMBIN; PLASMA; IDENTIFICATION	Previously we defined binding sites for high molecular weight kininogen (HK) and thrombin in the Apple 1 (Al) domain of factor XI (FM). Since prothrombin (and Ca2+) can bind FXI and can substitute for HK (and Zn2+) as a cofactor for FXI binding to platelets, we have attempted to identify a prothrombin-binding site in FXI. The recombinant Al domain (rAl, Glu(1)-Ser(90)) inhibited the saturable, specific and reversible binding of prothrombin to FXI, whereas neither the rA2 domain (Ser(90)-Ala(181)), rA3 domain (Ala(181)-Val(271)), nor rA4 domain (Phe(272)-Glu(361)) inhibited prothrombin binding to FXI. Kinetic binding studies using surface plasmon resonance showed binding of FXI (K-d similar to 71 nn) and the rAl domain (K-d similar to 239 nM) but not rA2, rA3, or rA4 to immobilized prothrombin. Reciprocal binding studies revealed that synthetic peptides (encompassing residues Ala(45)-Ser(86)) containing both HK- and thrombin-binding sites, inhibit I-125-rAl (Glu(1)-Ser(90)) binding to prothrombin, I-125-prothrombin binding to FXI, and 125I-prothrombin fragment 2 (Ser(156)-Arg(271)) binding to FXI. However, homologous prekallikrein-derived peptides (encompassing Pro(45)-Gly(86)) did not inhibit FXI rAl binding to prothrombin. The peptides Ala(45)-Arg(54), Phe(56)-Val(71), and Asp(72)-Ser(86), derived from sequences of the Al domain of FXI, acted synergistically to inhibit I-125-rAl binding to prothrombin. Mutant rAl peptides (V64A and I77A), which did not inhibit FXI binding to III, retained full capacity to inhibit rAl domain binding to prothrombin, and mutant rAl peptides Ala(45)-Ala(54) (D51A) and Val(59)-Arg(70) (E66A), which did not inhibit FXI binding to thrombin, retained full capacity to inhibit rAl domain binding to prothrombin. Thus, these experiments demonstrate that a prothrombin binding site exists in the Al domain of FXI spanning residues Ala(45)-Ser(86) that is contiguous with but separate and distinct from the HK- and thrombin-binding sites and that this interaction occurs through the kringle II domain of prothrombin.	Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; NCI, Med Branch, NIH, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Walsh, PN (corresponding author), Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, 3400 N Broad St, Philadelphia, PA 19140 USA.	pnw@astro.ocis.temple.edu		Dasari, Venkat/0000-0001-9795-6567	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056153, R01HL046213, P01HL056914] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46213, HL56153, HL56914] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGLIA FA, 1991, J BIOL CHEM, V266, P24190; BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734; BAGLIA FA, 1992, J BIOL CHEM, V267, P4247; BAGLIA FA, 1990, J BIOL CHEM, V265, P4149; Baglia FA, 1996, J BIOL CHEM, V271, P3652; BAGLIA FA, 1993, J BIOL CHEM, V268, P3838; Baglia FA, 1998, BIOCHEMISTRY-US, V37, P2271, DOI 10.1021/bi972113+; BAGLIA FA, 1999, THROMB DIATH HAEMO, V82, P428; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; BRUNNEE T, 1993, BLOOD, V81, P580; Davie E W, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P277; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GAILANI D, 1993, SEMIN THROMB HEMOST, V19, P396, DOI 10.1055/s-2007-993291; GRIFFIN JH, 1976, P NATL ACAD SCI USA, V73, P2554, DOI 10.1073/pnas.73.8.2554; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HERWALD H, 1993, J BIOL CHEM, V268, P14527; Ho DH, 1998, J BIOL CHEM, V273, P16382, DOI 10.1074/jbc.273.26.16382; KENT SBH, 1985, SYNTHETIC PEPTIDES B, P29; KERBIRIOU DM, 1979, J BIOL CHEM, V254, P2020; KURACHI K, 1980, BIOCHEMISTRY-US, V19, P1330, DOI 10.1021/bi00548a011; KURACHI K, 1977, BIOCHEMISTRY-US, V16, P5831, DOI 10.1021/bi00645a030; Mann KG., 1994, HEMOSTASIS THROMBOSI, P184; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008; NAITO K, 1991, J BIOL CHEM, V266, P7353; SCOTT CF, 1984, BLOOD, V63, P42; SCOTT CF, 1992, P NATL ACAD SCI USA, V89, P11189, DOI 10.1073/pnas.89.23.11189; SEAMAN FS, 1994, BIOCHEM J, V304, P715, DOI 10.1042/bj3040715; SINHA D, 1985, J BIOL CHEM, V260, P714; STEVENS WK, 1993, BIOCHEMISTRY-US, V32, P2787, DOI 10.1021/bi00062a008; THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898; VANDERGRAAF F, 1983, J BIOL CHEM, V258, P9669; WALSH PN, 1993, METHOD ENZYMOL, V222, P65	33	30	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31954	31962		10.1074/jbc.M005465200	http://dx.doi.org/10.1074/jbc.M005465200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10924522	hybrid			2022-12-27	WOS:000089858900057
J	Balija, VS; Chakraborty, TR; Nikonov, AV; Morimoto, T; Haldar, D				Balija, VS; Chakraborty, TR; Nikonov, AV; Morimoto, T; Haldar, D			Identification of two transmembrane regions and a cytosolic domain of rat mitochondrial glycerophosphate acyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SN-GLYCEROL 3-PHOSPHATE; COA-BINDING PROTEIN; LIVER MITOCHONDRIA; ACYL-COA; MEMBRANE; TOPOGRAPHY; ACYLATION; SUBSTRATE; CLONING	The topography of rat glycerophosphate acyltransferase (GAT) in the transverse plane of the mitochondrial outer membrane (MOM) was investigated. Computer analysis of the amino acid (aa) sequence derived from rat mitochondrial GAT cDNA (GenBank(TM) accession nos. U36771 and AF021348) predicts the presence of two possible transmembrane domains (aa 473-493 and 574-594) separated by an 80-aa stretch (aa 494-573), To determine the actual orientation of the native protein, we prepared anti-peptide antibodies to three regions: one in between (aa 543-559) and the other two (aa 420-435 and 726-740) flanking the two putative transmembrane regions. Both immunoreaction and immunoprecipitation experiments employing intact and solubilized mitochondria indicate that regions on the N- and C-terminal sides of the transmembrane regions are sequestered on the inner surface of the MOM, while the region between the transmembrane domains is present on the cytosolic face of the MOM. Additionally, two green fluorescent protein (GFP) fusion proteins consisting of full-length GAT fused to GFP at either the C terminus or inserted 115 amino acids from the N terminus were also constructed to determine the orientation of the N and C termini. COS-l cells expressing these fusion proteins were fractionated to obtain mitochondria. Protease digestion of intact and solubilized COS-l cell mitochondria revealed that the GFP domains of these fusion proteins are sequestered on the inner side of the MOM. The present findings indicate that GAT is a dual-spanning, transmembrane protein adopting an inverted "U" conformation in the transverse plane of the MOM, where the N and C termini are sequestered on the inner surface of the MOM, while aa 494-573 are exposed on the cytosolic surface of the MOM.	St Johns Univ, Dept Biol Sci, Jamaica, NY 11432 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA	Saint John's University; New York University	Haldar, D (corresponding author), St Johns Univ, Dept Biol Sci, Jamaica, NY 11432 USA.				NIGMS NIH HHS [GM-46692, GM-57643] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046692, R15GM057643] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; Bhat BG, 1999, BBA-MOL CELL BIOL L, V1439, P415, DOI 10.1016/S1388-1981(99)00103-1; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; CARROLL MA, 1982, ARCH BIOCHEM BIOPHYS, V214, P12; Chakraborty TR, 1999, J BIOL CHEM, V274, P29786, DOI 10.1074/jbc.274.42.29786; DAAE LNW, 1973, BIOCHIM BIOPHYS ACTA, V306, P186, DOI 10.1016/0005-2760(73)90224-5; DAS SK, 1981, BIOCHEM BIOPH RES CO, V101, P237, DOI 10.1016/S0006-291X(81)80036-8; DAS SK, 1987, LIPIDS, V22, P757, DOI 10.1007/BF02533977; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V882, P1; FITZPATRICK SM, 1982, J NEUROCHEM, V39, P286, DOI 10.1111/j.1471-4159.1982.tb04738.x; GROSJEAN CD, 1982, FEBS LETT, V145, P281, DOI 10.1016/0014-5793(82)80183-X; Haldar D, 1983, Trans N Y Acad Sci, V41, P173; HALDAR D, 1979, J BIOL CHEM, V254, P4502; HESLER CB, 1985, J BIOL CHEM, V260, P7452; HOFFMAN K, 1993, BIOL CHEM HOPPESEYLE, V347, P166; HOSTETLER KY, 1982, PHOSPHOLIPIDS, P481; KENNEDY EP, 1953, J BIOL CHEM, V201, P399; KENNEDY EP, 1961, FED PROC, V20, P934; KORNBERG A, 1953, J BIOL CHEM, V204, P345; MANDRUP S, 1993, BIOCHEM J, V290, P369, DOI 10.1042/bj2900369; MONROY G, 1972, J BIOL CHEM, V247, P6884; MUDIO PM, 1999, BIOCHEM J, V338, P783; NIKONOV AV, 1998, RRD LIP RES 2, V2, P207; NIMO HG, 1979, FEBS LETT, V101, P262; PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013; RASMUSSEN JT, 1993, BIOCHEM J, V292, P907, DOI 10.1042/bj2920907; SCHLAME M, 1993, J BIOL CHEM, V268, P74; SHIN DH, 1991, J BIOL CHEM, V266, P23834; SHINDO Y, 1978, J BIOCHEM, V84, P1177, DOI 10.1093/oxfordjournals.jbchem.a132234; STERN W, 1978, J BIOL CHEM, V253, P8047; VANCURA A, 1992, J BIOL CHEM, V267, P14353; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C	32	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31668	31673		10.1074/jbc.M002963200	http://dx.doi.org/10.1074/jbc.M002963200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10924502	hybrid			2022-12-27	WOS:000089858900019
J	Berenstein, D; Christensen, JF; Kristensen, T; Hofbauer, R; Munch-Petersen, B				Berenstein, D; Christensen, JF; Kristensen, T; Hofbauer, R; Munch-Petersen, B			Valine, not methionine, is amino acid 106 in human cytosolic thymidine kinase (TK1) - Impact on oligomerization, stability, and kinetic properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; MAMMALIAN-CELLS; SEQUENCE; GENE; OVEREXPRESSION; PREDICTION; MUTATIONS; COMPLEX; CYCLE; POOL	Cytosolic thymidine kinase (TK1) cDNA from human lymphocytes was cloned, expressed in Escherichia coli, purified, and characterized with respect to the ATP effect on thymidine affinity and oligomerization, Sequence analysis of this lymphocyte TK1 cDNA and 21 other cDNAs or genomic TK1 DNAs from healthy cells or leukemic or transformed cell lines revealed a valine at amino acid position 106. The TK1 sequence in NCBI GenBank(TM) has methionine at this position. The recombinant lymphocyte TK1(Val-106) (rLy-TK1(Val-106)) has the same enzymatic and oligomerization properties as endogenous human lymphocyte TK1 (Ly-TK1); ATP exposure induces an enzyme concentration-dependent reversible transition from a dimer to a tetramer with 20-30-fold higher thymidine affinity (K-m about 15 and 0.5 mu M, respectively). Substitution of Val-106 with methionine to give rLy-TK1(Met-106) results in a permanent tetramer with the high thymidine affinity (K-m about 0.5 mu M), even without ATP exposure. Furthermore, rLy-TK1(Met-106) is considerably less stable than rLy-TK1(Val-106) (t(1/2) at 15 degrees C is 41 and 392 min, respectively). Because valine with high probability is the naturally occurring amino acid at position 106 in human TK1 and because this position has high impact on the enzyme properties, the Val-106 form should be used in future investigations of recombinant human TK1.	Roskilde Univ, Dept Life Sci & Chem, DK-4000 Roskilde, Denmark; Vienna Bioctr, Dept Mol Biol, Inst Med Biochem, A-1030 Vienna, Austria	Roskilde University; Vienna Biocenter (VBC)	Munch-Petersen, B (corresponding author), Roskilde Univ, Dept Life Sci & Chem, DK-4000 Roskilde, Denmark.							BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADSHAW HD, 1984, MOL CELL BIOL, V4, P2316, DOI 10.1128/MCB.4.11.2316; BROWN DG, 1995, NAT STRUCT BIOL, V2, P876, DOI 10.1038/nsb1095-876; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FLEMINGTON E, 1987, GENE, V52, P267, DOI 10.1016/0378-1119(87)90053-9; FOLKERS G, 1991, J COMPUT AID MOL DES, V5, P385, DOI 10.1007/BF00125660; GIVER CR, 1995, CARCINOGENESIS, V16, P267, DOI 10.1093/carcin/16.2.267; GROSOVSKY AJ, 1993, MUTAT RES, V289, P231, DOI 10.1016/0027-5107(93)90074-P; HIRAGA S, 1967, BIOCHIM BIOPHYS ACTA, V145, P41, DOI 10.1016/0005-2787(67)90652-1; KAUFFMAN MG, 1991, MOL CELL BIOL, V11, P2538, DOI 10.1128/MCB.11.5.2538; Kim CH, 1997, GENE, V199, P293, DOI 10.1016/S0378-1119(97)00384-3; KRISTENSEN T, 1994, LEUKEMIA RES, V18, P861, DOI 10.1016/0145-2126(94)90168-6; Lei HX, 1998, BIOMED ENVIRON SCI, V11, P354; MEUTH M, 1989, EXP CELL RES, V181, P305, DOI 10.1016/0014-4827(89)90090-6; Munch-Petersen B, 2000, J BIOL CHEM, V275, P6673, DOI 10.1074/jbc.275.9.6673; MUNCHPETERSEN B, 1995, ADV ENZYME REGUL, V35, P69, DOI 10.1016/0065-2571(94)00014-T; MUNCHPETERSEN B, 1993, J BIOL CHEM, V268, P15621; MUNCHPETERSEN B, 1973, EXP CELL RES, V79, P249, DOI 10.1016/0014-4827(73)90442-4; Oliver FJ, 1997, J BIOL CHEM, V272, P10624; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SAMBROOK J, 1989, MOL CLONING, V2, P9; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; STEWART CJ, 1987, MOL CELL BIOL, V7, P1156, DOI 10.1128/MCB.7.3.1156; Wild K, 1997, PROTEIN SCI, V6, P2097	27	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32187	32192		10.1074/jbc.M005325200	http://dx.doi.org/10.1074/jbc.M005325200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10924519	hybrid			2022-12-27	WOS:000089858900087
J	Boll, M; Fuchs, G; Meier, C; Trautwein, A; Lowe, DJ				Boll, M; Fuchs, G; Meier, C; Trautwein, A; Lowe, DJ			EPR and Mossbauer studies of Benzoyl-CoA reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAEROBIC AROMATIC METABOLISM; IRON-SULFUR PROTEIN; ELECTRON-PARAMAGNETIC-RES; ACIDAMINOCOCCUS-FERMENTANS; CLOSTRIDIUM-PASTEURIANUM; THAUERA-AROMATICA; KEY ENZYME; 2-HYDROXYGLUTARYL-COA DEHYDRATASE; 2<4FE-4SE>+ FERREDOXIN; CLUSTER	Benzoyl-CoA reductase catalyzes the two-electron transfer from a reduced ferredoxin to the aromatic ring of benzoyl-CoA; this reaction is coupled to stoichiometrical ATP hydrolysis, A very low reduction potential (less than -1V) is required for the first electron transfer to the aromatic ring, In this work the nature of the redox centers of purified benzoyl-CoA reductase from Thauera aromatica was studied by EPR and Mossbauer spectroscopy. The results obtained indicated the presence of three [4Fe-4S] clusters. Redox titration studies revealed that the reduction potentials of all three clusters were below -500 mV. The previously reported S = 7/2 state of the enzyme during benzoyl-CoA-independent ATPase activity (Boll, M., Albracht, S. J, P., and Fuchs, G, (1997) fur. J. Biochem. 244, 840-851) was confirmed by Mossbauer spectroscopy. Inactivation by oxygen was associated with the irreversible conversion of part of the [4Fe-4S] clusters to [3Fe-4S] clusters. Acetylene stimulated the benzoyl-CoA-independent ATPase activity and induced novel EPR signals with g(av) > 2. The presence of simple cubane clusters in benzoyl-CoA reductase as the sole redox-active metal centers demonstrates novel aspects of [4Fe-4S] clusters since they adopt the role of elemental sodium or lithium which are used as electron donors in the analogous chemical Birch reduction of aromatic rings.	Univ Freiburg, Inst Biol 2, D-79104 Freiburg, Germany; John Innes Ctr Plant Sci Res, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England; Med Univ Lubeck, Inst Phys, D-2358 Lubeck, Germany	University of Freiburg; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of Lubeck	Boll, M (corresponding author), Univ Freiburg, Inst Biol 2, Schanzlestr 1, D-79104 Freiburg, Germany.	boll@uni-freiburg.de						ABRAGAM A, 1951, PROC R SOC LON SER-A, V205, P135, DOI 10.1098/rspa.1951.0022; ANDERS HJ, 1995, INT J SYST BACTERIOL, V45, P327, DOI 10.1099/00207713-45-2-327; AURIC P, 1987, BIOCHEM J, V242, P525, DOI 10.1042/bj2420525; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; BENDRAT K, 1993, FEBS LETT, V329, P329, DOI 10.1016/0014-5793(93)80247-R; Boll M, 1995, EUR J BIOCHEM, V234, P921, DOI 10.1111/j.1432-1033.1995.921_a.x; Boll M, 2000, BIOCHEMISTRY-US, V39, P4929, DOI 10.1021/bi9927890; Boll M, 1997, EUR J BIOCHEM, V244, P840, DOI 10.1111/j.1432-1033.1997.00840.x; Boll M, 1998, EUR J BIOCHEM, V251, P946, DOI 10.1046/j.1432-1327.1998.2510946.x; BRACKMANN R, 1993, EUR J BIOCHEM, V213, P563, DOI 10.1111/j.1432-1033.1993.tb17795.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breese K, 1998, EUR J BIOCHEM, V256, P148, DOI 10.1046/j.1432-1327.1998.2560148.x; Buckel W, 1996, FEBS LETT, V389, P20, DOI 10.1016/0014-5793(96)00530-3; Buckel W., 1995, ANGEW CHEM, V107, P1595; DUNHAM WR, 1991, BIOCHIM BIOPHYS ACTA, V1079, P253, DOI 10.1016/0167-4838(91)90066-9; DUTSCHO R, 1989, EUR J BIOCHEM, V181, P741, DOI 10.1111/j.1432-1033.1989.tb14786.x; Egland PG, 1997, P NATL ACAD SCI USA, V94, P6484, DOI 10.1073/pnas.94.12.6484; FRAISSE L, 1988, ARCH MICROBIOL, V150, P381, DOI 10.1007/BF00408311; HAGEN WR, 1987, EUR J BIOCHEM, V169, P457, DOI 10.1111/j.1432-1033.1987.tb13633.x; Hans M, 1999, EUR J BIOCHEM, V265, P404, DOI 10.1046/j.1432-1327.1999.00748.x; Harwood CS, 1998, FEMS MICROBIOL REV, V22, P439, DOI 10.1016/S0168-6445(98)00026-6; HEERING HA, 1995, EUR J BIOCHEM, V232, P811, DOI 10.1111/j.1432-1033.1995.811zz.x; Heider J, 1997, EUR J BIOCHEM, V243, P577, DOI 10.1111/j.1432-1033.1997.00577.x; Jung YS, 1997, J BIOL INORG CHEM, V2, P209, DOI 10.1007/s007750050126; KIM J, 1994, BIOCHEMISTRY-US, V33, P389, DOI 10.1021/bi00168a001; KOCH J, 1993, EUR J BIOCHEM, V211, P649, DOI 10.1111/j.1432-1033.1993.tb17593.x; KRAPCHO AP, 1959, J AM CHEM SOC, V81, P3658, DOI 10.1021/ja01523a042; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE DJ, 1978, BIOCHEM J, V173, P277, DOI 10.1042/bj1730277; MIDDLETON P, 1978, EUR J BIOCHEM, V88, P135, DOI 10.1111/j.1432-1033.1978.tb12430.x; MITTELBERGER T, 1996, THESIS U FREIBURG GE; MOULIS JM, 1984, J BIOL CHEM, V259, P1396; MULLER U, 1995, EUR J BIOCHEM, V230, P698, DOI 10.1111/j.1432-1033.1995.tb20611.x; NOODLEMAN L, 1991, INORG CHEM, V30, P246, DOI 10.1021/ic00002a019; ONATE YA, 1989, J BIOL CHEM, V264, P18386; SCHACHTER D, 1953, J BIOL CHEM, V203, P925; SCHWEIGER G, 1987, EUR J BIOCHEM, V169, P441, DOI 10.1111/j.1432-1033.1987.tb13631.x; THOMPSON CL, 1974, BIOCHEM J, V139, P97, DOI 10.1042/bj1390097; ZEHR BD, 1989, ANAL BIOCHEM, V182, P157, DOI 10.1016/0003-2697(89)90734-3	39	33	34	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31857	31868		10.1074/jbc.M001508200	http://dx.doi.org/10.1074/jbc.M001508200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10903310	hybrid			2022-12-27	WOS:000089858900045
J	Fogel, BL; McNally, MT				Fogel, BL; McNally, MT			A cellular protein, hnRNP H, binds to the negative regulator of splicing element from Rous sarcoma virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RIBONUCLEOPROTEIN-H; MESSENGER-RNA; MASS-SPECTROMETRY; SR PROTEINS; IN-VITRO; 5'-SPLICE-SITE; SEQUENCES; GENE; U11; IDENTIFICATION	Incomplete RNA splicing is a key feature of the retroviral life cycle. This is in contrast to the processing of most cellular pre-mRNAs, which are usually spliced to completion. In Rous sarcoma virus, splicing control is achieved in part through a cis-acting RNA element termed the negative regulator of splicing (NRS). The NRS is functionally divided into two parts termed NRS5' and NRS3', which bind a number of splicing factors. The U1 and U11 small nuclear ribonucleoproteins interact with sequences in NRS3', whereas NRS5' binds several proteins including members of the family of proteins. Among the proteins that specifically bind NRS5' is a previously unidentified 55-kDa protein (p55), In this report we describe the isolation and identification of p55. The p55 binding site was localized by UV cross-linking to a 31-nucleotide segment, and a protein that binds specifically to it was isolated by RNA affinity selection and identified by mass spectrometry as hnRNP H. Antibodies against hnRNP H immunoprecipitated crosslinked p55 and induced a supershift of a p55-containing complex formed in HeLa nuclear extract. Furthermore, UV cross-linking and electrophoretic mobility shift assays indicated that recombinant hnRNP H specifically interacts with the p55 binding site, confirming that hnRNP H is p55, The possible roles of hnRNP H in NRS function are discussed.	Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA	Medical College of Wisconsin	McNally, MT (corresponding author), Med Coll Wisconsin, Dept Microbiol & Mol Genet, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	mtm@mcw.edu			NCI NIH HHS [R01 CA78709] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078709] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARRIGO S, 1988, MOL CELL BIOL, V8, P4858, DOI 10.1128/MCB.8.11.4858; Bagga PS, 1998, NUCLEIC ACIDS RES, V26, P5343, DOI 10.1093/nar/26.23.5343; BECKLER GS, 1992, PROMEGA NOTES, V39, P12; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; Chaurand P, 1999, J AM SOC MASS SPECTR, V10, P91, DOI 10.1016/S1044-0305(98)00145-7; Chen CD, 1999, GENE DEV, V13, P593, DOI 10.1101/gad.13.5.593; Chou MY, 1999, MOL CELL BIOL, V19, P69; Coffin JM, 1996, FIELDS VIROLOGY, P1767; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FU XD, 1995, RNA, V1, P663; Ginisty H, 1999, J CELL SCI, V112, P761; GONTAREK RR, 1993, GENE DEV, V7, P1926, DOI 10.1101/gad.7.10.1926; HALL SL, 1994, J MOL BIOL, V239, P357, DOI 10.1006/jmbi.1994.1377; Hibbert CS, 1999, RNA, V5, P333, DOI 10.1017/S1355838299981347; Holzmann K, 1997, EUR J BIOCHEM, V244, P479, DOI 10.1111/j.1432-1033.1997.00479.x; HONORE B, 1995, J BIOL CHEM, V270, P28780; Jiang WP, 1997, J VIROL, V71, P6526, DOI 10.1128/JVI.71.9.6526-6533.1997; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Kolossova I, 1997, RNA, V3, P227; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MATUNIS MJ, 1994, NUCLEIC ACIDS RES, V22, P1059, DOI 10.1093/nar/22.6.1059; McNally LM, 1996, J VIROL, V70, P1163, DOI 10.1128/JVI.70.2.1163-1172.1996; McNally LM, 1999, J VIROL, V73, P2385, DOI 10.1128/JVI.73.3.2385-2393.1999; McNally LM, 1998, MOL CELL BIOL, V18, P3103, DOI 10.1128/MCB.18.6.3103; MCNALLY MT, 1991, VIROLOGY, V185, P99, DOI 10.1016/0042-6822(91)90758-4; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERIC C, 1986, J VIROL, V60, P450; MILLER JT, 1992, J VIROL, V66, P4242, DOI 10.1128/JVI.66.7.4242-4251.1992; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; Moore MJ, 1993, TNA WORLD, P303; PURCELL DFJ, 1993, J VIROL, V67, P6365, DOI 10.1128/JVI.67.11.6365-6378.1993; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; SAPP M, 1989, EUR J BIOCHEM, V179, P541, DOI 10.1111/j.1432-1033.1989.tb14581.x; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SCHWARTZ S, 1990, J VIROL, V64, P2519, DOI 10.1128/JVI.64.6.2519-2529.1990; Smith MR, 1997, J VIROL, V71, P6534, DOI 10.1128/JVI.71.9.6534-6540.1997; STOLTZFUS CM, 1989, J VIROL, V63, P1669, DOI 10.1128/JVI.63.4.1669-1676.1989; Tarn WY, 1996, CELL, V84, P801, DOI 10.1016/S0092-8674(00)81057-0; Wang J, 1997, CURR OPIN GENET DEV, V7, P205, DOI 10.1016/S0959-437X(97)80130-X; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837	41	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32371	32378		10.1074/jbc.M005000200	http://dx.doi.org/10.1074/jbc.M005000200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10934202	hybrid			2022-12-27	WOS:000089858900111
J	Ito, M; Achermann, JC; Jameson, JL				Ito, M; Achermann, JC; Jameson, JL			A naturally occurring steroidogenic factor-1 mutation exhibits differential binding and activation of target genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; ORPHAN NUCLEAR RECEPTOR; AMINO-ACID-SEQUENCE; DNA-BINDING; FACTOR-I; GLUCOCORTICOID RECEPTOR; RESPONSE ELEMENTS; ESTROGEN-RECEPTOR; GRANULOSA-CELLS; HIGH-AFFINITY	Steroidogenic factor-1 (SF-l) is an orphan nuclear receptor that binds DNA as a monomer and regulates the transcription of multiple target genes. A mutation in the proximal (P)-box of the first zinc finger of SF-l (G35E) has been reported to cause complete XY sex reversal and adrenal insufficiency. Because this P-box region dictates DNA binding specificity, we investigated the effect of this mutation on DNA binding and regulation of target genes. Binding of the P-box mutant was markedly impaired for most native SF-1 response elements. However, mutant SF-l bound to a subset of response elements containing a CCA AGGTCA motif. Mutagenesis studies of response elements revealed that the first nucleotide position in the 5'-flanking sequence triplet and the central part of the half-site dictate DNA binding specificity by the mutant SF-1. Further, introduction of a mutation into the SF-l A-box, which has been proposed to bind to the 5'-flanking sequence triplet, eliminated binding by mutant SF-1 to all response elements tested. These data support the idea that the A-box stabilizes monomeric binding by nuclear receptors. This action may be particularly important when P-box binding affinity is compromised either by mutations in SF-l or by sequence alterations in its binding site.	Northwestern Univ, Div Endocrinol Metab & Mol Med, Sch Med, Chicago, IL 60611 USA	Northwestern University	Jameson, JL (corresponding author), Northwestern Univ, Div Endocrinol Metab & Mol Med, Sch Med, Tarry Bldg 15-709,303 E Chicago Ave, Chicago, IL 60611 USA.	ljameson@northwestern.edu	Achermann, John/C-5476-2008; Achermann, John/N-2906-2019	Achermann, John/0000-0001-8787-6272; Achermann, John/0000-0001-8787-6272; Jameson, James/0000-0001-9538-4059	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD021921] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD029164] Funding Source: NIH RePORTER; NICHD NIH HHS [U54-HD-29164, P01-HD-21921] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Achermann JC, 1999, NAT GENET, V22, P125, DOI 10.1038/9629; CLEMENS JW, 1994, ENDOCRINOLOGY, V134, P1499, DOI 10.1210/en.134.3.1499; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; De Santa Barbara P, 1998, MOL CELL BIOL, V18, P6653, DOI 10.1128/MCB.18.11.6653; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FITZPATRICK SL, 1993, MOL ENDOCRINOL, V7, P341, DOI 10.1210/me.7.3.341; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Halvorson LM, 1998, J BIOL CHEM, V273, P14712, DOI 10.1074/jbc.273.24.14712; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; HONDA S, 1993, J BIOL CHEM, V268, P7494; Ito M, 2000, MOL ENDOCRINOL, V14, P66, DOI 10.1210/me.14.1.66; Ito M, 1998, MOL ENDOCRINOL, V12, P290, DOI 10.1210/me.12.2.290; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; KATZ RW, 1993, J BIOL CHEM, V268, P19392; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; LYNCH JP, 1993, MOL ENDOCRINOL, V7, P776, DOI 10.1210/me.7.6.776; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Monte D, 1998, J BIOL CHEM, V273, P4585, DOI 10.1074/jbc.273.8.4585; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; NELSON CC, 1995, J BIOL CHEM, V270, P16981, DOI 10.1074/jbc.270.28.16981; NELSON CC, 1995, J BIOL CHEM, V270, P16988, DOI 10.1074/jbc.270.28.16988; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; Sugawara T, 1996, BIOCHEMISTRY-US, V35, P9052, DOI 10.1021/bi960057r; TSUKIYAMA T, 1992, NUCLEIC ACIDS RES, V20, P1477, DOI 10.1093/nar/20.7.1477; UEDA H, 1992, MOL CELL BIOL, V12, P5667, DOI 10.1128/MCB.12.12.5667; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; Yu RN, 1998, MOL ENDOCRINOL, V12, P1010, DOI 10.1210/me.12.7.1010; ZILLIACUS J, 1992, J BIOL CHEM, V267, P24941; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	38	73	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31708	31714		10.1074/jbc.M002892200	http://dx.doi.org/10.1074/jbc.M002892200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10913126	hybrid			2022-12-27	WOS:000089858900025
J	Nathanson, L; Deutscher, MP				Nathanson, L; Deutscher, MP			Accelerated publication - Active aminoacyl-tRNA synthetases are present in nuclei as a high molecular weight multienzyme complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; PROTEIN-PROTEIN INTERACTIONS; EXPORT; ORGANIZATION; COMPONENTS; EUKARYOTES; SYSTEM; CELLS; FORMS	Recent studies suggest that aminoacylation of tRNA may play an important role in the transport of these molecules from the nucleus to the cytoplasm. However, there is almost no information regarding the status of active aminoacyl-tRNA synthetases within the nuclei of eukaryotic cells. Here we show that at least 13 active aminoacyl-tRNA synthetases are present in purified nuclei of both Chinese hamster ovary and rabbit kidney cells, although their steady-state levels represent only a small percentage of those found in the cytoplasm. Most interestingly, all the nuclear aminoacyl-tRNA synthetases examined can be isolated as part of a multienzyme complex that is more stable, and consequently larger, than the comparable complex isolated from the cytoplasm. These data directly demonstrate the presence of active aminoacyl-tRNA synthetases in mammalian cell nuclei. Moreover, their unexpected structural organization raises important questions about the functional significance of these multienzyme complexes and whether they might play a more direct role in nuclear to cytoplasmic transport of tRNAs.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA	University of Miami	Deutscher, MP (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA.	mdeutsch@med.miami.edu	Nathanson, Lubov/ABC-2642-2021	Nathanson, Lubov/0000-0003-1038-9083	NIGMS NIH HHS [GM16317] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMARCOSTESEC A, 1989, BIOL CELL, V65, P21; Arts GJ, 1998, EMBO J, V17, P7430, DOI 10.1093/emboj/17.24.7430; BANDYOPADHYAY AK, 1971, J MOL BIOL, V60, P113, DOI 10.1016/0022-2836(71)90451-7; BARBARESE E, 1995, J CELL SCI, V108, P2781; DEUTSCHER MP, 1982, J BIOL CHEM, V257, P6003; FILONENKO VV, 1994, J BIOL CHEM, V269, P17375; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; GREENBERG ME, 1997, CURRENT PROTOCOLS MO, V1; Grosshans H, 2000, GENE DEV, V14, P830; HAMPEL A, 1973, J MOL BIOL, V79, P285, DOI 10.1016/0022-2836(73)90006-5; Hopper AK, 1998, SCIENCE, V282, P2003, DOI 10.1126/science.282.5396.2003; Ibba M, 1997, TRENDS BIOCHEM SCI, V22, P39, DOI 10.1016/S0968-0004(96)20033-7; KISSELEV LL, 1994, PROG NUCLEIC ACID RE, V48, P83, DOI 10.1016/S0079-6603(08)60854-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lipowsky G, 1999, RNA, V5, P539, DOI 10.1017/S1355838299982134; Lund E, 1998, SCIENCE, V282, P2082, DOI 10.1126/science.282.5396.2082; MIRANDE M, 1985, EUR J BIOCHEM, V147, P281, DOI 10.1111/j.1432-1033.1985.tb08748.x; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; MURAMATSU M, 1963, CANCER RES, V23, P510; Negrutskii BS, 1999, J BIOL CHEM, V274, P4545, DOI 10.1074/jbc.274.8.4545; NEGRUTSKII BS, 1991, P NATL ACAD SCI USA, V88, P4991, DOI 10.1073/pnas.88.11.4991; NEGRUTSKII BS, 1994, P NATL ACAD SCI USA, V91, P964, DOI 10.1073/pnas.91.3.964; POPENKO VI, 1994, EUR J CELL BIOL, V65, P60; Quevillon S, 1999, J MOL BIOL, V285, P183, DOI 10.1006/jmbi.1998.2316; Rho SB, 1999, P NATL ACAD SCI USA, V96, P4488, DOI 10.1073/pnas.96.8.4488; Sanders J, 1996, J CELL SCI, V109, P1113; Sarkar S, 1999, P NATL ACAD SCI USA, V96, P14366, DOI 10.1073/pnas.96.25.14366; Schimmel P, 1999, TRENDS BIOCHEM SCI, V24, P127, DOI 10.1016/S0968-0004(99)01369-9; SIVARAM P, 1990, P NATL ACAD SCI USA, V87, P3665, DOI 10.1073/pnas.87.10.3665; STAPULIONIS R, 1995, P NATL ACAD SCI USA, V92, P7158, DOI 10.1073/pnas.92.16.7158; VELLEKAMP G, 1985, J BIOL CHEM, V260, P9843; Yang DCH, 1996, CURR TOP CELL REGUL, V34, P101, DOI 10.1016/S0070-2137(96)80004-5	32	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31559	31562		10.1074/jbc.C000385200	http://dx.doi.org/10.1074/jbc.C000385200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10930398	hybrid			2022-12-27	WOS:000089858900002
J	Gilstring, CF; Ljungdahl, PO				Gilstring, CF; Ljungdahl, PO			A method for determining the in vivo topology of yeast polytopic membrane proteins demonstrates that Gap1p fully integrates into the membrane independently of Shr3p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID PERMEASES; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; TRANSPORT VESICLES; P-GLYCOPROTEIN; GENE FUSION; GLYCOSYLATION; INSERTION; GOLGI	The general amino acid permease (Gap1p) of Saccharomyces cerevisiae is an integral membrane protein that contains 12 hydrophobic regions predicted to be membrane-spanning segments. A topological reporter construct, encoding an internal 53-amino acid peptide of invertase (Suc2p) containing three Asp-X-Ser/Thr glycosylation sites, was inserted in-frame into the hydrophilic NH2- and COOH-terminal domains and each of the 11 hydrophilic loops that separate the 12 hydrophobic segments of Gap1p. The resulting 13 gene sandwich fusion proteins were expressed in a gap1 Delta null mutant strain; 9 of these retain amino acid transport activity and are folded and correctly targeted to the plasma membrane. The glycosylation state of each of the fusion proteins was monitored; the results indicate that all 12 hydrophobic segments of Gap1p span the membrane, and the MI, and COOH termini are cytoplasmically oriented. These results were independently tested by isolating sealed right-side out microsomes from sec12-1 strains expressing six different Gap1p constructs containing functional factor Xa protease cleavage sites. The pattern of factor Xa protease cleavage was found to be consistent with the presence of 12 membrane-spanning domains. Gap1p exhibited the same membrane topology in strains lacking Shr3p; therefore, Gap1p fully integrates into the ER membrane independently of this permease-specific packaging chaperone.	Ludwig Inst Canc Res, S-17177 Stockholm, Sweden	Ludwig Institute for Cancer Research	Ljungdahl, PO (corresponding author), Ludwig Inst Canc Res, Box 240, S-17177 Stockholm, Sweden.	plju@licr.ki.se	Ljungdahl, Per O/M-5258-2013	Ljungdahl, Per O/0000-0002-6625-3540				AHMAD M, 1988, MOL MICROBIOL, V2, P627, DOI 10.1111/j.1365-2958.1988.tb00071.x; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; Barlowe C, 1998, BBA-MOL CELL RES, V1404, P67, DOI 10.1016/S0167-4889(98)00047-0; CHANG XB, 1994, J BIOL CHEM, V269, P18572; Cosgriff AJ, 1997, J BACTERIOL, V179, P3317, DOI 10.1128/jb.179.10.3317-3323.1997; DENFERT C, 1991, MOL CELL BIOL, V11, P5727, DOI 10.1128/MCB.11.11.5727; Didion T, 1998, MOL MICROBIOL, V27, P643, DOI 10.1046/j.1365-2958.1998.00714.x; EHRMANN M, 1990, P NATL ACAD SCI USA, V87, P7574, DOI 10.1073/pnas.87.19.7574; ELLIS J, 1995, MICROBIOL-UK, V141, P1927, DOI 10.1099/13500872-141-8-1927; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; GAFVELIN G, 1994, CELL, V77, P401, DOI 10.1016/0092-8674(94)90155-4; Gilstring CF, 1999, MOL BIOL CELL, V10, P3549, DOI 10.1091/mbc.10.11.3549; GREEN GN, 1989, J CELL SCI, P109; Guthrie C, 1991, METHODS ENZYMOL, V194; HEESEN ST, 1991, EUR J CELL BIOL, V56, P8; HOFFMANN W, 1987, MOL GEN GENET, V210, P277, DOI 10.1007/BF00325694; Holst B, 1996, EMBO J, V15, P3538, DOI 10.1002/j.1460-2075.1996.tb00723.x; HORAK J, 1993, BIOCHEM MOL BIOL INT, V29, P907; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; Iraqui I, 1999, MOL CELL BIOL, V19, P989; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAUNIAUX JC, 1990, EUR J BIOCHEM, V190, P39, DOI 10.1111/j.1432-1033.1990.tb15542.x; Jorgensen MU, 1998, YEAST, V14, P103, DOI 10.1002/(SICI)1097-0061(19980130)14:2<103::AID-YEA203>3.0.CO;2-C; Kaiser C, 1998, CURR OPIN CELL BIOL, V10, P477, DOI 10.1016/S0955-0674(98)80062-8; Klasson H, 1999, MOL CELL BIOL, V19, P5405; Kuehn MJ, 1996, J CELL BIOL, V135, P585, DOI 10.1083/jcb.135.3.585; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lau WTW, 2000, P NATL ACAD SCI USA, V97, P1107, DOI 10.1073/pnas.97.3.1107; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NILSSON I, 1993, J BIOL CHEM, V268, P5798; ORLEAN P, 1991, METHOD ENZYMOL, V194, P682; Paulsen IT, 1998, FEBS LETT, V430, P116, DOI 10.1016/S0014-5793(98)00629-2; Pi J, 1996, J BACTERIOL, V178, P2650, DOI 10.1128/jb.178.9.2650-2655.1996; REDDY VA, 1988, J BIOL CHEM, V263, P6978; Regenberg B, 1999, CURR GENET, V36, P317, DOI 10.1007/s002940050506; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; RYTKA J, 1975, J BACTERIOL, V121, P562, DOI 10.1128/JB.121.2.562-570.1975; SAHINTOTH M, 1995, BIOCHEMISTRY-US, V34, P1107, DOI 10.1021/bi00004a001; SENGSTAG C, 1990, MOL CELL BIOL, V10, P672, DOI 10.1128/MCB.10.2.672; Sherwood PW, 1999, P NATL ACAD SCI USA, V96, P7415, DOI 10.1073/pnas.96.13.7415; SILVE S, 1991, MOL CELL BIOL, V11, P1114, DOI 10.1128/MCB.11.2.1114; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; TRAXLER B, 1993, J MEMBRANE BIOL, V132, P1; Trilla JA, 1999, J CELL BIOL, V145, P1153, DOI 10.1083/jcb.145.6.1153; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; Zhang JT, 1996, MOL BIOL CELL, V7, P1709, DOI 10.1091/mbc.7.11.1709; ZHANG JT, 1995, J BIOL CHEM, V270, P1742, DOI 10.1074/jbc.270.4.1742	53	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31488	31495		10.1074/jbc.M005047200	http://dx.doi.org/10.1074/jbc.M005047200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10903320	hybrid			2022-12-27	WOS:000089762700103
J	Barbeyron, T; Michel, G; Potin, P; Henrissat, B; Kloareg, B				Barbeyron, T; Michel, G; Potin, P; Henrissat, B; Kloareg, B			iota-Carrageenases constitute a novel family of glycoside hydrolases, unrelated to that of kappa-carrageenases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; HYDROPHOBIC CLUSTER-ANALYSIS; ACID-SEQUENCE SIMILARITIES; BACILLUS-LICHENIFORMIS; CRYSTAL-STRUCTURE; ALTEROMONAS-CARRAGEENOVORA; CARBOXYLIC RESIDUES; MARINE BACTERIUM; CLEAVAGE SITES; ALPHA-AGARASE	i-Carrageenases are polysaccharide hydrolases that cleave the beta -1,4 linkages between the D-galactose-4-sulfate and 3,6-anhydro-D-galactose-2-sulfate residues in the red algal galactans known as i-carrageenans. We report here on the purification of i-carrageenase activity from the marine bacterium Zobeellia galactanovorans and on the characterization of L-carrageenase structural. genes. Genomic libraries from this latter bacterium as well as from Alteromonas fortis were functionally screened for the presence of i-carrageenase(+) clones. The Z. galactanovorans and a fortis L-carrageenase genes encode homologous proteins of 53.4 and 54.8 kDa, respectively. Based on hydrophobic cluster analysis and on the H-1 NMR monitoring of the products of the overexpressed A. fortis L-carrageenase, these enzymes appear to form a new family of glycoside hydrolases, unrelated to that of kappa -carrageenases and with an inverting mechanism of hydrolysis. They both feature a 45-amino acid-long N-terminal segment with sequence similarity to the N-terminal region of several other polysaccharidases, In those for which a three-dimensional structure is available, this conspicuous segment, also deemed "glycanase motif" (Chua, J, E, H,, Manning, P, A., and Morons, R, (1999) Microbiology (Reading) 145, 1649-1659), corresponds to a strand-helix-strand "cap" that covers the N-terminal end of a common, right-handed beta -helical fold.	CNRS, UMR 1931, Stn Biol Roscoff, F-29680 Roscoff, France; CEA, CNRS, Inst Biol Struct Jean Pierre Ebel, Lab Cristallog Macromol, F-38027 Grenoble 1, France; CNRS, IFR 1, F-13402 Marseille 20, Provence, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Kloareg, B (corresponding author), CNRS, UMR 1931, Stn Biol Roscoff, Pl Georges Teissier, F-29680 Roscoff, France.	kloareg@sb-roscoff.fr	MICHEL, Gurvan/B-3490-2008; Henrissat, Bernard/J-2475-2012	Henrissat, Bernard/0000-0002-3434-8588; MICHEL, Gurvan/0000-0002-3009-6205				Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; BARBEYRON T, 1994, GENE, V139, P105, DOI 10.1016/0378-1119(94)90531-2; Barbeyron T, 1998, MOL BIOL EVOL, V15, P528, DOI 10.1093/oxfordjournals.molbev.a025952; BUTTNER MJ, 1987, MOL GEN GENET, V209, P101, DOI 10.1007/BF00329843; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Chua JEH, 1999, MICROBIOL-UK, V145, P1649, DOI 10.1099/13500872-145-7-1649; Craigie JS., 1990, BIOL RED ALGAE, P221; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; De Ruiter GA, 1997, TRENDS FOOD SCI TECH, V8, P389, DOI 10.1016/S0924-2244(97)01091-1; FIRPO MA, 1990, POSTTRANSCRIPTIONAL, P185; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; GEBLER J, 1992, J BIOL CHEM, V267, P12559; GREER CW, 1984, CAN J MICROBIOL, V30, P1500, DOI 10.1139/m84-239; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; JUNCOSA M, 1994, J BIOL CHEM, V269, P14530; KIDBY DK, 1973, ANAL BIOCHEM, V55, P321, DOI 10.1016/0003-2697(73)90323-0; KNUTSEN SH, 1992, CARBOHYD RES, V229, P233, DOI 10.1016/S0008-6215(00)90573-1; KNUTSEN SH, 1994, CARBOHYD POLYM, V19, P199; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; Krah M, 1998, EUR J BIOCHEM, V257, P101, DOI 10.1046/j.1432-1327.1998.2570101.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEMESLEVARLOOT L, 1990, BIOCHIMIE, V72, P555, DOI 10.1016/0300-9084(90)90120-6; MALET C, 1993, BIOCHEM J, V296, P753, DOI 10.1042/bj2960753; Maniatis T, 1982, MOL CLONING LABORATO, P68; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Michel G, 1999, ACTA CRYSTALLOGR D, V55, P918, DOI 10.1107/S0907444998018526; Michel G, 2000, ACTA CRYSTALLOGR D, V56, P766, DOI 10.1107/S0907444900004844; NAKAI K, 1991, PROTEINS, V11, P95, DOI 10.1002/prot.340110203; NISHITANI K, 1992, J BIOL CHEM, V267, P21058; Petersen TN, 1997, STRUCTURE, V5, P533, DOI 10.1016/S0969-2126(97)00209-8; Pickersgill R, 1998, J BIOL CHEM, V273, P24660, DOI 10.1074/jbc.273.38.24660; PLANAS A, 1992, FEBS LETT, V308, P141, DOI 10.1016/0014-5793(92)81262-K; POTIN P, 1995, EUR J BIOCHEM, V228, P971, DOI 10.1111/j.1432-1033.1995.0971m.x; POTIN P, 1991, EUR J BIOCHEM, V201, P241, DOI 10.1111/j.1432-1033.1991.tb16280.x; POTIN P, 1993, EUR J BIOCHEM, V214, P599, DOI 10.1111/j.1432-1033.1993.tb17959.x; Rees D A, 1969, Adv Carbohydr Chem Biochem, V24, P267; ROCHAS C, 1994, CARBOHYD RES, V253, P69, DOI 10.1016/0008-6215(94)80056-1; ROCHAS C, 1981, POLYM BULL, V5, P81; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; van Santen Y, 1999, J BIOL CHEM, V274, P30474, DOI 10.1074/jbc.274.43.30474; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; ZABLACKIS E, 1990, BOT MAR, V33, P273, DOI 10.1515/botm.1990.33.3.273; Zobell CE, 1941, J MAR RES, V4, P42	54	93	98	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35499	35505		10.1074/jbc.M003404200	http://dx.doi.org/10.1074/jbc.M003404200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10934194	hybrid			2022-12-27	WOS:000165422800088
J	Okado-Matsumoto, A; Fridovich, I				Okado-Matsumoto, A; Fridovich, I			The role of alpha,beta-dicarbonyl compounds in the toxicity of short chain sugars	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PHYSIOLOGICAL CONDITIONS; GLYOXALASE-I; DNA-DAMAGE; METHYLGLYOXAL; SUPEROXIDE; IDENTIFICATION; AUTOXIDATION; PROTEINS; OXIDASE	The extent to which sugars serve as targets for superoxide was examined using glycolaldehyde as the simplest sugar and using superoxide dismutase (SOD)-replete and SOD-null strains growing under aerobic and anaerobic conditions. Glycolaldehyde was more toxic to the SOD-null strain than to its SOD replete parent, and this differential effect was oxygen-dependent. The product, glyoxal, could be trapped in the medium by 1,2-diaminobenzene and assayed as quinoxaline. The SOD-null strain produced more glyoxal and eliminated it more slowly than the SOD-replete parent strain. Glyoxal was similar to 10 times more toxic than glycolaldehyde and was more toxic to the SOD-null strain than to the parental strain. 1,2-Diaminobenzene protected against the toxicity of glycolaldehyde, These Escherichia coli strains contained the glutathione-dependent glyoxalases I and II, as well as the glutathione-independent glyoxalase III. Of these enzymes, glyoxalase III was most abundant, and it was inactivated within the aerobic SOD-null strain and also in extracts when exposed to the flux of superoxide and hydrogen peroxide imposed by the xanthine oxidase reaction. Thus, it appears that short chain sugars are oxidized by superoxide yielding toxic dicarbonyls, Moreover, the defensive glyoxalase III is also inactivated by the oxidative stress imposed by the lack of SOD, thereby exacerbating the deleterious effect of sugar oxidation.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Fridovich, I (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.							Benov L, 1998, J BIOL CHEM, V273, P25741, DOI 10.1074/jbc.273.40.25741; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; Cordeiro C, 1996, ANAL BIOCHEM, V234, P221, DOI 10.1006/abio.1996.0076; Deng YL, 1999, ANAL BIOCHEM, V270, P97, DOI 10.1006/abio.1999.4058; Ferguson GP, 1999, TRENDS MICROBIOL, V7, P242, DOI 10.1016/S0966-842X(99)01510-3; FRAENKEL DG, 1964, J BIOL CHEM, V239, P2765; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; HIRSCH J, 1995, CARBOHYD RES, V267, P17, DOI 10.1016/0008-6215(94)00285-N; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; KEYER K, 1995, J BACTERIOL, V177, P6782, DOI 10.1128/jb.177.23.6782-6790.1995; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; LIOCHEV SI, 1994, FREE RADICAL BIO MED, V16, P29, DOI 10.1016/0891-5849(94)90239-9; LO TWC, 1994, J BIOL CHEM, V269, P32299; MacLean MJ, 1998, MOL MICROBIOL, V27, P563, DOI 10.1046/j.1365-2958.1998.00701.x; Maniatis T, 1982, MOL CLONING LABORATO, P68; MANNERVIK B, 1982, METHOD ENZYMOL, V90, P535; MASHINO T, 1987, ARCH BIOCHEM BIOPHYS, V254, P547, DOI 10.1016/0003-9861(87)90136-6; Meyer D, 1997, J BACTERIOL, V179, P1298, DOI 10.1128/jb.179.4.1298-1306.1997; MISRA K, 1995, BIOCHEM J, V305, P999, DOI 10.1042/bj3050999; ORAY B, 1982, METHOD ENZYMOL, V90, P547; PAPOULIS A, 1995, BIOCHEMISTRY-US, V34, P648, DOI 10.1021/bi00002a032; ROBERTSON P, 1981, ARCH BIOCHEM BIOPHYS, V207, P282, DOI 10.1016/0003-9861(81)90035-7; Saadat D, 1998, BIOCHEMISTRY-US, V37, P10074, DOI 10.1021/bi980409p; SAKURAI T, 1988, FEBS LETT, V236, P406, DOI 10.1016/0014-5793(88)80066-8; THORNALLEY P, 1984, BIOCHIM BIOPHYS ACTA, V797, P276, DOI 10.1016/0304-4165(84)90131-4; Thornalley PJ, 1999, BIOCHEM J, V344, P109, DOI 10.1042/0264-6021:3440109; Totemeyer S, 1998, MOL MICROBIOL, V27, P553, DOI 10.1046/j.1365-2958.1998.00700.x	27	51	53	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34853	34857		10.1074/jbc.M005536200	http://dx.doi.org/10.1074/jbc.M005536200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10931845	hybrid			2022-12-27	WOS:000165422800006
J	Staropoli, I; Chanel, C; Girard, M; Altmeyer, R				Staropoli, I; Chanel, C; Girard, M; Altmeyer, R			Processing, stability, and receptor binding properties of oligomeric envelope glycoprotein from a primary HIV-1 isolate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HAMSTER OVARY CELLS; GP120 GLYCOPROTEIN; TRANSMEMBRANE GLYCOPROTEIN; DISULFIDE BONDS; CD4 RECEPTOR; TYPE-1; GP41; INHIBITION; PROTEIN	The envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1) is thought to exist on the virion surface as a trimer of non-covalently associated gp120/gp41 molecules. We expressed trimeric envelope glycoprotein from three primary, macrophage tropic HIV-1 isolates in baby hamster kidney cells and analyzed the furin-mediated cleavage, stability, and receptor binding properties of the oligomers. The envelope glycoprotein was secreted in a soluble form deleted of its transmembrane anchor and the intracytoplasmic domain (gp140). A mixture of trimers, dimers, and monomers of gp140 as well as monomeric gp120 was detected on polyacrylamide gels. Analysis by sucrose gradient centrifugation revealed that trimers and dimers were essentially composed of uncleaved gp140, whereas most of the gp120 was found in the monomeric fraction. To analyze the effect of the cleavage of gp140 to gp120/Delta 41 on trimerization, we co-expressed the furin protease along with gp140. Surprisingly, furin expression changed the subcellular localization of the envelope glycoprotein, which became in majority sequestered in the major furin compartment, the trans-Golgi network, as judged by confocal laser microscopy. The envelope glycoprotein secreted from furin-co-expressing cells was almost completely cleaved to gp120 and Delta gp41, but gp120 was found exclusively in the monomeric fraction, with a few residual oligomers being composed of uncleaved gp140. Secreted uncleaved gp140 trimers were purified to homogeneity and analyzed for their capacity to interact with cellular receptors CD4 and CC chemokine receptor 5 (CCR5). Receptor binding was analyzed on CD4- and CCR5-expressing cells as well as on peripheral blood mononuclear cells. Trimers showed greatly reduced binding to CD4 as compared with monomers. Neither monomers nor trimers bound directly to CCR5. In conclusion, our results show that the cleaved form of the envelope glycoprotein does not form stable trimers, suggesting that gp120/gp41 oligomers on the virion surface might be stabilized by a yet to be identified mechanism and that the virion might attach to CD4 via a monomeric form of gp120. These results are relevant to the development of an envelope-based vaccine against AIDS.	Inst Pasteur, Unite Virol Mol, F-75724 Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Altmeyer, R (corresponding author), Inst Pasteur, Unite Immunol Virale, F-75015 Paris, France.							Altmeyer R, 1999, VIROLOGY, V259, P314, DOI 10.1006/viro.1999.9780; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; BERGLUND P, 1993, BIO-TECHNOL, V11, P916, DOI 10.1038/nbt0893-916; Binley JM, 2000, J VIROL, V74, P627, DOI 10.1128/JVI.74.2.627-643.2000; BRITT WJ, 1994, VIROLOGY, V201, P294, DOI 10.1006/viro.1994.1294; Caffrey M, 1999, PROTEIN SCI, V8, P1904, DOI 10.1110/ps.8.9.1904; Center RJ, 2000, J VIROL, V74, P4448, DOI 10.1128/JVI.74.10.4448-4455.2000; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; EARL PL, 1990, P NATL ACAD SCI USA, V87, P648, DOI 10.1073/pnas.87.2.648; Farzan M, 1998, J VIROL, V72, P7620, DOI 10.1128/JVI.72.9.7620-7625.1998; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Fischer PB, 1996, J VIROL, V70, P7153, DOI 10.1128/JVI.70.10.7153-7160.1996; Fouts TR, 1998, AIDS RES HUM RETROV, V14, P591, DOI 10.1089/aid.1998.14.591; Gao F, 1996, J VIROL, V70, P7013, DOI 10.1128/JVI.70.10.7013-7029.1996; GAUDIN Y, 1992, VIROLOGY, V187, P627, DOI 10.1016/0042-6822(92)90465-2; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HALLENBERGER S, 1993, VIROLOGY, V193, P510, DOI 10.1006/viro.1993.1156; HEALEY D, 1990, J EXP MED, V172, P1233, DOI 10.1084/jem.172.4.1233; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HELSETH E, 1991, J VIROL, V65, P2119, DOI 10.1128/JVI.65.4.2119-2123.1991; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; Klimstra WB, 1999, J VIROL, V73, P6299, DOI 10.1128/JVI.73.8.6299-6306.1999; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; LITTMAN DR, 1988, CELL, V55, P541, DOI 10.1016/0092-8674(88)90211-5; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; MCGINNES LW, 1994, VIROLOGY, V200, P470, DOI 10.1006/viro.1994.1210; McInerney TL, 1998, J VIROL, V72, P1523, DOI 10.1128/JVI.72.2.1523-1533.1998; Meanger J, 1997, BIOTECHNIQUES, V23, P432, DOI 10.2144/97233bm18; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; MOORE JP, 1992, J VIROL, V66, P235, DOI 10.1128/JVI.66.1.235-243.1992; Moulard M, 1999, VIRUS RES, V60, P55, DOI 10.1016/S0168-1702(99)00002-7; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; PINTER A, 1989, J VIROL, V63, P2674, DOI 10.1128/JVI.63.6.2674-2679.1989; Poumbourios P, 1997, J VIROL, V71, P2041, DOI 10.1128/JVI.71.3.2041-2049.1997; RHODES AD, 1994, J GEN VIROL, V75, P207, DOI 10.1099/0022-1317-75-1-207; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; RYSER HJP, 1994, P NATL ACAD SCI USA, V91, P4559, DOI 10.1073/pnas.91.10.4559; RYSER HJP, 1991, J BIOL CHEM, V266, P18439; Saphire ACS, 1999, EMBO J, V18, P6771, DOI 10.1093/emboj/18.23.6771; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; SCHAWALLER M, 1989, VIROLOGY, V172, P367, DOI 10.1016/0042-6822(89)90142-6; Shugars DC, 1996, J VIROL, V70, P2982, DOI 10.1128/JVI.70.5.2982-2991.1996; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; TUCKER SP, 1991, VIROLOGY, V185, P710, DOI 10.1016/0042-6822(91)90542-J; Ugolini S, 1999, TRENDS MICROBIOL, V7, P144, DOI 10.1016/S0966-842X(99)01474-2; VANCOTT TC, 1995, J IMMUNOL METHODS, V183, P103, DOI 10.1016/0022-1759(95)00038-C; Verrier FC, 1997, P NATL ACAD SCI USA, V94, P9326, DOI 10.1073/pnas.94.17.9326; WEISS CD, 1990, J VIROL, V64, P5674, DOI 10.1128/JVI.64.11.5674-5677.1990; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; Yang XZ, 2000, J VIROL, V74, P5716, DOI 10.1128/JVI.74.12.5716-5725.2000; Zhang LQ, 1998, J VIROL, V72, P9307, DOI 10.1128/JVI.72.11.9307-9312.1998; Zhang YJ, 1998, J VIROL, V72, P9337, DOI 10.1128/JVI.72.11.9337-9344.1998; ZOLLAPAZNER S, 1995, J VIROL, V69, P3807, DOI 10.1128/JVI.69.6.3807-3815.1995	69	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35137	35145		10.1074/jbc.M003868200	http://dx.doi.org/10.1074/jbc.M003868200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10926931	hybrid			2022-12-27	WOS:000165422800043
J	Lefai, E; Fernandez-Moreno, MA; Alahari, A; Kaguni, LS; Garesse, R				Lefai, E; Fernandez-Moreno, MA; Alahari, A; Kaguni, LS; Garesse, R			Differential regulation of the catalytic and accessory subunit genes of Drosophila mitochondrial DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION-RELATED ELEMENT; SYNTHASE BETA-SUBUNIT; SEA-URCHIN; TRANSCRIPTIONAL REGULATION; BINDING PROTEIN; MAMMALIAN-CELLS; NUCLEAR GENES; FACTOR DREF; EXPRESSION; CLONING	The developmental pattern of expression of the genes encoding the catalytic (alphay) and accessory (beta) subunits of mitochondrial DNA polymerase (pol gamma) has been examined in Drosophila melanogaster. The steady-state level of pol gamma-beta mRNA increases during the first hours of development, reaching its maximum value at the start of mtDNA replication in Drosophila embryos. In contrast, the steady-state level of pol gamma-alpha mRNA decreases as development proceeds and is low in stages of active mtDNA replication. This difference in mRNA abundance results at least in part from differences in the rates of mRNA synthesis. The pol gamma genes are located in a compact cluster of five genes that contains three promoter regions (P1-P3), The P1 region directs divergent transcription of the pol gamma-beta gene and the adjacent rpII33 gene. P1 contains a DNA replication-related element (DRE) that is essential for pol gamma-beta promoter activity, but not for rpII33 promoter activity in Schneider's cells. A second divergent promoter region (P2) controls the expression of the orc5 and sop2 genes. The P2 region contains two DREs that are essential for orc5 promoter activity, but not for sop2 promoter activity. The expression of the pol gamma-alpha gene is directed by P3, a weak promoter that does not contain DREs, Electrophoretic mobility shift experiments demonstrate that the DRE-binding factor (DREF) regulatory protein binds to the DREs in P1 and P2, DREF regulates the expression of several genes encoding key factors involved in nuclear DNA replication. Its role in controlling the expression of the pol gamma-beta and orc5 genes establishes a common regulatory mechanism linking nuclear and mitochondrial DNA replication. Overall, our results suggest that the accessory subunit of mtDNA polymerase plays an important role in the control of mtDNA replication in Drosophila.	Univ Autonoma Madrid, Fac Med, CSIC, Inst Invest Biomed Alberto Sols,Dept Bioquim, E-28029 Madrid, Spain; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Michigan State University	Garesse, R (corresponding author), Univ Autonoma Madrid, Fac Med, CSIC, Inst Invest Biomed Alberto Sols,Dept Bioquim, C Arzobispo Morcillo 4, E-28029 Madrid, Spain.	rafael.garesse@uam.es	Fernandez-Moreno, Miguel Angel/K-4425-2017; Garesse, Rafael/F-3836-2012; Lefai, Etienne/E-9615-2019; Lefai, Etienne/L-7961-2019	Fernandez-Moreno, Miguel Angel/0000-0002-3461-0726; Lefai, Etienne/0000-0002-3042-7801; Lefai, Etienne/0000-0002-3042-7801	NHLBI NIH HHS [HL59656] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059656] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ashburner M, 1999, GENETICS, V153, P179; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; CALZONE FJ, 1991, DEVELOPMENT, V112, P335; Carrodeguas JA, 2000, NUCLEIC ACIDS RES, V28, P1237, DOI 10.1093/nar/28.5.1237; Carrodeguas JA, 1999, MOL CELL BIOL, V19, P4039; CHUNG AB, 1992, J BIOL CHEM, V267, P21154; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; Davis AF, 1996, J CELL BIOL, V135, P883, DOI 10.1083/jcb.135.4.883; Davis AF, 1996, NUCLEIC ACIDS RES, V24, P2753, DOI 10.1093/nar/24.14.2753; de Mena IR, 2000, J BIOL CHEM, V275, P13628, DOI 10.1074/jbc.275.18.13628; DESIMONE SM, 1993, MOL CELL BIOL, V13, P3641, DOI 10.1128/MCB.13.6.3641; Fan L, 1999, P NATL ACAD SCI USA, V96, P9527, DOI 10.1073/pnas.96.17.9527; FLEMING RJ, 1989, MOL CELL BIOL, V9, P719, DOI 10.1128/MCB.9.2.719; FOURY F, 1992, EMBO J, V11, P2717, DOI 10.1002/j.1460-2075.1992.tb05337.x; Giraud S, 1998, J MOL BIOL, V281, P409, DOI 10.1006/jmbi.1998.1955; GRIVELL LA, 1995, CRIT REV BIOCHEM MOL, V30, P121, DOI 10.3109/10409239509085141; GUGNEJA S, 1995, MOL CELL BIOL, V15, P102, DOI 10.1128/MCB.15.1.102; Gugneja S, 1996, MOL CELL BIOL, V16, P5708; Hermann GJ, 1998, ANNU REV CELL DEV BI, V14, P265, DOI 10.1146/annurev.cellbio.14.1.265; Hirose F, 1996, J BIOL CHEM, V271, P3930; HIROSE F, 1993, J BIOL CHEM, V268, P2092; Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Lavia P, 1999, BIOESSAYS, V21, P221; Lefai E, 2000, INSECT MOL BIOL, V9, P315, DOI 10.1046/j.1365-2583.2000.00191.x; Lewis DL, 1996, J BIOL CHEM, V271, P23389, DOI 10.1074/jbc.271.38.23389; Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; Moyes CD, 1997, AM J PHYSIOL-CELL PH, V272, pC1345, DOI 10.1152/ajpcell.1997.272.4.C1345; Ohno K, 1996, NUCLEIC ACIDS RES, V24, P3942, DOI 10.1093/nar/24.20.3942; OLSON MW, 1995, J BIOL CHEM, V270, P28932, DOI 10.1074/jbc.270.48.28932; Pena P, 1995, BIOCHEM J, V312, P887, DOI 10.1042/bj3120887; POLLAK JK, 1980, TRENDS BIOCHEM SCI, V5, P23, DOI 10.1016/S0968-0004(80)80073-9; Rinaldi T, 1998, MOL BIOL CELL, V9, P2917, DOI 10.1091/mbc.9.10.2917; RUBENSTEIN JLR, 1977, CELL, V12, P471, DOI 10.1016/0092-8674(77)90123-4; Ryu JR, 1997, NUCLEIC ACIDS RES, V25, P794, DOI 10.1093/nar/25.4.794; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sawado T, 1998, J BIOL CHEM, V273, P26042, DOI 10.1074/jbc.273.40.26042; Scarpulla RC, 1997, J BIOENERG BIOMEMBR, V29, P109, DOI 10.1023/A:1022681828846; Schultz RA, 1998, J BIOL CHEM, V273, P3447, DOI 10.1074/jbc.273.6.3447; Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; SUZUKI H, 1991, J BIOL CHEM, V266, P2333; Takahashi Y, 1996, J BIOL CHEM, V271, P14541, DOI 10.1074/jbc.271.24.14541; Talamillo A, 1998, MOL BIOL REP, V25, P87, DOI 10.1023/A:1006868306735; Vallejo CG, 1996, BIOCHEM J, V314, P505, DOI 10.1042/bj3140505; VEGANUNEZ E, 1995, J CLIN INVEST, V96, P893, DOI 10.1172/JCI118136; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; Wang YX, 1999, J BIOL CHEM, V274, P28972, DOI 10.1074/jbc.274.41.28972; Wang YX, 1997, J BIOL CHEM, V272, P13640, DOI 10.1074/jbc.272.21.13640; WILLIAMS RS, 1986, J BIOL CHEM, V261, P376; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Ye F, 1996, NUCLEIC ACIDS RES, V24, P1481, DOI 10.1093/nar/24.8.1481	54	32	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33123	33133		10.1074/jbc.M003024200	http://dx.doi.org/10.1074/jbc.M003024200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10930405	hybrid			2022-12-27	WOS:000090003800101
J	Pasco, S; Monboisse, JC; Kieffer, N				Pasco, S; Monboisse, JC; Kieffer, N			The alpha 3(IV)185-206 peptide from noncollagenous domain 1 of type IV collagen interacts with a novel binding site on the beta(3) subunit of integrin alpha(v)beta(3) and stimulates focal adhesion kinase and phosphatidylinositol 3-kinase phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COLLAGEN; MELANOMA CELL-ADHESION; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; ALPHA-3 CHAIN; PROTEIN; EXPRESSION; LIGAND; INVASION; ALPHA-V-BETA-3	We have recently identified integrin alpha (v)beta (3), and the associated CD47/integrin-associated protein (IAP) together with three other proteins as the potential tumor cell receptors for the ly, chain of basement membrane type IV collagen (Shahan, T.A., Ziaie, Z., Pasco, S., Fawzi, A., Bellon, G., Monboisse, J. C., and Kefalides, N. A. (1999) Cancer Res. 59, 4584-4590). Using different cell lines expressing alpha (v)beta (3), alpha (IIb)beta (3), and/or CD47 and a liquid phase receptor capture assay, we now provide direct evidence that the synthetic and biologically active alpha3(IV)185-206 peptide, derived from the alpha3(IV) chain, interacts with the beta (3) subunit of integrin alpha (v)beta (3), independently of CD47. Increased alpha3(IV) peptide binding was observed on transforming growth factor-beta (1)-stimulated HT-144 cells shown to up-regulate alpha (v)beta (3) independently of CD47. Also, incubation of HT-144 melanoma cells in suspension induced de novo exposure of ligand-induced binding site epitopes on the beta (3) subunit similar to those observed following Arg-Gly-Asp-Ser (RGDS) stimulation. However, RGDS did not prevent HT-144 cell attachment and spreading on the alpha3(TV) peptide, suggesting that the alpha3(TV) binding domain on the beta (3) subunit is distinct from the RGD recognition site. alpha3(IV) peptide binding to HT-144 cells in suspension stimulated time-dependent tyrosine phosphorylation, while the RGDS peptide did not. Two major phosphotyrosine proteins of 120-130 and 85 kDa were immunologically identified as focal adhesion kinase and phosphatidylinositol 3-kinase (PI3-kinase). A direct involvement of PI3-kinase in alpha3(IV)-dependent beta (3) integrin signaling could be documented, since pretreatment of HT-144 cells with wortmannin, a PI3-kinase inhibitor, reverted the known inhibitory effect of alpha3(IV) on HT-144 cell proliferation as well as membrane type 1-matrix metalloproteinase gene expression. These results provide evidence that the alpha3(TV)185-206 peptide, by directly interacting with the beta (3) subunit of alpha (v)beta (3), activates a signaling cascade involving focal adhesion kinase and PI3-kinase.	Ctr Univ, Lab Franco Luxembourgeois Rech Biomed, CNRS, CRP Sante, L-1511 Luxembourg, Luxembourg; Univ Reims Champagne Ardenne, Fac Med, CNRS UPRESA 6021, Lab Biochim Med & Biol Mol, F-51095 Reims, France	Luxembourg Institute of Health; University of Luxembourg; Centre National de la Recherche Scientifique (CNRS); Universite de Reims Champagne-Ardenne	Kieffer, N (corresponding author), Ctr Univ, Lab Franco Luxembourgeois Rech Biomed, CNRS, CRP Sante, 162A Ave Faiencerie, L-1511 Luxembourg, Luxembourg.			Brassart-Pasco, Sylvie/0000-0002-1340-7868				BHATTACHARYA S, 1995, J BIOL CHEM, V270, P16781, DOI 10.1074/jbc.270.28.16781; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; CHELBERG MK, 1990, J CELL BIOL, V111, P261, DOI 10.1083/jcb.111.1.261; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; Edinger RS, 1999, AM J PHYSIOL-RENAL, V277, pF575, DOI 10.1152/ajprenal.1999.277.4.F575; Esparza J, 1999, BLOOD, V94, P2754, DOI 10.1182/blood.V94.8.2754.420k09_2754_2766; FIELDS CG, 1993, J BIOL CHEM, V268, P14153; Frazier WA, 1999, J BIOL CHEM, V274, P8554, DOI 10.1074/jbc.274.13.8554; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GRESHAM HD, 1989, J CELL BIOL, V108, P1935, DOI 10.1083/jcb.108.5.1935; Han J, 1997, J BIOL CHEM, V272, P20395, DOI 10.1074/jbc.272.33.20395; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; Janji B, 1999, INT J CANCER, V83, P255, DOI 10.1002/(SICI)1097-0215(19991008)83:2<255::AID-IJC18>3.3.CO;2-O; Juliano D, 1996, EXP CELL RES, V225, P132, DOI 10.1006/excr.1996.0164; Kieffer N, 1996, CELL ADHES COMMUN, V4, P25, DOI 10.3109/15419069609010761; Lauer JL, 1998, BIOCHEMISTRY-US, V37, P5279, DOI 10.1021/bi972958l; LESTER BR, 1992, CANCER METAST REV, V11, P31, DOI 10.1007/BF00047601; Lichte A, 1996, FEBS LETT, V397, P277, DOI 10.1016/S0014-5793(96)01206-9; LIOTTA LA, 1991, CANCER RES, V51, pS5054; LOVELAND BE, 1992, BIOCHEM INT, V27, P501; MARIYAMA M, 1994, J BIOL CHEM, V269, P23013; MILES AJ, 1994, J BIOL CHEM, V269, P30939; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MONBOISSE JC, 1994, J BIOL CHEM, V269, P25475; Pampori N, 1999, J BIOL CHEM, V274, P21609, DOI 10.1074/jbc.274.31.21609; Pasco S, 2000, CANCER RES, V60, P467; Pelletier AJ, 1996, J BIOL CHEM, V271, P1364, DOI 10.1074/jbc.271.3.1364; Polette M, 1997, J PATHOL, V182, P185, DOI 10.1002/(SICI)1096-9896(199706)182:2<185::AID-PATH828>3.0.CO;2-F; Sado Y, 1998, J BIOCHEM-TOKYO, V123, P767; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; Shahan TA, 1999, CONNECT TISSUE RES, V40, P221, DOI 10.3109/03008209909005285; Shahan TA, 1999, CANCER RES, V59, P4584; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; Yu M, 1998, CLIN EXP METASTAS, V16, P185; ZHOU J, 1994, J BIOL CHEM, V269, P13193	44	47	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32999	33007		10.1074/jbc.M005235200	http://dx.doi.org/10.1074/jbc.M005235200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10934203	hybrid			2022-12-27	WOS:000090003800085
J	Tomlinson, EJ; Ferguson, SJ				Tomlinson, EJ; Ferguson, SJ			Loss of either of the two heme-binding cysteines from a class I c-type cytochrome has a surprisingly small effect on physicochemical properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SEQUENCE; CLONING; C(552)	Almost without exception, c-type cytochromes have heme covalently attached via two thioether linkages to the cysteine residues of a CXXCH motif, The reasons for the covalent attachment are not understood. Reported here is cytoplasmic expression in Escherichia coli of AXXCH and CXXAH variants of cytochrome c(552) from Hydrogenobacter thermophilus; remarkably, the single thioether bond proteins have, apart from an altered visible absorption spectrum, almost identical properties, including thermal stability and reduction potential, to the wild type CXXCH protein. In combination with previous work showing that an AXXAH variant of cytochrome c(552) is much less stable than the CXXCH form, it can be concluded that covalent attachment of heme via either of thioether bonds is sufficient to confer considerable stability and that these bonds contribute little to the setting of the reduction potential. The absence of AXXCH or CXXAH heme-binding motifs from bacterial cytochromes c may relate to the coexistence of the assembly pathway with that for formation of disulfide bonds in the bacterial periplasm.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford	Ferguson, SJ (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.							Arnesano F, 2000, BIOCHEMISTRY-US, V39, P1499, DOI 10.1021/bi991831o; Barker PD, 1999, STRUCTURE, V7, pR281, DOI 10.1016/S0969-2126(00)88334-3; Bartsch R. G., 1971, METHODS ENZYMOL, V23, P344, DOI [10.1016/S0076-6879(71)23110-4, DOI 10.1016/S0076-6879(71)23110-4]; Dutton P L, 1978, Methods Enzymol, V54, P411; Keightley JA, 1998, J BIOL CHEM, V273, P12006, DOI 10.1074/jbc.273.20.12006; MOORE GR, 1985, BIOCHIM BIOPHYS ACTA, V829, P83, DOI 10.1016/0167-4838(85)90071-8; MUKAI K, 1989, EUR J BIOCHEM, V178, P649, DOI 10.1111/j.1432-1033.1989.tb14494.x; MUKAI K, 1989, J BIOCHEM-TOKYO, V106, P479, DOI 10.1093/oxfordjournals.jbchem.a122877; NALL BT, 1981, BIOCHEMISTRY-US, V20, P5403, DOI 10.1021/bi00522a008; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; PETTIGRE.GW, 1972, FEBS LETT, V22, P64, DOI 10.1016/0014-5793(72)80220-5; Pettigrew G.W., 1990, CYTOCHROMES C EVOLUT; PETTIGREW GW, 1973, NATURE, V241, P531, DOI 10.1038/241531a0; PETTIGREW GW, 1975, BIOCHEM J, V149, P155, DOI 10.1042/bj1490155; PRIEST JW, 1992, J BIOL CHEM, V267, P20188; SAMBONGI Y, 1994, FEBS LETT, V340, P65, DOI 10.1016/0014-5793(94)80174-6; SCHEJTER A, 1988, BIOCHEM J, V255, P353; Sinha N, 1998, FEMS MICROBIOL LETT, V161, P1; TANAKA Y, 1990, J BIOCHEM-TOKYO, V108, P7, DOI 10.1093/oxfordjournals.jbchem.a123165; TEALE FWJ, 1959, BIOCHIM BIOPHYS ACTA, V35, P543, DOI 10.1016/0006-3002(59)90407-X; Tomlinson EJ, 2000, P NATL ACAD SCI USA, V97, P5156, DOI 10.1073/pnas.090089397; Wittung-Stafshede P, 1998, BBA-PROTEIN STRUCT M, V1382, P324, DOI 10.1016/S0167-4838(97)00176-3; WOOD PM, 1983, FEBS LETT, V164, P223, DOI 10.1016/0014-5793(83)80289-0	23	41	43	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32530	32534		10.1074/jbc.M004022200	http://dx.doi.org/10.1074/jbc.M004022200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10922364	hybrid			2022-12-27	WOS:000090003800022
J	Bein, K; Simons, M				Bein, K; Simons, M			Thrombospondin type 1 repeats interact with matrix metalloproteinase 2 - Regulation of metalloproteinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE INHIBITOR; IV COLLAGENASE; CIRCUMSPOROZOITE PROTEIN; COMPLEMENT COMPONENTS; MOLECULAR-CLONING; CELL INVASION; ANGIOGENESIS; GENE; EXPRESSION; SEQUENCE	Thrombospondins are thought to function as inhibitors of angiogenesis, However, the mechanism(s) of this activity is not well understood. In this study, we have used the yeast two-hybrid system to identify proteins that interact with the thrombospondins 1 (TSP1) and 2 (TSP2) properdin-like type 1 repeats (TSR), One of the proteins identified that interacted with both TSR was matrix metalloproteinase 2 (MMP2). The isolated MMP2 cDNA clone encoded amino acid residues 237-633, which include the fibronectin-like gelatin binding region flanking the catalytic center and the carboxyl hemopexin-like region. Further testing of this clone demonstrated that the TSR interacted with the WH,terminal region of the MMP2 that contains the catalytic domain. The protein interaction observed in yeast was further demonstrated by immunoprecipitation and Western blotting using purified intact TSP1, TSP2, MMP2, and MMP9. Although MMP2 interacted with TSP1 and TSP2 via its gelatin-binding domain or a closely mapping site, neither TSP1 nor TSP2 was degraded by MMP2 in vitro. Tissue culture and in vitro assays demonstrated that the presence of purified TSR and intact TSP1 resulted in inhibition of MMP activity. The ability of TSP1 to inhibit MMP3-dependent activation of pro-MMP3 and thrombin-induced activation of pro-MMP2 suggests that the TSPs may inhibit MMP activity by preventing activation of the MMP2 and MMP9 zymogens.	Beth Israel Deaconess Med Ctr, Div Cardiovasc, Dept Med, Angiogenesis Res Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Simons, M (corresponding author), Beth Israel Deaconess Med Ctr, Div Cardiovasc, Dept Med, Angiogenesis Res Ctr, RW 453,330 Brookline Ave, Boston, MA 02215 USA.	msimons@bidmc.harvard.edu	Simons, Michael/G-8553-2014	Simons, Michael/0000-0003-0348-7734; Bein, Kiflai/0000-0002-5206-0801				AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; BENELLI R, 1994, ONCOL RES, V6, P251; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GOUNDIS D, 1988, NATURE, V335, P82, DOI 10.1038/335082a0; Guo NH, 1998, CANCER RES, V58, P3154; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Kyriakides TR, 1998, J CELL BIOL, V140, P419, DOI 10.1083/jcb.140.2.419; Kyriakides TR, 1999, P NATL ACAD SCI USA, V96, P4449, DOI 10.1073/pnas.96.8.4449; LAHERTY CD, 1992, J BIOL CHEM, V267, P3274; LAWLER J, 1993, J MOL EVOL, V36, P509, DOI 10.1007/BF00556355; Lawler J, 1998, J CLIN INVEST, V101, P982, DOI 10.1172/JCI1684; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER J, 1992, BIOCHEMISTRY-US, V31, P1173, DOI 10.1021/bi00119a029; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; Lurlaro M, 1999, EUR J CLIN INVEST, V29, P793; MAJACK RA, 1987, J BIOL CHEM, V262, P8821; Nguyen M, 2000, INT J BIOCHEM CELL B, V32, P621, DOI 10.1016/S1357-2725(00)00013-3; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OZAKI LS, 1983, CELL, V34, P815, DOI 10.1016/0092-8674(83)90538-X; Panetti TS, 1999, J BIOL CHEM, V274, P430, DOI 10.1074/jbc.274.1.430; PATTHY L, 1988, J MOL BIOL, V202, P689, DOI 10.1016/0022-2836(88)90550-5; Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; REPONEN P, 1992, J BIOL CHEM, V267, P7856; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; Spano F, 1998, MOL BIOCHEM PARASIT, V92, P147, DOI 10.1016/S0166-6851(97)00243-0; Stearns ME, 1999, CLIN CANCER RES, V5, P189; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; Streit M, 1999, P NATL ACAD SCI USA, V96, P14888, DOI 10.1073/pnas.96.26.14888; SUN XJ, 1989, J BIOL CHEM, V264, P11288; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; TOMLEY FM, 1991, MOL BIOCHEM PARASIT, V49, P277, DOI 10.1016/0166-6851(91)90071-D; VOLPERT OV, 1995, BIOCHEM BIOPH RES CO, V217, P326, DOI 10.1006/bbrc.1995.2780; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201	48	201	207	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32167	32173		10.1074/jbc.M003834200	http://dx.doi.org/10.1074/jbc.M003834200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10900205	hybrid			2022-12-27	WOS:000089858900084
J	Kupke, T; Uebele, M; Schmid, D; Jung, G; Blaesse, M; Steinbacher, S				Kupke, T; Uebele, M; Schmid, D; Jung, G; Blaesse, M; Steinbacher, S			Molecular characterization of lantibiotic-synthesizing enzyme EpiD reveals a function for bacterial Dfp proteins in coenzyme A biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENTLY BOUND PYRUVATE; OXIDATIVE DECARBOXYLATION; SACCHAROMYCES-CEREVISIAE; STREPTOCOCCUS-MUTANS; FLAVOPROTEIN; PURIFICATION; EPIDERMIN; SUBSTRATE; PEPTIDES; ACID	The lantibiotic-synthesizing flavoprotein EpiD catalyzes the oxidative decarboxylation of peptidylcysteines to peptidyl-aminoenethiols. The sequence motif responsible for flavin coenzyme binding and enzyme activity is conserved in different proteins from all kingdoms of life. Dfp proteins of eubacteria and archaebacteria and salt tolerance proteins of yeasts and plants belong to this new family of flavoproteins. The enzymatic function of all these proteins was not known, but our experiments suggested that they catalyze a similar reaction like EpiD and/or may have similar substrates and are homododecameric flavoproteins. We demonstrate that the N-terminal domain of the Escherichia coli Dfp protein catalyzes the decarboxylation of (R)-4'-phospho-N-pantothenoylcysteine to 4'-phosphopantetheine. This reaction is essential for coenzyme A biosynthesis.	Univ Tubingen, Lehrstuhl Mikrobielle Genet, D-72076 Tubingen, Germany; Univ Tubingen, Inst Organ Chem, D-72076 Tubingen, Germany; Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Planegg Martinsried, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Max Planck Society	Kupke, T (corresponding author), Univ Tubingen, Lehrstuhl Mikrobielle Genet, Morgenstelle 15, D-72076 Tubingen, Germany.		Zhang, Ning/F-1387-2014	Kupke, Thomas/0000-0003-2341-1710				ABIKO Y, 1967, J BIOCHEM-TOKYO, V61, P300, DOI 10.1093/oxfordjournals.jbchem.a128548; Abiko Y., 1975, Metabolism of sulphur compounds., P1; ALLGAIER H, 1985, ANGEW CHEM INT EDIT, V24, P1051, DOI 10.1002/anie.198510511; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breukink E, 1999, SCIENCE, V286, P2361, DOI 10.1126/science.286.5448.2361; BROWN GM, 1959, J BIOL CHEM, V234, P370; CLAUSEN M, 1994, GENE, V142, P107, DOI 10.1016/0378-1119(94)90363-8; Cormack B., 1991, CURRENT PROTOCOLS MO, V1, P851; de Nadal E, 1998, P NATL ACAD SCI USA, V95, P7357, DOI 10.1073/pnas.95.13.7357; DICOMO CJ, 1995, GENETICS, V139, P95; Duus F., 1978, COMPREHENSIVE ORGANI, V3, P373; Espinosa-Ruiz A, 1999, PLANT J, V20, P529, DOI 10.1046/j.1365-313X.1999.00626.x; FERRANDO A, 1995, MOL CELL BIOL, V15, P5470; GOLDWHITE H, 1957, J CHEM SOC, P2409, DOI 10.1039/jr9570002409; Gutierrez JA, 1996, J BACTERIOL, V178, P4166, DOI 10.1128/jb.178.14.4166-4175.1996; JACKOWSKI S, 1996, ESCHERICHIA COLI SAL, V1, P687; Kempter C, 1996, ANGEW CHEM INT EDIT, V35, P2104, DOI 10.1002/anie.199621041; Kupke T, 1997, J BIOL CHEM, V272, P4759, DOI 10.1074/jbc.272.8.4759; KUPKE T, 1993, FEMS MICROBIOL LETT, V112, P43, DOI 10.1016/0378-1097(93)90535-A; KUPKE T, 1992, J BACTERIOL, V174, P5354, DOI 10.1128/JB.174.16.5354-5361.1992; KUPKE T, 1994, J BIOL CHEM, V269, P5653; KUPKE T, 1995, J BIOL CHEM, V270, P11282, DOI 10.1074/jbc.270.19.11282; NAGASE O, 1967, CHEM PHARM BULL, V15, P648; Qi FX, 1999, APPL ENVIRON MICROB, V65, P3880; Sahl HG, 1998, ANNU REV MICROBIOL, V52, P41, DOI 10.1146/annurev.micro.52.1.41; SCANDURRA R, 1987, FEBS LETT, V212, P79, DOI 10.1016/0014-5793(87)81560-0; SCANDURRA R, 1974, EUR J BIOCHEM, V49, P1, DOI 10.1111/j.1432-1033.1974.tb03805.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; SCHNELL N, 1988, NATURE, V333, P276, DOI 10.1038/333276a0; SPITZER ED, 1988, J BACTERIOL, V170, P872, DOI 10.1128/jb.170.2.872-876.1988; SPITZER ED, 1985, J BACTERIOL, V164, P994, DOI 10.1128/JB.164.3.994-1003.1985; THORPE C, 1995, FASEB J, V9, P718, DOI 10.1096/fasebj.9.9.7601336; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANPOELJE PD, 1990, ANNU REV BIOCHEM, V59, P29, DOI 10.1146/annurev.bi.59.070190.000333; YANG HC, 1987, BIOCHEMISTRY-US, V26, P4076, DOI 10.1021/bi00387a050	37	79	119	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31838	31846		10.1074/jbc.M004273200	http://dx.doi.org/10.1074/jbc.M004273200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10922366	hybrid			2022-12-27	WOS:000089858900043
J	Schultz, SJ; Zhang, MH; Kelleher, CD; Champoux, JJ				Schultz, SJ; Zhang, MH; Kelleher, CD; Champoux, JJ			Analysis of plus-strand primer selection, removal, and reutilization by retroviral reverse transcriptases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; RNASE-H-DOMAIN; SEQUENCE FEATURES IMPORTANT; LONG TERMINAL REPEAT; DNA-SYNTHESIS; HIV-1 REVERSE; RIBONUCLEASE-H; DISPLACEMENT SYNTHESIS; POLYPURINE TRACT	The ability of reverse transcriptase to generate, extend, and remove the primer derived from the polypurine tract (PPT) is vital for reverse transcription, since this process determines one of the ends required for integration of the viral DNA. Based on the ability of the RNase H activity of Moloney murine leukemia virus reverse transcriptase to cleave a long RNA/DNA hybrid containing the PPT, it appears that cleavages that could generate the plus-strand primer can occur by an internal cleavage mechanism without any positioning by an RNA 5'-end, and such cleavages may serve to minimize cleavage events within the PPT itself. If the PPT were to be cleaved inappropriately just upstream of the normal plus-strand origin site, the resulting 3'-ends would not be extended by reverse transcriptase. Extension of the PPT primer by at least 2 nucleotides is sufficient for recognition and correct cleavage by RNase H at the RNA-DNA junction to remove the primer. Specific removal of the PPT primer after polymerase extension deviates from the general observation that primer removal occurs by cleavage one nucleotide away from the RNA-DNA junction and suggests that the same PPT specificity determinants responsible for generation of the PPT primer also direct PPT primer removal. Once the PPT primer has been extended and removed from the nascent plus-strand DNA, reinitiation at the resulting plus-strand primer terminus does not occur, providing a mechanism to prevent the repeated initiation of plus strands.	Univ Washington, Dept Microbiol, Sch Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Champoux, JJ (corresponding author), Univ Washington, Dept Microbiol, Sch Med, Box 357242, Seattle, WA 98195 USA.				NATIONAL CANCER INSTITUTE [R37CA051605] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA51605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arts EJ, 1998, PROG NUCLEIC ACID RE, V58, P339; BENARTZI H, 1993, J BIOL CHEM, V268, P16465; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; CHAMPOUX JJ, 1984, J VIROL, V49, P686, DOI 10.1128/JVI.49.3.686-691.1984; CHAMPOUX JJ, 1993, REVERSE TRANSCRIPTAS, P103; COLICELLI J, 1988, J MOL BIOL, V199, P47, DOI 10.1016/0022-2836(88)90378-6; COLLETT MS, 1978, J VIROL, V26, P498, DOI 10.1128/JVI.26.2.498-509.1978; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; DESTEFANO JJ, 1994, NUCLEIC ACIDS RES, V22, P3793, DOI 10.1093/nar/22.18.3793; DESTEFANO JJ, 1995, NUCLEIC ACIDS RES, V23, P3901, DOI 10.1093/nar/23.19.3901; DESTEFANO JJ, 1993, NUCLEIC ACIDS RES, V21, P4330, DOI 10.1093/nar/21.18.4330; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P24295; Fedoroff OY, 1997, J MOL BIOL, V269, P225, DOI 10.1006/jmbi.1997.1024; FEDOROFF OY, 1993, J MOL BIOL, V233, P509, DOI 10.1006/jmbi.1993.1528; FINSTON WI, 1984, J VIROL, V51, P26, DOI 10.1128/JVI.51.1.26-33.1984; FU TB, 1992, J VIROL, V66, P4271, DOI 10.1128/JVI.66.7.4271-4278.1992; FUENTES GM, 1995, J BIOL CHEM, V270, P28169, DOI 10.1074/jbc.270.47.28169; Fuentes GM, 1996, NUCLEIC ACIDS RES, V24, P1719, DOI 10.1093/nar/24.9.1719; Fuentes GM, 1996, J BIOL CHEM, V271, P1966, DOI 10.1074/jbc.271.4.2063; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; FURFINE ES, 1991, BIOCHEMISTRY-US, V30, P7041, DOI 10.1021/bi00243a001; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; GOTTE M, 1995, EMBO J, V14, P833, DOI 10.1002/j.1460-2075.1995.tb07061.x; Gotte M, 1999, J BIOL CHEM, V274, P11159, DOI 10.1074/jbc.274.16.11159; HOTTIGER M, 1994, J BIOL CHEM, V269, P986; HUBER HE, 1990, J BIOL CHEM, V265, P10565; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kelleher CD, 1998, J BIOL CHEM, V273, P9976, DOI 10.1074/jbc.273.16.9976; Kelleher CD, 2000, J BIOL CHEM, V275, P13061, DOI 10.1074/jbc.275.17.13061; Klarmann GJ, 1997, J VIROL, V71, P9259, DOI 10.1128/JVI.71.12.9259-9269.1997; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KOTEWICZ ML, 1988, NUCLEIC ACIDS RES, V16, P265, DOI 10.1093/nar/16.1.265; KRUG MS, 1989, P NATL ACAD SCI USA, V86, P3539, DOI 10.1073/pnas.86.10.3539; KULKOSKY J, 1990, J ACQ IMMUN DEF SYND, V3, P852; LEVIN JG, 1988, J VIROL, V62, P4376, DOI 10.1128/JVI.62.11.4376-4380.1988; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; OMER CA, 1982, CELL, V30, P797, DOI 10.1016/0092-8674(82)90284-7; OYAMA F, 1989, J BIOL CHEM, V264, P18808; Palaniappan C, 1998, J BIOL CHEM, V273, P3808, DOI 10.1074/jbc.273.7.3808; Palaniappan C, 1996, J BIOL CHEM, V271, P2063, DOI 10.1074/jbc.271.47.29605; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; POST K, 1993, BIOCHEMISTRY-US, V32, P5508, DOI 10.1021/bi00072a004; Powell MD, 1996, J VIROL, V70, P5288, DOI 10.1128/JVI.70.8.5288-5296.1996; PULLEN KA, 1992, J VIROL, V66, P367, DOI 10.1128/JVI.66.1.367-373.1992; PULLEN KA, 1993, J BIOL CHEM, V268, P6221; RANDOLPH CA, 1994, J BIOL CHEM, V269, P19207; RATTRAY AJ, 1989, J MOL BIOL, V208, P445, DOI 10.1016/0022-2836(89)90508-1; RATTRAY AJ, 1987, J VIROL, V61, P2843, DOI 10.1128/JVI.61.9.2843-2851.1987; RESNICK R, 1984, J VIROL, V51, P813, DOI 10.1128/JVI.51.3.813-821.1984; ROTH MJ, 1989, CELL, V58, P47, DOI 10.1016/0092-8674(89)90401-7; RYCHLIK W, 1990, NUCLEIC ACIDS RES, V18, P6409, DOI 10.1093/nar/18.21.6409; SALAZAR M, 1993, BIOCHEMISTRY-US, V32, P4207, DOI 10.1021/bi00067a007; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; SCHULTZ SJ, 1995, J BIOL CHEM, V270, P24135, DOI 10.1074/jbc.270.41.24135; Schultz SJ, 1999, J BIOL CHEM, V274, P34547, DOI 10.1074/jbc.274.49.34547; Schultz SJ, 1996, J VIROL, V70, P8630, DOI 10.1128/JVI.70.12.8630-8638.1996; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SHOEMAKER C, 1980, P NATL ACAD SCI-BIOL, V77, P3932, DOI 10.1073/pnas.77.7.3932; SKALKA A, 1993, REVERSE TRANSCRIPTAS; Smith CM, 1998, J VIROL, V72, P6805, DOI 10.1128/JVI.72.8.6805-6812.1998; Smith CM, 1997, VIROLOGY, V229, P437, DOI 10.1006/viro.1997.8454; SMITH JK, 1984, J VIROL, V52, P314, DOI 10.1128/JVI.52.2.314-319.1984; SMITH JS, 1992, J BIOL CHEM, V267, P15071; SMITH JS, 1993, J VIROL, V67, P4037, DOI 10.1128/JVI.67.7.4037-4049.1993; SMITH JS, 1990, J VIROL, V64, P6286, DOI 10.1128/JVI.64.12.6286-6290.1990; Sugimoto N, 1996, NUCLEIC ACIDS RES, V24, P4501, DOI 10.1093/nar/24.22.4501; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12468, DOI 10.1021/bi971218+; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; TANESE N, 1991, J VIROL, V65, P4387, DOI 10.1128/JVI.65.8.4387-4397.1991; TELESNITSKY A, 1993, P NATL ACAD SCI USA, V90, P1276, DOI 10.1073/pnas.90.4.1276; WHITCOMB JM, 1990, J VIROL, V64, P4903, DOI 10.1128/JVI.64.10.4903-4906.1990; Whiting SH, 1998, J MOL BIOL, V278, P559, DOI 10.1006/jmbi.1998.1720; WHITING SH, 1994, J VIROL, V68, P4747, DOI 10.1128/JVI.68.8.4747-4758.1994; WOHRL BM, 1990, BIOCHEMISTRY-US, V29, P10141, DOI 10.1021/bi00496a001; WOHRL BM, 1995, SCIENCE, V267, P96, DOI 10.1126/science.7528942; Wu WX, 1996, J VIROL, V70, P7132, DOI 10.1128/JVI.70.10.7132-7142.1996; Zhan XY, 1997, J BIOL CHEM, V272, P22023, DOI 10.1074/jbc.272.35.22023	80	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32299	32309		10.1074/jbc.M000021200	http://dx.doi.org/10.1074/jbc.M000021200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10913435	hybrid			2022-12-27	WOS:000089858900102
J	Taira, Y; Kubo, T; Natori, S				Taira, Y; Kubo, T; Natori, S			Participation of transcription elongation factor XSII-K1 in mesoderm-derived tissue development in Xenopus laevis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; FACTOR-S-II; ASCITES TUMOR-CELLS; FACTOR-SII; EUKARYOTIC TRANSCRIPTION; MOLECULAR-CLONING; DEPENDENT TRANSCRIPTION; STIMULATORY FACTOR; MESSENGER-RNA; FACTOR TFIIS	We isolated a cDNA clone for a novel member of the S-II family of transcription elongation factors from;Xenopus laevis. This S-II, named XSII-K1, is assumed to be the Xenopus homologue of mouse SII-K1 that we reported previously (Taira, Y., Kubo, T., and Natori, S. (1998) Genes Cells 3, 289-296). Expression of the XSII-K1 gene was found to be restricted to mesoderm-derived tissues such as liver, kidney, and skeletal muscle. Contrary to the general S-II gene, expression of the XSII-K1 gene was not detected in embryos at stages earlier than 11. The animal cap assay revealed that activin A, but not basic fibroblast growth factor, induced expression of the XSII-K1 gene and that it participated in the expression of mesoderm-specific genes such as Xbra and X alpha-actin. This is the first demonstration that the regulation at the level of transcription elongation is included in the development of mesoderm-derived tissues.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; RIKEN, Inst Phys & Chem Res, Natori Special Lab, Wako, Saitama 3510198, Japan	University of Tokyo; RIKEN	Natori, S (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan.			Kubo, Takeo/0000-0002-5914-5269				ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; BURATOWSKI S, 1995, SCIENCE, V270, P1773, DOI 10.1126/science.270.5243.1773; CHEN HC, 1992, GENE, V116, P253, DOI 10.1016/0378-1119(92)90522-Q; CORNELL RA, 1995, DEVELOPMENT, V121, P2429; DJE MK, 1990, NUCLEIC ACIDS RES, V18, P3489, DOI 10.1093/nar/18.12.3489; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; GU WG, 1993, J BIOL CHEM, V268, P25604; GUO HL, 1993, J BIOL CHEM, V268, P18762; GURDON JB, 1985, J EMBRYOL EXP MORPH, V89, P125; Hatada S, 1997, GENE, V203, P183, DOI 10.1016/S0378-1119(97)00512-X; HIRASHIMA S, 1988, J BIOL CHEM, V263, P3858; HORIKOSHI M, 1984, J BIOL CHEM, V259, P608; Ito T, 1996, FEBS LETT, V385, P21, DOI 10.1016/0014-5793(96)00340-7; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; KANAI A, 1991, J BIOCHEM-TOKYO, V109, P674, DOI 10.1093/oxfordjournals.jbchem.a123439; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KEPHART DD, 1994, J BIOL CHEM, V269, P13536; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kugawa F, 1996, BIOCHEM BIOPH RES CO, V222, P541, DOI 10.1006/bbrc.1996.0780; Labhart P, 1998, GENOMICS, V52, P278, DOI 10.1006/geno.1998.5449; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; MARSHALL TK, 1990, NUCLEIC ACIDS RES, V18, P6293, DOI 10.1093/nar/18.21.6293; NAKANISHI T, 1992, J BIOL CHEM, V267, P13200; NATORI S, 1982, MOL CELL BIOCHEM, V46, P173; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Plant KE, 1996, NUCLEIC ACIDS RES, V24, P3514, DOI 10.1093/nar/24.18.3514; PRINCE DH, 1989, MOL CELL BIOLL, V9, P1465; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; Roeder RG, 1998, COLD SPRING HARB SYM, V63, P201, DOI 10.1101/sqb.1998.63.201; SEKIMIZU K, 1979, BIOCHEMISTRY-US, V18, P1582, DOI 10.1021/bi00575a031; SEKIMIZU K, 1982, J BIOL CHEM, V257, P2719; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SLACK JMW, 1990, PHILOS T R SOC B, V327, P75, DOI 10.1098/rstb.1990.0044; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; Taira Y, 1998, GENES CELLS, V3, P289, DOI 10.1046/j.1365-2443.1998.00188.x; Takebayashi K, 1997, EMBO J, V16, P384, DOI 10.1093/emboj/16.2.384; UENO K, 1979, NATURE, V277, P145, DOI 10.1038/277145a0; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; XU QH, 1994, J BIOL CHEM, V269, P3100; Yokota C, 1998, J BIOCHEM, V123, P339	51	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32011	32015		10.1074/jbc.M003920200	http://dx.doi.org/10.1074/jbc.M003920200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10900206	hybrid			2022-12-27	WOS:000089858900064
J	Wu, K; Chen, A; Pan, ZQ				Wu, K; Chen, A; Pan, ZQ			Conjugation of Nedd8 to CUL1 enhances the ability of the ROC1-CUL1 complex to promote ubiquitin polymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULLIN PARTNERS; LIGASE ACTIVITY; PROTEIN LIGASE; PATHWAY; YEAST; SCF; SYSTEM; RBX1; E3; IDENTIFICATION	The SCF-ROC1 ubiquitin-protein isopeptide ligase (E3) ubiquitin ligase complex targets the ubiquitination and subsequent degradation of protein substrates required for the regulation of cell cycle progression and signal transduction pathways. We have previously shown that ROC1-CUL1 is a core subassembly within the SCF-ROC1 complex, capable of supporting the polymerization of ubiquitin. This report describes that the CUL1 subunit of the bacterially expressed, unmodified ROC1-CUL1 complex is conjugated with Nedd8 at Lys-720 by HeLa cell extracts or by a purified Nedd8 conjugation system (consisting of APP-BP1/Uba3, Ubc12, and Nedd8). This covalent linkage of Nedd8 to CUL1 is both necessary and sufficient to markedly enhance the ability of the ROC1-CUL1 complex to promote ubiquitin polymerization. A mutation of Lys-720 to arginine in CUL1 eliminates the Nedd8 modification, abolishes the activation of the ROC1-CUL1 ubiquitin ligase complex, and significantly reduces the ability of SCFHOS/beta-TRCP-ROC1 to support the ubiquitination of phosphorylated I kappa B alpha. Thus, although regulation of the SCF-ROC1 action has been previously shown to preside at the level of recognition of a phosphorylated substrate, we demonstrate that Nedd8 is a novel regulator of the efficiency of polyubiquitin chain synthesis and, hence, promotes rapid turnover of protein substrates.	Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Pan, ZQ (corresponding author), Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, 1 Gustave L Levy Pl, New York, NY 10029 USA.	zq_pan@smtplink.mssm.edu			NIGMS NIH HHS [GM55059] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chen A, 2000, J BIOL CHEM, V275, P15432, DOI 10.1074/jbc.M907300199; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; Chow NW, 1996, J BIOL CHEM, V271, P11339, DOI 10.1074/jbc.271.19.11339; del Pozo JC, 1998, SCIENCE, V280, P1760, DOI 10.1126/science.280.5370.1760; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093; Jallepalli PV, 1998, P NATL ACAD SCI USA, V95, P8159, DOI 10.1073/pnas.95.14.8159; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Morimoto M, 2000, BIOCHEM BIOPH RES CO, V270, P1093, DOI 10.1006/bbrc.2000.2576; MuziFalconi M, 1996, P NATL ACAD SCI USA, V93, P1566, DOI 10.1073/pnas.93.4.1566; Ohta T, 1999, ONCOGENE, V18, P6758, DOI 10.1038/sj.onc.1203115; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Osaka F, 2000, EMBO J, V19, P3475, DOI 10.1093/emboj/19.13.3475; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Pause A, 1999, P NATL ACAD SCI USA, V96, P9533, DOI 10.1073/pnas.96.17.9533; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Wada H, 1999, BIOCHEM BIOPH RES CO, V257, P100, DOI 10.1006/bbrc.1999.0339; Whitby FG, 1998, J BIOL CHEM, V273, P34983, DOI 10.1074/jbc.273.52.34983; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; Xie YM, 1999, EMBO J, V18, P6832, DOI 10.1093/emboj/18.23.6832	37	161	163	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32317	32324		10.1074/jbc.M004847200	http://dx.doi.org/10.1074/jbc.M004847200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10921923	hybrid			2022-12-27	WOS:000089858900104
J	Farrar, MA; Tian, J; Perlmutter, RM				Farrar, MA; Tian, J; Perlmutter, RM			Membrane localization of Raf assists engagement of downstream effecters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MURINE SARCOMA-VIRUS; MAP KINASE; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; MAMMALIAN-CELLS; T-CELLS; CASCADE; PHOSPHORYLATION; DOMAIN	We have previously described a small molecule-directed protein dimerization strategy, using coumermycin to juxtapose Raf fusion proteins containing the coumermycin-binding domain GyrB. Oligomerization of cytoplasmically localized Raf-GyrB fusion proteins leads to an increase in the kinase activity of both Raf and its substrate Mek. Surprisingly, more distal targets, such as Erk1 and Erk2, are not activated using this approach. Here we report that coumermycin-induced oligomerization of a membrane-localized Raf-GyrB fusion protein potently activated Erk1 and Erk2, up-regulated Fos protein levels, and induced expression of many immediate-early response genes. Thus, both membrane localization and oligomerization of Raf-GyrB are required to target Raf signals to downstream effecters. The ability to activate the entire Raf signal transduction cascade conditionally, using coumermycin-induced oligomerization, should prove useful for dissecting Raf-mediated effects on gene expression and cellular differentiation.	Univ Minnesota, Ctr Immunol, Minneapolis, MN 55455 USA; Merck & Co Inc, Merck Sharp & Dohme Res Labs, Rahway, NJ 07065 USA	University of Minnesota System; University of Minnesota Twin Cities; Merck & Company	Farrar, MA (corresponding author), Univ Minnesota, Dept Lab Med & Pathol, 312 Church St SE,BSBE,Rm 6-116, Minneapolis, MN 55455 USA.		Farrar, Michael A/M-7802-2013	Farrar, Michael/0000-0002-5569-0366				AHN NG, 1991, J BIOL CHEM, V266, P4220; BOS JL, 1989, CANCER RES, V49, P4682; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; CANTRELL D, 1997, ANNU REV IMMUNOL, V15, P259; CASTLE JD, 1999, CURRENT PROTOCOLS PR, V1; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHOI KY, 1994, CELL, V78, P499; DHAR R, 1982, SCIENCE, V217, P934, DOI 10.1126/science.6287572; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; EISENMANN DM, 1994, CURR OPIN GENET DEV, V4, P508, DOI 10.1016/0959-437X(94)90065-B; Farrar MA, 1998, BBA-REV CANCER, V1377, pF35, DOI 10.1016/S0304-419X(97)00038-3; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; Inouye K, 2000, J BIOL CHEM, V275, P3737, DOI 10.1074/jbc.275.6.3737; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mineo C, 1997, J BIOL CHEM, V272, P10345; Nelson BH, 1996, MOL CELL BIOL, V16, P309; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PRINTEN JA, 1994, GENETICS, V138, P609; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; SEGER R, 1994, J BIOL CHEM, V269, P25699; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; Sim ATR, 1999, CELL CALCIUM, V26, P209, DOI 10.1054/ceca.1999.0072; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; THORNTON M, 1994, MICROBIOL-UK, V140, P2371, DOI 10.1099/13500872-140-9-2371; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; Yablonski D, 1996, P NATL ACAD SCI USA, V93, P13864, DOI 10.1073/pnas.93.24.13864; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	50	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31318	31324		10.1074/jbc.M003399200	http://dx.doi.org/10.1074/jbc.M003399200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10913130	hybrid			2022-12-27	WOS:000089762700081
J	Naryshkina, T; Rogulja, D; Golub, L; Severinov, K				Naryshkina, T; Rogulja, D; Golub, L; Severinov, K			Inter- and intrasubunit interactions during the formation of RNA polymerase assembly intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BETA-SUBUNIT; 3-DIMENSIONAL STRUCTURE; ACTIVE-CENTER; YEAST; BINDING; MUTATIONS; GENE; PROTEIN; ENZYME	We used yeast two-hybrid and in vitro co-immobilization assays to study the interaction between the Escherichia coli RNA polymerase (RNAP) alpha and beta subunits during the formation of alpha(2)beta, a physiological RNAP assembly intermediate. We show that a 430-amino acid-long fragment containing beta conserved segments F, Gr, H, and a short part of segment I forms a minimal domain capable of specific interaction with alpha, The alpha-interacting domain is held together by protein-protein interactions between beta segments F and I. Residues in catalytically important beta segments H and I directly participate in ct binding; substitutions of strictly conserved segment H Asp(1084) and segment I Gly(1215) abolish alpha(2)beta formation in vitro and are lethal in vivo. The importance of these beta amino acids in cw binding is fully supported by the structural model of the Thermus aquaticus RNAP core enzyme. We also demonstrate that determinants of RNAP assembly are conserved, and that a homologue of beta Asp(1084) in A135, the beta-Like subunit of yeast RNAP I, is responsible for interaction with AC40, the largest alpha-like subunit, However, the A135-AC40 interaction is weak compared with the E. coli alpha-beta interaction, and A135 mutation that abolishes the interaction is phenotypically silent. The results suggest that in eukaryotes additional RNAP subunits orchestrate the enzyme assembly by stabilizing weak, but specific interactions of core subunits.	Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick	Severinov, K (corresponding author), Rutgers State Univ, Waksman Inst, 190 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	severik@waksman.rutgers.edu	Severinov, Konstantin/C-8545-2016		PHS HHS [R01 59295] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; AZUMA Y, 1993, NUCLEIC ACIDS RES, V21, P3749, DOI 10.1093/nar/21.16.3749; Bai C, 1996, METHOD ENZYMOL, V273, P331; BORUKHOV S, 1991, J BIOL CHEM, V266, P23921; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; Flores A, 1999, P NATL ACAD SCI USA, V96, P7815, DOI 10.1073/pnas.96.14.7815; IGARASHI K, 1990, NUCLEIC ACIDS RES, V18, P5945, DOI 10.1093/nar/18.20.5945; Ishihama A, 1981, Adv Biophys, V14, P1; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; Keener J, 1998, J BIOL CHEM, V273, P33795, DOI 10.1074/jbc.273.50.33795; Kimura M, 1997, J BIOL CHEM, V272, P25851, DOI 10.1074/jbc.272.41.25851; KOLODZIEJ PA, 1991, MOL CELL BIOL, V11, P4669, DOI 10.1128/MCB.11.9.4669; LALO D, 1993, P NATL ACAD SCI USA, V90, P5524, DOI 10.1073/pnas.90.12.5524; LEE JY, 1991, P NATL ACAD SCI USA, V88, P6018, DOI 10.1073/pnas.88.14.6018; MUSTAEV A, 1991, J BIOL CHEM, V266, P23927; Nedea EC, 1999, J BACTERIOL, V181, P2663, DOI 10.1128/JB.181.8.2663-2665.1999; NOGI Y, 1991, P NATL ACAD SCI USA, V88, P3962, DOI 10.1073/pnas.88.9.3962; Nomura T, 1999, BIOCHEMISTRY-US, V38, P1346, DOI 10.1021/bi982381n; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; PUHLER G, 1989, P NATL ACAD SCI USA, V86, P4569, DOI 10.1073/pnas.86.12.4569; SAGITOV V, 1993, J BIOL CHEM, V268, P2195; SCHULTZ P, 1993, EMBO J, V12, P2601, DOI 10.1002/j.1460-2075.1993.tb05920.x; SEVERINOV K, 1993, J BIOL CHEM, V268, P14820; SEVERINOV K, 1995, P NATL ACAD SCI USA, V92, P4591, DOI 10.1073/pnas.92.10.4591; Severinov K, 1996, J BIOL CHEM, V271, P27969, DOI 10.1074/jbc.271.44.27969; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; TANG H, 1995, P NATL ACAD SCI USA, V92, P4902, DOI 10.1073/pnas.92.11.4902; Wang DG, 1997, P NATL ACAD SCI USA, V94, P8433, DOI 10.1073/pnas.94.16.8433; Wang Y, 1997, J MOL BIOL, V270, P648, DOI 10.1006/jmbi.1997.1139; XIE WQ, 1989, J BACTERIOL, V171, P1967, DOI 10.1128/jb.171.4.1967-1973.1989; ZALENSKAYA K, 1990, GENE, V89, P7, DOI 10.1016/0378-1119(90)90199-2; Zaychikov E, 1996, SCIENCE, V273, P107, DOI 10.1126/science.273.5271.107; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9; ZILLIG W, 1976, RNA POLYMERASE, P101	36	8	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31183	31190		10.1074/jbc.M003884200	http://dx.doi.org/10.1074/jbc.M003884200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906130	hybrid			2022-12-27	WOS:000089762700062
J	Faenza, I; Matteucci, A; Manzoli, L; Billi, AM; Aluigi, M; Peruzzi, D; Vitale, M; Castorina, S; Suh, PG; Cocco, L				Faenza, I; Matteucci, A; Manzoli, L; Billi, AM; Aluigi, M; Peruzzi, D; Vitale, M; Castorina, S; Suh, PG; Cocco, L			A role for nuclear phospholipase C beta(1) in cell cycle control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIACYLGLYCEROL KINASE; SIGNAL-TRANSDUCTION; C BETA(1); 2 FORMS; DIFFERENTIATION; LOCALIZATION; PROGRESSION; PROTEIN; PHASE; G(1)	Phosphoinositide signaling resides in the nucleus, and among the enzymes of the cycle, phospholipase C (PLC) appears as the key element both in Saccharomyces cerevisiae and in mammalian cells. The yeast PLC pathway produces multiple inositol polyphosphates that modulate distinct nuclear processes. The mammalian PLC beta(1), which localizes in the nucleus, is activated in insulin-like growth factor 1-mediated mitogenesis and undergoes down-regulation during murine erythroleukemia differentiation. PLC beta(1) exists as two polypeptides of 150 and 140 kDa generated from a single gene by alternative RNA splicing, both of them containing in the COOH-terminal tail a cluster of lysine residues responsible for nuclear localization. These clues prompted us to try to establish the critical nuclear target(s) of PLC beta(1) subtypes in the control of cell cycle progression. The results reveal that the two subtypes of PLC beta(1) that localize in the nucleus induce cell cycle progression in Friend erythroleukemia cells. In fact when they are overexpressed in the nucleus, cyclin D3, along with its kinase (cdk4) but not cyclin E is overexpressed even though cells are serum-starved. As a consequence of this enforced expression, retinoblastoma protein is phosphorylated and E2F-1 transcription factor is activated as well. On the whole the results reveal a direct effect of nuclear PLC beta(1) signaling in G(1) progression by means of a specific target, i.e. cyclin D3/cdk4.	Univ Bologna, Dept Anat Sci, Cellular Signalling Lab, I-40126 Bologna, Italy; Rizzoli Inst, CNR, Inst Cytomorphol, I-40136 Bologna, Italy; Univ Brescia, Dept Biomed Sci & Biotechnol, I-25123 Brescia, Italy; Univ Catania, Dept Anat, I-95124 Catania, Italy; Pohang Univ Sci & Technol, Dept Life Sci, Div Mol Life Sci, Pohang 633165, South Korea	University of Bologna; Consiglio Nazionale delle Ricerche (CNR); University of Brescia; University of Catania; Pohang University of Science & Technology (POSTECH)	Cocco, L (corresponding author), Univ Bologna, Dept Anat Sci, Cellular Signalling Lab, Via Irnerio 48, I-40126 Bologna, Italy.		Vitale, Marco/O-8751-2015; Suh, Pann-Ghill/F-3610-2010	Vitale, Marco/0000-0002-3261-6868; Castorina, Sergio/0000-0002-0745-4107				Bahk YY, 1998, BBA-LIPID LIPID MET, V1389, P76, DOI 10.1016/S0005-2760(97)00128-8; BAHK YY, 1994, J BIOL CHEM, V269, P8240; Chi TH, 2000, SCIENCE, V287, P1937, DOI 10.1126/science.287.5460.1937; Cocco L, 1998, ADV ENZYME REGUL, V38, P351, DOI 10.1016/S0065-2571(97)00014-9; COCCO L, 1995, ADV ENZYME REGUL, V35, P23, DOI 10.1016/0065-2571(94)00004-M; Divecha N, 1998, NATURE, V394, P619, DOI 10.1038/29174; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; KATO J, 1993, P NATL ACAD SCI USA, V9, P11513; Kim CG, 1996, J BIOL CHEM, V271, P21187, DOI 10.1074/jbc.271.35.21187; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Manzoli L, 1997, CANCER RES, V57, P2137; Maraldi NM, 1999, J CELL PHYSIOL, V181, P203, DOI 10.1002/(SICI)1097-4652(199911)181:2<203::AID-JCP3>3.0.CO;2-O; MARKS PA, 1994, P NATL ACAD SCI USA, V91, P10251, DOI 10.1073/pnas.91.22.10251; MARMIROLI S, 1994, J BIOL CHEM, V269, P13; Martelli AM, 2000, CANCER RES, V60, P815; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; Matteucci A, 1998, CANCER RES, V58, P5057; MURRAY A, 1994, CURR OPIN CELL BIOL, V6, P872, DOI 10.1016/0955-0674(94)90059-0; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; YORK JD, 1994, J BIOL CHEM, V269, P7847	28	132	146	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30520	30524		10.1074/jbc.M004630200	http://dx.doi.org/10.1074/jbc.M004630200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10913438	hybrid			2022-12-27	WOS:000089577900082
J	Guedin, S; Willery, E; Tommassen, J; Fort, E; Drobecq, H; Locht, C; Jacob-Dubuisson, F				Guedin, S; Willery, E; Tommassen, J; Fort, E; Drobecq, H; Locht, C; Jacob-Dubuisson, F			Novel topological features of FhaC, the outer membrane transporter involved in the secretion of the Bordetella pertussis filamentous hemagglutinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; FERRIC ENTEROBACTIN RECEPTOR; GRAM-NEGATIVE BACTERIA; 3-DIMENSIONAL STRUCTURE; SERRATIA-MARCESCENS; CRYSTAL-STRUCTURES; PROTEIN SECRETION; REPORTER EPITOPE; IRON RECEPTOR; HEMOLYSIN	Many pathogenic Gram-negative bacteria secrete virulence factors across the cell envelope into the extracellular milieu. The secretion of filamentous hemagglutinin (FHA) by Bordetella pertussis depends on the pore-forming outer membrane protein FhaC, which belongs to a growing family of protein transporters. Protein alignment and secondary structure predictions indicated that FhaC is likely to be a beta-barrel protein with an odd number of transmembrane beta-strands connected by large surface loops and short periplasmic turns. The membrane topology of FhaC was investigated by random insertion of the c-Myc epitope and the tobacco etch virus protease-specific cleavage sequence. FhaC was fairly permissive to short linker insertions. Furthermore, FhaC appeared to undergo conformational changes upon FHA secretion. Surface detection of the inserted sequences indicated that several predicted loops in the C-terminal moiety as well as the N terminus of the protein are exposed. However, a large surface-predicted region in the N-terminal moiety of FhaC was inaccessible from the surface. In addition, the activity and the stability of the protein were affected by insertions in that region, indicating that it may have important structural and/or functional roles. The surface exposure of the N terminus and the presence of an odd number of beta-strands are novel features for beta-barrel outer membrane proteins.	Inst Pasteur, IBL, INSERM, U447, F-59019 Lille, France; Univ Utrecht, Dept Mol Cell Biol, NL-3584 CH Utrecht, Netherlands; Inst Pasteur, IBL, CNRS, UMR 8525, F-59019 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Utrecht University; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Jacob-Dubuisson, F (corresponding author), Inst Pasteur, IBL, INSERM, U447, 1 Rue Calmette, F-59019 Lille, France.		Jacob-Dubuisson, Françoise/F-1610-2018; Locht, Camille/L-3516-2018; Tommassen, Jan/I-1690-2016	Jacob-Dubuisson, Françoise/0000-0002-5102-1704; Tommassen, Jan/0000-0001-7633-4945; Drobecq, Herve/0000-0002-4081-1575				ARMSTRONG SK, 1995, J BIOL CHEM, V270, P2483, DOI 10.1074/jbc.270.6.2483; BARANY F, 1988, DNA PROTEIN ENG TECH, V1, P29; BARENKAMP SJ, 1994, INFECT IMMUN, V62, P3320, DOI 10.1128/IAI.62.8.3320-3328.1994; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; CHARBIT A, 1991, J BACTERIOL, V173, P262, DOI 10.1128/jb.173.1.262-275.1991; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DELISSEGATHOYE AM, 1990, INFECT IMMUN, V58, P2895, DOI 10.1128/IAI.58.9.2895-2905.1990; DOMENIGHINI M, 1990, MOL MICROBIOL, V4, P787, DOI 10.1111/j.1365-2958.1990.tb00649.x; Ehrmann M, 1997, P NATL ACAD SCI USA, V94, P13111, DOI 10.1073/pnas.94.24.13111; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; Guedin S, 1998, MOL MICROBIOL, V29, P763, DOI 10.1046/j.1365-2958.1998.00970.x; Hirono I, 1997, MOL MICROBIOL, V24, P851, DOI 10.1046/j.1365-2958.1997.3971760.x; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Jacob-Dubuisson F, 1999, J BIOL CHEM, V274, P37731, DOI 10.1074/jbc.274.53.37731; JacobDubuisson F, 1996, MOL MICROBIOL, V19, P65, DOI 10.1046/j.1365-2958.1996.349883.x; JacobDubuisson F, 1997, J BACTERIOL, V179, P775, DOI 10.1128/jb.179.3.775-783.1997; KOEBNIK R, 1993, J BACTERIOL, V175, P826, DOI 10.1128/JB.175.3.826-839.1993; Konninger UW, 1999, MOL MICROBIOL, V32, P1212, DOI 10.1046/j.1365-2958.1999.01433.x; Lambert-Buisine C, 1998, MOL MICROBIOL, V28, P1283, DOI 10.1046/j.1365-2958.1998.00892.x; Lee CA, 1997, TRENDS MICROBIOL, V5, P148, DOI 10.1016/S0966-842X(97)01029-9; Letoffe S, 1996, EMBO J, V15, P5804, DOI 10.1002/j.1460-2075.1996.tb00967.x; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; Locht C, 1999, Int Microbiol, V2, P137; LOCHT C, 1993, MOL MICROBIOL, V9, P653, DOI 10.1111/j.1365-2958.1993.tb01725.x; Merck KB, 1997, J BACTERIOL, V179, P3443, DOI 10.1128/jb.179.11.3443-3450.1997; MOECK GS, 1995, J BACTERIOL, V177, P6118, DOI 10.1128/jb.177.21.6118-6125.1995; MOECK GS, 1994, J BACTERIOL, V176, P4250, DOI 10.1128/jb.176.14.4250-4259.1994; MURPHY CK, 1990, J BACTERIOL, V172, P2736, DOI 10.1128/jb.172.5.2736-2746.1990; Newton SMC, 1996, J BACTERIOL, V178, P3447, DOI 10.1128/jb.178.12.3447-3456.1996; Palmer KL, 1995, MOL MICROBIOL, V18, P821, DOI 10.1111/j.1365-2958.1995.18050821.x; PAUL C, 1985, EMBO J, V4, P1593, DOI 10.1002/j.1460-2075.1985.tb03822.x; Pautsch A, 1998, NAT STRUCT BIOL, V5, P1013, DOI 10.1038/2983; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RenauldMongenie G, 1996, J BACTERIOL, V178, P1053, DOI 10.1128/jb.178.4.1053-1060.1996; ROSQVIST R, 1995, EMBO J, V14, P4187, DOI 10.1002/j.1460-2075.1995.tb00092.x; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; SCHONHERR R, 1993, MOL MICROBIOL, V9, P1229, DOI 10.1111/j.1365-2958.1993.tb01252.x; STRUYVE M, 1993, MOL MICROBIOL, V7, P131, DOI 10.1111/j.1365-2958.1993.tb01104.x; STRUYVE M, 1991, J MOL BIOL, V218, P141, DOI 10.1016/0022-2836(91)90880-F; SUKHAN A, 1995, J BACTERIOL, V177, P4914, DOI 10.1128/jb.177.17.4914-4920.1995; Thanabalu T, 1998, EMBO J, V17, P6487, DOI 10.1093/emboj/17.22.6487; TOMMASSEN J, 1988, NATO ASI SERIES H, V16, P352; WEISS MS, 1990, FEBS LETT, V267, P268, DOI 10.1016/0014-5793(90)80942-C; WILLEMS RJL, 1994, MOL MICROBIOL, V11, P337, DOI 10.1111/j.1365-2958.1994.tb00314.x	45	79	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30202	30210		10.1074/jbc.M005515200	http://dx.doi.org/10.1074/jbc.M005515200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10906141	hybrid			2022-12-27	WOS:000089577900041
J	Onofri, F; Giovedi, S; Kao, HT; Valtorta, F; Borbone, LB; De Camilli, P; Greengard, P; Benfenati, F				Onofri, F; Giovedi, S; Kao, HT; Valtorta, F; Borbone, LB; De Camilli, P; Greengard, P; Benfenati, F			Specificity of the binding of synapsin I to Src homology 3 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE ENDOCYTOSIS; SH3 DOMAINS; F-ACTIN; NEUROTRANSMITTER RELEASE; SH3-LIGAND INTERACTIONS; PROTEIN MODULES; SKELETAL-MUSCLE; DISTINCT SITES; GENERAL-MODEL; C-SRC	Synapsins are synaptic vesicle-associated phosphoproteins involved in synapse formation and regulation of neurotransmitter release. Recently, synapsin I has been found to bind the Src homology 3 (SH3) domains of Grb2 and c-Src. In this work we have analyzed the interactions between synapsins and an array of SH3 domains belonging to proteins involved in signal transduction, cytoskeleton assembly, or endocytosis. The binding of synapsin I was specific for a subset of SH3 domains. The highest binding was observed with SH3 domains of c-Src, phospholipase C-gamma, p85 subunit of phosphatidylinositol 3-kinase, full-length and NH2-terminal Grb2, whereas binding was moderate with the SH3 domains of amphiphysins I/II, Crk, alpha-spectrin, and NADPH oxidase factor p47(phox) and negligible with the SH3 domains of p21(ras) GTPase-activating protein and COOH-terminal Grb2. Distinct sites in the proline-rich COOH-terminal region of synapsin I were found to be involved in binding to the various SH3 domains. Synapsin II also interacted with SH3 domains with a partly distinct binding pattern. Phosphorylation of synapsin I in the COOH-terminal region by Ca2+/calmodulin-dependent protein kinase II or mitogen-activated protein kinase modulated the binding to the SH3 domains of amphiphysins I/II, Crk, and alpha-spectrin without affecting the high affinity interactions. The SH3-mediated interaction of synapsin I with amphiphysins affected the ability of synapsin I to interact with actin and synaptic vesicles, and pools of synapsin I and amphiphysin I were shown to associate in isolated nerve terminals. The ability to bind multiple SH3 domains further implicates the synapsins in signal transduction and protein-protein interactions at the nerve terminal level.	Univ Modena, Physiol Sect, Dept Biomed Sci, I-41100 Modena, Italy; Univ Genoa, Physiol Sect, Dept Expt Med, I-16132 Genoa, Italy; Univ Roma Tor Vergata, Dept Neurosci, I-00133 Rome, Italy; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; NYU Med Ctr, Dept Psychiat, New York, NY 10016 USA; Ist Sci San Raffaele, Dept Neurosci, I-20132 Milan, Italy; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06536 USA	Universita di Modena e Reggio Emilia; University of Genoa; University of Rome Tor Vergata; Rockefeller University; New York University; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Yale University	Benfenati, F (corresponding author), Univ Modena, Physiol Sect, Dept Biomed Sci, Via Campi 287, I-41100 Modena, Italy.	benfenat@mail.unimo.it	Giovedì, Silvia/AAB-7614-2019; Flavia, Valtorta/F-3450-2012	Flavia, Valtorta/0000-0001-9556-4746; GIOVEDI', SILVIA/0000-0001-7949-4274	NIA NIH HHS [AG15072] Funding Source: Medline; NIMH NIH HHS [MH39327] Funding Source: Medline; Telethon [1131] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH039327, R01MH039327] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG015072] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BAHLER M, 1989, J CELL BIOL, V108, P1841, DOI 10.1083/jcb.108.5.1841; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BENFENATI F, 1990, J BIOL CHEM, V265, P12584; BENFENATI F, 1989, J CELL BIOL, V108, P1863, DOI 10.1083/jcb.108.5.1863; BENFENATI F, 1992, NATURE, V359, P417, DOI 10.1038/359417a0; BENFENATI F, 1992, NEURON, V8, P377, DOI 10.1016/0896-6273(92)90303-U; Benfenati F, 1999, PHILOS T R SOC B, V354, P243, DOI 10.1098/rstb.1999.0376; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; Cestra G, 1999, J BIOL CHEM, V274, P32001, DOI 10.1074/jbc.274.45.32001; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; Esser L, 1998, EMBO J, V17, P977, DOI 10.1093/emboj/17.4.977; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Foster-Barber A, 1998, P NATL ACAD SCI USA, V95, P4673, DOI 10.1073/pnas.95.8.4673; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Hosaka M, 1999, J BIOL CHEM, V274, P16747, DOI 10.1074/jbc.274.24.16747; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; Matsuda M, 1996, J BIOL CHEM, V271, P14468, DOI 10.1074/jbc.271.24.14468; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Mundigl O, 1998, J NEUROSCI, V18, P93; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Nielander HB, 1997, EUR J NEUROSCI, V9, P2712, DOI 10.1111/j.1460-9568.1997.tb01700.x; Onofri F, 1997, P NATL ACAD SCI USA, V94, P12168, DOI 10.1073/pnas.94.22.12168; PANG DT, 1988, P NATL ACAD SCI USA, V85, P762, DOI 10.1073/pnas.85.3.762; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PIERIBONE VA, 1995, NATURE, V375, P493, DOI 10.1038/375493a0; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Ringstad N, 1999, NEURON, V24, P143, DOI 10.1016/S0896-6273(00)80828-4; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; SIMON JA, 1995, CHEM BIOL, V2, P53, DOI 10.1016/1074-5521(95)90080-2; SIOW YL, 1992, BIOCHEMISTRY-US, V31, P4268, DOI 10.1021/bi00132a017; SIVADON P, 1995, MOL GEN GENET, V246, P485, DOI 10.1007/BF00290452; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEDA T, 1973, J BIOL CHEM, V248, P8295; Urquhart AJ, 2000, J BIOL CHEM, V275, P4127, DOI 10.1074/jbc.275.6.4127; Vaccaro P, 1997, MOL BRAIN RES, V52, P1, DOI 10.1016/S0169-328X(97)00219-2; VALTORTA F, 1992, J BIOL CHEM, V267, P11281; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8	58	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29857	29867		10.1074/jbc.M006018200	http://dx.doi.org/10.1074/jbc.M006018200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10899172	hybrid			2022-12-27	WOS:000089439800092
J	Kim, IS; Kim, DH; Han, SM; Chin, MU; Nam, HJ; Cho, HP; Choi, SY; Song, BJ; Kim, ER; Bae, YS; Moon, YH				Kim, IS; Kim, DH; Han, SM; Chin, MU; Nam, HJ; Cho, HP; Choi, SY; Song, BJ; Kim, ER; Bae, YS; Moon, YH			Truncated form of importin alpha identified in breast cancer cell inhibits nuclear import of p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOCYTOPLASMIC TRANSPORT; PROTEIN IMPORT; EXPORT SIGNAL; PORE COMPLEX; LOCALIZATION; GENE; MECHANISMS; MUTATIONS; SUBSTRATE; BINDING	Disruption of the function of tumor suppressor proteins occasionally can be dependent on their subcellular localization. In about 40% of the breast cancer tissues, p53 is found in the cytoplasm as opposed to the nucleus, where it resides in normal breast cells. This means that the regulation of subcellular location of p53 is an important mechanism in controlling its function. The transport factors required for the nuclear export of p53 and the mechanisms of their nuclear export have been extensively characterized. However, little is known about the mechanism of nuclear import of p53, p53 contains putative nuclear localization signals (NLSs) which would interact with a nuclear transport factor, importin alpha. In this report we demonstrate that importin a binds to NLSI in p53 and mediates the nuclear import of p53, Reverse transcriptase-polymerase chain reaction and sequencing analyses showed that a truncated importin alpha deleted the region encoding the putative NLS-binding domain of p53, suggesting that it could not bind to NLSs of p53 proteins. Binding of importin alpha to p53 was confirmed by using yeast two-hybrid assay. When expressed in CHO-K1 cells, the truncated importin alpha predominantly localized to the cytoplasm, In truncated importin alpha expressing cells, p53 preferentially localized to cytoplasmic sites as well, A significant increase in the p21(waf1/cip1) mRNA level and induction of apoptosis were also observed in importin alpha overexpressing cells. These results strongly suggest that importin alpha functions as a component of the NLS receptor for p53 and mediates nuclear import of p53.	Sung Ae Life Sci Res Inst, Kyeonggi 423030, South Korea; Hannam Univ, Dept Microbiol, Daeduk Gu, Taejon 306791, South Korea	Hannam University	Moon, YH (corresponding author), 389 Chulsan Kwangmyeong, Kyeonggi 423030, South Korea.	hjyhdjsj@sungae.co.kr						BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Boche I, 1997, J CELL BIOL, V139, P313, DOI 10.1083/jcb.139.2.313; BOSARI S, 1995, AM J PATHOL, V147, P790; DANG CV, 1989, J BIOL CHEM, V264, P18019; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Herold A, 1998, J CELL BIOL, V143, P309, DOI 10.1083/jcb.143.2.309; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KRAEMER DM, 1995, J BIOL CHEM, V270, P19017, DOI 10.1074/jbc.270.32.19017; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; Lee MP, 1997, CANCER RES, V57, P3131; Li S, 1998, J BIOL CHEM, V273, P6183, DOI 10.1074/jbc.273.11.6183; Liang SH, 1999, J BIOL CHEM, V274, P32699, DOI 10.1074/jbc.274.46.32699; LIANG XH, 1993, ONCOGENE, V8, P2645; Lu ML, 1996, CANCER RES, V56, P4578; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moore MS, 1998, J BIOL CHEM, V273, P22857, DOI 10.1074/jbc.273.36.22857; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; SaporitoIrwin SM, 1997, BIOTECHNIQUES, V23, P424, DOI 10.2144/97233bm16; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; Smith HMS, 1998, PLANT CELL, V10, P1791, DOI 10.1105/tpc.10.11.1791; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; SUNDARESAN V, 1998, EMBO J, V17, P4657; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x	36	101	103	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23139	23145		10.1074/jbc.M909256199	http://dx.doi.org/10.1074/jbc.M909256199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10930427	hybrid			2022-12-27	WOS:000088419400073
J	Koundrioukoff, S; Jonsson, ZO; Hasan, S; de Jong, RN; van der Vliet, PC; Hottiger, MO; Hubscher, U				Koundrioukoff, S; Jonsson, ZO; Hasan, S; de Jong, RN; van der Vliet, PC; Hottiger, MO; Hubscher, U			A direct interaction between proliferating cell nuclear antigen (PCNA) and Cdk2 targets PCNA-interacting proteins for phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; DNA-REPLICATION; BINDING-PROTEIN; REPAIR; SUBUNIT; CYCLINS; FEN-1; ALPHA; P21	Proliferating cell nuclear antigen is best known as a DNA polymerase accessory protein but has more recently also been shown to have different functions in important cellular processes such as DNA replication, DNA repair, and cell cycle control. PCNA has been found in quaternary complexes with the cyclin kinase inhibitor p21 and several pairs of cyclin-dependent protein kinases and their regulatory partner, the cyclins. Here we show a direct interaction between PCNA and Cdk2. This interaction involves the regions of the PCNA trimer close to the C termini. We found that PCNA and Cdk2 form a complex together with cyclin A. This ternary PCNA-Cdk2-cyclin A complex was able to phosphorylate the PCNA binding region of the large subunit of replication factor C as well as DNA ligase I. Furthermore, PCNA appears to be a connector between Cdk2 and DNA ligase I and to stimulate phosphorylation of DNA ligase I. Based on our results, we propose the model that PCNA brings Cdk2 to proteins involved in DNA replication and possibly might act as an "adaptor" for Cdk2-cyclin A to PCNA-binding DNA replication proteins.	Univ Zurich Irchel, Inst Vet Biochem, CH-8057 Zurich, Switzerland; Univ Utrecht, Physiol Chem Lab, NL-3584 CG Utrecht, Netherlands; Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands	University of Zurich; Utrecht University	Hubscher, U (corresponding author), Univ Zurich Irchel, Inst Vet Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	hubscher@vetbio.unizh.ch	Jónsson, Zophonías/E-1960-2015; Jónsson, Zophonías Oddur/AAO-1354-2020; Hottiger, Michael O./J-7747-2013	Jónsson, Zophonías Oddur/0000-0001-5798-9647; Hottiger, Michael O./0000-0002-7323-2270; de Jong, Rob N./0000-0002-9300-6633				Adams PD, 1996, MOL CELL BIOL, V16, P6623; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Dekker J, 1998, J MOL BIOL, V277, P825, DOI 10.1006/jmbi.1998.1652; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; Fotedar A, 1996, J BIOL CHEM, V271, P31627, DOI 10.1074/jbc.271.49.31627; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Knibiehler M, 1996, FEBS LETT, V391, P66, DOI 10.1016/0014-5793(96)00702-8; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; MCVEY D, 1993, J VIROL, V67, P5206, DOI 10.1128/JVI.67.9.5206-5215.1993; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Rossi R, 1999, EMBO J, V18, P5745, DOI 10.1093/emboj/18.20.5745; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; Schurtenberger P, 1998, J MOL BIOL, V275, P123, DOI 10.1006/jmbi.1997.1435; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Voitenleitner C, 1997, ONCOGENE, V14, P1611, DOI 10.1038/sj.onc.1200975; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wu SM, 1998, J BIOL CHEM, V273, P9561, DOI 10.1074/jbc.273.16.9561; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	27	101	107	3	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22882	22887		10.1074/jbc.M001850200	http://dx.doi.org/10.1074/jbc.M001850200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10930425	hybrid, Green Accepted			2022-12-27	WOS:000088419400040
J	Ayukawa, K; Taniguchi, S; Masumoto, J; Hashimoto, S; Sarvotham, H; Hara, A; Aoyama, T; Sagara, J				Ayukawa, K; Taniguchi, S; Masumoto, J; Hashimoto, S; Sarvotham, H; Hara, A; Aoyama, T; Sagara, J			La autoantigen is cleaved in the COOH terminus and loses the nuclear localization signal during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; TERMINATION FACTOR LA; SS-B AUTOANTIGEN; TRANSCRIPTION TERMINATION; POLY(ADP-RIBOSE) POLYMERASE; LUPUS-ERYTHEMATOSUS; MATRIX PROTEINS; POLIOVIRUS RNA; CASPASE FAMILY; DEATH	La autoantigen is a 47-kDa nuclear protein that binds to nascent polymerase III transcripts and a number of viral RNAs. We show that La protein was cleaved to generate a 43-kDa fragment during apoptosis of human leukemic HL-60 cells treated with camptothecin or etoposide. Immunofluorescence microscopy showed that the La protein level was increased in the cytoplasm during apoptosis of HL-60 cells. In addition, UV irradiation of HeLa cells led to the cleavage and redistribution of La protein upon apoptosis. Several lines of evidence show that La protein is cleaved by caspase-3 or closely related proteases at Asp-374 in the COOH terminus. When the full-length (La) and COOH-terminally truncated (La Delta C374) forms of La protein were expressed as fusion proteins with green fluorescence protein (GFP), GFP-La Delta C374 was predominantly cytoplasmic, whereas GFP-La was localized in the nucleus. These results suggest that La protein loses the nuclear localization signal residing in the COOH terminus upon cleavage and is thus redistributed to the cytoplasm during apoptosis.	Shinshu Univ, Sch Med, Res Ctr Aging & Adaptat, Dept Mol Oncol & Angiol, Nagano 3908621, Japan; Shinshu Univ, Sch Med, Res Ctr Aging & Adaptat, Dept Aging Biochem, Nagano 3908621, Japan	Shinshu University; Shinshu University	Sagara, J (corresponding author), Shinshu Univ, Sch Med, Res Ctr Aging & Adaptat, Dept Mol Oncol & Angiol, Asahi 3-1-1, Nagano 3908621, Japan.		Hara, Atsushi/B-1127-2008					Ali N, 1997, P NATL ACAD SCI USA, V94, P2249, DOI 10.1073/pnas.94.6.2249; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; CHAMBERS JC, 1985, P NATL ACAD SCI USA, V82, P2115, DOI 10.1073/pnas.82.7.2115; CHAMBERS JC, 1988, J BIOL CHEM, V263, P18043; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FEY EG, 1988, P NATL ACAD SCI USA, V85, P121, DOI 10.1073/pnas.85.1.121; Galfre G, 1981, Methods Enzymol, V73, P3; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GOTTLIEB EL, 1989, EMBO J, V8, P841, DOI 10.1002/j.1460-2075.1989.tb03445.x; JEMMERSON R, 1985, P NATL ACAD SCI USA, V82, P1508, DOI 10.1073/pnas.82.5.1508; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; LERNER MR, 1981, SCIENCE, V211, P400, DOI 10.1126/science.6164096; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; Maraia RJ, 1996, P NATL ACAD SCI USA, V93, P3383, DOI 10.1073/pnas.93.8.3383; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; Miranda ME, 1998, J IMMUNOL, V161, P5061; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; PIENTA KJ, 1994, MED HYPOTHESES, V42, P45, DOI 10.1016/0306-9877(94)90035-3; Pommier Y, 1993, CANCER CHEMOTHERAPY, P214; Rosen A, 1999, CELL DEATH DIFFER, V6, P6, DOI 10.1038/sj.cdd.4400460; Rutjes SA, 1999, CELL DEATH DIFFER, V6, P976, DOI 10.1038/sj.cdd.4400571; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Simons FHM, 1996, EXP CELL RES, V224, P224, DOI 10.1006/excr.1996.0132; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SVITKIN YV, 1994, J VIROL, V68, P1544, DOI 10.1128/JVI.68.3.1544-1550.1994; SVITKIN YV, 1994, J VIROL, V68, P7001, DOI 10.1128/JVI.68.11.7001-7007.1994; Talanian RV, 1997, J BIOL CHEM, V272, P9677; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; vanVenrooij WJ, 1995, CURR OPIN IMMUNOL, V7, P819, DOI 10.1016/0952-7915(95)80054-9; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZWEYER M, 1995, EXP CELL RES, V221, P27, DOI 10.1006/excr.1995.1349	40	74	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34465	34470		10.1074/jbc.M003673200	http://dx.doi.org/10.1074/jbc.M003673200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10913436	hybrid			2022-12-27	WOS:000165095300063
J	Delesque-Touchard, N; Park, SH; Waxman, DJ				Delesque-Touchard, N; Park, SH; Waxman, DJ			Synergistic action of hepatocyte nuclear factors 3 and 6 on CYP2C12 gene expression and suppression by growth hormone-activated - STAT5b proposed model for female-specific expression of CYP2C12 in adult rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED TRANSCRIPTION FACTOR; TYROSINE PHOSPHORYLATION; SEXUAL DIMORPHISM; BINDING-PROTEIN; RECEPTOR; IDENTIFICATION; INHIBITION; PROLACTIN; SECRETION; INSULIN	Growth hormone (GH) exerts sexually dimorphic effects on liver gene transcription through its sex-dependent temporal pattern of pituitary hormone secretion. CYP2C12 encodes a female-specific rat liver P450 steroid hydroxylase whose expression is activated by continuous GH stimulation of hepatocytes. Presently, we investigated the role of liver-enriched and GH-regulated transcription factors in the activation of CYP2C12 gene expression in GH-stimulated liver cells. Transcription of a CYP2C12 promoter-luciferase reporter gene in transfected HepG2 cells was activated 15-40-fold by the liver-enriched hepatocyte nuclear factor (HNF) 3 alpha, HNF3 beta, and HNF6. Synergistic interactions leading to an similar to 300-fold activation of the promoter by HNF3 beta in combination with HNF6 were observed. S'-Deletion analysis localized the HNF6 response to a single 5'-proximal 96-nucleotide segment. By contrast, the stimulatory effects of HNF3 alpha and HNF3 beta were attributable to five distinct regions within the 1.6-kilobase CYP2C12 proximal promoter. GH activation of the signal transducer and transcriptional activator STAT5b, which proceeds efficiently in male but not female rat liver, inhibited CYP2C12 promoter activation by HNF3 beta and HNF6, despite the absence of a classical STAT5-binding site. The female-specific pattern of CYP2C12 expression is thus proposed to reflect the positive synergistic action in female liver of liver-enriched and GH-regulated transcription factors, such as HNF3 beta and HNF6, coupled with a dominant inhibitory effect of GH-activated STAT5b that is manifest in males.	Boston Univ, Dept Biol, Div Cell & Mol Biol, Boston, MA 02215 USA	Boston University	Waxman, DJ (corresponding author), Boston Univ, Dept Biol, Div Cell & Mol Biol, 5 Cummington St, Boston, MA 02215 USA.	djw@bio.bu.edu		Waxman, David/0000-0001-7982-9206	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033765] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK033765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Argetsinger LS, 1996, PHYSIOL REV, V76, P1089, DOI 10.1152/physrev.1996.76.4.1089; BICHELL DP, 1992, MOL ENDOCRINOL, V6, P1899, DOI 10.1210/me.6.11.1899; Buggs C, 1998, MOL ENDOCRINOL, V12, P1294, DOI 10.1210/me.12.9.1294; Choi HK, 1999, ENDOCRINOLOGY, V140, P5126, DOI 10.1210/en.140.11.5126; Choi HK, 2000, ENDOCRINOLOGY, V141, P3245, DOI 10.1210/en.141.9.3245; CLARKSON RWE, 1995, MOL ENDOCRINOL, V9, P108, DOI 10.1210/me.9.1.108; Davey HW, 1999, AM J HUM GENET, V65, P959, DOI 10.1086/302599; Davey HW, 1999, J BIOL CHEM, V274, P35331, DOI 10.1074/jbc.274.50.35331; Ganguly TC, 1997, J CLIN INVEST, V99, P2906, DOI 10.1172/JCI119485; Gebert CA, 1999, MOL ENDOCRINOL, V13, P213, DOI 10.1210/me.13.2.213; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; GURLAND G, 1990, ENDOCRINOLOGY, V127, P3187, DOI 10.1210/endo-127-6-3187; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; JANSSON JO, 1985, ENDOCR REV, V6, P128, DOI 10.1210/edrv-6-2-128; Lahuna O, 1997, P NATL ACAD SCI USA, V94, P12309, DOI 10.1073/pnas.94.23.12309; Lahuna O, 2000, MOL ENDOCRINOL, V14, P285, DOI 10.1210/me.14.2.285; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; Landry C, 1997, DEV BIOL, V192, P247, DOI 10.1006/dbio.1997.8757; LEGRAVEREND C, 1992, MOL ENDOCRINOL, V6, P259, DOI 10.1210/me.6.2.259; Lemaigre FP, 1996, P NATL ACAD SCI USA, V93, P9460, DOI 10.1073/pnas.93.18.9460; Luo GY, 1997, J BIOL CHEM, V272, P26841, DOI 10.1074/jbc.272.43.26841; MACGEOCH C, 1984, J BIOL CHEM, V259, P5433; MODE A, 1992, ADV ENZYME REGUL, V32, P255; Moutoussamy S, 1998, EUR J BIOCHEM, V255, P1, DOI 10.1046/j.1432-1327.1998.2550001.x; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; Park SH, 1999, J BIOL CHEM, V274, P7421, DOI 10.1074/jbc.274.11.7421; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; Samadani U, 1996, GENE EXPRESSION, V6, P23; Samadani U, 1996, MOL CELL BIOL, V16, P6273; Sasaki Y, 1999, J BIOL CHEM, V274, P37117, DOI 10.1074/jbc.274.52.37117; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Soldaini E, 2000, MOL CELL BIOL, V20, P389, DOI 10.1128/MCB.20.1.389-401.2000; STROM A, 1995, J BIOL CHEM, V270, P11276, DOI 10.1074/jbc.270.19.11276; Subramanian A, 1998, NUCLEIC ACIDS RES, V26, P2173, DOI 10.1093/nar/26.9.2173; Sueyoshi T, 1999, MOL PHARMACOL, V56, P473, DOI 10.1124/mol.56.3.473; SUNDSETH SS, 1992, J BIOL CHEM, V267, P3907; TANNENBAUM GS, 1976, ENDOCRINOLOGY, V98, P562, DOI 10.1210/endo-98-3-562; TOLLET P, 1990, MOL ENDOCRINOL, V4, P1934, DOI 10.1210/mend-4-12-1934; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Waxman David J., 1995, P391; Waxman DJ, 1996, J BIOL CHEM, V271, P29978, DOI 10.1074/jbc.271.47.29978; Waxman DJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P11, DOI 10.1006/abbi.1999.1351; WAXMAN DJ, 1984, J BIOL CHEM, V259, P5481; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; Yamashita H, 1998, J BIOL CHEM, V273, P30218, DOI 10.1074/jbc.273.46.30218; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607; Zhou YC, 1999, J BIOL CHEM, V274, P29874, DOI 10.1074/jbc.274.42.29874; Zhou YC, 1999, J BIOL CHEM, V274, P2672, DOI 10.1074/jbc.274.5.2672	51	65	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34173	34182		10.1074/jbc.M004027200	http://dx.doi.org/10.1074/jbc.M004027200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10931833	Green Submitted, hybrid			2022-12-27	WOS:000165095300026
J	Mutucumarana, VP; Stafford, DW; Stanley, TB; Jin, DY; Solera, J; Brenner, B; Azerad, R; Wu, SM				Mutucumarana, VP; Stafford, DW; Stanley, TB; Jin, DY; Solera, J; Brenner, B; Azerad, R; Wu, SM			Expression and characterization of the naturally occurring mutation L394R in human gamma-glutamyl carboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-DEPENDENT CARBOXYLASE; BLOOD-COAGULATION FACTORS; FACTOR-IX; CONGENITAL DEFICIENCY; RECOGNITION SITE; CARBOXYGLUTAMIC ACID; PROPEPTIDE REGION; PEPTIDE-SUBSTRATE; ENZYME-ACTIVITY; PROTEIN-C	Patients with mutation L394R in gamma -glutamyl carboxylase have a severe bleeding disorder because of decreased biological activities of all vitamin K-dependent coagulation proteins. Vitamin K administration partially corrects this deficiency. To characterize L394R, we purified recombinant mutant L394R and wild-type carboxylase expressed in baculovirus-infected insect cells. By kinetic studies, we analyzed the catalytic activity of mutant L394R and its binding to factor M's propeptide and vitamin KM2. Mutant L394R differs from its wild-type counterpart as follows: 1) 110-fold higher K-i for Boc-mEEV, an active site-specific, competitive inhibitor of FLEEL; 2) 30-fold lower V-max/K-m toward the substrate FLEEL in the presence of the propeptide; 3) severely reduced activity toward FLEEL carboxylation in the absence of the propeptide; 4) 7-fold decreased affinity for the propeptide; 5) 9-fold higher K-m for FIXproGla, a substrate containing the propeptide and the Gla domain of human factor IX; and 6) B-fold higher K-m, for vitamin KH2. The primary defect in mutant L394R appears to be in its glutamate-binding site. To a lesser degree, the propeptide and KH2 binding properties are altered in the L394R mutant. Compared with its wildtype counterpart, the L394R mutant shows an augmented activation of FLEEL carboxylation by the propeptide.	Hosp Univ La Paz, Dept Mol Genet, Madrid 28046, Spain; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Rambam Med Ctr, Inst Hematol, Thrombosis & Hemostasis Unit, IL-31096 Haifa, Israel; Univ Paris 05, Chim & Biochim Pharmacol & Toxicol Lab, UFR Biomed St Peres, F-75270 Paris 06, France	Hospital Universitario La Paz; University of North Carolina; University of North Carolina Chapel Hill; Rambam Health Care Campus; Technion Israel Institute of Technology; UDICE-French Research Universities; Universite Paris Cite	Wu, SM (corresponding author), Univ N Carolina, Dept Biol, CB 3280, Chapel Hill, NC 27599 USA.				NHLBI NIH HHS [HL48313] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048313] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AZERAD R, 1988, CURRENT ADV VITAMIN, P17; BEGLEY GS, 2000, J BIOL CHEM     0712; BRENNER B, 1990, BRIT J HAEMATOL, V75, P537, DOI 10.1111/j.1365-2141.1990.tb07795.x; Brenner B, 1998, BLOOD, V92, P4554, DOI 10.1182/blood.V92.12.4554.424k42_4554_4559; CHEUNG A, 1989, ARCH BIOCHEM BIOPHYS, V274, P574, DOI 10.1016/0003-9861(89)90472-4; Chu K, 1996, J CLIN INVEST, V98, P1619, DOI 10.1172/JCI118956; Clackson T, 1998, J MOL BIOL, V277, P1111, DOI 10.1006/jmbi.1998.1669; ESMON CT, 1975, J BIOL CHEM, V250, P4744; FASCO MJ, 1982, J BIOL CHEM, V257, P1210; GOLDSMITH GH, 1982, J CLIN INVEST, V69, P1253, DOI 10.1172/JCI110564; HUBBARD BR, 1989, J BIOL CHEM, V264, P14145; JOHNSON CA, 1980, BRIT J HAEMATOL, V44, P461, DOI 10.1111/j.1365-2141.1980.tb05916.x; JORGENSEN MJ, 1987, CELL, V48, P185, DOI 10.1016/0092-8674(87)90422-3; KNOBLOCH JE, 1987, J BIOL CHEM, V262, P15334; KULIOPULOS A, 1994, J BIOL CHEM, V269, P21364; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Li T, 2000, J BIOL CHEM, V275, P18291, DOI 10.1074/jbc.M001790200; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MCMILLAN CW, 1966, NEW ENGL J MED, V274, P1313, DOI 10.1056/NEJM196606092742309; MORRIS DP, 1993, J BIOL CHEM, V268, P8735; Morris DP, 1995, J BIOL CHEM, V270, P30491, DOI 10.1074/jbc.270.51.30491; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; PAULI RM, 1987, AM J HUM GENET, V41, P566; PECHLANER C, 1992, THROMB HAEMOSTASIS, V68, P617; REHEMTULLA A, 1993, P NATL ACAD SCI USA, V90, P4611, DOI 10.1073/pnas.90.10.4611; Romero EE, 1998, BIOCHEM BIOPH RES CO, V248, P783, DOI 10.1006/bbrc.1998.8987; SOUTE BAM, 1990, BIOCHIM BIOPHYS ACTA, V1034, P11, DOI 10.1016/0304-4165(90)90146-N; SOUTE BAM, 1992, THROMB HAEMOSTASIS, V68, P521; Stanley TB, 1998, BIOCHEMISTRY-US, V37, P13262, DOI 10.1021/bi981031y; Stanley TB, 1999, J BIOL CHEM, V274, P16940, DOI 10.1074/jbc.274.24.16940; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; Sugiura I, 1996, J BIOL CHEM, V271, P17837, DOI 10.1074/jbc.271.30.17837; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; THIJSSEN HHW, 1986, BIOCHEM PHARMACOL, V35, P3277, DOI 10.1016/0006-2952(86)90424-7; ULRICH MMW, 1988, J BIOL CHEM, V263, P9697; VICENTE V, 1984, THROMB HAEMOSTASIS, V51, P343; WALLIN R, 1982, ARCH BIOCHEM BIOPHYS, V214, P155, DOI 10.1016/0003-9861(82)90017-0; WOOD GM, 1988, J BIOL CHEM, V263, P3234; WU SM, 1990, J BIOL CHEM, V265, P13124; Wu SM, 1997, METHOD ENZYMOL, V282, P346; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935; WU SM, 1991, P NATL ACAD SCI USA, V88, P2236, DOI 10.1073/pnas.88.6.2236	42	40	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32572	32577		10.1074/jbc.M006808200	http://dx.doi.org/10.1074/jbc.M006808200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10934213	hybrid, Green Published			2022-12-27	WOS:000090003800028
J	Palmieri, D; Camardella, L; Ulivi, V; Guasco, G; Manduca, P				Palmieri, D; Camardella, L; Ulivi, V; Guasco, G; Manduca, P			Trimer carboxyl propeptide of collagen I produced by mature osteoblasts is chemotactic for endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN ALPHA-1-BETA-1; EXTRACELLULAR-MATRIX; TERMINAL PROPEPTIDE; GENE-EXPRESSION; GROWTH-FACTOR; C-PROPEPTIDE; ANGIOGENESIS; PROCOLLAGEN; MIGRATION; BINDING	During the second phase of osteogenesis in vitro, rat osteoblasts secrete inducer(s) of chemotaxis and chemoinvasion of endothelial and tumor cells. We report here the characterization and purification from mature osteoblast conditioned medium of the agent chemotactic for endothelial cells. The chemoactive conditioned medium specifically induces directional migration of endothelial cells, not affecting the expression and activation of gelatinases, cell proliferation, and scattering. Directional migration induced in endothelial cells by conditioned medium from osteoblasts is inhibited by pertussis toxin, by blocking antibodies to integrins alpha (1), beta (1), and beta (3), and by antibodies to metalloproteinase 2 and 9. The biologically active purified protein has two sequences, coincident with the amino-terminal amino acids, respectively, of the alpha (2) and of the alpha (2) carboxyl propeptides of type I collagen, as physiologically produced by procollagen C proteinase. Antibodies to type I collagen and to the carboxyl terminus of alpha (1) or alpha (2) chains inhibit chemotaxis. The chemoattractant is the propeptide trimer carboxyl-terminal to type I collagen, and its activity is lost upon reduction. These data illustrate a previously unknown function for the carboxyl-terminal trimer, possibly relevant in promoting endothelial cell migration and vascularization of tissues producing collagen type I.	Univ Genoa, Dipartimento Oncol Biol & Genet, I-16132 Genoa, Italy; CNR, IBPE, I-80100 Naples, Italy	University of Genoa; Consiglio Nazionale delle Ricerche (CNR)	Manduca, P (corresponding author), Univ Genoa, Dipartimento Oncol Biol & Genet, C Europa 26, I-16132 Genoa, Italy.							ALINI M, 1992, CALCIFIED TISSUE INT, V50, P327, DOI 10.1007/BF00301630; AYCOCK RS, 1986, J BIOL CHEM, V261, P14355; Broberg A, 1996, EXP CELL RES, V228, P29, DOI 10.1006/excr.1996.0295; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; CHOGLAY AA, 1993, J BIOL CHEM, V268, P6107; Davies D, 1997, EUR J BIOCHEM, V246, P274, DOI 10.1111/j.1432-1033.1997.t01-1-00274.x; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DEJANA E, 1985, J CLIN INVEST, V75, P11, DOI 10.1172/JCI111661; Dickeson SK, 1997, J BIOL CHEM, V272, P7661, DOI 10.1074/jbc.272.12.7661; Festuccia C, 1999, ONCOL RES, V11, P17; Festuccia C, 1999, INT J CANCER, V81, P395, DOI 10.1002/(SICI)1097-0215(19990505)81:3<395::AID-IJC13>3.0.CO;2-V; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Gardner H, 1999, J CELL SCI, V112, P263; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; GIUNCIUGLIO D, 1995, CANCER LETT, V97, P69, DOI 10.1016/0304-3835(95)03955-V; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; Kamphaus GD, 2000, J BIOL CHEM, V275, P1209, DOI 10.1074/jbc.275.2.1209; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; Manduca P, 1997, BONE, V21, P31, DOI 10.1016/S8756-3282(97)00037-9; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Pozzi M, 1998, J CELL BIOL, V142, P587; Ramchandran R, 1999, BIOCHEM BIOPH RES CO, V255, P735, DOI 10.1006/bbrc.1999.0248; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; STRINGA E, 1995, BONE, V16, P663, DOI 10.1016/8756-3282(95)00100-R; VANDERREST M, 1986, BIOCHEM J, V237, P923, DOI 10.1042/bj2370923; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; WESTON SA, 1994, J BIOL CHEM, V269, P20982; WU CH, 1991, J BIOL CHEM, V266, P2983; YOSHITAKE H, 1999, J BONE MINER RES  S1, V14, P1004	35	32	34	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32658	32663		10.1074/jbc.M002698200	http://dx.doi.org/10.1074/jbc.M002698200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10924500	hybrid			2022-12-27	WOS:000090003800040
J	Dallabrida, SM; De Sousa, MA; Farrell, DH				Dallabrida, SM; De Sousa, MA; Farrell, DH			Expression of antisense to integrin subunit beta(3) inhibits microvascular endothelial cell capillary tube formation in fibrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; FIBROBLAST GROWTH-FACTOR; ALPHA-V INTEGRINS; ALPHA(V)BETA(3) INTEGRIN; GLANZMANN THROMBASTHENIA; ADHESION MOLECULES; BLOOD-VESSELS; GENE-THERAPY; ANGIOGENESIS; RECEPTOR	alpha(v)beta(3) antagonists are potent angiogenesis inhibitors, and several different classes of inhibitors have been developed, including monoclonal antibodies, synthetic peptides, and small organic molecules. However, each class of inhibitor works by the same principal, by blocking the binding of ligands to alpha(v)beta(3). In an effort to develop an alpha(v)beta(3) inhibitor that down-regulates the actual level of alpha(v)beta(3), we developed an antisense strategy to inhibit alpha(v)beta(3) expression in vitro. beta(3) antisense expressed in endothelial cells specifically down-regulated alpha(v)beta(3) and inhibited capillary tube formation, with the extent of down-regulation correlating with the extent of tube formation inhibition. This inhibition was matrix-specific, since tube formation was not inhibited in Matrigel. These findings support the notion that alpha(v)beta(3) is required for an essential step of angiogenesis in fibrin, namely capillary tube formation. These results suggest that pseudogenetic inhibition of beta(3) integrins using antisense techniques may ultimately provide a therapeutic means to inhibit angiogenesis in vivo.	Oregon Hlth & Sci Univ, Sch Dent, Dept Oral Mol Biol, Portland, OR 97201 USA; Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA	Oregon Health & Science University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Farrell, DH (corresponding author), Oregon Hlth & Sci Univ, Sch Dent, Dept Oral Mol Biol, Portland, OR 97201 USA.	farrelld@ohsu.edu			NHLBI NIH HHS [R29HL53997, K02HL04215] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL053997, K02HL004215] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Bach TL, 1998, J BIOL CHEM, V273, P30719, DOI 10.1074/jbc.273.46.30719; Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; BOLEN JB, 1987, J VIROL, V61, P1079, DOI 10.1128/JVI.61.4.1079-1085.1987; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CHANG MC, 1995, THROMB HAEMOSTASIS, V74, P764; Cheresh DA, 1998, NAT MED, V4, P395, DOI 10.1038/nm0498-395; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; COLLER BS, 1991, BLOOD, V77, P75; COLLER BS, 1983, J CLIN INVEST, V72, P325, DOI 10.1172/JCI110973; Davis GE, 1996, EXP CELL RES, V224, P39, DOI 10.1006/excr.1996.0109; DEJANA E, 1988, BLOOD, V71, P566; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; DRAKE CJ, 1995, J CELL SCI, V108, P2655; Falls LA, 1997, J BIOL CHEM, V272, P14251, DOI 10.1074/jbc.272.22.14251; FINLAYSON JS, 1960, J CLIN INVEST, V39, P1837, DOI 10.1172/JCI104207; Folkman J, 1998, ENDOCRINOLOGY, V139, P441, DOI 10.1210/en.139.2.441; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Folkman J, 1998, P NATL ACAD SCI USA, V95, P9064, DOI 10.1073/pnas.95.16.9064; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; GAMBLE JR, 1993, J CELL BIOL, V121, P931, DOI 10.1083/jcb.121.4.931; GOTO F, 1993, LAB INVEST, V69, P508; Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529; Hodivala-Dilke KM, 1999, J CLIN INVEST, V103, P229, DOI 10.1172/JCI5487; HOSHIGA M, 1995, CIRC RES, V77, P1129, DOI 10.1161/01.RES.77.6.1129; KARNOVSKY MJ, 1965, J CELL BIOL, V27, pA137; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; Keenan RM, 1997, J MED CHEM, V40, P2289, DOI 10.1021/jm970205r; Koch AE, 1998, ARTHRITIS RHEUM-US, V41, P951, DOI 10.1002/1529-0131(199806)41:6<951::AID-ART2>3.0.CO;2-D; KOIVISTO L, 1994, BIOCHEM J, V300, P771, DOI 10.1042/bj3000771; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XW, 1998, INVAS METAST, V18, P1, DOI 10.1159/000024494; Losordo DW, 1998, CIRCULATION, V98, P2800, DOI 10.1161/01.CIR.98.25.2800; NEHLS V, 1995, MICROVASC RES, V50, P311, DOI 10.1006/mvre.1995.1061; Nicolaou KC, 1998, BIOORGAN MED CHEM, V6, P1185, DOI 10.1016/S0968-0896(98)00090-X; NICOSIA RF, 1991, AM J PATHOL, V138, P829; OBRIEN ER, 1994, AM J PATHOL, V145, P883; Okada Y, 1996, AM J PATHOL, V149, P37; Panda D, 1997, P NATL ACAD SCI USA, V94, P9308, DOI 10.1073/pnas.94.17.9308; PYTELA R, 1994, METHOD ENZYMOL, V245, P420; Roush W, 1997, SCIENCE, V276, P1192, DOI 10.1126/science.276.5316.1192; SAELMAN EUM, 1995, J CELL SCI, V108, P3531; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; SEPP NT, 1994, J INVEST DERMATOL, V103, P295, DOI 10.1111/1523-1747.ep12394617; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; STUPACK DG, 1991, SCAND J IMMUNOL, V34, P761, DOI 10.1111/j.1365-3083.1991.tb01601.x; Tam SH, 1998, CIRCULATION, V98, P1085, DOI 10.1161/01.CIR.98.11.1085; Thiagarajan P, 1996, BIOCHEMISTRY-US, V35, P4169, DOI 10.1021/bi952532b; Topol EJ, 1997, JAMA-J AM MED ASSOC, V278, P479, DOI 10.1001/jama.278.6.479; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WILLIAMS S, 1993, LAB INVEST, V69, P491; Wu HR, 1998, P NATL ACAD SCI USA, V95, P6037, DOI 10.1073/pnas.95.11.6037; XU YL, 1994, J INVEST DERMATOL, V102, P833, DOI 10.1111/1523-1747.ep12382086	59	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32281	32288		10.1074/jbc.M001446200	http://dx.doi.org/10.1074/jbc.M001446200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10922359	hybrid			2022-12-27	WOS:000089858900100
J	Kahnert, A; Kertesz, MA				Kahnert, A; Kertesz, MA			Characterization of a sulfur-regulated oxygenative alkylsulfatase from Pseudomonas putida S-313	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; ESCHERICHIA-COLI; FOREST SOIL; DIOXYGENASE; BIODEGRADATION; PURIFICATION; ACTIVATION; ENZYME; RESISTANCE; CLONING	The atsK gene of Pseudomonas putida S-313 was required for growth with alkyl sulfate esters as sulfur source. The AtsK protein was overexpressed in Escherichia coli and purified to homogeneity. Sequence analysis revealed that AtsK was closely related to E. coli taurine dioxygenase (38% amino acid identity). The AtsK protein catalyzed the alpha-ketoglutarate-dependent cleavage of a range of alkyl sulfate esters, with chain lengths ranging from C-4 to C-12, required oxygen and Fe2+ for activity and released succinate, sulfate, and the corresponding aldehyde as products. Enzyme activity was optimal at pH 7 and was strongly stimulated by ascorbate. Unlike most other characterized alpha-ketoglutarate-dependent dioxygenases, AtsK accepted a range of alpha-keto acids as co-substrates, including alpha-ketoglutarate (K-m 140 mu M), alpha-ketoadipate, alpha-ketovalerate, and alpha-ketooctanoate. The measured K-m values for hexyl sulfate and SDS were 40 and 34 mu M, respectively. The apparent M-r of the purified enzyme of 121,000 was consistent with a homotetrameric structure, which is unusual for this enzyme superfamily, members of which are usually monomeric or dimeric, The properties and amino acid sequence of the AtsK enzyme thus define it as an unusual oxygenolytic alkylsulfatase and a novel member of the alpha-ketoglutarate-dependent dioxygenase family.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; ETH Zentrum, Swiss Fed Inst Technol, Inst Microbiol, CH-8092 Zurich, Switzerland	University of Manchester; Swiss Federal Institutes of Technology Domain; ETH Zurich	Kertesz, MA (corresponding author), Univ Manchester, Sch Biol Sci, 1-800 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	michael.kertesz@man.ac.uk	Kertesz, Michael/A-6720-2011; KERTESZ, Michael/Q-7642-2019	Kertesz, Michael/0000-0003-2112-4451; KERTESZ, Michael/0000-0003-2112-4451				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; AUTRY AR, 1990, BIOL FERT SOILS, V10, P50; BARRETT CH, 1980, BIOCHEM J, V191, P467, DOI 10.1042/bj1910467; BARTHOLOMEW B, 1977, BIOCHEM J, V165, P575, DOI 10.1042/bj1650575; BATEMAN TJ, 1986, BIOCHEM J, V236, P401, DOI 10.1042/bj2360401; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLOVES JM, 1980, BIOCHEM J, V185, P23, DOI 10.1042/bj1850023; Davies I, 1990, BIODEGRADATION, V1, P229, DOI 10.1007/BF00119760; DAVISON J, 1992, GENE, V114, P19, DOI 10.1016/0378-1119(92)90702-Q; DECAROLIS E, 1994, PHYTOCHEMISTRY, V36, P1093, DOI 10.1016/S0031-9422(00)89621-1; Dodgson K.S., 1982, SULFATASES MICROBIAL; Eichhorn E, 1997, J BIOL CHEM, V272, P23031, DOI 10.1074/jbc.272.37.23031; FITZGERALD JW, 1975, CAN J MICROBIOL, V21, P59, DOI 10.1139/m75-008; FUKUMORI F, 1993, J BIOL CHEM, V268, P24311; HAINES TH, 1973, ANNU REV MICROBIOL, V27, P403, DOI 10.1146/annurev.mi.27.100173.002155; Hegg EL, 1999, BIOCHEMISTRY-US, V38, P16714, DOI 10.1021/bi991796l; Hegg EL, 1999, J AM CHEM SOC, V121, P1972, DOI 10.1021/ja983867u; HIGGINS TP, 1993, J GEN MICROBIOL, V139, P2915, DOI 10.1099/00221287-139-12-2915; Higgins TP, 1996, MICROBIOL-SGM, V142, P251, DOI 10.1099/13500872-142-2-251; Hummerjohann J, 2000, J BACTERIOL, V182, P2055, DOI 10.1128/JB.182.7.2055-2058.2000; Kahnert A, 2000, J BACTERIOL, V182, P2869, DOI 10.1128/JB.182.10.2869-2878.2000; KERTESZ MA, 1993, J BACTERIOL, V175, P1187, DOI 10.1128/JB.175.4.1187-1190.1993; Kertesz MA, 2000, FEMS MICROBIOL REV, V24, P135, DOI 10.1016/S0168-6445(99)00033-9; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; LIEM PQ, 1976, BIOCHIMIE, V58, P1381; LILLIS V, 1983, APPL ENVIRON MICROB, V46, P988, DOI 10.1128/AEM.46.5.988-994.1983; MATCHAM GWJ, 1977, BIOCHEM J, V167, P723, DOI 10.1042/bj1670723; MATTS PJ, 1994, BIOCHEM J, V304, P937, DOI 10.1042/bj3040937; MYLLYLA R, 1984, J BIOL CHEM, V259, P5403; PRESCOTT AG, 1993, J EXP BOT, V44, P849, DOI 10.1093/jxb/44.5.849; Quadroni M, 1999, EUR J BIOCHEM, V266, P986, DOI 10.1046/j.1432-1327.1999.00941.x; Que L, 1996, CHEM REV, V96, P2607, DOI 10.1021/cr960039f; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Serre L, 1999, STRUCTURE, V7, P977, DOI 10.1016/S0969-2126(99)80124-5; THOMAS ORT, 1989, BIOTECHNOL APPL BIOC, V11, P318; THOMAS ORT, 1988, J GEN MICROBIOL, V134, P1229; Valegard K, 1998, NATURE, V394, P805, DOI 10.1038/29575; vanderPloeg JR, 1996, J BACTERIOL, V178, P5438, DOI 10.1128/jb.178.18.5438-5446.1996; WATWOOD ME, 1986, CAN J FOREST RES, V16, P689, DOI 10.1139/x86-124; WEST SEH, 1994, GENE, V148, P81, DOI 10.1016/0378-1119(94)90237-2; WHITE GF, 1985, ENVIRON POLLUT A, V37, P1, DOI 10.1016/0143-1471(85)90020-0; YAGI T, 1966, J BIOCHEM-TOKYO, V59, P495, DOI 10.1093/oxfordjournals.jbchem.a128333	42	80	82	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31661	31667		10.1074/jbc.M005820200	http://dx.doi.org/10.1074/jbc.M005820200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10913158	hybrid			2022-12-27	WOS:000089858900018
J	Tremblay, LO; Herscovics, A				Tremblay, LO; Herscovics, A			Characterization of a cDNA encoding a novel human Golgi alpha 1,2-mannosidase (IC) involved in N-glycan biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; SACCHAROMYCES-CEREVISIAE; GLYCOPROTEIN-BIOSYNTHESIS; ENDOPLASMIC-RETICULUM; ALPHA-MANNOSIDASE; MOLECULAR-CLONING; PIG-LIVER; EXPRESSION; GLYCOSIDASES; ENZYME	A human cDNA encoding a 70.9-kDa type II membrane protein with sequence similarity to class I alpha 1,2-mannosidases was isolated. The enzymatic properties of the novel alpha 1,2-mannosidase IC were studied by expressing its catalytic domain in Pichia pastoris as a secreted glycoprotein. alpha 1,2-Mannosidase IC sequentially hydrolyzes the alpha 1,2-linked mannose residues of [H-3]mannose-labeled Man(9)GlcNAc to form [H-3]Man(6)GlcNAc and a small amount of [H-3]Man(5)GlcNAc. The enzyme requires calcium for activity and is inhibited by both 1-deoxymannojirimycin and kifunensine. The order of mannose removal was determined by separating oligosaccharide isomers formed from pyridylaminated Man(9)GlcNAc(2) by high performance liquid chromatography. The terminal alpha 1,2-linked mannose residue from the middle branch is the last mannose removed by the enzyme. This residue is the mannose cleaved from Man(9)GlcNAc(2) by the endoplasmic reticulum alpha 1,2-mannosidase I to form Man(8)GlcNAc(2) isomer B. The order of mannose hydrolysis from either pyridylaminated Man(9)GlcNAc(2) or Man(8)GlcNAc(2) isomer B differs from that previously reported for mammalian Golgi alpha 1,2-mannosidases LA and IB. The full-length alpha 1,2-mannosidase IC was localized to the Golgi of MDBK and MDCK cells by indirect immunofluorescence. Northern blot analysis showed tissue-specific expression of a major transcript of 3.8 kilobase pairs. The expression pattern is different from that of human Golgi alpha 1,2-mannosidases IA and IB. Therefore, the human genome contains at least three differentially regulated Golgi alpha 1,2-mannosidase genes encoding enzymes with similar, but not identical specificities.	McGill Univ, Ctr Canc, Montreal, PQ H3G 1Y6, Canada	McGill University	Herscovics, A (corresponding author), McGill Univ, Ctr Canc, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.							BAUSE E, 1993, EUR J BIOCHEM, V217, P535, DOI 10.1111/j.1432-1033.1993.tb18274.x; BAUSE E, 1992, EUR J BIOCHEM, V208, P451, DOI 10.1111/j.1432-1033.1992.tb17207.x; Bieberich E, 1997, EUR J BIOCHEM, V246, P681, DOI 10.1111/j.1432-1033.1997.t01-1-00681.x; CAMIRAND A, 1991, J BIOL CHEM, V266, P15120; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Gonzalez DS, 2000, MOL BIOL EVOL, V17, P292, DOI 10.1093/oxfordjournals.molbev.a026309; Gonzalez DS, 1999, J BIOL CHEM, V274, P21375, DOI 10.1074/jbc.274.30.21375; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HERSCOVICS A, 1987, ANAL BIOCHEM, V166, P85, DOI 10.1016/0003-2697(87)90550-1; Herscovics A, 1999, BBA-GEN SUBJECTS, V1473, P96, DOI 10.1016/S0304-4165(99)00171-3; HERSCOVICS A, 1994, J BIOL CHEM, V269, P9864; Igdoura SA, 1999, EUR J CELL BIOL, V78, P441, DOI 10.1016/S0171-9335(99)80071-5; JELINEKKELLY S, 1985, J BIOL CHEM, V260, P2253; Kawar Z, 2000, GLYCOBIOLOGY, V10, P347, DOI 10.1093/glycob/10.4.347; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAL A, 1994, J BIOL CHEM, V269, P9872; Lal A, 1998, GLYCOBIOLOGY, V8, P981, DOI 10.1093/glycob/8.10.981; Lipari F, 1999, BIOCHEMISTRY-US, V38, P1111, DOI 10.1021/bi981643i; Lipari F, 1996, J BIOL CHEM, V271, P27615, DOI 10.1074/jbc.271.44.27615; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; ROMERO PA, 1985, BIOCHEM J, V226, P733, DOI 10.1042/bj2260733; ROMERO PA, 1994, GLYCOBIOLOGY, V4, P135, DOI 10.1093/glycob/4.2.135; Romero PA, 2000, J BIOL CHEM, V275, P11071, DOI 10.1074/jbc.275.15.11071; SHAPER NL, 1985, J CELL BIOCHEM, V28, P229, DOI 10.1002/jcb.240280305; TABAS I, 1979, J BIOL CHEM, V254, P1655; Tremblay LO, 1998, GLYCOBIOLOGY, V8, P585, DOI 10.1093/glycob/8.6.585; Tremblay LO, 1999, GLYCOBIOLOGY, V9, P1073, DOI 10.1093/glycob/9.10.1073; Vallee F, 2000, EMBO J, V19, P581, DOI 10.1093/emboj/19.4.581; Yoshida T, 1998, BIOSCI BIOTECH BIOCH, V62, P309, DOI 10.1271/bbb.62.309	31	64	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31655	31660		10.1074/jbc.M004935200	http://dx.doi.org/10.1074/jbc.M004935200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10915796	hybrid			2022-12-27	WOS:000089858900017
J	Xie, YQ; Denison, C; Yang, SH; Fancy, DA; Kodadek, T				Xie, YQ; Denison, C; Yang, SH; Fancy, DA; Kodadek, T			Biochemical characterization of the TATA-binding protein-Gal4 activation domain complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; FUSION PROTEINS; BOX COMPLEX; YEAST; TBP; DNA; TRANSACTIVATION; DIMER; COACTIVATORS; AFFINITIES	It has been suggested that complexes between gene-specific activators and the TATA-binding protein (TBP) play an important role in the expression of many genes. However, few detailed studies of well defined activator-TBP complexes have been reported. An analysis of the biochemical properties of the complex formed by the acidic activation domain (AAD) of the yeast activator Gal4 and TBP is presented here. This is shown to be composed of two AAD and one TBP molecule. DNA binding experiments reveal that TATA-containing DNAs and the Gal4 AAD bind TBP competitively, suggesting that the AAD and TATA boxes recognize overlapping surfaces of TBP. The kinetics of the formation and dissociation of the AAD(2)-TBP complex is also probed. The impact of these findings on models for Gal4-mediated transcriptional activation is considered.	Univ Texas, SW Med Ctr, Ryburn Ctr Mol Cardiol, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ryburn Ctr Mol Cardiol, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kodadek, T (corresponding author), Univ Texas, SW Med Ctr, Ryburn Ctr Mol Cardiol, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Fancy, David A./0000-0001-7786-936X; Kodadek, Thomas/0000-0003-1930-4795	NHLBI NIH HHS [HLO7360] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Burley SK, 1998, CELL, V94, P551, DOI 10.1016/S0092-8674(00)81596-2; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; COLEMAN RA, 1995, J BIOL CHEM, V270, P13850, DOI 10.1074/jbc.270.23.13850; Coleman RA, 1997, P NATL ACAD SCI USA, V94, P7221, DOI 10.1073/pnas.94.14.7221; COLEMAN RA, 1995, J BIOL CHEM, V270, P13842, DOI 10.1074/jbc.270.23.13842; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; Fancy DA, 1999, P NATL ACAD SCI USA, V96, P6020, DOI 10.1073/pnas.96.11.6020; Fancy DA, 1996, CHEM BIOL, V3, P551, DOI 10.1016/S1074-5521(96)90146-5; Heyduk T, 1996, METHOD ENZYMOL, V274, P492; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; JOHNSTON SA, 1987, CELL, V50, P143, DOI 10.1016/0092-8674(87)90671-4; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; MELCHER K, 1995, MOL CELL BIOL, V15, P2839; Nishikawa J, 1997, P NATL ACAD SCI USA, V94, P85, DOI 10.1073/pnas.94.1.85; Paal K, 1997, NUCLEIC ACIDS RES, V25, P1050, DOI 10.1093/nar/25.5.1050; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; Patikoglou GA, 1999, GENE DEV, V13, P3217, DOI 10.1101/gad.13.24.3217; POON D, 1993, J BIOL CHEM, V268, P15325; REECE RJ, 1993, GENE, V126, P105, DOI 10.1016/0378-1119(93)90596-U; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; Wu YB, 1996, EMBO J, V15, P3951, DOI 10.1002/j.1460-2075.1996.tb00769.x; XU HE, 1995, P NATL ACAD SCI USA, V92, P7677, DOI 10.1073/pnas.92.17.7677	30	16	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31914	31920		10.1074/jbc.M003760200	http://dx.doi.org/10.1074/jbc.M003760200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10931832	hybrid			2022-12-27	WOS:000089858900052
J	da Silva, EF; Reha-Krantz, LJ				da Silva, EF; Reha-Krantz, LJ			Dinucleotide repeat expansion catalyzed by bacteriophage T4 DNA polymerase in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMPLE REPETITIVE DNA; SACCHAROMYCES-CEREVISIAE; REPLICATION ERRORS; OKAZAKI FRAGMENT; MISMATCH REPAIR; MUTATIONS; SEQUENCE; YEAST; DESTABILIZATION; EXONUCLEASE	DNA replication normally occurs with high fidelity, but certain "slippery" regions of DNA with tracts of mono-, di-, and trinucleotide repeats are frequently mutation hot spots. We have developed an in vitro assay to study the mechanism of dinucleotide repeat expansion. The primer-template resembles a base excision repair substrate with a single nucleotide gap centered opposite a tract of nine CA repeats; nonrepeat sequences flank the dinucleotide repeats. DNA polymerases are expected to repair the gap, but further extension is possible if the DNA polymerase can displace the downstream oligonucleotide. We report here that the wild type bacteriophage T4 DNA polymerase carries out gap and strand displacement replication and also catalyzes a dinucleotide expansion reaction. Repeat expansion was not detected for an exonuclease-deficient T4 DNA polymerase or for Escherichia coli DNA polymerase I. The dinucleotide repeat expansion reaction catalyzed by wild type T4 DNA polymerase required a downstream oligonucleotide to "stall" replication and 3' --> 5' exonuclease activity to remove the 3'-nonrepeat sequence adjacent to the repeat tract in the template strand. These results suggest that dinucleotide repeat expansion may be stimulated in vivo during DNA repair or during processing of Okazaki fragments.	Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada	University of Alberta	Reha-Krantz, LJ (corresponding author), Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada.	LREHA@gpu.srv.ualberta.ca	Reha-Krantz, Linda/A-3748-2014	Reha-Krantz, Linda/0000-0003-4497-423X; Fidalgo da Silva, Elizabeth/0000-0003-3540-9335				Beechem JM, 1998, BIOCHEMISTRY-US, V37, P10144, DOI 10.1021/bi980074b; BENZER S, 1960, GENETICS, V47, P403; BLOOM LB, 1994, BIOCHEMISTRY-US, V33, P7576, DOI 10.1021/bi00190a010; Fujii S, 1999, J MOL BIOL, V289, P835, DOI 10.1006/jmbi.1999.2802; GUPTA A, 1982, J BIOL CHEM, V257, P7689; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; HADJIMARCON MI, 1999, CONSTRUCTION IN VIVO; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; Kokoska RJ, 1998, MOL CELL BIOL, V18, P2779, DOI 10.1128/MCB.18.5.2779; KORNBERG A, 1964, P NATL ACAD SCI USA, V51, P315, DOI 10.1073/pnas.51.2.315; Kroutil LC, 1998, J MOL BIOL, V278, P135, DOI 10.1006/jmbi.1998.1676; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; Lyons-Darden T, 1999, NUCLEIC ACIDS RES, V27, P2235, DOI 10.1093/nar/27.11.2235; Maxam A M, 1980, Methods Enzymol, V65, P499; MORRISON A, 1993, EMBO J, V12, P1467, DOI 10.1002/j.1460-2075.1993.tb05790.x; Petruska J, 1998, J BIOL CHEM, V273, P5204, DOI 10.1074/jbc.273.9.5204; PRIBNOW D, 1981, J MOL BIOL, V149, P337, DOI 10.1016/0022-2836(81)90477-0; REHAKRANTZ LJ, 1993, J BIOL CHEM, V268, P27100; REHAKRANTZ LJ, 1993, J VIROL, V67, P60, DOI 10.1128/JVI.67.1.60-66.1993; SCHLOTTERER C, 1992, NUCLEIC ACIDS RES, V20, P211, DOI 10.1093/nar/20.2.211; Sinden Richard R., 1992, Current Opinion in Biotechnology, V3, P612, DOI 10.1016/0958-1669(92)90005-4; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2	29	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31528	31535		10.1074/jbc.M004594200	http://dx.doi.org/10.1074/jbc.M004594200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10924513	hybrid			2022-12-27	WOS:000089762700108
J	Hasty, AH; Shimano, H; Yahagi, N; Amemiya-Kudo, M; Perrey, S; Yoshikawa, T; Osuga, J; Okazaki, H; Tamura, Y; Iizuka, Y; Shionoiri, F; Ohashi, K; Harada, K; Gotoda, T; Nagai, R; Ishibashi, S; Yamada, N				Hasty, AH; Shimano, H; Yahagi, N; Amemiya-Kudo, M; Perrey, S; Yoshikawa, T; Osuga, J; Okazaki, H; Tamura, Y; Iizuka, Y; Shionoiri, F; Ohashi, K; Harada, K; Gotoda, T; Nagai, R; Ishibashi, S; Yamada, N			Sterol regulatory element-binding protein-1 is regulated by glucose at the transcriptional level	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; LIPOPROTEIN RECEPTOR PROMOTER; LIPOGENIC GENE-EXPRESSION; SREBP-1C MESSENGER-RNA; DIFFERENTIATION FACTOR-1; SYNTHASE PROMOTER; CULTURED-CELLS; INSULIN; LIVERS; ACTIVATION	In vivo studies suggest that sterol regulatory element-binding protein (SREBP)-1 plays a key role in the upregulation of lipogenic genes in the livers of animals that have consumed excess amounts of carbohydrates. In light of this, we sought to use an established mouse hepatocyte cell line, H2-35, to further define the mechanism by which glucose regulates nuclear SREBP-1 levels, First, we show that these cells transcribe high levels of SREBP-1c that are increased 4-fold upon differentiation from a prehepatocyte to a hepatocyte phenotype, making them an ideal cell culture model for the study of SREBP-1c induction. Second, we demonstrate that the presence of precursor and mature forms of SREBP-1 protein are positively regulated by medium glucose concentrations ranging from 5.5 to 25 mM, and are also regulated by insulin, with the amount of insulin in the fetal bovine serum being sufficient for maximal stimulation of SREBP-1 expression. Third, we show that the increase in SREBP-1 protein is due to an increase in SREBP-1 mRNA, Reporter gene analysis of the SREBP-1c promoter demonstrated a glucose-dependent induction of transcription. In contrast, expression of a fixed amount of the precursor form of SREBP-1c protein showed that glucose does not influence its cleavage. Fourth, we demonstrate that the glucose induction of SREBP could not be reproduced by fructose, xylose, or galactose nor by glucose analogs a-deoxy glucose and 3-O-methyl glucopyranose. These data provide strong evidence for the induction of SREBP-1c mRNA by glucose leading to increased mature protein in the nucleus, thus providing a potential mechanism for the up-regulation of lipogenic genes by glucose in vivo.	Univ Tsukuba, Inst Clin Med, Dept Internal Med, Tsukuba, Ibaraki 3058575, Japan; Univ Tokyo, Dept Metab Dis, Tokyo 1138655, Japan	University of Tsukuba; University of Tokyo	Shimano, H (corresponding author), Univ Tsukuba, Inst Clin Med, Dept Internal Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.		Yahagi, Naoya/D-2360-2014; Shimano, Hitoshi/AAI-5648-2020; perrey, stephane/B-7483-2008; Hasty, Alyssa/AAA-2757-2020; Shimano, Hitoshi/V-1761-2019	Yahagi, Naoya/0000-0002-1823-1865; perrey, stephane/0000-0002-8741-629X; Hasty, Alyssa/0000-0001-7302-8045; Shimano, Hitoshi/0000-0002-5562-5572				Alessi DR, 1998, BBA-MOL CELL BIOL L, V1436, P151, DOI 10.1016/S0005-2760(98)00133-7; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; DIPERSIO CM, 1991, MOL CELL BIOL, V11, P4405, DOI 10.1128/MCB.11.9.4405; DOIRON B, 1994, J BIOL CHEM, V269, P10213; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; GOODRIDGE AG, 1987, ANNU REV NUTR, V7, P157, DOI 10.1146/annurev.nu.07.070187.001105; Guan GM, 1997, J BIOL CHEM, V272, P10295; HASAN MT, 1994, SOMAT CELL MOLEC GEN, V20, P183, DOI 10.1007/BF02254759; HERBERT LF, 1996, J CLIN INVEST, V98, P930; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Kim HJ, 1999, J BIOL CHEM, V274, P25892, DOI 10.1074/jbc.274.36.25892; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kolm-Litty V, 1998, J CLIN INVEST, V101, P160, DOI 10.1172/JCI119875; Koo SH, 2000, J BIOL CHEM, V275, P5200, DOI 10.1074/jbc.275.7.5200; Kotzka J, 2000, J LIPID RES, V41, P99; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Mater MK, 1999, J BIOL CHEM, V274, P32725, DOI 10.1074/jbc.274.46.32725; McClain DA, 1996, DIABETES, V45, P1003, DOI 10.2337/diabetes.45.8.1003; Mourrieras F, 1997, BIOCHEM J, V326, P345, DOI 10.1042/bj3260345; Ntambi JM, 1996, BIOCHEM BIOPH RES CO, V220, P990, DOI 10.1006/bbrc.1996.0520; Rawson RB, 1999, J BIOL CHEM, V274, P28549, DOI 10.1074/jbc.274.40.28549; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sato R, 2000, J BIOL CHEM, V275, P12497, DOI 10.1074/jbc.275.17.12497; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Streicher R, 1996, J BIOL CHEM, V271, P7128, DOI 10.1074/jbc.271.12.7128; Tabor DE, 1998, J BIOL CHEM, V273, P22052, DOI 10.1074/jbc.273.34.22052; Takemoto M, 1999, BIOCHEM BIOPH RES CO, V258, P722, DOI 10.1006/bbrc.1999.0701; Thewke DP, 1998, J BIOL CHEM, V273, P21402, DOI 10.1074/jbc.273.33.21402; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; Wang JL, 1998, NATURE, V393, P684, DOI 10.1038/31474; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WANG XD, 1993, J BIOL CHEM, V268, P14497; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537; Yahagi N, 1999, J BIOL CHEM, V274, P35840, DOI 10.1074/jbc.274.50.35840; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; ZARET KS, 1988, P NATL ACAD SCI USA, V85, P9076, DOI 10.1073/pnas.85.23.9076; ZARET KS, 1990, MOL CELL BIOL, V10, P4582, DOI 10.1128/MCB.10.9.4582	52	121	130	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31069	31077		10.1074/jbc.M003335200	http://dx.doi.org/10.1074/jbc.M003335200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10913129	hybrid			2022-12-27	WOS:000089762700047
J	Johnson, BW; Cepero, E; Boise, LH				Johnson, BW; Cepero, E; Boise, LH			Bcl-x(L) inhibits cytochrome c release but not mitochondrial depolarization during the activation of multiple death pathways by tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; INDUCED CELL-DEATH; MEDIATED APOPTOSIS; SIGNALING COMPLEX; CYCLOSPORINE-A; INNER MEMBRANE; BCL-2; CASPASES; FAS; PROTEASE	Cells can respond differently to anti-CD95 antibody treatment. Type I cells show strong activation of caspase-8 and directly activate caspase-3, Type II cells weakly activate caspase-8 and must amplify their death signal through the mitochondria, These cells can be rescued by Bcl-x(L). Here we show that tumor necrosis factor-alpha induces both Type I and II pathways, which can be inhibited by benzyloxycarbonyl-val-Ala-Asp-fluoromethyl ketone (Z-VAD-fmk) and Bcl-x(L) in a cooperative fashion. Death induced in the presence of Z-VAD-fmk was associated with a partial inhibition of caspase-8, whereas no effects on cytochrome c release, DEVDase activity, and intranucleosomal DNA cleavage were ob served. Thus, Z-VAD-fmk is likely weakening the death-inducing signaling complex-mediated activation of caspase-8 and diverting cells to a Type TI pathway, Bcl-x(L) cooperates with Z-VAD-fmk by blocking the Type II pathway at the level of cytochrome c release. Surprisingly, although Bcl-xL was able to block cytochrome c release, it was unable to block mitochondrial depolarization, suggesting that these are separate events, This suggests that mitochondria occupy two places in apoptotic signaling, as initiators of apoptosis through the release of cytochrome c as well as a target for effector caspases.	Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33101 USA; Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33101 USA	University of Miami; University of Miami	Boise, LH (corresponding author), Univ Miami, Sch Med, Dept Microbiol & Immunol, POB 016960 R-138, Miami, FL 33101 USA.		Boise, Lawrence/AAD-2314-2019	Boise, Lawrence/0000-0001-9436-8815	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM020435] Funding Source: NIH RePORTER; NIGMS NIH HHS [F31 GM20435] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; Johnson BW, 1999, J BIOL CHEM, V274, P18552, DOI 10.1074/jbc.274.26.18552; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Mesner PW, 1999, J BIOL CHEM, V274, P22635, DOI 10.1074/jbc.274.32.22635; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XH, 1998, J BIOL CHEM, V273, P34278, DOI 10.1074/jbc.273.51.34278; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	50	51	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31546	31553		10.1074/jbc.M001363200	http://dx.doi.org/10.1074/jbc.M001363200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10913120	hybrid			2022-12-27	WOS:000089762700110
J	Li, XG; Multon, MC; Henin, Y; Schweighoffer, F; Venot, C; Josef, J; Zhou, CH; LaVecchio, J; Stuckert, P; Raab, M; Mhashilkar, A; Tocque, B; Marasco, WA				Li, XG; Multon, MC; Henin, Y; Schweighoffer, F; Venot, C; Josef, J; Zhou, CH; LaVecchio, J; Stuckert, P; Raab, M; Mhashilkar, A; Tocque, B; Marasco, WA			Grb3-3 is up-regulated in HIV-1-infected T-cells and can potentiate cell activation through NFATc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; TRANSCRIPTION FACTOR NFAT1; NF-KAPPA-B; SIGNAL-TRANSDUCTION; TAT PROTEIN; HIV-1 INFECTION; CYCLOSPORINE-A; CD28 RECEPTOR; KINASE; PATHWAY	The MAPK pathway is required for T-cell activation; however, its role in modulating T-cell function following human immunodeficiency virus type 1 (HIV-1) infection is poorly understood. In this report, we investigated whether Grb3-3, an isoform of the Grb2 (growth factor receptor-bound protein-2) adaptor molecule that is associated with the MAPK pathway, could be involved. We found that Grb3-3, but not its isoform Grb2, is markedly up-regulated in CD4(+) peripheral blood mononuclear cells derived from either in vitro HIV-1-infected cultures or HIV-1-infected human subjects. Analysis of HIV-1 gene products indicated that Tat and Nef, both of which have been implicated in modulating T-cell function, can independently induce expression of Grb3-3. By using NFAT/AP-1, AP-1, or NFAT reporter assays, we found that Grb3-3 can potentiate NFAT (but not AP-1) promoter activity in Jurkat T-cells upon engagement of the T-cell receptor and CD28 co-receptor. In addition, potentiation of NFAT by Grb3-3 is substantially suppressed by MEKK1, a kinase that may play an important role in retaining NFAT in the cytoplasm, and by cyclosporin A. Finally, we also found that Grb3-3 potentiates HIV-1 long terminal (LTR) repeat promoter activity following T-cell receptor stimulation, an effect that can be largely suppressed by cyclosporin A. Taken together, this study indicates that Grb3-3 is a cellular factor that can be up-regulated by HIV-1. In addition, Grb3-3 can also function as a positive factor for T-cell activation and, in doing so, may aid in establishing an intracellular environment that can optimally support HIV-1 replication.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA; Aventis Pharma Inc, F-94403 Vitry Sur Seine, France; Exonhit Therapeut, F-75013 Paris, France	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Sanofi-Aventis; Sanofi France	Marasco, WA (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St,JFB 824, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [P30CA006516] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041954, R01AI028785] Funding Source: NIH RePORTER; NCI NIH HHS [CA06516] Funding Source: Medline; NIAID NIH HHS [AI28785, AI41954] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Biggs TE, 1999, J MOL BIOL, V290, P21, DOI 10.1006/jmbi.1999.2849; Briant L, 1998, J IMMUNOL, V160, P1875; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; Folgueira L, 1996, J VIROL, V70, P2332, DOI 10.1128/JVI.70.4.2332-2338.1996; FOLKS T, 1986, J IMMUNOL, V136, P4049; FRASER JD, 1993, IMMUNOL TODAY, V14, P357, DOI 10.1016/0167-5699(93)90236-E; Ganju RK, 1998, J VIROL, V72, P6131, DOI 10.1128/JVI.72.7.6131-6137.1998; Greenway A, 1996, J VIROL, V70, P6701, DOI 10.1128/JVI.70.10.6701-6708.1996; HOLSINGER LJ, 1995, P NATL ACAD SCI USA, V92, P9810, DOI 10.1073/pnas.92.21.9810; Iafrate A.J., 1997, EMBO J, V16, P673; Jacque JM, 1998, EMBO J, V17, P2607, DOI 10.1093/emboj/17.9.2607; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; Kinoshita S, 1998, CELL, V95, P595, DOI 10.1016/S0092-8674(00)81630-X; Kumar A, 1998, J IMMUNOL, V161, P776; Li CJ, 1997, P NATL ACAD SCI USA, V94, P8116, DOI 10.1073/pnas.94.15.8116; Li XG, 1997, J VIROL, V71, P6003, DOI 10.1128/JVI.71.8.6003-6010.1997; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Luo W, 1997, J VIROL, V71, P9531, DOI 10.1128/JVI.71.12.9531-9537.1997; Macian F, 1999, MOL CELL BIOL, V19, P3645, DOI 10.1128/mcb.19.5.3645; Manninen A, 2000, J BIOL CHEM, V275, P16513, DOI 10.1074/jbc.M910032199; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Ott M, 1997, SCIENCE, V275, P1481, DOI 10.1126/science.275.5305.1481; PANTALEO G, 1995, ANNU REV IMMUNOL, V13, P487, DOI 10.1146/annurev.immunol.13.1.487; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; Pomerance M, 1998, J BIOL CHEM, V273, P24301, DOI 10.1074/jbc.273.38.24301; Popik W, 1998, J VIROL, V72, P6406, DOI 10.1128/JVI.72.8.6406-6413.1998; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RAO A, 1995, J LEUKOCYTE BIOL, V57, P536, DOI 10.1002/jlb.57.4.536; RAO A, 1991, CRIT REV IMMUNOL, V10, P495; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; Schrager JA, 1999, P NATL ACAD SCI USA, V96, P8167, DOI 10.1073/pnas.96.14.8167; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; SPINA CA, 1995, J VIROL, V69, P2997; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; VACCA A, 1994, BIOCHEM BIOPH RES CO, V205, P467, DOI 10.1006/bbrc.1994.2689; Wang JK, 2000, P NATL ACAD SCI USA, V97, P394, DOI 10.1073/pnas.97.1.394; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Yang XY, 1999, J BIOL CHEM, V274, P27981, DOI 10.1074/jbc.274.39.27981; ZACK JA, 1988, SCIENCE, V240, P1026, DOI 10.1126/science.2835813; ZAGURY D, 1986, SCIENCE, V231, P850, DOI 10.1126/science.2418502; Zauli G, 1996, J IMMUNOL, V157, P2216; ZHANG W, 1998, IMMUNITY, V9, P1; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	57	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30925	30933		10.1074/jbc.M005535200	http://dx.doi.org/10.1074/jbc.M005535200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906142	hybrid			2022-12-27	WOS:000089762700029
J	Hill, WG; Zeidel, ML				Hill, WG; Zeidel, ML			Reconstituting the barrier properties of a water-tight epithelial membrane by design of leaflet-specific liposomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN URINARY-BLADDER; CANINE KIDNEY-CELLS; APICAL MEMBRANE; NONELECTROLYTE PERMEABILITIES; BIOLOGICAL-MEMBRANES; PROTON; ASYMMETRY; VESICLES; CHOLESTEROL; CONDUCTANCE	To define aspects of lipid composition and bilayer asymmetry critical to barrier function, we examined the permeabilities of liposomes that model individual leaflets of the apical membrane of a barrier epithelium, Madin-Darby canine kidney type 1 cells. Using published Lipid compositions we prepared exofacial liposomes containing phosphatidylcholine, sphingomyelin, glycosphingolipids, and cholesterol; and cytoplasmic liposomes containing phosphatidylethanolamine, phosphatidylserine, and cholesterol. The osmotic permeability of cytoplasmic liposomes to water (P-f), solutes, and NH3 was 18-90-fold higher than for the exofacial liposomes (P-f(ex) = 2.4 +/- 0.4 x 10(-4) cm/s, P-f(cy) = 4.4 +/- 0.3 x 10(-3) cm/s; P-glycerol(ex) = 2.5 +/- 0.3 x 10(-8) cm/s, P-glycerol(cy) = 2.2 +/- 0.02 x 10(-6) cm/s; P-NH3(ex) = 0.13 +/- 0.4 x 10(-4) cm/s, P-NH3(cy) = 7.9 +/- 1.0 x 10(-3) cm/s). By contrast, the apparent proton permeability of exofacial liposomes was 4-fold higher than cytoplasmic liposomes (PH+(ex) = 1.1 +/- 0.1 x 10(-2) cm/s, PH+(cy) = 2.7 +/- 0.6 x 10(-3) cm/s). By adding single leaflet permeabilities, we calculated a theoretical P-f for a Madin-Darby canine kidney apical membrane of 4.6 x 10(-4) cm/s, which compares favorably with experimentally determined values. In exofacial liposomes lacking glycosphingolipids or sphingomyelin, permeabilities were 2-7-fold higher, indicating that both species play a role in barrier function. Removal of cholesterol resulted in 40-280-fold increases in permeability. Fire conclude: 1) that we have reconstituted the biophysical properties of a barrier membrane, 2) that the barrier resides in the exofacial leaflet, 3) that both sphingomyelin and glycosphingolipids play a role in reducing membrane permeability but that there is an ab solute requirement for cholesterol to mediate this effect, 4) that these results further validate the hypothesis that each leaflet offers an independent resistance to permeation, and 5) that proton permeation was enhanced by sphingolipid/cholesterol interactions.	Univ Pittsburgh, Renal Electrolyte Div, Lab Epithelial Cell Biol, Dept Med, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zeidel, ML (corresponding author), Univ Pittsburgh, Renal Electrolyte Div, Lab Epithelial Cell Biol, Dept Med, 1218 Scaifie Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	zeidel@msx.dept-med.pitt.edu	Hill, Warren/AAM-1917-2020	Hill, Warren/0000-0002-2772-7264	NIDDK NIH HHS [DK43955] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043955] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARSUKOV LI, 1986, BIOCHIM BIOPHYS ACTA, V862, P87, DOI 10.1016/0005-2736(86)90472-4; BITTMAN R, 1994, BIOCHEMISTRY-US, V33, P11776, DOI 10.1021/bi00205a013; Brookes PS, 1997, BBA-BIOMEMBRANES, V1330, P157, DOI 10.1016/S0005-2736(97)00160-0; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brown RE, 1998, J CELL SCI, V111, P1; CHANG A, 1994, AM J PHYSIOL-CELL PH, V267, pC1483, DOI 10.1152/ajpcell.1994.267.5.C1483; DEAMER DW, 1983, P NATL ACAD SCI-BIOL, V80, P165, DOI 10.1073/pnas.80.1.165; DEAMER DW, 1995, PERMEABILITY STABILI, P161; Farinas J, 1996, BIOPHYS J, V71, P3511, DOI 10.1016/S0006-3495(96)79546-2; GROSSMAN EB, 1992, AM J PHYSIOL, V262, pC1109, DOI 10.1152/ajpcell.1992.262.5.C1109; GUTKNECHT J, 1987, J BIOENERG BIOMEMBR, V19, P427; GUTKNECHT J, 1987, P NATL ACAD SCI USA, V84, P6443, DOI 10.1073/pnas.84.18.6443; HANSSON GC, 1986, EMBO J, V5, P483, DOI 10.1002/j.1460-2075.1986.tb04237.x; Hill WG, 1999, J GEN PHYSIOL, V114, P405, DOI 10.1085/jgp.114.3.405; LANDE MB, 1994, AM J PHYSIOL, V267, pC367, DOI 10.1152/ajpcell.1994.267.2.C367; LANDE MB, 1995, J GEN PHYSIOL, V106, P67, DOI 10.1085/jgp.106.1.67; Lavelle JP, 1997, AM J PHYSIOL-RENAL, V273, pF67, DOI 10.1152/ajprenal.1997.273.1.F67; Lavelle JP, 1998, AM J PHYSIOL-RENAL, V274, pF205, DOI 10.1152/ajprenal.1998.274.1.F205; Lavelle JP, 2000, AM J PHYSIOL-RENAL, V278, pF540, DOI 10.1152/ajprenal.2000.278.4.F540; LEWIS SA, 1977, AM J PHYSIOL, V232, pF187, DOI 10.1152/ajprenal.1977.232.3.F187; LEWIS SA, 1984, J MEMBRANE BIOL, V82, P123, DOI 10.1007/BF01868937; LEWIS SA, 1990, METHOD ENZYMOL, V192, P632; LEWIS SA, 1977, J GEN PHYSIOL, V70, P427, DOI 10.1085/jgp.70.4.427; LICHTENBERGER LM, 1987, CLIN INVEST MED, V10, P181; NAGLE JF, 1978, P NATL ACAD SCI USA, V75, P298, DOI 10.1073/pnas.75.1.298; Negrete HO, 1996, J BIOL CHEM, V271, P11627, DOI 10.1074/jbc.271.20.11627; Negrete HO, 1996, AM J PHYSIOL-RENAL, V271, pF886, DOI 10.1152/ajprenal.1996.271.4.F886; NICHOLS JW, 1980, P NATL ACAD SCI-BIOL, V77, P2038, DOI 10.1073/pnas.77.4.2038; NOZAKI Y, 1981, P NATL ACAD SCI-BIOL, V78, P4324, DOI 10.1073/pnas.78.7.4324; OPDENKAMP JAF, 1979, ANNU REV BIOCHEM, V48, P47, DOI 10.1146/annurev.bi.48.070179.000403; Prasad GVR, 1998, J BIOL CHEM, V273, P33123, DOI 10.1074/jbc.273.50.33123; PRIVER NA, 1993, BIOCHEMISTRY-US, V32, P2459, DOI 10.1021/bi00061a002; Rivers R, 1998, AM J PHYSIOL-RENAL, V274, pF453, DOI 10.1152/ajprenal.1998.274.3.F453; Rivers RL, 1996, AM J PHYSIOL-CELL PH, V271, pC226, DOI 10.1152/ajpcell.1996.271.1.C226; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; Smaby JM, 1996, BIOCHEMISTRY-US, V35, P5696, DOI 10.1021/bi953057k; Timbs MM, 1996, J MEMBRANE BIOL, V153, P1, DOI 10.1007/s002329900104; VAN GENDEREN I, 1995, J CELL BIOL, V131, P645, DOI 10.1083/jcb.131.3.645; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; VAN MEER G, 1986, NATURE, V322, P639, DOI 10.1038/322639a0; VAN MEER G, 1986, EMBO J, V5, P1455, DOI 10.1002/j.1460-2075.1986.tb04382.x; VENIEN C, 1988, BIOCHIM BIOPHYS ACTA, V942, P159, DOI 10.1016/0005-2736(88)90285-4; Zeidel ML, 1996, AM J PHYSIOL-RENAL, V271, pF243, DOI 10.1152/ajprenal.1996.271.2.F243	45	75	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30176	30185		10.1074/jbc.M003494200	http://dx.doi.org/10.1074/jbc.M003494200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10903312	hybrid			2022-12-27	WOS:000089577900038
J	Shangary, S; Brown, KD; Adamson, AW; Edmonson, S; Ng, B; Pandita, TK; Yalowich, J; Taccioli, GE; Baskaran, R				Shangary, S; Brown, KD; Adamson, AW; Edmonson, S; Ng, B; Pandita, TK; Yalowich, J; Taccioli, GE; Baskaran, R			Regulation of DNA-dependent protein kinase activity by ionizing radiation-activated Abl kinase is an ATM-dependent process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ABL; TYROSINE KINASE; CELL-CYCLE; CATALYTIC SUBUNIT; NUCLEAR-PROTEIN; GENE-PRODUCT; DAMAGE; BINDING; MUTANT; STRESS	Ionizing radiation (IR) treatment results in activation of the nonreceptor tyrosine kinase c-Abl because of phosphorylation by ATM. In vitro evidence indicates that DNA-dependent protein kinase (DNA-PK) can also phosphorylate and thus potentially activate Abl kinase activity in response to IR exposure. To unravel the role of ATM and DNA-PK in the activation of Abl, we assayed Abl, ATM, and DNA-PK activity in ATM- and DNA-PKcs-deficient cells after irradiation. Our results show that despite the presence of higher than normal levels of DNA-PK kinase activity, c-Abl fails to become activated after IR exposure in ATM-deficient cells. Conversely, normal activation of both ATM and c-Abl occurs in DNA-PKcs- deficient cells, indicating that ATM but not DNA-PK is required for activation of Abl in response to IR treatment. Moreover, activation of Abl kinase activity by IR correlates well with activation of ATM activity in all phases of the cell cycle. These results indicate that ATM is primarily responsible for activation of Abl in response to IR exposure in a cell cycle-independent fashion. Examination of DNA-PK activity in response to IR treatment in Abl-deficient cells expressing mutant forms of Abl or in normal cells exposed to an inhibitor of Abl suggests an in vivo role for Abl in the down-regulation of DNA-PK activity. Collectively, these results suggest a convergence of the ATM and DNA-PK pathways in the cellular response to IR through c-Abl kinase.	Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Med Ctr, Dept Pharmacol, Pittsburgh, PA 15261 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA; Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA; Columbia Univ, Ctr Radiol Res, New York, NY 10032 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Boston University; Columbia University	Baskaran, R (corresponding author), Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, E1205 Biomed Sci Tower, Pittsburgh, PA 15261 USA.		Pandita, Tej K/AAM-9188-2020	Yalowich, Jack/0000-0001-5414-573X	NATIONAL CANCER INSTITUTE [R01CA076409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034746] Funding Source: NIH RePORTER; NCI NIH HHS [CA76409] Funding Source: Medline; NINDS NIH HHS [NS 34746] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baskaran R, 1996, MOL CELL BIOL, V16, P3361; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Kumar S, 1998, J BIOL CHEM, V273, P25654, DOI 10.1074/jbc.273.40.25654; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Muller C, 1999, BIOCHIMIE, V81, P117, DOI 10.1016/S0300-9084(99)80044-3; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PANDITA TK, 1992, RADIAT RES, V130, P94, DOI 10.2307/3578485; Pandita TK, 2000, ONCOGENE, V19, P1386, DOI 10.1038/sj.onc.1203444; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; WANG JYJ, 1994, TRENDS BIOCHEM SCI, V19, P373, DOI 10.1016/0968-0004(94)90114-7; Wang JYJ, 1998, CURR OPIN CELL BIOL, V10, P240, DOI 10.1016/S0955-0674(98)80146-4; Watters D, 1999, IMMUNOL CELL BIOL, V77, P263, DOI 10.1046/j.1440-1711.1999.00824.x; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456	29	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30163	30168		10.1074/jbc.M004302200	http://dx.doi.org/10.1074/jbc.M004302200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10906134	hybrid			2022-12-27	WOS:000089577900036
J	Smith, AJ; van Helvoort, A; van Meer, G; Szabo, K; Welker, E; Szakacs, G; Varadi, A; Sarkadi, B; Borst, P				Smith, AJ; van Helvoort, A; van Meer, G; Szabo, K; Welker, E; Szakacs, G; Varadi, A; Sarkadi, B; Borst, P			MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL INTRAHEPATIC CHOLESTASIS; RESISTANCE-ASSOCIATED PROTEIN; HUMAN MULTIDRUG TRANSPORTER; CANINE KIDNEY-CELLS; PLASMA-MEMBRANE; MONOCLONAL-ANTIBODIES; HOMOZYGOUS DISRUPTION; CYCLOSPORINE-A; INSECT CELLS; GENE FAMILY	The human MDR3 gene is a member of the multidrug resistance (MDR) gene family. The MDR3 P-glycoprotein is a transmembrane protein that translocates phosphatidylcholine. The MDR1 P-glycoprotein related transports cytotoxic drugs. Its overexpression can make cells resistant to a variety of drugs. Attempts to show that MDR3 P-glycoprotein can cause MDR have been unsuccessful thus far. Here, we report an increased directional transport of several MDR1 P-glycoprotein substrates, such as digoxin, paclitaxel, and vinblastine, through polarized monolayers of MDR3-transfected cells. Transport of other good MDR1 P-glycoprotein substrates, including cyclosporin A and dexamethasone, was not detectably increased. MDR3 P-glycoprotein-dependent transport of a short-chain phosphatidylcholine analog and drugs was inhibited by several MDR reversal agents and other drugs, indicating an interaction between these compounds and MDR3 P-gp, Insect cell membranes from Sf9 cells overexpressing MDR3 showed specific MgATP binding and a vanadate-dependent, N-ethylmaleimide-sensitive nucleotide trapping activity, visualized by covalent binding with [alpha-P-32]8 azido-ATP. Nucleotide trapping was (nearly) abolished by paclitaxel, vinblastine, and the MDR reversal agents verapamil, cyclosporin A, and PSC 833. We conclude that MDR3 P-glycoprotein can bind and transport a subset of MDR1 P-glycoprotein substrates. The rate of MDR3 P-wglycoprotein-mediated transport is low for most drugs, explaining why this protein is not detectably involved in multidrug resistance. It remains possible, however, that drug binding to MDR3 P-glycoprotein could adversely affect phospholipid or toxin secretion under conditions of stress (e.g. in pregnant heterozygotes with one MDR3 null allele).	Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Cell Biol & Histol Lab, NL-1105 AZ Amsterdam, Netherlands; Hungarian Acad Sci, Membrane Res Grp, Natl Inst Haematol & Immunol, H-1113 Budapest, Hungary; Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1113 Budapest, Hungary; Univ Utrecht, Fac Med, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, NL-3584 CX Utrecht, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; University of Amsterdam; Academic Medical Center Amsterdam; Hungarian Academy of Sciences; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Utrecht University; Utrecht University	Borst, P (corresponding author), Netherlands Canc Inst, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Welker, Ervin/AAC-6493-2022; van Meer, Gerrit/AAH-1560-2021; Smith, Alexander/A-5142-2009; Szakacs, Gergely/A-2580-2009; van Helvoort, Ardy/U-7549-2019; Sarkadi, Balazs/I-5024-2013; Varadi, Andras/A-2055-2012	Szakacs, Gergely/0000-0002-9311-7827; van Helvoort, Ardy/0000-0002-3585-0676; van Meer, Gerrit/0000-0002-5976-6436				BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BUSCHMAN E, 1994, CANCER RES, V54, P4892; BUSCHMAN E, 1991, MOL CELL BIOL, V11, P595, DOI 10.1128/MCB.11.2.595; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIN KV, 1992, J CELL PHYSIOL, V152, P87, DOI 10.1002/jcp.1041520112; Crawford AR, 1997, J CLIN INVEST, V100, P2562, DOI 10.1172/JCI119799; De Vree JML, 1998, P NATL ACAD SCI USA, V95, P282, DOI 10.1073/pnas.95.1.282; Evers R, 1996, J CLIN INVEST, V97, P1211, DOI 10.1172/JCI118535; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; Germann UA, 1996, EUR J CANCER, V32A, P927, DOI 10.1016/0959-8049(96)00057-3; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; Groen AK, 1996, J THEOR BIOL, V182, P427, DOI 10.1006/jtbi.1996.0183; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; HERWEIJER H, 1990, JNCI-J NATL CANCER I, V82, P1133, DOI 10.1093/jnci/82.13.1133; Jacquemin E, 1999, LANCET, V353, P210, DOI 10.1016/S0140-6736(05)77221-4; Kino K, 1996, FEBS LETT, V399, P29, DOI 10.1016/S0014-5793(96)01265-3; LINCKE CR, 1991, J BIOL CHEM, V266, P5303; MAUAD TH, 1994, AM J PATHOL, V145, P1237; Mayer U, 1997, J CLIN INVEST, V100, P2430, DOI 10.1172/JCI119784; NOOTER K, 1990, INT J CANCER, V45, P626, DOI 10.1002/ijc.2910450409; Raggers RJ, 1999, J CELL SCI, V112, P415; RAYMOND M, 1990, MOL CELL BIOL, V10, P1642, DOI 10.1128/MCB.10.4.1642; RUETZ S, 1994, TRENDS PHARMACOL SCI, V15, P260, DOI 10.1016/0165-6147(94)90322-0; RUETZ S, 1995, J BIOL CHEM, V270, P25388, DOI 10.1074/jbc.270.43.25388; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Scheffer G. L., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P667; SCHINKEL AH, 1993, J BIOL CHEM, V268, P7474; Schinkel AH, 1997, P NATL ACAD SCI USA, V94, P4028, DOI 10.1073/pnas.94.8.4028; SCHINKEL AH, 1991, CANCER RES, V51, P2628; SCHINKEL AH, 1995, J CLIN INVEST, V96, P1698, DOI 10.1172/JCI118214; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; Smith AJ, 1998, J NATL CANCER I, V90, P1161, DOI 10.1093/jnci/90.15.1161; SMITH AJ, 1994, FEBS LETT, V354, P263, DOI 10.1016/0014-5793(94)01135-4; Smith AJ, 1998, HEPATOLOGY, V28, P530, DOI 10.1002/hep.510280234; Szabo K, 1998, J BIOL CHEM, V273, P10132, DOI 10.1074/jbc.273.17.10132; TANAKA S, 1990, BIOCHEM BIOPH RES CO, V166, P180, DOI 10.1016/0006-291X(90)91928-L; TANIGAWARA Y, 1992, J PHARMACOL EXP THER, V263, P840; UEDA K, 1992, J BIOL CHEM, V267, P24248; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; van der Bijl P, 1996, J CELL BIOL, V132, P813, DOI 10.1083/jcb.132.5.813; VAN GENDEREN I, 1995, J CELL BIOL, V131, P645, DOI 10.1083/jcb.131.3.645; VAN HELVOORT A, 1994, J BIOL CHEM, V269, P1763; VANDERBLIEK AM, 1987, EMBO J, V6, P3325, DOI 10.1002/j.1460-2075.1987.tb02653.x; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; VANDERBLIEK AM, 1988, CANCER RES, V48, P5927; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; ZAMAN GJR, 1996, MULTIDRUG RESISTANCE, P95	51	209	221	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23530	23539		10.1074/jbc.M909002199	http://dx.doi.org/10.1074/jbc.M909002199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10918072	hybrid, Green Published			2022-12-27	WOS:000088564200019
J	Horlitz, M; Klaff, P				Horlitz, M; Klaff, P			Gene-specific trans-regulatory functions of magnesium for chloroplast mRNA stability in higher plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' UNTRANSLATED REGION; IN-VIVO ANALYSIS; TRANSCRIPT LEVELS; BINDING-PROTEIN; ANTICODON LOOP; PSAA-PSAB; PSBA; EXPRESSION; TRANSLATION; LIGHT	In higher plant chloroplasts the accumulation of plastid-encoded mRNAs during leaf maturation is regulated via gene-specific mRNA stabilization. The half-lives of chloroplast RNAs are specifically affected by magnesium ions. psbA mRNA (D1 protein of photosystem II), rbcL mRNA (large subunit of ribulose-1,5-bisphosphate carboxylase), 16 S rRNA, and tRNA(His) gain stability at specific magnesium concentrations in an in vitro degradation system from spinach chloroplasts. Each RNA exhibits a typical magnesium concentration-dependent stabilization profile. It shows a cooperative response of the stability-regulated psbA mRNA and a saturation curve for the other RNAs. The concentration of free Mg2+ rises during chloroplast development within a range sufficient to mediate gene-specific mRNA stabilization in vivo as observed in vitro. We suggest that magnesium ions are a trans-acting factor mediating differential mRNA stability.	Univ Dusseldorf, Inst Phys Biol, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Klaff, P (corresponding author), Univ Dusseldorf, Inst Phys Biol, Univ Str 1, D-40225 Dusseldorf, Germany.	klaff@biophys.uni-duesseldorf.de						ADAMS CC, 1990, NUCLEIC ACIDS RES, V18, P6003, DOI 10.1093/nar/18.20.6003; Alexander C, 1998, NUCLEIC ACIDS RES, V26, P2265, DOI 10.1093/nar/26.10.2265; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; ATWATER JA, 1990, ANNU REV GENET, V24, P519; Barber J., 1976, Topics in photosynthesis - Volume 1. The intact chloroplast., P89; BARKAN A, 1993, PLANT CELL, V5, P389, DOI 10.1105/tpc.5.4.389; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BUJALOWSKI W, 1986, BIOCHEMISTRY-US, V25, P6372, DOI 10.1021/bi00369a005; Cantor C.R., 1980, BIOPHYS CHEM; CHEN HC, 1991, MOL CELL BIOL, V11, P4380, DOI 10.1128/MCB.11.9.4380; CHEN QY, 1995, MOL CELL BIOL, V15, P2010; Drager RG, 1996, RNA, V2, P652; Eibl C, 1999, PLANT J, V19, P333, DOI 10.1046/j.1365-313X.1999.00543.x; Fargo DC, 1999, MOL CELL BIOL, V19, P6980; GRUISSEM W, 1986, METHOD ENZYMOL, V118, P253; GRUISSEM W, 1993, CRIT REV PLANT SCI, V12, P19, DOI 10.1080/07352689309382355; Gruissem W., 1993, CONTROL MRNA STABILI, P329; Grunberg-Manago M, 1999, ANNU REV GENET, V33, P193, DOI 10.1146/annurev.genet.33.1.193; Hayes R, 1999, TRENDS BIOCHEM SCI, V24, P199, DOI 10.1016/S0968-0004(99)01388-2; Hayes R, 1996, EMBO J, V15, P1132, DOI 10.1002/j.1460-2075.1996.tb00451.x; HELDT HW, 1973, BIOCHIM BIOPHYS ACTA, V314, P224, DOI 10.1016/0005-2728(73)90137-0; Higgs DC, 1999, MOL CELL BIOL, V19, P8479; JOHNSON CH, 1995, SCIENCE, V269, P1863, DOI 10.1126/science.7569925; KIM J, 1994, J BIOL CHEM, V269, P17918; Klaff P, 1997, RNA, V3, P1468; KLAFF P, 1991, PLANT CELL, V3, P517, DOI 10.1105/tpc.3.5.517; Klaff P, 1995, NUCLEIC ACIDS RES, V23, P4885, DOI 10.1093/nar/23.23.4885; Klaff P, 1995, PHOTOSYNTH RES, V46, P235, DOI 10.1007/BF00020436; KLEIN RR, 1987, J BIOL CHEM, V262, P4341; KLEIN RR, 1988, J CELL BIOL, V106, P289, DOI 10.1083/jcb.106.2.289; KUCHKA MR, 1989, CELL, V58, P869, DOI 10.1016/0092-8674(89)90939-2; LABUDA D, 1982, BIOCHEMISTRY-US, V21, P49, DOI 10.1021/bi00530a009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lilley DMJ, 1999, CURR OPIN STRUC BIOL, V9, P330, DOI 10.1016/S0959-440X(99)80044-X; Lisitsky I, 1997, PLANT J, V12, P1173, DOI 10.1046/j.1365-313X.1997.12051173.x; Lisitsky I, 1996, P NATL ACAD SCI USA, V93, P13398, DOI 10.1073/pnas.93.23.13398; MAYFIELD SP, 1994, J CELL BIOL, V127, P1537, DOI 10.1083/jcb.127.6.1537; Menger M, 1996, BIOCHEMISTRY-US, V35, P14710, DOI 10.1021/bi960440w; Misra VK, 1998, BIOPOLYMERS, V48, P113, DOI 10.1002/(SICI)1097-0282(1998)48:2<113::AID-BIP3>3.0.CO;2-Y; NICKELSEN J, 1994, EMBO J, V13, P3182, DOI 10.1002/j.1460-2075.1994.tb06617.x; Nickelsen J, 1999, PLANT CELL, V11, P957, DOI 10.1105/tpc.11.5.957; Noah JW, 1998, BIOCHEMISTRY-US, V37, P15442, DOI 10.1021/bi981148m; ROCHAIX JD, 1992, ANNU REV CELL BIOL, V8, P1, DOI 10.1146/annurev.cb.08.110192.000245; SAKAMOTO W, 1993, P NATL ACAD SCI USA, V90, P497, DOI 10.1073/pnas.90.2.497; SALVADOR ML, 1993, P NATL ACAD SCI USA, V90, P1556, DOI 10.1073/pnas.90.4.1556; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schuster G, 1999, PLANT PHYSIOL, V120, P937, DOI 10.1104/pp.120.4.937; SCHUSTER G, 1991, EMBO J, V10, P1493, DOI 10.1002/j.1460-2075.1991.tb07669.x; Scott WG, 1996, TRENDS BIOCHEM SCI, V21, P220; Shiina T, 1998, PLANT CELL, V10, P1713, DOI 10.1105/tpc.10.10.1713; STAUB JM, 1994, PLANT J, V6, P547, DOI 10.1046/j.1365-313X.1994.6040547.x; STERN DB, 1989, PLANT MOL BIOL, V13, P615, DOI 10.1007/BF00016017; STERN DB, 1991, PLANT CELL, V3, P285; Yang JJ, 1996, PLANT CELL, V8, P1409, DOI 10.1105/tpc.8.8.1409; ZHANG W, 1997, MAGNES B, V17, P125; ZURAWSKI G, 1982, P NATL ACAD SCI-BIOL, V79, P7699, DOI 10.1073/pnas.79.24.7699; ZURAWSKI G, 1981, NUCLEIC ACIDS RES, V9, P3251, DOI 10.1093/nar/9.14.3251	57	25	36	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35638	35645		10.1074/jbc.M005622200	http://dx.doi.org/10.1074/jbc.M005622200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10918066	hybrid			2022-12-27	WOS:000165422800107
J	Kim, HY; Akbar, M; Lau, A; Edsall, L				Kim, HY; Akbar, M; Lau, A; Edsall, L			Inhibition of neuronal apoptosis by docosahexaenoic acid (22 : 6n-3) - Role of phosphatidylserine in antiapoptotic effect	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; ARACHIDONIC-ACID; CELL-DEATH; RETINAL PHOTORECEPTORS; RAF-1; SURVIVAL; PHOSPHORYLATION; SERINE; ACTIVATION; BINDING	Enrichment of Neuro 2A cells with docosahexaenoic acid (22:6n-3) decreased apoptotic cell death induced by serum starvation as evidenced by the reduced DNA fragmentation and caspase-3 activity. The protective effect of 22:6n-3 became evident only after at least 24 h of enrichment before serum starvation and was potentiated as a function of the enrichment period, During enrichment 22:6n-3 incorporated into phosphatidylserine (PS) steadily, resulting in a significant increase in the total PS content. Similar treatment with oleic acid (18:1n-9) neither altered PS content nor resulted in protective effect. Hindering PS accumulation by enriching cells in a serine-free medium diminished the protective effect of 22:6n-3. Membrane translocation of Raf-l was significantly enhanced by 22:6n-3 enrichment in Neuro 2A cells. Consistently, in vitro biomolecular interaction between PS/phosphatidylethanolamine /phosphatidylcholine liposomes, and Raf-l increased in a PS concentration-dependent manner. Collectively, enrichment of neuronal cells with 22:6n-3 increases the PS content and Raf-l translocation, down-regulates caspase-3 activity, and prevents apoptotic cell death. Both the antiapoptotic effect of 22:6n-3 and Raf-l translocation are sensitive to 22:6n-3 enrichment-induced PS accumulation, strongly suggesting that the protective effect of 22:6n-3 may be mediated at least in part through the promoted accumulation of PS in neuronal membranes.	NIAAA, LMBB, Sect Mass Spectrometry, NIH, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Kim, HY (corresponding author), NIAAA, LMBB, Sect Mass Spectrometry, NIH, 12420 Parklawn Dr, Rockville, MD 20852 USA.	hykim@nih.gov						Atsumi G, 2000, J BIOL CHEM, V275, P18248, DOI 10.1074/jbc.M000271200; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; Birch EE, 1998, PEDIATR RES, V44, P201, DOI 10.1203/00006450-199808000-00011; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRIGHAMBURKE M, 1992, ANAL BIOCHEM, V205, P125, DOI 10.1016/0003-2697(92)90588-X; Carrie I, 1999, NEUROSCI LETT, V266, P69, DOI 10.1016/S0304-3940(99)00265-7; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DUKE RC, 1992, CURRENT PROTOCOLS S, V3; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; Gamoh S, 1999, NEUROSCIENCE, V93, P237, DOI 10.1016/S0306-4522(99)00107-4; Garcia MC, 1998, J NEUROCHEM, V70, P24; Garcia MC, 1997, BRAIN RES, V768, P43, DOI 10.1016/S0006-8993(97)00583-0; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Goswami R, 2000, J NEUROSCI RES, V60, P141, DOI 10.1002/(SICI)1097-4547(20000415)60:2<141::AID-JNR2>3.0.CO;2-5; GRABER R, 1994, J LIPID MEDIAT CELL, V9, P91; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hamilton J, 2000, LIPIDS, V35, P863, DOI 10.1007/S11745-000-0595-x; HITZEMANN R, 1981, NEUROCHEM RES, V6, P935, DOI 10.1007/BF00965025; Hoffman DR, 1998, WORLD REV NUTR DIET, V83, P52; HOMMA S, 1994, J COMP NEUROL, V345, P377, DOI 10.1002/cne.903450305; Hoyle PE, 2000, LEUKEMIA, V14, P642, DOI 10.1038/sj.leu.2401720; KANFER JN, 1980, CAN J BIOCHEM CELL B, V58, P1370, DOI 10.1139/o80-186; Kaplan DR, 1998, PROG BRAIN RES, V117, P35; KIM HY, 1994, ANAL CHEM, V66, P3977, DOI 10.1021/ac00094a020; Kim HY, 1999, LIPIDS, V34, pS249, DOI 10.1007/BF02562308; Kim HY, 1999, ADV EXP MED BIOL, V447, P75; Kim HY, 2000, LIPIDS, V35, P187, DOI 10.1007/BF02664769; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kishida E, 1998, BBA-LIPID LIPID MET, V1391, P401, DOI 10.1016/S0005-2760(98)00015-0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Majewski M, 1999, CANCER RES, V59, P2815; MARTINEZ M, 1992, BRAIN RES, V583, P171, DOI 10.1016/S0006-8993(10)80021-6; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; Mitoma J, 1998, J BIOL CHEM, V273, P19363, DOI 10.1074/jbc.273.31.19363; MOORE SA, 1991, J NEUROCHEM, V56, P518, DOI 10.1111/j.1471-4159.1991.tb08180.x; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Mosior M, 1998, BIOCHEMISTRY-US, V37, P17271, DOI 10.1021/bi981344t; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Neuringer M, 2000, AM J CLIN NUTR, V71, p256S, DOI 10.1093/ajcn/71.1.256S; OPPENHEIM RW, 1992, J NEUROBIOL, V23, P1111, DOI 10.1002/neu.480230903; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Rotstein NP, 1997, J NEUROCHEM, V69, P504; Rotstein NP, 1996, J NEUROCHEM, V66, P1851; SALEM N, 1989, OMEGA 3 FATTY ACIDS, P109; Salomoni P, 1998, J EXP MED, V187, P1995, DOI 10.1084/jem.187.12.1995; Sastry PS, 2000, J NEUROCHEM, V74, P1, DOI 10.1046/j.1471-4159.2000.0740001.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; White DA, 1973, FORM FUNCTION PHOSPH, P441; Winkler DG, 1998, J BIOL CHEM, V273, P21578, DOI 10.1074/jbc.273.34.21578; Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349; Yoshida S, 1997, J NEUROCHEM, V68, P1261; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	57	224	241	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35215	35223		10.1074/jbc.M004446200	http://dx.doi.org/10.1074/jbc.M004446200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10903316	hybrid			2022-12-27	WOS:000165422800053
J	Zhou, Q; Melkoumian, ZK; Lucktong, A; Moniwa, M; Davie, JR; Strobl, JS				Zhou, Q; Melkoumian, ZK; Lucktong, A; Moniwa, M; Davie, JR; Strobl, JS			Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER-CELLS; TRANSCRIPTIONAL ACTIVATION; EXPRESSION; INHIBITOR; GROWTH; CYCLE; P53; TRANSFORMATION; PROGRESSION; CARCINOMA	Quinidine inhibits proliferation and promotes cellular differentiation in human breast tumor epithelial cells. Previously we showed quinidine arrested MCF-7 cells in G(1) phase of the cell cycle and led to a G(1) to G(0) transition followed by apoptotic cell death, The present experiments demonstrated that MCF 7, MCF-7ras, T47D, MDA-MB-231, and MDA-MB-435 cells transiently differentiate before undergoing apoptosis in response to quinidine. The cells accumulated lipid droplets, and the cytokeratin 18 cytoskeleton was reorganized, Hyperacetylated histone H4 appeared within 2 h of the addition of quinidine to the medium, and levels Were maximal by 24 h, Quinidine-treated MCF-7 cells showed elevated p21(WAF1) hypophosphorylation and suppression of retinoblastoma protein, and down-regulation of cyclin D1, similar to the cell cycle response observed with cells induced to differentiate by histone deacetylase inhibitors, trichostatin A, and trapoxin. Quinidine did not show evidence for direct inhibition of histone deacetylase enzymatic activity in vitro. HDAC1 was undetectable in MCF-7 cells 30 min after addition of quinidine to the growth medium. The proteasome inhibitors MG-132 and lactacystin completely protected HDAC1 from the action of quinidine. We conclude that quinidine is a breast tumor cell differentiating agent that causes the loss of HDAC1 via a proteasomal sensitive mechanism.	W Virginia Univ, Robert C Byrd Hlth Sci Ctr, Dept Pharmacol & Toxicol, Morgantown, WV 26506 USA; Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada	West Virginia University; University of Manitoba	Strobl, JS (corresponding author), W Virginia Univ, Robert C Byrd Hlth Sci Ctr, Dept Pharmacol & Toxicol, Morgantown, WV 26506 USA.	jstrobl@hsc.wvu.edu		Davie, James/0000-0002-0420-6888				Ameyar M, 1999, ONCOGENE, V18, P5464, DOI 10.1038/sj.onc.1202919; BACUS SS, 1990, MOL CARCINOGEN, V3, P350, DOI 10.1002/mc.2940030607; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Davie JR, 1998, J CELL BIOCHEM, P203; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Douglas AM, 1998, INT J CANCER, V75, P64, DOI 10.1002/(SICI)1097-0215(19980105)75:1<64::AID-IJC11>3.0.CO;2-D; Evers BM, 1996, AM J PHYSIOL-GASTR L, V271, pG722, DOI 10.1152/ajpgi.1996.271.4.G722; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Freemerman AJ, 1997, LEUKEMIA, V11, P504, DOI 10.1038/sj.leu.2400625; Fuqua SAW, 1999, CANCER RES, V59, P5425; FUTAMURA M, 1995, ONCOGENE, V10, P1119; Giani C, 1998, ONCOGENE, V17, P425, DOI 10.1038/sj.onc.1201954; GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965; HALM HA, 1990, IN VITRO CELL DEV, V26, P803; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; ILIEV IG, 1993, CELL MOL BIOL RES, V39, P601; ITAZAKI H, 1990, J ANTIBIOT, V43, P1524, DOI 10.7164/antibiotics.43.1524; Jing YK, 1996, DIFFERENTIATION, V60, P109, DOI 10.1046/j.1432-0436.1996.6020109.x; KASID A, 1985, SCIENCE, V228, P725, DOI 10.1126/science.4039465; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; Kim YB, 1999, ONCOGENE, V18, P2461, DOI 10.1038/sj.onc.1202564; Klimatcheva E, 1999, J MEMBRANE BIOL, V171, P35, DOI 10.1007/s002329900556; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu XS, 1999, J BIOL CHEM, V274, P13836, DOI 10.1074/jbc.274.20.13836; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Medina V, 1997, CANCER RES, V57, P3697; Mehta RR, 2000, INT J ONCOL, V16, P65; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; Nakanishi M, 1999, BIOCHEM BIOPH RES CO, V263, P35, DOI 10.1006/bbrc.1999.1296; Nieves-Neira W, 1999, INT J CANCER, V82, P396, DOI 10.1002/(SICI)1097-0215(19990730)82:3<396::AID-IJC13>3.0.CO;2-Z; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Saunders N, 1999, CANCER RES, V59, P399; Schmidt K, 1999, ARCH PHARM, V332, P353, DOI 10.1002/(SICI)1521-4184(199910)332:10<353::AID-ARDP353>3.0.CO;2-X; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; Sowa Y, 1999, CANCER RES, V59, P4266; STAMPFER MR, 1993, CANCER SURV, V18, P7; Stingl J, 1998, DIFFERENTIATION, V63, P201, DOI 10.1111/j.1432-0436.1998.00201.x; Sun JM, 1999, BIOCHEMISTRY-US, V38, P5939, DOI 10.1021/bi982633k; Sweeney KJ, 1998, ONCOGENE, V16, P2865, DOI 10.1038/sj.onc.1201814; TOSCANI A, 1990, J BIOL CHEM, V265, P5722; VanLint C, 1996, GENE EXPRESSION, V5, P245; Vladusic EA, 2000, ONCOL REP, V7, P157; Wang SY, 1998, J CELL PHYSIOL, V176, P456, DOI 10.1002/(SICI)1097-4652(199809)176:3<456::AID-JCP2>3.0.CO;2-N; WOODFORK KA, 1995, J CELL PHYSIOL, V162, P163, DOI 10.1002/jcp.1041620202; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; Yeola SW, 1996, CIRC RES, V78, P1105, DOI 10.1161/01.RES.78.6.1105; Yoshida M, 1999, ANN NY ACAD SCI, V886, P23, DOI 10.1111/j.1749-6632.1999.tb09397.x; ZHANG LS, 1995, CANCER RES, V55, P3890	54	83	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35256	35263		10.1074/jbc.M003106200	http://dx.doi.org/10.1074/jbc.M003106200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10938272	hybrid			2022-12-27	WOS:000165422800058
J	Lund-Katz, S; Zaiou, M; Wehrli, S; Dhanasekaran, P; Baldwin, F; Weisgraber, KH; Phillips, MC				Lund-Katz, S; Zaiou, M; Wehrli, S; Dhanasekaran, P; Baldwin, F; Weisgraber, KH; Phillips, MC			Effects of lipid interaction on the lysine microenvironments in apolipoprotein E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RECEPTOR-BINDING DOMAIN; N-TERMINAL DOMAIN; III HYPERLIPOPROTEINEMIA; CHOLESTEROL MOLECULES; ALZHEIMERS-DISEASE; E DEFICIENCY; NMR; CONFORMATION; ATHEROSCLEROSIS	Lysines in apolipoprotein (apo) E are key factors in the binding of apoE to the low density lipoprotein receptor, and high affinity binding requires that apoE be associated with lipid. To gain insight into this effect, we examined the microenvironments of the eight lysines in the 22-kDa fragment of apoE3 (residues 1-191) in the lipid-free and lipid-associated states. As shown by H-1,C-13 heteronuclear single quantum coherence nuclear magnetic resonance, lysine resonances in the lipid-free fragment were poorly resolved over a wide pH range, whereas in apoE3 dimyristoyl phosphatidylcholine (DMPC) discs, the lysine microenvironments and protein conformation were significantly altered. Sequence-specific assignments of the lysine resonances in the spectrum of the lipidated 22-kDa fragment were made. In the lipid-free protein, six lysines could be resolved, and all had pK(a) values above 10, In apoE3 DMPC complexes, however, all eight lysines were resolved, and the pK(a) values were 9.2-11.1, Lys-143 and Lys-146, both in the receptor binding region in helix 4, had unusually low pK(a) values of 9.5 and 9.2, respectively, likely as a result of local increases in positive electrostatic potential with lipid association, Shift reagent experiments with potassium ferricyanide showed that Lys-143 and Lys-146 were much more accessible to the ferricyanide anion in the apoE3 DMPC complex than in the lipid-free state. The angle of the nonpolar face of helix 4 is smaller than the angles of helices 1, 2, and 3, suggesting that helix 4 cannot penetrate as deeply into the DMPC acyl chains at the edge of the complex and that its polar face protrudes from the edge of the disc, This increased exposure and the greater positive electrostatic potential created by interaction with DMPC may explain why lipid association is required for high affinity binding of apoE to the low density lipoprotein receptor.	Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, Philadelphia, PA 19104 USA; Med Coll Penn & Hahnemann Univ, Dept Biochem, Philadelphia, PA 19129 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, Cardiovasc Res Inst, San Francisco, CA 94141 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Drexel University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes	Lund-Katz, S (corresponding author), Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, Abramson Res Bldg,Suite 302,3516 Civic Ctr Blvd, Philadelphia, PA 19104 USA.		Zaiou, Mohamed/AAG-8923-2019	ZAIOU, Mohamed/0000-0002-4113-4350; Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056083, P01HL041633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56083, HL41633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANANTHARAMAIAH GM, 1993, AMPHIPATHIC HELIX, P109; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; DEPAUW M, 1995, BIOCHEMISTRY-US, V34, P10953, DOI 10.1021/bi00034a030; Dong LM, 1996, NAT STRUCT BIOL, V3, P718, DOI 10.1038/nsb0896-718; Fisher CA, 1999, J LIPID RES, V40, P93; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; HAMILTON JA, 1986, METHOD ENZYMOL, V128, P472; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu B, 2000, J BIOL CHEM, V275, P20775, DOI 10.1074/jbc.M003508200; LUNDKATZ S, 1991, J BIOL CHEM, V266, P2701; LUNDKATZ S, 1984, BIOCHEMISTRY-US, V23, P1130, DOI 10.1021/bi00301a015; LUNDKATZ S, 1995, BIOCHEMISTRY-US, V34, P9219, DOI 10.1021/bi00028a035; LUNDKATZ S, 1986, BIOCHEMISTRY-US, V25, P1562, DOI 10.1021/bi00355a016; LUNDKATZ S, 1988, J BIOL CHEM, V263, P13831; LUNDKATZ S, 1993, J BIOL CHEM, V268, P23008; MABUCHI H, 1989, METABOLISM, V38, P115, DOI 10.1016/0026-0495(89)90249-7; Mahley RW, 1996, ISRAEL J MED SCI, V32, P414; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1995, METABOLIC MOL BASES, P1953; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MAVRI J, 1994, PROTEINS, V18, P381, DOI 10.1002/prot.340180408; Morrow JA, 1999, PROTEIN EXPRES PURIF, V16, P224, DOI 10.1006/prep.1999.1069; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; North CL, 2000, BIOCHEMISTRY-US, V39, P2564, DOI 10.1021/bi992087a; Raussens V, 1998, J BIOL CHEM, V273, P25825, DOI 10.1074/jbc.273.40.25825; REDDICK RL, 1994, ARTERIOSCLER THROMB, V14, P141, DOI 10.1161/01.ATV.14.1.141; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; Segelke BW, 2000, PROTEIN SCI, V9, P886, DOI 10.1110/ps.9.5.886; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; Vallejo Abbe N., 1995, P603; WEISGRABER KH, 1978, J BIOL CHEM, V253, P9053; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WEISGRABER KH, 1992, HIGH DENSITY LIPOPRO, V3, P175; Zaiou M, 2000, J LIPID RES, V41, P1087; ZHANG MJ, 1994, J BIOL CHEM, V269, P5099; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	42	49	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34459	34464		10.1074/jbc.M005265200	http://dx.doi.org/10.1074/jbc.M005265200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10921925	hybrid			2022-12-27	WOS:000165095300062
J	Draganov, DI; Stetson, PL; Watson, CE; Billecke, SS; La Du, BN				Draganov, DI; Stetson, PL; Watson, CE; Billecke, SS; La Du, BN			Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-LIPOPROTEINS; IDENTIFICATION; ARYLESTERASE; DISPOSITION; LOVASTATIN; SEQUENCE; ENZYMES; FAMILY; LIVER	The paraoxonase gene family contains at least three members: PON1, PON2, and PON3, The physiological roles of the corresponding gene products are still uncertain. Until recently, only the serum paraoxonase/arylesterase (PON1) had been purified and characterized. Here we report the purification, cloning, and characterization of rabbit serum PON3, PON3 is a 40-kDa protein associated with the high density lipoprotein fraction of serum. In contrast to PON1, PON3 has very limited arylesterase and no paraoxonase activities but rapidly hydrolyzes lactones such as statin prodrugs (e.g. lovastatin), These differences facilitated the complete separation of PON3 from PON1 during purification. PON3 hydrolyzes aromatic lactones and 5- or 6-member ring lactones with aliphatic substituents but not simple lactones or those with polar substituents. We cloned PON3 from total rabbit liver RNA and expressed it in mammalian 293T/17 cells, The recombinant PON3 has the same apparent molecular mass and substrate specificity as the enzyme purified from serum. Rabbit serum PON3 is more efficient than rabbit PON1 in protecting low density lipoprotein from copper-induced oxidation, This is the first report that identifies a second PON enzyme in mammalian serum and the first to describe an enzymatic activity for PON3.	Univ Michigan, Dept Anesthesiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; Mil Med Acad, Lab Expt Toxicol, Sofia 1606, Bulgaria	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Military Medical Academy Sofia	Draganov, DI (corresponding author), Univ Michigan, Dept Anesthesiol, 7422 Med Sci 1 Bldg,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.							Aviram M, 1999, MOL MED TODAY, V5, P381, DOI 10.1016/S1357-4310(99)01546-4; Aviram M, 2000, CIRCULATION, V101, P2510, DOI 10.1161/01.CIR.101.21.2510; Aviram M, 1998, ARTERIOSCL THROM VAS, V18, P1617, DOI 10.1161/01.ATV.18.10.1617; Aviram M, 1999, FREE RADICAL BIO MED, V26, P892, DOI 10.1016/S0891-5849(98)00272-X; Aviram M, 1998, J CLIN INVEST, V101, P1581, DOI 10.1172/JCI1649; BILLECKE S, 2000, IN PRESS DRUG METAB, V28; Billecke SS, 1999, FASEB J, V13, pA1013; Billecke SS, 1999, CHEM-BIOL INTERACT, V119, P251, DOI 10.1016/S0009-2797(99)00034-4; BLATTER MC, 1993, EUR J BIOCHEM, V211, P871, DOI 10.1111/j.1432-1033.1993.tb17620.x; Davies HG, 1996, NAT GENET, V14, P334, DOI 10.1038/ng1196-334; Doorn JA, 1999, CHEM-BIOL INTERACT, V119, P235, DOI 10.1016/S0009-2797(99)00032-0; DUGGAN DE, 1989, DRUG METAB DISPOS, V17, P166; ELSAADANI M, 1989, J LIPID RES, V30, P627; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; GAN KN, 1991, DRUG METAB DISPOS, V19, P100; Granjeaud S, 1999, IMMUNOGENETICS, V49, P964, DOI 10.1007/s002510050580; HASSETT C, 1991, BIOCHEMISTRY-US, V30, P10141, DOI 10.1021/bi00106a010; Hatch F T, 1968, Adv Lipid Res, V6, P1; Josse D, 1999, CHEM-BIOL INTERACT, V119, P79, DOI 10.1016/S0009-2797(99)00016-2; Josse D, 1999, BIOCHEMISTRY-US, V38, P2816, DOI 10.1021/bi982281h; KANAGASUNDARAM V, 1992, BIOCHIM BIOPHYS ACTA, V1171, P198, DOI 10.1016/0167-4781(92)90120-O; KELSO GJ, 1994, BIOCHEMISTRY-US, V33, P284; KIEFT KA, 1991, J LIPID RES, V32, P859; Kobayashi M, 1998, P NATL ACAD SCI USA, V95, P12787, DOI 10.1073/pnas.95.22.12787; KUO CL, 1995, DRUG METAB DISPOS, V23, P935; La Du BN, 1999, CHEM-BIOL INTERACT, V119, P599, DOI 10.1016/S0009-2797(99)00075-7; La Du BN, 1999, CHEM-BIOL INTERACT, V119, P379, DOI 10.1016/S0009-2797(99)00049-6; La Du BN, 1992, PHARMACOGENETICS DRU, P51; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mackness MI, 1996, CURR OPIN LIPIDOL, V7, P69, DOI 10.1097/00041433-199604000-00004; Navab M, 1998, CURR OPIN LIPIDOL, V9, P449, DOI 10.1097/00041433-199810000-00009; Ozols J, 1999, BIOCHEM J, V338, P265, DOI 10.1042/0264-6021:3380265; PrimoParmo SL, 1996, GENOMICS, V33, P498, DOI 10.1006/geno.1996.0225; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; Shih DM, 1998, NATURE, V394, P284, DOI 10.1038/28406; Sorenson RC, 1999, ARTERIOSCL THROM VAS, V19, P2214, DOI 10.1161/01.ATV.19.9.2214; TANG BK, 1995, EUR J CLIN PHARMACOL, V47, P449; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; VICKERS S, 1990, DRUG METAB DISPOS, V18, P138; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359	40	254	269	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33435	33442		10.1074/jbc.M004543200	http://dx.doi.org/10.1074/jbc.M004543200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10931838	hybrid			2022-12-27	WOS:000090104600037
J	Pasolli, HA; Klemke, M; Kehlenbach, RH; Wang, YZ; Huttner, WB				Pasolli, HA; Klemke, M; Kehlenbach, RH; Wang, YZ; Huttner, WB			Characterization of the extra-large G protein alpha-subunit XL alpha s - I. Tissue distribution and subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE SECRETORY VESICLES; SIGNAL-TRANSDUCTION; SECRETOGRANIN-I; CHROMOGRANIN-B; RECEPTOR; CELLS; EXPRESSION; GENE; MEMBRANE; GRANULES	Our group previously described a new type of G protein, the 78-kDa XL alphas (extra large as) (Kehlenbach, R. H., Matthey, J., and Huttner, W. B. (1994) Nature 372, 804-809 and (1995) Nature 375, 253). Upon subcellular fractionation, XLas labeled by ADP-ribosylation with cholera toxin was previously mainly detected in the bottom fractions of a velocity sucrose gradient that contained trans-Golgi network and was differentially distributed to G alphas, which also peaked in the top fractions containing plasma membrane. Here, we investigate, using a new antibody specific for the XL domain, the tissue distribution and subcellular localization of XL alphas and novel splice variants referred to as XLN1. Upon immunoblotting and immunofluorescence analysis of various adult rat tissues, XLas and XLN1 were found to be enriched in neuroendocrine tissues, with a particularly high level of expression in the pituitary, By both immunofluorescence and immunogold electron microscopy, endogenous as well as transfected XL alphas and XLN1 were found to be predominantly associated with the plasma membrane, with only little immunoreactivity on internal, perinuclear membranes. Upon subcellular fractionation, immunoreactive XL alphas behaved similarly to G alphas but was differentially distributed to ADP-ribosylated XL alphas. Moreover, the bottom fractions of the velocity sucrose gradient were found to contain not only trans-Golgi network membranes but also certain subdomains of the plasma membrane, which reconciles the present with the previous observations. To further investigate the molecular basis of the association of XL alphas with the plasma membrane, chimeric proteins consisting of the YL domain or portions thereof fused to green fluorescent protein were analyzed by fluorescence and subcellular fractionation, In both neuroendocrine and non-neuroendocrine cells, a fusion protein containing the entire XL domain, in contrast to one containing only the proline-rich and cysteine-rich regions, was exclusively localized at the plasma membrane. We conclude that the physiological role of XL alphas is at the plasma membrane, where it presumably is involved in signal transduction processes characteristic of neuroendocrine cells.	Univ Heidelberg, Dept Neurobiol, D-69120 Heidelberg, Germany; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany	Ruprecht Karls University Heidelberg; Max Planck Society	Huttner, WB (corresponding author), Univ Heidelberg, Dept Neurobiol, Neuenheimer Feld 364, D-69120 Heidelberg, Germany.		Huttner, Wieland B./P-4080-2018; Wang, Yanzhuang/AAE-5299-2019	Wang, Yanzhuang/0000-0002-1864-7094; Pasolli, Hilda Amalia/0000-0003-3899-3530; Kehlenbach, Ralph/0000-0003-4920-9916				AUSUBEL FM, 1997, CURRENT PROTOCOLS MO, V2; BIRNBAUMER L, 1995, J RECEPT SIGNAL TR R, V15, P213; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAWFORD JA, 1993, J BIOL CHEM, V268, P9879; Evanko DS, 2000, J BIOL CHEM, V275, P1327, DOI 10.1074/jbc.275.2.1327; Farfel Z, 1999, NEW ENGL J MED, V340, P1012, DOI 10.1056/NEJM199904013401306; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GORMAN CM, 1983, NUCLEIC ACIDS RES, V11, P7631, DOI 10.1093/nar/11.21.7631; Hayward BE, 1998, P NATL ACAD SCI USA, V95, P15475, DOI 10.1073/pnas.95.26.15475; Hayward BE, 1998, P NATL ACAD SCI USA, V95, P10038, DOI 10.1073/pnas.95.17.10038; Iacopetti P, 1999, P NATL ACAD SCI USA, V96, P4639, DOI 10.1073/pnas.96.8.4639; INAGAKI N, 1994, P NATL ACAD SCI USA, V91, P2679, DOI 10.1073/pnas.91.7.2679; KEHLENBACH RH, 1995, NATURE, V375, P253, DOI 10.1038/375253b0; KEHLENBACH RH, 1994, NATURE, V372, P804; Klemke M, 2000, J BIOL CHEM, V275, P33633, DOI 10.1074/jbc.M006594200; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Peters J, 1999, P NATL ACAD SCI USA, V96, P3830, DOI 10.1073/pnas.96.7.3830; PIMPLIKAR SW, 1992, J BIOL CHEM, V267, P4110; Rawlings SR, 1996, ENDOCR REV, V17, P4, DOI 10.1210/er.17.1.4; REGNIERVIGOUROUX A, 1991, EMBO J, V10, P3589, DOI 10.1002/j.1460-2075.1991.tb04925.x; Rodbell M, 1997, ADV ENZYME REGUL, V37, P427, DOI 10.1016/S0065-2571(96)00020-9; ROSA P, 1989, J CELL BIOL, V109, P17, DOI 10.1083/jcb.109.1.17; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; TOOZE SA, 1992, METHOD ENZYMOL, V219, P81; TOOZE SA, 1991, J CELL BIOL, V115, P1491, DOI 10.1083/jcb.115.6.1491; Ugur O, 2000, MOL BIOL CELL, V11, P1421, DOI 10.1091/mbc.11.4.1421; Weinstein LS, 1999, TRENDS ENDOCRIN MET, V10, P81, DOI 10.1016/S1043-2760(98)00124-6; Xie W.Q., 1991, BIOTECHNIQUES, V11, P326	32	88	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33622	33632		10.1074/jbc.M001335200	http://dx.doi.org/10.1074/jbc.M001335200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10931823	hybrid			2022-12-27	WOS:000090104600063
J	Chong, NW; Bernard, M; Klein, DC				Chong, NW; Bernard, M; Klein, DC			Characterization of the chicken serotonin N-acetyltransferase gene - Activation via clock gene heterodimer/e box interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCADIAN CLOCK; PINEAL-GLAND; TRANSCRIPTION FACTOR; MELATONIN SYNTHESIS; MESSENGER-RNA; RETINA; EXPRESSION; PROTEIN; RHYTHMS; LOOP	The abundance of serotonin N-acetyltransferase (arylalkylamine N-acetyltransferase, AANAT) mRNA in the chicken pineal gland exhibits a circadian rhythm, which is translated into a circadian rhythm in melatonin production. Here we have started to elucidate the molecular basis of the circadian rhythm in chicken AANAT (cAANAT), The 5'-flanking region of the cAANAT gene was isolated and found to contain an E box DNA element that confers strong luciferase reporter activity. In transfection experiments using chicken pineal cells, an E box mutation dramatically decreased reporter activity. Northern blot analysis indicated that several putative clock genes (bmal1, Clock, and MOP4) are co-expressed in the chicken pineal gland. bmal1 mRNA is expressed in a rhythmic manner in the chicken pineal gland, with peak levels at early subjective night, coincident with the increase in cAANAT expression. Co-transfection experiments in COS cells demonstrated that chicken BMAL1/CLOCK and human BMAL1/MOP4 heterodimers bound the AANAT E box element and enhanced transcription. These observations suggest that binding of clock gene heterodimers to the cAANAT E box is a critical element in the expression of the cAANAT gene in vitro.	NICHD, Sect Neuroendocrinol, Lab Dev Neurobiol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Klein, DC (corresponding author), NICHD, Sect Neuroendocrinol, Lab Dev Neurobiol, NIH, Bldg 49,Rm 6A80, Bethesda, MD 20892 USA.	Klein@helix.nih.gov		Klein, David/0000-0002-1792-5806	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000095, ZIAHD000095] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arendt J., 1995, MELATONIN MAMMALIAN; Baler R, 1997, J BIOL CHEM, V272, P6979, DOI 10.1074/jbc.272.11.6979; BARRETT RK, 1995, J NEUROSCI, V15, P5681; BARTNESS TJ, 1989, EXPERIENTIA, V45, P939, DOI 10.1007/BF01953051; Begay V, 1998, ENDOCRINOLOGY, V139, P905, DOI 10.1210/en.139.3.905; Bernard M, 1997, J NEUROCHEM, V68, P213; Bernard M, 1997, P NATL ACAD SCI USA, V94, P304, DOI 10.1073/pnas.94.1.304; BINKLEY S, 1988, PINEAL ENDOCRINE NEU; BINKLEY SA, 1978, SCIENCE, V202, P1198, DOI 10.1126/science.214852; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; Cahill GM, 1997, BIOL SIGNAL, V6, P191; Cahill GM, 1996, BRAIN RES, V708, P177, DOI 10.1016/0006-8993(95)01365-2; CAHILL GM, 1995, PROG RETIN EYE RES, V14, P267, DOI 10.1016/1350-9462(94)00001-Y; CAHILL GM, 1993, NEURON, V10, P573, DOI 10.1016/0896-6273(93)90160-S; CASSONE VM, 1990, TRENDS NEUROSCI, V13, P457, DOI 10.1016/0166-2236(90)90099-V; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; CHEN W, 2000, IN PRESS MOL BRAIN R; Chong NW, 1998, MOL BRAIN RES, V61, P243, DOI 10.1016/S0169-328X(98)00219-8; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; DEGUCHI T, 1979, NATURE, V282, P94, DOI 10.1038/282094a0; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Falcon J, 1999, PROG NEUROBIOL, V58, P121, DOI 10.1016/S0301-0082(98)00078-1; Furukawa T, 1999, NAT GENET, V23, P466, DOI 10.1038/70591; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GREEN CB, 1994, J NEUROCHEM, V62, P2420; Green CB, 1998, TRENDS CELL BIOL, V8, P342, DOI 10.1016/S0962-8924(98)01338-5; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Honma S, 1998, BIOCHEM BIOPH RES CO, V250, P83, DOI 10.1006/bbrc.1998.9275; Ikeda M, 1997, BIOCHEM BIOPH RES CO, V233, P258, DOI 10.1006/bbrc.1997.6371; Iuvone PM, 1996, RETINAL DEGENERATION AND REGENERATION, P3; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; KARSCH FJ, 1991, SUPRACHIASMATIC NUCL, P217; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Klein D.C., 1991, SUPRACHIASMATIC NUCL; KLEIN DC, 1985, CIBA F SYMP, V117, P38; KLEIN DC, 1998, HDB BEHAV STATE CONT, V4, P45; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Larkin P, 1999, MOL BRAIN RES, V70, P253, DOI 10.1016/S0169-328X(99)00154-0; Li XD, 1998, P NATL ACAD SCI USA, V95, P1876, DOI 10.1073/pnas.95.4.1876; Mani SS, 1999, J BIOL CHEM, V274, P15590, DOI 10.1074/jbc.274.22.15590; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Namihira M, 1999, NEUROSCI LETT, V271, P1, DOI 10.1016/S0304-3940(99)00407-3; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; Reppert SM, 1998, NEURON, V21, P1, DOI 10.1016/S0896-6273(00)80234-2; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; Shearman LP, 1999, NEUROSCIENCE, V89, P387, DOI 10.1016/S0306-4522(98)00325-X; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Sonnenfeld M, 1997, DEVELOPMENT, V124, P4571; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; TAKAHASHI JS, 1980, P NATL ACAD SCI-BIOL, V77, P2319, DOI 10.1073/pnas.77.4.2319; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; Tosini G, 1998, BRAIN RES, V789, P221, DOI 10.1016/S0006-8993(97)01446-7; UNDERWOOD H, 1989, EXPERIENTIA, V45, P914, DOI 10.1007/BF01953048; Wada-Kiyama Y, 1999, FEBS LETT, V444, P117, DOI 10.1016/S0014-5793(99)00041-1; WADAKIYAMA Y, 1995, J BIOL CHEM, V270, P12439, DOI 10.1074/jbc.270.21.12439; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Zatz M, 1996, SEMIN CELL DEV BIOL, V7, P811, DOI 10.1006/scdb.1996.0099; Zelzer E, 1997, GENE DEV, V11, P2079, DOI 10.1101/gad.11.16.2079; Zhou YD, 1997, P NATL ACAD SCI USA, V94, P713, DOI 10.1073/pnas.94.2.713	66	124	131	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32991	32998		10.1074/jbc.M005671200	http://dx.doi.org/10.1074/jbc.M005671200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10931848	hybrid			2022-12-27	WOS:000090003800084
J	Dana, RR; Eigsti, C; Holmes, KL; Leto, TL				Dana, RR; Eigsti, C; Holmes, KL; Leto, TL			A regulatory role for ADP-ribosylation factor 6 (ARF6) in activation of the phagocyte NADPH oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-D ACTIVITY; GTP-BINDING-PROTEIN; HUMAN-NEUTROPHILS; PLASMA-MEMBRANE; MAMMALIAN-CELLS; OXIDATIVE BURST; HL-60 CELLS; TRANSLOCATION; INVOLVEMENT; REQUIREMENT	In activated neutrophils NADPH oxidase is regulated through various signaling intermediates, including heterotrimeric G proteins, kinases, GTPases, and phospholipases, ADP-ribosylation factor (ARF) describes a family of GTPases associated with phospholipase D (PLD) activation. PLD is implicated in NADPH oxidase activation, although it is unclear whether activation of PLD by ARF is linked to receptor-mediated oxidase activation. We explored whether ARF participates in NADPH oxidase activation by formyl-methionine-leucine-phenylalanine (fMLP) and whether this involves PLD. Using multicolor forward angle light scattering analyses to measure superoxide production in differentiated neutrophil-like PLB-985 cells, we tested enhanced green fluorescent fusion proteins of wild-type ARF1 or ARF6, or their mutant counterparts. The ARF6(Q67L) mutant defective in GTP hydrolysis caused increased superoxide production, whereas the ARF6(T27N) mutant defective in GTP binding caused diminished responses to fMLP. The ARF1 mutants had no effect on fMLP responses, and none of the ARF proteins affected phorbol 12-myristate 13-acetate-elicited oxidase activity. PLD inhibitors 1-butanol and 2,3-diphosphoglycerate, or the ARF6(N48R) mutant assumed to be defective in PLD activation, blocked fMLP-elicited oxidase activity in transfected cells. The data suggest that ARF6 but not ARF1 modulates receptor-mediated NADPH oxidase activation in a PLD-dependent mechanism. Because PMA-elicited NADPH oxidase activation also appears to be PLD-dependent, but ARF-independent, ARF6 and protein kinase C may act through distinct pathways, both involving PLD.	NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA; NIAID, Flow Cytometry Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Leto, TL (corresponding author), NIAID, Host Def Lab, NIH, Bldg 10,Rm 11N106, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000614, Z01AI000614] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Caumont AS, 1998, J BIOL CHEM, V273, P1373, DOI 10.1074/jbc.273.3.1373; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; Dana R, 1998, J BIOL CHEM, V273, P441, DOI 10.1074/jbc.273.1.441; DEMENDEZ I, 1995, BLOOD, V85, P1104, DOI 10.1182/blood.V85.4.1104.bloodjournal8541104; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Fensome A, 1996, CURR BIOL, V6, P730, DOI 10.1016/S0960-9822(09)00454-0; Fensome A, 1998, J BIOL CHEM, V273, P13157, DOI 10.1074/jbc.273.21.13157; HOULE MG, 1995, J BIOL CHEM, V270, P22795, DOI 10.1074/jbc.270.39.22795; Jones DH, 1999, BIOCHEM J, V341, P185, DOI 10.1042/0264-6021:3410185; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KANAHO Y, 1993, J BIOL CHEM, V268, P12492; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KURIBAYASHI F, 1995, BIOCHEM BIOPH RES CO, V209, P146, DOI 10.1006/bbrc.1995.1482; Kusner DJ, 1996, J EXP MED, V184, P585, DOI 10.1084/jem.184.2.585; Leto TL., 1999, INFLAMMATION BASIC P, P769; MALY FE, 1994, J BIOL CHEM, V269, P18743; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MCPHAIL LC, 1993, EUR J HAEMATOL, V51, P294; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Model MA, 1997, J IMMUNOL METHODS, V202, P105, DOI 10.1016/S0022-1759(96)00241-4; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Olson SC, 1996, CHEM PHYS LIPIDS, V80, P3, DOI 10.1016/0009-3084(96)02541-8; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Serrander L, 1996, INFLAMMATION, V20, P439, DOI 10.1007/BF01486745; Shome K, 2000, ENDOCRINOLOGY, V141, P2200, DOI 10.1210/en.141.6.2200; Shome K, 1998, J BIOL CHEM, V273, P30836, DOI 10.1074/jbc.273.46.30836; Song J, 1998, J CELL SCI, V111, P2257; Toda K, 1999, FEBS LETT, V442, P221, DOI 10.1016/S0014-5793(98)01646-9; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; Vasudevan C, 1998, J CELL SCI, V111, P1277; Zhang Q, 1998, J BIOL CHEM, V273, P19977, DOI 10.1074/jbc.273.32.19977	41	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32566	32571		10.1074/jbc.M005406200	http://dx.doi.org/10.1074/jbc.M005406200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10931844	hybrid			2022-12-27	WOS:000090003800027
J	Boyd, MT; Vlatkovic, N; Haines, DS				Boyd, MT; Vlatkovic, N; Haines, DS			A novel cellular protein (MTBP) binds to MDM2 and induces a G(1) arrest that is suppressed by MDM2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53 TUMOR SUPPRESSION; HUMAN CANCER-CELLS; WILD-TYPE P53; P53-INDEPENDENT ROLE; ONCOPROTEIN MDM2; HUMAN SARCOMAS; GENE; AMPLIFICATION; EXPRESSION; MUTATIONS	The MDM2 protein, through its interaction with p53, plays an important role in the regulation of the G(1) checkpoint of the cell cycle. In addition to binding to and inhibiting the transcriptional activation function of the p53 protein, MDM2 binds, inter alia, to RE and the E2F-1.DP-1 complex and in so doing may promote progression of cells into S phase, Mice transgenic for Mdm2 possess cells that have cell cycle regulation defects and develop an altered tumor profile independent of their p53 status. MDM2 also blocks the growth inhibitory effects of transforming growth factor-pr in a p53-independent manner. We show here that a novel growth regulatory molecule is also the target of MDM2-mediated inhibition, Using a yeast two-hybrid screen, we have identified a gene that encodes a novel cellular protein (MTBP) that binds to MDM2. MTBP can induce G(1) arrest, which in turn can be blocked by MDM2. Our results suggest the existence of another growth control pathway that may be regulated, at least in part, by MDM2.	Med Coll Penn & Hahnemann Univ, Ctr Canc, Div Hematol Oncol, Philadelphia, PA 19102 USA	Drexel University	Boyd, MT (corresponding author), Univ Liverpool, Dept Surg, Daulby St, Liverpool L69 3GA, Merseyside, England.		Boyd, Mark/AAB-8564-2021; Boyd, Mark T/I-6792-2012; Vlatkovic, Nikolina/I-3481-2013; Vlatkovic, Nikolina/AAH-6654-2020	Boyd, Mark/0000-0002-2336-2106; Boyd, Mark T/0000-0002-2336-2106; Vlatkovic, Nikolina/0000-0003-3003-794X; Vlatkovic, Nikolina/0000-0003-3003-794X	NATIONAL CANCER INSTITUTE [R29CA070165] Funding Source: NIH RePORTER; NCI NIH HHS [CA70165] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attardi LD, 1999, CELL MOL LIFE SCI, V55, P48, DOI 10.1007/s000180050269; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bender L, 1996, J CELL BIOL, V133, P879, DOI 10.1083/jcb.133.4.879; Cabib E, 1998, ANNU REV BIOCHEM, V67, P307, DOI 10.1146/annurev.biochem.67.1.307; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DASMAHAPATRA B, 1987, NUCLEIC ACIDS RES, V15, P3933, DOI 10.1093/nar/15.9.3933; DEOCALUNA R, 1995, NATURE, V0378; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; JUVEN T, 1993, ONCOGENE, V8, P3411; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LADANYI M, 1993, CANCER RES, V53, P16; LEACH FS, 1993, CANCER RES, V53, P2231; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Matsui Y, 1996, J CELL BIOL, V133, P865, DOI 10.1083/jcb.133.4.865; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; REIFENBERGER G, 1993, CANCER RES, V53, P2736; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Sambrook J., 2002, MOL CLONING LAB MANU; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vlatkovic N, 2000, NUCLEIC ACIDS RES, V28, P3581, DOI 10.1093/nar/28.18.3581; WALDMAN T, 1995, CANCER RES, V55, P5187; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	52	80	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31883	31890		10.1074/jbc.M004252200	http://dx.doi.org/10.1074/jbc.M004252200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10906133	hybrid			2022-12-27	WOS:000089858900048
J	Deng, SJ; Bickett, DM; Mitchell, JL; Lambert, MH; Blackburn, RK; Carter, HL; Neugebauer, J; Pahel, G; Weiner, MP; Moss, ML				Deng, SJ; Bickett, DM; Mitchell, JL; Lambert, MH; Blackburn, RK; Carter, HL; Neugebauer, J; Pahel, G; Weiner, MP; Moss, ML			Substrate specificity of human collagenase 3 assessed using a phage-displayed peptide library	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST CARCINOMAS; MATRIX; DEGRADATION; CARTILAGE; MMP-13; OPTIMIZATION; STROMELYSIN; EXPRESSION; ACTIVATION; INHIBITORS	The substrate specificity of human collagenase 3 (MMP-13), a member of the matrix metalloproteinase family, is investigated using a phage-displayed random hexapeptide Library containing 2 x 10(8) independent recombinants, A total of 35 phage clones that express a peptide sequence that can be hydrolyzed by the recombinant catalytic domain of human collagenase 3 are identified. The translated DNA sequence of these clones reveals highly conserved putative P1, P2, P3 and P1', P2', and P3' subsites of the peptide substrates, Kinetic analysis of synthetic peptide substrates made from human collagenase 3 selected phage clones reveals that some of the substrates are highly active and selective. The most active substrate, 2,4-dinitrophenyl-GPLGMRGL-NH2 (CP), has a k(cat)/K-m value of 4.22 x 10(6) M-1 s(-1) for hydrolysis by collagenase 3, CP was synthesized as a consensus sequence deduced from the preferred sub sites of the aligned 35 phage clones. Peptide substrate CP is 1300-, 11-, and 820-fold selective for human collagenase 3 over the MMPs stromelysin-l, gelatinase B, and collagenase 1, respectively. In addition, cleavage of CP is 37-fold faster than peptide NF derived from the major MMP-processing site in aggrecan, Phage display screening also selected five substrate sequences that share sequence homology with a major MMP cleavage sequence in aggrecan and seven substrate sequences that share sequence homology with the primary collagenase cleavage site of human type II collagen. In addition, putative cleavage sites similar to the consensus sequence are found in human type N collagen. These findings support previous observations that human collagenase 3 can degrade aggrecan, type Il and type IV collagens.	Glaxo Wellcome Inc, Dept Mol Sci, Res & Dev, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Dept Mol Biochem, Res & Dev, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Dept Struct Chem, Res & Dev, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Dept Genomic Sci, Res & Dev, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Deng, SJ (corresponding author), Glaxo Wellcome Inc, Dept Mol Sci, Res & Dev, POB 13398,5 Moore Dr, Res Triangle Pk, NC 27709 USA.	sjd20506@glaxowellcome.com						Beekman B, 1997, FEBS LETT, V418, P305, DOI 10.1016/S0014-5793(97)01371-9; BERMAN J, 1992, J BIOL CHEM, V267, P1434; Billinghurst RC, 1997, J CLIN INVEST, V99, P1534, DOI 10.1172/JCI119316; COX DA, 1995, CELL BIOL INT, V19, P357, DOI 10.1006/cbir.1995.1082; DING L, 1995, P NATL ACAD SCI USA, V92, P7627, DOI 10.1073/pnas.92.17.7627; FIELDS GB, 1991, J THEOR BIOL, V153, P585, DOI 10.1016/S0022-5193(05)80157-2; FISHER LW, 1989, J BIOL CHEM, V264, P4571; Flaumenhaft R, 1993, Adv Pharmacol, V24, P51, DOI 10.1016/S1054-3589(08)60933-3; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HASSELL AM, 1994, J MOL BIOL, V236, P1410, DOI 10.1016/0022-2836(94)90068-X; KASSEL DB, 1995, ANAL BIOCHEM, V228, P259, DOI 10.1006/abio.1995.1348; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Lauer-Fields JL, 2000, J BIOL CHEM, V275, P13282, DOI 10.1074/jbc.275.18.13282; Lovejoy B, 1999, NAT STRUCT BIOL, V6, P217; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; MCGEEHAN GM, 1994, J BIOL CHEM, V269, P32814; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; MIYAZONO K, 1991, CIBA F SYMP, V157, P81; NAGASE H, 1994, J BIOL CHEM, V269, P20952; Nagase H, 1996, BIOPOLYMERS, V40, P399, DOI 10.1002/(SICI)1097-0282(1996)40:4<399::AID-BIP5>3.0.CO;2-R; Parish CR, 1998, IMMUNOL CELL BIOL, V76, P104, DOI 10.1046/j.1440-1711.1998.00722.x; Reboul P, 1996, J CLIN INVEST, V97, P2011, DOI 10.1172/JCI118636; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; SINGH J, 1995, J MED CHEM, V38, P217, DOI 10.1021/jm00002a001; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; STACK MS, 1989, J BIOL CHEM, V264, P4277; Tozser J, 1996, J BIOL CHEM, V271, P6781, DOI 10.1074/jbc.271.12.6781; Willmroth F, 1998, IMMUNOBIOLOGY, V198, P375, DOI 10.1016/S0171-2985(98)80046-6; Yu Q, 2000, GENE DEV, V14, P163	34	109	118	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31422	31427		10.1074/jbc.M004538200	http://dx.doi.org/10.1074/jbc.M004538200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906330	hybrid			2022-12-27	WOS:000089762700095
J	Diamond, SE; Gutierrez-Hartmann, A				Diamond, SE; Gutierrez-Hartmann, A			The Pit-1 beta domain dictates active repression and alteration of histone acetylation of the proximal prolactin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; GENE-EXPRESSION; TRANSCRIPTIONAL REPRESSION; FUNCTIONAL INTERACTION; PROTEIN; RAS; DEACETYLASE; ACTIVATION; ISOFORMS; PHOSPHORYLATION	A critical problem in current molecular biology is to gain a detailed understanding of the molecular mechanisms by which related transcription factor isoforms with identical DNA sequence specificity mediate distinct transcription responses. Pit-1 and Plt-1 beta constitute such a pair of transcription factor isoforms. Pit-1 enhances the Ras signaling pathway to the prolactin promoter, and Pit-1 beta represses basal prolactin promoter activity as well as Ras signaling to the prolactin promoter in pituitary cells. We have previously demonstrated that the beta-domain amino acid sequence dictates the transcriptional properties of Pit-1 beta. Here, we show that five hydrophobic beta-domain residues are required for Pit-1 isoform-specific repression of Res signaling, and we demonstrate that sodium butyrate and trichostatin A, pharmacological inhibitors of histone deacetylation, as well as viral Ski protein, a dominant-negative inhibitor of recruitment of N-CoR/mSin(3) histone deacetylase complexes, specifically reverse beta isoform-specific repression of Ras signaling. Moreover, we directly demonstrate, with a chromatin immunoprecipitation assay, that the Pit-1 beta isoform alters the histone acetylation state of the proximal prolactin promoter. This differential analysis of Pit-1/Pit-1 beta isoform function provides significant insights into the structural determinants that govern how different transcription factors with identical DNA sequence specificity can display opposite effects on target gene activity.	Univ Colorado, Hlth Sci Ctr, Colorado Canc Ctr, Program Mol Biol,Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Colorado Canc Ctr, Program Mol Biol,Dept Biochem & Mol Genet, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Gutierrez-Hartmann, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Colorado Canc Ctr, Program Mol Biol,Dept Med, 4200 E 9th Ave,Box B-151, Denver, CO 80262 USA.		Gutierrez-Hartmann, Arthur/F-1295-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037667, K01DK002752] Funding Source: NIH RePORTER; NIDDK NIH HHS [K01 DK02752-01, R01 DK37667] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agata Y, 1999, J BIOL CHEM, V274, P16412, DOI 10.1074/jbc.274.23.16412; Bradford AP, 1996, J BIOL CHEM, V271, P24639, DOI 10.1074/jbc.271.40.24639; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; Bradford AP, 2000, J BIOL CHEM, V275, P3100, DOI 10.1074/jbc.275.5.3100; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; CANDIDO EPM, 1978, CELL, V14, P105, DOI 10.1016/0092-8674(78)90305-7; Choi CY, 1997, J BIOL CHEM, V272, P16934, DOI 10.1074/jbc.272.27.16934; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; CONRAD KE, 1992, ONCOGENE, V7, P1279; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Diamond SE, 1999, MOL ENDOCRINOL, V13, P228, DOI 10.1210/me.13.2.228; Diamond SE, 1996, J BIOL CHEM, V271, P28925, DOI 10.1074/jbc.271.46.28925; DIAMOND SE, 1994, J VIROL, V68, P863, DOI 10.1128/JVI.68.2.863-876.1994; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; HOCH M, 1992, SCIENCE, V256, P94, DOI 10.1126/science.1348871; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; Hollenberg AN, 1996, J BIOL CHEM, V271, P28516, DOI 10.1074/jbc.271.45.28516; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KEECH CA, 1989, MOL ENDOCRINOL, V3, P832, DOI 10.1210/mend-3-5-832; Koenig RJ, 1998, THYROID, V8, P703, DOI 10.1089/thy.1998.8.703; KOIZUMI S, 1990, ONCOGENE, V5, P675; KONZAK KE, 1992, MOL ENDOCRINOL, V6, P241, DOI 10.1210/me.6.2.241; LAMBERT JR, 2000, METHODS STEROID RECE; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; LIM PS, 1990, J INFECT DIS, V162, P1263, DOI 10.1093/infdis/162.6.1263; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; OTTAVIANO Y, 1985, J BIOL CHEM, V260, P624; PICKETT CA, 1997, CONT ENDOCRINOL, V3, P1; Sanchez-Pacheco A, 1998, FEBS LETT, V422, P103, DOI 10.1016/S0014-5793(97)01609-8; Saunders N, 1999, CANCER RES, V59, P399; Sladek FM, 1999, MOL CELL BIOL, V19, P6509; THEILL LE, 1992, EMBO J, V11, P2261, DOI 10.1002/j.1460-2075.1992.tb05285.x; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; Tolon RM, 1998, J BIOL CHEM, V273, P26652, DOI 10.1074/jbc.273.41.26652; TREACY MN, 1992, CELL, V68, P491, DOI 10.1016/0092-8674(92)90186-G; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; WERTMAN KF, 1992, GENETICS, V132, P337; WIRTH T, 1991, NUCLEIC ACIDS RES, V19, P43, DOI 10.1093/nar/19.1.43; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yang BS, 1996, MOL CELL BIOL, V16, P538; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	49	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30977	30986		10.1074/jbc.M006048200	http://dx.doi.org/10.1074/jbc.M006048200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10921928	hybrid			2022-12-27	WOS:000089762700036
J	Kim, SS; Tam, JK; Wang, AF; Hegde, RS				Kim, SS; Tam, JK; Wang, AF; Hegde, RS			The structural basis of DNA target discrimination by papillomavirus E2 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA CELL-LINES; BINDING DOMAIN; BACTERIOPHAGE-434 REPRESSOR; SEPARATE REGULATION; CRYSTAL-STRUCTURE; AFFINITY; SITE; RECOGNITION; SEQUENCE; PROMOTER	The papillomavirus E2 proteins regulate the transcription of all papillomavirus genes and are necessary for viral DNA replication. Disruption of the E2 gene is commonly associated with malignancy in cervical carcinoma, indicating that E2 has a role in regulating tumor progression. Although the E2 proteins from all characterized papillomaviruses bind specifically to the same la-base pair DNA sequence, the cancer-associated human papillomavirus E2 proteins display a unique ability to detect DNA flexibility and intrinsic curvature. To understand the structural basis for this phenomenon, we have determined the crystal structures of the human papillomavirus-ls E2 DNA-binding domain and its complexes with high and low affinity binding sites. The E2 protein is a dimeric P-barrel and the EB-DNA interaction is accompanied by a large deformation of the DNA as it conforms to the E2 surface. DNA conformation and E2-DNA contacts are similar in both high and low affinity complexes. The differences in affinity correlate with the flexibility of the DNA sequence. Preferences of E2 proteins from different papillomavirus strains for flexible or prebent DNA targets correlate with the distribution of positive charge on their DNA interaction surfaces, suggesting a role for electrostatic forces in the recognition of DNA deformability.	NYU, Med Ctr, Skirball Inst Biomol Med, Dept Biochem, New York, NY 10016 USA; NYU, Med Ctr, Skirball Inst Biomol Med, Program Struct Biol, New York, NY 10016 USA	New York University; New York University	Hegde, RS (corresponding author), NYU, Med Ctr, Skirball Inst Biomol Med, Dept Biochem, 540 1st Ave, New York, NY 10016 USA.				NATIONAL CANCER INSTITUTE [R01CA066964] Funding Source: NIH RePORTER; NCI NIH HHS [CA66964] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; Alexander KA, 1996, BIOCHEMISTRY-US, V35, P9864, DOI 10.1021/bi960447d; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BEDROSIAN CL, 1990, VIROLOGY, V174, P557, DOI 10.1016/0042-6822(90)90109-5; Berg M, 1997, J VIROL, V71, P3853, DOI 10.1128/JVI.71.5.3853-3863.1997; Bostock-Smith CE, 1999, BIOCHEM J, V342, P125, DOI 10.1042/0264-6021:3420125; BRUNGER A, 1992, CNS VERSION 0 9; Bussiere DE, 1998, ACTA CRYSTALLOGR D, V54, P1367, DOI 10.1107/S0907444998005587; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Chen G, 2000, J VIROL, V74, P1506, DOI 10.1128/JVI.74.3.1506-1512.2000; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; Dickerson RE, 1998, NUCLEIC ACIDS RES, V26, P1906, DOI 10.1093/nar/26.8.1906; DILORENZO TP, 1995, J VIROL, V69, P6865, DOI 10.1128/JVI.69.11.6865-6872.1995; DiLorenzo TP, 1998, VIROLOGY, V243, P130, DOI 10.1006/viro.1998.9042; Duong TH, 1998, J MOL BIOL, V280, P31, DOI 10.1006/jmbi.1998.1846; Grassmann K, 1996, J VIROL, V70, P2339, DOI 10.1128/JVI.70.4.2339-2349.1996; HEDGE RS, 1998, J MOL BIOL, V276, P797; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; Hegde RS, 1998, J MOL BIOL, V284, P1479, DOI 10.1006/jmbi.1998.2260; Hines CS, 1998, J MOL BIOL, V276, P809, DOI 10.1006/jmbi.1997.1578; KOUDELKA GB, 1992, NATURE, V355, P89, DOI 10.1038/355089a0; KOUDELKA GB, 1988, P NATL ACAD SCI USA, V85, P4633, DOI 10.1073/pnas.85.13.4633; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; Liang H, 1996, BIOCHEMISTRY-US, V35, P2095, DOI 10.1021/bi951932w; Merkel JS, 1999, STRUCT FOLD DES, V7, P1333, DOI 10.1016/S0969-2126(00)80023-4; Merkel JS, 1998, FOLD DES, V3, P449, DOI 10.1016/S1359-0278(98)00062-5; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Olson WK, 1998, P NATL ACAD SCI USA, V95, P11163, DOI 10.1073/pnas.95.19.11163; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Rapp B, 1997, J VIROL, V71, P6956, DOI 10.1128/JVI.71.9.6956-6966.1997; Rozenberg H, 1998, P NATL ACAD SCI USA, V95, P15194, DOI 10.1073/pnas.95.26.15194; Schneider-Gadicke A, 1987, Haematol Blood Transfus, V31, P380; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SENEAR DF, 1993, ELECTROPHORESIS, V14, P704, DOI 10.1002/elps.11501401112; SENEAR DF, 1991, J BIOL CHEM, V266, P13661; Steger G, 1997, J VIROL, V71, P50, DOI 10.1128/JVI.71.1.50-58.1997; STUBENRAUCH F, 1994, J VIROL, V68, P6959, DOI 10.1128/JVI.68.11.6959-6966.1994; Stubenrauch F, 1998, J VIROL, V72, P8115, DOI 10.1128/JVI.72.10.8115-8123.1998; Thain A, 1997, J BIOL CHEM, V272, P8236, DOI 10.1074/jbc.272.13.8236; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	44	80	83	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31245	31254		10.1074/jbc.M004541200	http://dx.doi.org/10.1074/jbc.M004541200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906136	hybrid			2022-12-27	WOS:000089762700071
J	McKenzie, M; Trounce, I				McKenzie, M; Trounce, I			Expression of Rattus norvegicus mtDNA in Mus musculus cells results in multiple respiratory chain defects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY OPTIC NEUROPATHY; MITOCHONDRIAL-DNA; XENOMITOCHONDRIAL CYBRIDS; TRANSMITOCHONDRIAL MICE; MOUSE; CHLORAMPHENICOL; SEQUENCE; HETEROPLASMY; DISEASES	The production of in vitro and in vivo models of mitochondrial DNA (mtDNA) defects is currently limited by a lack of characterized mouse cell mtDNA mutants that may be expected to model human mitochondrial diseases. Here we describe the creation of transmitochondrial mouse (Mus musculus) cells repopulated with mtDNA from different murid species (xenomitochondrial cybrids). The closely related Mus spretus mtDNA is readily maintained when introduced into IM. musculus mtDNA-less (rho(0)) cells, and the resulting cybrids have normal oxidative phosphorylation (OXPHOS). When the more distantly related Rattus norvegicus mtDNA is transferred to the mouse nuclear background the mtDNA is replicated, transcribed, and translated efficiently. However, function of several OXPHOS complexes that depend on the coordinated assembly of nuclear and mtDNA-encoded proteins is impaired. Complex I activity in the Rattus xenocybrid was 46% of the control mean; complex III was 37%, and complex IV was 78%. These defects combined to restrict maximal respiration to 12-31% of the control and M. spretus xenocybrids, as measured polarographically using isolated cybrid mitochondria. These defects are distinct to those previously reported for human/primate xenocybrids. It should be possible to produce other mouse xenocybrid constructs with less severe OXPHOS phenotypes, to model human mtDNA diseases.	St Vincents Hosp, Mutat Res Ctr, Fitzroy, Vic 3065, Australia; Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia	St Vincent's Hospital Melbourne; St Vincent's Hospital Melbourne; University of Melbourne	Trounce, I (corresponding author), St Vincents Hosp, Mutat Res Ctr, 41 Victoria Parade, Fitzroy, Vic 3065, Australia.	trouncia@svhm.org.au	Trounce, Ian A/F-8338-2010; McKenzie, Matthew/H-4926-2019	Trounce, Ian A/0000-0002-1070-8892; McKenzie, Matthew/0000-0001-7508-1800				Barrientos A, 1998, J BIOL CHEM, V273, P14210, DOI 10.1074/jbc.273.23.14210; Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; BLANC H, 1981, P NATL ACAD SCI-BIOL, V78, P3789, DOI 10.1073/pnas.78.6.3789; Bonhomme F., 1996, GENETIC VARIANTS STR, P1577; BROWN MD, 1992, AM J HUM GENET, V51, P378; CATZEFLIS FM, 1993, MAMMAL PHYLOGENY : PLACENTALS, P159; Clayton DA, 2000, EXP CELL RES, V255, P4, DOI 10.1006/excr.1999.4763; Dey R, 2000, J BIOL CHEM, V275, P31520, DOI 10.1074/jbc.M004053200; ESTORNELL E, 1993, FEBS LETT, V332, P127, DOI 10.1016/0014-5793(93)80498-J; GADALETA G, 1989, J MOL EVOL, V28, P497, DOI 10.1007/BF02602930; Graff C, 1999, J INTERN MED, V246, P11, DOI 10.1046/j.1365-2796.1999.00514.x; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; HOWELL N, 1988, SOMAT CELL MOLEC GEN, V14, P185, DOI 10.1007/BF01534403; Irwin MH, 1999, TRANSGENIC RES, V8, P119, DOI 10.1023/A:1008925419758; Kenyon L, 1997, P NATL ACAD SCI USA, V94, P9131, DOI 10.1073/pnas.94.17.9131; King M P, 1996, Methods Enzymol, V264, P313, DOI 10.1016/S0076-6879(96)64030-0; Kwong LK, 1998, ARCH BIOCHEM BIOPHYS, V350, P118, DOI 10.1006/abbi.1997.0489; Levy SE, 1999, TRANSGENIC RES, V8, P137, DOI 10.1023/A:1008967412955; Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3; Marchington DR, 1999, NAT MED, V5, P957, DOI 10.1038/11403; Moraes CT, 1999, MOL BIOL CELL, V10, P3345, DOI 10.1091/mbc.10.10.3345; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Seibel M, 1999, BIOL CHEM, V380, P961, DOI 10.1515/BC.1999.119; SEIBEL P, 1995, NUCLEIC ACIDS RES, V23, P10, DOI 10.1093/nar/23.1.10; Silver L. M., 1995, MOUSE GENETICS; TAYLOR RW, 1993, BIOCHIM BIOPHYS ACTA, V1181, P261, DOI 10.1016/0925-4439(93)90030-5; Trounce I, 2000, NUCLEIC ACIDS RES, V28, P2164, DOI 10.1093/nar/28.10.2164; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Verneau O, 1997, J MOL EVOL, V45, P424, DOI 10.1007/PL00006247; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wallace DC, 1999, AM J HUM GENET, V65, pA18; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231	33	74	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31514	31519		10.1074/jbc.M004070200	http://dx.doi.org/10.1074/jbc.M004070200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10908563	hybrid, Green Published			2022-12-27	WOS:000089762700106
J	Nicolas, E; Beggs, JM; Taraschi, TF				Nicolas, E; Beggs, JM; Taraschi, TF			Gelonin is an unusual DNA glycosylase that removes adenine from single-stranded DNA, normal base pairs and mismatches	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME-INACTIVATING PROTEINS; POLYNUCLEOTIDE-ADENOSINE GLYCOSIDASE; POKEWEED ANTIVIRAL PROTEIN; ESCHERICHIA-COLI MUTY; RICIN A-CHAIN; EXCISION-REPAIR; DEOXYRIBONUCLEASE ACTIVITY; DIVALENT-CATIONS; RNA; MECHANISM	We reported that plant ribosome inactivating proteins (RIP) have a unique DNA glycosylase activity that removes adenine from single-stranded DNA (Nicolas, E,, Beggs, J, M,, Haltiwanger, B, M,, and Taraschi, T. F, (1998) J. Biol, Chem. 273, 17216-17220), In this investigation, we further characterized the interaction of the RIP gelonin with single stranded oligonucleotides and investigated its activity on double-stranded oligonucleotides. At physiological pH, zinc and p-mercaptoethanol stimulated the adenine DNA glycosylase activity of gelonin, Under these conditions, gelonin catalytically removed adenine from single-stranded DNA and, albeit to a lesser extent, from normal base pairs and mismatches in duplex DNA, Also unprecedented was the finding that activity on single-stranded and double-stranded oligonucleotides containing multiple adenines generated unstable products with several abasic sites, producing strand breakage and duplex melting respectively. The results from competition experiments suggested similar interactions between gelonin's DNA-binding domain and oligonucleotides with and without adenine. A reexamination of the classification of gelonin as a DNA glycosylase/AP lyase using the borohydride trapping assay revealed that gelonin was similar to the DNA glycosylase MutY: both enzymes are monofunctional glycosylases, which are trappable to their DNA substrates, The k(cat) for the removal of adenine from single-stranded DNA was close to the values observed with multisubstrate DNA glycosylases, suggesting that the activity of RIPs on DNA may be physiologically relevant.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Jefferson University	Taraschi, TF (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, JAH 229,1020 Locust St, Philadelphia, PA 19107 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041761] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-41761] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAILLY V, 1988, NUCLEIC ACIDS RES, V16, P9489, DOI 10.1093/nar/16.20.9489; Barbieri L, 1998, MOL MICROBIOL, V29, P661, DOI 10.1046/j.1365-2958.1998.00911.x; Barbieri L, 1997, NUCLEIC ACIDS RES, V25, P518, DOI 10.1093/nar/25.3.518; Barbieri L, 1996, BIOCHEM J, V319, P507, DOI 10.1042/bj3190507; BARBIERI L, 1994, NATURE, V372, P624, DOI 10.1038/372624a0; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; Berdal KG, 1998, EMBO J, V17, P363, DOI 10.1093/emboj/17.2.363; BETTER M, 1994, J BIOL CHEM, V269, P9644; Bjelland S, 1996, FEBS LETT, V397, P127, DOI 10.1016/S0014-5793(96)01166-0; Brigotti M, 1996, BIOCHEM MOL BIOL INT, V40, P181; Chen XY, 1998, BIOCHEMISTRY-US, V37, P11605, DOI 10.1021/bi980990p; David SS, 1998, CHEM REV, V98, P1221, DOI 10.1021/cr980321h; Day PJ, 1998, EUR J BIOCHEM, V258, P540, DOI 10.1046/j.1432-1327.1998.2580540.x; DIANOV GL, 1991, MOL GEN GENET, V225, P448, DOI 10.1007/BF00261686; Glassner BJ, 1998, P NATL ACAD SCI USA, V95, P9997, DOI 10.1073/pnas.95.17.9997; Gluck A, 1996, BIOCHEM MOL BIOL INT, V39, P285; GOODHEAD DT, 1994, INT J RADIAT BIOL, V65, P7, DOI 10.1080/09553009414550021; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; HABUKA N, 1991, J BIOL CHEM, V266, P23558; Harrison L, 1999, J MOL BIOL, V290, P667, DOI 10.1006/jmbi.1999.2892; HELENE C, 1975, NUCLEIC ACIDS RES, V2, P961, DOI 10.1093/nar/2.6.961; HUANG QC, 1995, BIOCHEM J, V309, P285, DOI 10.1042/bj3090285; Ishchenko AA, 1999, J BIOMOL STRUCT DYN, V17, P301, DOI 10.1080/07391102.1999.10508363; Kavli B, 1996, EMBO J, V15, P3442, DOI 10.1002/j.1460-2075.1996.tb00710.x; Krokan HE, 1997, BIOCHEM J, V325, P1; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; McFail-Isom L, 1998, BIOCHEMISTRY-US, V37, P17105, DOI 10.1021/bi982201+; MCGRATH MS, 1989, P NATL ACAD SCI USA, V86, P2844, DOI 10.1073/pnas.86.8.2844; Nicolas E, 1997, FEBS LETT, V406, P162, DOI 10.1016/S0014-5793(97)00267-6; Nicolas E, 1998, J BIOL CHEM, V273, P17216, DOI 10.1074/jbc.273.27.17216; Nicolas E, 1997, BIOCHEM J, V327, P413, DOI 10.1042/bj3270413; Noll DM, 1999, BIOCHEMISTRY-US, V38, P6374, DOI 10.1021/bi990335x; PERENTESIS JP, 1992, BIOFACTORS, V3, P173; POVIRK LF, 1988, BIOCHEMISTRY-US, V27, P380; Putnam CD, 2000, NAT STRUCT BIOL, V7, P17, DOI 10.1038/71211; RAY T, 1995, ELECTROPHORESIS, V16, P888, DOI 10.1002/elps.11501601149; Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; TELTOW GJ, 1983, ANTIMICROB AGENTS CH, V23, P390, DOI 10.1128/AAC.23.3.390; Tumer NE, 1997, P NATL ACAD SCI USA, V94, P3866, DOI 10.1073/pnas.94.8.3866; Verdine GL, 1997, CHEM BIOL, V4, P329, DOI 10.1016/S1074-5521(97)90123-X; VESNAVER G, 1989, P NATL ACAD SCI USA, V86, P3614, DOI 10.1073/pnas.86.10.3614; Wang P, 1999, NUCLEIC ACIDS RES, V27, P1900, DOI 10.1093/nar/27.8.1900; Wang YX, 1999, CELL, V99, P433, DOI 10.1016/S0092-8674(00)81529-9; Waters TR, 1998, J BIOL CHEM, V273, P20007, DOI 10.1074/jbc.273.32.20007; Williams SD, 1998, NUCLEIC ACIDS RES, V26, P5123, DOI 10.1093/nar/26.22.5123; Williams SD, 1999, BIOCHEMISTRY-US, V38, P15417, DOI 10.1021/bi992013z; Wright PM, 1999, J BIOL CHEM, V274, P29011, DOI 10.1074/jbc.274.41.29011; Wyatt MD, 1999, BIOESSAYS, V21, P668, DOI 10.1002/(SICI)1521-1878(199908)21:8<668::AID-BIES6>3.3.CO;2-4; Zharkov DO, 1998, BIOCHEMISTRY-US, V37, P12384, DOI 10.1021/bi981066y	50	32	34	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31399	31406		10.1074/jbc.M004505200	http://dx.doi.org/10.1074/jbc.M004505200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10906135	hybrid			2022-12-27	WOS:000089762700092
J	Nikolaishvili-Feinberg, N; Cordeiro-Stone, M				Nikolaishvili-Feinberg, N; Cordeiro-Stone, M			Discrimination between translesion synthesis and template switching during bypass replication of thymine dimers in duplex DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENTOSUM VARIANT CELLS; IRRADIATED HUMAN-CELLS; XERODERMA-PIGMENTOSUM; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; MISMATCH REPAIR; N-2-ACETYLAMINOFLUORENE ADDUCTS; POSTREPLICATION REPAIR; METHYLATION ANALYSIS; PYRIMIDINE DIMER	The goal of this study was to determine whether bypass replication occurs by translesion synthesis or template switching (copy choice) when a duplex molecule carrying a single cis,syn-cyclobutane thymine dimer is replicated in vitro by human cell extracts. Circular heteroduplex DNA molecules were constructed to contain the SV40 origin of replication and a mismatch opposite to or nearby the dimer. Control molecules with only the mismatch were also prepared. Heteroduplexes were methylated at CpG islands and replicated in vitro (30 min). Following bisulfite treatment, the nascent DNA complementary to the dimer-containing template was distinguished from the other three strands by methylation-specific polymerase chain reaction. Cloning and sequencing of polymerase chain reaction products revealed that 80-98% carried the sequence predicted for translesion synthesis, with two adenines incorporated opposite the dimer. The fraction of clones with sequence predictive of template switching was reduced when extracts deficient in mismatch repair or nucleotide excision repair activities were used to replicate the heteroduplex molecules. These results support the conclusion that lesion bypass during in vitro replication of duplex DNA containing thymine dimers occurs by translesion synthesis.	Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Cordeiro-Stone, M (corresponding author), Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Lineberger Comprehens Canc Ctr, 517 Brinkhous Bullitt Bldg, Chapel Hill, NC 27599 USA.	uncmcs@med.unc.edu			NATIONAL CANCER INSTITUTE [R55CA055065, R01CA055065] Funding Source: NIH RePORTER; NCI NIH HHS [CA55065] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baynton K, 1998, MOL CELL BIOL, V18, P960, DOI 10.1128/MCB.18.2.960; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cleaver JE, 1995, METABOLIC MOL BASES, VIII, P4393; Cordeiro-Stone M, 1999, J MOL BIOL, V289, P1207, DOI 10.1006/jmbi.1999.2847; CordeiroStone M, 1997, J BIOL CHEM, V272, P13945, DOI 10.1074/jbc.272.21.13945; CORDEIROSTONE M, 1979, BIOPHYS J, V27, P287, DOI 10.1016/S0006-3495(79)85218-2; Cordonnier AM, 1999, MOL CELL BIOL, V19, P2206; Ensch-Simon I, 1998, BIOCHEMISTRY-US, V37, P8218, DOI 10.1021/bi972460j; FEIL R, 1994, NUCLEIC ACIDS RES, V22, P695, DOI 10.1093/nar/22.4.695; Friedberg E.C., 1995, DNA REPAIR MUTAGENES, P407; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; FUJIWARA Y, 1976, MUTAT RES, V37, P91, DOI 10.1016/0027-5107(76)90058-0; Gerlach VL, 1999, P NATL ACAD SCI USA, V96, P11922, DOI 10.1073/pnas.96.21.11922; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; Gibbs PEM, 2000, P NATL ACAD SCI USA, V97, P4186, DOI 10.1073/pnas.97.8.4186; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HIGGINS NP, 1976, J MOL BIOL, V101, P417, DOI 10.1016/0022-2836(76)90156-X; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; Hubscher U, 2000, TRENDS BIOCHEM SCI, V25, P143, DOI 10.1016/S0968-0004(99)01523-6; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, P NATL ACAD SCI USA, V97, P3838, DOI 10.1073/pnas.97.8.3838; Johnson RE, 1999, P NATL ACAD SCI USA, V96, P12224, DOI 10.1073/pnas.96.22.12224; KoffelSchwartz N, 1996, P NATL ACAD SCI USA, V93, P7805, DOI 10.1073/pnas.93.15.7805; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LEHMANN AR, 1972, J MOL BIOL, V66, P319, DOI 10.1016/0022-2836(72)90418-4; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; MAHER VM, 1976, NATURE, V261, P593, DOI 10.1038/261593a0; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; McDonald JP, 1999, GENOMICS, V60, P20, DOI 10.1006/geno.1999.5906; McDonald JP, 1997, GENETICS, V147, P1557; MENEGHINI R, 1981, BIOPHYS J, V33, P81, DOI 10.1016/S0006-3495(81)84873-4; MENEGHINI R, 1976, BIOCHIM BIOPHYS ACTA, V425, P428, DOI 10.1016/0005-2787(76)90007-1; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; MYHR BC, 1979, MUTAT RES, V62, P341, DOI 10.1016/0027-5107(79)90089-7; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; RAIZIS AM, 1995, ANAL BIOCHEM, V226, P161, DOI 10.1006/abio.1995.1204; RENBAUM P, 1990, NUCLEIC ACIDS RES, V18, P1145, DOI 10.1093/nar/18.5.1145; ROBERTS JD, 1988, P NATL ACAD SCI USA, V85, P7064, DOI 10.1073/pnas.85.19.7064; ROBERTS JD, 1993, METHODS MOL GENET, V2, P295; SHAY JW, 1992, EXP GERONTOL, V27, P477, DOI 10.1016/0531-5565(92)90003-I; Svoboda DL, 1995, P NATL ACAD SCI USA, V92, P11975, DOI 10.1073/pnas.92.26.11975; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; THOMAS DC, 1995, J BIOL CHEM, V270, P21226, DOI 10.1074/jbc.270.36.21226; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; THOMAS DC, 1994, P NATL ACAD SCI USA, V91, P7752, DOI 10.1073/pnas.91.16.7752; UMAR A, 1994, J BIOL CHEM, V269, P14367; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; WANG YC, 1991, P NATL ACAD SCI USA, V88, P7810, DOI 10.1073/pnas.88.17.7810; WANG YC, 1993, MOL CELL BIOL, V13, P4276, DOI 10.1128/MCB.13.7.4276; Washington MT, 2000, P NATL ACAD SCI USA, V97, P3094, DOI 10.1073/pnas.050491997; Washington MT, 1999, J BIOL CHEM, V274, P36835, DOI 10.1074/jbc.274.52.36835; WATERS HL, 1993, J INVEST DERMATOL, V101, P744, DOI 10.1111/1523-1747.ep12371686; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191	60	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30943	30950		10.1074/jbc.M005225200	http://dx.doi.org/10.1074/jbc.M005225200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10913440	Green Published, hybrid			2022-12-27	WOS:000089762700031
J	Sherman, LS; Atit, R; Rosenbaum, T; Cox, AD; Ratner, N				Sherman, LS; Atit, R; Rosenbaum, T; Cox, AD; Ratner, N			Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALIGNANT MYELOID DISORDERS; TYPE-1 GENE; NF1 GENE; SIGNALING PATHWAY; BINDING DOMAIN; DROSOPHILA NF1; PROTEIN-KINASE; BONE-MARROW; ACTIVATION; EXPRESSION	Neurofibromatosis type 1 (NF1) is a common genetic disorder characterized by multiple neurofibromas, peripheral nerve tumors containing mainly Schwann cells and fibroblasts. The NF1 gene encodes neurofibromin, a tumor suppressor postulated to function in part as a Ras GTPase-activating protein. The roles of different cell types and of elevated Ras-GTP in neurofibroma formation are unclear. To determine which neurofibroma cell type has altered Ras-GTP regulation, we developed an immunocytochemical assay for active, GTP-bound Ras. In NIH 3T3 cells, the assay detected overexpressed, constitutively activated K-, N-, and Ha-Ras and insulin-induced endogenous Ras GTP. In dissociated neurofibroma cells from NF1 patients, Ras-GTP was elevated in Schwann cells but not fibroblasts. Twelve to 62% of tumor Schwann cells showed elevated Ras-GTP, unexpectedly revealing neurofibroma Schwann cell heterogeneity. Increased basal Ras-GTP did not correlate with increased cell proliferation. Normal human Schwann cells, however, did not demonstrate elevated basal Ras activity. Furthermore, compared with cells from wild type littermates, Ras-GTP was elevated in all mouse Nf1(-/-) Schwann cells but never in Nf1(-/-) mouse fibroblasts. Our results indicate that Ras activity is detectably increased in only some neurofibroma Schwann cells and suggest that neurofibromin is not an essential regulator of Ras activity in fibroblasts.	Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA; Univ Dusseldorf, Childrens Hosp, Dept Neuropediat, D-4000 Dusseldorf, Germany; Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University System of Ohio; University of Cincinnati; Heinrich Heine University Dusseldorf; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Ratner, N (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, 3125 Eden Ave, Cincinnati, OH 45267 USA.	Nancy.Ratner@uc.edu		RATNER, NANCY/0000-0001-5030-9354; Cox, Adrienne D./0000-0002-4901-2454	NCI NIH HHS [CA76092] Funding Source: Medline; NINDS NIH HHS [R01 NS028840-09, R01 NS028840, NS10297, NS28840] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028840] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Atit RP, 1999, J INVEST DERMATOL, V112, P835, DOI 10.1046/j.1523-1747.1999.00609.x; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; BOSSE F, 1994, J NEUROSCI RES, V37, P529, DOI 10.1002/jnr.490370412; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; COX AD, 1995, METHOD ENZYMOL, V255, P195; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; FIORDALISI JJ, 2000, IN PRESS METHODS ENZ, V322; GRIESSER J, 1995, BIOL CHEM H-S, V376, P91, DOI 10.1515/bchm3.1995.376.2.91; Guha A, 1996, ONCOGENE, V12, P507; Guo HF, 1997, SCIENCE, V276, P795, DOI 10.1126/science.276.5313.795; Gutmann DH, 1997, JAMA-J AM MED ASSOC, V278, P51, DOI 10.1001/jama.278.1.51; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; JOHNSON MR, 1994, MOL CELL BIOL, V14, P641, DOI 10.1128/MCB.14.1.641; KIM HA, 1995, ONCOGENE, V11, P325; Kim HA, 1997, MOL CELL BIOL, V17, P862, DOI 10.1128/MCB.17.2.862; KIM MR, 1998, NEUROFIBROMATOSIS TY, P89; Kitano Yukio, 1994, Journal of Dermatological Science, V7, P96, DOI 10.1016/0923-1811(94)90082-5; Kluwe L, 1999, GENE CHROMOSOME CANC, V24, P283, DOI 10.1002/(SICI)1098-2264(199903)24:3<283::AID-GCC15>3.0.CO;2-K; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; Largaespada DA, 1996, NAT GENET, V12, P137, DOI 10.1038/ng0296-137; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; Mikol DD, 1999, GLIA, V27, P39; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Pelton PD, 1998, ONCOGENE, V17, P2195, DOI 10.1038/sj.onc.1202141; PELTONEN J, 1984, ACTA NEUROPATHOL, V63, P269, DOI 10.1007/BF00687332; PLEASURE D, 1986, ANN NY ACAD SCI, V486, P227, DOI 10.1111/j.1749-6632.1986.tb48076.x; Prendergast GC, 2000, CURR OPIN CELL BIOL, V12, P166, DOI 10.1016/S0955-0674(99)00072-1; Riccardi V. M., 1992, NEUROFIBROMATOSIS PH; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; Rosenbaum T, 1997, NEUROSCIENTIST, V3, P412, DOI 10.1177/107385849700300614; ROSENBAUM T, 1995, DEVELOPMENT, V121, P3583; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Sawada S, 1996, NAT GENET, V14, P110, DOI 10.1038/ng0996-110; Serra E, 1997, AM J HUM GENET, V61, P512, DOI 10.1086/515504; SHANNON KM, 1994, NEW ENGL J MED, V330, P597, DOI 10.1056/NEJM199403033300903; SHEELA S, 1990, J CELL BIOL, V111, P645, DOI 10.1083/jcb.111.2.645; SHERMAN LS, 2000, IN PRESS METHODS ENZ, V332; Side L, 1997, NEW ENGL J MED, V336, P1713, DOI 10.1056/NEJM199706123362404; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; The I, 1997, SCIENCE, V276, P791, DOI 10.1126/science.276.5313.791; vanderGeer P, 1997, MOL CELL BIOL, V17, P1840, DOI 10.1128/MCB.17.4.1840; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Wallace MR, 2000, GENE CHROMOSOME CANC, V27, P117, DOI 10.1002/(SICI)1098-2264(200002)27:2<117::AID-GCC1>3.0.CO;2-H; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YAN N, 1995, CANCER RES, V55, P3569; ZELKOWITZ M, 1981, PEDIATR RES, V15, P290, DOI 10.1203/00006450-198103000-00018	57	100	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30740	30745		10.1074/jbc.M001702200	http://dx.doi.org/10.1074/jbc.M001702200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10900196	Green Submitted, Green Accepted, hybrid			2022-12-27	WOS:000089577900112
J	Smits, VAJ; Klompmaker, R; Vallenius, T; Rijksen, G; Makela, TP; Medema, RH				Smits, VAJ; Klompmaker, R; Vallenius, T; Rijksen, G; Makela, TP; Medema, RH			p21 Inhibits Thr(161) phosphorylation of Cdc2 to enforce the G(2) DNA damage checkpoint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; CDK-ACTIVATING KINASE; CELL-CYCLE; NUCLEAR EXPORT; PROTEIN-KINASE; 2 POINTS; LOCALIZATION; MITOSIS; P53; 14-3-3-SIGMA	The cyclin-dependent kinase inhibitor p21 is required for a sustained G(2) arrest after activation of the DNA damage checkpoint. Here we have addressed the mechanism by which p21 can contribute to this arrest in G(2). We show that p21 blocks the activating phosphorylation of Cdc2 on Thr(161). p21 does not interfere with the dephosphorylation of two inhibitory phosphorylation sites on Cdc2, Thr(14) and Tyr(15), indicating that p21 targets a different event in Cdc2 activation as the well described DNA damage checkpoint pathway involving Chk1 and Cdc25C. Taken together our data show that a cell is equipped with at least two independent pathways to ensure efficient inhibition of Cdc2 activity in response to DNA damage, influencing both positive and negative regulatory phosphorylation events on Cdc2.	Univ Med Ctr Utrecht, Dept Hematol, Jordan Lab, NL-3508 GA Utrecht, Netherlands; Univ Helsinki, Haartman Inst, FIN-00014 Helsinki, Finland	Utrecht University; Utrecht University Medical Center; University of Helsinki	Medema, RH (corresponding author), Univ Med Ctr Utrecht, Jordan Lab, G03-647,Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	R.H.Medema@lab.azu.nl	Medema, Rene H/E-2981-2013; Smits, Veronique A.J./R-2302-2019; makela, tomi/B-3734-2009; Medema, Rene H/G-5415-2011	Smits, Veronique A.J./0000-0002-9160-4525; makela, tomi/0000-0002-4869-8044; Medema, Rene/0000-0002-6754-0381				APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hitomi M, 1998, ONCOGENE, V17, P959, DOI 10.1038/sj.onc.1202005; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KORNBLUTH S, 1994, MOL BIOL CELL, V5, P273, DOI 10.1091/mbc.5.3.273; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; LI Y, 1994, ONCOGENE, V9, P2261; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Smits VAJ, 1999, FEBS LETT, V457, P23, DOI 10.1016/S0014-5793(99)01002-9; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Winters ZE, 1998, ONCOGENE, V17, P673, DOI 10.1038/sj.onc.1201991; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131	39	176	179	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30638	30643		10.1074/jbc.M005437200	http://dx.doi.org/10.1074/jbc.M005437200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10913154	hybrid			2022-12-27	WOS:000089577900099
J	Williams, LJS; Lyons, V; MacLeod, I; Rajan, V; Darlington, GJ; Poli, V; Seckl, JR; Chapman, KE				Williams, LJS; Lyons, V; MacLeod, I; Rajan, V; Darlington, GJ; Poli, V; Seckl, JR; Chapman, KE			C/EBP regulates hepatic transcription of 11 beta-hydroxysteroid dehydrogenase type 1 - A novel mechanism for cross-talk between the C/EBP and glucocorticoid signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT/ENHANCER-BINDING PROTEIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; RNA POLYMERASE-II; NF-KAPPA-B; MINERALOCORTICOID ACTION; TISSUE-DISTRIBUTION; GENE-TRANSCRIPTION; RAT HEPATOCYTES; KNOCKOUT MICE; EXPRESSION	Glucocorticoid action within individual cells is potently modulated by 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD), which, by interconverting active and inert glucocorticoids, determines steroid access to receptors. Type 1 11 beta-HSD (11 beta-HSD1) is highly expressed in liver where it regenerates glucocorticoids, thus amplifying their action and contributing to induction of glucocorticoid-responsive genes, most of which are also regulated by members of the C/EBP (CAAT/enhancer-binding protein) family of transcription factors. Here we demonstrate that C/EBP alpha is a potent activator of the 11 beta-HSD1 gene in hepatoma cells and that mice deficient in C/EBP alpha have reduced hepatic 11 beta-HSD1 expression. In contrast, C/EBP beta is a relatively weak activator of 11 beta- HSD1 transcription in hepatoma cells and attenuates C/EBP alpha induction, and mice that lack C/EBP beta have increased hepatic 11 beta-HSD1 mRNA. The 11 beta-HSD1 promoter (between -812 and +76) contains 10 C/EBP binding sites, and mutation of the promoter proximal sites decreases the C/EBP inducibility of the promoter. One site encompasses the transcription start, and both C/EBP alpha and C/EBP beta are present in complexes formed by liver nuclear proteins at this site. The regulation of 11 beta-HSD1 expression, and hence intracellular glucocorticoid levels, by members of the C/EBP family provides a novel mechanism for cross-talk between the C/EBP family of transcription factors and the glucocorticoid signaling pathway.	Univ Edinburgh, Western Gen Hosp, Mol Endocrinol Grp, Mol Med Ctr, Edinburgh EH4 2XU, Midlothian, Scotland; Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA; Univ Dundee, Dept Biochem, Dundee DD1 4HN, Scotland	University of Edinburgh; Baylor College of Medicine; University of Dundee	Chapman, KE (corresponding author), Univ Edinburgh, Western Gen Hosp, Mol Endocrinol Grp, Mol Med Ctr, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.		Poli, Valeria/A-9215-2012; Seckl, Jonathan R/C-3555-2013	Poli, Valeria/0000-0002-3739-3966; Chapman, Karen/0000-0001-7777-6817				AGARWAL AK, 1989, J BIOL CHEM, V264, P18939; ALBISTON AL, 1994, MOL CELL ENDOCRINOL, V105, pR11, DOI 10.1016/0303-7207(94)90176-7; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAKKER O, 1991, NUCLEIC ACIDS RES, V19, P1213, DOI 10.1093/nar/19.6.1213; BALMAIN A, 1982, NUCLEIC ACIDS RES, V10, P4259, DOI 10.1093/nar/10.14.4259; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Breed DR, 1997, ENDOCRINOLOGY, V138, P5527, DOI 10.1210/en.138.12.5527; Brown RW, 1996, BIOCHEM J, V313, P1007, DOI 10.1042/bj3131007; Cappelletti M, 1996, CELL DEATH DIFFER, V3, P29; Chapman KE, 1997, BIOCHEM SOC T, V25, P583, DOI 10.1042/bst0250583; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; Croniger C, 1998, J BIOL CHEM, V273, P31629, DOI 10.1074/jbc.273.48.31629; DARLINGTON GJ, 1995, CURR OPIN GENET DEV, V5, P565, DOI 10.1016/0959-437X(95)80024-7; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDWARDS CRW, 1988, LANCET, V2, P986, DOI 10.1016/S0140-6736(88)90742-8; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; Gotoh T, 1997, J BIOL CHEM, V272, P3694, DOI 10.1074/jbc.272.6.3694; Jamieson, 1997, Stress, V2, P123; Jamieson PM, 1999, J STEROID BIOCHEM, V68, P245, DOI 10.1016/S0960-0760(99)00037-0; Jamieson PM, 1999, J ENDOCRINOL, V160, P103, DOI 10.1677/joe.0.1600103; JAMIESON PM, 1995, ENDOCRINOLOGY, V136, P4754, DOI 10.1210/en.136.11.4754; Kotelevtsev Y, 1997, P NATL ACAD SCI USA, V94, P14924, DOI 10.1073/pnas.94.26.14924; Kotelevtsev Y, 1999, J CLIN INVEST, V103, P683, DOI 10.1172/JCI4445; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LOW SC, 1994, J MOL ENDOCRINOL, V13, P167, DOI 10.1677/jme.0.0130167; MACDOUGALD OA, 1994, J BIOL CHEM, V269, P19041; Matsuno F, 1996, J BIOCHEM-TOKYO, V119, P524; MAURER RA, 1987, MOL CELL BIOL, V7, P4247, DOI 10.1128/MCB.7.12.4247; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; MOISAN MP, 1992, MOL ENDOCRINOL, V6, P1082, DOI 10.1210/me.6.7.1082; Napolitano A, 1998, J STEROID BIOCHEM, V64, P251, DOI 10.1016/S0960-0760(97)00200-8; NYE JA, 1990, P NATL ACAD SCI USA, V87, P3992, DOI 10.1073/pnas.87.10.3992; PARK EA, 1993, J BIOL CHEM, V268, P613; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; RAJAN V, 1995, J STEROID BIOCHEM, V52, P141, DOI 10.1016/0960-0760(94)00159-J; Ramos RA, 1996, MOL CELL BIOL, V16, P5288; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Seckl JR, 1997, EUR J BIOCHEM, V249, P361, DOI 10.1111/j.1432-1033.1997.t01-1-00361.x; SIERRA F, 1993, GENE TRANSCRIPTION P, P125; Voice MW, 1996, BIOCHEM J, V317, P621, DOI 10.1042/bj3170621; WALKER BR, 1995, J CLIN ENDOCR METAB, V80, P3155, DOI 10.1210/jc.80.11.3155; WALKER BR, 1992, CLIN ENDOCRINOL, V37, P483, DOI 10.1111/j.1365-2265.1992.tb01478.x; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553	53	100	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30232	30239		10.1074/jbc.M001286200	http://dx.doi.org/10.1074/jbc.M001286200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10906322	hybrid			2022-12-27	WOS:000089577900045
J	Iwaki, S; Tamura, N; Kimura-Someya, T; Nada, S; Yamaguchi, A				Iwaki, S; Tamura, N; Kimura-Someya, T; Nada, S; Yamaguchi, A			Cysteine-scanning mutagenesis of transmembrane segments 4 and 5 of the Tn10-encoded metal tetracycline/H+ antiporter reveals a permeability barrier in the middle of a transmembrane water-filled channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-TRANSPORT PROTEIN; SITE-DIRECTED MUTAGENESIS; DUAL AMBER METHOD; ESCHERICHIA-COLI; LACTOSE PERMEASE; ACTIVE EFFLUX; RESISTANCE PROTEIN; SEQUENCE MOTIF; TOPOLOGY; RESIDUES	Cysteine-scanning mutants as to putative transmembrane segments 4 and 5 and the flanking regions of Tn10-encoded metal-tetracycline/H+ antiporter (TetA (B)) were constructed. All mutants were normally expressed, Among the 57 mutants (L99C to I155C), nine conserved arginine-, aspartate-, and glycine-replaced ones exhibited greatly reduced tetracycline resistance and almost no transport activity, and five conserved glycine- and proline-replaced mutants exhibited greatly reduced tetracycline transport activity in inverted membrane vesicles despite their high or moderate drug resistance. All other cysteine-scanning mutants retained normal drug resistance and normal tetracycline transport activity except for the L142C and I143C mutants. The transmembrane (TM) regions TM4 and TM5 were determined to comprise 20 amino acid residues, Leu-99 to Ile-118, and 17 amino acid residues, Ala-136 to Ala-152, respectively, on the basis of N-[C-14]ethylmaleimide ([C-14]NEM) reactivity, The NEM reactivity patterns of the TM4 and TM5 mutants were quite different from each other. TM4 could be divided into two halves, that is, a NEM nonreactive periplasmic half and a periodically reactive cytoplasmic half, indicating that TM4 is tilted toward a water-filled transmembrane channel and that only its cytoplasmic half faces the channel. On the other hand, NEM-reactive mutations were observed periodically (every two residues) along the whole length of TM5, A permeability barrier for a membrane-impermeable sulfhydryl reagent, 4-acetamido-4'-maleimidylstilbene-2,2'-disulfonic acid, was present in the middle of TM5 between Leu-142 and Gly-145, whereas all the NEM-reactive mutants as to TM4 were not accessible to 4-acetamido-4'-maleimidylstilbene-2,2'-disulfonic acid, indicating that the channel-facing side of TM4 is located inside the permeability barrier. Tetracycline protected the G141C mutant from the NEM binding, whereas the other mutants in TM4 and TM5 were not protected by tetracycline.	Osaka Univ, Inst Sci & Ind Res, Dept Cell Membrane Biol, Ibaraki, Osaka 5670047, Japan; Japan Sci & Technol Corp, CREST, Osaka 5670047, Japan; Osaka Univ, Fac Pharmaceut Sci, Suita, Osaka 5650871, Japan	Osaka University; Japan Science & Technology Agency (JST); Osaka University	Yamaguchi, A (corresponding author), Osaka Univ, Inst Sci & Ind Res, Dept Cell Membrane Biol, 8-1 Mihogaoka, Ibaraki, Osaka 5670047, Japan.		Kimura-Someya, Tomomi/C-4169-2017	Kimura-Someya, Tomomi/0000-0003-2232-1801				COPUE JJ, 1993, EMBO J, V12, P631; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P12644, DOI 10.1021/bi00210a012; ECKERT B, 1989, J BIOL CHEM, V264, P11663; Frillingos S, 1997, PROTEIN SCI, V6, P431; Frillingos S, 1997, BIOCHEMISTRY-US, V36, P269, DOI 10.1021/bi9618629; FRILLINGOS S, 1994, BIOCHEMISTRY-US, V33, P8074, DOI 10.1021/bi00192a012; HANSEN LM, 1993, ANTIMICROB AGENTS CH, V37, P2699, DOI 10.1128/AAC.37.12.2699; HASHIMOTOGOTOH T, 1995, GENE, V152, P271, DOI 10.1016/0378-1119(94)00750-M; HashimotoGotoh T, 1995, GENE, V167, P333, DOI 10.1016/0378-1119(95)00705-9; He MM, 1996, BIOCHEMISTRY-US, V35, P12909, DOI 10.1021/bi960876b; HENDERSON PJF, 1990, J BIOENERG BIOMEMBR, V22, P525, DOI 10.1007/BF00762961; Javadpour MM, 1999, BIOPHYS J, V77, P1609, DOI 10.1016/S0006-3495(99)77009-8; JUNG K, 1995, BIOCHEMISTRY-US, V34, P1030, DOI 10.1021/bi00003a038; Kimura T, 1998, BIOCHEMISTRY-US, V37, P5475, DOI 10.1021/bi973188g; Kimura T, 1997, J BIOL CHEM, V272, P580; KIMURA T, 1995, FEBS LETT, V362, P47, DOI 10.1016/0014-5793(95)00205-N; Kimura T, 1998, J BIOL CHEM, V273, P5243, DOI 10.1074/jbc.273.9.5243; Kimura T, 1996, BIOCHEMISTRY-US, V35, P15896, DOI 10.1021/bi961568g; Kimura-Someya T, 1998, J BIOL CHEM, V273, P32806, DOI 10.1074/jbc.273.49.32806; Konishi S, 1999, FEBS LETT, V461, P315, DOI 10.1016/S0014-5793(99)01490-8; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEVY SB, 1992, ANTIMICROB AGENTS CH, V36, P695, DOI 10.1128/AAC.36.4.695; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; MCMURRY L, 1980, P NATL ACAD SCI-BIOL, V77, P3974, DOI 10.1073/pnas.77.7.3974; MENEZES ME, 1990, P NATL ACAD SCI USA, V87, P1638, DOI 10.1073/pnas.87.5.1638; Mordoch SS, 1999, J BIOL CHEM, V274, P19480, DOI 10.1074/jbc.274.27.19480; PHILIPSON L, 1978, CELL, V13, P189, DOI 10.1016/0092-8674(78)90149-6; SAHINTOTH M, 1993, PROTEIN SCI, V2, P1024, DOI 10.1002/pro.5560020615; Someya Y, 2000, J BIOL CHEM, V275, P210, DOI 10.1074/jbc.275.1.210; SOMEYA Y, 1995, BIOCHEMISTRY-US, V34, P7, DOI 10.1021/bi00001a002; Tang XB, 1998, J BIOL CHEM, V273, P22545, DOI 10.1074/jbc.273.35.22545; TERCERO JA, 1993, EUR J BIOCHEM, V218, P963, DOI 10.1111/j.1432-1033.1993.tb18454.x; Varela MF, 1995, MOL MEMBR BIOL, V12, P313, DOI 10.3109/09687689509072433; WEITZMAN C, 1995, BIOCHEMISTRY-US, V34, P9374, DOI 10.1021/bi00029a013; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P4809; YAMAGUCHI A, 1990, FEBS LETT, V265, P17, DOI 10.1016/0014-5793(90)80872-G; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P15525; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P19155; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973	39	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22704	22712		10.1074/jbc.M910354199	http://dx.doi.org/10.1074/jbc.M910354199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10930423	hybrid			2022-12-27	WOS:000088419400017
J	De Leo, R; Miccadei, S; Zammarchi, E; Civitareale, D				De Leo, R; Miccadei, S; Zammarchi, E; Civitareale, D			Role for p300 in Pax 8 induction of thyroperoxidase gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL COACTIVATORS; BINDING PROTEINS; THYROID-GLAND; CYCLIC-AMP; CBP; DIFFERENTIATION; E1A; MECHANISMS; PROMOTER; ENHANCER	The nuclear p300 protein functions as a co-activator of gene transcription. Here we show that p300 works as a ca-activator of the transcription factor Pax 8 on the thyroperoxidase gene promoter. Consistent with its role as co-activator, p300 potentiates Pax 8-activated transcription. Furthermore, we provide evidence supporting the formation of a complex between both factors in vitro and in vitro. This interaction involves the aminoterminal and CH3 domains of p300 and the trans-activation domain of Pax 8 at its carboxyl-terminal end. We show that the CH3 domain is crucial for the co-activator role of p300 on the thyroperoxidase gene promoter. In agreement with our finding and with the ability of the adenoviral protein E1A to bind p300, we show that EIA down-regulates Pax 8 activity.	Regina Elena Inst Canc Res, Lab Mol Pathol & Ultrastruct, I-00158 Rome, Italy; Regina Elena Inst Canc Res, Lab Cell Metab & Pharmacokinet, I-00158 Rome, Italy; Univ Florence, Dept Pediat, Meyer Hosp, I-50100 Florence, Italy; CNR, Inst Expt Med, I-00100 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; Consiglio Nazionale delle Ricerche (CNR)	Civitareale, D (corresponding author), Regina Elena Inst Canc Res, Lab Mol Pathol & Ultrastruct, Via Messi Oro 156, I-00158 Rome, Italy.	dciv@yahoo.com	Civitareale, Donato/B-4889-2015; , stefaniamiccadei/J-2640-2017	Civitareale, Donato/0000-0001-5719-9098; , stefaniamiccadei/0000-0001-8890-6998	Telethon [E.0254] Funding Source: Medline	Telethon(Fondazione Telethon)		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BERLINGIERI MT, 1993, ONCOGENE, V8, P249; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; DAMANTE G, 1994, BBA-GENE STRUCT EXPR, V1218, P255, DOI 10.1016/0167-4781(94)90176-7; De Felice M, 1998, NAT GENET, V19, P395, DOI 10.1038/1289; De Vita G, 1998, CELL GROWTH DIFFER, V9, P97; Dorfler P, 1996, EMBO J, V15, P1971, DOI 10.1002/j.1460-2075.1996.tb00548.x; Eberhard D, 1999, CANCER RES, V59, p1716S; Esposito C, 1998, BIOCHEM J, V331, P37, DOI 10.1042/bj3310037; Fabbro D, 1998, J MOL ENDOCRINOL, V21, P347, DOI 10.1677/jme.0.0210347; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GERARD CM, 1989, MOL ENDOCRINOL, V3, P2110, DOI 10.1210/mend-3-12-2110; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Gingras S, 1999, NUCLEIC ACIDS RES, V27, P2722, DOI 10.1093/nar/27.13.2722; GUARENTE L, 1995, TRENDS BIOCHEM SCI, V20, P517, DOI 10.1016/S0968-0004(00)89120-3; HOLLON T, 1989, ANAL BIOCHEM, V182, P411, DOI 10.1016/0003-2697(89)90616-7; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Mansouri A, 1998, NAT GENET, V19, P87, DOI 10.1038/ng0598-87; Mansouri A, 1996, CURR OPIN CELL BIOL, V8, P851, DOI 10.1016/S0955-0674(96)80087-1; McKnight SL, 1996, GENE DEV, V10, P367, DOI 10.1101/gad.10.4.367; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ohno M, 1999, MOL CELL BIOL, V19, P2051; PASCA M, 1997, J ENDOCRINOL INVE S5, V20, P1; PLACHOV D, 1990, DEVELOPMENT, V110, P643; RUTBERG SE, 1992, NUCLEIC ACIDS RES, V20, P1815, DOI 10.1093/nar/20.7.1815; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; Taurog A., 1996, WERNER INGBARS THYRO, V7th, P47; VanRenterghem P, 1996, BBA-GENE STRUCT EXPR, V1307, P97, DOI 10.1016/0167-4781(96)00018-8; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	41	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34100	34105		10.1074/jbc.M003043200	http://dx.doi.org/10.1074/jbc.M003043200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10924503	hybrid			2022-12-27	WOS:000165095300017
J	George, SJ; Allen, JWA; Ferguson, SJ; Thorneley, RNF				George, SJ; Allen, JWA; Ferguson, SJ; Thorneley, RNF			Time-resolved infrared spectroscopy reveals a stable ferric heme-NO intermediate in the reaction of Paracoccus pantotrophus cytochrome cd(1) nitrite reductase with nitrite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOSPHAERA-PANTOTROPHA; DISSIMILATORY NITRITE; STOPPED-FLOW; PSEUDOMONAS-STUTZERI; ELECTRON-TRANSFER; OXIDE; BINDING; CYCLE; RECONSTITUTION; DENITRIFICANS	Cytochrome cd(1) is a respiratory enzyme that catalyzes the physiological one-electron reduction of nitrite to nitric oxide. The enzyme is a dimer, each monomer containing one c-type cytochrome center and one active site d(1) heme, We present stopped-flow Fourier transform infrared data showing the formation of a stable ferric heme d(1)-NO complex (formally d(1)Fe(II)-NO+) as a product of the reaction between fully reduced Paracoccus pantotrophus cytochrome ed, and nitrite, in the absence of excess reductant, The Fe-(NO)-N-14 nu>(*) over bar * (NO) stretching mode is observed at 1913 cm(-1) with the corresponding Fe-(NO)-N-15 band at 1876 cm(-1). This d(1) heme-NO complex is still readily observed after 15 min. EPR and visible absorption spectroscopic data show that within 4 ms of the initiation of the reaction, nitrite is reduced at the d(1) heme, and a cFe(III) d(1)Fe(II)-NO complex is formed. Over the next 100 ms there is an electron redistribution within the enzyme to give a mixed species, 55% cFe(III) d(1)Fe(II)-NO and 45% cFe(II) d(1)Fe(II)-NO+. No kinetically competent release of NO could be detected, indicating that at least one additional factor is required for product release by the enzyme. Implications for the mechanism of P. pantotrophus cytochrome cd(1) are discussed.	John Innes Ctr Plant Sci Res, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of Oxford	Thorneley, RNF (corresponding author), John Innes Ctr Plant Sci Res, Dept Biol Chem, Colney Lane, Norwich NR4 7UH, Norfolk, England.			George, Simon/0000-0002-4864-5479				Allen JWA, 2000, NAT STRUCT BIOL, V7, P885; Averill BA, 1996, CHEM REV, V96, P2951, DOI 10.1021/cr950056p; Berks BC, 1995, BBA-BIOENERGETICS, V1232, P97, DOI 10.1016/0005-2728(95)00092-5; BRAY R C, 1973, Biochemical Society Transactions, V1, P1067; Cheesman MR, 1997, BIOCHEMISTRY-US, V36, P16267, DOI 10.1021/bi971677a; Cutruzzola F, 1999, BBA-BIOENERGETICS, V1411, P231, DOI 10.1016/S0005-2728(99)00017-1; Ding XD, 1999, J AM CHEM SOC, V121, P128, DOI 10.1021/ja982979i; Ferguson SJ, 1998, CURR OPIN CHEM BIOL, V2, P182, DOI 10.1016/S1367-5931(98)80059-8; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; GARBER EAE, 1982, J BIOL CHEM, V257, P8091; George SJ, 1997, J AM CHEM SOC, V119, P6450, DOI 10.1021/ja971088s; HILL KE, 1978, J BIOL CHEM, V253, P489; JOHNSON MK, 1980, BIOCHEM J, V189, P285, DOI 10.1042/bj1890285; Kobayashi K, 1997, BIOCHEMISTRY-US, V36, P13611, DOI 10.1021/bi971045o; Koppenhofer A, 2000, BIOCHEMISTRY-US, V39, P4028, DOI 10.1021/bi991912k; Koppenhofer A, 2000, BIOCHEMISTRY-US, V39, P4243, DOI 10.1021/bi000192a; KOPPENHOFER A, 1998, THESIS U OXFORD; MOIR JWB, 1993, EUR J BIOCHEM, V212, P377, DOI 10.1111/j.1432-1033.1993.tb17672.x; OZAWA S, 1995, INORG CHEM, V34, P6362, DOI 10.1021/ic00129a022; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; PARR SR, 1977, BIOCHEM J, V167, P447, DOI 10.1042/bj1670447; Rainey FA, 1999, INT J SYST BACTERIOL, V49, P645, DOI 10.1099/00207713-49-2-645; Richardson DJ, 1999, CURR OPIN CHEM BIOL, V3, P207, DOI 10.1016/S1367-5931(99)80034-9; Scheidt WR, 1999, ACCOUNTS CHEM RES, V32, P350, DOI 10.1021/ar9700116; SILVESTRINI MC, 1982, BIOCHEM J, V203, P445, DOI 10.1042/bj2030445; SILVESTRINI MC, 1990, J BIOL CHEM, V265, P11783; SINGH J, 1973, BIOCHIM BIOPHYS ACTA, V333, P28; Thorneley RNF, 2000, PROKARYOTIC NITROGEN FIXATION, P81; TIMKOVICH R, 1982, ARCH BIOCHEM BIOPHYS, V215, P47, DOI 10.1016/0003-9861(82)90277-6; Wang YN, 1996, J AM CHEM SOC, V118, P3972, DOI 10.1021/ja9538647; WEEGAERSSENS E, 1991, J BIOL CHEM, V266, P7496; WHITE AJ, 1995, BIOCHEM J, V306, P843, DOI 10.1042/bj3060843; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; WILLIAMS PA, 1995, NAT STRUCT BIOL, V2, P975, DOI 10.1038/nsb1195-975; WU WS, 1987, J AM CHEM SOC, V109, P3149, DOI 10.1021/ja00244a050; YAMANAKA T, 1963, BIOCHEM Z, V338, P62; YU NT, 1986, METHOD ENZYMOL, V130, P350; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	38	59	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33231	33237		10.1074/jbc.M005033200	http://dx.doi.org/10.1074/jbc.M005033200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10922371	hybrid			2022-12-27	WOS:000090104600010
J	Homori, K; Miyata, T; DiRuggiero, J; Holley-Shanks, R; Hayashi, I; Cann, IKO; Mayanagi, K; Shinagawa, H; Ishino, Y				Homori, K; Miyata, T; DiRuggiero, J; Holley-Shanks, R; Hayashi, I; Cann, IKO; Mayanagi, K; Shinagawa, H; Ishino, Y			Both RadA and RadB are involved in homologous recombination in Pyrococcus furiosus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; DNA STRAND EXCHANGE; HYPERTHERMOPHILIC ARCHAEON; ESCHERICHIA-COLI; RECA PROTEIN; ATP HYDROLYSIS; IN-VITRO; SACCHAROMYCES-CEREVISIAE; GLUTAMATE-DEHYDROGENASE; BREAK REPAIR	RecA and Rad51 proteins are essential for homologous recombination in Bacteria and Eukarya, respectively. Homologous proteins, called RadA, have been described for Archaea, Here we present the characterization of two RecA/Rad51 family proteins, RadA and RadB, from Pyrococcus furiosus, The radA and radB genes mere not induced by DNA damage resulting from exposure of the cells to gamma and UV irradiation and heat shock, suggesting that they might be constitutively expressed in this hyperthermophile, RadA had DNA-dependent ATPase, D-loop formation, and strand exchange activities. In contrast, RadB had a very weak ATPase activity that is not stimulated by DNA. This protein had a strong binding affinity for DNA, but little strand exchange activity could be detected. A direct interaction between RadA and RadB was detected by an immunoprecipitation assay. Moreover, RadB, but not RadA, coprecipitated with Ajc, a Holliday junction resolvase found in P, furiosus, in the absence of ATP, This interaction was suppressed in the presence of ATP, The Holliday junction cleavage activity of Hjc was inhibited by RadB in the absence, but not in the presence, of ATP, These results suggest that RadB has important roles in homologous recombination in Archaea and may regulate the cleavage reactions of the branch-structured DNA.	Biomol Engn Res Inst, Dept Mol Biol, Suita, Osaka 5650874, Japan; Biomol Engn Res Inst, Dept Biol Struct, Suita, Osaka 5650874, Japan; Univ Maryland, Inst Biotechnol, Ctr Marine Biotechnol, Baltimore, MD 21202 USA; Osaka Univ, Dept Mol Microbiol, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan	University System of Maryland; University of Maryland Baltimore; Osaka University	Ishino, Y (corresponding author), Biomol Engn Res Inst, Dept Mol Biol, 6-2-3 Furuedai, Suita, Osaka 5650874, Japan.	ishino@beri.co.jp						BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; BIANCO PR, 1998, FRONT BIOSCI, V8, P570; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Davies AA, 1998, CURR BIOL, V8, P725, DOI 10.1016/S0960-9822(98)70282-9; DEHENESTROSA ARF, 1991, MOL GEN GENET, V226, P503, DOI 10.1007/BF00260664; DIRUGGIERO J, 1995, APPL ENVIRON MICROB, V61, P159, DOI 10.1128/AEM.61.1.159-164.1995; DiRuggiero J, 1999, J MOL EVOL, V49, P474, DOI 10.1007/PL00006570; DiRuggiero J, 1998, NEW DEVELOPMENTS IN MARINE BIOTECHNOLOGY, P193; DiRuggiero J, 1997, J BACTERIOL, V179, P4643, DOI 10.1128/jb.179.14.4643-4645.1997; Diruggiero Jocelyne, 1995, P97; DONOVAN JW, 1994, GENE DEV, V8, P2552, DOI 10.1101/gad.8.21.2552; Dosanjh MK, 1998, NUCLEIC ACIDS RES, V26, P1179, DOI 10.1093/nar/26.5.1179; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; Hayashi I, 1999, NUCLEIC ACIDS RES, V27, P4695, DOI 10.1093/nar/27.24.4695; HOLDEN JF, 1993, J BACTERIOL, V175, P2839, DOI 10.1128/JB.175.10.2839-2843.1993; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; Karthikeyan G., 1999, Journal of Molecular Microbiology and Biotechnology, V1, P149; Katagiri T, 1998, GENE CHROMOSOME CANC, V21, P217, DOI 10.1002/(SICI)1098-2264(199803)21:3<217::AID-GCC5>3.0.CO;2-2; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; Kil YV, 2000, J BACTERIOL, V182, P130, DOI 10.1128/JB.182.1.130-134.2000; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; Komori K, 1999, NUCLEIC ACIDS RES, V27, P4167, DOI 10.1093/nar/27.21.4167; Komori K, 1999, P NATL ACAD SCI USA, V96, P8873, DOI 10.1073/pnas.96.16.8873; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; LAUDER SD, 1991, J BIOL CHEM, V266, P5450; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Masson JY, 1999, EMBO J, V18, P6552, DOI 10.1093/emboj/18.22.6552; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; MORIMATSU K, 1995, EUR J BIOCHEM, V228, P779, DOI 10.1111/j.1432-1033.1995.0779m.x; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Olsen GJ, 1997, CELL, V89, P991, DOI 10.1016/S0092-8674(00)80284-6; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Radman M., 1975, MOL MECHANISMS REPAI, P355; Rashid N, 1996, MOL GEN GENET, V253, P397, DOI 10.1007/s004380050337; ROBB FT, 1992, BIOCHIM BIOPHYS ACTA, V1120, P267, DOI 10.1016/0167-4838(92)90247-B; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; ROSSELLI W, 1990, J MOL BIOL, V216, P335, DOI 10.1016/S0022-2836(05)80325-0; Sandler SJ, 1999, J BACTERIOL, V181, P907, DOI 10.1128/JB.181.3.907-915.1999; Sandler SJ, 1996, NUCLEIC ACIDS RES, V24, P2125, DOI 10.1093/nar/24.11.2125; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Seitz EM, 1998, GENE DEV, V12, P1248, DOI 10.1101/gad.12.9.1248; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Spies M, 2000, EUR J BIOCHEM, V267, P1125, DOI 10.1046/j.1432-1327.2000.01108.x; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Sung P, 1996, J BIOL CHEM, V271, P27983, DOI 10.1074/jbc.271.45.27983; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Thacker J, 1999, TRENDS GENET, V15, P166, DOI 10.1016/S0168-9525(99)01733-3; TRENT JD, 1994, J BACTERIOL, V176, P6148, DOI 10.1128/jb.176.19.6148-6152.1994; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; Uemori T, 1997, GENES CELLS, V2, P499, DOI 10.1046/j.1365-2443.1997.1380336.x; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8829; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Woods WG, 1997, MOL MICROBIOL, V23, P791, DOI 10.1046/j.1365-2958.1997.2651626.x	72	21	29	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33782	33790						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10903318				2022-12-27	WOS:000090104600084
J	Read, EK; Gumport, RI; Gardner, JF				Read, EK; Gumport, RI; Gardner, JF			Specific recognition of DNA by integration host factor - Glutamic acid 44 of the beta-subunit specifies the discrimination of a T : A from an A : T base pair without directly contacting the DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BINDING-SITES; FACTOR IHF; PROTEIN; DEFICIENT; MUTANTS; MU	Integration host factor (IHF) is a protein that binds to the H' site of bacteriophage lambda with sequence specificity. Genetic experiments implicated amino acid residue Glu(44) of the beta -subunit of HH in discrimination against substitution of A for T at position 44 of the TTR submotif of the binding site (Lee, E, C,, Hales, L, M,, Gumport, R, I., Gardner, J, F, (1992) EMBO J,, 11, 305-313), We have extended this observation by generating all possible single-base substitutions at positions 43, 44, and 45 of the H' site. IHF failed to bind these H' site substitution mutants in vivo. The K-d(app) value for each H' site substitution, except for H'45A mutant, was reduced >2000-fold relative to the wild-type site. Substitution of amino acid beta -Glu(44) with alanine prevented IHF from discriminating against the H'44A variant but not the other H' site substitution mutants. Further analysis with other substitutions at position beta 44 demonstrated that both oxygens of the wild-type glutamic acid are necessary for discrimination of AT at position 44, Because the beta -Glu(44) residue does not contact the DNA, this residue probably enforces binding specificity indirectly through interaction with amino acids that themselves contact the DNA.	Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Coll Med, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Gardner, JF (corresponding author), Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, 601 S Goodwin Ave, Urbana, IL 61801 USA.				NIGMS NIH HHS [GM28717] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028717] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; GOODRICH JA, 1990, NUCLEIC ACIDS RES, V18, P4993, DOI 10.1093/nar/18.17.4993; GOOSEN N, 1984, GENE, V30, P41, DOI 10.1016/0378-1119(84)90103-3; GRANSTON AE, 1993, J MOL BIOL, V234, P45, DOI 10.1006/jmbi.1993.1562; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; KANO Y, 1993, GENE, V126, P93; LEE EC, 1992, EMBO J, V11, P305, DOI 10.1002/j.1460-2075.1992.tb05053.x; LEE EC, 1991, J BACTERIOL, V173, P609, DOI 10.1128/jb.173.2.609-617.1991; MANIATIS T, 1982, MOL CLONING LABORATO, P122; MENGERITSKY G, 1993, J MOL BIOL, V231, P646, DOI 10.1006/jmbi.1993.1316; NASH HA, 1981, J BIOL CHEM, V256, P9246; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; STENZEL TT, 1987, CELL, V49, P709, DOI 10.1016/0092-8674(87)90547-2; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; WANG SQ, 1995, BIOCHEMISTRY-US, V34, P13082, DOI 10.1021/bi00040a020; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5; Yang SW, 1995, EMBO J, V14, P6292, DOI 10.1002/j.1460-2075.1995.tb00319.x; ZULIANELLO L, 1995, J BIOL CHEM, V270, P17902, DOI 10.1074/jbc.270.30.17902	19	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33759	33764		10.1074/jbc.M910381199	http://dx.doi.org/10.1074/jbc.M910381199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10930420	hybrid			2022-12-27	WOS:000090104600080
J	Seiser, RM; Nicchitta, CV				Seiser, RM; Nicchitta, CV			The fate of membrane-bound ribosomes following the termination of protein synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY PROTEIN; ROUGH MICROSOMES; 2 STEPS; TRANSLOCATION; POLYSOMES; CELLS; SUBUNITS; INVITRO; IMPORT	Contemporary models for protein translocation in the mammalian endoplasmic reticulum (ER) identify the termination of protein synthesis as the signal for ribosome release from the ER membrane, We have utilized morphometric and biochemical methods to assess directly the fate of membrane-bound ribosomes following the termination of protein synthesis. In these studies, tissue culture cells were treated with cycloheximide to inhibit elongation, with pactamycin to inhibit initiation, or with puromycin to induce premature chain termination, and ribosome-membrane interactions were subsequently analyzed. It was found that following the termination of protein synthesis, the majority of ribosomal particles remained membrane-associated. Analysis of the subunit structure of the membrane-bound ribosomal particles remaining after termination was conducted by negative stain electron microscopy and sucrose gradient sedimentation. By both methods of analysis, the termination of protein synthesis on membrane-bound ribosomes was accompanied by the release of small ribosomal subunits from the ER membrane; the majority of the large subunits remained membrane-bound. On the basis of these results, we propose that large ribosomal subunit release from the ER membrane is regulated independently of protein translocation.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Nicchitta, CV (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, POB 3709, Durham, NC 27710 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047897] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47897] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BAGLIONI C, 1971, NATURE-NEW BIOL, V232, P8, DOI 10.1038/newbio232008a0; BALIGA BS, 1969, J BIOL CHEM, V244, P4480; BARBACID M, 1975, J ANTIBIOT, V28, P453, DOI 10.7164/antibiotics.28.453; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BORGESE D, 1973, J MOL BIOL, V74, P415, DOI 10.1016/0022-2836(73)90037-5; Christensen AK, 1999, ANAT REC, V255, P116, DOI 10.1002/(SICI)1097-0185(19990601)255:2<116::AID-AR2>3.0.CO;2-O; FALVEY AK, 1970, J MOL BIOL, V53, P21, DOI 10.1016/0022-2836(70)90043-4; FLORENDO NT, 1969, J CELL BIOL, V41, P335, DOI 10.1083/jcb.41.1.335; GAETANI S, 1983, METHOD ENZYMOL, V96, P3; GILMORE R, 1983, CELL, V35, P677, DOI 10.1016/0092-8674(83)90100-9; GOLDBERG IH, 1973, FED PROC, V32, P1688; KAEMPFER R, 1969, COLD SPRING HARB SYM, V34, P209, DOI 10.1101/SQB.1969.034.01.027; KAPPEN LS, 1976, BIOCHEMISTRY-US, V15, P811, DOI 10.1021/bi00649a013; LUTSCH G, 1986, EUR J CELL BIOL, V40, P257; MECHLER B, 1975, J CELL BIOL, V67, P1, DOI 10.1083/jcb.67.1.1; MECHLER B, 1975, J CELL BIOL, V67, P25, DOI 10.1083/jcb.67.1.25; MEECHLER B, 1975, J CELL BIOL, V75, P16; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MONRO RE, 1969, COLD SPRING HARB SYM, V34, P357, DOI 10.1101/SQB.1969.034.01.042; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; NONOMURA Y, 1971, J MOL BIOL, V60, P303, DOI 10.1016/0022-2836(71)90296-8; PALADE GE, 1956, J BIOPHYS BIOCHEM CY, V2, P171, DOI 10.1083/jcb.2.2.171; Potter MD, 2000, J BIOL CHEM, V275, P33828, DOI 10.1074/jbc.M005294200; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; SABATINI DD, 1966, J MOL BIOL, V19, P503, DOI 10.1016/S0022-2836(66)80019-0; TRAUT RR, 1964, J MOL BIOL, V10, P63, DOI 10.1016/S0022-2836(64)80028-0; UNWIN PNT, 1977, NATURE, V269, P118, DOI 10.1038/269118a0; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WEIBEL ER, 1969, J CELL BIOL, V42, P68, DOI 10.1083/jcb.42.1.68	31	60	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33820	33827		10.1074/jbc.M004462200	http://dx.doi.org/10.1074/jbc.M004462200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10931837	hybrid			2022-12-27	WOS:000090104600089
J	Reiter, CD; Teng, RJ; Beckman, JS				Reiter, CD; Teng, RJ; Beckman, JS			Superoxide reacts with nitric oxide to nitrate tyrosine at physiological pH via peroxynitrite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; AMYOTROPHIC-LATERAL-SCLEROSIS; PROSTACYCLIN SYNTHASE; OXIDATIVE DAMAGE; URIC-ACID; HYDROGEN-PEROXIDE; NITROGEN-DIOXIDE; SOLID ARGON; INACTIVATION; DISMUTASE	Tyrosine nitration is a widely used marker of peroxynitrite (ONOO-) produced from the reaction of nitric oxide with superoxide. Pfeiffer and Mayer (Pfeiffer, S., and Mayer, B, (1998) J. Biol; Chem, 273, 27280-27285) reported that superoxide produced from hypoxanthine plus xanthine oxidase in combination with nitric oxide produced from spermine NONOate did not nitrate tyrosine at neutral pH, They suggested that nitric oxide and superoxide at neutral pH form a less reactive intermediate distinct from preformed alkaline peroxynitrite that does not nitrate tyrosine, Using a stopped-flow spectrophotometer to rapidly mix potassium superoxide with nitric oxide at pH 7.4, we report that an intermediate spectrally and kinetically identical to preformed alkaline cis-peroxynitrite was formed in 100% yield. Furthermore, this intermediate nitrated tyrosine in the same yield and at the same rate as preformed peroxynitrite. Equivalent concentrations of nitric oxide under aerobic conditions in the absence of superoxide did not produce detectable concentrations of nitrotyrosine. Carbon dioxide increased the efficiency of nitration by nitric oxide plus superoxide to the same extent as peroxynitrite, In experiments using xanthine oxidase as a source of superoxide, tyrosine nitration was substantially inhibited by urate formed from hypoxanthine oxidation, which was sufficient to account for the lack of tyrosine nitration previously reported. We conclude that peroxynitrite formed from the reaction of nitric oxide with superoxide at physiological pH remains an important species responsible for tyrosine nitration in vivo.	Univ Alabama, Dept Anesthesiol, Ctr Free Radical Biol, Birmingham, AL 35233 USA; Univ Alabama, Dept Biochem & Mol Genet, Ctr Free Radical Biol, Birmingham, AL 35233 USA; Univ Alabama, Dept Pediat, Ctr Free Radical Biol, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Beckman, JS (corresponding author), Univ Alabama, Dept Anesthesiol, Ctr Free Radical Biol, Birmingham, AL 35233 USA.							AMES BN, 1981, P NATL ACAD SCI-BIOL, V78, P6858, DOI 10.1073/pnas.78.11.6858; Ara J, 1998, P NATL ACAD SCI USA, V95, P7659, DOI 10.1073/pnas.95.13.7659; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; Beckman JS, 1996, METHODS NITRIC OXIDE, P61; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BOHLE DS, 1994, J AM CHEM SOC, V116, P7423, DOI 10.1021/ja00095a062; BRUNELLI L, 1995, ARCH BIOCHEM BIOPHYS, V316, P327, DOI 10.1006/abbi.1995.1044; BUTLER J, 1982, J BIOL CHEM, V257, P747; CELIO XC, 1999, ARCH BIOCHEM BIOPHYS, V372, P285; Crow JP, 1997, J NEUROCHEM, V69, P1945; Crow JP, 1997, NITRIC OXIDE-BIOL CH, V1, P145, DOI 10.1006/niox.1996.0113; Daiber A, 1998, NITRIC OXIDE-BIOL CH, V2, P259, DOI 10.1006/niox.1998.0186; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Eiserich JP, 1996, J BIOL CHEM, V271, P19199, DOI 10.1074/jbc.271.32.19199; Estevez AG, 1998, J NEUROSCI, V18, P923; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; Estevez AG, 2000, FREE RADICAL BIO MED, V28, P437, DOI 10.1016/S0891-5849(99)00261-0; Estevez AG, 1998, J NEUROSCI, V18, P3708; Ferrante RJ, 1997, ANN NEUROL, V42, P326, DOI 10.1002/ana.410420309; Ferrante RJ, 1997, J NEUROCHEM, V69, P2064; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; Fukuyama N, 1997, FREE RADICAL BIO MED, V22, P771, DOI 10.1016/S0891-5849(96)00401-7; Goldstein S, 2000, J BIOL CHEM, V275, P3031, DOI 10.1074/jbc.275.5.3031; HADDAD IY, 1994, AM J PHYSIOL, V267, pL242, DOI 10.1152/ajplung.1994.267.3.L242; HADDAD IY, 1993, AM J PHYSIOL, V265, P555; Hooper DC, 1998, P NATL ACAD SCI USA, V95, P675, DOI 10.1073/pnas.95.2.675; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; Kelm M, 1997, J BIOL CHEM, V272, P9922; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; Klebl BM, 1998, FEBS LETT, V422, P381, DOI 10.1016/S0014-5793(98)00053-2; Kooy NW, 1997, CRIT CARE MED, V25, P812, DOI 10.1097/00003246-199705000-00017; KOOY NW, 1994, FREE RADICAL BIO MED, V16, P149, DOI 10.1016/0891-5849(94)90138-4; KOOY NW, 1995, AM J RESP CRIT CARE, V151, P1250; Koppenol WH, 1996, METHOD ENZYMOL, V269, P296; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; KRAUSS M, 1994, CHEM PHYS LETT, V222, P513, DOI 10.1016/0009-2614(94)00381-5; LO WJ, 1995, CHEM PHYS LETT, V242, P147, DOI 10.1016/0009-2614(95)00702-6; LO WJ, 1995, J CHEM PHYS, V103, P4026, DOI 10.1063/1.469588; MacMillan-Crow LA, 1998, BIOCHEMISTRY-US, V37, P1613, DOI 10.1021/bi971894b; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; Mehl M, 1999, NITRIC OXIDE-BIOL CH, V3, P142, DOI 10.1006/niox.1999.0217; MILLER MJS, 1995, GASTROENTEROLOGY, V109, P1475, DOI 10.1016/0016-5085(95)90633-9; PACE MD, 1993, FREE RADICAL BIO MED, V15, P337, DOI 10.1016/0891-5849(93)90080-E; Pfeiffer S, 2000, J BIOL CHEM, V275, P6346, DOI 10.1074/jbc.275.9.6346; Pfeiffer S, 1998, J BIOL CHEM, V273, P27280, DOI 10.1074/jbc.273.42.27280; PRUTZ WA, 1985, ARCH BIOCHEM BIOPHYS, V243, P125, DOI 10.1016/0003-9861(85)90780-5; PRYOR WA, 1995, FREE RADICAL BIO MED, V18, P75, DOI 10.1016/0891-5849(94)00105-S; Sampson JB, 1998, ARCH BIOCHEM BIOPHYS, V356, P207, DOI 10.1006/abbi.1998.0772; Sawa T, 2000, J BIOL CHEM, V275, P32467, DOI 10.1074/jbc.M910169199; Shin JT, 1996, ARCH BIOCHEM BIOPHYS, V335, P32, DOI 10.1006/abbi.1996.0479; Skinner KA, 1998, J BIOL CHEM, V273, P24491, DOI 10.1074/jbc.273.38.24491; Skinner KA, 1997, ARCH BIOCHEM BIOPHYS, V342, P282, DOI 10.1006/abbi.1997.0114; Smith MA, 1997, J NEUROSCI, V17, P2653; Souza JM, 1999, ARCH BIOCHEM BIOPHYS, V371, P169, DOI 10.1006/abbi.1999.1480; Strong MJ, 1998, BIOCHEM BIOPH RES CO, V248, P157, DOI 10.1006/bbrc.1998.8930; Tsai HH, 1996, J PHYS CHEM-US, V100, P15087, DOI 10.1021/jp961091i; TSAI JHM, 1994, J AM CHEM SOC, V116, P4115, DOI 10.1021/ja00088a072; TSAI JHM, 1994, THESIS U ALABAMA BIR; VANDERVLIET A, 1995, ARCH BIOCHEM BIOPHYS, V319, P341, DOI 10.1006/abbi.1995.1303; Viner RI, 1996, FEBS LETT, V379, P286, DOI 10.1016/0014-5793(95)01530-2; Viner RI, 1996, FREE RADICAL RES, V24, P243, DOI 10.3109/10715769609088022; Worle M, 1999, CHEM RES TOXICOL, V12, P305, DOI 10.1021/tx990013u; Yamakura F, 1998, J BIOL CHEM, V273, P14085, DOI 10.1074/jbc.273.23.14085; Zou MH, 1998, BIOCHEM J, V336, P507, DOI 10.1042/bj3360507; Zou MH, 1996, FEBS LETT, V382, P101, DOI 10.1016/0014-5793(96)00160-3; Zou MH, 1997, BIOL CHEM, V378, P707, DOI 10.1515/bchm.1997.378.7.707	70	325	335	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32460	32466		10.1074/jbc.M910433199	http://dx.doi.org/10.1074/jbc.M910433199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10906340	hybrid			2022-12-27	WOS:000090003800013
J	Wang, N; Silver, DL; Costet, P; Tall, AR				Wang, N; Silver, DL; Costet, P; Tall, AR			Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; SCAVENGER RECEPTOR BI; CORONARY HEART-DISEASE; KNOCK-OUT MICE; TANGIER-DISEASE; CELLULAR CHOLESTEROL; CASSETTE TRANSPORTER-1; SR-BI; ATHEROSCLEROTIC LESIONS	Mutations of the ABC1 transporter have been identified as the defect in Tangier disease, characterized by low HDL and cholesterol ester accumulation in macrophages. A full-length mouse ABC1 cDNA was used to investigate the mechanisms of lipid efflux to apoA-I or HDL in transfected 293 cells, ABC1 expression markedly increased cellular cholesterol and phospholipid efflux to apoA-I but had only minor effects on lipid efflux to HDL. The increased lipid efflux appears to involve a direct interaction between apoA-I and ABC1, because ABC1 expression substantially increased apoA-I binding at the cell, surface, and chemical cross-linking and immunoprecipitation analysis showed that apoA-I binds directly to ABC1. In contrast to scavenger receptor BI (SR-BI), another cell surface molecule capable of facilitating cholesterol efflux, ABC1 preferentially bound lipid-free apoA-I but not HDL, Immunofluorescence confocal microscopy showed that ABC1 is primarily localized on the cell surface. In the absence of apoA-I, cells overexpressing ABC1 displayed a distinctive morphology, characterized by plasma membrane protrusions and resembling echinocytes that form when there are excess lipids in the outer membrane hemileaflet, The studies provide evidence for a direct interaction between ABC1 and apoA-I, but not HDL, indicating that free apoA-I is the metabolic substrate for ABC1, Plasma membrane ABC1 may act as a phospholipid/cholesterol flippase, providing lipid to bound apoA-I, or to the outer membrane hemileaflet.	Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA	Columbia University	Wang, N (corresponding author), Columbia Univ, Dept Med, Div Mol Med, 630 W 168th St, New York, NY 10032 USA.		costet, philippe/A-5314-2010; Tall, Alan/AAT-8528-2021	Silver, David/0000-0002-7289-9890	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056984, R01HL022682, R37HL022682] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56984, HL22682] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; Arai T, 1999, P NATL ACAD SCI USA, V96, P12050, DOI 10.1073/pnas.96.21.12050; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BOVET P, 1989, ATHEROSCLEROSIS, V80, P41, DOI 10.1016/0021-9150(89)90066-X; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; Chinetti G, 2000, CIRCULATION, V101, P2411, DOI 10.1161/01.CIR.101.20.2411; Connors TD, 1997, GENOMICS, V39, P231, DOI 10.1006/geno.1996.4500; Costet P, 2000, J BIOL CHEM, V275, P28240; Croop JM, 1998, METHOD ENZYMOL, V292, P101; Duverger N, 1996, SCIENCE, V273, P966, DOI 10.1126/science.273.5277.966; FERRELL JE, 1985, BIOCHEMISTRY-US, V24, P2849, DOI 10.1021/bi00333a006; FIELDING CJ, 2000, BIOCH CELL BIOL, V271, P451; Fournier N, 2000, ARTERIOSCL THROM VAS, V20, P1283, DOI 10.1161/01.ATV.20.5.1283; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; HAYEK T, 1995, J CLIN INVEST, V96, P2071, DOI 10.1172/JCI118255; Hirano K, 1999, CIRC RES, V85, P108; ISHIDA BY, 1987, J LIPID RES, V28, P778; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Liadaki KN, 2000, J BIOL CHEM, V275, P21262, DOI 10.1074/jbc.M002310200; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; Plump AS, 1996, J CLIN INVEST, V97, P2660, DOI 10.1172/JCI118716; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SCHAEFER EJ, 1980, ANN INTERN MED, V93, P261, DOI 10.7326/0003-4819-93-2-261; SHEETZ MP, 1974, P NATL ACAD SCI USA, V71, P4457, DOI 10.1073/pnas.71.11.4457; Silver DL, 2000, J CLIN INVEST, V105, P151, DOI 10.1172/JCI8087; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; SUNE A, 1988, BIOCHEMISTRY-US, V27, P6794, DOI 10.1021/bi00418a022; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; WALTER M, 1994, BIOCHEM BIOPH RES CO, V205, P850, DOI 10.1006/bbrc.1994.2742; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; Williams DL, 2000, J BIOL CHEM, V275, P18897, DOI 10.1074/jbc.M002411200; Xu SZ, 1997, J LIPID RES, V38, P1289	47	488	506	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33053	33058		10.1074/jbc.M005438200	http://dx.doi.org/10.1074/jbc.M005438200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10918065	hybrid			2022-12-27	WOS:000090003800092
J	Wariishi, H; Nonaka, D; Johjima, T; Nakamura, N; Naruta, Y; Kubo, S; Fukuyama, K				Wariishi, H; Nonaka, D; Johjima, T; Nakamura, N; Naruta, Y; Kubo, S; Fukuyama, K			Direct binding of hydroxylamine to the heme iron of Arthromyces ramosus peroxidase - Substrate analogue that inhibits compound I formation in a competitive manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPRINUS-CINEREUS PEROXIDASE; AROMATIC DONOR MOLECULES; BASIDIOMYCETE PHANEROCHAETE-CHRYSOSPORIUM; RAY CRYSTALLOGRAPHIC ANALYSIS; NUCLEAR MAGNETIC-RESONANCE; HORSERADISH-PEROXIDASE; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; LIGNIN PEROXIDASE; HYDROGEN-PEROXIDE	The interaction of hydroxylamine (HA) with Arthromyces ramosus peroxidase (ARP) was investigated by kinetic, spectroscopic, and x-ray crystallographic techniques. HA inhibited the reaction of native ARP with H2O2 in a competitive manner. Electron absorption and resonance Raman spectroscopic studies indicated that pentacoordinate high spin species of native ARP are converted to hexacoordinate low spin species upon the addition of HA, strongly suggesting the occurrence of a direct interaction of HA with ARP heme iron. Kinetic analysis exhibited that the apparent dissociation constant is 6.2 mM at pH 7.0 and that only one HA molecule likely binds to the vicinity of the heme. pH dependence of HA binding suggested that the nitrogen atom of HA could be involved in the interaction with the heme iron. X-ray crystallographic analysis of ARP in complex with HA at 2.0 Angstrom resolution revealed that the electron density ascribed to HA is located in the distal pocket between the heme iron and the distal His(56). HA seems to directly interact with the heme iron but is too far away to interact with Arg(52). In HA, it is likely that the nitrogen atom is coordinated to the heme iron and that hydroxyl group is hydrogen bonded to the distal His(56).	Osaka Univ, Grad Sch Sci, Dept Biol, Toyonaka, Osaka 5600043, Japan; Kyushu Univ, Dept Forest Prod, Fukuoka 8128581, Japan; Kyushu Univ, Inst Fundamental Res Organ Chem, Fukuoka 8128581, Japan	Osaka University; Kyushu University; Kyushu University	Fukuyama, K (corresponding author), Osaka Univ, Grad Sch Sci, Dept Biol, Toyonaka, Osaka 5600043, Japan.		Nakamura, Nobuhumi/C-1972-2013	Nakamura, Nobuhumi/0000-0002-5373-2972				Abelskov AK, 1997, BIOCHEMISTRY-US, V36, P9453, DOI 10.1021/bi970387r; AKIMOTO K, 1990, ANAL BIOCHEM, V189, P182, DOI 10.1016/0003-2697(90)90104-H; ANDERSEN MB, 1991, ACTA CHEM SCAND, V45, P1080, DOI 10.3891/acta.chem.scand.45-1080; ATOR MA, 1987, J BIOL CHEM, V262, P1542; BAEK HK, 1989, BIOCHEMISTRY-US, V28, P5714, DOI 10.1021/bi00440a003; BAEK HK, 1992, J AM CHEM SOC, V114, P718, DOI 10.1021/ja00028a046; Berg R, 1940, BER DTSCH CHEM GES, V73, P172, DOI 10.1002/cber.19400730303; BRUNGER AT, 1992, XPLOR VERSION 3 0; Davey CA, 1996, BIOCHEMISTRY-US, V35, P10967, DOI 10.1021/bi960577m; DEPILLIS GD, 1989, BIOCHEMISTRY-US, V28, P7947, DOI 10.1021/bi00445a059; Doyle WA, 1998, BIOCHEMISTRY-US, V37, P15097, DOI 10.1021/bi981633h; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; FREAR DS, 1955, ANAL CHEM, V27, P1664, DOI 10.1021/ac60106a054; Fukuyama K, 1997, J BIOL CHEM, V272, P5752, DOI 10.1074/jbc.272.9.5752; Gajhede M, 1997, NAT STRUCT BIOL, V4, P1032, DOI 10.1038/nsb1297-1032; GOLD MH, 1989, ACS SYM SER, V389, P127; Henriksen A, 1999, J BIOL CHEM, V274, P35005, DOI 10.1074/jbc.274.49.35005; Henriksen A, 1998, J BIOL CHEM, V273, P2241, DOI 10.1074/jbc.273.4.2241; Henriksen A, 1998, BIOCHEMISTRY-US, V37, P8054, DOI 10.1021/bi980234j; HIGASHI T, 1990, PROCESS PROGRAM INDE; Ignatenko V. E., 1994, Proceedings of the Third International Symposium on Corrosion and Reliability of Electronic Materials and Devices, P392; Itakura H, 1997, FEBS LETT, V412, P107, DOI 10.1016/S0014-5793(97)00751-5; Johjima T, 1999, P NATL ACAD SCI USA, V96, P1989, DOI 10.1073/pnas.96.5.1989; KJALKE M, 1992, BIOCHIM BIOPHYS ACTA, V1120, P248, DOI 10.1016/0167-4838(92)90244-8; KUNISHIMA N, 1993, PROTEINS, V15, P216, DOI 10.1002/prot.340150213; Kunishima N, 1996, FEBS LETT, V378, P291, DOI 10.1016/0014-5793(95)01458-6; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; LAMAR GN, 1995, J AM CHEM SOC, V117, P411, DOI 10.1021/ja00106a047; MORISHIMA I, 1979, J BIOL CHEM, V254, P2814; Ozaki S, 1998, J AM CHEM SOC, V120, P8020, DOI 10.1021/ja9714696; PATTERSON WR, 1995, BIOCHEMISTRY-US, V34, P4331, DOI 10.1021/bi00013a023; PIONTEK K, 1993, FEBS LETT, V315, P119, DOI 10.1016/0014-5793(93)81146-Q; POULOS TL, 1993, J BIOL CHEM, V268, P4429; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SAKURADA J, 1986, J BIOL CHEM, V261, P9657; SCHONBAUM GR, 1973, J BIOL CHEM, V248, P502; Schuller DJ, 1996, STRUCTURE, V4, P311, DOI 10.1016/S0969-2126(96)00035-4; SHINMEN Y, 1986, AGR BIOL CHEM TOKYO, V50, P247, DOI 10.1080/00021369.1986.10867369; SMITH AT, 1992, EUR J BIOCHEM, V207, P507, DOI 10.1111/j.1432-1033.1992.tb17077.x; Smulevich G, 1996, BIOCHEMISTRY-US, V35, P10576, DOI 10.1021/bi9605898; Sundaramoorthy M, 1995, STRUCTURE, V3, P1367, DOI 10.1016/S0969-2126(01)00274-X; SUNDARAMOORTHY M, 1994, J BIOL CHEM, V269, P32759; Tsukamoto K, 1999, BIOCHEMISTRY-US, V38, P12558, DOI 10.1021/bi982925l; WARIISHI H, 1992, J BIOL CHEM, V267, P23688	44	15	16	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32919	32924		10.1074/jbc.M004223200	http://dx.doi.org/10.1074/jbc.M004223200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10915789	hybrid			2022-12-27	WOS:000090003800075
J	Blackburn, MR; Aldrich, M; Volmer, JB; Chen, W; Zhong, HY; Kelly, S; Hershfield, MS; Datta, SK; Kellems, RE				Blackburn, MR; Aldrich, M; Volmer, JB; Chen, W; Zhong, HY; Kelly, S; Hershfield, MS; Datta, SK; Kellems, RE			The use of enzyme therapy to regulate the metabolic and phenotypic consequences of adenosine deaminase deficiency in mice - Differential impact on pulmonary and immunologic abnormalities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; S-ADENOSYLHOMOCYSTEINE HYDROLASE; GENE-THERAPY; REPLACEMENT THERAPY; CELL-DEATH; 2'-DEOXYADENOSINE; DEOXYNUCLEOTIDES; INACTIVATION; LYMPHOCYTES; ONTOGENY	Adenosine deaminase (ADA) deficiency results in a combined immunodeficiency brought about by the immunotoxic properties of elevated ADA substrates. Additional non-lymphoid abnormalities are associated with ADA deficiency, however, little is known about how these relate to the metabolic consequences of ADA deficiency. ADA-deficient mice develop a combined immunodeficiency as well as severe pulmonary insufficiency. ADA enzyme therapy was used to examine the relative impact of ADA substrate elevations on these phenotypes. A " low-dose " enzyme therapy protocol prevented the pulmonary phenotype seen in ADA-deficient mice, but did little to improve their immune status. This treatment protocol reduced metabolic disturbances in the circulation and lung, but not in the thymus and spleen. A "high-dose" enzyme therapy protocol resulted in decreased metabolic disturbances in the thymus and spleen and was associated with improvement in immune status. These findings suggest that the pulmonary and immune phenotypes are separable and are related to the severity of metabolic disturbances in these tissues. This model will be useful in examining the efficacy of ADA enzyme therapy and studying the mechanisms underlying the immunodeficiency and pulmonary phenotypes associated with ADA deficiency.	Univ Texas, Hlth Sci Ctr, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27707 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27707 USA	University of Texas System; University of Texas Health Science Center Houston; Duke University; Duke University	Blackburn, MR (corresponding author), Univ Texas, Hlth Sci Ctr, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA.	Michael.R.Blackburn@uth.tmc.edu		Blackburn, Michael/0000-0002-1394-9966	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046207] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61888] Funding Source: Medline; NIAID NIH HHS [AI43572] Funding Source: Medline; NIDDK NIH HHS [DK46207] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELARDINELLI L, 1989, PROG CARDIOVASC DIS, V32, P73, DOI 10.1016/0033-0620(89)90015-7; BENVENISTE P, 1995, J IMMUNOL, V155, P536; Blackburn MR, 2000, J EXP MED, V192, P159, DOI 10.1084/jem.192.2.159; Blackburn MR, 1996, J BIOL CHEM, V271, P15203, DOI 10.1074/jbc.271.25.15203; Blackburn MR, 1998, J BIOL CHEM, V273, P5093, DOI 10.1074/jbc.273.9.5093; BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; Bollinger ME, 1996, NEW ENGL J MED, V334, P1367, DOI 10.1056/NEJM199605233342104; BORDIGNON C, 1995, SCIENCE, V270, P470, DOI 10.1126/science.270.5235.470; Buckley RH, 1997, J PEDIATR-US, V130, P378, DOI 10.1016/S0022-3476(97)70199-9; CARSON DA, 1986, EXP CELL RES, V164, P273, DOI 10.1016/0014-4827(86)90028-5; CHURCHILL PC, 1982, J PHARMACOL EXP THER, V222, P319; COLEMAN MS, 1978, J BIOL CHEM, V253, P1619; Cronstein Bruce N., 1997, P285; DONOFRIO J, 1978, J CLIN INVEST, V62, P884, DOI 10.1172/JCI109201; FREDHOLM BB, 1988, TRENDS PHARMACOL SCI, V9, P130, DOI 10.1016/0165-6147(88)90194-0; FUKUNAGA AF, 1982, ANESTH ANALG, V61, P273; GIBLETT ER, 1972, LANCET, V2, P1067; Hershfield M S, 1985, Prog Clin Biol Res, V198, P305; HERSHFIELD MS, 1979, J CLIN INVEST, V63, P807, DOI 10.1172/JCI109367; HERSHFIELD MS, 1995, CLIN IMMUNOL IMMUNOP, V76, pS228, DOI 10.1016/S0090-1229(95)90306-2; HERSHFIELD MS, 1979, J BIOL CHEM, V254, P22; HERSHFIELD MS, 1993, PEDIATR RES, V33, pS42; HERSHFIELD MS, 1987, NEW ENGL J MED, V316, P589, DOI 10.1056/NEJM198703053161005; HERSHFIELD MS, 1995, METABOLIC MOL BASIS, V1, P1725; HIRSCHHORN R, 1980, NEW ENGL J MED, V303, P377, DOI 10.1056/NEJM198008143030706; Hirschhorn R, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P121; Huang S, 1997, BLOOD, V90, P1600, DOI 10.1182/blood.V90.4.1600.1600_1600_1610; JACOBSON MA, 1997, PURINERGIC APPROACHE, P585; KIZAKI H, 1990, J BIOL CHEM, V265, P5280; KNUDSEN TB, 1992, TERATOLOGY, V45, P91, DOI 10.1002/tera.1420450109; Kohn DB, 1998, NAT MED, V4, P775, DOI 10.1038/nm0798-775; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MIGCHIELSEN AAJ, 1995, NAT GENET, V10, P279, DOI 10.1038/ng0795-279; MITCHELL BS, 1985, ANN NY ACAD SCI, V451, P129, DOI 10.1111/j.1749-6632.1985.tb27103.x; MORGAN G, 1987, CLIN EXP IMMUNOL, V70, P491; OLAH ME, 1995, ANNU REV PHARMACOL, V35, P581, DOI 10.1146/annurev.pa.35.040195.003053; RATECH H, 1985, AM J PATHOL, V120, P157; Tourigny MR, 1997, J EXP MED, V185, P1549, DOI 10.1084/jem.185.9.1549; ULLMAN B, 1978, CELL, V14, P365, DOI 10.1016/0092-8674(78)90122-8; WAKAMIYA M, 1995, P NATL ACAD SCI USA, V92, P3673, DOI 10.1073/pnas.92.9.3673; WEINBERG K, 1993, J CLIN INVEST, V92, P596, DOI 10.1172/JCI116626	41	82	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32114	32121		10.1074/jbc.M005153200	http://dx.doi.org/10.1074/jbc.M005153200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10908569	hybrid			2022-12-27	WOS:000089858900077
J	Che, FS; Nakajima, Y; Tanaka, N; Iwano, M; Yoshida, T; Takayama, S; Kadota, I; Isogai, A				Che, FS; Nakajima, Y; Tanaka, N; Iwano, M; Yoshida, T; Takayama, S; Kadota, I; Isogai, A			Flagellin from an incompatible strain of Pseudomonas avenae induces a resistance response in cultured rice cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT-PATHOGEN INTERACTIONS; HOST SPECIES-SPECIFICITY; HYPERSENSITIVE RESPONSE; DEFENSE RESPONSES; POSTTRANSLATIONAL MODIFICATION; SALMONELLA-TYPHIMURIUM; PHYTOALEXIN PRODUCTION; N-ACETYLCHITOHEPTAOSE; MICROBE INTERACTIONS; DISEASE RESISTANCE	The host range of Pseudomonas avenae is wide among monocotyledonous plants, but individual strains can infect only one or a few host species. The resistance response of rice cells to pathogens has been previously shown to be induced by a rice-incompatible strain, N1141, but not by a rice-compatible strain, H8301. To clarify the molecular mechanism of the host specificity in P. avenae, a strain-specific antibody that was raised against N1141 cells and then absorbed with H8301 cells was prepared. When a cell extract of strain N1141 was separated by SDS-polyacrylamide gel electrophoresis and immunostained with the N1141 strain-specific antibody, only a flagellin protein was detected. Purified N1141 flagellin induced the hypersensitive cell death in cultured rice cells within 6 h of treatment, whereas the H8301 flagellin did not. The hypersensitive cell death could be blocked by pretreatment with anti-N1141 flagellin antibody. Furthermore, a flagellin-deficient N1141 strain lost not only the induction ability of hypersensitive cell death but also the expression ability of the EL2 gene, which is thought to be one of the defense-related genes. These results demonstrated that the resistance response in cultured rice cells is induced by the flagellin existing in the incompatible strain of P. avenae but not in the flagellin of the compatible strain.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan; Natl Inst Agroenvironm Sci, Tsukuba, Ibaraki 3058602, Japan	Nara Institute of Science & Technology; National Institute for Agro-Environmental Sciences (NIAES) Japan	Che, FS (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, 8916-5 Takayama, Nara 6300101, Japan.	fsche@bs.aist-nara.ac.jp	Isogai, Akira/O-8897-2017; Nakajima, Yoshihiro/M-6935-2018	Isogai, Akira/0000-0001-8095-0441; Nakajima, Yoshihiro/0000-0002-7422-730X				AGRIOS GN, 1997, PLANT PATHOL, P93; AMBLER RP, 1959, NATURE, V184, P56, DOI 10.1038/184056b0; ARLAT M, 1994, EMBO J, V13, P543, DOI 10.1002/j.1460-2075.1994.tb06292.x; BABA A, 1986, PLANT CELL PHYSIOL, V27, P463; BAKER CJ, 1993, PLANT PHYSIOL, V102, P1341, DOI 10.1104/pp.102.4.1341; BLAIR DF, 1995, ANNU REV MICROBIOL, V49, P489, DOI 10.1146/annurev.mi.49.100195.002421; BOLLER T, 1995, ANNU REV PLANT PHYS, V46, P189, DOI 10.1146/annurev.arplant.46.1.189; Che FS, 1999, PLANT CELL PHYSIOL, V40, P1036, DOI 10.1093/oxfordjournals.pcp.a029485; CULVER JN, 1991, MOL PLANT MICROBE IN, V4, P458, DOI 10.1094/MPMI-4-458; Dangl JL, 1996, PLANT CELL, V8, P1793, DOI 10.1105/tpc.8.10.1793; DIXON RA, 1994, ANNU REV PHYTOPATHOL, V32, P479, DOI 10.1146/annurev.py.32.090194.002403; Doig P, 1996, MOL MICROBIOL, V19, P379, DOI 10.1046/j.1365-2958.1996.370890.x; EBEL J, 1994, INT REV CYTOL, V148, P1; Felix G, 1999, PLANT J, V18, P265, DOI 10.1046/j.1365-313X.1999.00265.x; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; GABRIEL DW, 1990, ANNU REV PHYTOPATHOL, V28, P365, DOI 10.1146/annurev.py.28.090190.002053; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GILBERTOGONZALEZ R, 1980, BIOCHEMISTRY-US, V19, P4299, DOI 10.1021/bi00559a023; Greenberg JT, 1997, ANNU REV PLANT PHYS, V48, P525, DOI 10.1146/annurev.arplant.48.1.525; Guerry P, 1996, MOL MICROBIOL, V19, P369, DOI 10.1046/j.1365-2958.1996.369895.x; He DY, 1998, MOL PLANT MICROBE IN, V11, P1167, DOI 10.1094/MPMI.1998.11.12.1167; He SY, 1996, PLANT PHYSIOL, V112, P865, DOI 10.1104/pp.112.3.865; HE SY, 1993, CELL, V73, P1255, DOI 10.1016/0092-8674(93)90354-S; HE XS, 1994, J BACTERIOL, V176, P2406, DOI 10.1128/JB.176.8.2406-2414.1994; HEATH MC, 1991, PHYTOPATHOLOGY, V81, P127; HUET JC, 1995, MOL PLANT MICROBE IN, V8, P302, DOI 10.1094/MPMI-8-0302; IINO T, 1969, BACTERIOL REV, V33, P454, DOI 10.1128/MMBR.33.4.454-475.1969; Joys Terence M., 1992, Biomedical Letters, V47, P371; JOYS TM, 1988, CAN J MICROBIOL, V34, P452, DOI 10.1139/m88-078; JOYS TM, 1985, J BIOL CHEM, V260, P5758; KADOTA I, 1991, Annals of the Phytopathological Society of Japan, V57, P268, DOI 10.3186/jjphytopath.57.268; Kadota Ikuo, 1996, Annals of the Phytopathological Society of Japan, V62, P425, DOI 10.3186/jjphytopath.62.425; KALMOKOFF ML, 1988, J BACTERIOL, V170, P1752, DOI 10.1128/jb.170.4.1752-1758.1988; Kamoun S, 1998, PLANT CELL, V10, P1413, DOI 10.1105/tpc.10.9.1413; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; Keller H, 1999, PLANT CELL, V11, P223, DOI 10.1105/tpc.11.2.223; KELLYWINTENBERG K, 1993, J BACTERIOL, V175, P2458, DOI 10.1128/JB.175.8.2458-2461.1993; Kombrink E, 1995, ADV BOT RES, V21, P1; KUCHITSU K, 1993, PROTOPLASMA, V174, P79, DOI 10.1007/BF01404046; KUWAJIMA G, 1988, J BACTERIOL, V170, P485, DOI 10.1128/jb.170.1.485-488.1988; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; McCabe PF, 1997, PLANT J, V12, P267, DOI 10.1046/j.1365-313X.1997.12020267.x; Minami E, 1996, PLANT CELL PHYSIOL, V37, P563, DOI 10.1093/oxfordjournals.pcp.a028981; MOENS S, 1995, MICROBIOL-UK, V141, P2651, DOI 10.1099/13500872-141-10-2651; Namba K, 1997, Q REV BIOPHYS, V30, P1, DOI 10.1017/S0033583596003319; NAMBA K, 1989, NATURE, V342, P648, DOI 10.1038/342648a0; NEWTON SMC, 1991, MOL MICROBIOL, V5, P419, DOI 10.1111/j.1365-2958.1991.tb02124.x; NISHIYAMA K, 1979, Annals of the Phytopathological Society of Japan, V45, P25, DOI 10.3186/jjphytopath.45.25; Panabieres F, 1995, MOL PLANT MICROBE IN, V8, P996, DOI 10.1094/MPMI-8-0996; PERNOLLET JC, 1993, PHYSIOL MOL PLANT P, V42, P53, DOI 10.1006/pmpp.1993.1005; Ricci P., 1997, PLANT MICROBE INTERA, V3, P53; Ryerson DE, 1996, PLANT CELL, V8, P393, DOI 10.1105/tpc.8.3.393; Scofield SR, 1996, SCIENCE, V274, P2063, DOI 10.1126/science.274.5295.2063; SHIBUYA N, 1993, FEBS LETT, V329, P75, DOI 10.1016/0014-5793(93)80197-3; SOBERON X, 1977, GENE, V2, P95; Stocker B A, 1994, Int Rev Immunol, V11, P167, DOI 10.3109/08830189409061724; SWEIGARD JA, 1995, PLANT CELL, V7, P1221, DOI 10.1105/tpc.7.8.1221; Tang XY, 1996, SCIENCE, V274, P2060, DOI 10.1126/science.274.5295.2060; TURNER JG, 1974, PHYTOPATHOLOGY, V64, P885, DOI 10.1094/Phyto-64-885; Umemoto N, 1997, P NATL ACAD SCI USA, V94, P1029, DOI 10.1073/pnas.94.3.1029; Wang H, 1996, PLANT CELL, V8, P375, DOI 10.1105/tpc.8.3.375; WEI LN, 1986, NUCLEIC ACIDS RES, V14, P8227, DOI 10.1093/nar/14.20.8227; WEI ZM, 1992, SCIENCE, V257, P85, DOI 10.1126/science.1621099; WIELAND F, 1985, J BIOL CHEM, V260, P5180; Wilson K., 2001, CURR PROTOC MOL BIOL, V56, P241, DOI [DOI 10.1002/0471142727.MB0204S56, 10.1002/0471142727.mb0204s56]; Yang YO, 1997, GENE DEV, V11, P1621, DOI 10.1101/gad.11.13.1621; YOSHIOKA K, 1995, J BACTERIOL, V177, P1090, DOI 10.1128/jb.177.4.1090-1093.1995	67	99	109	1	16	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32347	32356		10.1074/jbc.M004796200	http://dx.doi.org/10.1074/jbc.M004796200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10922369	hybrid			2022-12-27	WOS:000089858900108
J	Michel, YM; Poncet, D; Piron, M; Kean, KM; Borman, AM				Michel, YM; Poncet, D; Piron, M; Kean, KM; Borman, AM			Cap-poly(A) synergy in mammalian cell-free extracts - Investigation of the requirements for poly(A)mediated stimulation of translation initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(A) BINDING-PROTEIN; HUMAN RHINOVIRUS RNA; MESSENGER-RNA; POLY(A)-TAIL-PROMOTED TRANSLATION; SACCHAROMYCES-CEREVISIAE; POLY(A)-BINDING PROTEIN; INTERNAL INITIATION; CAP STRUCTURE; HUMAN EIF4G; TAIL	The 5' cap and 3' poly(A) tail of eukaryotic mRNAs cooperate to stimulate synergistically translation initiation in vivo, a phenomenon observed to date in vitro only in translation systems containing endogenous com petitor mRNAs, Here we describe nuclease-treated rabbit reticulocyte lysates and HeLa cell cytoplasmic extracts that reproduce cap-poly(A) synergy in the absence of such competitor RNAs, Extracts were rendered poly(A)-dependent by ultracentrifugation to partially deplete them of ribosomes and associated initiation factors. Under optimal conditions, values for synergy in reticulocyte lysates approached 10-fold. By using this system, we investigated the molecular mechanism of poly(A) stimulation of translation. Maximal cap-poly(A) cooperativity required the integrity of the eukaryotic initiation factor 4G-poly(A)-binding protein (eIF4G-PABP) interaction, suggesting that synergy results from mRNA circularization. In addition, polyadenylation stimulated uncapped cellular mRNA translation and that driven by the encephalomyocarditis virus internal ribosome entry segment (IRES), These effects of poly(A) were also sensitive to disruption of the eIF4G-PABP interaction, suggesting that 5'-3' end crosstalk is functionally conserved between classical mRNAs and an IRES-containing mRNA. Finally, we demonstrate that a rotaviral non-structural protein that evicts PABP from eIF4G is capable of provoking the shut-off of host cell translation seen during rotavirus infection.	Inst Pasteur, CNRS URA 1966, Unite Genet Mol Virus Resp, F-75724 Paris 15, France; INRA, CRJJ, Lab Virol & Immunol Mol, F-78352 Jouy En Josas, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Kean, KM (corresponding author), Inst Pasteur, CNRS URA 1966, Unite Genet Mol Virus Resp, 25 Rue Dr Roux, F-75724 Paris 15, France.		Borman, Andy/H-3663-2019; Poncet, Didier/AAV-6583-2021	Borman, Andy/0000-0003-0585-5721; Poncet, Didier/0000-0001-7689-0175				BANERJEE AK, 1980, MICROBIOL REV, V44, P175, DOI 10.1128/MMBR.44.2.175-205.1980; BORMAN A, 1992, VIROLOGY, V188, P685, DOI 10.1016/0042-6822(92)90523-R; BORMAN A, 1993, J GEN VIROL, V74, P1775, DOI 10.1099/0022-1317-74-9-1775; Borman AM, 1997, RNA, V3, P186; DASSO MC, 1989, NUCLEIC ACIDS RES, V17, P6485, DOI 10.1093/nar/17.16.6485; De Gregorio E, 1998, RNA, V4, P828, DOI 10.1017/S1355838298980372; DOEL MT, 1976, CELL, V8, P51, DOI 10.1016/0092-8674(76)90184-7; FOIANI M, 1991, MOL CELL BIOL, V11, P3203, DOI 10.1128/MCB.11.6.3203; Gallie DR, 1998, GENE, V216, P1, DOI 10.1016/S0378-1119(98)00318-7; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; Gebauer F, 1999, EMBO J, V18, P6146, DOI 10.1093/emboj/18.21.6146; Hoshino S, 1999, J BIOL CHEM, V274, P16677, DOI 10.1074/jbc.274.24.16677; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; IZUKA N, 1994, MOL CELL BIOL, V14, P7322; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; JACKSON RJ, 1994, MOL BIOL REP, V19, P147, DOI 10.1007/BF00986957; Jacobson A., 1996, TRANSLATIONAL CONTRO, P451; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; LIEBIG HD, 1993, BIOCHEMISTRY-US, V32, P7581, DOI 10.1021/bi00080a033; MOLLA A, 1991, SCIENCE, V254, P1647, DOI 10.1126/science.1661029; Morley SJ, 1997, RNA, V3, P1085; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; Piron M, 1999, J VIROL, V73, P5411, DOI 10.1128/JVI.73.7.5411-5421.1999; Piron M, 1998, EMBO J, V17, P5811, DOI 10.1093/emboj/17.19.5811; PONCET D, 1993, J VIROL, V67, P3159, DOI 10.1128/JVI.67.6.3159-3165.1993; Preiss T, 1998, RNA, V4, P1321, DOI 10.1017/S1355838298980669; Preiss T, 1998, NATURE, V392, P516, DOI 10.1038/33192; Proweller A, 1997, J BIOL CHEM, V272, P6004, DOI 10.1074/jbc.272.9.6004; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; Wei CC, 1998, BIOCHEMISTRY-US, V37, P1910, DOI 10.1021/bi9724570; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7	35	119	124	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32268	32276		10.1074/jbc.M004304200	http://dx.doi.org/10.1074/jbc.M004304200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10922367	Green Published, hybrid			2022-12-27	WOS:000089858900098
J	Dhe-Paganon, S; Shigeta, R; Chi, YI; Ristow, M; Shoelson, SE				Dhe-Paganon, S; Shigeta, R; Chi, YI; Ristow, M; Shoelson, SE			Crystal structure of human frataxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PROCESSING PEPTIDASE; FRIEDREICHS-ATAXIA; YEAST; IRON; MATURATION; HOMOLOG; ASSOCIATION; DEFICIENCY; DNA	Friedreich's ataxia, an autosomal recessive neurodegenerative disorder characterized by progressive gait and limb ataxia, cardiomyopathy, and diabetes mellitus, is caused by decreased frataxin production or function. The structure of human frataxin, which we have determined at 1.8-Angstrom resolution, reveals a novel protein fold. A five-stranded, antiparallel beta sheet provides a flat platform, which supports a pair of parallel alpha helices, to form a compact arp sandwich. A cluster of 12 acidic residues from the first helix and the first strand of the large sheet form a contiguous anionic surface on the protein. The overall protein structure and the anionic patch are conserved in eukaryotes, including animals, plants, and yeast, and in prokaryotes. Additional conserved residues create an extended 1008-Angstrom(2) patch on a distinct surface of the protein. Side chains of disease-associated mutations either contribute to the anionic patch, help create the second conserved surface, or point toward frataxin's hydrophobic core. These structural findings predict potential modes of protein-protein and protein-iron binding.	Joslin Diabet Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Univ Cologne, Dept Internal Med 2, D-50931 Cologne, Germany	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; University of Cologne	Shoelson, SE (corresponding author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.		Ristow, Michael/O-9858-2014	Ristow, Michael/0000-0003-2109-2453	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007260] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK4312, DK07260] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; BLASS JP, 1976, NEW ENGL J MED, V295, P62, DOI 10.1056/NEJM197607082950202; Bradley JL, 2000, HUM MOL GENET, V9, P275, DOI 10.1093/hmg/9.2.275; Branda SS, 1999, J BIOL CHEM, V274, P22763, DOI 10.1074/jbc.274.32.22763; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Campuzano V, 1997, HUM MOL GENET, V6, P1771, DOI 10.1093/hmg/6.11.1771; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHAMBERLAIN S, 1988, NATURE, V334, P248, DOI 10.1038/334248a0; Chasteen ND, 1999, J STRUCT BIOL, V126, P182, DOI 10.1006/jsbi.1999.4118; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; *COLL COMP PROJ 4, 1994, ACTA CRYSTALLOGR D, V50, P7608; Cossee M, 2000, HUM MOL GENET, V9, P1219, DOI 10.1093/hmg/9.8.1219; Cossee M, 1999, ANN NEUROL, V45, P200, DOI 10.1002/1531-8249(199902)45:2<200::AID-ANA10>3.0.CO;2-U; De Michele G, 2000, NEUROLOGY, V54, P496, DOI 10.1212/WNL.54.2.496; Durr A, 1996, NEW ENGL J MED, V335, P1169, DOI 10.1056/NEJM199610173351601; Gordon DM, 1999, HUM MOL GENET, V8, P2255, DOI 10.1093/hmg/8.12.2255; Gray JV, 1997, NAT GENET, V16, P323, DOI 10.1038/ng0897-323; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Knight SAB, 1998, J BIOL CHEM, V273, P18389, DOI 10.1074/jbc.273.29.18389; Koutnikova H, 1998, HUM MOL GENET, V7, P1485, DOI 10.1093/hmg/7.9.1485; Koutnikova H, 1997, NAT GENET, V16, P345, DOI 10.1038/ng0897-345; La Fortelle Ed, 1997, CRYSTALLOGRAPHIC COM; Lodi R, 1999, P NATL ACAD SCI USA, V96, P11492, DOI 10.1073/pnas.96.20.11492; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; Sakamoto N, 1999, MOL CELL, V3, P465, DOI 10.1016/S1097-2765(00)80474-8; Wilson RB, 1997, NAT GENET, V16, P352, DOI 10.1038/ng0897-352; Wong A, 1999, HUM MOL GENET, V8, P425, DOI 10.1093/hmg/8.3.425	30	171	178	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30753	30756		10.1074/jbc.C000407200	http://dx.doi.org/10.1074/jbc.C000407200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10900192	hybrid			2022-12-27	WOS:000089762700003
J	Haldrup, A; Simpson, DJ; Scheller, HV				Haldrup, A; Simpson, DJ; Scheller, HV			Down-regulation of the PSI-F subunit of photosystem I (PSI) in Arabidopsis thaliana - The PSI-F subunit is essential for photoautotrophic growth and contributes to antenna function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPHYLL-PROTEIN COMPLEXES; CHLAMYDOMONAS-REINHARDTII; THYLAKOID MEMBRANES; BINDS PLASTOCYANIN; ELECTRON-TRANSFER; CYTOCHROME C(6); HEAT-STRESS; BARLEY; IDENTIFICATION; POLYPEPTIDES	The PSI-F subunit of photosystem I is a transmembrane protein with a large lumenal domain, The role of PSI-F was investigated in Arabidopsis plants transformed with an antisense construct of the psaF cDNA. Several plant lines with reduced amounts of the PSI-F subunit were generated. Many of the transgenic plants died, apparently because they were unable to survive without the PSI-F subunit. Plants with 5% of PSI-F were capable of photoautotrophic growth but were much smaller than wild-type plants. The plants suffered severely under normal growth conditions but recovered somewhat in the dark indicating chronic photoinhibition. Photosystem I lacking PSI-F was less stable, and the stromal subunits PSI-C, PSI-D, and PSI-E were present in lower amounts than in wild type, The lack of PSI-F resulted in an inability of light-harvesting complex I-730 to transfer energy to the P700 reaction center. In thylakoids deficient in PSI-F, the steady state NADP reduction rate was only 10% of the wild-type levels indicating a lower efficiency in oxidation of plastocyanin. Surprisingly, the lack of PSI-F also gave rise to disorganization of the thylakoids, The strict arrangement in grana and stroma lamellae was lost, and instead a network of elongated and distorted grana was observed.	Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, DK-1871 Frederiksberg C, Denmark; Carlsberg Lab, Dept Physiol, DK-2500 Copenhagen, Denmark	University of Copenhagen	Scheller, HV (corresponding author), Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, 40 Thorvaldsensvej, DK-1871 Frederiksberg C, Denmark.		Scheller, Henrik V/A-8106-2008; Scheller, Henrik/AAH-4770-2020	Scheller, Henrik V/0000-0002-6702-3560; Scheller, Henrik/0000-0002-6702-3560; Haldrup, Anna/0000-0002-2348-7072				Allen JF, 1997, PHYSIOL PLANTARUM, V100, P863, DOI 10.1034/j.1399-3054.1997.1000412.x; ANANDAN S, 1989, FEBS LETT, V256, P150, DOI 10.1016/0014-5793(89)81737-5; ANDERSEN B, 1992, PHYSIOL PLANTARUM, V84, P154, DOI 10.1111/j.1399-3054.1992.tb08778.x; ANDERSON JM, 1986, ANNU REV PLANT PHYS, V37, P93, DOI 10.1146/annurev.arplant.37.1.93; ANDERSSON B, 1980, BIOCHIM BIOPHYS ACTA, V593, P427, DOI 10.1016/0005-2728(80)90078-X; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; Baena-Gonzalez E, 1999, PLANTA, V208, P196, DOI 10.1007/s004250050550; BASSI R, 1992, J BIOL CHEM, V267, P25714; BASSI R, 1987, EUR J BIOCHEM, V163, P221, DOI 10.1111/j.1432-1033.1987.tb10791.x; BENNOUN P, 1982, P NATL ACAD SCI-BIOL, V79, P4352, DOI 10.1073/pnas.79.14.4352; BURKEY KO, 1993, PHOTOSYNTH RES, V36, P103, DOI 10.1007/BF00016275; Burrows PA, 1998, EMBO J, V17, P868, DOI 10.1093/emboj/17.4.868; Catala R, 1997, PLANT CELL PHYSIOL, V38, P1382, DOI 10.1093/oxfordjournals.pcp.a029133; CHITNIS PR, 1991, J BIOL CHEM, V266, P20146; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Croce R, 1998, BIOCHEMISTRY-US, V37, P17355, DOI 10.1021/bi9813227; Durnford DG, 1999, J MOL EVOL, V48, P59, DOI 10.1007/PL00006445; FARAH J, 1995, EMBO J, V14, P4976, DOI 10.1002/j.1460-2075.1995.tb00180.x; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; Haldrup A, 1999, PLANT J, V17, P689, DOI 10.1046/j.1365-313X.1999.00419.x; Hippler M, 1999, J BIOL CHEM, V274, P4180, DOI 10.1074/jbc.274.7.4180; Hippler M, 1997, BIOCHEMISTRY-US, V36, P6343, DOI 10.1021/bi970082c; HIPPLER M, 1989, FEBS LETT, V250, P280, DOI 10.1016/0014-5793(89)80738-0; Hippler M, 1998, P NATL ACAD SCI USA, V95, P7339, DOI 10.1073/pnas.95.13.7339; Hippler M, 1996, EMBO J, V15, P6374, DOI 10.1002/j.1460-2075.1996.tb01028.x; Hippler M, 2000, J BIOL CHEM, V275, P5852, DOI 10.1074/jbc.275.8.5852; HIYAMA T, 1972, BIOCHIM BIOPHYS ACTA, V267, P160, DOI 10.1016/0005-2728(72)90147-8; Horton P, 1999, AUST J PLANT PHYSIOL, V26, P659, DOI 10.1071/PP99095; Jansson S, 1996, PLANT PHYSIOL, V112, P409, DOI 10.1104/pp.112.1.409; JANSSON S, 1991, MOL GEN GENET, V229, P67, DOI 10.1007/BF00264214; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; JANSSON S, 1994, BBA-BIOENERGETICS, V1184, P1, DOI 10.1016/0005-2728(94)90148-1; Jansson S, 1992, PLANT MOL BIOL REP, V10, P242, DOI 10.1007/BF02668357; Jensen PE, 2000, J BIOL CHEM, V275, P24701, DOI 10.1074/jbc.M000550200; KANA TM, 1992, J PHYCOL, V28, P304, DOI 10.1111/j.0022-3646.1992.00304.x; KAY R, 1987, SCIENCE, V236, P1299, DOI 10.1126/science.236.4806.1299; Klukas O, 1999, J BIOL CHEM, V274, P7351, DOI 10.1074/jbc.274.11.7351; KNOETZEL J, 1992, EUR J BIOCHEM, V206, P209, DOI 10.1111/j.1432-1033.1992.tb16918.x; Knoetzel J, 1998, FEBS LETT, V436, P339, DOI 10.1016/S0014-5793(98)01158-2; Lajko F, 1997, PHOTOSYNTHETICA, V33, P217, DOI 10.1023/A:1022160213152; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; Martin M, 1996, PLANT CELL PHYSIOL, V37, P293, DOI 10.1093/oxfordjournals.pcp.a028945; Naver H, 1996, J BIOL CHEM, V271, P8996, DOI 10.1074/jbc.271.15.8996; Naver H, 1999, J BIOL CHEM, V274, P10784, DOI 10.1074/jbc.274.16.10784; NAVER H, 1995, PHYSIOL PLANTARUM, V95, P19, DOI 10.1111/j.1399-3054.1995.tb00802.x; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; Sazanov LA, 1998, FEBS LETT, V429, P115, DOI 10.1016/S0014-5793(98)00573-0; SCHELLER HV, 1990, PHYSIOL PLANTARUM, V78, P484, DOI 10.1034/j.1399-3054.1990.780326.x; Schmid VHR, 1997, P NATL ACAD SCI USA, V94, P7667, DOI 10.1073/pnas.94.14.7667; SHEN WJ, 1989, NUCLEIC ACIDS RES, V17, P8385, DOI 10.1093/nar/17.20.8385; SHUVALOV VA, 1986, BIOCHIM BIOPHYS ACTA, V850, P319, DOI 10.1016/0005-2728(86)90187-8; SIMPSON DJ, 1980, CARLSBERG RES COMMUN, V45, P283, DOI 10.1007/BF02906180; Sonoike K, 1996, PLANT CELL PHYSIOL, V37, P239, DOI 10.1093/oxfordjournals.pcp.a028938; TEICHER HB, 2000, IN PRESS PHOTOSYNTH; Tjus SE, 1998, PLANT PHYSIOL, V116, P755, DOI 10.1104/pp.116.2.755; Tjus SE, 1999, PHOTOSYNTH RES, V60, P75, DOI 10.1023/A:1006283618695; Varotto C, 2000, PLANT J, V22, P115, DOI 10.1046/j.1365-313x.2000.00717.x; WYNN RM, 1988, BIOCHEMISTRY-US, V27, P5863, DOI 10.1021/bi00416a007; WYNN RM, 1989, PLANT PHYSIOL, V91, P445, DOI 10.1104/pp.91.1.445; WYNN RM, 1989, BIOCHEMISTRY-US, V28, P5554, DOI 10.1021/bi00439a032; XU QA, 1994, J BIOL CHEM, V269, P3205; ZAMBRYSKI P, 1983, EMBO J, V2, P2143, DOI 10.1002/j.1460-2075.1983.tb01715.x; Zhang H, 1997, PLANT PHYSIOL, V115, P1525, DOI 10.1104/pp.115.4.1525	63	80	88	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31211	31218		10.1074/jbc.M002933200	http://dx.doi.org/10.1074/jbc.M002933200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10900198	hybrid			2022-12-27	WOS:000089762700066
J	Lock, LS; Royal, I; Naujokas, MA; Park, M				Lock, LS; Royal, I; Naujokas, MA; Park, M			Identification of an atypical Grb2 carboxyl-terminal SH3 domain binding site in Gab docking proteins reveals Grb2-dependent and -independent recruitment of Gab1 to receptor tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; PLECKSTRIN HOMOLOGY DOMAIN; PROLINE-RICH PEPTIDE; C-MET RECEPTOR; SCATTER FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; EPITHELIAL MORPHOGENESIS; ADAPTER PROTEIN; T-CELL; SIGNAL-TRANSDUCTION	The Gab family of docking proteins is phosphorylated in response to various growth factors and cytokines and serves to recruit multiple signaling proteins. Gab1 acts downstream from the Met-hepatocyte growth factor receptor, and Gab1 overexpression promotes Met dependent morphogenesis of epithelial cells. Recruitment of Gab1 to Met or epidermal growth factor (EGF) receptors requires a receptor-binding site for the Grb2 adapter protein and a proline-rich domain in Gab1, defined as the Met-binding domain. To determine the requirement for Grb2 in Gab1 recruitment, we have mapped two Grb2 carboxyl-terminal SH3 domain binding sites conserved in Gab1 and related protein Gab2. One corresponds to a canonical Grb2-binding motif, whereas the second, located within the Gab1 Met-binding domain, requires the proline and arginine residues of an atypical PXXXR motif. The PXXXR motif is required but not sufficient for Grb2 binding, whereas an extended motif, PX3RX2KPX7PLD, conserved in Gab proteins as well as the Grb2/Gads-docking protein, Slp-76, efficiently competes binding of Grb2 or Gads adapter proteins. The association of Gab1 with Grb2 is required for Gab1 recruitment to the EGF receptor but not the Met receptor. Hence different mechanisms of Gab1 recruitment may reflect the distinct biological functions for Gab1 downstream from the EGF and Met receptors.	McGill Univ, Ctr Hlth, Dept Biochem, Mol Oncol Grp H5 10, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hlth, Dept Med, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hlth, Dept Oncol, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada	McGill University; McGill University; McGill University	Park, M (corresponding author), McGill Univ, Ctr Hlth, Dept Biochem, Mol Oncol Grp H5 10, 687 Pine Ave W,Rm H5-10, Montreal, PQ H3A 1A1, Canada.	morag@lan1.molone.mcgill.ca		Royal, Isabelle/0000-0002-7548-1182				Asada H, 1999, J EXP MED, V189, P1383, DOI 10.1084/jem.189.9.1383; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GOUDREAU N, 1994, NAT STRUCT BIOL, V1, P898, DOI 10.1038/nsb1294-898; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Harmer SL, 1999, J BIOL CHEM, V274, P12183, DOI 10.1074/jbc.274.17.12183; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Ingham RJ, 1998, J BIOL CHEM, V273, P30630, DOI 10.1074/jbc.273.46.30630; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; KOMADA M, 1993, ONCOGENE, V8, P2381; Korhonen JM, 1999, J BIOL CHEM, V274, P37307, DOI 10.1074/jbc.274.52.37307; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Liu SK, 1998, ONCOGENE, V17, P3073, DOI 10.1038/sj.onc.1202337; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Maroun CR, 1999, J BIOL CHEM, V274, P31719, DOI 10.1074/jbc.274.44.31719; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Matsumoto K, 1993, EXS, V65, P225; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; Qiu MS, 1998, BIOCHEM BIOPH RES CO, V253, P443, DOI 10.1006/bbrc.1998.9795; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; RAMOSMORALES F, 1995, ONCOGENE, V11, P1665; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; TERASAWA H, 1994, NAT STRUCT BIOL, V1, P891, DOI 10.1038/nsb1294-891; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649; ZHU H, 1994, CELL GROWTH DIFFER, V5, P359; ZHU H, 1994, J BIOL CHEM, V269, P29943	63	145	148	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31536	31545		10.1074/jbc.M003597200	http://dx.doi.org/10.1074/jbc.M003597200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10913131	hybrid			2022-12-27	WOS:000089762700109
J	Hinoi, T; Yamamoto, H; Kishida, M; Takada, S; Kishida, S; Kikuchi, A				Hinoi, T; Yamamoto, H; Kishida, M; Takada, S; Kishida, S; Kikuchi, A			Complex formation of adenomatous polyposis coli gene product and Axin facilitates glycogen synthase kinase-3 beta-dependent phosphorylation of beta-catenin and down-regulates beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; WNT SIGNALING PATHWAY; MOUSE FUSED LOCUS; F-BOX PROTEIN; XENOPUS EMBRYOS; NEGATIVE REGULATOR; FUNCTIONAL INTERACTION; PHOSPHATASE 2A; APC; TRANSCRIPTION	Adenomatous polyposis coli gene product (APC) functions as a tumor suppressor and its mutations in familial adenomatous polyposis and colorectal cancers lead to the accumulation of cytoplasmic beta -catenin. The molecular mechanism by which APC regulates the stability of beta -catenin was investigated. The central region of APC, APC-(1211-2075), has the beta -catenin- and Axin-binding sites and down-regulates beta -catenin. Glycogen synthase kinase-3 beta (GSK-3 beta) phosphorylated beta -catenin slightly in the presence of either APC-(1211-2075) or Axin(Delta beta -catenin) in which the beta -catenin-binding site is deleted, and greatly in the presence of both proteins. The enhancement of the GSK-3 beta -dependent phosphorylation of beta -catenin was eliminated by the APC-binding site of Axin. Axin down-regulated beta -catenin in SW480 cells, but not Axin(Delta beta -catenin). I, L cells where APC is intact, Axin(Delta beta -catenin) inhibited Wnt-dependent accumulation of beta -catenin but not Axin-(298-832)(Delta beta -catenin) in which the APC- and beta -catenin-binding sites are deleted. These results indicate that the complex formation of APC and Axin enhances the phosphorylation of beta -catenin by GSK-3 beta, leading to the down-regulation of beta -catenin.	Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; Japan Sci & Technol Corp, PRESTO, Hiroshima 7348551, Japan; Kyoto Univ, Fac Sci, Ctr Mol & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan	Hiroshima University; Japan Science & Technology Agency (JST); Kyoto University	Kikuchi, A (corresponding author), Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.			Takada, Shinji/0000-0003-4125-6056; kishida, shosei/0000-0003-0405-851X				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Dale TC, 1998, BIOCHEM J, V329, P209; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; GLUECKSOHNSCHOENHEIMER S, 1949, J EXP ZOOL, V110, P47, DOI 10.1002/jez.1401100105; Hamada F, 1999, SCIENCE, V283, P1739, DOI 10.1126/science.283.5408.1739; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Itoh K, 2000, MOL CELL BIOL, V20, P2228, DOI 10.1128/MCB.20.6.2228-2238.2000; Jho EH, 1999, BIOCHEM BIOPH RES CO, V266, P28, DOI 10.1006/bbrc.1999.1760; Kawahara K, 2000, J BIOL CHEM, V275, P8369, DOI 10.1074/jbc.275.12.8369; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kikuchi A, 1999, CELL SIGNAL, V11, P777, DOI 10.1016/S0898-6568(99)00054-6; Kikuchi A, 1999, CYTOKINE GROWTH F R, V10, P255, DOI 10.1016/S1359-6101(99)00017-9; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; Kishida M, 1999, ONCOGENE, V18, P979, DOI 10.1038/sj.onc.1202388; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kodama S, 1999, J BIOL CHEM, V274, P27682, DOI 10.1074/jbc.274.39.27682; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; PERRY WL, 1995, GENETICS, V141, P321; PIERCE SB, 1995, DEVELOPMENT, V121, P755; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Rubinfeld B, 1997, CANCER RES, V57, P4624; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Shibamoto S, 1998, GENES CELLS, V3, P659; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Yanagawa SI, 1997, J BIOL CHEM, V272, P25243, DOI 10.1074/jbc.272.40.25243; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	58	104	113	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34399	34406		10.1074/jbc.M003997200	http://dx.doi.org/10.1074/jbc.M003997200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10906131	hybrid			2022-12-27	WOS:000165095300055
J	Copeland, RA; Marcinkeviciene, J; Haque, TS; Kopcho, LM; Jiang, WJ; Wang, K; Ecret, LD; Sizemore, C; Amsler, KA; Foster, L; Tadesse, S; Combs, AP; Stern, AM; Trainor, GL; Slee, A; Rogers, MJ; Hobbs, F				Copeland, RA; Marcinkeviciene, J; Haque, TS; Kopcho, LM; Jiang, WJ; Wang, K; Ecret, LD; Sizemore, C; Amsler, KA; Foster, L; Tadesse, S; Combs, AP; Stern, AM; Trainor, GL; Slee, A; Rogers, MJ; Hobbs, F			Helicobacter pylori-selective antibacterials based on inhibition of pyrimidine biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DIHYDROOROTATE DEHYDROGENASE; BREQUINAR SODIUM; ESCHERICHIA-COLI; SEQUENCE; MECHANISM; INVITRO; ACID	We report the discovery of a class of pyrazole-based compounds that are potent inhibitors of the dihydroorotate dehydrogenase of Helicobacter pylori but that do not inhibit the cognate enzymes from Gram-positive bacteria or humans. In culture these compounds inhibit the growth of H, pylori selectively, showing no effect on other Gram-negative or Gram-positive bacteria or human cell lines. These compounds represent the first examples of H, pylori-specific antibacterial agents. Cellular activity within this structural class appears to be due to dihydroorotate dehydrogenase inhibition. Minor structural changes that abrogate in vitro inhibition of the enzyme likewise eliminate cellular activity. Furthermore, the minimum inhibitory concentrations of these compounds increase upon addition of orotate to the culture medium in a concentration-dependent manner, consistent with dihydroorotate dehydrogenase inhibition as the mechanism of cellular inhibition, The data presented here suggest that targeted inhibition of de novo pyrimidine biosynthesis may be a valuable mechanism for the development of antimicrobial agents selective for H, pylori.	Dupont Merck Pharmaceut Co, Dept Chem Enzymol, Expt Stn, Wilmington, DE 19880 USA; Dupont Merck Pharmaceut Co, Dept Chem & Phys Sci, Wilmington, DE 19880 USA; Dupont Merck Pharmaceut Co, Antimicrobials Grp, Wilmington, DE 19880 USA	DuPont; DuPont; DuPont	Copeland, RA (corresponding author), Dupont Merck Pharmaceut Co, Dept Chem Enzymol, Expt Stn, POB 80400, Wilmington, DE 19880 USA.			Sizemore, Christine/0000-0002-2807-471X; Stern, Andrew/0000-0002-8437-2957				Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Blaser MJ, 1998, BRIT MED J, V316, P1507, DOI 10.1136/bmj.316.7143.1507; Cleland W W, 1979, Methods Enzymol, V63, P103; COPELAND RA, 1995, ARCH BIOCHEM BIOPHYS, V323, P79, DOI 10.1006/abbi.1995.0012; Copeland RA., 2000, ENZYME PRACTICAL INT, P266, DOI 10.1002/0471220639.ch8; Davis JP, 1996, BIOCHEMISTRY-US, V35, P1270, DOI 10.1021/bi952168g; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; HINES V, 1989, BIOCHEMISTRY-US, V28, P1222, DOI 10.1021/bi00429a040; JAFFEE BD, 1993, TRANSPLANT P, V25, P19; Jensen KF, 1998, PATHS PYRIMIDINES, V6, P20; LAKASCHUS G, 1992, BIOCHEM PHARMACOL, V43, P1025, DOI 10.1016/0006-2952(92)90609-M; LARSEN JN, 1985, EUR J BIOCHEM, V151, P59, DOI 10.1111/j.1432-1033.1985.tb09068.x; Liu SP, 2000, STRUCT FOLD DES, V8, P25, DOI 10.1016/S0969-2126(00)00077-0; LOMOVSKAYA O, 1992, P NATL ACAD SCI USA, V89, P8938, DOI 10.1073/pnas.89.19.8938; Marcelli SW, 1996, FEMS MICROBIOL LETT, V138, P59; Marcinkeviciene J, 2000, BIOCHEM PHARMACOL, V60, P339, DOI 10.1016/S0006-2952(00)00348-8; Marcinkeviciene J, 1999, BIOCHEMISTRY-US, V38, P13129, DOI 10.1021/bi990674q; Marcinkeviciene J, 2000, ARCH BIOCHEM BIOPHYS, V377, P178, DOI 10.1006/abbi.2000.1769; McGowan CC, 1996, GASTROENTEROLOGY, V110, P926, DOI 10.1053/gast.1996.v110.pm8608904; MENDZ GL, 1994, J APPL BACTERIOL, V77, P1, DOI 10.1111/j.1365-2672.1994.tb03036.x; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MOSS CW, 1990, J CLIN MICROBIOL, V28, P395, DOI 10.1128/JCM.28.2.395-397.1990; Motulsky H., 1995, INTUITIVE BIOSTATIST, P155; Nair R., 1995, Journal of Heart and Lung Transplantation, V14, pS54; Neidhardt Edie A., 1999, Journal of Molecular Microbiology and Biotechnology, V1, P183; PECK RM, 1999, CANCER RES, V59, P6124; Reynolds David J., 1997, P53; SIMON P, 1993, TRANSPLANT P, V25, P77; Suerbaum S, 1998, P NATL ACAD SCI USA, V95, P12619, DOI 10.1073/pnas.95.21.12619; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483	31	57	59	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33373	33378		10.1074/jbc.M004451200	http://dx.doi.org/10.1074/jbc.M004451200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10938275	hybrid			2022-12-27	WOS:000090104600029
J	Shirakawa, R; Yoshioka, A; Horiuchi, H; Nishioka, H; Tabuchi, A; Kita, T				Shirakawa, R; Yoshioka, A; Horiuchi, H; Nishioka, H; Tabuchi, A; Kita, T			Small GTPase Rab4 regulates Ca2+-induced alpha-granule secretion in platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-DISSOCIATION INHIBITOR; BINDING PROTEIN; PLASMA-MEMBRANE; GDP/GTP EXCHANGE; BOVINE BRAIN; ENDOCYTIC PATHWAY; TRANSPORT; FUSION; DOCKING; CELLS	Upon activation, platelets release many active substances stored in alpha- and dense-core granules. However, the molecular mechanisms governing regulated exocytosis are not yet fully understood. Here, we have established an assay system using permeabilized platelets to analyze the Ca2+-induced exocytosis of both types of granules, focusing on RabGTPases. Incubation with Rab GDP dissociation inhibitor, an inhibitory regulator of RabGTPases, reduced membrane-bound RabGTPases extensively, and caused strong inhibition of the Ca2+-induced secretion of von Willebrand factor (VWF) stored in alpha -granules, but not that of [H-3]5-hydroxytryptamine (5-HT) in dense-core granules, Specifically, Rab4 cofractionated with vWF and P-selectin (an alpha -granule marker) upon separation of platelet organelles by density gradient centrifugation. Incubation of the permeabilized platelets with cell extracts expressing the dominant negative mutant of His-tagged Rab4S22N, but not with those of similar mutant His-Rab3BT36N, inhibited the vWF secretion, whereas neither of the cell extracts affected the [H-3]5-HT secretion. Importantly, the inhibition of vWF secretion was rescued by depleting the cell extracts of the His-Rab4S22N crith nickel beads. Thus, in platelets, the regulatory mechanisms governing alpha- and dense-core granule secretions are distinct, and Rab4 is an essential regulator of the Ca2+-induced exocytosis of alpha -granules.	Kyoto Univ, Grad Sch Med, Dept Geriatr Med, Kyoto 6068507, Japan	Kyoto University	Horiuchi, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Geriatr Med, Kyoto 6068507, Japan.	horiuchi@kuhp.kyoto-u.ac.jp						AKAYAMA M, 1986, CELL STRUCT FUNCT, V11, P259, DOI 10.1247/csf.11.259; Ayad N, 1997, EMBO J, V16, P4497, DOI 10.1093/emboj/16.15.4497; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BURGOYNE RD, 1993, BIOCHEM J, V293, P305, DOI 10.1042/bj2930305; Castillo PE, 1997, NATURE, V388, P590, DOI 10.1038/41574; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; Chen D, 2000, BLOOD, V95, P921, DOI 10.1182/blood.V95.3.921.003k17_921_929; Chen W, 1998, MOL BIOL CELL, V9, P3241, DOI 10.1091/mbc.9.11.3241; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; CONNER GE, 1992, J BIOL CHEM, V267, P21738; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Flaumenhaft R, 1999, J BIOL CHEM, V274, P2492, DOI 10.1074/jbc.274.4.2492; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; HORIUCHI H, 1995, J BIOL CHEM, V270, P11257, DOI 10.1074/jbc.270.19.11257; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; KARNIGUIAN A, 1993, P NATL ACAD SCI USA, V90, P7647, DOI 10.1073/pnas.90.16.7647; KNIGHT DE, 1982, NATURE, V296, P256, DOI 10.1038/296256a0; KREISEL W, 1994, ACTA HISTOCHEM, V96, P51, DOI 10.1016/S0065-1281(11)80009-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; LLEDO PM, 1993, NATURE, V364, P540, DOI 10.1038/364540a0; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; Mayer A, 1999, CURR OPIN CELL BIOL, V11, P447, DOI 10.1016/S0955-0674(99)80064-7; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; NAGATA K, 1993, BIOCHEM BIOPH RES CO, V195, P1081, DOI 10.1006/bbrc.1993.2155; NAGATA K, 1992, BIOCHEM BIOPH RES CO, V189, P330, DOI 10.1016/0006-291X(92)91562-5; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Ohnishi H, 1999, GASTROENTEROLOGY, V116, P943, DOI 10.1016/S0016-5085(99)70078-8; Olkkonen VM, 1997, INT REV CYTOL, V176, P1, DOI 10.1016/S0074-7696(08)61608-3; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; PLOW EF, 2000, HEMATOLOGY BASIC PRI, P1741; Polgar J, 1999, BLOOD, V94, P1313, DOI 10.1182/blood.V94.4.1313.416k27_1313_1318; SASAKI T, 1990, J BIOL CHEM, V265, P2333; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; Shibata H, 1996, J BIOL CHEM, V271, P9704, DOI 10.1074/jbc.271.16.9704; SILVERSTEIN RL, 1992, BLOOD, V80, P1470; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247	49	82	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33844	33849		10.1074/jbc.M002834200	http://dx.doi.org/10.1074/jbc.M002834200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10938270	hybrid			2022-12-27	WOS:000090104600092
J	Cartwright, JL; Gasmi, L; Spiller, DG; McLennan, AG				Cartwright, JL; Gasmi, L; Spiller, DG; McLennan, AG			The Saccharomyces cerevisiae PCD1 gene encodes a peroxisomal nudix hydrolase active toward coenzyme A and its derivatives	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTT MOTIF; 3-OXOACYL-COA THIOLASE; PROTEIN; FAMILY; SEQUENCE; IMPORT; PURIFICATION; EXPRESSION; SIGNAL; YEAST	The PCD1 nudix hydrolase gene of Saccharomyces cerevisiae has been cloned and the Pcd1p protein characterized as a diphosphatase (pyrophosphatase) with specificity for coenzyme A and CoA derivatives. Oxidized CoA disulfide is preferred over CoA as a substrate with K-m and k(cat) values of 24 muM and 5.0 s(-1), respectively, compared with values for CoA of 280 muM and 4.6 s(-1) respectively. The products of CoA hydrolysis were 3'-phosphoadenosine 5'-monophosphate and 4'-phosphopantetheine. F- ions inhibited the activity with an IC50 of 22 muM. The sequence of Pcd1p contains a potential PTS2 peroxisomal targeting signal. When fused to the N terminus of yeast-enhanced green fluorescent protein, Pcd1p was shown to locate to peroxisomes by confocal microscopy. It was also shown to co-localize with peroxisomal thiolase by immunofluorescence microscopy. N-terminal sequence analysis of the expressed protein revealed the loss of 7 or 8 amino acids, suggesting processing of the proposed PTS2 signal after import, The function of Pcd1p may be to remove potentially toxic oxidized CoA disulfide from peroxisomes in order to maintain the capacity for beta -oxidation of fatty acids.	Univ Liverpool, Cell Regulat & Signalling Grp, Liverpool L69 7ZB, Merseyside, England; Univ Liverpool, Ctr Cell Imaging, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England	University of Liverpool; University of Liverpool	McLennan, AG (corresponding author), Univ Liverpool, Cell Regulat & Signalling Grp, Life Sci Bldg, Liverpool L69 7ZB, Merseyside, England.	agmclen@liv.ac.uk	Zhang, Ning/F-1387-2014; Spiller, David G/I-3645-2012	Spiller, David Geoffrey/0000-0003-2502-6787				Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BOCHNER BR, 1984, CELL, V37, P225, DOI 10.1016/0092-8674(84)90318-0; Bucovaz ET, 1997, BIOCHIMIE, V79, P787, DOI 10.1016/S0300-9084(97)86938-6; Cartwright JL, 1999, J BIOL CHEM, V274, P8604, DOI 10.1074/jbc.274.13.8604; Cormack BP, 1997, MICROBIOL-UK, V143, P303, DOI 10.1099/00221287-143-2-303; DEHOOP MJ, 1992, BIOCHEM J, V286, P657, DOI 10.1042/bj2860657; delCardayre SB, 1998, J BIOL CHEM, V273, P5752, DOI 10.1074/jbc.273.10.5752; Dunckley T, 1999, EMBO J, V18, P5411, DOI 10.1093/emboj/18.19.5411; ERDMANN R, 1994, YEAST, V10, P1173, DOI 10.1002/yea.320100905; ERDMANN R, 1994, YEAST, V10, P935, DOI 10.1002/yea.320100708; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Gasmi L, 1999, BIOCHEM J, V344, P331, DOI 10.1042/0264-6021:3440331; Gaudon C, 1999, EMBO J, V18, P2229, DOI 10.1093/emboj/18.8.2229; Geraghty MT, 1999, P NATL ACAD SCI USA, V96, P2937, DOI 10.1073/pnas.96.6.2937; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; JACKOWSKI S, 1986, J BACTERIOL, V166, P866, DOI 10.1128/jb.166.3.866-871.1986; Kim JS, 1998, INT J BIOCHEM CELL B, V30, P629, DOI 10.1016/S1357-2725(97)00142-8; KING MT, 1985, ANAL BIOCHEM, V146, P173, DOI 10.1016/0003-2697(85)90412-9; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P4847, DOI 10.1093/nar/21.20.4847; MATHEW N, 1995, BIOCHEM J, V311, P717, DOI 10.1042/bj3110717; McLennan AG, 1999, INT J MOL MED, V4, P79; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; OSUMI T, 1992, BIOCHEM BIOPH RES CO, V186, P811, DOI 10.1016/0006-291X(92)90818-6; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; Safrany ST, 1999, J BIOL CHEM, V274, P21735, DOI 10.1074/jbc.274.31.21735; Sekiguchi M, 1996, GENES CELLS, V1, P139, DOI 10.1046/j.1365-2443.1996.d01-232.x; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; VALLARI DS, 1988, J BACTERIOL, V170, P3961, DOI 10.1128/jb.170.9.3961-3966.1988; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571; Xu WL, 2000, BIOCHEM BIOPH RES CO, V273, P753, DOI 10.1006/bbrc.2000.2999	33	55	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32925	32930		10.1074/jbc.M005015200	http://dx.doi.org/10.1074/jbc.M005015200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10922370	hybrid			2022-12-27	WOS:000090003800076
J	Honda, S; Kashiwagi, M; Miyamoto, K; Takei, Y; Hirose, S				Honda, S; Kashiwagi, M; Miyamoto, K; Takei, Y; Hirose, S			Multiplicity, structures, and endocrine and exocrine natures of eel fucose-binding lectins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY CHROMATOGRAPHY; SPECIFICITY; MARKERS; SERUM	Lectins, a group of proteins that bind to cell surface carbohydrates and play important roles in innate immunity, are widely used experimentally to distinguish cell types and to induce cell proliferation. Eel serum lectins have been useful as anti-H hemagglutinins and also in lectin histochemistry as fucose-binding lectins (fucolectins), but their structures have not been determined. Here we report the primary structures and the sites of synthesis of eel fucolectins. Eel serum fucolectins were separated by two-dimensional gel electrophoresis and sequenced. cDNA cloning, based on the amino acid sequence information, and Northern blot analysis indicated that 1) the fucose-binding lectins are secretory proteins and have unique structures among the lectins, exhibiting only weak similarities to frog pentraxin, horseshoe crab tachylectin-4, and fly fw protein; 2) there are at least seven closely related members; and 3) their messages are abundantly expressed in the liver and in significant levels in the gill and intestine. The lectin-producing hepatic cells were identified by immunostaining; in the gill, exocrine mucous cells were stained, suggesting that serum fucolectins derive from the liver. Using primary culture of eel hepatocytes, the message levels were shown to be increased by lipopolysaccharide, suggesting a role for fucolectins in host defense. SDS-polyacrylamide gel electrophoresis analysis showed that eel fucolectins have a SDS-resistant tetrameric structure consisting of two disulfide-linked dimers.	Tokyo Inst Technol, Dept Biol Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Univ Tokyo, Ocean Res Inst, Nakano Ku, Tokyo 1648639, Japan	Tokyo Institute of Technology; University of Tokyo	Hirose, S (corresponding author), Tokyo Inst Technol, Dept Biol Sci, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.		; Takei, Yoshio/R-2368-2017	Honda, Shinji/0000-0002-1584-4156; Takei, Yoshio/0000-0003-3004-8905				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Baldus SE, 1996, GLYCOCONJUGATE J, V13, P585, DOI 10.1007/BF00731446; BEZKOROVAINY A, 1971, BIOCHEMISTRY-US, V10, P3761; DANGUY A, 1988, Biological Structures and Morphogenesis, V1, P93; DCruz OJ, 1996, FERTIL STERIL, V65, P843, DOI 10.1016/S0015-0282(16)58224-7; Gabius HJ, 1998, BIOTECH HISTOCHEM, V73, P263, DOI 10.3109/10520299809141120; GERCKEN J, 1994, COMP BIOCHEM PHYS B, V108, P449, DOI 10.1016/0305-0491(94)90098-1; HAYASHI S, 1985, B JPN SOC SCI FISH, V51, P765; HAYASHI S, 1998, CELL TISSUE CULTURE, pA23; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; HOREJSI V, 1978, BIOCHIM BIOPHYS ACTA, V538, P299, DOI 10.1016/0304-4165(78)90358-6; Iwamatsu A, 1996, J BIOCHEM-TOKYO, V120, P29; JONSSON B, 1944, ACTA PATH MICROBIO S, V54, P456; JUDD WJ, 1980, CRC CR REV CL LAB SC, V12, P171, DOI 10.3109/10408368009108729; KATAFUCHI T, 1994, EUR J BIOCHEM, V222, P835, DOI 10.1111/j.1432-1033.1994.tb18930.x; KELLY C, 1984, BIOCHEM J, V220, P221, DOI 10.1042/bj2200221; KONAMI Y, 1991, J BIOCHEM-TOKYO, V109, P650, DOI 10.1093/oxfordjournals.jbchem.a123435; LeshkoLindsay L, 1997, DEVELOPMENT, V124, P169; MATSUMOTO I, 1974, BIOCHEMISTRY-US, V13, P582, DOI 10.1021/bi00700a028; Saito T, 1997, J BIOL CHEM, V272, P30703, DOI 10.1074/jbc.272.49.30703; SEERY LT, 1993, P ROY SOC B-BIOL SCI, V253, P263, DOI 10.1098/rspb.1993.0112; Sengupta Susmita, 1997, Indian Journal of Experimental Biology, V35, P103; TAKEI Y, 1988, COMP BIOCHEM PHYS A, V91, P293, DOI 10.1016/0300-9629(88)90419-7; Wagner M, 1988, Acta Histochem Suppl, V36, P115; WATKINS WM, 1952, NATURE, V169, P825, DOI 10.1038/169825a0; XU XF, 1994, EXP PARASITOL, V79, P399, DOI 10.1006/expr.1994.1102	26	84	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33151	33157		10.1074/jbc.M002337200	http://dx.doi.org/10.1074/jbc.M002337200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10924498	hybrid			2022-12-27	WOS:000090003800104
J	Johnson, BD; Chadli, A; Felts, SJ; Bouhouche, I; Catelli, MG; Toft, DO				Johnson, BD; Chadli, A; Felts, SJ; Bouhouche, I; Catelli, MG; Toft, DO			Hsp90 chaperone activity requires the full-length protein and interaction among its multiple domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; C-TERMINAL REGION; ATP-BINDING; IN-VIVO; MOLECULAR CHAPERONE; ESTROGEN-RECEPTOR; TYROSINE KINASE; IDENTIFICATION; HYDROLYSIS; HSP70	Hsp90 is an abundant and ubiquitous protein involved in a diverse array of cellular processes. Mechanistically we understand little of the apparently complex interactions of this molecular chaperone. Recently, progress has been made in assigning some of the known functions of hsp90, such as nucleotide binding and peptide binding, to particular domains within the protein. We used fragments of hsp90 and chimeric proteins containing functional domains from hsp90 or its mitochondrial homolog, TRAP1, to study the requirements for this protein in the folding of firefly luciferase as well as in the prevention of citrate synthase aggregation. In agreement with others who have found peptide binding and Limited chaperone ability in fragments of hsp90, we see that multiple fragments from hsp90 can prevent the aggregation of thermally denatured citrate synthase, a measure of passive chaperoning activity. However, in contrast to these results, the luciferase folding assay was found to be much more demanding. Here, folding is mediated by hsp70 and hsp40, requires ATP, and thus is a measure of active chaperoning. Hsp90 and the cochaperone, Hop, enhance this process. This hsp90 activity was only observed using full-length hsp90 indicating that the cooperation of multiple functional domains is essential for active, chaperone-mediated folding.	Mayo Clin & Mayo Grad Sch Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; CNRS UPR 1524, F-75014 Paris, France	Mayo Clinic; Centre National de la Recherche Scientifique (CNRS)	Toft, DO (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD009140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046249] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 09140] Funding Source: Medline; NIDDK NIH HHS [DK 46249] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; ALNEMRI ES, 1993, BIOCHEMISTRY-US, V32, P5387, DOI 10.1021/bi00071a014; Bartha BB, 1998, BIOPHYS CHEM, V72, P313, DOI 10.1016/S0301-4622(98)00114-8; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; CHADLI A, 2000, IN PRESS P NATL ACAD; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; Chen CF, 1996, MOL CELL BIOL, V16, P4691; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Felts SJ, 2000, J BIOL CHEM, V275, P3305, DOI 10.1074/jbc.275.5.3305; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; GUPTA RS, 1995, MOL BIOL EVOL, V12, P1063; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; Johnson J, 1996, J STEROID BIOCHEM, V56, P31, DOI 10.1016/0960-0760(95)00221-9; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Maruya M, 1999, J MOL BIOL, V285, P903, DOI 10.1006/jmbi.1998.2349; Meng X, 1996, J CELL SCI, V109, P1677; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; NEMOTO T, 1995, EUR J BIOCHEM, V233, P1, DOI 10.1111/j.1432-1033.1995.001_1.x; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Pearl LH, 2000, CURR OPIN STRUC BIOL, V10, P46, DOI 10.1016/S0959-440X(99)00047-0; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Scheibel T, 1997, J BIOL CHEM, V272, P18608, DOI 10.1074/jbc.272.30.18608; Scheibel T, 1999, P NATL ACAD SCI USA, V96, P1297, DOI 10.1073/pnas.96.4.1297; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Toft DO, 1998, TRENDS ENDOCRIN MET, V9, P238, DOI 10.1016/S1043-2760(98)00060-5; Young JC, 1997, FEBS LETT, V418, P139, DOI 10.1016/S0014-5793(97)01363-X; Yue L, 1999, GENETICS, V151, P1065	45	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32499	32507		10.1074/jbc.M005195200	http://dx.doi.org/10.1074/jbc.M005195200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10913439	hybrid			2022-12-27	WOS:000090003800018
J	Mio, K; Carrette, O; Maibach, HI; Stern, R				Mio, K; Carrette, O; Maibach, HI; Stern, R			Evidence that the serum inhibitor of hyaluronidase may be a member of the inter-alpha-inhibitor family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN PH-20; MAJOR THERMAL-INJURY; EXTRACELLULAR-MATRIX; TRYPSIN-INHIBITOR; SOLUBLE HYALURONIDASE; PLASMA HYALURONAN; MARKED INCREASE; ELEVATED LEVELS; MESSENGER-RNA; HEAVY-CHAINS	A study of the uncharacterized serum inhibitors of hyaluronidase, first described half a century ago, was undertaken. Activity was measured against bovine testicular hyaluronidase using a microtiter-based assay and reverse hyaluronan substrate gel zymography, The predominant inhibitory activity was magnesium-dependent and could be eliminated by protease or chondroitinase digestion and by heat treatment. Kinetics of inhibition were similar against hyaluronidases from testis and snake and bee venoms. The inhibitor had no effect on Streptomyces hyaluronidase, indicating that inhibition was not through protection of the hyaluronan substrate. Inhibition levels in serum were increased in mice following carbon tetrachloride or interleukin-1 injection, inducers of the acute-phase response. Reverse zymography identified a predominant band of 120-kDa relative molecular size, with two bands of greater and one of smaller size. The predominant protein was tentatively identified as a member of the inter-or-inhibitor family. Inhibition was also observed using either purified inter-cu-inhibitor or an inter-or-inhibitor-related 120-kDa complex. Inter-cu-inhibitor, found in the hyaluronan-rich cumulus mass surrounding mammalian ova and the coat of fibroblasts and mesothelial cells, may function to stabilize such matrices by protecting against hyaluronidase degradation. Turnover of circulating hyaluronan is extraordinarily rapid, with a half-life of 2-5 min. Prompt increases in levels of serum hyaluronan occur in patients with shock, septicemia, or massive burns, increases that can be attributed, in part, to suppression of degradation by these acute-phase reactants, the inhibitors of hyaluronidase.	Univ Calif San Francisco, Sch Med, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Dermatol, San Francisco, CA 94143 USA; Lion Corp, Life Sci Res Ctr, Kanagawa 2560811, Japan; Univ Cincinnati, Vontz Ctr Mol Studies, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Lion Corporation; University System of Ohio; University of Cincinnati	Stern, R (corresponding author), Univ Calif San Francisco, Sch Med, Dept Pathol, San Francisco, CA 94143 USA.	rstern@itsa.ucsf.edu	Mio, Kazuhiro/L-7488-2018	Mio, Kazuhiro/0000-0002-1655-8231	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029894] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE011912] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-29894] Funding Source: Medline; NIDCR NIH HHS [P50 DE/CA 11912] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AUSTIN CR, 1948, NATURE, V162, P63, DOI 10.1038/162063a0; Balazs EA, 1998, WENN GR INT, V72, P185; BALDUYCK M, 1989, BIOL CHEM H-S, V370, P329, DOI 10.1515/bchm3.1989.370.1.329; BERG S, 1988, SCAND J CLIN LAB INV, V48, P727, DOI 10.3109/00365518809088752; CAMAIONI A, 1993, J BIOL CHEM, V268, P20473; Carrette O, 1997, BBA-PROTEIN STRUCT M, V1338, P21, DOI 10.1016/S0167-4838(96)00184-7; CASTILLO GM, 1993, FEBS LETT, V318, P292, DOI 10.1016/0014-5793(93)80531-X; CHEN L, 1992, J BIOL CHEM, V267, P12380; Chen L, 1996, J BIOL CHEM, V271, P19409, DOI 10.1074/jbc.271.32.19409; Cherr GN, 1996, DEV BIOL, V175, P142, DOI 10.1006/dbio.1996.0102; Csoka AB, 1999, GENOMICS, V60, P356, DOI 10.1006/geno.1999.5876; CSOKA AB, 2001, ENCY MOL MED; Csoka TB, 1997, FEBS LETT, V417, P307, DOI 10.1016/S0014-5793(97)01309-4; Csoka TB, 1998, GENOMICS, V48, P63, DOI 10.1006/geno.1997.5158; Csoka TB, 1997, INVAS METAST, V17, P297; Delpech B, 1997, J INTERN MED, V242, P41, DOI 10.1046/j.1365-2796.1997.00172.x; DORFMAN A, 1948, J BIOL CHEM, V174, P621; Ellis IR, 1998, CYTOKINE, V10, P281, DOI 10.1006/cyto.1997.0294; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; FERRARA JJ, 1991, J SURG RES, V50, P240, DOI 10.1016/0022-4804(91)90185-O; FISZERSZAFARZ B, 1968, P SOC EXP BIOL MED, V129, P300; Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x; Fries E, 1998, WENN GR INT, V72, P149; Frost GI, 1997, BIOCHEM BIOPH RES CO, V236, P10, DOI 10.1006/bbrc.1997.6773; Frost GI, 1997, ANAL BIOCHEM, V251, P263, DOI 10.1006/abio.1997.2262; Furuya T, 1997, BIOL PHARM BULL, V20, P973, DOI 10.1248/bpb.20.973; GMACHL M, 1993, FEBS LETT, V336, P545, DOI 10.1016/0014-5793(93)80873-S; GRAIS ML, 1948, J INVEST DERMATOL, V11, P259, DOI 10.1038/jid.1948.95; GUERRA F, 1946, SCIENCE, V103, P686, DOI 10.1126/science.103.2684.686; GUNTENHONER MW, 1992, MATRIX, V12, P388, DOI 10.1016/S0934-8832(11)80035-1; HAAS E, 1946, J BIOL CHEM, V163, P63; Heckel D, 1998, HUM MOL GENET, V7, P1859, DOI 10.1093/hmg/7.12.1859; HELDIN P, 1989, BIOCHEM J, V258, P919, DOI 10.1042/bj2580919; Hunnicutt GR, 1996, BIOL REPROD, V54, P1343, DOI 10.1095/biolreprod54.6.1343; HYMAN LJ, 1955, SURG GYNECOL OBSTET, V100, P515; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; JONES CP, 1989, THROMB RES, V55, P791; KAKEGAWA H, 1985, CHEM PHARM BULL, V33, P5079; KAKEGAWA H, 1988, PLANTA MED, P385, DOI 10.1055/s-2006-962477; KAKEGAWA H, 1985, CHEM PHARM BULL, V33, P3738; KINOSHITA T, 1989, BIOCHEM BIOPH RES CO, V165, P1229, DOI 10.1016/0006-291X(89)92733-2; Knudson W, 1996, AM J PATHOL, V148, P1721; KNUDSON W, 1989, BIOL HYALURONAN, P151; KOLAROVA M, 1977, NEOPLASMA, V24, P285; KREIL G, 1995, PROTEIN SCI, V4, P1666, DOI 10.1002/pro.5560040902; KUPPUSAMY UR, 1990, BIOCHEM PHARMACOL, V40, P397, DOI 10.1016/0006-2952(90)90709-T; KUPPUSAMY UR, 1993, PHARMACOL TOXICOL, V72, P290, DOI 10.1111/j.1600-0773.1993.tb01652.x; KUPPUSAMY UR, 1991, EXPERIENTIA, V47, P1196, DOI 10.1007/BF01918384; KUSHWAH A, 1978, INDIAN J EXP BIOL, V16, P222; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Li MW, 1997, BIOL REPROD, V56, P1383, DOI 10.1095/biolreprod56.6.1383; LIN Y, 1994, J CELL BIOL, V125, P1157, DOI 10.1083/jcb.125.5.1157; Lokeshwar VB, 1996, CANCER RES, V56, P651; Madan AK, 1999, ONCOL REP, V6, P607; MATHEWS MB, 1952, ARCH BIOCHEM BIOPHYS, V35, P93, DOI 10.1016/S0003-9861(52)80053-0; MATHEWS MB, 1955, PHYSIOL REV, V35, P381, DOI 10.1152/physrev.1955.35.2.381; McClean D, 1942, NATURE, V150, P627, DOI 10.1038/150627a0; Meyer MF, 1997, FEBS LETT, V413, P385, DOI 10.1016/S0014-5793(97)00936-8; MOORE DH, 1949, J BIOL CHEM, V179, P377; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NEWMAN JK, 1955, J BIOL CHEM, V217, P31; ONARHEIM H, 1991, SCAND J CLIN LAB INV, V51, P693, DOI 10.3109/00365519109104582; ONARHEIM H, 1992, CIRC SHOCK, V37, P159; ONARHEIM H, 1991, J SURG RES, V50, P259, DOI 10.1016/0022-4804(91)90188-R; PERREAULT S, 1980, J REPROD FERTIL, V60, P461, DOI 10.1530/jrf.0.0600461; POGREL MA, 1999, INT J ORAL BIOL, V24, P75; PRIMAKOFF P, 1985, J CELL BIOL, V101, P2239, DOI 10.1083/jcb.101.6.2239; Salier JP, 1996, BIOCHEM J, V315, P1, DOI 10.1042/bj3150001; SALIER JP, 1990, TRENDS BIOCHEM SCI, V15, P435, DOI 10.1016/0968-0004(90)90282-G; Scott J. W., 1989, Circular - Agricultural Experiment Station, University of Florida; SJOBERG EM, 1990, BIOCHEM J, V272, P113; SNIVELY GG, 1950, J CLIN INVEST, V29, P1087, DOI 10.1172/JCI102340; Spicer AP, 1997, J BIOL CHEM, V272, P8957; Sun LK, 1998, KIDNEY BLOOD PRESS R, V21, P413, DOI 10.1159/000025893; SZARY A, 1975, Archivum Immunologiae et Therapiae Experimentalis, V23, P131; TOLKSDORF S, 1949, J LAB CLIN MED, V34, P74; TONNESEN HH, 1989, INT J PHARM, V50, P91, DOI 10.1016/0378-5173(89)90132-4; Toole B. P., 1991, CELL BIOL EXTRACELLU, P305; TOOLE BP, 1984, ROLE EXTRACELLULAR M, P43; Tschesche H, 1998, J PROTEIN CHEM, V17, P549; WEIGEL PH, 1986, J THEOR BIOL, V119, P219, DOI 10.1016/S0022-5193(86)80076-5; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WOLF RA, 1984, AM J CARDIOL, V53, P941, DOI 10.1016/0002-9149(84)90529-0; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YUKI H, 1963, J BIOL CHEM, V238, P1877	86	50	59	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32413	32421		10.1074/jbc.M005428200	http://dx.doi.org/10.1074/jbc.M005428200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10908571	hybrid			2022-12-27	WOS:000090003800007
J	Park, JK; Keyhani, NO; Roseman, S				Park, JK; Keyhani, NO; Roseman, S			Chitin catabolism in the marine bacterium Vibrio furnissii - Identification, molecular cloning, and characterization of a N-N '-diacetylchitobiose phosphorylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLOBIOSE PHOSPHORYLASE; CELLVIBRIO-GILVUS; CASCADE; OLIGOSACCHARIDES; DEGRADATION; CHEMOTAXIS; EXPRESSION; TRANSPORT; MECHANISM; GLUCOSE	The major product of bacterial chitinases is N,N'-diacetylchitobiose or (GlcNAc)(2). We have previously demonstrated that (GlcNAc)(2) is taken up unchanged by a specific permease in Vibrio furnissii (unlike Escherichia coli). It is generally held that marine Vibrios further metabolize cytoplasmic (GlcNAc)(2) by hydrolyzing it to two GlcNAcs (i.e. a "chitobiase"). Here we report instead that V. furnissii expresses a novel phosphorylase. The gene, chbP, was cloned into E. coli; the enzyme, ChbP, was purified to apparent homogeneity, and characterized kinetically. The DNA sequence indicates that chbP encodes an 89-kDa protein. The enzymatic reaction was characterized as follows. (GlcNAc)2 + Pi reversible arrow GlcNAc-alpha -1-P + GlcNAc K'cq = 1.0 +/- 0.2 REACTION 1 The K-m values for the four substrates were in the range 0.3-1 mM. p-Nitrophenyl-(GlcNAc)(2) was cleaved at 8.5% the rate of (GlcNAc)(2), and p-nitrophenyl (PNP)-GlcNAc was 36% as active as GlcNAc in the reverse direction. ALL other compounds tested displayed less than or equal to 1% of the activity of the indicated substrates including: for phosphorolysis, higher chitin oliogsaccharides, (GlcNAc)(n), n = 3-5, cellobiose, PNP-GlcNAc, and PNP-(GlcNAc)(3); for synthesis, (GlcNAc)(n) (n = 2-5), glucose, etc. (GlcNAc)(2) is a major regulator of the chitin catabolic cascade. Conceivably GlcNAc-alpha -1-P plays a similar but different role in regulation.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, McCollum Pratt Inst, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Roseman, S (corresponding author), Johns Hopkins Univ, Dept Biol, Mudd Hall, Rm 214,3400 N Charles St, Baltimore, MD 21218 USA.		Keyhani, Nemat O/I-8150-2013		NIGMS NIH HHS [GM51215] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; AUSUBEL FM, 1996, CURRENT PROTOCOLS MO, V1; BASSLER BL, 1991, J BIOL CHEM, V266, P24268; BASSLER BL, 1991, J BIOL CHEM, V266, P24276; BOCHNER BR, 1982, ANAL BIOCHEM, V122, P100, DOI 10.1016/0003-2697(82)90257-3; Bouma CL, 1996, J BIOL CHEM, V271, P33457, DOI 10.1074/jbc.271.52.33457; Chitlaru E, 1996, J BIOL CHEM, V271, P33433, DOI 10.1074/jbc.271.52.33433; COMB DG, 1960, J BIOL CHEM, V235, P2529; DAKHOVA ON, 1993, BIOCHEM BIOPH RES CO, V194, P1359, DOI 10.1006/bbrc.1993.1974; FOSTER AB, 1960, ADV CARBOHYD CHEM, V15, P371; HOROWITZ ST, 1957, J AM CHEM SOC, V79, P5046, DOI 10.1021/ja01575a059; Keyhani N, 2000, J BIOL CHEM, V275, P33110, DOI 10.1074/jbc.M001717200; Keyhani NO, 1999, BBA-GEN SUBJECTS, V1473, P108, DOI 10.1016/S0304-4165(99)00172-5; Keyhani NO, 2000, J BIOL CHEM, V275, P33102, DOI 10.1074/jbc.M001045200; Keyhani NO, 2000, J BIOL CHEM, V275, P33091, DOI 10.1074/jbc.M001044200; Keyhani NO, 2000, J BIOL CHEM, V275, P33084, DOI 10.1074/jbc.M001043200; Keyhani NO, 2000, J BIOL CHEM, V275, P33068, DOI 10.1074/jbc.M001041200; Keyhani NO, 1996, J BIOL CHEM, V271, P33425, DOI 10.1074/jbc.271.52.33425; Keyhani NO, 1996, J BIOL CHEM, V271, P33414, DOI 10.1074/jbc.271.52.33414; Keyhani NO, 1996, J BIOL CHEM, V271, P33409, DOI 10.1074/jbc.271.52.33409; KITAOKA M, 1992, BIOSCI BIOTECH BIOCH, V56, P652, DOI 10.1271/bbb.56.652; Liu AM, 1998, J FERMENT BIOENG, V85, P511, DOI 10.1016/S0922-338X(98)80071-8; MATHEIS G, 1984, INT J BIOCHEM, V16, P867, DOI 10.1016/0020-711X(84)90145-9; MIEYAL JJ, 1972, ENZYMES, V7, P515; PERKINS SJ, 1977, CARBOHYD RES, V59, P19, DOI 10.1016/S0008-6215(00)83289-9; Reichenbecher M, 1997, EUR J BIOCHEM, V247, P262, DOI 10.1111/j.1432-1033.1997.00262.x; ROSEMAN S, 1956, ANAL CHEM, V28, P1743, DOI 10.1021/ac60119a028; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SOTOGIL RW, 1984, CHITIN CHITOSAN RELA; VOET JG, 1970, J BIOL CHEM, V245, P1020; VOGEL HJ, 1989, METHOD ENZYMOL, V177, P263; WOOD WA, 1988, METHODS ENZYMOL, V161; YU C, 1993, J BIOL CHEM, V268, P9405; YU C, 1991, J BIOL CHEM, V266, P24260; Zechmeister L, 1939, ENZYMOLOGIA, V7, P165; Zechmeister L, 1939, ENZYMOLOGIA, V7, P170; Zobell CE, 1938, J BACTERIOL, V35, P275, DOI 10.1128/JB.35.3.275-287.1938; [No title captured]	38	60	64	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33077	33083		10.1074/jbc.M001042200	http://dx.doi.org/10.1074/jbc.M001042200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10913116	hybrid			2022-12-27	WOS:000090003800095
J	Taguchi, T; Ogawa, T; Inoue, S; Inoue, Y; Sakamoto, Y; Korekane, H; Taniguchi, N				Taguchi, T; Ogawa, T; Inoue, S; Inoue, Y; Sakamoto, Y; Korekane, H; Taniguchi, N			Purification and characterization of UDP-GlcNAc: GlcNac beta 1-6(GlcNAc beta 1-2)Man alpha 1-R [GlcNAc to man]-beta 1, 4-N-acetylglucosaminyltransferase VI from hen oviduct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINYLTRANSFERASE-V; GLYCOPROTEIN-SYNTHESIS; CDNA CLONING; UDP-N-ACETYLGLUCOSAMINE-ALPHA-3-D-MANNOSIDE BETA-1,2-N-ACETYLGLUCOSAMINYLTRANSFE; MOLECULAR-CLONING; RAT-KIDNEY; CELL-LINE; EXPRESSION; BETA-1,4-N-ACETYLGLUCOSAMINYLTRANSFERASE; LIVER	A new beta1,4-N-acetylglucosaminyltransferase (GnT) responsible for the formation of branched N-linked complex-type sugar chains has been purified 64,000-fold in 16% yield from a homogenate of hen oviduct by column chromatography procedures using Q-Sepharose FF, Ni2+-chelating Sepharose FF, and UDP-hexanolamineagarose. This enzyme catalyzes the transfer of GlcNAc from UDP-GlcNAc to tetraantennary oligosaccharide and produces pentaantennary oligosaccharide with the beta1-4-linked GlcNAc residue on the Man alpha1-6 arm. It requires a divalent cation such as Mn2+ and has an apparent molecular weight of 72,000 under nonreducing conditions. The enzyme does not act on biantennary oligosaccharide (GnT I and II product), and beta1,6-N-acetylglucosaminylation of the Man alpha1-6 arm (GnT V product) is essential for its activity. This clearly distinguishes it from GnT TV, which is known to generate a beta1-4-linked GlcNAc residue only on the Man alpha1-3 arm. Based on these findings, we conclude that this enzyme is UDP-GlcNAc:GlcNAc beta 1-6 (GlcNAc beta1-2)Man alpha1-R [Glc-NAc to Man]-beta1,4-N-acetylglucosaminyltransferase VI. This is the only known enzyme that has not been previously purified among GnTs responsible for antenna formation on the cores of N-linked complex-type sugar chains.	Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; RIKEN, Wako, Saitama 3510198, Japan; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan	Osaka University; RIKEN; Academia Sinica - Taiwan	Taniguchi, N (corresponding author), Osaka Univ, Sch Med, Dept Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	proftani@biochem.med.osaka-u.ac.jp	Taguchi, Tomohiko/I-5014-2019; Taniguchi, Naoyuki/I-4182-2014; Taniguchi, Naoyuki/A-7086-2016	Taguchi, Tomohiko/0000-0003-0464-6370; Taniguchi, Naoyuki/0000-0001-5889-5968; 				BENDIAK B, 1987, J BIOL CHEM, V262, P5775; BROCKHAUSEN I, 1989, J BIOL CHEM, V264, P11211; BROCKHAUSEN I, 1992, CARBOHYD RES, V236, P281, DOI 10.1016/0008-6215(92)85022-R; CAMPION B, 1989, EUR J BIOCHEM, V184, P405, DOI 10.1111/j.1432-1033.1989.tb15032.x; DAGOSTARO GAF, 1995, J BIOL CHEM, V270, P15211, DOI 10.1074/jbc.270.25.15211; GU JG, 1993, J BIOCHEM, V113, P614, DOI 10.1093/oxfordjournals.jbchem.a124091; IHARA Y, 1993, J BIOCHEM-TOKYO, V113, P692, DOI 10.1093/oxfordjournals.jbchem.a124105; INOUE S, 1997, GLYCOPROTEINS, V2, P143; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Minowa MT, 1998, J BIOL CHEM, V273, P11556, DOI 10.1074/jbc.273.19.11556; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; NISHIKAWA A, 1990, BIOCHIM BIOPHYS ACTA, V1035, P313, DOI 10.1016/0304-4165(90)90094-D; NISHIKAWA Y, 1988, J BIOL CHEM, V263, P8270; Oguri S, 1997, J BIOL CHEM, V272, P22721, DOI 10.1074/jbc.272.36.22721; OPPENHEIMER CL, 1981, J BIOL CHEM, V256, P799; PARENTE JP, 1982, J BIOL CHEM, V257, P13173; Raju TS, 1998, J BIOL CHEM, V273, P14090, DOI 10.1074/jbc.273.23.14090; SAITO H, 1994, BIOCHEM BIOPH RES CO, V198, P318, DOI 10.1006/bbrc.1994.1045; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SCHACHTER H, 1991, Glycobiology, V1, P453, DOI 10.1093/glycob/1.5.453; SHOREIBAH M, 1993, J BIOL CHEM, V268, P15381; SHOREIBAH MG, 1992, J BIOL CHEM, V267, P2920; Taguchi T, 1997, BIOCHEM BIOPH RES CO, V230, P533, DOI 10.1006/bbrc.1996.6013; Taguchi T, 1998, ANAL BIOCHEM, V255, P155, DOI 10.1006/abio.1997.2465; YAMASHITA K, 1982, J BIOL CHEM, V257, P2809; Yoshida A, 1999, GLYCOBIOLOGY, V9, P303, DOI 10.1093/glycob/9.3.303	27	20	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32598	32602		10.1074/jbc.M004673200	http://dx.doi.org/10.1074/jbc.M004673200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10903319	hybrid			2022-12-27	WOS:000090003800032
J	Chappell, J; Golovchenko, I; Wall, K; Stjernholm, R; Leitner, JW; Goalstone, M; Draznin, B				Chappell, J; Golovchenko, I; Wall, K; Stjernholm, R; Leitner, JW; Goalstone, M; Draznin, B			Potentiation of Rho-A-mediated lysophosphatidic acid activity by hyperinsulinemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; SERINE/THREONINE KINASE; FAMILY GTPASES; KAPPA-B; RAS; PROTEIN; ACTIVATION; INSULIN; FARNESYLTRANSFERASE; CELLS	We have shown previously that insulin promotes phosphorylation and activation of farnesyltransferase and geranylgeranyltransferase (GGTase) II. We have now examined the effect of insulin on geranylgeranyltransferase I in MCF-7 breast cancer cells. Insulin increased GGTase I activity 3-fold and augmented the amounts of geranylgeranylated Rho-A by 18%. Both effects of the insulin were blocked by an inhibitor of GGTase I, GGTI-286. The insulin-induced increases in the amounts of geranylgeranylated Rho-A resulted in potentiation of the Rho-A-mediated effects of lysophosphatidic acid (LPA) on a serum response element-luciferase construct. Preincubation of cells with insulin augmented the LPA-stimulated serum response element-luciferase activation to la-fold, compared with just g-fold for LPA alone (p < 0.05). The potentiating effect of insulin was dose-dependent, inhibited by GGTI-286 and not mimicked by insulin-like growth factor-1. We conclude that insulin activates GGTase I, increases the amounts of geranylgeranylated Rho-A protein, and potentiates the Rho-A-dependent nuclear effects of LPA in MCF-7 breast cancer cells.	Univ Colorado, Hlth Sci Ctr, Dept Vet Affairs, Res Serv, Denver, CO 80220 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80220 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Draznin, B (corresponding author), Vet Affairs Hosp 151, 1055 Clermont St, Denver, CO 80220 USA.							BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Goalstone M, 1997, ENDOCRINOLOGY, V138, P5119, DOI 10.1210/en.138.12.5119; Goalstone ML, 1999, DIABETOLOGIA, V42, P310, DOI 10.1007/s001250051156; Goalstone ML, 1998, ENDOCRINOLOGY, V139, P4067, DOI 10.1210/en.139.10.4067; Goalstone ML, 1998, J BIOL CHEM, V273, P23892, DOI 10.1074/jbc.273.37.23892; Goalstone ML, 1999, J BIOL CHEM, V274, P2880, DOI 10.1074/jbc.274.5.2880; Goalstone ML, 1996, J BIOL CHEM, V271, P27585, DOI 10.1074/jbc.271.44.27585; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Katzung BG, 1989, BASIC CLIN PHARM; KWAK JY, 1995, J BIOL CHEM, V270, P27093, DOI 10.1074/jbc.270.45.27093; Leitner JW, 1997, ENDOCRINOLOGY, V138, P2211, DOI 10.1210/en.138.5.2211; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; MOORES SL, 1991, J BIOL CHEM, V266, P14603; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TAKAISHI K, 1994, ONCOGENE, V9, P273; Tanaka T, 1998, J BIOL CHEM, V273, P26772, DOI 10.1074/jbc.273.41.26772; van Dijk MCM, 1998, CURR BIOL, V8, P386, DOI 10.1016/S0960-9822(98)70157-5; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; YOSHIOKA K, 1995, FEBS LETT, V372, P25, DOI 10.1016/0014-5793(95)00937-5; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	35	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31792	31797		10.1074/jbc.M004798200	http://dx.doi.org/10.1074/jbc.M004798200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10930411	hybrid			2022-12-27	WOS:000089858900036
J	Clyde-Smith, J; Silins, G; Gartside, M; Grimmond, S; Etheridge, M; Apolloni, A; Hayward, N; Hancock, JF				Clyde-Smith, J; Silins, G; Gartside, M; Grimmond, S; Etheridge, M; Apolloni, A; Hayward, N; Hancock, JF			Characterization of RasGRP2, a plasma membrane-targeted, dual specificity Ras/Rap exchange factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; RAS SIGNALING PATHWAY; BINDING DOMAIN; FACTOR SOS; ACTIVATION; PROTEIN; GRB2; RECEPTOR; SHC; COMPLEXES	Ras proteins operate as molecular switches in signal transduction pathways downstream of tyrosine kinases and G-protein-coupled receptors. Ras is switched from the inactive GDP-bound state to the active GTP-bound state by guanine nucleotide exchange factors (GEFs), We report here the cloning and characterization of RasGRP2, a longer alternatively spliced form of the recently cloned RapGEF, CalDAG-GEFI. A unique feature of RasGRP2 is that it is targeted to the plasma membrane by a combination of N-terminal myristoylation and palmitoylation. In vivo, RasGRP2 selectively catalyzes nucleotide exchange on N- and Ki-Ras, but not Ha-Pas. RasGRP2 also catalyzes nucleotide exchange on Rap1, but this RapGEF activity is less potent than that associated with CalDAG-GEFI. The nucleotide exchange activity of RasGRP2 toward N-Ras is stimulated by diacylglycerol and inhibited by calcium. The effects of diacylglycerol and calcium are additive but are not accompanied by any detectable change in the subcellular localization of RasGRP2. In contrast, CalDAG-GEFI is localized predominantly to the cytosol and lacks Pas exchange activity in vivo. However, prolonged exposure to phorbol esters, or growth in serum, results in localization of CalDAG-GEFI to the cell membrane and restoration of Pas exchange activity. Expression of RasGRP2 or CalDAG-GEFI in NIH3T3 cells transfected with wild type N-Ras results in an accelerated growth rate but not morphologic transformation. Thus, under appropriate growth conditions, CalDAG-GEFI and RasGRP2 are dual specificity Ras and Rap exchange factors.	Univ Queensland, Sch Med, Dept Pathol, Queensland Canc Fund,Lab Expt Oncol, Brisbane, Qld 4006, Australia; Queensland Inst Med Res, Bancroft Ctr, Queensland Canc Fund, Res Unit, Brisbane, Qld 4006, Australia	Cancer Council Queensland; University of Queensland; Cancer Council Queensland; QIMR Berghofer Medical Research Institute	Hancock, JF (corresponding author), Univ Queensland, Sch Med, Dept Pathol, Queensland Canc Fund,Lab Expt Oncol, Herston Rd, Brisbane, Qld 4006, Australia.		Clyde-Smith, Jodi/R-8910-2016; hayward, nick/AAV-8802-2020; Grimmond, Sean M/J-5304-2016; hayward, nicholas k/C-1367-2015; Grimmond, Sean/K-3246-2019	Clyde-Smith, Jodi/0000-0001-9798-9924; Grimmond, Sean M/0000-0002-8102-7998; hayward, nicholas k/0000-0003-4760-1033; Grimmond, Sean/0000-0002-8102-7998; Hancock, John/0000-0003-0542-4710				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Bergman L, 1999, GENOMICS, V55, P49, DOI 10.1006/geno.1998.5625; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Byrne JL, 1996, ONCOGENE, V13, P2055; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; Harmer SL, 1997, MOL CELL BIOL, V17, P4087, DOI 10.1128/MCB.17.7.4087; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kedra D, 1997, HUM GENET, V100, P611, DOI 10.1007/s004390050562; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; Sturani E, 1997, EXP CELL RES, V235, P117, DOI 10.1006/excr.1997.3660; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; Wittinghofer F, 1998, NATURE, V394, P317, DOI 10.1038/28492	46	104	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32260	32267		10.1074/jbc.M006087200	http://dx.doi.org/10.1074/jbc.M006087200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10918068	hybrid			2022-12-27	WOS:000089858900097
J	DeLong, CJ; Qin, LY; Cui, Z				DeLong, CJ; Qin, LY; Cui, Z			Nuclear localization of enzymatically active green fluorescent protein-CTP : phosphocholine cytidylyltransferase alpha fusion protein is independent of cell cycle conditions and cell types	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CTP; PHOSPHATIDYLCHOLINE SYNTHESIS; ENDOPLASMIC-RETICULUM; HELA-CELLS; IDENTIFICATION; TRANSLOCATION; BIOSYNTHESIS; HEPATOCYTES; EXPRESSION; CYTOSOL	To address the recent controversy about the subcellular localization of CTP:phosphocholine cytidylyltransferase alpha (CT alpha), this study was designed to visualize green fluorescent protein (GFP).CT alpha fusion proteins directly and continuously under different conditions of cell cycling and in various cell lines. The GFP.CT alpha fusion proteins were enzymatically active and capable of rescuing mutant cells with a temperature-sensitive CT. The expressed GFP-CT alpha fusion protein was localized to the nucleus in all cell lines and required the N-terminal nuclear targeting sequence. Serum depletion/replenishment did not cause shuttling of CT alpha between the nucleus and cytoplasm. Moreover, the subcellular localization of CT alpha was examined continuously through all stages of the cell cycle in synchronized cells. No shuttling of CT alpha between the nucleus and cytoplasm was observed at any stage of the cell cycle. Stimulation of cells with oleate had no effect on the localization of CT alpha. The GFP.CT alpha lacking the nuclear targeting sequence stayed exclusively in the cytoplasm. Regardless of their localization, the GFP.CT alpha fusion proteins were equally active for phosphatidylcholine synthesis and mutant rescue. We conclude that the nuclear localization of CT alpha is a biological event independent of cell cycle in most mammalian cells and is unrelated to activation of phosphatidylcholine synthesis.	Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University	Cui, Z (corresponding author), Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA.			DeLong, Cynthia/0000-0002-6823-8619	NCI NIH HHS [R01-CA79670, CA-09422] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009422, R01CA079670] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CORNELL R, 1987, BIOCHIM BIOPHYS ACTA, V919, P26, DOI 10.1016/0005-2760(87)90214-1; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; DAVIS RA, 1979, J BIOL CHEM, V254, P2010; ESKO JD, 1980, P NATL ACAD SCI-BIOL, V77, P5192, DOI 10.1073/pnas.77.9.5192; GEORGE TP, 1989, BIOCHIM BIOPHYS ACTA, V1004, P283, DOI 10.1016/0005-2760(89)90075-1; GOSLIN K, 1989, J CELL BIOL, V109, P1621, DOI 10.1083/jcb.109.4.1621; Houweling M, 1996, EUR J CELL BIOL, V69, P55; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Jack DB, 1996, MOL MED TODAY, V2, P271; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lykidis A, 1998, J BIOL CHEM, V273, P14022, DOI 10.1074/jbc.273.22.14022; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; Northwood IC, 1999, J BIOL CHEM, V274, P26240, DOI 10.1074/jbc.274.37.26240; PELECH SL, 1983, J BIOL CHEM, V258, P6782; SWEITZER TD, 1994, ARCH BIOCHEM BIOPHYS, V311, P107, DOI 10.1006/abbi.1994.1215; TERCE F, 1992, BIOCHEM J, V282, P333, DOI 10.1042/bj2820333; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; WANG Y, 1995, J BIOL CHEM, V270, P18948, DOI 10.1074/jbc.270.32.18948; WANG YL, 1993, J BIOL CHEM, V268, P5512; WANG YL, 1993, J BIOL CHEM, V268, P5899; WANG YL, 1995, J BIOL CHEM, V270, P354, DOI 10.1074/jbc.270.1.354; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; WAWRA E, 1983, MOL CELL BIOL, V3, P297, DOI 10.1128/MCB.3.3.297; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; Yang JL, 1997, BIOCHEM J, V325, P29, DOI 10.1042/bj3250029	30	50	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32325	32330		10.1074/jbc.M004644200	http://dx.doi.org/10.1074/jbc.M004644200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10918057	hybrid			2022-12-27	WOS:000089858900105
J	Mould, JA; Drury, JE; Frings, SM; Kaupp, UB; Pekosz, A; Lamb, RA; Pinto, LH				Mould, JA; Drury, JE; Frings, SM; Kaupp, UB; Pekosz, A; Lamb, RA; Pinto, LH			Permeation and activation of the M-2 ion channel of influenza A virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; M2 PROTEIN; A VIRUSES; TRANSMEMBRANE DOMAIN; PROTON MOVEMENT; LIPID BILAYERS; MOBILE BUFFERS; PH; HEMAGGLUTININ; AMANTADINE	The M-2 ion channel protein of influenza A virus is essential for mediating protein-protein dissociation during the virus uncoating process that occurs when the virus is in the acidic environment of the lumen of the secondary endosome. The difficulty of determining the ion selectivity of this minimalistic ion channel is due in part to the fact that the channel activity is so great that it causes local acidification in the expressing cells and a consequent alteration of reversal voltage, V-rev. We have confirmed the high proton selectivity of the channel (1.5-2.0 x 10(6)) in both oocytes and mammalian cells by using four methods as follows: 1) comparison of V-rev with proton equilibrium potential; 2) measurement of pH(in) and V-rev while Na-out(+) was replaced; 3) measurements with limiting external buffer concentration to limit proton currents specifically; and 4) comparison of measurements of M-2-expressing cells with cells exposed to a protonophore. Increased currents at low pH(out) are due to true activation and not merely increased [H+](out) because increased pH(out) stops the outward current of acidified cells. Although the proton conductance is the biologically relevant conductance in an influenza virus-infected cell, experiments employing methods 1-3 show that the channel is also capable of conducting NH4+, probably by a different mechanism from H+.	Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Northwestern Univ, Howard Hughes Med Inst, Evanston, IL 60208 USA; Forschungszentrum, Inst Biol Informat Verarbeitung, D-52425 Julich, Germany	Northwestern University; Northwestern University; Howard Hughes Medical Institute; Northwestern University; Helmholtz Association	Pinto, LH (corresponding author), Northwestern Univ, Dept Neurobiol & Physiol, Hogan Hall,2153 N Campus Dr, Evanston, IL 60208 USA.			Pekosz, Andrew/0000-0003-3248-1761	NIAID NIH HHS [AI-20201, AI-31882] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020201, R01AI031882, R01AI020201] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENZ R, 1983, BIOPHYS J, V41, P381, DOI 10.1016/S0006-3495(83)84449-X; BURCKHARDT BC, 1992, PFLUG ARCH EUR J PHY, V420, P83, DOI 10.1007/BF00378645; BYERLY L, 1986, J PHYSIOL-LONDON, V376, P477, DOI 10.1113/jphysiol.1986.sp016165; Chizhmakov IV, 1996, J PHYSIOL-LONDON, V494, P329, DOI 10.1113/jphysiol.1996.sp021495; CIAMPOR F, 1992, VIRUS RES, V22, P247, DOI 10.1016/0168-1702(92)90056-F; DUFF KC, 1992, VIROLOGY, V190, P485, DOI 10.1016/0042-6822(92)91239-Q; Frazier CJ, 2000, BIOPHYS J, V78, P1872, DOI 10.1016/S0006-3495(00)76736-1; Gandhi CS, 1999, J BIOL CHEM, V274, P5474, DOI 10.1074/jbc.274.9.5474; GRAMBAS S, 1992, VIROLOGY, V191, P541, DOI 10.1016/0042-6822(92)90229-I; GRAMBAS S, 1992, VIROLOGY, V190, P11, DOI 10.1016/0042-6822(92)91187-Y; GREGORIADES A, 1981, J VIROL, V40, P323, DOI 10.1128/JVI.40.1.323-328.1981; Hay A.J., 1992, SEMIN VIROL, V3, P21, DOI DOI 10.1016/J.BMC.2015.06.030; HOLSINGER LJ, 1994, J VIROL, V68, P1551, DOI 10.1128/JVI.68.3.1551-1563.1994; HOLSINGER LJ, 1991, VIROLOGY, V183, P32, DOI 10.1016/0042-6822(91)90115-R; IRVING M, 1990, BIOPHYS J, V57, P717, DOI 10.1016/S0006-3495(90)82592-3; JAMESKRACKE MR, 1992, J CELL PHYSIOL, V151, P596, DOI 10.1002/jcp.1041510320; JUNGE W, 1987, BIOCHIM BIOPHYS ACTA, V890, P1, DOI 10.1016/0005-2728(87)90061-2; KURTZ S, 1995, ANTIMICROB AGENTS CH, V39, P2204, DOI 10.1128/AAC.39.10.2204; LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9; Lin TI, 1997, J GEN VIROL, V78, P767, DOI 10.1099/0022-1317-78-4-767; Mould JA, 2000, J BIOL CHEM, V275, P8592, DOI 10.1074/jbc.275.12.8592; PANAYOTOV PP, 1992, VIROLOGY, V186, P352, DOI 10.1016/0042-6822(92)90096-8; Pinto LH, 1997, P NATL ACAD SCI USA, V94, P11301, DOI 10.1073/pnas.94.21.11301; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; Ruigrok RWH, 2000, VIROLOGY, V267, P289, DOI 10.1006/viro.1999.0134; Sakaguchi T, 1997, P NATL ACAD SCI USA, V94, P5000, DOI 10.1073/pnas.94.10.5000; Sakaguchi T, 1996, J CELL BIOL, V133, P733, DOI 10.1083/jcb.133.4.733; SCHROEDER C, 1994, J GEN VIROL, V75, P3477, DOI 10.1099/0022-1317-75-12-3477; SHIMBO K, 1996, BIOPHYS J, V70, P1336; Stewart AK, 1999, J PHYSIOL-LONDON, V516, P209, DOI 10.1111/j.1469-7793.1999.209aa.x; SUGRUE RJ, 1990, EMBO J, V9, P3469, DOI 10.1002/j.1460-2075.1990.tb07555.x; SUGRUE RJ, 1991, VIROLOGY, V180, P617, DOI 10.1016/0042-6822(91)90075-M; TAKEUCHI K, 1994, J VIROL, V68, P911, DOI 10.1128/JVI.68.2.911-919.1994; TOSTESON MT, 1994, J MEMBRANE BIOL, V142, P117; WANG C, 1995, BIOPHYS J, V69, P1363, DOI 10.1016/S0006-3495(95)80003-2; WANG C, 1994, VIROLOGY, V205, P133, DOI 10.1006/viro.1994.1628; ZHIRNOV OP, 1992, VIROLOGY, V186, P324, DOI 10.1016/0042-6822(92)90090-C; Zhu GY, 1998, J NEUROSCI METH, V81, P73, DOI 10.1016/S0165-0270(98)00019-3	38	132	135	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31038	31050		10.1074/jbc.M003663200	http://dx.doi.org/10.1074/jbc.M003663200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10913133	Green Published, hybrid			2022-12-27	WOS:000089762700044
J	Proenza, C; Wilkens, CM; Beam, KG				Proenza, C; Wilkens, CM; Beam, KG			Excitation-contraction coupling is not affected by scrambled sequence in residues 681-690 of the dihydropyridine receptor II-III loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; CALCIUM CURRENT; RYANODINE RECEPTOR; ACTIVATION; CHANNELS; MYOTUBES	A peptide corresponding to residues 681-690 of the II-III loop of the skeletal muscle dihydropyridine receptor alpha(1) subunit (DHPR, alpha(1S)) has been reported to activate the skeletal muscle ryanodine receptor (RyR1) in vitro. Within this region of alpha(1S), a cluster of basic residues, Arg(681)-Lys(685), was previously reported to be indispensable for the activation of RyR1 in microsomal preparations and lipid bilayers. We have used an intact alpha(1S) subunit with scrambled sequence in this region of the II-III loop (alpha(1S)-scr) to test the importance of residues 681-690 and the basic motif for skeletal-type excitation-contraction (EC) coupling and retrograde signaling in vivo. When expressed in dysgenic myotubes (which lack endogenous alpha(1S)), alpha(1S)-scr restored calcium currents that were indistinguishable, in current density and voltage dependence, from those restored by wild-type alpha(1S). The scrambled DHPR also rescued skeletal-type EC coupling, as indicated by electrically evoked contractions in the presence of 0.5 mM Cd2+ and 0.1 mM La3+. Furthermore, the release of intracellular Ca2+, as assayed by the indicator dye, Fluo-3, had similar kinetics and voltage dependence for alpha(1S) and alpha(1S)-scr. These data suggest that residues 681-690 of the alpha(1S) II-III loop are not essential in muscle cells for normal functioning of the DHPR, including skeletal-type EC coupling and retrograde signaling.	Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Anat & Neurobiol, Ft Collins, CO 80523 USA; Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Physiol, Ft Collins, CO 80523 USA	Colorado State University; Colorado State University	Beam, KG (corresponding author), Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Anat & Neurobiol, Ft Collins, CO 80523 USA.			Proenza, Catherine/0000-0003-4324-6206				ADAMS BA, 1989, J GEN PHYSIOL, V94, P429, DOI 10.1085/jgp.94.3.429; ARMSTRONG CM, 1972, BIOCHIM BIOPHYS ACTA, V267, P605, DOI 10.1016/0005-2728(72)90194-6; Casarotto MG, 2000, J BIOL CHEM, V275, P11631, DOI 10.1074/jbc.275.16.11631; Dulhunty AF, 1999, BIOPHYS J, V77, P189, DOI 10.1016/S0006-3495(99)76881-5; El-Hayek R, 1998, BIOCHEMISTRY-US, V37, P7015, DOI 10.1021/bi972907o; ELHAYEK R, 1995, J BIOL CHEM, V270, P2211; GARCIA J, 1994, J GEN PHYSIOL, V103, P107, DOI 10.1085/jgp.103.1.107; Grabner M, 1998, P NATL ACAD SCI USA, V95, P1903, DOI 10.1073/pnas.95.4.1903; Grabner M, 1999, J BIOL CHEM, V274, P21913, DOI 10.1074/jbc.274.31.21913; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Nakai J, 1998, J BIOL CHEM, V273, P24983, DOI 10.1074/jbc.273.39.24983; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; Zhu XS, 1999, FEBS LETT, V450, P221, DOI 10.1016/S0014-5793(99)00496-2	16	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					29935	29937		10.1074/jbc.C000464200	http://dx.doi.org/10.1074/jbc.C000464200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10915779	hybrid			2022-12-27	WOS:000089577900004
J	Yang, TX; Huang, YN; Heasley, LE; Berl, T; Schnermann, JB; Briggs, JP				Yang, TX; Huang, YN; Heasley, LE; Berl, T; Schnermann, JB; Briggs, JP			MAPK mediation of hypertonicity-stimulated cyclooxygenase-2 expression in renal medullary collecting duct cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASE; OSMOTIC RESPONSE ELEMENT; CANINE KIDNEY-CELLS; N-TERMINAL KINASE; EPITHELIAL-CELLS; TYROSINE PHOSPHORYLATION; MESANGIAL CELLS; MAMMALIAN-CELLS; P38 KINASE	We have previously shown that hypertonicity stimulates cyclooxygenase-2 (COX-2) expression in cultured medullary epithelial cells. The aims of the present study were (i) to examine the role of cytoplasmic signaling through MAPK pathways in tonicity regulation of COX-2 expression in collecting duct cells and (ii) to assess the possible contribution of COX-2 to the survival of inner medullary collecting duct (IMCD) cells under hypertonic conditions. In mIMCD-K2 cells, a cell line derived from mouse IMCDs, hypertonicity induced a marked increase in COX-2 protein expression, The stimulation was reduced significantly by inhibition of MEK1 (PD-98059, 5-50 mu M and p38 (SB-203580, 5-100 mu M) and was almost abolished by the combination of the two compounds. To study the role of JNK in tonicity-stimulated COX-2 expression, IMCD-3 cell lines stably transfected with dominant-negative mutants of three JNKs (JNK-1, -2, and -3) were used. Hypertonicity-stimulated COX-2 protein expression was significantly reduced in dominant-negative JNK-2-expressing cells and was unchanged in dominant-negative JNK-1- and JNK-3-expressing cells compared with controls. The reduction of COX-2 expression was associated with greatly reduced viability of dominant-negative JNK-2-expressing cells during hypertonicity treatment, 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) (2-8 mu M), an inhibitor of Src kinases, reduced the tonicity-stimulated COX-2 expression in a dose-dependent manner, whereas PP3, an inactive analog of PP2, had no effect. Inhibition of COX-2 activity by NS-398 (30-90 mu M) and SC-58236 (10-20 mu M) significantly reduced viability of mIMCD-K2 cells subjected to prolonged hypertonic treatment. We conclude that 1) all three members of the MAPK family (ERK, JNK-2, and p38) as well as Src kinases are required for tonicity-stimulated COX-2 expression in mouse collecting duct cells and that 2) COX-2 may play a role in cell survival of medullary cells under hypertonic conditions.	NIDDK, NIH, Bethesda, MD 20892 USA; Univ Colorado, Dept Internal Med, Denver, CO 80262 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Colorado System; University of Colorado Denver	Briggs, JP (corresponding author), NIDDK, NIH, Bldg 31,Rm 9A17,31 Ctr Dr,MSC 2560, Bethesda, MD 20892 USA.	BriggsJ@hq.niddk.nih.gov	Briggs, Josephine P/B-9394-2009	Briggs, Josephine P/0000-0003-0798-1190	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040042, P50DK039255, R01DK037448] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-40042, DK-39255, DK-37448] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; Berl T, 1997, AM J PHYSIOL-RENAL, V272, pF305, DOI 10.1152/ajprenal.1997.272.3.F305; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; Burg MB, 1997, ANNU REV PHYSIOL, V59, P437, DOI 10.1146/annurev.physiol.59.1.437; BURG MB, 1995, AM J PHYSIOL-RENAL, V268, pF983, DOI 10.1152/ajprenal.1995.268.6.F983; COHEN DM, 1993, AM J PHYSIOL, V264, pF593, DOI 10.1152/ajprenal.1993.264.4.F593; Corbett JA, 1996, AM J PHYSIOL-CELL PH, V270, pC1581, DOI 10.1152/ajpcell.1996.270.6.C1581; Coroneos EJ, 1997, J AM SOC NEPHROL, V8, P1080; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Guan YF, 1997, AM J PHYSIOL-RENAL, V273, pF1013, DOI 10.1152/ajprenal.1997.273.6.F1013; Guan ZH, 1998, J BIOL CHEM, V273, P28670, DOI 10.1074/jbc.273.44.28670; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hao CM, 1999, AM J PHYSIOL-RENAL, V277, pF352, DOI 10.1152/ajprenal.1999.277.3.F352; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; ITOH T, 1994, J CLIN INVEST, V93, P2387, DOI 10.1172/JCI117245; KIZER ZL, 1995, AM J PHYSIOL, V37, pF347; Kultz D, 1997, J BIOL CHEM, V272, P13165, DOI 10.1074/jbc.272.20.13165; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; Nadkarni V, 1999, J BIOL CHEM, V274, P20185, DOI 10.1074/jbc.274.29.20185; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; Sheikh-Hamad D, 1998, J BIOL CHEM, V273, P1832, DOI 10.1074/jbc.273.3.1832; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; Subbaramaiah K, 1998, J BIOL CHEM, V273, P32943, DOI 10.1074/jbc.273.49.32943; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Szaszi K, 1997, J BIOL CHEM, V272, P16670, DOI 10.1074/jbc.272.26.16670; TERADA Y, 1994, J BIOL CHEM, V269, P31296; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Wojtaszek PA, 1998, J BIOL CHEM, V273, P800, DOI 10.1074/jbc.273.2.800; Yang TX, 1999, AM J PHYSIOL-RENAL, V277, pF1, DOI 10.1152/ajprenal.1999.277.1.F1; Yang TX, 1998, AM J PHYSIOL-RENAL, V274, pF481, DOI 10.1152/ajprenal.1998.274.3.F481; Yang TX, 1999, AM J PHYSIOL-RENAL, V277, pF966, DOI 10.1152/ajprenal.1999.277.6.F966; Zhang Z, 1997, AM J PHYSIOL-RENAL, V273, pF837, DOI 10.1152/ajprenal.1997.273.5.F837	37	100	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23281	23286		10.1074/jbc.M910237199	http://dx.doi.org/10.1074/jbc.M910237199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10930430	hybrid			2022-12-27	WOS:000088419400094
J	Lyu, RM; Germano, PM; Choi, JK; Le, SV; Pisegna, JR				Lyu, RM; Germano, PM; Choi, JK; Le, SV; Pisegna, JR			Identification of an essential amino acid motif within the C terminus of the pituitary adenylate cyclase-activating polypeptide type I receptor that is critical for signal transduction but not for receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; SITE-DIRECTED MUTAGENESIS; PROTEIN-COUPLED RECEPTOR; CARBOXYL-TERMINUS; FUNCTIONAL EXPRESSION; CYTOPLASMIC DOMAINS; PEPTIDE RECEPTOR; SPLICE VARIANTS; A RECEPTOR; CELLS	The pituitary adenylate cyclase-activating polypeptide (PACAP) type 1 (PAC1) receptor is a G protein-coupled receptor and class II receptor member. The receptor domains critical for signaling are unknown. To explore the role of the C terminus, truncations of 63 residues(Tr-406), 53 residues (Tr-416), 49 residues (Tr-420), 44 residues (Tr-424), and 37 residues (Tr-433) were constructed and expressed in NIH/3T3 cells, and immunofluorescence, radioligand binding, adenylyl cyclase (AC) and phospholipase C (PLC) assays were performed. I-125-PACAP-27 binding (K-d = 0.6-1.5 nM) for the Tr-406 and Tr-433 were similar to wild type Hop and Null splice variants (K-d = similar to1.1 nM), Although internalization of ligand for both the Tr-406 and Tr-433 mutants was reduced to 50-60% at 60 min compared with 76-87% for WT, loss of G-protein coupling did not account for differences in internalization. Despite similar binding properties Tr-406 and Tr-416 mutants showed no AC or PLC response. Addition of 14 amino acids distal to HopTr(406) resulted in normal AC and PLC responses. Site-directed mutagenesis indicated that Arg(416) and Ser(417) are essential for G protein activation. The proximal C terminus mediates signal transduction, and the distal is involved with internalization. Two residues within the C terminus, Arg(416) and Ser(417) conserved among class II receptors are the likely sites for G protein coupling.	VA Greater Los Angeles Healthcare Syst 111C, Gastroenterol & Hepatol Sect, CURE, Vet Affairs UCLA Digest Dis Res Ctr, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles	Pisegna, JR (corresponding author), VA Greater Los Angeles Healthcare Syst 111C, Gastroenterol & Hepatol Sect, CURE, Vet Affairs UCLA Digest Dis Res Ctr, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.				NIDDK NIH HHS [DK 52274-01, P30 DK041301] Funding Source: Medline; RRD VA [I01 RX000194] Funding Source: Medline; BLRD VA [I01 BX004560] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK052274] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); RRD VA; BLRD VA; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIKO IK, 1997, J BIOL CHEM, V272, P6882; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; BURNSTEIN ES, 1998, J BIOL CHEM, V273, P24322; CHAZENBALK GD, 1990, J BIOL CHEM, V265, P20970; CHEUNG AH, 1989, MOL PHARMACOL, V35, P132; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; FINDLAY DM, 1994, MOL ENDOCRINOL, V8, P1691, DOI 10.1210/me.8.12.1691; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Gardella TJ, 1996, J BIOL CHEM, V271, P12820, DOI 10.1074/jbc.271.22.12820; Go WY, 1998, AM J PHYSIOL-GASTR L, V275, pG56, DOI 10.1152/ajpgi.1998.275.1.G56; Harmar AJ, 1998, PHARMACOL REV, V50, P265; Holtmann MH, 1996, J BIOL CHEM, V271, P23566, DOI 10.1074/jbc.271.38.23566; HUANG ZM, 1995, MOL ENDOCRINOL, V9, P1240, DOI 10.1210/me.9.9.1240; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; NAKAMURA M, 1995, J BIOL CHEM, V270, P30102, DOI 10.1074/jbc.270.50.30102; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PISEGNA JR, 1993, P NATL ACAD SCI USA, V90, P6345, DOI 10.1073/pnas.90.13.6345; Pisegna JR, 1996, J BIOL CHEM, V271, P17267, DOI 10.1074/jbc.271.29.17267; Pohl M, 1997, J BIOL CHEM, V272, P18179, DOI 10.1074/jbc.272.29.18179; Prado GN, 1996, J BIOL CHEM, V271, P19186, DOI 10.1074/jbc.271.32.19186; Roettger BF, 1997, MOL PHARMACOL, V51, P357; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; UNSON CG, 1995, J BIOL CHEM, V270, P27720, DOI 10.1074/jbc.270.46.27720; VARRAULT A, 1992, MOL PHARMACOL, V41, P999; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Wu V, 1997, J BIOL CHEM, V272, P9037; ZANOLARI B, 1992, CELL, V71, P755, DOI 10.1016/0092-8674(92)90552-N; ZHU X, 1994, MOL PHARMACOL, V46, P460	42	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36134	36142		10.1074/jbc.M004612200	http://dx.doi.org/10.1074/jbc.M004612200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10908567	Green Accepted, hybrid			2022-12-27	WOS:000165382000070
J	Oram, JF; Lawn, RM; Garvin, MR; Wade, DP				Oram, JF; Lawn, RM; Garvin, MR; Wade, DP			ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER-1; TANGIER-DISEASE; CELLULAR CHOLESTEROL; A-I; REMOVAL; PHOSPHOLIPIDS; FIBROBLASTS; MUTATIONS; EFFLUX; CELLS	Lipid-poor high density lipoprotein apolipoproteins remove cholesterol and phospholipids from cells by an active secretory pathway controlled by an ABC transporter called ABCA1, This pathway is induced by cholesterol and cAMP analogs in a cell-specific manner. Here we provide evidence that increased plasma membrane ABCA1 accounts for the enhanced apolipoprotein-mediated Lipid secretion from macrophages induced by cAMP analogs. Treatment of RAW264 macrophages with 8-bromo-cAMP caused parallel increases in apoA-I-mediated cholesterol efflux, ABCA1 mRNA and protein levels, incorporation of ABCA1 into the plasma membrane, and binding of apoA-I to cell-surface ABCA1, All of these parameters declined to near base-line values within 6 h after removal of 8-bromo-cAMP, indicating that ABCA1 is highly unstable and is degraded rapidly in the absence of inducer. Thus, ABCA1 is likely to be the cAMP-inducible apolipoprotein receptor that promotes removal of cholesterol and phospholipids from macrophages.	Univ Washington, Dept Med, Seattle, WA 98195 USA; CV Therapeut Inc, Palo Alto, CA 94304 USA	University of Washington; University of Washington Seattle; CV Therapeutics, Inc.	Oram, JF (corresponding author), Univ Washington, Dept Med, Seattle, WA 98195 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055362, R29HL053451] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53451, HL55362] Funding Source: Medline; NIDDK NIH HHS [DK02456] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASSMAN G, 1995, METALOLIC MOL BASES, P2058; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Costet P, 2000, J BIOL CHEM, V275, P28240; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; ORAM JF, 1983, J CLIN INVEST, V72, P1611, DOI 10.1172/JCI111120; Oram JF, 1999, J LIPID RES, V40, P1769; Oram JF, 1996, J LIPID RES, V37, P2473; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Remaley AT, 1999, P NATL ACAD SCI USA, V96, P12685, DOI 10.1073/pnas.96.22.12685; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sakr SW, 1999, BBA-MOL CELL BIOL L, V1438, P85, DOI 10.1016/S1388-1981(99)00041-4; SERFATYLACROSNIERE C, 1994, ATHEROSCLEROSIS, V107, P85, DOI 10.1016/0021-9150(94)90144-9; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647	17	453	480	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34508	34511		10.1074/jbc.M006738200	http://dx.doi.org/10.1074/jbc.M006738200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10918070	hybrid			2022-12-27	WOS:000165095300069
J	Klemke, M; Pasolli, HA; Kehlenbach, RH; Offermanns, S; Schultz, G; Huttner, WB				Klemke, M; Pasolli, HA; Kehlenbach, RH; Offermanns, S; Schultz, G; Huttner, WB			Characterization of the extra-large G protein alpha-subunit XL alpha s - II. Signal transduction properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; ESCHERICHIA-COLI; ADP-RIBOSYLATION; TERMINAL DOMAIN; RECEPTOR; ACTIVATION; CELLS; RECONSTITUTION; IDENTIFICATION; HETEROTRIMER	In the preceding paper (Pasolli, H. A., Klemke, M., Kehlenbach, R. H., Wang, Y., and Huttner, W. B. (2000) J. Biol. Chem. 275, 33622-33632), we report on the tissue distribution and subcellular localization of XL alphas (extra large alphas), a neuroendocrine-specific, plasma membrane-associated protein consisting of a novel 37-kDa XL domain followed by a 41-kDa alphas domain encoded by exons 2-13 of the G alphas gene. Here, we have studied the signal transduction properties of XL alphas. Like G alphas, XL alphas undergoes a conformational change upon binding of GTP gammaS (guanosine 5'-O-(thio)triphosphate), as revealed by its partial resistance to tryptic digestion, which generated the same fragments as in the case of G alphas. Two approaches were used to analyze XL alphas-beta gamma interactions: (i) ADP-ribosylation by cholera toxin to detect even weak or transient XL alphas-beta gamma interactions and (ii) sucrose density gradient centrifugation to reveal stable heterotrimer formation. The addition of beta gamma subunits resulted in an increased ADP-ribosylation of XL alphas as well as an increased sedimentation rate of XL alphas in sucrose density gradients, indicating that XL alphas interacts with the beta gamma dimer. Surprisingly, however, XL alphas, in contrast to G alphas, was not activated by the beta2-adrenergic receptor upon reconstitution of S49cyc(-) membranes. Similarly, using photoaffinity labeling of pituitary membranes with azidoanilide-GTP, XL alphas was not activated upon stimulation of pituitary adenylyl cyclase-activating polypeptide (PACAP) receptors or other G alphas-coupled receptors known to be present in these membranes, whereas G alphas was. Despite the apparent inability of XL alphas to undergo receptor-mediated activation, XL alphas-GTP gammaS markedly stimulated adenylyl cyclase in S49cyc(-) membranes. Moreover, transfection of PC12 cells with a GTPase-deficient mutant of XL alphas, XL alphas-Q548L, resulted in a massive increase in adenylyl cyclase activity. Our results suggest that in neuroendocrine cells, the two related G proteins, G alphas and XL alphas, exhibit distinct properties with regard to receptor-mediated activation but converge onto the same effector system, adenylyl cyclase.	Univ Heidelberg, Dept Neurobiol, D-69120 Heidelberg, Germany; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pharmakol, D-14195 Berlin, Germany	Ruprecht Karls University Heidelberg; Max Planck Society; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Huttner, WB (corresponding author), Univ Heidelberg, Dept Neurobiol, Neuenheimer Feld 364, D-69120 Heidelberg, Germany.		Huttner, Wieland B./P-4080-2018; Offermanns, Stefan/L-3313-2017	Kehlenbach, Ralph/0000-0003-4920-9916; Offermanns, Stefan/0000-0001-8676-6805; Pasolli, Hilda Amalia/0000-0003-3899-3530				AUDIGIER Y, 1990, J CELL BIOL, V111, P1427, DOI 10.1083/jcb.111.4.1427; AUDIGIER Y, 1994, METHOD ENZYMOL, V237, P239; BOURNE HR, 1975, SCIENCE, V187, P750, DOI 10.1126/science.163487; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; DENKER BM, 1992, J BIOL CHEM, V267, P6272; GORMAN CM, 1983, NUCLEIC ACIDS RES, V11, P7631, DOI 10.1093/nar/11.21.7631; GRAZIANO MP, 1987, J BIOL CHEM, V262, P11375; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; Hayward BE, 1998, P NATL ACAD SCI USA, V95, P10038, DOI 10.1073/pnas.95.17.10038; HIDE I, 1992, MOL PHARMACOL, V41, P352; JOHNSON GL, 1978, P NATL ACAD SCI USA, V75, P3113, DOI 10.1073/pnas.75.7.3113; JOHNSON GL, 1978, J BIOL CHEM, V253, P7120; JOURNOT L, 1989, FEBS LETT, V251, P230, DOI 10.1016/0014-5793(89)81460-7; JOURNOT L, 1991, J BIOL CHEM, V266, P9009; KEHLENBACH RH, 1995, NATURE, V375, P253, DOI 10.1038/375253b0; KEHLENBACH RH, 1994, NATURE, V372, P804; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LAUGWITZ KL, 1994, METHOD ENZYMOL, V237, P283; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; Pasolli HA, 2000, J BIOL CHEM, V275, P33622, DOI 10.1074/jbc.M001335200; Peters J, 1999, P NATL ACAD SCI USA, V96, P3830, DOI 10.1073/pnas.96.7.3830; ROSKOSKI R, 1989, J NEUROCHEM, V53, P1934, DOI 10.1111/j.1471-4159.1989.tb09264.x; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; TOOZE SA, 1992, METHOD ENZYMOL, V219, P81; TOYOSHIGE M, 1994, BIOCHEMISTRY-US, V33, P4865, DOI 10.1021/bi00182a014; Ugur O, 2000, MOL BIOL CELL, V11, P1421, DOI 10.1091/mbc.11.4.1421; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEST RE, 1985, J BIOL CHEM, V260, P4428	32	75	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33633	33640		10.1074/jbc.M006594200	http://dx.doi.org/10.1074/jbc.M006594200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10931851	hybrid			2022-12-27	WOS:000090104600064
J	Wixler, V; Geerts, D; Laplantine, E; Westhoff, D; Smyth, N; Aumailley, M; Sonnenberg, A; Paulsson, M				Wixler, V; Geerts, D; Laplantine, E; Westhoff, D; Smyth, N; Aumailley, M; Sonnenberg, A; Paulsson, M			The LIM-only protein DRAL/FHL2 binds to the cytoplasmic domain of several alpha and beta integrin chains and is recruited to adhesion complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; ZINC-FINGER; SIGNAL-TRANSDUCTION; CYSTEINE-RICH; SKELETAL-MUSCLE; CALCIUM-BINDING; INTERACTS; TAIL; IDENTIFICATION; SEQUENCE	LIM proteins contain one or more double zinc finger structures (LIM domains) mediating specific contacts between proteins that participate in the formation of multiprotein complexes. We report that the LIM-only protein DRAL/FHL2, with four and a half LIM domains, can associate with alpha (3A), alpha (3B), alpha (7A), and several beta integrin subunits as shown in yeast two-hybrid assays as well as after overexpression in human cells. The amino acid sequence immediately following the conserved membrane-proximal region in the integrin alpha subunits or the C-terminal region with the conserved NXXY motif of the integrin beta subunits are critical for binding DRAL/FHL2. Furthermore, the DRAL/FHL2 associates with itself and with other molecules that bind to the cytoplasmic domain of integrin alpha subunits. Deletion analysis of DRAL/FHL2 revealed that particular LIM domains or LIM domain combinations bind the different proteins. These results, together with the fact that full-length DRAW FHL2 is found in cell adhesion complexes, suggest that it is an adaptor/docking protein involved in integrin signaling pathways.	Univ Cologne, Fac Med, Inst Biochem 2, D-50931 Cologne, Germany; Netherlands Canc Inst, NL-1066 CX Amsterdam, Netherlands	University of Cologne; Netherlands Cancer Institute	Aumailley, M (corresponding author), Univ Cologne, Fac Med, Inst Biochem 2, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.	aumailley@uni-koeln.de	Geerts, Dirk/K-8260-2015	Geerts, Dirk/0000-0002-6386-8187; Smyth, Neil/0000-0002-3734-2149				Beckerle MC, 1997, BIOESSAYS, V19, P949, DOI 10.1002/bies.950191104; Burridge K, 1997, TRENDS CELL BIOL, V7, P342, DOI 10.1016/S0962-8924(97)01127-6; Chan KK, 1998, GENE, V210, P345, DOI 10.1016/S0378-1119(97)00644-6; Chan KK, 2000, J CELL BIOCHEM, V76, P499, DOI 10.1002/(SICI)1097-4644(20000301)76:3<499::AID-JCB16>3.0.CO;2-4; Chang DD, 1997, J CELL BIOL, V138, P1149, DOI 10.1083/jcb.138.5.1149; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; Dogic D, 1999, MATRIX BIOL, V18, P433, DOI 10.1016/S0945-053X(99)00046-3; Dogic D, 1998, J CELL SCI, V111, P793; Eigenthaler R, 1997, J BIOL CHEM, V272, P7693, DOI 10.1074/jbc.272.12.7693; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; Fimia GM, 1999, NATURE, V398, P165, DOI 10.1038/18237; Genini M, 1997, DNA CELL BIOL, V16, P433, DOI 10.1089/dna.1997.16.433; Haas TA, 1997, PROTEIN ENG, V10, P1395, DOI 10.1093/protein/10.12.1395; Hagmann J, 1998, J CELL SCI, V111, P2181; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HEMLER ME, 1984, J IMMUNOL, V132, P3011; Hobert O, 1999, J CELL BIOL, V144, P45, DOI 10.1083/jcb.144.1.45; Hodivala-Dilke KM, 1998, J CELL BIOL, V142, P1357, DOI 10.1083/jcb.142.5.1357; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Kaapa A, 1999, EXP CELL RES, V250, P524, DOI 10.1006/excr.1999.4533; KASSNER PD, 1994, J BIOL CHEM, V269, P19859; KAWAGUCHI S, 1994, MOL BIOL CELL, V5, P977, DOI 10.1091/mbc.5.9.977; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; Konrat R, 1998, J BIOL CHEM, V273, P23233, DOI 10.1074/jbc.273.36.23233; Kowalski K, 1999, J BIOMOL NMR, V13, P249, DOI 10.1023/A:1008309602929; LaFlamme SE, 1997, MATRIX BIOL, V16, P153, DOI 10.1016/S0945-053X(97)90003-2; Laplantine E, 2000, J CELL SCI, V113, P1167; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; Mastrangelo AM, 1999, J CELL SCI, V112, P217; Morgan MJ, 1999, BIOCHEM BIOPH RES CO, V255, P245, DOI 10.1006/bbrc.1999.0179; Morgan MJ, 1999, BIOCHEM BIOPH RES CO, V255, P251, DOI 10.1006/bbrc.1999.0180; Morgan MJ, 1996, BIOCHEM BIOPH RES CO, V225, P632, DOI 10.1006/bbrc.1996.1222; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; Nix DA, 1997, J CELL BIOL, V138, P1139, DOI 10.1083/jcb.138.5.1139; OTEY CA, 1993, J BIOL CHEM, V268, P21193; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; PerezAlvarado GC, 1996, J MOL BIOL, V257, P153, DOI 10.1006/jmbi.1996.0153; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Pomies P, 1997, J CELL BIOL, V139, P157, DOI 10.1083/jcb.139.1.157; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; Retta SF, 1998, MOL BIOL CELL, V9, P715, DOI 10.1091/mbc.9.4.715; Rietzler M, 1998, J BIOL CHEM, V273, P27459, DOI 10.1074/jbc.273.42.27459; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; Roof DJ, 1997, J CELL BIOL, V138, P575, DOI 10.1083/jcb.138.3.575; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHARMA CP, 1995, J IMMUNOL, V154, P3461; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; Sondermann H, 1999, CELL ADHES COMMUN, V7, P43, DOI 10.3109/15419069909034391; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Thomas SM, 1999, J CELL SCI, V112, P181; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Vallar L, 1999, J BIOL CHEM, V274, P17257, DOI 10.1074/jbc.274.24.17257; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wixler V, 1999, FEBS LETT, V445, P351, DOI 10.1016/S0014-5793(99)00151-9; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Zhang XA, 1999, J BIOL CHEM, V274, P11, DOI 10.1074/jbc.274.1.11	66	117	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33669	33678		10.1074/jbc.M002519200	http://dx.doi.org/10.1074/jbc.M002519200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10906324	hybrid			2022-12-27	WOS:000090104600069
J	Coburn, CT; Knapp, FF; Febbraio, M; Beets, AL; Silverstein, RL; Abumrad, NA				Coburn, CT; Knapp, FF; Febbraio, M; Beets, AL; Silverstein, RL; Abumrad, NA			Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIACYLGLYCEROL ACYLTRANSFERASE; TRIACYLGLYCEROL SYNTHESIS; MEMBRANE-PROTEIN; CARDIAC MYOCYTES; BINDING PROTEIN; RAT HEPATOCYTES; UP-REGULATION; METABOLISM; TRANSPORT; ADIPOCYTES	The transmembrane protein CD36 has been identified in isolated cell studies as a putative transporter of long chain fatty acids. In humans, an association between CD36 deficiency and defective myocardial uptake of the fatty acid analog 15-(p-iodophenyl)-3-(R,S)-methyl pentadecanoic acid (BMIPP) has been reported. To determine whether this association represents a causal link and to assess the physiological role of CD36, we compared tissue uptake and metabolism of two iodinated fatty acid analogs BMIPP and 15-(p-iodophenyl) pentadecanoic acid (IPPA) in CD36 null and wild type mice. We also investigated the uptake and lipid incorporation of palmitate by adipocytes isolated from both groups. Compared with wild type, uptake of BMIPP and IPPA was reduced in heart (50-80%), skeletal muscle (40-75%), and adipose tissues (60-70%) of nub mice. The reduction was associated with a 50-68% decrease in label incorporation into triglycerides and in 2-3-fold accumulation of label in diglycerides, Identical results were obtained from studies of [H-3]palmitate uptake in isolated adipocytes, The block in diglyceride to triglyceride conversion could not be explained by changes in specific activities of the key enzymes long chain acyl-CoA synthetase and diacylglycerol acyltransferase, which were similar in tissues from wild type and null mice. It is concluded that CD36 facilitates a large fraction of fatty acid uptake by heart, skeletal muscle, and adipose tissues and that CD36 deficiency in humans is the cause of the reported defect in myocardial BMIPP uptake. In CD36-expressing tissues, uptake regulates fatty acid esterification at the level of diacylglycerol acyltransferase by determining fatty acyl-CoA supply. The membrane transport step may represent an important control site for fatty acid metabolism in vivo.	SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Oak Ridge Natl Lab, Nucl Med Program, Oak Ridge, TN 37831 USA; Cornell Univ, Weill Med Coll, Div Hematol & Med Oncol, Dept Med, New York, NY 10021 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; United States Department of Energy (DOE); Oak Ridge National Laboratory; Cornell University	Abumrad, NA (corresponding author), SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.				NHLBI NIH HHS [1R29 HL58559, HL42540] Funding Source: Medline; NIDDK NIH HHS [DK33301] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL058559, R01HL042540] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033301] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abumrad N, 1998, J LIPID RES, V39, P2309; ABUMRAD NA, 1984, J BIOL CHEM, V259, P8945; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ABUMRAD NA, 1981, J BIOL CHEM, V256, P9183; Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; AMBROSE KR, 1987, EUR J NUCL MED, V12, P486, DOI 10.1007/BF00620471; Antozzi C, 1997, CARDIOVASC RES, V35, P184, DOI 10.1016/S0008-6363(97)00141-7; Baillie AGS, 1996, J MEMBRANE BIOL, V153, P75, DOI 10.1007/s002329900111; Berk PD, 1999, J BIOL CHEM, V274, P28626, DOI 10.1074/jbc.274.40.28626; Binas B, 1999, FASEB J, V13, P805, DOI 10.1096/fasebj.13.8.805; Bonen A, 1999, AM J PHYSIOL-ENDOC M, V276, pE642, DOI 10.1152/ajpendo.1999.276.4.E642; Bonen A, 1998, AM J PHYSIOL-ENDOC M, V275, pE471, DOI 10.1152/ajpendo.1998.275.3.E471; BURKHOLDER TJ, 1994, J MORPHOL, V221, P177, DOI 10.1002/jmor.1052210207; COLEMAN RA, 1992, METHOD ENZYMOL, V209, P98; DEUTSCH J, 1994, ANAL BIOCHEM, V220, P321, DOI 10.1006/abio.1994.1344; DOUMAS BT, 1971, CLIN CHIM ACTA, V31, P87, DOI 10.1016/0009-8981(71)90365-2; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fukuchi K, 1999, J NUCL MED, V40, P239; GREEN HJ, 1984, HISTOCHEMISTRY, V81, P67, DOI 10.1007/BF00495403; GREENWALT DE, 1985, J CELL BIOL, V100, P397, DOI 10.1083/jcb.100.2.397; GREENWALT DE, 1995, J CLIN INVEST, V96, P1382, DOI 10.1172/JCI118173; Hamilton JA, 1998, J LIPID RES, V39, P467; Ibrahimi A, 1999, J BIOL CHEM, V274, P26761, DOI 10.1074/jbc.274.38.26761; Ibrahimi A, 1996, P NATL ACAD SCI USA, V93, P2646, DOI 10.1073/pnas.93.7.2646; Knapp F F Jr, 1996, Q J Nucl Med, V40, P252; KNAPP FF, 1986, J NUCL MED, V27, P521; KROPP J, 1992, NUCL MED BIOL, V19, P283; Lee K, 1999, TRANSFUSION, V39, P873, DOI 10.1046/j.1537-2995.1999.39080873.x; Luiken JJFP, 1997, J LIPID RES, V38, P745; MAYOREK N, 1989, EUR J BIOCHEM, V182, P395, DOI 10.1111/j.1432-1033.1989.tb14844.x; Memon RA, 1998, AM J PHYSIOL-ENDOC M, V274, pE210, DOI 10.1152/ajpendo.1998.274.2.E210; Memon RA, 1999, DIABETES, V48, P121, DOI 10.2337/diabetes.48.1.121; Pelsers MMAL, 1999, BIOCHEM J, V337, P407, DOI 10.1042/0264-6021:3370407; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Poirier H, 1996, EUR J BIOCHEM, V238, P368, DOI 10.1111/j.1432-1033.1996.0368z.x; RESKE SN, 1985, EUR J NUCL MED, V10, P228; RICHIERI GV, 1995, J LIPID RES, V36, P229; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SORRENTINO D, 1989, J CLIN INVEST, V84, P1325, DOI 10.1172/JCI114301; SPITSBERG VL, 1995, EUR J BIOCHEM, V230, P872, DOI 10.1111/j.1432-1033.1995.tb20630.x; STALS HK, 1994, FEBS LETT, V343, P99, DOI 10.1016/0014-5793(94)80615-2; STUMP DD, 1993, AM J PHYSIOL, V265, pG894, DOI 10.1152/ajpgi.1993.265.5.G894; Tanaka T, 1981, Methods Enzymol, V71 Pt C, P334; Tanaka T, 1997, J MOL CELL CARDIOL, V29, P121, DOI 10.1006/jmcc.1996.0257; Tontonoz P, 1999, CURR OPIN LIPIDOL, V10, P485, DOI 10.1097/00041433-199912000-00002; Torizuka K., 1991, JPN J NUCL MED, V28, P681; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Zakim D, 1996, P SOC EXP BIOL MED, V212, P5	49	498	515	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32523	32529		10.1074/jbc.M003826200	http://dx.doi.org/10.1074/jbc.M003826200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10913136	hybrid			2022-12-27	WOS:000090003800021
J	Landriscina, M; Prudovsky, I; Carreira, CM; Soldi, R; Tarantini, F; Maciag, T				Landriscina, M; Prudovsky, I; Carreira, CM; Soldi, R; Tarantini, F; Maciag, T			Amlexanox reversibly inhibits cell migration and proliferation and induces the Src-dependent disassembly of actin stress fibers in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; FACTOR-I; TYROSINE PHOSPHORYLATION; SUBCELLULAR-LOCALIZATION; FACTOR RECEPTOR-1; DNA-SYNTHESIS; C-SRC; BINDING; RELEASE; PROTEIN	Amlexanox binds S100A13 and inhibits the release of fibroblast growth factor 1 (FGF1). Because members of the S100 gene family are known to be involved with the function of the cytoskeleton, we examined the ability of amlexanox to modify the cytoskeleton and report that amlexanox induces a dramatic reduction in the presence of actin stress fibers and the appearance of a random, non-oriented distribution of focal adhesion sites. Correspondingly, amlexanox induces the complete and reversible non-apoptotic inhibition of cell migration and proliferation, and although amlexanox does not induce either the down-regulation of F-actin levels or the depolymerization of actin filaments, it does induce the tyrosine phosphorylation of cortactin, a Src substrate known to regulate actin bundling. In addition, a dominant negative form of Src is able to partially rescue cells from the effect of amlexanox on both the actin cytoskeleton and cell migration. In contrast, the inhibition of cell proliferation by amlexanox correlates with the inhibition of cyclin D1 expression without interference of the receptor tyrosine kinase/mitogen-activated protein kinase signaling pathway. Last, the ability of amlexanox to inhibit FGF1 release is reversible and correlates with the restoration of the actin cytoskeleton, suggesting a role for the actin cytoskeleton in the FGF1 release pathway.	Maine Med Ctr, Res Inst, Ctr Mol Med, S Portland, ME 04106 USA	Maine Medical Center	Maciag, T (corresponding author), Maine Med Ctr, Res Inst, Ctr Mol Med, 125 John Roberts Rd, S Portland, ME 04106 USA.		Prudovsky, Igor/GVU-1521-2022; Landriscina, Matteo/K-1092-2016; Tarantini, Francesca/I-6332-2012	Landriscina, Matteo/0000-0003-0591-9799; TARANTINI, FRANCESCA/0000-0002-1390-2965	NHLBI NIH HHS [HL32348, HL35627] Funding Source: Medline; NIA NIH HHS [AG07450] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032348, R01HL035627] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Carreira CM, 1998, J BIOL CHEM, V273, P22224, DOI 10.1074/jbc.273.35.22224; Chan AY, 1998, J CELL SCI, V111, P199; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; Cramer LP, 1999, CURR BIOL, V9, P1095, DOI 10.1016/S0960-9822(99)80478-3; Felsenfeld DP, 1999, NAT CELL BIOL, V1, P200, DOI 10.1038/12021; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; Garfinkel S, 1996, J CELL BIOL, V134, P783, DOI 10.1083/jcb.134.3.783; Gimona M, 1997, J CELL SCI, V110, P611; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Ishikawa R, 1998, J BIOL CHEM, V273, P26991, DOI 10.1074/jbc.273.41.26991; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; Kilby PM, 1997, PROTEIN SCI, V6, P2494; LaVallee TM, 1998, J BIOL CHEM, V273, P22217, DOI 10.1074/jbc.273.35.22217; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; LIBERMANN TA, 1987, EMBO J, V6, P1627, DOI 10.1002/j.1460-2075.1987.tb02410.x; MACIAG T, 1979, P NATL ACAD SCI USA, V76, P5674, DOI 10.1073/pnas.76.11.5674; MAKINO H, 1987, INT ARCH ALLER A IMM, V82, P66, DOI 10.1159/000234292; Mandinova A, 1998, J CELL SCI, V111, P2043; Mulholland J, 1997, MOL BIOL CELL, V8, P1481, DOI 10.1091/mbc.8.8.1481; Nelson W J, 1991, Semin Cell Biol, V2, P375; Osterloh D, 1998, CELL CALCIUM, V24, P137, DOI 10.1016/S0143-4160(98)90081-1; Oyama Y, 1997, BIOCHEM BIOPH RES CO, V240, P341, DOI 10.1006/bbrc.1997.7476; PAVALKO FM, 1991, BIOCHEM SOC T, V19, P1065, DOI 10.1042/bst0191065; PERIN MS, 1991, J BIOL CHEM, V266, P623; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Sheetz MP, 1998, TRENDS CELL BIOL, V8, P51, DOI 10.1016/S0962-8924(98)80005-6; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; Tarantini F, 1998, J BIOL CHEM, V273, P22209, DOI 10.1074/jbc.273.35.22209; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; Wicki R, 1996, BIOCHEM BIOPH RES CO, V227, P594, DOI 10.1006/bbrc.1996.1551; Winkles JA, 1996, AM J PATHOL, V149, P2119; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1993, J BIOL CHEM, V268, P9611; ZHAN X, 1994, J BIOL CHEM, V269, P20221; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	39	36	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32753	32762		10.1074/jbc.M002336200	http://dx.doi.org/10.1074/jbc.M002336200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10921913	hybrid			2022-12-27	WOS:000090003800053
J	Meriane, M; Mary, S; Comunale, F; Vignal, E; Fort, P; Gauthier-Rouviere, C				Meriane, M; Mary, S; Comunale, F; Vignal, E; Fort, P; Gauthier-Rouviere, C			Cdc42Hs and Rac1 GTPases induce the collapse of the vimentin intermediate filament network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; ACTIN-CYTOSKELETON; RHO-FAMILY; INDEPENDENT PATHWAYS; PROTEIN-KINASES; TYROSINE KINASE; LIVING CELLS; DYNAMICS; PHOSPHORYLATION; MICROTUBULES	In this study we show that expression of active Cdc42Hs and Rac1 GTPases, two Rho family members, leads to the reorganization of the vimentin intermediate filament (IF) network, showing a perinuclear collapse. Cdc42Hs displays a stronger effect than Rad as 90% versus 75% of GTPase-expressing cells show vimentin collapse. Similar vimentin IF modifications were observed when endogenous Cdc42Hs was activated by bradykinin treatment, endogenous Rad by platelet-derived growth factor/epidermal growth factor, or both endogenous proteins upon expression of active RhoG. This reorganization of the vimentin IF network is not associated with any significant increase in soluble vimentin. Using effector loop mutants of Cdc42Hs and Rac1, we show that the vimentin collapse is mostly independent of CRIB (Cdc42Hs or Rac-interacting binding)-mediated pathways such as JNK or PAK activation but is associated with actin reorganization. This does not result from F-actin depolymerization, because cytochalasin D treatment or Scar-WA expression have merely no effect on vimentin organization. Finally, we show that genistein treatment of Cdc42 and Rac1-expressing cells strongly reduces vimentin collapse, whereas staurosporin, wortmannin, LY-294002, R-p-cAMP, or RII, the regulatory subunit of protein kinase A, remain ineffective. Moreover, we detected an increase in cellular tyrosine phosphorylation content after Cdc42Hs and Rad expression without modification of the vimentin phosphorylation status. These data indicate that Cdc42Hs and Rad GTPases control vimentin IF organization involving tyrosine phosphorylation events.	Ctr Rech Biochim Macromol, CNRS, UPR 1086, F-34293 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Gauthier-Rouviere, C (corresponding author), Ctr Rech Biochim Macromol, CNRS, UPR 1086, 1919 Route de Mende, F-34293 Montpellier, France.		Fort, Philippe/M-9498-2015; Vignal, Emmanuel/B-6985-2009	Fort, Philippe/0000-0001-5997-8722; GAUTHIER-ROUVIERE, Cecile/0000-0002-8364-3882; Comunale, Franck/0000-0001-8838-2151; Vignal, Emmanuel/0000-0002-2585-119X				AEPFELBACHER M, 1994, P NATL ACAD SCI USA, V91, P4263, DOI 10.1073/pnas.91.10.4263; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Chou YH, 1997, CURR OPIN CELL BIOL, V9, P49, DOI 10.1016/S0955-0674(97)80151-2; CiesielskiTreska J, 1995, EUR J CELL BIOL, V68, P369; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; Djabali K, 1999, HISTOL HISTOPATHOL, V14, P501, DOI 10.14670/HH-14.501; DRABEROVA E, 1993, J CELL SCI, V106, P1263; Dutartre H, 1996, J CELL SCI, V109, P367; Fincham VJ, 1996, J CELL BIOL, V135, P1551, DOI 10.1083/jcb.135.6.1551; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; GYOEVA FK, 1991, NATURE, V353, P445, DOI 10.1038/353445a0; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HIRATA K, 1992, J BIOL CHEM, V267, P8719; Ho CL, 1998, J CELL SCI, V111, P1767; Inada H, 1999, J BIOL CHEM, V274, P34932, DOI 10.1074/jbc.274.49.34932; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; Jeffcoat Sheila, 1995, Cytobios, V82, P81; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Kosako H, 1997, J BIOL CHEM, V272, P10333; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; LAMB NJC, 1989, J CELL BIOL, V108, P2409, DOI 10.1083/jcb.108.6.2409; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; Mukai H, 1996, J BIOL CHEM, V271, P9816, DOI 10.1074/jbc.271.16.9816; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Prahlad V, 1998, J CELL BIOL, V143, P159, DOI 10.1083/jcb.143.1.159; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Schliwa Manfred, 1993, Trends in Cell Biology, V3, P377; Sin WC, 1998, MOL CELL BIOL, V18, P6325, DOI 10.1128/MCB.18.11.6325; SOELLNER P, 1985, P NATL ACAD SCI USA, V82, P7929, DOI 10.1073/pnas.82.23.7929; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Valgeirsdottir S, 1998, J CELL SCI, V111, P1973; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; YANG HY, 1992, CELL MOTIL CYTOSKEL, V22, P185, DOI 10.1002/cm.970220306; YANO H, 1993, J BIOL CHEM, V268, P25846; Yoon M, 1998, J CELL BIOL, V143, P147, DOI 10.1083/jcb.143.1.147	49	53	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33046	33052		10.1074/jbc.M001566200	http://dx.doi.org/10.1074/jbc.M001566200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10900195	Green Published, hybrid			2022-12-27	WOS:000090003800091
J	Osborne, TF				Osborne, TF			Sterol regulatory element-binding proteins (SREBPs): Key regulators of nutritional homeostasis and insulin action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							POLYUNSATURATED FATTY-ACIDS; LIPOGENIC GENE-EXPRESSION; TRANSCRIPTION FACTOR; TRANSGENIC MICE; DIABETES-MELLITUS; ADIPOSE-TISSUE; CHOLESTEROL-SYNTHESIS; NUCLEAR SREBP-1C; MESSENGER-RNAS; CULTURED-CELLS		Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Osborne, TF (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL004804] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL4804] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Athanikar JN, 1998, P NATL ACAD SCI USA, V95, P4935, DOI 10.1073/pnas.95.9.4935; Boizard M, 1998, J BIOL CHEM, V273, P29164, DOI 10.1074/jbc.273.44.29164; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Casado M, 1999, J BIOL CHEM, V274, P2009, DOI 10.1074/jbc.274.4.2009; Ericsson J, 1998, J BIOL CHEM, V273, P17865, DOI 10.1074/jbc.273.28.17865; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Horton JD, 1999, J CLIN INVEST, V103, P1067, DOI 10.1172/JCI6246; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; HUA XX, 1995, GENOMICS, V25, P667, DOI 10.1016/0888-7543(95)80009-B; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Kim HJ, 1999, J BIOL CHEM, V274, P25892, DOI 10.1074/jbc.274.36.25892; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kotzka J, 1998, BIOCHEM BIOPH RES CO, V249, P375, DOI 10.1006/bbrc.1998.9161; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Magana MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726; Mater MK, 1999, J BIOL CHEM, V274, P32725, DOI 10.1074/jbc.274.46.32725; MILLINDERVALLET.S, 1996, J BIOL CHEM, V271, P12247; Miserez AR, 1997, GENOMICS, V40, P31, DOI 10.1006/geno.1996.4525; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Parraga A, 1998, STRUCT FOLD DES, V6, P661, DOI 10.1016/S0969-2126(98)00067-7; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Shimomura I, 1997, P NATL ACAD SCI USA, V94, P12354, DOI 10.1073/pnas.94.23.12354; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Thewke DP, 1998, J BIOL CHEM, V273, P21402, DOI 10.1074/jbc.273.33.21402; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Towle HC, 1997, ANNU REV NUTR, V17, P405, DOI 10.1146/annurev.nutr.17.1.405; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537; Xu J, 1999, J BIOL CHEM, V274, P23577, DOI 10.1074/jbc.274.33.23577; Yahagi N, 1999, J BIOL CHEM, V274, P35840, DOI 10.1074/jbc.274.50.35840; Yokoyama C., 1993, CELL, V75, P185	49	418	436	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32379	32382		10.1074/jbc.R000017200	http://dx.doi.org/10.1074/jbc.R000017200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10934219	hybrid			2022-12-27	WOS:000090003800001
J	Xu, Q; Li, YH; Cyras, C; Sanan, DA; Cordell, B				Xu, Q; Li, YH; Cyras, C; Sanan, DA; Cordell, B			Isolation and characterization of apolipoproteins from murine microglia - Identification of a low density lipoprotein-like apolipoprotein J-rich but E-poor spherical particle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID BETA-PEPTIDE; ISOFORM-SPECIFIC BINDING; DIFFERENT PLAQUE TYPES; ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; IN-VITRO; MESSENGER-RNA; CELL-DEATH; EXPRESSION; PROTEIN	Amyloid A beta deposition is a neuropathologic hallmark of Alzheimer's disease. Activated microglia are intimately associated with plaques and appear to facilitate A beta deposition, an event believed to contribute to pathogenesis. It is unclear if microglia can modulate pathogenesis of Alzheimer's disease by secreting lipoprotein particles. Here we show that cultured BV2 murine microglial cells, like astrocytes, secrete apolipoprotein E (apoE) and apolipoprotein J (apoJ) in a time-dependent manner. To isolate and identify BV2 microglial particles, gel filtration chromatography was employed to fractionate BV2-conditioned medium. Analyses by Western blot, lipid determination, electron microscopy, and native gel electrophoresis demonstrate that BV2 microglial cells release spherical low density lipoprotein (LDL)-like lipid-containing particles rich in apoJ but poor in apoE, These microglial particles are dissimilar in size, shape, and lipoprotein composition to astrocyte-derived particles. The microglial-derived particles were tested for functional activity. Under conditions of suppressed de novo cholesterol synthesis, the LDL-like particles effectively rescued primary rat cortical neurons from mevastatin-induced neurotoxicity, The particles were also shown to bind A beta, We speculate that the LDL-like apoJ-rich apoE-poor microglial lipoproteins preferentially bind the lipoprotein receptor, recognizing apoJ, which is abundant in the choroid plexus, facilitating A beta clearance from the brain. BV2 cells also secrete an apoE-rich lipid-poor species that binds A beta. Consistent with the role of apoE in A beta fibril formation and deposition, this microglial species may promote plaque formation.	Scios Inc, Sunnyvale, CA 94085 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA	Scios; University of California System; University of California San Francisco; The J David Gladstone Institutes	Cordell, B (corresponding author), Scios Inc, 820 W Maude Ave, Sunnyvale, CA 94085 USA.							ARAUJO DM, 1992, BRAIN RES, V569, P141, DOI 10.1016/0006-8993(92)90380-R; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; BASU SK, 1983, SCIENCE, V219, P871, DOI 10.1126/science.6823554; Bitting L, 1996, J BIOL CHEM, V271, P16084, DOI 10.1074/jbc.271.27.16084; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; BOCCHINI V, 1992, J NEUROSCI RES, V31, P616, DOI 10.1002/jnr.490310405; BORGHINI I, 1995, BBA-LIPID LIPID MET, V1255, P192, DOI 10.1016/0005-2760(94)00232-N; BURKEY BF, 1992, J LIPID RES, V33, P1517; CHAO CC, 1994, MOL CHEM NEUROPATHOL, V23, P159, DOI 10.1007/BF02815409; CHOIMIURA NH, 1992, ACTA NEUROPATHOL, V83, P260, DOI 10.1007/BF00296787; Chung HY, 1999, J BIOL CHEM, V274, P32301, DOI 10.1074/jbc.274.45.32301; Cole GM, 1999, J NEUROSCI RES, V57, P504, DOI 10.1002/(SICI)1097-4547(19990815)57:4<504::AID-JNR10>3.0.CO;2-H; CORDER EH, 1995, NEUROLOGY, V45, P1323, DOI 10.1212/WNL.45.7.1323; DAVIS JB, 1992, BIOCHEM BIOPH RES CO, V189, P1096, DOI 10.1016/0006-291X(92)92317-Q; DESILVA HV, 1990, J BIOL CHEM, V265, P13240; Dickson DW, 1999, AM J PATHOL, V154, P1627, DOI 10.1016/S0002-9440(10)65416-8; Fagan AM, 1999, J BIOL CHEM, V274, P30001, DOI 10.1074/jbc.274.42.30001; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; GRIFFIN WST, 1995, J NEUROPATH EXP NEUR, V54, P276; Griffin WST, 1998, BRAIN PATHOL, V8, P65; Hammad SM, 1997, J BIOL CHEM, V272, P18644, DOI 10.1074/jbc.272.30.18644; ITAGAKI S, 1989, J NEUROIMMUNOL, V24, P173, DOI 10.1016/0165-5728(89)90115-X; JORDANSTARCK TC, 1994, J LIPID RES, V35, P194; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070; LADU MJ, 1994, J BIOL CHEM, V269, P23403; LADU MJ, 1995, J BIOL CHEM, V270, P9039, DOI 10.1074/jbc.270.16.9039; LaDu MJ, 1998, J NEUROCHEM, V70, P2070; Li YH, 1997, NEURON, V19, P453, DOI 10.1016/S0896-6273(00)80953-8; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; Mackenzie IRA, 1998, NEUROLOGY, V50, P986, DOI 10.1212/WNL.50.4.986; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Matsubara E, 1996, BIOCHEM J, V316, P671, DOI 10.1042/bj3160671; MAY PC, 1990, NEURON, V5, P831, DOI 10.1016/0896-6273(90)90342-D; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MessmerJoudrier S, 1996, EUR J NEUROSCI, V8, P2652, DOI 10.1111/j.1460-9568.1996.tb01560.x; Michel D, 1997, J CELL SCI, V110, P1635; Michikawa M, 1998, J NEUROSCI RES, V54, P58, DOI 10.1002/(SICI)1097-4547(19981001)54:1<58::AID-JNR7>3.0.CO;2-G; Murphy GM, 1998, J BIOL CHEM, V273, P20967, DOI 10.1074/jbc.273.33.20967; Nakai M, 1996, NEUROSCI LETT, V211, P41, DOI 10.1016/0304-3940(96)12716-6; Overmyer M, 1999, ACTA NEUROPATHOL, V97, P383, DOI 10.1007/s004010051002; Reardon CA, 1998, J LIPID RES, V39, P1372; Rogers J, 1996, NEUROBIOL AGING, V17, P681, DOI 10.1016/0197-4580(96)00115-7; ROZEMULLER JM, 1989, J NEUROPATH EXP NEUR, V48, P674, DOI 10.1097/00005072-198911000-00009; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; Sasaki A, 1997, ACTA NEUROPATHOL, V94, P316, DOI 10.1007/s004010050713; Saunders AM, 1996, LANCET, V348, P90, DOI 10.1016/S0140-6736(96)01251-2; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; Sheng JG, 1996, NEUROPATH APPL NEURO, V22, P334, DOI 10.1111/j.1365-2990.1996.tb01112.x; SHENG JG, 1995, NEUROPATH APPL NEURO, V21, P290, DOI 10.1111/j.1365-2990.1995.tb01063.x; Sheng JG, 1996, NEUROBIOL AGING, V17, P761; Stone DJ, 1997, EXP NEUROL, V143, P313, DOI 10.1006/exnr.1996.6360; Tornqvist E, 1996, NEUROBIOL AGING, V17, P695; Weisgraber K H, 1986, Methods Enzymol, V129, P145; WOOD PL, 1994, NEUROREPORT, V5, P977, DOI 10.1097/00001756-199404000-00031; Zlokovic BV, 1996, P NATL ACAD SCI USA, V93, P4229, DOI 10.1073/pnas.93.9.4229	56	59	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31770	31777		10.1074/jbc.M002796200	http://dx.doi.org/10.1074/jbc.M002796200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10918055	hybrid			2022-12-27	WOS:000089858900033
J	March, ME; Lucas, DM; Aman, MJ; Ravichandran, KS				March, ME; Lucas, DM; Aman, MJ; Ravichandran, KS			P135 Src homology 2 domain-containing inositol 5 '-phosphatase (SHIP beta) isoform can substitute for p145 SHIP in F-c gamma RIIB1-mediated inhibitory signaling in B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-GAMMA-RIIB; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE 5-PHOSPHATASE; PHOSPHOTYROSINE-BINDING DOMAIN; FOCAL ADHESION KINASE; PHOSPHATASE SHIP; ANTIGEN RECEPTOR; MULTIPLE FORMS; SHC; ACTIVATION; ASSOCIATION	The inositol 5'-phosphatase, SHIP (also referred to as SHIP-1 or SHIP alpha), is expressed in all cells of the hematopoietic lineage. Depending on the cell type being investigated and the state of differentiation, SHIP isoforms of several different molecular masses (170, 160, 145, 135, 125, and 110 kDa) have been seen in immunoblots. However, the function of the individual isoforms and the effect of expressing multiple isoforms simultaneously are not understood. Some of these SHIP isoforms have recently been characterized at the level of primary sequence. In this report, we investigated the function of the recently characterized 135-kDa SHIP isoform (SHIP beta), which appears to possess the catalytic domain but lacks some of the protein-protein interaction motifs at the C terminus. By reconstituting SHIP-deficient DT40 B cells with either SHIP beta or the better-characterized p145 SHIP alpha, we addressed the function of SHIP beta in the complete absence of SHIP alpha. We observed that SHIP beta had enzymatic activity comparable with SHIP alpha and that SHIP beta was able to reconstitute F(c)gamma RIIB1-mediated inhibition of B cell receptor-induced signaling events such as calcium flux and Akt and mitogen-activated protein kinase activation. SHIP beta was readily phosphorylated in response to B cell receptor cross-linking with the inhibitory receptor F(c)gamma RIIB1 and SHIP beta also interacted with the adapter protein Shc. During these studies we also observed that the SHIP alpha or SHIP beta interaction with Grb2 is not required for F(c)gamma RIIB1-mediated inhibition of calcium flux. These data suggest that SHIP beta, which is normally expressed in B cells along with SHIP alpha, functions comparably with SHIP alpha and that these two isoforms are not likely to be antagonistic in their function in vivo.	Univ Virginia, Hlth Sci Ctr, Beirne B Carter Ctr Immunol Res, Charlottesville, VA 22908 USA; Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA	University of Virginia; Ohio State University	Ravichandran, KS (corresponding author), Univ Virginia, Hlth Sci Ctr, Beirne B Carter Ctr Immunol Res, Bldg MR4,Rm 4012F, Charlottesville, VA 22908 USA.	kr4h@virginia.edu	Lucas, David M/E-3555-2011	March, Michael/0000-0001-9173-6862	NIAID NIH HHS [AI-43425] Funding Source: Medline; NIDDK NIH HHS [F32 DK09774-01] Funding Source: Medline; NIGMS NIH HHS [GM-55761] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055761] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aman MJ, 2000, MOL CELL BIOL, V20, P3576, DOI 10.1128/MCB.20.10.3576-3589.2000; Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; Astoul E, 1999, J CELL BIOL, V145, P1511, DOI 10.1083/jcb.145.7.1511; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; Carver DJ, 2000, BLOOD, V96, P1449, DOI 10.1182/blood.V96.4.1449.h8001449_1449_1456; Coggeshall KM, 2000, CURR TOP MICROBIOL, V245, P213; Coggeshall KM, 1998, CURR OPIN IMMUNOL, V10, P306, DOI 10.1016/S0952-7915(98)80169-6; DAmbrosio D, 1996, IMMUNOL LETT, V54, P77, DOI 10.1016/S0165-2478(96)02653-3; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Damen JE, 1998, BLOOD, V92, P1199, DOI 10.1182/blood.V92.4.1199.416k16_1199_1205; DeFranco AL, 1997, CURR OPIN IMMUNOL, V9, P296, DOI 10.1016/S0952-7915(97)80074-X; DeuterReinhard M, 1997, MOL CELL BIOL, V17, P2559, DOI 10.1128/MCB.17.5.2559; Drayer AL, 1996, BIOCHEM BIOPH RES CO, V225, P243, DOI 10.1006/bbrc.1996.1161; Geier SJ, 1997, BLOOD, V89, P1876, DOI 10.1182/blood.V89.6.1876; Gold MR, 1999, J IMMUNOL, V163, P1894; Harmer SL, 1999, J BIOL CHEM, V274, P12183, DOI 10.1074/jbc.274.17.12183; Hashimoto A, 1998, J EXP MED, V188, P1287, DOI 10.1084/jem.188.7.1287; Hashimoto A, 1999, J BIOL CHEM, V274, P11203, DOI 10.1074/jbc.274.16.11203; Helgason CD, 2000, J EXP MED, V191, P781, DOI 10.1084/jem.191.5.781; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Huber M, 1998, P NATL ACAD SCI USA, V95, P11330, DOI 10.1073/pnas.95.19.11330; Jacob A, 1999, J BIOL CHEM, V274, P13704, DOI 10.1074/jbc.274.19.13704; Jefferson AB, 1997, J BIOL CHEM, V272, P5983, DOI 10.1074/jbc.272.9.5983; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Kiener PA, 1997, J BIOL CHEM, V272, P3838, DOI 10.1074/jbc.272.6.3838; Lamkin TD, 1997, J BIOL CHEM, V272, P10396; Lemay S, 2000, MOL CELL BIOL, V20, P2743, DOI 10.1128/MCB.20.8.2743-2754.2000; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu L, 1997, J BIOL CHEM, V272, P10998; Liu QR, 1998, J EXP MED, V188, P1333, DOI 10.1084/jem.188.7.1333; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; Lucas DM, 1999, BLOOD, V93, P1922, DOI 10.1182/blood.V93.6.1922.406k21_1922_1933; Mason JM, 2000, J BIOL CHEM, V275, P4398, DOI 10.1074/jbc.275.6.4398; Mikhalap SV, 1999, J IMMUNOL, V162, P5719; Okada H, 1998, J IMMUNOL, V161, P5129; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Rohrschneider LR, 2000, GENE DEV, V14, P505; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Sieg DJ, 1999, J CELL SCI, V112, P2677; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; Tridandapani S, 1998, MOL IMMUNOL, V35, P1135, DOI 10.1016/S0161-5890(98)00097-2; Tridandapani S, 1997, IMMUNOL TODAY, V18, P424, DOI 10.1016/S0167-5699(97)01112-2; Tridandapani S, 1997, MOL CELL BIOL, V17, P4305, DOI 10.1128/MCB.17.8.4305; Ware MD, 1996, BLOOD, V88, P2833, DOI 10.1182/blood.V88.8.2833.bloodjournal8882833; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	49	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					29960	29967		10.1074/jbc.M003714200	http://dx.doi.org/10.1074/jbc.M003714200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10900203	hybrid			2022-12-27	WOS:000089577900008
J	Mucke, M; Lurz, R; Mackeldanz, P; Behlke, J; Kruger, DH; Reuter, M				Mucke, M; Lurz, R; Mackeldanz, P; Behlke, J; Kruger, DH; Reuter, M			Imaging DNA loops induced by restriction endonuclease EcoRII - A single amino acid substitution uncouples target recognition from cooperative DNA interaction and cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; MEMBRANE-PROTEIN COMPLEXES; MODIFICATION SYSTEM; NAEI ENDONUCLEASE; ESCHERICHIA-COLI; SITES; BINDING; ENZYME	EcoRII is a type IIE restriction endonuclease characterized by a highly cooperative reaction mechanism that depends on simultaneous binding of the dimeric enzyme molecule to two copies of its DNA recognition site. Transmission electron microscopy provided direct evidence that EcoRII mediates loop formation of linear DNA containing two EcoRII. recognition sites. Specific DNA binding of EcoRII revealed a symmetrical DNase I footprint occupying 16-18 bases. Single amino acid replacement of Val(258) by Asn yielded a mutant enzyme that was unaffected in substrate affinity and DNase I footprinting properties, but exhibited a profound decrease in cooperative DNA binding and cleavage activity. Because the electrophoretic mobility of the mutant enzyme-DNA complexes was significantly higher than that of the wild-type, we investigated if mutant V258N binds as a monomer to the substrate DNA. Analysis of the molecular mass of mutant V258N showed a high percentage of protein monomers in solution. The dissociation constant of mutant V258N confirmed a 350-fold decrease of the enzyme dimerization capability. We conclude that Val(258) is located in a region of EcoRII involved in homodimerization. This is the first report of a specific amino acid replacement in a restriction endonuclease leading to the loss of dimerization and DNA cleavage while retaining specific DNA binding.	Humboldt Univ, Fak Med, Inst Virol, Charite, D-10098 Berlin, Germany; Max Planck Inst Mol Genet, D-14159 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Max Planck Society; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Reuter, M (corresponding author), Humboldt Univ, Fak Med, Inst Virol, Charite, D-10098 Berlin, Germany.							AGGARWAL AK, 1995, CURR OPIN STRUC BIOL, V5, P11, DOI 10.1016/0959-440X(95)80004-K; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Behlke J, 1998, BIOCHEMISTRY-US, V37, P11989, DOI 10.1021/bi980914m; BICKLE TA, 1993, MICROBIOL REV, V57, P434, DOI 10.1128/MMBR.57.2.434-450.1993; Bilcock DT, 1999, MOL MICROBIOL, V31, P1243, DOI 10.1046/j.1365-2958.1999.01266.x; Christ F, 1999, EMBO J, V18, P6908, DOI 10.1093/emboj/18.24.6908; Colandene JD, 1998, P NATL ACAD SCI USA, V95, P3531, DOI 10.1073/pnas.95.7.3531; GABBARA S, 1992, J BIOL CHEM, V267, P18623; Huai Q, 2000, EMBO J, V19, P3110, DOI 10.1093/emboj/19.12.3110; JO K, 1995, SCIENCE, V267, P1817, DOI 10.1126/science.7892605; Karpova EA, 1999, IUBMB LIFE, V48, P91, DOI 10.1080/713803460; Kim JJ, 1998, J BIOCHEM MOL BIOL, V31, P149; KRUGER DH, 1988, NUCLEIC ACIDS RES, V16, P3997; KRUGER DH, 1995, FEMS MICROBIOL REV, V17, P177; KUPPER D, 1995, PROTEIN EXPRES PURIF, V6, P1, DOI 10.1006/prep.1995.1001; MERELO JJ, 1994, NEUROCOMPUTING, V6, P1; Morgan R, 1998, APPL ENVIRON MICROB, V64, P3669; Nobbs TJ, 1998, J MOL BIOL, V281, P419, DOI 10.1006/jmbi.1998.1966; OLLER AR, 1991, BIOCHEMISTRY-US, V30, P2543, DOI 10.1021/bi00223a035; PETRAUSKENE OV, 1994, BIOCHEM BIOPH RES CO, V198, P885, DOI 10.1006/bbrc.1994.1126; Petrauskene OV, 1998, FEBS LETT, V425, P29, DOI 10.1016/S0014-5793(98)00184-7; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; REUTER M, 1993, ANAL BIOCHEM, V209, P232, DOI 10.1006/abio.1993.1113; Reuter M, 1998, J BIOL CHEM, V273, P8294, DOI 10.1074/jbc.273.14.8294; Reuter M, 1999, J BIOL CHEM, V274, P5213, DOI 10.1074/jbc.274.8.5213; Rudnick J, 1999, BIOPHYS J, V76, P1725, DOI 10.1016/S0006-3495(99)77334-0; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Siksnys V, 1999, J MOL BIOL, V291, P1105, DOI 10.1006/jmbi.1999.2977; SPIESS E, 1988, METHOD MICROBIOL, V20, P293, DOI 10.1016/S0580-9517(08)70057-6; TOPAL MD, 1993, NUCLEIC ACIDS RES, V21, P2599, DOI 10.1093/nar/21.11.2599; TOPAL MD, 1991, BIOCHEMISTRY-US, V30, P2006, DOI 10.1021/bi00221a038; VINOGRADOVA M V, 1990, Molekulyarnaya Biologiya (Moscow), V24, P847; WENTZELL LM, 1995, J MOL BIOL, V248, P581, DOI 10.1006/jmbi.1995.0244; Wentzell LM, 1998, J MOL BIOL, V281, P433, DOI 10.1006/jmbi.1998.1967; YOLOV AA, 1984, FEBS LETT, V167, P147, DOI 10.1016/0014-5793(84)80850-9	36	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30631	30637		10.1074/jbc.M003904200	http://dx.doi.org/10.1074/jbc.M003904200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10903314	hybrid			2022-12-27	WOS:000089577900098
J	Odajima, J; Matsumura, I; Sonoyama, J; Daino, H; Kawasaki, A; Tanaka, H; Inohara, N; Kitamura, T; Downward, J; Nakajima, K; Hirano, T; Kanakura, Y				Odajima, J; Matsumura, I; Sonoyama, J; Daino, H; Kawasaki, A; Tanaka, H; Inohara, N; Kitamura, T; Downward, J; Nakajima, K; Hirano, T; Kanakura, Y			Fall oncogenic activities of v-Src are mediated by multiple signaling pathways - Ras as an essential mediator for cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; CYCLIN D1 PROMOTER; C-MYC EXPRESSION; HEMATOPOIETIC-CELLS; TRANSCRIPTION FACTORS; STAT3 ACTIVATION; GENE-REGULATION; LEUKEMIA-CELLS; 3T3 CELLS; TRANSFORMATION	Tyrosine kinase oncoproteins cause simultaneous activation of multiple intracellular signaling pathways. However, the precise mechanisms by which individual pathways induce oncogenesis are not well understood. We have investigated the roles of individual signaling pathways in v-Src-dependent cell growth and survival by inhibiting one particular pathway. v-Src induced constitutive activation of signal transducers and activators of transcription 3 (STAT3), phosphatidylinositol 3-kinase, and Res in murine Ba/F3 cells and led to factor-independent proliferation. Dominant-negative mutants of STAT3 (STAT3D) and phosphatidylinositol 3-kinase (Delta p85) inhibited v-Src-dependent growth by similar to 60 and similar to 40%, respectively. Moreover, dominant-negative Res (N17) induced severe apoptosis, which was accompanied by down regulation of Bcl-2 and activation of caspase-3. Although cells overexpressing Bcl-2 or caspase-3 inhibitors remained viable even when N17 was expressed, the growth was reduced by similar to 85%. During N17- and STAT3D-induced growth suppression, expression of cyclin D2, cyclin D3, c-myc, and c-fos was suppressed by N17, whereas that of cyclin D2, cyclin E, and c-myc was suppressed by STAT3D, Thus, v-Src-activated Ras and STAT3 are involved in distinct but partly overlapping transcriptional regulation of cell cycle regulatory molecules. These results suggest that the full oncogenic activity of v-Src requires simultaneous activation of multiple signalings, in which Ras is particularly required for survival.	Osaka Univ, Sch Med, Dept Hematol Oncol, Biomed Res Ctr, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Mol Oncol, Biomed Res Ctr, Suita, Osaka 5650871, Japan; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Tokyo, Inst Med Sci, Dept Hematopoiet Factors, Tokyo 1080071, Japan; Imperial Canc Res Fund, London WC2A 3PX, England; Osaka City Univ, Sch Med, Dept Immunol, Abeno Ku, Osaka 5450051, Japan	Osaka University; Osaka University; University of Michigan System; University of Michigan; University of Tokyo; Cancer Research UK; Osaka Metropolitan University	Matsumura, I (corresponding author), Osaka Univ, Sch Med, Dept Hematol Oncol, Biomed Res Ctr, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Kitamura, Toshio/AAA-2071-2021; Hirano, Toshio/C-8194-2009	Downward, Julian/0000-0002-2331-4729				Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BOS JL, 1989, CANCER RES, V49, P4682; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; CHEN SY, 1994, ONCOGENE, V9, P2691; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; GouilleuxGruart V, 1996, BLOOD, V87, P1692; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Haefner B, 1997, BIOCHEM J, V328, P649, DOI 10.1042/bj3280649; HIRAI H, 1985, BLOOD, V66, P1371; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Matsumura I, 1998, MOL CELL BIOL, V18, P4282, DOI 10.1128/MCB.18.7.4282; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oldham SM, 1998, ONCOGENE, V16, P2565, DOI 10.1038/sj.onc.1201784; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WHITE MA, 1995, CELL, V80, P535; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586; Zhang Q, 1996, P NATL ACAD SCI USA, V93, P9148, DOI 10.1073/pnas.93.17.9148	56	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					24096	24105		10.1074/jbc.M001606200	http://dx.doi.org/10.1074/jbc.M001606200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10918073	hybrid			2022-12-27	WOS:000088564200094
J	Schlador, ML; Grubbs, RD; Nathanson, NM				Schlador, ML; Grubbs, RD; Nathanson, NM			Multiple topological domains mediate subtype-specific internalization of the M-2 muscarinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; BETA-ARRESTIN; DIFFERENTIAL REGULATION; INDEPENDENT MECHANISMS; ADENYLYL-CYCLASE; DOWN-REGULATION; M2; ENDOCYTOSIS; AGONIST	Endocytosis of agonist-activated G protein-coupled receptors (GPCRs) is required for both resensitization and recycling to the cell surface as well as lysosomal degradation. Thus, this process is crucial for regulation of receptor signaling and cellular responsiveness. Although many GPCRs internalize into clathrin-coated vesicles in a dynamin-dependent manner, some receptors, including the M-2 muscarinic acetylcholine receptor (mAChR), can also exhibit dynamin-independent internalization. We have identified five amino acids, located in the sixth and seventh transmembrane domains and the third intracellular loop, that are essential for agonist-induced M-2 mAChR internalization via a dynamin-independent mechanism in JEG-3 choriocarcinoma cells. Substitution of these residues into the M-1 mAChR, which does not internalize in these cells, is sufficient for conversion to the internalization-competent M-2 mAChR phenotype, whereas removal of these residues from the M-2 mAChR blocks internalization. Cotransfection of a dominant-negative isoform of dynamin has no effect on M-2 mAChR internalization. An internalization-incompetent M-2 mutant that lacks a subset of the necessary residues can still internalize via a G protein-coupled receptor kinase-2 and beta-arrestin-dependent pathway. Furthermore, internalization is independent of the signal transduction pathway that is activated. These results identify a novel motif that specifies structural requirements for subtype-specific dynamin-independent internalization of a GPCR.	Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA; Wright State Univ, Sch Med, Dept Pharmacol & Toxicol, Dayton, OH 45435 USA	University of Washington; University of Washington Seattle; Wright State University Dayton	Nathanson, NM (corresponding author), Univ Washington, Sch Med, Dept Pharmacol, Box 357750, Seattle, WA 98195 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058676] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58676] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abdulaev NG, 1998, P NATL ACAD SCI USA, V95, P12854, DOI 10.1073/pnas.95.22.12854; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; Bogatkewitsch GS, 1996, MOL PHARMACOL, V50, P424; Bohm SK, 1997, J BIOL CHEM, V272, P2363; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; GOLDMAN PS, 1994, J BIOL CHEM, V269, P15640; Goldman PS, 1996, J BIOL CHEM, V271, P4215; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; Haasemann M, 1998, J CELL SCI, V111, P917; Han M, 1998, BIOCHEMISTRY-US, V37, P8253, DOI 10.1021/bi980147r; Hukovic N, 1998, J BIOL CHEM, V273, P21416, DOI 10.1074/jbc.273.33.21416; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Kostenis E, 1997, BIOCHEMISTRY-US, V36, P1487, DOI 10.1021/bi962554d; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lee KB, 1998, J BIOL CHEM, V273, P12967, DOI 10.1074/jbc.273.21.12967; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; McClure SJ, 1996, MOL MEMBR BIOL, V13, P189, DOI 10.3109/09687689609160598; MIGEON JC, 1995, J BIOL CHEM, V270, P16070, DOI 10.1074/jbc.270.27.16070; MIGEON JC, 1994, J BIOL CHEM, V269, P9767; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; NATHANSON NM, 1992, METHODS NEUROSCI, V9, P116; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Pogozheva ID, 1997, BIOPHYS J, V72, P1963, DOI 10.1016/S0006-3495(97)78842-8; Roseberry AG, 1999, J BIOL CHEM, V274, P33671, DOI 10.1074/jbc.274.47.33671; Sambrook J., 2002, MOL CLONING LAB MANU; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHERER NM, 1990, BIOCHEMISTRY-US, V29, P8475, DOI 10.1021/bi00488a039; Schlador ML, 1997, J BIOL CHEM, V272, P18882, DOI 10.1074/jbc.272.30.18882; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; SWANSON E, 1995, PSSHOW VERSION 4; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; Vogler O, 1998, J BIOL CHEM, V273, P12155, DOI 10.1074/jbc.273.20.12155; Walker JKL, 1999, J BIOL CHEM, V274, P31515, DOI 10.1074/jbc.274.44.31515; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	48	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23295	23302		10.1074/jbc.M002380200	http://dx.doi.org/10.1074/jbc.M002380200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10930431	hybrid			2022-12-27	WOS:000088419400096
